PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Dewson, G; Snowden, RT; Almond, JB; Dyer, MJS; Cohen, GM				Dewson, G; Snowden, RT; Almond, JB; Dyer, MJS; Cohen, GM			Conformational change and mitochondrial translocation of Bax accompany proteasome inhibitor-induced apoptosis of chronic lymphocytic leukemic cells	ONCOGENE			English	Article						Bax; chronic lymphocytic leukemia; proteasome inhibitors	CYTOCHROME-C RELEASE; TRAIL-INDUCED APOPTOSIS; BCL-2 FAMILY MEMBERS; CASPASE ACTIVATION; HUMAN TISSUES; SURVIVAL; KINASE; RESISTANCE; EXPRESSION; PROTEIN	Chemotherapy resistance remains a major clinical problem in patients with B-cell chronic lymphocytic leukemia (B-CLL). Proteasome inhibitors are able to induce apoptosis in chemotherapy-resistant B-CLL cells in vitro. Exposure of B-CLL cells to the proteasome inhibitors, MG132 and lactacystin, resulted in inhibition of proteasomal activity within 30 min of treatment and was accompanied by an increase in the level of ubiquitinated proteins. Proteasome inhibitors did not alter the levels of expression of the proapoptotic Bcl-2 family proteins, Bax and Bid, prior to the onset of apoptosis. Instead, proteasome inhibitors induced a caspase-independent conformational change in Bax (as shown by a conformation-specific Bax antibody) and its translocation to mitochondria, resulting in mitochondrial perturbation, as evidenced by loss of the mitochondrial membrane potential and cytochrome c release. Similar conformational change and subcellular localization of Bax were observed during apoptosis induced with fludarabine, chlorambucil and prednisolone. These data suggest that alteration of Bax conformation and its redistribution to mitochondria are common and early features of B-CLL apoptosis in response to proteasome inhibitors and other chemotherapeutic agents.	Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England; Univ Leicester, Leicester Royal Infirm, Dept Hematol, Leicester LE2 7LX, Leics, England	University of Leicester; University of Leicester	Cohen, GM (corresponding author), Univ Leicester, MRC, Toxicol Unit, Hodgkin Bldg,POB 138,Lancaster Rd, Leicester LE1 9HN, Leics, England.	gmc2@le.ac.uk	dewson, grant/C-7646-2013; Cohen, Gerald M/A-1687-2008; Dyer, Martin/F-2691-2014	dewson, grant/0000-0003-4251-8898; Dyer, Martin/0000-0002-5033-2236				Adams J, 2002, CURR OPIN CHEM BIOL, V6, P493, DOI 10.1016/S1367-5931(02)00343-5; Adams J, 2000, ONCOGENE, V19, P6687, DOI 10.1038/sj.onc.1204088; Almond JB, 2002, LEUKEMIA, V16, P433, DOI 10.1038/sj.leu.2402417; Almond JB, 2001, LEUKEMIA, V15, P1388, DOI 10.1038/sj.leu.2402201; An B, 1998, CELL DEATH DIFFER, V5, P1062, DOI 10.1038/sj.cdd.4400436; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Bannerji R, 2000, CURR OPIN ONCOL, V12, P22, DOI 10.1097/00001622-200001000-00004; Barragan M, 2002, BLOOD, V99, P2969, DOI 10.1182/blood.V99.8.2969; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Bosanquet AG, 2002, LEUKEMIA, V16, P1035, DOI 10.1038/sj.leu.2402539; Bratton SB, 2001, EMBO J, V20, P998, DOI 10.1093/emboj/20.5.998; Breitschopf K, 2000, J BIOL CHEM, V275, P21648, DOI 10.1074/jbc.M001083200; Cain K, 1999, J BIOL CHEM, V274, P22686, DOI 10.1074/jbc.274.32.22686; Chandra J, 1998, BLOOD, V92, P4220, DOI 10.1182/blood.V92.11.4220.423k49_4220_4229; Chang YC, 1998, CELL GROWTH DIFFER, V9, P79; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Delic J, 1998, BRIT J CANCER, V77, P1103, DOI 10.1038/bjc.1998.183; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Dewson G, 2001, BLOOD, V98, P2239, DOI 10.1182/blood.V98.7.2239; Dou QP, 1999, DRUG RESIST UPDATE, V2, P215, DOI 10.1054/drup.1999.0095; Drexler HCA, 1997, P NATL ACAD SCI USA, V94, P855, DOI 10.1073/pnas.94.3.855; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hideshima T, 2001, CANCER RES, V61, P3071; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kalil N, 1999, Oncologist, V4, P352; Kitada S, 1998, AM J PATHOL, V152, P51; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; MacFarlane M, 2002, ONCOGENE, V21, P6809, DOI 10.1038/sj.onc.1205853; MacFarlane M, 2000, BIOCHEM J, V348, P93, DOI 10.1042/0264-6021:3480093; Maianski NA, 2002, BLOOD, V99, P672, DOI 10.1182/blood.V99.2.672; Makin GWJ, 2001, EMBO J, V20, P6306, DOI 10.1093/emboj/20.22.6306; Marshansky V, 2001, J IMMUNOL, V166, P3130, DOI 10.4049/jimmunol.166.5.3130; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; McConkey DJ, 1996, J IMMUNOL, V156, P2624; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; Murray RZ, 2000, ANTI-CANCER DRUG, V11, P407, DOI 10.1097/00001813-200007000-00001; Naujokat C, 2000, EUR J HAEMATOL, V65, P221, DOI 10.1034/j.1600-0609.2000.065004221.x; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Orlowski RZ, 1999, CELL DEATH DIFFER, V6, P303, DOI 10.1038/sj.cdd.4400505; Penault-Llorca F, 1998, PATHOL RES PRACT, V194, P457, DOI 10.1016/S0344-0338(98)80114-3; Pepper C, 1999, BRIT J HAEMATOL, V104, P581, DOI 10.1046/j.1365-2141.1999.01210.x; Pepper C, 1998, LEUKEMIA LYMPHOMA, V28, P355, DOI 10.3109/10428199809092690; Putcha GV, 1999, J NEUROSCI, V19, P7476, DOI 10.1523/JNEUROSCI.19-17-07476.1999; Reed JC, 1998, SEMIN HEMATOL, V35, P3; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Scaduto RC, 1999, BIOPHYS J, V76, P469, DOI 10.1016/S0006-3495(99)77214-0; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shinohara K, 1996, BIOCHEM J, V317, P385, DOI 10.1042/bj3170385; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tsubuki S, 1996, J BIOCHEM-TOKYO, V119, P572, DOI 10.1093/oxfordjournals.jbchem.a021280; Tsuruta F, 2002, J BIOL CHEM, V277, P14040, DOI 10.1074/jbc.M108975200; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yamaguchi H, 2001, ONCOGENE, V20, P7779, DOI 10.1038/sj.onc.1204984	71	93	94	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2003	22	17					2643	2654		10.1038/sj.onc.1206326	http://dx.doi.org/10.1038/sj.onc.1206326			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730678				2022-12-28	WOS:000182569000012
J	Landowski, TH; Olashaw, NE; Agrawal, D; Dalton, WS				Landowski, TH; Olashaw, NE; Agrawal, D; Dalton, WS			Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB/p50) in myeloma cells	ONCOGENE			English	Article						myeloma; drug resistance; adhesion; NF-kappa B; microarray	INDUCED APOPTOSIS; CONFERS RESISTANCE; EXPRESSION; INHIBITOR; FIBRONECTIN; INDUCTION; DEATH; BCL-2; TRANSCRIPTION; FIBROBLASTS	The microenvironment has been shown to influence tumor cell phenotype with respect to growth, metastasis, and response to chemotherapy. We have utilized oligonucleotide microarray analysis to identify signal transduction pathways and gene products altered by the interaction of myeloma tumor cells with the extracellular matrix component fibronectin that may contribute to the antiapoptotic phenotype conferred by the microenvironment. Genes with altered expression associated with fibronectin cell adhesion, either induced or repressed, were numerically ranked by fold change. FN adhesion repressed the expression of 469 gene products, while 53 genes with known coding sequences were induced by twofold or more. Of these 53 genes with two fold, or greater increase in expression, 11 have been reported to be regulated by the nuclear factor-kappa B (NF-kappaB) family of transcription factors. EMSA analysis demonstrated NF-kappaB binding activity significantly increased in cells adhered to fibronectin compared to cells in suspension. This DNA binding activity consisted primarily of RelB-p50 heterodimers, which was distinct from the NF-kappaB activation of TNFalpha. These data demonstrate the selectivity of signal transduction from the microenvironment that may contribute to tumor cell resistance to programmed cell death.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Cell Biol, Tampa, FL 33612 USA; Univ Arizona, Arizona Canc Ctr, Dept Med, Tucson, AZ 85724 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Arizona Center Cancer Care; University of Arizona	Dalton, WS (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA.							Bearz A, 1998, BIOCHEM BIOPH RES CO, V243, P732, DOI 10.1006/bbrc.1997.8017; Bian X, 2001, J BIOL CHEM, V276, P48921, DOI 10.1074/jbc.M108674200; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Do RKG, 2000, J EXP MED, V192, P953, DOI 10.1084/jem.192.7.953; Do RKG, 2002, CYTOKINE GROWTH F R, V13, P19, DOI 10.1016/S1359-6101(01)00025-9; Feinman R, 1999, BLOOD, V93, P3044; Green SK, 1999, ANTI-CANCER DRUG DES, V14, P153; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Gugasyan R, 2000, IMMUNOL REV, V176, P134; Hazlehurst LA, 2001, BLOOD, V98, P1897, DOI 10.1182/blood.V98.6.1897; Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782; Hideshima T, 2001, CANCER RES, V61, P3071; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kudoh K, 2000, CANCER RES, V60, P4161; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; MAYO MW, 2000, BIOCHIM BIOPHYS ACTA, V1470, P55; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; QWARNSTROM EE, 1994, J BIOL CHEM, V269, P30765; Rosales C, 1996, CANCER RES, V56, P2302; Scupoli MT, 2000, J CELL SCI, V113, P169; Shain KH, 2002, J IMMUNOL, V168, P2544, DOI 10.4049/jimmunol.168.5.2544; Shain KH, 1999, J CELL BIOCHEM, V73, P237, DOI 10.1002/(SICI)1097-4644(19990501)73:2<237::AID-JCB10>3.0.CO;2-H; StCroix B, 1996, NAT MED, V2, P1204; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	33	151	154	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 24	2003	22	16					2417	2421		10.1038/sj.onc.1206315	http://dx.doi.org/10.1038/sj.onc.1206315			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	670AD	12717418				2022-12-28	WOS:000182383500004
J	Lee, GH; Nishimori, H; Sasaki, Y; Matsushita, H; Kitagawa, T; Tokino, T				Lee, GH; Nishimori, H; Sasaki, Y; Matsushita, H; Kitagawa, T; Tokino, T			Analysis of lung tumorigenesis in chimeric mice indicates the Pulmonary adenoma resistance 2 (Par2) locus to operate in the tumor-initiation stage in a cell-autonomous manner: detection of polymorphisms in the Poh gene as a candidate for Par2	ONCOGENE			English	Article						chimeric mouse; lung tumor; resistance locus; cell-autonomy; candidate gene	HUMAN DNA-POLYMERASE; URETHANE-INDUCTION; BALB/CBYJ MICE; RAS GENE; IOTA; SUSCEPTIBILITY; CARCINOGENESIS; IDENTIFICATION; HOMOLOG; LESIONS	The Pulmonary adenoma resistance 2 (Par2) locus of the BALB/cByJ mouse, located within 0.5 cM of chromosome 18, is responsible for reducing the mean multiplicity of urethane-induced lung tumors relative to those in C57BL/6J, A/J and C3H/HeJ mice. Thus, BALB/B6-Par2 congenic strain genetically identical to BALB/cByJ except carrying C57BL/6J Par2 alleles develops seven times more tumors than BALB/cByJ. To gain clues for identification of Par2 candidate genes, we analysed lung tumorigenesis in BALB/cByJ <----> BALB.B6-Par2 chimeric animals. Of 100 tumors induced by urethane in 16 chimeras, 82 originated from BALB.B6-Par2 cells, indicating the Par2 phenotype to be cell-autonomous. In addition, the BALB.B6-Par2- and BALB/cByJ-derived tumors were similar in mean size, implying that the phenotype is primarily expressed during initiation rather than in the promotion stage of carcinogenesis. Given these results, we surveyed a comprehensive mouse genome database and physically mapped Par2 within a 2.3 Mbp segment containing three known genes, Poh, Mbd2 and Dcc. Among those, the Poh seemed to be the most reasonable Par2 candidate, since it encodes an extremely error-prone DNA polymerase preferentially incorporating G or T opposite template T in vitro, reminiscent of the Kras2 activation because of an A to G or T point mutation within codon 61 with which most urethane-induced lung tumors are initiated. Indeed, our sequencing of Poh cDNAs from BALB/cByJ, C57BL/6J, A/J and C3H/HeJ lungs revealed 21 BALB/cByJ-specific single-nucleotide polymorphisms in the coding region accompanied by seven amino-acid substitutions and an elevated frequency of alternative splicing, while no polymorphisms associated with tumor susceptibility were found for either Mbd2 or Dcc. Notably, we obtained evidence that BALB/cByJ Par2 alleles may selectively decrease the frequency of Kras2-mutated tumors compared with C57BL/6J alleles. Consequently, the Poh is an intriguing Par2 candidate clearly deserving further evaluation.	Toranomon Gen Hosp, Dept Pathol, Minato Ku, Tokyo 1058470, Japan; Okinaka Mem Inst Med Res, Minato Ku, Tokyo 1058470, Japan; Sapporo Med Univ, Inst Canc Res, Dept Mol Biol, Sapporo, Hokkaido 0608556, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Pathol, Tokyo 1708455, Japan	Toranomon Hospital; Sapporo Medical University; Japanese Foundation for Cancer Research	Lee, GH (corresponding author), Toranomon Gen Hosp, Dept Pathol, Minato Ku, 2-2-2 Toranomon, Tokyo 1058470, Japan.	lee@toranomon.gr.jp	Tokino, Takashi/AAI-9887-2021; Sasaki, Yasushi/AAA-3079-2019	Sasaki, Yasushi/0000-0002-3500-8059				Bebenek K, 2001, SCIENCE, V291, P2156, DOI 10.1126/science.1058386; CHEN B, 1994, P NATL ACAD SCI USA, V91, P1589, DOI 10.1073/pnas.91.4.1589; Cooper HM, 1995, ONCOGENE, V11, P2243; Devereux TR, 1997, CARCINOGENESIS, V18, P1751, DOI 10.1093/carcin/18.9.1751; DEVEREUX TR, 1994, MAMM GENOME, V5, P749, DOI 10.1007/BF00292007; Dragani TA, 1995, ADV CANCER RES, V67, P83, DOI 10.1016/S0065-230X(08)60711-3; FESTING MFW, 1994, GENET RES, V64, P99, DOI 10.1017/S0016672300032705; GARIBOLDI M, 1993, NAT GENET, V3, P132, DOI 10.1038/ng0293-132; Haracska L, 2001, P NATL ACAD SCI USA, V98, P14256, DOI 10.1073/pnas.261560798; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Karasaki H, 1997, ONCOGENE, V15, P1833, DOI 10.1038/sj.onc.1201357; LEE GH, 1991, CANCER RES, V51, P3257; LEE GH, 1987, HEPATOLOGY, V7, P937, DOI 10.1002/hep.1840070524; Lee GH, 2001, ONCOGENE, V20, P3979, DOI 10.1038/sj.onc.1204562; MALKINSON AM, 1983, J NATL CANCER I, V70, P931; MANAM S, 1992, MOL CARCINOGEN, V6, P68, DOI 10.1002/mc.2940060111; McDonald JP, 1999, GENOMICS, V60, P20, DOI 10.1006/geno.1999.5906; Obata M, 1996, ONCOGENE, V13, P1599; Tissier A, 2000, GENE DEV, V14, P1642; Tissier A, 2000, EMBO J, V19, P5259, DOI 10.1093/emboj/19.19.5259; YOU M, 1992, P NATL ACAD SCI USA, V89, P5804, DOI 10.1073/pnas.89.13.5804; Zhang YB, 2000, MOL CELL BIOL, V20, P7099, DOI 10.1128/MCB.20.19.7099-7108.2000; Zhang YB, 2001, NUCLEIC ACIDS RES, V29, P928, DOI 10.1093/nar/29.4.928; Zhang ZQ, 2000, EXP LUNG RES, V26, P627, DOI 10.1080/01902140150216710	25	29	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2003	22	15					2374	2382		10.1038/sj.onc.1206387	http://dx.doi.org/10.1038/sj.onc.1206387			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	667KV	12700672				2022-12-28	WOS:000182231500015
J	Woerner, SM; Benner, A; Sutter, C; Schiller, M; Yuan, YP; Keller, G; Bork, P; Doeberitz, MV; Gebert, JF				Woerner, SM; Benner, A; Sutter, C; Schiller, M; Yuan, YP; Keller, G; Bork, P; Doeberitz, MV; Gebert, JF			Pathogenesis of DNA repair-deficient cancers: a statistical meta-analysis of putative Real Common Target genes	ONCOGENE			English	Article						mismatch repair; coding microsatellite; microsatellite instability; Real Common Target genes; ByStander genes	MICROSATELLITE MUTATOR PHENOTYPE; FREQUENT FRAMESHIFT MUTATIONS; REPEATED SEQUENCES REVEAL; II RECEPTOR GENE; MISMATCH REPAIR; COLORECTAL CANCERS; REPLICATION FIDELITY; BETA RECEPTOR; COLON-CANCER; INSTABILITY	DNA mismatch repair deficiency is observed in about 15% of human colorectal, gastric, and endometrial tumors and in lower frequencies in a minority of other tumors thereby causing insertion/deletion mutations at short repetitive sequences, recognized as microsatellite instability (MSI). Evolution of tumors, including those with MSI, is a continuous process of mutation and selection favoring neoplastic growth. Mutations in microsatellite-bearing genes that promote tumor cell growth in general (Real Common Target genes) are assumed to be the driving force during MSI carcinogenesis. Thus, microsatellite mutations in these genes should occur more frequently than mutations in microsatellite genes without contribution to malignancy (ByStander genes). So far, only a few Real Common Target genes have been identified by functional studies. Thus, comprehensive analysis of microsatellite mutations will provide important clues to the understanding of MSI-driven carcinogenesis. Here, we evaluated published mutation frequencies on 194 repeat tracts in 137 genes in MSI-H colorectal, endometrial, and gastric carcinomas and propose a statistical model that aims to identify Real Common Target genes. According to our model nine genes including BAX and TGFbetaRII were identified as Real Common Targets in colorectal cancer, one gene in gastric cancer, and three genes in endometrial cancer. Microsatellite mutations in five additional genes seem to be counterselected in gastrointestinal tumors. Overall, the general applicability, the capacity to unlimited data analysis, the inclusion of mutation data generated by different groups on different sets of tumors make this model a useful tool for predicting Real Common Target genes with specificity for MSI-H tumors of different organs, guiding subsequent functional studies to the most likely targets among numerous microsatellite harboring genes.	Heidelberg Univ, Inst Pathol, Dept Mol Pathol, D-69120 Heidelberg, Germany; Deutsch Krebsforschungszentrum, Cent Unit, D-69120 Heidelberg, Germany; European Mol Biol Lab, D-69117 Heidelberg, Germany; Tech Univ Munich, Inst Pathol, D-81675 Munich, Germany; Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); European Molecular Biology Laboratory (EMBL); Technical University of Munich; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Gebert, JF (corresponding author), Heidelberg Univ, Inst Pathol, Dept Mol Pathol, Neuenheimer Feld 220-221, D-69120 Heidelberg, Germany.	Johannes_gebert@med.uni-heidelberg.de	Yuan, Yanping/D-5257-2013; Bork, Peer/F-1813-2013; von Knebel Doeberitz, Magnus/D-2372-2016; Woerner, Stefan/A-2187-2010	Yuan, Yanping/0000-0003-4284-3973; Bork, Peer/0000-0002-2627-833X; von Knebel Doeberitz, Magnus/0000-0002-0498-6781; 				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Bicknell DC, 1996, CURR BIOL, V6, P1695, DOI 10.1016/S0960-9822(02)70795-1; Boland CR, 1998, CANCER RES, V58, P5248; Chadwick RB, 2000, P NATL ACAD SCI USA, V97, P2662, DOI 10.1073/pnas.040579497; Duval A, 1999, CANCER RES, V59, P4213; Duval A, 2002, CANCER RES, V62, P1609; Duval A, 2002, CANCER RES, V62, P2447; Duval A, 2001, HUM MOL GENET, V10, P513, DOI 10.1093/hmg/10.5.513; Hediger MA, 2002, NAT MED, V8, P445, DOI 10.1038/nm0502-445; Huet S., 1996, STAT TOOLS NONLINEAR, DOI [10.1007/978-1-4757-2523-0.41, DOI 10.1007/978-1-4757-2523-0.41]; Ionov Y, 2000, P NATL ACAD SCI USA, V97, P10872, DOI 10.1073/pnas.190210897; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859; Loeb LA, 2001, CANCER RES, V61, P3230; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Mignone F, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-3-reviews0004; Mori Y, 2001, CANCER RES, V61, P6046; MYEROFF LL, 1995, CANCER RES, V55, P5545; O'Donnell M, 2001, CURR BIOL, V11, pR935, DOI 10.1016/S0960-9822(01)00559-0; PERUCHO M, 1994, COLD SPRING HARB SYM, V59, P339, DOI 10.1101/SQB.1994.059.01.038; Perucho M, 1999, CANCER RES, V59, P249; Piao Z, 2000, CANCER RES, V60, P4701; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Sagher D, 1999, MUTAT RES-FUND MOL M, V423, P73, DOI 10.1016/S0027-5107(98)00227-9; Sakurada K, 2001, GENE CHROMOSOME CANC, V30, P207, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1080>3.0.CO;2-V; Schwartz S, 1999, CANCER RES, V59, P2995; Sia EA, 1997, MOL CELL BIOL, V17, P2851, DOI 10.1128/MCB.17.5.2851; Sotiriou S, 2002, NAT MED, V8, P514, DOI 10.1038/nm0502-514; Souza RF, 1999, ONCOGENE, V18, P4063, DOI 10.1038/sj.onc.1202768; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Woerner SM, 2001, INT J CANCER, V93, P12, DOI 10.1002/ijc.1299; Zhang L, 2001, CANCER RES, V61, P3801	38	129	134	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2003	22	15					2226	2235		10.1038/sj.onc.1206421	http://dx.doi.org/10.1038/sj.onc.1206421			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	667KV	12700659				2022-12-28	WOS:000182231500002
J	Kim, JE; Kim, SJ; Jeong, HW; Lee, BH; Choi, JY; Park, RW; Park, JY; Kim, IS				Kim, JE; Kim, SJ; Jeong, HW; Lee, BH; Choi, JY; Park, RW; Park, JY; Kim, IS			RGD peptides released from beta ig-h3, a TGF-beta-induced cell-adhesive molecule, mediate apoptosis	ONCOGENE			English	Article						beta ig-h3; RGD peptide; apoptosis; TGF-beta; cell adhesion; anoikis	GROWTH-FACTOR-BETA; IN-VITRO; PROTEIN; GENE; CHONDROCYTES; INVOLVEMENT; FIBROBLASTS; PROTEASES; CLONING; LINE	betaig-h3 is a transforming growth factor-beta (TGF-beta)-induced cell-adhesive molecule and has an RGD sequence at its C-terminus. A previous report suggested that betaig-h3 normally undergoes carboxy-terminal processing that results in the loss of the RGD sequence. RGD peptides appear to play various roles in cell function. Here we show that the RGD peptides released from betaig-h3 may facilitate TGF-beta-induced apoptosis. We found that carboxy-terminal cleavage of betaig-h3 occurred after its secretion, and that overexpression of the wild-type betaig-h3 induced apoptosis, unlike the C-terminal deleted but RGD-containing mutant betaig-h3, which is resistant to C-terminal processing. The betaig-h3-induced apoptosis was abolished by either deletion of the RGD sequence or mutation of RGD to RAE. Synthetic peptides of ERGDEL and GRGDSP derived from betaig-h3 and fibronectin, respectively, also induced apoptosis, unlike ERGEEL and GRGESP. Culture supernatants of cells overexpressing betaig-h3 filtered to isolate molecules smaller than 3 kDa also induced apoptosis. A fusion protein composed of the N-terminal 100 amino acids of fibronectin and the RGD-containing C-terminal part of betaig-h3 was also subjected to C-terminal cleavage and overexpression resulted in apoptosis. The anti-betaig-h3 antibody blocks TGF-beta-induced apoptosis. Thus, betaig-h3 may be important in regulating cell apoptosis by providing soluble RGD peptides.	Kyungpook Natl Univ, Dept Biochem, Sch Med, Jung Gu, Taegu 700722, South Korea; Kyungpook Natl Univ, Sch Med, Natl Res Lab, Taegu 700722, South Korea; Kyungpook Natl Univ, Sch Med, Dept Internal Med, Taegu 700722, South Korea	Kyungpook National University; Kyungpook National University; Kyungpook National University	Kim, IS (corresponding author), Kyungpook Natl Univ, Dept Biochem, Sch Med, Jung Gu, 101 Dongin Dong, Taegu 700722, South Korea.	iskim@knu.ac.kr	김, 인산/I-8988-2014					Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Buckley CD, 1999, NATURE, V397, P534, DOI 10.1038/17409; Chen RH, 1997, CELL GROWTH DIFFER, V8, P821; Choi KS, 1999, J BIOL CHEM, V274, P31775, DOI 10.1074/jbc.274.45.31775; Dieudonne SC, 2000, J CELL BIOCHEM, V76, P231, DOI 10.1002/(SICI)1097-4644(20000201)76:2<231::AID-JCB7>3.0.CO;2-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Genini M, 1996, INT J CANCER, V66, P571; Hishikawa K, 1999, J BIOL CHEM, V274, P37461, DOI 10.1074/jbc.274.52.37461; InayatHussain SH, 1997, HEPATOLOGY, V25, P1516, DOI 10.1002/hep.510250634; Kawamoto T, 1998, BBA-GENE STRUCT EXPR, V1395, P288, DOI 10.1016/S0167-4781(97)00172-3; Kim JE, 2000, J CELL BIOCHEM, V77, P169, DOI 10.1002/(SICI)1097-4644(20000501)77:2<169::AID-JCB1>3.0.CO;2-L; Kim JE, 2000, J BIOL CHEM, V275, P30907, DOI 10.1074/jbc.M002752200; Kim JE, 2002, INVEST OPHTH VIS SCI, V43, P656; Lafon C, 1996, CELL GROWTH DIFFER, V7, P1095; LEBARON RG, 1995, J INVEST DERMATOL, V104, P844, DOI 10.1111/1523-1747.ep12607024; Munier FL, 1997, NAT GENET, V15, P247, DOI 10.1038/ng0397-247; Ohno S, 1999, BBA-MOL CELL RES, V1451, P196, DOI 10.1016/S0167-4889(99)00093-2; Perlot RL, 2002, J BONE MINER RES, V17, P66, DOI 10.1359/jbmr.2002.17.1.66; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; Rawe IM, 1997, INVEST OPHTH VIS SCI, V38, P893; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; Schenker T, 1998, EXP CELL RES, V239, P161, DOI 10.1006/excr.1997.3896; SKONIER J, 1994, DNA CELL BIOL, V13, P571, DOI 10.1089/dna.1994.13.571; SKONIER J, 1992, DNA CELL BIOL, V11, P511, DOI 10.1089/dna.1992.11.511	26	90	99	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2003	22	13					2045	2053		10.1038/sj.onc.1206269	http://dx.doi.org/10.1038/sj.onc.1206269			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	662UR	12673209				2022-12-28	WOS:000181967700014
J	Oertle, T; Merkler, D; Schwab, ME				Oertle, T; Merkler, D; Schwab, ME			Do cancer cells die because of Nogo-B?	ONCOGENE			English	Article						ASY; Nogo-B; apoptosis; cancer; endoplasmatic reticulum; SaOS-2	NSP-ENCODED RETICULONS; ENDOPLASMIC-RETICULUM; LUNG-CANCER; SUBCELLULAR-LOCALIZATION; NEUROENDOCRINE MARKERS; GENE FAMILY; PROTEIN; APOPTOSIS; BCL-2; SURVIVAL	Nogo-A is a potent neurite outgrowth inhibitory protein in vitro and is suggested to play a role in the lack of regeneration in the central nervous system of adult higher vertebrates. A shorter splice isoform, ASY/Nogo-B, has recently been reported to act as a proapoptotic protein, the loss of which would be typical for cancer cells. Here, we show that the osteosarcoma cell line SaOS-2 and the cell line CHO do express high levels of endogenous Nogo-B and that stable transfectants overexpressing high levels of Nogo-B do not differ significantly from the respective parental wild-type or control cell lines both in respect to cell proliferation and to spontaneous apoptosis or cell death induced by staurosporine and tunicamycin. The deletion of the second transmembrane domain of Nogo-B, which has been claimed to abolish its proapoptotic activity, leads to a shift of the protein from the ER to a cytoplasmic localization, suggesting that ER stress of highly overexpressed Nogo-B may lead to aversive cellular reactions under particular conditions. Our data do not support a function of Nogo-B as a physiological proapoptotic protein in certain types of cancer.	Univ Zurich, Brain Res Inst, CH-8057 Zurich, Switzerland; Swiss Fed Inst Technol, Dept Biol, CH-8057 Zurich, Switzerland	University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich	Oertle, T (corresponding author), Univ Zurich, Brain Res Inst, Winterthurerstr 190, CH-8057 Zurich, Switzerland.		Schwab, Martin E/B-6818-2016; Merkler, Doron/N-9157-2016	Merkler, Doron/0000-0002-0247-2007				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Annis MG, 2001, ONCOGENE, V20, P1939, DOI 10.1038/sj.onc.1204288; Bongarzone ER, 2001, J NEUROSCI RES, V65, P485, DOI 10.1002/jnr.1178; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hacki J, 2000, ONCOGENE, V19, P2286, DOI 10.1038/sj.onc.1203592; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Huber AB, 2002, J NEUROSCI, V22, P3553; Li Q, 2001, ONCOGENE, V20, P3929, DOI 10.1038/sj.onc.1204536; MICHEL A, 1999, ELECT J PATHOL HISTO, V5, P993; Morris NJ, 1999, BBA-MOL CELL RES, V1450, P68, DOI 10.1016/S0167-4889(99)00033-6; Nagase T, 1998, DNA Res, V5, P355, DOI 10.1093/dnares/5.6.355; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nilsson I, 1998, J MOL BIOL, V284, P1165, DOI 10.1006/jmbi.1998.2217; Oertle T, 2003, J MOL BIOL, V325, P299, DOI 10.1016/S0022-2836(02)01179-8; Pahl HL, 1999, PHYSIOL REV, V79, P683, DOI 10.1152/physrev.1999.79.3.683; Senden N, 1997, HISTOCHEM CELL BIOL, V108, P155, DOI 10.1007/s004180050157; Senden NHM, 1996, EUR J CELL BIOL, V69, P197; SENDEN NHM, 1994, EUR J CELL BIOL, V65, P341; Senden NHM, 1997, J PATHOL, V182, P13; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Tagami S, 2000, ONCOGENE, V19, P5736, DOI 10.1038/sj.onc.1203948; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VANDEVELDE HJK, 1994, J CELL SCI, V107, P2403; VANDEVELDE HJK, 1994, CANCER RES, V54, P4769; Woynarowska BA, 2002, BBA-MOL BASIS DIS, V1587, P309, DOI 10.1016/S0925-4439(02)00094-7	29	61	69	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2003	22	9					1390	1399		10.1038/sj.onc.1206278	http://dx.doi.org/10.1038/sj.onc.1206278			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618765				2022-12-28	WOS:000181360900014
J	Agirre, X; Vizmanos, JL; Calasanz, MJ; Garcia-Delgado, M; Larrayoz, MJ; Novo, FJ				Agirre, X; Vizmanos, JL; Calasanz, MJ; Garcia-Delgado, M; Larrayoz, MJ; Novo, FJ			Methylation of CpG dinucleotides and/or CCWGG motifs at the promoter of TP53 correlates with decreased gene expression in a subset of acute lymphoblastic leukemia patients	ONCOGENE			English	Article						TP53; methylation analysis; promoter analysis; gene expression; ALL	TUMOR-SUPPRESSOR GENE; P53 GENE; DNA METHYLATION; IN-VIVO; CARCINOGENESIS; REGION; CELLS	It has been shown that methylation of CpG dinucleotides located in the promoter region of TP53 is associated with low expression levels of this gene. We have analysed the methylation status of one CpG dinucleotide and of three CCWGG motifs, also located in the promoter region of the gene, in bone marrow samples obtained from patients with acute lymphoblastic leukemia (ALL). Eight out of 25 samples analysed showed methylation of either the CpG dinucleotide, the CCWGG motifs or both. Relative to nonmethylated leukemia samples, TP53 expression levels were decreased in all methylated samples in which TP53 expression could be measured. Methylation of CpG and CCWGG motifs in the promoter of TP53 could represent a novel mechanism leading to functional impairment of this tumor suppressor gene in ALL.	Univ Navarra, Sch Sci, Dept Genet, E-31080 Pamplona, Navarra, Spain	University of Navarra	Vizmanos, JL (corresponding author), Univ Navarra, Sch Sci, Dept Genet, C Irunlarrea S-N, E-31080 Pamplona, Navarra, Spain.		Novo, Francisco/M-7596-2015; Vizmanos, José L./G-2833-2012; Calasanz, MJ/R-5813-2016; Agirre, Xabier/ABE-4110-2020	Novo, Francisco/0000-0003-4961-3097; Vizmanos, José L./0000-0001-7416-3679; Calasanz, MJ/0000-0002-0374-3008; 				Agirre X, 2002, BIOTECHNIQUES, V32, P1064, DOI 10.2144/02325rr01; BIENZTADMOR B, 1985, EMBO J, V4, P3209, DOI 10.1002/j.1460-2075.1985.tb04067.x; Davis CD, 2000, J NUTR, V130, P2903, DOI 10.1093/jn/130.12.2903; Herman JG, 1996, CANCER RES, V56, P722; Kang JH, 2001, LAB INVEST, V81, P573, DOI 10.1038/labinvest.3780266; Malone CS, 2001, P NATL ACAD SCI USA, V98, P10404, DOI 10.1073/pnas.181206898; Mass MJ, 1997, MUTAT RES-REV MUTAT, V386, P263, DOI 10.1016/S1383-5742(97)00008-2; Pogribny IP, 2000, CANCER RES, V60, P588; Pogribny IP, 2002, CANCER LETT, V176, P169, DOI 10.1016/S0304-3835(01)00748-0; Preudhomme C, 1997, BRIT J HAEMATOL, V98, P502, DOI 10.1046/j.1365-2141.1997.2403057.x; Roman-Gomez J, 2002, BLOOD, V99, P2291, DOI 10.1182/blood.V99.7.2291; Schroeder M, 1997, BIOCHEM BIOPH RES CO, V235, P403, DOI 10.1006/bbrc.1997.6796; Schutte M, 1997, CANCER RES, V57, P3126; TUCK SP, 1989, MOL CELL BIOL, V9, P2163, DOI 10.1128/MCB.9.5.2163; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657	15	63	64	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 20	2003	22	7					1070	1072		10.1038/sj.onc.1206236	http://dx.doi.org/10.1038/sj.onc.1206236			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	644PB	12592393				2022-12-28	WOS:000180926100012
J	Pajer, P; Pecenka, V; Karafiat, V; Kralova, J; Horejsi, Z; Dvorak, M				Pajer, P; Pecenka, V; Karafiat, V; Kralova, J; Horejsi, Z; Dvorak, M			The twist gene is a common target of retroviral integration and transcriptional deregulation in experimental nephroblastoma	ONCOGENE			English	Article						Twist gene; MAV retrovirus; common viral integration site; nephroblastoma	MYELOBLASTOSIS-ASSOCIATED VIRUS; SAETHRE-CHOTZEN-SYNDROME; PROTEIN; MUTATIONS; ONCOGENE; CANCER; CELLS; BHLH; NOV	The genes involved in the transformation of kidney blastema cells were searched for in avian nephroblastomas induced by the MAV2 retrovirus. The twist gene was identified as a common site of provirus integration in tumor cells. Twist was rearranged by the MAV2 provirus in three out of 76 independent nephroblastoma samples. The MAV2 integration sites were localized within 40 nucleotides of the twist 5'UTR region, right upstream from the ATG initiation codon. The integrated proviruses were deleted at their 5'ends. As a consequence, twist transcription became controlled by the retroviral 3'LTR promoter and was strongly upregulated, more than 200 times. In addition, 2-100 times elevated twist transcription was also detected in the majority of other nephroblastoma samples not containing MAV2 in the twist locus. We propose that chicken nephroblastoma originates from a single blastemic cell in which the MAV retrovirus, through its integration, has deregulated specific combinations of genes controlling proliferation and differentiation. The activation of the twist gene expression appears to contribute to tumorigenesis, as there is an in vivo positive selection of tumor cell clones containing the twist gene hyperactivated by MAV2 sequences inserted within the twist promoter.	Acad Sci Czech Republ, Inst Mol Genet, CR-16637 Prague 6, Czech Republic	Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences	Dvorak, M (corresponding author), Acad Sci Czech Republ, Inst Mol Genet, Flemingovo 2, CR-16637 Prague 6, Czech Republic.		Kralova, Jarmila/G-3834-2014; Dvořák, Michal/I-9939-2014; Dvorak, Michal/G-5861-2014; Pajer, Petr/G-5869-2014	Kralova, Jarmila/0000-0002-4735-8857; Licenikova Horejsi, Zuzana/0000-0002-9943-1649				Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Baskaran N, 1996, GENOME RES, V6, P633, DOI 10.1101/gr.6.7.633; BONISCHNETZLER M, 1985, J VIROL, V55, P213; Bourgeois P, 1998, HUM MOL GENET, V7, P945, DOI 10.1093/hmg/7.6.945; Castanon I, 2002, GENE, V287, P11, DOI 10.1016/S0378-1119(01)00893-9; Coffin J, 1997, RETROVIRUSES; COLLART KL, 1990, J VIROL, V64, P3541, DOI 10.1128/JVI.64.7.3541-3544.1990; Dome JS, 2002, CURR OPIN PEDIATR, V14, P5, DOI 10.1097/00008480-200202000-00002; ElGhouzzi V, 1997, NAT GENET, V15, P42; Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3; Howard TD, 1997, NAT GENET, V15, P36, DOI 10.1038/ng0197-36; ISHIGURO H, 1962, J NATL CANCER I, V29, P1; Joliot V, 1996, J VIROL, V70, P2576, DOI 10.1128/JVI.70.4.2576-2580.1996; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; Lee MS, 1999, J CELL BIOCHEM, V75, P566, DOI 10.1002/(SICI)1097-4644(19991215)75:4<566::AID-JCB3>3.0.CO;2-0; LI L, 1995, DEV BIOL, V172, P280, DOI 10.1006/dbio.1995.0023; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; PECENKA V, 1988, FOLIA BIOL-PRAGUE, V34, P147; PECENKA V, 1988, FOLIA BIOL-PRAGUE, V34, P215; PECENKA V, 1988, FOLIA BIOL-PRAGUE, V34, P129; Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P57, DOI 10.1136/mp.54.2.57; Plachy J, 1997, FOLIA BIOL-PRAGUE, V43, P133; ROBINSON HL, 1986, J VIROL, V57, P28, DOI 10.1128/JVI.57.1.28-36.1986; Scharnhorst V, 2001, GENE, V273, P141, DOI 10.1016/S0378-1119(01)00593-5; Spicer DB, 1996, SCIENCE, V272, P1476, DOI 10.1126/science.272.5267.1476; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; WESTAWAY D, 1986, EMBO J, V5, P301, DOI 10.1002/j.1460-2075.1986.tb04213.x	28	25	25	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 6	2003	22	5					665	673		10.1038/sj.onc.1206105	http://dx.doi.org/10.1038/sj.onc.1206105			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569359				2022-12-28	WOS:000180642100004
J	Routhier, EL; Donover, PS; Prendergast, GC				Routhier, EL; Donover, PS; Prendergast, GC			hob1+, the fission yeast homolog of Bin1, is dispensable for endocytosis or actin organization, but required for the response to starvation or genotoxic stress	ONCOGENE			English	Article						amphiphysin; Rvs167; endocytosis; Myc; cell cycle; DNA damage	CYCLIN-DEPENDENT KINASE-5; MYC-INTERACTING PROTEIN; TUMOR-SUPPRESSOR BIN1; APOPTOTIC CELL-DEATH; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; AMPHIPHYSIN ISOFORM; ASTROCYTOMA-CELLS; SPLICE VARIANTS; GENE	BAR (Bin/Amphiphysin/Rvs) adapter proteins have been suggested to regulate endocytosis, actin organization, apoptosis, and transcription, but their precise roles are obscure. There are at least five mammalian genes that encode BAR adapter proteins, including the evolutionarily conserved and ubiquitously expressed Bin1/Amphiphysin-II and Bin3 genes. Bin1 holds special interest as certain splice isoforms localize to the nucleus, interact with the c-Ab1 and c-Myc oncoproteins, and display tumor suppressor properties. To obtain functional insights, we embarked upon a genetic analysis of the two BAR adapter proteins expressed in the fission yeast Schizosaccharomyces pombe. In a previous work, a role in actin organization and cytokinesis was identified for the Bin3 homolog hob3+. In this study, a role in stress signaling was defined for the Bin1 homolog, hob1 +. Notably, hoh1 + was dispensable for endocytosis, actin organization, or osmotic sensitivity. Instead, mutation of hob1 + led to slight cell elongation and faulty cell cycle arrest upon nutrient starvation. These defects were complemented by Bin1, but not by Amphiphyrsin-I, arguing that these genes have distinct functions despite their structural similarity. hob1 A mutant cells were also hypersensitive to genotoxic stress. This was not related to faulty checkpoint response, but mutation in the checkpoint gene rad3(+) further exacerbated the sensitivity of hob1Delta mutant cells. Interestingly, mutation of the cell cycle regulator wee1(+) partially relieved the sensitivity defect, suggesting that hob1 + may influence the efficiency of DNA repair or checkpoint release after DNA damage. Genetic and biochemical evidence indicated that hob3 + is epistatic to hob1 + in the response to genotoxic stress. Our findings indicate that the Bin1 homolog hob1 + participates in DNA damage signaling and they suggest a novel role for BAR adapter proteins in stress response processes.	Lankenau Inst Med Res, Wynnewood, PA 19096 USA; DuPont Pharmaceut Co, Glenolden Lab, Canc Res Grp, Glenolden, PA 19036 USA	Lankenau Medical Center; Lankenau Institute for Medical Research; DuPont	Prendergast, GC (corresponding author), Lankenau Inst Med Res, 100 Lancaster Ave, Wynnewood, PA 19096 USA.	prendergastg@mlhs.org						Ahuja HS, 1997, DEV GENET, V21, P258, DOI 10.1002/(SICI)1520-6408(1997)21:4<258::AID-DVG3>3.0.CO;2-6; ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Balguerie A, 1999, J CELL SCI, V112, P2529; BAUER F, 1993, MOL CELL BIOL, V13, P5070, DOI 10.1128/MCB.13.8.5070; Brazer SCW, 2000, YEAST, V16, P149, DOI 10.1002/(SICI)1097-0061(20000130)16:2<149::AID-YEA514>3.0.CO;2-C; Breeding CS, 1998, MOL BIOL CELL, V9, P3399, DOI 10.1091/mbc.9.12.3399; Breton AM, 1998, CURR GENET, V34, P280, DOI 10.1007/s002940050397; Butler MH, 1997, J CELL BIOL, V137, P1355, DOI 10.1083/jcb.137.6.1355; Colwill K, 1999, GENETICS, V152, P881; CROUZET M, 1991, YEAST, V7, P727, DOI 10.1002/yea.320070708; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DuHadaway JB, 2001, CANCER RES, V61, P3151; Elliott K, 2000, ONCOGENE, V19, P4669, DOI 10.1038/sj.onc.1203681; FANTES P, 1977, EXP CELL RES, V107, P377, DOI 10.1016/0014-4827(77)90359-7; Galderisi U, 1999, J CELL BIOCHEM, V74, P313, DOI 10.1002/(SICI)1097-4644(19990901)74:3<313::AID-JCB1>3.3.CO;2-Q; Gao C, 2001, J CELL SCI, V114, P1145; Ge K, 2000, INT J CANCER, V86, P155, DOI 10.1002/(SICI)1097-0215(20000415)86:2<155::AID-IJC2>3.0.CO;2-M; Ge K, 1999, P NATL ACAD SCI USA, V96, P9689, DOI 10.1073/pnas.96.17.9689; Ge K, 2000, INT J CANCER, V85, P376; Ge K, 2000, GENOMICS, V67, P210, DOI 10.1006/geno.2000.6216; Hogarty MD, 2000, MED PEDIATR ONCOL, V35, P559, DOI 10.1002/1096-911X(20001201)35:6<559::AID-MPO14>3.3.CO;2-A; Huang DQ, 1999, P NATL ACAD SCI USA, V96, P14445, DOI 10.1073/pnas.96.25.14445; Kanoh J, 1998, MOL BIOL CELL, V9, P3321, DOI 10.1091/mbc.9.12.3321; Lee J, 1998, CURR BIOL, V8, P1310, DOI 10.1016/S0960-9822(07)00561-1; Li FQ, 2000, MOL CELL BIOL, V20, P5129, DOI 10.1128/MCB.20.14.5129-5139.2000; Lila T, 1997, MOL BIOL CELL, V8, P367, DOI 10.1091/mbc.8.2.367; Mao NC, 1999, GENOMICS, V56, P51, DOI 10.1006/geno.1998.5709; MARKS J, 1986, J CELL SCI, P229; Matsumoto T, 1997, MOL CELL BIOL, V17, P742, DOI 10.1128/MCB.17.2.742; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Pelloquin L, 1999, FEBS LETT, V443, P71, DOI 10.1016/S0014-5793(98)01682-2; PRAMANIK A, 1995, CELL MOL BIOL, V41, pS73; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; Ramjaun AR, 1998, J NEUROCHEM, V70, P2369; Routhier EL, 2001, J BIOL CHEM, V276, P21670, DOI 10.1074/jbc.M101096200; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; SAZER S, 1990, J CELL SCI, V97, P509; SIVADON P, 1995, MOL GEN GENET, V246, P485, DOI 10.1007/BF00290452; Tsutsui K, 1997, BIOCHEM BIOPH RES CO, V236, P178, DOI 10.1006/bbrc.1997.6927; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; Wechsler-Reya RJ, 1998, MOL CELL BIOL, V18, P566, DOI 10.1128/MCB.18.1.566; WechslerReya R, 1997, J BIOL CHEM, V272, P31453, DOI 10.1074/jbc.272.50.31453; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; Yin MB, 1999, INT J CANCER, V83, P341, DOI 10.1002/(SICI)1097-0215(19991029)83:3<341::AID-IJC9>3.0.CO;2-3; Zhang Q, 1997, DEV BIOL, V183, P222, DOI 10.1006/dbio.1996.8494	51	24	25	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2003	22	5					637	648		10.1038/sj.onc.1206162	http://dx.doi.org/10.1038/sj.onc.1206162			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569356				2022-12-28	WOS:000180642100001
J	Tsou, AP; Yang, CW; Huang, CYF; Yu, RCT; Lee, YCG; Chang, CW; Chen, BR; Chung, YF; Fann, MJ; Chi, CW; Chiu, JH; Chou, CK				Tsou, AP; Yang, CW; Huang, CYF; Yu, RCT; Lee, YCG; Chang, CW; Chen, BR; Chung, YF; Fann, MJ; Chi, CW; Chiu, JH; Chou, CK			Identification of a novel cell cycle regulated gene, HURP, overexpressed in human hepatocellular carcinoma	ONCOGENE			English	Article						HURP; heptocellular carcinoma; liver regeneration; cell cycle regulator; bioinformatics	MITOTIC CHECKPOINT GENES; LIVER-REGENERATION; HUMAN CANCERS; HEPATITIS-B; EXPRESSION; KINASE; PROGRESSION; PATHOGENESIS; MUTATIONS; HOMOLOG	An analytic strategy was followed to identify putative regulatory genes during the development of human hepatocellular carcinoma (HCC). This strategy employed a bioinformatics analysis that used a database search to identify genes, which are differentially expressed in human HCC and are also under cell cycle regulation. A novel cell cycle regulated gene (HURP) that is overexpressed in HCC was identified. Full-length cDNAs encoding the human and mouse HURP genes were isolated. They share 72 and 61% identity at the nucleotide level and amino-acid level, respectively. Endogenous levels of HURP mRNA were found to be tightly regulated during cell cycle progression as illustrated by its elevated expression in the G(2)/M phase of synchronized HeLa cells and in regenerating mouse liver after partial hepatectomy. Immunofluorescence studies revealed that hepatoma up-regulated protein (HURP) localizes to the spindle poles during mitosis. Overexpression of HURP in 293T cells resulted in an enhanced cell growth at low serum levels and at polyhema-based, anchorage-independent growth assay. Taken together, these results strongly suggest that HURP is a potential novel cell cycle regulator that may play a role in the carcinogenesis of human cancer cells.	Natl Yang Ming Univ, Dept Life Sci, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Biotechnol Med, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan; Natl Hlth Res Inst, Div Mol & Genom Med, Taipei 115, Taiwan; Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Genet, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Neurosci, Taipei 112, Taiwan; Vet Gen Hosp, Dept Med Res & Educ, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Pharmacol, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Tradit Med, Taipei 112, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Health Research Institutes - Taiwan; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	Chou, CK (corresponding author), Natl Yang Ming Univ, Dept Life Sci, Taipei 112, Taiwan.		Huang, Chi-Ying/AFL-7729-2022; Huang, Chi-Ying/AAG-7672-2022	Huang, Chi-Ying/0000-0003-4898-4937; Huang, Chi-Ying/0000-0003-4898-4937				Albrecht JH, 1999, CELL GROWTH DIFFER, V10, P397; Bassal S, 2001, GENOMICS, V77, P5, DOI 10.1006/geno.2001.6570; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bosch FX, 1999, SEMIN LIVER DIS, V19, P271, DOI 10.1055/s-2007-1007117; Boyer N, 2000, J HEPATOL, V32, P98, DOI 10.1016/S0168-8278(00)80419-5; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Cho RJ, 2001, NAT GENET, V27, P48, DOI 10.1038/83751; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Feitelson MA, 1997, AM J PATHOL, V150, P1141; Ferea TL, 1999, CURR OPIN GENET DEV, V9, P715, DOI 10.1016/S0959-437X(99)00033-7; Hansen LK, 1999, J CELL SCI, V112, P2971; Higgins GM, 1931, ARCH PATHOL, V12, P186; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Kawada M, 1997, BIOCHEM BIOPH RES CO, V231, P735, DOI 10.1006/bbrc.1997.6179; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Menjo M, 1998, J GASTROEN HEPATOL, V13, pS100; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Nelsen CJ, 2001, ONCOGENE, V20, P1825, DOI 10.1038/sj.onc.1204248; Okabe H, 2001, CANCER RES, V61, P2129; Okuda K, 2000, J HEPATOL, V32, P225, DOI 10.1016/S0168-8278(00)80428-6; Pfleger CM, 2000, GENE DEV, V14, P655; SU Q, 1994, HEPATOLOGY, V20, P788, DOI 10.1002/hep.1840200404; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; Tsou AP, 1998, GENOMICS, V50, P331, DOI 10.1006/geno.1998.5338; Tsukasaki K, 2001, ONCOGENE, V20, P3301, DOI 10.1038/sj.onc.1204421; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	29	116	122	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 16	2003	22	2					298	307		10.1038/sj.onc.1206129	http://dx.doi.org/10.1038/sj.onc.1206129			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527899				2022-12-28	WOS:000180322400015
J	Nair, A; Venkatraman, M; Maliekall, TT; Nair, B; Karunagaran, D				Nair, A; Venkatraman, M; Maliekall, TT; Nair, B; Karunagaran, D			NF-kappa B is constitutively activated in high-grade squamous intraepithelial lesions and squamous cell carcinomas of the human uterine cervix	ONCOGENE			English	Article						NF-kappa B; Re1A; I kappa B; cervical cancer; immunohistochemistry	BREAST-CANCER; INDUCED APOPTOSIS; TRANSCRIPTION FACTOR; DNA-BINDING; EXPRESSION; ALPHA; PROTEIN; INHIBITOR; DEATH; GENES	We demonstrate, for the first time, that the transcription factor NF-kappaB is constitutively activated during human cervical cancer progression. Immunohistochemical analysis was done using 106 paraffin-embedded cervical tissue specimens of different histological grades. In normal cervical tissue and low-grade squamous intraepithelial lesions, p50, RelA and IkappaB-alpha were mainly localized in the cytosol, whereas in high-grade lesions and squamous cell carcinomas, p50-RelA heterodimers translocated into the nucleus with a concurrent decrease in IkappaB-alpha protein. By Western blot analysis, p50 and RelA were detectable mainly in the cytosolic and nuclear extracts in normal and cancer tissues, respectively, and cytosolic IkappaB-alpha expression was detectable in normal but not in cancer cervical tissues. NF-kappaB DNA-binding activity increased during cervical cancer progression and the binding complex was mainly composed of the p50-RelA heterodimers as revealed by electrophoretic mobility shift assays. Semi-quantitative RT-PCR analysis, however, showed increased levels of IkappaB-alpha mRNA in cancer samples presumably because of feedback regulation as a result of enhanced NF-kappaB DNA-binding activity and a consequent functional activation of NF-kappaB. Further immunohistochemical analysis with an antibody to phospho IkappaB-alpha revealed that phosphorylation occurs mainly in squamous intraepithelial lesions, suggesting that the IkappaB-alpha gets phosphorylated initially and degraded as the tumor progressed.	Rajiv Gandhi Ctr Biotechnol, Div Canc Biol, Thiruvananthapuram 695014, Kerala, India; Doctors Diagnost & Res Ctr, Dept Pathol, Thiruvananthapuram 695011, Kerala, India	Department of Biotechnology (DBT) India; Rajiv Gandhi Centre for Biotechnology (RGCB)	Karunagaran, D (corresponding author), Rajiv Gandhi Ctr Biotechnol, Div Canc Biol, Thiruvananthapuram 695014, Kerala, India.		Karunagaran, Devarajan/A-8148-2010	Karunagaran, Devarajan/0000-0001-9331-8947; Maliekal, Tessy/0000-0002-7311-7950				Anto RJ, 2000, J BIOL CHEM, V275, P15601, DOI 10.1074/jbc.C000105200; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; Barabas E, 2001, BRAZ J MED BIOL RES, V34, P1271, DOI 10.1590/S0100-879X2001001000006; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; BOURS V, 1994, BIOCHEM PHARMACOL, V47, P145, DOI 10.1016/0006-2952(94)90448-0; Budunova IV, 1999, ONCOGENE, V18, P7423, DOI 10.1038/sj.onc.1203104; Cabannes E, 1999, ONCOGENE, V18, P3063, DOI 10.1038/sj.onc.1202893; Cain JM, 2000, SCIENCE, V288, P1753, DOI 10.1126/science.288.5472.1753; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Chopra V, 1998, CANCER INVEST, V16, P152, DOI 10.3109/07357909809050029; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Cusack JC, 2001, CANCER RES, V61, P3535; Dejardin E, 1999, ONCOGENE, V18, P2567, DOI 10.1038/sj.onc.1202599; Fontaine V, 2000, VIROLOGY, V272, P40, DOI 10.1006/viro.2000.0363; Grendys EC, 1997, GYNECOL ONCOL, V65, P343, DOI 10.1006/gyno.1997.4649; Hazelbag S, 2001, GYNECOL ONCOL, V83, P235, DOI 10.1006/gyno.2001.6378; Herrmann JL, 1997, EXP CELL RES, V237, P101, DOI 10.1006/excr.1997.3737; Hockel M, 1999, CANCER RES, V59, P4525; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Lahiri DK, 2000, BRAIN RES PROTOC, V5, P257, DOI 10.1016/S1385-299X(00)00021-0; Li JJ, 2000, MOL CARCINOGEN, V29, P159, DOI 10.1002/1098-2744(200011)29:3<159::AID-MC5>3.0.CO;2-W; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Manna SK, 1999, J IMMUNOL, V162, P2095; Mori N, 1999, BLOOD, V93, P2360; Nair P, 1999, Pathol Oncol Res, V5, P95, DOI 10.1053/paor.1999.0161; Nair S. Asha, 1997, General and Diagnostic Pathology, V142, P297; Nair SA, 1998, TUMORI J, V84, P583, DOI 10.1177/030089169808400514; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Nees M, 2001, J VIROL, V75, P4283, DOI 10.1128/JVI.75.9.4283-4296.2001; Newton TR, 1999, J BIOL CHEM, V274, P18827, DOI 10.1074/jbc.274.26.18827; Nguyen HN, 1999, SEMIN SURG ONCOL, V16, P217, DOI 10.1002/(SICI)1098-2388(199904/05)16:3<217::AID-SSU4>3.0.CO;2-U; Pillai MR, 1996, CANCER EPIDEM BIOMAR, V5, P329; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Sankaranarayanan R, 2001, B WORLD HEALTH ORGAN, V79, P954; Sasaki N, 2001, CLIN CANCER RES, V7, P4136; Schoell WMJ, 1999, SEMIN SURG ONCOL, V16, P203, DOI 10.1002/(SICI)1098-2388(199904/05)16:3<203::AID-SSU2>3.0.CO;2-C; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Suk K, 2001, FEBS LETT, V495, P66, DOI 10.1016/S0014-5793(01)02335-3; Sumitomo M, 1999, J UROLOGY, V161, P674, DOI 10.1016/S0022-5347(01)61993-1; Tai DI, 2000, CANCER, V89, P2274, DOI 10.1002/1097-0142(20001201)89:11<2274::AID-CNCR16>3.0.CO;2-2; VAN AD, 1996, SCIENCE, V274, P787; Visconti R, 1997, ONCOGENE, V15, P1987, DOI 10.1038/sj.onc.1201373; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang WX, 1999, CLIN CANCER RES, V5, P119; Wei LH, 2001, ONCOGENE, V20, P5799, DOI 10.1038/sj.onc.1204733; WOODWORTH CD, 1995, P NATL ACAD SCI USA, V92, P2840, DOI 10.1073/pnas.92.7.2840; Yang JM, 2001, CANCER RES, V61, P4901; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	54	127	150	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 9	2003	22	1					50	58		10.1038/sj.onc.1206043	http://dx.doi.org/10.1038/sj.onc.1206043			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527907				2022-12-28	WOS:000180166900006
J	Ren, RB				Ren, RB			The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine model	ONCOGENE			English	Review						CML; BCR-ABL; mouse model; signalling; oncogene cooperation	CHRONIC MYELOID-LEUKEMIA; COLONY-STIMULATING FACTOR; SEQUENCE BINDING-PROTEIN; ABL TYROSINE KINASE; ACUTE LYMPHOBLASTIC-LEUKEMIA; COILED-COIL DOMAIN; P210 BCR-ABL; MYELOPROLIFERATIVE DISEASE; INTERFERON-ALPHA; SH2 DOMAIN	Chronic myelogenous leukemia (CML) is a malignant disease resulting from the neoplastic transformation of a hematopoietic stem cell. Generation of the BCR-ABL fusion gene plays an essential role in causing the vast majority of CML. Clinical and laboratory studies have indicated that development of CML involves both the effects of BCR-ABL within its correct target cells and interactions of BCR-ABL target cells with the rest of the in vivo environment, and that the progression of the disease to blast crisis involves multiple genetic alterations. An efficient mouse bone marrow transduction and transplantation model for CML has recently been developed. This review summarizes the analysis of the roles of functional domains and downstream signaling pathways of BCR-ABL, of altered cytokine production, of interferon signaling pathways and of oncogene cooperation in the pathogenesis of CML using this murine model. The in vivo studies of leukemogenesis will help to advance mechanism-based therapies for CML, as well as to understand fundamental rules of leukemogenesis and hematopoiesis.	Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Dept Biol, Waltham, MA 02454 USA	Brandeis University	Ren, RB (corresponding author), Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Dept Biol, MS029,415 South St, Waltham, MA 02454 USA.	ren@brandeis.edu			NATIONAL CANCER INSTITUTE [R01CA068008] Funding Source: NIH RePORTER; NCI NIH HHS [CA 68008] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; AHUJA HG, 1990, BLOOD, V75, P1684; Ahuja HG, 2001, GENE CHROMOSOME CANC, V30, P410, DOI 10.1002/1098-2264(2001)9999:9999<::AID-GCC1108>3.0.CO;2-9; Bhatia R, 1998, LEUKEMIA LYMPHOMA, V28, P241, DOI 10.3109/10428199809092680; Bonifazi F, 2001, BLOOD, V98, P3074, DOI 10.1182/blood.V98.10.3074; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Buchdunger E, 1996, CANCER RES, V56, P100; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Castellanos A, 1997, BLOOD, V90, P2168, DOI 10.1182/blood.V90.6.2168.2168_2168_2174; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; Colovic M, 1998, MED ONCOL, V15, P199, DOI 10.1007/BF02821939; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; Cuenco GM, 2000, P NATL ACAD SCI USA, V97, P1760, DOI 10.1073/pnas.030421197; Cuenco GM, 2001, ONCOGENE, V20, P8236, DOI 10.1038/sj.onc.1205095; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1991, P NATL ACAD SCI USA, V88, P11335, DOI 10.1073/pnas.88.24.11335; de Groot RP, 1999, BLOOD, V94, P1108, DOI 10.1182/blood.V94.3.1108.415k07_1108_1112; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Deng M, 2001, BLOOD, V97, P3491, DOI 10.1182/blood.V97.11.3491; Druker B J, 2001, Hematology Am Soc Hematol Educ Program, P87; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; ElAhmady O, 1997, ANTICANCER RES, V17, P3179; ELEFANTY AG, 1992, MOL CELL BIOL, V12, P1755, DOI 10.1128/MCB.12.4.1755; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; Era T, 2000, P NATL ACAD SCI USA, V97, P1737, DOI 10.1073/pnas.97.4.1737; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; Frank DA, 1996, LEUKEMIA, V10, P1724; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; Gabriele L, 1999, J EXP MED, V190, P411, DOI 10.1084/jem.190.3.411; Ghaffari S, 1999, LEUKEMIA, V13, P1200, DOI 10.1038/sj.leu.2401467; GISHIZKY ML, 1993, P NATL ACAD SCI USA, V90, P3755, DOI 10.1073/pnas.90.8.3755; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; Goldman JM, 2001, BLOOD, V98, P2039, DOI 10.1182/blood.V98.7.2039; Golub TR, 1996, MOL CELL BIOL, V16, P4107; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Gross AW, 1999, MOL CELL BIOL, V19, P6918; Gross AW, 2000, ONCOGENE, V19, P6286, DOI 10.1038/sj.onc.1204023; Hao SX, 2000, MOL CELL BIOL, V20, P1149, DOI 10.1128/MCB.20.4.1149-1161.2000; Harada H, 1998, BIOCHIMIE, V80, P641, DOI 10.1016/S0300-9084(99)80017-0; HAWLEY RG, 1994, ANN NY ACAD SCI, V716, P327, DOI 10.1111/j.1749-6632.1994.tb21724.x; He YP, 2002, BLOOD, V99, P2957, DOI 10.1182/blood.V99.8.2957; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; Heisterkamp Nora, 1991, Transgenic Research, V1, P45, DOI 10.1007/BF02512996; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Honda H, 2000, BLOOD, V95, P1144, DOI 10.1182/blood.V95.4.1144.004k04_1144_1150; HONDA H, 1995, BLOOD, V85, P2853, DOI 10.1182/blood.V85.10.2853.bloodjournal85102853; Honda H, 1998, BLOOD, V91, P2067, DOI 10.1182/blood.V91.6.2067.2067_2067_2075; Huettner CS, 2000, NAT GENET, V24, P57, DOI 10.1038/71691; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; ILARIA RL, 1995, BLOOD, V86, P3897, DOI 10.1182/blood.V86.10.3897.bloodjournal86103897; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JANSSEN JWG, 1995, BRIT J HAEMATOL, V90, P222, DOI 10.1111/j.1365-2141.1995.tb03407.x; Jiang XY, 1999, P NATL ACAD SCI USA, V96, P12804, DOI 10.1073/pnas.96.22.12804; Jonuleit T, 1998, BRIT J HAEMATOL, V100, P295, DOI 10.1046/j.1365-2141.1998.00564.x; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KELLIHER MA, 1993, ONCOGENE, V8, P1249; Kieslinger M, 2000, GENE DEV, V14, P232; Landolfo S, 2000, Hematol J, V1, P7, DOI 10.1038/sj.thj.6200004; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Li SG, 2001, BLOOD, V97, P1442, DOI 10.1182/blood.V97.5.1442; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; Melo JV, 1997, BAILLIERE CLIN HAEM, V10, P203, DOI 10.1016/S0950-3536(97)80003-0; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Million RP, 2000, BLOOD, V96, P664; Mittrucker HW, 1997, SCIENCE, V275, P540, DOI 10.1126/science.275.5299.540; NEUBAUER A, 1994, BLOOD, V83, P1603; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Niki M, 1997, P NATL ACAD SCI USA, V94, P5697, DOI 10.1073/pnas.94.11.5697; O'Dwyer ME, 2001, J INTERN MED, V250, P3, DOI 10.1046/j.1365-2796.2001.00823.x; ODA T, 1995, LEUKEMIA, V9, P295; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Pane F, 1999, BLOOD, V94, P2200, DOI 10.1182/blood.V94.7.2200.419a33_2200_2207; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; Pfeffer LM, 1998, CANCER RES, V58, P2489; Pluk H, 2002, CELL, V108, P247, DOI 10.1016/S0092-8674(02)00623-2; Ren RB, 2002, LEUKEMIA LYMPHOMA, V43, P1549, DOI 10.1080/1042819021000002875; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; Roumiantsev S, 2001, BLOOD, V97, P4, DOI 10.1182/blood.V97.1.4; Sawyers CL, 2001, SEMIN HEMATOL, V38, P15, DOI 10.1053/shem.2001.27078; Sawyers CL, 1997, BAILLIERE CLIN HAEM, V10, P223, DOI 10.1016/S0950-3536(97)80004-2; Scheijen B, 2001, BLOOD, V98, p144A; Schmidt M, 1998, BLOOD, V91, P22, DOI 10.1182/blood.V91.1.22.22_22_29; Schmidt M, 2001, BLOOD, V97, P3648, DOI 10.1182/blood.V97.11.3648; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; Shuai K, 1996, ONCOGENE, V13, P247; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Sood R, 1999, LEUKEMIA, V13, P348, DOI 10.1038/sj.leu.2401360; Talpaz M, 2001, SEMIN HEMATOL, V38, P22, DOI 10.1053/shem.2001.27080; Tamura T, 2000, IMMUNITY, V13, P155, DOI 10.1016/S1074-7613(00)00016-9; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Van Etten RA, 2001, BLOOD CELL MOL DIS, V27, P201, DOI 10.1006/bcmd.2000.0370; Verfaillie CM, 1997, ACTA HAEMATOL-BASEL, V97, P40; VONCKEN JW, 1995, BLOOD, V86, P4603, DOI 10.1182/blood.V86.12.4603.bloodjournal86124603; VONCKEN JW, 1992, CANCER RES, V52, P4534; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Wolff NC, 2001, BLOOD, V98, P2808, DOI 10.1182/blood.V98.9.2808; Wong S, 2001, ONCOGENE, V20, P5644, DOI 10.1038/sj.onc.1204638; YAISH P, 1988, SCIENCE, V242, P933, DOI 10.1126/science.3263702; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Zhang XW, 1998, BLOOD, V92, P3829, DOI 10.1182/blood.V92.10.3829; Zhang XW, 2001, BLOOD, V97, P277, DOI 10.1182/blood.V97.1.277; Zhang XW, 2001, MOL CELL BIOL, V21, P840, DOI 10.1128/MCB.21.3.840-853.2001; Zhao X, 2002, NAT STRUCT BIOL, V9, P117; Zou XM, 1999, J BIOL CHEM, V274, P18141, DOI 10.1074/jbc.274.26.18141	116	36	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2002	21	56					8629	8642		10.1038/sj.onc.1206090	http://dx.doi.org/10.1038/sj.onc.1206090			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZF	12476309				2022-12-28	WOS:000179734300012
J	Shore, SK; Tantravahi, RV; Reddy, EP				Shore, SK; Tantravahi, RV; Reddy, EP			Transforming pathways activated by the v-Abl tyrosine kinase	ONCOGENE			English	Article						A-MuLV; tyrosine kinase; transformation; cytokines; apoptosis; signal transduction	MURINE LEUKEMIA-VIRUS; NF-KAPPA-B; C-MYC TRANSCRIPTION; ABELSON-VIRUS; PROTEIN-KINASE; INTERLEUKIN-3 DEPENDENCE; LYMPHOID-CELLS; IN-VITRO; PHOSPHATIDYLINOSITOL 3-KINASE; ONCOGENIC TRANSFORMATION	The Abelson Murine Leukemia Virus (A-MuLV) is the acute transforming retrovirus encoding the v-abl oncogene. Two isolates of the virus encoding proteins of p120 Kd and 160 Kd have been extensively studied. These viral isolates have been found to transform both hematopoietic and fibroblastic cells in vitro, while inducing predominantly pre-B cell leukemias in vivo. Both p120(v-Abl) and p160(v-Abl) are plasma membrane-associated non-receptor tyrosine kinases and the transforming activity of these proteins requires their tyrosine kinase activity. A-MuLV infection of hematopoietic cells has often been found to result in the abrogation of their cytokine-dependence for growth. In addition, v-Abl expressing hematopoietic cells often lose their ability to differentiate in response to appropriate cytokines. This review discusses some of the early transformation studies of A-MuLV, as well as some of the findings concerning the structure and biochemical activity of the v-Abl protein. Finally, we discuss the mechanisms associated with v-Abl mediated transformation through examination of the various signal transduction pathways activated by this oncogene.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Reddy, EP (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.	reddy@unix.temple.edu	Reddy, E. Premkumar/F-6233-2011					ABELSON HT, 1970, CANCER RES, V30, P2208; ABELSON HT, 1970, CANCER RES, V30, P2213; Banerjee A, 1998, J IMMUNOL, V161, P4611; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; Burfoot MS, 1997, J BIOL CHEM, V272, P24183, DOI 10.1074/jbc.272.39.24183; Chen CF, 1999, J COMPUT ACOUST, V7, P15, DOI 10.1142/S0218396X99000035; CHEN YY, 1994, GENE DEV, V8, P688, DOI 10.1101/gad.8.6.688; CHEN YY, 1992, P NATL ACAD SCI USA, V89, P6683, DOI 10.1073/pnas.89.15.6683; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; Cong F, 1999, MOL CELL BIOL, V19, P8314; Cong F, 1999, ONCOGENE, V18, P7731, DOI 10.1038/sj.onc.1203290; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; Coutts M, 2000, ONCOGENE, V19, P801, DOI 10.1038/sj.onc.1203398; Danial NN, 1998, MOL CELL BIOL, V18, P6795, DOI 10.1128/MCB.18.11.6795; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Di Cristofano A, 2001, J EXP MED, V194, P275, DOI 10.1084/jem.194.3.275; ENGELMAN A, 1990, MOL CELL BIOL, V10, P4365, DOI 10.1128/MCB.10.8.4365; EVANS CA, 1995, J CELL SCI, V108, P2591; Foo SY, 1999, TRENDS GENET, V15, P229; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GREEN PL, 1989, J VIROL, V63, P1989, DOI 10.1128/JVI.63.5.1989-1994.1989; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hinz M, 1999, MOL CELL BIOL, V19, P2690; HORI Y, 1990, ONCOGENE, V5, P1201; Huang TS, 1996, ONCOGENE, V13, P625; HUNTER T, 1993, NATURE, V366, P114, DOI 10.1038/366114a0; Jahn T, 2001, J BIOL CHEM, V276, P43419, DOI 10.1074/jbc.M107030200; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KELLER JR, 1990, ONCOGENE, V5, P549; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KIPREOS ET, 1988, ONCOGENE RES, V2, P277; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KLUG CA, 1994, GENE DEV, V8, P678, DOI 10.1101/gad.8.6.678; LATT SA, 1983, J VIROL, V45, P1195, DOI 10.1128/JVI.45.3.1195-1199.1983; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; MATHEYPREVOT B, 1988, MOL CELL BIOL, V8, P234, DOI 10.1128/MCB.8.1.234; MCGAHON AJ, 1995, J BIOL CHEM, V270, P22625, DOI 10.1074/jbc.270.38.22625; MOLONEY JB, 1960, J NATL CANCER I, V24, P933; NEPVEU A, 1985, NATURE, V317, P440, DOI 10.1038/317440a0; OPPI C, 1987, P NATL ACAD SCI USA, V84, P8200, DOI 10.1073/pnas.84.23.8200; OWEN PJ, 1993, J BIOL CHEM, V268, P15696; Parmar K, 1996, J VIROL, V70, P1009, DOI 10.1128/JVI.70.2.1009-1015.1996; PREMKUMAR E, 1975, CELL, V6, P149, DOI 10.1016/0092-8674(75)90005-7; PRYWES R, 1983, CELL, V34, P569, DOI 10.1016/0092-8674(83)90389-6; PRYWES R, 1985, J VIROL, V54, P114, DOI 10.1128/JVI.54.1.114-122.1985; RABSTEIN LS, 1971, J NATL CANCER I, V46, P481; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Raffel GD, 1996, J BIOL CHEM, V271, P4640; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; RASCHKE WC, 1975, J NATL CANCER I, V54, P1249, DOI 10.1093/jnci/54.5.1249; REDDY E P, 1980, Cell, V19, P663, DOI 10.1016/S0092-8674(80)80043-2; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; Renshaw MW, 1996, CURR BIOL, V6, P76, DOI 10.1016/S0960-9822(02)00424-4; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; ROSENBERG N, 1976, J EXP MED, V143, P1453, DOI 10.1084/jem.143.6.1453; ROSENBERG N, 1975, P NATL ACAD SCI USA, V72, P1932, DOI 10.1073/pnas.72.5.1932; ROSENBERG N, 1980, COLD SPRING HARB SYM, V44, P859, DOI 10.1101/SQB.1980.044.01.092; ROSENBERG N, 1980, J VIROL, V33, P340, DOI 10.1128/JVI.33.1.340-348.1980; ROSENBERG NE, 1980, J VIROL, V36, P766, DOI 10.1128/JVI.36.3.766-774.1980; ROVERA G, 1987, ONCOGENE, V1, P29; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; SAEZ E, 1995, CANCER RES, V55, P6196; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SCHER CD, 1975, NATURE, V253, P729, DOI 10.1038/253729a0; SCHULTZ A, 1984, VIROLOGY, V133, P431, DOI 10.1016/0042-6822(84)90409-4; SIEGLER R, 1972, J NATL CANCER I, V48, P189; SKLAR MD, 1974, P NATL ACAD SCI USA, V71, P4077, DOI 10.1073/pnas.71.10.4077; Songyang Z, 2001, J BIOL CHEM, V276, P2459, DOI 10.1074/jbc.M005504200; SRINIVASAN A, 1981, P NATL ACAD SCI-BIOL, V78, P2077, DOI 10.1073/pnas.78.4.2077; SRINIVASAN A, 1982, P NATL ACAD SCI-BIOL, V79, P5508, DOI 10.1073/pnas.79.18.5508; STACEY DW, 1991, ONCOGENE, V6, P2297; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Tang XW, 2000, J BIOL CHEM, V275, P13142, DOI 10.1074/jbc.275.17.13142; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; Thome KC, 1997, J VIROL, V71, P8149, DOI 10.1128/JVI.71.11.8149-8156.1997; Unnikrishnan I, 1999, MOL CELL BIOL, V19, P4825, DOI 10.1128/mcb.19.7.4825; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; WANECK GL, 1986, CELL, V44, P337, DOI 10.1016/0092-8674(86)90768-3; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WANG JYJ, 1984, CELL, V36, P349; WANG N, 1993, FOCUS, V3, P3; WHITLOCK CA, 1983, MOL CELL BIOL, V3, P596, DOI 10.1128/MCB.3.4.596; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837; WITTE ON, 1980, COLD SPRING HARB SYM, V44, P855, DOI 10.1101/SQB.1980.044.01.091; WITTE ON, 1980, NATURE, V283, P826, DOI 10.1038/283826a0; WONG KK, 1995, MOL CELL BIOL, V15, P6535; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Zhu JY, 1996, BLOOD, V87, P4368, DOI 10.1182/blood.V87.10.4368.bloodjournal87104368; ZIEGLER SF, 1981, CELL, V27, P477, DOI 10.1016/0092-8674(81)90389-5; Zou XM, 1997, GENE DEV, V11, P654, DOI 10.1101/gad.11.5.654; Zou XM, 2000, MOL CELL BIOL, V20, P628, DOI 10.1128/MCB.20.2.628-633.2000	98	29	30	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2002	21	56					8568	8576		10.1038/sj.onc.1206084	http://dx.doi.org/10.1038/sj.onc.1206084			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZF	12476303	Bronze			2022-12-28	WOS:000179734300006
J	Tworkowski, KA; Salghetti, SE; Tansey, WP				Tworkowski, KA; Salghetti, SE; Tansey, WP			Stable and unstable pools of Myc protein exist in human cells	ONCOGENE			English	Article						Myc; Max; ubiquitin-mediated proteolysis	UBIQUITIN-MEDIATED PROTEOLYSIS; C-MYC; IN-VIVO; BURKITTS-LYMPHOMA; CDK INHIBITOR; DNA-BINDING; DEGRADATION; PATHWAY; DOMAIN; TRANSCRIPTION	The oncoprotein transcription factor Myc plays a crucial role in the control of cell growth and proliferation. Consistent with its potent growth-promoting properties, cells have evolved a number of mechanisms to limit the activity and accumulation of the Myc protein. One of the most striking of these mechanisms is ubiquitin (Ub)-mediated proteolysis, which typically destroys Myc within minutes of its synthesis. Here we show that, despite the extreme instability of the Myc protein, cells contain a pool of Myc that is metabolically stable. Entry of Myc into the stable pool is signaled by an element within the carboxy-terminus of the protein, and is a cell-specific process that is regulated during mitosis and by interaction with Max. These data demonstrate that even for a rapidly turned-over protein such as Myc metabolically stable and unstable forms of a protein can co-exist in cells, and suggest that the rate of destruction of Myc molecules is linked to their specific functions.	SUNY Stony Brook, Mol & Cellular Biol Program, Stony Brook, NY 11794 USA; Cold Spring Harbor Lab, New York, NY 11724 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Cold Spring Harbor Laboratory	Tansey, WP (corresponding author), SUNY Stony Brook, Mol & Cellular Biol Program, Stony Brook, NY 11794 USA.				NATIONAL CANCER INSTITUTE [P30CA045508, P01CA013106] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008468] Funding Source: NIH RePORTER; NCI NIH HHS [CA-13106, CA45508] Funding Source: Medline; NIGMS NIH HHS [1T32-GM08468] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu Hatoum O, 1998, MOL CELL BIOL, V18, P5670, DOI 10.1128/MCB.18.10.5670; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; EVAN GI, 1985, CELL, V43, P253, DOI 10.1016/0092-8674(85)90030-3; Furstenthal L, 2001, NAT CELL BIOL, V3, P715, DOI 10.1038/35087026; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Hancock R, 2000, CHROMOSOMA, V109, P219, DOI 10.1007/s004120000077; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Mendez J, 2002, MOL CELL, V9, P481, DOI 10.1016/S1097-2765(02)00467-7; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; Niklinski J, 2000, MOL CELL BIOL, V20, P5276, DOI 10.1128/MCB.20.14.5276-5284.2000; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; PRESCOTT DM, 1962, EXP CELL RES, V26, P260, DOI 10.1016/0014-4827(62)90176-3; Rudolph C, 1999, ANAL BIOCHEM, V269, P66, DOI 10.1006/abio.1999.3095; Sacco-Bubulya P, 2002, J CELL BIOL, V156, P425, DOI 10.1083/jcb.200107017; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Salghetti SE, 2000, P NATL ACAD SCI USA, V97, P3118, DOI 10.1073/pnas.050007597; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5	25	36	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 5	2002	21	55					8515	8520		10.1038/sj.onc.1205976	http://dx.doi.org/10.1038/sj.onc.1205976			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466972				2022-12-28	WOS:000179480100015
J	Stead, E; White, J; Faast, R; Conn, S; Goldstone, S; Rathjen, J; Dhingra, U; Rathjen, P; Walker, D; Dalton, S				Stead, E; White, J; Faast, R; Conn, S; Goldstone, S; Rathjen, J; Dhingra, U; Rathjen, P; Walker, D; Dalton, S			Pluripotent cell division cycles are driven by ectopic Cdk2, cyclin A/E and E2F activities	ONCOGENE			English	Article						cell cycle; pluripotent; stem cell	EMBRYONIC STEM-CELLS; DIFFERENTIATION INHIBITING ACTIVITY; RETINOIC ACID; MOUSE EMBRYOS; BREAST-CANCER; ES CELLS; RETINOBLASTOMA PROTEIN; REGULATED EXPRESSION; GERM-CELLS; IN-VITRO	Pluripotent cells of embryonic origin proliferate at unusually rapid rates and have a characteristic cell cycle structure with truncated gap phases. To define the molecular basis for this we have characterized the cell cycle control of murine embryonic stem cells and early primitive ectoderm-like cells. These cells display precocious Cdk2, cyclin A and cyclin E kinase activities that are conspicuously cell cycle independent. Suppression of Cdk2 activity significantly decreased cycling times of pluripotent cells, indicating it to be rate-limiting for rapid cell division, although this had no impact on cell cycle structure and the establishment of extended gap phases. Cdc2-cyclin B was the only Cdk activity that was identified to be cell cycle regulated in pluripotent cells. Cell cycle regulation of cyclin B levels and Y-15 regulation of Cdc2 contribute to the temporal changes in Cdc2-cyclin B activity. E2F target genes are constitutively active throughout the cell cycle, reflecting the low activity of pocket proteins such as p107 and pRb and constitutive activity of pRb-kinases. These results show that rapid cell division cycles in primitive cells of embryonic origin are driven by extreme levels of Cdk activity that lack normal cell cycle periodicity.	Univ Adelaide, Dept Mol Biosci, Adelaide, SA 5005, Australia; Univ Adelaide, Ctr Mol Genet Dev, Adelaide, SA 5005, Australia; Univ Adelaide, BresaGen Luminis Cell Therapy Program, Adelaide, SA 5005, Australia; Hoffmann La Roche, Nutley, NJ 07110 USA	University of Adelaide; University of Adelaide; University of Adelaide; Roche Holding	Dalton, S (corresponding author), Univ Adelaide, Dept Mol Biosci, Adelaide, SA 5005, Australia.	Stephen.Dalton@adelaide.edu.au	Conn, Simon/G-1191-2012	Conn, Simon/0000-0002-1376-4515; Wright, Josephine/0000-0003-4588-8827				BEDDINGTON RSP, 1989, DEVELOPMENT, V105, P733; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; Brook FA, 1997, P NATL ACAD SCI USA, V94, P5709, DOI 10.1073/pnas.94.11.5709; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; CHISHOLM JC, 1985, J EMBRYOL EXP MORPH, V86, P311; DHINGRA UH, 1998, Patent No. 5811420; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Edgar BA, 1996, SCIENCE, V274, P1646, DOI 10.1126/science.274.5293.1646; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Gabrielli BG, 1997, J BIOL CHEM, V272, P28607, DOI 10.1074/jbc.272.45.28607; GARDNER RL, 1988, J CELL SCI, P11; GARDNER RL, 1979, J EMBRYOL EXP MORPH, V52, P141; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; GrayBablin J, 1996, P NATL ACAD SCI USA, V93, P15215, DOI 10.1073/pnas.93.26.15215; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; Haas K, 1997, ONCOGENE, V15, P2615, DOI 10.1038/sj.onc.1201434; Harwell RM, 2000, CANCER RES, V60, P481; HAUB O, 1991, DEVELOPMENT, V112, P397; HEBERT JM, 1990, DEV BIOL, V138, P454, DOI 10.1016/0012-1606(90)90211-Z; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HOGAN B, 1989, MANIPULATING MOUSE E; HOSLER BA, 1989, MOL CELL BIOL, V9, P5623, DOI 10.1128/MCB.9.12.5623; Hu B, 2001, MOL CELL BIOL, V21, P2755, DOI 10.1128/MCB.21.8.2755-2766.2001; Humbert PO, 2000, MOL CELL, V6, P281, DOI 10.1016/S1097-2765(00)00029-0; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; KEYOMARSI K, 1995, ONCOGENE, V11, P941; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; KRANENBURG O, 1995, ONCOGENE, V10, P87; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Lake JA, 2000, J CELL SCI, V113, P555; MACAULEY A, 1993, DEVELOPMENT, V117, P873; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; Meijer L, 1997, METHOD ENZYMOL, V283, P113; Mumberg D, 1996, ONCOGENE, V13, P2493; MUMMERY CL, 1987, DEV BIOL, V121, P10, DOI 10.1016/0012-1606(87)90133-3; MUMMERY CL, 1987, CELL DIFFER DEV, V20, P153, DOI 10.1016/0045-6039(87)90429-5; MURRAY A, 1993, CELL CYCLE; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; NICHOLS J, 1990, DEVELOPMENT, V110, P1341; Nielsen NH, 1997, ONCOGENE, V14, P295, DOI 10.1038/sj.onc.1200833; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Nurse P, 2000, CELL, V100, P71, DOI 10.1016/S0092-8674(00)81684-0; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PEASE S, 1990, DEV BIOL, V141, P344, DOI 10.1016/0012-1606(90)90390-5; PEDERSEN RA, 1994, REPROD FERT DEVELOP, V6, P543, DOI 10.1071/RD9940543; Pelton TA, 1998, REPROD FERT DEVELOP, V10, P535, DOI 10.1071/RD98084; POWER MA, 1993, ANAT EMBRYOL, V187, P493; Rathjen J, 1999, J CELL SCI, V112, P601; RATHJEN PD, 1990, GENE DEV, V4, P2308, DOI 10.1101/gad.4.12b.2308; REMPEL RE, 1995, J BIOL CHEM, V270, P6843, DOI 10.1074/jbc.270.12.6843; RESNICK JL, 1992, NATURE, V359, P550, DOI 10.1038/359550a0; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROGERS MB, 1991, DEVELOPMENT, V113, P815; Savatier P, 1996, ONCOGENE, V12, P309; SAVATIER P, 1994, ONCOGENE, V9, P809; SCHOLER HR, 1990, EMBO J, V9, P2185, DOI 10.1002/j.1460-2075.1990.tb07388.x; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; Smith C.S., 1999, Biological Invasions, V1, P89, DOI 10.1023/A:1010091918466; SNOW MHL, 1977, J EMBRYOL EXP MORPH, V42, P293; SOLTER D, 1971, EXP CELL RES, V64, P331, DOI 10.1016/0014-4827(71)90084-X; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Sweeney C, 1996, DEVELOPMENT, V122, P53; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Wianny F, 1998, DEV DYNAM, V212, P49, DOI 10.1002/(SICI)1097-0177(199805)212:1<49::AID-AJA5>3.0.CO;2-2; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; WIMMEL A, 1994, ONCOGENE, V9, P995; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Yarden A, 1996, DEV DYNAM, V206, P1	75	286	295	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 28	2002	21	54					8320	8333		10.1038/sj.onc.1206015	http://dx.doi.org/10.1038/sj.onc.1206015			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447695				2022-12-28	WOS:000179323900010
J	Rebbaa, A; Zheng, X; Chou, PM; Mirkin, BL				Rebbaa, A; Zheng, X; Chou, PM; Mirkin, BL			Caspase inhibition switches doxorubicin-induced apoptosis to senescence	ONCOGENE			English	Article						apoptosis; senescence; P21/WAF1; drug resistance	CYTOCHROME-C RELEASE; PROTEIN EXPRESSION; CANCER CELLS; DEATH; P53; RESISTANCE; SURVIVAL; PATHWAY; P21; CYTOTOXICITY	The inhibition of apoptosis is generally believed to be a major determinant of resistance to chemotherapy. However, recent findings have shown that caspase inhibitors do not protect cancer cells from death by cytotoxic agents, but may switch drug-induced apoptosis to an alternative 'default death'. The primary goals of this study were to determine the major characteristics of the 'default death' and the mechanism by which this switch is activated. For this purpose, we first investigated putative cell death modes induced by doxorubicin. Molecular markers associated with these death modes were utilized to identify the default death resulting from the inhibition of apoptosis. Our findings demonstrated that doxorubicin induced at least three distinct types of cell death, senescence, apoptosis and a type of necrosis, which were concentration dependent. Specific molecular markers such as p21/WAF1, activated caspase-3 and activated Akt were associated with these death modes. The pan-caspase inhibitor (Q-VD-OPH) greatly reduced doxorubicin-induced caspase-3 activation but did not protect cells against drug toxicity. The combination of doxorubicin and Q-VD-OPH caused an increased expression of p21/WAF1 and senescence -associated -beta-galactosidase activity, but did not alter Akt activation. Collectively, these findings suggest that the inhibition of apoptosis may lead to an increased expression of cell cycle inhibitors and cellular senescence.	Childrens Mem Hosp, Childrens Mem Inst Educ & Res, Dept Pediat, Chicago, IL 60614 USA; Childrens Mem Hosp, Childrens Mem Inst Educ & Res, Dept Pathol, Chicago, IL 60614 USA; Northwestern Univ, Feinberg Sch Med, Dept Biol Chem & Mol Pharmacol, Chicago, IL 60611 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine	Rebbaa, A (corresponding author), Childrens Mem Hosp, Childrens Mem Inst Educ & Res, Dept Pediat, M-C 224,2300 Childrens Plaza, Chicago, IL 60614 USA.	arebbaa@childrensmemorial.org						Ahrendt SA, 2000, SURGERY, V128, P520, DOI 10.1067/msy.2000.108052; Borst P, 2001, DRUG RESIST UPDATE, V4, P129, DOI 10.1054/drup.2001.0187; Brognard J, 2001, CANCER RES, V61, P3986; Brown JM, 1999, CANCER RES, V59, P1391; Chang BD, 2002, P NATL ACAD SCI USA, V99, P389, DOI 10.1073/pnas.012602599; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Emran MA, 2002, CANCER LETT, V182, P53, DOI 10.1016/S0304-3835(02)00062-9; Ferrandina G, 2000, INT J ONCOL, V17, P1231; Friesen C, 1999, LEUKEMIA, V13, P1854, DOI 10.1038/sj.leu.2401333; Friesen C, 1997, LEUKEMIA, V11, P1833, DOI 10.1038/sj.leu.2400827; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Han ZY, 2002, J BIOL CHEM, V277, P17154, DOI 10.1074/jbc.M112401200; Hartmann A, 2001, J NEUROSCI, V21, P2247, DOI 10.1523/JNEUROSCI.21-07-02247.2001; Jin YH, 2000, J BIOL CHEM, V275, P30256, DOI 10.1074/jbc.M001902200; Kapranos N, 2001, ANTICANCER RES, V21, P521; Kim SO, 2001, J ENDOTOXIN RES, V7, P292, DOI 10.1179/096805101101532873; Kim TH, 2000, J BIOL CHEM, V275, P39474, DOI 10.1074/jbc.M003370200; Kojima H, 1998, J BIOL CHEM, V273, P16647, DOI 10.1074/jbc.273.27.16647; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Luschen S, 2000, J BIOL CHEM, V275, P24670, DOI 10.1074/jbc.M003280200; Martinsson P, 2001, ANTI-CANCER DRUG, V12, P699, DOI 10.1097/00001813-200109000-00009; Nakashima S, 2000, ANTICANCER RES, V20, P1933; Rebbaa A, 2001, CANCER CHEMOTH PHARM, V48, P423, DOI 10.1007/s002800100375; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; RONINSON IB, 2002, DRUG RESIST UPDATE, V252, P1; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; te Poele RH, 2002, CANCER RES, V62, P1876; Yaginuma H, 2001, MOL CELL NEUROSCI, V18, P168, DOI 10.1006/mcne.2001.1009; Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483; Zunino F, 1997, PHARMACOL THERAPEUT, V76, P177, DOI 10.1016/S0163-7258(97)00086-7	33	147	160	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2003	22	18					2805	2811		10.1038/sj.onc.1206366	http://dx.doi.org/10.1038/sj.onc.1206366			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ	12743603				2022-12-28	WOS:000182569300011
J	Usui, K; Saijo, Y; Narumi, K; Koyama, S; Maemondo, M; Kikuchi, T; Tazawa, R; Hagiwara, K; Ishibashi, Y; Ohta, S; Nukiwa, T				Usui, K; Saijo, Y; Narumi, K; Koyama, S; Maemondo, M; Kikuchi, T; Tazawa, R; Hagiwara, K; Ishibashi, Y; Ohta, S; Nukiwa, T			N-terminal deletion augments the cell-death-inducing activity of BAX in adenoviral gene delivery to nonsmall cell lung cancers	ONCOGENE			English	Article						BAX; apoptosis; gene therapy	MITOCHONDRIAL DYSFUNCTION; BACTERIAL DEATH; BCL-2 PROTEIN; CYTOCHROME-C; IN-VIVO; APOPTOSIS; EXPRESSION; THERAPY; OVEREXPRESSION; DIMERIZATION	Therapeutic modalities that overcome the antiapoptotic function of Bcl-2 that is often overexpressed in cancer cells are expected to be a novel strategy for cancer treatment. We previously reported that the leukemic cell death induced by an N-terminally truncated Bax (DeltaN Bax: corresponding to amino acid 112-192 of full-length Bax) was not blocked by Bcl-2 or Bcl-x(L) owing to the lack of the BH3 domain needed to interact with the antiapoptotic Bcl-2 family molecules. In this study, we used the Cre-loxP system that allowed us to propagate adenoviruses expressing DeltaN Bax, and investigated the effects of the DeltaN Bax gene transfer into A549 and NCI-H1299 nonsmall cell lung cancer cell tines. DeltaN Bax showed more cell-death-inducing activity in both cells than did the full-length Bax in vitro. It was found that the DeltaN Bax-induced cell death was not inhibited by the pan-caspase inhibitor z-VAD-fmk, suggesting that DeltaN Bax induces cell death through a caspase-independent mechanism. Intratumoral injection of adenoviruses expressing AN Bax into A549 tumors in Balb/c nude mice showed a significantly stronger suppression of tumor growth (74%) than full-length Bax (25%) compared to the control. Our results suggest that DeltaN Bax may provide a better alternative than currently used cytotoxic genes in cancer gene therapy trials.	Tohoku Univ, Grad Sch Med, Dept Mol Med & Gene Transfer Res, Aoba Ku, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Inst Dev Aging & Canc, Dept Resp Oncol & Mol Med, Aoba Ku, Sendai, Miyagi 9808575, Japan; Nippon Med Coll, Inst Gerontol, Dept Biochem & Cell Biol, Nakahara Ku, Kawasaki, Kanagawa 2118533, Japan	Tohoku University; Tohoku University; Nippon Medical School	Saijo, Y (corresponding author), Tohoku Univ, Grad Sch Med, Dept Mol Med & Gene Transfer Res, Aoba Ku, 2-1 Seiryomachi, Sendai, Miyagi 9808575, Japan.	yasoj@idac.tohoku.ac.jp	Tazawa, Ryushi/AAM-6915-2020; Koyama, Shohei/AAU-4113-2021	Tazawa, Ryushi/0000-0002-4580-004X; Koyama, Shohei/0000-0002-6897-9417; Usui, Kazuhiro/0000-0002-4492-9327				Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Aritomi M, 1997, J BIOL CHEM, V272, P27886, DOI 10.1074/jbc.272.44.27886; Asoh S, 1998, J BIOL CHEM, V273, P11384, DOI 10.1074/jbc.273.18.11384; BECK WT, 1997, CANER PRINCIPLES PRA, P333; Costantini P, 2000, J NATL CANCER I, V92, P1042, DOI 10.1093/jnci/92.13.1042; Cregan SP, 2002, J CELL BIOL, V158, P507, DOI 10.1083/jcb.200202130; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Fan LF, 1999, HUM GENE THER, V10, P2273, DOI 10.1089/10430349950016924; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Gu J, 2002, GENE THER, V9, P30, DOI 10.1038/sj.gt.3301619; Gu J, 2000, CANCER RES, V60, P5359; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Huang ZW, 2000, ONCOGENE, V19, P6627, DOI 10.1038/sj.onc.1204087; Hunter JJ, 1996, J BIOL CHEM, V271, P8521, DOI 10.1074/jbc.271.15.8521; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; IKEGAKI N, 1994, CANCER RES, V54, P6; Ishibashi Y, 1998, BIOCHEM BIOPH RES CO, V243, P609, DOI 10.1006/bbrc.1998.8145; Joseph B, 2002, ONCOGENE, V21, P65, DOI 10.1038/sj/onc/1205018; Jurgensmeier JM, 1997, MOL BIOL CELL, V8, P325; Kagawa S, 2000, GENE THER, V7, P75, DOI 10.1038/sj.gt.3301048; Kagawa S, 2000, CANCER RES, V60, P1157; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li XY, 2001, CANCER RES, V61, P186; McCormick F, 2001, NAT REV CANCER, V1, P130, DOI 10.1038/35101008; Mohiuddin M, 2001, CANCER GENE THER, V8, P547, DOI 10.1038/sj.cgt.7700332; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; PEZZELLA F, 1993, NEW ENGL J MED, V329, P690, DOI 10.1056/NEJM199309023291003; Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tai YT, 1999, CANCER RES, V59, P2121; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Tamm I, 1998, CANCER RES, V58, P5315; Wang K, 1998, MOL CELL BIOL, V18, P6083, DOI 10.1128/MCB.18.10.6083; Wu CH, 2002, ONCOGENE, V21, P5160, DOI 10.1038/sj.onc.1205639; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yamashita YI, 2002, HUM GENE THER, V13, P275, DOI 10.1089/10430340252769798; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	45	10	10	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2003	22	17					2655	2663		10.1038/sj.onc.1206331	http://dx.doi.org/10.1038/sj.onc.1206331			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730679	Bronze			2022-12-28	WOS:000182569000013
J	van Golen, CM; Soules, ME; Grauman, AR; Feldman, EL				van Golen, CM; Soules, ME; Grauman, AR; Feldman, EL			N-Myc overexpression leads to decreased beta 1 integrin expression and increased apoptosis in human neuroblastoma cells	ONCOGENE			English	Article						Myc; neuroblastoma; apoptosis; integrin; adhesion	GROWTH-FACTOR-I; CHEMOTHERAPY-INDUCED APOPTOSIS; ADHESION CHARACTERISTICS; RECEPTOR ACTIVATION; MEDIATED SURVIVAL; GENE-EXPRESSION; C-MYC; BCL-2; AMPLIFICATION; DIFFERENTIATION	Neuroblastoma is a childhood tumor thought to arise through improper differentiation of neural crest cells. Increased N-Myc expression in neuroblastoma indicates highly malignant disease and poor patient prognosis. N-myc enhances cell growth, insulin-like growth factor type I receptor (IGF-IR) expression, and tumorigenicity in combination with Bcl-2. Despite these effects, N-Myc overexpression in SHEP neuroblastoma cells (SHEP/N-Myc cells) increases serum-withdrawal and mannitol-induced apoptosis. Although we have previously shown a protective effect of IGF-I in SHEP cells, in SHEP/N-Myc cells IGF-I rescue from mannitol-induced apoptosis is prevented. N-Myc overexpression has little effect on IGF-IR signaling pathways, but results in increased Akt phosphorylation when Bcl-2 is coexpressed. A loss of integrin-mediated adhesion promotes apoptosis in many systems. SHEP/N-Myc cells have dramatically less beta1 integrin expression than control cells, consistent with previous reports. beta1 integrin expression is decreased in more tumorigenic neuroblastoma cells lines, including IMR32 and SH-SY5Y cells. Reintroduction of beta1 integrin into the N-Myc-overexpressing cells prevents mannitol-mediated apoptosis. We speculate that N-Myc repression of beta1 integrin expression leads to a less differentiated phenotype, resulting in increased growth and tumorigenesis if properly supported or apoptosis if deprived of growth sustaining molecules.	Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Feldman, EL (corresponding author), Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA.	efeldman@umich.edu		Feldman, Eva/0000-0002-9162-2694	NCI NIH HHS [CA46592] Funding Source: Medline; NIAMS NIH HHS [AR20557] Funding Source: Medline; NINDS NIH HHS [R01 NS36778, T32 NS07222] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA046592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036778, T32NS007222] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amendola R, 1997, JNCI-J NATL CANCER I, V89, P1300, DOI 10.1093/jnci/89.17.1300; Amendola R, 2001, MED PEDIATR ONCOL, V36, P93, DOI 10.1002/1096-911X(20010101)36:1<93::AID-MPO1021>3.0.CO;2-3; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; Bonfoco E, 2000, NEUROSCIENCE, V101, P1145, DOI 10.1016/S0306-4522(00)00429-2; Bordow SB, 1998, J CLIN ONCOL, V16, P3286, DOI 10.1200/JCO.1998.16.10.3286; Bozzo C, 1997, EXP CELL RES, V237, P326, DOI 10.1006/excr.1997.3777; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CASTLE VP, 1993, AM J PATHOL, V143, P1543; Castleberry RP, 1997, PEDIATR CLIN N AM, V44, P919, DOI 10.1016/S0031-3955(05)70537-X; Chambery D, 1999, CANCER RES, V59, P2898; Cheng HL, 2000, J BIOL CHEM, V275, P27197; Cianfarani S, 1997, EUR J PEDIATR, V156, P256, DOI 10.1007/s004310050595; Corvi R, 1997, J NEURO-ONCOL, V31, P25, DOI 10.1023/A:1005721027709; Dabrowska M, 2001, GYNECOL OBSTET INVES, V51, P248, DOI 10.1159/000058059; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; DOLE M, 1994, CANCER RES, V54, P3253; DOLE MG, 1995, CANCER RES, V55, P2576; FAVROT MC, 1991, INT J CANCER, V49, P347, DOI 10.1002/ijc.2910490306; FLICKINGER KS, 1994, EXP CELL RES, V213, P156, DOI 10.1006/excr.1994.1185; Fulda S, 2000, MED PEDIATR ONCOL, V35, P582, DOI 10.1002/1096-911X(20001201)35:6<582::AID-MPO19>3.0.CO;2-2; Galderisi U, 1999, J CELL BIOCHEM, V73, P97, DOI 10.1002/(SICI)1097-4644(19990401)73:1<97::AID-JCB11>3.0.CO;2-M; Gelbard HA, 1997, PEDIATR NEUROL, V16, P93, DOI 10.1016/S0887-8994(96)00258-5; George RE, 2001, MED PEDIATR ONCOL, V36, P169, DOI 10.1002/1096-911X(20010101)36:1<169::AID-MPO1041>3.0.CO;2-U; Gladson CL, 1996, AM J PATHOL, V148, P1423; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Gross N, 2000, EXP CELL RES, V260, P396, DOI 10.1006/excr.2000.5007; HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; HOEHNER JC, 1995, INT J CANCER, V62, P19, DOI 10.1002/ijc.2910620106; IKEDA H, 1995, J PEDIATR SURG, V30, P805, DOI 10.1016/0022-3468(95)90752-1; Jasty R, 2001, NEOPLASIA, V3, P304, DOI 10.1038/sj.neo.7900171; Judware R, 1997, ONCOGENE, V14, P1341, DOI 10.1038/sj.onc.1200955; Judware R, 1995, ONCOGENE, V11, P2599; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; Kim B, 1997, J BIOL CHEM, V272, P21268, DOI 10.1074/jbc.272.34.21268; KOIZUMI H, 1995, VIRCHOWS ARCH, V427, P167; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; Leventhal Phillip S., 1999, V17, P425; Leventhal PS, 1997, TRENDS ENDOCRIN MET, V8, P1, DOI 10.1016/S1043-2760(96)00202-0; LEVENTHAL PS, 1995, EXP CELL RES, V221, P179, DOI 10.1006/excr.1995.1365; Liu XD, 1998, CANCER RES, V58, P5432; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; MARTIN DM, 1992, MOL BRAIN RES, V15, P241, DOI 10.1016/0169-328X(92)90114-Q; Mathews CC, 1996, J CELL PHYSIOL, V166, P323; Matthews CC, 1997, NEUROSCIENCE, V79, P525, DOI 10.1016/S0306-4522(96)00611-2; Mejia MC, 1998, ANTICANCER RES, V18, P801; Meyer GE, 2001, ONCOGENE, V20, P7542, DOI 10.1038/sj.onc.1204927; Miller SE, 2001, CELL BIOL INT, V25, P61, DOI 10.1006/cbir.2000.0678; Mooney A, 1999, AM J PATHOL, V155, P599, DOI 10.1016/S0002-9440(10)65155-3; PHILIP T, 1992, AM J PEDIAT HEMATOL, V14, P97; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; REED JC, 1991, CANCER RES, V51, P6529; Rohn JL, 1998, ONCOGENE, V17, P2811, DOI 10.1038/sj.onc.1202393; ROSSINO P, 1991, CELL REGUL, V2, P1021, DOI 10.1091/mbc.2.12.1021; Rossler J, 2001, BIOCHEM BIOPH RES CO, V281, P272, DOI 10.1006/bbrc.2001.4342; Rozzo C, 1997, INT J CANCER, V70, P688, DOI 10.1002/(SICI)1097-0215(19970317)70:6<688::AID-IJC11>3.3.CO;2-V; ROZZO C, 1993, FEBS LETT, V332, P263, DOI 10.1016/0014-5793(93)80646-C; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; Shakibaei M, 1999, BIOCHEM J, V342, P615, DOI 10.1042/0264-6021:3420615; Singleton JR, 1996, CANCER RES, V56, P4522; Singleton JR, 1996, J BIOL CHEM, V271, P31791, DOI 10.1074/jbc.271.50.31791; Stallmach A, 2001, EUR J IMMUNOL, V31, P1228, DOI 10.1002/1521-4141(200104)31:4<1228::AID-IMMU1228>3.0.CO;2-K; SULLIVAN KA, 1995, AM J PATHOL, V147, P1790; TANABE M, 1995, MED PEDIATR ONCOL, V24, P292, DOI 10.1002/mpo.2950240505; Valentinis B, 1998, J CELL PHYSIOL, V176, P648, DOI 10.1002/(SICI)1097-4652(199809)176:3<648::AID-JCP22>3.3.CO;2-6; van Golen CM, 2001, CELL GROWTH DIFFER, V12, P371; van Golen CM, 2000, CELL DEATH DIFFER, V7, P654, DOI 10.1038/sj.cdd.4400693; Van Golen CM, 2000, J CELL PHYSIOL, V182, P24, DOI 10.1002/(SICI)1097-4652(200001)182:1<24::AID-JCP3>3.0.CO;2-6; Wewer UM, 1997, AM J PATHOL, V151, P1191	69	33	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2003	22	17					2664	2673		10.1038/sj.onc.1206362	http://dx.doi.org/10.1038/sj.onc.1206362			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730680				2022-12-28	WOS:000182569000014
J	Halkidou, K; Gnanapragasam, VJ; Mehta, PB; Logan, IR; Brady, ME; Cook, S; Leung, HY; Neal, DE; Robson, CN				Halkidou, K; Gnanapragasam, VJ; Mehta, PB; Logan, IR; Brady, ME; Cook, S; Leung, HY; Neal, DE; Robson, CN			Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development	ONCOGENE			English	Article						Tip60; co-activator; CWR22 xenograft; hormone refractory; prostate cancer	HORMONAL-REGULATION; BREAST-CANCER; CELL-LINE; PROTEIN; LNCAP; APOPTOSIS; ANTIGEN; ALPHA; TRANSCRIPTION; METHYLATION	Prostate cancer (CaP) is initially androgen sensitive and responsive to hormone ablation therapy. However, cancer growth recurs despite androgen deprivation in the majority of cases of advanced disease. The molecular basis of this progression still remains unknown. The significance of androgen receptor (AR) coactivator proteins in this androgen-dependent malignancy is only beginning to emerge. In the present study, we examined the role of Tat interactive protein, 60kDa (Tip60), an AR coactivator, in CaP progression. In hormone refractory CaP biopsies, we observed a nuclear accumulation of Tip60 expression in contrast to a more diffuse distribution pattern observed in benign prostate hyperplasia and primary CaP. Furthermore, in both the prostate xenograft model CWR22 and the LNCaP CaP cell line, we observed that androgen withdrawal promoted upregulation of Tip60 as well as nuclear accumulation. In contrast, androgen exposure resulted in decreased Tip60 expression that was more closely linked to a cytoplasmic presence. Chromatin immunoprecipitation analysis revealed Tip60's recruitment to the PSA gene promoter in both androgen dependent and -independent cell lines. Thus, in vitro and in vivo data support a possible role for Tip60 in the molecular pathway leading to the development of androgen-independent CaP following long-term androgen deprivation therapy.	Univ Newcastle Upon Tyne, Sch Surg & Reprod Sci, Prostate Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Cambridge, Addenbrookes Hosp, Ctr Oncol, Cambridge CB2 2QQ, England	Newcastle University - UK; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Robson, CN (corresponding author), Univ Newcastle Upon Tyne, Sch Surg & Reprod Sci, Prostate Res Grp, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.			Neal, David/0000-0002-6033-5086; Leung, Hing Y./0000-0002-3933-3975				Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; Brawer MK, 2000, SEMIN SURG ONCOL, V18, P3, DOI 10.1002/(SICI)1098-2388(200001/02)18:1<3::AID-SSU2>3.3.CO;2-9; Burkhart BA, 1999, EXP CELL RES, V247, P168, DOI 10.1006/excr.1998.4345; Caira F, 2000, J BIOL CHEM, V275, P5308, DOI 10.1074/jbc.275.8.5308; CATALONA WJ, 1994, NEW ENGL J MED, V331, P996; Chen SL, 2001, MOL ENDOCRINOL, V15, P783, DOI 10.1210/me.15.5.783; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; CRAWFORD ED, 1992, BRIT J UROL, V70, P33, DOI 10.1111/j.1464-410X.1992.tb15865.x; Cutress RI, 2001, J CLIN ONCOL, V19, P3706, DOI 10.1200/JCO.2001.19.16.3706; Gao M, 1999, J CELL PHYSIOL, V179, P336, DOI 10.1002/(SICI)1097-4652(199906)179:3<336::AID-JCP11>3.0.CO;2-Q; Gaughan L, 2002, J BIOL CHEM, V277, P25904, DOI 10.1074/jbc.M203423200; Gaughan L, 2001, J BIOL CHEM, V276, P46841, DOI 10.1074/jbc.M103710200; Gnanapragasam VJ, 2002, ONCOGENE, V21, P5069, DOI 10.1038/sj.onc.1205663; Gregory CW, 2001, CANCER RES, V61, P4315; Horikawa I, 2001, J CELL BIOCHEM, V82, P415, DOI 10.1002/jcb.1169; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Jaffe ES, 1996, J CELL PATHOL, V1, P125; Kinoshita H, 2000, CANCER RES, V60, P3623; Koken MHM, 1997, P NATL ACAD SCI USA, V94, P10255, DOI 10.1073/pnas.94.19.10255; Kurebayashi J, 2000, CLIN CANCER RES, V6, P512; Kurihara I, 2000, ENDOCR RES, V26, P1033, DOI 10.3109/07435800009048635; LEE C, 1995, ENDOCRINOLOGY, V136, P796, DOI 10.1210/en.136.2.796; Lee HJ, 2001, J BIOL CHEM, V276, P16597, DOI 10.1074/jbc.C000909200; Majeed A, 2000, BJU INT, V85, P1058, DOI 10.1046/j.1464-410x.2000.00661.x; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Misiti S, 1998, ENDOCRINOLOGY, V139, P2493, DOI 10.1210/en.139.5.2493; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; Nagabhushan M, 1996, CANCER RES, V56, P3042; NORTON AJ, 1994, J PATHOL, V173, P371, DOI 10.1002/path.1711730413; Ran QT, 2000, GENE, V258, P141, DOI 10.1016/S0378-1119(00)00410-8; Reutens AT, 2001, MOL ENDOCRINOL, V15, P797, DOI 10.1210/me.15.5.797; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Sheridan AM, 2001, MOL CELL BIOL, V21, P4470, DOI 10.1128/MCB.21.14.4470-4481.2001; Shi YH, 2001, GENE DEV, V15, P1140, DOI 10.1101/gad.871201; Sliva D, 1999, BIOCHEM BIOPH RES CO, V263, P149, DOI 10.1006/bbrc.1999.1083; Soto AM, 1995, ONCOL RES, V7, P545; Spector DL, 1993, CURR OPIN CELL BIOL, V5, P442, DOI 10.1016/0955-0674(93)90009-F; SWINNEN JV, 1994, MOL CELL ENDOCRINOL, V104, P153, DOI 10.1016/0303-7207(94)90118-X; Tekur S, 2001, MOL CARCINOGEN, V30, P1, DOI 10.1002/1098-2744(200101)30:1<1::AID-MC1008>3.0.CO;2-X; Thenot S, 1999, MOL CELL ENDOCRINOL, V156, P85, DOI 10.1016/S0303-7207(99)00139-2; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; WAINSTEIN MA, 1994, CANCER RES, V54, P6049; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; YOUNG CYF, 1992, BIOCHEMISTRY-US, V31, P818, DOI 10.1021/bi00118a026; Zeng CQ, 1997, EMBO J, V16, P1401, DOI 10.1093/emboj/16.6.1401	46	174	183	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 24	2003	22	16					2466	2477		10.1038/sj.onc.1206342	http://dx.doi.org/10.1038/sj.onc.1206342			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	670AD	12717424				2022-12-28	WOS:000182383500010
J	Kim, JH; Leem, SH; Sunwoo, Y; Kouprina, N				Kim, JH; Leem, SH; Sunwoo, Y; Kouprina, N			Separation of long-range human TERT gene haplotypes by transformation-associated recombination cloning in yeast	ONCOGENE			English	Article						hTERT; VNTR; polymorphism; haplotypes; TAR cloning	TELOMERASE ACTIVITY; DNA; MINISATELLITES; AMPLIFICATION; POLYMORPHISMS; CHROMOSOMES; EXPRESSION; SEQUENCE	The hTERT gene encoding a catalytic subunit of human telomerase contains four blocks of variable number of tandem repeats (VNTRs) - two in intron 2 and two in intron 6. The segregation of hTERT VNTRs was analysed in families, revealing that all of them were transmitted through meiosis following a Mendelian inheritance. The work reports a further characterization of the minisatellites in hTERT. We employed transformation-associated recombination (TAR) cloning to isolate parental hTERT alleles and determined the specific combination of minisatellites at each of the polymorphic sites. A long-range haplotyping of hTERT determined by TAR cloning was verified by classical Mendelian analysis. Since such a strategy can be applied for any chromosomal locus, we conclude that recombinational gene capture could greatly facilitate haplotypes analysis.	NCI, Lab Biosyst & Canc, NIH, Bethesda, MD 20892 USA; Dong A Univ, Dept Biol, Pusan 604714, South Korea	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Dong A University	Kouprina, N (corresponding author), NCI, Lab Biosyst & Canc, NIH, Bldg 37,Room 5032, Bethesda, MD 20892 USA.	kouprinn@mail.nih.gov						Chiu CP, 1997, P SOC EXP BIOL MED, V214, P99; FUKE S, 2001, PHARMACOGENOMICS J, V2, P152; JEFFREYS AJ, 1990, CELL, V60, P473, DOI 10.1016/0092-8674(90)90598-9; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kouprina N, 1998, P NATL ACAD SCI USA, V95, P4469, DOI 10.1073/pnas.95.8.4469; KOUPRINA N, 1999, CURRENT PROTOCOLS HU, V1; Larionov V, 1997, P NATL ACAD SCI USA, V94, P7384, DOI 10.1073/pnas.94.14.7384; Larionov V, 1996, P NATL ACAD SCI USA, V93, P491, DOI 10.1073/pnas.93.1.491; Leem SH, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng029; Leem SH, 2002, ONCOGENE, V21, P769, DOI 10.1038/sj.onc.1205122; LI HH, 1988, NATURE, V335, P414, DOI 10.1038/335414a0; LUDECKE HJ, 1989, NATURE, V338, P348, DOI 10.1038/338348a0; Noskov V, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.2.e8; Noskov VN, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.6.e32; NOSKOV VN, 2003, IN PRESS J MOL EVOL, V56; Paquette J, 1998, J BIOL CHEM, V273, P14158, DOI 10.1074/jbc.273.23.14158; RUANO G, 1990, P NATL ACAD SCI USA, V87, P6296, DOI 10.1073/pnas.87.16.6296; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Szutorisz H, 2001, ONCOGENE, V20, P2600, DOI 10.1038/sj.onc.1204346; Yan P, 1999, J PATHOL, V189, P207, DOI 10.1002/(SICI)1096-9896(199910)189:2<207::AID-PATH424>3.0.CO;2-H; Yoshida R, 1999, ANTICANCER RES, V19, P2167	21	15	17	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2003	22	16					2452	2456		10.1038/sj.onc.1206316	http://dx.doi.org/10.1038/sj.onc.1206316			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	670AD	12717422				2022-12-28	WOS:000182383500008
J	Petrovas, C; Jeay, S; Lewis, RE; Sonenshein, GE				Petrovas, C; Jeay, S; Lewis, RE; Sonenshein, GE			B-Myb repressor function is regulated by cyclin A phosphorylation and sequences within the C-terminal domain	ONCOGENE			English	Article						B-myb oncogene; gene repression; cyclin A; type V collagen; smooth muscle cells	SMOOTH-MUSCLE CELLS; GENE-PRODUCT; DNA-BINDING; A-MYB; TRANSCRIPTION; TRANSACTIVATION; EXPRESSION; PROTEIN; PROMOTER; PROLIFERATION	B-Myb is a widely expressed member of the myh oncogene family that has been shown to act as either an activator or repressor of gene transcription in a cell-type-specific fashion. For example, in aortic smooth muscle cells B-Myb represses transcription of the alpha2(V) collagen gene. Recently, phosphorylation of B-Myb by cyclin A was shown to enhance greatly its ability to transactivate. Here, we have tested the effects of cyclin A on the ability of B-Myb to repress. We report that coexpression of cyclin A abolished repression of the alpha2(V) collagen promoter, whereas a dominant-negative cyclin-dependent kinase 2 (cdk2) enhanced repression by ectopic and endogenous B-Myb protein. Mutation of 10 of 22 putative cyclin A sites, which greatly reduces the effects of cyclin A on transactivation by B-Myb, had no effect on the ability of cyclin A to alleviate B-Myb-mediated repression of alpha2(V) collagen promoter activity. Furthermore, the stability of the mutant B-Myb protein was largely unaffected by cyclin A, although ectopic expression of cyclin A enhanced the rate of decay of wild-type B-Myb protein. Thus, the mechanisms of repression and activation appear distinct, for example, mediated by different critical phosphorylation sites or protein-protein interactions. B-Myb mutants with either deletion of aa 374-581 (B-Myb-Mut3) or C-terminal truncation beyond aa 491 (B-Myb-491) positively regulated alpha2(V) collagen promoter activity, and were not affected by cyclin A. Thus, our findings indicate that the ability of B-Myb to function as a repressor of matrix promoter activity is abolished by cyclin A, and maps the sites mediating negative regulation by B-Myb to the region between aa 491 and 582.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Univ Nebraska, Med Ctr, Eppley Canc Inst, Omaha, NE 68198 USA	Boston University; University of Nebraska System; University of Nebraska Medical Center	Sonenshein, GE (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.		Lewis, Robert E./H-3404-2019	JEAY, SEBASTIEN/0000-0001-7476-3340	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL013262] Funding Source: NIH RePORTER; NHLBI NIH HHS [5 P01 HL13262] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARSURA M, 1994, BLOOD, V83, P1778, DOI 10.1182/blood.V83.7.1778.bloodjournal8371778; Bartsch O, 1999, EUR J BIOCHEM, V260, P384, DOI 10.1046/j.1432-1327.1999.00191.x; BELDEKAS JC, 1982, J BIOL CHEM, V257, P2252; Bessa M, 2001, ONCOGENE, V20, P3376, DOI 10.1038/sj.onc.1204439; Bruno MD, 1999, J BIOL CHEM, V274, P27523, DOI 10.1074/jbc.274.39.27523; Cervellera M, 2000, J BIOL CHEM, V275, P21055, DOI 10.1074/jbc.M002055200; Cervellera MN, 2000, J BIOL CHEM, V275, P10692, DOI 10.1074/jbc.275.14.10692; Charrasse S, 2000, ONCOGENE, V19, P2986, DOI 10.1038/sj.onc.1203618; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GOLAY J, 1991, BLOOD, V77, P149; Grassilli E, 1999, CANCER RES, V59, P2451; Horstmann S, 2000, ONCOGENE, V19, P298, DOI 10.1038/sj.onc.1203302; HOWE KM, 1991, NUCLEIC ACIDS RES, V19, P3913, DOI 10.1093/nar/19.14.3913; Iwai N, 2001, ONCOGENE, V20, P1425, DOI 10.1038/sj.onc.1204236; Johnson LR, 2002, J BIOL CHEM, V277, P4088, DOI 10.1074/jbc.M105112200; Johnson TK, 1999, J BIOL CHEM, V274, P36741, DOI 10.1074/jbc.274.51.36741; Kypreos KE, 1999, MATRIX BIOL, V18, P275, DOI 10.1016/S0945-053X(99)00023-2; Kypreos KE, 1998, CELL GROWTH DIFFER, V9, P723; LAM EWF, 1992, ONCOGENE, V7, P1885; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; Li XL, 2002, MOL CELL BIOL, V22, P3663, DOI 10.1128/MCB.22.11.3663-3673.2002; Marhamati DJ, 1996, J BIOL CHEM, V271, P3359; Masselink H, 2001, CANCER LETT, V171, P87, DOI 10.1016/S0304-3835(01)00631-0; MIZUGUCHI G, 1995, J BIOL CHEM, V270, P9384, DOI 10.1074/jbc.270.16.9384; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; Muller-Tidow C, 2001, BLOOD, V97, P2091, DOI 10.1182/blood.V97.7.2091; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Oh IH, 1998, MOL CELL BIOL, V18, P499, DOI 10.1128/MCB.18.1.499; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Penkov D, 2000, J BIOL CHEM, V275, P16681, DOI 10.1074/jbc.M909345199; Piccinini G, 1999, J INVEST DERMATOL, V112, P191, DOI 10.1046/j.1523-1747.1999.00485.x; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Sala A, 1999, J CELL PHYSIOL, V179, P245; TAKEMOTO Y, 1994, FEBS LETT, V350, P55, DOI 10.1016/0014-5793(94)00733-0; Tanaka Y, 1999, J BIOL CHEM, V274, P28067, DOI 10.1074/jbc.274.40.28067; TASHIRO S, 1995, ONCOGENE, V10, P1699; Ying GG, 2000, J BIOL CHEM, V275, P4152, DOI 10.1074/jbc.275.6.4152; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7	39	7	7	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 3	2003	22	13					2011	2020		10.1038/sj.onc.1206231	http://dx.doi.org/10.1038/sj.onc.1206231			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	662UR	12673206				2022-12-28	WOS:000181967700011
J	Mehta, PB; Jenkins, BL; McCarthy, L; Thilak, L; Robson, CN; Neal, DE; Leung, HY				Mehta, PB; Jenkins, BL; McCarthy, L; Thilak, L; Robson, CN; Neal, DE; Leung, HY			MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion	ONCOGENE			English	Article						MAPK; MEK5; ERK5; prostate cancer; metastasis	NF-KAPPA-B; BONE MORPHOGENETIC PROTEIN-6; SIGNAL-REGULATED KINASE; BREAST-CANCER; TRANSFORMING GROWTH-FACTOR-BETA-1; MATRIX METALLOPROTEINASES; TIMP-2 EXPRESSION; GENE-EXPRESSION; CARCINOMA-CELLS; GROWTH-FACTOR	The novel mitogen/extracellular-signal-regulated kinase kinase 5/extracellular signal-regulated kinase-5 (MEK5/ERK5) pathway has been implicated in the regulation of cellular proliferation. MEK5 expression has been detected in prostate cancer cells, although the significance of the MEK5/ERK5 pathway in human prostate cancer has not been tested. We examined MEK5 expression in 127 cases of prostate cancer and 20 cases of benign prostatic hypertrophy (BPH) by immunohistochemistry and compared the results to clinical parameters. We demonstrated that MEK5 expression is increased in prostate cancer as compared to benign prostatic tissue. Strong MEK5 expression correlates with the presence of bony metastases and less favourable disease-specific survival. Furthermore, among the patients with high Gleason score of 8-10, MEK5 overexpression has an additional prognostic value in survival. MEK5 transfection experiments confirm its ability to induce proliferation (P<0.0001), motility (P=0.0001) and invasion in prostate cancer cells (P=0.0001). MEK5 expression drastically increased MMP-9, but not MMP-2 mRNA expression. Luciferase report assays suggest that the -670/MMP-9 promoter is upregulated by MEK5 and electromobility shift assay further suggests the involvement of activator protein-I (AP-1), but not the NF-kappaB, binding site in the MMP-9 promoter. Using an AP-1 luciferase construct, activation of MEK5 was confirmed to enhance AP-1 activities up to twofold. Taken together, our results establish MEK5 as a key signalling molecule associated with prostate carcinogenesis. As the MEK5/ERK5 interaction is highly specific, it represents a potential target of therapy.	Univ Newcastle Upon Tyne, Sch Med, Dept Surg, Prostate Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Leung, HY (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Dept Surg, Prostate Res Grp, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.			Leung, Hing Y./0000-0002-3933-3975; Neal, David/0000-0002-6033-5086				Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Adler HL, 1999, J UROLOGY, V161, P182, DOI 10.1016/S0022-5347(01)62092-5; Autzen P, 1998, BRIT J CANCER, V78, P1219, DOI 10.1038/bjc.1998.658; Dong Z, 2001, INT J CANCER, V93, P507, DOI 10.1002/ijc.1358; EASTHAM JA, 1995, LAB INVEST, V73, P628; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; Esparis-Ogando A, 2002, MOL CELL BIOL, V22, P270, DOI 10.1128/MCB.22.1.270-285.2002; Foda HD, 2001, DRUG DISCOV TODAY, V6, P478, DOI 10.1016/S1359-6446(01)01752-4; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; HAMDY FC, 1994, BRIT J CANCER, V69, P177, DOI 10.1038/bjc.1994.30; Hamdy FC, 1997, CANCER RES, V57, P4427; Hayakawa J, 1999, J BIOL CHEM, V274, P31648, DOI 10.1074/jbc.274.44.31648; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Jenkins BL, 2001, BRIT J CANCER, V85, P22; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; KOSTENUIK PJ, 1992, CLIN EXP METASTAS, V10, P411, DOI 10.1007/BF00133470; McCawley LJ, 2000, MOL MED TODAY, V6, P149, DOI 10.1016/S1357-4310(00)01686-5; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; Okamoto M, 1997, CANCER RES, V57, P141; Pearson G, 2001, J BIOL CHEM, V276, P7927, DOI 10.1074/jbc.M009764200; Price DT, 1999, J UROLOGY, V162, P1537, DOI 10.1016/S0022-5347(05)68354-1; Ricca A, 2000, INT J CANCER, V86, P188, DOI 10.1002/(SICI)1097-0215(20000415)86:2<188::AID-IJC7>3.3.CO;2-N; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; SATO H, 1993, ONCOGENE, V8, P395; Scorilas A, 2001, BRIT J CANCER, V84, P1488, DOI 10.1054/bjoc.2001.1810; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sehgal G, 1998, AM J PATHOL, V152, P591; Stack MS, 1998, INT J ONCOL, V12, P569; Stadheim TA, 2000, BIOCHEM PHARMACOL, V59, P407, DOI 10.1016/S0006-2952(99)00330-5; STEARNS ME, 1993, CANCER RES, V53, P878; Stone AA, 2000, EXP CELL RES, V254, P110, DOI 10.1006/excr.1999.4731; Thomas RJ, 1999, ENDOCRINOLOGY, V140, P4451, DOI 10.1210/en.140.10.4451; Troussard AA, 2000, ONCOGENE, V19, P5444, DOI 10.1038/sj.onc.1203928; Wood M, 1997, CLIN EXP METASTAS, V15, P246, DOI 10.1023/A:1018421431388; Yan CH, 2001, J BIOL CHEM, V276, P1164, DOI 10.1074/jbc.M008681200; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	38	146	154	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2003	22	9					1381	1389		10.1038/sj.onc.1206154	http://dx.doi.org/10.1038/sj.onc.1206154			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618764	Bronze			2022-12-28	WOS:000181360900013
J	Zhang, DL; Brodt, P				Zhang, DL; Brodt, P			Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/Akt signaling	ONCOGENE			English	Article						IGF-I; MT1-MMP; PI 3-kinase; Akt; PTEN; invasion	MEMBRANE-TYPE-1 MATRIX-METALLOPROTEINASE; ACTIVATED PROTEIN-KINASE; HEPATIC STELLATE CELLS; HUMAN GLIOMA-CELLS; FACTOR-I; CARCINOMA-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; FACTOR RECEPTOR; EXTRACELLULAR-MATRIX; INHIBITS APOPTOSIS	The membrane type I matrix metalloproteinase (MT1-MMP) has been identified as a major activator of MMP-2 - a process involving the formation of a trimolecular complex with TIMP-2. We previously identified the IGF-I receptor as a positive regulator of MMP-2 synthesis. Here, we investigated the role of IGF-IR in the regulation of MT1-MMP. Highly invasive Lewis lung carcinoma subline H-59 cells express MT1-MMP and utilize it to activate their major extracellular matrix degrading proteinase-MMP-2. These cells were transiently transfected with a plasmid vector expressing a luciferase reporter gene downstream of the mouse MT1-MMP promoter. IGF-I treatment increased luciferase activity in the transfected cells by up to 10-fold and augmented endogenous MT1-MMP mRNA and protein synthesis by up to 2-3-fold, relative to controls. MT1-MMP induction and invasion were blocked by the PI 3-kinase inhibitors LY294002 and wortmannin and by rapamycin, but not by the MEK inhibitor PD98059. Overexpression of a dominant negative Akt mutant or of the tumor suppressor phosphatase and tensin homologue, PTEN, in these cells also caused a significant reduction in MT1-MMP expression and invasion. The results demonstrate that IGF-IR controls tumor cell invasion by coordinately regulating MMP-2 expression and its MT1-MMP-mediated activation and identify PI 3-kinase/Akt/mTOR signaling as critical to this regulation.	McGill Univ, Royal Victoria Hosp, Div Surg Res, Hlth Ctr,Dept Surg, Montreal, PQ H3A 1A1, Canada; McGill Univ, Royal Victoria Hosp, Div Surg Res, Hlth Ctr,Dept Med, Montreal, PQ H3A 1A1, Canada	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital	Brodt, P (corresponding author), McGill Univ, Royal Victoria Hosp, Div Surg Res, Hlth Ctr,Dept Surg, Room H6-25,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	pnina.brodt@muhc.mcgill.ca						Allgayer H, 1998, ONCOLOGY-BASEL, V55, P152, DOI 10.1159/000011850; Baserga R, 1996, TRENDS BIOTECHNOL, V14, P150, DOI 10.1016/0167-7799(96)10023-8; Blum S, 2001, J BIOL CHEM, V276, P33428, DOI 10.1074/jbc.M105474200; BRODT P, 1992, BIOCHIM BIOPHYS ACTA, V1139, P77, DOI 10.1016/0925-4439(92)90085-2; BRODT P, 1986, CANCER RES, V46, P2442; Brodt P, 2001, J BIOL CHEM, V276, P33608, DOI 10.1074/jbc.M102754200; Brodt P, 2000, BIOCHEM PHARMACOL, V60, P1101, DOI 10.1016/S0006-2952(00)00422-6; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; Butler AA, 1998, COMP BIOCHEM PHYS B, V121, P19, DOI 10.1016/S0305-0491(98)10106-2; Castillo AI, 1998, ONCOGENE, V16, P1981, DOI 10.1038/sj.onc.1200204; Cha HJ, 2001, CLIN EXP METASTAS, V18, P675, DOI 10.1023/A:1013190118556; Davies MA, 1998, CANCER RES, V58, P5285; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; Ellenrieder V, 2000, INT J CANCER, V85, P14, DOI 10.1002/(SICI)1097-0215(20000101)85:1<14::AID-IJC3>3.3.CO;2-F; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanemaaijer R, 2000, INT J CANCER, V86, P204, DOI 10.1002/(SICI)1097-0215(20000415)86:2<204::AID-IJC9>3.0.CO;2-6; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hwang PH, 2001, CANCER LETT, V172, P83, DOI 10.1016/S0304-3835(01)00632-2; Johansson N, 2000, CELL MOL LIFE SCI, V57, P5, DOI 10.1007/s000180050495; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Kanayama Hiro-omi, 2001, Journal of Medical Investigation, V48, P31; Kermer P, 2000, J NEUROSCI, V20, P722, DOI 10.1523/JNEUROSCI.20-02-00722.2000; Khatib AM, 1999, CANCER RES, V59, P1356; Kim D, 2001, FASEB J, V15, P1953, DOI 10.1096/fj.01-0198com; Koul D, 2001, ONCOGENE, V20, P6669, DOI 10.1038/sj.onc.1204799; Lavandero S, 1998, FEBS LETT, V422, P193, DOI 10.1016/S0014-5793(98)00008-8; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Liu ZX, 2002, J BIOL CHEM, V277, P10452, DOI 10.1074/jbc.M107551200; Long L, 1998, CANCER RES, V58, P3243; LONG L, 1994, CANCER RES, V54, P3732; Long L, 1998, EXP CELL RES, V238, P116, DOI 10.1006/excr.1997.3814; MACAULAY VM, 1992, BRIT J CANCER, V65, P311, DOI 10.1038/bjc.1992.65; Matsuzaki H, 1999, J NEUROCHEM, V73, P2037; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Navab R, 2001, J BIOL CHEM, V276, P13644, DOI 10.1074/jbc.M100019200; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Parrizas M, 1997, J BIOL CHEM, V272, P154; Penninger JM, 2001, SCIENCE, V294, P2116, DOI 10.1126/science.1067931; Petley T, 1999, HORM METAB RES, V31, P70, DOI 10.1055/s-2007-978701; Polette M, 1998, INT J BIOCHEM CELL B, V30, P1195, DOI 10.1016/S1357-2725(98)00083-1; Roudabush FL, 2000, J BIOL CHEM, V275, P22583, DOI 10.1074/jbc.M002915200; Samani A A, 2001, Surg Oncol Clin N Am, V10, P289; Sato H, 1997, THROMB HAEMOSTASIS, V78, P497; Sato T, 1999, BRIT J CANCER, V80, P1137, DOI 10.1038/sj.bjc.6690477; Seddighzadeh M, 1999, CLIN EXP METASTAS, V17, P649, DOI 10.1023/A:1006741228402; Shimada T, 2000, CLIN EXP METASTAS, V18, P179, DOI 10.1023/A:1006749501682; Simpson L, 2001, MOL CELL BIOL, V21, P3947, DOI 10.1128/MCB.21.12.3947-3958.2001; Skrtic S, 1999, ENDOCRINOLOGY, V140, P5729, DOI 10.1210/en.140.12.5729; Stetler-Stevenson W G, 2001, Surg Oncol Clin N Am, V10, P383; Sugiyama H, 1998, KIDNEY INT, V54, P1188, DOI 10.1046/j.1523-1755.1998.00116.x; Svegliati-Baroni G, 1999, HEPATOLOGY, V29, P1743, DOI 10.1002/hep.510290632; Toth M, 2000, J BIOL CHEM, V275, P41415, DOI 10.1074/jbc.M006871200; TRUMPER K, 2002, ANN NY ACAD SCI, V921, P242; Wang H, 2000, BIOCHEM BIOPH RES CO, V272, P900, DOI 10.1006/bbrc.2000.2852; Weng LP, 1999, CANCER RES, V59, P5808; WojtowiczPraga SM, 1997, INVEST NEW DRUG, V15, P61, DOI 10.1023/A:1005722729132; Yart A, 2002, BBA-MOL CELL BIOL L, V1582, P107, DOI 10.1016/S1388-1981(02)00144-0	60	138	153	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2003	22	7					974	982		10.1038/sj.onc.1206197	http://dx.doi.org/10.1038/sj.onc.1206197			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	644PB	12592384	Bronze			2022-12-28	WOS:000180926100003
J	Albagli-Curiel, O				Albagli-Curiel, O			Ambivalent role of BCL6 in cell survival and transformation	ONCOGENE			English	Article						BCL6; B-cell lymphoma; germinal centre; cell survival; apoptosis	ZINC-FINGER PROTEIN; TUMOR-SUPPRESSOR GENE; NON-HODGKINS-LYMPHOMA; GERMINAL-CENTER FORMATION; ACID RECEPTOR-ALPHA; CENTER B-CELLS; SOMATIC HYPERMUTATION; PROMYELOCYTIC LEUKEMIA; GAGA FACTOR; TERMINAL DIFFERENTIATION	The BCL6 gene is often structurally altered and probably 'misregulated' in two different types of human B-cell non-Hodgkin lymphomas (BNHL) thought to arise from germinal centre B cells. BCL6 encodes a BTB/POZ and zinc finger protein whose biochemical properties support a role as a DNA-binding transcriptional repressor and disclose, in part, the underlying mechanisms. In contrast, the study of the 'oncogenic' structural alterations of BCL6 in BNHL and of its cellular functions gives rise to much more heterogeneous data with no obvious unifying picture so that how and even whether BCL6 contributes to lymphomagenesis remains unclear. This review will summarize the current knowledge about the 'oncogenic' alterations and cellular functions of BCL6 and, based on some results, will propose the following hypotheses: (1) In various systems, including in memory T cells and also in germinal centre B cells and possibly in certain postmitotic cells, BCL6 may act by stabilizing a particular stage of differentiation. (2) Both its ambivalent effects on cell survival and the heterogeneous consequences of its alterations in BNHL suggest that BCL6 can be oncogenic not only upon overexpression or persistent expression, as often proposed, but also, similar to some of its relatives, upon 'accidental' downregulation.	Inst Andre Lwoff, CNRS, UPR 1983, F-94801 Villejuif, France	Centre National de la Recherche Scientifique (CNRS)	Albagli-Curiel, O (corresponding author), Inst Andre Lwoff, CNRS, UPR 1983, 7 Rue Guy Moquet,BP8, F-94801 Villejuif, France.	olivier.albagli@ujf-grenoble.fr						Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Albagli O, 1999, ONCOGENE, V18, P5063, DOI 10.1038/sj.onc.1202892; Albagli O, 2000, MOL CELL BIOL, V20, P8560, DOI 10.1128/MCB.20.22.8560-8570.2000; Albagli-Curiel O, 1998, DIFFERENTIATION, V64, P33, DOI 10.1046/j.1432-0436.1998.6410033.x; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Allman D, 1996, BLOOD, V87, P5257, DOI 10.1182/blood.V87.12.5257.bloodjournal87125257; Arima M, 2002, J IMMUNOL, V169, P829, DOI 10.4049/jimmunol.169.2.829; Artiga MJ, 2002, AM J PATHOL, V160, P1371, DOI 10.1016/S0002-9440(10)62564-3; Badenhorst P, 2001, DEVELOPMENT, V128, P4093; Baron BW, 2002, P NATL ACAD SCI USA, V99, P2860, DOI 10.1073/pnas.042702599; Bernardin F, 1997, ONCOGENE, V14, P849, DOI 10.1038/sj.onc.1200903; Busturia A, 2001, DEVELOPMENT, V128, P2163; Carter MG, 2000, HUM MOL GENET, V9, P413, DOI 10.1093/hmg/9.3.413; Cattoretti G., 1997, Blood, V90, p175A; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; CHEN SJ, 1993, J CLIN INVEST, V91, P2260, DOI 10.1172/JCI116453; Chen WY, 1998, ONCOGENE, V17, P1717, DOI 10.1038/sj.onc.1202098; Chen WY, 2001, GENE CHROMOSOME CANC, V32, P281, DOI 10.1002/gcc.1191; Chen WY, 1998, BLOOD, V91, P603, DOI 10.1182/blood.V91.2.603.603_603_607; DAI MS, 2002, J BIOL CHEM, V1, P1; Dalla-Favera R, 1999, CURR TOP MICROBIOL, V246, P257; Davies JM, 1999, ONCOGENE, V18, P365, DOI 10.1038/sj.onc.1202332; Dent AL, 2002, CRIT REV ONCOL HEMAT, V41, P1, DOI 10.1016/S1040-8428(01)00164-0; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Dhordain P, 1998, NUCLEIC ACIDS RES, V26, P4645, DOI 10.1093/nar/26.20.4645; Dhordain P, 1995, ONCOGENE, V11, P2689; Dhordain P, 2000, ONCOGENE, V19, P6240, DOI 10.1038/sj.onc.1203976; Dickson BJ, 1998, CURR BIOL, V8, pR90, DOI 10.1016/S0960-9822(98)70054-5; Espinas ML, 2000, EMBO REP, V1, P253, DOI 10.1093/embo-reports/kvd046; Fukuda T, 1997, J EXP MED, V186, P439, DOI 10.1084/jem.186.3.439; FUKUDA T, 1995, ONCOGENE, V11, P1657; Galiegue-Zouitina S, 1999, GENE CHROMOSOME CANC, V26, P97, DOI 10.1002/(SICI)1098-2264(199910)26:2<97::AID-GCC1>3.0.CO;2-9; Guerardel C, 2001, J BIOL CHEM, V276, P3078, DOI 10.1074/jbc.M008690200; Gupta S, 1999, J EXP MED, V190, P1837, DOI 10.1084/jem.190.12.1837; Gupta S, 2001, J IMMUNOL, V166, P6104, DOI 10.4049/jimmunol.166.10.6104; He LZ, 2000, MOL CELL, V6, P1131, DOI 10.1016/S1097-2765(00)00111-8; Horard B, 2000, MOL CELL BIOL, V20, P3187, DOI 10.1128/MCB.20.9.3187-3197.2000; Hosokawa Y, 2001, BIOCHEM BIOPH RES CO, V283, P563, DOI 10.1006/bbrc.2001.4820; Humphrey GW, 2001, J BIOL CHEM, V276, P6817, DOI 10.1074/jbc.M007372200; Huynh KD, 2000, GENE DEV, V14, P1810; ICHII H, 2002, NAT IMMUNOL, V20, P20; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Kikuchi M, 2000, ONCOGENE, V19, P4941, DOI 10.1038/sj.onc.1203864; Kojima S, 2001, DEVELOPMENT, V128, P57; Kumagai T, 1999, ONCOGENE, V18, P467, DOI 10.1038/sj.onc.1202306; LEMERCIER C, 2002, J BIOL CHEM, V19, P19; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Licht JD, 1996, ONCOGENE, V12, P323; LO CF, 1994, BLOOD, V83, P1757; Lossos IS, 2000, BLOOD, V95, P1400, DOI 10.1182/blood.V95.4.1400.004k43_1400_1405; Lossos IS, 2001, LEUKEMIA LYMPHOMA, V42, P1343, DOI 10.1080/10428190127508; McKnight SL, 2001, CELL, V107, P259, DOI 10.1016/S0092-8674(01)00543-8; Melnick A, 2002, MOL CELL BIOL, V22, P1804, DOI 10.1128/MCB.22.6.1804-1818.2002; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; MIKI T, 1994, BLOOD, V83, P26; Moriyama M, 1997, ONCOGENE, V14, P2465, DOI 10.1038/sj.onc.1201084; Nakamura T, 2000, MOL CELL BIOL, V20, P3178, DOI 10.1128/MCB.20.9.3178-3186.2000; Nakamura Y, 1996, LEUKEMIA, V10, P658; Nason-Burchenal K, 1998, ONCOGENE, V17, P1759, DOI 10.1038/sj.onc.1202075; Niu HF, 1998, GENE DEV, V12, P1953, DOI 10.1101/gad.12.13.1953; Ohno H, 1997, LEUKEMIA LYMPHOMA, V27, P53, DOI 10.3109/10428199709068271; Okabe S, 1998, MOL CELL BIOL, V18, P4235, DOI 10.1128/MCB.18.7.4235; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; OTSUKI T, 1995, BLOOD, V85, P2877, DOI 10.1182/blood.V85.10.2877.bloodjournal85102877; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; Pasqualucci L, 1998, P NATL ACAD SCI USA, V95, P11816, DOI 10.1073/pnas.95.20.11816; Pasqualucci L, 2000, BLOOD, V96, p703A; Preudhomme C, 2000, ONCOGENE, V19, P2023, DOI 10.1038/sj.onc.1203521; Reljic R, 2000, J EXP MED, V192, P1841, DOI 10.1084/jem.192.12.1841; Reuter S, 1998, EMBO J, V17, P215, DOI 10.1093/emboj/17.1.215; Rubin H, 2002, NAT BIOTECHNOL, V20, P675, DOI 10.1038/nbt0702-675; Shaffer AL, 2000, IMMUNITY, V13, P199, DOI 10.1016/S1074-7613(00)00020-0; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Shen HM, 1998, SCIENCE, V280, P1750, DOI 10.1126/science.280.5370.1750; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Shvarts A, 2002, GENE DEV, V16, P681, DOI 10.1101/gad.929302; Strutt H, 1997, EMBO J, V16, P3621, DOI 10.1093/emboj/16.12.3621; TANG TT, 2002, J BIOL CHEM, V2, P2; Toney LM, 2000, NAT IMMUNOL, V1, P214, DOI 10.1038/79749; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; Ueda C, 2002, ONCOGENE, V21, P368, DOI 10.1038/sj.onc.1205099; Ueda C, 2002, BLOOD, V99, P2624, DOI 10.1182/blood-2001-11-0117; Vasanwala FH, 2002, J IMMUNOL, V169, P1922, DOI 10.4049/jimmunol.169.4.1922; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; Wang J, 1997, CANCER RES, V57, P351; Xiao H, 2001, MOL CELL, V8, P531, DOI 10.1016/S1097-2765(01)00345-8; Yamochi T, 1999, ONCOGENE, V18, P487, DOI 10.1038/sj.onc.1202334; Yamochi T, 1997, LEUKEMIA, V11, P694, DOI 10.1038/sj.leu.2400631; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; Yoshida S, 1999, ONCOGENE, V18, P7994, DOI 10.1038/sj.onc.1203293; Yoshida T, 1999, CARDIOVASC RES, V42, P670, DOI 10.1016/S0008-6363(99)00007-3; Yoshida T, 1996, BIOCHEM BIOPH RES CO, V228, P216, DOI 10.1006/bbrc.1996.1642; Zan H, 2000, J IMMUNOL, V165, P830, DOI 10.4049/jimmunol.165.2.830; Zan H, 2001, IMMUNITY, V14, P643, DOI 10.1016/S1074-7613(01)00142-X; Zhang H, 2001, BBA-MOL CELL RES, V1540, P188, DOI 10.1016/S0167-4889(01)00128-8	99	50	50	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2003	22	4					507	516		10.1038/sj.onc.1206152	http://dx.doi.org/10.1038/sj.onc.1206152			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555064				2022-12-28	WOS:000180538200004
J	Ramirez, RD; Herbert, BS; Vaughan, MB; Zou, Y; Gandia, K; Morales, CP; Wright, WE; Shay, JW				Ramirez, RD; Herbert, BS; Vaughan, MB; Zou, Y; Gandia, K; Morales, CP; Wright, WE; Shay, JW			Bypass of telomere-dependent replicative senescence (M1) upon overexpression of Cdk4 in normal human epithelial cells	ONCOGENE			English	Article						replicative senescence; epithelial cells; cell cycle; ageing; Cdk inhibitors	HUMAN-DIPLOID FIBROBLASTS; CELLULAR SENESCENCE; DNA-REPLICATION; G(1) ARREST; LIFE-SPAN; GROWTH; P16; P53; RB; IMMORTALIZATION	Many stimuli causing 'stress' or DNA damage in cells can produce phenotypes that overlap with telomere-based replicative senescence. In epithelial systems, the p16/RB pathway may function as a stress senescence-signaling pathway independent of telomere shortening. Overexpressing cyclin-dependent kinase 4 (Cdk4) in human epidermal keratinocytes and human mammary epithelial cells not only prevents the p16(INK4a)-associated premature growth arrest due to telomere-independent stress (e.g., inadequate culture conditions), but also bypasses the ensuing telomere-dependent senescence (M1). Overexpressed Cdk4 in epithelial cells induces a dramatic upregulation of p16(INK4a) and milder upregulation of p53 and p21(WAF1), which become unresponsive to UV irradiation. Despite the high levels of these checkpoint factors, Cdk4-overexpressing cells divide in an apparently normal regulated fashion, are able to respond to changes in calcium levels, retain the stem cell phenotype, and fully differentiate and stratify. These results suggest that the differentiation pathways in Cdk4-overexpressing cells remain intact.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; Dallas Vet Affairs Med Ctr, Dept Internal Med, Dallas, TX 75216 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Ramirez, RD (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.	ruben.ramirez@utsouthwestern.edu	Vaughan, Melville B/J-6637-2016; Shay, Jerry W/F-7878-2011	Vaughan, Melville B/0000-0003-4648-6141; Zou, Ying/0000-0003-2787-1917	NIA NIH HHS [AG01228] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG001228, R01AG001228] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; Coleman KG, 1997, J BIOL CHEM, V272, P18869, DOI 10.1074/jbc.272.30.18869; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Dumont P, 2000, FREE RADICAL BIO MED, V28, P361, DOI 10.1016/S0891-5849(99)00249-X; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Farwell DG, 2000, AM J PATHOL, V156, P1537, DOI 10.1016/S0002-9440(10)65025-0; Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793; Gazdar AF, 1998, INT J CANCER, V78, P766, DOI 10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L; HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1992, EXP GERONTOL, V27, P375, DOI 10.1016/0531-5565(92)90068-B; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; Herbert BS, 2002, ONCOGENE, V21, P7897, DOI 10.1038/sj.onc.1205902; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; Jarrard DF, 1999, CANCER RES, V59, P2957; Jones CJ, 2000, MOL CELL BIOL, V20, P5690, DOI 10.1128/MCB.20.15.5690-5699.2000; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Lomazzi M, 2002, NAT GENET, V31, P190, DOI 10.1038/ng891; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Morris M, 2002, ONCOGENE, V21, P4277, DOI 10.1038/sj.onc.1205492; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Opitz OG, 2001, J CLIN INVEST, V108, P725, DOI 10.1172/JCI11909; Ouellette MM, 2000, J BIOL CHEM, V275, P10072, DOI 10.1074/jbc.275.14.10072; PARENTEAU N, 1994, KERATINOCYTE METHODS, P45; Pavey S, 1999, CANCER RES, V59, P4185; Piatyszek Mieczyslaw A., 1995, Methods in Cell Science, V17, P1, DOI 10.1007/BF00981880; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Reddel RR, 2001, J CLIN INVEST, V108, P665, DOI 10.1172/JCI200113818; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Shay Jerry W., 1994, Molecular and Cellular Differentiation, V2, P1; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Smogorzewska A, 2002, EMBO J, V21, P4338, DOI 10.1093/emboj/cdf433; STAMPFER M, 1980, IN VITRO CELL DEV B, V16, P415; Stein GH, 1999, MOL CELL BIOL, V19, P2109; VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794	52	73	75	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2003	22	3					433	444		10.1038/sj.onc.1206046	http://dx.doi.org/10.1038/sj.onc.1206046			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545164				2022-12-28	WOS:000180379100012
J	La, P; Morgan, TA; Sykes, SM; Mao, H; Schnepp, RW; Petersen, CD; Hua, XX				La, P; Morgan, TA; Sykes, SM; Mao, H; Schnepp, RW; Petersen, CD; Hua, XX			Fusion proteins of retinoid receptors antagonize TGF-beta-induced growth inhibition of lung epithelial cells	ONCOGENE			English	Article						TGF-beta; retinoic acid; RXR beta; PLZF-RAR alpha; p15(ink4b)	ACUTE PROMYELOCYTIC LEUKEMIA; PLZF-RAR-ALPHA; TREATED HL-60 CELLS; SMAD PROTEINS; INDUCED TRANSCRIPTION; FUNCTIONAL INTERACTIONS; INDUCED PHOSPHORYLATION; MOLECULAR PATHOGENESIS; TARGETED DISRUPTION; SIGNAL-TRANSDUCTION	Transforming growth factor-beta1 (TGF-beta) is a growth factor that has multiple functions including potent inhibition of cell growth. TGF-beta signals by binding to its cell surface serine/threonine kinase receptors, which in turn phosphorylate downstream signal transducers, Smad2 and Smad3. Phosphorylated Smad2 and Smad3, together with Smad4, enter the nucleus and associate with various transcription factors. This complex of transcription factors regulates transcription of a diverse group of genes, leading to growth arrest at G1 phase. Through a functional expression cloning approach, a gag-retinoid X receptor beta (gag-RXRbeta) fusion protein was found to antagonize TGF-beta-induced growth inhibition of mink lung epithelial cells and the fusion between gag and RXRbeta is essential for resistance to the growth inhibition. Like gag-RXRbeta, the oncogenic PLZF-RARalpha fusion protein also antagonizes TGF-beta-induced growth inhibition, and the fusion between PLZF and RARalpha is essential for resistance to TGF-beta. Moreover, TGF-beta and retinoic acid (RA) cooperatively induce growth inhibition as well as transcription of the p15(inkb) gene, while PLZF-RARalpha represses TGF-beta-induced expression of the p15(ink4b) gene. Together, these results suggest that the TGF-beta and RA pathways cooperate to inhibit cell growth and that PLZF-RARalpha -mediated resistance to TGF-beta may facilitate the development of the PLZF-RARalpha-induced leukemia.	Univ Penn, Dept Canc Biol, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Hua, XX (corresponding author), Univ Penn, Dept Canc Biol, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.	huax@mail.med.upenn.edu			NATIONAL CANCER INSTITUTE [K01CA078592] Funding Source: NIH RePORTER; NCI NIH HHS [1K01CA78592] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; BATOVA A, 1992, CELL GROWTH DIFFER, V3, P763; Blobe GC, 2001, J BIOL CHEM, V276, P39608, DOI 10.1074/jbc.M106831200; Borger DR, 2000, VIROLOGY, V270, P397, DOI 10.1006/viro.2000.0282; Bottinger EP, 1997, EMBO J, V16, P2621, DOI 10.1093/emboj/16.10.2621; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chipuk JE, 2002, J BIOL CHEM, V277, P1240, DOI 10.1074/jbc.M108855200; Danielpour D, 1996, J CELL PHYSIOL, V166, P231, DOI 10.1002/(SICI)1097-4652(199601)166:1<231::AID-JCP24>3.0.CO;2-G; Datta PK, 2000, J BIOL CHEM, V275, P40014, DOI 10.1074/jbc.C000508200; Datto MB, 1999, MOL CELL BIOL, V19, P2495; Defacque H, 1999, J CELL PHYSIOL, V178, P109, DOI 10.1002/(SICI)1097-4652(199901)178:1<109::AID-JCP14>3.3.CO;2-O; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; DICKENS TA, 1993, BIOESSAYS, V15, P71, DOI 10.1002/bies.950150111; Dragnev KH, 2001, ANN NY ACAD SCI, V952, P13, DOI 10.1111/j.1749-6632.2001.tb02724.x; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FALK LA, 1991, BLOOD, V77, P1248; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; GERADTS J, 1993, CELL GROWTH DIFFER, V4, P799; GLICK AB, 1989, CELL REGUL, V1, P87, DOI 10.1091/mbc.1.1.87; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Han GR, 1997, J BIOL CHEM, V272, P13711, DOI 10.1074/jbc.272.21.13711; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hayes SA, 2001, CANCER RES, V61, P2112; He LZ, 2000, MOL CELL, V6, P1131, DOI 10.1016/S1097-2765(00)00111-8; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Hua XX, 1999, P NATL ACAD SCI USA, V96, P13130, DOI 10.1073/pnas.96.23.13130; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; HUA XX, 1995, J BIOL CHEM, V270, P29422, DOI 10.1074/jbc.270.49.29422; Imai S, 1997, FEBS LETT, V411, P102, DOI 10.1016/S0014-5793(97)00673-X; Imai Y, 2001, ONCOGENE, V20, P88, DOI 10.1038/sj.onc.1204057; Jakubowiak A, 2000, J BIOL CHEM, V275, P40282, DOI 10.1074/jbc.C000485200; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Kim RH, 2000, GENE DEV, V14, P1605; Kishi H, 2001, CELL BIOL INT, V25, P1125, DOI 10.1006/cbir.2001.0795; KOJIMA S, 1993, J CELL PHYSIOL, V155, P323, DOI 10.1002/jcp.1041550213; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lardon F, 1996, LEUKEMIA, V10, P1937; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MEYSKENS FL, 1995, AM J CLIN NUTR, V62, P1417, DOI 10.1093/ajcn/62.6.1417S; MORALES TI, 1992, ARCH BIOCHEM BIOPHYS, V293, P79, DOI 10.1016/0003-9861(92)90368-7; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nunes I, 1996, CANCER RES, V56, P495; Okuno M, 1997, HEPATOLOGY, V26, P913, DOI 10.1002/hep.510260417; Okuno M, 2002, FRONT BIOSCI-LANDMRK, V7, pD204, DOI 10.2741/okuno; Onishi M, 1996, EXP HEMATOL, V24, P324; Pandolfi PP, 2001, HUM MOL GENET, V10, P769, DOI 10.1093/hmg/10.7.769; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Razani B, 2001, J BIOL CHEM, V276, P6727, DOI 10.1074/jbc.M008340200; ROBERTS AB, 1992, CANCER SURV, V14, P205; Ruthardt M, 1997, MOL CELL BIOL, V17, P4859, DOI 10.1128/MCB.17.8.4859; Sambrook J, 1989, MOL CLONING; Schiemann WP, 2002, J BIOL CHEM, V277, P27367, DOI 10.1074/jbc.M200148200; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Slack James L., 1999, Current Opinion in Oncology, V11, P9, DOI 10.1097/00001622-199901000-00003; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Ten Dijke PT, 2002, J CELL PHYSIOL, V191, P1, DOI 10.1002/jcp.10066; Thormeyer D, 1999, INT J MOL MED, V4, P351; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Valette A, 1990, GROWTH FACTORS, V2, P283, DOI 10.3109/08977199009078016; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; Wrana JL, 2000, CYTOKINE GROWTH F R, V11, P5, DOI 10.1016/S1359-6101(99)00024-6; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	89	15	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2003	22	2					198	210		10.1038/sj.onc.1206100	http://dx.doi.org/10.1038/sj.onc.1206100			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527889				2022-12-28	WOS:000180322400005
J	Moynahan, ME				Moynahan, ME			The cancer connection: BRCA1 and BRCA2 tumor suppression in mice and humans	ONCOGENE			English	Article						BRCA1; BRCA2; tumor suppression; genetic instability	SINGLE NUCLEOTIDE POLYMORPHISM; GENE-EXPRESSION PROFILES; FAMILIAL BREAST-CANCER; DNA-REPAIR; EMBRYONIC LETHALITY; SUSCEPTIBILITY GENE; MAMMARY-TUMORS; CENTROSOME AMPLIFICATION; OVARIAN-CANCER; MOUSE MODEL	BRCA1 and BRCA2 mutations are estimated to be responsible for the great majority of familial breast and ovarian cancers. Much progress has been made toward the understanding of the function of these proteins through genetic, biochemical, and structural studies. The embryonic lethality encountered in the knockout mouse initially hindered the development of mouse models aimed at studying tumor suppression. However, mice that harbor hypomorphic Brca1 and Brca2 alleles and cre-mediated tissue-specific deletions for Brca1 and Brca2 have been generated. Mice deficient for either Brca1 or Brca2 sustain a wide range of carcinoma and mammary epithelium deleted for Brca1 or Brca2 is highly susceptible to mammary tumorigenesis. Mammary (and other) tumors occur at long latency as compared to oncogene-induced mouse tumors. p53 deficiency is highly cooperative with both Brca1 and Brca2 in promoting tumorigenesis. Analysis of Brca1-associated mammary tumors reveals significant similarities to BRCA1-associated breast cancer in regard to high tumor grade, hormone receptor negativity, a high incidence of p53 mutations and genetic instability.	Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Moynahan, ME (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA.	moynaham@mskcc.org		Moynahan, Mary Ellen/0000-0002-0167-1020				Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Basham VM, 2002, BREAST CANCER RES, V4, DOI 10.1186/bcr419; Begg CB, 2002, J NATL CANCER I, V94, P1221; Bennett LM, 2000, MOL CARCINOGEN, V28, P174, DOI 10.1002/1098-2744(200007)28:3<174::AID-MC6>3.0.CO;2-C; Bennett LM, 2001, TOXICOL PATHOL, V29, P117, DOI 10.1080/019262301301418928; Bennett LM, 2000, CANCER RES, V60, P3461; Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310; Brodie SG, 2001, ONCOGENE, V20, P7514, DOI 10.1038/sj.onc.1204929; Brose MS, 2002, J NATL CANCER I, V94, P1365, DOI 10.1093/jnci/94.18.1365; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Cressman VL, 1999, MOL CELL BIOL, V19, P7061; Cressman VL, 1999, CELL GROWTH DIFFER, V10, P1; Crook T, 1998, ONCOGENE, V17, P1681, DOI 10.1038/sj.onc.1202106; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Deng CX, 2002, ONCOGENE, V21, P6222, DOI 10.1038/sj.onc.1205713; Deng CX, 2001, SEMIN CANCER BIOL, V11, P387, DOI 10.1006/scbi.2001.0394; EASTON DF, 1993, AM J HUM GENET, V52, P678; Frank TS, 2002, J CLIN ONCOL, V20, P1480, DOI 10.1200/JCO.20.6.1480; Friedman LS, 1998, CANCER RES, V58, P1338; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Greenblatt MS, 2001, CANCER RES, V61, P4092; Gruber SB, 2002, J NATL CANCER I, V94, P1344; Hakem R, 2001, ANNU REV GENET, V35, P209, DOI 10.1146/annurev.genet.35.102401.090432; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; Hohenstein P, 2001, ONCOGENE, V20, P2544, DOI 10.1038/sj.onc.1204363; Janocko LE, 2001, CYTOMETRY, V46, P136, DOI 10.1002/cyto.1098; Jazaeri AA, 2002, JNCI-J NATL CANCER I, V94, P990, DOI 10.1093/jnci/94.13.990; Jones C, 2001, BRIT J CANCER, V85, P422, DOI 10.1054/bjoc.2001.1869; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Karabinis ME, 2001, CARCINOGENESIS, V22, P343, DOI 10.1093/carcin/22.2.343; Kuperwasser C, 2000, AM J PATHOL, V157, P2151, DOI 10.1016/S0002-9440(10)64853-5; Lakhani SR, 2002, J CLIN ONCOL, V20, P2310, DOI 10.1200/JCO.2002.09.023; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Levy-Lahad E, 2001, P NATL ACAD SCI USA, V98, P3232, DOI 10.1073/pnas.051624098; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Ludwig T, 2001, ONCOGENE, V20, P3937, DOI 10.1038/sj.onc.1204512; Ludwig T, 2001, GENE DEV, V15, P1188, DOI 10.1101/gad.879201; MacLachlan TK, 2002, MOL CELL BIOL, V22, P4280, DOI 10.1128/MCB.22.12.4280-4292.2002; Mak TW, 2000, NAT IMMUNOL, V1, P77, DOI 10.1038/76950; McAllister KA, 2002, CANCER RES, V62, P990; Medina D, 2002, ENVIRON MOL MUTAGEN, V39, P178, DOI 10.1002/em.10064; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 2002, CANCER BIOL THER, V1, P187, DOI 10.4161/cbt.66; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Moynahan ME, 2001, CANCER RES, V61, P4842; Phillips KA, 2000, J CLIN ONCOL, V18, p107S; Risch HA, 2001, AM J HUM GENET, V68, P700, DOI 10.1086/318787; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Seidman AD, 2001, J CLIN ONCOL, V19, P2587, DOI 10.1200/JCO.2001.19.10.2587; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Shin SJ, 2002, AM J SURG PATHOL, V26, P413, DOI 10.1097/00000478-200204000-00002; Smith PD, 1999, ONCOGENE, V18, P2451, DOI 10.1038/sj.onc.1202565; Thompson D, 2002, JNCI-J NATL CANCER I, V94, P1358, DOI 10.1093/jnci/94.18.1358; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Turner BC, 2002, CANCER RES, V62, P4054; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Tutt ANJ, 2002, EMBO REP, V3, P255, DOI 10.1093/embo-reports/kvf037; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang WW, 2001, CANCER EPIDEM BIOMAR, V10, P955; Weaver Z, 2002, ONCOGENE, V21, P5097, DOI 10.1038/sj.onc.1205636; Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705; Welcsh PL, 2002, P NATL ACAD SCI USA, V99, P7560, DOI 10.1073/pnas.062181799; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Yu VPCC, 2000, GENE DEV, V14, P1400	77	84	84	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2002	21	58					8994	9007		10.1038/sj.onc.1206177	http://dx.doi.org/10.1038/sj.onc.1206177			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	626TP	12483515				2022-12-28	WOS:000179889500010
J	Liu, YQ; Jovanovic, B; Pins, M; Lee, C; Bergan, RC				Liu, YQ; Jovanovic, B; Pins, M; Lee, C; Bergan, RC			Over expression of endoglin in human prostate cancer suppresses cell detachment, migration and invasion	ONCOGENE			English	Article						adhesion; motility; transforming growth factor beta; carcinogenesis	GROWTH-FACTOR-BETA; FOCAL ADHESION KINASE; HEMORRHAGIC TELANGIECTASIA TYPE-1; BINDING PROTEIN ENDOGLIN; HUMAN ENDOTHELIAL-CELLS; TRANSFORMING GROWTH-FACTOR-BETA-1; IN-VITRO; INTEGRIN; INHIBITION; TGF-BETA-1	The regulation of cell adhesion and motility in human prostate is not well understood. We have previously shown that the endoglin gene is differently expressed during changes in prostate cell adhesion. Endoglin is a transmembrane transforming growth factor beta binding protein typically expressed by endothelial cells. In this report we demonstrate that endoglin over expression increases prostate cell attachment, while decreasing migration and invasion. Engineered decreases in endoglin expression have opposite effects. While endoglin exerted only relatively small effects upon cell adhesion, large effects upon cell migration and invasion were observed. Endoglin was shown to localize to focal adhesion plaques, consistent with its role in regulating cell adhesion and motility. Loss of endoglin expression in cancer, as compared to normal prostate, was seen in human prostate cell lines. Suppression of endoglin expression in a panel of normal human prostate cell lines led to cell detachment. Endoglin is identified as a regulator of cell adhesion, motility and invasion in human prostate. Loss of endoglin expression appears to be associated with prostate cancer progression, at least in vitro.	Northwestern Univ, Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL 60611 USA; Northwestern Univ, Robert H Lurie Canc Ctr, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Prevent Med, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Urol, Chicago, IL 60611 USA	Northwestern University; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Northwestern University; Northwestern University	Bergan, RC (corresponding author), Northwestern Univ, Sch Med, Dept Med, Div Hematol Oncol, Olson 8524,710 N Fairbanks, Chicago, IL 60611 USA.	r-bergan@northwestern.edu	Piris, Miguel A/AAP-1445-2020	Piris, Miguel A/0000-0001-5839-3634	NCI NIH HHS [CA90386] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA090386] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albo D, 1997, SURGERY, V122, P493, DOI 10.1016/S0039-6060(97)90043-X; Altomonte M, 1996, BRIT J CANCER, V74, P1586, DOI 10.1038/bjc.1996.593; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; BELLON T, 1993, EUR J IMMUNOL, V23, P2340, DOI 10.1002/eji.1830230943; Bergan R, 1996, CLIN EXP METASTAS, V14, P389, DOI 10.1007/BF00123398; BERGAN R, 1993, NUCLEIC ACIDS RES, V21, P3567, DOI 10.1093/nar/21.15.3567; BERGAN R, 1994, NUCLEIC ACIDS RES, V22, P2150, DOI 10.1093/nar/22.11.2150; Bergan R, 1996, BLOOD, V88, P731, DOI 10.1182/blood.V88.2.731.bloodjournal882731; Bright RK, 1997, CANCER RES, V57, P995; Cai T, 2000, BIOCHEM BIOPH RES CO, V274, P519, DOI 10.1006/bbrc.2000.3177; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; CRESS AE, 1995, CANCER METAST REV, V14, P219, DOI 10.1007/BF00690293; Dakhama A, 1996, J HISTOCHEM CYTOCHEM, V44, P1205, DOI 10.1177/44.10.8813086; Eckstein F, 1996, ANTISENSE NUCLEIC A, V6, P149, DOI 10.1089/oli.1.1996.6.149; Festuccia C, 1999, INT J CANCER, V81, P395, DOI 10.1002/(SICI)1097-0215(19990505)81:3<395::AID-IJC13>3.0.CO;2-V; Fornaro M, 1996, AM J PATHOL, V149, P765; Fornaro M, 1999, J CLIN INVEST, V103, P321, DOI 10.1172/JCI4585; Games PA, 1976, J EDUCATIONAL STATIS, V1, P113, DOI [10.3102/10769986001002113, DOI 10.2307/1164979]; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Goldfinger LE, 1999, J CELL SCI, V112, P2615; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; Guerrero-Esteo M, 1999, EUR J CELL BIOL, V78, P614, DOI 10.1016/S0171-9335(99)80046-6; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Jovanovic B D, 2001, Am J Pharmacogenomics, V1, P145, DOI 10.2165/00129785-200101020-00007; JOVANOVIC BD, 2002, ANAL GENE ARRAY DATA; KOZLOWSKI JM, 1984, CANCER RES, V44, P3522; Kyle E, 1997, MOL PHARMACOL, V51, P193, DOI 10.1124/mol.51.2.193; LASTRES P, 1994, BIOCHEM J, V301, P765, DOI 10.1042/bj3010765; Lastres P, 1996, J CELL BIOL, V133, P1109, DOI 10.1083/jcb.133.5.1109; Letamendia A, 1998, J BIOL CHEM, V273, P33011, DOI 10.1074/jbc.273.49.33011; Liu YQ, 2000, CLIN EXP METASTAS, V18, P203, DOI 10.1023/A:1006729106034; LIU YQ, 2001, PROSTATIC DIS, V4, P1; Loganadane LD, 1999, CELL ADHES COMMUN, V7, P57, DOI 10.3109/15419069909034392; Luo Jan, 1997, Pathol Oncol Res, V3, P264; MCALLISTER KA, 1995, HUM MOL GENET, V4, P1983, DOI 10.1093/hmg/4.10.1983; MEREDITH J, 1995, SCIENCE, V269, P1570, DOI 10.1126/science.7545312; MERZAK A, 1994, BRIT J CANCER, V70, P199, DOI 10.1038/bjc.1994.280; NAGLE RB, 1994, J CELL BIOCHEM, P232; Pece-Barbara N, 1999, HUM MOL GENET, V8, P2171, DOI 10.1093/hmg/8.12.2171; Sastry SK, 2000, EXP CELL RES, V261, P25, DOI 10.1006/excr.2000.5043; SCHOENENBERGER CA, 1994, J CELL SCI, V107, P527; Schwartz GN, 1998, ANTISENSE NUCLEIC A, V8, P329, DOI 10.1089/oli.1.1998.8.329; Sharma N, 2002, PROSTATE, V50, P189, DOI 10.1002/pros.10048; Takahashi N, 2001, CLIN CANCER RES, V7, P524; Teti A, 1997, INT J CANCER, V72, P1013; Tremblay L, 1996, INT J CANCER, V68, P164, DOI 10.1002/(SICI)1097-0215(19961009)68:2<169::AID-IJC4>3.0.CO;2-W; WITKOWSKI CM, 1993, J CANCER RES CLIN, V119, P637, DOI 10.1007/BF01215981; Yamada KM, 1997, MATRIX BIOL, V16, P137, DOI 10.1016/S0945-053X(97)90001-9	49	87	94	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 28	2002	21	54					8272	8281		10.1038/sj.onc.1206117	http://dx.doi.org/10.1038/sj.onc.1206117			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447690				2022-12-28	WOS:000179323900005
J	Yuan, JP; Eckerdt, F; Bereiter-Hahn, J; Kurunci-Csacsko, E; Kaufmann, M; Strebhardt, K				Yuan, JP; Eckerdt, F; Bereiter-Hahn, J; Kurunci-Csacsko, E; Kaufmann, M; Strebhardt, K			Cooperative phosphorylation including the activity of polo-like kinase 1 regulates the subcellular localization of cyclin B1	ONCOGENE			English	Article						phosphorylation; cyclin B1; mitotic kinases; polo-like kinase; cell cycle	PROTEIN-KINASE; CELL-CYCLE; NUCLEAR-LOCALIZATION; PROMOTING FACTOR; XENOPUS; P34CDC2; MATURATION; ACTIVATION; CDC2; PLK	The cyclin-dependent kinase 1 (Cdc2)/cyclin B1 complex performs cardinal roles for eukaryotic mitotic progression. Phosphorylation of four serine residues within cyclin B1 promotes the rapid nuclear translocation of Cdc2/cyclin B1 at the G(2)/M transition. Still, the role of individual phosphorylation sites and their corresponding kinases remain to be elucidated. Polo-like kinase I (Plk1) shows a spatial and temporal distribution which makes it a candidate kinase for the phosphorylation of cyclin B1. We could demonstrate the interaction of both proteins in mammalian cells. Plk1 phosphorylated wildtype cyclin 111 expressed in bacteria and in mammalian cells. Ser-133 within the cytoplasmic retention signal (CRS) of cyclin B1, which regulates the nuclear entry of the heterodimeric complex during prophase, is a target of Plk1. In contrast, MAPK (Erk2) and MPF phosphorylate Ser-126 and Ser-128 within the CRS. Phosphorylation of CRS by MAPK (Erk2) prior to Plk1 treatment induced enhanced phosphorylation of cyclin 131 by Plk1 suggesting a synergistic action of both enzymes towards cyclin B1. In addition, pretreatment of cyclin B1 by MAPK (Erk2) altered the phosphorylation pattern of Plk 1. Mutation of Ser-133 to Ala decreased the phosphorylation of cyclin 131 in vivo. An immunofluorescence study revealed that a mutation of Ser-133 reduced the nuclear import rate of cyclin B1. Still, multiple serine mutations are required to prevent nuclear translocation completely indicating that orchestrated phosphorylation within the CRS triggers rapid import of cyclin B1.	Univ Frankfurt, Dept Obstet & Gynecol, D-60590 Frankfurt, Germany; Univ Frankfurt, Dept Biol, D-60439 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt	Strebhardt, K (corresponding author), Univ Frankfurt, Dept Obstet & Gynecol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.		Strebhardt, Klaus/E-8765-2011	Strebhardt, Klaus/0000-0003-2173-9763				BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; Borgne A, 1999, J BIOL CHEM, V274, P11977, DOI 10.1074/jbc.274.17.11977; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; Clute P, 1999, NAT CELL BIOL, V1, P82, DOI 10.1038/10049; Cogswell JP, 2000, CELL GROWTH DIFFER, V11, P615; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GAUTIER J, 1991, EMBO J, V10, P177, DOI 10.1002/j.1460-2075.1991.tb07934.x; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Hagting A, 1999, CURR BIOL, V9, P680, DOI 10.1016/S0960-9822(99)80308-X; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; Hock B, 1998, ONCOGENE, V17, P255, DOI 10.1038/sj.onc.1201907; Holtrich U, 2000, ONCOGENE, V19, P4832, DOI 10.1038/sj.onc.1203845; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; IZUMI T, 1991, MOL CELL BIOL, V11, P3860, DOI 10.1128/MCB.11.8.3860; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; LAKE RJ, 1993, MOL CELL BIOL, V13, P7793, DOI 10.1128/MCB.13.12.7793; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; LEE KS, 1995, MOL CELL BIOL, V15, P7143; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; LI JK, 1995, MOL BIOL CELL, V6, P1111, DOI 10.1091/mbc.6.9.1111; Lin CY, 2000, P NATL ACAD SCI USA, V97, P12589, DOI 10.1073/pnas.220423497; MEIJER L, 1991, EMBO J, V10, P1545, DOI 10.1002/j.1460-2075.1991.tb07674.x; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Ohi R, 1999, CURR OPIN CELL BIOL, V11, P267, DOI 10.1016/S0955-0674(99)80036-2; Porter CM, 2000, J BIOL CHEM, V275, P3543, DOI 10.1074/jbc.275.5.3543; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Yang J, 2001, J BIOL CHEM, V276, P3604, DOI 10.1074/jbc.M008151200; Yuan JP, 1997, AM J PATHOL, V150, P1165	37	108	112	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 28	2002	21	54					8282	8292		10.1038/sj.onc.1206011	http://dx.doi.org/10.1038/sj.onc.1206011			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447691				2022-12-28	WOS:000179323900006
J	Chen, MW; Vacherot, F; de la Taille, A; Gil-Diez-de-Medina, S; Shen, RQ; Friedman, RA; Burchardt, M; Chopin, DK; Buttyan, R				Chen, MW; Vacherot, F; de la Taille, A; Gil-Diez-de-Medina, S; Shen, RQ; Friedman, RA; Burchardt, M; Chopin, DK; Buttyan, R			The emergence of protocadherin-PC expression during the acquisition of apoptosis-resistance by prostate cancer cells	ONCOGENE			English	Article						prostate cancer; hormone-resistance; apoptosis; protocadherins; beta-catenin	ANDROGEN RECEPTOR MUTATIONS; IN-SITU HYBRIDIZATION; Y-CHROMOSOME GENES; PROTEIN; BCL-2; IDENTIFICATION; INDUCTION; CARCINOMA; CADHERIN; THERAPY	In order to identify gene products associated with the development of acquired therapeutic resistance by prostate cancer cells, we created two novel apoptosis-resistant prostate cancer cell lines, LNCaP-TR (phorbol-ester [TPA]-Resistant) and LNCaP-SSR (Serum Starvation-Resistant) by repeated transient exposure of cultured human LNCaP cells to apoptotic stimuli followed by expansion of surviving cell populations. These cell lines were found to be cross-resistant to the alternative selective agent and also hormone-resistant when xenografted into castrated male immunodeficient mice. RNA from the LNCaP-TR line was comparatively screened using a subtractive hybridization-PCR procedure. This allowed us to identify a 249 bp cDNA fragment that hybridized to a 4.8 kb mRNA preferentially expressed toy the apoptosis-resistant cells. Using RACE procedures, we cloned and sequenced the complete 4.8 kb cDNA. It is an unusual member of the protocadherin gene family containing two large overlapping open reading frames encoding homologous polypeptides, one having a signal sequence and the other lacking a signal sequence and we refer to it as protocadherin-PC. LNCaP cells directly transformed with protocadherin-PC cDNA were comparatively resistant to phorbol-ester induced apoptosis. Antibody recognition studies demonstrating the cytoplasmic nature of the protcadherin-PC translation product and its propensity to bind beta-catenin suggest that it might influence the apoptotic sensitivity of prostate cancer cells through a unique mechanism.	Columbia Univ Coll Phys & Surg, Dept Urol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Comp & Informat Resource Ctr, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Univ Paris 07, INSERM, CHU Henri Mondor, Serv Urol,EMI 99 09,Assistance Publ Hop Paris, Paris, France	Columbia University; Columbia University; Columbia University; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite	Buttyan, R (corresponding author), Herbert Irving Pavil,11th Floor,161 Ft Washington, New York, NY 10032 USA.	rb46@columbia.edu	Vacherot, Francis/R-6588-2018; de la taille, Alex/ABE-8422-2021	Vacherot, Francis/0000-0002-3677-1267; 				Blanco P, 2000, MAMM GENOME, V11, P906, DOI 10.1007/s003350010177; Brothman AR, 1997, CANCER GENET CYTOGEN, V95, P116, DOI 10.1016/S0165-4608(96)00302-0; Bucher P, 1996, COMPUT CHEM, V20, P3, DOI 10.1016/S0097-8485(96)80003-9; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; Chesire DR, 2002, ONCOGENE, V21, P2679, DOI 10.1038/sj.onc.1205352; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; Dasari VK, 2001, J UROLOGY, V165, P1335, DOI 10.1016/S0022-5347(01)69895-1; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDDY S, 1998, HMMER USERS GUIDE BI; Furuya Y, 1996, CLIN CANCER RES, V2, P389; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115; Hsiao PW, 1999, J BIOL CHEM, V274, P22373, DOI 10.1074/jbc.274.32.22373; Huggins C, 1941, CANCER RES, V1, P293; Karan D, 2001, CLIN CANCER RES, V7, P3472; Krajewska M, 1996, AM J PATHOL, V148, P1567; Lau YFC, 2000, MOL CARCINOGEN, V27, P308, DOI 10.1002/(SICI)1098-2744(200004)27:4<308::AID-MC9>3.0.CO;2-R; Marcelli M, 2000, CANCER RES, V60, P944; McDonnell TJ, 1997, J UROLOGY, V157, P569, DOI 10.1016/S0022-5347(01)65204-2; MURPHY GP, 1980, UROL CLIN N AM, V7, P631; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Pearson WR, 1996, METHOD ENZYMOL, V266, P227; RAFFO AJ, 1995, CANCER RES, V55, P4438; Resnick M I, 1975, Urol Clin North Am, V2, P141; ROST B, 1995, PROTEIN SCI, V4, P521; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; Shen R, 1997, Urol Oncol, V3, P67, DOI 10.1016/S1078-1439(97)00039-2; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; Sonnhammer ELL, 1997, PROTEINS, V28, P405, DOI 10.1002/(SICI)1097-0134(199707)28:3<405::AID-PROT10>3.0.CO;2-L; STAPPERT J, 1994, CELL ADHES COMMUN, V2, P319, DOI 10.3109/15419069409014207; Suzuki ST, 1996, J CELL BIOCHEM, V61, P531, DOI 10.1002/(SICI)1097-4644(19960616)61:4<531::AID-JCB6>3.0.CO;2-P; Takahashi S, 1996, CLIN CANCER RES, V2, P137; Taplin ME, 1999, CANCER RES, V59, P2511; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Tricoli JV, 1999, CANCER GENET CYTOGEN, V111, P1, DOI 10.1016/S0165-4608(98)00212-X; VANDERKWAST TH, 1991, INT J CANCER, V48, P189, DOI 10.1002/ijc.2910480206; Wang X, 2001, J BIOL CHEM, V276, P40417, DOI 10.1074/jbc.M104765200; Wootton JC, 1996, METHOD ENZYMOL, V266, P554; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; Yoshida K, 1999, GENOMICS, V62, P540, DOI 10.1006/geno.1999.6042; ZHANG XJ, 1994, BIOCHEM BIOPH RES CO, V198, P1189, DOI 10.1006/bbrc.1994.1168; [No title captured]	45	52	58	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2002	21	51					7861	7871		10.1038/sj.onc.1205991	http://dx.doi.org/10.1038/sj.onc.1205991			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	610DT	12420223				2022-12-28	WOS:000178946000011
J	Marchetti, B; Ashrafi, GH; Tsirimonaki, E; O'Brien, PM; Campo, MS				Marchetti, B; Ashrafi, GH; Tsirimonaki, E; O'Brien, PM; Campo, MS			The bovine papillomavirus oncoprotein E5 retains MHC class I molecules in the Golgi apparatus and prevents their transport to the cell surface	ONCOGENE			English	Article						papillomavirus; E5; MHC class I; immune evasion; Golgi apparatus	INTERCELLULAR COMMUNICATION; TRANSFORMING FUNCTIONS; DOWN-REGULATION; E8 PROTEIN; TYPE-4 E8; MONENSIN; DUCTIN; BINDS; MECHANISMS; EXPRESSION	During papillomavirus infection, the E5 protein localizes in the cell Golgi apparatus and other endomembrane compartments. Cells transformed by E5 do not express major histocompatibility class I complex (MHC 1) on the cell surface, while cells transformed by the other transforming proteins E6 and E7 do. In addition, the total amount of both MHC I protein and mRNA is reduced in E5-transformed cells. Here we show that expression of bovine papillomavirus E5 causes the retention of MHC I in the Golgi apparatus, thus preventing its transport to the cell surface. We ascribe this effect to a failure of acidification of the Golgi apparatus, as similar effects are observed in control cells treated with the ionophore monensin. Treatment of E5-transformed cells with either beta- or gamma-interferon increases the synthesis of MHC 1, showing that inhibition of MHC I expression by E5 is not irreversible. However, even after interferon treatment, MHC 1, although increased in quantity, is not transported to the cell surface. E5 therefore affects MHC I at several levels, but prevention of MHC I transport to the cell surface appears to be the dominant effect. Lack of surface MHC I would have profound consequences for presentation of viral peptides to the immune system.	Univ Glasgow, Sch Vet, Inst Comparat Med, Glasgow G61 1QH, Lanark, Scotland	University of Glasgow	Campo, MS (corresponding author), Univ Glasgow, Sch Vet, Inst Comparat Med, Garscube Estate, Glasgow G61 1QH, Lanark, Scotland.	s.campo@vet.gla.ac.uk		Ashrafi, G. Hossein/0000-0002-4516-5111				Agrawal S, 2000, J HEMATOTH STEM CELL, V9, P795, DOI 10.1089/152581600750062237; Anderson RA, 1997, VET J, V154, P69, DOI 10.1016/S1090-0233(05)80010-3; ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0; Ashby ADM, 2001, J GEN VIROL, V82, P2353, DOI 10.1099/0022-1317-82-10-2353; Ashrafi GH, 2000, J GEN VIROL, V81, P689, DOI 10.1099/0022-1317-81-3-689; Ashrafi GH, 2002, ONCOGENE, V21, P248; ASHRAFI GH, 1998, THESIS GLASGOW U UK; Bachert C, 2001, MOL BIOL CELL, V12, P3152, DOI 10.1091/mbc.12.10.3152; Barr FA, 1998, EMBO J, V17, P3258, DOI 10.1093/emboj/17.12.3258; BENSAID A, 1989, ANIM GENET, V20, P241; BOSS WF, 1984, EUR J CELL BIOL, V34, P1; Briggs MW, 2001, VIROLOGY, V280, P169, DOI 10.1006/viro.2000.0783; BURKHARDT A, 1989, VIROLOGY, V170, P334, DOI 10.1016/0042-6822(89)90391-7; BURNETT S, 1992, P NATL ACAD SCI USA, V89, P5665, DOI 10.1073/pnas.89.12.5665; Chang JL, 2001, J BIOMED SCI, V8, P206, DOI 10.1007/BF02256414; Chikuma T, 2002, NEUROSCI LETT, V326, P89, DOI 10.1016/S0304-3940(02)00329-4; CONRAD M, 1993, J VIROL, V67, P6170, DOI 10.1128/JVI.67.10.6170-6178.1993; DiMaio D, 2001, ONCOGENE, V20, P7866, DOI 10.1038/sj.onc.1204915; Faccini AM, 1996, J VIROL, V70, P9041, DOI 10.1128/JVI.70.12.9041-9045.1996; FINBOW ME, 1995, BIOESSAYS, V17, P247, DOI 10.1002/bies.950170311; FRANCHINI G, 1993, J VIROL, V67, P7701, DOI 10.1128/JVI.67.12.7701-7704.1993; FRAZER JH, 1996, PAPILLOMAVIRUS REV, P151; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; GRAHAM SP, 1995, J COMP PATHOL, V112, P185, DOI 10.1016/S0021-9975(05)80060-X; Halaban R, 2002, J BIOL CHEM, V277, P14821, DOI 10.1074/jbc.M111497200; HAM J, 1991, TRENDS BIOCHEM SCI, V16, P440, DOI 10.1016/0968-0004(91)90172-R; JACKSON ME, 1991, MOL CARCINOGEN, V4, P382, DOI 10.1002/mc.2940040510; Johnson JM, 2001, J VIROL, V75, P6086, DOI 10.1128/JVI.75.13.6086-6094.2001; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Morgan IM, 2000, PAPILLOMAVIRUS REP, V11, P127; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; O'Brien V, 1999, VIROLOGY, V255, P385, DOI 10.1006/viro.1998.9563; OBRIEN PM, 2002, VIRUS RES VIRUS ESCA; OELZE I, 1995, J VIROL, V69, P4489, DOI 10.1128/JVI.69.7.4489-4494.1995; PENNIE WD, 1993, VIROLOGY, V193, P614, DOI 10.1006/viro.1993.1169; RAPOSO G, 1995, J CELL BIOL, V131, P1403, DOI 10.1083/jcb.131.6.1403; Schapiro F, 2000, J CELL BIOL, V148, P305, DOI 10.1083/jcb.148.2.305; Schoonderwoert VTG, 2002, EUR J BIOCHEM, V269, P1844, DOI 10.1046/j.1432-1033.2002.02831.x; Skinner MA, 2001, J BIOL CHEM, V276, P48451, DOI 10.1074/jbc.M103569200; STRAIGHT SW, 1995, J VIROL, V69, P3185, DOI 10.1128/JVI.69.5.3185-3192.1995; Surti T, 1998, PROTEINS, V33, P601; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; Thomsen P, 2000, ONCOGENE, V19, P6023, DOI 10.1038/sj.onc.1204010; Tindle RW, 2002, NAT REV CANCER, V2, P59, DOI 10.1038/nrc700; TOYE PG, 1990, IMMUNOLOGY, V70, P20; Yewdell JW, 1999, ANNU REV CELL DEV BI, V15, P579, DOI 10.1146/annurev.cellbio.15.1.579; ZHANG GF, 1993, J CELL SCI, V104, P819; Zhang GF, 1996, EUR J CELL BIOL, V71, P332	48	60	64	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2002	21	51					7808	7816		10.1038/sj.onc.1205885	http://dx.doi.org/10.1038/sj.onc.1205885			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	610DT	12420217				2022-12-28	WOS:000178946000005
J	Xi, YG; Ding, KY; Ren, YH; Shen, Y; Ke, Y				Xi, YG; Ding, KY; Ren, YH; Shen, Y; Ke, Y			Esophageal cancer in Chinese population: no polymorphism in codon 149 of P21(Waf1/Cip1) cyclin dependent kinase gene	ONCOGENE			English	Article						P21(Waf1/Cip1); esophageal cancer; single nucleotide polymorphism	DNA-REPLICATION; INHIBITOR GENE; CELL-CYCLE; EXPRESSION; P21; WAF1; P53; ASSOCIATION; WAF1/CIP1; SEQUENCE	It has recently been suggested that people of the Indian population who carried the codon 149 polymorphism (G (A) under barT-->G (G) under barT) of P21(Waf1/Cip1) gene were more susceptible to esophageal cancer and oral cancer than the individuals without that polymorphism. Since esophageal cancer is a high incident neoplasm in China, we analysed the same codon of P21(Waf1/Cip1) in the Chinese population. Blood samples from 80 esophageal cancer patients and 80 normal blood donors were collected for DNA extraction. Methods of Polymerase Chain Reaction (PCR) and direct sequencing were used for detection of the polymorphism in codon 149 of P21(Waf/Cip1). Bioinformatics analysis was also thoroughly performed for this gene. No polymorphism was found in all samples tested. Bioinformatics analysis revealed that the so-called polymorphism of codon 149 reported previously was a wrong one. In conclusion, no polymorphism exists in codon 149 of P21(Waf1/Cip1). It is not appropriate to use it as a susceptible site of the gene in cancer study.	Peking Univ, Sch Oncol, Beijing Inst Canc Res, Genet Lab, Beijing 100034, Peoples R China; Peking Union Med Coll, Natl Lab Med Mol Biol, Beijing 100005, Peoples R China; Chinese Natl Human Genome Ctr, Beijing 100176, Peoples R China	Peking University; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Ke, Y (corresponding author), Peking Univ, Sch Oncol, Beijing Inst Canc Res, Genet Lab, 1 Da Hong Luo Chang St,Western Dist, Beijing 100034, Peoples R China.			Xi, Yaguang/0000-0003-3681-9352; Ding, Keyue/0000-0002-3496-6415				Bahl R, 2000, ONCOGENE, V19, P323, DOI 10.1038/sj.onc.1203325; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; CHEDID M, 1994, ONCOGENE, V9, P3021; CHEN J, 1995, NATURE, V375, P386; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Florea L, 1998, GENOME RES, V8, P967, DOI 10.1101/gr.8.9.967; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; GOUBIN F, 1995, ONCOGENE, V10, P2281; GUJULUVA CN, 1994, ONCOGENE, V9, P1819; HUPPI K, 1994, ONCOGENE, V9, P3017; JIANG HP, 1994, ONCOGENE, V9, P3397; Nickerson DA, 1997, NUCLEIC ACIDS RES, V25, P2745, DOI 10.1093/nar/25.14.2745; Ralhan R, 2000, CLIN CANCER RES, V6, P2440; SHEIKH MS, 1994, ONCOGENE, V9, P3407; Zeng YX, 1996, ONCOGENE, V12, P1557	18	4	5	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 31	2002	21	50					7745	7748		10.1038/sj.onc.1205873	http://dx.doi.org/10.1038/sj.onc.1205873			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	606VW	12400017				2022-12-28	WOS:000178756200014
J	Heliez, C; Baricault, L; Barboule, N; Valette, A				Heliez, C; Baricault, L; Barboule, N; Valette, A			Paclitaxel increases p21 synthesis and accumulation of its AKT-phosphorylated form in the cytoplasm of cancer cells	ONCOGENE			English	Article						paclitaxel; p21 localization and phosphorylation	CYCLE ARREST; MICROTUBULE DISRUPTION; MITOTIC EXIT; P53; APOPTOSIS; G(1); P21(WAF1); INHIBITOR; G1; OVEREXPRESSION	CKI p21 is a regulator of cellular responses to microtubule damage induced by drugs such as paclitaxel (PTX). It mediates the G1 4N arrest postactivation of the spindle assembly checkpoint and protects cancer cells against PTX-induced cytotoxicity. We demonstrated here that low doses of PTX that are unable to activate the spindle assembly checkpoint, upregulate p21 by a p53-dependent pathway and induce its translocation to the cytoplasm. This cytoplasmic accumulation of p21 resulted from an AKT-dependent p21 phosphorylation leading to an association of p21 with 14-3-3. Furthermore, the cytoplasmic p21 accumulation observed in PTX-treated cells was inhibited by LY 294002, a specific PI-3 kinase inhibitor or by the expression of a dominant-negative AKT mutant. However, the kinase activity of AKT was unchanged in PTX-treated cells, suggesting that low doses of PTX could regulate p21 phosphorylation via inhibition of its dephosphorylation. As a functional consequence, we found that cytoplasmic accumulation of the phosphorylated form of p21 prevents the inhibitory effect of p21, enabling these cells to escape to the p53-dependent GI/S and G2/M checkpoints.	Univ Toulouse 3, CNRS, UMR 5088, IFR 109,LBCMCP, F-31062 Toulouse 4, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Valette, A (corresponding author), Univ Toulouse 3, CNRS, UMR 5088, IFR 109,LBCMCP, Bat 4R3B1,118 Route Narbonne, F-31062 Toulouse 4, France.	valette@cict.fr	Baricault, Laurent/G-3396-2017					Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Barboule N, 1997, ONCOGENE, V15, P2867, DOI 10.1038/sj.onc.1201469; Blagosklonny MV, 2000, J CLIN INVEST, V105, P533, DOI 10.1172/JCI8625; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; Blajeski AL, 2002, J CLIN INVEST, V110, P91, DOI 10.1172/JCI200213275; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; Chen JG, 2002, CANCER RES, V62, P1935; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Giannakakou P, 2001, ONCOGENE, V20, P3806, DOI 10.1038/sj.onc.1204487; Gorospe M, 1999, GENE EXPRESSION, V7, P377; HARPER JW, 1993, CELL, V75, P805; Jordan MA, 1996, CANCER RES, V56, P816; Khan SH, 1998, CANCER RES, V58, P396; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Lawrence JW, 2001, J BIOL CHEM, V276, P31521, DOI 10.1074/jbc.M103306200; Li WW, 1999, MOL PHARMACOL, V55, P1088, DOI 10.1124/mol.55.6.1088; Mitsuuchi Y, 2000, CANCER RES, V60, P5390; Rossig L, 2001, MOL CELL BIOL, V21, P5644, DOI 10.1128/MCB.21.16.5644-5657.2001; Sablina AA, 2001, ONCOGENE, V20, P899, DOI 10.1038/sj.onc.1204156; Schmidt M, 2000, ONCOGENE, V19, P2423, DOI 10.1038/sj.onc.1203546; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Stewart ZA, 1999, CANCER RES, V59, P3831; Stewart ZA, 2001, ONCOGENE, V20, P113, DOI 10.1038/sj.onc.1204060; Stewart ZA, 1999, MOL CELL BIOL, V19, P205; Torres K, 1998, CANCER RES, V58, P3620; Trielli MO, 1996, J CELL BIOL, V135, P689, DOI 10.1083/jcb.135.3.689; Vikhanskaya F, 1998, EXP CELL RES, V241, P96, DOI 10.1006/excr.1998.4018; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zugasti O, 2001, MOL CELL BIOL, V21, P6706, DOI 10.1128/MCB.21.19.6706-6717.2001	33	54	56	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2003	22	21					3260	3268		10.1038/sj.onc.1206409	http://dx.doi.org/10.1038/sj.onc.1206409			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681MM	12761496				2022-12-28	WOS:000183040000008
J	Kovar, H; Pospisilova, S; Jug, G; Printz, D; Gadner, H				Kovar, H; Pospisilova, S; Jug, G; Printz, D; Gadner, H			Response of Ewing tumor cells to forced and activated p53 expression	ONCOGENE			English	Article						Ewing's sarcoma; apoptosis; p53; EWS-FLI1; irradiation	P53-DEPENDENT GROWTH ARREST; WILD-TYPE P53; PROGNOSTIC IMPACT; DNA-DAMAGE; P53-MEDIATED APOPTOSIS; ANTICANCER AGENTS; ADENOVIRUS E1A; PROTEIN-KINASE; CYCLE ARREST; C-MYC	The EWS-FLI1 transcription factor is consistently expressed in 85% of Ewing tumors (EFT). In heterologous cells, EWS-FLI1 induces p53-dependent cell cycle arrest or apoptosis. It has been speculated that the p53 tumor suppressor pathway may be generally compromised in EFT despite only rare p53 mutations. In order to test for functional integrity of this pathway, we have investigated a series of EFT cell lines that differ from each other with respect to their endogenous p53 and INK4A gene status for their response to ectopic p53 expression and to stimulation of endogenous p53 activity by X-ray treatment. Significant interindividual and intratumoral variations in the apoptotic propensity of EFT cell lines to transient expression of ectopic p53 were observed, which was independent of the level of p53 expression. In cell lines with a low apoptotic incidence, apoptosis was delayed and the surviving fraction showed a prolonged growth arrest. Complete resistance to p53-induced apoptosis in two cell lines established from the same patient was associated with a high BCL2/BAX ratio and low levels of APAF1. Sensitivity to X-rays showed a trend towards a higher apoptotic rate in wild-type (wt) p53 expressing than in p53 mutant cells. However, one wt p53-expressing EFT cell line was completely refractory to irradiation-stimulated cell death despite high apoptotic responsiveness to ectopic p53. No difference in Ser15 phosphorylation and the transcriptional activation of p53 targets was observed in wt p53 EFT cell lines irrespective of the induction of cell death or growth arrest. All together, our results demonstrate that despite significant variability in the outcome, cell death or cell cycle arrest, the p53 downstream pathway and the DNA damage signaling pathway are functionally intact in EFT.	St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria	Saint Anna Children's Hospital	Kovar, H (corresponding author), St Anna Childrens Hosp, Childrens Canc Res Inst, Kinderspitalgasse 6, A-1090 Vienna, Austria.		Pospisilova, Sarka/D-7200-2012	Pospisilova, Sarka/0000-0001-7136-2680; Kovar, Heinrich/0000-0001-6873-9109				Beltinger CP, 1996, GENOMICS, V35, P94, DOI 10.1006/geno.1996.0327; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; de Alava E, 2000, CANCER-AM CANCER SOC, V89, P783, DOI 10.1002/1097-0142(20000815)89:4<783::AID-CNCR10>3.0.CO;2-Q; DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503; Deneen B, 2001, ONCOGENE, V20, P6731, DOI 10.1038/sj.onc.1204875; Di Como CJ, 1998, ONCOGENE, V16, P2527; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Gorgoulis VG, 1998, BRIT J CANCER, V77, P374, DOI 10.1038/bjc.1998.60; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Grenet J, 1998, GENOMICS, V49, P385, DOI 10.1006/geno.1998.5300; Guimaraes DP, 2002, BIOCHIMIE, V84, P83, DOI 10.1016/S0300-9084(01)01356-6; Hadano S, 1999, MAMM GENOME, V10, P757; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; HAMELIN R, 1994, INT J CANCER, V57, P336, DOI 10.1002/ijc.2910570308; Hattinger CM, 1999, GENE CHROMOSOME CANC, V24, P243, DOI 10.1002/(SICI)1098-2264(199903)24:3<243::AID-GCC10>3.0.CO;2-A; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAUPT Y, 1995, ONCOGENE, V10, P1563; HERMEKING H, 1995, ONCOGENE, V11, P1409; Ichimiya S, 1999, ONCOGENE, V18, P1061, DOI 10.1038/sj.onc.1202390; Kovar H, 1997, ONCOGENE, V15, P2225, DOI 10.1038/sj.onc.1201397; KOVAR H, 1993, ONCOGENE, V8, P2683; Kovar H, 2000, CANCER RES, V60, P1557; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; Kovar H, 2000, ONCOGENE, V19, P4096, DOI 10.1038/sj.onc.1203780; Kovar Heinrich, 1998, Current Opinion in Oncology, V10, P334, DOI 10.1097/00001622-199807000-00010; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LADANYI M, 1995, J PATHOL, V175, P211, DOI 10.1002/path.1711750209; Lahti J M, 1995, Prog Cell Cycle Res, V1, P329; Lassus P, 1996, EMBO J, V15, P4566, DOI 10.1002/j.1460-2075.1996.tb00834.x; Lessnick SL, 2002, CANCER CELL, V1, P393, DOI 10.1016/S1535-6108(02)00056-9; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MCKEON C, 1988, CANCER RES, V48, P4307; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; Mukae N, 1998, P NATL ACAD SCI USA, V95, P9123, DOI 10.1073/pnas.95.16.9123; OConnor PM, 1997, CANCER RES, V57, P4285; OUCHIDA M, 1995, ONCOGENE, V11, P1049; PARK DJ, 1994, ONCOGENE, V9, P1899; Pietenpol JA, 1996, P NATL ACAD SCI USA, V93, P8390, DOI 10.1073/pnas.93.16.8390; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RENZING J, 1995, ONCOGENE, V10, P1865; Sanchez-Prieto R, 1999, NAT MED, V5, P1076, DOI 10.1038/12516; Sollazzo MR, 1999, TUMORI, V85, P167, DOI 10.1177/030089169908500304; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tanaka K, 1997, J CLIN INVEST, V99, P239, DOI 10.1172/JCI119152; Thomas M, 1999, ONCOGENE, V18, P7690, DOI 10.1038/sj.onc.1202953; Toretsky JA, 1997, J NEURO-ONCOL, V31, P9, DOI 10.1023/A:1005716926800; VECCHIO G, 1989, ONCOGENE, V4, P897; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wei G, 2000, CANCER-AM CANCER SOC, V89, P793, DOI 10.1002/1097-0142(20000815)89:4<793::AID-CNCR11>3.0.CO;2-M; Woo RA, 2002, EMBO J, V21, P3000, DOI 10.1093/emboj/cdf307; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yonish-Rouach E, 1994, Cell Death Differ, V1, P39; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x; Zucman-Rossi J, 1998, P NATL ACAD SCI USA, V95, P11786, DOI 10.1073/pnas.95.20.11786	57	20	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 22	2003	22	21					3193	3204		10.1038/sj.onc.1206391	http://dx.doi.org/10.1038/sj.onc.1206391			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681MM	12761489				2022-12-28	WOS:000183040000001
J	Tourneur, L; Mistou, S; Michiels, FM; Devauchelle, V; Renia, L; Feunteun, J; Chiocchia, G				Tourneur, L; Mistou, S; Michiels, FM; Devauchelle, V; Renia, L; Feunteun, J; Chiocchia, G			Loss of FADD protein expression results in a biased Fas-signaling pathway and correlates with the development of tumoral status in thyroid follicular cells	ONCOGENE			English	Article						FADD; Fas ligand; thyroid; tumor	FLICE-INHIBITORY PROTEIN; COLON-CANCER CELLS; IMMUNE EVASION; DEATH PATHWAY; TRANSGENIC EXPRESSION; LYMPHOCYTE APOPTOSIS; LIGAND EXPRESSION; ENTRY SITE; PROLIFERATION; CD95	Downregulation of proapoptotic molecules like Fas or caspase 8, or upregulation of antiapoptotic molecules like FLICE inhibitory protein has been suggested to be a regulatory mechanism set up by tumor cells to block the death signal received via death receptors. In an in-depth study of the Fas/FasL-signaling pathway in thyroid tumor development, we have demonstrated that tumor cells specifically downregulate the multideath receptor adapter Fas-associated death domain (FADD). The regulation of FADD expression occurred only at the protein level. Furthermore, in the absence of FADD, Fas-signaling resulted in accelerated growth of thyrocytes. Since thyrocytes also acquired FasL expression during tumor development, the absence of FADD protein could lead to greater resistance to numerous death receptor-mediated apoptosis, stimulation of their own proliferation through Fas/FasL interaction, and the capacity to counter-attack the infiltrating lymphocytes.	Univ Paris 05, Inst Cochin, Dept Immunol, IFR 116,CNRS,UMR 8104,INSERM,U567, F-75014 Paris, France; Inst Gustave Roussy, Oncol Mol Lab, CNRS, Unite Rech Associee 1158, F-94805 Villejuif, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Chiocchia, G (corresponding author), Univ Paris 05, Inst Cochin, Dept Immunol, IFR 116,CNRS,UMR 8104,INSERM,U567, 27 Rue Fbg St Jacques, F-75014 Paris, France.		Feunteun, Jean/AAZ-1267-2020; CHIOCCHIA, Gilles R/F-6287-2013; Renia, Laurent/E-2117-2011	CHIOCCHIA, Gilles R/0000-0001-9973-0940; Renia, Laurent/0000-0003-0349-1557; Feunteun, Jean/0000-0003-1212-9189				Baker JR, 1999, J CLIN ENDOCR METAB, V84, P2593, DOI 10.1210/jc.84.8.2593; Batteux F, 2000, J IMMUNOL, V164, P1681, DOI 10.4049/jimmunol.164.4.1681; Bernstein J, 1997, J BIOL CHEM, V272, P9356; Bretz JD, 1999, J BIOL CHEM, V274, P23627, DOI 10.1074/jbc.274.33.23627; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Clemens MJ, 2000, CELL DEATH DIFFER, V7, P603, DOI 10.1038/sj.cdd.4400695; Desbarats J, 2000, NAT MED, V6, P920, DOI 10.1038/78688; Desbarats J, 1999, P NATL ACAD SCI USA, V96, P8104, DOI 10.1073/pnas.96.14.8104; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; Droin N, 2001, ONCOGENE, V20, P260, DOI 10.1038/sj.onc.1204066; Droin N, 2000, CANCER RES, V60, P7039; DUMONT JE, 1992, PHYSIOL REV, V72, P667, DOI 10.1152/physrev.1992.72.3.667; Favre-Felix N, 2000, J IMMUNOL, V164, P5023, DOI 10.4049/jimmunol.164.10.5023; Freiberg RA, 1997, J INVEST DERMATOL, V108, P215, DOI 10.1111/1523-1747.ep12334273; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Giordano C, 1997, SCIENCE, V275, P960, DOI 10.1126/science.275.5302.960; Hiromatsu Y, 1999, J CLIN ENDOCR METAB, V84, P2896, DOI 10.1210/jc.84.8.2896; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Kim PKM, 1996, J IMMUNOL, V157, P5461; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; MAZIER D, 1985, SCIENCE, V227, P440, DOI 10.1126/science.3880923; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; MICHIELS FM, 1994, P NATL ACAD SCI USA, V91, P10488, DOI 10.1073/pnas.91.22.10488; Miller DL, 1998, FEBS LETT, V434, P417, DOI 10.1016/S0014-5793(98)01025-4; Mitsiades N, 1999, J CLIN ENDOCR METAB, V84, P2924, DOI 10.1210/jc.84.8.2924; MOLLER P, 1994, INT J CANCER, V57, P371, DOI 10.1002/ijc.2910570314; Nagata S, 1996, NAT MED, V2, P1306, DOI 10.1038/nm1296-1306; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Newton K, 2000, EMBO J, V19, P931, DOI 10.1093/emboj/19.5.931; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; OWENSCHAUB LB, 1993, J IMMUNOTHER, V14, P234, DOI 10.1097/00002371-199310000-00011; Pomerance M, 2000, J BIOL CHEM, V275, P40539, DOI 10.1074/jbc.M002097200; Restifo NP, 2000, NAT MED, V6, P493, DOI 10.1038/74955; SAID S, 1994, J ENDOCRINOL INVEST, V17, P371, DOI 10.1007/BF03349004; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; SUAREZ HG, 1991, ONCOGENE, V6, P677; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Tourneur U, 2001, J IMMUNOL, V167, P1338, DOI 10.4049/jimmunol.167.3.1338; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681	46	47	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2003	22	18					2795	2804		10.1038/sj.onc.1206399	http://dx.doi.org/10.1038/sj.onc.1206399			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ	12743602				2022-12-28	WOS:000182569300010
J	Li, ML; Ren, SX; Tilli, MT; Flaws, JA; Lubet, R; Grubbs, CJ; Furth, PA				Li, ML; Ren, SX; Tilli, MT; Flaws, JA; Lubet, R; Grubbs, CJ; Furth, PA			Chemoprevention of mammary carcinogenesis in a transgenic mouse model by alpha-difluoromethylornithine (DFMO) in the diet is associated with decreased cyclin D1 activity	ONCOGENE			English	Article						DFMO; cell proliferation; apoptosis; cyclin D1; transgenic mouse model; mammary cancer progression	CANCER CELL-LINES; TUMOR PROGRESSION; ORNITHINE DECARBOXYLASE; GROWTH-INHIBITION; MICE; APOPTOSIS; PROLIFERATION; EXPRESSION; INDUCTION; PROTEIN	Mechanisms underlying the chemopreventive effect of difluoromethylornithine (DFMO) on the development of mammary cancer were investigated utilizing the whey acidic protein promoter-T antigen transgenic mouse model of breast cancer progression. Mice were exposed to four different doses of DFMO in the diet (3.5, 4.9, 7.0 and 10 g/kg diet). Tumor latency was increased in a dose-dependent manner. DFMO at the highest dose significantly delayed tumor onset (131 days as compared to 109 days in control unexposed mice, P=0.018). Analyses of preneoplastic mammary tissue collected 1 month after DFMO treatment demonstrated that DFMO (10 g/kg diet) significantly increased the ratio of apoptotic to proliferative indices (P = 0.013) and significantly reduced the percentage of cells demonstrating nuclear localized cyclin D1 (P = 0.013). Nuclear localizations of p27, p21 and Stat5a were not affected. Inhibitory effects of DFMO on cell growth and survival were lost as the cells progressed to cancer. In conclusion, the chemopreventive effects of DFMO on mammary cancer progression were mediated by changes in both apoptosis and cell proliferation in preneoplastic cells. Alterations in cyclin D1 activity in preneoplastic cells could represent an early biomarker of chemopreventive action and are consistent with a mechanistic role for cyclin D1 in progression of mammary cancer.	Georgetown Univ, Lombardi Canc Ctr, Dept Oncol, Washington, DC 20057 USA; Univ Maryland, Program Human Genet, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Baltimore, MD 21201 USA; NCI, Div Canc Prevent, Rockville, MD 20892 USA; Univ Alabama Birmingham, Birmingham, AL 35294 USA	Georgetown University; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Alabama System; University of Alabama Birmingham	Furth, PA (corresponding author), Georgetown Univ, Lombardi Canc Ctr, Dept Oncol, Res Bldg,E518,3970 Reservoir Rd NW, Washington, DC 20057 USA.	paf3@georgetown.edu		Flaws, Jodi/0000-0001-5579-9268	NCI NIH HHS [N01-CN-85076-46] Funding Source: Medline; NICHD NIH HHS [HD 38955] Funding Source: Medline; DIVISION OF CANCER PREVENTION AND CONTROL [N01CN085076] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038955] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alt JR, 2002, J BIOL CHEM, V277, P8517, DOI 10.1074/jbc.M108867200; Arbeit JM, 1999, CANCER RES, V59, P3610; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Cooper R., 1993, METHODS TOXICOLOGY B, P45; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; FOZARD JR, 1980, EUR J PHARMACOL, V65, P379, DOI 10.1016/0014-2999(80)90342-8; Furth PA, 1999, ONCOGENE, V18, P6589, DOI 10.1038/sj.onc.1203073; Furth PA, 1998, DEV BIOL STAND, V94, P281; Green JE, 2001, CANCER RES, V61, P7449; Gupta S, 2002, ONCOGENE, V21, P3727, DOI 10.1038/sj.onc.1205474; Hursting SD, 2001, J NUTR, V131, p3092S, DOI 10.1093/jn/131.11.3092S; Ioachim EE, 2000, ANTICANCER RES, V20, P4221; Joe AK, 2002, CLIN CANCER RES, V8, P893; Kelloff GJ, 1998, CANCER EPIDEM BIOMAR, V7, P65; KINGSNORTH AN, 1983, CANCER RES, V43, P4035; Li ML, 1996, CELL GROWTH DIFFER, V7, P3; Li ML, 2000, ONCOGENE, V19, P1010, DOI 10.1038/sj.onc.1203271; Masuda M, 2002, JPN J CANCER RES, V93, P329, DOI 10.1111/j.1349-7006.2002.tb02176.x; NANDI S, 1995, P NATL ACAD SCI USA, V92, P3650, DOI 10.1073/pnas.92.9.3650; PEGG AE, 1987, BIOCHEM J, V241, P305, DOI 10.1042/bj2410305; Pidgeon GP, 2002, CANCER RES, V62, P2721; RATKO TA, 1990, ANTICANCER RES, V10, P67; REDDY BS, 1990, CANCER RES, V50, P2562; REDDY PRK, 1981, CONTRACEPTION, V24, P215, DOI 10.1016/0010-7824(81)90094-9; REN S, 2000, CONT TOP LAB ANIMAL, V40, P27; Ren SX, 2002, ONCOGENE, V21, P4335, DOI 10.1038/sj.onc.1205484; Russo IH, 1996, ENVIRON HEALTH PERSP, V104, P938, DOI 10.2307/3433143; Seufferlein T, 2002, BRIT J CANCER, V86, P1188, DOI 10.1038/sj/bjc/6600186; Soler AP, 1998, CANCER RES, V58, P1654; THOMPSON HJ, 1986, CARCINOGENESIS, V7, P2003, DOI 10.1093/carcin/7.12.2003; TZENG YJ, 1993, ONCOGENE, V8, P1965; Yoshidome K, 2000, CANCER RES, V60, P6901; Zhai SP, 2002, ANN PHARMACOTHER, V36, P905; Zhang M, 2000, ONCOGENE, V19, P6053, DOI 10.1038/sj.onc.1204006	34	7	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2003	22	17					2568	2572		10.1038/sj.onc.1206314	http://dx.doi.org/10.1038/sj.onc.1206314			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730671				2022-12-28	WOS:000182569000004
J	Dowen, SE; Neutze, DM; Pett, MR; Cottage, A; Stern, P; Coleman, N; Stanley, MA				Dowen, SE; Neutze, DM; Pett, MR; Cottage, A; Stern, P; Coleman, N; Stanley, MA			Amplification of chromosome 5p correlates with increased expression of Skp2 in HPV-immortalized keratinocytes	ONCOGENE			English	Article						5p; HPV; SKP2; p27	HUMAN-PAPILLOMAVIRUS TYPE-16; F-BOX PROTEIN; CARCINOMA CELL-LINES; CYTOGENETIC ANALYSIS; RECURRENT PATTERN; GENOMIC CHANGES; CERVIX UTERI; HELA-CELL; IN-SITU; S-PHASE	The oncogenic HPVs immortalize primary genital keratinocytes in vitro and there is evidence that such lines represent suitable models to examine HPV-induced carcinogenesis. Early in vivo studies and more recent CGH analyses have revealed amplification of chromosome 5p in advanced stage carcinoma of the uterine cervix (CaCx). In the present study, a panel of established CaCx-derived cell tines were analysed by M-FISH to identify recurrent karyotypic abnormalities. Amplification of 5p was observed in I I of 13 CaCx cell lines harbouring HR (high-risk) HPV. The region of 5p undergoing amplification was confirmed using human band-specific paints. The F-box protein Skp2 is present at 5p13 and its protein is present at increased levels in many cancers of an advanced stage. The HPV16-harbouring cell line W12 shows progressive morphological abnormality with in vitro passage, culminating in an invasive phenotype. The expression of Skp2 at different stages of this progression was investigated utilizing Western blot and TaqMan quantitative PCR. At medium to late passage, gain of 5p as an isochromosome was observed. Increased expression of Skp2 and a reduction in the expression of its target p27 correlated with increasing passage in this line.	Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England; MRC, Res Ctr, Cambridge CB2 2QH, England; Christie Hosp NHS Trust, Canc Res UK, Paterson Inst Canc Res, Manchester M20 4BX, Lancs, England	University of Cambridge; Cancer Research UK; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; University of Manchester	Dowen, SE (corresponding author), Univ Cambridge, Dept Pathol, Tennis Court Rd, Cambridge CB2 1QP, England.	sally-dowen@hotmail.com						ATKIN NB, 1982, CANCER GENET CYTOGEN, V7, P209, DOI 10.1016/0165-4608(82)90068-1; ATKIN NB, 1984, CANCER GENET CYTOGEN, V13, P189, DOI 10.1016/0165-4608(84)90043-8; Aubele M, 1998, CANCER CYTOPATHOL, V84, P375, DOI 10.1002/(SICI)1097-0142(19981225)84:6<375::AID-CNCR10>3.0.CO;2-1; AUERSPERG N, 1964, J NATL CANCER I, V32, P135; Brady CS, 2000, TISSUE ANTIGENS, V55, P401, DOI 10.1034/j.1399-0039.2000.550502.x; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Carrano AC, 2001, J CELL BIOL, V153, P1381, DOI 10.1083/jcb.153.7.1381; Ciaparrone M, 1998, CANCER RES, V58, P114; Cottage A, 2001, GENE CHROMOSOME CANC, V30, P72, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1060>3.0.CO;2-X; Cuthill S, 1999, GENE CHROMOSOME CANC, V26, P304, DOI 10.1002/(SICI)1098-2264(199912)26:4<304::AID-GCC4>3.0.CO;2-1; Demetrick DJ, 1996, CYTOGENET CELL GENET, V73, P104, DOI 10.1159/000134318; DURST M, 1987, ONCOGENE, V1, P251; FRIEDL F, 1970, P SOC EXP BIOL MED, V135, P543; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; Hershko D, 2001, CANCER, V91, P1745, DOI 10.1002/1097-0142(20010501)91:9<1745::AID-CNCR1193>3.0.CO;2-H; HERZ F, 1977, CANCER RES, V37, P3209; Heselmeyer K, 1997, GENE CHROMOSOME CANC, V19, P233, DOI 10.1002/(SICI)1098-2264(199708)19:4<233::AID-GCC5>3.0.CO;2-Y; *INT AG RES CANC, 1995, IARC MONOGRAPHS EVAL, V74; JAMES GK, 1989, CANCER GENET CYTOGEN, V38, P53, DOI 10.1016/0165-4608(89)90165-9; Jee KJ, 2001, MODERN PATHOL, V14, P377, DOI 10.1038/modpathol.3880321; JEON S, 1995, J VIROL, V69, P2989, DOI 10.1128/JVI.69.5.2989-2997.1995; JONES HW, 1971, OBSTET GYNECOL, V38, P945; Kirchhoff M, 1999, GENE CHROMOSOME CANC, V24, P144, DOI 10.1002/(SICI)1098-2264(199902)24:2<144::AID-GCC7>3.0.CO;2-9; Kudo Y, 2001, CANCER RES, V61, P7044; Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; MAEVILLE M, 1999, CANCER RES, V59, P141; Matthews CP, 2000, P SOC EXP BIOL MED, V223, P316, DOI 10.1046/j.1525-1373.2000.22345.x; MILLER OJ, 1971, CYTOGENETICS, V10, P338, DOI 10.1159/000130152; PATER MM, 1985, VIROLOGY, V145, P313, DOI 10.1016/0042-6822(85)90164-3; PATTILLO R A, 1977, Science (Washington D C), V196, P1456, DOI 10.1126/science.867042; POPESCU NC, 1987, CYTOGENET CELL GENET, V44, P58, DOI 10.1159/000132342; REZNIKOFF CA, 1994, GENE DEV, V8, P2227, DOI 10.1101/gad.8.18.2227; Ried T, 1999, GENE CHROMOSOME CANC, V25, P195, DOI 10.1002/(SICI)1098-2264(199907)25:3<195::AID-GCC1>3.0.CO;2-8; Roberts I, 1999, GENE CHROMOSOME CANC, V25, P241, DOI 10.1002/(SICI)1098-2264(199907)25:3<241::AID-GCC6>3.0.CO;2-7; Savelieva E, 1997, ONCOGENE, V14, P551, DOI 10.1038/sj.onc.1200868; SCHIFFMAN MH, 1995, CANCER-AM CANCER SOC, V76, P1888, DOI 10.1002/1097-0142(19951115)76:10+<1888::AID-CNCR2820761305>3.0.CO;2-H; SMITH PP, 1989, INT J CANCER, V44, P1124, DOI 10.1002/ijc.2910440631; STANLEY M, 1994, PAPILLOMAVIRUS REV, P131; STANLEY MA, 1989, INT J CANCER, V43, P672, DOI 10.1002/ijc.2910430422; STANLEY MA, 1991, CULTURE EPITHELIAL C, P135; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; TELENIUS H, 1992, GENOMICS, V13, P718, DOI 10.1016/0888-7543(92)90147-K; TELENIUS H, 1992, GENE CHROMOSOME CANC, V4, P257, DOI 10.1002/gcc.2870040311; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690; ZURHAUSEN H, 1994, COLD SPRING HARB SYM, V59, P623, DOI 10.1101/SQB.1994.059.01.071	49	29	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2003	22	16					2531	2540		10.1038/sj.onc.1206296	http://dx.doi.org/10.1038/sj.onc.1206296			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	670AD	12717429				2022-12-28	WOS:000182383500015
J	Ohtsuka, T; Ryu, H; Minamishima, YA; Ryo, A; Lee, SW				Ohtsuka, T; Ryu, H; Minamishima, YA; Ryo, A; Lee, SW			Modulation of p53 and p73 levels by cyclin G: implication of a negative feedback regulation	ONCOGENE			English	Article						p53; p73; cyclin G; siRNA; negative feedback regulation	DNA-DAMAGE; P53-INDUCED APOPTOSIS; G2/M ARREST; MDM2; GENE; GROWTH; CELLS; DEGRADATION; PROMOTES; PROTEIN	Cyclin G is a transcriptional target gene of tumor suppressor p53. Recent studies present evidence that cyclin G may play a central role in the p53-Mdm2 autoregulated module, but the precise function of cyclin G remains elusive. Here, we show a negative effect of cyclin G on the stability of p53 and p73. Cyclin G expression resulted in a dramatic decrease of p53 protein levels in response to DNA damage and abrogated irradiation-mediated G1 arrest along with an increase of S phase in MCF7 cells containing wild-type p53. In p53-null Saos2 cells, cyclin G inhibited p73 induction in response to genotoxic stress and delayed the camptothecin-mediated cell cycle arrest. Cyclin G interacts with p53 as well as p73, and its binding to p53 or p73 presumably mediates downregulation of p53 and p73. We also found that cyclin G-mediated reduction of p53 but not of p73 is Mdm2-dependent. Moreover, inhibition of cyclin G by small interfering RNA (siRNA) caused the accumulation of p53 and p73 protein levels in response to DNA damage. Therefore, our results imply that cyclin G is transcriptionally activated by p53 or p73, and, in turn, cyclin G negatively regulates the stabilization of p53 family proteins through an unknown mechanism different from ubiquitination or transcriptional control.	Harvard Univ, Sch Med, Inst Med, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Div Hematol & Oncol, Canc Biol Program, Boston, MA 02215 USA; Univ Massachusetts, Sch Med, Dept Neurol, Worcester, MA 01605 USA; Mem Hlth Care Ctr, Worcester, MA 01605 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; University of Massachusetts System; University of Massachusetts Worcester	Lee, SW (corresponding author), Harvard Univ, Sch Med, Inst Med, 77 Ave Louis Pasteur,Room 921, Boston, MA 02115 USA.		Minamishima, Yoji Andrew/E-5380-2010	Minamishima, Yoji Andrew/0000-0001-7995-9318; Ryu, Hoon/0000-0001-6544-3732	NCI NIH HHS [CA85681, CA78356, CA80058] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085681, R01CA078356] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attardi LD, 2000, GENE DEV, V14, P704; Bean LJH, 2002, J BIOL CHEM, V277, P1864, DOI 10.1074/jbc.M108881200; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; BURNS TF, 1999, J CELL PHYSL, V181, P371; Chen XB, 2002, DEV CELL, V2, P518, DOI 10.1016/S1534-5807(02)00182-X; Chen XB, 2001, ONCOGENE, V20, P769, DOI 10.1038/sj.onc.1204149; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gong JG, 1999, NATURE, V399, P806; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HE TC, 1996, P NATL ACAD SCI USA, V93, P8390; Inoue T, 2001, FEBS LETT, V490, P196, DOI 10.1016/S0014-5793(01)02123-8; Kimura SH, 2002, GENES CELLS, V7, P869, DOI 10.1046/j.1365-2443.2002.00564.x; Kimura SH, 2001, ONCOGENE, V20, P3290, DOI 10.1038/sj.onc.1204270; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MIYASHITA T, 1995, CELL, V80, P293; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Okamoto K, 1999, ONCOGENE, V18, P4606, DOI 10.1038/sj.onc.1202821; Okamoto K, 2002, MOL CELL, V9, P761, DOI 10.1016/S1097-2765(02)00504-X; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Reimers L, 1999, J BIOL CHEM, V274, P11022, DOI 10.1074/jbc.274.16.11022; Shimizu A, 1998, BIOCHEM BIOPH RES CO, V242, P529, DOI 10.1006/bbrc.1997.8004; SKOTZKO M, 1995, CANCER RES, V55, P5493; Smith ML, 1997, EXP CELL RES, V230, P61, DOI 10.1006/excr.1996.3402; TAMURA K, 1993, ONCOGENE, V8, P2113; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; Zeng XY, 1999, MOL CELL BIOL, V19, P3257	37	68	69	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 20	2003	22	11					1678	1687		10.1038/sj.onc.1206306	http://dx.doi.org/10.1038/sj.onc.1206306			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642871				2022-12-28	WOS:000181580500010
J	Kuefer, MU; Chinwalla, V; Zeleznik-Le, NJ; Behm, FG; Naeve, CW; Rakestraw, KM; Mukatira, ST; Raimondi, SC; Morris, SW				Kuefer, MU; Chinwalla, V; Zeleznik-Le, NJ; Behm, FG; Naeve, CW; Rakestraw, KM; Mukatira, ST; Raimondi, SC; Morris, SW			Characterization of the MLL partner gene AF15q14 involved in t(11;15)(q23;q14)	ONCOGENE			English	Article						t(11;15)(q23;q14); 11q23; MLL; AF15q14; leukemia	ACUTE MYELOID-LEUKEMIA; E1A-ASSOCIATED PROTEIN P300; CHROMOSOMAL TRANSLOCATIONS; DROSOPHILA-TRITHORAX; 11Q23 TRANSLOCATIONS; HRX-ENL; DE-NOVO; BREAKPOINT; REGION; HOMOLOG	Translocations interrupting the mixed lineage leukemia gene (MLL) occur in 7-10% of acute lymphoblastic leukemia (ALL) and 5-6% of acute myeloid leukemia (AML) cases. One of these translocations, t(11;15)(q23;q14), occurs rarely in both ALL and AML. The gene on chromosome 15, AF15q14, was cloned recently in a patient with AML-M4. We have identified the same gene in a de novo T-ALL patient. However, both the MLL and AF15q14 breakpoints in these patients differed: in the previously reported AML-M4, both gene breaks were within exons, while in our ALL case the MLL break is intronic and the AF15q14 break is exonic. The MLL-AF15q14 fusion described previously shares no AF15q14 residues in common with the chimera reported here. The fusion proteins also differ with respect to MLL - the previously described fusion contains 55 extra amino acids as its MLL break is in exon 11, while the chimera we report breaks in intron 9. Contrary to the originally described normal AF15q14 (5925-bp cDNA encoding a 1833-aa protein), we identify a 7542-bp cDNA and a 2342-aa AF15q14 protein. AF15q14 appears identical to an mRNA previously found to be expressed in melanoma rendered nontumorigenic by microcell-mediated introduction of normal chromosome 6, suggesting the gene may function normally to suppress cell growth and/or enhance maturation.	St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; Landratsamt Ostallgau, Abt Gesundheitswesen, D-87610 Marktoberdorf, Germany; Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA; St Jude Childrens Res Hosp, Hartwell Ctr Biotechnol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; Univ Tennessee, Coll Med, Memphis, TN USA	St Jude Children's Research Hospital; University of Chicago; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Morris, SW (corresponding author), St Jude Childrens Res Hosp, Dept Pathol, Room 4026,Thomas Tower,332 N Lauderdale St, Memphis, TN 38105 USA.	steve.morris@stjude.org	Raimondi, Susana C/N-8166-2018		NCI NIH HHS [CA76301, CA21756, CA40046, CA78438] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA078438, R01CA076301] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Archimbaud E, 1998, LEUKEMIA, V12, P25, DOI 10.1038/sj.leu.2400853; Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Broeker PLS, 1996, BLOOD, V87, P1912, DOI 10.1182/blood.V87.5.1912.bloodjournal8751912; Chinwalla V, 2003, ONCOGENE, V22, P1400, DOI 10.1038/sj.onc.1206273; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; GREGOIRE MJ, 1993, LEUKEMIA, V7, P10; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Harrison CJ, 1998, LEUKEMIA, V12, P811, DOI 10.1038/sj.leu.2401017; Hayette S, 2000, ONCOGENE, V19, P4446, DOI 10.1038/sj.onc.1203789; HERNANDEZ JM, 1995, LEUKEMIA, V9, P1162; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Kuefer M. U., 1997, Blood, V90, p318A; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Nilson I, 1996, BRIT J HAEMATOL, V93, P966, DOI 10.1046/j.1365-2141.1996.d01-1748.x; RAIMONDI SC, 1991, BLOOD, V77, P2016; Ray ME, 1996, ONCOGENE, V12, P2527; Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; Takimoto M, 2002, BRIT J CANCER, V86, P1757, DOI 10.1038/sj.bjc.6600328; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	25	14	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2003	22	9					1418	1424		10.1038/sj.onc.1206272	http://dx.doi.org/10.1038/sj.onc.1206272			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618768				2022-12-28	WOS:000181360900017
J	Plymate, SR; Haugk, KH; Sprenger, CC; Nelson, PS; Tennant, MK; Zhang, YP; Oberley, LW; Zhong, WX; Drivdahl, R; Oberley, TD				Plymate, SR; Haugk, KH; Sprenger, CC; Nelson, PS; Tennant, MK; Zhang, YP; Oberley, LW; Zhong, WX; Drivdahl, R; Oberley, TD			Increased manganese superoxide dismutase (SOD-2) is part of the mechanism for prostate tumor suppression by Mac25/insulin-like growth factor binding-protein-related protein-1	ONCOGENE			English	Article						SOD-2; Mac25; prostate; cancer; IGFBP-rP1	EPITHELIAL-CELLS; EXPRESSION; APOPTOSIS; P53; OVEREXPRESSION; FIBROBLASTS; INHIBITION; SENESCENCE; IGFBP-RP1; SUBLINES	Increased expression of mac25/insulin-like growth factor binding-protein related protein-1 (IGFBP-rP1) in human breast and prostate epithelial cell lines results in the suppression of tumor growth. CDNA expression array analysis revealed increased manganese superoxide dismutase (SOD-2) expression in the mac25/IGFBP-rP1-transfected M12 human prostate cancer cell line compared to M12 control cells. SOD-2 has been postulated to be a tumor suppressor. SOD-2 was also increased in LNCaP cells stably transfected with mac25/IGFBP-rP1, but not in mac25/IGFBP-rP1-transfected PC-3 cells. Mac25 LNCaP cells had a marked decrease in tumor growth in nude mice compared to controls, but there was no difference in tumor growth in mac25 PC-3 cells compared to control. Phosphorylated Erk and Akt were increased in the M12 and LNCaP transfected mac25/ IGFBP-rP1 cells but not PC-3 mac25. Inhibition of PI-3 kinase results in a marked decrease in viability of the M12-mac25 cells compared to M12 controls. Cells treated with H2O2 result, in an increase in phospho-ERK. Transfection of SOD-2 in M12 cells markedly decreased tumor growth, apoptosis, G1 delay in the cell cycle, and expression of senescence associated beta-galactosidase. These results suggest that one of the downstream mediators of the senescence-associated tumor suppression effect of mac25/IGFBP-rP1 is SOD-2.	Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98105 USA; Univ Washington, Sch Med, Dept Med, Seattle, WA 98105 USA; Univ Washington, Sch Med, Dept Mol, Seattle, WA 98105 USA; Univ Washington, Sch Med, Cell Biol Program, Seattle, WA 98105 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98107 USA; Univ Iowa, Dept Radiol, Iowa City, IA 52242 USA; Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53705 USA; William S Middleton Mem Vet Adm Med Ctr, Pathol Serv, Madison, WI 53705 USA	University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; University of Iowa; University of Wisconsin System; University of Wisconsin Madison; US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital	Plymate, SR (corresponding author), Univ Washington, Harborview Med Ctr, 325 9Th Ave,Box 359755, Seattle, WA 98104 USA.	splymate@u.washington.edu			NATIONAL CANCER INSTITUTE [P01CA085859] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052683] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA 85859] Funding Source: Medline; NIDDK NIH HHS [DK52683] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAE V, 1995, P AM ASS CANC RES CA, V642, P55; BAE VL, 1994, INT J CANCER, V58, P721, DOI 10.1002/ijc.2910580517; Bae VL, 1998, PROSTATE, V34, P275, DOI 10.1002/(SICI)1097-0045(19980301)34:4<275::AID-PROS5>3.0.CO;2-G; Baker AM, 1997, PROSTATE, V32, P229, DOI 10.1002/(SICI)1097-0045(19970901)32:4<229::AID-PROS1>3.0.CO;2-E; Birkenkamp KU, 1999, LEUKEMIA, V13, P1037, DOI 10.1038/sj.leu.2401447; BIRNBAUM RS, 1994, J ENDOCRINOL, V141, P535, DOI 10.1677/joe.0.1410535; Bost F, 2002, BIOCHEM J, V361, P621, DOI 10.1042/0264-6021:3610621; Bostwick DG, 2000, CANCER, V89, P123, DOI 10.1002/1097-0142(20000701)89:1<123::AID-CNCR17>3.0.CO;2-9; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; deHaan JB, 1996, HUM MOL GENET, V5, P283, DOI 10.1093/hmg/5.2.283; Hawkins V, 1999, NUCLEIC ACIDS RES, V27, P204, DOI 10.1093/nar/27.1.204; Huang CS, 2000, J BIOL CHEM, V275, P32516, DOI 10.1074/jbc.M005366200; Hwa V, 1998, J CLIN ENDOCR METAB, V83, P4355, DOI 10.1210/jc.83.12.4355; HWA V, 1998, ACTA PAEDIATR SCAND, V428, P37; JacksonCook C, 1996, CANCER GENET CYTOGEN, V87, P14, DOI 10.1016/0165-4608(95)00232-4; Kim HP, 1999, J BIOL CHEM, V274, P37455, DOI 10.1074/jbc.274.52.37455; Kim KH, 2001, ANTIOXID REDOX SIGN, V3, P361, DOI 10.1089/15230860152409013; Kinscherf R, 1998, FASEB J, V12, P461, DOI 10.1096/fasebj.12.6.461; Li N, 1998, J CELL PHYSIOL, V175, P359, DOI 10.1002/(SICI)1097-4652(199806)175:3<359::AID-JCP14>3.0.CO;2-0; Li N, 1998, PROSTATE, V35, P221, DOI 10.1002/(SICI)1097-0045(19980515)35:3<221::AID-PROS8>3.0.CO;2-J; Lopez-Bermejo A, 2000, ENDOCRINOLOGY, V141, P4072, DOI 10.1210/en.141.11.4072; McCord JM, 2000, AM J MED, V108, P652, DOI 10.1016/S0002-9343(00)00412-5; Oberley TD, 1997, HISTOL HISTOPATHOL, V12, P525; Oh YM, 1996, J BIOL CHEM, V271, P30322, DOI 10.1074/jbc.271.48.30322; Plymate SR, 1996, J CLIN ENDOCR METAB, V81, P3709, DOI 10.1210/jc.81.10.3709; Pritchard CC, 2001, P NATL ACAD SCI USA, V98, P13266, DOI 10.1073/pnas.221465998; RHEE SG, 2000, SCI STKE, P1; Sachdeva RM, 2001, AM J HUM GENET, V69, P261; Sprenger CC, 1999, CANCER RES, V59, P2370; Sprenger CC, 2002, ONCOGENE, V21, P140, DOI 10.1038/sj.onc.1205021; Wartenberg M, 1999, J BIOL CHEM, V274, P27759, DOI 10.1074/jbc.274.39.27759; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Wilson EM, 2001, J CLIN ENDOCR METAB, V86, P4504, DOI 10.1210/jc.86.9.4504; Zhong WX, 2001, CANCER RES, V61, P7071	34	55	58	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2003	22	7					1024	1034		10.1038/sj.onc.1206210	http://dx.doi.org/10.1038/sj.onc.1206210			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	644PB	12592389				2022-12-28	WOS:000180926100008
J	Kwong, KY; Zou, YY; Day, CP; Hung, MC				Kwong, KY; Zou, YY; Day, CP; Hung, MC			The suppression of colon cancer cell growth in nude mice by targeting beta-catenin/TCF pathway	ONCOGENE			English	Article						APC; beta-catenin; Tcf; colon cancer; adenovirus; thymidine kinase	CYCLIN D1; MUTATIONS; EXPRESSION; TUMOR; GENE; APC	The adenomatous polyposis coli (APC) or beta-catenin genes are frequently mutated in colorectal cancers, leading to activation of downstream genes with beta-catenin/T-cell factor (Tcf)-responsive promoters. We have developed a gene therapy approach selectively targeting colorectal cancer cells in which beta-catenin/Tcf4 pathway is activated by using a recombinant adenovirus AdTOP-CMV-TK, which carries a herpes simplex virus thymidine kinase gene (HSV TK) under the control of a beta-catenin/Tcf-response promoter linking to a minimum CMV promoter. AdTOP-CMV-TK and ganciclovir (GCV) treatment significantly suppressed the growth of human DLD-1 colon cancer cells in nude mice. Furthermore, no significant tumor suppression effect was observed in human hepatoma cell line SK-HEP-1, in which the beta-catenin/Tcf pathway is not activated, as a control experiment. In summary, we demonstrated the selective targeting of colorectal cancers with activated beta-catenin by AdTOP-CMV-TK and GCV treatment in animal models, as well as its therapeutic potential for colon cancer metastasized to liver.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Hung, MC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740				Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; Chen RH, 2001, CANCER RES, V61, P4445; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Goss KH, 2000, J CLIN ONCOL, V18, P1967, DOI 10.1200/JCO.2000.18.9.1967; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; MELTON RG, 1999, ENZYME PRODRUG STRAT, P216; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Polakis P, 2000, GENE DEV, V14, P1837; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884	15	32	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 28	2002	21	54					8340	8346		10.1038/sj.onc.1206050	http://dx.doi.org/10.1038/sj.onc.1206050			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447697				2022-12-28	WOS:000179323900012
J	Lin, HM; Pestell, RG; Raz, A; Kim, HRC				Lin, HM; Pestell, RG; Raz, A; Kim, HRC			Galectin-3 enhances cyclin D-1 promoter activity through SP1 and a cAMP-responsive element in human breast epithelial cells	ONCOGENE			English	Article						galectin-3; cyclin D; promoter; cell cycle; anoikis; Rb	BINDING PROTEIN GALECTIN-3; KINASE-ACTIVITY; GENE-PRODUCT; D1 PROMOTER; TRANSCRIPTIONAL REGULATION; OVEREXPRESSION PROTECTS; RETINOBLASTOMA PROTEIN; G1 PHASE; EXPRESSION; ACTIVATION	Galectin-3 is a multifunctional carbohydrate-binding protein found in the nucleus, cytoplasm and the extracellular milieu. Nuclear galectin-3 expression is associated with cell proliferation, and its role in pre-mRNA splicing has been suggested. In this report, we investigated the role of galectin-3 on cyclin D-1 gene expression, a critical inducer of the cell cycle and a potential oncogene in human cancer. We found that galectin-3 induces cyclin D-1 promoter activity in human breast epithelial cells independent of cell adhesion through multiple cis-elements, including the SP1 and CRE sites. We present evidence that galectin-3 induction of the cyclin D, promoter may result from enhancement/stabilization of nuclear protein-DNA complex formation at the CRE site of the cyclin D-1 promoter. We also show that galectin-3 co-operates with, but does not depend on, pRb for cyclin D, promoter activation. The present study reveals a growth promoting activity of galectin-3 through cyclin D, induction, and suggests a novel function of nuclear galectin-3 in the regulation of gene transcription.	Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Breast Canc Program, Detroit, MI 48201 USA; Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Med & Dev & Mol Biol, Bronx, NY 10461 USA	Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University; Yeshiva University; Albert Einstein College of Medicine	Kim, HRC (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, 540 E Canfield, Detroit, MI 48201 USA.				NCI NIH HHS [CA-64139] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064139, R29CA064139] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akahani S, 1997, CANCER RES, V57, P5272; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Bienvenu F, 2001, J BIOL CHEM, V276, P16840, DOI 10.1074/jbc.M100795200; Bresalier RS, 1997, CANCER, V80, P776; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; DAGHER SF, 1995, P NATL ACAD SCI USA, V92, P1213, DOI 10.1073/pnas.92.4.1213; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Kadrofske MM, 1998, ARCH BIOCHEM BIOPHYS, V349, P7, DOI 10.1006/abbi.1997.0447; Kim HRC, 1999, CANCER RES, V59, P4148; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; Konstantinov KN, 1996, AM J PATHOL, V148, P25; Latella L, 2001, MOL CELL BIOL, V21, P5631, DOI 10.1128/MCB.21.16.5631-5643.2001; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Le Gall M, 1998, ONCOGENE, V17, P1271, DOI 10.1038/sj.onc.1202057; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; LeMarer N, 1996, J CELL PHYSIOL, V168, P51, DOI 10.1002/(SICI)1097-4652(199607)168:1<51::AID-JCP7>3.0.CO;2-7; Lin HM, 1998, DNA CELL BIOL, V17, P197, DOI 10.1089/dna.1998.17.197; Lin HM, 2000, CARCINOGENESIS, V21, P1941, DOI 10.1093/carcin/21.11.1941; LOTAN R, 1994, INT J CANCER, V56, P474, DOI 10.1002/ijc.2910560404; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; Matarrese P, 2000, INT J CANCER, V85, P545, DOI 10.1002/(SICI)1097-0215(20000215)85:4<545::AID-IJC17>3.3.CO;2-E; Matarrese P, 2000, FEBS LETT, V473, P311, DOI 10.1016/S0014-5793(00)01547-7; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; Nagata D, 2001, J BIOL CHEM, V276, P662, DOI 10.1074/jbc.M005522200; Nangia-Makker P, 1998, BREAST CANCER RES TR, V49, P171, DOI 10.1023/A:1005913810250; Openo KP, 2000, EXP CELL RES, V255, P278, DOI 10.1006/excr.1999.4782; Pestell RG, 1999, ENDOCR REV, V20, P501, DOI 10.1210/er.20.4.501; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; RAZ A, 1989, CANCER RES, V49, P3489; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; SATO S, 1992, J BIOL CHEM, V267, P6983; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; WANG L, 1995, BIOCHEM BIOPH RES CO, V217, P292, DOI 10.1006/bbrc.1995.2777; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; Watanabe G, 1996, J BIOL CHEM, V271, P22570, DOI 10.1074/jbc.271.37.22570; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737, DOI 10.1073/pnas.93.13.6737; Yoshii T, 2002, J BIOL CHEM, V277, P6852, DOI 10.1074/jbc.M107668200; Yu F, 2002, J BIOL CHEM, V277, P15819, DOI 10.1074/jbc.M200154200; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	47	109	118	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 14	2002	21	52					8001	8010		10.1038/sj.onc.1205820	http://dx.doi.org/10.1038/sj.onc.1205820			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	612VY	12439750				2022-12-28	WOS:000179097200009
J	Lin, TY; Huang, XF; Gu, J; Zhang, LD; Roth, JA; Xiong, MM; Curley, SA; Yu, YH; Hunt, KK; Fang, BL				Lin, TY; Huang, XF; Gu, J; Zhang, LD; Roth, JA; Xiong, MM; Curley, SA; Yu, YH; Hunt, KK; Fang, BL			Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells	ONCOGENE			English	Article						apoptosis; drug-resistance; telomerase; doxorubicin; gene therapy	TRANSGENE EXPRESSION; TELOMERASE ACTIVITY; APOPTOSIS; CHEMOTHERAPY	We evaluated anti-tumor activity and toxic effect of an adenoviral vector expressing the GFP/TRAIL fusion gene from the hTERT promoter (designated Ad/gTRAIL) on human breast cancer cell tines and on normal human breast cells. Treatment with Ad/gTRAIL elicited high levels of transgene expression and apoptosis in a variety of breast cancer cell lines. Furthermore, treatment with Ad/gTRAIL was effective in killing breast cancer lines resistant to doxorubicin or soluble TRAIL protein. In contrast, only minimal transgene expression and toxicity was detected in normal human primary mammary epithelial cells after treatment with this vector. An in vivo study further showed that the intralesional administration of Ad/gTRAIL effectively suppressed the growth of human tumor xenografts derived from both doxorubicin-sensitive and doxorubicin-resistant breast cancer lines. Specifically, about 50% of animals bearing doxorubicin-sensitive and doxorubicin-resistant breast cancer xenografts showed complete tumor regression and remained tumor-free for over 5 months. These results suggest that the adenovirus encoding the GFP/TRAIL gene driven by the hTERT promoter has potential application in cancer therapy.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Ctr Human Genet, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Fang, BL (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, Unit 445,1515 Holcombe Blvd, Houston, TX 77030 USA.		Gu, Jian/Q-4780-2018; Yu, Yan/GYV-4514-2022	Gu, Jian/0000-0003-3499-0973; 	NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		de Jong S, 2001, CANCER METAST REV, V20, P51, DOI 10.1023/A:1013112624971; Griffith TS, 2000, J IMMUNOL, V165, P2886, DOI 10.4049/jimmunol.165.5.2886; Gu J, 2000, CANCER RES, V60, P5359; Gu J, 2002, ONCOGENE, V21, P4757, DOI 10.1038/sj.onc.1205582; Jazirehi AR, 2001, CLIN CANCER RES, V7, P3874; Kagawa S, 2001, CANCER RES, V61, P3330; Keane MM, 1999, CANCER RES, V59, P734; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Klement G, 2002, CLIN CANCER RES, V8, P221; Koch PE, 2001, MOL THER, V3, P278, DOI 10.1006/mthe.2001.0273; Lebwohl DE, 1999, ANN ONCOL, V10, P139, DOI 10.1023/A:1008318725670; Levine MN, 1998, J CLIN ONCOL, V16, P2651, DOI 10.1200/JCO.1998.16.8.2651; Nagane M, 2001, APOPTOSIS, V6, P191, DOI 10.1023/A:1011336726649; Nguyen T, 2001, CLIN CANCER RES, V7, p966S; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; Seth P, 1997, CANCER GENE THER, V4, P383; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Stampfer M R, 1994, Cancer Treat Res, V71, P29; STEWART CF, 2001, PRINCIPLES PRACTICE, P425; Voelkel-Johnson C, 2002, CANCER GENE THER, V9, P164, DOI 10.1038/sj.cgt.7700420; ZHANG L, 2002, IN PRESS GENE THER	21	95	103	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 14	2002	21	52					8020	8028		10.1038/sj.onc.1205926	http://dx.doi.org/10.1038/sj.onc.1205926			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	612VY	12439752				2022-12-28	WOS:000179097200011
J	Alcock, RA; Dey, S; Chendil, D; Inayat, MS; Mohiuddin, M; Hartman, G; Chatfield, LK; Gallicchio, VS; Ahmed, MM				Alcock, RA; Dey, S; Chendil, D; Inayat, MS; Mohiuddin, M; Hartman, G; Chatfield, LK; Gallicchio, VS; Ahmed, MM			Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2	ONCOGENE			English	Article						pancreatic cancer; TGF-beta signaling; radiosensitization; farnesyltransferase inhibitor (FTI); DNA methyltransferase; TGF-beta type II receptor (TGF-beta RII)	GROWTH-FACTOR-BETA; TRANSCRIPTION FACTOR EGR-1; DNA METHYLTRANSFERASE; ONCOGENIC RAS; ADENOCARCINOMA CELLS; SIGNALING PATHWAY; EPITHELIAL-CELLS; RESISTANCE; ACTIVATION; APOPTOSIS	Activated ras is known to dysregulate TGF-beta signaling by altering the expression of TGF-beta type 11 receptor (RII). It is well documented that tumor cells harboring mutant ras are, more resistant to radiation than cells with wild-type ras. In this study, we hypothesized that the use of farneyltransferase inhibitor (FTI, L-744,832) may directly restore TGF-beta signaling through RII expression via ras dependent or independent pathway leading to induction of radiation sensitivity. Two pancreatic cancer cell, lines, BxPC-3 and MIA PaCa-2 were used in this study. FTI inhibited farnesylation of Ras protein more significantly in MIA PaCa-2 than BxPC-3 cells. In contrast, MIA PaCa-2 cells were resistant to radiation when compared to BxPC-3 cells. BxPC-3 cells were more resistant to FTI than MIA PaCa-2 cells. In combination treatment, no significant radiosensitizing effect of FTI was 6 bserved in BxPC-3 cells at 5 or 10 pm. However, in MIA PaCa-2 cells, a significant radiosensitizing effect was observed at both 5 and 10 muM concentrations (P > 0.004). The TGF-beta effector gene p21(waf1/cip1) was elevated in combination treatment in MIA PaCa-2 but not in BxPC-3 cells. In MIA PaCa-2 cells, FTI induced TGF-beta responsive promoter activity as assessed by 3TP-luciferase activity. A further induction of luciferase activity was observed in MIA PaCa-2 cells treated with radiation and FTI. Induction of TGF-beta signaling by FTI was mediated through restoration of the RII expression, as demonstrated by RT - PCR analysis. In addition, re-expression of RII by FTI Was associated with a decrease in 131 A methyltransferase 1 (DNMT1) levels. Thus, these findings suggest that the L-744,832 treatment restores the RII expression through inhibition of DNMT1 levels causing induction of TGF-beta signaling by radiation and this forms a novel molecular mechanism of radiosensitization by FTI.	Univ Kentucky, Dept Radiat Med, UKMC, Lexington, KY 40536 USA; Univ Kentucky, Dept Clin Sci, Lexington, KY 40536 USA; Univ Cent Lancashire, Ctr Forens Sci, Preston PR1 2HE, Lancs, England; Merck Pharmaceut, Westpoint, PA USA	University of Kentucky; University of Kentucky; University of Central Lancashire; Merck & Company	Ahmed, MM (corresponding author), Univ Kentucky, Dept Radiat Med, UKMC, C-15,800 Rose St, Lexington, KY 40536 USA.		Ahmed, Mansoor/AAK-5988-2020		NATIONAL CANCER INSTITUTE [R01CA086937] Funding Source: NIH RePORTER; NCI NIH HHS [CA86937] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adnane J, 2000, ONCOGENE, V19, P5525, DOI 10.1038/sj.onc.1203920; Ahmed MM, 2002, J BIOL CHEM, V277, P2234, DOI 10.1074/jbc.M110168200; Ahmed MM, 1997, J BIOL CHEM, V272, P33056, DOI 10.1074/jbc.272.52.33056; ALEXANDROW MG, 1995, CANCER RES, V55, P1452; BAE HW, 1995, J BIOL CHEM, V270, P29460, DOI 10.1074/jbc.270.49.29460; BASOLO F, 1994, INT J CANCER, V56, P736, DOI 10.1002/ijc.2910560521; Bernhard EJ, 2000, CANCER RES, V60, P6597; Bigey P, 2000, GENE, V242, P407, DOI 10.1016/S0378-1119(99)00501-6; BRUYNEEL EA, 1993, EUR J CANCER, V29A, P1958, DOI 10.1016/0959-8049(93)90452-L; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Calonge MJ, 1999, J BIOL CHEM, V274, P33637, DOI 10.1074/jbc.274.47.33637; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3407; FILMUS J, 1992, ONCOGENE, V7, P521; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Fralix KD, 2000, CANCER, V88, P2010, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2010::AID-CNCR5>3.0.CO;2-5; FREEMAN JW, 1995, J CELL PHYSIOL, V165, P155, DOI 10.1002/jcp.1041650118; GALANG CK, 1994, ONCOGENE, V9, P2913; Grady WM, 1999, CANCER RES, V59, P320; Gupta AK, 2001, CANCER RES, V61, P4278; Gupta AK, 2000, RADIAT RES, V154, P64, DOI 10.1667/0033-7587(2000)154[0064:RMRRIN]2.0.CO;2; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HERMENS AF, 1992, CANCER RES, V52, P3073; Hu YX, 1998, CLIN CANCER RES, V4, P1147; JOSHIBARVE SS, 1993, J BIOL CHEM, V268, P18018; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594; Leach SD, 1998, PANCREAS, V16, P491, DOI 10.1097/00006676-199805000-00006; MACLEOD AR, 1995, J BIOL CHEM, V270, P11327, DOI 10.1074/jbc.270.19.11327; MACLEOD AR, 1995, J BIOL CHEM, V270, P8037, DOI 10.1074/jbc.270.14.8037; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; MASSAGUE J, 1990, ANN REV CELL BIOL, V6, P1; MILLER AC, 1993, INT J CANCER, V53, P302, DOI 10.1002/ijc.2910530222; Nalca A, 1999, J BIOL CHEM, V274, P29976, DOI 10.1074/jbc.274.42.29976; Reiss M, 1997, BREAST CANCER RES TR, V45, P81, DOI 10.1023/A:1005865812918; ROULEAU J, 1995, J BIOL CHEM, V270, P1595, DOI 10.1074/jbc.270.4.1595; Saha D, 2001, J BIOL CHEM, V276, P29531, DOI 10.1074/jbc.M100069200; SELLS SF, 1995, MOL CELL BIOL, V15, P682; Shichinohe T, 1996, J SURG RES, V66, P125, DOI 10.1006/jsre.1996.0383; Simeone DM, 2000, ANN SURG, V232, P73, DOI 10.1097/00000658-200007000-00011; Song SY, 2000, NEOPLASIA, V2, P261, DOI 10.1038/sj.neo.7900088; SPORN MB, 1990, ANN NY ACAD SCI, V593, P1, DOI 10.1111/j.1749-6632.1990.tb16095.x; Venkatasubbarao K, 2001, CANCER RES, V61, P6239; Venkatasubbarao K, 2000, ANTICANCER RES, V20, P43; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; ZHAO J, 1995, CANCER RES, V55, P6181	48	34	40	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 7	2002	21	51					7883	7890		10.1038/sj.onc.1205948	http://dx.doi.org/10.1038/sj.onc.1205948			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	610DT	12420225				2022-12-28	WOS:000178946000013
J	Matsuda, A; Suzuki, Y; Honda, G; Muramatsu, S; Matsuzaki, O; Nagano, Y; Doi, T; Shimotohno, K; Harada, T; Nishida, E; Hayashi, H; Sugano, S				Matsuda, A; Suzuki, Y; Honda, G; Muramatsu, S; Matsuzaki, O; Nagano, Y; Doi, T; Shimotohno, K; Harada, T; Nishida, E; Hayashi, H; Sugano, S			Large-scale identification and characterization of human genes that activate NF-kappa B and MAPK signaling pathways	ONCOGENE			English	Article						full-length cDNA; signaling pathways; NF-kappa B; MAPK; oligo-capping	UBIQUITIN-PROTEIN LIGASE; TRANSCRIPTION FACTORS; MOLECULAR-CLONING; LYMPHOID-TISSUE; KINASE; EXPRESSION; APOPTOSIS; CELLS; CARCINOMA; MEDIATORS	We have carried out a large-scale identification and characterization of human genes that activate the NF-kappaB and MARK signaling pathways. We constructed full-length cDNA libraries using the oligo-capping method and prepared an arrayed cDNA pool consisting of 150 000 cDNAs randomly isolated from the libraries. For analysis of the NF-kappaB signaling pathway, we introduced each of the cDNAs into human embryonic kidney 293 cells and examined whether it activated the transcription of a luciferase reporter gene driven by a promoter containing the consensus NF-kappaB binding sites. In total, we identified 299 cDNAs that activate the NF-kappaB pathway, and we classified them into 83 genes, including 30 characterized activator genes of the NF-kappaB pathway, 28 genes whose involvement in the NF-kappaB pathways have not been characterized and 25 novel genes. We then carried out a similar analysis for the identification of genes that activate the MARK pathway, utilizing the same cDNA resource. We assayed 145 000 cDNAs and identified 57 genes that activate the MARK pathway. Interestingly, 27 genes were overlapping between the NF-kappaB and the MAPK pathways, which may indicate that these genes play cross-talking roles between these two pathways.	ASAHI KASEI Corp, Hlth Care Co, Life Sci Res Inst, Biol Lab, Fuji, Shizuoka 4168501, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Lab Genome Struct Anal,Minato Ku, Tokyo 1088639, Japan; Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan	Asahi Kasei Corporation; University of Tokyo; Kyoto University; Kyoto University	Matsuda, A (corresponding author), ASAHI KASEI Corp, Hlth Care Co, Life Sci Res Inst, Biol Lab, 2-1 Samejima, Fuji, Shizuoka 4168501, Japan.	matsuda.ab@om.asahi-kasei.co.jp	Doi, Takahiro/ABA-5913-2021	Doi, Takahiro/0000-0001-8133-558X				Akagi T, 1999, ONCOGENE, V18, P5785, DOI 10.1038/sj.onc.1203018; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Baetu TM, 2001, J IMMUNOL, V167, P3164, DOI 10.4049/jimmunol.167.6.3164; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; Bannai H., 2001, Proceedings of the Fourteenth International Florida Artificial Intelligence Research Society Conference, P233; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Barstead R, 2001, CURR OPIN CHEM BIOL, V5, P63, DOI 10.1016/S1367-5931(00)00173-3; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Dong G, 2001, CANCER RES, V61, P4797; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Florea L, 1998, GENOME RES, V8, P967, DOI 10.1101/gr.8.9.967; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Hinz M, 2001, BLOOD, V97, P2798, DOI 10.1182/blood.V97.9.2798; ISHIKAWA J, 1995, GENOMICS, V26, P527, DOI 10.1016/0888-7543(95)80171-H; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Jolliffe CN, 2000, BIOCHEM J, V351, P557, DOI 10.1042/0264-6021:3510557; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Kopp EB, 1999, CURR OPIN IMMUNOL, V11, P13, DOI 10.1016/S0952-7915(99)80003-X; Kurata H, 1999, IMMUNITY, V11, P677, DOI 10.1016/S1074-7613(00)80142-9; Liu HX, 2001, BLOOD, V98, P1182, DOI 10.1182/blood.V98.4.1182; MARUYAMA K, 1994, GENE, V138, P171; Mencinger M, 1997, GENOMICS, V41, P327, DOI 10.1006/geno.1997.4625; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; Ohtomo T, 1999, BIOCHEM BIOPH RES CO, V258, P583, DOI 10.1006/bbrc.1999.0683; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Perier RC, 2000, NUCLEIC ACIDS RES, V28, P302, DOI 10.1093/nar/28.1.302; Reed JC, 2001, TRENDS MOL MED, V7, P314, DOI 10.1016/S1471-4914(01)02026-3; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schmitz ML, 2001, TRENDS BIOCHEM SCI, V26, P186, DOI 10.1016/S0968-0004(00)01753-9; Schulze-Osthoff K, 1997, IMMUNOBIOLOGY, V198, P35, DOI 10.1016/S0171-2985(97)80025-3; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; Strausberg RL, 1999, SCIENCE, V286, P455, DOI 10.1126/science.286.5439.455; Suzuki Y, 1997, GENE, V200, P149, DOI 10.1016/S0378-1119(97)00411-3; Suzuki Y, 2001, EMBO REP, V2, P388, DOI 10.1093/embo-reports/kve085; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(05)00086-9; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; Wingender E, 2001, NUCLEIC ACIDS RES, V29, P281, DOI 10.1093/nar/29.1.281; Xie YM, 2001, P NATL ACAD SCI USA, V98, P3056, DOI 10.1073/pnas.071022298; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948	47	316	371	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2003	22	21					3307	3318		10.1038/sj.onc.1206406	http://dx.doi.org/10.1038/sj.onc.1206406			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681MM	12761501				2022-12-28	WOS:000183040000013
J	Stockl, L; Berting, A; Malkowski, B; Foerste, R; Hofschneider, PH; Hildt, E				Stockl, L; Berting, A; Malkowski, B; Foerste, R; Hofschneider, PH; Hildt, E			Integrity of c-Raf-1/MEK signal transduction cascade is essential for hepatitis B virus gene expression	ONCOGENE			English	Article						hepatitis B virus; transactivation; replication; antivirals	NF-KAPPA-B; PROTEIN-KINASE-C; HBX PROTEIN; X-PROTEIN; TRANSCRIPTIONAL ACTIVATOR; REPLICATION; RAS; IDENTIFICATION; PATHWAYS	The genome of hepatitis B virus (HBV) encodes two transcriptional activators: the HBx protein and the PreS2-activator large surface protein (LHBs). Both proteins trigger activation of c-Raf-1/MEK kinase cascade. In case of HBx this can be mediated by a PKC-independent and Ras-dependent mechanism, in case of LHBs activation is PKC-dependent and does not require Ras. Selective destruction of either LHBs- or of HBx-specific activation does not result in significant decrease of viral production from transfected HepG2 cells. Simultaneous inhibition of LHBs- and HBx-dependent activation by blocking signaling steps common to both activators, using trans dominant negative c-Raf-1- or MEK-specific inhibitors, abolished HBV gene expression. In accordance with this no HBV propagation was observed after transfection of a mutated HBV genome defective for HBx- and PreS2-activator function. A detailed analysis revealed that the observed inhibition of HBV- propagation is because of a significant reduction of HBV-specific RNA resulting in an inhibition of the de novo synthesis of viral compounds (viral proteins and nucleic acid) and not by blocking secretion or assembly of the virus. Based on these results we conclude that transcriptional-activator function, mediated by the c-Raf-1/MEK signaling cascade, is essential for HBV gene expression.	Robert Koch Inst, D-13353 Berlin, Germany; Max Planck Inst Biochem, D-82152 Martinsried, Germany	Robert Koch Institute; Max Planck Society	Hildt, E (corresponding author), Robert Koch Inst, Nordufer 20, D-13353 Berlin, Germany.		Małkowski, Bogdan/H-7131-2014; Hildt, Eberhard/A-1040-2015	Małkowski, Bogdan/0000-0001-6092-2283; 				Andrisani OM, 1999, INT J ONCOL, V15, P373; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; Bouchard MJ, 2001, SCIENCE, V294, P2376, DOI 10.1126/science.294.5550.2376; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BRUSS V, 1994, EMBO J, V13, P2273, DOI 10.1002/j.1460-2075.1994.tb06509.x; HEERMANN KH, 1984, J VIROL, V52, P396, DOI 10.1128/JVI.52.2.396-402.1984; Hildt E, 1996, VIROLOGY, V225, P235, DOI 10.1006/viro.1996.0594; HILDT E, 1995, ONCOGENE, V11, P2055; Hildt E, 1998, RECENT RES CANCER, V154, P315; Hildt E, 2002, EMBO J, V21, P525, DOI 10.1093/emboj/21.4.525; Hildt E, 1999, J EXP MED, V189, P1707, DOI 10.1084/jem.189.11.1707; KEKULE AS, 1990, NATURE, V343, P457, DOI 10.1038/343457a0; Klein NP, 1999, EMBO J, V18, P5019, DOI 10.1093/emboj/18.18.5019; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; LUCITO R, 1992, J VIROL, V66, P983, DOI 10.1128/JVI.66.2.983-991.1992; MURAKAMI S, 1994, VIROLOGY, V199, P243, DOI 10.1006/viro.1994.1119; Oess S, 2000, GENE THER, V7, P750, DOI 10.1038/sj.gt.3301154; Pleschka S, 2001, NAT CELL BIOL, V3, P301, DOI 10.1038/35060098; Sambrook J., 2002, MOL CLONING LAB MANU; SCHRECK R, 1992, J VIROL, V66, P6288, DOI 10.1128/JVI.66.11.6288-6293.1992; Su F, 2001, J VIROL, V75, P215, DOI 10.1128/JVI.75.1.215-225.2001; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; Weiss L, 1996, VIROLOGY, V216, P214, DOI 10.1006/viro.1996.0049; WOLLERSHEIM M, 1988, ONCOGENE, V3, P545; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	26	36	41	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2003	22	17					2604	2610		10.1038/sj.onc.1206320	http://dx.doi.org/10.1038/sj.onc.1206320			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730674				2022-12-28	WOS:000182569000008
J	Settle, M; Gordon, MD; Nadella, M; Dankort, D; Muller, W; Jacobs, JR				Settle, M; Gordon, MD; Nadella, M; Dankort, D; Muller, W; Jacobs, JR			Genetic identification of effectors downstream of Neu (ErbB-2) autophosphorylation sites in a Drosophila model	ONCOGENE			English	Article						apoptosis; DEgft; Grb-2; Neu; SHC	EPIDERMAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASES; GUANINE-NUCLEOTIDE EXCHANGE; PHOSPHOLIPASE C-GAMMA; EGF RECEPTOR; SIGNAL-TRANSDUCTION; ADAPTER PROTEIN; SH3 DOMAINS; PTB DOMAIN; MAMMARY TUMORIGENESIS	The ErbB-2/Neu receptor tyrosine kinase plays a causal role in tumorigenesis in mammals. Neu's carboxyl terminus contains five phosphorylated tyrosines that mediate transformation through interaction with cytoplasmic SH2 or PTB containing adaptor proteins. We show that Drosophild adaptors signal from individual phosphotyrosine sites of rat Neu. Activated Neu expression in the midline glia suppressed apoptosis, similar to that seen with activated Drosophild EGF-R expression. Expression in eye and wing tissues generated graded phenotypes suitable for dos F-sensitive modifier genetics. Suppression of ErbB-2/Neu-induced phenotypes in tissues haplosufficient for genes encoding adaptor protein or second messengers suggests that pTyr 1227(YD) signals require Shc, and that pTyr 1253 (YE) signalling does not employ Ras, but does require Raf function. Signalling from pTyr (YB) was affected by a haplosufficiency in drk (Grb-2), and in genes thought to function downstream of Grb-2: dab, sos, csw (Shp-2), and dos (Gab-1). These data demonstrate the power of Drosophila genetics to unmask the molecules that signal from oncogenic ErbB-2/Neu.	McMaster Univ, Dept Biol, Hamilton, ON L8S 4K1, Canada	McMaster University	Jacobs, JR (corresponding author), McMaster Univ, Dept Biol, 1280 Main St W, Hamilton, ON L8S 4K1, Canada.	jacobsr@mcmaster.ca	Gordon, Michael D/H-9586-2012	Gordon, Michael D/0000-0002-5440-986X; jacobs, j roger/0000-0002-5878-5416; Dankort, David/0000-0002-5862-6829				BAKER NE, 1989, NATURE, V340, P150, DOI 10.1038/340150a0; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BAUMANN P, 1993, DEVELOPMENT, P65; Bhandari P, 2001, ONCOGENE, V20, P6871, DOI 10.1038/sj.onc.1204849; BRAND AH, 1994, METHOD CELL BIOL, V44, P635, DOI 10.1016/S0091-679X(08)60936-X; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Cleghon V, 1998, MOL CELL, V2, P719, DOI 10.1016/S1097-2765(00)80287-7; Cunnick JM, 2001, J BIOL CHEM, V276, P24380, DOI 10.1074/jbc.M010275200; Dankort D, 2001, MOL CELL BIOL, V21, P1540, DOI 10.1128/MCB.21.5.1540-1551.2001; Dankort DL, 2000, ONCOGENE, V19, P1038, DOI 10.1038/sj.onc.1203272; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; Dong R, 1997, DEV BIOL, V190, P165, DOI 10.1006/dbio.1997.8688; Dougall WC, 1996, DNA CELL BIOL, V15, P31, DOI 10.1089/dna.1996.15.31; Firth L, 2000, GENETICS, V156, P733; Gayko U, 1999, P NATL ACAD SCI USA, V96, P523, DOI 10.1073/pnas.96.2.523; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Gustafson K, 1996, GENOME, V39, P174, DOI 10.1139/g96-023; Hamlet MRJ, 2001, GENETICS, V159, P1073; Hay BA, 1997, P NATL ACAD SCI USA, V94, P5195, DOI 10.1073/pnas.94.10.5195; Herbst R, 1999, EMBO J, V18, P6950, DOI 10.1093/emboj/18.24.6950; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Jacobs JR, 2000, PROG NEUROBIOL, V62, P475, DOI 10.1016/S0301-0082(00)00016-2; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; LAI KMV, 1995, MOL CELL BIOL, V15, P4810; Lanoue BR, 2000, GENOME, V43, P564, DOI 10.1139/gen-43-3-564; Lanoue BR, 1999, DEV GENET, V25, P321, DOI 10.1002/(SICI)1520-6408(1999)25:4<321::AID-DVG6>3.0.CO;2-Y; Le N, 1998, MOL CELL BIOL, V18, P4844, DOI 10.1128/MCB.18.8.4844; Lee T, 1996, DEVELOPMENT, V122, P409; Lesa GM, 1997, MOL BIOL CELL, V8, P779, DOI 10.1091/mbc.8.5.779; Lesokhin AM, 1999, DEV BIOL, V205, P129, DOI 10.1006/dbio.1998.9121; Lock P, 1999, J BIOL CHEM, V274, P22775, DOI 10.1074/jbc.274.32.22775; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LU XY, 1994, EMBO J, V13, P2592, DOI 10.1002/j.1460-2075.1994.tb06549.x; Ludlow C, 1996, DEV BIOL, V178, P149, DOI 10.1006/dbio.1996.0205; Maixner A, 1998, DEV GENET, V23, P347, DOI 10.1002/(SICI)1520-6408(1998)23:4<347::AID-DVG9>3.0.CO;2-C; Margolis B, 1999, KIDNEY INT, V56, P1230, DOI 10.1046/j.1523-1755.1999.00700.x; Obermeier A, 1996, EMBO J, V15, P73, DOI 10.1002/j.1460-2075.1996.tb00335.x; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PATEL NH, 1994, METHOD CELL BIOL, V44, P445, DOI 10.1016/S0091-679X(08)60927-9; Pawson T, 2000, GENE DEV, V14, P1027; PAWSON T, 1994, ADV CANCER RES, V64, P87, DOI 10.1016/S0065-230X(08)60835-0; PAWSON T, 1993, PHILOS T R SOC B, V340, P279, DOI 10.1098/rstb.1993.0069; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; Phelps CB, 1998, METHODS, V14, P367, DOI 10.1006/meth.1998.0592; RAZ E, 1993, GENE DEV, V7, P1937, DOI 10.1101/gad.7.10.1937; RICCI A, 1995, ONCOGENE, V11, P1519; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; Ross JS, 1999, SEMIN CANCER BIOL, V9, P125, DOI 10.1006/scbi.1998.0083; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SHILO BZ, 1991, TRENDS GENET, V7, P388, DOI 10.1016/0168-9525(91)90261-N; SIMON JA, 1995, CHEM BIOL, V2, P53, DOI 10.1016/1074-5521(95)90080-2; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STERN MJ, 1993, MOL BIOL CELL, V4, P1175, DOI 10.1091/mbc.4.11.1175; Stewart BA, 2001, DEV BIOL, V234, P13, DOI 10.1006/dbio.2001.0228; STURTEVANT MA, 1995, DEVELOPMENT, V121, P785; STURTEVANT MA, 1993, GENE DEV, V7, P961, DOI 10.1101/gad.7.6.961; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; Whitfield CW, 1999, MOL BIOL CELL, V10, P2087, DOI 10.1091/mbc.10.6.2087; Xu XX, 1998, ONCOGENE, V16, P1561, DOI 10.1038/sj.onc.1201678; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	69	9	10	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2003	22	13					1916	1926		10.1038/sj.onc.1206240	http://dx.doi.org/10.1038/sj.onc.1206240			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	662UR	12673197				2022-12-28	WOS:000181967700002
J	Vukovic, B; Park, PC; Al-Maghrabi, J; Beheshti, B; Sweet, J; Evans, A; Trachtenberg, J; Squire, J				Vukovic, B; Park, PC; Al-Maghrabi, J; Beheshti, B; Sweet, J; Evans, A; Trachtenberg, J; Squire, J			Evidence of multifocality of telomere erosion in high-grade prostatic intraepithelial neoplasia (HPIN) and concurrent carcinoma	ONCOGENE			English	Article						prostate; telomere; heterogeneity	IN-SITU HYBRIDIZATION; ATYPICAL ADENOMATOUS HYPERPLASIA; NUMERICAL CHROMOSOMAL CHANGES; INDEPENDENT ORIGIN; TUMOR PROGRESSION; ALLELIC LOSS; INSTABILITY; CANCER; IMMUNOHISTOCHEMISTRY; EPIDEMIOLOGY	Mechanisms underlying prostate cancer (CaP) initiation and progression are poorly understood. A chromosomal instability mechanism leading to the generation of numerical and structural chromosomal changes has been implicated in the preneoplastic and neoplastic stages of CaP. Telomere dysfunction is one potential mechanism associated with the onset of such instability. To determine whether there was alteration in telomere length and chromosome number, 15 paraffin-embedded prostatectomy specimens were investigated using quantitative peptide nucleic acid (PNA) FISH analysis of representative foci of carcinoma, putative precancerous lesions (high-grade prostatic intraepithelial neoplasia, HPIN) and nondysplastic prostate epithelium. A significant decrease in telomere length was shown in both HPIN and CaP in comparison with normal epithelium. In addition, elevated rates of aneusomy suggested that increased levels of chromosomal aberrations were associated with decreased telomere length. Moreover, multiple foci of HPIN were shown to have a heterogeneous overall reduction of telomere length. This reduction was more evident in the histologic regions of the prostate containing CaP. Such observations lend support to the hypothesis that telomere erosion may be a consistent feature of CaP oncogenesis and may also be associated with the generation of chromosomal instability that characterizes this malignancy.	Univ Toronto, Princess Margaret Hosp, Ontario Canc Inst, Hlth Network, Toronto, ON M5G 2M9, Canada; Univ Toronto, Fac Med, Dept Med Biophys, Hlth Network, Toronto, ON M5G 2M9, Canada; Univ Toronto, Fac Med, Lab Med & Pathobiol, Hlth Network, Toronto, ON M5G 2M9, Canada; Univ Toronto, Fac Med, Div Pathol, Hlth Network, Toronto, ON M5G 2M9, Canada; Univ Toronto, Fac Med, Div Urol, Hlth Network, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Squire, J (corresponding author), Univ Toronto, Hlth Network, Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	jeremy.squire@utoronto.ca	Al-Maghrabi, Jaudah/L-4367-2013; Squire, Jeremy A/A-9352-2012	Al-Maghrabi, Jaudah/0000-0002-0812-9592; Squire, Jeremy A/0000-0002-9863-468X; Sweet, Joan/0000-0002-6791-4929				Al-Maghrabi J, 2002, ARCH PATHOL LAB MED, V126, P165; Al-Maghrabi J, 2001, MODERN PATHOL, V14, P1252, DOI 10.1038/modpathol.3880471; Artandi SE, 2000, CURR OPIN GENET DEV, V10, P39, DOI 10.1016/S0959-437X(99)00047-7; BAAS IO, 1994, J PATHOL, V172, P5, DOI 10.1002/path.1711720104; BASTACKY SI, 1995, J UROLOGY, V153, P987, DOI 10.1016/S0022-5347(01)67619-5; Beheshti B, 2001, NEOPLASIA, V3, P62, DOI 10.1038/sj.neo.7900125; Bohr V, 1998, TOXICOL LETT, V103, P47; BONKHOFF H, 1994, PROSTATE, V24, P114, DOI 10.1002/pros.2990240303; Bonsing BA, 1997, CYTOMETRY, V28, P11, DOI 10.1002/(SICI)1097-0320(19970501)28:1<11::AID-CYTO2>3.3.CO;2-H; Bostwick DG, 1998, CANCER, V83, P1995, DOI 10.1002/(SICI)1097-0142(19981101)83:9<1995::AID-CNCR16>3.0.CO;2-2; CAMPBELL C, 1993, BRIT J DERMATOL, V129, P235, DOI 10.1111/j.1365-2133.1993.tb11840.x; Cheng L, 1998, J NATL CANCER I, V90, P233, DOI 10.1093/jnci/90.3.233; COLEMAN WB, 1995, CLIN CHEM, V41, P644; Counter CM, 1996, MUTAT RES-REV GENET, V366, P45, DOI 10.1016/S0165-1110(96)90006-8; Cunningham JM, 1996, CANCER RES, V56, P4475; Dong Jin-Tang, 1997, Current Opinion in Oncology, V9, P101; Ducray C, 1999, ONCOGENE, V18, P4211, DOI 10.1038/sj.onc.1202797; EMMERTBUCK MR, 1995, CANCER RES, V55, P2959; Erbersdobler A, 1996, PATHOL RES PRACT, V192, P418, DOI 10.1016/S0344-0338(96)80003-3; Erbersdobler A, 1999, PROSTATE, V38, P92, DOI 10.1002/(SICI)1097-0045(19990201)38:2<92::AID-PROS2>3.0.CO;2-6; Foster CS, 2000, SCAND J UROL NEPHROL, V34, P19, DOI 10.1080/003655900750169284; GIARETTI W, 1990, INT J CANCER, V45, P597, DOI 10.1002/ijc.2910450404; Goyns MH, 2000, MECH AGEING DEV, V114, P69, DOI 10.1016/S0047-6374(00)00095-6; GRAHAM SD, 1992, CANCER, V70, P359, DOI 10.1002/1097-0142(19920701)70:1+<359::AID-CNCR2820701329>3.0.CO;2-B; Grobelny JV, 2001, HUM MOL GENET, V10, P1953, DOI 10.1093/hmg/10.18.1953; Haas GP, 1997, CA-CANCER J CLIN, V47, P273, DOI 10.3322/canjclin.47.5.273; Hande MP, 1999, J CELL BIOL, V144, P589, DOI 10.1083/jcb.144.4.589; Harding MA, 2000, UROL ONCOL, V5, P258, DOI 10.1016/S1078-1439(00)00073-9; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; Hixon ML, 2000, FRONT BIOSCI, V5, pD50, DOI 10.2741/Hixon; ISAACS WB, 1994, SEMIN ONCOL, V21, P514; Kallakury BVS, 1997, DIAGN MOL PATHOL, V6, P192, DOI 10.1097/00019606-199708000-00003; Koeneman KS, 1998, J UROLOGY, V160, P1533, DOI 10.1016/S0022-5347(01)62608-9; Lin Y, 1997, J UROLOGY, V157, P1161, DOI 10.1016/S0022-5347(01)65160-7; MACOSKA JA, 1994, CANCER RES, V54, P3824; McClintock B, 1941, GENETICS, V26, P234; MCNEAL J, 1986, HUM PATHOL, V17; Meeker AK, 2002, AM J PATHOL, V160, P1259, DOI 10.1016/S0002-9440(10)62553-9; Morgan WF, 1998, MUTAT RES-FUND MOL M, V404, P125, DOI 10.1016/S0027-5107(98)00104-3; MUIR CS, 1991, ACTA ONCOL, V30, P133, DOI 10.3109/02841869109092336; MULLER HJ, 1938, COLLECTING NET, V13, P183; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; Poon SSS, 1999, CYTOMETRY, V36, P267, DOI 10.1002/(SICI)1097-0320(19990801)36:4<267::AID-CYTO1>3.0.CO;2-O; Qian JQ, 1999, EUR UROL, V35, P479, DOI 10.1159/000019883; QIAN JQ, 1995, UROLOGY, V46, P837, DOI 10.1016/S0090-4295(99)80354-9; Rasnick D, 1999, BIOCHEM J, V340, P621, DOI 10.1042/0264-6021:3400621; Sakr WA, 1998, ANAL QUANT CYTOL, V20, P417; Sakr WA, 1996, EUR UROL, V30, P138; SAKR WA, 1993, J UROLOGY, V150, P379, DOI 10.1016/S0022-5347(17)35487-3; Sakr WA, 2001, UROLOGY, V57, P115, DOI 10.1016/S0090-4295(00)00953-5; SAKR WA, 1995, PATHOL RES PRACT, V191, P838, DOI 10.1016/S0344-0338(11)80965-9; Scates DK, 1997, BRIT J UROL, V80, P263, DOI 10.1046/j.1464-410X.1997.00248.x; Shackney SE, 1995, CYTOMETRY, V22, P307, DOI 10.1002/cyto.990220407; Takahashi C, 1997, EUR UROL, V32, P494, DOI 10.1159/000480814; Takahashi S, 1996, CLIN CANCER RES, V2, P137; van der Kwast TH, 1999, EUR UROL, V35, P508, DOI 10.1159/000019889; Wen JP, 1998, HUM MOL GENET, V7, P1137, DOI 10.1093/hmg/7.7.1137; Wullich B, 1999, J UROLOGY, V161, P1997, DOI 10.1016/S0022-5347(05)68872-6; Zhang WB, 1998, CANCER RES, V58, P619	59	65	69	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2003	22	13					1978	1987		10.1038/sj.onc.1206227	http://dx.doi.org/10.1038/sj.onc.1206227			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	662UR	12673203				2022-12-28	WOS:000181967700008
J	Hooper, JD; Zijlstra, A; Aimes, RT; Liang, HY; Claassen, GF; Tarin, D; Testa, JE; Quigley, JP				Hooper, JD; Zijlstra, A; Aimes, RT; Liang, HY; Claassen, GF; Tarin, D; Testa, JE; Quigley, JP			Subtractive immunization using highly metastatic human tumor cells identifies SIMA135/CDCP1, a 135 kDa cell surface phosphorylated glycoprotein antigen	ONCOGENE			English	Article						subtractive immunization; metastasis; SIMA135/CDCP1; proteomics; colon cancer; CUB	MONOCLONAL-ANTIBODIES; SERINE PROTEASES; PROTEINS; BINDING; ACTIVATION; EXPRESSION; PHENOTYPE; DOMAINS; CANCER; GROWTH	We have previously used a subtractive immunization (SI) approach to generate monoclonal antibodies (mAbs) against proteins preferentially expressed by the highly metastatic human epidermoid carcinoma cell line, M(+)HEp3. Here we report the immunopurification, identification and characterization of SIMA135/CDCP1 (subtractive immunization M(+)HEp3 associated 135kDa protein/CUB domain containing protein 1) using one of these mAbs designated 41-2. Protein expression levels of SIMA135/CDCP1 correlated with the metastatic ability of variant HEp3 cell lines. Protein sequence analysis predicted a cell surface location and type I orientation of SIMA135/CDCP1, which was confirmed directly by immunocytochemistry. Analysis of deglycosylated cell lysates indicated that up to 40 kDa of the apparent molecular weight of SIMA135/CDCP1 is because of N-glycosylation. Western blot analysis using a antiphosphotyrosine antibody demonstrated that SIMA135/CDCP1 from HEp3 cells is tyrosine phosphorylated. Selective inhibitor studies indicated that an Src kinase family member is involved in the tyrosine phosphorylation of the protein. In addition to high expression in M(+)HEp3 cells, the SIMA135/CDCP1 protein is expressed to varying levels in 13 other human tumor cell lines, manifesting only a weak correlation with the reported metastatic ability of these tumor cell lines. The protein is not detected in normal human fibroblasts and endothelial cells. Northern blot analysis indicated that SIMA135/CDCP1 mRNA has a restricted expression pattern in normal human tissues with highest levels of expression in skeletal muscle and colon. Immunohistochemical analysis indicated apical and basal plasma membrane expression of SIMA135/CDCP1 in epithelial cells in normal colon. in colon tumor, SIMA135/CDCP1 expression appeared dysregulated showing extensive cell surface as well as cytoplasmic expression. Consistent with in vitro shedding experiments on HEp3 cells, SIMA135/CDCP1 was also detected within the lumen of normal and cancerous colon crypts, suggesting that protein shedding may occur in vivo. Thus, specific immunodetection followed by proteomic analysis allows for the identification and partial characterization of a heretofore uncharacterized human cell surface antigen.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA	Scripps Research Institute; University of California System; University of California San Diego	Quigley, JP (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jquigley@scripps.edu	Hooper, John/B-4153-2011; zijlstra, andries/G-4564-2013; Hooper, John/C-1481-2016	zijlstra, andries/0000-0001-8460-8803; Hooper, John/0000-0003-1054-8486	NATIONAL CANCER INSTITUTE [R01CA065660] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007695, T32HL007195, P01HL031950] Funding Source: NIH RePORTER; NCI NIH HHS [CA65660] Funding Source: Medline; NHLBI NIH HHS [HL31950, T32 HL07695, T32 HL07195] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADHAM IM, 1990, HUM GENET, V84, P125; Bajorath J, 2000, PROTEINS, V39, P103, DOI 10.1002/(SICI)1097-0134(20000501)39:2<103::AID-PROT1>3.3.CO;2-7; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; BRINER TJ, 1993, P NATL ACAD SCI USA, V90, P7608, DOI 10.1073/pnas.90.16.7608; BROOKS PC, 1993, J CELL BIOL, V122, P1351, DOI 10.1083/jcb.122.6.1351; Chen CB, 2001, J BIOL CHEM, V276, P25894, DOI 10.1074/jbc.M103539200; Falquet L, 2002, NUCLEIC ACIDS RES, V30, P235, DOI 10.1093/nar/30.1.235; Goebeler M, 1996, J CELL SCI, V109, P1957; Gorelik E, 2001, CANCER METAST REV, V20, P245, DOI 10.1023/A:1015535427597; Grogan MJ, 2002, ANNU REV BIOCHEM, V71, P593, DOI 10.1146/annurev.biochem.71.110601.135334; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hansen SG, 1999, VIROLOGY, V254, P124, DOI 10.1006/viro.1998.9543; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; Hooper JD, 2001, J BIOL CHEM, V276, P857, DOI 10.1074/jbc.R000020200; KING SW, 1988, BIOTECHNIQUES, V6, P856; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Maruo Y, 2002, INT J CANCER, V100, P486, DOI 10.1002/ijc.10514; MATTHEW WD, 1983, COLD SPRING HARB SYM, V48, P625, DOI 10.1101/SQB.1983.048.01.066; Mayer BJ, 2001, J CELL SCI, V114, P1253; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; NIELSENPREISS SM, 1993, J CELL BIOCHEM, V51, P219, DOI 10.1002/jcb.240510214; OSSOWSKI L, 1983, CELL, V33, P323, DOI 10.1016/0092-8674(83)90414-2; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; Riggott MJ, 1996, J NEUROSCI METH, V68, P235; Rye PD, 2001, TUMOR BIOL, V22, P269, DOI 10.1159/000050626; Scherl-Mostageer M, 2001, ONCOGENE, V20, P4402, DOI 10.1038/sj.onc.1204566; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Sieron AL, 2000, BIOCHEMISTRY-US, V39, P3231, DOI 10.1021/bi992312o; Sleister HM, 2002, J IMMUNOL METHODS, V261, P213, DOI 10.1016/S0022-1759(01)00567-1; Soos G, 1997, ANTICANCER RES, V17, P4253; Stocker J W, 1976, Contemp Top Immunobiol, V5, P191; TESTA JE, 1992, CANCER RES, V52, P5597; Testa JE, 1999, CANCER RES, V59, P3812; Wajih N, 2002, CIRC RES, V90, P46, DOI 10.1161/hh0102.102756; WILLIAMS CV, 1992, BIOTECHNIQUES, V12, P842; Yammani RR, 2001, J BIOL CHEM, V276, P44777, DOI 10.1074/jbc.M106419200; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	40	106	115	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2003	22	12					1783	1794		10.1038/sj.onc.1206220	http://dx.doi.org/10.1038/sj.onc.1206220			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660814				2022-12-28	WOS:000181678200005
J	Rossman, TG; Visalli, MA; Komissarova, EV				Rossman, TG; Visalli, MA; Komissarova, EV			fau and its ubiquitin-like domain (FUBI) transforms human osteogenic sarcoma (HOS) cells to anchorage-independence	ONCOGENE			English	Article						transformation; fau; ubiquitin-like protein; arsenic; hygromycin; ribosomal protein	PROTEIN; ARSENITE; INDUCTION; FUSION; CDNA; GENE; PATHWAYS; SEQUENCE; HOMOLOG; CLONING	Arsenite is the most likely carcinogenic form of arsenic in the environment. Previously, expression cloning for cDNAs whose overexpression confers arsenite-resistance in Chinese hamster V79 cells identified two genes:fau and a novel gene, asr2. The fau gene encodes a ubiquitin-like protein (here called FUBI) fused to the ribosomal S30 protein. Since the expression of the fox sequence (antisense to fau) increased the tumorigenicity of a mouse sarcoma virus, it was proposed that fau might be a tumor suppressor gene. We intended to test its ability to block arsenite-induced transformation of human osteogenic sarcoma (HOS) cells to anchorage-independence. Instead, we found that overexpressing fau itself was able to transform HOS cells. When the two domains were expressed separately, only FUBI was transforming and only the S30 domain conferred arsenite resistance. An incidental finding was the transforming activity of the selectable marker, hyg. FUBI belongs to the ubiquitin-like protein group that is capable of forming conjugates to other proteins, although none have so far been identified. Alternatively, FUBI may act as a substitute or inhibitor of ubiquitin, to which it is most closely related, or to close ubiquitin-like relatives UCRP, FAT10, and/or Nedd8.	NYU, Sch Med, Nelson Inst Environm Med, Tuxedo Pk, NY 10987 USA; NYU, Sch Med, Inst Canc, Tuxedo Pk, NY 10987 USA	New York University; New York University	Rossman, TG (corresponding author), NYU, Sch Med, Nelson Inst Environm Med, 57 Old Forge Rd, Tuxedo Pk, NY 10987 USA.	rossman@env.med.nyu.edu		Komissarova, Elena V./0000-0001-6848-0635	NATIONAL CANCER INSTITUTE [P30CA016087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES010344, P30ES000260, R01ES009252] Funding Source: NIH RePORTER; NCI NIH HHS [CA16087] Funding Source: Medline; NIEHS NIH HHS [P42 ES10344, R01 ES09252, ES00260] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Baker RT, 1996, J BIOL CHEM, V271, P13549, DOI 10.1074/jbc.271.23.13549; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; DCunha J, 1996, P NATL ACAD SCI USA, V93, P211, DOI 10.1073/pnas.93.1.211; Finkel M P, 1976, Recent Results Cancer Res, P92; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hiemstra PS, 1999, J LEUKOCYTE BIOL, V66, P423, DOI 10.1002/jlb.66.3.423; Hochstrasser M, 2000, SCIENCE, V289, P563, DOI 10.1126/science.289.5479.563; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; Hori T, 1999, ONCOGENE, V18, P6829, DOI 10.1038/sj.onc.1203093; Huang CS, 2001, MOL CELL BIOCHEM, V222, P29, DOI 10.1023/A:1017974131948; Huang SC, 1998, CARCINOGENESIS, V19, P889, DOI 10.1093/carcin/19.5.889; Hummer BT, 2001, J VIROL, V75, P7774, DOI 10.1128/JVI.75.16.7774-7777.2001; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; Johnson DG, 2000, MOL CARCINOGEN, V27, P151, DOI 10.1002/(SICI)1098-2744(200003)27:3<151::AID-MC1>3.0.CO;2-C; KLEMPERER NS, 1989, J BIOL CHEM, V264, P19245; Kurz T, 2002, SCIENCE, V295, P1294, DOI 10.1126/science.1067765; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; LIN XH, 1994, ENVIRON HEALTH PERSP, V102, P289, DOI 10.2307/3431804; Liu YC, 1999, P NATL ACAD SCI USA, V96, P4313, DOI 10.1073/pnas.96.8.4313; LOEB KR, 1992, J BIOL CHEM, V267, P7806; McLaughlin PMJ, 2000, INT J CANCER, V85, P871, DOI 10.1002/(SICI)1097-0215(20000315)85:6<871::AID-IJC22>3.0.CO;2-O; MICHIELS L, 1993, ONCOGENE, V8, P2537; Miller AC, 1998, ENVIRON HEALTH PERSP, V106, P465, DOI 10.1289/ehp.98106465; Nakamura M, 1999, J BIOL CHEM, V274, P18026, DOI 10.1074/jbc.274.25.18026; NAKAMURA M, 1995, P NATL ACAD SCI USA, V92, P3463, DOI 10.1073/pnas.92.8.3463; Nakamura M, 1996, J IMMUNOL, V156, P533; Podust VN, 2000, P NATL ACAD SCI USA, V97, P4579, DOI 10.1073/pnas.090465597; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Potter JL, 1999, J BIOL CHEM, V274, P25061, DOI 10.1074/jbc.274.35.25061; Raasi S, 2001, J BIOL CHEM, V276, P35334, DOI 10.1074/jbc.M105139200; Ramirez P, 1997, MUTAT RES-REV MUTAT, V386, P291, DOI 10.1016/S1383-5742(97)00018-5; RANI AS, 1992, CARCINOGENESIS, V13, P2021, DOI 10.1093/carcin/13.11.2021; Read MA, 2000, MOL CELL BIOL, V20, P2326, DOI 10.1128/MCB.20.7.2326-2333.2000; REDMAN KL, 1996, BIOCHEM J, V315, P21; RHIM JS, 1975, NATURE, V256, P751, DOI 10.1038/256751a0; Rossman TG, 1999, CARCINOGENESIS, V20, P311, DOI 10.1093/carcin/20.2.311; Rossman TG, 2001, ARSENIC EXPOSURE AND HEALTH EFFECTS IV, P285; Sambrook J, 1989, MOL CLONING; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; Tateishi K, 2001, J CELL BIOL, V155, P571, DOI 10.1083/jcb.200104035; Tornaletti S, 1999, BIOCHIMIE, V81, P139, DOI 10.1016/S0300-9084(99)80046-7; VOGT B, 2001, MUTAT RES, V478, P59; WANG ZL, 1994, BIOTECHNIQUES, V16, P460; WONG JM, 1993, CANCER RES, V53, P1916; Wright GD, 1998, ADV EXP MED BIOL, V456, P27; Yang JJ, 1998, MOL CELL BIOL, V18, P2586, DOI 10.1128/MCB.18.5.2586; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6	48	22	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2003	22	12					1817	1821		10.1038/sj.onc.1206283	http://dx.doi.org/10.1038/sj.onc.1206283			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660817				2022-12-28	WOS:000181678200008
J	Tanuma, N; Shima, H; Shimada, S; Kikuchi, K				Tanuma, N; Shima, H; Shimada, S; Kikuchi, K			Reduced tumorigenicity of murine leukemia cells expressing protein-tyrosine phosphatase, PTP epsilon C	ONCOGENE			English	Article						PTP; PTP epsilon; tumorigenicity; M1	MACROPHAGE DIFFERENTIATION; MICE; M1; TRANSFORMATION; TRANSMEMBRANE; SUPPRESSES; FAMILY	Recently, we reported that a cytosolic isoform of protein-tyrosine phosphatase epsilon (PTPepsilonC), when overexpressed, inhibits terminal differentiation and apoptosis of murine M1 myeloblastic leukemia cells induced by interleukin-6. To determine whether these observed effects in vitro correspond to a tumorigenicity of PTPepsilonC-expresser (M1-epsilonC) cells in vivo, parent M1 and M1-epsilonC cells were intravenously inoculated into scid or nude mice, and survival of mice receiving these cell lines was monitored. Unexpectedly, both scid and nude mice inoculated with M1-epsilonC cells showed significantly prolonged survival time than those receiving parent M1 cells. While parent M1 cells inoculated by intravenous injection formed metastatic tumors in the spleen, expression of PTPepsilonC suppressed tumor development in the spleen. The results suggest a suppressive role of PTPepsilonC in tumorigenesis.	Hokkaido Univ, Inst Med Genet, Div Biochem Oncol & Immunol, Kita Ku, Sapporo, Hokkaido 0600815, Japan; Hokkaido Univ, Inst Med Genet, Div Immunobiol, Kita Ku, Sapporo, Hokkaido 0600815, Japan	Hokkaido University; Hokkaido University	Kikuchi, K (corresponding author), Hokkaido Univ, Inst Med Genet, Div Biochem Oncol & Immunol, Kita Ku, Kita 15 Nishi 7, Sapporo, Hokkaido 0600815, Japan.	kikuchi@imm.hokudai.ac.jp	Tanuma, Naoyuki/V-7911-2019					Andersen JN, 2001, BIOCHEM J, V354, P581, DOI 10.1042/0264-6021:3540581; Elson A, 1999, ONCOGENE, V18, P7535, DOI 10.1038/sj.onc.1203098; Elson A, 1995, P NATL ACAD SCI USA, V92, P12235, DOI 10.1073/pnas.92.26.12235; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; Gil-Henn H, 2000, ONCOGENE, V19, P4375, DOI 10.1038/sj.onc.1203790; Gil-Henn H, 2001, J BIOL CHEM, V276, P31772, DOI 10.1074/jbc.M103395200; HOFFMANLIEBERMANN B, 1991, ONCOGENE, V6, P903; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; Klingler-Hoffmann M, 2001, J BIOL CHEM, V276, P46313, DOI 10.1074/jbc.M106571200; Krishnaraju K, 1998, BLOOD, V92, P1957, DOI 10.1182/blood.V92.6.1957.418k24_1957_1966; LaMontagne KR, 1998, MOL CELL BIOL, V18, P2965, DOI 10.1128/MCB.18.5.2965; LaMontagne KR, 1998, P NATL ACAD SCI USA, V95, P14094, DOI 10.1073/pnas.95.24.14094; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; McArdle L, 2001, J INVEST DERMATOL, V117, P1255, DOI 10.1046/j.0022-202x.2001.01534.x; Nakamura K, 1996, BIOCHEM BIOPH RES CO, V218, P726, DOI 10.1006/bbrc.1996.0129; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Peretz A, 2000, EMBO J, V19, P4036, DOI 10.1093/emboj/19.15.4036; Qiao S, 2001, J BIOL CHEM, V276, P9460, DOI 10.1074/jbc.M008744200; Smith SI, 2000, CANCER RES, V60, P808; Tanuma N, 1999, EUR J BIOCHEM, V259, P46, DOI 10.1046/j.1432-1327.1999.00004.x; Tanuma N, 2001, BLOOD, V98, P3030, DOI 10.1182/blood.V98.10.3030; Tanuma N, 2000, J BIOL CHEM, V275, P28216; Urushibara N, 1998, INT J ONCOL, V12, P603; Warabi M, 2000, EXP MOL PATHOL, V68, P187, DOI 10.1006/exmp.2000.2303; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	25	14	14	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2003	22	12					1758	1762		10.1038/sj.onc.1206267	http://dx.doi.org/10.1038/sj.onc.1206267			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660811				2022-12-28	WOS:000181678200002
J	Benn, DE; Croxson, MS; Tucker, K; Bambach, CP; Richardson, AL; Delbridge, L; Pullan, PT; Hammond, J; Marsh, DJ; Robinson, BG				Benn, DE; Croxson, MS; Tucker, K; Bambach, CP; Richardson, AL; Delbridge, L; Pullan, PT; Hammond, J; Marsh, DJ; Robinson, BG			Novel succinate dehydrogenase subunit B (SDHB) mutations in familial phaeochromocytomas and paragangliomas, but an absence of somatic SDHB mutations in sporadic phaeochromocytomas	ONCOGENE			English	Article						phaeochromocytoma; paraganglioma; SDHB; SDHD; leaky splicing	GERM-LINE MUTATIONS; COMPLEX-II GENE; RET; VHL	Phaeochromocytomas arising in adrenal or extra-adrenal sites and paragangliomas of the head and neck, in particular of the carotid bodies, occur sporadically and also in a familial setting. In addition to mutations in RET and VHL in familial disease, germline mutations in SDHD and SDHB genes that encode subunits of mitochondrial complex 11 have also been associated with the development of familial phaeochromocytomas. To further investigate the role of SDHD and SDHB in the development of these tumours we determined the occurrence of germline SDHD and SDHB mutations in four patients with a family history of phaeochromocytoma with associated head and neck paraganglioma, one patient with a family history of phaeochromocytoma only and two patients with apparently sporadic extra-adrenal phaeochromocytoma, one of whom had early onset disease. Secondly, we investigated whether somatic SDHB mutations correlated with loss of heterozygosity at 1p36 in a subgroup of 11 sporadic and three MEN 2-associated RET-mutation-positive phaeochromocytomas. Novel SDHB mutations were identified in the probands from four families and two apparently sporadic cases (six of seven probands studied), including two missense mutations, a single nonsense and frameshift mutation, as well as two splice site mutations, one of which was shown to have partial penetrance resulting in 'leaky' splicing Further, five intronic polymorphisms in SDHB were found. No SDHD mutations were identified. In addition, no somatic SDHB mutations were found in the remaining allele of the 11 sporadic adrenal phaeochromocytomas with allelic loss at 1p36 or the three MEN 2-associated RET-mutation-positive phaeochromocytomas. Therefore, we conclude that SDHB has a major role in the pathogenesis of familial phaeochromocytomas, but the possible role of SDHB in sporadic tumours showing allelic loss at 1p36 has yet to be ascertained.	Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia; Univ Sydney, Dept Mol Med, Sydney, NSW 2006, Australia; Auckland Hosp, Dept Endocrinol, Auckland, New Zealand; Prince Wales Hosp, Hereditary Canc Clin, Sydney, NSW 2031, Australia; Univ New S Wales, Sch Med, Sydney, NSW 2031, Australia; Royal N Shore Hosp, Dept Surg, St Leonards, NSW 2065, Australia; Univ Sydney, Dept Surg, Sydney, NSW 2006, Australia; Sir Charles Gairdner Hosp, Dept Endocrinol & Diabet, Nedlands, WA 6009, Australia; Univ WA, Dept Med, Nedlands, WA 6009, Australia; Melbourne Hypertens Clin, Melbourne, Vic 3002, Australia; Univ Sydney, Dept Med, Sydney, NSW 2006, Australia	Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research; University of Sydney; Auckland City Hospital; University of New South Wales Sydney; Royal North Shore Hospital; University of Sydney; University of Western Australia; University of Western Australia; University of Sydney	Marsh, DJ (corresponding author), Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia.	Debbie_Marsh@med.usyd.edu.au; bgr@med.usyd.edu.au	Marsh, Deborah J/I-1491-2014	Marsh, Deborah J/0000-0001-5899-4931; Delbridge, leigh/0000-0001-8281-8831				Astuti, 2002, AM J HUM GENET, V70, P565; Astuti D, 2001, LANCET, V357, P1181, DOI 10.1016/S0140-6736(00)04378-6; Astuti D, 2001, AM J HUM GENET, V69, P49, DOI 10.1086/321282; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Baysal BE, 2002, J MED GENET, V39, P178, DOI 10.1136/jmg.39.3.178; Baysal BE, 2001, OTOLARYNG CLIN N AM, V34, P863, DOI 10.1016/S0030-6665(05)70352-2; Baysal BE, 2001, J MOL MED, V79, P495, DOI 10.1007/s001090100267; Benn DE, 2000, CANCER RES, V60, P7048; BENN DE, 2002, CURR OPIN ENDOCRINOL, V9, P79; Caron H, 2001, GENE CHROMOSOME CANC, V30, P168, DOI 10.1002/1098-2264(200102)30:2<168::AID-GCC1072>3.0.CO;2-E; Elder EE, 2002, WORLD J SURG, V26, P965, DOI 10.1007/s00268-002-6626-8; ENG C, 1995, J MED GENET, V32, P934, DOI 10.1136/jmg.32.12.934; Gimenez-Roqueplo AP, 2002, J CLIN ENDOCR METAB, V87, P4771, DOI 10.1210/jc.2002-020525; Gimm O, 2000, CANCER RES, V60, P6822; Hofstra RMW, 1996, J CLIN ENDOCR METAB, V81, P2881, DOI 10.1210/jc.81.8.2881; KNUDSON AG, 1993, NAT GENET, V5, P103, DOI 10.1038/ng1093-103; Koch CA, 2002, ONCOGENE, V21, P479, DOI 10.1038/sj.onc.1205133; Lack EE, 1997, ATLAS TUMOR PATHOL, V3, P223; LECKSCHAT S, 1993, SOMAT CELL MOLEC GEN, V19, P505, DOI 10.1007/BF01233256; LEE SP, 1977, PATHOLOGY, V9, P173, DOI 10.3109/00313027709085255; Neumann HPH, 2002, NEW ENGL J MED, V346, P1459, DOI 10.1056/NEJMoa020152; Niemann S, 2000, NAT GENET, V26, P268, DOI 10.1038/81551; Scheffler IE, 1998, PROG NUCLEIC ACID RE, V60, P267, DOI 10.1016/S0079-6603(08)60895-8; SOLCIA E, 2000, WORLD HLTH ORG INT H; Svenson IK, 2001, AM J HUM GENET, V69, P1407, DOI 10.1086/324593; Taschner PEM, 2001, GENE CHROMOSOME CANC, V31, P274, DOI 10.1002/gcc.1144; Williamson C, 1997, J MED GENET, V34, P617, DOI 10.1136/jmg.34.8.617	27	90	94	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2003	22	9					1358	1364		10.1038/sj.onc.1206300	http://dx.doi.org/10.1038/sj.onc.1206300			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618761				2022-12-28	WOS:000181360900010
J	Yunta, M; Lazo, PA				Yunta, M; Lazo, PA			Apoptosis protection and survival signal by the CD53 tetraspanin antigen	ONCOGENE			English	Article						CD53; tetraspanin antigen; apoptosis; AKT	B-CELL LYMPHOMA; GENE-EXPRESSION; KAI1/CD82 EXPRESSION; HOMOTYPIC ADHESION; PROTEIN MRP-1/CD9; BREAST-CANCER; GROWTH-FACTOR; MOTILITY; METASTASIS; IDENTIFICATION	The CD53 antigen is a tetraspanin protein of the lymphoid-myeloid lineage, but its implication in biological effects is hardly known. Radioresistant tumor cells express very high levels of this antigen. We have studied the effect of CD53 antigen ligation on the survival response of tumor cells to serum deprivation, a well-known stimulator of cell death that may mimic the tumor environment; for this aim IR938F and Jurkat cells, a Band T-cell lymphoma, were used. Ligation of CD53 triggers a survival response and reduces the number of cells that enter apoptosis. In CD53- stimulated cells there is a significant reduction in caspase activation, measured by caspase processing of poly ADP-ribose polymerase, as well as a reduction in the fragmentation of DNA. CD53-stimulated cells also have an increase in the level of bcl-X-L and a reduction of bax protein, two components of the mitochondrial apoptotic pathway, changing their ratio by 24-fold in the direction of survival. This survival signal appears to be mediated by activation of the AKT, as detected by its phosphorylation in Ser473 upon CD53 ligation. The CD53 antigen interactions might contribute to cell survival in poorly vascularized regions of the tumor mass.	Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, Ctr Invest Canc, E-37007 Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Lazo, PA (corresponding author), Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, Ctr Invest Canc, Campus Miguel de Unamuno, E-37007 Salamanca, Spain.		Lazo, Pedro A./M-6435-2014	Lazo, Pedro A./0000-0001-8997-3025; Yunta, Monica/0000-0002-8060-9582				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; ANGELISOVA P, 1990, IMMUNOGENETICS, V32, P281, DOI 10.1007/BF00187099; Barcia R, 1996, CELL IMMUNOL, V169, P107, DOI 10.1006/cimm.1996.0097; Berditchevski F, 2001, J CELL SCI, V114, P4143; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOSCA L, 1994, J EXP MED, V179, P1119, DOI 10.1084/jem.179.4.1119; Boucheix C, 2001, CELL MOL LIFE SCI, V58, P1189, DOI 10.1007/PL00000933; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Ferrer M, 1998, CLIN EXP IMMUNOL, V113, P346; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; Guo XZ, 1996, CANCER RES, V56, P4876; Hemler ME, 2001, J CELL BIOL, V155, P1103, DOI 10.1083/jcb.200108061; Henkel GW, 2002, INT IMMUNOL, V14, P723, DOI 10.1093/intimm/dxf040; Hernandez-Torres J, 2001, J BIOL CHEM, V276, P35405, DOI 10.1074/jbc.M104723200; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; HIGASHIYAMA M, 1995, CANCER RES, V55, P6040; Higashiyama M, 1997, INT J CANCER, V74, P205, DOI 10.1002/(SICI)1097-0215(19970422)74:2<205::AID-IJC12>3.0.CO;2-C; Huang CI, 1998, AM J PATHOL, V153, P973, DOI 10.1016/S0002-9440(10)65639-8; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Lagaudriere-Gesbert C, 1997, CELL IMMUNOL, V182, P105, DOI 10.1006/cimm.1997.1223; Lazo PA, 1997, CELL IMMUNOL, V178, P132, DOI 10.1006/cimm.1997.1139; Levy S, 1998, ANNU REV IMMUNOL, V16, P89, DOI 10.1146/annurev.immunol.16.1.89; Longhurst CM, 2002, J BIOL CHEM, V277, P32445, DOI 10.1074/jbc.M204420200; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; MASELLISSMITH A, 1990, J IMMUNOL, V144, P1607; MIYAKE M, 1995, CANCER RES, V55, P4127; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Mollinedo F, 1997, CLIN DIAGN LAB IMMUN, V4, P229, DOI 10.1128/CDLI.4.2.229-231.1997; Musashi M, 2000, INT J HEMATOL, V72, P12; Puls KL, 2002, INT IMMUNOL, V14, P249, DOI 10.1093/intimm/14.3.249; RADFORD KJ, 1995, INT J CANCER, V62, P631, DOI 10.1002/ijc.2910620523; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Shibagaki N, 1999, EUR J IMMUNOL, V29, P4081, DOI 10.1002/(SICI)1521-4141(199912)29:12<4081::AID-IMMU4081>3.3.CO;2-9; Stipp CS, 2001, J BIOL CHEM, V276, P40545, DOI 10.1074/jbc.M107338200; Sugiura T, 1999, J CELL BIOL, V146, P1375, DOI 10.1083/jcb.146.6.1375; Testa JE, 1999, CANCER RES, V59, P3812; TRAVIS GH, 1991, NEURON, V6, P61, DOI 10.1016/0896-6273(91)90122-G; Uchida S, 1999, BRIT J CANCER, V79, P1168, DOI 10.1038/sj.bjc.6690186; Van Soest S, 1999, SURV OPHTHALMOL, V43, P321, DOI 10.1016/S0039-6257(98)00046-0; Voehringer DW, 2000, P NATL ACAD SCI USA, V97, P2680, DOI 10.1073/pnas.97.6.2680; Wang YD, 2002, ONCOGENE, V21, P2584, DOI 10.1038/sj.onc.1205355; Yanez-Mo M, 1998, J CELL BIOL, V141, P791, DOI 10.1083/jcb.141.3.791; Yunta M, 2002, EUR J BIOCHEM, V269, P1012, DOI 10.1046/j.0014-2956.2001.02741.x; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200	49	43	46	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 27	2003	22	8					1219	1224		10.1038/sj.onc.1206183	http://dx.doi.org/10.1038/sj.onc.1206183			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650EK	12606948				2022-12-28	WOS:000181249700010
J	Afaq, F; Adhami, VM; Ahmad, N; Mukhtar, H				Afaq, F; Adhami, VM; Ahmad, N; Mukhtar, H			Inhibition of ultraviolet B-mediated activation of nuclear factor kappa B in normal human epidermal keratinocytes by green tea Constituent (-)-epigallocatechin-3-gallate	ONCOGENE			English	Article						photochemopreventive; EGCG; NF-kappa B; NHEK; UVB	HUMAN SKIN; MOUSE SKIN; TRANSCRIPTION FACTOR; PYRIMIDINE DIMERS; IN-VITRO; CANCER; RADIATION; LIGHT; PROTEIN; KINASE	Epigallocatechin-3-gallate (EGCG), the major constituent of green tea, possesses significant anti-inflammatory and cancer chemopreventive properties. Studies have shown the photochemopreventive effects of green tea and EGCG in cell culture, animal models, and human skin. The molecular mechanism(s) of photochemopreventive effects of EGCG are incompletely understood. We recently showed that EGCG treatment of the normal human epidermal keratinocytes (NHEK) inhibits ultraviolet (UV)B-mediated activation of the mitogen-activated protein kinase (MAPK) pathway. In this study, we evaluated the effect of EGCG on UVB-mediated modulation of the nuclear factor kappa B (NF-kappaB) pathway, which is known to play a critical role in a variety of physiological functions and is involved in inflammation and development of cancer. Immunoblot analysis demonstrated that the treatment of NHEK with EGCG (10-40 mum) for 24 h resulted in a significant inhibition of UVB (40mJ/cm(2))-mediated degradation and phosphorylation of IkappaBalpha and activation of IKKalpha, in a dose-dependent manner. UVB-mediated degradation and phosphorylation of IkappaBalpha and activation of IKKalpha was also observed in a time-dependent protocol (15 and 30min, 1, 2, 3, 6, 12h post-UVB exposure). Employing immunoblot analysis, enzyme-linked immunosorbent assay, and gel shift assay, we demonstrate that EGCG treatment of the cells resulted in a significant dose- and time-dependent inhibition of UVB-mediated activation and nuclear translocation of a NF-kappaB/p65. Our data suggest that EGCG protects against the adverse effects of UV radiation via modulations in NF-kappaB pathway, and provide a molecular basis for the photochemopreventive effect of EGCG.	Univ Wisconsin, Med Sci Ctr, Dept Dermatol, Madison, WI 53706 USA; Case Western Reserve Univ, Dept Dermatol, Cleveland, OH 44106 USA	University of Wisconsin System; University of Wisconsin Madison; Case Western Reserve University	Mukhtar, H (corresponding author), Univ Wisconsin, Med Sci Ctr, Dept Dermatol, Room B25,1300 Univ Ave, Madison, WI 53706 USA.	hmukhtar@wisc.edu	Adhami, Vaqar/AAY-2837-2020	Adhami, Vaqar/0000-0002-2048-4570				Afaq F, 2002, FRONT BIOSCI-LANDMRK, V7, pD784, DOI 10.2741/afaq; Afaq F, 2001, J PHOTOCH PHOTOBIO B, V63, P61, DOI 10.1016/S1011-1344(01)00217-2; Ahmad N, 2000, ARCH BIOCHEM BIOPHYS, V376, P338, DOI 10.1006/abbi.2000.1742; Ahmad N, 2001, SKIN PHARMACOL APPL, V14, P69, DOI 10.1159/000056336; AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; Ananthaswamy HN, 1997, NAT MED, V3, P510, DOI 10.1038/nm0597-510; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BLOCK G, 1993, J NATL CANCER I, V85, P846, DOI 10.1093/jnci/85.11.846; Breuer-McHam J, 2001, PHOTOCHEM PHOTOBIOL, V74, P805, DOI 10.1562/0031-8655(2001)074&lt;0805:AOHIHS&gt;2.0.CO;2; Burren R, 1998, INT J CANCER, V76, P201, DOI 10.1002/(SICI)1097-0215(19980413)76:2<201::AID-IJC6>3.0.CO;2-0; Chen NY, 1999, J BIOL CHEM, V274, P15389, DOI 10.1074/jbc.274.22.15389; de Gruijl FR, 1999, EUR J CANCER, V35, P2003, DOI 10.1016/S0959-8049(99)00283-X; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; Eller MS, 1997, P NATL ACAD SCI USA, V94, P12627, DOI 10.1073/pnas.94.23.12627; Elmets CA, 2001, J AM ACAD DERMATOL, V44, P425, DOI 10.1067/mjd.2001.112919; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gilchrest BA, 1996, PHOTOCHEM PHOTOBIOL, V63, P1, DOI 10.1111/j.1751-1097.1996.tb02988.x; GoihmanYahr M, 1996, CLIN DERMATOL, V14, P153, DOI 10.1016/0738-081X(95)00150-E; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Griffiths HR, 1998, CRIT REV CL LAB SCI, V35, P189, DOI 10.1080/10408369891234192; Haas AF, 1998, FREE RADICAL BIO MED, V25, P998, DOI 10.1016/S0891-5849(98)00135-X; Helenius M, 1999, EXP CELL RES, V248, P194, DOI 10.1006/excr.1999.4393; Hong JT, 2001, MOL CARCINOGEN, V31, P152, DOI 10.1002/mc.1050; Ikeda M, 2002, J DERMATOL SCI, V28, P159, DOI 10.1016/S0923-1811(01)00164-5; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; Katiyar SK, 2000, CLIN CANCER RES, V6, P3864; Katiyar SK, 2001, TOXICOL APPL PHARM, V176, P110, DOI 10.1006/taap.2001.9276; Katiyar SK, 2001, CARCINOGENESIS, V22, P287, DOI 10.1093/carcin/22.2.287; Katiyar SK, 2001, J LEUKOCYTE BIOL, V69, P719; Katiyar SK, 1997, JNCI-J NATL CANCER I, V89, P556, DOI 10.1093/jnci/89.8.556; Katiyar SK, 1997, CARCINOGENESIS, V18, P497, DOI 10.1093/carcin/18.3.497; Kaufman CK, 2000, J CELL BIOL, V149, P999, DOI 10.1083/jcb.149.5.999; Kim J, 2001, SKIN PHARMACOL APPL, V14, P11, DOI 10.1159/000056329; KLIGMAN LH, 1980, J AM ACAD DERMATOL, V3, P30, DOI 10.1016/S0190-9622(80)80221-0; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; KRIPKE ML, 1992, P NATL ACAD SCI USA, V89, P7516, DOI 10.1073/pnas.89.16.7516; Lefort K, 2001, ONCOGENE, V20, P7375, DOI 10.1038/sj.onc.1204923; Legrand-Poels S, 1998, J PHOTOCH PHOTOBIO B, V45, P1, DOI 10.1016/S1011-1344(98)00118-3; Lu YP, 2000, CANCER RES, V60, P4785; Majumdar S, 2002, J IMMUNOL, V168, P2644, DOI 10.4049/jimmunol.168.6.2644; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; Morita A, 1997, J EXP MED, V186, P1763, DOI 10.1084/jem.186.10.1763; Mukhtar H, 1996, PHOTOCHEM PHOTOBIOL, V63, P355, DOI 10.1111/j.1751-1097.1996.tb03040.x; Naylor MF, 1997, ARCH DERMATOL, V133, P373, DOI 10.1001/archderm.133.3.373; Nomura M, 2000, CARCINOGENESIS, V21, P1885, DOI 10.1093/carcin/21.10.1885; Nomura M, 2001, J BIOL CHEM, V276, P46624, DOI 10.1074/jbc.M107897200; Okabe S, 1999, JPN J CANCER RES, V90, P733, DOI 10.1111/j.1349-7006.1999.tb00808.x; Pfundt R, 2001, J PATHOL, V193, P248; Rice-Evans C, 1999, P SOC EXP BIOL MED, V220, P262, DOI 10.1046/j.1525-1373.1999.d01-45.x; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Saliou C, 1999, FREE RADICAL BIO MED, V26, P174, DOI 10.1016/S0891-5849(98)00212-3; Scharffetter-Kochanek K, 1997, BIOL CHEM, V378, P1247; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VILE GF, 1995, PHOTOCHEM PHOTOBIOL, V62, P463, DOI 10.1111/j.1751-1097.1995.tb02369.x; Vink AA, 1997, P NATL ACAD SCI USA, V94, P5255, DOI 10.1073/pnas.94.10.5255; Yamazaki S, 2001, J BIOL CHEM, V276, P27657, DOI 10.1074/jbc.M103426200; Yang FJ, 1998, J NUTR, V128, P2334, DOI 10.1093/jn/128.12.2334	64	179	193	0	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2003	22	7					1035	1044		10.1038/sj.onc.1206206	http://dx.doi.org/10.1038/sj.onc.1206206			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	644PB	12592390				2022-12-28	WOS:000180926100009
J	Dong, S; Qiu, JH; Stenoien, DL; Brinkley, WR; Mancini, MA; Tweardy, DJ				Dong, S; Qiu, JH; Stenoien, DL; Brinkley, WR; Mancini, MA; Tweardy, DJ			Essential role for the dimerization domain of NuMA-RAR alpha in its oncogenic activities and localization to NuMA sites within the nucleus	ONCOGENE			English	Article						NuMA-RAR alpha; dimerization domain; coiled-coil domain; acute promyclocytic leukemia	ACUTE PROMYELOCYTIC LEUKEMIA; RETINOIC ACID RECEPTORS; FUSION; PROTEINS; TRANSLOCATION; HOMODIMERS; GENE	Nuclear mitotic apparatus protein-retinoic acid receptor alpha (NuMA-RARalpha) is the fourth of five fusion proteins identified in acute promyelocytic leukemia (APL) patients. The molecular basis for its oncogenic activity has not been delineated. In gel-shift assays, NuMA-RARalpha bound to retinoic acid response elements (RAREs) both as a homodimer and as a heterodimer with RXRalpha. The binding profile of NuMA-RARalpha to a panel of RAREs was very similar to PML-RARalpha and PLZF-RARalpha. In transient transfection assays using HepG2 cells, NuMA-RARalpha inhibited wild-type RARalpha transcriptional activity, while it augmented STAT3 transcriptional activity. In GST-pull down experiments, NuMA-RARalpha formed a complex with the corepressor SMRT, was released from the NuMA-RARalpha/SMRT complexes by all-trans retinoic acid (ATRA) at 10(-7)-10(-6) (M) and became associated with the coactivator TRAM-1 at 10(-8) (M) ATRA. Studies comparing NuMA-RARalpha with NuMA-RARalpha(DeltaCC) demonstrated that the dimerization or alpha-helical coiled-coil domain of NuMA was required for homodimer formation, transcriptional repression of wild-type RARalpha, transcriptional activation of STAT3, and stability of the NuMA-RARalpha/SMRT complex. Confocal fluorescent microscopy of HeLa cells was performed following transient expression of cyan fluorescent protein (CFP)-tagged proteins and incubation of cells with or without ATRA. Within the nucleus, CFP-NuMA-RARalpha exhibited a speckled pattern identical to that observed in cells transfected with CFP-NuMA. Furthermore, CFP-NuMA-RARalpha colocalized with yellow fluorescent protein-tagged (YFP)-NuMA. In contrast, CFP-NuMA-RARalpha(DeltaCC) exhibited a diffuse granular pattern within the nucleus, similar to RARalpha. These results indicate that the dimerization domain of NuMA-RARalpha is critical for each of the known oncogenic activities of NuMA fusion proteins as well as its sequestration to nuclear sites normally occupied by NuMA and is distinct from RARalpha.	Baylor Coll Med, Infect Dis Sect, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Hematol Oncol Sect, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Tweardy, DJ (corresponding author), Baylor Coll Med, Infect Dis Sect, Dept Med, 1 Baylor Plaza,BCM 286,Room N1319, Houston, TX 77030 USA.		Tweardy, David/L-3929-2019					Benekli M, 2002, BLOOD, V99, P252, DOI 10.1182/blood.V99.1.252; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; COMPTON DA, 1993, J CELL BIOL, V120, P947, DOI 10.1083/jcb.120.4.947; Dong S, 2002, BLOOD, V99, P2637, DOI 10.1182/blood.V99.8.2637; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; Hummel JL, 2002, CELL GROWTH DIFFER, V13, P173; Kawasaki A, 2000, BLOOD, V96, p684A; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; Stenoien DL, 1999, HUM MOL GENET, V8, P731, DOI 10.1093/hmg/8.5.731; Uchida H, 1999, ONCOGENE, V18, P1015, DOI 10.1038/sj.onc.1202383; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109; Xia Z, 1998, CANCER RES, V58, P3173; YON J, 1989, NUCLEIC ACIDS RES, V17, P4895, DOI 10.1093/nar/17.12.4895; Zelent A, 2001, ONCOGENE, V20, P7186, DOI 10.1038/sj.onc.1204766	20	23	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 13	2003	22	6					858	868		10.1038/sj.onc.1206182	http://dx.doi.org/10.1038/sj.onc.1206182			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584566				2022-12-28	WOS:000180864300009
J	Famulski, KS; Al-Hijailan, RS; Dobler, K; Pienkowska, M; Al-Mohanna, F; Paterson, MC				Famulski, KS; Al-Hijailan, RS; Dobler, K; Pienkowska, M; Al-Mohanna, F; Paterson, MC			Aberrant sensing of extracellular Ca2+ by cultured ataxia telangiectasia fibroblasts	ONCOGENE			English	Article						ataxia telangiectasia; extracellular calcium-sensing receptor; intracellular Ca2+ mobilization; mitogen-activated protein kinase; calmodulin-dependent protein kinase II	ACTIVATED PROTEIN-KINASE; DNA-DAMAGE; SIGNAL-TRANSDUCTION; OXIDATIVE STRESS; ATM; RADIATION; RECEPTOR; CELLS; EXPRESSION; GROWTH	Ataxia telangiectasia (AT) is a human hereditary syndrome whose underlying gene product, ataxia telangiectasia mutated (ATM) protein kinase, is involved in multiple intracellular signaling pathways. We demonstrated previously that AT fibroblasts are defective in intracellular Ca2+ mobilization in response to both stress-inducing and mitogenic stimuli. To extend these findings, normal and AT cells were exposed to serum in the presence of different concentrations of extracellular Ca2+ ([Ca2+](o)), and release of intracellular Ca2+, activation of calmodulin-dependent protein kinase 11 and phosphorylation of kinases ERK1 and 2 were monitored. When maintained in high [Ca2+](o) (0.42 mM), normal fibroblasts responded to serum introduction more rapidly and efficiently than did AT cells. Unexpectedly, decreasing the [Ca2+](o) in the medium had a diametrically opposite effect. Under low [Ca2+](o) (0.0022 mM) conditions, normal cells were slow and inefficient in their responses, whereas AT cells showed a substantial improvement in all three end points. These findings demonstrate that loss of ATM kinase function deregulates the extracellular calcium-sensing receptor (CaR). This malfunction presumably arises from a post-transcriptional event, since CaR mRNA proved to be normal in AT cells. Together, our data suggest that ATM may mediate cell response to mitogenic factors by tightly regulating the set point of the CaR and thereby modulating the crosstalk between this metabotropic receptor and growth factor receptors. Alternatively, the faulty sensing of extracellular calcium in AT cells may be secondary to a state of chronic oxidative stress attributable to ATM deficiency.	King Faisal Specialist Hosp & Res Ctr, Dept Biol & Med Res, Riyadh 11211, Saudi Arabia; Natl Canc Ctr, Div Cellular & Mol Res, Singapore 169610, Singapore	King Faisal Specialist Hospital & Research Center; National Cancer Centre Singapore (NCCS)	Famulski, KS (corresponding author), King Faisal Specialist Hosp & Res Ctr, Dept Biol & Med Res, MCB-03,POB 3354, Riyadh 11211, Saudi Arabia.	konrad@kfshrc.edu.sa	Famulski, Konrad/J-8685-2012					Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Brown EM, 2000, ANNU REV NUTR, V20, P507, DOI 10.1146/annurev.nutr.20.1.507; Chattopadhyay N, 2000, INT J BIOCHEM CELL B, V32, P789, DOI 10.1016/S1357-2725(00)00031-5; Chiesa N, 2000, NEUROSCIENCE, V96, P575, DOI 10.1016/S0306-4522(99)00581-3; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Enns L, 1999, BRIT J CANCER, V81, P959, DOI 10.1038/sj.bjc.6690793; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Famulski KS, 1999, FEBS LETT, V453, P183, DOI 10.1016/S0014-5793(99)00664-X; Fukao T, 1999, BLOOD, V94, P1998; Gueven N, 2001, J BIOL CHEM, V276, P8884, DOI 10.1074/jbc.M006190200; Hall J, 1999, MOL MED TODAY, V5, P157, DOI 10.1016/S1357-4310(99)01435-5; Heyer BS, 2000, GENE DEV, V14, P2072; HUANG SX, 1995, BIOCHEM J, V310, P881, DOI 10.1042/bj3100881; Kamsler A, 2001, CANCER RES, V61, P1849; Keating KE, 2001, ONCOGENE, V20, P4281, DOI 10.1038/sj.onc.1204527; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; McNeil L, 1998, AM J OBSTET GYNECOL, V178, P305, DOI 10.1016/S0002-9378(98)80017-3; McNeil SE, 1998, J BIOL CHEM, V273, P1114, DOI 10.1074/jbc.273.2.1114; MIRZAYANS R, 1995, ONCOGENE, V11, P1597; Nagasawa H, 1999, RADIAT RES, V152, P552, DOI 10.2307/3580153; Peretz S, 2001, P NATL ACAD SCI USA, V98, P1676, DOI 10.1073/pnas.041416598; PIENKOWSKA M, 2002, CANC DETECT PREV S1, V26, pS64; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Soares HD, 1998, NEUROSCIENCE, V86, P1045, DOI 10.1016/S0306-4522(98)00117-1; Speer G, 2002, INT J COLORECTAL DIS, V17, P20, DOI 10.1007/s003840100359; Squier TC, 2001, EXP GERONTOL, V36, P1539, DOI 10.1016/S0531-5565(01)00139-5; Taylor AMR, 1998, INT J RADIAT BIOL, V73, P365, DOI 10.1080/095530098142185; Yan J, 2000, INT J RADIAT BIOL, V76, P1025, DOI 10.1080/09553000050111497; Yang DQ, 2000, NAT CELL BIOL, V2, P893, DOI 10.1038/35046542; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	34	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2003	22	3					471	475		10.1038/sj.onc.1206167	http://dx.doi.org/10.1038/sj.onc.1206167			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545170				2022-12-28	WOS:000180379100018
J	Rushton, JJ; Davis, LM; Lei, WL; Mo, XM; Leutz, A; Ness, SA				Rushton, JJ; Davis, LM; Lei, WL; Mo, XM; Leutz, A; Ness, SA			Distinct changes in gene expression induced by A-Myb, B-Myb and c-Myb proteins	ONCOGENE			English	Article						microarrays; differentiation; transcription; breast cancer; oncogenes	BREAST-CANCER; ACTIVATION; SYSTEM; FAMILY; CELLS	The c-Myb, A-Myb and B-Myb transcription factors have nearly identical DNA-binding domains, activate the same reporter gene constructs in animal cells, but have different biological roles. The Myb proteins are often coexpressed in the same cells, raising questions about whether they activate similar or distinct gene expression profiles, and whether they cooperate or compete in regulating the same promoters. Here, recombinant adenoviruses were used to express each protein in human mammary cells, and then microarray assays were used to assess global changes in gene expression. Each Myb protein induced a unique and specific set of changes, displaying activities far more complex than revealed by standard reporter gene assays. These results have important implications for the roles of various Myb proteins in normal and transformed human cells, for regulatory pathways that might modify their activities and for the importance of acquired mutations that may qualitatively alter their functions in tumors.	Univ New Mexico, Hlth Sci Ctr, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA; Univ New Mexico, Hlth Sci Ctr, Keck Genom Resource, Albuquerque, NM 87131 USA; Univ New Mexico, Hlth Sci Ctr, Canc Res & Treatment Ctr, Albuquerque, NM 87131 USA; Exagen Corp, Albuquerque, NM USA; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany	University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico; University of New Mexico's Health Sciences Center; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Ness, SA (corresponding author), Univ New Mexico, Hlth Sci Ctr, Dept Mol Genet & Microbiol, 915 Camino Salud NE, Albuquerque, NM 87131 USA.		Leutz, Achim/K-9643-2013; Ness, Scott/AAV-4009-2020	Leutz, Achim/0000-0001-8259-927X; Ness, Scott/0000-0001-6965-8909	NCI NIH HHS [R01 CA58443] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058443] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; Buckhaults P, 2001, CANCER RES, V61, P6996; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; FOOS G, 1994, ONCOGENE, V9, P2481; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GABRIELLI F, 1995, EUR J BIOCHEM, V232, P473, DOI 10.1111/j.1432-1033.1995.tb20833.x; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GUERIN M, 1990, ONCOGENE, V5, P131; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Heinz S, 2002, GENOMICS, V79, P608, DOI 10.1006/geno.2002.6743; Kamano H, 1995, ONCOGENE, V11, P2575; Kauraniemi P, 2000, CANCER RES, V60, P5323; McClowry TL, 2002, J MED VIROL, V66, P96, DOI 10.1002/jmv.2116; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; Ness SA, 1996, BBA-REV CANCER, V1288, pF123, DOI 10.1016/S0304-419X(96)00027-3; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; Ness SA, 1999, ONCOGENE, V18, P3039, DOI 10.1038/sj.onc.1202726; Paramio JM, 1999, MOL CELL BIOL, V19, P3086; Rushton JJ, 2001, BLOOD CELL MOL DIS, V27, P459, DOI 10.1006/bcmd.2001.0405; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Stewart H, 1999, OPHTHALMOLOGY, V106, P964, DOI 10.1016/S0161-6420(99)00539-4; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; Yu DG, 2000, P NATL ACAD SCI USA, V97, P5978, DOI 10.1073/pnas.100127597	25	78	79	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 16	2003	22	2					308	313		10.1038/sj.onc.1206131	http://dx.doi.org/10.1038/sj.onc.1206131			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527900				2022-12-28	WOS:000180322400016
J	Huang, M; Dorsey, JF; Epling-Burnette, PK; Nimmanapalli, R; Landowski, TH; Mora, LB; Niu, GL; Sinibaldi, D; Bai, FQ; Kraker, A; Yu, H; Moscinski, L; Wei, S; Djeu, J; Dalton, WS; Bhalla, K; Loughran, TP; Wu, J; Jove, R				Huang, M; Dorsey, JF; Epling-Burnette, PK; Nimmanapalli, R; Landowski, TH; Mora, LB; Niu, GL; Sinibaldi, D; Bai, FQ; Kraker, A; Yu, H; Moscinski, L; Wei, S; Djeu, J; Dalton, WS; Bhalla, K; Loughran, TP; Wu, J; Jove, R			Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells	ONCOGENE			English	Article						Stat5; Bcr-Abl; CML; PD180970; apoptosis; cell cycle	DNA-BINDING ACTIVITY; MYELOGENOUS LEUKEMIA-CELLS; CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE; C-MYC; PHOSPHATIDYLINOSITOL 3-KINASE; HEMATOPOIETIC-CELLS; SIGNAL TRANSDUCER; BCL-2 FAMILY; SH2 DOMAINS	Chronic myelogenous leukemia (CML) is a myeloproliferative disease characterized by the BCR-ABL genetic translocation and constitutive activation of the Abl tyrosine kinase. Among members of the Signal Transducers and Activators of Transcription (STAT) family of transcription factors, Stat5 is activated by the Ber-Abl kinase and is implicated in the pathogenesis of CML. We recently identified PD180970 as a new and highly potent inhibitor of Bcr-Abl kinase. In this study, we show that blocking Bcr-Abl kinase activity using PD180970 in the human K562 CML cell line resulted in inhibition of Stat5 DNA-binding activity with an IC50 of 5 nM. Furthermore, abrogation of Abl kinase-mediated Stat5 activation suppressed cell proliferation and induced apoptosis in K562 cells, but not in the Ber-Abl-negative myeloid cell lines, HEL 92.1.7 and HL-60. Dominant-negative Stat5 protein expressed from a vaccinia virus vector also induced apoptosis of K562 cells, consistent with earlier studies that demonstrated an essential role of Stat5 signaling in growth and survival of CML cells. RNA and protein analyses revealed several candidate target genes of Stat5, including Bcl-x, Mcl-1, c-Myc and cyclin D2, which were down-regulated after treatment with PD180970. In addition, PD180970 inhibited Stat5 DNA-binding activity in cultured primary leukemic cells derived from CML patients. To detect activated Stat5 in CML patient specimens, we developed an immunocytochemical assay that can be used as a molecular end-point assay to monitor inhibition of Bcr-Abl signaling. Moreover, PD180970 blocked Stat5 signaling and induced apoptosis of STI-571 (Gleevec, Imatinib)-resistant Bcr-Abl-positive cells. Together, these results suggest that the mechanism of action of PD180970 involves inhibition of Bcr-Abl-mediated Stat5 signaling and provide further evidence that compounds in this structural class may represent potential therapeutic agents for CML.	Univ S Florida, H Lee Moffitt Canc Ctr, Res Inst, Mol Oncol Program, Tampa, FL 33682 USA; Pfizer Global Res & Dev, Dept Canc Res, Ann Arbor, MI 48106 USA; Univ Arizona, Hlth Sci Ctr, Dept Med, Tucson, AZ 85724 USA; Univ S Florida, Coll Med, Dept Oncol, Tampa, FL 33612 USA; H Lee Moffitt Canc Ctr & Res Inst, Program Immunol, Tampa, FL 33612 USA; H Lee Moffitt Canc Ctr & Res Inst, Expt Therapeut Program, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Pfizer; University of Arizona; University of Arizona Health Sciences; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute	Jove, R (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, 12902 Magnolia Dr, Tampa, FL 33612 USA.	richjove@moffitt.usf.edu	Wu, Jie/R-2404-2019; Herrmann, Eva/E-8215-2010	Wu, Jie/0000-0002-2864-1606; YU, Hua/0000-0003-0931-1000; Bhalla, Kapil/0000-0001-5209-5126	NATIONAL CANCER INSTITUTE [P01CA082533, R01CA055652] Funding Source: NIH RePORTER; NCI NIH HHS [CA82533, CA55652] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; Benito A, 1996, BLOOD, V87, P3837, DOI 10.1182/blood.V87.9.3837.bloodjournal8793837; Besser D, 1999, MOL CELL BIOL, V19, P1401; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chai SK, 1997, J IMMUNOL, V159, P4720; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; Coffer PJ, 2000, ONCOGENE, V19, P2511, DOI 10.1038/sj.onc.1203479; Cortez D, 1996, ONCOGENE, V13, P2589; Dang CV, 1999, EXP CELL RES, V253, P63, DOI 10.1006/excr.1999.4686; Danial NN, 2000, ONCOGENE, V19, P2523, DOI 10.1038/sj.onc.1203484; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; de Groot RP, 1999, BLOOD, V94, P1108, DOI 10.1182/blood.V94.3.1108.415k07_1108_1112; Dorsey JF, 2000, CANCER RES, V60, P3127; Dorsey JF, 2002, LEUKEMIA, V16, P1589, DOI 10.1038/sj.leu.2402678; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; Epling-Burnette PK, 2001, J IMMUNOL, V166, P7486, DOI 10.4049/jimmunol.166.12.7486; Fang GF, 2000, BLOOD, V96, P2246, DOI 10.1182/blood.V96.6.2246.h8002246_2246_2253; Frank DA, 1996, LEUKEMIA, V10, P1724; Gelfanov VM, 2001, BLOOD, V98, P2508, DOI 10.1182/blood.V98.8.2508; Gesbert F, 2000, BLOOD, V96, P2269, DOI 10.1182/blood.V96.6.2269.h8002269_2269_2276; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Ibrado AM, 1996, CANCER RES, V56, P4743; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Jain SK, 1996, BLOOD, V88, P1542; Jiang K, 2000, NAT IMMUNOL, V1, P419, DOI 10.1038/80859; Jonuleit T, 1998, BRIT J HAEMATOL, V100, P295, DOI 10.1046/j.1365-2141.1998.00564.x; Kolibaba KS, 1999, LEUKEMIA LYMPHOMA, V33, P119, DOI 10.3109/10428199909093732; Kraker AJ, 2000, BIOCHEM PHARMACOL, V60, P885, DOI 10.1016/S0006-2952(00)00405-6; Landowski TH, 1999, BLOOD, V94, P265, DOI 10.1182/blood.V94.1.265.413k37_265_274; Lin TS, 2000, ONCOGENE, V19, P2496, DOI 10.1038/sj.onc.1203486; Lionberger JM, 2000, J BIOL CHEM, V275, P18581, DOI 10.1074/jbc.C000126200; Lord JD, 2000, J IMMUNOL, V164, P2533, DOI 10.4049/jimmunol.164.5.2533; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; Nagar B, 2002, CANCER RES, V62, P4236; Nelson KL, 1998, J BIOL CHEM, V273, P7072, DOI 10.1074/jbc.273.12.7072; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; NIMMANAPALLI R, 2002, IN PRESS CANC RES; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; Porosnicu M, 2001, LEUKEMIA, V15, P772, DOI 10.1038/sj.leu.2402104; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; REYNOLDS JE, 1994, CANCER RES, V54, P6348; Rhodes J, 2000, EXP HEMATOL, V28, P305, DOI 10.1016/S0301-472X(99)00148-4; Roumiantsev S, 2001, BLOOD, V97, P4, DOI 10.1182/blood.V97.1.4; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; Schwaller J, 2000, MOL CELL, V6, P693, DOI 10.1016/S1097-2765(00)00067-8; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Smithgall TE, 2000, ONCOGENE, V19, P2612, DOI 10.1038/sj.onc.1203477; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; Sonoyama J, 2002, J BIOL CHEM, V277, P8076, DOI 10.1074/jbc.M111501200; Thiesing JT, 2000, BLOOD, V96, P3195, DOI 10.1182/blood.V96.9.3195.h8003195_3195_3199; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Wei S, 2000, J IMMUNOL, V165, P3811, DOI 10.4049/jimmunol.165.7.3811; Wisniewski D, 2002, CANCER RES, V62, P4244; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065	74	116	131	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2002	21	57					8804	8816		10.1038/sj.onc.1206028	http://dx.doi.org/10.1038/sj.onc.1206028			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483533	Bronze			2022-12-28	WOS:000179734400014
J	Mukhopadhyay, A; Banerjee, S; Stafford, LJ; Xia, CZ; Liu, MY; Aggarwal, BB				Mukhopadhyay, A; Banerjee, S; Stafford, LJ; Xia, CZ; Liu, MY; Aggarwal, BB			Curcumin-induced suppression of cell proliferation correlates with down-regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation	ONCOGENE			English	Article						curcumin; cyclin D1; CDK4; Rb; retinoic acid; NF-kappa B	NF-KAPPA-B; HUMAN BREAST-CANCER; MAMMARY-GLAND DEVELOPMENT; HUMAN LEUKEMIA-CELLS; HEPATOCELLULAR-CARCINOMA; TRANSGENIC MICE; KINASE-ACTIVITY; APOPTOSIS; ACTIVATION; OVEREXPRESSION	Cyclin D1 is a proto-oncogene that is overexpressed in many cancers including breast and prostate. It plays a role in cell proliferation through activation of cyclin-dependent kinases. Curcumin, a diferuloylmethane, is a chemopreventive agent known to inhibit the proliferation of several breast and prostate cancer cell lines. It is possible that the effect of curcumin is mediated through the regulation of cyclin D1. In the present report we show that inhibition of the proliferation of various prostate, breast and squamous cell carcinoma cell lines by curcumin correlated with the down-regulation of the expression of cyclin D1 protein. In comparison, the down-regulation by curcumin of cyclin D2 and cyclin D3 was found only in selective cell lines. The suppression of cyclin D1 by curcumin led to inhibition of CDK4-mediated phosphorylation of retinoblastoma protein. We found that curcumin-induced down-regulation of cyclin D1 was inhibited by lactacystin, an inhibitor of 26S proteosome, suggesting that curcumin represses cyclin D1 expression by promoting proteolysis. We found that curcumin also down-regulated mRNA expression, thus suggesting transcriptional regulation. Curcumin also inhibited the activity of the cyclin D1 promoter-dependent reporter gene expression. Overall our results suggest that curcumin down-regulates cyclin D1 expression through activation of both transcriptional and post-transcriptional mechanisms, and this may contribute to the antiproliferative effects of curcumin against various cell types.	Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Lab, Houston, TX 77030 USA; Texas A&M Univ, Hlth Sci Ctr, Dept Med Biochem & Genet, Houston, TX 77030 USA; Texas A&M Univ, Hlth Sci Ctr, Inst Biosci & Technol, Houston, TX 77030 USA; Texas A&M Univ, Hlth Sci Ctr, Ctr Canc Biol & Nutr, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Lab, 1515 Holcombe Blvd,Box 143, Houston, TX 77030 USA.		Aggarwal, Bharat B/G-3388-2013	Liu, Mingyao/0000-0001-7339-5048				ADELAIDE J, 1995, BRIT J CANCER, V71, P64, DOI 10.1038/bjc.1995.13; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Anto RJ, 2002, CARCINOGENESIS, V23, P143, DOI 10.1093/carcin/23.1.143; Arber N, 1996, GASTROENTEROLOGY, V110, P669, DOI 10.1053/gast.1996.v110.pm8608874; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARTKOVA J, 1995, CANCER RES, V55, P949; BARTKOVA J, 1994, INT J CANCER, V58, P568, DOI 10.1002/ijc.2910580420; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Bhaumik S, 1999, FEBS LETT, V456, P311, DOI 10.1016/S0014-5793(99)00969-2; Caputi M, 1999, AM J RESP CELL MOL, V20, P746, DOI 10.1165/ajrcmb.20.4.3366; Chen H, 1999, ANTICANCER RES, V19, P3675; Chen HW, 1998, BRIT J PHARMACOL, V124, P1029, DOI 10.1038/sj.bjp.0701914; Deane NG, 2001, CANCER RES, V61, P5389; DICKSON C, 1995, CANCER LETT, V90, P43, DOI 10.1016/0304-3835(94)03676-A; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Drobnjak M, 2000, CLIN CANCER RES, V6, P1891; DUCKETT CS, 1995, J BIOL CHEM, V270, P18836, DOI 10.1074/jbc.270.32.18836; Evron E, 2001, CANCER RES, V61, P2782; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Fantl V, 2000, ADV EXP MED BIOL, V480, P1; GILLETT C, 1994, CANCER RES, V54, P1812; Gumbiner LM, 1999, PROSTATE, V38, P40, DOI 10.1002/(SICI)1097-0045(19990101)38:1<40::AID-PROS5>3.0.CO;2-I; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Han SS, 1999, CLIN IMMUNOL, V93, P152, DOI 10.1006/clim.1999.4769; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Haridas V, 1998, J IMMUNOL, V160, P3152; Henry DO, 2000, MOL CELL BIOL, V20, P8084, DOI 10.1128/MCB.20.21.8084-8092.2000; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Jiang MC, 1996, NUTR CANCER, V26, P111, DOI 10.1080/01635589609514468; Jobin C, 1999, J IMMUNOL, V163, P3474; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Kumar A, 1998, BIOCHEM PHARMACOL, V55, P775, DOI 10.1016/S0006-2952(97)00557-1; Kuo ML, 1996, BBA-MOL BASIS DIS, V1317, P95, DOI 10.1016/S0925-4439(96)00032-4; Langenfeld J, 1997, P NATL ACAD SCI USA, V94, P12070, DOI 10.1073/pnas.94.22.12070; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Liu MY, 1996, NATURE, V382, P83, DOI 10.1038/382083a0; LUKAS J, 1995, ONCOGENE, V10, P2125; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Mehta K, 1997, ANTI-CANCER DRUG, V8, P470, DOI 10.1097/00001813-199706000-00010; NISHIDA N, 1994, CANCER RES, V54, P3107; Pervin S, 2001, P NATL ACAD SCI USA, V98, P3583, DOI 10.1073/pnas.041603998; Piwocka K, 1999, EXP CELL RES, V249, P299, DOI 10.1006/excr.1999.4480; Plummer SM, 1999, ONCOGENE, V18, P6013, DOI 10.1038/sj.onc.1202980; Ramachandran C, 1999, BREAST CANCER RES TR, V54, P269, DOI 10.1023/A:1006170224414; Ranjan D, 1999, J SURG RES, V87, P1, DOI 10.1006/jsre.1999.5719; Sauter ER, 1999, CANCER RES, V59, P4876; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Sicinski P, 1997, J MAMMARY GLAND BIOL, V2, P335, DOI 10.1023/A:1026391128117; Simon A, 1998, CANCER LETT, V129, P111, DOI 10.1016/S0304-3835(98)00092-5; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Vrana JA, 2001, BLOOD, V97, P2105, DOI 10.1182/blood.V97.7.2105; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500	53	277	298	2	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 12	2002	21	57					8852	8861		10.1038/sj.onc.1206048	http://dx.doi.org/10.1038/sj.onc.1206048			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483537				2022-12-28	WOS:000179734400018
J	Shivapurkar, N; Reddy, J; Matta, H; Sathyanarayana, UG; Huang, CX; Toyooka, S; Minna, JD; Chaudhary, PM; Gazdar, AF				Shivapurkar, N; Reddy, J; Matta, H; Sathyanarayana, UG; Huang, CX; Toyooka, S; Minna, JD; Chaudhary, PM; Gazdar, AF			Loss of expression of death-inducing signaling complex (DISC) components in lung cancer cell lines and the influence of MYC amplification	ONCOGENE			English	Article						CASP8; DISC; MYC; TRAIL	NF-KAPPA-B; CASPASE 8; C-MYC; APOPTOSIS; ACTIVATION; ONCOGENE	We have previously reported that the key apoptosis related gene caspase 8 (CASP8) is frequently silenced in small cell lung cancer (SCLC) tumors and cell lines usually, but not always, by aberrant promoter methylation. Because CASP8 is a key component of the death-inducing signaling complex (DISC) when specific death receptors (including DR4, DR5, FAS) are activated by their specific ligands (TRAIL/FASL), we examined expression of the components of the DISC complex in lung cancer cell lines. MYC family members are frequently amplified (MYC+ve) in SCLC, and MYC is a potent inducer of apoptosis. We examined 34 SCLC tines (12 of which were MYC+ve) and 22 NSCLC lines. CASP8 gene expression was frequently lost (79%) at message and protein levels in SCLC but not in non-SCLC (NSCLC). MYC amplification was present in 45% of SCLC cell lines, which had lost CASP8 expression, but not in any of the CASP8 positive lines. The frequency of CASP8 loss was significantly higher in MYC+ve SCLC compared to MYC-ve SCLC or in NSCLC. Analyses of other DISC components showed significantly higher rates of loss of expression of CASP10, DR5, FAS and FASL in SCLC compared to NSCLC. The loss of expression of proapoptotic DISC components was significantly higher in MYC+ve SCLC cell lines and these lines were completely resistant to TRAIL. Expression of CASP10 (a caspase closely related to CASP8) was frequently absent at the protein level in both SCLC and NSCLC lines. Expression of c-FLIP (proteolytically inactive homolog of CASP8) was inversely related to expression of CASP8. Our major conclusions are: (a) The death receptor pathway is differently inactivated at multiple levels in lung cancer cell lines; and (b) MYC amplification in SCLC is associated with inactivation of most components of the DISC complex, with resistance to TRAIL and with expression of c-FLIP. These findings may have considerable clinical and therapeutic implications.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gazdar, AF (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, NB8 106,5323 Harry Hines Blvd, Dallas, TX 75390 USA.	adi.gazdar@UTSouthwestern.edu	Chaudhary, Preet/E-1970-2018		NCI NIH HHS [P50-CA70907] Funding Source: Medline; NIAID NIH HHS [AI/AR47230-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047230] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BROERS JLV, 1993, AM J RESP CELL MOL, V9, P33, DOI 10.1165/ajrcmb/9.1.33; Chaudhary PM, 2000, ONCOGENE, V19, P4451, DOI 10.1038/sj.onc.1203812; Griffith TS, 1998, J IMMUNOL, V161, P2833; Hopkins-Donaldson S, 2000, MED PEDIATR ONCOL, V35, P608; Johnson BE, 1996, J CELL BIOCHEM, P210; Joseph B, 1999, BIOCHEM BIOPH RES CO, V262, P381, DOI 10.1006/bbrc.1999.1191; Kataoka T, 2000, CURR BIOL, V10, P640, DOI 10.1016/S0960-9822(00)00512-1; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Kumar A, 2001, ONCOGENE, V20, P1010, DOI 10.1038/sj.onc.1204154; MORSTYN G, 1984, JNCI-J NATL CANCER I, V73, P801; Ng PWP, 1999, J BIOL CHEM, V274, P10301, DOI 10.1074/jbc.274.15.10301; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; Ozkara HA, 1999, TUMORI J, V85, P508; Phelps RM, 1996, J CELL BIOCHEM, P32; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Schneider P, 2000, Pharm Acta Helv, V74, P281, DOI 10.1016/S0031-6865(99)00038-2; Shivapurkar N, 2002, CANCER BIOL THER, V1, P65, DOI 10.4161/cbt.1.1.45; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; Wang XD, 2001, GENE DEV, V15, P2922; Zajac-Kaye M, 2001, LUNG CANCER-J IASLC, V34, pS43, DOI 10.1016/S0169-5002(01)00343-9; Zochbauer-Muller S, 2002, ANNU REV PHYSIOL, V64, P681, DOI 10.1146/annurev.physiol.64.081501.155828	23	64	67	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	2002	21	55					8510	8514		10.1038/sj.onc.1205941	http://dx.doi.org/10.1038/sj.onc.1205941			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466971	Bronze			2022-12-28	WOS:000179480100014
J	Yin, D; Xie, D; Hofmann, WK; Miller, CW; Black, KL; Koeffler, HP				Yin, D; Xie, D; Hofmann, WK; Miller, CW; Black, KL; Koeffler, HP			Methylation, expression, and mutation analysis of the cell cycle control genes in human brain tumors	ONCOGENE			English	Article						Methylation; p14(ARF); p15(INK4B); p16(INK4A); RB; brain tumors; p53 mutation	HOMOZYGOUS DELETION; SUPPRESSOR GENE; CPG ISLAND; P16 GENE; SOMATIC MUTATIONS; FAMILIAL MELANOMA; P16(INK4A) GENES; DNA METHYLATION; STABILIZES P53; HUMAN CANCERS	Methylation status of the p(15INK4B), p16(INK4A), p14(ARF) and retinoblastoma (RB) genes was studied using methylation specific polymerase chain reaction (MSP) in 85 human brain tumors of various subtypes and four normal brain samples. These genes play an important role in the control of the cell cycle. Twenty-four out of 85 cases (28%) had at least one of these genes methylated. The frequency of p14ARF methylation was 15 out of 85 (18%) cases, and the expression of p14(ARF) in methylated gliomas was significantly lower than in unmethylated gliomas. The incidence of methylation of p15(INK4B), p16(INK4A) and RB gene was 4%, 7%, and 4%, respective . Samples with p14(ARF) methylation did not have p16(INK4A) methylation even though both genes physically overlap. None of the target genes was methylated in the normal brain samples. In addition, the p53 gene was mutated in 19 out of 85 (22%) samples as determined by single strand conformation polymorphism (SSCP) analysis and DNA sequencing. Thirty out of 85 (35%) brain tumors had either a p53 mutation or methylation of p14(ARF). Also, the p14(ARF) expression in p53 wild-type gliomas was lower than levels in p53 mutated gliomas. This finding is consistent with wild-type p53 being able to autoregulate its levels by down-regulating expression of p14(ARF). In summary, inactivation of the apoptosis pathway that included the p14(ARF) and p53 genes by hypermethylation and mutation, respectively, occurred frequently in human brain tumors. Down-regulation of p14(ARF) in gliomas was associated with hypermethylation of its promoter and the presence of a wild-type p53 in these samples.	Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Div Hematol Oncol, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Maxine Dunitz Neurosurg Inst, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Yin, D (corresponding author), Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Div Hematol & Oncol, 8700 Beverly Blvd,Suite BM-1,Room 109, Los Angeles, CA 90048 USA.			Black, Keith/0000-0002-0546-4934; Xie, Dong/0000-0002-1150-8657				BARTSCH D, 1995, GENE CHROMOSOME CANC, V14, P189, DOI 10.1002/gcc.2870140306; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Costello JF, 1996, CANCER RES, V56, P2405; Duerr EM, 1998, ONCOGENE, V16, P2259, DOI 10.1038/sj.onc.1201756; Duro D, 1996, CANCER RES, V56, P848; Esteller M, 2000, CANCER RES, V60, P129; GREGER V, 1994, HUM GENET, V94, P491; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; IGAKI H, 1994, BIOCHEM BIOPH RES CO, V203, P1090, DOI 10.1006/bbrc.1994.2294; IMAI Y, 1994, MODERN PATHOL, V7, P766; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LIU L, 1995, ONCOGENE, V11, P405; LIU QY, 1995, ONCOGENE, V10, P619; LOUIS DN, 1994, J NEUROPATH EXP NEUR, V53, P11, DOI 10.1097/00005072-199401000-00002; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MAO L, 1995, CANCER RES, V55, P2995; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Nakamura M, 2001, CANCER RES, V61, P6335; Nakamura M, 2001, BRAIN PATHOL, V11, P159; NISHIKAWA R, 1995, CANCER RES, V55, P1941; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OGAWA S, 1994, BLOOD, V84, P2431, DOI 10.1182/blood.V84.8.2431.bloodjournal8482431; OhtaniFujita N, 1997, CANCER GENET CYTOGEN, V98, P43, DOI 10.1016/S0165-4608(96)00395-0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; QUELLE DE, 1995, CELL, V83, P993; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; SAKAI T, 1991, AM J HUM GENET, V48, P880; Schmidt EE, 1997, BRIT J CANCER, V75, P2, DOI 10.1038/bjc.1997.2; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Simon M, 1999, ACTA NEUROPATHOL, V98, P444, DOI 10.1007/s004010051107; Simpson DJ, 2000, CANCER RES, V60, P1211; Stirzaker C, 1997, CANCER RES, V57, P2229; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Watanabe T, 2001, ACTA NEUROPATHOL, V101, P185; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	49	41	43	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 28	2002	21	54					8372	8378		10.1038/sj.onc.1206031	http://dx.doi.org/10.1038/sj.onc.1206031			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447702				2022-12-28	WOS:000179323900017
J	Dahm, K; Hubscher, U				Dahm, K; Hubscher, U			Colocalization of human Rad17 and PCNA in late S phase of the cell cycle upon replication block	ONCOGENE			English	Article						DNA replication checkpoint; hRad17; PCNA; hRad9; confocal microscopy	DNA-DAMAGE CHECKPOINT; FACTOR-C COMPLEX; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; IONIZING-RADIATION; NUCLEAR ANTIGEN; PROTEIN-KINASE; BUDDING YEAST; FISSION YEAST; SMALL-SUBUNIT	In response to replication block or DNA damage in S phase the DNA replication and DNA damage checkpoints are activated. The current model in human predicts, that a Rad17/Replication factor C (RF-C) complex might serve as a recruitment complex for the Rad9/Hus1/Rad1 complex to sites of replication block or DNA damage. In this study we have investigated the fate of the Rad17/RF-C complex after treatment of synchronized Hela cells with the replication inhibitor hydroxyurea. In hydroxyurea treated cells the RF-C p37 subunit became more resistant to extraction. Moreover, co-immunoprecipitation studies with extracts of hydroxyurea treated cells showed an interaction of RF-C p37 with Rad17 and of PCNA with Rad9 and RF-C p37. An enhanced colocalization of Rad17 and PCNA in late S phase after hydroxyurea treatment was observed. Our data suggested, that upon replication block a Rad17/RFC complex is recruited to sites of DNA lesions in late S phase, binds the Rad9/Hus1/Rad1 complex and enables it to interact with PCNA. An interaction of Rad17/RF-C with PCNA appears to be mediated by the small RF-C p37 subunit, suggesting that PCNA might provide communication between replication checkpoint control and DNA replication and repair.	Univ Zurich Irchel, Inst Vet Biochem & Mol Biol, CH-8057 Zurich, Switzerland	University of Zurich	Hubscher, U (corresponding author), Univ Zurich Irchel, Inst Vet Biochem & Mol Biol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.			Dahm, Kirsten/0000-0001-7194-6600				Bao SD, 2001, NATURE, V411, P969, DOI 10.1038/35082110; Bessho T, 2000, J BIOL CHEM, V275, P7451, DOI 10.1074/jbc.275.11.7451; BRAVO R, 1986, EXP CELL RES, V163, P287, DOI 10.1016/0014-4827(86)90059-5; BRAVO R, 1985, EMBO J, V4, P655, DOI 10.1002/j.1460-2075.1985.tb03679.x; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; Burtelow MA, 2001, J BIOL CHEM, V276, P25903, DOI 10.1074/jbc.M102946200; Chang MS, 1999, J BIOL CHEM, V274, P36544, DOI 10.1074/jbc.274.51.36544; Chen MJ, 2001, J BIOL CHEM, V276, P16580, DOI 10.1074/jbc.M008871200; Chen MS, 2001, GENE, V277, P145, DOI 10.1016/S0378-1119(01)00692-8; de la Torre-Ruiz MA, 1998, EMBO J, V17, P2687, DOI 10.1093/emboj/17.9.2687; Donaldson AD, 2001, CURR BIOL, V11, pR979, DOI 10.1016/S0960-9822(01)00579-6; FOX MH, 1991, J CELL SCI, V99, P247; Green CM, 2000, CURR BIOL, V10, P39, DOI 10.1016/S0960-9822(99)00263-8; Griffith JD, 2002, J BIOL CHEM, V277, P15233, DOI 10.1074/jbc.C200129200; Kai M, 2001, MOL CELL BIOL, V21, P3289, DOI 10.1128/MCB.21.10.3289-3301.2001; Komatsu K, 2000, ONCOGENE, V19, P5291, DOI 10.1038/sj.onc.1203901; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; Lindsey-Boltz LA, 2001, P NATL ACAD SCI USA, V98, P11236, DOI 10.1073/pnas.201373498; Loor G, 1997, NUCLEIC ACIDS RES, V25, P5041, DOI 10.1093/nar/25.24.5041; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; Mitchell A, 2001, NAT REV MOL CELL BIO, V2, P563, DOI 10.1038/35085000; Miura M, 1999, J RADIAT RES, V40, P1, DOI 10.1269/jrr.40.1; Mossi R, 1997, J BIOL CHEM, V272, P1769, DOI 10.1074/jbc.272.3.1769; Mossi R, 1998, EUR J BIOCHEM, V254, P209, DOI 10.1046/j.1432-1327.1998.254209.x; Naiki T, 2000, MOL CELL BIOL, V20, P5888, DOI 10.1128/MCB.20.16.5888-5896.2000; Noskov VN, 1998, MOL CELL BIOL, V18, P4914, DOI 10.1128/MCB.18.8.4914; Parker AE, 1998, J BIOL CHEM, V273, P18332, DOI 10.1074/jbc.273.29.18332; Rauen M, 2000, J BIOL CHEM, V275, P29767, DOI 10.1074/jbc.M005782200; Reynolds N, 1999, NUCLEIC ACIDS RES, V27, P462, DOI 10.1093/nar/27.2.462; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; SASAKI K, 1993, CYTOMETRY, V14, P876, DOI 10.1002/cyto.990140805; Schmidt SLG, 2001, J BIOL CHEM, V276, P34792, DOI 10.1074/jbc.M011671200; Shimada M, 1999, MOL BIOL CELL, V10, P3991, DOI 10.1091/mbc.10.12.3991; Shimomura T, 1998, MOL CELL BIOL, V18, P5485, DOI 10.1128/MCB.18.9.5485; Shirahige K, 1998, NATURE, V395, P618, DOI 10.1038/27007; Sugimoto K, 1996, P NATL ACAD SCI USA, V93, P7048, DOI 10.1073/pnas.93.14.7048; Sugimoto K, 1997, MOL CELL BIOL, V17, P5905, DOI 10.1128/MCB.17.10.5905; Tercero JA, 2001, NATURE, V412, P553, DOI 10.1038/35087607; Tsurimoto T., 1999, FRONT BIOSCI, V4, P849; Venclovas C, 2000, NUCLEIC ACIDS RES, V28, P2481, DOI 10.1093/nar/28.13.2481; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302	42	25	27	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 31	2002	21	50					7710	7719		10.1038/sj.onc.1205872	http://dx.doi.org/10.1038/sj.onc.1205872			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	606VW	12400013	Green Accepted			2022-12-28	WOS:000178756200010
J	Kamiguti, AS; Harris, RJ; Slupsky, JR; Baker, PK; Cawley, JC; Zuzel, M				Kamiguti, AS; Harris, RJ; Slupsky, JR; Baker, PK; Cawley, JC; Zuzel, M			Regulation of hairy-cell survival through constitutive activation of mitogen-activated protein kinase pathways	ONCOGENE			English	Article						cell survival; hairy-cell leukemia; MAPK; PKC; Src	P38 MAP KINASE; GROWTH-FACTOR; RAF-1; APOPTOSIS; LEUKEMIA; PHOSPHORYLATION; ERK; RECEPTORS; STRESS; JNK	The hairy cells (HCs) of hairy-cell leukemia are intrinsically activated mature clonal B cells. The aims of this study were to gain further insights into the nature of this activation and to assess its importance for the prolonged HC survival in this chronic disease. We show that HCs contain phosphorylated/activated p38 MAPK, JNK and ERK1/ERK2 (ERK1/2). PKC inhibitors increased the activation of p38 and JNK, but reduced the phosphorylation of ERK1/2. Moreover, PKC inhibition resulted in cell death; cell death was also observed when the activation of ERK1/2 in HCs was abrogated with an inhibitor of MEK1/2 activation. In addition to PKC, active Src kinase was also shown to be involved in the maintenance of Raf-independent ERK activation in HCs. During cell culture on a nonadherent surface, ERK phosphorylation was sustained, while phosphorylation of p38 and JNK decreased. This decrease was not observed in HCs cultured on vitronectin (VN), indicating that p38/JNK activation is probably a consequence of in vivo HC interaction with VN present in abundance in the red pulp of the spleen. Taken together, these results suggest that active p38/JNK make HCs susceptible to apoptosis, but the cells are effectively rescued by ERK activation involving constitutively active PKC and Src. These findings are relevant for the understanding of the prolonged cell survival of HCs and their selective sensitivity to some chemotherapeutic agents.	Univ Liverpool, Royal Liverpool Hosp, Dept Haematol, Liverpool L69 3GA, Merseyside, England	Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool	Kamiguti, AS (corresponding author), Univ Liverpool, Royal Liverpool Hosp, Dept Haematol, Daulby St, Liverpool L69 3GA, Merseyside, England.	aurakami@liverpool.ac.uk	Slupsky, Joseph/H-2843-2019	Slupsky, Joseph/0000-0002-7410-9004				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Avdi NJ, 1996, J BIOL CHEM, V271, P33598, DOI 10.1074/jbc.271.52.33598; Baines CP, 2002, CIRC RES, V90, P390, DOI 10.1161/01.RES.0000012702.90501.8D; Baker PK, 2002, BLOOD, V100, P647, DOI 10.1182/blood.V100.2.647; Bastie JN, 1999, LEUKEMIA LYMPHOMA, V35, P555, DOI 10.1080/10428199909169620; Behrens MM, 1999, NEUROSCIENCE, V94, P917, DOI 10.1016/S0306-4522(99)00212-2; Birkenkamp KU, 1999, LEUKEMIA, V13, P1037, DOI 10.1038/sj.leu.2401447; Brandlin I, 2002, J BIOL CHEM, V277, P6490, DOI 10.1074/jbc.M106083200; BURTHEM J, 1994, BLOOD, V84, P873; BURTHEM J, 1996, HAIRY CELL LEUKAEMIA; Busuttil V, 2002, ONCOGENE, V21, P3213, DOI 10.1038/sj.onc.1205433; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CALIGARISCAPPIO F, 1985, BLOOD, V66, P1035; Carlomagno F, 2002, CANCER RES, V62, P1077; CAWLEY JC, 2000, ADV BLOOD DISORD, V5, P9; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen HJ, 1999, BRIT J HAEMATOL, V105, P87; Chen J, 2001, J BIOL CHEM, V276, P47901, DOI 10.1074/jbc.M107574200; Clarke H, 2000, EXP CELL RES, V261, P239, DOI 10.1006/excr.2000.5035; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Corbit KC, 1999, MOL CELL BIOL, V19, P4209; CORDINGLEY FT, 1988, LANCET, V1, P969; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Dent P, 1998, LEUKEMIA, V12, P1843, DOI 10.1038/sj.leu.2401222; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREXLER HG, 1989, BLOOD, V74, P1747; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; GENOT EM, 1993, J IMMUNOL, V151, P71; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; Gruber G, 1999, BLOOD, V94, P1077, DOI 10.1182/blood.V94.3.1077.415k06_1077_1085; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Hall-Jackson CA, 1999, CHEM BIOL, V6, P559, DOI 10.1016/S1074-5521(99)80088-X; Harris RJ, 2000, J IMMUNOL, V164, P3887, DOI 10.4049/jimmunol.164.7.3887; Herrmann C, 1998, ONCOGENE, V17, P1769, DOI 10.1038/sj.onc.1202085; Hindley A, 2002, J CELL SCI, V115, P1575; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Karandikar M, 2000, J BIOL CHEM, V275, P40120, DOI 10.1074/jbc.M005926200; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kreitman RJ, 2001, NEW ENGL J MED, V345, P241, DOI 10.1056/NEJM200107263450402; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LYNCH SA, 1993, LEUKEMIA, V7, P1416; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; McCubrey JA, 2000, LEUKEMIA, V14, P9, DOI 10.1038/sj.leu.2401657; Milella M, 2001, J CLIN INVEST, V108, P851, DOI 10.1172/JCI200112807; Nadal-Wollbold F, 2002, FEBS LETT, V531, P475, DOI 10.1016/S0014-5793(02)03587-1; Nagata Y, 1999, BLOOD, V94, P853, DOI 10.1182/blood.V94.3.853.415a12_853_863; Pettitt AR, 1999, BRIT J HAEMATOL, V106, P2; PING P, 1999, AM J PHYSIOL, V276, P468; PIRO LD, 1990, NEW ENGL J MED, V322, P1117, DOI 10.1056/NEJM199004193221605; REUTER CWM, 1992, BLOOD, V96, P655; Savoie L, 2001, Curr Treat Options Oncol, V2, P217, DOI 10.1007/s11864-001-0035-3; SIMONTON SC, 1985, LAB INVEST, V52, pA63; SOUTHERN C, 1995, IMMUNOLOGY, V84, P326; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAM LT, 1971, NEW ENGL J MED, V284, P357, DOI 10.1056/NEJM197102182840704; Zhang Z, 1999, J NEUROCHEM, V73, P1502, DOI 10.1046/j.1471-4159.1999.0731502.x	62	45	45	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2003	22	15					2272	2284		10.1038/sj.onc.1206398	http://dx.doi.org/10.1038/sj.onc.1206398			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	667KV	12700663				2022-12-28	WOS:000182231500006
J	Sonderegger, CK; Narisawa-Saito, M; Vogt, PK				Sonderegger, CK; Narisawa-Saito, M; Vogt, PK			The C-terminal region of cellular Qin oligomerizes: correlation with oncogenic transformation and transcriptional repression	ONCOGENE			English	Article						FoxG1; oncogenic transformation; chicken embryo fibroblasts; oligomerization; transcriptional repression	DNA-RECOGNITION; ACUTE LEUKEMIAS; MLL GENE; PROTEIN; BF-1; CLONING; EXPRESSION; MEMBER; PAX3; CONVERSION	Expression of the oncoprotein Qin induces tumors in chickens and oncogenic transformation of chicken embryo fibroblasts in culture. We performed a detailed deletion analysis of the C-terminal region of Qin (amino acids 246-451, extending from the winged helix domain to the C-terminus) and identified amino acids 246-379 as important for transformation. The same region mediates homo-oligomerization of Qin as documented in vitro by GST pulldowns and in vivo by coimmunoprecipitation. A 60 amino-acid region within the oligomerization domain is necessary and sufficient for transcriptional repression induced by Qin.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Vogt, PK (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	pkvogt@scripps.edu	Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500				Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BIEGEL JA, 1991, GENE CHROMOSOME CANC, V3, P483, DOI 10.1002/gcc.2870030612; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Bourguignon C, 1998, DEVELOPMENT, V125, P4889; Chang HW, 1996, ONCOGENE, V13, P441; CHANG HW, 1995, P NATL ACAD SCI USA, V92, P447, DOI 10.1073/pnas.92.2.447; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CORRAL J, 1993, P NATL ACAD SCI USA, V90, P8538, DOI 10.1073/pnas.90.18.8538; Dou CL, 2000, MOL CELL BIOL, V20, P6201, DOI 10.1128/MCB.20.17.6201-6211.2000; DOUGLASS EC, 1991, GENE CHROMOSOME CANC, V3, P480, DOI 10.1002/gcc.2870030611; Gajiwala KS, 2000, NATURE, V403, P916, DOI 10.1038/35002634; Gajiwala KS, 2000, CURR OPIN STRUC BIOL, V10, P110, DOI 10.1016/S0959-440X(99)00057-3; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; HATINI V, 1994, J NEUROBIOL, V25, P1293, DOI 10.1002/neu.480251010; JIANG J, 1993, EMBO J, V12, P3201, DOI 10.1002/j.1460-2075.1993.tb05989.x; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KIROV N, 1993, EMBO J, V12, P3193, DOI 10.1002/j.1460-2075.1993.tb05988.x; Li J, 1997, P NATL ACAD SCI USA, V94, P10885, DOI 10.1073/pnas.94.20.10885; LI J, 1995, CANCER RES, V55, P5540; Lu XY, 2000, P NATL ACAD SCI USA, V97, P1988, DOI 10.1073/pnas.040573197; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; Ma Y, 2000, ONCOGENE, V19, P4815, DOI 10.1038/sj.onc.1203834; MCCABE NR, 1992, P NATL ACAD SCI USA, V89, P11794, DOI 10.1073/pnas.89.24.11794; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; PARRY P, 1994, GENE CHROMOSOME CANC, V11, P79, DOI 10.1002/gcc.2870110203; RAO A, 2001, SCI STKE, pE1; Rodriguez C, 2001, J BIOL CHEM, V276, P30224, DOI 10.1074/jbc.M102759200; SHAPIRO DN, 1993, CANCER RES, V53, P5108; SONDEREGGER CK, 2003, IN PRESS ONCOGENE; SONDEREGGER CK, 2001, UNPUB; TAO W, 1992, NEURON, V8, P957, DOI 10.1016/0896-6273(92)90210-5; WHANGPENG J, 1992, GENE CHROMOSOME CANC, V5, P299, DOI 10.1002/gcc.2870050405; XUAN SH, 1995, NEURON, V14, P1141, DOI 10.1016/0896-6273(95)90262-7; Yao J, 2001, MOL CELL BIOL, V21, P1962, DOI 10.1128/MCB.21.6.1962-1972.2001; Yuasa J, 1996, NATURE, V382, P632, DOI 10.1038/382632a0; Zhang JS, 2001, MOL CELL BIOL, V21, P156, DOI 10.1128/MCB.21.1.156-163.2001; Zheng N, 1999, GENE DEV, V13, P666, DOI 10.1101/gad.13.6.666	38	4	4	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2003	22	13					1908	1915		10.1038/sj.onc.1206307	http://dx.doi.org/10.1038/sj.onc.1206307			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	662UR	12673196				2022-12-28	WOS:000181967700001
J	Geisen, C; Karsunky, H; Yucel, R; Moroy, T				Geisen, C; Karsunky, H; Yucel, R; Moroy, T			Loss of P27(Kip1) cooperates with cyclin E in T-cell lymphomagenesis	ONCOGENE			English	Article						cyclin E; p27(Kip11); oncogene cooperation; lymphomagenesis	MALIGNANT TRANSFORMATION; TRANSGENIC MICE; CDK INHIBITORS; PROGNOSTIC IMPLICATIONS; ONCOGENIC ACTIVITY; RESTRICTION POINT; TUMOR SUPPRESSION; DEPENDENT KINASES; HA-RAS; MYC	Cyclin E and p27(Kip1) are key regulators for cyclin-dependent kinases (Cdks) acting at the G1-/S-phase transition of the cell cycle. Whereas cyclin E is required for the activation of Cdk2, p27(Kip1) is a specific Cdk inhibitor and can block cell division. High levels of cyclin E and low levels of p27(Kip1) expression have been associated with malignant lymphomas in humans; the level of p27(Kip1) is even considered of prognostic significance. However, mice that lack p27(Kip1) do not develop any malignant lymphomas despite a pronounced lymphoid hyperplasia in thymus and spleen. We have previously described transgenic mice that carry a construct in which the cyclin E cDNA is under the control of the CD2 promoter/enhancer region and thus express high levels of cyclin E in the T-cell compartment (CD2-cyclin E). These animals are not predisposed for T-cell lymphomas in the absence of other cooperating events. Here we show that T-cells from CD2-cyclin E mice that at the same time are deficient for p27(Kip1) show a significantly higher Cdk2 activity than cells from wilde-type or single mutant animals. Accordingly, a higher percentage of T cells in S/G2/M phase is found in CD2-cyclin E/p27(Kip2-/-) mice. After a long latency period of over 200 days, these animals develop spontaneous monoclonal T cell lymphoma whereas none of the single CD2-cyclin E transgenics or the p27(Kip1)-deficient mice showed any sign of lymphoid malignancies. Our findings demonstrate that a deregulation of control mechanisms at the G1/S transition by the combination of high cyclin E levels in the absence of p27(Kip1) is sufficient to predispose mice to develop lymphoid malignancies and further support a role of p27(Kip1) as a tumor suppressor and of cyclin E as a dominant oncogene.	Univ Essen Gesamthsch Klinikum, IFZ, Inst Zellbiol Tumorforsch, D-45122 Essen, Germany	University of Duisburg Essen	Moroy, T (corresponding author), Univ Essen Gesamthsch Klinikum, IFZ, Inst Zellbiol Tumorforsch, Virchowstr 173, D-45122 Essen, Germany.		Moroy, Tarik/D-9923-2011					Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Donnellan R, 1999, FASEB J, V13, P773, DOI 10.1096/fasebj.13.8.773; Erlanson M, 1998, BLOOD, V92, P770; Erlanson M, 2001, LEUKEMIA LYMPHOMA, V40, P461, DOI 10.3109/10428190109097645; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Geisen C, 2002, J BIOL CHEM, V277, P39909, DOI 10.1074/jbc.M205919200; Haas K, 1997, ONCOGENE, V15, P179, DOI 10.1038/sj.onc.1201171; Haas K, 1997, ONCOGENE, V15, P2615, DOI 10.1038/sj.onc.1201434; HALL M, 1995, ONCOGENE, V11, P1581; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; Hogan B, 1994, MANIPULATING MOUSE E; Hwang HC, 2002, P NATL ACAD SCI USA, V99, P11293, DOI 10.1073/pnas.162356099; Karsunky H, 1999, ONCOGENE, V18, P7816, DOI 10.1038/sj.onc.1203205; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; LOVEC H, 1994, ONCOGENE, V9, P323; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; Luscher B, 2001, GENE, V277, P1, DOI 10.1016/S0378-1119(01)00697-7; Martins CP, 2002, EMBO J, V21, P3739, DOI 10.1093/emboj/cdf364; Minella AC, 2002, CURR BIOL, V12, P1817, DOI 10.1016/S0960-9822(02)01225-3; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOROY T, 1993, P NATL ACAD SCI USA, V90, P10734, DOI 10.1073/pnas.90.22.10734; MOROY T, 1990, EMBO J, V9, P3659, DOI 10.1002/j.1460-2075.1990.tb07577.x; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; PlanasSilva MD, 1997, CURR OPIN CELL BIOL, V9, P768, DOI 10.1016/S0955-0674(97)80076-2; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sambrook J., 2002, MOL CLONING LAB MANU; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1	40	26	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 20	2003	22	11					1724	1729		10.1038/sj.onc.1206340	http://dx.doi.org/10.1038/sj.onc.1206340			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642875				2022-12-28	WOS:000181580500014
J	Fink, SP; Mikkola, D; Willson, JKV; Markowitz, S				Fink, SP; Mikkola, D; Willson, JKV; Markowitz, S			TGF-beta-induced nuclear localization of Smad2 and Smad3 in Smad4 null cancer cell lines	ONCOGENE			English	Article						TGF-beta; Smad4; Smad2; Smad3; colon cancer	GROWTH-FACTOR-BETA; HUMAN PANCREATIC ADENOCARCINOMA; TUMOR-SUPPRESSOR GENE; SIGNALING PATHWAYS; RECEPTOR; DPC4; INHIBITION; COMPLEX; PHOSPHORYLATION; ACTIVATION	Smad4 is a tumor suppressor gene that is commonly lost or mutated in colorectal and pancreatic cancers. The activated transforming growth factor-beta (TGF-beta) receptor phosphorylates Smad2 and Smad3, which then complex with Smad4 and translocate to the nucleus. Smad4 mutations when detected as present in some human cancers have been considered sufficient to inactivate TGF-beta signaling. In this work, we describe a colon cancer cell line, VACO-9M, that is Smad4 null when analysed by multiple assays. To study the role of Smad4 in TGF-beta-induced translocation of the receptor-activated Smads to the nucleus, we analysed by immunofluorescence the cellular localization of endogenous Smad2 and Smad3 after TGF-beta treatment of VACO-9M, plus four additional Smad4 null cell lines of breast (MDA-MB-468), or pancreatic (BxPC3, Hs766T, CFPAC-1) origin. In each cell line, TGF-beta treatment resulted in both Smad2 and Smad3 moving to the nucleus in a Smad4-independent fashion. Nuclear translocation of Smad2 and Smad3 was, however, not sufficient to activate reporters for TGF-beta-induced transcriptional responses, which were however restored by transient transfection of wild-type Smad4. We conclude that Smad4 is not required for nuclear translocation of Smad2 and Smad3, but is needed activation of at least certain transcriptional responses.	Case Western Reserve Univ, Ireland Canc Ctr, Cleveland, OH 44106 USA; Howard Hughes Med Inst, Cleveland, OH 44106 USA; Dept Med, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Res Inst, Cleveland, OH 44106 USA	Case Western Reserve University; Howard Hughes Medical Institute; University Hospitals of Cleveland	Markowitz, S (corresponding author), Case Western Reserve Univ, Ireland Canc Ctr, Coroners Bldg,Suite 200,11001 Cedar Rd, Cleveland, OH 44106 USA.			Fink, Stephen/0000-0003-4107-7912	NATIONAL CANCER INSTITUTE [P30CA043703, R01CA067409, R01CA072160] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA43703, R01 CA67409, R01 CA72160] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; Calonge MJ, 1999, J BIOL CHEM, V274, P33637, DOI 10.1074/jbc.274.47.33637; Dai JL, 1999, MOL CARCINOGEN, V26, P37, DOI 10.1002/(SICI)1098-2744(199909)26:1<37::AID-MC5>3.0.CO;2-6; Fink SP, 2001, CANCER RES, V61, P256; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; Giehl K, 2000, ONCOGENE, V19, P4531, DOI 10.1038/sj.onc.1203806; Grady WM, 1999, CANCER RES, V59, P320; Grau AM, 1997, CANCER RES, V57, P3929; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; Schutte M, 1996, CANCER RES, V56, P2527; Simeone DM, 2000, ANN SURG, V232, P73, DOI 10.1097/00000658-200007000-00011; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; Venkatasubbarao K, 2000, ANTICANCER RES, V20, P43; WILLSON JKV, 1987, CANCER RES, V47, P2704; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Zhou SB, 1998, P NATL ACAD SCI USA, V95, P2412, DOI 10.1073/pnas.95.5.2412	26	71	73	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2003	22	9					1317	1323		10.1038/sj.onc.1206128	http://dx.doi.org/10.1038/sj.onc.1206128			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618756				2022-12-28	WOS:000181360900005
J	Schroeder, JA; Adriance, MC; Thompson, MC; Camenisch, TD; Gendler, SJ				Schroeder, JA; Adriance, MC; Thompson, MC; Camenisch, TD; Gendler, SJ			MUC1 alters beta-catenin-dependent tumor formation and promotes cellular invasion	ONCOGENE			English	Article						MUC 1; beta-catenin; C-src; erbB; breast cancer; invasion	GROWTH-FACTOR RECEPTOR; CARCINOMA-ASSOCIATED ANTIGEN; ACTIN-BUNDLING PROTEIN; BREAST-CANCER; EPISIALIN MUC1; MAMMARY-GLAND; E-CADHERIN; TYROSINE PHOSPHORYLATION; TRANSGENIC MICE; C-SRC	MUC1 is aberrantly expressed in greater than 90% of all breast carcinomas, yet its function as a tumor antigen is not fully understood. Recently, studies have shown that MUC1 interacts with beta-catenin, erbB receptors, src, GSK-3beta and protein kinase Cdelta, possibly in a complex that promotes the disassembly of adherens junctions and the invasion of cells. Here we show that the deletion of Muc1 expression from MMTV-Wnt-1 transgenic mice results in a significant increase in the time to mammary gland tumor onset. Analysis of MMTV-Wnt-1 tumors on a wild-type Muc1 background shows a tumor-specific complex formation between Muc1 and beta-catenin that can be observed in both the membrane and the cytoplasm of transformed epithelium. Analysis of primary human adenocarcinomas revealed that this MUC1/beta-catenin interaction occurs in both primary and metastatic tumors, but is dramatically increased in metastatic lesions. Addition of MUC1-cytoplasmic domain peptides to the invasive MDA-MB-468 and MDA-MB-231 cell lines increases their invasive capability, and these peptides colocalize with both beta-catenin and the focal adhesion protein vinculin, primarily at sites of membrane invasion into a collagen matrix. These data indicate a potential mechanism for MUC1 promotion of invasive tumorigenesis in the breast through the modulation of beta-catenin localization and subsequent cytoskeletal dynamics.	Mayo Clin & Mayo Grad Sch Med, Tumor Biol Program, Scottsdale, AZ 85259 USA; Mayo Clin & Mayo Grad Sch Med, Dept Biochem & Mol Biol, Scottsdale, AZ 85259 USA	Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix	Gendler, SJ (corresponding author), Mayo Clin & Mayo Grad Sch Med, Tumor Biol Program, Scottsdale, AZ 85259 USA.	gendler.sandra@mayo.edu		Camenisch, Todd/0000-0002-7797-9822; schroeder, joyce/0000-0003-1277-5172	NCI NIH HHS [CA90204, F32 CA081703-03, F32 CA081703, CA64389, CA81703] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA081703, F31CA090204, R01CA064389] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JC, 1997, MOL BIOL CELL, V8, P2345, DOI 10.1091/mbc.8.11.2345; Biscardi JS, 1998, MOL CARCINOGEN, V21, P261, DOI 10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO;2-N; BURCHELL J, 1984, INT J CANCER, V34, P763, DOI 10.1002/ijc.2910340605; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; Hazan RB, 1998, J BIOL CHEM, V273, P9078, DOI 10.1074/jbc.273.15.9078; Hazan RB, 1996, CELL ADHES COMMUN, V4, P399, DOI 10.3109/15419069709004457; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HILKENS J, 1995, CANCER LETT, V90, P27, DOI 10.1016/0304-3835(94)03674-8; Kondo K, 1998, CANCER RES, V58, P2014; Li Y, 2000, ONCOGENE, V19, P1002, DOI 10.1038/sj.onc.1203273; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; MCGUCKIN MA, 1995, HUM PATHOL, V26, P432, DOI 10.1016/0046-8177(95)90146-9; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; Piedra J, 2001, J BIOL CHEM, V276, P20436, DOI 10.1074/jbc.M100194200; Rahn JJ, 2001, CANCER, V91, P1973, DOI 10.1002/1097-0142(20010601)91:11<1973::AID-CNCR1222>3.0.CO;2-A; Ren J, 2002, J BIOL CHEM, V277, P17616, DOI 10.1074/jbc.M200436200; Schroeder JA, 2002, J BIOL CHEM, V277, P22692, DOI 10.1074/jbc.M201975200; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; SPICER AP, 1995, J BIOL CHEM, V270, P30093; Tao YS, 1996, J CELL BIOL, V134, P1271, DOI 10.1083/jcb.134.5.1271; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Walsh MD, 1999, BREAST CANCER RES TR, V58, P255; WESSELING J, 1995, J CELL BIOL, V129, P255, DOI 10.1083/jcb.129.1.255; Wesseling J, 1996, MOL BIOL CELL, V7, P565, DOI 10.1091/mbc.7.4.565; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; Yamashiro S, 1998, MOL BIOL CELL, V9, P993, DOI 10.1091/mbc.9.5.993; ZOTTER S, 1988, CANCER RES, V111, P55; ZRIHANLICHT S, 1994, FEBS LETT, V356, P130, DOI 10.1016/0014-5793(94)01251-2	32	146	151	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2003	22	9					1324	1332		10.1038/sj.onc.1206291	http://dx.doi.org/10.1038/sj.onc.1206291			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618757				2022-12-28	WOS:000181360900006
J	Thorland, EC; Myers, SL; Gostout, BS; Smith, DI				Thorland, EC; Myers, SL; Gostout, BS; Smith, DI			Common fragile sites are preferential targets for HPV16 integrations in cervical tumors	ONCOGENE			English	Article						common fragile sites; cervical cancer; human papillomavirus; viral integration; RS-PCR	HUMAN-PAPILLOMAVIRUS TYPE-16; VIRAL INTEGRATION; MOLECULAR CHARACTERIZATION; CELL-LINE; E2 GENE; CANCER; CARCINOMA; REGION; DNA; ONCOGENES	The development of cervical cancer is highly associated with human papillomavirus (HPV) infection. HPV integration into the genome of infected cervical cells is temporally associated with the acquisition of the malignant phenotype. A relationship between the sites of HPV integration in cervical cancer and the position of the common fragile sites (CFSs) has been observed at both the cytogenetic and molecular levels. To further explore this relationship at the molecular level, we used RS-PCR to rapidly isolate cellular sequences flanking the sites of HPV16 integration in 26 primary cervical tumors. Human bacterial artificial chromosome clones were isolated based on these flanking sequences and used as probes for fluorescence in situ hybridization on aphidicolin-stimulated metaphases. Our data demonstrate that 11/23 HPV16 integrations in cervical tumors occurred within CFSs (P < 0.001). In addition, we show that deletions and complex rearrangements frequently occur in the cellular sequences targeted by the integrations and that integrations cluster in FRA13C (13q22), FRA3B (3p14.2), and FRA17B (17q23). Finally, our data suggest that cellular genes, such as Notch 1, are disrupted by the HPV16 integrations, which may contribute to the malignant phenotype.	Mayo Clin & Mayo Fdn, Dept Expt Pathol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Tumor Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Obstet & Gynecol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Smith, DI (corresponding author), Mayo Clin & Mayo Fdn, Dept Expt Pathol, Hilton 8,200 1st St SW, Rochester, MN 55905 USA.	smith.david@mayo.edu			NCI NIH HHS [CA48031] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048031] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Arlt MF, 2002, GENE CHROMOSOME CANC, V33, P82, DOI 10.1002/gcc.10000; BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; BauerHofmann R, 1996, VIROLOGY, V217, P33, DOI 10.1006/viro.1996.0090; BECKER NA, 2002, IN PRESS ONCOGENE; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; CANNIZZARO LA, 1988, CANCER GENET CYTOGEN, V33, P93, DOI 10.1016/0165-4608(88)90054-4; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Chen CS, 2001, GENE CHROMOSOME CANC, V31, P333, DOI 10.1002/gcc.1152; Choo KB, 1996, J MED VIROL, V49, P15, DOI 10.1002/(SICI)1096-9071(199605)49:1<15::AID-JMV3>3.3.CO;2-4; CHOO KB, 1995, CANCER LETT, V93, P249, DOI 10.1016/0304-3835(95)03817-G; CHOO KB, 1987, VIROLOGY, V161, P259, DOI 10.1016/0042-6822(87)90195-4; CHOO KB, 1990, VIROLOGY, V178, P621, DOI 10.1016/0042-6822(90)90366-Y; CROOK T, 1988, P NATL ACAD SCI USA, V85, P8820, DOI 10.1073/pnas.85.23.8820; CULLEN AP, 1991, J VIROL, V65, P606, DOI 10.1128/JVI.65.2.606-612.1991; Desseyn JL, 1997, J BIOL CHEM, V272, P3168, DOI 10.1074/jbc.272.6.3168; Dong JT, 2000, CANCER RES, V60, P3880; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Gallego MI, 1997, MOL CARCINOGEN, V19, P114, DOI 10.1002/(SICI)1098-2744(199707)19:2<114::AID-MC6>3.0.CO;2-F; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; GLOVER TW, 1986, CANCER GENET CYTOGEN, V19, P141, DOI 10.1016/0165-4608(86)90381-X; Gostout BS, 1998, AM J OBSTET GYNECOL, V179, P56, DOI 10.1016/S0002-9378(98)70251-0; HECHT F, 1988, CANCER GENET CYTOGEN, V31, P17, DOI 10.1016/0165-4608(88)90005-2; Huang HJ, 1998, GENE CHROMOSOME CANC, V21, P152, DOI 10.1002/(SICI)1098-2264(199802)21:2<152::AID-GCC11>3.0.CO;2-T; Inohara N, 1998, J BIOL CHEM, V273, P12296, DOI 10.1074/jbc.273.20.12296; JEON S, 1995, J VIROL, V69, P2989, DOI 10.1128/JVI.69.5.2989-2997.1995; Ji YG, 2000, GENOME RES, V10, P597, DOI 10.1101/gr.10.5.597; KAHN T, 1994, CANCER RES, V54, P1305; Kainu T, 2000, P NATL ACAD SCI USA, V97, P9603, DOI 10.1073/pnas.97.17.9603; Kalantari M, 1998, INT J GYNECOL PATHOL, V17, P146, DOI 10.1097/00004347-199804000-00009; Krummel KA, 2000, GENOMICS, V69, P37, DOI 10.1006/geno.2000.6321; Lazo PA, 1999, BRIT J CANCER, V80, P2008, DOI 10.1038/sj.bjc.6690635; Luft F, 2001, INT J CANCER, V92, P9, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1144>3.0.CO;2-L; Mangelsdorf M, 2000, CANCER RES, V60, P1683; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; Mishmar D, 1998, P NATL ACAD SCI USA, V95, P8141, DOI 10.1073/pnas.95.14.8141; Morelli C, 2002, ONCOGENE, V21, P7266, DOI 10.1038/sj.onc.1205573; Paige AJW, 2000, CANCER RES, V60, P1690; PECORARO G, 1989, P NATL ACAD SCI USA, V86, P563, DOI 10.1073/pnas.86.2.563; POPESCU NC, 1989, CANCER GENET CYTOGEN, V42, P157, DOI 10.1016/0165-4608(89)90084-8; POPESCU NC, 1990, HUM GENET, V84, P383; Rangarajan A, 2001, VIROLOGY, V286, P23, DOI 10.1006/viro.2001.0867; Reuter S, 1998, EMBO J, V17, P215, DOI 10.1093/emboj/17.1.215; Richards RI, 2001, TRENDS GENET, V17, P339, DOI 10.1016/S0168-9525(01)02303-4; Sarkar G, 1993, PCR Methods Appl, V2, P318; Sastre-Garau X, 2000, J GEN VIROL, V81, P1983, DOI 10.1099/0022-1317-81-8-1983; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Smith DI, 1998, INT J ONCOL, V12, P187; Thome M, 1998, CURR BIOL, V8, P885, DOI 10.1016/S0960-9822(07)00352-1; Thorland EC, 2000, CANCER RES, V60, P5916; VERMA RS, 1989, HUMAN CHROMOSOME MAN; Vernon SD, 1997, INT J CANCER, V74, P50, DOI 10.1002/(SICI)1097-0215(19970220)74:1<50::AID-IJC9>3.3.CO;2-P; WAGATSUMA M, 1990, J VIROL, V64, P813, DOI 10.1128/JVI.64.2.813-821.1990; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Wilke CM, 1996, HUM MOL GENET, V5, P187, DOI 10.1093/hmg/5.2.187; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036; YUNIS JJ, 1987, ONCOGENE, V1, P59; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414	61	198	210	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2003	22	8					1225	1237		10.1038/sj.onc.1206170	http://dx.doi.org/10.1038/sj.onc.1206170			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650EK	12606949				2022-12-28	WOS:000181249700011
J	Krokan, HE; Drablos, F; Slupphaug, G				Krokan, HE; Drablos, F; Slupphaug, G			Uracil in DNA - occurrence, consequences and repair	ONCOGENE			English	Review						uracil; uracil-DNA glycosylase; DNA repair	BASE-EXCISION-REPAIR; CYTIDINE DEAMINASE AID; DOUBLE-STRANDED DNA; ESCHERICHIA-COLI; GLYCOSYLASE ACTIVITY; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; 5-HYDROXYMETHYLURACIL-DNA GLYCOSYLASE; SUBSTRATE RECOGNITION; MISMATCH GLYCOSYLASE	Uracil in DNA results from deamination of cytosine, resulting in mutagenic U:G mispairs, and misincorporation of dUMP, which gives a less harmful U: A pair. At least four different human DNA glycosylases may remove uracil and thus generate an abasic site, which is itself cytotoxic and potentially mutagenic. These enzymes are UNG, SMUG1, TDG and MBD4. The base excision repair process is completed either by a short patch- or long patch pathway, which largely use different proteins. UNG2 is a major nuclear uracil-DNA glycosylase central in removal of misincorporated dUMP in replication foci, but recent evidence also indicates an important role in repair of U : G mispairs and possibly U in single-stranded DNA. SMUG1 has broader specificity than UNG2 and may serve as a relatively efficient backup for UNG in repair of U:G mismatches and single-stranded DNA. TDG and MBD4 may have specialized roles in the repair of U and T in mismatches in CpG contexts. Recently, a role for UNG2, together with activation induced deaminase (AID) which generates uracil, has been demonstrated in immunoglobulin diversification. Studies are now underway to examine whether mice deficient in Ung develop lymphoproliferative malignancies and have a different life span.	Norwegian Univ Sci & Technol, Inst Canc Res & Mol Biol, N-7489 Trondheim, Norway	Norwegian University of Science & Technology (NTNU)	Krokan, HE (corresponding author), Norwegian Univ Sci & Technol, Inst Canc Res & Mol Biol, N-7489 Trondheim, Norway.	hans.krokan@medisin.ntnu.no	Slupphaug, Geir/AAN-3794-2020; Drablos, Finn/L-4970-2019	Drablos, Finn/0000-0001-5794-828X; Slupphaug, Geir/0000-0002-7498-3500				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Aravind L, 2000, GENOME BIOL, V1, P1, DOI DOI 10.1186/GB-2000-1-4-RESEARCH0007; Baker D, 2002, CHEM RES TOXICOL, V15, P33, DOI 10.1021/tx010113b; Barrett TE, 1999, EMBO J, V18, P6599, DOI 10.1093/emboj/18.23.6599; Barrett TE, 1998, CELL, V92, P117, DOI 10.1016/S0092-8674(00)80904-6; Bartsch H, 2000, TOXICOLOGY, V153, P105, DOI 10.1016/S0300-483X(00)00307-3; BASU AK, 1993, BIOCHEMISTRY-US, V32, P12793, DOI 10.1021/bi00210a031; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Bellacosa A, 1999, P NATL ACAD SCI USA, V96, P3969, DOI 10.1073/pnas.96.7.3969; Bellacosa A, 2001, J CELL PHYSIOL, V187, P137, DOI 10.1002/jcp.1064; Bellamy SRW, 2001, NUCLEIC ACIDS RES, V29, P3857, DOI 10.1093/nar/29.18.3857; BENNETT SE, 1995, BIOCHEMISTRY-US, V34, P6109, DOI 10.1021/bi00018a014; Bharati S, 1998, NUCLEIC ACIDS RES, V26, P4953, DOI 10.1093/nar/26.21.4953; BOORSTEIN RJ, 1987, MUTAT RES, V183, P257, DOI 10.1016/0167-8817(87)90008-3; Boorstein RJ, 2001, J BIOL CHEM, V276, P41991, DOI 10.1074/jbc.M106953200; Bouhamdan M, 1996, J VIROL, V70, P697, DOI 10.1128/JVI.70.2.697-704.1996; BROWN TC, 1987, CELL, V50, P945, DOI 10.1016/0092-8674(87)90521-6; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; CANNONCARLSON SV, 1989, J BIOL CHEM, V264, P13306; Di Noia J, 2002, NATURE, V419, P43, DOI 10.1038/nature00981; Dinner AR, 2001, NATURE, V413, P752, DOI 10.1038/35099587; Dogliotti E, 2001, PROG NUCLEIC ACID RE, V68, P3; Drohat AC, 1999, BIOCHEMISTRY-US, V38, P11876, DOI 10.1021/bi9910880; EFTEDAL I, 1993, NUCLEIC ACIDS RES, V21, P2095, DOI 10.1093/nar/21.9.2095; EFTEDAL I, 1994, ANN NY ACAD SCI, V726, P312, DOI 10.1111/j.1749-6632.1994.tb52836.x; Eisen JA, 1999, MUTAT RES-DNA REPAIR, V435, P171, DOI 10.1016/S0921-8777(99)00050-6; Faure H, 1998, FREE RADICAL RES, V28, P377, DOI 10.3109/10715769809070806; Friedberg E.C., 1995, DNA REPAIR MUTAGENES, P698; Gruss A, 2001, CURR OPIN MICROBIOL, V4, P595, DOI 10.1016/S1369-5274(00)00256-3; Handa P, 2001, J BIOL CHEM, V276, P17324, DOI 10.1074/jbc.M011166200; Hang B, 1998, P NATL ACAD SCI USA, V95, P13561, DOI 10.1073/pnas.95.23.13561; Haracska L, 2001, P NATL ACAD SCI USA, V98, P14256, DOI 10.1073/pnas.261560798; Hardeland U, 2000, J BIOL CHEM, V275, P33449, DOI 10.1074/jbc.M005095200; Hardeland U, 2002, EMBO J, V21, P1456, DOI 10.1093/emboj/21.6.1456; Hardeland U, 2001, PROG NUCLEIC ACID RE, V68, P235; Haug T, 1998, NUCLEIC ACIDS RES, V26, P1449, DOI 10.1093/nar/26.6.1449; Haushalter KA, 1999, CURR BIOL, V9, P174, DOI 10.1016/S0960-9822(99)80087-6; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; Hendrich B, 2000, CURR TOP MICROBIOL, V249, P55; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Horsfall MJ, 1997, J BACTERIOL, V179, P2835, DOI 10.1128/jb.179.9.2835-2839.1997; Hubbard T, 2002, NUCLEIC ACIDS RES, V30, P38, DOI 10.1093/nar/30.1.38; Jiang YL, 2001, BIOCHEMISTRY-US, V40, P7710, DOI 10.1021/bi010622c; Kavli B, 1996, EMBO J, V15, P3442, DOI 10.1002/j.1460-2075.1996.tb00710.x; KAVLI B, 2002, IN PRESS J BIOL CHEM; Krokan HE, 1997, BIOCHEM J, V325, P1; Krokan HE, 2001, PROG NUCLEIC ACID RE, V68, P365; LEVY DD, 1991, NUCLEIC ACIDS RES, V19, P3337, DOI 10.1093/nar/19.12.3337; LINDAHL T, 1974, P NATL ACAD SCI USA, V71, P3649, DOI 10.1073/pnas.71.9.3649; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MELLAC S, 1993, BIOCHEMISTRY-US, V32, P7779, DOI 10.1021/bi00081a025; Missero C, 2001, J BIOL CHEM, V276, P33569, DOI 10.1074/jbc.M104963200; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; Mol CD, 2002, J MOL BIOL, V315, P373, DOI 10.1006/jmbi.2001.5264; MORIYA M, 1994, P NATL ACAD SCI USA, V91, P11899, DOI 10.1073/pnas.91.25.11899; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; NEDDERMANN P, 1993, J BIOL CHEM, V268, P21218; Neddermann P, 1996, J BIOL CHEM, V271, P12767, DOI 10.1074/jbc.271.22.12767; NILSEN H, 1995, FEBS LETT, V362, P205, DOI 10.1016/0014-5793(95)00244-4; Nilsen H, 2000, MOL CELL, V5, P1059, DOI 10.1016/S1097-2765(00)80271-3; Nilsen H, 1997, NUCLEIC ACIDS RES, V25, P750, DOI 10.1093/nar/25.4.750; Nilsen H, 2001, EMBO J, V20, P4278, DOI 10.1093/emboj/20.15.4278; OLSEN LC, 1989, EMBO J, V8, P3121, DOI 10.1002/j.1460-2075.1989.tb08464.x; Otterlei M, 2000, EMBO J, V19, P5542, DOI 10.1093/emboj/19.20.5542; Otterlei M, 1998, NUCLEIC ACIDS RES, V26, P4611, DOI 10.1093/nar/26.20.4611; Otterlei M, 1999, EMBO J, V18, P3834, DOI 10.1093/emboj/18.13.3834; Parikh SS, 2000, P NATL ACAD SCI USA, V97, P5083, DOI 10.1073/pnas.97.10.5083; Parikh SS, 1998, EMBO J, V17, P5214, DOI 10.1093/emboj/17.17.5214; Parikh SS, 2000, MUTAT RES-DNA REPAIR, V460, P183, DOI 10.1016/S0921-8777(00)00026-4; Pasternack LB, 1996, NUCLEIC ACIDS RES, V24, P2740, DOI 10.1093/nar/24.14.2740; Pearl FMG, 2000, NUCLEIC ACIDS RES, V28, P277, DOI 10.1093/nar/28.1.277; Pearl LH, 2000, MUTAT RES-DNA REPAIR, V460, P165, DOI 10.1016/S0921-8777(00)00025-2; Petersen-Mahrt SK, 2002, NATURE, V418, P99, DOI 10.1038/nature00862; Petronzelli F, 2000, J BIOL CHEM, V275, P32422, DOI 10.1074/jbc.M004535200; Radany EH, 2000, MUTAT RES-DNA REPAIR, V461, P41, DOI 10.1016/S0921-8777(00)00040-9; Riccio A, 1999, NAT GENET, V23, P266, DOI 10.1038/15443; Robu ME, 2001, P NATL ACAD SCI USA, V98, P8211, DOI 10.1073/pnas.131022698; Rossi R, 1999, EMBO J, V18, P5745, DOI 10.1093/emboj/18.20.5745; Rusmintratip V, 2000, P NATL ACAD SCI USA, V97, P14183, DOI 10.1073/pnas.97.26.14183; Saparbaev M, 1998, P NATL ACAD SCI USA, V95, P8508, DOI 10.1073/pnas.95.15.8508; Sartori AA, 2002, EMBO J, V21, P3182, DOI 10.1093/emboj/cdf309; Sartori AA, 2001, J BIOL CHEM, V276, P29979, DOI 10.1074/jbc.M102985200; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; SEKIGUCHI M, 1976, BIOCHEM BIOPH RES CO, V73, P293, DOI 10.1016/0006-291X(76)90706-3; Shapiro R, 1980, CHROMOSOME DAMAGE RE, P3; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Shroyer MJN, 1999, BIOCHEMISTRY-US, V38, P4834, DOI 10.1021/bi982986j; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; SLUPPHAUG G, 1995, BIOCHEMISTRY-US, V34, P128, DOI 10.1021/bi00001a016; Spek EJ, 2001, J BACTERIOL, V183, P131, DOI 10.1128/JB.183.1.131-138.2001; Stivers JT, 1999, BIOCHEMISTRY-US, V38, P952, DOI 10.1021/bi9818669; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; Tu YQ, 1998, J MOL BIOL, V284, P297, DOI 10.1006/jmbi.1998.2176; TYE BK, 1977, P NATL ACAD SCI USA, V74, P154, DOI 10.1073/pnas.74.1.154; Um S, 1998, J BIOL CHEM, V273, P20728, DOI 10.1074/jbc.273.33.20728; Vidal AE, 2001, NUCLEIC ACIDS RES, V29, P1285, DOI 10.1093/nar/29.6.1285; VILPO JA, 1995, MUTAT RES-DNAGING G, V316, P123, DOI 10.1016/0921-8734(95)90005-5; Waters TR, 1999, J BIOL CHEM, V274, P67, DOI 10.1074/jbc.274.1.67; Waters TR, 2000, MUTAT RES-REV MUTAT, V462, P137, DOI 10.1016/S1383-5742(00)00031-4; Werner RM, 2000, BIOCHEMISTRY-US, V39, P14054, DOI 10.1021/bi0018178; Werner RM, 2000, BIOCHEMISTRY-US, V39, P12585, DOI 10.1021/bi001532v; Willetts KE, 1999, J VIROL, V73, P1682, DOI 10.1128/JVI.73.2.1682-1688.1999; WIST E, 1978, BIOCHIM BIOPHYS ACTA, V520, P253, DOI 10.1016/0005-2787(78)90225-3; WITTWER CU, 1989, BIOCHEMISTRY-US, V28, P780, DOI 10.1021/bi00428a055; Wong I, 2002, J BIOL CHEM, V277, P19424, DOI 10.1074/jbc.M201198200; Xiao GY, 1999, PROTEINS, V35, P13; Zhu B, 2000, NUCLEIC ACIDS RES, V28, P4157, DOI 10.1093/nar/28.21.4157; Zhu B, 2000, P NATL ACAD SCI USA, V97, P5135, DOI 10.1073/pnas.100107597	111	354	371	2	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2002	21	58					8935	8948		10.1038/sj.onc.1205996	http://dx.doi.org/10.1038/sj.onc.1205996			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	626TP	12483510				2022-12-28	WOS:000179889500005
J	Guo, WH; Weng, LQ; Ito, K; Chen, LF; Nakanishi, H; Tatematsu, M; Ito, Y				Guo, WH; Weng, LQ; Ito, K; Chen, LF; Nakanishi, H; Tatematsu, M; Ito, Y			Inhibition of growth of mouse gastric cancer cells by Runx3, a novel tumor suppressor	ONCOGENE			English	Article						Runx3; tumor suppressor; methylation; gastric cancer	METHYL-N-NITROSOUREA; P53 GENE-MUTATIONS; HISTONE DEACETYLASE; INDUCTION; PROMOTER; LINES; MECP2	We reported recently that the silencing of RUNX3 is causally related to gastric cancer in humans. Here we report that in three of four cell tines derived from N-methyl-N-nitrosourea-induced mouse glandular stomach carcinomas, Runx3 is silenced due to hypermethylation of CpG islands in the promoter region, as we also observed for human gastric cancer cells. Although two of the sites we tested in the promoter of the fourth line were not methylated, in all four cases the silencing of Runx3 could be reversed by treatment of the cells with 5'-azacytidine and trichostatin A. Interestingly, the exogenous expression of RUNX3 in cell lines that do not express the endogenous gene caused an inhibition of growth in soft agar, suggesting that anchorage-independent growth could be used as an assay of RUNX3 activity in vitro. These observations suggest that the mouse system described here may be useful as a model for the study of human gastric carcinogenesis.	Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068507, Japan; Aichi Canc Ctr, Res Inst, Pathol Lab, Chikusa Ku, Nagoya, Aichi 4648681, Japan	Kyoto University; Aichi Cancer Center	Ito, Y (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.							AMY SY, 1998, FRONT BIOSCI, V3, P532; Fearon ER, 2000, JNCI-J NATL CANCER I, V92, P515, DOI 10.1093/jnci/92.7.515; Furihata C, 1997, JPN J CANCER RES, V88, P363, DOI 10.1111/j.1349-7006.1997.tb00390.x; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Ichinose M, 1998, JPN J CANCER RES, V89, P516, DOI 10.1111/j.1349-7006.1998.tb03292.x; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; KIM JH, 1991, J NATL CANCER I, V83, P938, DOI 10.1093/jnci/83.13.938; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; TAMURA G, 1991, CANCER RES, V51, P3056; TATEMATSU M, 1993, JPN J CANCER RES, V84, P1258, DOI 10.1111/j.1349-7006.1993.tb02831.x; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6	16	78	90	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 28	2002	21	54					8351	8355		10.1038/sj.onc.1206037	http://dx.doi.org/10.1038/sj.onc.1206037			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447699	Green Submitted			2022-12-28	WOS:000179323900014
J	Billottet, C; Janji, B; Thiery, JP; Jouanneau, J				Billottet, C; Janji, B; Thiery, JP; Jouanneau, J			Rapid tumor development and potent vascularization are independent events in carcinoma producing FGF-1 or FGF-2	ONCOGENE			English	Article						FGF signaling; tumor growth; angiogenesis; MMPs; uPA/uPAR	FIBROBLAST-GROWTH-FACTOR; RAT BLADDER-CARCINOMA; MEMBRANE-TYPE-1 MATRIX METALLOPROTEINASE; PLASMINOGEN-ACTIVATOR; ENDOTHELIAL-CELLS; FACTOR EXPRESSION; CANCER INVASION; HUMAN GLIOMAS; IN-VITRO; ANGIOGENESIS	FGF-1 and FGF-2 are pleiotropic growth factors for many cell types, operating through the activation of specific transmembrane FGF receptors (FGFRs). The role of these factors in tumor progression was investigated, with specific discrimination between their autocrine and non autocrine cellular activity. The rat bladder carcinoma NBT-II cells were engineered to produce FGF-1 or 18 kDa FGF-2 in the presence or absence of their specific receptor. Non-autocrine cells that produced FGF-1 or FGF-2 but lacked FGFRs were epithelial and reminiscent of the parental NBT-II cells. Whilst autocrine cells, which both constitutively produced and secreted the growth factor and expressed FGFRs, had a highly invasive mesenchymal phenotype. Correspondingly, the autocrine cells were highly tumorigenic in vivo compared to the parental and non-autocrine cells, which correlated with the increased production of uPAR and active uPA and increased in vitro invasive potential. Although all cells produced VEGF, only tumors derived from cells that produced FGF-1 or FGF-2 were highly vascularized, suggesting that these two growth factors could be involved in the angiogenic process by activating host endothelial cells. As a result of activation of the FGFR in autocrine cells, changes in cell morphology and an increase in the invasive and tumorigenic properties were observed, however no in vitro or in vivo differential functions between FGF-1 and FGF-2 could be identified in this system. In conclusion, our data demonstrates that rapid tumor development is not dependent upon increased tumor vascularization, suggesting that 'basal' angiogenesis, probably mediated by VEGF, is sufficient to support tumor growth.	Inst Curie, UMR 144 CNRS, Lab Cell Morphogenesis & Tumor Progress, Sect Rech, F-75248 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite	Jouanneau, J (corresponding author), Inst Curie, UMR 144 CNRS, Lab Cell Morphogenesis & Tumor Progress, Sect Rech, 26 Rue Ulm, F-75248 Paris 05, France.		Thiery, Jean Paul/M-9387-2019; Thiery, Jean Paul/H-1550-2011	Thiery, Jean Paul/0000-0003-0478-5020; JANJI, Bassam/0000-0002-9763-0943; Billottet, Clotilde/0000-0003-1819-984X				Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bergers G, 2000, CURR OPIN GENET DEV, V10, P120, DOI 10.1016/S0959-437X(99)00043-X; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Boilly B, 2000, CYTOKINE GROWTH F R, V11, P295, DOI 10.1016/S1359-6101(00)00014-9; Borgfeldt C, 2001, INT J CANCER, V92, P497, DOI 10.1002/ijc.1215; Claffey KP, 2001, LAB INVEST, V81, P61, DOI 10.1038/labinvest.3780212; Compagni A, 2000, CANCER RES, V60, P7163; Dano K, 1999, APMIS, V107, P120, DOI 10.1111/j.1699-0463.1999.tb01534.x; Fang JM, 2000, P NATL ACAD SCI USA, V97, P3884, DOI 10.1073/pnas.97.8.3884; FLORKIEWICZ RZ, 1995, J CELL PHYSIOL, V162, P388, DOI 10.1002/jcp.1041620311; FOROUGH R, 1993, J BIOL CHEM, V268, P2960; GATELY S, 1995, NEUROSURGERY, V36, P780, DOI 10.1227/00006123-199504000-00020; Giavazzi R, 2001, CANCER RES, V61, P309; Giri D, 1999, CLIN CANCER RES, V5, P1063; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; JOUANNEAU J, 1991, P NATL ACAD SCI USA, V88, P2893, DOI 10.1073/pnas.88.7.2893; Jouanneau J, 1997, ONCOGENE, V14, P671, DOI 10.1038/sj.onc.1200883; Jouanneau J, 1999, ONCOGENE, V18, P327, DOI 10.1038/sj.onc.1202285; Kinoshita T, 1998, J BIOL CHEM, V273, P16098, DOI 10.1074/jbc.273.26.16098; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; Maatta M, 2000, CLIN CANCER RES, V6, P2726; Mazzieri R, 1997, EMBO J, V16, P2319, DOI 10.1093/emboj/16.9.2319; McCawley LJ, 2000, MOL MED TODAY, V6, P149, DOI 10.1016/S1357-4310(00)01686-5; Miyake H, 1997, J UROLOGY, V157, P2351, DOI 10.1016/S0022-5347(01)64779-7; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Nesbit M, 1999, ONCOGENE, V18, P6469, DOI 10.1038/sj.onc.1203066; Oh LYS, 1999, J NEUROSCI, V19, P8464; Okada-Ban M, 1999, ONCOGENE, V18, P6719, DOI 10.1038/sj.onc.1203092; Pili R, 1997, INT J CANCER, V73, P258; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; SAVAGNER P, 1994, MOL BIOL CELL, V5, P851, DOI 10.1091/mbc.5.8.851; Schmidt NO, 1999, INT J CANCER, V84, P10, DOI 10.1002/(SICI)1097-0215(19990219)84:1<10::AID-IJC3>3.3.CO;2-C; Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659; Soslow RA, 1999, HISTOPATHOLOGY, V35, P31; TAKAHASHI JA, 1992, J NEUROSURG, V76, P792, DOI 10.3171/jns.1992.76.5.0792; TOYOSHIMA K, 1971, JNCI-J NATL CANCER I, V47, P979; TSUBOI R, 1990, J CELL BIOL, V110, P511, DOI 10.1083/jcb.110.2.511; VALLES AM, 1990, P NATL ACAD SCI USA, V87, P1124, DOI 10.1073/pnas.87.3.1124; Weidner N, 1999, J PATHOL, V189, P297; Zheng Q, 2000, J CANCER RES CLIN, V126, P641, DOI 10.1007/s004320000146	43	34	43	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 21	2002	21	53					8128	8139		10.1038/sj.onc.1205935	http://dx.doi.org/10.1038/sj.onc.1205935			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615DW	12444548				2022-12-28	WOS:000179231400006
J	Lakka, SS; Rajan, M; Gondi, C; Yanamandra, N; Chandrasekar, N; Jasti, SL; Adachi, Y; Siddique, K; Gujrati, M; Olivero, W; Dinh, DH; Kouraklis, G; Kyritsis, AP; Rao, JS				Lakka, SS; Rajan, M; Gondi, C; Yanamandra, N; Chandrasekar, N; Jasti, SL; Adachi, Y; Siddique, K; Gujrati, M; Olivero, W; Dinh, DH; Kouraklis, G; Kyritsis, AP; Rao, JS			Adenovirus-mediated expression of antisense MMP-9 in glioma cells inhibits tumor growth and invasion	ONCOGENE			English	Article						ECM; MMP-9; MT-MMP; adenovirus; antisense; glioma	MATRIX-METALLOPROTEINASE INHIBITOR; PLASMINOGEN-ACTIVATOR RECEPTOR; IV COLLAGENASE; GELATINASE-B; IN-VIVO; MATRIX-METALLOPROTEINASE-9 EXPRESSION; EXTRACELLULAR-MATRIX; DOWN-REGULATION; METASTASIS; PROLIFERATION	Matrix metalloproteinase 9 (MMP-9) is known to play a major role in cell migration and invasion in both physiological and pathological processes. Our previous work has shown that increased MMP-9 levels are associated with human glioma tumor progression. In this study, we evaluated the ability of an adenovirus containing a 528 bp cDNA sequence in antisense orientation to the 5' end of the human MMP-9 gene (Ad-MMP-9AS) to inhibit the invasiveness and migratory capacity of the human glioblastoma cell line SBN19 in in vitro and in vivo models. Infection of glioma cells with Ad-MMP-9AS reduced MMP-9 enzyme activity by approximately 90% compared with mock- or Ad-CMV-infected cells. Migration and invasion of glioblastoma cells infected with Ad-MMP-9AS were significantly inhibited relative to Ad-CMV-infected controls in spheroid and Matrigel assays. Intracranial injections of SNB19 cells infected with Ad-MMP-9AS did not produce tumors in nude mice. However, injecting the Ad-MMP-9AS construct into subcutaneous U87MG tumors in nude mice caused regression of tumor growth. These results support the theory that adenoviral-mediated delivery of the MMP-9 gene in the antisense orientation has therapeutic potential for treating gliomas.	Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Div Canc Biol, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Neurosurg, Peoria, IL 61656 USA; Univ Illinois, Dept Neuropathol, Peoria, IL 61656 USA; Univ Texas, MD Anderson Canc Ctr, Dept Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; Okayama Univ, Sch Med, Dept Neurol Surg, Okayama 700, Japan; Univ Athens, Sch Med, Dept Propedeut Surg, GR-11527 Athens, Greece; Univ Ioannina, Sch Med, Dept Neurol, GR-45110 Ioannina, Greece	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Okayama University; Athens Medical School; National & Kapodistrian University of Athens; University of Ioannina	Rao, JS (corresponding author), Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Div Canc Biol, Box 1649, Peoria, IL 61656 USA.	jsrao@uic.edu		Gondi, Christopher/0000-0002-3036-9920	NCI NIH HHS [CA75557, CA76350] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075557, R01CA076350] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi Y, 2001, J BIOL CHEM, V276, P47171, DOI 10.1074/jbc.M104334200; Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; Arndt GM, 1997, GENOME, V40, P785, DOI 10.1139/g97-802; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; Baxter AD, 2000, CANC DRUG DISC DEV, P193; Brown PD, 1999, APMIS, V107, P174, DOI 10.1111/j.1699-0463.1999.tb01541.x; Brown PD, 2000, EXPERT OPIN INV DRUG, V9, P2167, DOI 10.1517/13543784.9.9.2167; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Chintala SK, 1996, CANCER LETT, V102, P57, DOI 10.1016/0304-3835(96)04163-8; Chintala SK, 1996, CANCER LETT, V101, P107, DOI 10.1016/0304-3835(96)04124-9; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; CRABBE T, 1994, BIOCHEMISTRY-US, V33, P14419, DOI 10.1021/bi00252a007; DAVIES B, 1993, CANCER RES, V53, P5365; DAVIES B, 1993, CANCER RES, V53, P2087; Dubois B, 1999, J CLIN INVEST, V104, P1507, DOI 10.1172/JCI6886; Eberhardt W, 2000, J IMMUNOL, V165, P5788, DOI 10.4049/jimmunol.165.10.5788; Folkman J, 1999, NAT BIOTECHNOL, V17, P749, DOI 10.1038/11676; Forsyth PA, 1998, J NEURO-ONCOL, V36, P21, DOI 10.1023/A:1005879027267; GARBISA S, 1987, CANCER RES, V47, P1523; Go Y, 1997, CLIN EXP METASTAS, V15, P440, DOI 10.1023/A:1018410523635; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; HOUDE M, 1993, INT J CANCER, V53, P395, DOI 10.1002/ijc.2910530309; Hua J, 1996, CANCER RES, V56, P5279; IMAI K, 1995, J BIOL CHEM, V270, P6691, DOI 10.1074/jbc.270.12.6691; Jones JL, 1999, J PATHOL, V189, P161, DOI 10.1002/(SICI)1096-9896(199910)189:2<161::AID-PATH406>3.0.CO;2-2; Kahari VM, 1999, ANN MED, V31, P34, DOI 10.3109/07853899909019260; Kin Y, 2000, INT J ONCOL, V17, P61; Kondraganti S, 2000, CANCER RES, V60, P6851; Konduri SD, 2000, CLIN EXP METASTAS, V18, P303, DOI 10.1023/A:1011085820250; KOOCHEKPOUR S, 1995, NEUROSCI LETT, V186, P53, DOI 10.1016/0304-3940(95)11280-A; Lakka SS, 2000, CLIN EXP METASTAS, V18, P245, DOI 10.1023/A:1006724826083; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Lozonschi L, 1999, CANCER RES, V59, P1252; Mohan PM, 1999, CLIN EXP METASTAS, V17, P617, DOI 10.1023/A:1006779902978; Nakada M, 1999, AM J PATHOL, V154, P417, DOI 10.1016/S0002-9440(10)65288-1; NAKAJIMA M, 1993, CANCER RES, V53, P5802; Parks PJ, 1999, GENE THER, V6, P1349, DOI 10.1038/sj.gt.3301013; Price A, 1999, CLIN CANCER RES, V5, P845; Rao JS, 1996, CLIN EXP METASTAS, V14, P12, DOI 10.1007/BF00157681; RAO JS, 1993, CANCER RES, V53, P2208; Rasmussen HS, 1997, PHARMACOL THERAPEUT, V75, P69, DOI 10.1016/S0163-7258(97)00023-5; SATO H, 1993, ONCOGENE, V8, P395; Scatena R, 2000, EXPERT OPIN INV DRUG, V9, P2159, DOI 10.1517/13543784.9.9.2159; Seiki M, 1999, APMIS, V107, P137, DOI 10.1111/j.1699-0463.1999.tb01536.x; Shalinsky DR, 1999, ANN NY ACAD SCI, V878, P236, DOI 10.1111/j.1749-6632.1999.tb07689.x; Shingleton WD, 1996, BIOCHEM CELL BIOL, V74, P759, DOI 10.1139/o96-083; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; Tonn JC, 1999, INT J CANCER, V80, P764, DOI 10.1002/(SICI)1097-0215(19990301)80:5<764::AID-IJC22>3.0.CO;2-J; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; Yamamoto M, 1996, CANCER RES, V56, P384; Yip D, 1999, INVEST NEW DRUG, V17, P387, DOI 10.1023/A:1006386406584	53	83	93	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2002	21	52					8011	8019		10.1038/sj.onc.1205894	http://dx.doi.org/10.1038/sj.onc.1205894			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	612VY	12439751				2022-12-28	WOS:000179097200010
J	Afonja, O; Raaka, BM; Huang, A; Das, S; Zhao, XY; Helmer, E; Juste, D; Samuels, HH				Afonja, O; Raaka, BM; Huang, A; Das, S; Zhao, XY; Helmer, E; Juste, D; Samuels, HH			RAR agonists stimulate SOX9 gene expression in breast cancer cell lines: evidence for a role in retinoid-mediated growth inhibition	ONCOGENE			English	Article						SOX9; retinoids; retinoic acid receptor; breast cancer; cell cycle; growth inhibition	ACUTE PROMYELOCYTIC LEUKEMIA; MAMMARY EPITHELIAL-CELLS; ACID RECEPTOR-ALPHA; MAMMALIAN SEX DETERMINATION; II COLLAGEN GENE; CARCINOMA CELLS; SELECTIVE RETINOIDS; APOPTOSIS INDUCTION; G(1) ARREST; VITAMIN-A	Retinoic acid receptors (RARs) are ligand-dependent transcription factors which are members of the steroid/thyroid hormone receptor gene family. RAR-agonists inhibit the proliferation of many human breast cancer cell lines, particularly those whose growth is stimulated by estradiol (E2) or growth factors. PCR-amplified subtractive hybridization was used to identify candidate retinoid-regulated genes that may be involved in growth inhibition. One candidate gene identified was SOX9, a member of the high mobility group (HMG) box gene family of transcription factors. SOX9 gene expression is rapidly stimulated by RAR-agonists in T-47D cells and other retinoid-inhibited breast cancer cell lines. In support of this finding, a database search indicates that SOX9 is expressed as an EST in breast tumor cells. SOX9 is known to be expressed in chondrocytes where it regulates the transcription of type 11 collagen and in testes where it plays a role in male sexual differentiation. RAR pan-agonists and the RARalpha-selective agonist Am580, but not RXR agonists, stimulate the expression of SOX9 in a wide variety of retinoid-inhibited breast cancer cell lines. RAR-agonists did not stimulate SOX9 in breast cancer cell lines which were not growth inhibited by retinoids. Expression of SOX9 in T-47D cells leads to cycle changes similar to those found with RAR-agonists while expression of a dominant negative form of SOX9 blocks RA-mediated cell cycle changes, suggesting a role for SOX9 in retinoid-mediated growth inhibition.	NYU, Sch Med, Dept Pediat, New York, NY 10016 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; Long Isl Univ, Dept Biol, Brooklyn, NY 11201 USA	New York University; New York University; Long Island University-Brooklyn Campus	Samuels, HH (corresponding author), NYU, Sch Med, Dept Pediat, 550 1st Ave, New York, NY 10016 USA.	herbert.samuels@med.nyu.edu			NCI NIH HHS [K12CA01713, CO15710] Funding Source: Medline; PHS HHS [D16636] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K12CA001713] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO015710] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGADIR A, 1994, CELL MOL BIOL, V40, P263; AMOS B, 1990, METHOD ENZYMOL, V190, P217; Arafa HMM, 1996, J CHROMATOGR A, V729, P125, DOI 10.1016/0021-9673(95)00980-9; Arafa HMM, 2000, ARCH TOXICOL, V73, P547, DOI 10.1007/s002040050007; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; Brooks SC, 1996, BLOOD, V87, P227; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAWSON MI, 1995, CANCER RES, V55, P4446; Desai SH, 2000, BIOCHEM PHARMACOL, V59, P1265, DOI 10.1016/S0006-2952(00)00269-0; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Easwaran V, 1999, CURR BIOL, V9, P1415, DOI 10.1016/S0960-9822(00)80088-3; Fanjul AN, 1996, CANCER RES, V56, P1571; FENAUX P, 1993, ACTA HAEMATOL-BASEL, V89, P22; Fitzgerald P, 1997, CANCER RES, V57, P2642; FONTANA JA, 1990, CANCER RES, V50, P1977; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; Gianni M, 1996, BLOOD, V87, P1520, DOI 10.1182/blood.V87.4.1520.bloodjournal8741520; Giese K, 1997, P NATL ACAD SCI USA, V94, P12845, DOI 10.1073/pnas.94.24.12845; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; Graham JD, 1999, J MOL ENDOCRINOL, V22, P295, DOI 10.1677/jme.0.0220295; Graves JAM, 1998, BIOESSAYS, V20, P264, DOI 10.1002/(SICI)1521-1878(199803)20:3&lt;264::AID-BIES10&gt;3.0.CO;2-1; Grunt TW, 1998, BRIT J CANCER, V78, P79, DOI 10.1038/bjc.1998.446; Hanley NA, 2000, MECH DEVELOP, V91, P403, DOI 10.1016/S0925-4773(99)00307-X; HAWKINS JR, 1995, J ENDOCRINOL, V147, P183, DOI 10.1677/joe.0.1470183; Healy C, 1999, DEV DYNAM, V215, P69, DOI 10.1002/(SICI)1097-0177(199905)215:1<69::AID-DVDY8>3.3.CO;2-E; Hong W K, 1995, J Natl Cancer Inst Monogr, P49; Hong WK, 1997, SCIENCE, V278, P1073, DOI 10.1126/science.278.5340.1073; Jinno H, 1999, CARCINOGENESIS, V20, P229, DOI 10.1093/carcin/20.2.229; KAGECHIKA H, 1988, J MED CHEM, V31, P2182, DOI 10.1021/jm00119a021; Kent J, 1996, DEVELOPMENT, V122, P2813; Koopman P, 1999, CELL MOL LIFE SCI, V55, P839; Koopman P, 2001, EXS, V91, P25; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LACROIX A, 1980, J CLIN INVEST, V65, P586, DOI 10.1172/JCI109703; Langenfeld J, 1996, ONCOGENE, V13, P1983; Lefebvre V, 1998, MATRIX BIOL, V16, P529; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; MANGELSDORF DJ, 1993, RECENT PROG HORM RES, V48, P99; MANGELSDORF DJ, 1994, NUTR REV, V52, P32; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Mangiarotti R, 1998, BRIT J CANCER, V77, P186, DOI 10.1038/bjc.1998.32; MARTH C, 1984, BIOCHEM PHARMACOL, V33, P2217, DOI 10.1016/0006-2952(84)90657-9; Nagai K, 2001, GENE, V270, P161, DOI 10.1016/S0378-1119(01)00479-6; Offterdinger M, 1998, BIOCHEM BIOPH RES CO, V251, P907, DOI 10.1006/bbrc.1998.9570; Olney PN, 1999, AM J MED GENET, V84, P20, DOI 10.1002/(SICI)1096-8628(19990507)84:1<20::AID-AJMG5>3.3.CO;2-E; Panda DK, 2001, J BIOL CHEM, V276, P41229, DOI 10.1074/jbc.M104231200; Raffo P, 2000, ANTICANCER RES, V20, P1535; Schafer AJ, 1996, ANN NY ACAD SCI, V785, P137, DOI 10.1111/j.1749-6632.1996.tb56252.x; Schneider SM, 2000, CANCER RES, V60, P5479; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Seewaldt VL, 1999, CELL GROWTH DIFFER, V10, P49; Seewaldt VL, 1997, CELL GROWTH DIFFER, V8, P631; Seewaldt VL, 1997, EXP CELL RES, V236, P16, DOI 10.1006/excr.1997.3694; Sekiya I, 2000, J BIOL CHEM, V275, P10738, DOI 10.1074/jbc.275.15.10738; Sekiya I, 2001, J CELL BIOCHEM, P71, DOI 10.1002/jcb.1077; SHAO ZM, 1995, ONCOGENE, V11, P493; SHEIKH MS, 1993, J CELL BIOCHEM, V53, P394, DOI 10.1002/jcb.240530417; SHEIKH MS, 1994, J BIOL CHEM, V269, P21440; SHEIKH MS, 1995, ONCOGENE, V11, P1899; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; SPORN MB, 1983, CANCER RES, V43, P3034; Sudbeck P, 1997, J BIOL CHEM, V272, P27848, DOI 10.1074/jbc.272.44.27848; Teixeira C, 1997, MOL ENDOCRINOL, V11, P1191, DOI 10.1210/me.11.9.1191; Toma S, 1997, INT J CANCER, V70, P619, DOI 10.1002/(SICI)1097-0215(19970304)70:5<619::AID-IJC21>3.0.CO;2-6; VANDERBURG B, 1993, MOL CELL ENDOCRINOL, V91, P149, DOI 10.1016/0303-7207(93)90267-N; VANDERLEEDE BJM, 1995, MOL CELL ENDOCRINOL, V109, P77, DOI 10.1016/0303-7207(95)03487-R; Watanabe K, 2000, P NATL ACAD SCI USA, V97, P1624, DOI 10.1073/pnas.97.4.1624; Willhite CC, 1996, DRUG METAB REV, V28, P105, DOI 10.3109/03602539608993994; Zhou Q, 1997, ONCOGENE, V15, P107, DOI 10.1038/sj.onc.1201142	75	65	72	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2002	21	51					7850	7860		10.1038/sj.onc.1205985	http://dx.doi.org/10.1038/sj.onc.1205985			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	610DT	12420222				2022-12-28	WOS:000178946000010
J	Herbert, BS; Wright, WE; Shay, JW				Herbert, BS; Wright, WE; Shay, JW			p16(INK4a) inactivation is not required to immortalize human mammary epithelial cells	ONCOGENE			English	Article						telomerase; senescence; culture; methylation; growth arrest	TELOMERASE ACTIVITY; SENESCENCE; EXPRESSION	Using standard culture conditions, primary human mammary epithetial cells (HMECs) undergo a premature, transient growth arrest termed MO (mortality stage 0) after 10 - 15 population doublings in vitro. It has been reported that emergence from this growth arrest by the abrogation of p16(INK4a), a cyclin-dependent kinase inhibitor, and expression of the catalytic component of human telomerase (hTERT) are necessary for HMEC immortalization. Here we show that primary HMECs, grown on feeder layers, do not undergo this growth arrest and can be immortalized without abrogating p16. These findings support the concept that the so-called M0 stage represents a cell culture stress-induced growth arrest and that hTERT is sufficient to immortalize HMECs when cultured under adequate conditions.	Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Shay, JW (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Shay, Jerry W/F-7878-2011					Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919; DiRenzo J, 2002, CANCER RES, V62, P89; ETHIER SP, 1993, CANCER RES, V53, P627; Huschtscha LI, 1998, CANCER RES, V58, P3508; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Ouellette MM, 1999, BIOCHEM BIOPH RES CO, V254, P795, DOI 10.1006/bbrc.1998.0114; Piatyszek Mieczyslaw A., 1995, Methods in Cell Science, V17, P1, DOI 10.1007/BF00981880; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Wright WE, 2002, NAT BIOTECHNOL, V20, P682, DOI 10.1038/nbt0702-682; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794	14	68	70	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 7	2002	21	51					7897	7900		10.1038/sj.onc.1205902	http://dx.doi.org/10.1038/sj.onc.1205902			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	610DT	12420227				2022-12-28	WOS:000178946000015
J	Mohanam, S; Chandrasekar, N; Yanamandra, N; Khawar, S; Mirza, F; Dinh, DH; Olivero, WC; Rao, JS				Mohanam, S; Chandrasekar, N; Yanamandra, N; Khawar, S; Mirza, F; Dinh, DH; Olivero, WC; Rao, JS			Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator	ONCOGENE			English	Article						ATF; uPA; glioblastoma; invasiveness	TUMOR-GROWTH; RECEPTOR CD87; IN-VIVO; METASTASIS; INHIBITION; SYSTEM; CANCER; ANGIOGENESIS; TRANSFECTION; LOCALIZATION	The binding of urokinase-type plasminogen activator (uPA) to its receptor (uPAR) on the surface of tumor cells is involved in the activation of proteolytic cascades responsible for the invasiveness of those cells. The diffuse, extensive infiltration of glioblastomas into the surrounding normal brain tissue is believed to rely on modifications of the proteolysis of extracellular matrix components; blocking the interaction between uPA and uPAR might be a suitable approach for inhibiting glioma tumorigenesis. We assessed how expression of an amino-terminal fragment (ATF) of uPA that contains binding site to uPAR affects the invasiveness of SNB19 human glioblastoma cells. SNB19 cells were transfected with an expression plasmid (pcDNA3-ATF) containing a cDNA sequence of ATF-uPA. The resulting ATF-uPA-expressing clones showed markedly less cell adhesion, spreading, and clonogenicity than did control cells. Endogenous ATF expression also significantly decreased the invasive capacity of transfected glioblastoma cells in Matrigel and spheroid-rat brain cell aggregate models. ATF-uPA transfectants were also markedly less invasive than parental SNB19 cells after injection into the brains of nude mice, suggesting that competitive inhibition of the uPA-uPAR interaction on SNB19 cells by means of transfection with ATF cDNA could be a useful therapeutic strategy for inhibiting tumor progression.	Univ Illinois, Coll Med, Div Canc Biol, Dept Biomed & Therapeut Sci, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Neurosurg, Peoria, IL 61656 USA	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria	Rao, JS (corresponding author), Univ Illinois, Coll Med, Div Canc Biol, Dept Biomed & Therapeut Sci, 1 Illini Dr, Peoria, IL 61656 USA.				NCI NIH HHS [CA75557, CA76350, CA85216] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076350, R01CA085216, R01CA075557] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Burgle M, 1997, BIOL CHEM, V378, P231, DOI 10.1515/bchm.1997.378.3-4.231; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; Dear AE, 1998, EUR J BIOCHEM, V252, P185, DOI 10.1046/j.1432-1327.1998.2520185.x; Duffy MJ, 1996, CLIN CANCER RES, V2, P613; Festuccia C, 1998, CLIN EXP METASTAS, V16, P513, DOI 10.1023/A:1006590217724; Go Y, 1997, CLIN EXP METASTAS, V15, P440, DOI 10.1023/A:1018410523635; KOBAYASHI H, 1994, INT J CANCER, V57, P727, DOI 10.1002/ijc.2910570520; Kruger A, 2000, CANCER GENE THER, V7, P292, DOI 10.1038/sj.cgt.7700144; Li H, 1998, GENE THER, V5, P1105, DOI 10.1038/sj.gt.3300742; Luparello C, 1996, EUR J CANCER, V32A, P702, DOI 10.1016/0959-8049(95)00657-5; Min HY, 1996, CANCER RES, V56, P2428; Mohanam S, 2001, CLIN CANCER RES, V7, P2519; Mohanam S, 1997, ONCOGENE, V14, P1351, DOI 10.1038/sj.onc.1200963; MOHANAM S, 1993, CANCER RES, V53, P4143; Quax PHA, 1998, ARTERIOSCL THROM VAS, V18, P693, DOI 10.1161/01.ATV.18.5.693; Quax PHA, 2001, CIRCULATION, V103, P562, DOI 10.1161/01.CIR.103.4.562; RABBANI SA, 1992, J BIOL CHEM, V267, P14151; Reuning U, 1998, INT J ONCOL, V13, P893; Schmitt M, 2000, FIBRINOLYSIS PROTEOL, V14, P114, DOI 10.1054/fipr.2000.0079; Stahl A, 1997, INT J CANCER, V71, P116, DOI 10.1002/(SICI)1097-0215(19970328)71:1<116::AID-IJC19>3.3.CO;2-Z; Waltz DA, 2000, AM J RESP CELL MOL, V22, P316, DOI 10.1165/ajrcmb.22.3.3713; YAMAMOTO M, 1994, CANCER RES, V54, P5016; YAMAMOTO M, 1994, CANCER RES, V54, P3656; Zhu FX, 2001, DNA CELL BIOL, V20, P297, DOI 10.1089/104454901750232490	25	34	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 7	2002	21	51					7824	7830		10.1038/sj.onc.1205893	http://dx.doi.org/10.1038/sj.onc.1205893			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	610DT	12420219				2022-12-28	WOS:000178946000007
J	Knuefermann, C; Lu, Y; Liu, BL; Jin, WD; Liang, K; Wu, L; Schmidt, M; Mills, GB; Mendelsohn, J; Fan, Z				Knuefermann, C; Lu, Y; Liu, BL; Jin, WD; Liang, K; Wu, L; Schmidt, M; Mills, GB; Mendelsohn, J; Fan, Z			HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells	ONCOGENE			English	Article						HER2; PI-3K; Akt; chemotherapy; breast cancer	SERINE-THREONINE KINASE; NF-KAPPA-B; V-HA-RAS; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNALING PATHWAY; OVARIAN-CANCER; GROWTH-FACTORS; AKT2 ONCOGENE; INHIBITION; PROTEIN	Growth factor receptor-mediated signal transduction has been implicated in conferring resistance to conventional chemotherapy on cancer cells. In this study, we delineated a pathway that involves HER2/PI-3K/Akt in mediating multidrug resistance in human breast cancer cells. We found that the cell lines that express both HER2 and HER3 appear to have a higher phosphorylation level of Akt (activated Akt). Transfection of HER2 in MCF7 breast cancer cells that express. HER3 caused a phosphoinoside-3 kinase (PI-3K)-dependent activation of Akt, and was associated with an increased resistance of the cells to multiple chemotherapeutic agents (paclitaxel, doxorubicin, 5-fluorouracil, etoposide, and camptothecin). Selective inhibition of PI-3K or Akt activity with their respective dominant-negative expression vectors sensitized the cells to the induction of apoptosis by the chemotherapeutic agents. We further demonstrated that MCF7 cells expressing a constitutively active Akt, in which the phospholipid-interactive PH domain of Akt was replaced by a farnesylation sequence for, constitutive membrane anchorage (DeltaPH-Akt1-farn), showed a similar increased resistance to the chemotherapeutic agents. Our results suggest that activation of AM by HER2/PI-3K plays an important role in conferring a broad-spectrum chemoresistance on breast cancer cells and that Akt may therefore be a novel molecular target for therapies that would improve the outcome of patients with breast cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Unit 36, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Fan, Z (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Unit 36, 1515 Holcombe Blvd, Houston, TX 77030 USA.			Liu, Bolin/0000-0003-0150-8650	NATIONAL CANCER INSTITUTE [P30CA016672, R01CA082716] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, R01 CA82716] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cheng JQ, 1997, ONCOGENE, V14, P2793, DOI 10.1038/sj.onc.1201121; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; DEL PL, 1997, SCIENCE, V278, P687; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; Hermanto U, 2001, ONCOGENE, V20, P7551, DOI 10.1038/sj.onc.1204964; Liu AX, 1998, CANCER RES, V58, P2973; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Ozes ON, 1999, NATURE, V401, P82; Perez-Tenorio G, 2002, BRIT J CANCER, V86, P540, DOI 10.1038/sj.bjc.6600126; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Sun M, 2001, CANCER RES, V61, P5985; Teng DHF, 1997, CANCER RES, V57, P5221; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Yu DH, 2000, ONCOGENE, V19, P6115, DOI 10.1038/sj.onc.1203972; Yuan ZQ, 2000, ONCOGENE, V19, P2324, DOI 10.1038/sj.onc.1203598	25	360	383	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 22	2003	22	21					3205	3212		10.1038/sj.onc.1206394	http://dx.doi.org/10.1038/sj.onc.1206394			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681MM	12761490				2022-12-28	WOS:000183040000002
J	Schneiderhan, N; Budde, A; Zhang, YP; Brune, B				Schneiderhan, N; Budde, A; Zhang, YP; Brune, B			Nitric oxide induces phosphorylation of p53 and impairs nuclear export	ONCOGENE			English	Article						p53-ubiquitination; Mdm2; nucleo-cytoplasmic; shuttling; leptomycin; heterokaryon analysis	RING-FINGER DOMAIN; TUMOR-SUPPRESSOR; INDUCED APOPTOSIS; DNA-BINDING; IN-VIVO; MDM2; DEGRADATION; ACTIVATION; PROTEIN; SIGNAL	The tumor suppressor p53 accumulates under diverse stress conditions and affects cell cycle progression and/or apoptosis. This has been exemplified for endogenously produced or exogenously supplied nitric oxide (NO) and thus accounts at least in part for pathophysiological signaling of that bioactive molecule, although detailed mechanisms remain to be elucidated. By using luciferase reporter assays, we show that NO stabilized a transcriptionally active p53 protein. Considering that p53 is targeted by murine double minute (Mdm2) for ubiquitination and subsequent proteasomal degradation and knowing that this interaction is impaired by, for example, UV-treatment with concomitant stabilization of p53 we questioned the p53/Mdm2 interaction in the presence of NO. Although p53 became phosphorylated at serine 15 under the impact of NO, coimmunoprecipitation with Mdm2 and ubiquitination remained intact, thus excluding any interference of NO with this pathway. The importance of N-terminal p53 phosphorylation was verified with p53 mutants where the first six serine residues have been converted to alanine, and which do not accumulate in response to NO. Regulation of p53 stability can be also achieved by affecting nuclear-cytoplasmic shuttling and it was presented that leptomycin B, an inhibitor of nuclear export, caused p53 accumulation. Cell fractionation and immunofluorescence staining following NO-treatment revealed predominant nuclear accumulation of p53 in close association with serine 15-phosphorylation, which suggests impaired nuclear-cytoplasmic shuttling. This was verified by heterokaryon analysis. We conclude that attenuated nuclear export contributes to stabilization and activation of p53 under the influence of NO.	Univ Kaiserslautern, Fac Biol, Dept Cell Biol, D-67663 Kaiserslautern, Germany; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Erlangen Nurnberg, Fac Med, Dept Med 4, Expt Div, D-91054 Erlangen, Germany	University of Kaiserslautern; University of Texas System; UTMD Anderson Cancer Center; University of Erlangen Nuremberg	Brune, B (corresponding author), Univ Kaiserslautern, Fac Biol, Dept Cell Biol, Erwin Schrodinger Str, D-67663 Kaiserslautern, Germany.	BRUENE@rhrk.uni-kl.de			NCI NIH HHS [K01 CA087580] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA087580] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Berendji D, 1997, FEBS LETT, V405, P37, DOI 10.1016/S0014-5793(97)00150-6; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Brune B, 2001, CELL SIGNAL, V13, P525, DOI 10.1016/S0898-6568(01)00175-9; Brune B, 1999, CELL DEATH DIFFER, V6, P969, DOI 10.1038/sj.cdd.4400582; Callsen D, 1999, BIOCHEMISTRY-US, V38, P2279, DOI 10.1021/bi982292a; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; Chen JD, 1996, MOL CELL BIOL, V16, P2445; Davis DW, 2000, J EXP MED, V192, P857, DOI 10.1084/jem.192.6.857; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Gottifredi V, 2001, SCIENCE, V292, P1851, DOI 10.1126/science.1062238; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HART TW, 1985, TETRAHEDRON LETT, V26, P2013, DOI 10.1016/S0040-4039(00)98368-0; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hengstermann A, 1998, ONCOGENE, V17, P2933, DOI 10.1038/sj.onc.1202282; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kim SJ, 2002, J BIOL CHEM, V277, P33501, DOI 10.1074/jbc.M202862200; KRONCKE KD, 1994, BIOCHEM BIOPH RES CO, V200, P1105, DOI 10.1006/bbrc.1994.1564; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Liang SH, 2001, EUR J BIOCHEM, V268, P2779, DOI 10.1046/j.1432-1327.2001.02227.x; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; Maki CG, 1996, CANCER RES, V56, P2649; Maki CG, 1999, J BIOL CHEM, V274, P16531, DOI 10.1074/jbc.274.23.16531; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Matsuoka M, 2001, BIOCHEM BIOPH RES CO, V282, P1120, DOI 10.1006/bbrc.2001.4700; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; Messmer UK, 1996, BIOCHEM J, V319, P299, DOI 10.1042/bj3190299; MESSMER UK, 1994, FEBS LETT, V355, P23; MIYASHITA T, 1995, CELL, V80, P293; Nakaya N, 2000, ONCOGENE, V19, P6369, DOI 10.1038/sj.onc.1204100; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Shaw P, 1996, ONCOGENE, V12, P921; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Turenne GA, 2001, ONCOGENE, V20, P5100, DOI 10.1038/sj.onc.1204665; Wang XJ, 2002, J BIOL CHEM, V277, P15697, DOI 10.1074/jbc.M112068200; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yang F, 2000, J LEUKOCYTE BIOL, V68, P916; Zhang YP, 2001, CELL GROWTH DIFFER, V12, P175; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	58	66	70	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2003	22	19					2857	2868		10.1038/sj.onc.1206431	http://dx.doi.org/10.1038/sj.onc.1206431			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771937				2022-12-28	WOS:000182824800001
J	Gingras, B; Rodier, G; Giasson, E; Coulombe, P; Chassagne, C; Meloche, S				Gingras, B; Rodier, G; Giasson, E; Coulombe, P; Chassagne, C; Meloche, S			Expression of angiotensin type II receptor downregulates Cdk4 synthesis and inhibits cell-cycle progression	ONCOGENE			English	Article						angiotensin receptor; cell proliferation; cell cycle; CDK4	GROWTH-FACTOR-BETA; RETINOBLASTOMA PROTEIN; PHOSPHORYLATION; PROLIFERATION; FIBROBLASTS; ACTIVATION; CLONING	Accumulating evidence suggests that angiotensin II type II (AT(2)) receptor subtype negatively regulates cell proliferation in pathophysiological conditions associated with tissue remodeling. However, the mechanisms through which AT(2) receptor achieves this effect remain poorly understood. In this study, we demonstrate that expression of AT(2) receptor inhibits the proliferation of rat fibroblasts in a ligand-independent manner. The antiproliferative action of AT(2) is dependent on the density of surface receptors. We show that AT(2) receptor expression negatively regulates G1 phase progression in both cycling cells and G0-arrested cells stimulated to re-enter the cell cycle, but has no detectable effect on apoptosis. The delay in cell-cycle progression of AT(2)-expressing cells is associated with downregulation of cyclin E expression, decreased assembly of cyclin E-Cdk2 complexes, and the resulting attenuation of Cdk2 activation. The induction of Cdk4 expression and activity is also markedly attenuated, which likely contributes to the inhibition of cyclin E expression. Ectopic expression of Cdk4 alleviates the proliferation defect of AT2-expressing cells. These findings suggest that the growth-inhibitory effects of the AT(2) receptor are attributable in part to its spontaneous inhibitory action on the cell cycle machinery.	Inst Rech Clin Montreal, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Dept Pharmacol, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Dept Mol Biol, Montreal, PQ H2W 1R7, Canada; Univ Paris 07, Hop Lariboisiere, Inst Federat Rech Circulat Paris 7, INSERM,U127, Paris, France	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; Universite de Montreal; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Meloche, S (corresponding author), Inst Rech Clin Montreal, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.	melochs@ircm.qc.ca	GIASSON, ELVIO/J-3623-2012	GIASSON, ELVIO/0000-0003-3659-6873; COULOMBE, Philippe/0000-0002-4638-9694; RODIER, Genevieve/0000-0002-9901-639X				Akishita M, 1999, J CLIN INVEST, V103, P63, DOI 10.1172/JCI5182; Allan LA, 2000, MOL CELL BIOL, V20, P1291, DOI 10.1128/MCB.20.4.1291-1298.2000; Bedecs K, 1997, BIOCHEM J, V325, P449, DOI 10.1042/bj3250449; Blume A, 2001, CURR OPIN NEPHROL HY, V10, P239, DOI 10.1097/00041552-200103000-00013; BOND RA, 1998, DRUGS PHARM SCI, V89, P363; CHAASSAGNE C, 1995, GENOMICS, V25, P601, DOI 10.1016/0888-7543(95)80072-T; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; de Gasparo M, 2000, PHARMACOL REV, V52, P415; DELEAN A, 1982, MOL PHARMACOL, V21, P5; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; DUDLEY DT, 1993, REGUL PEPTIDES, V44, P199, DOI 10.1016/0167-0115(93)90243-2; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ewen ME, 2000, GENE DEV, V14, P2265, DOI 10.1101/gad.842100; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; Goto M, 1997, HYPERTENSION, V30, P358, DOI 10.1161/01.HYP.30.3.358; GRADY EF, 1991, J CLIN INVEST, V88, P921, DOI 10.1172/JCI115395; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Horiuchi M, 1999, HYPERTENSION, V33, P613, DOI 10.1161/01.HYP.33.2.613; Huang XC, 1996, J BIOL CHEM, V271, P15635, DOI 10.1074/jbc.271.26.15635; Hutchinson HG, 1999, CARDIOVASC RES, V41, P689, DOI 10.1016/S0008-6363(98)00267-3; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; Kim S, 2000, PHARMACOL REV, V52, P11; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; LAMBERT C, 1995, CIRC RES, V77, P1001, DOI 10.1161/01.RES.77.5.1001; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Leurs R, 1998, TRENDS BIOCHEM SCI, V23, P418, DOI 10.1016/S0968-0004(98)01287-0; Maric C, 1998, KIDNEY INT, V53, P92, DOI 10.1046/j.1523-1755.1998.00749.x; Masaki H, 1998, J CLIN INVEST, V101, P527, DOI 10.1172/JCI1885; Matsubara H, 1998, CIRC RES, V83, P1182, DOI 10.1161/01.RES.83.12.1182; Meffert S, 1996, MOL CELL ENDOCRINOL, V122, P59, DOI 10.1016/0303-7207(96)03873-7; MELOCHE S, 1986, MOL PHARMACOL, V30, P537; MELOCHE S, 1995, J CELL PHYSIOL, V163, P577, DOI 10.1002/jcp.1041630319; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Miller SJ, 2000, MOL CELL BIOL, V20, P8420, DOI 10.1128/MCB.20.22.8420-8431.2000; Miura SI, 2000, EMBO J, V19, P4026, DOI 10.1093/emboj/19.15.4026; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; NAKAJIMA M, 1995, P NATL ACAD SCI USA, V92, P10663, DOI 10.1073/pnas.92.23.10663; Nouet S, 2000, TRENDS ENDOCRIN MET, V11, P1, DOI 10.1016/S1043-2760(99)00205-2; Ohkubo N, 1997, CIRCULATION, V96, P3954; Reed SI, 1997, CANCER SURV, V29, P7; Servant MJ, 2000, J CELL BIOL, V148, P543, DOI 10.1083/jcb.148.3.543; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; STOLL M, 1995, J CLIN INVEST, V95, P651, DOI 10.1172/JCI117710; VISWANATHAN M, 1992, PEPTIDES, V13, P783, DOI 10.1016/0196-9781(92)90187-8; Wang HM, 2002, EMBO J, V21, P930, DOI 10.1093/emboj/21.5.930; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Yamada T, 1996, P NATL ACAD SCI USA, V93, P156, DOI 10.1073/pnas.93.1.156; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738	53	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2003	22	17					2633	2642		10.1038/sj.onc.1206346	http://dx.doi.org/10.1038/sj.onc.1206346			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730677				2022-12-28	WOS:000182569000011
J	Mackay, A; Jones, C; Dexter, T; Silva, RLA; Bulmer, K; Jones, A; Simpson, P; Harris, RA; Jat, PS; Neville, AM; Reis, LFL; Lakhani, SR; O'Hare, MJ				Mackay, A; Jones, C; Dexter, T; Silva, RLA; Bulmer, K; Jones, A; Simpson, P; Harris, RA; Jat, PS; Neville, AM; Reis, LFL; Lakhani, SR; O'Hare, MJ			cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells	ONCOGENE			English	Article						ERBB2 (HER2/neu); breast cancer; cDNA microarray; expression profiling; tissue array	METASTATIC BREAST-CANCER; GALACTOSIDE-BINDING-PROTEIN; MONOCLONAL-ANTIBODY; PROGNOSTIC-SIGNIFICANCE; MEMBRANE-PROTEIN; GROWTH-FACTOR; CARCINOMA CELLS; P-CADHERIN; PHASE-II; EXPRESSION	To investigate changes in gene expression associated with ERBB2, expression profiting of immortalized human mammary luminal epithelial cells and variants expressing a moderate and high level of ERBB2 has been carried out using cDNA microarrays corresponding to approximately 6000 unique genes/ESTs. A total of 61 significantly up- or downregulated (>2.0-fold) genes were identified and further validated by RT-PCR analysis as well as microarray comparisons with a spontaneously ERBB2-overexpressing breast cancer cell line and ERBB2-positive primary breast tumors. The expression and clinical relevance of proteins predicted to be associated with ERBB2 overexpression in breast cancers were analysed together with their clinical relevance by antibody screening using a tissue array. Differentially regulated genes include those involved in cell-matrix interactions including proline 4-hydroxylase (P4HA2), galectin 1 (LGALS1) and galectin 3 (LGALS3), fibronectin 1 (FN1) and p-cadherin (CDH3), and cell proliferation (CRIP1, IGFBP3) and transformation (S100P, S100A4). A number of genes associated with MYC signalling were also differentially expressed, including NDRG1, USF2 and the epithelial membrane proteins 1 and 3 (EMP1, EMP3). These data represent profiles of the transcriptional changes associated with ERBB2-related pathways in the breast, and identify novel and potentially useful targets for prognosis and therapy.	UCL, LICR UCL Breast Canc Lab, London W1W 7EJ, England; Inst Canc Res, Breakthrough Toby Robins Breast Canc Res Ctr, London SW3 6JB, England; Ludwig Inst Canc Res, Sao Paulo, Brazil; UCL, Ludwig Inst Canc Res, London, England; Royal Marsden Hosp, London SW3 6JJ, England	University of London; University College London; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Ludwig Institute for Cancer Research; Ludwig Institute for Cancer Research; University of London; University College London; Royal Marsden NHS Foundation Trust	Mackay, A (corresponding author), UCL, LICR UCL Breast Canc Lab, Charles Bell House,Riding House St, London W1W 7EJ, England.	alan.mackay@ucl.ac.uk	Simpson, Peter/F-1225-2010; Lakhani, Sunil R/I-1970-2018; Jones, Chris/ABE-6059-2021; Reis, Luiz F. L./C-4556-2013	Simpson, Peter/0000-0002-4816-8289; Lakhani, Sunil R/0000-0003-4067-2760; Jones, Chris/0000-0001-8118-2296; Reis, Luiz/0000-0002-4040-2456				Andre S, 1999, J CANCER RES CLIN, V125, P461, DOI 10.1007/s004320050303; BALDINI A, 1993, GENOMICS, V15, P216, DOI 10.1006/geno.1993.1039; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Ben-Porath I, 1998, GENOMICS, V49, P443, DOI 10.1006/geno.1998.5238; Ben-Porath I, 1999, MOL CELL BIOL, V19, P3529; Bieche I, 1996, CANCER RES, V56, P3886; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Chen Y, 1997, GENOMICS, V41, P40, DOI 10.1006/geno.1997.4524; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Cuny M, 2000, CANCER RES, V60, P1077; Da Silva IDCG, 2000, INT J ONCOL, V16, P231; De Iorio P, 2001, ANTICANCER RES, V21, P1395; Gamallo C, 2001, MODERN PATHOL, V14, P650, DOI 10.1038/modpathol.3880367; GOLDSTONE SD, 1991, BIOCHEM BIOPH RES CO, V178, P746, DOI 10.1016/0006-291X(91)90171-3; Harris RA, 1999, INT J CANCER, V80, P477, DOI 10.1002/(SICI)1097-0215(19990129)80:3<477::AID-IJC23>3.0.CO;2-W; Hippo Y, 2001, CANCER RES, V61, P889; Houston SJ, 1999, BRIT J CANCER, V79, P1220, DOI 10.1038/sj.bjc.6690196; Hughes RC, 2001, BIOCHIMIE, V83, P667; Ignatoski KMW, 2000, BRIT J CANCER, V82, P666, DOI 10.1054/bjoc.1999.0979; Kauraniemi P, 2001, CANCER RES, V61, P8235; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Liehr T, 1999, GENOMICS, V58, P106, DOI 10.1006/geno.1999.5803; Lu YH, 2001, JNCI-J NATL CANCER I, V93, P1852, DOI 10.1093/jnci/93.24.1852; Mazzucchelli L, 2002, AM J PATHOL, V160, P7, DOI 10.1016/S0002-9440(10)64342-8; Menard S, 2001, ONCOLOGY-BASEL, V61, P67, DOI 10.1159/000055404; Miles DW, 1999, INT J CANCER, V84, P354, DOI 10.1002/(SICI)1097-0215(19990820)84:4<354::AID-IJC4>3.0.CO;2-6; Moon BK, 2001, AM J PATHOL, V159, P1055, DOI 10.1016/S0002-9440(10)61780-4; Paz A, 2001, ONCOGENE, V20, P7486, DOI 10.1038/sj.onc.1204950; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; Perillo NL, 1998, J MOL MED, V76, P402, DOI 10.1007/s001090050232; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Rocha RL, 1996, J NATL CANCER I, V88, P601, DOI 10.1093/jnci/88.9.601; Ross, 1998, Oncologist, V3, P237; Ross JS, 1999, SEMIN CANCER BIOL, V9, P125, DOI 10.1006/scbi.1998.0083; Rudland PS, 2000, CANCER RES, V60, P1595; Schiemann S, 1997, ANTICANCER RES, V17, P13; Scorilas A, 1999, BRIT J CANCER, V81, P1385, DOI 10.1038/sj.bjc.6693404; Shen L, 1998, BIOCHEM PHARMACOL, V55, P1711, DOI 10.1016/S0006-2952(98)00045-8; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Soler AP, 1999, CANCER-AM CANCER SOC, V86, P1263, DOI 10.1002/(SICI)1097-0142(19991001)86:7<1263::AID-CNCR23>3.3.CO;2-U; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Stoll BA, 1997, BRIT J CANCER, V76, P1652, DOI 10.1038/bjc.1997.612; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; Werbajh SE, 1998, FEBS LETT, V440, P277, DOI 10.1016/S0014-5793(98)01473-2; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Yu DH, 2000, BIOESSAYS, V22, P673, DOI 10.1002/1521-1878(200007)22:7<673::AID-BIES10>3.0.CO;2-A	49	132	144	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2003	22	17					2680	2688		10.1038/sj.onc.1206349	http://dx.doi.org/10.1038/sj.onc.1206349			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730682				2022-12-28	WOS:000182569000016
J	Goodman, PA; Burkhardt, N; Juran, B; Tibbles, HE; Uckun, FM				Goodman, PA; Burkhardt, N; Juran, B; Tibbles, HE; Uckun, FM			Hypermethylation of the spleen tyrosine kinase promoter in T-lineage acute lymphoblastic leukemia	ONCOGENE			English	Article						CpG island; methylation-specific; PCR; T-lineage leukemia	LYMPHOMA B-CELLS; HUMAN BREAST-CANCER; DNA METHYLATION; CPG ISLANDS; PHOSPHOLIPASE C-GAMMA-2; RECEPTOR STIMULATION; MEDIATED ACTIVATION; INDUCED APOPTOSIS; BINDING PROTEINS; MYELOID-LEUKEMIA	Sequence analysis of the noncoding first exon (exon 1) of the Syk gene demonstrated the presence of a previously cloned CpG island (GenBank #Z 65706). Transient transfection analysis in Daudi cells demonstrated promoter activity (18-fold increase over parental luciferase plasmid) for a 348 bp BstXI-BsrBI fragment containing this island. This region exhibits a high GC content (similar to75%), contains several SP1 binding sites and a potential initiator sequence, but lacks a strong TATA consensus. Bisulfite sequencing and methylation-specific PCR (MSP) of this region demonstrated that the Syk promoter CpG island was largely unmethylated in B-lineage leukemia cell lines, control peripheral blood cells, human thymocytes and CD3(+) T lymphocytes. However, dense methylation was seen in four T-lineage leukemia cell lines, Jurkat, H9, Molt 3 and HUT 78. MSP screening of leukemia cells from six T-lineage acute lymphoblastic leukemia (ALL) patients demonstrated methylation of the Syk promoter CpG island in one T-lineage ALL patient. Promoter methylation was correlated with reduced to absent expression of Syk mRNA and SYK protein in the T-lineage leukemia cell lines. Treatment of the leukemia lines Ha and Molt 3, with the methylation inhibitor, 5-aza-2'-deoxycytidine (5-aza-CdR) resulted in increased Syk mRNA expression. The presence of a methylated promoter sequence in these T-lineage leukemia cell lines and in one T-lineage patient suggests a potential role for SYK as a tumor suppressor in T-ALL.	Parker Hughes Inst, Dept Mol Oncol, St Paul, MN 55113 USA; Parker Hughes Canc Ctr, St Paul, MN 55113 USA; Parker Hughes Inst, Dept Mol Genet, St Paul, MN 55113 USA; Parker Hughes Inst, Dept Biochem, St Paul, MN 55113 USA		Uckun, FM (corresponding author), Parker Hughes Inst, Dept Mol Oncol, 2699 Patton Rd, St Paul, MN 55113 USA.	faith_uckun@mercury.ih.org		Uckun, Fatih M./0000-0001-9334-183X				Akanuma D, 1999, ORAL ONCOL, V35, P476, DOI 10.1016/S1368-8375(99)00020-2; ALCALAY M, 1988, NUCLEIC ACIDS RES, V16, P9527, DOI 10.1093/nar/16.20.9527; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; Ballestar E, 2001, EUR J BIOCHEM, V268, P1, DOI 10.1046/j.1432-1327.2001.01869.x; Baylin SB, 1998, ADV CANCER RES, V72, P141; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Birger Y, 1999, NATURE, V397, P84, DOI 10.1038/16291; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; Bolen JB, 1997, ANNU REV IMMUNOL, V15, P371, DOI 10.1146/annurev.immunol.15.1.371; BOLEN JB, 1995, CURR OPIN IMMUNOL, V7, P306, DOI 10.1016/0952-7915(95)80103-0; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; CHAN AC, 1994, J IMMUNOL, V152, P4758; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; Chu DH, 1999, J IMMUNOL, V163, P2610; Coopman PJP, 2000, NATURE, V406, P742, DOI 10.1038/35021086; Cornall RJ, 2000, P NATL ACAD SCI USA, V97, P1713, DOI 10.1073/pnas.97.4.1713; Craig NL, 1996, CURR TOP MICROBIOL, V204, P27; CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; Dibirdik I, 1998, J BIOL CHEM, V273, P4035, DOI 10.1074/jbc.273.7.4035; Dodge JE, 1998, INT J CANCER, V78, P561, DOI 10.1002/(SICI)1097-0215(19981123)78:5<561::AID-IJC6>3.0.CO;2-R; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLATAU E, 1983, CANCER RES, V43, P4901; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Glavac Damjan, 1996, Pfluegers Archiv European Journal of Physiology, V431, pR193, DOI 10.1007/BF02346334; Goodman PA, 2002, LEUKEMIA LYMPHOMA, V43, P1627, DOI 10.1080/1042819021000002965; Goodman PA, 2001, ONCOGENE, V20, P3969, DOI 10.1038/sj.onc.1204515; Goodman PA, 1998, J BIOL CHEM, V273, P17742, DOI 10.1074/jbc.273.28.17742; GOOTENBERG JE, 1981, J EXP MED, V154, P1403, DOI 10.1084/jem.154.5.1403; GULBINS E, 1994, J IMMUNOL, V152, P2123; Guo SX, 2000, LEUKEMIA RES, V24, P39, DOI 10.1016/S0145-2126(99)00158-7; Harmer SL, 1997, MOL CELL BIOL, V17, P4087, DOI 10.1128/MCB.17.7.4087; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Jones PA, 1996, CANCER RES, V56, P2463; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; JOST JP, 1992, P NATL ACAD SCI USA, V89, P9499, DOI 10.1073/pnas.89.20.9499; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; KOEFFLER HP, 1980, BLOOD, V56, P344; KUROSAKI T, 1995, J EXP MED, V182, P1815, DOI 10.1084/jem.182.6.1815; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; Latour S, 1996, J BIOL CHEM, V271, P22782, DOI 10.1074/jbc.271.37.22782; Law CL, 1996, MOL CELL BIOL, V16, P1305; Li HL, 1997, J BIOL CHEM, V272, P18200, DOI 10.1074/jbc.272.29.18200; LOZZIO BB, 1979, LEUKEMIA RES, V3, P363, DOI 10.1016/0145-2126(79)90033-X; LOZZIO BB, 1981, P SOC EXP BIOL MED, V166, P546; MAHAJAN S, 1995, MOL CELL BIOL, V15, P5304; MallickWood CA, 1996, P NATL ACAD SCI USA, V93, P9704, DOI 10.1073/pnas.93.18.9704; MANN DL, 1989, AIDS RES HUM RETROV, V5, P253, DOI 10.1089/aid.1989.5.253; MINOWADA J, 1981, J CANCER RES CLIN, V101, P91, DOI 10.1007/BF00405069; MINOWADA J, 1972, J NATL CANCER I, V49, P891; NAGAI K, 1995, J BIOL CHEM, V270, P6824, DOI 10.1074/jbc.270.12.6824; NEUHAUSEN SL, 1994, HUM MOL GENET, V3, P1919, DOI 10.1093/hmg/3.11.1919; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Okamura S, 1999, ONCOL RES, V11, P281; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PAWLAK A, 1991, NUCLEIC ACIDS RES, V19, P1029; Qin SF, 1998, FEBS LETT, V427, P139, DOI 10.1016/S0014-5793(98)00383-4; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; SHEPHERD NS, 1994, P NATL ACAD SCI USA, V91, P2629, DOI 10.1073/pnas.91.7.2629; SIDORENKO SP, 1995, P NATL ACAD SCI USA, V92, P359, DOI 10.1073/pnas.92.2.359; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; Smiraglia DJ, 2001, HUM MOL GENET, V10, P1413, DOI 10.1093/hmg/10.13.1413; Stellwagen AE, 1997, EMBO J, V16, P6823, DOI 10.1093/emboj/16.22.6823; STERNBERG NL, 1992, TRENDS GENET, V8, P11, DOI 10.1016/0168-9525(92)90018-Y; Stewart ZA, 2001, BREAST CANCER RES, V3, P5, DOI 10.1186/bcr261; Stirzaker C, 1997, CANCER RES, V57, P2229; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Tibbles HE, 2001, J BIOL CHEM, V276, P17815, DOI 10.1074/jbc.M011405200; Turner M, 1997, J EXP MED, V186, P2013, DOI 10.1084/jem.186.12.2013; UCKUN FM, 1989, BLOOD, V73, P1000; UCKUN FM, 1992, P NATL ACAD SCI USA, V89, P9005, DOI 10.1073/pnas.89.19.9005; Uckun FM, 1996, J BIOL CHEM, V271, P6389, DOI 10.1074/jbc.271.11.6389; UCKUN FM, 1991, J BIOL CHEM, V266, P17478; Uckun FM, 1997, BLOOD, V89, P2488; UCKUN FM, 1985, J IMMUNOL, V135, P3817; Uckun FM, 1996, SCIENCE, V273, P1096, DOI 10.1126/science.273.5278.1096; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; Vassilev A, 1999, J BIOL CHEM, V274, P1646, DOI 10.1074/jbc.274.3.1646; Yeivin A, 1993, EXS, V64, P523; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416; Yuan YF, 2001, CANCER RES, V61, P5558; ZHANG XY, 1993, MOL CELL BIOL, V13, P6810, DOI 10.1128/MCB.13.11.6810	84	28	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2003	22	16					2504	2514		10.1038/sj.onc.1206313	http://dx.doi.org/10.1038/sj.onc.1206313			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	670AD	12717427				2022-12-28	WOS:000182383500013
J	Zhou, A; Scoggin, S; Gaynor, RB; Williams, NS				Zhou, A; Scoggin, S; Gaynor, RB; Williams, NS			Identification of NF-kappa B-regulated genes induced by TNF alpha utilizing expression profiling and RNA interference	ONCOGENE			English	Article						TNF alpha; NF-kappa B; cDNA microarrays; RNA interference; gene expression profiles; apoptosis	TUMOR-NECROSIS-FACTOR; MONOCYTE CHEMOATTRACTANT PROTEIN-1; CULTURED-MAMMALIAN-CELLS; PROSTAGLANDIN-E SYNTHASE; ZINC FINGER PROTEIN; SIGNAL-TRANSDUCTION; TRANSCRIPTIONAL REGULATION; INDUCIBLE EXPRESSION; ENDOTHELIAL-CELLS; EGR-1 PROMOTER	Tumor necrosis factor alpha (TNFalpha) is a proinflammatory cytokine with important roles in regulating inflammatory responses as well as cell cycle proliferation and apoptosis. Although TNFalpha stimulates apoptosis, it also activates the transcription factor NF-kappaB, and studies have shown that inhibition of NF-kappaB potentiates the cytotoxicity of TNFalpha. Since several chemotherapy agents act like TNFalpha to both promote apoptosis and activate NF-kappaB, understanding the role of NF-kappaB in suppressing apoptosis may have significant clinical applications. To understand the effects of stimulation with TNFalpha and the role of NF-kappaB in regulating this response, a 23k human cDNA microarray was used to screen TNFalpha-inducible genes in HeLa cells. Real-time PCR verified expression changes in 16 of these genes and revealed three distinct temporal patterns of expression after TNFalpha stimulation. Using RNA interference to disrupt expression of the p65 subunit of NF-kappaB, all but two of the genes were shown to depend on this transcription factor for their expression, which correlated well with the existence of NF-kappaB binding sites in most of their promoters. Inflammatory, proapoptotic, and antiapoptotic genes were all shown to be regulated by NF-kappaB, demonstrating the wide variety of targets activated by NF-kappaB signaling and the necessity of differentiating among these genes for therapeutic purposes.	Univ Texas, SW Med Ctr, Div Hematol Oncol, Dept Med,Harold Simmons Canc Ctr, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Williams, NS (corresponding author), Univ Texas, SW Med Ctr, Div Hematol Oncol, Dept Med,Harold Simmons Canc Ctr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Scoggin, Shane/0000-0003-2510-2823	NCI NIH HHS [CA74128] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074128] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AntrasFerry J, 1997, FEBS LETT, V403, P100, DOI 10.1016/S0014-5793(97)00033-1; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Barnes PJ, 1997, INT J BIOCHEM CELL B, V29, P867, DOI 10.1016/S1357-2725(96)00159-8; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Berman KS, 2002, CLIN CANCER RES, V8, P354; Brown RT, 1995, J BIOL CHEM, V270, P31129, DOI 10.1074/jbc.270.52.31129; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Chang HY, 2000, MICROBIOL MOL BIOL R, V64, P821, DOI 10.1128/MMBR.64.4.821-846.2000; Chaudhary LR, 1996, MOL CELL BIOCHEM, V156, P69; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Chung KC, 2000, EUR J BIOCHEM, V267, P4676, DOI 10.1046/j.1432-1327.2000.01517.x; COFFER P, 1995, ONCOGENE, V10, P985; CORNELIUS P, 1990, J BIOL CHEM, V265, P20506; DAS KC, 1995, AM J PHYSIOL-LUNG C, V269, pL588, DOI 10.1152/ajplung.1995.269.5.L588; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Dong G, 1999, CANCER RES, V59, P3495; Dudley NR, 2002, P NATL ACAD SCI USA, V99, P4191, DOI 10.1073/pnas.062605199; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fautsch MP, 1998, GENOMICS, V51, P408, DOI 10.1006/geno.1998.5388; Finch JS, 2001, GENE, V267, P135, DOI 10.1016/S0378-1119(01)00398-5; Forsberg L, 2000, FEBS LETT, V471, P78, DOI 10.1016/S0014-5793(00)01367-3; Grimbacher B, 1998, RHEUMATOL INT, V17, P185, DOI 10.1007/s002960050032; Guo YL, 1998, J BIOL CHEM, V273, P4027, DOI 10.1074/jbc.273.7.4027; Harborth J, 2001, J CELL SCI, V114, P4557; HASKILL S, 1990, P NATL ACAD SCI USA, V87, P7732, DOI 10.1073/pnas.87.19.7732; Ivanov D, 2000, MOL CELL BIOL, V20, P2970, DOI 10.1128/MCB.20.9.2970-2983.2000; KAKIZAKI Y, 1995, KIDNEY INT, V48, P1866, DOI 10.1038/ki.1995.485; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; KWAK SP, 1994, J BIOL CHEM, V269, P3596; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; Leong KG, 2000, HISTOL HISTOPATHOL, V15, P1303, DOI 10.14670/HH-15.1303; Maehara K, 2000, J CELL BIOCHEM, V77, P474, DOI 10.1002/(SICI)1097-4644(20000601)77:3<474::AID-JCB12>3.0.CO;2-H; Maehara K, 2001, FASEB J, V15, P2025, DOI 10.1096/fj.00-0909fje; Manos EJ, 2001, CANCER RES, V61, P433; Murakami T, 2000, J Atheroscler Thromb, V7, P39; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; SAKAMOTO KM, 1994, MOL CELL BIOL, V14, P5975, DOI 10.1128/MCB.14.9.5975; SARMA V, 1992, J IMMUNOL, V148, P3302; Schageman JJ, 2002, BIOTECHNIQUES, V32, P338, DOI 10.2144/02322st07; STEPHENS JM, 1992, J MOL ENDOCRINOL, V9, P61, DOI 10.1677/jme.0.0090061; Stichtenoth DO, 2001, J IMMUNOL, V167, P469, DOI 10.4049/jimmunol.167.1.469; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; Tsai JC, 2000, FASEB J, V14, P1870; Ueda A, 1997, J BIOL CHEM, V272, P31092, DOI 10.1074/jbc.272.49.31092; VAN AD, 1996, SCIENCE, V274, P787; Vanden Berghe W, 2000, BIOCHEM PHARMACOL, V60, P1185, DOI 10.1016/S0006-2952(00)00412-3; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WOOD LD, 1995, NUCLEIC ACIDS RES, V23, P4210, DOI 10.1093/nar/23.20.4210; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Zhang YF, 1999, J BIOL CHEM, V274, P14786, DOI 10.1074/jbc.274.21.14786	59	152	165	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 3	2003	22	13					2054	2064		10.1038/sj.onc.1206262	http://dx.doi.org/10.1038/sj.onc.1206262			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	662UR	12673210				2022-12-28	WOS:000181967700015
J	Pourtier-Manzanedo, A; Vercamer, C; Van Belle, E; Mattot, V; Mouquet, F; Vandenbunder, B				Pourtier-Manzanedo, A; Vercamer, C; Van Belle, E; Mattot, V; Mouquet, F; Vandenbunder, B			Expression of an Ets-1 dominant-negative mutant perturbs normal and tumor angiogenesis in a mouse ear model	ONCOGENE			English	Article						in vivo model; growth factors; tumor; angiogenesis; inhibition; Ets-1	TRANSCRIPTION FACTOR; ENDOTHELIAL-CELLS; PLASMINOGEN-ACTIVATOR; MAST-CELLS; GROWTH; GENE; PROMOTER; FAMILY; INHIBITOR; TNP-470	We and others have shown that members of the Ets family of transcription factors are involved in morphogenic properties of endothelial cells in vitro. To investigate the role of these factors in the transcriptional regulation of angiogenesis in vivo, we set up a nontramnatic model that allows daily macroscopic examination of both growth factor- and tumor-induced angiogenesis in mouse ears. In the same animal, we were thus able to record variations in the patterns of neovessels induced and cell populations recruited by the angiogenic factors FGF-2 and VEGF. In this model, inhibition of FGF-2-induced angiogenesis by the pharmacological compound TNP-470 was readily observed, demonstrating that the mouse ear model is also useful in the evaluation of antiangiogenic strategies. Our functional analysis of Ets transcription factors activity utilized a competitor protein, Ets1-DB, a dominant negative Ets1 mutant lacking the transactivation domain. Retrovirus-mediated expression of Ets1-DB inhibited FGF-2-induced angiogenesis, while the expression of Ets1-DB in cancerous and stromal cells disturbed tumor-induced angiogenesis. These results illustrate the value of the ear model and highlight the role of Ets family members in the transcriptional regulation of tumor angiogenesis.	Univ Lille 2, CNRS, Inst Biol Lille,FRE 2353, Inst Pasteur, F-59021 Lille, France; Univ Lille 2, CNRS, Inst Biol Lille,UMR 8526, Inst Pasteur, F-59021 Lille, France; Univ Lille 2, Hop Cardiol, Serv Cardiol & Hemodynam B, F-59037 Lille, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Universite de Lille - ISITE; CHU Lille; Universite de Lille	Vandenbunder, B (corresponding author), Univ Lille 2, CNRS, Inst Biol Lille,IPL, FRE 2527, 1 Rue Calmette,BP 447, F-59021 Lille, France.	bernard.vandenbunder@ibl.fr	POURTIER, ALBIN/G-7401-2012; Mouquet, Frederic/P-6899-2019	POURTIER, ALBIN/0000-0002-1576-3946; VAN BELLE, ERIC/0000-0001-6509-443X				Anderson MK, 1999, DEVELOPMENT, V126, P3131; Artuc M, 1999, EXP DERMATOL, V8, P1, DOI 10.1111/j.1600-0625.1999.tb00342.x; Barton K, 1998, IMMUNITY, V9, P555, DOI 10.1016/S1074-7613(00)80638-X; Behrens P, 2001, J PATHOL, V194, P43, DOI 10.1002/path.844; Behrens P, 2001, INT J MOL MED, V8, P149; Bolon I, 1996, LAB INVEST, V75, P1; BOLON I, 1995, AM J PATHOL, V147, P1298; Bond SJ, 2000, J SURG RES, V92, P18, DOI 10.1006/jsre.2000.5854; COURDENT AD, 1996, INT J DEV BIOL, V40, P1097; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Dellian M, 1996, AM J PATHOL, V149, P59; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; Edel MJ, 1998, ANTICANCER RES, V18, P4505; Fafeur V, 1997, CELL GROWTH DIFFER, V8, P655; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; Iljin K, 1999, FASEB J, V13, P377, DOI 10.1096/fasebj.13.2.377; Ito M, 1998, BIOCHEM BIOPH RES CO, V246, P123, DOI 10.1006/bbrc.1998.8585; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; Jain RK, 1997, NAT MED, V3, P1203, DOI 10.1038/nm1197-1203; Konerding MA, 1998, AM J PATHOL, V152, P1607; Kria L, 1998, CURR EYE RES, V17, P986, DOI 10.1076/ceyr.17.10.986.5245; Laudet V, 1999, ONCOGENE, V18, P1351, DOI 10.1038/sj.onc.1202444; Lelievre E, 2001, INT J BIOCHEM CELL B, V33, P391, DOI 10.1016/S1357-2725(01)00025-5; Lelievre E, 2000, ONCOGENE, V19, P2438, DOI 10.1038/sj.onc.1203563; Lichtenberg J, 1997, PHARMACOL TOXICOL, V81, P280; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; Macias D, 1998, ANAT EMBRYOL, V198, P307, DOI 10.1007/s004290050186; Mager AM, 1998, INT J DEV BIOL, V42, P561; Maier JAM, 1997, ANTI-CANCER DRUG, V8, P238, DOI 10.1097/00001813-199703000-00004; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; Mattot V, 2000, ONCOGENE, V19, P762, DOI 10.1038/sj.onc.1203248; MCLACHLIN JR, 1993, VIROLOGY, V195, P1, DOI 10.1006/viro.1993.1340; Nakano T, 2000, J CELL PHYSIOL, V184, P255, DOI 10.1002/1097-4652(200008)184:2<255::AID-JCP14>3.0.CO;2-J; Oda N, 1999, J CELL PHYSIOL, V178, P121, DOI 10.1002/(SICI)1097-4652(199902)178:2<121::AID-JCP1>3.3.CO;2-6; Rinsch C, 2001, GENE THER, V8, P523, DOI 10.1038/sj.gt.3301436; Sapi E, 1998, CANCER RES, V58, P1027; Schwachtgen JL, 1997, ONCOGENE, V15, P3091, DOI 10.1038/sj.onc.1201502; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; Tanaka K, 1998, J CELL PHYSIOL, V176, P235, DOI 10.1002/(SICI)1097-4652(199808)176:2<235::AID-JCP2>3.0.CO;2-P; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WERNERT N, 1994, CANCER RES, V54, P5683; WERNERT N, 1992, AM J PATHOL, V140, P119; XU L, 1989, VIROLOGY, V171, P331, DOI 10.1016/0042-6822(89)90600-4	43	41	44	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2003	22	12					1795	1806		10.1038/sj.onc.1206215	http://dx.doi.org/10.1038/sj.onc.1206215			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660815				2022-12-28	WOS:000181678200006
J	Schagdarsurengin, U; Wilkens, L; Steinemann, D; Flemming, P; Kreipe, HH; Pfeifer, GP; Schlegelberger, B; Dammann, R				Schagdarsurengin, U; Wilkens, L; Steinemann, D; Flemming, P; Kreipe, HH; Pfeifer, GP; Schlegelberger, B; Dammann, R			Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma	ONCOGENE			English	Article						hepatocellular carcinoma; hepatocellular adenoma; methylation; RASSF1; tumor suppressor gene	TUMOR-SUPPRESSOR GENE; COMPARATIVE GENOMIC HYBRIDIZATION; HUMAN-CHROMOSOME 3P21.3; CPG ISLAND; DNA METHYLATION; LUNG-CANCER; PROMOTER HYPERMETHYLATION; ABERRANT METHYLATION; BREAST CANCERS; CIRRHOSIS	Aberrant promoter methylation is a fundamental mechanism of inactivation of tumor suppressor genes in cancer. The Ras association domain family 1A gene (RASSF1A) is frequently epigenetically silenced in several types of human solid tumors. In this study, we have investigated the expression and methylation status of the RASSF1A gene in hepatocellular carcinoma (HCC). In two HCC cell tines (HepG2 and Hep3B) RASSF1A was inactivated and treatment of these cell lines with a DNA methylation inhibitor reactivated the transcription of RASSF1A. The methylation status of the RASSF1A promoter region was analysed in 26 primary liver tissues including HCC, hepatocellular adenoma (HCA), liver fibrosis, hepatocirrhosis. Out of 15, 14 (93%) HCC were methylated at the RASSF1A CpG island and hypermethylation was independent of hepatitis virus infection. RASSF1A was also methylated in two out of two fibrosis and in three (75%) out of four cirrhosis; the latter carries an increased risk of developing HCC. Additionally, we analysed the methylation status of p16(INK4A), and other cancer-related genes in the same liver tumors. Aberrant methylation in the HCC samples was detected in 71% of samples for p16, 25% for TIMP3, 17% for PTEN, 13% for CDH1, and 7% for RARbeta2. In conclusion, our results demonstrate that RASSF1A and p16(INK4a) inactivation by methylation are frequent events in hepatocellular carcinoma, but not in HCA, which is in contrast to HCC without cirrhosis, viral hepatitis, storage diseases, or genetic background. Therefore, this study gives additional evidence against a progression of adenoma to carcinoma in the liver. Thus, RASSF1A hypermethylation could be useful as a marker of malignancy and to distinguish between the distinct forms of highly differentiated liver neoplasm.	Univ Halle Wittenberg, Inst Human Genet & Med Biol, AG Tumorgenet Med Fak, D-06097 Halle Saale, Germany; Hannover Med Sch, Inst Pathol, D-30625 Hannover, Germany; Hannover Med Sch, Inst Zell & Mol Pathol, D-30625 Hannover, Germany; City Hope Canc Ctr, Beckman Res Inst, Dept Biol, Duarte, CA 91010 USA	Martin Luther University Halle Wittenberg; Hannover Medical School; Hannover Medical School; City of Hope; Beckman Research Institute of City of Hope	Dammann, R (corresponding author), Univ Halle Wittenberg, Inst Human Genet & Med Biol, AG Tumorgenet Med Fak, Magdeburger Str 2, D-06097 Halle Saale, Germany.	reinhard.dammann@medizin.uni-halle.de	Schagdarsurengin, Undraga/AAH-4312-2020; Schagdarsurengin, Undraga/AAH-4346-2020	Schagdarsurengin, Undraga/0000-0003-0127-4938; 	NATIONAL CANCER INSTITUTE [R01CA088873] Funding Source: NIH RePORTER; NCI NIH HHS [CA88873] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Bachman KE, 1999, CANCER RES, V59, P798; Boige V, 1997, CANCER RES, V57, P1986; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Cote S, 1998, ANTI-CANCER DRUG, V9, P743; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024; Feitelson MA, 2002, ONCOGENE, V21, P2593, DOI 10.1038/sj.onc.1205434; Flemming P, 2001, PATHOLOGE, V22, P184, DOI 10.1007/s002920100456; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kang GH, 2002, AM J PATHOL, V160, P787, DOI 10.1016/S0002-9440(10)64901-2; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Kondo Y, 2000, HEPATOLOGY, V32, P970, DOI 10.1053/jhep.2000.19797; Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8; Lerman MI, 2000, CANCER RES, V60, P6116; Li SP, 2001, J HEPATOL, V34, P840, DOI 10.1016/S0168-8278(01)00047-2; Liew CT, 1999, ONCOGENE, V18, P789, DOI 10.1038/sj.onc.1202359; Liu LM, 2002, ONCOGENE, V21, P6835, DOI 10.1038/sj.onc.1205814; Lo KW, 2001, CANCER RES, V61, P3877; Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.0.CO;2-0; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Roncalli M, 2000, HEPATOLOGY, V31, P846, DOI 10.1053/he.2000.5790; Roncalli M, 2002, HEPATOLOGY, V36, P427, DOI 10.1053/jhep.2002.34852; Schafer DF, 1999, LANCET, V353, P1253, DOI 10.1016/S0140-6736(98)09148-X; Schagdarsurengin U, 2002, CANCER RES, V62, P3698; Shen LL, 2002, J NATL CANCER I, V94, P755, DOI 10.1093/jnci/94.10.755; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Soria JC, 2002, CLIN CANCER RES, V8, P1178; Tomizawa Y, 2002, CLIN CANCER RES, V8, P2362; Toyooka S, 2001, CANCER RES, V61, P5727; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Wilkens L, 2001, J PATHOL, V193, P476, DOI 10.1002/path.825; Wistuba II, 2000, CANCER RES, V60, P1949; Wong IHN, 1999, CANCER RES, V59, P71; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Zhong S, 2002, CLIN CANCER RES, V8, P1087	44	143	159	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2003	22	12					1866	1871		10.1038/sj.onc.1206338	http://dx.doi.org/10.1038/sj.onc.1206338			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660822				2022-12-28	WOS:000181678200013
J	Seker, H; Rubbi, C; Linke, SP; Bowman, ED; Garfield, S; Hansen, L; Borden, KLB; Milner, J; Harris, CC				Seker, H; Rubbi, C; Linke, SP; Bowman, ED; Garfield, S; Hansen, L; Borden, KLB; Milner, J; Harris, CC			UV-C-induced DNA damage leads to p53-dependent nuclear trafficking of PML	ONCOGENE			English	Article						P53; PML; DNA repair; BLM	NUCLEOTIDE EXCISION-REPAIR; ACUTE PROMYELOCYTIC LEUKEMIA; BLOOM-SYNDROME; PREMATURE SENESCENCE; TUMOR SUPPRESSION; SYNDROME PROTEIN; MESSENGER-RNA; ONCOGENIC RAS; CELL-CYCLE; P53	The promyelocytic leukemia protein (PML) is a nuclear phosphoprotein that localizes to distinct domains in the nucleus, described as PML nuclear bodies (PML-NBs). Recent findings indicate that PML regulates the p53 response to oncogenic signals. Here, we define a p53-dependent role for PML in response to DNA damage. We exposed cells to ultraviolet light (UV-C) and imaged the nuclear distribution of PML, p53, and the BLM helicase by confocal microscopy. After DNA damage, PML partially relocated out of the PML-NBs, and colocalized with BLM and p53 at sites of DNA repair. In addition, using the isogenic HCT116 cell tines (p53+/+ and -/-), we show that the redistribution of PML was dependent on functional p53. Western analysis revealed that the level of PML protein remained unaltered after UV-C treatment. These results are consistent with the hypothesis that PML, in conjunction with p53 and BLM, contributes to the cellular response to UV-C-induced DNA damage and its repair.	NCI, Human Carcinogenesis Lab, CCR, NIH, Bethesda, MD 20892 USA; Univ York, Dept Biol, YCR Lab P53, York YO1 5DD, N Yorkshire, England; NCI, Expt Carcinogenesis Lab, CCR, NIH, Bethesda, MD 20892 USA; Creighton Univ, Sch Med, Dept Biomed Sci, Omaha, NE 68178 USA; Mt Sinai Sch Med, Dept Physiol & Biophys, Struct Biol Program, New York, NY 10029 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of York - UK; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Creighton University; Icahn School of Medicine at Mount Sinai	Harris, CC (corresponding author), NCI, Human Carcinogenesis Lab, CCR, NIH, 37 Convent Dr,Bldg 37,Room 2C05, Bethesda, MD 20892 USA.	Curtis_Harris@nih.gov		Linke, Steven/0000-0001-8584-4947	NATIONAL CANCER INSTITUTE [Z01BC005795, ZIABC005795] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adamson AL, 2001, J VIROL, V75, P2388, DOI 10.1128/JVI.75.5.2388-2399.2001; Ahn JH, 2000, VIROLOGY, V274, P39, DOI 10.1006/viro.2000.0448; Auerbach Arleen D., 1997, Current Opinion in Pediatrics, V9, P600, DOI 10.1097/00008480-199712000-00010; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; BOOTSMA D, 1993, NATURE, V363, P114, DOI 10.1038/363114a0; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chan JYH, 1997, BIOCHEM BIOPH RES CO, V240, P640, DOI 10.1006/bbrc.1997.7692; Cohen N, 2001, EMBO J, V20, P4547, DOI 10.1093/emboj/20.16.4547; CONCHELLO JA, 1994, APPL OPTICS, V33, P3740, DOI 10.1364/AO.33.003740; de Boer J, 2000, CARCINOGENESIS, V21, P453, DOI 10.1093/carcin/21.3.453; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Ellis NA, 2001, HUM GENET, V108, P167, DOI 10.1007/s004390000447; Ellis NA, 1999, AM J HUM GENET, V65, P1368, DOI 10.1086/302616; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Ferbeyre G, 2000, GENE DEV, V14, P2015; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; Gottifredi V, 2001, TRENDS CELL BIOL, V11, P184, DOI 10.1016/S0962-8924(01)01983-3; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Hu P, 2001, HUM MOL GENET, V10, P1287, DOI 10.1093/hmg/10.12.1287; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Maul GG, 2000, J STRUCT BIOL, V129, P278, DOI 10.1006/jsbi.2000.4239; Maul GG, 1995, J CELL BIOCHEM, V59, P498, DOI 10.1002/jcb.240590410; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Negorev D, 2001, ONCOGENE, V20, P7234, DOI 10.1038/sj.onc.1204764; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Robles AI, 1999, ONCOGENE, V18, P4681, DOI 10.1038/sj.onc.1202862; Rubbi CP, 2000, ONCOGENE, V19, P85, DOI 10.1038/sj.onc.1203378; Rubbi CP, 2001, CARCINOGENESIS, V22, P1789, DOI 10.1093/carcin/22.11.1789; Ruggero D, 2000, BIOESSAYS, V22, P827, DOI 10.1002/1521-1878(200009)22:9<827::AID-BIES8>3.3.CO;2-T; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Sanz MM, 2000, CYTOGENET CELL GENET, V91, P217, DOI 10.1159/000056848; Stadler M, 1995, ONCOGENE, V11, P2565; STUURMAN N, 1992, J CELL SCI, V101, P773; Tchang F, 1999, EXP CELL RES, V251, P46, DOI 10.1006/excr.1999.4570; Vallian S, 1998, MOL CELL BIOL, V18, P7147, DOI 10.1128/MCB.18.12.7147; van Brabant AJ, 2000, ANNU REV GENOM HUM G, V1, P409, DOI 10.1146/annurev.genom.1.1.409; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang WS, 2000, EMBO J, V19, P3428, DOI 10.1093/emboj/19.13.3428; Wang XW, 2001, J BIOL CHEM, V276, P32948, DOI 10.1074/jbc.M103298200; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wood RD, 1997, J BIOL CHEM, V272, P23465, DOI 10.1074/jbc.272.38.23465; Wu WS, 2001, MOL CELL BIOL, V21, P2259, DOI 10.1128/MCB.21.7.2259-2268.2001; Yankiwski V, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-11; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zong S, 1999, ONCOGENE, V18, P7941, DOI 10.1038/sj.onc.1203367	53	41	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	2003	22	11					1620	1628		10.1038/sj.onc.1206140	http://dx.doi.org/10.1038/sj.onc.1206140			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642865				2022-12-28	WOS:000181580500004
J	Tagliafico, E; Siena, M; Zanocco-Marani, T; Manfredini, R; Tenedini, E; Montanari, M; Grande, A; Ferrari, S				Tagliafico, E; Siena, M; Zanocco-Marani, T; Manfredini, R; Tenedini, E; Montanari, M; Grande, A; Ferrari, S			Requirement of the coiled-coil domains of p92(c-Fes) for nuclear localization in myeloid cells upon induction of differentiation	ONCOGENE			English	Article						c-Fes; oligomerization; myeloid differentiation; phosphorylation; nuclear localization; tyrosine kinase	FES TYROSINE KINASE; HUMAN C-FES; GREEN FLUORESCENT PROTEIN; HEMATOPOIETIC STEM-CELLS; VITAMIN-D-RECEPTOR; RETROVIRAL VECTORS; FPS FES; EXPRESSION; FPS/FES; GENE	The nonreceptor tyrosine kinase Fes is implicated in myeloid cells differentiation. It has been observed that its localization can be cytoplasmic, perinuclear, or nuclear. To further characterize this point, we studied Fes subcellular localization in myeloid cell lines (HL60 and K562) and in COS1 cells. Fes was observed in both the nucleus and the cytoplasm of HL60, K562 cells over-expressing Fes and only in the cytoplasm of COS1 cells, suggesting that nuclear localization is cell context dependent. Moreover, in myeloid cells, the treatment with differentiation-inducing agents such as retinoic acid, phorbol esters and vitamin D, is followed by an increase of the oligomeric form of Fes in the nucleus. In fact, oligomerization seems to be necessary for translocation to occur, since Fes mutants missing the coiled-coil domains are not able to form oligomers and fail to localize in the nucleus. The active form of Fes is tyrosine phosphorylated; however, phosphorylation is not required for Fes to localize in the nucleus, since tyrosine kinase inhibitors do not block the translocation process.	Univ Modena, Dipartimento Sci Biomed, Sez Chim Biol, I-41100 Modena, Italy	Universita di Modena e Reggio Emilia	Ferrari, S (corresponding author), Univ Modena, Dipartimento Sci Biomed, Sez Chim Biol, Via Campi 287, I-41100 Modena, Italy.		Manfredini, Rossella/C-5625-2015; Tagliafico, Enrico/C-9079-2009; Ferrari, Sergio/A-1110-2010; Zanocco Marani, Tommaso/D-5801-2015; tenedini, elena/ABB-3411-2020; Grande, Alexis/D-5816-2015	Manfredini, Rossella/0000-0003-0660-6110; Tagliafico, Enrico/0000-0003-0981-2542; Ferrari, Sergio/0000-0002-4822-2521; Zanocco Marani, Tommaso/0000-0002-9911-7078; Grande, Alexis/0000-0003-3319-1707; TENEDINI, Elena/0000-0003-0285-765X				ARECES LB, 1994, MOL CELL BIOL, V14, P4606, DOI 10.1128/MCB.14.7.4606; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CANCE WG, 1994, CELL GROWTH DIFFER, V5, P1347; CARE A, 1994, ONCOGENE, V9, P739; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Cheng HY, 1999, MOL CELL BIOL, V19, P8335; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREXLER HG, 1987, LEUKEMIA, V1, P697; EMILIA G, 1986, BRIT J HAEMATOL, V62, P287, DOI 10.1111/j.1365-2141.1986.tb02931.x; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; FERRARI S, 1994, LEUKEMIA, V8, pS91; FERRARI S, 1995, CELL DEATH DIFFER, V2, P155; FERRARI S, 1985, BRIT J HAEMATOL, V59, P21, DOI 10.1111/j.1365-2141.1985.tb02959.x; Grande A, 1999, BLOOD, V93, P3276, DOI 10.1182/blood.V93.10.3276.410k08_3276_3285; Grande A, 1997, CELL DEATH DIFFER, V4, P497, DOI 10.1038/sj.cdd.4400270; GREER P, 1994, MOL CELL BIOL, V14, P6755, DOI 10.1128/MCB.14.10.6755; Greer P, 2002, NAT REV MOL CELL BIO, V3, P278, DOI 10.1038/nrm783; Haas J, 1996, CURR BIOL, V6, P315, DOI 10.1016/S0960-9822(02)00482-7; Hackenmiller R, 2000, IMMUNITY, V13, P397, DOI 10.1016/S1074-7613(00)00039-X; Hackenmiller R, 2002, DEV BIOL, V245, P255, DOI 10.1006/dbio.2002.0643; Haigh J, 1996, CELL GROWTH DIFFER, V7, P931; HAZAN B, 1993, CELL GROWTH DIFFER, V4, P443; HJERMSTAD SJ, 1993, ONCOGENE, V8, P2283; Hovland AR, 2001, J NEUROSCI RES, V64, P302; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; INOUYE S, 1994, FEBS LETT, V341, P277, DOI 10.1016/0014-5793(94)80472-9; IZUHARA K, 1994, J BIOL CHEM, V269, P18623; JUCKER M, 1992, ONCOGENE, V7, P943; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Li JZ, 1996, J BIOL CHEM, V271, P32930, DOI 10.1074/jbc.271.51.32930; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; Manfredini R, 1999, CANCER RES, V59, P3803; MANFREDINI R, 1993, J EXP MED, V178, P381, DOI 10.1084/jem.178.2.381; Manfredini R, 1997, BLOOD, V89, P135, DOI 10.1182/blood.V89.1.135.135_135_145; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MATSUDA T, 1995, J BIOL CHEM, V270, P11037, DOI 10.1074/jbc.270.19.11037; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; NELSON KL, 1998, J BIOL CHEM; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pendergast AM, 1996, CURR OPIN CELL BIOL, V8, P174, DOI 10.1016/S0955-0674(96)80063-9; Phillips RL, 2000, SCIENCE, V288, P1635, DOI 10.1126/science.288.5471.1635; Pinna LA, 1996, BBA-MOL CELL RES, V1314, P191, DOI 10.1016/S0167-4889(96)00083-3; Read RD, 1997, J BIOL CHEM, V272, P18498, DOI 10.1074/jbc.272.29.18498; Rogers JA, 1996, J BIOL CHEM, V271, P17519, DOI 10.1074/jbc.271.29.17519; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; Smithgall TE, 1998, CRIT REV ONCOGENESIS, V9, P43, DOI 10.1615/CritRevOncog.v9.i1.40; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; YATES KE, 1995, ONCOGENE, V10, P1239; YU G, 1989, J BIOL CHEM, V264, P10276; Zirngibl R, 2001, EXP CELL RES, V266, P87, DOI 10.1006/excr.2001.5217; Zirngibl RA, 2002, MOL CELL BIOL, V22, P2472, DOI 10.1128/MCB.22.8.2472-2486.2002	53	9	9	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 20	2003	22	11					1712	1723		10.1038/sj.onc.1206279	http://dx.doi.org/10.1038/sj.onc.1206279			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642874				2022-12-28	WOS:000181580500013
J	Chinwalla, V; Chien, A; Odero, M; Neilly, MB; Zeleznik-Le, NJ; Rowley, JD				Chinwalla, V; Chien, A; Odero, M; Neilly, MB; Zeleznik-Le, NJ; Rowley, JD			A t(11;15) fuses MLL to two different genes, AF15q14 and a novel gene MPFYVE on chromosome 15	ONCOGENE			English	Article						t(11;15)(q23;ql5); MLL; AF15q14; MPFYVE; FYVE domain; leukemia	ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID LEUKEMIAS; DROSOPHILA-TRITHORAX; 11Q23 TRANSLOCATIONS; FYVE-FINGER; REARRANGEMENTS; TRANSCRIPTS; BINDING; LEUKEMOGENESIS; DUPLICATION	The mixed lineage leukemia gene (MLL, also known as HRX, ALL-1 and Htrx) located at 11q23 is involved in translocations with over 40 different chromosomal bands in a variety of leukemia subtypes. Here we report our analysis of a rare but recurring translocation, t(11;15)(q23;q14). This translocation has been described in a small subset of cases with both acute myeloblastic leukemia and ALL. Recent studies have shown that MLL is fused to AF15q14 in the t(11;15). Here we analyse a sample from another patient with this translocation and confirm the presence of an MLL-AF15q14 fusion. However, we have also identified and cloned another fusion transcript from the same patient sample. In this fusion transcript, MLL is fused to a novel gene, MLL partner containing FYVE domain (MPFYVE). Both MLL-AF15q14 and MLL-MPFYVE are in-frame fusion transcripts with the potential to code for novel fusion proteins. MPFYVE is also located on chromosome 15, approximately 170kb telomeric to AF15q14. MPFYVE contains a highly conserved motif, the FYVE domain which, in other proteins, has been shown to bind to phosphotidyl-inositol-3 phosphate (PtdIns(3)P). The MLL-MPFYVE fusion may be functionally important in the leukemia process in at least some patients containing this translocation.	Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA	University of Chicago	Rowley, JD (corresponding author), Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA.		Odero/ABG-9860-2020	Odero/0000-0002-8858-2054	NCI NIH HHS [CA 84405, CA42557, CA78438, CA40046, T32 CA09595] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084405, R29CA078438, R35CA042557, T32CA009595] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; BERNARD OA, 1995, GENE CHROMOSOME CANC, V13, P75, DOI 10.1002/gcc.2870130202; BREEN TR, 1993, DEVELOPMENT, V117, P119; Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; Caldas C, 1998, GENE, V208, P167, DOI 10.1016/S0378-1119(97)00640-9; DiMartino JF, 1999, BRIT J HAEMATOL, V106, P614, DOI 10.1046/j.1365-2141.1999.01439.x; Divoky V, 2000, GENE, V247, P111, DOI 10.1016/S0378-1119(00)00111-6; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; GIBBONS B, 1990, BRIT J HAEMATOL, V74, P264, DOI 10.1111/j.1365-2141.1990.tb02581.x; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Hanson RD, 1999, P NATL ACAD SCI USA, V96, P14372, DOI 10.1073/pnas.96.25.14372; Hayette S, 2000, ONCOGENE, V19, P4446, DOI 10.1038/sj.onc.1203789; HERNANDEZ JM, 1995, LEUKEMIA, V9, P1162; Hillion J, 1997, BLOOD, V90, P3714, DOI 10.1182/blood.V90.9.3714; HUNGER SP, 1993, BLOOD, V81, P3197; KANEKO Y, 1988, LEUKEMIA, V2, P672; KUEFER MU, 1997, BLOOD S, V90, P1235; Lavau C, 2000, P NATL ACAD SCI USA, V97, P10984, DOI 10.1073/pnas.190167297; Lavau C, 2000, EMBO J, V19, P4655, DOI 10.1093/emboj/19.17.4655; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; MARTINEZCLIMENT JA, 1995, LEUKEMIA, V9, P1299; Nilson I, 1996, BRIT J HAEMATOL, V93, P966, DOI 10.1046/j.1365-2141.1996.d01-1748.x; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; RAIMONDI SC, 1989, BLOOD, V73, P1627; Rowley JD, 1999, SEMIN HEMATOL, V36, P59; ROWLEY JD, 1993, SEMIN CANCER BIOL, V4, P377; RUBNITZ JE, 1994, BLOOD, V84, P570; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; Stenmark H, 1999, J CELL SCI, V112, P4175; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; THIRMAN MJ, 1993, NEW ENGL J MED, V329, P909, DOI 10.1056/NEJM199309233291302; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Waring PM, 1997, CURR TOP MICROBIOL, V220, P1; Whitman SP, 2001, CANCER RES, V61, P59; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610	38	17	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2003	22	9					1400	1410		10.1038/sj.onc.1206273	http://dx.doi.org/10.1038/sj.onc.1206273			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618766	Green Published			2022-12-28	WOS:000181360900015
J	Kotlo, KU; Yehiely, F; Efimova, E; Harasty, H; Hesabi, B; Shchors, K; Einat, P; Rozen, A; Berent, E; Deiss, LP				Kotlo, KU; Yehiely, F; Efimova, E; Harasty, H; Hesabi, B; Shchors, K; Einat, P; Rozen, A; Berent, E; Deiss, LP			Nrf2 is an inhibitor of the Fas pathway as identified by Achilles' Heel Method, a new function-based approach to gene identification in human cells	ONCOGENE			English	Article						apoptosis; function profiling; functional genomics; FaS; Nrf2; phase II detoxifying enzymes	ACTIVATED PROTEIN-KINASE; MEDIATED APOPTOSIS; DT-DIAPHORASE; INTERFERON-GAMMA; BINDING PROTEIN; DEATH; ELEMENT; TRANSCRIPTION; EXPRESSION; INDUCTION	Here we describe the Achilles' Heel Method (AHM), a new function-based approach for identification of inhibitors of signaling pathways, optimized for human cells. The principle of AHM is the identification of 'sensitizing' cDNAs based on their decreased abundance following selection. As a proof of principle, we have employed AHM for the identification of Fas/CD95/APO-1 pathway inhibitors. HeLa cells were transfected with an antisense cDNA expression library in an episomal vector followed by selection with a suboptimal dose of the apoptotic inducer. Antisense inactivation of Fas inhibitors rendered the cells more sensitive to apoptosis resulting in their preferential death and consequent loss of their sensitizing episomes that were identified by subtraction. We show that the resulting products were enriched for sensitizing cDNAs as seven out of eight candidates tested were confirmed as inhibitors of Fas-induced killing either by transfection or by pharmacological inhibition. Furthermore, we demonstrate by multiple approaches that one candidate, NF-E2 related factor 2 (Nrf2), is an inhibitor of Fas-induced apoptosis. Inactivation of Nrf2 by antisense or by a membrane permeable dominant-negative polypeptide sensitized cells while overexpression of Nrf2 protected cells from Fas-induced apoptosis. In addition, dicumarol, an inhibitor of the phase 11 detoxifying enzyme NQO1, a downstream target of Nrf2, sensitized cells. Nrf2 induces the production of Glutathione (GSH) and we demonstrated that N-acetyl L-cysteine (NAC), a precursor to GSH, protected cells from Fas-mediated killing. Taken together, AHM is a powerful approach for the identification of inhibitors of a signaling pathway with a low rate of false positives that opens new avenues for function profiling of human genes and discovery of new drug targets.	Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA; Quark Biotech Inc, Cleveland, OH 44106 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Deiss, LP (corresponding author), Univ Illinois, Dept Mol Genet, M-C 669,900 S Ashland Ave, Chicago, IL 60607 USA.	Ldeiss@uic.edu						Asher G, 2001, P NATL ACAD SCI USA, V98, P1188, DOI 10.1073/pnas.021558898; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Begleiter A, 1997, ONCOL RES, V9, P371; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Cross JV, 1999, J BIOL CHEM, V274, P31150, DOI 10.1074/jbc.274.44.31150; De Flora S, 2001, CARCINOGENESIS, V22, P999, DOI 10.1093/carcin/22.7.999; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Hitoshi Y, 1998, IMMUNITY, V8, P461, DOI 10.1016/S1074-7613(00)80551-8; Holmstrom TH, 1999, MOL CELL BIOL, V19, P5991; HOSODA S, 1974, J BIOL CHEM, V249, P6416; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jaiswal AK, 2000, FREE RADICAL BIO MED, V29, P254, DOI 10.1016/S0891-5849(00)00306-3; JOSEPH P, 1994, ONCOL RES, V6, P525; Kazama H, 2000, J CELL BIOL, V148, P557, DOI 10.1083/jcb.148.3.557; Kimchi A, 1998, BBA-REV CANCER, V1377, pF13, DOI 10.1016/S0304-419X(98)00002-X; KISSIL JL, 1995, J BIOL CHEM, V270, P27932, DOI 10.1074/jbc.270.46.27932; Ko BCB, 2000, BIOCHEM BIOPH RES CO, V270, P52, DOI 10.1006/bbrc.2000.2376; Krause D, 2001, J BIOL CHEM, V276, P19244, DOI 10.1074/jbc.M008186200; LevyStrumpf N, 1997, MOL CELL BIOL, V17, P1615, DOI 10.1128/MCB.17.3.1615; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Meyer UA, 1996, J PHARMACOKINET BIOP, V24, P449, DOI 10.1007/BF02353473; Miyakawa H, 1999, P NATL ACAD SCI USA, V96, P2538, DOI 10.1073/pnas.96.5.2538; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Moinova HR, 1999, BIOCHEM BIOPH RES CO, V261, P661, DOI 10.1006/bbrc.1999.1109; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; Ohtsubo T, 1999, CELL DEATH DIFFER, V6, P865, DOI 10.1038/sj.cdd.4400566; Pinkoski MJ, 1999, CELL DEATH DIFFER, V6, P1174, DOI 10.1038/sj.cdd.4400611; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; Salinas AE, 1999, CURR MED CHEM, V6, P279; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Siemankowski LM, 2000, CANCER RES, V60, P3638; Stark GR, 1999, HUM MOL GENET, V8, P1925, DOI 10.1093/hmg/8.10.1925; TEWARI M, 1995, J BIOL CHEM, V270, P22705, DOI 10.1074/jbc.270.39.22705; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Yu R, 1999, J BIOL CHEM, V274, P27545, DOI 10.1074/jbc.274.39.27545; Yu R, 2000, J BIOL CHEM, V275, P2322, DOI 10.1074/jbc.275.4.2322; Yu R, 2000, J BIOL CHEM, V275, P39907, DOI 10.1074/jbc.M004037200	44	67	73	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2003	22	6					797	806		10.1038/sj.onc.1206077	http://dx.doi.org/10.1038/sj.onc.1206077			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584558				2022-12-28	WOS:000180864300001
J	Shimizu, H; Seiki, T; Asada, M; Yoshimatsu, K; Koyama, N				Shimizu, H; Seiki, T; Asada, M; Yoshimatsu, K; Koyama, N			alpha 6 beta 1 integrin induces proteasome-mediated cleavage of erbB2 in breast cancer cells	ONCOGENE			English	Article						integrin; erbB2; proteasome; breast cancer	EPIDERMAL-GROWTH-FACTOR; EGF RECEPTOR; ALPHA(2)BETA(1) INTEGRIN; P185(HER2) ONCOPROTEIN; DIFFERENTIATION FACTOR; PROTOONCOGENE PRODUCT; EXTRACELLULAR DOMAIN; CARCINOMA; ACTIVATION; EXPRESSION	ErbB2 and alpha6 integrin have been implicated in malignancy of breast cancer cells. Here we have determined the influence of alpha6beta1 integrin on erbB2 signaling in anchorage-independent growth, using MDA-MB435 breast cancer cells. Firstly, we transfected the cells with erbB2 cDNA, and isolated cells with high or low levels of alpha6beta1 integrin by cell sorting (alpha6H-ErbB and alpha6L-ErbB). We found that an erbB ligand, heregulin beta1, enhanced growth activity of alpha6L-ErbB cells, but not alpha6H-ErbB cells. Secondly, we established cells expressing a beta4 integrin deletion mutant (beta4-Deltacyt), which selectively inhibited alpha6beta1 integrin expression and adhesion to laminin-1. Again, heregulin beta1 enhanced the growth of erbB2 cDNA-transfected beta4-Deltacyt cells, but not mock cells. Western blot analysis revealed that heregulin beta1 stimulated phosphorylation of Akt and its downstream molecules, GSK3beta and p70S6kinase, and that the extent of phosphorylation was greater in ErbB2/beta4-Deltacyt cells than ErbB2/mock cells. Furthermore, we found that the erbB2 cytoplasmic domain was truncated in ErbB2/mock cells, which was independent of ligand stimulation and adhesion, and was suppressed by proteasome inhibitors. These results suggest that alpha6beta1 integrin inhibits erbB2 signals by inducing proteasome-dependent proteolytic cleavage of the erbB2 cytoplasmic domain, and may thereby contribute to the regulation of tumor growth.	Eisai & Co Ltd, Tsukuba Res Labs, Tsukuba, Ibaraki 3002635, Japan	Eisai Co Ltd	Shimizu, H (corresponding author), Eisai & Co Ltd, Tsukuba Res Labs, 5-1-3 Tokodai, Tsukuba, Ibaraki 3002635, Japan.	h4-shimizu@hhc.eisai.co.jp		Koyama, Noriyuki/0000-0002-7509-6583				Adelsman MA, 1999, MOL BIOL CELL, V10, P2861, DOI 10.1091/mbc.10.9.2861; Aguilar Z, 1999, ONCOGENE, V18, P6050, DOI 10.1038/sj.onc.1202993; Amundadottir LT, 1998, ONCOGENE, V16, P737, DOI 10.1038/sj.onc.1201829; Bachelder RE, 1999, J CELL BIOL, V147, P1063, DOI 10.1083/jcb.147.5.1063; Bao WJ, 2002, MOL CELL BIOL, V22, P4587, DOI 10.1128/MCB.22.13.4587-4597.2002; Baron V, 2000, J BIOL CHEM, V275, P39318, DOI 10.1074/jbc.M003618200; Bialkowska K, 2000, J CELL BIOL, V151, P685, DOI 10.1083/jcb.151.3.685; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; CAMPIGLIO M, 1994, J CELL BIOCHEM, V55, P409, DOI 10.1002/jcb.240550402; Carrano AC, 2001, J CELL BIOL, V153, P1381, DOI 10.1083/jcb.153.7.1381; Christianson TA, 1998, CANCER RES, V58, P5123; CLARKE AS, 1995, J BIOL CHEM, V270, P22673, DOI 10.1074/jbc.270.39.22673; Codony-Servat J, 1999, CANCER RES, V59, P1196; DANILENKO DM, 1995, J CLIN INVEST, V95, P842, DOI 10.1172/JCI117734; Falcioni R, 1997, EXP CELL RES, V236, P76, DOI 10.1006/excr.1997.3695; FRIEDRICHS K, 1995, CANCER RES, V55, P901; Gambaletta D, 2000, J BIOL CHEM, V275, P10604, DOI 10.1074/jbc.275.14.10604; Hammond DE, 2001, ONCOGENE, V20, P2761, DOI 10.1038/sj.onc.1204475; Hijazi MM, 2000, INT J ONCOL, V17, P629; Hintermann E, 2001, J CELL BIOL, V153, P465, DOI 10.1083/jcb.153.3.465; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; KOUKOULIS GK, 1991, AM J PATHOL, V139, P787; Kozlova NI, 2001, ONCOGENE, V20, P4710, DOI 10.1038/sj.onc.1204619; Krane IM, 1996, ONCOGENE, V12, P1781; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; Lee YJ, 1999, J BIOL CHEM, V274, P22401, DOI 10.1074/jbc.274.32.22401; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; LICHTNER RB, 1995, ONCOGENE, V10, P1823; LIN YZJ, 1991, ONCOGENE, V6, P639; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Manenti S, 2002, BIOCHEM BIOPH RES CO, V294, P976, DOI 10.1016/S0006-291X(02)00594-6; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; MORI S, 1995, J BIOL CHEM, V270, P29447, DOI 10.1074/jbc.270.49.29447; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Mukhopadhyay R, 1999, CLIN EXP METASTAS, V17, P325; NATALI PG, 1992, BRIT J CANCER, V66, P318, DOI 10.1038/bjc.1992.263; Neve RM, 2000, ONCOGENE, V19, P1647, DOI 10.1038/sj.onc.1203470; O'Connor KL, 1998, J CELL BIOL, V143, P1749, DOI 10.1083/jcb.143.6.1749; Ojaniemi M, 1997, J BIOL CHEM, V272, P3780, DOI 10.1074/jbc.272.6.3780; Perez-Tenorio G, 2002, BRIT J CANCER, V86, P540, DOI 10.1038/sj.bjc.6600126; PIGNATELLI M, 1991, J PATHOL, V165, P25, DOI 10.1002/path.1711650106; Plath T, 2000, J CELL BIOL, V150, P1467, DOI 10.1083/jcb.150.6.1467; PUPA SM, 1993, ONCOGENE, V8, P2917; Renshaw MW, 1999, J CELL BIOL, V147, P611, DOI 10.1083/jcb.147.3.611; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Shimizu H, 2002, INT J ONCOL, V21, P1073; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Sun H, 1998, CANCER RES, V58, P2224; Tagliabue E, 1996, BRIT J CANCER, V74, P1427, DOI 10.1038/bjc.1996.560; Tagliabue E, 1998, CLIN CANCER RES, V4, P407; Tan M, 1997, CANCER RES, V57, P1199; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; TZAHAR E, 1998, BIOCHIM BIOPHYS ACTA, V1377, P25; Vafa A, 1998, INT J ONCOL, V13, P1191; VARNER JA, 1995, MOL BIOL CELL, V6, P725, DOI 10.1091/mbc.6.6.725; Vogelmann R, 1999, INT J CANCER, V80, P791, DOI 10.1002/(SICI)1097-0215(19990301)80:5<791::AID-IJC25>3.0.CO;2-4; Wang F, 1998, P NATL ACAD SCI USA, V95, P14821, DOI 10.1073/pnas.95.25.14821; Wewer UM, 1997, AM J PATHOL, V151, P1191; Xu FJ, 1997, CLIN CANCER RES, V3, P1629; Yarwood SJ, 2001, P NATL ACAD SCI USA, V98, P4472, DOI 10.1073/pnas.081069098; Yebra M, 1999, EXP CELL RES, V250, P231, DOI 10.1006/excr.1999.4510; Yu DH, 1996, ONCOGENE, V13, P1359; Yu X, 2000, J CELL SCI, V113, P2139; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027; ZUTTER MM, 1995, P NATL ACAD SCI USA, V92, P7411, DOI 10.1073/pnas.92.16.7411	68	12	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2003	22	6					831	839		10.1038/sj.onc.1206203	http://dx.doi.org/10.1038/sj.onc.1206203			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584562				2022-12-28	WOS:000180864300005
J	Carboni, GL; Gao, BN; Nishizaki, M; Xu, K; Minna, JD; Roth, JA; Ji, L				Carboni, GL; Gao, BN; Nishizaki, M; Xu, K; Minna, JD; Roth, JA; Ji, L			CACNA2D2-mediated apoptosis in NSCLC cells is associated with alterations of the intracellular calcium signaling and disruption of mitochondria membrane integrity	ONCOGENE			English	Article						tumor suppressor genes; apoptosis; calcium channel proteins; human chromosome 3p21.3; lung cancer	CHANNEL SUBUNIT; GABAPENTIN BINDING; CHROMOSOME 3P21.3; TUMOR-SUPPRESSOR; CA2+ HOMEOSTASIS; MULTIPLE GENES; CYTOCHROME-C; ALPHA(2)DELTA; RELEASE; DEATH	The CACNA2D2 gene, a new subunit of the Ca2+-channel complex, was identified in the homozygous deletion region of chromosome 3p21.3 in human lung and breast cancers. Expression deficiency of the CACNA2D2 in cancer cells suggests a possible link of it to Ca2+ signaling in the pathogenesis of lung cancer and other cancers. We investigated the effects of overexpression of CACNA2D2 on intracellular Ca2+ contents, mitochondria homeostasis, cell proliferation, and apoptosis by adenoviral vector-mediated wild-type CACNA2D2 gene transfer in 3p21.3-deficient nonsmall cell lung cancer cell lines. Exogenous expression of CACNA2D2 significantly inhibited tumor cell growth compared with the controls. Overexpression of CACNA2D2 induced apoptosis in H1299 (12.5%), H358 (13.7%), H460 (22.3%), and A549 (50.1%) cell lines. Levels of intracellular free Ca2+ were elevated in AdCACNA2D2-transduced cells compared with the controls. Mitochondria membrane depolarization was observed prior to apoptosis in Ad-CACNA2D2 and Adp53-transduced H460 and A549 cells. Release of cyt c into the cytosol, caspase 3 activation, and PARP cleavage were also detected in these cells. Together, these results suggest that one of the pathways in CACNA2D2-induced apoptosis is mediated through disruption of mitochondria membrane integrity, the release of cyt c, and the activation of caspases, a process that is associated with regulation of cytosolic free Ca2+ contents.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Sect Thorac Mol Oncol, Houston, TX 77030 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dept Internal Med & Pharmacol, Dallas, TX 75390 USA; Univ Hosp Bern, Div Gen Thorac Surg, Bern, Switzerland	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Bern; University Hospital of Bern	Ji, L (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, 1515 Holcombe Blvd,Box 445, Houston, TX 77030 USA.		Carboni, Giovanni/AAA-1780-2021	Carboni, Giovanni/0000-0003-3969-1227	NCI NIH HHS [P01 CA78778-01A1, R01 CA071618, CA16672, 2P50-CA70907-04, P50 CA070907, P30 CA016672, P01 CA078778, CA71618] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA071618, P50CA070907, P01CA078778] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Angeloni D, 2000, MOL CELL PROBE, V14, P53, DOI 10.1006/mcpr.1999.0277; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Barclay J, 2001, J NEUROSCI, V21, P6095, DOI 10.1523/JNEUROSCI.21-16-06095.2001; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Brown JP, 1998, J BIOL CHEM, V273, P25458, DOI 10.1074/jbc.273.39.25458; Burgess DL, 1999, GENOME RES, V9, P1204, DOI 10.1101/gr.9.12.1204; CASTELLANO A, 1993, J BIOL CHEM, V268, P3450; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Chen Q, 2000, CELL DEATH DIFFER, V7, P227, DOI 10.1038/sj.cdd.4400629; COSSARIZZA A, 1995, BIOCHEM BIOPH RES CO, V214, P503, DOI 10.1006/bbrc.1995.2315; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Felix R, 1999, RECEPTOR CHANNEL, V6, P351; Fondon JW, 1998, P NATL ACAD SCI USA, V95, P7514, DOI 10.1073/pnas.95.13.7514; Gao BN, 2000, J BIOL CHEM, V275, P12237, DOI 10.1074/jbc.275.16.12237; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hobom M, 2000, EUR J NEUROSCI, V12, P1217, DOI 10.1046/j.1460-9568.2000.01009.x; Hofmann F, 1999, REV PHYSIOL BIOCH P, V139, P33, DOI 10.1007/BFb0033648; Hurley JF, 2000, P NATL ACAD SCI USA, V97, P9293, DOI 10.1073/pnas.160589697; Ji L, 1999, CANCER RES, V59, P3333; KAO JPY, 1989, J BIOL CHEM, V264, P8179; Klugbauer N, 1999, J NEUROSCI, V19, P684; Kochegarov AA, 2001, COMP BIOCHEM PHYS A, V128, P279, DOI 10.1016/S1095-6433(00)00306-8; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lacinova L, 2000, GEN PHYSIOL BIOPHYS, V19, P121; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Lerman MI, 2000, CANCER RES, V60, P6116; Marais E, 2001, MOL PHARMACOL, V59, P1243, DOI 10.1124/mol.59.5.1243; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Nishizaki M, 2001, CLIN CANCER RES, V7, P2887; Raveh T, 2001, EXP CELL RES, V264, P185, DOI 10.1006/excr.2000.5134; Reed JC, 2000, CELL DEATH DIFFER, V7, P1145, DOI 10.1038/sj.cdd.4400777; Rutter GA, 2000, TRENDS BIOCHEM SCI, V25, P215, DOI 10.1016/S0968-0004(00)01585-1; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; Toyota M, 1999, CANCER RES, V59, P4535; Ueki T, 2000, CANCER RES, V60, P1835; Varadi G, 1999, CRIT REV BIOCHEM MOL, V34, P181, DOI 10.1080/10409239991209264; Vieira HLA, 2000, CELL DEATH DIFFER, V7, P1146, DOI 10.1038/sj.cdd.4400778; Von Ahsen O, 2000, CELL DEATH DIFFER, V7, P1192, DOI 10.1038/sj.cdd.4400782; Walker D, 1998, TRENDS NEUROSCI, V21, P148, DOI 10.1016/S0166-2236(97)01200-9; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang MH, 1999, BIOCHEM J, V342, P313, DOI 10.1042/0264-6021:3420313; Zhu LP, 2000, CELL CALCIUM, V28, P107, DOI 10.1054/ceca.2000.0138; Zhu LP, 1999, J BIOL CHEM, V274, P33267, DOI 10.1074/jbc.274.47.33267; Zochbauer-Muller S, 2001, CANCER RES, V61, P249	46	57	63	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 30	2003	22	4					615	626		10.1038/sj.onc.1206134	http://dx.doi.org/10.1038/sj.onc.1206134			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555074	Green Accepted			2022-12-28	WOS:000180538200014
J	Fujita, M; Ichinose, S; Kiyono, T; Tsurumi, T; Omori, A				Fujita, M; Ichinose, S; Kiyono, T; Tsurumi, T; Omori, A			Establishment of latrunculin-A resistance in HeLa cells by expression of R183A D184A mutant beta-actin	ONCOGENE			English	Article							CYTOCHALASIN; MOTILITY; YEAST	Actin plays central roles in cell motility through formation of the actin cytoskeleton. Recently, the very intriguing possibility that actin also contributes to processes in the cell nucleus has been emerging. To dissect its dynamics and functions, several actin-disrupting drugs have been widely and effectively employed. Among them, latrunculin-A has proved particularly useful, supplanting the classical drug cytochalasin-D. One reason is that latrunculin-A appears to bind only to actin monomers impairing the nucleotide exchange, the mode being simpler than with cytochalasin. This property may be especially crucial when studying actin functions as a monomer, as suggested for nuclear actin. Very importantly, actin mutations that cause cells to become resistant to the effects of latrunculin-A have been identified in budding yeast. However, it remains controversial as to whether all of the various phenotypes observed with latrunculin in mammalian cells more complicated than yeast are truly the consequence of its specific actions against actin. Here, we show that the expression of R183A D184A mutant beta-actin specifically confers resistance to the effects of latrunculin-A on actin cytoskeleton formation and cell growth in HeLa cells. The established system provides a strong tool to address the various functions of actin in mammalian cells.			Fujita, M (corresponding author), Natl Canc Ctr, Virol Div, Chuoh Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	mafujita@gan2.res.ncc.go.jp	Kiyono, Tohru/H-5834-2011	Fujita, Masatoshi/0000-0001-6617-2452				Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; COUE M, 1987, FEBS LETT, V213, P316, DOI 10.1016/0014-5793(87)81513-2; Kimura T, 2000, GENES CELLS, V5, P289, DOI 10.1046/j.1365-2443.2000.00326.x; Lamaze C, 1997, J BIOL CHEM, V272, P20332, DOI 10.1074/jbc.272.33.20332; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Morales M, 2000, NEURON, V27, P539, DOI 10.1016/S0896-6273(00)00064-7; Morton WM, 2000, NAT CELL BIOL, V2, P376, DOI 10.1038/35014075; OHMORI H, 1992, J CELL BIOL, V116, P933, DOI 10.1083/jcb.116.4.933; Rando OJ, 2000, TRENDS CELL BIOL, V10, P92, DOI 10.1016/S0962-8924(99)01713-4; SPECTOR I, 1983, SCIENCE, V219, P493, DOI 10.1126/science.6681676; TOYAMA S, 1984, CELL, V37, P609, DOI 10.1016/0092-8674(84)90391-X; Wasser M, 2000, NAT CELL BIOL, V2, P268, DOI 10.1038/35010535; WERTMAN KF, 1992, GENETICS, V132, P337; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	14	12	12	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2003	22	4					627	631		10.1038/sj.onc.1206173	http://dx.doi.org/10.1038/sj.onc.1206173			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555075				2022-12-28	WOS:000180538200015
J	Vandesompele, J; Edsjo, A; De Preter, K; Axelson, H; Speleman, F; Pahlman, S				Vandesompele, J; Edsjo, A; De Preter, K; Axelson, H; Speleman, F; Pahlman, S			ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value	ONCOGENE			English	Article						ID2; MYC; MYCN; neuroblastoma; prognosis	N-MYC; GENE-EXPRESSION; PROTEINS; CELLS	The MYCN proto-oncogene is frequently amplified in a subgroup of highly aggressive neuroblastomas. The molecular mechanism(s) by which the overexpressed MYCN contributes to an aggressive tumor cell behavior is not well understood. Recently, it was reported that the ID2 gene is a direct target for the MYCN and MYC transcription factors, and that ID2 expression and MYCN amplification correlate positively in neuroblastoma. In addition, ID2 expression was proposed as a negative prognostic parameter. As these results are of potential clinical importance, but not in agreement with our own initial observations, the putative correlation between ID2 and MYC(N) expression in neuroblastoma cell lines and tumors was reinvestigated. We found no correlation between MYCN and ID2 expression in neuroblastoma cell lines or tumor specimens. However, we did find a significant positive correlation between MYC and ID2 expressions in both MYCN-amplified and single-copy tumor specimens, and in MYCN single-copy cell lines. As previously reported, we also found an inverse correlation between MYC and MYCN expressions. Importantly, we could not confirm the reported prognostic power of ID2-expression in neuroblastoma. These data, obtained in two independent laboratories, challenge the previously proposed ID2-MYCN relation.	Lund Univ, Univ Hosp MAS, Dept Lab Med, Div Mol Med, S-20502 Malmo, Sweden; Ghent Univ Hosp, Ctr Med Genet, B-9000 Ghent, Belgium	Lund University; Skane University Hospital; Ghent University; Ghent University Hospital	Pahlman, S (corresponding author), Lund Univ, Univ Hosp MAS, Dept Lab Med, Div Mol Med, Entrance 78, S-20502 Malmo, Sweden.	sven.pahlman@molmed.mas.lu.se	Edsjö, Anders/AAC-8658-2019; speleman, frank/AAR-5184-2020; De Preter, Katleen/I-7135-2013; Vandesompele, Jo/W-3411-2018	speleman, frank/0000-0002-6628-8559; De Preter, Katleen/0000-0002-7726-5096; Vandesompele, Jo/0000-0001-6274-0184				Bown N, 2001, J CLIN PATHOL, V54, P897, DOI 10.1136/jcp.54.12.897; BREIT S, 1989, J NEUROSCI RES, V24, P21, DOI 10.1002/jnr.490240105; De Preter K, 2002, MODERN PATHOL, V15, P159, DOI 10.1038/modpathol.3880508; Hoehner JC, 1998, LAB INVEST, V78, P29; Hoehner JC, 1996, LAB INVEST, V75, P659; Jogi A, 2002, P NATL ACAD SCI USA, V99, P7021, DOI 10.1073/pnas.102660199; Jogi A, 2002, J BIOL CHEM, V277, P9118, DOI 10.1074/jbc.M107713200; Judware R, 1995, ONCOGENE, V11, P2599; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lasorella A, 2002, CANCER RES, V62, P301; Lasorella A, 2001, ONCOGENE, V20, P8326, DOI 10.1038/sj.onc.1205093; Lutz W, 1996, ONCOGENE, V13, P803; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; Reiter JL, 1998, GENE CHROMOSOME CANC, V23, P134, DOI 10.1002/(SICI)1098-2264(199810)23:2<134::AID-GCC6>3.0.CO;2-3; SAWAI S, 1993, DEVELOPMENT, V117, P1445; Vandesompele J, 2002, ANAL BIOCHEM, V303, P95, DOI 10.1006/abio.2001.5564; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Wakamatsu Y, 1997, DEVELOPMENT, V124, P1953; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Zebedee Z, 2001, ONCOGENE, V20, P8317, DOI 10.1038/sj.onc.1205092	20	35	35	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2003	22	3					456	460		10.1038/sj.onc.1206148	http://dx.doi.org/10.1038/sj.onc.1206148			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545167				2022-12-28	WOS:000180379100015
J	Demeret, C; Garcia-Carranca, A; Thierry, F				Demeret, C; Garcia-Carranca, A; Thierry, F			Transcription-independent triggering of the extrinsic pathway of apoptosis by human papillomavirus 18 E2 protein	ONCOGENE			English	Article						HPV18 E2; apoptosis; caspases; extrinsic pathway; transactivation domain	CERVICAL-CARCINOMA; TRANSACTIVATION DOMAIN; CASPASE FAMILY; HELA-CELLS; TYPE-16; ACTIVATION; E6; PROLIFERATION; DEGRADATION; ONCOPROTEIN	Cervical carcinomas are most frequently associated with human papillomaviruses (HPV), whose E6 and E7 oncogenes products induce cellular immortalization. The papillomavirus E2 protein is a transcription factor, which represses the expression of the viral oncogenes, and activates viral DNA replication during the vegetative viral cycle. This protein is specifically inactivated in HPV18-associated carcinoma cells, suggesting that E2 functions prevent carcinogenic progression. Indeed, ectopic expression of E2 in cervical carcinoma cells strongly inhibits cell proliferation. Here we show that above a threshold level of expression, the E2 protein induces apoptosis, independently of other viral functions. The amino-terminal domain is responsible for this apoptotic activity, but surprisingly with no involvement of its transcriptional functions. The death pathway triggered by E2 relies on activation of the initiator caspase 8, specific of the extrinsic pathway of apoptosis. E2 itself is cleaved by caspases during cell death, providing an example of an apoptotic inducer that is itself a target for caspase processing. The autonomous proapoptotic activity of HPV18 E2 described here may counteract the proliferative functions of viral oncogenes, and renders the inactivation of E2 crucial for carcinogenic progression.	Inst Pasteur, Unit Gene Express & Dis, URA 1644, CNRS, F-75724 Paris 15, France; Univ Nacl Autonoma Mexico, Inst Invest Biomed, Mexico City, DF, Mexico	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universidad Nacional Autonoma de Mexico	Demeret, C (corresponding author), Inst Pasteur, Unit Gene Express & Dis, URA 1644, CNRS, Fernbach Bldg,25 Rue Dr Roux, F-75724 Paris 15, France.			Demeret, caroline/0000-0002-1103-6805				Antson AA, 2000, NATURE, V403, P805, DOI 10.1038/35001638; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bellanger S, 2001, J VIROL, V75, P7244, DOI 10.1128/JVI.75.16.7244-7251.2001; Corden SA, 1999, J CLIN PATHOL-MOL PA, V52, P275, DOI 10.1136/mp.52.5.275; Crouzet J, 1997, P NATL ACAD SCI USA, V94, P1414, DOI 10.1073/pnas.94.4.1414; DARZYNKIEWICZ Z, 1994, METHODS CELL BIOL; Desaintes C, 1999, ONCOGENE, V18, P4538, DOI 10.1038/sj.onc.1202818; Desaintes C, 1996, SEMIN CANCER BIOL, V7, P339, DOI 10.1006/scbi.1996.0043; Desaintes C, 1997, EMBO J, V16, P504, DOI 10.1093/emboj/16.3.504; DOWHANICK JJ, 1995, J VIROL, V69, P7791, DOI 10.1128/JVI.69.12.7791-7799.1995; Drewett V, 2001, J BIOL CHEM, V276, P33444, DOI 10.1074/jbc.M103877200; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P10978, DOI 10.1073/pnas.97.20.10978; HWANG ES, 1993, J VIROL, V67, P3720, DOI 10.1128/JVI.67.7.3720-3729.1993; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Levkau B, 1999, NAT CELL BIOL, V1, P227, DOI 10.1038/12050; Maitland NJ, 1998, J PATHOL, V186, P275, DOI 10.1002/(SICI)1096-9896(1998110)186:3&lt;275::AID-PATH159&gt;3.0.CO;2-E; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; THIERRY F, 1990, MOL CELL BIOL, V10, P4431, DOI 10.1128/MCB.10.8.4431; THIERRY F, 1987, EMBO J, V6, P3391, DOI 10.1002/j.1460-2075.1987.tb02662.x; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Webster K, 2000, J BIOL CHEM, V275, P87, DOI 10.1074/jbc.275.1.87; Weil M, 1999, CURR BIOL, V9, P361, DOI 10.1016/S0960-9822(99)80162-6; Wells SI, 2000, EMBO J, V19, P5762, DOI 10.1093/emboj/19.21.5762; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049	27	67	79	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 16	2003	22	2					168	175		10.1038/sj.onc.1206108	http://dx.doi.org/10.1038/sj.onc.1206108			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527886				2022-12-28	WOS:000180322400002
J	Arlinghaus, RB				Arlinghaus, RB			Bcr: a negative regulator of the Bcr-Abi oncoprotein in leukemia	ONCOGENE			English	Article						chronic myelogenous leukemia (CML); Bcr-Abl oncoprotein; phosphoserine Bcr; inhibition of Bcr-Abl	PHOSPHOTYROSINE-DEPENDENT MANNER; MUSCLE PYRUVATE-KINASE; SH2 DOMAIN; C-ABL; TYROSINE PHOSPHORYLATION; FIRST EXON; P160 BCR; PROTEIN; SEQUENCES; CELLS	The fusion of 5' parts of the BCR gene to the ABL gene at the second exon yields several forms of an oncogenic Bcr-Abl oncoprotein observed in several types of Philadelphia chromosome positive leukemia patients. The first exon of the BCR gene is a critical part of this fusion, as the coiled-coil domain at the amino terminal domain of the Bcr protein causes oligomerization of the Bcr-Abl oncoprotein forming tetramers, thereby activating the tyrosine kinase activity of the normally silent c-Abl protein. Another consequence of this Ber-Abl fusion is the extensive autophosphorylation of the cis Bcr protein sequences on tyrosine residues. This review will summarize the effects of Bcr-Abl autophosphorylation on tyrosines as they relate to the oncogenic activity of Bcr-Abl, and as a means to inactivate the serine/threonine kinase activity of the Bcr protein. The review also discusses our findings that show that phosphoserine Bcr by means of a unique structure, binds to the Abl SH2 domain of the Bcr-Abl oncoprotein, and as a result this SH2 binding inhibits the oncogenic effects of the oncoprotein. Our results indicate that one effect of this binding is inhibition of the Bcr-Abl tyrosine kinase. Serine 354 of Bcr plays a major role in this inhibition. In the case of Bcr(64-413), serine 354 is required for the formation of the unique Bcr structure that binds to the Abl SH2 domain.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Arlinghaus, RB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA49639, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, P01CA049639] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANNAMALAI AE, 1981, J BIOL CHEM, V256, P276; Arlinghaus RB, 1998, CRIT REV ONCOGENESIS, V9, P1; CAMPBELL ML, 1990, ONCOGENE, V5, P773; Che W, 2001, CIRCULATION, V104, P1399, DOI 10.1161/hc3701.095581; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; Hawk N, 2002, CANCER RES, V62, P386; He YP, 2002, BLOOD, V99, P2957, DOI 10.1182/blood.V99.8.2957; KLOETZER W, 1985, VIROLOGY, V140, P230, DOI 10.1016/0042-6822(85)90361-7; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; LI WJ, 1989, ONCOGENE, V4, P127; Lin F, 2001, ONCOGENE, V20, P1873, DOI 10.1038/sj.onc.1204409; Liu JX, 1996, CANCER RES, V56, P5120; Liu JX, 1996, MOL CELL BIOL, V16, P998; LIU JX, 1993, ONCOGENE, V8, P101; LU D, 1993, BLOOD, V82, P1257; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; McWhirter JR, 1997, ONCOGENE, V15, P1625, DOI 10.1038/sj.onc.1201342; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; Park I, 1995, P NATL ACAD SCI USA, V92, P12338, DOI 10.1073/pnas.92.26.12338; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; Pluk H, 2002, CELL, V108, P247, DOI 10.1016/S0092-8674(02)00623-2; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; Sun T, 2001, BIOPOLYMERS, V60, P61, DOI 10.1002/1097-0282(2001)60:1<61::AID-BIP1004>3.0.CO;2-4; TOMICH JM, 1981, BIOCHEMISTRY-US, V20, P6711, DOI 10.1021/bi00526a029; Wang Y, 2001, CANCER RES, V61, P138; Wu Y, 1999, ONCOGENE, V18, P4416, DOI 10.1038/sj.onc.1202828; Wu Y, 1998, ONCOGENE, V16, P141, DOI 10.1038/sj.onc.1201524; Zhang XW, 2001, MOL CELL BIOL, V21, P840, DOI 10.1128/MCB.21.3.840-853.2001	32	23	26	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	2002	21	56					8560	8567		10.1038/sj.onc.1206083	http://dx.doi.org/10.1038/sj.onc.1206083			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZF	12476302				2022-12-28	WOS:000179734300005
J	Druker, BJ				Druker, BJ			Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML	ONCOGENE			English	Article						Bcr-Abl; tyrosine kinase; inhibitor; CML; STI571	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; IMATINIB MESYLATE; CYTOGENETIC RESPONSES; BLAST CRISIS; ERYTHROID-DIFFERENTIATION; CLINICAL RESISTANCE; CELL-PROLIFERATION; POSITIVE LEUKEMIA		Oregon Hlth & Sci Univ, Inst Canc, Portland, OR 97239 USA	Oregon Health & Science University	Druker, BJ (corresponding author), Oregon Hlth & Sci Univ, Inst Canc, L592,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.			Druker, Brian/0000-0001-8331-8206				ANAFI M, 1993, BLOOD, V82, P3524; Beran M, 1998, CLIN CANCER RES, V4, P1661; BOUTIN JA, 1994, INT J BIOCHEM, V26, P1203, DOI 10.1016/0020-711X(94)90091-4; Branford S, 2002, BLOOD, V99, P3472, DOI 10.1182/blood.V99.9.3472; Buchdunger E, 2001, BBA-REV CANCER, V1551, pM11, DOI 10.1016/S0304-419X(01)00022-1; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; Casnellie J E, 1991, Adv Pharmacol, V22, P167, DOI 10.1016/S1054-3589(08)60035-6; CHANG CJ, 1992, J NAT PROD, V55, P1529, DOI 10.1021/np50089a001; Corbin AS, 2002, J BIOL CHEM, V277, P32214, DOI 10.1074/jbc.M111525200; Corbin AS, 2000, BLOOD, V96, p470A; Deininger MWN, 1997, BLOOD, V90, P3691, DOI 10.1182/blood.V90.9.3691; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809a0; Dorsey JF, 2000, CANCER RES, V60, P3127; Druker B.J, 2002, P AN M AM SOC CLIN, V21, P1; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; GambacortiPasserini C, 1997, BLOOD CELL MOL DIS, V23, P380, DOI 10.1006/bcmd.1997.0155; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Graham SM, 2002, BLOOD, V99, P319, DOI 10.1182/blood.V99.1.319; HOCHHAUS A, 2002, IN PRESS LEUKEMIA; Hofmann WK, 2002, BLOOD, V99, P1860, DOI 10.1182/blood.V99.5.1860; Holtz MS, 2002, BLOOD, V99, P3792, DOI 10.1182/blood.V99.10.3792; HONMA Y, 1990, JPN J CANCER RES, V81, P1132, DOI 10.1111/j.1349-7006.1990.tb02524.x; HONMA Y, 1989, CANCER RES, V49, P331; Hoover RR, 2002, BLOOD, V100, P1068, DOI 10.1182/blood.V100.3.1068; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; Kasper B, 1999, CANCER CHEMOTH PHARM, V44, P433, DOI 10.1007/s002800051001; KAUR G, 1994, ANTI-CANCER DRUG, V5, P213, DOI 10.1097/00001813-199404000-00013; KAWADA M, 1993, DRUG EXP CLIN RES, V19, P235; La Rosee P, 2002, EXP HEMATOL, V30, P729, DOI 10.1016/S0301-472X(02)00836-6; le Coutre P, 1999, J NATL CANCER I, V91, P163, DOI 10.1093/jnci/91.2.163; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Marley SB, 2000, EXP HEMATOL, V28, P551, DOI 10.1016/S0301-472X(00)00142-9; Mow BMF, 2002, BLOOD, V99, P664, DOI 10.1182/blood.V99.2.664; NICHOLS GL, 1994, BLOOD, V84, P2912; ODA T, 1994, J BIOL CHEM, V269, P22925; Okuda K, 2001, BLOOD, V97, P2440, DOI 10.1182/blood.V97.8.2440; Ottmann OG, 2002, BLOOD, V100, P1965, DOI 10.1182/blood-2001-12-0181; PENG B, 2001, P AN M AM SOC CLIN, V20, pA280; Porosnicu M, 2001, LEUKEMIA, V15, P772, DOI 10.1038/sj.leu.2402104; Roche-Lestienne C, 2002, BLOOD, V100, P1014, DOI 10.1182/blood.V100.3.1014; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; Sawyers CL, 2002, BLOOD, V99, P3530, DOI 10.1182/blood.V99.10.3530; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; Senechal K, 1998, MOL CELL BIOL, V18, P5082, DOI 10.1128/MCB.18.9.5082; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; Soriano P, 1997, DEVELOPMENT, V124, P2691; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; Sun XM, 2001, BLOOD, V97, P2008, DOI 10.1182/blood.V97.7.2008; Talpaz M, 2002, BLOOD, V99, P1928, DOI 10.1182/blood.V99.6.1928; TENHOEVE J, 1994, BLOOD, V84, P1731; Topaly J, 2001, BLOOD, V98, p617A; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; von Bubnoff N, 2002, LANCET, V359, P487, DOI 10.1016/S0140-6736(02)07679-1; YAISH P, 1988, SCIENCE, V242, P933, DOI 10.1126/science.3263702	59	91	95	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2002	21	56					8541	8546		10.1038/sj.onc.1206081	http://dx.doi.org/10.1038/sj.onc.1206081			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZF	12476300				2022-12-28	WOS:000179734300003
J	Salesse, S; Verfaillie, CM				Salesse, S; Verfaillie, CM			Mechanisms underlying abnormal trafficking and expansion of malignant progenitors in CML: BCR/ABL-induced defects in integrin function in CML	ONCOGENE			English	Article						CML; BCR/ABL; integrin; adhesion; proliferation; molecular mechanisms	CHRONIC MYELOGENOUS LEUKEMIA; DEPENDENT KINASE INHIBITOR; CHRONIC MYELOID-LEUKEMIA; BONE-MARROW STROMA; FOCAL ADHESION PROTEINS; BCR-ABL ONCOPROTEIN; HEMATOPOIETIC PROGENITORS; SIGNAL-TRANSDUCTION; TYROSINE KINASE; MEDIATED ADHESION		Univ Minnesota, Ctr Canc, Stem Cell Inst, Minneapolis, MN 55455 USA; Univ Minnesota, Ctr Canc, Dept Med, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Verfaillie, CM (corresponding author), Univ Minnesota, Ctr Canc, Stem Cell Inst, MMC 708,420 Delaware St SE, Minneapolis, MN 55455 USA.		Verfaillie, Catherine/H-5148-2013	Verfaillie, Catherine/0000-0001-7564-4079				Bazzoni G, 1996, J CLIN INVEST, V98, P521, DOI 10.1172/JCI118820; Bhatia R, 1999, EXP HEMATOL, V27, P1384, DOI 10.1016/S0301-472X(99)00084-3; Bhatia R, 1996, BLOOD, V87, P3883, DOI 10.1182/blood.V87.9.3883.bloodjournal8793883; BHATIA R, 1995, J CLIN INVEST, V96, P931, DOI 10.1172/JCI118141; Bhatia R, 1998, BLOOD, V91, P3414, DOI 10.1182/blood.V91.9.3414.3414_3414_3422; BHATIA R, 1994, J CLIN INVEST, V94, P384, DOI 10.1172/JCI117333; Bhatia R, 1998, LEUKEMIA, V12, P1708, DOI 10.1038/sj.leu.2401193; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CASHMAN J, 1985, BLOOD, V66, P1002; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; EAVES AC, 1986, P NATL ACAD SCI USA, V83, P5306, DOI 10.1073/pnas.83.14.5306; Gesbert F, 2000, J BIOL CHEM, V275, P39223, DOI 10.1074/jbc.M007291200; GORDON MY, 1989, CURR TOP MICROBIOL, V149, P151; GORDON MY, 1987, NATURE, V328, P342, DOI 10.1038/328342a0; GOTOH A, 1995, EXP HEMATOL, V23, P1153; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Hurley RW, 1997, EXP HEMATOL, V25, P321; HURLEY RW, 1995, J CLIN INVEST, V96, P511, DOI 10.1172/JCI118063; Jiang YH, 2000, BLOOD, V95, P846, DOI 10.1182/blood.V95.3.846.003k31_846_854; Jiang YH, 2000, P NATL ACAD SCI USA, V97, P10538, DOI 10.1073/pnas.190104497; Jonuleit T, 2000, BLOOD, V96, P1933, DOI 10.1182/blood.V96.5.1933.h8001933_1933_1939; Kramer A, 1999, P NATL ACAD SCI USA, V96, P2087, DOI 10.1073/pnas.96.5.2087; Lloyd RV, 1999, AM J PATHOL, V154, P313, DOI 10.1016/S0002-9440(10)65277-7; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Lundell BI, 1996, BLOOD, V87, P2450, DOI 10.1182/blood.V87.6.2450.bloodjournal8762450; Lundell BI, 1997, LEUKEMIA, V11, P822, DOI 10.1038/sj.leu.2400653; MATULONIS U, 1993, EXP HEMATOL, V21, P1460; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; NOWELL PC, 1960, SCIENCE, V132, P1497; ODA T, 1994, J BIOL CHEM, V269, P22925; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Rosenbauer F, 2002, EMBO J, V21, P211, DOI 10.1093/emboj/21.3.211; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Salgia R, 1996, EXP HEMATOL, V24, P310; SALGIA R, 1995, ONCOGENE, V11, P1149; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sattler M, 1998, LEUKEMIA, V12, P637, DOI 10.1038/sj.leu.2401010; Sattler M, 2002, ONCOGENE, V21, P1423, DOI 10.1038/sj.onc.1205202; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Shiohara M, 1997, LEUKEMIA LYMPHOMA, V26, P35, DOI 10.3109/10428199709109155; Sugiyama Y, 2001, J BIOL CHEM, V276, P12084, DOI 10.1074/jbc.M010811200; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; VERFAILLIE CM, 1992, J CLIN INVEST, V90, P1232, DOI 10.1172/JCI115985; VERFAILLIE CM, 1992, BLOOD, V79, P2821; Wertheim JA, 2002, BLOOD, V99, P4122, DOI 10.1182/blood.V99.11.4122; Zhao RC, 2001, BLOOD, V97, P2406, DOI 10.1182/blood.V97.8.2406	56	44	48	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	2002	21	56					8605	8611		10.1038/sj.onc.1206088	http://dx.doi.org/10.1038/sj.onc.1206088			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZF	12476307	Green Published			2022-12-28	WOS:000179734300010
J	Brachat, A; Pierrat, B; Xynos, A; Brecht, K; Simonen, M; Brungger, A; Heim, J				Brachat, A; Pierrat, B; Xynos, A; Brecht, K; Simonen, M; Brungger, A; Heim, J			A microarray-based, integrated approach to identify novel regulators of cancer drug response and apoptosis	ONCOGENE			English	Article						apoptosis; microarray; hemoglobin; camptothecin; methotrexate; cisplatin	GP49B INHIBITORY RECEPTOR; GENE-EXPRESSION; ADENYLATE KINASE; DNA-DAMAGE; IDENTIFICATION; PROTEIN; SENSITIVITY; CYCLOPHILIN; CLONING; STRESS	DNA microarrays are powerful tools for the analysis of gene expression on a genomic scale. The importance of individual regulatory events for the process under study can however not be deduced unequivocally without additional experiments. We devised a strategy to identify central regulators of cancer drug responses by combining the results of microarray experiments with efficient methods for phenotypic testing of candidate genes. We exposed murine FL5.12 pro-B cells to cisplatin, camptothecin, methotrexate or paclitaxel, respectively and analysed the patterns of gene expression with cDNA microarrays. Drug-specific regulatory events as well as intersections between different apoptotic pathways, including previously studied responses to staurosporine and interleukin-3 (IL-3) deprivation, were identified. Genes shared by at least three pathways were chosen for further analysis. Ectopic expression of three such genes, TEAP, GP49B, and Lipin1 was found to have an anti-proliferative effect on pro-B cells. Interestingly, we identified hemoglobin alpha as a strong pro-apoptotic regulator. While hemoglobin-expressing cells were growing normally in the presence of IL-3, they displayed accelerated apoptosis with similar kinetics as Bax overexpressing cells upon IL-3 removal. The proapoptotic effect of hemoglobin was suppressed by Bcl-2 and was characterized by enhanced stimulation of caspase activity.	Novartis Pharma AG, Oncol Res, CH-4002 Basel, Switzerland; Novartis Pharma AG, Mol & Cellular Biol Sr Sci Expert Lab, CH-4002 Basel, Switzerland	Novartis; Novartis	Heim, J (corresponding author), Novartis Pharma AG, Oncol Res, K-125-13-16, CH-4002 Basel, Switzerland.	jutta.heim@pharma.novartis.com		Brachat, Arndt/0000-0001-5768-3429				Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; Arevalo-Rodriguez M, 2000, EMBO J, V19, P3739, DOI 10.1093/emboj/19.14.3739; Beinert T, 2000, J LEUKOCYTE BIOL, V67, P369, DOI 10.1002/jlb.67.3.369; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Brachat A, 2000, ONCOGENE, V19, P5073, DOI 10.1038/sj.onc.1203882; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; Carrier A, 1999, IMMUNOGENETICS, V50, P255, DOI 10.1007/s002510050601; Cohen SM, 2001, PROG NUCLEIC ACID RE, V67, P93, DOI 10.1016/S0079-6603(01)67026-0; Dunn SE, 1997, CANCER RES, V57, P2687; Ferrante K, 1999, CANCER CHEMOTH PHARM, V43, pS61, DOI 10.1007/s002800051100; Gu ZM, 2000, MOL CELL BIOL, V20, P233, DOI 10.1128/MCB.20.1.233-241.2000; Katz HR, 1996, P NATL ACAD SCI USA, V93, P10809, DOI 10.1073/pnas.93.20.10809; Lee SP, 2001, J BIOL CHEM, V276, P29826, DOI 10.1074/jbc.M101822200; Lehar SM, 1996, ONCOGENE, V12, P1181; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Matsuda S, 1996, ONCOGENE, V12, P705; Matsumoto Y, 2001, J IMMUNOL, V166, P781, DOI 10.4049/jimmunol.166.2.781; Meguro T, 2001, J NEUROCHEM, V77, P1128, DOI 10.1046/j.1471-4159.2001.00313.x; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Noma T, 2001, BIOCHEM J, V358, P225, DOI 10.1042/0264-6021:3580225; Okamoto K, 1999, ONCOGENE, V18, P4606, DOI 10.1038/sj.onc.1202821; Peterfy M, 2001, NAT GENET, V27, P121, DOI 10.1038/83685; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Schneider E, 1990, Adv Pharmacol, V21, P149, DOI 10.1016/S1054-3589(08)60342-7; SWIFT S, 1999, CUR PROTO IMMUNOL S, V28; Tomasin R, 2001, J BIOL CHEM, V276, P44185, DOI 10.1074/jbc.M105647200; Voehringer DW, 2000, P NATL ACAD SCI USA, V97, P2680, DOI 10.1073/pnas.97.6.2680; Wang LL, 2000, J IMMUNOL, V164, P5215, DOI 10.4049/jimmunol.164.10.5215; Yang WM, 2001, EMBO J, V20, P4814, DOI 10.1093/emboj/20.17.4814; Yoneda T, 1998, MOL BRAIN RES, V62, P187, DOI 10.1016/S0169-328X(98)00249-6	32	28	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 28	2002	21	54					8361	8371		10.1038/sj.onc.1206016	http://dx.doi.org/10.1038/sj.onc.1206016			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447701				2022-12-28	WOS:000179323900016
J	Shah, RNH; Ibbitt, JC; Alitalo, K; Hurst, HC				Shah, RNH; Ibbitt, JC; Alitalo, K; Hurst, HC			FGFR4 overexpression in pancreatic cancer is mediated by an intronic enhancer activated by HNF1 alpha	ONCOGENE			English	Article						FGFR4; pancreatic cancer; HNF1; intronic enhancer	FIBROBLAST GROWTH-FACTORS; TRANSCRIPTION FACTORS; MULTIGENE FAMILY; FACTOR RECEPTORS; GENE; EXPRESSION; HOMEOPROTEIN; MUTATIONS; PROMOTERS; DIVERSITY	Fibroblast growth factor receptor 4 (FGFR4) is expressed in 50-70% of pancreatic carcinomas (PC) and a similar proportion of derived cell tines. Here we determine the sites of FGFR4 transcriptional initiation which show a pattern characteristic of genes with GC-rich, TATA-less promoters. We have examined the chromatin structure around the FGFR4 gene in a panel of expressing and non-expressing PC tines using the DNase I hypersensitive site assay. One region of hypersensitivity, located largely within intron 1, was found to be greatly extended in expressing cells. Subsequent functional analyses using reporter assays demonstrated that this region was able to act as a cell-specific enhancer, only showing significant activity in PC tines expressing endogenous FGFR4. Transcription factors able to bind to the enhancer were investigated using footprinting and mobility shift assays and two binding sites for Sp1 proteins and two sites able to bind hepatic nuclear factor 1 (HNF1) proteins were identified. Further reporter assays using constructs mutated in each binding site demonstrated that HNF1 binding was essential for enhancer activity in expressing cells, an observation that correlated with the increased abundance of HNF1alpha in these same cells as measured by Western blotting. Finally we show that exogenous expression of HNF1 factors in an FGFR4 non-expressing line led to an induction of enhancer activity in reporter assays and also activated expression of the endogenous gene. We conclude that HNF1alpha is a major determinant of FGFR4 expression in PC.	Hammersmith Hosp, ICSM, Canc Res UK Mol Oncol Unit, London W12 0NN, England; Biomedicum Helsinki, Helsinki 00014, Finland	Cancer Research UK; Imperial College London; University of Helsinki	Hurst, HC (corresponding author), Hammersmith Hosp, ICSM, Canc Res UK Mol Oncol Unit, London W12 0NN, England.		Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902				ARMSTRONG E, 1992, GENE CHROMOSOME CANC, V4, P94, DOI 10.1002/gcc.2870040116; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Bange J, 2002, CANCER RES, V62, P840; Becker M, 2000, BIOCHEM BIOPH RES CO, V276, P493, DOI 10.1006/bbrc.2000.3483; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; Coffinier C, 1999, MECH DEVELOP, V89, P211, DOI 10.1016/S0925-4773(99)00221-X; DESIMONE V, 1991, EMBO J, V10, P1435, DOI 10.1002/j.1460-2075.1991.tb07664.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; Hughes SE, 1997, J HISTOCHEM CYTOCHEM, V45, P1005, DOI 10.1177/002215549704500710; Ishiwata T, 1998, AM J PATHOL, V153, P213, DOI 10.1016/S0002-9440(10)65562-9; Jang JH, 2001, CANCER RES, V61, P3541; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kern SE, 2000, MED CLIN N AM, V84, P691, DOI 10.1016/S0025-7125(05)70251-0; KOBRIN MS, 1993, CANCER RES, V53, P937; Kostrzewa M, 1998, MAMM GENOME, V9, P131, DOI 10.1007/s003359900703; KUDO S, 1995, J BIOL CHEM, V270, P13298, DOI 10.1074/jbc.270.22.13298; Le Bras S, 1998, DIABETES, V47, P1236, DOI 10.2337/diabetes.47.8.1236; LEUNG HY, 1994, INT J CANCER, V59, P667, DOI 10.1002/ijc.2910590515; Li JX, 2000, GENE DEV, V14, P464; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; McEwen DG, 1998, J BIOL CHEM, V273, P5349, DOI 10.1074/jbc.273.9.5349; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; Miralles F, 1999, P NATL ACAD SCI USA, V96, P6267, DOI 10.1073/pnas.96.11.6267; OHATA T, 1995, BRIT J CANCER, V72, P824; Ornitz DM, 2001, GENOME BIOL, V2; Parakati R, 2002, J BIOL CHEM, V277, P9278, DOI 10.1074/jbc.M108411200; Pare JF, 2001, J BIOL CHEM, V276, P13136, DOI 10.1074/jbc.M010737200; REYCAMPOS J, 1991, EMBO J, V10, P1445, DOI 10.1002/j.1460-2075.1991.tb07665.x; Ryffel GU, 2001, J MOL ENDOCRINOL, V27, P11, DOI 10.1677/jme.0.0270011; Soutoglou E, 2000, J BIOL CHEM, V275, P12515, DOI 10.1074/jbc.275.17.12515; Soutoglou E, 2001, EMBO J, V20, P1984, DOI 10.1093/emboj/20.8.1984; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Wagner M, 1998, GASTROENTEROLOGY, V114, P798, DOI 10.1016/S0016-5085(98)70594-3; Xu XL, 1999, CELL TISSUE RES, V296, P33, DOI 10.1007/s004410051264	37	51	57	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 28	2002	21	54					8251	8261		10.1038/sj.onc.1206020	http://dx.doi.org/10.1038/sj.onc.1206020			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447688				2022-12-28	WOS:000179323900003
J	Qian, H; Wang, T; Naumovski, L; Lopez, CD; Brachmann, RK				Qian, H; Wang, T; Naumovski, L; Lopez, CD; Brachmann, RK			Groups of p53 target genes involved in specific p53 downstream effects cluster into different classes of DNA binding sites	ONCOGENE			English	Article						apoptosis; cell cycle; DNA binding site; DNA repair; p53	TUMOR-SUPPRESSOR P53; BAX PROMOTER; GROWTH; APOPTOSIS; PROTEIN; CANCER; DEATH; TRANSACTIVATION; PROTOONCOGENE; MUTATIONS	The tumor suppressor protein p53, once activated, can cause either cell cycle arrest or apoptosis through transactivation of target genes with p53 DNA binding sites (DBS). To investigate the role of p53 DBS in the regulation of this profound, yet poorly understood decision of life versus death, we systematically studied all known and potential p53 DBS. We analysed the DBS separated from surrounding promoter regions in yeast and mammalian assays with and without DNA damage. p53 efficiently utilized the DBS of MDM2 and of genes connected to cell cycle arrest, DNA repair and the death receptor pathway of apoptosis. However, p53 was unable to utilize two-thirds of the isolated DBS, a subset that included almost all DBS of apoptosis-related genes. Neither ASPP2, a p53-interacting protein reported to specifically stimulate p53 transcriptional activity on apoptosis-related promoters, nor DNA damage resulted in p53 utilization of isolated DBS of apoptosis-related genes. Thus, a major regulation of p53 activity occurs at the level of p53 DBS themselves by posing additional requirements for the successful utilization of apoptosis-related DBS.	Washington Univ, Sch Med, Div Oncol, Dept Med, St Louis, MO 63110 USA; Stanford Univ, Div Hematol Oncol & Stem Cell Transplantat, Stanford, CA 94305 USA; Oregon Hlth Sci Univ, Dept Med, Div Hematol & Med Oncol, Portland, OR 97201 USA	Washington University (WUSTL); Stanford University; Oregon Health & Science University	Brachmann, RK (corresponding author), Washington Univ, Sch Med, Div Oncol, Dept Med, 660 S Euclid Ave,Box 8069, St Louis, MO 63110 USA.				NCI NIH HHS [CA81511, CA76316] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081511, R01CA076316] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; Brachmann RK, 1996, P NATL ACAD SCI USA, V93, P4091, DOI 10.1073/pnas.93.9.4091; Brachmann RK, 1998, EMBO J, V17, P1847, DOI 10.1093/emboj/17.7.1847; Campomenosi P, 2001, ONCOGENE, V20, P3573, DOI 10.1038/sj.onc.1204468; Contente A, 2002, NAT GENET, V30, P315, DOI 10.1038/ng836; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Di Como CJ, 1998, ONCOGENE, V16, P2527; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elkeles A, 1999, MOL CELL BIOL, V19, P2594; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Friedlander P, 1996, J BIOL CHEM, V271, P25468, DOI 10.1074/jbc.271.41.25468; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lane D, 2001, NATURE, V414, P25, DOI 10.1038/35102132; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; MIYASHITA T, 1995, CELL, V80, P293; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Prives C, 1999, J PATHOL, V187, P112; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Seol DW, 1999, J BIOL CHEM, V274, P3565, DOI 10.1074/jbc.274.6.3565; SHIN TH, 1995, MOL CELL BIOL, V15, P4694; SIKORSKI RS, 1989, GENETICS, V122, P19; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; Thornborrow EC, 2001, J BIOL CHEM, V276, P15598, DOI 10.1074/jbc.M011643200; Thornborrow EC, 1999, J BIOL CHEM, V274, P33747, DOI 10.1074/jbc.274.47.33747; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; Urist M, 2002, CANCER CELL, V1, P311, DOI 10.1016/S1535-6108(02)00064-8; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10315, DOI 10.1073/pnas.93.19.10315; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wang T, 2001, EMBO J, V20, P6404, DOI 10.1093/emboj/20.22.6404; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7	42	111	116	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 7	2002	21	51					7901	7911		10.1038/sj.onc.1205974	http://dx.doi.org/10.1038/sj.onc.1205974			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	610DT	12420228				2022-12-28	WOS:000178946000016
J	Wu, KJ; Mattioli, M; Morse, HC; Dalla-Favera, R				Wu, KJ; Mattioli, M; Morse, HC; Dalla-Favera, R			c-MYC activates protein kinase A (PKA) by direct transcriptional activation of the PKA catalytic subunit beta (PKA-C beta) gene	ONCOGENE			English	Article						c-MYC; PKA; transcriptional activation	CYCLIC-AMP; CELL-PROLIFERATION; DIFFERENTIAL EXPRESSION; MYC/MAX/MAD NETWORK; ESTROGEN-RECEPTOR; 3T3 CELLS; BINDING; GROWTH; TRANSFORMATION; MAX	The c-MYC proto-oncogene encodes a ubiquitous transcription factor involved in the control of cell growth and differentiation and broadly implicated in tumorigenesis. Understanding the function of c-MYC and its role in cancer depends upon the identification of c-MYC target genes. Here we show that c-MYC induces the activity of Protein Kinase A (PKA), a key effector of cAMP-mediated signal transduction, by inducing the transcription of the gene encoding the PKA catalytic subunit beta (PKA-Cbeta). c-MYC-mediated induction of PKA-Cbeta gene transcription occurs in multiple tissues, is independent of cell proliferation and is mediated by direct binding of cMYC to the PKA-Cbeta gene promoter sequences. Constitutive expression of PKA-Cbeta in Rat1A cells induces their transformation, and c-MYC-induced transformation can be reverted by pharmacological inhibition of PKA, suggesting that up-regulation of PKA is critical for cMYC-associated tumorigenesis. These results indicate that, by activating PKA, c-MYC can provide endogenous activation of the cAMP signal transduction pathway independently of extracellular signals.	Columbia Univ, Inst Canc Genet, New York, NY 10032 USA; Columbia Univ, Dept Pathol, New York, NY 10032 USA; Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA; NIAID, Immunopathol Lab, NIH, Bethesda, MD 20892 USA	Columbia University; Columbia University; Columbia University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Dalla-Favera, R (corresponding author), Columbia Univ, Inst Canc Genet, New York, NY 10032 USA.	rd10@columbia.edu	Wu, Kou-Juey/P-4654-2015; Mattioli, Michela/K-3951-2013	Mattioli, Michela/0000-0002-1692-9178; Morse, Herbert/0000-0002-9331-3705	NATIONAL CANCER INSTITUTE [R01CA037165] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000858] Funding Source: NIH RePORTER; NCI NIH HHS [CA 37165] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; BURGERING BMT, 1994, CELL GROWTH DIFFER, V5, P341; CHEN JH, 1994, SCIENCE, V263, P1278, DOI 10.1126/science.8122111; Dang CV, 1999, MOL CELL BIOL, V19, P1; Daniel PB, 1998, ANNU REV NUTR, V18, P353, DOI 10.1146/annurev.nutr.18.1.353; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; Feuerstein N, 1996, J IMMUNOL, V156, P4582; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; James L, 2002, P NATL ACAD SCI USA, V99, P10429, DOI 10.1073/pnas.162369299; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KEMPKES B, 1995, EMBO J, V14, P88, DOI 10.1002/j.1460-2075.1995.tb06978.x; Kovalchuk AL, 2000, J EXP MED, V192, P1183, DOI 10.1084/jem.192.8.1183; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Pursiheimo JP, 2000, P NATL ACAD SCI USA, V97, P168, DOI 10.1073/pnas.97.1.168; Qi M, 1996, P NATL ACAD SCI USA, V93, P1571, DOI 10.1073/pnas.93.4.1571; SASSON S, 1991, PATHOL BIOL, V39, P59; Schmitt JM, 2001, MOL CELL BIOL, V21, P3671, DOI 10.1128/MCB.21.11.3671-3683.2001; SHUNTOH H, 1992, BIOCHIM BIOPHYS ACTA, V1131, P175, DOI 10.1016/0167-4781(92)90073-9; Skalhegg BS, 2000, FRONT BIOSCI-LANDMRK, V5, pD678, DOI 10.2741/Skalhegg; SKALHEGG BS, 1992, J BIOL CHEM, V267, P15707; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; ZACHARY I, 1990, BIOCHEM BIOPH RES CO, V168, P1184, DOI 10.1016/0006-291X(90)91154-K; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	45	40	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2002	21	51					7872	7882		10.1038/sj.onc.1205986	http://dx.doi.org/10.1038/sj.onc.1205986			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	610DT	12420224				2022-12-28	WOS:000178946000012
J	Sanceau, J; Poupon, MF; Delattre, O; Sastre-Garau, X; Wietzerbin, J				Sanceau, J; Poupon, MF; Delattre, O; Sastre-Garau, X; Wietzerbin, J			Strong inhibition of Ewing tumor xenograft growth by combination of human interferon-alpha or interferon-beta with ifosfamide	ONCOGENE			English	Article						Ewing's sarcoma; IFN-alpha; IFN-beta; ifosfamide; xenograft	SIGNAL-TRANSDUCTION; P53 MUTATIONS; THERAPY; SARCOMA; CANCER; GENE; ANGIOGENESIS; SUPPRESSION; CISPLATIN; ETOPOSIDE	Ewing sarcoma is the second most common bone tumor in childhood. Despite aggressive chemotherapy and radiotherapy strategies, the prognosis of patients with metastatic disease remains poor. We have recently reported that Ewing tumor cell proliferation was strongly inhibited by IFN-beta and to a lesser degree by IFN-alpha. Moreover, under IFN-beta treatment, some cell lines undergo apoptosis. Since the possibility of using IFNs for Ewing tumor treatments may be of interest, we have evaluated the efficacy of Hu-IFNs in a nude mice model of Ewing tumor xenografts. The results reported here show that human type I IFNs, Hu-IFN-alpha and Hu-IFN-beta impaired tumor xenograft take and displayed an anti-growth effect toward established xenografts. Furthermore, we have also shown that combined therapy with Hu-IFNs and ifosfamide (IFO), an alkylating agent widely used in high-dose chemotherapy of Ewing tumors, results in a strong antitumor effect. Pathological analysis showed that Hu-IFN-alpha/IFO and Hu-IFN-beta/IFO were characterized by a dramatic decrease in the mitotic index and marked necrosis, as well as extensive fibrosis associated with numerous calcifications. To our knowledge, this is the first demonstration of a potential antitumor effect of human type I IFNs and IFO on Ewing tumors, providing a rational foundation for a promising therapeutic approach to Ewing sarcoma.	Inst Curie, INSERM, U365, Sect Rech, F-75248 Paris 05, France; Inst Curie, Sect Rech, CNRS, UMR 147, F-75248 Paris 05, France; Inst Curie, Sect Rech, INSERM, U509, F-75248 Paris 05, France; Inst Curie, Med Sect, Dept Pathol, F-75248 Paris 05, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Wietzerbin, J (corresponding author), Inst Curie, INSERM, U365, Sect Rech, 26 Rue Ulm, F-75248 Paris 05, France.	Jeanne.Wietzerbin@curie.fr		Sastre-Garau, Xavier/0000-0001-5992-2083; delattre, olivier/0000-0002-8730-2276				AURIAS A, 1983, NEW ENGL J MED, V309, P496; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Biron CA, 2001, IMMUNITY, V14, P661, DOI 10.1016/S1074-7613(01)00154-6; Borden, 1998, Oncologist, V3, P198; Borden EC, 2000, SEMIN CANCER BIOL, V10, P125, DOI 10.1006/scbi.2000.0315; Brockmeyer NH, 1998, CHEMOTHERAPY, V44, P174, DOI 10.1159/000007112; BROSJO O, 1985, CANCER RES, V45, P5598; Chapman BA, 2001, NEW ZEAL MED J, V114, P103; Comi G, 2001, LANCET, V357, P1576, DOI 10.1016/S0140-6736(00)04725-5; Daponte A, 2000, CANCER, V89, P2630, DOI 10.1002/1097-0142(20001215)89:12<2630::AID-CNCR16>3.0.CO;2-Z; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Dong ZY, 1999, CANCER RES, V59, P872; Eck SL, 2001, HUM GENE THER, V12, P97; Faderl S, 1999, ONCOLOGY-NY, V13, P169; Fizazi K, 1998, J CLIN ONCOL, V16, P3736, DOI 10.1200/JCO.1998.16.12.3736; Freneaux P, 2000, BRIT J CANCER, V83, P1318, DOI 10.1054/bjoc.2000.1438; Garmendia G, 2001, J INTERF CYTOK RES, V21, P31, DOI 10.1089/107999001459132; Grander D, 2000, ACTA ONCOL, V39, P801, DOI 10.1080/028418600750063532; Grander D, 1997, EUR J HAEMATOL, V59, P129; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; Hall GL, 1997, TRENDS NEUROSCI, V20, P63, DOI 10.1016/S0166-2236(96)10071-0; HAMELIN R, 1994, INT J CANCER, V57, P336, DOI 10.1002/ijc.2910570308; Horowitz Marc E., 1997, P831; Horton HM, 1999, CANCER RES, V59, P4064; Horvath CM, 1997, CURR OPIN CELL BIOL, V9, P233, DOI 10.1016/S0955-0674(97)80067-1; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; KOVAR H, 1993, ONCOGENE, V8, P2683; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; KURZROCK R, 1991, BRIT J HAEMATOL, V79, P17, DOI 10.1111/j.1365-2141.1991.tb08112.x; Kushner BH, 2001, J CLIN ONCOL, V19, P870, DOI 10.1200/JCO.2001.19.3.870; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; Mizuno M, 1998, CANCER IMMUNOL IMMUN, V47, P227, DOI 10.1007/s002620050525; Monshouwer M, 1996, TOXICOL APPL PHARM, V137, P237, DOI 10.1006/taap.1996.0077; Nemati F, 2000, CLIN CANCER RES, V6, P2075; OUCHIDA M, 1995, ONCOGENE, V11, P1049; Ozawa S, 2001, NEOPLASIA, V3, P154, DOI 10.1038/sj.neo.7900128; Paulussen M, 2001, J CLIN ONCOL, V19, P1818, DOI 10.1200/JCO.2001.19.6.1818; Pfeffer LM, 1998, CANCER RES, V58, P2489; Pinkerton CR, 2001, EUR J CANCER, V37, P1338, DOI 10.1016/S0959-8049(01)00131-9; Qin XQ, 1998, P NATL ACAD SCI USA, V95, P14411, DOI 10.1073/pnas.95.24.14411; Rosito P, 1999, CANCER-AM CANCER SOC, V86, P421, DOI 10.1002/(SICI)1097-0142(19990801)86:3<421::AID-CNCR10>3.0.CO;2-O; Rosolen A, 1997, MODERN PATHOL, V10, P55; Ross C, 2000, ANN NEUROL, V48, P706, DOI 10.1002/1531-8249(200011)48:5<706::AID-ANA3>3.3.CO;2-M; Rumi MG, 1997, BLOOD, V89, P3529; Runkel L, 1998, J BIOL CHEM, V273, P8003, DOI 10.1074/jbc.273.14.8003; Sanceau J, 2000, ONCOGENE, V19, P3372, DOI 10.1038/sj.onc.1203670; Sandler AB, 1998, SEMIN ONCOL, V25, P38; Slaton JW, 1999, CLIN CANCER RES, V5, P2726; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Strander H, 1996, BIOTHERAPY, V8, P213, DOI 10.1007/BF01877207; Surin B, 2002, INT J MOL MED, V10, P25; Tada H, 2001, J CLIN INVEST, V108, P83, DOI 10.1172/JCI9841; Talpaz M, 2001, SEMIN HEMATOL, V38, P22, DOI 10.1053/shem.2001.27080; Tanneberger S, 1996, J INTERF CYTOK RES, V16, P339, DOI 10.1089/jir.1996.16.339; Todesco A, 2000, CANCER-AM CANCER SOC, V89, P2661, DOI 10.1002/1097-0142(20001215)89:12<2661::AID-CNCR20>3.0.CO;2-9; Wadler, 1997, Oncologist, V2, P254; WADLER S, 1990, CANCER RES, V50, P3473; Wexler LH, 1996, CANCER, V78, P901; Wollina U, 2001, J AM ACAD DERMATOL, V44, P253, DOI 10.1067/mjd.2001.110645; Worle H, 1999, EUR J PEDIATR, V158, P344, DOI 10.1007/s004310051089	60	63	73	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 31	2002	21	50					7700	7709		10.1038/sj.onc.1205881	http://dx.doi.org/10.1038/sj.onc.1205881			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	606VW	12400012				2022-12-28	WOS:000178756200009
J	Sonderegger, CK; Vogt, PK				Sonderegger, CK; Vogt, PK			Binding of the corepressor TLE1 to Qin enhances Qin-mediated transformation of chicken embryo fibroblasts	ONCOGENE			English	Article						corepressor; TLE1; FoxG1; oncogenic transformation; chicken embryo fibroblasts	TRANSCRIPTIONAL REPRESSION; ONCOGENIC TRANSFORMATION; GROUCHO; PROTEIN; EXPRESSION; AML1; OLIGOMERIZATION; IDENTIFICATION; INTERACTS; HOMOLOGS	The oncoprotein Qin is a member of the winged helix family of transcriptional regulators. The region C-terminal to its winged helix DNA-binding domain is required for transformation of chicken embryo fibroblasts. We isolated the corepressor TLE1 as a binding partner for Qin in a yeast two-hybrid screen and localized the TLE1-binding region to a 60 amino-acid stretch directly C-terminal of the winged helix domain of Qin. We show in vivo interaction of full-length Qin and TLE1 in a mammalian two-hybrid system. Coexpression of TLE1-binding Qin and TLE1 induces phosphorylation of TLEI. The DNA-binding activity of Qin is not required for this function. Binding of Qin to TLE1 correlates with Qin-induced transformation. Addition of the TLE1-binding motif WRPW to the C-terminus of a transformation-defective Qin deletion mutant restores binding to TLE1 and significantly enhances transformation. Expression of TLE1 in CEF by the retroviral vector RCAS enhances cell growth and induces formation of agar colonies.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Vogt, PK (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	pkvogt@scripps.edu	Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500				Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Aoki M, 2000, J BIOL CHEM, V275, P6267, DOI 10.1074/jbc.275.9.6267; AOKI M, 2002, COMMUNICATION; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Chang HW, 1996, ONCOGENE, V13, P441; Chen GQ, 2000, GENE, V249, P1, DOI 10.1016/S0378-1119(00)00161-X; Chen GQ, 1998, MOL CELL BIOL, V18, P7259, DOI 10.1128/MCB.18.12.7259; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; Choi CY, 1999, J BIOL CHEM, V274, P33194, DOI 10.1074/jbc.274.47.33194; Dubnicoff T, 1997, GENE DEV, V11, P2952, DOI 10.1101/gad.11.22.2952; DUFF RG, 1969, VIROLOGY, V39, P18, DOI 10.1016/0042-6822(69)90344-4; Eberhard D, 2000, EMBO J, V19, P2292, DOI 10.1093/emboj/19.10.2292; Gietz RD, 1997, MOL CELL BIOCHEM, V172, P67, DOI 10.1023/A:1006859319926; Husain J, 1996, BIOCHEM J, V317, P523, DOI 10.1042/bj3170523; Imai Y, 1998, BIOCHEM BIOPH RES CO, V252, P582, DOI 10.1006/bbrc.1998.9705; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Li J, 1997, P NATL ACAD SCI USA, V94, P10885, DOI 10.1073/pnas.94.20.10885; LI J, 1995, CANCER RES, V55, P5540; Liu YL, 1996, GENOMICS, V31, P58, DOI 10.1006/geno.1996.0009; Ma Y, 2000, ONCOGENE, V19, P4815, DOI 10.1038/sj.onc.1203834; Midorikawa Y, 2002, JPN J CANCER RES, V93, P636, DOI 10.1111/j.1349-7006.2002.tb01301.x; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; NISHIZAWA M, 2002, UNPUB; Nuthall HN, 2002, MOL CELL BIOL, V22, P389, DOI 10.1128/MCB.22.2.389-399.2002; Palaparti A, 1997, J BIOL CHEM, V272, P26604, DOI 10.1074/jbc.272.42.26604; SONDEREGGER CK, 2003, IN PRESS ONCOGENE; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; Yao J, 1998, DEV GROWTH DIFFER, V40, P133; Yao J, 2001, MOL CELL BIOL, V21, P1962, DOI 10.1128/MCB.21.6.1962-1972.2001; Yao J, 2000, MECH DEVELOP, V93, P105, DOI 10.1016/S0925-4773(00)00278-1; Zhang JS, 2001, MOL CELL BIOL, V21, P156, DOI 10.1128/MCB.21.1.156-163.2001	33	28	28	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2003	22	12					1749	1757		10.1038/sj.onc.1206308	http://dx.doi.org/10.1038/sj.onc.1206308			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660810				2022-12-28	WOS:000181678200001
J	Ariumi, Y; Ego, T; Kaida, A; Matsumoto, M; Pandolfi, PP; Shimotohno, K				Ariumi, Y; Ego, T; Kaida, A; Matsumoto, M; Pandolfi, PP; Shimotohno, K			Distinct nuclear body components, PML and SMRT, regulate the trans-acting function of HTLV-1 tax oncoprotein	ONCOGENE			English	Article						HTLV-1; tax; PML; SMRT; CBP; nuclear body	CELL LEUKEMIA-VIRUS; ACUTE PROMYELOCYTIC LEUKEMIA; CREB BINDING-PROTEIN; REPLICATION COMPARTMENTS; VIRAL TRANSACTIVATOR; TUMOR SUPPRESSION; COACTIVATOR CBP; TYPE-1 TAX; RAR-ALPHA; BODIES	Several viruses target cellular promyelocytic leukemia (PML)-nuclear bodies (PML-NBs) to induce their disruption, marked morphological changes in these structures or the relocation to PML-NB components to the cytoplasm of infected cells. PML conversely interferes with viral replication. We demonstrate that PML acts as a coactivator for the human T-cell leukemia virus type I (HTLV-1) Tax oncoprotein without direct binding. Tax was identified within interchromatin granule clusters (IGCs)/RNA splicing bodies (SBs), not PML-NBs; Tax expression did not affect PML-NB formation. Moreover, PML and CBP/p300 cooperatively activated Tax-mediated HTLV-1-LTR-dependent gene expression. Interestingly, two PML mutants, PML-RAR and PMLDelta216-331, which fail to form PML-NBs, could also coactivate Tax-mediated trans-acting function but had no effect on retinoic acid receptor (RAR)- or p53-dependent gene expression. In contrast, SMRT (silencing mediator for retinoic acid and thyroid hormone receptors), a nuclear corepressor found within the matrix-associated deacetylase (MAD) nuclear body, relocatized into Tax-associated nuclear bodies upon coexpression with Tax. SMRT coactivated the trans-acting function of Tax through direct binding. Coexpression of SMRT and PML resulted in an additive activation of Tax trans-acting function. Thus, crosstalk between distinct nuclear bodies may control Tax function.	Kyoto Univ, Inst Virus Res, Lab Human Tumor Viruses, Sakyo Ku, Kyoto 6068507, Japan; Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Dept Human Genet,Mol Biol Program, New York, NY 10021 USA	Kyoto University; Cornell University; Memorial Sloan Kettering Cancer Center	Shimotohno, K (corresponding author), Kyoto Univ, Inst Virus Res, Lab Human Tumor Viruses, Sakyo Ku, Kyoto 6068507, Japan.	kshimoto@virus.kyoto-u.ac.jp	Ariumi, Yasuo/F-5804-2013					Ahn JH, 1997, J VIROL, V71, P4599, DOI 10.1128/JVI.71.6.4599-4613.1997; Akagi T, 1997, ONCOGENE, V14, P2071, DOI 10.1038/sj.onc.1201045; Ariumi Y, 2000, ONCOGENE, V19, P1491, DOI 10.1038/sj.onc.1203450; Ariumi Y, 2001, BIOCHEM BIOPH RES CO, V287, P556, DOI 10.1006/bbrc.2001.5626; Borden KLB, 1998, J VIROL, V72, P758, DOI 10.1128/JVI.72.1.758-766.1998; Burkham J, 1998, J VIROL, V72, P10100, DOI 10.1128/JVI.72.12.10100-10107.1998; Burton M, 2000, J VIROL, V74, P2351, DOI 10.1128/JVI.74.5.2351-2364.2000; Chelbi-Alix MK, 1998, J VIROL, V72, P1043, DOI 10.1128/JVI.72.2.1043-1051.1998; Day PM, 1998, J VIROL, V72, P142, DOI 10.1128/JVI.72.1.142-150.1998; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2633, DOI 10.1073/pnas.96.6.2633; Doucas V, 1996, GENE DEV, V10, P196, DOI 10.1101/gad.10.2.196; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; DOUCAS V, 1996, BIOCHIM BIOPHYS ACTA, V1288, P25; Downes M, 2000, P NATL ACAD SCI USA, V97, P10330, DOI 10.1073/pnas.97.19.10330; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; Everett RD, 1999, J VIROL, V73, P417, DOI 10.1128/JVI.73.1.417-426.1999; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Gottifredi V, 2001, TRENDS CELL BIOL, V11, P184, DOI 10.1016/S0962-8924(01)01983-3; Ishov AM, 1996, J CELL BIOL, V134, P815, DOI 10.1083/jcb.134.4.815; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; MAUL GG, 1993, J GEN VIROL, V74, P2679, DOI 10.1099/0022-1317-74-12-2679; Maul GG, 1998, BIOESSAYS, V20, P660, DOI 10.1002/(SICI)1521-1878(199808)20:8<660::AID-BIES9>3.0.CO;2-M; MORI K, 1987, J GEN VIROL, V68, P499, DOI 10.1099/0022-1317-68-2-499; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Muller S, 1999, J VIROL, V73, P5137; NOSAKA T, 1993, EXP CELL RES, V208, P89; Ordentlich P, 1999, P NATL ACAD SCI USA, V96, P2639, DOI 10.1073/pnas.96.6.2639; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PUVIONDUTILLEUL F, 1995, EXP CELL RES, V218, P9, DOI 10.1006/excr.1995.1125; Regad T, 2001, EMBO J, V20, P3495, DOI 10.1093/emboj/20.13.3495; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Semmes OJ, 1996, J VIROL, V70, P6347, DOI 10.1128/JVI.70.9.6347-6357.1996; Suzuki T, 1999, ONCOGENE, V18, P4137, DOI 10.1038/sj.onc.1202766; Swindle CS, 1999, J VIROL, V73, P1001, DOI 10.1128/JVI.73.2.1001-1009.1999; Szekely L, 1996, J VIROL, V70, P2562, DOI 10.1128/JVI.70.4.2562-2568.1996; Turelli P, 2001, MOL CELL, V7, P1245, DOI 10.1016/S1097-2765(01)00255-6; Van Orden K, 1999, J BIOL CHEM, V274, P26321, DOI 10.1074/jbc.274.37.26321; Wang ZG, 1998, SCIENCE, V279, P1547; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752	47	22	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	2003	22	11					1611	1619		10.1038/sj.onc.1206244	http://dx.doi.org/10.1038/sj.onc.1206244			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642864				2022-12-28	WOS:000181580500003
J	Clark, J; Edwards, S; Feber, A; Flohr, P; John, M; Giddings, I; Crossland, S; Stratton, MR; Wooster, R; Campbell, C; Cooper, CS				Clark, J; Edwards, S; Feber, A; Flohr, P; John, M; Giddings, I; Crossland, S; Stratton, MR; Wooster, R; Campbell, C; Cooper, CS			Genome-wide screening for complete genetic loss in prostate cancer by comparative hybridization onto cDNA microarrays	ONCOGENE			English	Article							DNA COPY-NUMBER; LOCALLY WEIGHTED REGRESSION; TUMOR-SUPPRESSOR GENE; BREAST-CANCER; GROWTH-ARREST; CELL-LINES; STAT3; DIFFERENTIATION; PROTEIN; IDENTIFICATION	We demonstrate that comparative genomic hybridization (CGH) onto cDNA microarrays may be used to carry out genome-wide screens for regions of genetic loss, including homozygous (complete) deletions that may represent the possible location of tumour suppressor genes in human cancer. Screening of the prostate cancer cell lines LNCaP, PC3 and DU145 allowed the mapping of specific regions where genome copy number appeared altered and led to the identification of two novel regions of complete loss at 17q21.31 (500 kb spanning STAT3) and at 10q23.1 (50-350 kb spanning SFTPA2) in the PC3 cell line.	Inst Canc Res, Male Urol Canc Res Ctr, Mol Carcinogenesis Sect, Surrey, England; Inst Canc Res, Male Urol Canc Res Ctr, Canc Res UK DNA Microarray Facil, Surrey, England; Wellcome Trust Sanger Inst, Cambridge, England; Univ Bristol, Adv Comp Res Ctr, Bristol BS8 1TH, Avon, England	University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK; Wellcome Trust Sanger Institute; University of Bristol	Cooper, CS (corresponding author), Inst Canc Res, Male Urol Canc Res Ctr, Mol Carcinogenesis Sect, Surrey, England.			Feber, Andrew/0000-0001-5282-0498; Giddings, Ian/0000-0003-1078-5780				Aurich-Costa J, 2001, GENE CHROMOSOME CANC, V30, P143, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1076>3.0.CO;2-E; Bednarek AK, 2001, CANCER RES, V61, P8068; Bromberg JF, 2001, BIOESSAYS, V23, P161, DOI 10.1002/1521-1878(200102)23:2<161::AID-BIES1023>3.0.CO;2-0; Cai WW, 2002, NAT BIOTECHNOL, V20, P393, DOI 10.1038/nbt0402-393; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Chekmareva MA, 1997, PROSTATE, V33, P271; Clark J, 2002, GENE CHROMOSOME CANC, V34, P104, DOI 10.1002/gcc.10039; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; CLEVELAND WS, 1988, J AM STAT ASSOC, V83, P596, DOI 10.2307/2289282; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; England NL, 1996, CARCINOGENESIS, V17, P1567, DOI 10.1093/carcin/17.8.1567; Forozan F, 2000, CANCER RES, V60, P4519; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Heiskanen MA, 2000, CANCER RES, V60, P799; Hyytinen ER, 2002, GENE CHROMOSOME CANC, V34, P306, DOI 10.1002/gcc.10065; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Khubchandani KR, 2001, FASEB J, V15, P59, DOI 10.1096/fj.00-0318rev; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Monni O, 2001, P NATL ACAD SCI USA, V98, P5711, DOI 10.1073/pnas.091582298; MORTON RA, 1993, CANCER RES, V53, P3585; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Nielsen TO, 2002, LANCET, V359, P1301, DOI 10.1016/S0140-6736(02)08270-3; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Spiotto MT, 2000, PROSTATE, V42, P88, DOI 10.1002/(SICI)1097-0045(20000201)42:2<88::AID-PROS2>3.0.CO;2-P; Spiotto MT, 2000, PROSTATE, V42, P186, DOI 10.1002/(SICI)1097-0045(20000215)42:3<186::AID-PROS4>3.0.CO;2-E; Srivastava M, 2001, P NATL ACAD SCI USA, V98, P4575, DOI 10.1073/pnas.071055798; Uchida T, 1999, INT J CANCER, V84, P19, DOI 10.1002/(SICI)1097-0215(19990219)84:1<19::AID-IJC4>3.0.CO;2-S; Yang Y H, 2001, Brief Bioinform, V2, P341, DOI 10.1093/bib/2.4.341	33	77	81	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 27	2003	22	8					1247	1252		10.1038/sj.onc.1206247	http://dx.doi.org/10.1038/sj.onc.1206247			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650EK	12606952				2022-12-28	WOS:000181249700014
J	Schlegel, BP; Starita, LM; Parvin, JD				Schlegel, BP; Starita, LM; Parvin, JD			Overexpression of a protein fragment of RNA helicase A causes inhibition of endogenous BRCA1 function and defects in ploidy and cytokinesis in mammary epithelial cells	ONCOGENE			English	Article						BRCA1; RNA helicase A; aneuploidy; centrosome; PARP-1	POLYMERASE-II HOLOENZYME; TRANSCRIPTION IN-VITRO; POLY(ADP-RIBOSE) POLYMERASE; DNA-DAMAGE; HOMOLOGOUS RECOMBINATION; GENETIC INSTABILITY; BREAST-CANCER; EXPRESSION; CYCLE; ACTIVATION	The breast- and ovarian-specific tumor suppressor, BRCA1, has been implicated to function in many nuclear processes, including DNA damage repair, recombination, transcription, ubiquitination, cell cycle checkpoint enforcement, and centrosome regulation. Utilizing a previously described interaction between BRCA1 and RNA helicase A (RHA), we have developed a dominant-negative approach to block BRCA1 function in human breast epithelial cells. Overexpression of a truncated RHA peptide that can bind to the BRCA1 carboxy-terminus prevents normal BRCA1 function, such as BRCA1 association with nuclear foci following DNA damage. Overexpression of this dominant-negative protein induces pleomorphic nuclei, aberrant mitoses with extra centrosomes, and tetraploidy. This model system allows us to observe changes to mammary epithelial cells that occur acutely following loss of BRCA1 function. Furthermore, inhibition of BRCA1 via overexpressing the RHA fragment coincides with a reduction in PARP-1 protein expression, suggesting a possible mechanism for BRCA1 in the maintenance of genomic integrity.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Parvin, JD (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA.		Parvin, Jeffrey D/C-8955-2009		NCI NIH HHS [CA90281] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090281] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; BENJAMIN RC, 1980, J BIOL CHEM, V255, P1502; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Haile DT, 1999, J BIOL CHEM, V274, P2113, DOI 10.1074/jbc.274.4.2113; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Hsu LC, 2001, CANCER RES, V61, P7713; Hu YF, 1999, GENE DEV, V13, P637, DOI 10.1101/gad.13.6.637; Lafarge S, 2001, ONCOGENE, V20, P6597, DOI 10.1038/sj.onc.1204812; Larson JS, 1997, CANCER RES, V57, P3351; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; Meisterernst M, 1997, P NATL ACAD SCI USA, V94, P2261, DOI 10.1073/pnas.94.6.2261; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; OHGUSHI H, 1980, J BIOL CHEM, V255, P6205; Schlegel BP, 2000, P NATL ACAD SCI USA, V97, P3148, DOI 10.1073/pnas.070452397; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Simbulan-Rosenthal CM, 2000, P NATL ACAD SCI USA, V97, P11274, DOI 10.1073/pnas.200285797; Simbulan-Rosenthal CM, 1999, P NATL ACAD SCI USA, V96, P13191, DOI 10.1073/pnas.96.23.13191; Snouwaert JN, 1999, ONCOGENE, V18, P7900, DOI 10.1038/sj.onc.1203334; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; SZABO CI, 1995, HUM MOL GENET, V4, P1811, DOI 10.1093/hmg/4.suppl_1.1811; TANIGUCHI T, 1982, J BIOL CHEM, V257, P4027; Tomlinson GE, 1998, CANCER RES, V58, P3237; Vispe S, 2000, P NATL ACAD SCI USA, V97, P9886, DOI 10.1073/pnas.170280397; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9	39	86	88	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 20	2003	22	7					983	991		10.1038/sj.onc.1206195	http://dx.doi.org/10.1038/sj.onc.1206195			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	644PB	12592385				2022-12-28	WOS:000180926100004
J	Bundy, LM; Sealy, L				Bundy, LM; Sealy, L			CCAAT/enhancer binding protein beta (C/EBP beta)-2 transforms normal mammary epithelial cells and induces epithelial to mesenchymal transition in culture	ONCOGENE			English	Article						C/EBP transcription factor; anchorage independence; EMT; invasion; mammary gland; retroviral vector	HUMAN BREAST-CANCER; C/EBP-BETA; CYCLIN D1; TRANSCRIPTIONAL REGULATION; CYCLOOXYGENASE-2 GENE; INHIBITORY PROTEIN; GLAND DEVELOPMENT; TRANSGENIC MICE; MESSENGER-RNA; EXPRESSION	The transcription factor CCAAT/enhancer binding protein (C/EBP)p is critical for normal growth and differentiation of the mammary gland. The intronless C/EBPbeta gene encodes a single mRNA that produces three protein isoforms, C/EBPbeta-1, -2, and -3, which share a common basic-leucine zipper domain at their C-terminus, but are distinguished at their N-termini by the in-frame methionine codon used to initiate translation. Although C/EBPbeta-1 and -2 are both transactivators, they likely perform distinct functions in mammary epithelial cells. C/EBPbeta-1 is the only isoform detected in normal human mammary tissue. In breast cancer cell lines, C/EBPbeta-1 is absent, and the C/EBPbeta-2 transactivator is expressed. Moreover, our data suggest that C/EBPbeta-2 is upregulated in human primary breast tumors. To assess C/EBPbeta-2's ability to participate in the transformation process, we generated recombinant retrovirus selectively encoding epitope-tagged C/EBPbeta-2. Strikingly, 10 days after infecting a normal human mammary epithelial cell line (MCF10A) with C/EBPbeta-2 virus, transformed subcultures were readily generated. Specifically, C/EBPbeta-2-overexpressing MCF10A cells form foci, gain anchorage independence, express markers associated with having undergone an epithelial-to-mesenchymal transition, and acquire an invasive phenotype. These studies, and our previous observations, provide supportive evidence that deregulated expression of C/EBPbeta-2 contributes to malignant conversion of the human breast.	Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Vanderbilt University	Sealy, L (corresponding author), Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, 221 Kirkland Hall, Nashville, TN 37232 USA.				NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA68485, CA68485] Funding Source: Medline; NIDDK NIH HHS [DK20593] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baer M, 2000, J BIOL CHEM, V275, P26582, DOI 10.1074/jbc.M004268200; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Buck M, 1999, MOL CELL, V4, P1087, DOI 10.1016/S1097-2765(00)80237-3; Buck M, 2001, MOL CELL, V8, P807, DOI 10.1016/S1097-2765(01)00374-4; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Caivano M, 2001, J BIOL CHEM, V276, P48693, DOI 10.1074/jbc.M108282200; Calkhoven CF, 2000, GENE DEV, V14, P1920; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Eaton EM, 2001, J CELL PHYSIOL, V189, P91, DOI 10.1002/jcp.1139; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Fantl V, 1999, DEV BIOL, V212, P1, DOI 10.1006/dbio.1999.9329; GILLES C, 1996, BREAST J, V2, P83; Gorgoni B, 2001, J BIOL CHEM, V276, P40769, DOI 10.1074/jbc.M106865200; Grignani F, 1998, CANCER RES, V58, P14; Half E, 2002, CANCER RES, V62, P1676; Hanlon M, 2000, BMC Cell Biol, V1, P2, DOI 10.1186/1471-2121-1-2; Hay ED, 1995, ACTA ANAT, V154, P8; Hirai Y, 2001, J CELL BIOL, V153, P785, DOI 10.1083/jcb.153.4.785; Kim YS, 1998, J BIOL CHEM, V273, P27686, DOI 10.1074/jbc.273.42.27686; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200; Lochter A, 1997, J BIOL CHEM, V272, P5007, DOI 10.1074/jbc.272.8.5007; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Montell DJ, 2001, MECH DEVELOP, V105, P19, DOI 10.1016/S0925-4773(01)00393-8; Raught B, 1996, CANCER RES, V56, P4382; Reddy ST, 2000, J BIOL CHEM, V275, P3107, DOI 10.1074/jbc.275.5.3107; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; SEARS RC, 1994, MOL CELL BIOL, V14, P4855, DOI 10.1128/MCB.14.7.4855; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SOMMERS CL, 1992, CANCER RES, V52, P5190; SOMMERS CL, 1989, CANCER RES, V49, P4258; SOULE HD, 1990, CANCER RES, V50, P6075; TAIT L, 1990, CANCER RES, V50, P6087; Thomas B, 2000, EUR J BIOCHEM, V267, P6798, DOI 10.1046/j.1432-1327.2000.01778.x; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; Timchenko NA, 1999, NUCLEIC ACIDS RES, V27, P4517, DOI 10.1093/nar/27.22.4517; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wardlaw SA, 2002, MOL PHARMACOL, V62, P326, DOI 10.1124/mol.62.2.326; Xiong W, 2001, NUCLEIC ACIDS RES, V29, P3087, DOI 10.1093/nar/29.14.3087; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Yuan CJ, 2000, CANCER RES, V60, P1084; Zahnow CA, 1997, J NATL CANCER I, V89, P1887, DOI 10.1093/jnci/89.24.1887; Zahnow CA, 2001, CANCER RES, V61, P261; Zajchowski DA, 2001, CANCER RES, V61, P5168; Zhu SY, 2002, P NATL ACAD SCI USA, V99, P207, DOI 10.1073/pnas.012437299	49	101	103	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 13	2003	22	6					869	883		10.1038/sj.onc.1206216	http://dx.doi.org/10.1038/sj.onc.1206216			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584567				2022-12-28	WOS:000180864300010
J	Zermati, Y; De Sepulveda, P; Feger, F; Letard, S; Kersual, J; Casteran, N; Gorochov, G; Dy, M; Dumas, AR; Dorgham, K; Parizot, C; Bieche, Y; Vidaud, M; Lortholary, O; Arock, M; Hermine, O; Dubreuil, P				Zermati, Y; De Sepulveda, P; Feger, F; Letard, S; Kersual, J; Casteran, N; Gorochov, G; Dy, M; Dumas, AR; Dorgham, K; Parizot, C; Bieche, Y; Vidaud, M; Lortholary, O; Arock, M; Hermine, O; Dubreuil, P			Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms	ONCOGENE			English	Article						mastocytosis; c-kit; STI571; kinase inhibitor	GASTROINTESTINAL STROMAL TUMOR; ACTIVATING MUTATION; MYELOID-LEUKEMIA; CATALYTIC DOMAIN; ABL PROTEIN; BONE-MARROW; LINE UT-7; MASTOCYTOSIS; DIFFERENTIATION; ERYTHROPOIETIN	Systemic mastocytosis (SM) is a rare disease caused by an abnormal mast cell accumulation in various tissues. Two classes of constitutive activating e-kit mutations are found in SM. The most frequent class occurs in the catalytic pocket coding region with substitutions at codon 816 and the other in the intracellular juxtamembrane coding region. Therefore, kinase inhibitors that block mutated c-kit activity might be used as therapeutic agents in SM. Here, we show that STI571 inhibits both wild-type and juxtamembrane mutant c-kit kinase activity, but has no effect an the activity of the D816 V mutant. Accordingly, STI571 selectively decreases the survival of normal mast cell and of mast cell lines either with juxtamembrane c-kit mutations, but not that of tumoral mast cell from patient with SM or of mast cell lines with the D816 V mutation. Therefore, STI571 is not a good candidate to treat SM and specific kinase inhibitors should be designed to inhibit constitutive activating mutations at codon 816.	Hop Necker Enfants Malad, Dept Adult Hematol, F-75743 Paris 15, France; Univ Paris 05, Hop Necker Enfants Malad, CNRS UMR 8603, Paris, France; INSERM, U119, F-13258 Marseille, France; GHPS, Inserm U584, Lab Immunol Cellulaire & Tissulaire, Paris, France; Univ Paris 05, Fac Pharm, UPRES JE 2195, Genet Mol Lab, Paris, France; Hop Avicenne, Dept Internal Med & Infect Dis, F-93009 Bobigny, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13	Dubreuil, P (corresponding author), Hop Necker Enfants Malad, Dept Adult Hematol, 149-161 Rue Sevres, F-75743 Paris 15, France.		Dorgham, karim/A-2241-2016; Gorochov, Guy/P-2911-2017; dubreuil, patrice/F-5346-2011; Vidaud, Michel/O-7346-2017; Dubreuil, Patrice/V-4816-2019; Hermine, Olivier/Q-7072-2018; De sepulveda, paulo/K-6043-2015	Dorgham, karim/0000-0001-9539-3203; dubreuil, patrice/0000-0003-1155-1150; Dubreuil, Patrice/0000-0003-1155-1150; De sepulveda, paulo/0000-0001-8295-5414; PARIZOT, Christophe/0000-0001-5723-4471; LETARD, Sebastien/0000-0002-6508-7376; Hermine, Olivier/0000-0003-2574-3874; Gorochov, Guy/0000-0003-2097-9677				Beghini A, 2000, BLOOD, V95, P726, DOI 10.1182/blood.V95.2.726; Beslu N, 1996, J BIOL CHEM, V271, P20075, DOI 10.1074/jbc.271.33.20075; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Hashimoto K, 1996, AM J PATHOL, V148, P189; HERMINE O, 1992, BLOOD, V80, P3060; Hongyo T, 2000, CANCER RES, V60, P2345; Horny HP, 2001, LEUKEMIA RES, V25, P543, DOI 10.1016/S0145-2126(01)00021-2; Issaad C, 2000, LEUKEMIA, V14, P662, DOI 10.1038/sj.leu.2401730; Joensuu H, 2001, NEW ENGL J MED, V344, P1052, DOI 10.1056/NEJM200104053441404; KITAMURA Y, 1978, BLOOD, V52, P447; Kottaridis PD, 2001, BLOOD, V98, P1752, DOI 10.1182/blood.V98.6.1752; Longley BJ, 2000, HEMATOL ONCOL CLIN N, V14, P697, DOI 10.1016/S0889-8588(05)70303-8; Longley BJ, 1999, P NATL ACAD SCI USA, V96, P1609, DOI 10.1073/pnas.96.4.1609; LONGLEY J, 1995, J AM ACAD DERMATOL, V32, P545, DOI 10.1016/0190-9622(95)90336-4; Marone G, 2001, LEUKEMIA RES, V25, P583, DOI 10.1016/S0145-2126(01)00039-X; Tsujimura T, 1999, BLOOD, V93, P1319, DOI 10.1182/blood.V93.4.1319.404k11_1319_1329; Tsujimura T, 1996, BLOOD, V87, P273; Tuveson DA, 2001, ONCOGENE, V20, P5054, DOI 10.1038/sj.onc.1204704; Valent P, 2001, LEUKEMIA RES, V25, P603, DOI 10.1016/S0145-2126(01)00038-8; VALENT P, 1992, BLOOD, V80, P2237; Worobec AS, 2000, HEMATOL ONCOL CLIN N, V14, P659, DOI 10.1016/S0889-8588(05)70301-4; Yamamoto Y, 2001, BLOOD, V97, P2434, DOI 10.1182/blood.V97.8.2434; Zermati Y, 2000, EXP HEMATOL, V28, P256, DOI 10.1016/S0301-472X(99)00155-1	25	152	162	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 6	2003	22	5					660	664		10.1038/sj.onc.1206120	http://dx.doi.org/10.1038/sj.onc.1206120			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569358				2022-12-28	WOS:000180642100003
J	Lange, K; Uckert, W; Blankenstein, T; Nadrowitz, R; Bittner, C; Renauld, JC; van Snick, J; Feller, AC; Merz, H				Lange, K; Uckert, W; Blankenstein, T; Nadrowitz, R; Bittner, C; Renauld, JC; van Snick, J; Feller, AC; Merz, H			Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice	ONCOGENE			English	Article						t(2;5) translocation; anaplastic lymphoma kinase (ALK); IL-9 transgenic mice; retroviral-mediated gene transfer	NON-HODGKINS-LYMPHOMA; GENE-TRANSFER; TYROSINE KINASE; CELL LYMPHOMA; INTERLEUKIN-9; PROTEIN; FUSION; SUBTYPE; GROWTH; MODEL	Anaplastic large-cell lymphoma (ALCL) comprises approximately 25% of all non-Hodgkin lymphomas (NHL) in children and young adults, and up to 15% of high-grade NHL in older patients. Over 50% of these tumours carry the translocation t(2;5)(p23;q35). The result of this translocation is the fusion of the nucleophosmin (NPM) gene to the anaplastic lymphoma kinase (ALK) gene. The resulting hybrid protein contains the ALK catalytic domain that consequently confers transforming potential, which contributes to the pathogenesis of ALCL. To further analyse the transforming activity in an animal model, a cDNA encoding the protein product, NPM-ALK, was inserted into the retrovirus vector pLXSN and transduced into mouse bone marrow progenitors. These cells were subsequently used in a bone marrow transplant with the aim of reconstituting the haematopoietic compartments of lethally irradiated recipients. IL-9 transgenic mice were chosen as the animal model system, because dysregulated expression of the IL-9 gene in transgenic mice results in the sporadic development of spontaneous thymic lymphomas. Moreover, IL-9 is known to be expressed in cases of human ALCL. We used 15 IL-9 transgenic mice and eight corresponding wild-type mice (FVB/N) and transplanted them with NPM/ALK infected bone marrow cells. Eight IL-9 transgenic mice, serving as a control group, received pLXSN (vector only)-infected marrow. Reconstituted mice developed NPM-ALK-positive lymphomas, including lymphoblastic lymphomas of T-cell type (T-LB), mature and immature plasmacytoma (PC), and plasmoblastic/anaplastic diffuse large-B-cell lymphoma after about 19-20 weeks. The combined overexpression of NPM-ALK and IL-9 led to the transformation of murine lymphoid cells with accelerated and enhanced development of T-LB in 46% of the mice, which only very rarely occurs in IL-9 transgenic mice only. Of the 15 animals, five (33%) developed plasmacytic/plasmoblastic neoplasms, of which the most aggressive tumours share many features with anaplastic/plasmoblastic diffuse large-B-cell lymphoma on the basis of morphology, a characteristic growth pattern and ALK expression.	Med Univ Lubeck, Dept Pathol, D-23538 Lubeck, Germany; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany; Med Univ Lubeck, Inst Radiotherapy & Nucl Med, D-23538 Lubeck, Germany; Ludwig Inst Canc Res, B-1200 Brussels, Belgium	University of Lubeck; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Lubeck; Ludwig Institute for Cancer Research	Lange, K (corresponding author), Med Univ Lubeck, Dept Pathol, Ratzeburger Allee 160, D-23538 Lubeck, Germany.	lange@patho.mu-luebeck.de	Renauld, Jean-Christophe/B-7268-2012	Renauld, Jean-Christophe/0000-0003-1736-2131				Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; Bittner C, 2000, LAB INVEST, V80, P1523, DOI 10.1038/labinvest.3780162; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Delsol G, 1997, BLOOD, V89, P1483, DOI 10.1182/blood.V89.5.1483.1483_1483_1490; Demoulin J B, 1998, Int Rev Immunol, V16, P345, DOI 10.3109/08830189809043001; DUGAS B, 1993, EUR J IMMUNOL, V23, P1687, DOI 10.1002/eji.1830230743; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Kuefer MU, 1997, BLOOD, V90, P2901, DOI 10.1182/blood.V90.8.2901; Ladanyi M, 1997, CANCER SURV, V30, P59; Lawrence B, 2000, AM J PATHOL, V157, P377, DOI 10.1016/S0002-9440(10)64550-6; LEBEAU MM, 1989, LEUKEMIA, V3, P866; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Maes B, 2001, AM J PATHOL, V158, P2185, DOI 10.1016/S0002-9440(10)64690-1; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MERZ H, 1991, BLOOD, V78, P1311; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; PETITFRERE C, 1993, IMMUNOLOGY, V79, P146; Plowman GD, 1999, P NATL ACAD SCI USA, V96, P13603, DOI 10.1073/pnas.96.24.13603; Rabbitts TH, 2001, ONCOGENE, V20, P5763, DOI 10.1038/sj.onc.1204597; RENAULD JC, 1994, ONCOGENE, V9, P1327; RENAULD JC, 1995, BLOOD, V85, P1300, DOI 10.1182/blood.V85.5.1300.bloodjournal8551300; Robinson DR, 2000, ONCOGENE, V19, P5548, DOI 10.1038/sj.onc.1203957; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; Tort F, 2001, LAB INVEST, V81, P419, DOI 10.1038/labinvest.3780249; Touriol C, 2000, BLOOD, V95, P3204, DOI 10.1182/blood.V95.10.3204.010k04_3204_3207; Uckert W, 2000, METH MOLEC MED, V35, P275, DOI 10.1385/1-59259-086-1:275; UYTTENHOVE C, 1991, J EXP MED, V173, P519, DOI 10.1084/jem.173.2.519; VINK A, 1993, EUR J IMMUNOL, V23, P1134, DOI 10.1002/eji.1830230523; Wellmann A, 1997, FASEB J, V11, P965, DOI 10.1096/fasebj.11.12.9337149	33	64	67	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2003	22	4					517	527		10.1038/sj.onc.1206076	http://dx.doi.org/10.1038/sj.onc.1206076			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555065	Bronze			2022-12-28	WOS:000180538200005
J	Arsura, M; Panta, GR; Bilyeu, JD; Cavin, LG; Sovak, MA; Oliver, AA; Factor, V; Heuchel, R; MErcurio, F; Thorgeirsson, SS; Sonenshein, GE				Arsura, M; Panta, GR; Bilyeu, JD; Cavin, LG; Sovak, MA; Oliver, AA; Factor, V; Heuchel, R; MErcurio, F; Thorgeirsson, SS; Sonenshein, GE			Transient activation of NF-kappa B through a TAK1/IKK kinase pathway by TGF-beta 1 inhibits AP-1/SMAD signaling and apoptosis: implications in liver tumor formation	ONCOGENE			English	Article						NF-kappa B; IKK; TGF-beta 1; JNK; AP-1; apoptosis	GROWTH-FACTOR-BETA; MICE LACKING; IKK-ALPHA; EMBRYONIC LETHALITY; TRANSGENIC MICE; HEPATOCELLULAR CARCINOMAS; MEDIATED TRANSCRIPTION; TERMINAL KINASE; ADAPTER PROTEIN; JNK ACTIVATION	NF-kappaB has been implicated in the regulation of apoptosis, a key mechanism of normal and malignant growth control. Previously, we demonstrated that inhibition of NF-kappaB activity by TGF-beta1 leads directly to induction of apoptosis of murine B-cell lymphomas and hepatocytes. Thus, we were surprised to determine that NF-kappaB is transiently activated in response to TGF-beta1 treatment. Here we elucidate the mechanism of TGF-beta1-mediated regulation of NF-kappaB and induction of apoptosis in epithelial cells. We report that TGF-beta1 activates IKK kinase, which mediates IkappaB-alpha phosphorylation. In turn, the activation of IKK following TGF-beta1 treatment is mediated by the TAK1 kinase. As a result of NF-kappaB activation, IkappaB-alpha mRNA and protein levels are increased leading to postrepression of NF-kappaB and induction of cell death. Inhibition of NF-kappaB following TGF-beta1 treatment increased AP-1 complex transcriptional activity through sustained c-Jun phosphorylation, thereby potentiating AP-1/SMADs-mediated cell killing. Furthermore, TGF-beta1-mediated upregulation of Smad7 appeared independent of NF-kappaB. In hepatocellular carcinomas of TGF-beta1 or TGF-alpha/c-myc transgenic mice, we observed constitutive activation of NF-kappaB that led to inhibition of JNK signaling. Overall, our data illustrate an autocrine mechanism based on the ability of IKK/NF-kappaB/IkappaB-alpha signaling to negatively regulate NF-kappaB levels thereby permitting TGF-beta1-induced apoptosis through AP-1 activity.	Univ Tennessee, Coll Med, Dept Pharmacol, Memphis, TN 38163 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; NCI, CCR, Expt Carcinogenesis Lab, Bethesda, MD 20892 USA; Celgene Signal Res Div, San Diego, CA 92121 USA; Ludwig Inst Canc Res, S-75124 Uppsala, Sweden	University of Tennessee System; University of Tennessee Health Science Center; Boston University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Ludwig Institute for Cancer Research	Arsura, M (corresponding author), Univ Tennessee, Coll Med, Dept Pharmacol, 874 Union Ave, Memphis, TN 38163 USA.		Heuchel, Rainer/P-7875-2019	Heuchel, Rainer/0000-0002-2782-585X	NATIONAL CANCER INSTITUTE [R01CA036355, R01CA078616, R01CA082742, Z01BC010036] Funding Source: NIH RePORTER; NCI NIH HHS [CA78616-S1, CA82742, CA36355, CA78616] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Afrakhte M, 1998, BIOCHEM BIOPH RES CO, V249, P505, DOI 10.1006/bbrc.1998.9170; [Anonymous], GENOME BIOL; Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; Arsura M, 1997, CELL GROWTH DIFFER, V8, P1049; Arsura M, 2000, MOL CELL BIOL, V20, P5381, DOI 10.1128/MCB.20.15.5381-5391.2000; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Azuma M, 1999, EXP CELL RES, V250, P213, DOI 10.1006/excr.1999.4503; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Bitzer M, 2000, GENE DEV, V14, P187; Brodin G, 2000, J BIOL CHEM, V275, P29023, DOI 10.1074/jbc.M002815200; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chang H, 2001, MOL CELL ENDOCRINOL, V180, P39, DOI 10.1016/S0303-7207(01)00513-5; Conte D, 2001, P NATL ACAD SCI USA, V98, P5049, DOI 10.1073/pnas.081547998; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Factor V, 2001, HEPATOLOGY, V34, P32, DOI 10.1053/jhep.2001.25270; Factor VM, 1997, CANCER RES, V57, P2089; Holcik M, 2001, NAT REV MOL CELL BIO, V2, P550, DOI 10.1038/35080103; Holtmann H, 2001, J BIOL CHEM, V276, P3508, DOI 10.1074/jbc.M004376200; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Irie T, 2000, FEBS LETT, V467, P160, DOI 10.1016/S0014-5793(00)01146-7; Karin M, 1996, PHILOS T ROY SOC B, V351, P127, DOI 10.1098/rstb.1996.0008; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Kimura N, 2000, J BIOL CHEM, V275, P17647, DOI 10.1074/jbc.M908622199; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LEE HY, 1995, J EXP MED, V181, P1169, DOI 10.1084/jem.181.3.1169; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Lin RT, 1996, MOL CELL BIOL, V16, P1401; Luque I, 1997, SEMIN CANCER BIOL, V8, P103, DOI 10.1006/scbi.1997.0061; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Nagarajan RP, 2000, BIOCHEM J, V348, P591, DOI 10.1042/0264-6021:3480591; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; OBERHAMMER F, 1992, TOXICOL LETT, V64-5, P701, DOI 10.1016/0378-4274(92)90250-N; Patil S, 2000, J BIOL CHEM, V275, P38363, DOI 10.1074/jbc.M004861200; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Pianetti S, 2001, ONCOGENE, V20, P1287, DOI 10.1038/sj.onc.1204257; Reffey SB, 2001, J BIOL CHEM, V276, P26542, DOI 10.1074/jbc.M100331200; Rosenfeld ME, 2000, AM J PATHOL, V156, P997, DOI 10.1016/S0002-9440(10)64967-X; Rudolph D, 2000, GENE DEV, V14, P854; Sakurai H, 1998, BIOCHEM BIOPH RES CO, V243, P545, DOI 10.1006/bbrc.1998.8124; Sakurai H, 1999, J BIOL CHEM, V274, P10641, DOI 10.1074/jbc.274.15.10641; SANDERSON N, 1995, P NATL ACAD SCI USA, V92, P2572, DOI 10.1073/pnas.92.7.2572; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Sovak MA, 1999, CELL GROWTH DIFFER, V10, P537; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takaesu G, 2001, MOL CELL BIOL, V21, P2475, DOI 10.1128/MCB.21.7.2475-2484.2001; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Williams KL, 2001, EUR J IMMUNOL, V31, P1620, DOI 10.1002/1521-4141(200105)31:5<1620::AID-IMMU1620>3.0.CO;2-3; WU JC, 1994, CANCER RES, V54, P5964; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamaguchi K, 1999, EMBO J, V18, P179, DOI 10.1093/emboj/18.1.179; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200; Yao ZB, 1999, J BIOL CHEM, V274, P2118, DOI 10.1074/jbc.274.4.2118; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	73	119	125	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 23	2003	22	3					412	425		10.1038/sj.onc.1206132	http://dx.doi.org/10.1038/sj.onc.1206132			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545162				2022-12-28	WOS:000180379100010
J	Wu, SQ; Cetinkaya, C; Munoz-Alonso, MJ; von der Lehr, N; Bahram, F; Beuger, V; Eilers, M; Leon, J; Larsson, LG				Wu, SQ; Cetinkaya, C; Munoz-Alonso, MJ; von der Lehr, N; Bahram, F; Beuger, V; Eilers, M; Leon, J; Larsson, LG			Myc represses differentiation-induced p21CIP1 expression via Miz-1-dependent interaction with the p21 core promoter	ONCOGENE			English	Article						Myc; Miz-1; p21Cip1; differentiation; cell cycle; transcription	C-MYC; CELL-CYCLE; MYC/MAX/MAD NETWORK; HISTONE ACETYLATION; ESSENTIAL COFACTOR; LEUKEMIA-CELLS; GENE; GROWTH; ACTIVATION; P15(INK4B)	Inhibition of cellular differentiation is one of the well-known biological activities of c-Myc-family proteins. We show here that Myc represses differentiation-induced expression of the cyclin-dependent kinase (CDK) inhibitor p21CIP1 (CDKN1A, p21), known to play an important role in cell fate decisions during growth and differentiation, in hematopoietic cells. Our results demonstrate that the c-Myc-responsive region is situated in the p21 core promoter. c-Myc binds to this region in vitro and in vivo through interaction with the initiator-binding Zn-finger transcription factor Miz-1, which associates directly with the promoter. Association of Myc with the promoter in vivo correlates inversely with p21 expression. Using mutants of c-Myc with impaired binding to Miz-1, our results further show that repression of p21 promoter/reporters as well as the endogenous p21 gene by Myc depends on interaction with Miz-1. Expression of Miz-1 increases during hematopoietic differentiation and Miz-1 activates the p21 promoter under conditions of low Myc levels, indicating a positive role for free Miz-1 in this process. In conclusion, repression of differentiation-induced p21 expression through Miz-1 may be an important mechanism by which Myc blocks differentiation.	Swedish Univ Agr Sci, Dept Plant Biol, Uppsala Genet Ctr, S-75007 Uppsala, Sweden; Univ Cantabria, Dept Biol Mol, E-39005 Santander, Spain; Univ Cantabria, CSIC, Unidad Asociada, E-39005 Santander, Spain; Inst Mol Biol & Tumor Res, Marburg, Germany	Swedish University of Agricultural Sciences; Universidad de Cantabria; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Cantabria	Larsson, LG (corresponding author), Swedish Univ Agr Sci, Dept Plant Biol, Uppsala Genet Ctr, Box 7080, S-75007 Uppsala, Sweden.		Larsson, Lars-Gunnar/D-9747-2012; Leon, Javier/K-4615-2014	Leon, Javier/0000-0001-5803-0112; Eilers, Martin/0000-0002-0376-6533				Amati B, 2001, BBA-REV CANCER, V1471, pM135, DOI 10.1016/S0304-419X(01)00020-8; Bahram F, 1999, BLOOD, V93, P3900, DOI 10.1182/blood.V93.11.3900.411a42_3900_3912; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Ceballos E, 2000, ONCOGENE, V19, P2194, DOI 10.1038/sj.onc.1203541; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Delgado MD, 2000, ONCOGENE, V19, P783, DOI 10.1038/sj.onc.1203384; DELGADO MD, 1995, ONCOGENE, V10, P1659; Eberhardy SR, 2000, J BIOL CHEM, V275, P33798, DOI 10.1074/jbc.M005154200; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; James L, 2002, P NATL ACAD SCI USA, V99, P10429, DOI 10.1073/pnas.162369299; JIANG HP, 1994, ONCOGENE, V9, P3397; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; Levens D, 2002, P NATL ACAD SCI USA, V99, P5757, DOI 10.1073/pnas.102173199; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Mitchell KO, 1999, CELL GROWTH DIFFER, V10, P223; O'Hagan RC, 2000, NAT GENET, V24, P113, DOI 10.1038/72761; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; Ricci AR, 2002, MOL CELL BIOL, V22, P4033, DOI 10.1128/MCB.22.12.4033-4042.2002; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Steinman RA, 2002, ONCOGENE, V21, P3403, DOI 10.1038/sj.onc.1205325; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676; Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zezula J, 2001, EMBO REP, V2, P27, DOI 10.1093/embo-reports/kve008; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213	41	236	244	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 23	2003	22	3					351	360		10.1038/sj.onc.1206145	http://dx.doi.org/10.1038/sj.onc.1206145			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545156				2022-12-28	WOS:000180379100004
J	Elez, R; Piiper, A; Kronenberger, B; Kock, M; Brendel, M; Hermann, E; Pliquett, U; Neumann, E; Zeuzem, S				Elez, R; Piiper, A; Kronenberger, B; Kock, M; Brendel, M; Hermann, E; Pliquett, U; Neumann, E; Zeuzem, S			Tumor regression by combination antisense therapy against Plk1 and Bcl-2	ONCOGENE			English	Article						polo-like kinase 1 (PLK1); BCL-2; antisense therapy; electroporation; cell cycle; mitotic catastrophe	POLO-LIKE KINASE; PROGNOSTIC-SIGNIFICANCE; DNA-DAMAGE; MITOTIC CATASTROPHE; MALIGNANT-MELANOMA; DROSOPHILA POLO; PROTEIN-KINASE; EXPRESSION; INHIBITION; CANCER	Increased expression of the cell proliferation-associated polo-like kinase 1 (PLK1) and apoptosis-associated BCL-2 genes has been observed in different human malignancies. Inhibition of cell proliferation and reactivation of apoptosis are basic principles in anticancer therapy. The efficiency of this approach is often limited by insufficient targeting and delivery of anticancer drugs into the tumors. Phosphorothioate antisense oligodeoxynucleotides (ODNs) directed against PLK1 and BCL-2 were administered systemically via the tail vein into nude mice bearing A549, MDA-MB-435, and Detroit562 xenografts. To enhance tumor-specific uptake and to reduce systemic toxicity of antisense ODNs membrane electroporation transfer was applied in vivo. Northern and Western blot analyses were used to assess PLK1 and BCL-2 expression. Tumor mass was assessed after resection of tumors. All three cell lines and corresponding xenografts expressed high levels of PLK1 and were sensitive towards antisense PLK1 treatment. Antisense BCL-2 therapy was effective in tumors expressing high levels of BCL-2, but not in A549 cells and corresponding xenografts, which express low levels of BCL-2. Administration of antisense ODNs in a dose of 5mg/kg, twice weekly during four weeks supported by the membrane electroporation transfer, eradicated 60-100% of the xenografted tumors. Antitumor effect in BCL-2 overexpressing MDA-MB-435 cells was synergistic for BCL-2 and PLK1 combination therapy. This study provides evidence that combined systemic administration of antisense ODNs against proliferation and pro- survival associated targets and in vivo electroporation of tumors represents a promising antitumor therapeutic approach.	Univ Saarland, Dept Internal Med 2, Mol Oncol Unit, D-66422 Homburg, Germany; Univ Frankfurt, Dept Internal Med, D-60590 Frankfurt, Germany; Univ Frankfurt, Anim Res Facil, Sch Med, D-6000 Frankfurt, Germany; Univ Frankfurt, Inst Microbiol, Frankfurt, Germany; Univ Bielefeld, Fac Chem, D-4800 Bielefeld, Germany	Saarland University; Goethe University Frankfurt; Goethe University Frankfurt; Goethe University Frankfurt; University of Bielefeld	Elez, R (corresponding author), Univ Saarland, Dept Internal Med 2, Mol Oncol Unit, D-66422 Homburg, Germany.		Neumann, Eberhard/AAU-6955-2020; Zeuzem, Stefan/AAE-7435-2019	Neumann, Eberhard/0000-0003-0861-072X; Brendel, Martin/0000-0002-7716-7576				AGRAWAL S, 1991, P NATL ACAD SCI USA, V88, P7595, DOI 10.1073/pnas.88.17.7595; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Cogswell JP, 2000, CELL GROWTH DIFFER, V11, P615; Donaldson MM, 2001, J CELL SCI, V114, P2357; Draghia-Akli R, 1999, NAT BIOTECHNOL, V17, P1179, DOI 10.1038/70718; Elez R, 2000, BIOCHEM BIOPH RES CO, V269, P352, DOI 10.1006/bbrc.2000.2291; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; Grover R, 1996, EUR J SURG ONCOL, V22, P347, DOI 10.1016/S0748-7983(96)90176-6; HAMANAKA R, 1994, CELL GROWTH DIFFER, V5, P249; Heller R, 1998, CANCER-AM CANCER SOC, V83, P148, DOI 10.1002/(SICI)1097-0142(19980701)83:1<148::AID-CNCR20>3.0.CO;2-W; Heller R, 1996, CANCER-AM CANCER SOC, V77, P964, DOI 10.1002/(SICI)1097-0142(19960301)77:5<964::AID-CNCR24>3.0.CO;2-0; Henry SP, 1997, ANTISENSE NUCLEIC A, V7, P503, DOI 10.1089/oli.1.1997.7.503; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; Jansen B, 2000, LANCET, V356, P1728, DOI 10.1016/S0140-6736(00)03207-4; Jansen B, 1998, NAT MED, V4, P232, DOI 10.1038/nm0298-232; Khaled Z, 1996, NUCLEIC ACIDS RES, V24, P737, DOI 10.1093/nar/24.4.737; Knecht R, 1999, CANCER RES, V59, P2794; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; LAKE RJ, 1993, MOL CELL BIOL, V13, P7793, DOI 10.1128/MCB.13.12.7793; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Lebleu B., 1993, ANTISENSE RES APPL; Lee SE, 2001, CURR BIOL, V11, P784, DOI 10.1016/S0960-9822(01)00228-7; Liotta L, 2000, NAT REV GENET, V1, P48, DOI 10.1038/35049567; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MIR LM, 1991, CR ACAD SCI III-VIE, V313, P613; Monia BP, 1996, NAT MED, V2, P668, DOI 10.1038/nm0696-668; NEUMANN E, 1982, EMBO J, V1, P841, DOI 10.1002/j.1460-2075.1982.tb01257.x; Neumann E, 1999, BIOELECTROCH BIOENER, V48, P3, DOI 10.1016/S0302-4598(99)00008-2; Neumann E, 2000, METH MOLEC MED, V37, P1, DOI 10.1385/1-59259-080-2:1; Ramchandani S, 1997, P NATL ACAD SCI USA, V94, P684, DOI 10.1073/pnas.94.2.684; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Sambrook J., 2002, MOL CLONING LAB MANU; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Sheehan JP, 1998, BLOOD, V92, P1617, DOI 10.1182/blood.V92.5.1617.417k13_1617_1625; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; STEIN CA, 1995, NAT MED, V1, P1119, DOI 10.1038/nm1195-1119; SWANSON PE, 1995, AM J PATHOL, V146, P963; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; van Vugt MATM, 2001, J BIOL CHEM, V276, P41656, DOI 10.1074/jbc.M101831200; Wagner RW, 1997, MOL MED TODAY, V3, P31, DOI 10.1016/S1357-4310(96)10053-8; Wang H, 1999, P NATL ACAD SCI USA, V96, P13989, DOI 10.1073/pnas.96.24.13989; Wang YP, 1997, NAT MED, V3, P887, DOI 10.1038/nm0897-887; Webb A, 1997, LANCET, V349, P1137, DOI 10.1016/S0140-6736(96)11103-X; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862	46	77	88	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 9	2003	22	1					69	80		10.1038/sj.onc.1206038	http://dx.doi.org/10.1038/sj.onc.1206038			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527909				2022-12-28	WOS:000180166900008
J	Demple, B; DeMott, MS				Demple, B; DeMott, MS			Dynamics and diversions in base excision DNA repair of oxidized abasic lesions	ONCOGENE			English	Review						AP endonuclease; Apel protein; 2-deoxyribonolactone; 3 '-phosphoglycolate; radiation damage	CELL NUCLEAR ANTIGEN; APURINIC APYRIMIDINIC ENDONUCLEASE; HUMAN APURINIC/APYRIMIDINIC ENDONUCLEASE-1; DEOXYRIBOSE PHOSPHATE EXCISION; COLI EXONUCLEASE-III; ENZYME APEX NUCLEASE; ESCHERICHIA-COLI; POLYMERASE-BETA; STRAND BREAKS; SACCHAROMYCES-CEREVISIAE		Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Demple, B (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA.							BENNETT RAO, 1993, BIOCHEMISTRY-US, V32, P3188, DOI 10.1021/bi00063a034; Bennett RAO, 1999, MOL CELL BIOL, V19, P1800; BERNELOTMOENS C, 1989, NUCLEIC ACIDS RES, V17, P587, DOI 10.1093/nar/17.2.587; Betti M, 2001, J BIOL CHEM, V276, P18038, DOI 10.1074/jbc.M010648200; Blaisdell JO, 2001, P NATL ACAD SCI USA, V98, P7426, DOI 10.1073/pnas.131077798; Cappelli E, 2001, CARCINOGENESIS, V22, P387, DOI 10.1093/carcin/22.3.387; CHAN E, 1987, P NATL ACAD SCI USA, V84, P3189, DOI 10.1073/pnas.84.10.3189; Chappell C, 2002, EMBO J, V21, P2827, DOI 10.1093/emboj/21.11.2827; Chatgilialoglu C, 2001, EXP GERONTOL, V36, P1459, DOI 10.1016/S0531-5565(01)00132-2; Chaudhry MA, 1999, BIOCHEM PHARMACOL, V57, P531, DOI 10.1016/S0006-2952(98)00327-X; CHEN DS, 1991, NUCLEIC ACIDS RES, V19, P5907, DOI 10.1093/nar/19.21.5907; CUNNINGHAM RP, 1986, J BACTERIOL, V168, P1120, DOI 10.1128/jb.168.3.1120-1127.1986; David-Cordonnier MH, 2001, BIOCHEMISTRY-US, V40, P5738, DOI 10.1021/bi002605d; DEDON PC, 1992, CHEM RES TOXICOL, V5, P311, DOI 10.1021/tx00027a001; DeMott MS, 1996, J BIOL CHEM, V271, P30068, DOI 10.1074/jbc.271.47.30068; DeMott MS, 2002, J BIOL CHEM, V277, P7637, DOI 10.1074/jbc.C100577200; DeMott MS, 1998, J BIOL CHEM, V273, P27492, DOI 10.1074/jbc.273.42.27492; DEMPLE B, 1983, J BACTERIOL, V153, P1079, DOI 10.1128/JB.153.2.1079-1082.1983; DEMPLE B, 1986, P NATL ACAD SCI USA, V83, P7731, DOI 10.1073/pnas.83.20.7731; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; Dianov GL, 1999, J BIOL CHEM, V274, P13741, DOI 10.1074/jbc.274.20.13741; Dizdaroglu M, 2002, FREE RADICAL BIO MED, V32, P1102, DOI 10.1016/S0891-5849(02)00826-2; Feng JA, 1998, BIOCHEMISTRY-US, V37, P9605, DOI 10.1021/bi9808619; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Fung H, 1998, CANCER RES, V58, P189; GILONI L, 1981, J BIOL CHEM, V256, P8608; GOODHEAD DT, 1994, INT J RADIAT BIOL, V65, P7, DOI 10.1080/09553009414550021; Grosch S, 1999, BIOCHEM BIOPH RES CO, V261, P859, DOI 10.1006/bbrc.1999.1125; Grosch S, 1998, CANCER RES, V58, P4410; Hadi MZ, 2002, J MOL BIOL, V316, P853, DOI 10.1006/jmbi.2001.5382; Hadi MZ, 2000, ENVIRON MOL MUTAGEN, V36, P312, DOI 10.1002/1098-2280(2000)36:4<312::AID-EM7>3.0.CO;2-K; HARING M, 1994, NUCLEIC ACIDS RES, V22, P2010, DOI 10.1093/nar/22.11.2010; Harrison L, 1998, NUCLEIC ACIDS RES, V26, P932, DOI 10.1093/nar/26.4.932; Hashimoto M, 2001, J AM CHEM SOC, V123, P3161, DOI 10.1021/ja003354z; Hengge-Aronis R, 1999, CURR OPIN MICROBIOL, V2, P148, DOI 10.1016/S1369-5274(99)80026-5; HENNER WD, 1983, J BIOL CHEM, V258, P711; Hwang JT, 1999, NUCLEIC ACIDS RES, V27, P3805, DOI 10.1093/nar/27.19.3805; IDE H, 1994, BIOCHEMISTRY-US, V33, P7842, DOI 10.1021/bi00191a011; Izumi T, 2000, CARCINOGENESIS, V21, P1329, DOI 10.1093/carcin/21.7.1329; Jilani A, 2002, BIOCHEMISTRY-US, V41, P7688, DOI 10.1021/bi012213m; Jilani A, 1999, J CELL BIOCHEM, V73, P188, DOI 10.1002/(SICI)1097-4644(19990501)73:2<188::AID-JCB5>3.3.CO;2-8; Jilani A, 1999, J BIOL CHEM, V274, P24176, DOI 10.1074/jbc.274.34.24176; JOHNSON AW, 1988, J BIOL CHEM, V263, P18017; JOHNSON AW, 1988, J BIOL CHEM, V263, P18009; Johnson RE, 1998, GENE DEV, V12, P3137, DOI 10.1101/gad.12.19.3137; Johnson RE, 1998, CURR GENET, V34, P21, DOI 10.1007/s002940050362; Jourdan M, 1999, BIOCHEMISTRY-US, V38, P3985, DOI 10.1021/bi982743r; Kanno S, 1999, NUCLEIC ACIDS RES, V27, P3096, DOI 10.1093/nar/27.15.3096; Karmakar P, 2001, MUTAGENESIS, V16, P225, DOI 10.1093/mutage/16.3.225; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Kotera M, 2000, CHEM-EUR J, V6, P4163, DOI 10.1002/1521-3765(20001117)6:22<4163::AID-CHEM4163>3.0.CO;2-K; Lenox HJ, 2001, ORG LETT, V3, P2415, DOI 10.1021/ol016255e; Levin JD, 1996, NUCLEIC ACIDS RES, V24, P885, DOI 10.1093/nar/24.5.885; MARSHALL LE, 1981, BIOCHEMISTRY-US, V20, P244, DOI 10.1021/bi00505a003; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Matsumoto Y, 1999, J BIOL CHEM, V274, P33703, DOI 10.1074/jbc.274.47.33703; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; Meijler MM, 1997, J AM CHEM SOC, V119, P1135, DOI 10.1021/ja962409n; Minko IG, 2002, P NATL ACAD SCI USA, V99, P1905, DOI 10.1073/pnas.042700399; Mol CD, 2000, MUTAT RES-DNA REPAIR, V460, P211, DOI 10.1016/S0921-8777(00)00028-8; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; Nakamura J, 2000, J BIOL CHEM, V275, P5323, DOI 10.1074/jbc.275.8.5323; Nakamura J, 1999, CANCER RES, V59, P2522; Olivares M, 1999, J BIOL CHEM, V274, P23883, DOI 10.1074/jbc.274.34.23883; ONO Y, 1994, MUTAT RES, V315, P55, DOI 10.1016/0921-8777(94)90028-0; Perrin DM, 1996, PROG NUCLEIC ACID RE, V52, P123, DOI 10.1016/S0079-6603(08)60966-6; Piersen CE, 1996, J BIOL CHEM, V271, P17811, DOI 10.1074/jbc.271.30.17811; Pomposiello PJ, 2002, ADV MICROB PHYSIOL, V46, P319, DOI 10.1016/S0065-2911(02)46007-9; Pomposiello PJ, 2001, J BACTERIOL, V183, P3890, DOI 10.1128/JB.183.13.3890-3902.2001; POPE LM, 1982, J BIOL CHEM, V257, P2121; POPOFF SC, 1990, P NATL ACAD SCI USA, V87, P4193, DOI 10.1073/pnas.87.11.4193; Povirk LF, 1996, MUTAT RES-FUND MOL M, V355, P71, DOI 10.1016/0027-5107(96)00023-1; Prasad R, 2000, J BIOL CHEM, V275, P4460, DOI 10.1074/jbc.275.6.4460; RALEIGH JA, 1989, FREE RADICAL RES COM, V6, P141, DOI 10.3109/10715768909073453; Ramana CV, 1998, P NATL ACAD SCI USA, V95, P5061, DOI 10.1073/pnas.95.9.5061; RAMOTAR D, 1991, MOL CELL BIOL, V11, P4537, DOI 10.1128/MCB.11.9.4537; RAMOTAR D, 1993, J BIOL CHEM, V268, P20533; RICHARDSON CC, 1964, J BIOL CHEM, V239, P251; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P5519, DOI 10.1093/nar/19.20.5519; SAK BD, 1989, P NATL ACAD SCI USA, V86, P3271, DOI 10.1073/pnas.86.9.3271; Sander M, 1997, BIOCHEMISTRY-US, V36, P6100, DOI 10.1021/bi970048y; SANDER M, 1995, BIOCHEMISTRY-US, V34, P1267, DOI 10.1021/bi00004a021; SEKI S, 1991, J BIOL CHEM, V266, P20797; SEKI S, 1991, BIOCHIM BIOPHYS ACTA, V1079, P57, DOI 10.1016/0167-4838(91)90024-T; SIWEK B, 1988, NUCLEIC ACIDS RES, V16, P5031, DOI 10.1093/nar/16.11.5031; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; SOLTIS DA, 1982, J BIOL CHEM, V257, P1332; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Strauss PR, 1997, J BIOL CHEM, V272, P1302, DOI 10.1074/jbc.272.2.1302; Sutherland BM, 2000, P NATL ACAD SCI USA, V97, P103, DOI 10.1073/pnas.97.1.103; Sutherland BM, 2000, BIOCHEMISTRY-US, V39, P8026, DOI 10.1021/bi9927989; Tom S, 2000, J BIOL CHEM, V275, P10498, DOI 10.1074/jbc.275.14.10498; Tsuchimoto D, 2001, NUCLEIC ACIDS RES, V29, P2349, DOI 10.1093/nar/29.11.2349; Unk I, 2001, MOL CELL BIOL, V21, P1656, DOI 10.1128/MCB.21.5.1656-1661.2001; Von Sonntag C, 1987, CHEM BASIS RAD BIOL; WALKER LJ, 1994, NUCLEIC ACIDS RES, V22, P4884, DOI 10.1093/nar/22.23.4884; Whitehouse CJ, 2001, CELL, V104, P107, DOI 10.1016/S0092-8674(01)00195-7; Wilson DM, 1995, NUCLEIC ACIDS RES, V23, P5027; WINTERS TA, 1994, NUCLEIC ACIDS RES, V22, P1866, DOI 10.1093/nar/22.10.1866; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23; XU Y, 2002, IN PRESS DNA REPAIR; Xu YJ, 1998, J BIOL CHEM, V273, P28837, DOI 10.1074/jbc.273.44.28837; Zelenko O, 1998, INORG CHEM, V37, P2198, DOI 10.1021/ic971154r	109	82	82	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 16	2002	21	58					8926	8934		10.1038/sj.onc.1206178	http://dx.doi.org/10.1038/sj.onc.1206178			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	626TP	12483509				2022-12-28	WOS:000179889500004
J	Kadakia, M; Brown, TL; McGorry, MM; Berberich, SJ				Kadakia, M; Brown, TL; McGorry, MM; Berberich, SJ			MdmX inhibits Smad transactivation	ONCOGENE			English	Article						MdmX; Mdm2; Smad; TGF-beta	GROWTH-FACTOR-BETA; P53; EXPRESSION; PROTEIN; DIFFERENTIATION; DEGRADATION; INTERACTS; PROMOTES; PATHWAY; ARREST	Mdm2 overexpression confers a growth promoting activity upon cells primarily by downregulating the p53 tumor suppressor protein. Nevertheless, Mdm2 deregulation has also been implicated in inhibiting TGF-beta growth repression in a p53 independent manner. Our goal in this study was to examine whether overexpression of Mdm2 or MdmX, a Mdm2-related protein, could affect Smad-induced transactivation. As downstream signaling elements of the TGF-beta pathway, Smads represent one potential target for Mdm2 and MdmX. Here we show that MdmX but not Mdm2 is capable of inhibiting Smad induced transactivation. Based on deletion mutant analysis, MdmX inhibition of Smad transactivation was independent of the p53 and Mdm2 interaction domains, yet required amino acid residues 128-444. Using TGF-beta sensitive HepG2 cells, MdmX overexpression was shown to inhibit TGF-beta induced Smad transactivation. Additionally, mouse embryo fibroblasts (MEFs) lacking p53 and MdmX showed enhanced Smad transactivation when compared to MEFs lacking either p53 or p53 and Mdm2. Interestingly, the inhibition of Smad transactivation by MdmX could be reversed by p300, a functional co-activator of Smads and a necessary factor for Mdm2 nuclear export and did not result from altered Smad localization. In vitro studies demonstrate that MdmX binds to p300 as well as Smad3 and Smad4. Taken together, these results suggest that inhibition of Smad-induced transactivation by MdmX occurs by altering Smad interaction with its coactivator p300.	Wright State Univ, Dept Biochem & Mol Biol, Dayton, OH 45435 USA; Wright State Univ, Dept Physiol & Biophys, Dayton, OH 45435 USA	University System of Ohio; Wright State University Dayton; University System of Ohio; Wright State University Dayton	Berberich, SJ (corresponding author), Wright State Univ, Dept Biochem & Mol Biol, Dayton, OH 45435 USA.	steven.berberich@wright.edu			NATIONAL CANCER INSTITUTE [R29CA064430, R01CA064430] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA064430, CA64430, R01 CA064430-09] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Blain SW, 2000, J BIOL CHEM, V275, P32066, DOI 10.1074/jbc.M006496200; Brown TL, 1998, CELL GROWTH DIFFER, V9, P869; Datta PK, 2000, J BIOL CHEM, V275, P40014, DOI 10.1074/jbc.C000508200; Datto M, 2000, CYTOKINE GROWTH F R, V11, P37, DOI 10.1016/S1359-6101(99)00027-1; de Caestecker MP, 2000, J BIOL CHEM, V275, P2115, DOI 10.1074/jbc.275.3.2115; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Finch RA, 2002, CANCER RES, V62, P3221; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Iavarone A, 1999, MOL CELL BIOL, V19, P916; Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000; Jackson MW, 1999, DNA CELL BIOL, V18, P693, DOI 10.1089/104454999314971; JACKSON MW, 2001, J BIOL CHEM, V10, P10; Kadakia M, 2001, DNA CELL BIOL, V20, P321, DOI 10.1089/10445490152122433; Kim RH, 2000, GENE DEV, V14, P1605; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Luna RMD, 1997, NAT GENET, V16, P336; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Migliorini D, 2002, MOL CELL BIOL, V22, P5527, DOI 10.1128/MCB.22.15.5527-5538.2002; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; PENTTINEN RP, 1988, P NATL ACAD SCI USA, V85, P1105, DOI 10.1073/pnas.85.4.1105; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; SANDLER MA, 1994, J BIOL CHEM, V269, P21500; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; TERUEL T, 1995, FEBS LETT, V364, P193, DOI 10.1016/0014-5793(95)00385-M; Thomas A, 1998, GENE DEV, V12, P1975, DOI 10.1101/gad.12.13.1975; WARNER GL, 1992, CELL GROWTH DIFFER, V3, P175; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Wrana JL, 2000, CYTOKINE GROWTH F R, V11, P5, DOI 10.1016/S1359-6101(99)00024-6; Yam CH, 1999, CANCER RES, V59, P5075; Zhu QZ, 2001, J BIOL CHEM, V276, P29695, DOI 10.1074/jbc.M102634200	41	30	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2002	21	57					8776	8785		10.1038/sj.onc.1205993	http://dx.doi.org/10.1038/sj.onc.1205993			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483531				2022-12-28	WOS:000179734400012
J	Sitwala, KV; Adams, K; Markovitz, DM				Sitwala, KV; Adams, K; Markovitz, DM			YY1 and NF-Y binding sites regulate the transcriptional activity of the dek and dek-can promoter	ONCOGENE			English	Article						DEK; NF-Y; YY1; transcription; cancer	ACUTE MYELOID-LEUKEMIA; JUVENILE RHEUMATOID-ARTHRITIS; MESSENGER-RNA; EXPRESSION CLONING; PROTEIN; GENES; IDENTIFICATION; CELLS; TRANSLOCATION; ORGANIZATION	The mammalian protein DEK has been implicated in multiple cellular processes, including transcriptional regulation, mRNA processing, and chromatin remodeling, and is associated with a number of clinical autoimmune and neoplastic conditions. The connection between DEK and cancer exists at multiple levels: (a) the t(6;9) chromosomal translocation that characterizes a subtype of acute myelogenous leukemia cases results in the formation of a DEK-CAN fusion oncoprotein; (b) a fragment of dek cDNA is capable of partially reversing the radiation-sensitive phenotype of fibroblasts cultured from ataxia-telangiectasia patients; and (c) increased levels of dek mRNA have been found to be associated with hepatocellular carcinoma, glioblastoma, and melanoma. Despite the growing list of cancer subtypes with a connection to DEK, the factors that mediate its expression have yet to be characterized. Here we undertake the analysis of DEK regulation by mapping the discrete elements within the proximal promoter that are responsible for constitutive transcription of dek in transformed cells. We find that functional elements include an inverted CCAAT box and a YY1 consensus binding site, and the introduction of point mutations into these sites markedly diminishes transcriptional activity. In addition, we identify the transcriptional activator NF-Y as a member of the CCAAT-binding complex, and verify binding of the transcription factor YY1 at its consensus site in the dek promoter. The discovery of NF-Y and YY1 as regulatory determinants of DEK expression is consistent with the well-documented roles of these two factors in cellular proliferation and transformation.	Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Mol & Cellular Biol Program, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Markovitz, DM (corresponding author), Univ Michigan, Dept Internal Med, 1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	dmarkov@umich.edu			NIAID NIH HHS [AI 36685] Funding Source: Medline; NIGMS NIH HHS [T32 GM07863] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036685] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007863] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexiadis V, 2000, GENE DEV, V14, P1308; Aravind L, 2000, TRENDS BIOCHEM SCI, V25, P112, DOI 10.1016/S0968-0004(99)01537-6; Arnaudo JP, 1998, J RHEUMATOL, V25, P1861; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dong XW, 2000, ARTHRITIS RHEUM-US, V43, P85, DOI 10.1002/1529-0131(200001)43:1<85::AID-ANR11>3.0.CO;2-D; Donohoe ME, 1999, MOL CELL BIOL, V19, P7237; Duan ZJ, 2001, MOL CELL BIOL, V21, P3083, DOI 10.1128/MCB.21.9.3083-3095.2001; Faulkner NE, 2001, J BIOL CHEM, V276, P25804, DOI 10.1074/jbc.M006454200; FLANAGAN JR, 1995, CELL GROWTH DIFFER, V6, P185; FORNEROD M, 1995, ONCOGENE, V10, P1739; Fu GK, 1997, P NATL ACAD SCI USA, V94, P1811, DOI 10.1073/pnas.94.5.1811; Grottke C, 2000, INT J CANCER, V88, P535, DOI 10.1002/1097-0215(20001115)88:4<535::AID-IJC4>3.0.CO;2-V; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Hu QH, 2000, J BIOL CHEM, V275, P4435, DOI 10.1074/jbc.275.6.4435; Kondoh N, 1999, CANCER RES, V59, P4990; Kroes RA, 2000, CANCER LETT, V156, P191, DOI 10.1016/S0304-3835(00)00462-6; Le Hir H, 2000, EMBO J, V19, P6860, DOI 10.1093/emboj/19.24.6860; Le Hir H, 2001, EMBO J, V20, P4987, DOI 10.1093/emboj/20.17.4987; LI XY, 1992, J BIOL CHEM, V267, P8984; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; McGarvey T, 2000, J CELL BIOL, V150, P309, DOI 10.1083/jcb.150.2.309; MEYN MS, 1993, AM J HUM GENET, V53, P1206; Minuzzo M, 2000, P NATL ACAD SCI USA, V97, P6780, DOI 10.1073/pnas.97.12.6780; Murray KJ, 1997, J RHEUMATOL, V24, P560; Petkova V, 2001, J BIOL CHEM, V276, P7932, DOI 10.1074/jbc.M007411200; SHI Y, 1997, BIOCHIM BIOPHYS ACTA, V1332, P49; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; SIERAKOWSKA H, 1993, CLIN EXP IMMUNOL, V94, P435; Tanaka H, 1999, MOL PHARMACOL, V55, P356, DOI 10.1124/mol.55.2.356; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687; Zhou YH, 1998, J NATL CANCER I, V90, P381, DOI 10.1093/jnci/90.5.381	32	40	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2002	21	57					8862	8870		10.1038/sj.onc.1206041	http://dx.doi.org/10.1038/sj.onc.1206041			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483538				2022-12-28	WOS:000179734400019
J	Heisterkamp, N; Groffen, J				Heisterkamp, N; Groffen, J			Philadelphia-positive leukemia: a personal perspective	ONCOGENE			English	Article						BCR/ABL; leukemia; BCR; ABL; Crkl; somatic cell hybrids	CHRONIC MYELOGENOUS LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; C-ABL ONCOGENE; CHRONIC MYELOCYTIC-LEUKEMIA; TRANSFERASE INHIBITOR SCH66336; CHRONIC MYELOID-LEUKEMIA; ALTERED TRANSCRIPTION; TRANSGENIC MICE; KINASE-ACTIVITY; GENE-PRODUCT		Childrens Hosp Los Angeles, Res Inst, Div Hematol Oncol, Sect Mol Cacinogenesis, Los Angeles, CA 90027 USA; Univ So Calif, Keck Sch Med, Los Angeles, CA 90027 USA	Children's Hospital Los Angeles; University of Southern California	Heisterkamp, N (corresponding author), Childrens Hosp Los Angeles, Res Inst, Div Hematol Oncol, Sect Mol Cacinogenesis, Ms 54, Los Angeles, CA 90027 USA.		Heisterkamp, Nora/C-1698-2012	Heisterkamp, Nora/0000-0003-2769-2273	NCI NIH HHS [CA50248, CA90321] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090321, R01CA050248] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTRAM CR, 1983, NATURE, V306, P277, DOI 10.1038/306277a0; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; CANAANI E, 1984, LANCET, V1, P593; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; CHISSOE SL, 1995, GENOMICS, V27, P67, DOI 10.1006/geno.1995.1008; COLLINS SJ, 1984, SCIENCE, V225, P72, DOI 10.1126/science.6587568; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DEKLEIN A, 1986, BLOOD, V68, P1369; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; ERIKSON J, 1986, P NATL ACAD SCI USA, V83, P1807, DOI 10.1073/pnas.83.6.1807; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; FREED E, 1992, MOL CELL BIOL, V12, P1312, DOI 10.1128/MCB.12.3.1312; GALE RP, 1984, P NATL ACAD SCI-BIOL, V81, P5648, DOI 10.1073/pnas.81.18.5648; Goldman J, 2001, SEMIN HEMATOL, V38, P28, DOI 10.1053/shem.2001.27081; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; GROFFEN J, 1982, SCIENCE, V216, P1136, DOI 10.1126/science.6281890; GROFFEN J, 1983, NATURE, V304, P167, DOI 10.1038/304167a0; HARIHARAN IK, 1989, MOL CELL BIOL, V9, P2798, DOI 10.1128/MCB.9.7.2798; HEISTERKAMP N, 1982, NATURE, V299, P747, DOI 10.1038/299747a0; HEISTERKAMP N, 1983, Journal of Molecular and Applied Genetics, V2, P57; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HEISTERKAMP N, 1983, VIROLOGY, V126, P248, DOI 10.1016/0042-6822(83)90476-2; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HEISTERKAMP N, 1988, NUCLEIC ACIDS RES, V16, P10069, DOI 10.1093/nar/16.21.10069; Hemmeryckx B, 2002, ONCOGENE, V21, P3225, DOI 10.1038/sj.onc.1205452; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; Kardinal C, 2000, FASEB J, V14, P1529, DOI 10.1096/fj.14.11.1529; KLOETZER W, 1985, VIROLOGY, V140, P230, DOI 10.1016/0042-6822(85)90361-7; KOH EY, 2001, CHRONIC MYELOID LEUK, P55; KONOPKA JB, 1985, P NATL ACAD SCI USA, V82, P1810, DOI 10.1073/pnas.82.6.1810; Mauro MJ, 2002, J CLIN ONCOL, V20, P325, DOI 10.1200/JCO.20.1.325; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; NOWELL PC, 1960, SCIENCE, V132, P1497; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; Peters DG, 2001, BLOOD, V97, P1404, DOI 10.1182/blood.V97.5.1404; Reichert A, 2001, BLOOD, V97, P1399, DOI 10.1182/blood.V97.5.1399; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; STAM K, 1987, MOL CELL BIOL, V7, P1955, DOI 10.1128/MCB.7.5.1955; STAM K, 1985, NEW ENGL J MED, V313, P1429, DOI 10.1056/NEJM198512053132301; Tari AM, 1997, BIOCHEM BIOPH RES CO, V235, P383, DOI 10.1006/bbrc.1997.6791; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837	43	17	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	2002	21	56					8536	8540		10.1038/sj.onc.1206080	http://dx.doi.org/10.1038/sj.onc.1206080			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZF	12476299				2022-12-28	WOS:000179734300002
J	Perrotti, D; Calabretta, B				Perrotti, D; Calabretta, B			Post-transcriptional mechanisms in BCR/ABL leukemogenesis: role of shuttling RNA-binding proteins	ONCOGENE			English	Article						BCR/ABL; STAT-5; hnRNP Al; leukemogenesis; CML	CHRONIC MYELOGENOUS LEUKEMIA; ACUTE MYELOID-LEUKEMIA; BCR-ABL; HNRNP A1; TRANSCRIPTION FACTORS; MESSENGER-RNAS; BETA-CATENIN; KINASE-C; V-ABL; EXPRESSION	Shuttling hnRNPs control the fate of eukaryotic mRNAs throughout their journey from the active site of transcription to that of translation; thus, gain or loss of their function in hematopoietic cells might result in altered hematopoiesis and/or be associated with the process of leukemogenesis. In BCR/ABL-expressing cells, there is a marked increase in the protein levels FUS, hnRNP A1 and hnRNP E2, three RNA-binding proteins involved in the regulation of mRNA processing, nucleocytoplasmic export, and translation. Ectopic expression and/or inhibition of the activity of these RNA-binding proteins affects proliferation, survival, and differentiation of normal and BCR/ABL-expressing cells, suggesting that enhanced expression/activity of certain RNA-binding proteins plays an important, but as yet unrecognized, role in BCR/ABL leukemogenesis. The identification of the mRNA subsets associated with RNA-binding proteins upregulated in BCR/ABL-expressing cells should functionally link the process of leukemogenesis with alteration of mRNA metabolism.	Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University	Calabretta, B (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Bluemle Life Sci Bldg,Room 630,233 S 10th St, Philadelphia, PA 19107 USA.	Bruno.Calabretta@mail.tju.edu	Perrotti, Danilo/E-3852-2011					Akamatsu W, 1999, P NATL ACAD SCI USA, V96, P9885, DOI 10.1073/pnas.96.17.9885; Aman P, 1996, GENOMICS, V37, P1, DOI 10.1006/geno.1996.0513; BEDI A, 1994, BLOOD, V83, P2038; BHATIA R, 1994, J CLIN INVEST, V94, P384, DOI 10.1172/JCI117333; BIAMONTI G, 1993, J MOL BIOL, V230, P77, DOI 10.1006/jmbi.1993.1127; Blanchette M, 1999, EMBO J, V18, P1939, DOI 10.1093/emboj/18.7.1939; Brown V, 2001, CELL, V107, P477, DOI 10.1016/S0092-8674(01)00568-2; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; CALVIO C, 1995, RNA, V1, P724; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; CHABOT B, 1997, MOL CELL BIOL, V19, P251; Chansky HA, 2001, CANCER RES, V61, P3586; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; Dai ZH, 1998, GENE DEV, V12, P1415, DOI 10.1101/gad.12.10.1415; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Darnell JC, 2001, CELL, V107, P489, DOI 10.1016/S0092-8674(01)00566-9; Deutsch E, 2001, BLOOD, V97, P2084, DOI 10.1182/blood.V97.7.2084; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; Gouble A, 2002, CANCER RES, V62, P1489; Hamasaki M, 2001, ANTICANCER RES, V21, P979; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; Hicks GG, 2000, NAT GENET, V24, P175, DOI 10.1038/72842; Iervolino A, 2002, MOL CELL BIOL, V22, P2255, DOI 10.1128/MCB.22.7.2255-2266.2002; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Izaurralde E, 1997, J CELL BIOL, V137, P27, DOI 10.1083/jcb.137.1.27; Jin P, 2000, HUM MOL GENET, V9, P901, DOI 10.1093/hmg/9.6.901; KANTARJIAN HM, 1993, BLOOD, V82, P691; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; LANEUVILLE P, 1991, ONCOGENE, V6, P275; Lian Z, 2001, BLOOD, V98, P513, DOI 10.1182/blood.V98.3.513; Majewski M, 1999, CANCER RES, V59, P2815; Mandal M, 2001, J BIOL CHEM, V276, P9699, DOI 10.1074/jbc.M008514200; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MICHAEL WM, 1995, CELL, V83, P415; Mills KI, 2000, BRIT J HAEMATOL, V108, P316; NAKAJIMA H, 2001, BLOOD, V98, P2077; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Ostareck-Lederer A, 1998, TRENDS BIOCHEM SCI, V23, P409, DOI 10.1016/S0968-0004(98)01301-2; PANAGOPOULOS I, 1995, ONCOGENE, V11, P1133; Perrotti D, 2000, MOL CELL BIOL, V20, P6159, DOI 10.1128/MCB.20.16.6159-6169.2000; Perrotti D, 2002, NAT GENET, V30, P48, DOI 10.1038/ng791; Perrotti D, 1998, EMBO J, V17, P4442, DOI 10.1093/emboj/17.15.4442; PINOLROMA S, 1991, SCIENCE, V253, P312, DOI 10.1126/science.1857966; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; Ron D, 1997, CURR TOP MICROBIOL, V220, P131; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; Siomi MC, 1997, J CELL BIOL, V138, P1181, DOI 10.1083/jcb.138.6.1181; Skorski T, 1998, P NATL ACAD SCI USA, V95, P11858, DOI 10.1073/pnas.95.20.11858; Skorski T, 1996, BLOOD, V88, P1005, DOI 10.1182/blood.V88.3.1005.1005; Slupianek A, 2001, MOL CELL, V8, P795, DOI 10.1016/S1097-2765(01)00357-4; Sueoka E, 1999, CANCER RES, V59, P1404; Svitkin YV, 1996, EMBO J, V15, P7147, DOI 10.1002/j.1460-2075.1996.tb01106.x; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Tenenbaum SA, 2000, P NATL ACAD SCI USA, V97, P14085, DOI 10.1073/pnas.97.26.14085; Ward AC, 2000, LEUKEMIA, V14, P973, DOI 10.1038/sj.leu.2401808; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yang L, 2000, MOL CELL BIOL, V20, P3345, DOI 10.1128/MCB.20.10.3345-3354.2000; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zinszner H, 1997, J CELL SCI, V110, P1741; Zou XM, 1999, J BIOL CHEM, V274, P18141, DOI 10.1074/jbc.274.26.18141	68	50	54	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2002	21	56					8577	8583		10.1038/sj.onc.1206085	http://dx.doi.org/10.1038/sj.onc.1206085			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZF	12476304				2022-12-28	WOS:000179734300007
J	Heighway, J; Knapp, T; Boyce, L; Brennand, S; Field, JK; Betticher, DC; Ratschiller, D; Gugger, M; Donovan, M; Lasek, A; Rickert, P				Heighway, J; Knapp, T; Boyce, L; Brennand, S; Field, JK; Betticher, DC; Ratschiller, D; Gugger, M; Donovan, M; Lasek, A; Rickert, P			Expression profiling of primary non-small cell lung cancer for target identification	ONCOGENE			English	Article						lung; cancer; microarray; expression; target identification	TUMOR-SUPPRESSOR; GENE-EXPRESSION; OVARIAN-CANCER; MESSENGER-RNA; S100A2; CLASSIFICATION; ADENOCARCINOMA; DISTINCT; MUTATION; PROTEINS	Using a panel of cDNA microarrays comprising 47 650 transcript elements, we have carried out a dual-channel analysis of gene expression in 39 resected primary human non-small cell lung tumours versus normal lung tissue. Whilst similar to11000 elements were scored as differentially expressed at least twofold in at least one sample, 96 transcripts were scored as over-represented fourfold or more in at least seven out of 39 tumours and 30 sequences 16-fold in at least two out of 39 tumours, including 24 transcripts in common. Transcripts (178) were found under-represented fourfold in at least seven out of 39 tumours, 31 of which are under-represented 16-fold in at least two out of 39 lesions. The relative expression levels of representative genes from these lists were analysed by comparative multiplex RT-PCR and found to be broadly consistent with the microarray data. Two dramatically over-represented genes, previously designated as potential tumour suppressors in breast (maspin) and lung and breast (S100A2) cancers, were analysed more extensively and demonstrate the effectiveness of this approach in identifying potential lung cancer diagnostic or therapeutic targets. Whilst it has been reported that S100A2 is downregulated in NSCLC at an early stage, our microarray, cmRT-PCR, Western and immunohistochemistry data indicate that it is strongly expressed in the majority of tumours.	Univ Liverpool, Roy Castle Int Ctr Lung Canc Res, Target Identificat Grp, Liverpool, Merseyside, England; Univ Bern, Inst Med Oncol, CH-3010 Bern, Switzerland; Incyte Genom Inc, Palo Alto, CA 94304 USA	University of Liverpool; University of Bern; Incyte	Heighway, J (corresponding author), Univ Liverpool, Roy Castle Int Ctr Lung Canc Res, Target Identificat Grp, 200 London Rd, Liverpool, Merseyside, England.		Betticher, Daniel C/G-5849-2013; Field, John K./AAD-5674-2020	Field, John K./0000-0003-3951-6365				Agrawal D, 2002, J NATL CANCER I, V94, P513; Bertucci F, 2001, LANCET ONCOL, V2, P674, DOI 10.1016/S1470-2045(01)00557-5; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Bonomi P, 2002, SEMIN ONCOL, V29, P78, DOI 10.1053/sonc.2002.31528; Bray F, 2002, EUR J CANCER, V38, P99, DOI 10.1016/S0959-8049(01)00350-1; Feng G, 2001, CANCER RES, V61, P7999; Folkman J, 2000, NAT REV MOL CELL BIO, V1, P76, DOI 10.1038/35036100; FRAIRE AE, 1987, CANCER, V60, P370, DOI 10.1002/1097-0142(19870801)60:3<370::AID-CNCR2820600314>3.0.CO;2-W; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Giordano TJ, 2001, AM J PATHOL, V159, P1231, DOI 10.1016/S0002-9440(10)62509-6; Hayashi K, 2001, CANCER RES, V61, P2361; HEIGHWAY J, 2003, METHODS MOL MED; Hough CD, 2001, CANCER RES, V61, P3869; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; Ilg EC, 1996, INT J CANCER, V68, P325, DOI 10.1002/(SICI)1097-0215(19961104)68:3<325::AID-IJC10>3.0.CO;2-7; Joos L, 2002, HUM MOL GENET, V11, P569, DOI 10.1093/hmg/11.5.569; Kim JH, 2002, JAMA-J AM MED ASSOC, V287, P1671, DOI 10.1001/jama.287.13.1671; Kolligs FT, 2000, GENE DEV, V14, P1319; Lee PD, 2002, GENOME RES, V12, P292, DOI 10.1101/gr.217802; Liu D, 2000, BRIT J CANCER, V83, P1473, DOI 10.1054/bjoc.2000.1488; Maass N, 2001, CLIN CANCER RES, V7, P812; Matsumoto Y, 2001, JPN J CANCER RES, V92, P1133, DOI 10.1111/j.1349-7006.2001.tb01069.x; Nacht M, 2001, P NATL ACAD SCI USA, V98, P15203, DOI 10.1073/pnas.261414598; Pabon C, 2001, BIOTECHNIQUES, V31, P874, DOI 10.2144/01314mt05; Seftor REB, 1998, CANCER RES, V58, P5681; Sunday ME, 1999, ONCOGENE, V18, P4336, DOI 10.1038/sj.onc.1202810; THURLBECK WM, 1995, PATHOLOGY LUNG, P445; Topcu Z, 2001, J CLIN PHARM THER, V26, P405, DOI 10.1046/j.1365-2710.2001.00368.x; Umekita Y, 2002, INT J CANCER, V100, P452, DOI 10.1002/ijc.10500; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Wicki R, 1997, CELL CALCIUM, V22, P243, DOI 10.1016/S0143-4160(97)90063-4; Yue HB, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.8.e41; Zhu Y, 2001, CANCER RES, V61, P7825	33	133	144	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 31	2002	21	50					7749	7763		10.1038/sj.onc.1205979	http://dx.doi.org/10.1038/sj.onc.1205979			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	606VW	12400018				2022-12-28	WOS:000178756200015
J	Ozaki, T; Watanabe, KI; Nakagawa, T; Miyazaki, K; Takahashi, M; Nakagawara, A				Ozaki, T; Watanabe, KI; Nakagawa, T; Miyazaki, K; Takahashi, M; Nakagawara, A			Function of p73, not of p53, is inhibited by the physical interaction with RACK1 and its inhibitory effect is counteracted by pRB	ONCOGENE			English	Article						p53; pRB; p73; RACK1; two-hybrid	PROTEIN-KINASE-C; DNA-BINDING FUNCTION; TRANSCRIPTIONAL ACTIVATION; GROWTH SUPPRESSION; MAMMALIAN-CELLS; CANCER TISSUES; BETA-SUBUNIT; APOPTOSIS; GENE; SUMO-1	The newly identified p53-related gene, p73, encodes a nuclear transcription factor. Unlike p53, p73 has various isoforms with different NH2- and COOH-terminal tails. p73alpha with the longest COOH-terminal extension is most abundantly expressed in many tissues and cells among those splicing isoforms of p73 and the COON-terminal region appears to have an autoregulatory function. To isolate and characterize the cellular protein(s) that interacts with the unique COOH-terminal region of p73alpha, we employed a yeast two-hybrid screen with a human fetal brain and 293 cell cDNA libraries. We identified the receptor for activated C kinase (RACK1) as a new member of p73alpha-binding proteins. The interaction was confirmed by coimmunoprecipitation experiments, whereas RACK1 did not interact with p53 or p73beta. Ectopic overexpression of RACK1 in SAOS-2 cells reduced the p73alpha-mediated transcription from the p53/ p73-responsive promoters, and inhibited the p73alpha-dependent apoptosis. On the other hand, the p53-dependent transcriptional activation as well as apoptosis was unaffected in the presence of RACK1. Furthermore, we found that pRB physically bound to RACK1, and repressed the RACK1-dependent inhibition of p73alpha. Taken together, our observations suggest that pRB diminishes the RACK1-mediated inhibition of p73alpha activity through the interaction with RACK1.	Chiba Canc Ctr, Res Inst, Div Biochem, Chuo Ku, Chiba 2608717, Japan	Chiba Cancer Center	Nakagawara, A (corresponding author), Chiba Canc Ctr, Res Inst, Div Biochem, Chuo Ku, 666-2 Nitona, Chiba 2608717, Japan.							Baumann M, 2000, EUR J BIOCHEM, V267, P3891, DOI 10.1046/j.1432-1327.2000.01430.x; Chang BY, 2001, J BIOL CHEM, V276, P20346, DOI 10.1074/jbc.M101375200; Chen CL, 2000, CLIN CANCER RES, V6, P3910; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; De Laurenzi V, 2000, J BIOL CHEM, V275, P15226, DOI 10.1074/jbc.275.20.15226; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Fang L, 1999, J CELL BIOL, V147, P823, DOI 10.1083/jcb.147.4.823; Fontemaggi G, 2001, MOL CELL BIOL, V21, P8461, DOI 10.1128/MCB.21.24.8461-8470.2001; Geijsen N, 1999, ONCOGENE, V18, P5126, DOI 10.1038/sj.onc.1202896; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Ikawa S, 1999, CELL DEATH DIFFER, V6, P1154, DOI 10.1038/sj.cdd.4400631; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kwek SSS, 2001, ONCOGENE, V20, P2587, DOI 10.1038/sj.onc.1204362; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; McLeod M, 2000, MOL CELL BIOL, V20, P4016, DOI 10.1128/MCB.20.11.4016-4027.2000; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; Ozaki T, 1999, CANCER RES, V59, P5902; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Prives C, 1999, J PATHOL, V187, P112; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; RON D, 1995, P NATL ACAD SCI USA, V92, P492, DOI 10.1073/pnas.92.2.492; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Sang NL, 2001, J BIOL CHEM, V276, P27026, DOI 10.1074/jbc.M010346200; Shaw P, 1996, ONCOGENE, V12, P921; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; Ueda Y, 1999, ONCOGENE, V18, P4993, DOI 10.1038/sj.onc.1202817; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Watanabe K, 2002, J BIOL CHEM, V277, P15113, DOI 10.1074/jbc.M111281200; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yarwood SJ, 1999, J BIOL CHEM, V274, P14909, DOI 10.1074/jbc.274.21.14909; Zaika A, 2001, J BIOL CHEM, V276, P11310, DOI 10.1074/jbc.M005737200; Zaika AI, 1999, CANCER RES, V59, P3257; Zeng XY, 2000, MOL CELL BIOL, V20, P1299, DOI 10.1128/MCB.20.4.1299-1310.2000; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhu JH, 1998, CANCER RES, V58, P5061	60	42	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 22	2003	22	21					3231	3242		10.1038/sj.onc.1206382	http://dx.doi.org/10.1038/sj.onc.1206382			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681MM	12761493				2022-12-28	WOS:000183040000005
J	Maclaren, A; Clark, W; Black, EJ; Gregory, D; Fujii, H; Gillespie, DAF				Maclaren, A; Clark, W; Black, EJ; Gregory, D; Fujii, H; Gillespie, DAF			v-Jun stimulates both cdk2 kinase activity and G1/S progression via transcriptional repression of p2l CIP1	ONCOGENE			English	Article						Jun; p21CIP1; p53	S-PHASE ENTRY; C-JUN; CELL-CYCLE; GROWTH-FACTOR; GENE-EXPRESSION; HUMAN CANCER; DNA-DAMAGE; TRANSFORMATION; PROMOTER; P53	Previous studies have shown that the viral Jun (v-Jun) oncoprotein induces marked alterations in cell cycle control, which are associated with, and may be caused by, increased cdk2 kinase activity. Since p21 CIP1 is an important regulator of cdk2, we investigated whether aberrant expression of this cyclin-dependent kinase inhibitor might contribute to cell cycle deregulation by v-Jun. We find that the basal levels of p21 CIP1 mRNA and protein expression are greatly reduced in chick embryo fibroblasts (CEF) transformed by v-Jun, and that v-Jun blocks the increases in p21 CIP1 expression that normally accompany growth inhibition induced by serum deprivation or confluency in untransformed CEF. Importantly, ectopic expression of p21 CIP1 in v-Juntransformed CEF inhibits both cdk2 kinase activity and cell cycle progression, indicating that these alterations in p21 CIP1 expression are likely to be functionally significant for growth deregulation. We also investigated the mechanism through which v-Jun disturbs p21 CIP1 expression and the possible involvement of a known p21 CIP1 regulator, p53, as an intermediate in this process. This analysis revealed that repression is mediated primarily at the level of p21 CIP1 gene transcription, however the mechanism is complex; both p53-dependent and -independent mechanisms contribute as judged by analysis of p21 CIP1 promoter mutants and other assays of p53 transcriptional activity.	Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland; Univ Dundee, Sch Life Sci, Div Gene Regulat & Express, Dundee DD1 5EH, Scotland; Canc Res UK Dev Genet Lab, Lincolns Inn Fields, London WC2A 3PX, England	Beatson Institute; University of Glasgow; University of Dundee; Cancer Research UK	Maclaren, A (corresponding author), Beatson Inst Canc Res, Garscube Estate,Switchback Rd,Bearsden, Glasgow G61 1BD, Lanark, Scotland.		Gregory, David/P-2582-2015; Gillespie, David/R-4771-2019	Gregory, David/0000-0001-6534-7150; Gillespie, David/0000-0002-6338-0544				Bader AG, 2001, ONCOGENE, V20, P7524, DOI 10.1038/sj.onc.1204938; Blalock WL, 2000, ONCOGENE, V19, P526, DOI 10.1038/sj.onc.1203337; Chen BK, 2000, P NATL ACAD SCI USA, V97, P10406, DOI 10.1073/pnas.180321497; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Clark W, 2000, MOL CELL BIOL, V20, P2529, DOI 10.1128/MCB.20.7.2529-2542.2000; Clark W, 1997, CELL GROWTH DIFFER, V8, P371; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Cox LS, 1997, J PATHOL, V183, P134, DOI 10.1002/(SICI)1096-9896(199710)183:2<134::AID-PATH960>3.0.CO;2-D; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Erhardt JA, 1998, ONCOGENE, V16, P443, DOI 10.1038/sj.onc.1201577; Fu SL, 2000, ONCOGENE, V19, P3537, DOI 10.1038/sj.onc.1203691; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Gao MH, 1996, CANCER RES, V56, P4229; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; Givol I, 1995, ONCOGENE, V11, P2609; Haapajarvi T, 1999, EXP CELL RES, V248, P272, DOI 10.1006/excr.1999.4403; Hadman M, 1996, ONCOGENE, V12, P135; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HARTL M, 1995, P NATL ACAD SCI USA, V92, P11731, DOI 10.1073/pnas.92.25.11731; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; JUVEN T, 1993, ONCOGENE, V8, P3411; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; Kilbey A, 1996, ONCOGENE, V12, P2409; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; MacLaren A, 2000, ONCOGENE, V19, P5906, DOI 10.1038/sj.onc.1203954; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; Mitchell KO, 1999, CELL GROWTH DIFFER, V10, P223; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Tsao YP, 1996, J VIROL, V70, P7535, DOI 10.1128/JVI.70.11.7535-7539.1996; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang CH, 2000, BIOCHEM BIOPH RES CO, V270, P303, DOI 10.1006/bbrc.2000.2422; Wu RC, 1997, J BIOL CHEM, V272, P29091, DOI 10.1074/jbc.272.46.29091	41	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 24	2003	22	16					2383	2395		10.1038/sj.onc.1206329	http://dx.doi.org/10.1038/sj.onc.1206329			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	670AD	12717415				2022-12-28	WOS:000182383500001
J	Chuang, JI; Chang, TY; Liu, HS				Chuang, JI; Chang, TY; Liu, HS			Glutathione depletion-induced apoptosis of Ha-ras-transformed NIH3T3 cells can be prevented by melatonin	ONCOGENE			English	Article						reactive oxygen species; glutathione; melatonine; apoptosis; Ha-ras	CANCER CELLS; BUTHIONINE SULFOXIMINE; SELECTIVE ACTIVATION; NIH/3T3 CELLS; NEWBORN RATS; IN-VITRO; GROWTH; EXPRESSION; ONCOGENE; DEATH	It is well known that intracellular antioxidant glutathione (GSH) plays major roles in the maintenance of redox status and defense of oxidative stress. Ras, a small GTP-binding protein, may send growth-stimulating message to the nucleus through downstream Rac oncoprotein and superoxide (O-2(radical anion)). These findings led us to investigate the effects of GSH and melatonin, a free-radical scavenger, on Ras-Rac-O-2(radical anion)-related growth signal transduction. Our results demonstrate that overexpression of the inducible Ha-ras oncogene by isopropyl-beta-D-thiogalactoside (IPTG) increases the levels of reactive oxygen species (ROS, including O-2(radical anion) and hydrogen peroxide (H2O2)) and GSH in an Ha-ras-transformed NIH/3T3 fibroblast cell line. On the contrary, melatonin significantly suppresses ras-triggered cell growth by inhibiting the increase of ROS and GSH. Moreover, severe apoptosis of this transformed cell line occurred when the cell redox balance between ROS and GSH was dramatically changed in the presence of IPTG and L-buthionine-[S,R]-sulfoximine (BSO, a specific inhibitor of GSH synthetase). That BSO-induced cell apoptosis needs Ras to increase the ROS level was demonstrated by the free-radical scavenger melatonin. It effectively blocked cell apoptosis, but cell growth was also slowed without affecting Ras expression. Based on our studies, two approaches can be applied to treating ras-related cancers. One is utilizing melatonin to suppress cancer cell proliferation, and the other is utilizing BSO to induce cancer-cell apoptosis. Cotreatment of ras-related cancer cells with melatonin and BSO stops cell growth as well as apoptosis. Whether these cancer cells will undergo further regression or become recurrent merits investigation.	Natl Cheng Kung Univ, Coll Med, Dept Microbiol & Immunol, Tainan 701, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Physiol, Tainan 701, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Parasitol, Tainan 701, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University	Liu, HS (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Microbiol & Immunol, Tainan 701, Taiwan.			Liu, Hsiao-Sheng/0000-0003-0576-7203				ABE M, 1994, J PINEAL RES, V17, P94, DOI 10.1111/j.1600-079X.1994.tb00119.x; Agapito MT, 2001, J PINEAL RES, V31, P23, DOI 10.1034/j.1600-079X.2001.310104.x; Barranco SC, 2000, DIS COLON RECTUM, V43, P1133, DOI 10.1007/BF02236562; Beal MF, 1998, BBA-BIOENERGETICS, V1366, P211, DOI 10.1124/jpet.112.192138; Blask DE, 1997, CANCER RES, V57, P1909; Chang MY, 1999, EXP CELL RES, V248, P589, DOI 10.1006/excr.1999.4436; Chen ST, 1999, EXP BRAIN RES, V124, P241, DOI 10.1007/s002210050619; Chen ST, 2002, J PINEAL RES, V32, P262, DOI 10.1034/j.1600-079X.2002.01871.x; Chuang JI, 2001, J CHEM NEUROANAT, V21, P215, DOI 10.1016/S0891-0618(01)00109-0; Cos S, 2000, FRONT NEUROENDOCRIN, V21, P133, DOI 10.1006/frne.1999.0194; Granzotto M, 2001, J PINEAL RES, V31, P206, DOI 10.1034/j.1600-079X.2001.310303.x; Griffith OW, 1999, FREE RADICAL BIO MED, V27, P922, DOI 10.1016/S0891-5849(99)00176-8; Guha A, 1998, CAN J NEUROL SCI, V25, P267, DOI 10.1017/S0317167100034272; GUO N, 1992, NEUROSCIENCE, V51, P835, DOI 10.1016/0306-4522(92)90524-6; Irani K, 1998, BIOCHEM PHARMACOL, V55, P1339; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; ITO M, 1984, J INTERFERON RES, V22, P603; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; Karbownik M, 2001, INT J BIOCHEM CELL B, V33, P735, DOI 10.1016/S1357-2725(01)00059-0; Kilic E, 1999, J CEREBR BLOOD F MET, V19, P511, DOI 10.1097/00004647-199905000-00005; Kuo ML, 1996, BIOCHEM PHARMACOL, V52, P481, DOI 10.1016/0006-2952(96)00251-1; Li ZR, 1997, J PINEAL RES, V22, P117, DOI 10.1111/j.1600-079X.1997.tb00312.x; Lissoni P, 1996, ONCOLOGY, V53, P43; LISSONI P, 1999, METATONIN PROMOTION, P175; Liu HS, 1998, BRIT J CANCER, V77, P1777, DOI 10.1038/bjc.1998.296; Marelli MM, 2000, PROSTATE, V45, P238, DOI 10.1002/1097-0045(20001101)45:3<238::AID-PROS6>3.0.CO;2-W; Mayo JC, 1998, J PINEAL RES, V25, P12, DOI 10.1111/j.1600-079X.1998.tb00380.x; Mediavilla MD, 1999, LIFE SCI, V65, P415, DOI 10.1016/S0024-3205(99)00262-3; MEISTER A, 1994, CANCER RES, V54, pS1969; MILLER AC, 1993, MOL CELL BIOL, V13, P4416, DOI 10.1128/MCB.13.7.4416; Neri B, 1998, ANTICANCER RES, V18, P1329; OLANOW CW, 1993, TRENDS NEUROSCI, V16, P439, DOI 10.1016/0166-2236(93)90070-3; Panzer A, 1998, CANCER LETT, V122, P17, DOI 10.1016/S0304-3835(97)00360-1; Petranka J, 1999, J PINEAL RES, V26, P129, DOI 10.1111/j.1600-079X.1999.tb00574.x; Reiter RJ, 2000, J BIOMED SCI, V7, P444, DOI 10.1159/000025480; Reiter RJ, 2002, CARDIOVASC DRUG THER, V16, P5, DOI 10.1023/A:1015376328431; Roth JA, 1997, BRAIN RES, V768, P63, DOI 10.1016/S0006-8993(97)00549-0; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; Schnelldorfer T, 2000, CANCER-AM CANCER SOC, V89, P1440, DOI 10.1002/1097-0142(20001001)89:7<1440::AID-CNCR5>3.3.CO;2-S; Seyfried J, 1999, NEUROSCI LETT, V264, P1, DOI 10.1016/S0304-3940(99)00107-X; THRALL BD, 1991, CARCINOGENESIS, V12, P1319, DOI 10.1093/carcin/12.7.1319; Toffa S, 1997, J NEURAL TRANSM, V104, P67, DOI 10.1007/BF01271295; Vahrmeijer AL, 2000, BIOCHEM PHARMACOL, V59, P1557, DOI 10.1016/S0006-2952(00)00286-0; WALSH AC, 1995, CANCER LETT, V95, P105, DOI 10.1016/0304-3835(95)03871-S; Weijzen S, 1999, LEUKEMIA, V13, P502, DOI 10.1038/sj.leu.2401367; Xu MF, 2001, J PINEAL RES, V31, P301, DOI 10.1034/j.1600-079X.2001.310403.x	46	48	52	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2003	22	9					1349	1357		10.1038/sj.onc.1206289	http://dx.doi.org/10.1038/sj.onc.1206289			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618760				2022-12-28	WOS:000181360900009
J	Hesson, L; Dallol, A; Minna, JD; Maher, ER; Latif, F				Hesson, L; Dallol, A; Minna, JD; Maher, ER; Latif, F			NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers	ONCOGENE			English	Article						RASSF1A; NORE1; methylation	FREQUENT EPIGENETIC INACTIVATION; HUMAN-CHROMOSOME 3P21.3; PROMOTER HYPERMETHYLATION; CPG ISLAND; LUNG; CARCINOMA; REGION; IDENTIFICATION; EFFECTOR; BREAST	We recently demonstrated that RASSF1A, a new tumour-suppressor gene located at 3p21.3 is frequently inactivated by promoter region hypermethylation in a variety of human cancers including lung, breast, kidney and neuroblastoma. We have identified another member of the RASSF1 gene family by in silico sequence analysis using BLAST searches. NORE1 located at 1q32.1 exists in three isoforms (NORE1Aalpha, NORE1Abeta and NORE1B). Both NORE1A and NORE1B isoforms have separate CpG islands spanning their first exons. NORE1Aalpha Produces a 418 aa protein containing a Ras-association (RA) domain and a diacylglycerol (DAG) binding domain. NORE1Abeta produces a C-terminal truncation of the RA domain. NORE1B also contains the RA domain but not the DAG domain. NORE1 is the human homologue of the mouse Ras effector Nore1. No inactivating somatic mutations were found in lung tumour lines; however, NORE1A promoter region CpG island was hypermethylated in primary tumours and tumour cell lines. NORE1A promoter was methylated in 10/25 breast, 4/40 SCLC, 3/17 NSCLC, 1/6 colorectal and 3/9 kidney tumour cell lines, while NORE1B promoter was unmethylated in the same tumour cell lines. While 24% (6/25) of primary NSCLC underwent NORE1A methylation, methylation in SCLC was a rare event (0/22); (P = 0.0234). NORE1A expression in tumour cell lines was reactivated after treatment with a demethylating agent. There was no correlation between NORE1A and RASSF1A methylation status in NSCLC. Our results demonstrate that NOREIA is inactivated in a subset of human cancers by CpG island promoter hypermethylation, and in lung cancer this hypermethylation may be histological type specific.	Univ Birmingham, Sect Med & Mol Genet, Dept Paediat & Child Hlth, Sch Med, Birmingham B15 2TT, W Midlands, England; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Birmingham, Canc Res UK, Renal Mol Oncol Res Grp, Sch Med, Birmingham B15 2TT, W Midlands, England	University of Birmingham; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Cancer Research UK; University of Birmingham	Latif, F (corresponding author), Univ Birmingham, Sect Med & Mol Genet, Dept Paediat & Child Hlth, Sch Med, Edgbaston, Birmingham B15 2TT, W Midlands, England.		MAHER, EAMONN R/A-9507-2008; Hesson, Luke/HDM-0311-2022; Dallol, Ashraf/H-8661-2012	MAHER, EAMONN R/0000-0002-6226-6918; Dallol, Ashraf/0000-0002-8803-228X	NCI NIH HHS [P50CA70907] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968; Baylin S, 2002, CANCER CELL, V1, P299, DOI 10.1016/S1535-6108(02)00061-2; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Byun DS, 2001, CANCER RES, V61, P7034; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; Downward J, 2001, NATURE, V411, P759, DOI 10.1038/35081138; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Lee MG, 2001, CANCER RES, V61, P6688; Lerman MI, 2000, CANCER RES, V60, P6116; Lo KW, 2001, CANCER RES, V61, P3877; Maruyama R, 2002, CLIN CANCER RES, V8, P514; Morrissey C, 2001, CANCER RES, V61, P7277; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; Tommasi S, 2002, ONCOGENE, V21, P2713, DOI 10.1038/sj.onc.1205365; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200	22	105	115	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 13	2003	22	6					947	954		10.1038/sj.onc.1206191	http://dx.doi.org/10.1038/sj.onc.1206191			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584574				2022-12-28	WOS:000180864300017
J	Berg, CP; Rothbart, A; Lauber, K; Stein, GM; Engels, IH; Belka, C; Janicke, RU; Schulze-Osthoff, K; Wesselborg, S				Berg, CP; Rothbart, A; Lauber, K; Stein, GM; Engels, IH; Belka, C; Janicke, RU; Schulze-Osthoff, K; Wesselborg, S			Tributyltin (TBT) induces ultra-rapid caspase activation independent of apoptosome formation in human platelets	ONCOGENE			English	Article						organotin; tributyltin; platelets; caspase-9; apoptosome; apoptosis	DRUG-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; NONSPECIFIC RESISTANCE; DISTINCT PATHWAYS; TERM EXPOSURE; CELL-DEATH; RAT; BIS(TRI-NORMAL-BUTYLTIN)OXIDE; PHOSPHORYLATION; STAUROSPORINE	Activation of caspases has been demonstrated to be involved in thrombocytopenia and prolonged storage of platelet concentrates. Platelets represent enucleate cells that comprise all elements of the mitochondrial apoptosis pathway. However, no apoptotic stimuli capable of activating the endogenous caspase cascade have been identified so far. Using tributyltin (TBT) we could identify a compound that is capable of activating caspase-9 and -3 in platelets. Recent studies implicate that TBT induces apoptosis via the mitochondrial signaling pathway that is characterized by the formation of a high-molecular-weight complex (apoptosome) containing the adapter protein Apaf-1 and active caspase-9. Interestingly, addition of TBT induced the activation of caspase-9 in an ultra-rapid kinetic within the first 2 min. In addition, size exclusion chromatography revealed that TBT-mediated processing of caspase-9 occurs in the absence of the apoptosome. Thus, these data implicate that TBT induces the activation of caspase-9 by a mechanism not involving the formation of the apoptosome.	Univ Tubingen, Dept Internal Med 1, D-72076 Tubingen, Germany; Univ Munster, Div Cell Biol & Immunol, D-4400 Munster, Germany; Univ Tubingen, Dept Radiat & Oncol, Tubingen, Germany	Eberhard Karls University of Tubingen; University of Munster; Eberhard Karls University of Tubingen	Wesselborg, S (corresponding author), Univ Tubingen, Dept Internal Med 1, Otfried Muller Str 10, D-72076 Tubingen, Germany.		Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Wesselborg, Sebastian/0000-0002-5236-942X				AW TY, 1990, ARCH BIOCHEM BIOPHYS, V283, P46, DOI 10.1016/0003-9861(90)90610-B; Bantel H, 1999, CANCER RES, V59, P2083; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Berg CP, 2001, CELL DEATH DIFFER, V8, P1197, DOI 10.1038/sj.cdd.4400905; Bratosin D, 2001, CELL DEATH DIFFER, V8, P1143, DOI 10.1038/sj.cdd.4400946; CAIN K, 1977, FEBS LETT, V82, P23, DOI 10.1016/0014-5793(77)80877-6; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHOW SC, 1992, ARCH BIOCHEM BIOPHYS, V298, P143, DOI 10.1016/0003-9861(92)90105-6; de Botton S, 2002, BLOOD, V100, P1310, DOI 10.1182/blood-2002-03-0686; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; HARRIS EJ, 1973, FEBS LETT, V29, P339, DOI 10.1016/0014-5793(73)80054-7; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Lauber K, 2001, J BIOL CHEM, V276, P29772, DOI 10.1074/jbc.M101524200; Leist M, 2001, CELL DEATH DIFFER, V8, P324, DOI 10.1038/sj.cdd.4400859; Li JZ, 2000, TRANSFUSION, V40, P1320, DOI 10.1046/j.1537-2995.2000.40111320.x; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nishikimi A, 2001, BIOCHEM J, V356, P621, DOI 10.1042/0264-6021:3560621; Nopp A, 2002, CLIN EXP IMMUNOL, V128, P267, DOI 10.1046/j.1365-2249.2002.01824.x; Piguet PF, 2002, APOPTOSIS, V7, P91, DOI 10.1023/A:1014341611412; Plenchette S, 2001, LEUKEMIA, V15, P1572, DOI 10.1038/sj.leu.2402231; POWERS MF, 1991, J BIOL CHEM, V266, P17250; RAFFRAY M, 1993, ARCH TOXICOL, V67, P231, DOI 10.1007/BF01974341; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Robertson JD, 2000, J BIOL CHEM, V275, P32438, DOI 10.1074/jbc.C000518200; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; SEINEN W, 1977, TOXICOL APPL PHARM, V42, P213, DOI 10.1016/0041-008X(77)90211-3; Shcherbina A, 1999, BLOOD, V93, P4222, DOI 10.1182/blood.V93.12.4222.412k34_4222_4231; SNOEIJ NJ, 1988, INT J IMMUNOPHARMACO, V10, P891, DOI 10.1016/0192-0561(88)90014-8; Stepczynska A, 2001, ONCOGENE, V20, P1193, DOI 10.1038/sj.onc.1204221; Stridh H, 1998, FEBS LETT, V429, P351, DOI 10.1016/S0014-5793(98)00630-9; Stridh H, 1999, BIOCHEM BIOPH RES CO, V266, P460, DOI 10.1006/bbrc.1999.1821; Stridh H, 1999, CHEM RES TOXICOL, V12, P874, DOI 10.1021/tx990041c; Vanags DM, 1997, BRIT J HAEMATOL, V99, P824, DOI 10.1046/j.1365-2141.1997.4813284.x; VOS JG, 1990, TOXICOL APPL PHARM, V105, P144, DOI 10.1016/0041-008X(90)90366-3; VOS JG, 1984, TOXICOL APPL PHARM, V75, P387, DOI 10.1016/0041-008X(84)90177-7; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Wolf BB, 1999, BLOOD, V94, P1683, DOI 10.1182/blood.V94.5.1683.417k37_1683_1692	41	12	15	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 6	2003	22	5					775	780		10.1038/sj.onc.1206221	http://dx.doi.org/10.1038/sj.onc.1206221			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569371				2022-12-28	WOS:000180642100016
J	Antlsperger, DSM; Dirsch, VM; Ferreira, D; Su, JL; Kuo, ML; Vollmar, AM				Antlsperger, DSM; Dirsch, VM; Ferreira, D; Su, JL; Kuo, ML; Vollmar, AM			Ajoene-induced cell death in human promyeloleukemic cells does not require JNK but is amplified by the inhibition of ERK	ONCOGENE			English	Article						ajoene; apoptosis; mitogen-activated protein kinase; c-Jun NH2-terminal kinase; extracellular signal-regulated kinases	ACTIVATED PROTEIN-KINASE; N-TERMINAL KINASE; JUN NH2-TERMINAL KINASE; INDUCED APOPTOSIS; SIGNALING PATHWAYS; CANCER CELLS; CYTOCHROME-C; HL-60 CELLS; KAPPA-B; T-CELLS	Treatment of human promyeloleukemic HL-60 cells with the experimental antileukemic drug ajoene induces the activation of the mitogen-activated protein kinases (MAPKs) c-Jun NH2-terminal kinase (JNK), p38 and extracellular signal-regulated kinases (ERK) 1/2 as well as the survival kinase Akt. JNK activation occurred in HL-60/neo, HL-60/bcl-x(L), and in HL-60 cells pretreated with the pan-caspase inhibitor zVAD-fmk, indicating that JNK activation is not dependent on ajoene-induced mitochondria perturbation and subsequent caspase activation. Cells overexpressing a dominant-negative JNK showed no altered sensitivity towards ajoene suggesting that the activation of JNK is not necessary for ajoene-induced cell death. Inhibition of p38 MAPK by SB 203580 had no influence on ajoene-mediated apoptosis. In contrast, inhibition of ERK1/2 vastly enhanced ajoene-induced cell death. The survival kinase Akt, in contrast, did not participate in ajoene-induced death signaling as shown by the use of the phosphatidylinositol-3-kinase inhibitor wortmannin. Thus in contrast to the previous findings regarding stress-induced cell death, ajoene-mediated activation of JNK and p38 has no impact on ajoene-induced apoptosis in HL-60 cells. Blockade of ERK1/2 but not Akt pathways leads to sensitization of cells against ajoene-mediated apoptosis supporting the view that inhibition of ERK1/2 is a valuable strategy to increase the sensitivity of promyeloleukemic cells towards ajoene.	Univ Munich, Ctr Drug Res, Dept Pharm, D-81377 Munich, Germany; Natl Taiwan Univ, Coll Med, Inst Toxicol, Taipei, Taiwan	University of Munich; National Taiwan University	Dirsch, VM (corresponding author), Univ Munich, Ctr Drug Res, Dept Pharm, Butenandtstr 5-13, D-81377 Munich, Germany.		Kuo, Min-Liang/C-4872-2009	Dirsch, Verena/0000-0002-9261-5293				Agarwal KC, 1996, MED RES REV, V16, P111, DOI 10.1002/(SICI)1098-1128(199601)16:1&lt;111::AID-MED4&gt;3.0.CO;2-5; Bamford M, 2000, EXP CELL RES, V256, P1, DOI 10.1006/excr.2000.4837; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Butterfield L, 1997, J BIOL CHEM, V272, P10110; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen YR, 1998, J BIOL CHEM, V273, P1769, DOI 10.1074/jbc.273.3.1769; Chen YR, 1999, MOL PHARMACOL, V56, P1271, DOI 10.1124/mol.56.6.1271; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Dirsch VM, 2001, CANCER RES, V61, P5817; Dirsch VM, 1998, MOL PHARMACOL, V53, P402, DOI 10.1124/mol.53.3.402; Dirsch VM, 2002, LEUKEMIA, V16, P74, DOI 10.1038/sj.leu.2402337; Eichhorst ST, 2000, MOL CELL BIOL, V20, P7826, DOI 10.1128/MCB.20.20.7826-7837.2000; Eilers A, 2001, J NEUROCHEM, V76, P1439, DOI 10.1046/j.1471-4159.2001.00150.x; Galan A, 2000, J BIOL CHEM, V275, P11418, DOI 10.1074/jbc.275.15.11418; Gupta K, 1999, EXP CELL RES, V247, P495, DOI 10.1006/excr.1998.4359; Hancock JT, 2001, BIOCHEM SOC T, V29, P345, DOI 10.1042/BST0290345; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Ibrado AM, 1996, CANCER RES, V56, P4743; Jarvis WD, 1999, J PHARMACOL EXP THER, V290, P1384; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; Lali FV, 2000, J BIOL CHEM, V275, P7395, DOI 10.1074/jbc.275.10.7395; MacFarlane M, 2000, BIOCHEM J, V348, P93, DOI 10.1042/0264-6021:3480093; Mackay K, 1999, J BIOL CHEM, V274, P6272, DOI 10.1074/jbc.274.10.6272; MacKeigan JP, 2000, J BIOL CHEM, V275, P38953, DOI 10.1074/jbc.C000684200; Mandlekar S, 2000, CANCER RES, V60, P5995; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Oh-hashi K, 1999, BIOCHEM BIOPH RES CO, V263, P504, DOI 10.1006/bbrc.1999.1237; Sanchez-Perez I, 2000, ONCOGENE, V19, P5142, DOI 10.1038/sj.onc.1203887; Shiah SG, 2001, MOL PHARMACOL, V59, P254, DOI 10.1124/mol.59.2.254; Shiah SG, 1999, CANCER RES, V59, P391; Tang D, 2001, J BIOL CHEM, V276, P30461, DOI 10.1074/jbc.M102045200; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Wang TH, 2000, CANCER, V88, P2619, DOI 10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J; Watabe M, 1999, ONCOGENE, V18, P5211, DOI 10.1038/sj.onc.1202901; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yen A, 1998, CANCER RES, V58, P3163; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zechner D, 1998, J BIOL CHEM, V273, P8232, DOI 10.1074/jbc.273.14.8232; Zhuang SG, 2000, J BIOL CHEM, V275, P25939, DOI 10.1074/jbc.M001185200	44	29	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 30	2003	22	4					582	589		10.1038/sj.onc.1206161	http://dx.doi.org/10.1038/sj.onc.1206161			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555071				2022-12-28	WOS:000180538200011
J	Bhanoori, M; Yellaturu, CR; Ghosh, SK; Hassid, A; Jennings, LK; Rao, GN				Bhanoori, M; Yellaturu, CR; Ghosh, SK; Hassid, A; Jennings, LK; Rao, GN			Thiol alkylation inhibits the mitogenic effects of platelet-derived growth factor and renders it proapoptotic via activation of STATs and p53 and induction of expression of caspase1 and p21(waf1/cip1)	ONCOGENE			English	Article						apoptosis; cell growth; protein tyrosine phosphatases; protein tyrosine kinases; thiols; transcription factors	SMOOTH-MUSCLE CELLS; NF-KAPPA-B; PROTEIN-TYROSINE-PHOSPHATASE; DISULFIDE BOND FORMATION; NECROSIS-FACTOR-ALPHA; HYDROGEN-PEROXIDE; TRANSCRIPTION FACTOR; REDOX REGULATION; SIGNALING PATHWAY; KINASE ACTIVATION	Thiols provide the major intracellular redox milieu and can undergo reversible oxidation and reduction. To understand the role of thiols in redox signaling events, we have studied the effect of N-ethylmaleimide, a specific thiol alkylating agent, on platelet-derived growth factor-BB (PDGF-BB)-induced mitogenesis in vascular smooth muscle cells (VSMC). Thiol alkylation inhibited PDGF-BB-induced expression of the Fos and Jun family proteins and AP-1 activity in VSMC. Thiol alkylation also inhibited PDGF-BB-induced expression of cyclin A and growth in these cells. In contrast, thiol alkylation enhanced and sustained the effect of PDGF-BB on the activation of the Jak STAT pathway, and this event was correlated with inhibition of protein tyrosine phosphatase 1B activity. Thiol alkylation via inducing the expression of p21(waf1/cip1) in a STAT1- and p53-dependent manner antagonized the downregulation of this cell cycle inhibitory molecule by PDGF-BB. The inhibition of AP-1 and activation of STATs, particularly STAT1, by thiol alkylation correlated with increased production of active caspase 1 and apoptosis in VSMC. Together, these findings suggest a role for thiols in mediating mitogenic and/or apoptotic signaling events in VSMC. These results also show that a sustained change in the intracellular thiol redox state can convert a mitogen into a death promoter.	Univ Tennessee, Hlth Sci Ctr, Dept Physiol, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Ctr Vasc Biol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Rao, GN (corresponding author), Univ Tennessee, Hlth Sci Ctr, Dept Physiol, 894 Union Ave, Memphis, TN 38163 USA.		Bhanoori, Manjula/ACH-9333-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064165] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL64165] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aghdasi B, 1997, J BIOL CHEM, V272, P3739, DOI 10.1074/jbc.272.6.3739; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Aslund F, 1997, J BIOL CHEM, V272, P30780, DOI 10.1074/jbc.272.49.30780; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Chandel NS, 2000, ONCOGENE, V19, P3840, DOI 10.1038/sj.onc.1203727; Chen B, 2000, CANCER RES, V60, P3290; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; Chernoff J, 1999, J CELL PHYSIOL, V180, P173; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Clottes E, 1998, J BIOL CHEM, V273, P19391, DOI 10.1074/jbc.273.31.19391; Coffey RNT, 2000, CANCER-AM CANCER SOC, V88, P2092, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2092::AID-CNCR15>3.0.CO;2-9; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Denu JM, 1998, CURR OPIN CHEM BIOL, V2, P633, DOI 10.1016/S1367-5931(98)80095-1; DICK LR, 1992, BIOCHEMISTRY-US, V31, P7347, DOI 10.1021/bi00147a020; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Echarri A, 2001, CURR BIOL, V11, P1759, DOI 10.1016/S0960-9822(01)00538-3; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Ghosh SK, 2002, J BIOL CHEM, V277, P21325, DOI 10.1074/jbc.M201608200; Gottlieb E, 2000, MOL CELL BIOL, V20, P5680, DOI 10.1128/MCB.20.15.5680-5689.2000; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HANDEL ML, 1995, P NATL ACAD SCI USA, V92, P4497, DOI 10.1073/pnas.92.10.4497; Hirota K, 2000, BIOCHEM BIOPH RES CO, V274, P177, DOI 10.1006/bbrc.2000.3106; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; HOSHI T, 2001, J PHYSL, V15, P1; Huang YQ, 2000, J BIOL CHEM, V275, P6462, DOI 10.1074/jbc.275.9.6462; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; KRIEGERBRAUER HI, 1992, J CLIN INVEST, V89, P1006, DOI 10.1172/JCI115641; Kuge S, 2001, MOL CELL BIOL, V21, P6139, DOI 10.1128/MCB.21.18.6139-6150.2001; Kwaw I, 2001, BIOCHEMISTRY-US, V40, P10491, DOI 10.1021/bi010866x; Lee SL, 2001, AM J PHYSIOL-LUNG C, V281, pL646, DOI 10.1152/ajplung.2001.281.3.L646; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li YS, 2000, J BIOL CHEM, V275, P37187, DOI 10.1074/jbc.M000490200; Mahadev K, 2001, J BIOL CHEM, V276, P21938, DOI 10.1074/jbc.C100109200; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Myers MP, 2001, J BIOL CHEM, V276, P47771, DOI 10.1074/jbc.C100583200; Preston TJ, 2001, J BIOL CHEM, V276, P9558, DOI 10.1074/jbc.M004617200; Qin SF, 2000, P NATL ACAD SCI USA, V97, P7118, DOI 10.1073/pnas.130198197; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; RAO GN, 1993, ONCOGENE, V8, P2759; RAO GN, 1993, NUCLEIC ACIDS RES, V21, P1259, DOI 10.1093/nar/21.5.1259; Rao GN, 1996, J BIOL CHEM, V271, P27760, DOI 10.1074/jbc.271.44.27760; Rao GN, 1996, ONCOGENE, V13, P713; RAO GN, 1995, J CLIN INVEST, V96, P842, DOI 10.1172/JCI118130; Rao GN, 1999, J BIOL CHEM, V274, P6003, DOI 10.1074/jbc.274.9.6003; Schmidt KN, 1996, ADV EXP MED BIOL, V387, P63; Schnelldorfer T, 2000, CANCER-AM CANCER SOC, V89, P1440, DOI 10.1002/1097-0142(20001001)89:7<1440::AID-CNCR5>3.3.CO;2-S; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Stadtman ER, 2001, ANN NY ACAD SCI, V928, P22; Stephanou A, 2000, J BIOL CHEM, V275, P10002, DOI 10.1074/jbc.275.14.10002; Stewart EJ, 1998, EMBO J, V17, P5543, DOI 10.1093/emboj/17.19.5543; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Ungureanu D, 2002, MOL CELL BIOL, V22, P3316, DOI 10.1128/MCB.22.10.3316-3326.2002; Verdier F, 2000, J BIOL CHEM, V275, P18375, DOI 10.1074/jbc.275.24.18375; Wang DM, 2000, EMBO J, V19, P392, DOI 10.1093/emboj/19.3.392; Wei SJ, 2000, CANCER RES, V60, P6688; Wu YY, 2000, J BIOL CHEM, V275, P2147, DOI 10.1074/jbc.275.3.2147; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; Yellaturu CR, 2002, J BIOL CHEM, V277, P40148, DOI 10.1074/jbc.M206376200; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718	69	23	23	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 9	2003	22	1					117	130		10.1038/sj.onc.1206065	http://dx.doi.org/10.1038/sj.onc.1206065			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527914				2022-12-28	WOS:000180166900013
J	Wang, XH; Jin, DY; Wong, HL; Feng, HC; Wong, YC; Tsao, SW				Wang, XH; Jin, DY; Wong, HL; Feng, HC; Wong, YC; Tsao, SW			MAD2-induced sensitization to vincristine is associated with mitotic arrest and Raf/Bcl-2 phosphorylation in nasopharyngeal carcinoma cells	ONCOGENE			English	Article						MA132; Bcl-2; vincristine; Raf; nasopharyngeal carcinoma	SPINDLE ASSEMBLY CHECKPOINT; PROTEIN-KINASE; MAP KINASE; PROMOTING COMPLEX; GROWTH ARREST; HUMAN CANCERS; APOPTOSIS; BCL-2; DEATH; MAD2	Mitotic arrest deficient 2 (MAD2) is thought to be a key component of the mitotic checkpoint, which ensures accurate chromosome segregation. Reduced expression of MAD2 protein is associated with mitotic checkpoint abrogation and chromosomal instability in certain types of human cancers. To explore the possibility of developing a novel strategy for the treatment of cancer based on selective killing of mitotic checkpoint-defective or -competent cells, here we have investigated the effect of MAD2 expression on cellular sensitivity to checkpoint-targeting anticancer drugs. We reintroduced MAD2 protein in a mitotic checkpoint-defective nasopharyngeal carcinoma cell tine, CNE2, using an inducible expression vector. We found that overexpression of MAD2 led to an increased sensitivity to vincristine, which was accompanied by increased mitotic index and G2/M cell cycle arrest. In addition, increased phosphorylation of Raf, MEK1/2 and Bcl-2 was observed in MAD2-overexpressing cells in response to vincristine. Furthermore, inhibition of phosphorylation of MEK1/2 by its inhibitor PD098059 led to reduced sensitivity to vincristine, which was associated with decreased Bcl-2 phosphorylation. Our data suggest a role for MAD2 in the sensitization of cancer cells to certain mitotic checkpoint-targeting anticancer drugs.	Univ Hong Kong, Dept Anat, Hong Kong, Hong Kong, Peoples R China; Dept Biochem, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong	Tsao, SW (corresponding author), Univ Hong Kong, Dept Anat, 21 Sassoon Rd,1st Floor,Fac Med Bldg,Lab Block, Hong Kong, Hong Kong, Peoples R China.		Feng, Huichen/F-5502-2011	Feng, Huichen/0000-0003-3069-8174				Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Blagosklonny MV, 1997, CANCER RES, V57, P130; Bricker K.S., 1978, Kasetsart University Fisheries Research Bulletin, V10, P1; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; Fan MY, 2000, CANCER RES, V60, P6403; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Hayne C, 2000, J BIOL CHEM, V275, P31876, DOI 10.1074/jbc.M002766200; Huang STJ, 2002, FASEB J, V16, DOI 10.1096/fj.01-0852com; Huang Y, 1999, ONCOGENE, V18, P3431, DOI 10.1038/sj.onc.1202685; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Jordan MA, 1996, CANCER RES, V56, P816; Kallio M, 1998, J CELL BIOL, V141, P1393, DOI 10.1083/jcb.141.6.1393; Kasai T, 2002, J BIOL CHEM, V277, P5187, DOI 10.1074/jbc.M110295200; LAIRD AD, 1995, J BIOL CHEM, V270, P26742, DOI 10.1074/jbc.270.45.26742; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Lovric J, 1996, ONCOGENE, V12, P1109; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; Pennisi E, 1998, SCIENCE, V279, P477, DOI 10.1126/science.279.5350.477; SHERWOOD SW, 1994, EXP CELL RES, V215, P373, DOI 10.1006/excr.1994.1354; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; Stadheim TA, 2001, CANCER RES, V61, P1533; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; Takenaka K, 1997, J CELL BIOL, V136, P1091, DOI 10.1083/jcb.136.5.1091; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Wang TH, 1999, J BIOL CHEM, V274, P8208, DOI 10.1074/jbc.274.12.8208; Wang XH, 1999, INT J ONCOL, V15, P1097; Wang XH, 1998, CANCER RES, V58, P5019; Wang XH, 2002, CANCER RES, V62, P1662; Wang XH, 2000, CARCINOGENESIS, V21, P2293, DOI 10.1093/carcin/21.12.2293; Wang XM, 1997, J CELL BIOL, V137, P433, DOI 10.1083/jcb.137.2.433; Wassmann K, 2001, CURR OPIN GENET DEV, V11, P83, DOI 10.1016/S0959-437X(00)00161-1; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; Zhang YK, 2001, MOL CELL BIOL, V21, P5190, DOI 10.1128/MCB.21.15.5190-5199.2001	39	31	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 9	2003	22	1					109	116		10.1038/sj.onc.1206069	http://dx.doi.org/10.1038/sj.onc.1206069			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527913				2022-12-28	WOS:000180166900012
J	Sekiguchi, M; Tsuzuki, T				Sekiguchi, M; Tsuzuki, T			Oxidative nucleotide damage: consequences and prevention	ONCOGENE			English	Article						DNA replication fidelity; oxygen radicals; oxidized guanine base; mutagenesis; carcinogenesis; genomic stability	ESCHERICHIA-COLI MUTT; NUCLEOSIDE TRIPHOSPHATE PYROPHOSPHOHYDROLASE; GENERATES G.C->T.A TRANSVERSIONS; GENE ENCODING 8-OXO-DGTPASE; C-G TRANSVERSION; DNA-SYNTHESIS; MUTAGENIC SUBSTRATE; HUMAN-CELLS; MOLECULAR-CLONING; MTH1 GENE	8-Oxoguanine (8-oxo-7,8-dihydroguanine) is produced in DNA, as well as in nucleotide pools of cells, by reactive oxygen species normally formed during cellular metabolic processes. 8-Oxoguanine nucleotide can pair with cytosine and adenine nucleotides with an almost equal efficiency, then transversion mutation ensues. MutT protein of Escherichia coli and related mammalian protein MTH1 specifically degrade 8-oxo-dGTP to 8-oxo-dGMP, thereby preventing misincorporation of 8oxoguanine into DNA. The bacterial and mammalian enzymes are close in their size and share a highly conserved region consisting of 23 residues with 14 identical amino acids. Following saturation mutagenesis of this region, most of these residues proved to be essential to exert 8-oxo-dGTPase activity. Gene targeting was done to establish MTH1-deficient cell lines and mice for study. When examined 18 months after birth, a greater number of tumors were formed in the lungs, livers, and stomachs of MTHI-/- mice, as compared with findings in wild-type mice. These proteins protect genetic information from untoward effects of threats of endogenous oxygen.	Biomol Engn Res Inst, Suita, Osaka 5650874, Japan; Kyushu Univ, Fac Med Sci, Dept Med Biophys & Radiat Biol, Fukuoka 8128582, Japan	Kyushu University	Sekiguchi, M (corresponding author), Biomol Engn Res Inst, Suita, Osaka 5650874, Japan.							ABEYGUNAWARDANA C, 1995, BIOCHEMISTRY-US, V34, P14997, DOI 10.1021/bi00046a006; ABEYGUNAWARDANA C, 1993, BIOCHEMISTRY-US, V32, P13071, DOI 10.1021/bi00211a017; AKIYAMA M, 1987, MOL GEN GENET, V206, P9, DOI 10.1007/BF00326530; AKIYAMA M, 1989, P NATL ACAD SCI USA, V86, P3949, DOI 10.1073/pnas.86.11.3949; AMES BN, 1991, MUTAT RES, V250, P3, DOI 10.1016/0027-5107(91)90157-J; AU KG, 1988, P NATL ACAD SCI USA, V85, P9163, DOI 10.1073/pnas.85.23.9163; AU KG, 1989, P NATL ACAD SCI USA, V86, P8877, DOI 10.1073/pnas.86.22.8877; BESSHO T, 1992, BIOCHEM BIOPH RES CO, V188, P372, DOI 10.1016/0006-291X(92)92395-E; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; BESTWICK RK, 1982, J BIOL CHEM, V257, P9300; BHATNAGAR SK, 1988, J BIOL CHEM, V263, P8953; Boiteux S, 1999, BIOCHIMIE, V81, P59, DOI 10.1016/S0300-9084(99)80039-X; Brooks PJ, 2000, J BIOL CHEM, V275, P22355, DOI 10.1074/jbc.M002259200; BULLIONS LC, 1994, J BIOL CHEM, V269, P12339; CABRERA M, 1988, J BACTERIOL, V170, P5405, DOI 10.1128/jb.170.11.5405-5407.1988; CAI JP, 1995, CARCINOGENESIS, V16, P2343, DOI 10.1093/carcin/16.10.2343; CHENG KC, 1992, J BIOL CHEM, V267, P166; CHUNG MH, 1991, MUTAT RES, V254, P1, DOI 10.1016/0921-8777(91)90035-N; Colussi C, 2002, CURR BIOL, V12, P912, DOI 10.1016/S0960-9822(02)00863-1; COX EC, 1967, P NATL ACAD SCI USA, V58, P1895, DOI 10.1073/pnas.58.5.1895; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; EGASHIRA A, 2002, DNA REPAIR, V75, P1; EVANS J, 1993, MUTAT RES, V299, P147, DOI 10.1016/0165-1218(93)90092-R; FRAGA CG, 1990, P NATL ACAD SCI USA, V87, P4533, DOI 10.1073/pnas.87.12.4533; FRICK DN, 1995, BIOCHEMISTRY-US, V34, P5577, DOI 10.1021/bi00016a032; Fujii Y, 1999, J BIOL CHEM, V274, P38251, DOI 10.1074/jbc.274.53.38251; FURUICHI M, 1994, GENOMICS, V24, P485, DOI 10.1006/geno.1994.1657; GAJEWSKI E, 1990, BIOCHEMISTRY-US, V29, P7876, DOI 10.1021/bi00486a014; HAYAKAWA H, 1995, BIOCHEMISTRY-US, V34, P89, DOI 10.1021/bi00001a011; Hayakawa H, 1999, BIOCHEMISTRY-US, V38, P3610, DOI 10.1021/bi982361l; Henle ES, 1997, J BIOL CHEM, V272, P19095, DOI 10.1074/jbc.272.31.19095; Igarashi H, 1997, J BIOL CHEM, V272, P3766, DOI 10.1074/jbc.272.6.3766; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Jackson AL, 1998, GENETICS, V148, P1483; KAKUMA T, 1995, J BIOL CHEM, V270, P25942, DOI 10.1074/jbc.270.43.25942; KAMATH AV, 1993, GENE, V134, P99, DOI 10.1016/0378-1119(93)90180-B; KANG D, 1995, J BIOL CHEM, V270, P14659, DOI 10.1074/jbc.270.24.14659; KASAI H, 1984, NUCLEIC ACIDS RES, V12, P2137, DOI 10.1093/nar/12.4.2137; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; Kobayashi M, 1998, J BIOL CHEM, V273, P26394, DOI 10.1074/jbc.273.41.26394; Kornberg A., 1992, DNA REPLICATION; Kuraoka I, 2000, P NATL ACAD SCI USA, V97, P3832, DOI 10.1073/pnas.070471597; Lin J, 1996, BIOCHEMISTRY-US, V35, P6715, DOI 10.1021/bi953071x; Lin J, 1997, BIOCHEMISTRY-US, V36, P1199, DOI 10.1021/bi962619c; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; MICHAELS ML, 1991, NUCLEIC ACIDS RES, V19, P3629, DOI 10.1093/nar/19.13.3629; MINNICK DT, 1994, NUCLEIC ACIDS RES, V22, P5658, DOI 10.1093/nar/22.25.5658; Minowa O, 2000, P NATL ACAD SCI USA, V97, P4156, DOI 10.1073/pnas.050404497; MO JY, 1992, P NATL ACAD SCI USA, V89, P11021, DOI 10.1073/pnas.89.22.11021; MO JY, 1991, J MOL BIOL, V222, P925, DOI 10.1016/0022-2836(91)90586-U; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; NGHIEM Y, 1988, P NATL ACAD SCI USA, V85, P2709, DOI 10.1073/pnas.85.8.2709; O'Handley SF, 1998, J BIOL CHEM, V273, P3192, DOI 10.1074/jbc.273.6.3192; Oda H, 1997, J BIOL CHEM, V272, P17843, DOI 10.1074/jbc.272.28.17843; Oda H, 1999, NUCLEIC ACIDS RES, V27, P4335, DOI 10.1093/nar/27.22.4335; OHandley SF, 1996, J BIOL CHEM, V271, P24649, DOI 10.1074/jbc.271.40.24649; Ohtsubo T, 1998, MOL GEN GENET, V259, P577, DOI 10.1007/s004380050851; PAVLOV YI, 1994, BIOCHEMISTRY-US, V33, P4695, DOI 10.1021/bi00181a029; Poole TM, 1996, CARCINOGENESIS, V17, P191, DOI 10.1093/carcin/17.2.191; Safrany ST, 1998, EMBO J, V17, P6599, DOI 10.1093/emboj/17.22.6599; Sakai Y, 2002, J BIOL CHEM, V277, P8579, DOI 10.1074/jbc.M110566200; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; SCHAAPER RM, 1986, J MOL BIOL, V189, P273, DOI 10.1016/0022-2836(86)90509-7; Sheikh S, 1998, J BIOL CHEM, V273, P20924, DOI 10.1074/jbc.273.33.20924; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Shimokawa H, 2000, NUCLEIC ACIDS RES, V28, P3240, DOI 10.1093/nar/28.17.3240; Slupska MM, 1996, J BACTERIOL, V178, P3885, DOI 10.1128/jb.178.13.3885-3892.1996; SMITH KC, 1992, MUTAT RES, V277, P139, DOI 10.1016/0165-1110(92)90002-Q; Stoler DL, 1999, P NATL ACAD SCI USA, V96, P15121, DOI 10.1073/pnas.96.26.15121; Taddei F, 1997, SCIENCE, V278, P128, DOI 10.1126/science.278.5335.128; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; TCHOU J, 1993, MUTAT RES, V299, P277, DOI 10.1016/0165-1218(93)90104-L; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; TREFFERS HP, 1954, P NATL ACAD SCI USA, V40, P1064, DOI 10.1073/pnas.40.11.1064; Tsuzuki T, 2001, P NATL ACAD SCI USA, V98, P11456, DOI 10.1073/pnas.191086798; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; WEBER DJ, 1993, BIOCHEMISTRY-US, V32, P13081, DOI 10.1021/bi00211a018; YANOFSKY C, 1966, P NATL ACAD SCI USA, V55, P274, DOI 10.1073/pnas.55.2.274; YEH YC, 1991, J BIOL CHEM, V266, P6480	80	172	178	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 16	2002	21	58					8895	8904		10.1038/sj.onc.1206023	http://dx.doi.org/10.1038/sj.onc.1206023			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	626TP	12483507				2022-12-28	WOS:000179889500002
J	Amin, ARMR; Machida, K; Oshima, K; Oo, ML; Thant, AA; Senga, T; Matsuda, S; Akhand, AA; Maeda, A; Kurosaki, T; Hamaguchi, M				Amin, ARMR; Machida, K; Oshima, K; Oo, ML; Thant, AA; Senga, T; Matsuda, S; Akhand, AA; Maeda, A; Kurosaki, T; Hamaguchi, M			A role for SHPS-1/SIRP alpha 1 in IL-1 beta- and TNF alpha-dependent signaling	ONCOGENE			English	Article						cytokines; signal transduction; tyrosine kinases; tyrosine phosphatases; Erk 1/2; Akt	TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; PROTEIN-TYROSINE-PHOSPHATASE; MOLECULAR-CLONING; V-SRC; KINASE; INTERLEUKIN-1; ACTIVATION; PATHWAY; FAMILY	We investigated the role of SHPS-1/SIRPalpha1 in IL-1beta-and TNFalpha-dependent signaling that leads to the activation of Erk 1/2 and Akt. Treatment of Balb3T3 cells with IL-1beta or TNFalpha activated tyrosine phosphorylation of SHPS-1, its association with SHP-2 and the phosphorylation of Erk 1/2 and Akt. PP1, a specific inhibitor for the Src family protein tyrosine kinases, strongly inhibited tyrosine phosphorylation of SHPS-1 and complex formation of SHPS-1 with SHP-2 by IL-1beta. In addition, PP1 substantially inhibited the IL-2beta-and TNFalpha-dependent activation of Erk 1/2 and Akt. Exogenous expression of either SHPS-1 mutants that lack SHP-2 binding function or a dominant negative mutant of SHP-2 markedly inhibited the activation of Erk 1/2 and Akt by IL-1beta, whereas wild type SHPS-1 did not. Moreover, IL-1beta-stimulation induced association of SHPS-1 with IL-1RAcP, a second subunit of IL-1 receptor, whereas expression of SHPS-1 mutant that lack SHP-2 binding function clearly blocked the association and tyrosine phosphorylation of endogenous SHPS-1: Taken together, our results strongly suggest that activation of Erk 1/2 and Akt by proinflammatory cytokines requires tyrosine phosphorylation of SHPS-1 and subsequent association of SHPS-1 with SHP-2.	Nagoya Univ, Grad Sch Med, Lab Mol Pathogenesis, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Grad Sch Med, Dept Immunol, Showa Ku, Nagoya, Aichi 4668550, Japan; Kansai Med Univ, Inst Liver Res, Dept Mol Genet, Moriguchi, Osaka 5708506, Japan	Nagoya University; Nagoya University; Kansai Medical University	Hamaguchi, M (corresponding author), Nagoya Univ, Grad Sch Med, Lab Mol Pathogenesis, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.		Kurosaki, Tomohiro/D-1306-2009; Maeda, Akito/AAX-6252-2020	Kurosaki, Tomohiro/0000-0002-6352-304X; AMIN, ARM/0000-0001-9144-2960				ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; Araki T, 2000, J NEUROCHEM, V75, P1502, DOI 10.1046/j.1471-4159.2000.0751502.x; BankersFulbright JL, 1996, LIFE SCI, V59, P61, DOI 10.1016/0024-3205(96)00135-X; Cullinan EB, 1998, J IMMUNOL, V161, P5614; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; DINARELLO CA, 1993, NEW ENGL J MED, V328, P106; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; KAMPSCHMIDT RF, 1984, J LEUKOCYTE BIOL, V36, P341, DOI 10.1002/jlb.36.3.341; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Kurata H, 2000, EXP CELL RES, V254, P180, DOI 10.1006/excr.1999.4738; Lu W, 2001, MOL CELL, V8, P759, DOI 10.1016/S1097-2765(01)00369-0; Machida K, 2000, ONCOGENE, V19, P1710, DOI 10.1038/sj.onc.1203497; Madge LA, 2000, J BIOL CHEM, V275, P15458, DOI 10.1074/jbc.M001237200; Ozes ON, 1999, NATURE, V401, P82; Senga T, 2000, ONCOGENE, V19, P273, DOI 10.1038/sj.onc.1203296; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Takada T, 1998, J BIOL CHEM, V273, P9234, DOI 10.1074/jbc.273.15.9234; Takeda H, 1998, ONCOGENE, V16, P3019, DOI 10.1038/sj.onc.1201839; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; Thant AA, 1999, ONCOGENE, V18, P6555, DOI 10.1038/sj.onc.1203049; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Wu CJ, 2000, ONCOGENE, V19, P3999, DOI 10.1038/sj.onc.1203748; Yang CM, 2000, BRIT J PHARMACOL, V130, P891, DOI 10.1038/sj.bjp.0703359; You M, 2001, J EXP MED, V193, P101, DOI 10.1084/jem.193.1.101	27	19	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 12	2002	21	57					8871	8877		10.1038/sj.onc.1206018	http://dx.doi.org/10.1038/sj.onc.1206018			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483539				2022-12-28	WOS:000179734400020
J	Chau, CH; Chen, KY; Deng, HT; Kim, KJ; Hosoya, K; Terasaki, T; Shih, HM; Ann, DK				Chau, CH; Chen, KY; Deng, HT; Kim, KJ; Hosoya, K; Terasaki, T; Shih, HM; Ann, DK			Coordinating Etk/Bmx activation and VEGF upregulation to promote cell survival and proliferation	ONCOGENE			English	Article						Etk; VEGF; autocrine; survival; proliferation	ENDOTHELIAL GROWTH-FACTOR; FOCAL ADHESION KINASE; BMX TYROSINE KINASE; PROSTATE-CANCER CELLS; EPITHELIAL-CELLS; PHOSPHATIDYLINOSITOL 3'-KINASE; SIGNAL-TRANSDUCTION; FAMILY KINASES; PH-DOMAIN; EXPRESSION	Etk/Bmx, a member of the Tee family of non-receptor tyrosine kinase, is characterized by an N-terminal PH domain and has recently been shown to be involved in the regulation of various cellular processes, including proliferation, differentiation, motility and apoptosis. Since VEGF and the activation of its signaling pathway have been implicated in modulating a variety of biological responses, we characterized the role of Etk-dependent signaling pathways involved in the upregulation of VEGF expression, and explored the functional implications of this enhancement in sustaining cell proliferation and survival. Using Northern and Western analyses, transient transfections, and pharmacological agents, we demonstrate that Elk activation alone is sufficient to transcriptionally induce VEGF expression, independent of the previously identified hypoxia response element (HRE), in both Pa-4 epithelial and TR-BBB endothelial cells under normoxia. In addition, Elk utilizes both MEK/ERK and PI3-K/Pak1 signaling pathways in concert to activate VEGF transcription. Functionally, Etk activation elicits a profound stimulatory effect on TR-BBB cell proliferation and formation of capillary-like networks in Matrigel containing reduced levels of growth factors. Finally, antisense oligonucleotides against either endogenous VEGF or Etk abrogate the proliferation of Elk-activated TR-BBB cells, and exogenous VEGF treatment stimulates endogenous Elk tyrosine phosphorylation in HUVECs. Taken together, these results indicate that VEGF is both an Etk downstream target gene and an Elk upstream activator, constituting a reciprocal Etk-VEGF autoregulatory loop. These findings, to our knowledge, are the first delineation of a network of positive feedforward signaling pathways that converge on the Etk-VEGF axis, causally associating Elk-mediation of VEGF induction with enhanced cellular processes in both epithelial and endothelial cells.	Univ So Calif, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90033 USA; Tohoku Univ, Grad Sch Pharmaceut Sci, Dept Mol Biopharm & Genet, Aoba Ku, Sendai, Miyagi 9808578, Japan; Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Toyama 9300194, Japan; Natl Hlth Res Inst, Div Mol & Genomic Med, Taipei 11529, Taiwan; Univ So Calif, Ctr Craniofacial Mol Biol, Los Angeles, CA 90033 USA; Univ So Calif, Will Rogers Inst, Pulm Res Ctr, Los Angeles, CA 90033 USA; Univ So Calif, Dept Biomed Engn, Los Angeles, CA 90033 USA; Univ So Calif, Dept Physiol & Biophys, Los Angeles, CA 90033 USA; Univ So Calif, Dept Med, Los Angeles, CA 90033 USA	University of Southern California; Tohoku University; University of Toyama; National Health Research Institutes - Taiwan; University of Southern California; University of Southern California; University of Southern California; University of Southern California; University of Southern California	Ann, DK (corresponding author), Univ So Calif, Dept Mol Pharmacol & Toxicol, Hlth Sci Campus,PSC-210B,1985 Zonal Ave, Los Angeles, CA 90033 USA.		Shih, Hsiu-Ming/S-7023-2018; Terasaki, Tetsuya/K-6730-2012	Terasaki, Tetsuya/0000-0002-6332-7575	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064365, R01HL038658] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE010742] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE014183] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 64365, R01 HL 38658] Funding Source: Medline; NIDCR NIH HHS [R01 DE 14183, DE 07211, R01 DE 10742] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Bagheri-Yarmand R, 2001, J BIOL CHEM, V276, P29403, DOI 10.1074/jbc.M103129200; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Chen RY, 2001, NAT CELL BIOL, V3, P439, DOI 10.1038/35074500; Dias S, 2001, P NATL ACAD SCI USA, V98, P10857, DOI 10.1073/pnas.191117498; Dias S, 2002, BLOOD, V99, P2179, DOI 10.1182/blood.V99.6.2179; Dunk C, 2001, AM J PATHOL, V158, P265, DOI 10.1016/S0002-9440(10)63965-X; Ekman N, 1997, CIRCULATION, V96, P1729, DOI 10.1161/01.CIR.96.6.1729; Ekman N, 2000, ONCOGENE, V19, P4151, DOI 10.1038/sj.onc.1203763; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gotoh I, 1999, J BIOL CHEM, V274, P11874, DOI 10.1074/jbc.274.17.11874; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; Gupta K, 1999, EXP CELL RES, V247, P495, DOI 10.1006/excr.1998.4359; Hamm-Alvarez SF, 2001, AM J PHYSIOL-CELL PH, V280, pC1657, DOI 10.1152/ajpcell.2001.280.6.C1657; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Jui HY, 2000, J BIOL CHEM, V275, P41124, DOI 10.1074/jbc.M007772200; Kanellis J, 2000, AM J PHYSIOL-RENAL, V278, pF905, DOI 10.1152/ajprenal.2000.278.6.F905; Kanno S, 2000, ONCOGENE, V19, P2138, DOI 10.1038/sj.onc.1203533; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Li DX, 1997, J BIOL CHEM, V272, P25062, DOI 10.1074/jbc.272.40.25062; Lu ZM, 2001, MOL CELL BIOL, V21, P4016, DOI 10.1128/MCB.21.12.4016-4031.2001; Mahajan S, 1999, J BIOL CHEM, V274, P9587, DOI 10.1074/jbc.274.14.9587; Mao CD, 2001, J BIOL CHEM, V276, P26180, DOI 10.1074/jbc.M101188200; Masood R, 2001, BLOOD, V98, P1904, DOI 10.1182/blood.V98.6.1904; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Murakami H, 1999, BIOCHEM BIOPH RES CO, V262, P68, DOI 10.1006/bbrc.1999.1186; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Parrizas M, 1997, J BIOL CHEM, V272, P154; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Qiu Y, 2000, ONCOGENE, V19, P5651, DOI 10.1038/sj.onc.1203958; Rajantie I, 2001, MOL CELL BIOL, V21, P4647, DOI 10.1128/MCB.21.14.4647-4655.2001; RAK J, 1995, CANCER RES, V55, P4575; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Shaw LM, 2001, MOL CELL BIOL, V21, P5082, DOI 10.1128/MCB.21.15.5082-5093.2001; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Strizzi L, 2001, J PATHOL, V193, P468, DOI 10.1002/path.824; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; Terasaki T, 2001, BIOL PHARM BULL, V24, P111, DOI 10.1248/bpb.24.111; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Tsai YT, 2000, MOL CELL BIOL, V20, P2043, DOI 10.1128/MCB.20.6.2043-2054.2000; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Vassilev A, 1999, J BIOL CHEM, V274, P1646, DOI 10.1074/jbc.274.3.1646; Vega-Diaz B, 2001, J INVEST DERMATOL, V116, P525, DOI 10.1046/j.1523-1747.2001.01294.x; Veikkola T, 1999, SEMIN CANCER BIOL, V9, P211, DOI 10.1006/scbi.1998.0091; Wen X, 2000, Adv Dent Res, V14, P76; Wen X, 1999, J BIOL CHEM, V274, P38204, DOI 10.1074/jbc.274.53.38204; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Wu YM, 2001, J BIOL CHEM, V276, P17672, DOI 10.1074/jbc.M010964200; Xue LY, 1999, ONCOGENE, V18, P3391, DOI 10.1038/sj.onc.1202687; Zeng HY, 2001, J BIOL CHEM, V276, P26969, DOI 10.1074/jbc.M103213200; Zheng DQ, 2000, J BIOL CHEM, V275, P24565, DOI 10.1074/jbc.M002646200	57	49	52	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 12	2002	21	57					8817	8829		10.1038/sj.onc.1206032	http://dx.doi.org/10.1038/sj.onc.1206032			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483534				2022-12-28	WOS:000179734400015
J	Konduri, SD; Yanamandra, N; Siddique, K; Joseph, A; Dinh, DH; Olivero, WC; Gujrati, M; Kouraklis, G; Swaroop, A; Kyritsis, AP; Rao, JS				Konduri, SD; Yanamandra, N; Siddique, K; Joseph, A; Dinh, DH; Olivero, WC; Gujrati, M; Kouraklis, G; Swaroop, A; Kyritsis, AP; Rao, JS			Modulation of cystatin C expression impairs the invasive and tumorigenic potential of human glioblastoma cells	ONCOGENE			English	Article						glioma; invasion; cathepsin B; cystatin C	INHIBITORS STEFIN-A; CYSTEINE PROTEINASE-INHIBITORS; HUMAN COLORECTAL-CARCINOMA; HUMAN COLON-CARCINOMA; HUMAN BREAST-CANCER; CATHEPSIN-B; PROGNOSTIC-SIGNIFICANCE; ENDOGENOUS INHIBITORS; PROTEASE INHIBITORS; MOLECULAR-CLONING	Increases in the abundance of cathepsin B transcript and protein with increased tumor grade and changes in subcellular localization and activity of this enzyme. We observed progressive reductions in levels of the protease inhibitor cystatin C, an inhibitor of cathepsin B with corresponding increases in the malignancy of glioma cell lines, implying an inverse correlation between cystatin C and tumor grade. To investigate the role of cystatin C in the invasion of brain tumor cells, we stably transfected SNB19 glioblastoma cells with either a 0.4-kb cDNA construct of human cystatin C in the sense orientation or an empty vector. Clones expressing sense-cystatin C cDNA had higher cystatin C mRNA and protein levels than did control cells. Sense-transfected cells were also markedly less invasive than control cells in a Matrigel invasion assay and in a coculture assay of SNB19 spheroids and fetal rat brain aggregates. Finally, the sense-transfected cells did not form tumors in nude mice upon intracerebral injection. These results strongly implicate cystatin C in the invasiveness of human glioblastoma cells and suggest that sense transcripts of cystatin C may prove useful in cancer therapy.	Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Div Canc Biol, Peoria, IL 61656 USA; Univ Ioannina, Sch Med, Dept Neurol, GR-45110 Ioannina, Greece; Univ Michigan, Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci & Human Genet, Ann Arbor, MI 48109 USA; Univ Athens, Sch Med, Dept Propedeut Surg, GR-11527 Athens, Greece; Univ Illinois, Dept Neuropathol, Peoria, IL USA; Univ Illinois, Dept Neurosurg, Peoria, IL USA	University of Illinois System; University of Illinois Peoria; University of Ioannina; University of Michigan System; University of Michigan; Athens Medical School; National & Kapodistrian University of Athens; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria	Rao, JS (corresponding author), Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Div Canc Biol, Box 1649, Peoria, IL 61656 USA.	jsrao@uic.edu		Swaroop, Anand/0000-0002-1975-1141	NCI NIH HHS [CA 76350] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076350] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAMSON M, 1987, FEBS LETT, V216, P229, DOI 10.1016/0014-5793(87)80695-6; ABRAHAMSON M, 1986, J BIOL CHEM, V261, P1282; BARRETT AJ, 1987, TRENDS BIOCHEM SCI, V12, P193, DOI 10.1016/0968-0004(87)90092-2; BOBEK LA, 1992, CRIT REV ORAL BIOL M, V3, P307, DOI 10.1177/10454411920030040101; Calkins CC, 1998, J HISTOCHEM CYTOCHEM, V46, P745, DOI 10.1177/002215549804600607; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORTICCHIATO O, 1992, INT J CANCER, V52, P645; Coulibaly S, 1999, INT J CANCER, V83, P526, DOI 10.1002/(SICI)1097-0215(19991112)83:4<526::AID-IJC15>3.3.CO;2-D; Cox JL, 1999, MELANOMA RES, V9, P369, DOI 10.1097/00008390-199908000-00005; Foekens JA, 1998, J CLIN ONCOL, V16, P1013, DOI 10.1200/JCO.1998.16.3.1013; Gaumann A, 2001, PATHOL RES PRACT, V197, P257, DOI 10.1078/0344-0338-00044; HAWLEYNELSON P, 1988, MOL CARCINOGEN, V1, P202, DOI 10.1002/mc.2940010309; HEIDTMANN HH, 1992, BRIT J CANCER, V65, P154, DOI 10.1038/bjc.1992.33; HEIDTMANN HH, 1989, CANCER RES, V49, P6960; Hirai K, 1999, HUM PATHOL, V30, P680, DOI 10.1016/S0046-8177(99)90094-1; Huh CG, 1999, J CLIN PATHOL-MOL PA, V52, P332, DOI 10.1136/mp.52.6.332; KEPPLER D, 1994, BBA-MOL BASIS DIS, V1226, P117, DOI 10.1016/0925-4439(94)90018-3; Konduri SD, 2001, ONCOGENE, V20, P6938, DOI 10.1038/sj.onc.1204847; Kos J, 1997, CLIN CANCER RES, V3, P1815; Kos J, 2000, INT J BIOL MARKER, V15, P84, DOI 10.1177/172460080001500116; Kos J, 1998, CLIN CANCER RES, V4, P1511; Kos J, 2000, CLIN CANCER RES, V6, P505; Krepela E, 1998, NEOPLASMA, V45, P318; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAH TT, 1992, CANCER LETT, V61, P243, DOI 10.1016/0304-3835(92)90295-7; Lah TT, 2000, CLIN CANCER RES, V6, P578; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; Mangge H, 2000, CLIN CHIM ACTA, V300, P195, DOI 10.1016/S0009-8981(00)00322-3; Merz GS, 1997, J CELL PHYSIOL, V173, P423; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MORT JS, 1980, BIOCHIM BIOPHYS ACTA, V614, P134, DOI 10.1016/0005-2744(80)90174-6; MURNANE MJ, 1991, CANCER RES, V51, P1137; Pavlova A, 2000, FEBS LETT, V487, P156, DOI 10.1016/S0014-5793(00)02337-1; PEDERSEN PH, 1993, CANCER RES, V53, P5158; QIAN F, 1989, CANCER RES, V49, P4870; Randers E, 1999, CLIN CHEM LAB MED, V37, P389, DOI 10.1515/CCLM.1999.064; SCHMITT M, 1992, FIBRINOLYSIS, V6, P3; Sexton PS, 1997, MELANOMA RES, V7, P97, DOI 10.1097/00008390-199704000-00002; SHEAHAN K, 1989, CANCER RES, V49, P3809; Sloane B F, 1990, Semin Cancer Biol, V1, P137; SLOANE BF, 1990, CANCER METAST REV, V9, P333, DOI 10.1007/BF00049523; SLOANE BF, 1994, BIOCH MOL ASPECTS SE, V2, P411; Stabuc B, 2000, CLIN CHEM, V46, P193; Strojan P, 2000, CLIN CANCER RES, V6, P1052; Strojnik T, 1999, CLIN CANCER RES, V5, P559; SUKOH N, 1994, VIRCHOWS ARCH, V424, P33; TERADA T, 1995, HUM PATHOL, V26, P746, DOI 10.1016/0046-8177(95)90222-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WATANABE M, 1989, BIOCHEM MED METAB B, V42, P21, DOI 10.1016/0885-4505(89)90037-6; Werle B, 1999, BRIT J CANCER, V81, P510, DOI 10.1038/sj.bjc.6690723; Yano M, 2001, SURG TODAY, V31, P385, DOI 10.1007/s005950170126; Yoshimura K, 2000, ONCOL REP, V7, P27	53	65	71	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2002	21	57					8705	8712		10.1038/sj.onc.1205949	http://dx.doi.org/10.1038/sj.onc.1205949			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483523				2022-12-28	WOS:000179734400004
J	Wang, S; Fusaro, G; Padmanabhan, J; Chellappan, SP				Wang, S; Fusaro, G; Padmanabhan, J; Chellappan, SP			Prohibitin co-localizes with Rb in the nucleus and recruits N-CoR and HDAC1 for transcriptional repression	ONCOGENE			English	Article						prohibitin; Rb; histone deacetylase 1; IgM; marked box	RETINOBLASTOMA PROTEIN; HISTONE DEACETYLASE; TUMOR-SUPPRESSOR; ACUTE-LEUKEMIA; CELL-CYCLE; E2F; INTERACTS; RECEPTOR; COMPLEXES; TARGET	The potential tumor suppressor protein prohibitin can prevent cell proliferation and this required its binding to the Rb protein. Prohibitin could repress the transcriptional activity of E2F family members and this required a part of the marked box region of E2F. The sub-cellular localization of prohibitin has been variously attributed to the mitochondria as well as the inner cell membrane. Here we show that a subset of probibitin molecules are present in the nucleus where it co-localizes with the Rb protein. Deletion of a putative amino-terminal membrane-docking domain of prohibitin had no effect on its ability to suppress cell proliferation or inhibit E2F activity. Our experiments show that a 53 amino-acid stretch of E2F1 is sufficient for being targeted by prohibitin; fusion of this region to GAL4-VP16 construct could make it susceptible to prohibitin-mediated, but not Rb-mediated repression. Prohibitin, like Rb, could repress transcription from SV40 and major late promoters when recruited directly to DNA. Prohibitin mediated transcriptional repression required histone-deacetylase activity, but unlike Rb, additional co-repressors like N-CoR are also involved. Repression by prohibitin correlates with histone deacetylation on promoters and this was reversed by IgM stimulation of cells; IgM did not affect Rb-mediated repression or deacetylation of the promoters. Prohibitin thus appears to repress E2F-mediated transcription utilizing different molecular mediators and facilitate channeling of specific signaling pathways to the cell cycle machinery.	Univ S Florida, Dept Interdisciplinary Oncol, H Lee Moffitt Canc Ctr, Tampa, FL 33612 USA; Univ S Florida, Res Inst, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Chellappan, SP (corresponding author), Univ S Florida, Dept Interdisciplinary Oncol, H Lee Moffitt Canc Ctr, 12902 Magnolia Dr, Tampa, FL 33612 USA.	Chellasp@moffitt.usf.edu	Padmanabhan, Jaya/A-4226-2012	Padmanabhan, Jaya/0000-0003-2019-5135	NCI NIH HHS [CA 77301] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077301] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams PD, 1996, CURR TOP MICROBIOL, V208, P79; ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; ADNANE J, 1995, J BIOL CHEM, V270, P8837, DOI 10.1074/jbc.270.15.8837; Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Brehm A, 1999, TRENDS BIOCHEM SCI, V24, P142, DOI 10.1016/S0968-0004(99)01368-7; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Coates PJ, 2001, EXP CELL RES, V265, P262, DOI 10.1006/excr.2001.5166; Collingwood TN, 1999, J MOL ENDOCRINOL, V23, P255, DOI 10.1677/jme.0.0230255; Dahiya A, 2001, MOL CELL, V8, P557, DOI 10.1016/S1097-2765(01)00346-X; DEDON PC, 1991, ANAL BIOCHEM, V197, P83, DOI 10.1016/0003-2697(91)90359-2; Delage-Mourroux R, 2000, J BIOL CHEM, V275, P35848, DOI 10.1074/jbc.M001327200; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fusaro G, 2002, ONCOGENE, V21, P4539, DOI 10.1038/sj.onc.1205551; Harbour JW, 2000, CURR OPIN CELL BIOL, V12, P685, DOI 10.1016/S0955-0674(00)00152-6; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Howe L, 1999, CRIT REV EUKAR GENE, V9, P231, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.80; IKONEN E, 1995, FEBS LETT, V358, P273, DOI 10.1016/0014-5793(94)01444-6; Johnson David G., 1998, Frontiers in Bioscience, V3, pD447; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Luo RX, 1999, J NATL CANCER I, V91, P1288, DOI 10.1093/jnci/91.15.1288; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; MCCLUNG JK, 1995, EXP GERONTOL, V30, P99, DOI 10.1016/0531-5565(94)00069-7; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Nijtmans LGJ, 2002, CELL MOL LIFE SCI, V59, P143, DOI 10.1007/s00018-002-8411-0; Nijtmans LGJ, 2000, EMBO J, V19, P2444, DOI 10.1093/emboj/19.11.2444; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Ross JF, 1999, MOL CELL, V3, P195, DOI 10.1016/S1097-2765(00)80310-X; Sambrook J, 1989, MOL CLONING LABORATO, V9, P16; Steglich G, 1999, MOL CELL BIOL, V19, P3435; TERASHIMA M, 1994, EMBO J, V13, P3782, DOI 10.1002/j.1460-2075.1994.tb06689.x; Thompson WE, 1999, ANAT REC, V256, P40, DOI 10.1002/(SICI)1097-0185(19990901)256:1<40::AID-AR6>3.0.CO;2-X; Wang S, 1999, MOL CELL BIOL, V19, P7447; Wang S, 1999, ONCOGENE, V18, P3501, DOI 10.1038/sj.onc.1202684; Wang S, 1998, MOL CELL BIOL, V18, P7487, DOI 10.1128/MCB.18.12.7487; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; ZHANG YH, 1995, ONCOGENE, V10, P2085	46	175	186	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	2002	21	55					8388	8396		10.1038/sj.onc.1205944	http://dx.doi.org/10.1038/sj.onc.1205944			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466959				2022-12-28	WOS:000179480100002
J	Buckwalter, TLF; Venkateswaran, A; Lavender, M; La Perle, KMD; Cho, JY; Robinson, ML; Jhiang, SM				Buckwalter, TLF; Venkateswaran, A; Lavender, M; La Perle, KMD; Cho, JY; Robinson, ML; Jhiang, SM			The roles of phosphotyrosines-294,-404, and-451 in RET/PTC1-induced thyroid tumor formation	ONCOGENE			English	Article						RET/PTC1; mutagenesis; thyroid tumor; transgene	TRANSGENIC MICE; SIGNAL-TRANSDUCTION; RET; EXPRESSION; ONCOGENE; CARCINOMAS	RET/PTC1 is a rearranged form of the RET protooneogene detected in human papillary thyroid carcinomas. We previously showed that thyroid-targeted expression of RET/PTC1 leads to thyroid tumor formation in Tg-PTC1 transgenic mice. Signal transduction pathways mediated by phosphotyrosine 294, 404, or 451 in RET/PTC1 have been shown to be critical for RET-induced transforming activity in vitro. To investigate the contribution of these signaling pathways in RET/PTC1-induced thyroid tumor formation in vivo, we generated and characterized transgenic mice expressing thyroid-targeted RET/PTC1 mutants carrying a site-directed mutation changing tyrosine (Y) to phenylalanine (F) at the residue 294, 404, or 451. In contrast to the 100% tumor formation rate in Tg-PTC1 transgenic mice, tumor formation rates were significantly decreased in Tg-PTC1-Y294F (6%), Tg-PTC1-Y404F (41%), and Tg-PTC1-Y451F (30%) transgenic mice. This indicates that signaling pathways mediated by pY294, pY404, and pY451 do play a role in RET/PTC1-induced tumor formation. However, as tumors are still able to form in some mice within these three mutant transgenic groups, it indicates that none of the signaling pathways mediated by pY294, pY404, or pY451, are solely essential for RET/PTC1-induced tumor formation.	Ohio State Univ, Dept Physiol & Cell Biol, Columbus, OH 43210 USA; Ohio State Univ, Dept Vet Biosci, Columbus, OH 43210 USA; Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA	Ohio State University; Ohio State University; Ohio State University	Jhiang, SM (corresponding author), Ohio State Univ, Dept Physiol & Cell Biol, 304 Hamilton Hall,1645 Neil Ave, Columbus, OH 43210 USA.		La Perle, Krista Marie DuBray/B-3099-2015		NCI NIH HHS [R01 CA60074] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060074] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; Cho JY, 1999, ONCOGENE, V18, P3659, DOI 10.1038/sj.onc.1202709; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; Jhiang SM, 2000, ONCOGENE, V19, P5590, DOI 10.1038/sj.onc.1203857; Kato M, 1999, ONCOGENE, V18, P837, DOI 10.1038/sj.onc.1202329; KATO M, 2002, ONCOGENE, V62, P2414; Powell DJ, 2001, ONCOGENE, V20, P3235, DOI 10.1038/sj.onc.1204425; Santoro M, 1996, ONCOGENE, V12, P1821; Sweetser DA, 1999, ONCOGENE, V18, P877, DOI 10.1038/sj.onc.1202376; Tallini G, 2001, ADV ANAT PATHOL, V8, P345, DOI 10.1097/00125480-200111000-00005; van Weering DHJ, 1998, RECENT RES CANCER, V154, P271; Xing S, 1998, J BIOL CHEM, V273, P4909, DOI 10.1074/jbc.273.9.4909	12	26	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 21	2002	21	53					8166	8172		10.1038/sj.onc.1205938	http://dx.doi.org/10.1038/sj.onc.1205938			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615DW	12444552				2022-12-28	WOS:000179231400010
J	Arnuthan, G; Biswas, G; Ananadatheerthavarada, HK; Vijayasarathy, C; Shephard, HM; Avadhani, NG				Arnuthan, G; Biswas, G; Ananadatheerthavarada, HK; Vijayasarathy, C; Shephard, HM; Avadhani, NG			Mitochondrial stress-induced calcium signaling, phenotypic changes and invasive behavior in human lung carcinoma A549 cells	ONCOGENE			English	Article						mitochondria; calcium signaling; cathepsin L; TGF beta; tumor invasion; MAP kinases	CYTOSOLIC CALCIUM; EPITHELIAL-CELLS; ACTIVATED RAS; CYTOCHROME-C; CANCER-CELLS; APOPTOSIS; DNA; CA2+; SUPPRESSION; TUMORS	We have investigated mechanisms of mitochondrial stress-induced phenotypic changes and cell invasion in tumorigenic but poorly invasive human pulmonary carcinoma A549 cells that were partly depleted of mitochondrial DNA (mtDNA). Depletion of mtDNA (genetic stress) caused a markedly lower electron transport-coupled ATP synthesis, loss of mitochondrial membrane potential, elevation of steady state [Ca2+](c), and notably induction of both glycolysis and gluconeogenic pathway enzymes. Markers of tumor invasion, cathepsin L and TGFbeta1, were overexpressed; calcium-dependent MAP kinases (ERK1 and ERK2) and calcineurin were activated. The levels of anti-apoptotic proteins Bcl2 and BCl-X-L were increased, and the cellular levels of pro-apoptotic proteins Bid and Bax were reduced. Both mtDNA-depleted cells (genetic stress) and control cells treated with carbonyl cyanide m-chlorophenylhydrazone (metabolic stress) exhibited higher invasive behavior than control cells in a Matrigel basement membrane matrix assay system. MtDNA-depleted cells stably expressing anti-sense cathepsin L RNA, TGFbeta1 RNA, or treated with specific inhibitors showed reduced invasion. Reverted cells with 80% of control cell mtDNA exhibited marker protein levels, cell morphology and invasive property closer to control cells. Our results suggest that the mitochondria-to-nucleus signaling pathway operating through increased [Ca2+](c) plays an important role in cancer progression and metastasis.	Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Vet Med, Mari Lowe Ctr Comparat Oncol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Avadhani, NG (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, 3800 Spruce St, Philadelphia, PA 19104 USA.	narayan@vet.upenn.edu	Shephard, Henry M./ABG-4547-2021; Datta, Sayantan/D-1369-2010	Shephard, Henry M./0000-0003-0168-5462; 	NATIONAL CANCER INSTITUTE [R37CA022762, R01CA022762] Funding Source: NIH RePORTER; NCI NIH HHS [CA 22762] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Addya S, 1997, J CELL BIOL, V139, P589, DOI 10.1083/jcb.139.3.589; Amuthan G, 2001, EMBO J, V20, P1910, DOI 10.1093/emboj/20.8.1910; Andreyev A, 1999, CELL DEATH DIFFER, V6, P825, DOI 10.1038/sj.cdd.4400565; Arnould T, 2002, EMBO J, V21, P53, DOI 10.1093/emboj/21.1.53; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522; Buckman JF, 2001, J NEUROSCI METH, V104, P165, DOI 10.1016/S0165-0270(00)00340-X; Cavalli LR, 1997, CELL GROWTH DIFFER, V8, P1189; Cavalli LR, 1998, MUTAT RES-FUND MOL M, V398, P19, DOI 10.1016/S0027-5107(97)00223-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cuvier C, 1997, CLIN EXP METASTAS, V15, P19; DESJARDINS P, 1985, MOL CELL BIOL, V5, P1163, DOI 10.1128/MCB.5.5.1163; Dey R, 2000, J BIOL CHEM, V275, P7087, DOI 10.1074/jbc.275.10.7087; Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017; Fujimoto K, 2001, EXP CELL RES, V266, P239, DOI 10.1006/excr.2000.5229; GIGUERE L, 1981, SOMAT CELL GENET, V7, P457, DOI 10.1007/BF01542990; Gutierrez AA, 1999, J PHYSIOL-LONDON, V517, P95, DOI 10.1111/j.1469-7793.1999.0095z.x; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; HANSFORD RG, 1994, J BIOENERG BIOMEMBR, V26, P495, DOI 10.1007/BF00762734; Hata A, 2001, EXP CELL RES, V264, P111, DOI 10.1006/excr.2000.5140; Hehl S, 1996, CELL CALCIUM, V20, P515, DOI 10.1016/S0143-4160(96)90094-9; Hofer AM, 2000, NAT CELL BIOL, V2, P392, DOI 10.1038/35017020; Hofhaus G, 1999, BIOL CHEM, V380, P871, DOI 10.1515/BC.1999.107; Hojo M, 1999, NATURE, V397, P530, DOI 10.1038/17401; Horton TM, 1996, GENE CHROMOSOME CANC, V15, P95, DOI 10.1002/(SICI)1098-2264(199602)15:2<95::AID-GCC3>3.0.CO;2-Z; HOWELL AN, 1978, P NATL ACAD SCI USA, V75, P2358, DOI 10.1073/pnas.75.5.2358; ICHAS F, 1994, FEBS LETT, V348, P211, DOI 10.1016/0014-5793(94)00615-6; ISRAEL BA, 1987, IN VITRO CELL DEV B, V23, P627; ISRAEL BA, 1988, IN VITRO CELL DEV B, V24, P487; Iwakura T, 2000, BIOCHEM BIOPH RES CO, V271, P422, DOI 10.1006/bbrc.2000.2616; Jiang SN, 1999, J BIOL CHEM, V274, P29905, DOI 10.1074/jbc.274.42.29905; JONASSON J, 1977, J CELL SCI, V24, P217; JONES CT, 1976, ARCH BIOCHEM BIOPHYS, V174, P506, DOI 10.1016/0003-9861(76)90378-7; JOUAVILLE LS, 1995, NATURE, V377, P438, DOI 10.1038/377438a0; Kim K, 1998, INT J CANCER, V79, P324, DOI 10.1002/(SICI)1097-0215(19980821)79:4<324::AID-IJC4>3.3.CO;2-N; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; LIAO XS, 1993, CELL, V72, P61, DOI 10.1016/0092-8674(93)90050-Z; Luo Y, 1997, P NATL ACAD SCI USA, V94, P9705, DOI 10.1073/pnas.94.18.9705; MIRA N, 1967, METHOD ENZYMOL, V9, P371; Miranda S, 1999, BIOCHEM BIOPH RES CO, V258, P44, DOI 10.1006/bbrc.1999.0580; Missiaen L, 2000, CELL CALCIUM, V28, P1, DOI 10.1054/ceca.2000.0131; MOORADIAN DL, 1992, J NATL CANCER I, V84, P523, DOI 10.1093/jnci/84.7.523; MORAIS R, 1994, CANCER RES, V54, P3889; Nemoto S, 2000, MOL CELL BIOL, V20, P7311, DOI 10.1128/MCB.20.19.7311-7318.2000; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; Riccardi D, 1999, CELL CALCIUM, V26, P77, DOI 10.1054/ceca.1999.0066; RICHTER C, 1993, FEBS LETT, V325, P104, DOI 10.1016/0014-5793(93)81423-W; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; ROTHERMEL BA, 1995, J BIOL CHEM, V270, P29476, DOI 10.1074/jbc.270.49.29476; SHEAHAN K, 1989, CANCER RES, V49, P3809; SMITH L, 1955, Methods Biochem Anal, V2, P427, DOI 10.1002/9780470110188.ch13; Stridh H, 1999, BIOCHEM BIOPH RES CO, V266, P460, DOI 10.1006/bbrc.1999.1821; Szalai G, 1999, EMBO J, V18, P6349, DOI 10.1093/emboj/18.22.6349; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; WARBURG OTTO, 1926, KLIN WOCHENSCHR, V5, P829, DOI 10.1007/BF01726240; Wen HC, 2000, J CELL BIOCHEM, V79, P601, DOI 10.1002/1097-4644(20001215)79:4<601::AID-JCB90>3.0.CO;2-W; Werth JL, 1996, J NEUROSCI, V16, P1008; YAGEL S, 1989, CANCER RES, V49, P3553; Yeh JJ, 2000, ONCOGENE, V19, P2060, DOI 10.1038/sj.onc.1203537; ZAFAR MN, 1982, J ULTRA MOL STRUCT R, V81, P133	62	200	207	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2002	21	51					7839	7849		10.1038/sj.onc.1205983	http://dx.doi.org/10.1038/sj.onc.1205983			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	610DT	12420221				2022-12-28	WOS:000178946000009
J	Hampton, R; Walker, M; Marshall, J; Juhl, H				Hampton, R; Walker, M; Marshall, J; Juhl, H			Differential expression of carcinoembryonic antigen (CEA) splice variants in whole blood of colon cancer patients and healthy volunteers: implication for the detection of circulating colon cancer cells	ONCOGENE			English	Article						minimal residual disease; circulating cancer cells; colon cancer; CEA; CK20	POLYMERASE-CHAIN-REACTION; DISSEMINATED TUMOR-CELLS; BONE-MARROW; REVERSE-TRANSCRIPTASE; PERIPHERAL-BLOOD; PERITONEAL-CAVITY; CARCINOMA-CELLS; CYTOKINES; DISEASE; FAMILY	Quantification of circulating cancer cells in whole blood samples by real time quantitative RT-PCR might be of clinical value for monitoring therapeutic effectiveness. In colon cancer patients, carcinoembrynic antigen (CEA) and cytokeratin 20 (CK20) have been frequently used for RTPCR based tumor cell detection, but the specificity in particular for CEA has been questioned. In this study, we compared real-time RT-PCR for CEA. and CK20 and analysed patients with metastatic disease (n = 32) and healthy volunteers (n = 17). CK20 mean values were elevated in cancer patients (P < 0.001) and defined a subgroup (38%) who showed CK20 levels at least 100-fold above the highest value of the healthy control group. In contrast, only two cancer patients (6%) showed elevated CEA levels. Samples of the healthy control group showed exclusively a CEA-PCR product of 79degreesC melting temperature. Thirty per cent of the colon cancer patients showed an additional product of 82degreesC melting temperature. The 82degreesC product was identical with the amplification product of CEA-cDNA and cDNA from different colon cancer cell fines. Colon cancer cells were spiked into normal blood in 10-fold dilutions that resulted in a dose dependent shift of the melt curve from 79degreesC to the 82degreesC. Sequencing of the PCR products showed that white blood cells express a splice variant of CEA, which hinders detection of tumor cell cDNA in whole blood samples. Our findings have implications for the use of CEA as a diagnostic molecule (e.g. by RT - PCR). The discovery of a physiologically expressed CEA splice variant might lead to a better understanding of the biological function of CEA and its family members.	Georgetown Univ, Med Ctr, Dept Oncol, Lombardi Canc Ctr, Washington, DC 20007 USA	Georgetown University	Juhl, H (corresponding author), INDIVUMED, Ctr Canc Res, Israelit Krankenhaus, Orchideenstieg 14, D-22297 Hamburg, Germany.	juhl@indivumed.com			NATIONAL CANCER INSTITUTE [R01CA088972, P30CA051008] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA088972, 2P30-CA-51008] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; BURCHILL SA, 1995, BRIT J CANCER, V71, P278, DOI 10.1038/bjc.1995.56; Castells A, 1998, BRIT J CANCER, V78, P1368, DOI 10.1038/bjc.1998.686; ENGELL H, 1955, ACTA CHIR SCAND    S, V210, pS10; Gangopadhyay A, 1998, CLIN EXP METASTAS, V16, P703, DOI 10.1023/A:1006576627429; GERHARD M, 1994, J CLIN ONCOL, V12, P725, DOI 10.1200/JCO.1994.12.4.725; Goeminne JC, 2000, ANN ONCOL, V11, P785, DOI 10.1023/A:1008398228018; Grem Jean, 1997, Current Opinion in Oncology, V9, P380, DOI 10.1097/00001622-199709040-00012; Guadagni F, 2001, CANCER RES, V61, P2523; Hammarstrom S, 1999, SEMIN CANCER BIOL, V9, P67, DOI 10.1006/scbi.1998.0119; JUHL H, 1994, INT J CANCER, V57, P330, DOI 10.1002/ijc.2910570307; Jung R, 1998, BRIT J CANCER, V78, P1194, DOI 10.1038/bjc.1998.653; Ko Y, 1998, CLIN CANCER RES, V4, P2141; Liefers GJ, 1998, NEW ENGL J MED, V339, P223, DOI 10.1056/NEJM199807233390403; LINDEMANN F, 1992, LANCET, V340, P685, DOI 10.1016/0140-6736(92)92230-D; Mori M, 1996, INT J CANCER, V68, P739; REDDING WH, 1983, LANCET, V2, P1271; SCHLIMOK G, 1987, P NATL ACAD SCI USA, V84, P8672, DOI 10.1073/pnas.84.23.8672; Schott A, 1998, ANN SURG, V227, P372, DOI 10.1097/00000658-199803000-00009; SCHREWE H, 1990, MOL CELL BIOL, V10, P2738, DOI 10.1128/MCB.10.6.2738; Soeth E, 1996, INT J CANCER, V69, P278, DOI 10.1002/(SICI)1097-0215(19960822)69:4<278::AID-IJC7>3.0.CO;2-U; Soeth E, 2001, CLIN CANCER RES, V7, P2022; Soeth E, 1997, CANCER RES, V57, P3106; THOMPSON J, 1994, J BIOL CHEM, V269, P32924; Vogel I, 2001, AM J SURG, V181, P188, DOI 10.1016/S0002-9610(00)00555-9; Wirth T, 2002, CLIN EXP METASTAS, V19, P155, DOI 10.1023/A:1014566127493	26	45	48	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2002	21	51					7817	7823		10.1038/sj.onc.1205906	http://dx.doi.org/10.1038/sj.onc.1205906			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	610DT	12420218				2022-12-28	WOS:000178946000006
J	Djavaheri-Mergny, M; Wietzerbin, J; Besancon, F				Djavaheri-Mergny, M; Wietzerbin, J; Besancon, F			2-methoxyestradiol induces apoptosis in Ewing sarcoma cells through mitochondrial hydrogen peroxide production	ONCOGENE			English	Article						Ewing tumor; apoptosis; 2-methoxyestradiol; reactive oxygen species; mitochondria	N-TERMINAL KINASE; ENDOGENOUS ESTROGEN METABOLITE; CANCER-CELLS; GLUTATHIONE-PEROXIDASE; SIGNALING PATHWAY; INHIBITS ANGIOGENESIS; ENDOTHELIAL-CELLS; OXIDATIVE STRESS; PROSTATE-CANCER; TUMOR-GROWTH	The Ewing sarcoma is the second most common bone tumor in children and young adults. Despite the advances in therapy, the 5-year survival rate for patients with metastatic disease is poor, indicating the need for alternative treatments. Here, we report that 2-methoxy-estradiol (2-Me), a natural estrogen metabolite, induced a caspase-dependent apoptosis of Ewing sarcoma-derived cells independently of their p53 status. 2-Me-induced apoptosis occurred through the mitochondrial death pathway as evidenced by reduction of the mitochondrial transmembrane potential, cytochrome c release and caspase-9 activation. Treatment of cells with 2-Me resulted in generation of intracellular H2O2, which occurred earlier than caspase-9 activation. The H2O2-reducing agent Ebselen and the lipid peroxidation inhibitor vitamin E decreased both 2-Me-induced caspase-9 activation and cell death, thus providing evidence for a role of H2O2 and lipid peroxides in the initiation of this process. Rotenone, an inhibitor of the mitochondrial respiratory chain, abolished both apoptosis and H2O2 production, thereby identifying mitochondria as the source of H2O2. Moreover, we observed that treatment of cells with 2-Me or H2O2 induced activation of the c-Jun N-terminal kinase (JNK). Overexpression of a dominant-negative mutant of JNK1 reduced 2-Me-induced apoptosis indicating that JNK participates in this process. Altogether, our results provide evidence that 2-Me triggers apoptosis of Ewing sarcoma cells through induction of a mitochondria redox-dependent mechanism and suggest that this compound or other agents that selectively increase the level of reactive oxygen species may prove useful to the development of novel strategies for treatment of Ewing tumors.	Inst Curie, Sect Rech, INSERM, U365, F-75248 Paris 05, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Djavaheri-Mergny, M (corresponding author), Inst Curie, Sect Rech, INSERM, U365, 26 Rue Ulm, F-75248 Paris 05, France.		Djavaheri-Mergny, Mojgan/L-3890-2019; Djavaheri-Mergny, Mojgan/N-6315-2017	Djavaheri-Mergny, Mojgan/0000-0003-4893-6505; Djavaheri-Mergny, Mojgan/0000-0003-4893-6505				Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; Aoki H, 2002, J BIOL CHEM, V277, P10244, DOI 10.1074/jbc.M112355200; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Attalla H, 1998, BIOCHEM BIOPH RES CO, V247, P616, DOI 10.1006/bbrc.1998.8870; Benhar M, 2002, EMBO REP, V3, P420, DOI 10.1093/embo-reports/kvf094; Cai JY, 1999, J BIOENERG BIOMEMBR, V31, P327, DOI 10.1023/A:1005423818280; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; Curtin JF, 2002, J IMMUNOL METHODS, V265, P49, DOI 10.1016/S0022-1759(02)00070-4; Dauphinot L, 2001, ONCOGENE, V20, P3258, DOI 10.1038/sj.onc.1204437; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200; DeSilva DR, 1998, J IMMUNOL, V160, P4175; Djavaheri-Mergny M, 2001, FREE RADICAL RES, V34, P583, DOI 10.1080/10715760100300481; Ekert PG, 2001, J CELL BIOL, V152, P483, DOI 10.1083/jcb.152.3.483; Ferri KF, 2001, BIOESSAYS, V23, P111, DOI 10.1002/1521-1878(200102)23:2<111::AID-BIES1016>3.3.CO;2-P; Fleury C, 2002, BIOCHIMIE, V84, P131, DOI 10.1016/S0300-9084(02)01369-X; FOTSIS T, 1994, NATURE, V368, P237, DOI 10.1038/368237a0; Gupta S, 2001, LIFE SCI, V69, P2957, DOI 10.1016/S0024-3205(01)01404-7; HALLIWELL B, 1984, LANCET, V2, P1095; Hamel E, 1996, BIOCHEMISTRY-US, V35, P1304, DOI 10.1021/bi951559s; Hashimoto M, 2002, J BIOL CHEM, V277, P11465, DOI 10.1074/jbc.M111428200; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Javelaud D, 2001, ONCOGENE, V20, P4365, DOI 10.1038/sj.onc.1204570; Kotamraju S, 2000, J BIOL CHEM, V275, P33585, DOI 10.1074/jbc.M003890200; KOVAR H, 1993, ONCOGENE, V8, P2683; Kovar Heinrich, 1998, Current Opinion in Oncology, V10, P334, DOI 10.1097/00001622-199807000-00010; Kumar AP, 2001, MOL CARCINOGEN, V31, P111, DOI 10.1002/mc.1046; Kushner BH, 2001, J CLIN ONCOL, V19, P870, DOI 10.1200/JCO.2001.19.3.870; LEDENEV AN, 1986, BIOCHEM INT, V13, P391; Lin HL, 2000, CANCER-AM CANCER SOC, V89, P983, DOI 10.1002/1097-0142(20000901)89:5<983::AID-CNCR7>3.3.CO;2-7; Mukhopadhyay T, 1997, ONCOGENE, V14, P379, DOI 10.1038/sj.onc.1200835; Nakamura Y, 2002, J BIOL CHEM, V277, P2687, DOI 10.1074/jbc.M109641200; Nomura K, 2001, BIOL SIGNAL RECEPT, V10, P81; Oberlin O, 2001, BRIT J CANCER, V85, P1646, DOI 10.1054/bjoc.2001.2150; Ollinger Karin, 2002, Subcell Biochem, V36, P151; Petrosillo G, 2001, FEBS LETT, V509, P435, DOI 10.1016/S0014-5793(01)03206-9; Pinkerton CR, 2001, EUR J CANCER, V37, P1338, DOI 10.1016/S0959-8049(01)00131-9; Pribluda VS, 2000, CANCER METAST REV, V19, P173, DOI 10.1023/A:1026543018478; Qadan LR, 2001, BIOCHEM BIOPH RES CO, V285, P1259, DOI 10.1006/bbrc.2001.5320; Qanungo S, 2002, ONCOGENE, V21, P4149, DOI 10.1038/sj.onc.1205508; Ramachandran A, 2002, BIOL CHEM, V383, P693, DOI 10.1515/BC.2002.071; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; Reed JC, 2002, MOL CELL, V9, P1, DOI 10.1016/S1097-2765(02)00437-9; Sartorius U, 2001, CHEMBIOCHEM, V2, P20, DOI 10.1002/1439-7633(20010105)2:1<20::AID-CBIC20>3.3.CO;2-O; Schumacher G, 2001, J CANCER RES CLIN, V127, P405, DOI 10.1007/s004320000233; SIES H, 1994, METHOD ENZYMOL, V234, P476; Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304; Sitailo LA, 2002, J BIOL CHEM, V277, P19346, DOI 10.1074/jbc.M200401200; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Szibor M, 2001, ANTIOXID REDOX SIGN, V3, P515, DOI 10.1089/15230860152409149; Tang DG, 2002, BIOL CHEM, V383, P425, DOI 10.1515/BC.2002.046; YAGI K, 1987, CHEM PHYS LIPIDS, V45, P337, DOI 10.1016/0009-3084(87)90071-5; Yue TL, 1997, MOL PHARMACOL, V51, P951, DOI 10.1124/mol.51.6.951; Zhao R, 2002, P NATL ACAD SCI USA, V99, P8579, DOI 10.1073/pnas.122061399; Zhao YF, 2001, ANTIOXID REDOX SIGN, V3, P375, DOI 10.1089/15230860152409022	56	69	73	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2003	22	17					2558	2567		10.1038/sj.onc.1206356	http://dx.doi.org/10.1038/sj.onc.1206356			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730670				2022-12-28	WOS:000182569000003
J	Ko, JK; Lee, MJ; Cho, SH; Cho, JA; Lee, BY; Koh, JS; Lee, SS; Shim, YH; Kim, CW				Ko, JK; Lee, MJ; Cho, SH; Cho, JA; Lee, BY; Koh, JS; Lee, SS; Shim, YH; Kim, CW			Bfl-1S, a novel alternative splice variant of Bfl-1, localizes in the nucleus via its C-terminus and prevents cell death	ONCOGENE			English	Article						Bfl-1S; Bcl-2 family; alternative splice; apoptosis; Molt-4; nuclear localization	BCL-2 FAMILY MEMBER; TUMOR-NECROSIS-FACTOR; MEDIATED APOPTOSIS; UP-REGULATION; YEAST-CELLS; B-CELLS; A1; EXPRESSION; HOMOLOG; PROTEIN	Bfl-1 is an antiapoptotic Bcl-2 family member and a mouse A1 homologue. The mouse A1 has been reported to have three isoforms, but little is known about human Bfl-1. By reverse-transcriptase polymerase chain reaction analysis, we have identified Bfl-1S (short form), an alternative splice variant of Bfl-1. The Bfl-1S primary sequence contains four conserved Bcl-2 homology (BH) domains and a positive-charged C-terminus containing KKRK amino acids. The expression of Bfl-1S mRNA was detected predominantly in normal lymph nodes and in B-lymphoid leukemia cells. Confocal microscopic analysis using green fluorescence protein fusion proteins demonstrated that Bfl-1S is localized in the nucleus by its C-terminus as an intrinsic nuclear localization sequence. Bfl-1S acts as an antiapoptotic agent in coexpression experiments with Bax, a proapoptotic molecule. The expression of Bfl-1S provided significant resistance against staurosporine (STS) treatments in Molt-4 human T-leukemia cells. Bfl-1S also significantly inhibited the cleavage of Bid, and of caspases 3 and 8 against STS treatment. These results indicate that Bfl-1S is a novel human Bcl-2 family member that possesses antiapoptotic function.	Seoul Natl Univ, Coll Med, Inst Canc Res, Dept Pathol,Ghongno Gu, Seoul 110799, South Korea; Inst iNtRON Biotechnol, Seoul, South Korea; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurol, Boston, MA 02115 USA; Korea Canc Ctr Hosp, Lab Expt Pathol, Seoul, South Korea; Konkuk Univ, Dept Biol Sci, Seoul, South Korea	Seoul National University (SNU); Harvard University; Brigham & Women's Hospital; Harvard Medical School; National Cancer Center - Korea (NCC); Konkuk University	Kim, CW (corresponding author), Seoul Natl Univ, Coll Med, Inst Canc Res, Dept Pathol,Ghongno Gu, 28 Yongon Dong, Seoul 110799, South Korea.		Kim, Chul-Woo/F-7008-2011; Shim, Yhong-Hee/D-6691-2011	Shim, Yhong-Hee/0000-0002-8660-4176				BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Cheng QW, 2000, ONCOGENE, V19, P4936, DOI 10.1038/sj.onc.1203861; Cheung KJ, 2001, EXP CELL RES, V268, P1, DOI 10.1006/excr.2001.5258; CHOI SS, 1995, ONCOGENE, V11, P1693; D'Sa-Eipper C, 1998, ONCOGENE, V16, P3105, DOI 10.1038/sj.onc.1201851; DSaEipper C, 1996, CANCER RES, V56, P3879; Duriez PJ, 2000, J BIOL CHEM, V275, P18099, DOI 10.1074/jbc.M908925199; Ha SH, 2002, CANCER RES, V62, P1275; Han JH, 1998, MOL CELL BIOL, V18, P6052, DOI 10.1128/MCB.18.10.6052; Han ZY, 1999, MOL CELL BIOL, V19, P1381; Hatakeyama S, 1998, INT IMMUNOL, V10, P631, DOI 10.1093/intimm/10.5.631; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Holmgreen SP, 1999, CELL DEATH DIFFER, V6, P525, DOI 10.1038/sj.cdd.4400519; Jung-Ha H, 1998, HUM PATHOL, V29, P723, DOI 10.1016/S0046-8177(98)90282-9; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; Karsan A, 1996, BLOOD, V87, P3089, DOI 10.1182/blood.V87.8.3089.bloodjournal8783089; Kasof GM, 1999, MOL CELL BIOL, V19, P4390; KEPLER TB, 1993, IMMUNOL TODAY, V14, P412, DOI 10.1016/0167-5699(93)90145-B; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Perez D, 1998, J CELL BIOL, V141, P1255, DOI 10.1083/jcb.141.5.1255; Priault M, 1999, FEBS LETT, V443, P225, DOI 10.1016/S0014-5793(98)01661-5; Rao L, 1997, ONCOGENE, V15, P1587, DOI 10.1038/sj.onc.1201323; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Shim YH, 2000, INT J HEMATOL, V72, P484; Somogyi RD, 2001, CELL DEATH DIFFER, V8, P785, DOI 10.1038/sj.cdd.4400879; Tomayko MM, 1998, J IMMUNOL, V160, P107; Wang CY, 1999, MOL CELL BIOL, V19, P5923; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Werner AB, 2002, J BIOL CHEM, V277, P22781, DOI 10.1074/jbc.M201469200; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zhang H, 2000, J BIOL CHEM, V275, P11092, DOI 10.1074/jbc.275.15.11092; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	35	32	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 24	2003	22	16					2457	2465		10.1038/sj.onc.1206274	http://dx.doi.org/10.1038/sj.onc.1206274			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	670AD	12717423				2022-12-28	WOS:000182383500009
J	Abdulkarim, B; Sabri, S; Zelenika, D; Deutsch, E; Frascogna, V; Klijanienko, J; Vainchenker, W; Joab, I; Bourhis, J				Abdulkarim, B; Sabri, S; Zelenika, D; Deutsch, E; Frascogna, V; Klijanienko, J; Vainchenker, W; Joab, I; Bourhis, J			Antiviral agent Cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies	ONCOGENE			English	Article						cidofovir; ionizing radiation; EBV-associated cancer; oncoproteins; apoptosis	LATENT MEMBRANE-PROTEIN; LYMPHOMA CELL-LINE; HUMAN-IMMUNODEFICIENCY-VIRUS; IMMEDIATE-EARLY GENES; IMMORTALIZED B-CELLS; NASOPHARYNGEAL CARCINOMA; HUMAN-PAPILLOMAVIRUS; BCL-2 EXPRESSION; BURKITT-LYMPHOMA; KAPPA-B	The Epstein-Barr virus (EBV) is involved in the carcinogenesis of several human cancers such as nasopharyngeal carcinoma (NPC) and Burkitt lymphoma (BL). Given the consistent role of EBV in transformation and maintenance of malignant phenotype, antiviral strategies provide an attractive approach to target EBV-expressing cells. In that aim, we have tested the Cidofovir, which is an acyclic nucleoside phosphonate analog known to exert an antiproliferative activity in some human virus-related tumors. Here, we show that Cidofovir induces a downregulation of the EBV oncoprotein LMP1 associated with a decrease of the antiapoptotic Bcl-2 and an increase of the proapoptotic Bax protein in Raji (BL) and C15 (NPC) cells. Using BL cell line BL2 B95-8 (BL2 infected with the B95.8 strain of EBV), we addressed the relation between EBV genome expression and modulation of viral oncoproteins by Cidofovir and/or ionizing radiation (IR). Cidofovir was able to significantly reduce LMP1 and EBNA2 mRNA and protein expression. This effect was associated with inhibition of proliferation, stimulation of apoptosis, and decrease of Bcl-2 expression in BL2 B95.8 cells. In addition, Cidofovir enhanced the radiation-induced apoptosis and the radiosensitivity through the proteolytic cleavage of death effectors caspase-9 and -3, which was specifically induced by combined treatment in EBV-positive cells compared to their negative counterparts. Furthermore, the combined treatment in nude mice led to a complete tumor remission without increasing toxicity in two human EBV-related cancer xenografts (Raji and C15). These results provide the basis for a novel anticancer strategy to enhance the therapeutic ratio of IR in EBV-related cancers.	Inst Gustave Roussy, Lab Radiosensibil Tumeurs & Tissus Sains, UPRESEA 27 10, F-94805 Villejuif, France; Inst Curie, Paris, France; Hop St Louis, Inst Mol Genet, Paris, France	UNICANCER; Gustave Roussy; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Bourhis, J (corresponding author), Inst Gustave Roussy, Lab Radiosensibil Tumeurs & Tissus Sains, UPRESEA 27 10, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	bourhis@igr.fr	Sabri, Siham/K-1101-2015	Sabri, Siham/0000-0001-5792-689X; Vainchenker, William/0000-0003-4705-202X; Bourhis, Jean/0000-0001-5162-1171; deutsch, eric/0000-0002-8223-3697				ABBOT SD, 1990, J VIROL, V64, P2126, DOI 10.1128/JVI.64.5.2126-2134.1990; Abdulkarim B, 2002, ONCOGENE, V21, P2334, DOI 10.1038/sj.onc.1205006; Abdulkarim B, 2001, LANCET ONCOL, V2, P622, DOI 10.1016/S1470-2045(01)00520-4; BALZARINI J, 1991, BIOCHEM BIOPH RES CO, V178, P329, DOI 10.1016/0006-291X(91)91818-W; BUSSON P, 1988, INT J CANCER, V42, P599, DOI 10.1002/ijc.2910420422; Chung YL, 2000, CLIN CANCER RES, V6, P1452; D'Souza B, 2000, J VIROL, V74, P6652, DOI 10.1128/JVI.74.14.6652-6658.2000; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DECLERCQ E, 1986, NATURE, V323, P464, DOI 10.1038/323464a0; Eliopoulos AG, 1999, J VIROL, V73, P1023, DOI 10.1128/JVI.73.2.1023-1035.1999; Eliopoulos AG, 2001, SEMIN CANCER BIOL, V11, P435, DOI 10.1006/scbi.2001.0410; Eliopoulos AG, 1998, CURR BIOL, V8, pR196, DOI 10.1016/S0960-9822(98)70123-X; Fagard R, 2002, ONCOGENE, V21, P4473, DOI 10.1038/sj.onc.1205554; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; FAHRAEUS R, 1990, P NATL ACAD SCI USA, V87, P7390, DOI 10.1073/pnas.87.19.7390; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; Griffin B E, 2000, Mutat Res, V462, P395, DOI 10.1016/S1383-5742(00)00028-4; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Hong SY, 2000, J BIOL CHEM, V275, P18022, DOI 10.1074/jbc.M001202200; Johnson JA, 1999, ANTIMICROB AGENTS CH, V43, P1198, DOI 10.1128/AAC.43.5.1198; KEMPKES B, 1995, EMBO J, V14, P88, DOI 10.1002/j.1460-2075.1995.tb06978.x; Kenney JL, 1998, BLOOD, V92, P1721, DOI 10.1182/blood.V92.5.1721.417a08_1721_1727; Kieff E., 1996, FIELDS VIROLOGY, V2, P2343; KLEIN G, 1975, INTERVIROLOGY, V5, P319, DOI 10.1159/000149930; Komano J, 1998, J VIROL, V72, P9150, DOI 10.1128/JVI.72.11.9150-9156.1998; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Morgan MB, 1999, TUMOR TARGET, V4, P278; MURRAY RJ, 1988, J VIROL, V62, P3747, DOI 10.1128/JVI.62.10.3747-3755.1988; Neyts J, 1998, CANCER RES, V58, P384; PAUWELS R, 1988, ANTIMICROB AGENTS CH, V32, P1025, DOI 10.1128/AAC.32.7.1025; PRASAD AV, 1995, RADIAT RES, V143, P263, DOI 10.2307/3579212; ROTH G, 1994, BLOOD, V84, P582, DOI 10.1182/blood.V84.2.582.bloodjournal842582; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; SHIBATA D, 1992, AM J PATHOL, V140, P769; SINCLAIR AJ, 1994, EMBO J, V13, P3321, DOI 10.1002/j.1460-2075.1994.tb06634.x; SUNG NS, 1991, J VIROL, V65, P2164, DOI 10.1128/JVI.65.5.2164-2169.1991; WANG F, 1990, J VIROL, V64, P3407, DOI 10.1128/JVI.64.7.3407-3416.1990; WEICHSELBAUM RR, 1994, INT J RADIAT ONCOL, V30, P229, DOI 10.1016/0360-3016(94)90539-8; WEISS LM, 1989, NEW ENGL J MED, V320, P502, DOI 10.1056/NEJM198902233200806; Westphal EM, 2000, CANCER RES, V60, P5781; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G	43	36	43	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2003	22	15					2260	2271		10.1038/sj.onc.1206402	http://dx.doi.org/10.1038/sj.onc.1206402			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	667KV	12700662				2022-12-28	WOS:000182231500005
J	Uren, A; Merchant, MS; Sun, CJ; Vitolo, MI; Sun, Y; Tsokos, M; Illei, PB; Ladanyi, M; Passaniti, A; Mackall, C; Toretsky, JA				Uren, A; Merchant, MS; Sun, CJ; Vitolo, MI; Sun, Y; Tsokos, M; Illei, PB; Ladanyi, M; Passaniti, A; Mackall, C; Toretsky, JA			Beta-platelet-derived growth factor receptor mediates motility and growth of Ewing's sarcoma cells	ONCOGENE			English	Article						PDGF; PDGF receptors; Ewing's sarcoma	FACTOR-I RECEPTOR; SIGNAL-TRANSDUCTION; PDGF-C; TUMORS; LIGAND; TRANSFORMATION; FIBROBLASTS; INHIBITION; EXPRESSION; EWS/FLI-1	The Ewing's sarcoma family of tumors (ESFT) contain a translocation, t(11;22), which results in the novel oncogenic fusion protein EWS/FLI1. Platelet-derived growth factors (PDGF) and their receptors (PDGFR) are involved in the induction and proliferation of numerous solid tumors and are the potential candidates for novel targeted antitumor therapy. Since a relation was reported between PDGF-C and EWS/FLI1, we sought to characterize the PDGF signaling pathway in ESFT. Eight out of nine ESFT cell tines were found to express significant levels of beta-PDGFR. Interestingly, none of the tested cell lines expressed alpha-PDGFR, which is the receptor isotype required for PDGF-C binding. By immunohistochemical staining 47 of 52 (90.4%) archival tumor samples from patients with ESFT were positive for beta-PDGFR. ESFT cell lines were treated with PDGF-AA or PDGF-BB ligands to evaluate downstream signaling. Autophosphorylation of beta-PDGFR and tyrosine phosphorylation of PLC-gamma, PI3Kp85 and She were detected only in PDGF-BB-stimulated cells that express beta-PDGFR. Receptor function was further evaluated using chemotaxis assays that showed TC-32 cell migration towards PDGF-BB. A specific PDGFR kinase inhibitor AG1295 blocked beta-PDGFR activation, downstream signaling, growth in cell culture and chemotaxis of TC-32 cells. AG1295 also delayed tumor formation and prolonged survival in an ESFT animal model. We conclude that ESFT express beta-PDGFR and that this is a functional and potentially crucial signaling pathway. Therefore, beta-PDGFRs may provide a novel therapeutic target in ESFT that can be utilized to design better treatment modalities.	Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Washington, DC 20057 USA; NIH, Bethesda, MD 20892 USA; Univ Maryland, Dept Pathol, Baltimore, MD 21201 USA; Univ Maryland, Dept Pediat, Baltimore, MD 21201 USA; Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA	Georgetown University; National Institutes of Health (NIH) - USA; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Memorial Sloan Kettering Cancer Center	Uren, A (corresponding author), Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Res Bldg,Room W316,3970 Reservoir Rd,NW Box 57146, Washington, DC 20057 USA.		Ladanyi, Marc/AAG-8585-2019	Vitolo, Michele/0000-0001-8055-9645	NCI NIH HHS [R01 CA88004] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088004, Z01SC010289, Z01SC009431] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588; BRYCKAERT MC, 1992, EXP CELL RES, V199, P255, DOI 10.1016/0014-4827(92)90432-8; BUCHDUNGER E, 1995, P NATL ACAD SCI USA, V92, P2558, DOI 10.1073/pnas.92.7.2558; Denny CT, 1998, J PEDIAT HEMATOL ONC, V20, P421, DOI 10.1097/00043426-199809000-00002; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; Gilbertson DG, 2001, J BIOL CHEM, V276, P27406, DOI 10.1074/jbc.M101056200; Girnita L, 2000, ONCOGENE, V19, P4298, DOI 10.1038/sj.onc.1203755; Grier HE, 1997, PEDIATR CLIN N AM, V44, P991, DOI 10.1016/S0031-3955(05)70541-1; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; Kontny HU, 1998, CANCER RES, V58, P5842; KOVALENKO M, 1994, CANCER RES, V54, P6106; LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; Meyers PA, 2001, J CLIN ONCOL, V19, P2812, DOI 10.1200/JCO.2001.19.11.2812; MISER LS, 1996, P ANN M AM SOC CLIN, pA1472; Ostman A, 2001, ADV CANCER RES, V80, P1, DOI 10.1016/S0065-230X(01)80010-5; Ricotti E, 1998, BLOOD, V91, P2397, DOI 10.1182/blood.V91.7.2397.2397_2397_2405; Sanceau J, 2000, ONCOGENE, V19, P3372, DOI 10.1038/sj.onc.1203670; Scotlandi K, 1998, CANCER RES, V58, P4127; Toretsky JA, 1997, J BIOL CHEM, V272, P30822, DOI 10.1074/jbc.272.49.30822; Uren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374; UREN A, 1994, BIOCHEM BIOPH RES CO, V204, P628, DOI 10.1006/bbrc.1994.2505; van Oosterom AT, 2001, LANCET, V358, P1421, DOI 10.1016/S0140-6736(01)06535-7; VANVALEN F, 1992, J CANCER RES CLIN, V118, P269, DOI 10.1007/BF01208615; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YEE D, 1990, J CLIN INVEST, V86, P1806, DOI 10.1172/JCI114910; Zwerner JP, 2001, ONCOGENE, V20, P626, DOI 10.1038/sj.onc.1204133	28	67	71	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 17	2003	22	15					2334	2342		10.1038/sj.onc.1206330	http://dx.doi.org/10.1038/sj.onc.1206330			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	667KV	12700668				2022-12-28	WOS:000182231500011
J	Blazek, E; Wasmer, S; Kruse, U; Aronheim, A; Aoki, M; Vogt, PK				Blazek, E; Wasmer, S; Kruse, U; Aronheim, A; Aoki, M; Vogt, PK			Partial oncogenic transformation of chicken embryo fibroblasts by Jun dimerization protein 2, a negative regulator of TRE- and CRE-dependent transcription	ONCOGENE			English	Article						AP-1; JDP2; Jun; repressor; transformation	MAF NUCLEAR ONCOPROTEIN; C-JUN; LEUCINE-ZIPPER; V-JUN; CELL-PROLIFERATION; DELETION MUTANT; AP-1 REPRESSOR; GROWTH-FACTOR; FOS; IDENTIFICATION	Jun dimerization protein 2 (JDP2) was identified as a bZIP protein that forms dimers with Jun proteins. JDP2 represses transcriptional activation of reporter constructs containing 12-O-tetradecanoylphorbol 13-acetate (TPA)-responsive elements (TRE) or cyclic AMP responsive elements (CRE). JDP2, overexpressed by the avian retroviral vector RCAS, induces partial oncogenic transformation of chicken embryo fibroblasts. JDP2-expressing cells form multilayered foci in monolayer cultures but do not show anchorage-independent growth. Both the carboxyl and the amino terminus of JDP2 are required for the transforming activity. Chimeric constructs of JDP2 carrying the leucine zipper domain of Fos, GCN4 or EB1 fail to transform CEF. The leucine zipper of Fos mediates only heterodimerization; it cannot homodimerize. In contrast, the leucine zippers of GCN4 and of EB1 exclusively homodimerize and do not form dimers with other bZip proteins. The results with the JDP2 chimeras suggest that the JDP2 homodimer and the JDP2/Jun heterodimer (or other bZip heterodimers formed with the Fos leucine zipper) are nontransforming, leaving as possible transforming combination the JDP2/Fos heterodimer. The unexpected transforming activity of a negative regulator of TRE- and CRE-dependent transcription raises an important question concerning the mechanisms of transformation by the related bZIP proteins Jun and Fos that address the same target sequences.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Technion Israel Inst Technol, IL-31096 Haifa, Israel	Scripps Research Institute; Technion Israel Institute of Technology	Vogt, PK (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	pkvogt@scripps.edu	Vogt, Peter K./R-7547-2019; Aoki, Masahiro/A-5149-2016	Vogt, Peter K./0000-0002-4519-7500; Aoki, Masahiro/0000-0003-4316-9490; Aronheim, Ami/0000-0002-8575-4092				Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; Broder YC, 1998, CURR BIOL, V8, P1121, DOI 10.1016/S0960-9822(98)70467-1; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; BROWN PH, 1993, ONCOGENE, V8, P877; Cohen SB, 2001, ONCOGENE, V20, P141, DOI 10.1038/sj.onc.1204077; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Gao MH, 1996, CANCER RES, V56, P4229; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; HWANG HC, 2002, P NATL ACAD SCI USA, V31, P31; Jin CY, 2002, MOL CELL BIOL, V22, P4815, DOI 10.1128/MCB.22.13.4815-4826.2002; Jin CY, 2001, FEBS LETT, V489, P34, DOI 10.1016/S0014-5793(00)02387-5; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; Kataoka K, 2001, J BIOL CHEM, V276, P36849, DOI 10.1074/jbc.M102234200; Kataoka K, 1996, ONCOGENE, V12, P53; Kruse U, 1997, P NATL ACAD SCI USA, V94, P12396, DOI 10.1073/pnas.94.23.12396; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; Mathas S, 2002, EMBO J, V21, P4104, DOI 10.1093/emboj/cdf389; MORGAN IM, 1992, ONCOGENE, V7, P1119; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Perez S, 2001, ONCOGENE, V20, P1135, DOI 10.1038/sj.onc.1204200; Piu F, 2001, MOL CELL BIOL, V21, P3012, DOI 10.1128/MCB.21.9.3012-3024.2001; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Vasanwala FH, 2002, J IMMUNOL, V169, P1922, DOI 10.4049/jimmunol.169.4.1922; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Vogt PK, 2002, NAT REV CANCER, V2, P465, DOI 10.1038/nrc818; Vogt PK, 1969, FUNDAMENTAL TECHNIQU, P198	38	24	25	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2003	22	14					2151	2159		10.1038/sj.onc.1206312	http://dx.doi.org/10.1038/sj.onc.1206312			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664NJ	12687017				2022-12-28	WOS:000182066900009
J	Wei, YK; Sun, MH; Nilsson, G; Dwight, T; Xie, YT; Wang, J; Hou, YY; Larsson, O; Larsson, C; Zhu, XZ				Wei, YK; Sun, MH; Nilsson, G; Dwight, T; Xie, YT; Wang, J; Hou, YY; Larsson, O; Larsson, C; Zhu, XZ			Characteristic sequence motifs located at the genomic breakpoints of the translocation t(X;18) in synovial sarcomas	ONCOGENE			English	Article						synovial sarcoma; translocation; DNA sequence; breakpoints	TOPOISOMERASE-II CLEAVAGE; ACUTE MYELOID-LEUKEMIA; CHROMOSOMAL TRANSLOCATIONS; CLUSTER REGION; DNA-SEQUENCE; ILLEGITIMATE RECOMBINATION; ALVEOLAR RHABDOMYOSARCOMA; BCR GENE; TUMORS; SITES	The SYT-SSXI and SYT-SSX2 fusion genes, derived by reciprocal translocations t(X;18), are acquired genetic events strongly associated with the tumorigenesis of synovial sarcoma. In approaching the mechanisms underlying the formation of these fusion oncogenes, we have analysed the genomic sequences surrounding the SYT-SSX breakpoints in 10 tumors, two expressing SYT-SSXI and eight expressing SYT-SSX2 fusion transcripts. The breakpoints were found to be clustered in the 5' end of intron 10 of SYT, and in two cluster regions within intron 4 of SSX2, whereas the two breakpoints in SSX1 intron 4 were 0.5 kb apart. SYT intron 10 is abundant in repetitive regions with the interspersed repeats occupying 66% of the whole intron. Nine of the 10 breakpoints in intron 10 of SYT and six of the eight breakpoints in intron 4 of SSX2 were at or near repetitive regions. These findings suggest that repetitive regions may contribute to the distribution of genomic breakpoints. Several of the fusion sequences exhibited characteristic signs of nonhomologous end joining, including microhomologies at the end points as well as deletions. Sequences highly homologous (83-94%) to consensus topoisomerase II cleavage sites were identified at or near the breakpoints in all 10 tumors, suggesting a role of this enzyme in creating staggered ends at the breakpoint. Furthermore, sequences highly homologous to consensus Translin binding sequences were found at the breakpoints in two cases, and an Alu-Alu fusion and an insertion of a 206-bp LINE-1 element were found at the breakpoint in one case each. The demonstration of characteristic sequences at the SYT-SSX breakpoint regions is expected to improve our understanding of the molecular genetic mechanisms behind translocations in general, and of the SYT-SSX fusions in synovial sarcoma in particular.	Fudan Univ, Canc Hosp, Dept Pathol, Shanghai 200032, Peoples R China; Karolinska Hosp, CCK R8 04, Dept Pathol & Oncol, SE-17176 Stockholm, Sweden; Karolinska Hosp, Dept Surg Sci, Sect Orthoped, SE-17176 Stockholm, Sweden; Karolinska Hosp, CMM L8 01, Dept Mol Med, SE-17176 Stockholm, Sweden	Fudan University; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital	Zhu, XZ (corresponding author), Fudan Univ, Canc Hosp, Dept Pathol, 270 Dongan Rd, Shanghai 200032, Peoples R China.			Dwight, Trisha/0000-0003-1943-4514				AOKI K, 1995, NAT GENET, V10, P167, DOI 10.1038/ng0695-167; Barr FG, 1998, CANCER GENET CYTOGEN, V102, P32, DOI 10.1016/S0165-4608(97)00287-2; BOEHM T, 1989, EMBO J, V8, P2621, DOI 10.1002/j.1460-2075.1989.tb08402.x; Broeker PLS, 1996, BLOOD, V87, P1912, DOI 10.1182/blood.V87.5.1912.bloodjournal8751912; BULLOCK P, 1985, SCIENCE, V230, P954, DOI 10.1126/science.2997924; CAMERINIOTERO RD, 1993, CELL, V73, P217, DOI 10.1016/0092-8674(93)90224-E; Chalk JG, 1997, ONCOGENE, V15, P1199, DOI 10.1038/sj.onc.1201285; CHEN SJ, 1989, ONCOGENE, V4, P195; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; DELEEUW B, 1995, HUM MOL GENET, V4, P1097, DOI 10.1093/hmg/4.6.1097; FINGER LR, 1986, SCIENCE, V234, P982, DOI 10.1126/science.3490692; Hosaka T, 2000, ONCOGENE, V19, P5821, DOI 10.1038/sj.onc.1203943; Ishida S, 1998, CYTOGENET CELL GENET, V82, P278, DOI 10.1159/000015119; Kanoe H, 1999, ONCOGENE, V18, P721, DOI 10.1038/sj.onc.1202364; KAS E, 1992, EMBO J, V11, P705, DOI 10.1002/j.1460-2075.1992.tb05103.x; Kolomietz E, 2002, GENE CHROMOSOME CANC, V35, P97, DOI 10.1002/gcc.10111; KROWCZYNSKA AM, 1986, NUCLEIC ACIDS RES, V14, P7071; LADANYI M, 1995, DIAGN MOL PATHOL, V4, P162, DOI 10.1097/00019606-199509000-00003; Liu J, 1997, GENE CHROMOSOME CANC, V18, P232, DOI 10.1002/(SICI)1098-2264(199703)18:3<232::AID-GCC10>3.0.CO;2-K; Lovett BD, 2001, P NATL ACAD SCI USA, V98, P9802, DOI 10.1073/pnas.171309898; NICHOLLS RD, 1987, CELL, V49, P369, DOI 10.1016/0092-8674(87)90289-3; Nilsson G, 1999, CANCER RES, V59, P3180; Panagopoulos I, 1997, ONCOGENE, V15, P1357, DOI 10.1038/sj.onc.1201281; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANDER M, 1985, NUCLEIC ACIDS RES, V13, P1057, DOI 10.1093/nar/13.4.1057; Skytting B, 1999, J NATL CANCER I, V91, P974, DOI 10.1093/jnci/91.11.974; Sorensen PHB, 1996, SEMIN CANCER BIOL, V7, P3, DOI 10.1006/scbi.1996.0002; SOWERBY SJ, 1993, ONCOGENE, V8, P1679; SPERRY AO, 1989, P NATL ACAD SCI USA, V86, P5497, DOI 10.1073/pnas.86.14.5497; SPITZNER JR, 1988, NUCLEIC ACIDS RES, V16, P5533, DOI 10.1093/nar/16.12.5533; SREEKANTAIAH C, 1994, AM J PATHOL, V144, P1121; TOTH G, 1994, GENE, V140, P285, DOI 10.1016/0378-1119(94)90559-2; Villablanca A, 2002, EUR J ENDOCRINOL, V147, P313, DOI 10.1530/eje.0.1470313; WEISS SW, 2001, SOFT TISSUE TUMORS; Zhang YM, 2002, P NATL ACAD SCI USA, V99, P3070, DOI 10.1073/pnas.042702899; Zucman-Rossi J, 1998, P NATL ACAD SCI USA, V95, P11786, DOI 10.1073/pnas.95.20.11786	38	23	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2003	22	14					2215	2222		10.1038/sj.onc.1206343	http://dx.doi.org/10.1038/sj.onc.1206343			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664NJ	12687023				2022-12-28	WOS:000182066900015
J	Fitzsimmons, S; Ireland, H; Barr, NI; Cuthbert, AP; Going, JJ; Newbold, R; Parkinson, EK				Fitzsimmons, S; Ireland, H; Barr, NI; Cuthbert, AP; Going, JJ; Newbold, R; Parkinson, EK			Human squamous cell carcinomas lose a mortality gene from chromosome 6q14.3 to q15	ONCOGENE			English	Article						chromosome 6; senescence; keratinocyte; squamous cancer	TUMOR-SUPPRESSOR GENE; FUNCTIONAL EVIDENCE; GROWTH-ARREST; NASOPHARYNGEAL CARCINOMA; INDEFINITE DIVISION; HIGH-FREQUENCY; HUMAN CANCERS; SENESCENCE; REGION; IDENTIFICATION	Normal human keratinocytes possess a finite replicative lifespan. Most advanced squamous cell carcinomas (SCCs), however, are immortal, a phenotype that is associated with p53 and INK4A dysfunction, high levels of telomerase and loss of heterozygosity (LOH) at several genetic loci, suggestive of the dysfunction of other mortality genes. We show here that human chromosome 6 specifically reduces the proliferation or viability of a human SCC line, BICR31, possessing LOH across the chromosome. This was determined by an 88% reduction in colony yield (P < 0.001), following the reintroduction of an intact normal chromosome 6 by monochromosome transfer. Deletion analysis of immortal segregants using polymorphic markers revealed the loss of a 2.9 Mbp interval, centred on marker D6S1045 at 6q14.3-q15, in 6/19 segregants. Crucially, allelic losses of this region were not identified in control hybrids constructed between chromosome 6 and the BICR6 SCC cell line that is heterozygous for chromosome 6 and which showed no reduction in colony formation relative to the control chromosome transfers. This indicates that the minimally deleted region at D6S1045 is not the result of fragile sites, a recombination hot spot, or a feature of the monochromosome transfer technique. LOH of D6S1045 was found in 2/9 immortal SCC lines and was part of a minimally deleted region of line BICR19. Furthermore, allelic imbalance, consistent with LOH, was detected in 31 17 advanced SCCs of the tongue. These results suggest the existence of a suppressor of SCC immortality and tumour development at chromosome 6q14.3-q15, which is important to a subset of human SCCs.	Beatson Inst Canc Res, Canc Res UK Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Brunel Univ, Dept Biol & Biochem, Uxbridge UBS 3PH, Middx, England; Univ Glasgow, Glasgow Royal Infirm, Dept Pathol, Glasgow G4 0SF, Lanark, Scotland	Beatson Institute; Brunel University; University of Glasgow	Parkinson, EK (corresponding author), Beatson Inst Canc Res, Canc Res UK Beatson Labs, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.			Going, James/0000-0001-9120-919X				Azzalin CM, 1997, CYTOGENET CELL GENET, V78, P112, DOI 10.1159/000134640; Banga SS, 1997, ONCOGENE, V14, P313, DOI 10.1038/sj.onc.1200842; Benitez J, 1997, CANCER RES, V57, P4217; CASEY G, 1993, HUM MOL GENET, V2, P1921, DOI 10.1093/hmg/2.11.1921; Cheng Y, 1998, P NATL ACAD SCI USA, V95, P3042, DOI 10.1073/pnas.95.6.3042; CLARK LJ, 1993, BRIT J CANCER, V68, P617, DOI 10.1038/bjc.1993.396; Cooney KA, 1996, CANCER RES, V56, P4150; CUTHBERT AP, 1995, CYTOGENET CELL GENET, V71, P68, DOI 10.1159/000134066; Cuthbert AP, 1999, JNCI-J NATL CANCER I, V91, P37, DOI 10.1093/jnci/91.1.37; EDINGTON KG, 1995, MOL CARCINOGEN, V13, P254, DOI 10.1002/mc.2940130408; EDWARDS NL, 1978, SCIENCE, V201, P628, DOI 10.1126/science.27864; Engelman JA, 1998, FEBS LETT, V436, P403, DOI 10.1016/S0014-5793(98)01134-X; England NL, 1996, CARCINOGENESIS, V17, P1567, DOI 10.1093/carcin/17.8.1567; FANTES JA, 1995, GENOMICS, V25, P447, DOI 10.1016/0888-7543(95)80045-N; Forsyth NR, 2002, ONCOGENE, V21, P5135, DOI 10.1038/sj.onc.1205688; FUJIKAWAYAMAMOTO K, 1994, CELL STRUCT FUNCT, V19, P391, DOI 10.1247/csf.19.391; Going JJ, 1996, J PATHOL, V179, P121; GREEN RJ, 1988, HUM GENET, V81, P9, DOI 10.1007/BF00283720; Guan XY, 1996, BLOOD, V88, P1418, DOI 10.1182/blood.V88.4.1418.bloodjournal8841418; Hassfeld W, 1998, NUCLEIC ACIDS RES, V26, P439, DOI 10.1093/nar/26.2.439; Hatcher CJ, 2001, DEV BIOL, V230, P177, DOI 10.1006/dbio.2000.0134; HENSLER PJ, 1994, MOL CELL BIOL, V14, P2291, DOI 10.1128/MCB.14.4.2291; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; Karlsson C, 1996, CANCER RES, V56, P241; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; LEVY FO, 1994, GENOMICS, V22, P637, DOI 10.1006/geno.1994.1439; Lo KW, 2001, CANCER RES, V61, P3877; Loughran O, 1997, ONCOGENE, V14, P1955, DOI 10.1038/sj.onc.1201028; Morelli C, 1997, CANCER RES, V57, P4153; Nathrath MH, 2002, ONCOGENE, V21, P5975, DOI 10.1038/sj.onc.1205764; NING Y, 1991, P NATL ACAD SCI USA, V88, P5635, DOI 10.1073/pnas.88.13.5635; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; Parkinson EK, 1997, EUR J CANCER, V33, P727, DOI 10.1016/S0959-8049(97)00063-4; Resta R, 1998, IMMUNOL REV, V161, P95, DOI 10.1111/j.1600-065X.1998.tb01574.x; RIMESSI P, 1994, ONCOGENE, V9, P3467; Robertson GP, 1998, P NATL ACAD SCI USA, V95, P9418, DOI 10.1073/pnas.95.16.9418; SANDHU AK, 1994, P NATL ACAD SCI USA, V91, P5498, DOI 10.1073/pnas.91.12.5498; Sandhu AK, 1996, ONCOGENE, V12, P247; SASAKI M, 1994, CANCER RES, V54, P6090; Sheng ZM, 1996, BRIT J CANCER, V73, P144, DOI 10.1038/bjc.1996.27; STANTON P, 1994, BRIT J CANCER, V70, P427, DOI 10.1038/bjc.1994.322; Steenbergen RDM, 2001, JNCI-J NATL CANCER I, V93, P865, DOI 10.1093/jnci/93.11.865; Turker MS, 1999, CANCER RES, V59, P1837; UEJIMA H, 1995, GENE CHROMOSOME CANC, V14, P120, DOI 10.1002/gcc.2870140206; WANG XW, 1992, CARCINOGENESIS, V13, P555, DOI 10.1093/carcin/13.4.555; Wu CL, 1999, GENE CHROMOSOME CANC, V25, P16, DOI 10.1002/(SICI)1098-2264(199905)25:1<16::AID-GCC3>3.3.CO;2-U; Yi CH, 1999, GENOMICS, V55, P10, DOI 10.1006/geno.1998.5632; Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804; [No title captured]	49	4	4	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 20	2003	22	11					1737	1746		10.1038/sj.onc.1206295	http://dx.doi.org/10.1038/sj.onc.1206295			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642877				2022-12-28	WOS:000181580500016
J	Hyland, S; Beerli, RR; Barbas, CF; Hynes, NE; Wels, W				Hyland, S; Beerli, RR; Barbas, CF; Hynes, NE; Wels, W			Generation and functional characterization of intracellular antibodies interacting with the kinase domain of human EGF receptor	ONCOGENE			English	Article						epidermal growth factor receptor; receptor tyrosine kinase; single-chain Fv antibody; intrabody; yeast two-hybrid	GROWTH-FACTOR RECEPTOR; SINGLE-CHAIN ANTIBODY; ERBB SIGNALING NETWORK; MONOCLONAL-ANTIBODY; TARGETED THERAPY; HIV-1 INFECTION; FV FRAGMENTS; V-H; INHIBITION; PROTEIN	Intracellular expression of single-chain antibodies (scFvs) represents a promising approach for selective interference with cellular proto-oncogenes such as the epidermal growth factor receptor (EGFR). Previously, we have shown that intrabodies targeted to the lumen of the endoplasmic reticulum prevent the transit of EGFR or the related ErbB2 molecule to the cell surface, thereby inactivating their transforming potential. While intramolecular disulfide bridges important for antibody stability are correctly formed during expression in the secretory pathway, scFvs expressed in the reducing environment of the cytosol are often inactive. To overcome this problem and to generate antibody fragments that interact with the intracellular domain of human EGFR in the cytoplasm, here we have chosen a two-step approach combining classical selection of scFvs by phage display with subsequent expression in yeast. After enrichment of EGFR-specific antibody fragments from a combinatorial library by biopanning, a yeast two-hybrid screen was performed using the intracellular domain of EGFR as bait. Screening of 1.5 x 10(5) preselected scFv plasmids under highly stringent conditions yielded 223 colonies that represented at least five independent scFv clones functional in the intracellular milieu of eukaryotic cells. Interaction of selected antibody fragments with the intracellular domain of EGFR was confirmed in GST pull-down and coimmunoprecipitation experiments. Upon cytoplasmic expression in human tumor cells, scFvs colocalized with EGFR at the plasma membrane demonstrating their functionality in vivo.	Georg Speyer Haus, Chemotherapeut Forschungsinst, D-60596 Frankfurt, Germany; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Octapharma; Scripps Research Institute; Scripps Research Institute; Friedrich Miescher Institute for Biomedical Research	Wels, W (corresponding author), Georg Speyer Haus, Chemotherapeut Forschungsinst, Paul Ehrlich Str 42-44, D-60596 Frankfurt, Germany.	wels@em.uni-frankfurt.de		Wels, Winfried/0000-0001-9858-3643				Altenschmidt U, 1997, INT J CANCER, V73, P117, DOI 10.1002/(SICI)1097-0215(19970926)73:1<117::AID-IJC18>3.0.CO;2-D; Andris-Widhopf J, 2001, PHAGE DISPLAY LAB MA, V1st; Bach H, 2001, J MOL BIOL, V312, P79, DOI 10.1006/jmbi.2001.4914; Barbas C.F., 2001, PHAGE DISPLAY LAB MA; BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; Baselga J, 2000, J CLIN ONCOL, V18, P904, DOI 10.1200/JCO.2000.18.4.904; Beerli RR, 1996, BREAST CANCER RES TR, V38, P11, DOI 10.1007/BF01803779; BEERLI RR, 1994, BIOCHEM BIOPH RES CO, V204, P666, DOI 10.1006/bbrc.1994.2511; BEERLI RR, 1994, J BIOL CHEM, V269, P23931; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; BIOCCA S, 1995, BIO-TECHNOL, V13, P1110, DOI 10.1038/nbt1095-1110; BIOCCA S, 1994, BIO-TECHNOL, V12, P396, DOI 10.1038/nbt0494-396; Cardinale A, 2001, EUR J BIOCHEM, V268, P268, DOI 10.1046/j.1432-1033.2001.01876.x; Cattaneo A, 1999, TRENDS BIOTECHNOL, V17, P115, DOI 10.1016/S0167-7799(98)01268-2; De Jaeger G, 2000, FEBS LETT, V467, P316, DOI 10.1016/S0014-5793(00)01182-0; DESHANE J, 1994, GENE THER, V1, P332; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DUAN LX, 1994, P NATL ACAD SCI USA, V91, P5075, DOI 10.1073/pnas.91.11.5075; Gargano N, 1997, J GEN VIROL, V78, P2591, DOI 10.1099/0022-1317-78-10-2591; Goncalves J, 2002, J BIOL CHEM, V277, P32036, DOI 10.1074/jbc.M201906200; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; GULLICK WJ, 1985, EMBO J, V4, P2869, DOI 10.1002/j.1460-2075.1985.tb04016.x; GULLICK WJ, 1991, BRIT MED BULL, V47, P87, DOI 10.1093/oxfordjournals.bmb.a072464; HILLS D, 1995, INT J CANCER, V63, P537, DOI 10.1002/ijc.2910630414; HOLLIGER P, 1993, P NATL ACAD SCI USA, V90, P6444, DOI 10.1073/pnas.90.14.6444; Jannot CB, 1996, ONCOGENE, V13, P275; Jermutus L, 2001, P NATL ACAD SCI USA, V98, P75, DOI 10.1073/pnas.011311398; Kabat EA, 1991, SEQUENCES PROTEINS I; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Kile BT, 2002, TRENDS BIOCHEM SCI, V27, P235, DOI 10.1016/S0968-0004(02)02085-6; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; Klapper LN, 2000, ADV CANCER RES, V77, P25; Lener M, 2000, EUR J BIOCHEM, V267, P1196, DOI 10.1046/j.1432-1327.2000.01125.x; Marasco WA, 1997, GENE THER, V4, P11, DOI 10.1038/sj.gt.3300346; MARASCO WA, 1995, IMMUNOTECHNOLOGY, V1, P1, DOI 10.1016/1380-2933(95)00001-1; Martineau P, 1998, J MOL BIOL, V280, P117, DOI 10.1006/jmbi.1998.1840; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Mendelsohn J, 1997, CLIN CANCER RES, V3, P2703; MHASHILKAR AM, 1995, EMBO J, V14, P1542, DOI 10.1002/j.1460-2075.1995.tb07140.x; Ohage EC, 1999, J MOL BIOL, V291, P1129, DOI 10.1006/jmbi.1999.3020; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Parisien JP, 2001, VIROLOGY, V283, P230, DOI 10.1006/viro.2001.0856; Persic L, 1997, GENE, V187, P1, DOI 10.1016/S0378-1119(96)00627-0; Proba K, 1997, J MOL BIOL, V265, P161, DOI 10.1006/jmbi.1996.0726; Rader C, 1997, CURR OPIN BIOTECH, V8, P503, DOI 10.1016/S0958-1669(97)80075-4; RUSSO MW, 1985, J BIOL CHEM, V260, P5205; Shin DM, 2001, CLIN CANCER RES, V7, P1204; Steinberger P, 2000, P NATL ACAD SCI USA, V97, P805, DOI 10.1073/pnas.97.2.805; Tse E, 2002, J MOL BIOL, V317, P85, DOI 10.1006/jmbi.2002.5403; Visintin M, 1999, P NATL ACAD SCI USA, V96, P11723, DOI 10.1073/pnas.96.21.11723; Worn A, 2000, J BIOL CHEM, V275, P2795, DOI 10.1074/jbc.275.4.2795; Worn A, 1998, FEBS LETT, V427, P357, DOI 10.1016/S0014-5793(98)00463-3; Worn A, 2001, J MOL BIOL, V305, P989, DOI 10.1006/jmbi.2000.4265; Xu JL, 2000, IMMUNITY, V13, P37, DOI 10.1016/S1074-7613(00)00006-6; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yi KS, 2001, ONCOGENE, V20, P7954, DOI 10.1038/sj.onc.1204959; Zhu QA, 1999, J IMMUNOL METHODS, V231, P207, DOI 10.1016/S0022-1759(99)00158-1	58	34	46	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2003	22	10					1557	1567		10.1038/sj.onc.1206299	http://dx.doi.org/10.1038/sj.onc.1206299			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652ZZ	12629519				2022-12-28	WOS:000181411900013
J	Li, H; Fredriksson, L; Li, X; Eriksson, U				Li, H; Fredriksson, L; Li, X; Eriksson, U			PDGF-D is a potent transforming and angiogenic growth factor	ONCOGENE			English	Article						PDGF; VEGF; transformation; growth factor; tumour growth; angiogenesis	BETA-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; ENDOTHELIAL-CELLS; IN-VIVO; EXPRESSION; CANCER; TUMORS; ALPHA; MICE; ACTIVATION	Platelet-derived growth factors (PDGFs) are important for normal tissue growth and maintenance. Overexpression of the classical PDGFs, PDGF-A and PDGF-B, has been linked to several diseases, including cancer, fibrotic disease and atherosclerosis. Recently, two novel PDGFs, PDGF-C and PDGF-D, were discovered. It has not yet been established whether PDGF-C and PDGF-D are linked to disease phenotypes like the classical PDGFs. PDGF-B, the cellular homologue of the viral simian sarcoma oncogene v-sis, is known to potently induce cellular transformation through activation of PDGF receptor (PDGFR)-beta. In this work, we have determined the transformation efficacy of PDGF-D in comparison with that of PDGF-C and PDGF-B. PDGF-D is a potent transforming growth factor for NIH/3T3 cells, and the transformed cells displayed stress fibre reorganization, increased proliferation rate, anchorage-independent growth in soft agar, ability to induce tumours in nude mice, and upregulation of vascular endothelial growth factor. Morphological analyses of the vasculatures from the PDGF-isoform-expressing tumours revealed marked differences suggesting differential signalling through the two PDGF receptors in tumour vessel development and remodelling. In summary, these results suggest that PDGF-D induce cellular transformation and promote tumour growth by accelerating the proliferation rate of the tumour cells, and by stimulation of tumour neovascularization.	Ludwig Inst Canc Res, Stockholm Branch, S-17177 Stockholm, Sweden	Ludwig Institute for Cancer Research	Eriksson, U (corresponding author), Ludwig Inst Canc Res, Stockholm Branch, Box 240, S-17177 Stockholm, Sweden.			Fredriksson, Linda/0000-0003-4952-2742				Abramsson A, 2002, CIRCULATION, V105, P112, DOI 10.1161/hc0102.101437; BATTEGAY EJ, 1994, J CELL BIOL, V125, P917, DOI 10.1083/jcb.125.4.917; Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; BORK P, 1991, FEBS LETT, V282, P9, DOI 10.1016/0014-5793(91)80433-4; Bostrom H, 1996, CELL, V85, P863, DOI 10.1016/S0092-8674(00)81270-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRONZERT DA, 1987, P NATL ACAD SCI USA, V84, P5763, DOI 10.1073/pnas.84.16.5763; Cao RH, 2002, FASEB J, V16, P1575, DOI 10.1096/fj.02-0319com; Eberhard A, 2000, CANCER RES, V60, P1388; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; FLEMING TP, 1992, CANCER RES, V52, P4550; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GAZIT A, 1984, CELL, V39, P89, DOI 10.1016/0092-8674(84)90194-6; Gilbertson DG, 2001, J BIOL CHEM, V276, P27406, DOI 10.1074/jbc.M101056200; Hashizume H, 2000, AM J PATHOL, V156, P1363, DOI 10.1016/S0002-9440(10)65006-7; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; HSU S, 1995, J CELL PHYSIOL, V165, P239, DOI 10.1002/jcp.1041650204; JAIN RK, 1988, CANCER RES, V48, P2641; LaRochelle WJ, 2002, CANCER RES, V62, P2468; LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Lokker NA, 2002, CANCER RES, V62, P3729; NISTER M, 1991, J BIOL CHEM, V266, P16755; Risau W, 1992, GROWTH FACTORS, V7, P261, DOI 10.3109/08977199209046408; Simon MP, 1997, NAT GENET, V15, P95, DOI 10.1038/ng0197-95; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; Uutela M, 2001, CIRCULATION, V103, P2242; Wang DG, 1999, CANCER RES, V59, P1464; Yu JH, 2000, J BIOL CHEM, V275, P19076, DOI 10.1074/jbc.M910329199; Zwerner JP, 2001, ONCOGENE, V20, P626, DOI 10.1038/sj.onc.1204133	32	116	130	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 13	2003	22	10					1501	1510		10.1038/sj.onc.1206223	http://dx.doi.org/10.1038/sj.onc.1206223			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652ZZ	12629513				2022-12-28	WOS:000181411900007
J	Wang-Johanning, F; Frost, AR; Jian, BX; Epp, L; Lu, DW; Johanning, GL				Wang-Johanning, F; Frost, AR; Jian, BX; Epp, L; Lu, DW; Johanning, GL			Quantitation of HERV-K env gene expression and splicing in human breast cancer	ONCOGENE			English	Article						breast carcinoma; retrovirus; HERV envelope; and real-time RT-PCR	ENDOGENOUS RETROVIRUS-K; MAMMARY-TUMOR VIRUS; HTDV/HERV-K; IDENTIFICATION; GENOME; CORF; TRANSCRIPTS; PROTEIN; LOCALIZATION; CARCINOMAS	Human endogenous retroviruses (HERVs) comprise up to 8% of the human genome. In previous studies, we demonstrated that type I HERV-K envelope (env) transcripts are expressed in most human breast cancers, but not in normal breast tissues. In the current study, we report that type 2 HERV-K env transcripts are also present in human breast cancers. By real-time RT-PCR, the expression of HERV-K env transcripts was 5-10-fold higher in breast cancer cell lines treated with estradiol and progesterone than in cells without treatment, and expression was significantly higher in most breast cancer tissues than in normal breast tissues. Furthermore, both types of HERV-K env transcripts were capable of being spliced into subgenomic env transcripts and various splice donor and acceptor sites were detected in breast cancers. The selective expression and distribution of multiple HERV-K endogenous retroviral element splice variants in breast cancer, but not in normal controls, suggests that they are novel breast tumor markers.	Univ Alabama, Dept Med, Birmingham, AL 35294 USA; Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA; Univ Alabama, Dept Nutr Sci, Birmingham, AL 35294 USA; Washington Univ, Med Ctr, Dept Pathol & Immunol, Lauren V Ackerman Lab Surg Pathol, St Louis, MO USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Washington University (WUSTL)	Wang-Johanning, F (corresponding author), Univ Alabama, Dept Med, 1824 6th Ave S, Birmingham, AL 35294 USA.	fengj@uab.edu						Armbruester V, 2002, CLIN CANCER RES, V8, P1800; ASCH BB, 1993, INT J CANCER, V54, P813, DOI 10.1002/ijc.2910540516; Barbulescu M, 1999, CURR BIOL, V9, P861, DOI 10.1016/S0960-9822(99)80390-X; Boese A, 2000, ONCOGENE, V19, P4328, DOI 10.1038/sj.onc.1203794; Boese A, 2000, FEBS LETT, V468, P65, DOI 10.1016/S0014-5793(00)01197-2; Etkind PR, 1997, VIROLOGY, V234, P304, DOI 10.1006/viro.1997.8670; FRANKLIN GC, 1988, J VIROL, V62, P1203, DOI 10.1128/JVI.62.4.1203-1210.1988; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LOWER R, 1995, J VIROL, V69, P141; LOWER R, 1993, P NATL ACAD SCI USA, V90, P4480, DOI 10.1073/pnas.90.10.4480; Magin C, 2000, VIROLOGY, V274, P11, DOI 10.1006/viro.2000.0438; Magin C, 1999, J VIROL, V73, P9496, DOI 10.1128/JVI.73.11.9496-9507.1999; Mayer J, 1999, NAT GENET, V21, P257, DOI 10.1038/6766; MEDSTRAND P, 1993, J VIROL, V67, P6778, DOI 10.1128/JVI.67.11.6778-6787.1993; Natoli F, 1996, CANCER LETT, V99, P121, DOI 10.1016/0304-3835(95)04060-9; ONO M, 1987, J VIROL, V61, P2059, DOI 10.1128/JVI.61.6.2059-2062.1987; ONO M, 1986, J VIROL, V60, P589, DOI 10.1128/JVI.60.2.589-598.1986; Schiavetti F, 2002, CANCER RES, V62, P5510; Sugimoto J, 2001, GENOMICS, V72, P137, DOI 10.1006/geno.2001.6473; Tristem M, 2000, J VIROL, V74, P3715, DOI 10.1128/JVI.74.8.3715-3730.2000; Wang-Johanning F, 2002, CANCER-AM CANCER SOC, V94, P2199, DOI 10.1002/cncr.10439; Wang-Johanning F, 2001, CLIN CANCER RES, V7, P1553; Yang J, 1999, P NATL ACAD SCI USA, V96, P13404, DOI 10.1073/pnas.96.23.13404; Yin H, 1997, AIDS RES HUM RETROV, V13, P507, DOI 10.1089/aid.1997.13.507	24	138	165	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2003	22	10					1528	1535		10.1038/sj.onc.1206241	http://dx.doi.org/10.1038/sj.onc.1206241			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652ZZ	12629516				2022-12-28	WOS:000181411900010
J	Fenton, JAL; Pratt, G; Rawstron, AC; Sibley, K; Rothwell, D; Yates, Z; Dring, A; Richards, SJ; Ashcroft, AJ; Davies, FE; Owen, RG; Child, JA; Morgan, GJ				Fenton, JAL; Pratt, G; Rawstron, AC; Sibley, K; Rothwell, D; Yates, Z; Dring, A; Richards, SJ; Ashcroft, AJ; Davies, FE; Owen, RG; Child, JA; Morgan, GJ			Genomic characterization of the chromosomal breakpoints of t(4;14) of multiple myeloma suggests more than one possible aetiological mechanism	ONCOGENE			English	Article						primary translocation; class switch recombination; myeloma; t(4;14)	CLASS-SWITCH RECOMBINATION; B-CELLS; TRANSLOCATIONS; REGION; FREQUENT; GENE; DYSREGULATION; MUTATIONS; SEQUENCES	Using FISH-based techniques, rearrangements of the immunoglobulin heavy-chain (IgH) locus at 14q32 have been found in the majority of cases of multiple myeloma (MM). Some of these IgH translocations are recurrent and we have characterized the genomic breakpoints of seven t(4;14) translocations from MM patients, using a combination of vectorette and conventional polymerase chain reaction methods, the aim being to understand the molecular mechanism leading to MM. Conventionally, the chromosome 14q32 breakpoints in these reciprocal translocations are believed to be located in the IgH p switch (S) region and a further downstream S region with deletion of intervening DNA occurring as a result of aberrant class switch recombination (CSR); this was seen in five of the cases analysed. However, in two patients it was possible to demonstrate that the rearranged hybrid switch region sequence was joined to DNA from chromosome 4p16, suggesting that IgH translocations can occur in B cells that have already undergone legitimate CSR. The complex nature of these rearrangements leads us to speculate that primary IgH translocations may occur at different time points in the development in MM plasma cells, either at the time of physiological CSR or at a later stage, possibly involving a different mechanism.	Univ Leeds, Acad Unit Haematol & Oncol, Leeds LS2 9JT, W Yorkshire, England; Paterson Inst Canc Res, Manchester M20 9BX, Lancs, England	University of Leeds; Paterson Institute for Cancer Research	Fenton, JAL (corresponding author), Univ Leeds, Acad Unit Haematol & Oncol, Algernon Firth Bldg, Leeds LS2 9JT, W Yorkshire, England.	jamesf@lrf.leeds.ac.uk		morgan, gareth/0000-0002-4271-6360; Rawstron, Andy/0000-0003-0798-9790; Richards, Stephen/0000-0002-8421-5353; Davies, Faith/0000-0002-3971-2393				Avet-Loiseau H, 2002, BLOOD, V99, P2185, DOI 10.1182/blood.V99.6.2185; Avet-Loiseau H, 1998, CANCER RES, V58, P5640; Avet-Loiseau H, 2001, BLOOD, V98, P3082, DOI 10.1182/blood.V98.10.3082; Bergsagel PL, 2001, ONCOGENE, V20, P5611, DOI 10.1038/sj.onc.1204641; Casellas R, 1998, EMBO J, V17, P2404, DOI 10.1093/emboj/17.8.2404; Chen XC, 2001, P NATL ACAD SCI USA, V98, P13860, DOI 10.1073/pnas.241524898; Chesi M, 1996, BLOOD, V88, P674, DOI 10.1182/blood.V88.2.674.bloodjournal882674; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Chesi M, 1998, BLOOD, V91, P4457, DOI 10.1182/blood.V91.12.4457.412k48_4457_4463; DUNNICK W, 1993, NUCLEIC ACIDS RES, V21, P365, DOI 10.1093/nar/21.3.365; Ehrenstein MR, 1999, EMBO J, V18, P3484, DOI 10.1093/emboj/18.12.3484; Ehrenstein MR, 2001, P NATL ACAD SCI USA, V98, P14553, DOI 10.1073/pnas.241525998; Endele S, 1999, GENOMICS, V60, P218, DOI 10.1006/geno.1999.5881; Hallek M, 1998, BLOOD, V91, P3, DOI 10.1182/blood.V91.1.3.3_3_21; Ho PJ, 2001, BLOOD, V97, P490, DOI 10.1182/blood.V97.2.490; Kinoshita K, 1999, COLD SPRING HARB SYM, V64, P217, DOI 10.1101/sqb.1999.64.217; Kinoshita K, 2001, NAT REV MOL CELL BIO, V2, P493, DOI 10.1038/35080033; Kuehl WM, 2002, NAT REV CANCER, V2, P175, DOI 10.1038/nrc746; Kuppers R, 2001, ONCOGENE, V20, P5580, DOI 10.1038/sj.onc.1204640; Lee CG, 1998, CURR BIOL, V8, P227, DOI 10.1016/S0960-9822(98)70087-9; LIDA S, 1997, NAT GENET, V17, P226; MANDLER R, 1993, J IMMUNOL, V150, P407; Manis JP, 1998, J EXP MED, V187, P2081, DOI 10.1084/jem.187.12.2081; Manis JP, 2002, TRENDS IMMUNOL, V23, P31, DOI 10.1016/S1471-4906(01)02111-1; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Nishida K, 1997, BLOOD, V90, P526, DOI 10.1182/blood.V90.2.526.526_526_534; Petersen S, 2001, NATURE, V414, P660, DOI 10.1038/414660a; Proffitt J, 1999, LEUKEMIA, V13, P1100, DOI 10.1038/sj.leu.2401465; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; Rolink A, 1996, IMMUNITY, V5, P319, DOI 10.1016/S1074-7613(00)80258-7; Ronchetti D, 1999, BLOOD, V93, P1330, DOI 10.1182/blood.V93.4.1330.404k04_1330_1337; Shaughnessy J, 2001, BLOOD, V98, P217, DOI 10.1182/blood.V98.1.217; Sibley K, 2002, BRIT J HAEMATOL, V118, P514, DOI 10.1046/j.1365-2141.2002.03618.x; ZHANG K, 1995, J IMMUNOL, V154, P2237	34	18	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2003	22	7					1103	1113		10.1038/sj.onc.1206335	http://dx.doi.org/10.1038/sj.onc.1206335			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	644PB	12592397				2022-12-28	WOS:000180926100016
J	Shimizu, Y; Yamamichi, N; Saitoh, K; Watanabe, A; Ito, T; Yamamichi-Nishina, M; Mizutani, M; Yahagi, N; Suzuki, T; Sasakawa, C; Yasugi, S; Ichinose, M; Iba, H				Shimizu, Y; Yamamichi, N; Saitoh, K; Watanabe, A; Ito, T; Yamamichi-Nishina, M; Mizutani, M; Yahagi, N; Suzuki, T; Sasakawa, C; Yasugi, S; Ichinose, M; Iba, H			Kinetics of v-src-induced epithelial-mesenchymal transition in developing glandular stomach	ONCOGENE			English	Article						RSV; epithelial-mesenchymal transition; MAP kinase; apoptosis; v-src	HIGH-LEVEL EXPRESSION; CHICKEN-EMBRYO FIBROBLASTS; RETROVIRUS VECTORS; CELLULAR-TRANSFORMATION; PHOSPHORYLATION SITES; PROTEIN CAUSES; DEVELOPING GUT; GENE-TRANSFER; FOS GENE; C-JUN	The oncogene function in primary epithelial cells is largely unclear. Recombination organ cultures in combination with the stable and transient gene transfer techniques by retrovirus and electroporation, respectively, enable us to transfer oncogenes specifically into primary epithelial cells of the developing avian glandular stomach (proventriculns). In this system, the epithelium and mesenchyme are mutually dependent on each other for their growth and differentiation. We report here that either stable or transient expression of v-src in the epithelium causes budding and migration of epithelial cells into mesenchyme. In response to the transient expression of v-Src or a constitutive active mutant of MEK, we observed immediate downregulation of the Sonic hedgehog gene and subsequent elimination of E-cadherine expression in migrating cells, suggesting the involvement of MAP kinase signaling pathway in these processes. v-src-expressing cells that were retained in the epithelium underwent apoptosis (anoikis) and detached from the culture. Continuous expression of v-src by, for example, Rous sarcoma virus (RSV) was required for the epithetial cells to acquire the ability to express type I collagen and fihronectin genes (mesenchymal markers), and finally to establish the epithelial-mesenchymal transition. These observations would partly explain why RSV does not apparently cause carcinoma formation, but induces sarcomas exclusively.	Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Div Host Parasite Interact,Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Inst Med Sci, Div Bacterial Infect, Dept Microbiol & Immunol,Minato Ku, Tokyo 1088639, Japan; Nippon Inst Biol Sci, Lab Anim Res Stn, Yamanashi 4080041, Japan; Univ Tokyo, Dept Gastroenterol, Fac Internal Med, Bunkyo Ku, Tokyo 1138655, Japan; Tokyo Metropolitan Univ, Fac Sci, Dept Biol, Hachioji, Tokyo 1920397, Japan; Wakayama Med Coll, Dept Internal Med 2, Wakayama 6400012, Japan	University of Tokyo; University of Tokyo; University of Tokyo; Tokyo Metropolitan University; Wakayama Medical University	Iba, H (corresponding author), Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Div Host Parasite Interact,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.							BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BIRCHMEIER W, 1994, BIOESSAYS, V16, P305, DOI 10.1002/bies.950160503; Boyer B, 2000, BIOCHEM PHARMACOL, V60, P1091, DOI 10.1016/S0006-2952(00)00427-5; Daigo Y, 1999, CANCER RES, V59, P4222; Fialka I, 1996, J CELL BIOL, V132, P1115, DOI 10.1083/jcb.132.6.1115; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; FUJIWARA KT, 1987, J VIROL, V61, P4012, DOI 10.1128/JVI.61.12.4012-4018.1987; Fukuda K, 2000, DEV GROWTH DIFFER, V42, P207; Gailani MR, 1997, JNCI-J NATL CANCER I, V89, P1103, DOI 10.1093/jnci/89.15.1103; Hay E.D., 1990, Seminars in Developmental Biology, V1, P347; HAY ED, 1995, AM J KIDNEY DIS, V26, P678, DOI 10.1016/0272-6386(95)90610-X; HUANG WD, 1995, MOL BIOL CELL, V6, P237, DOI 10.1091/mbc.6.3.237; HUANG WD, 1994, P NATL ACAD SCI USA, V91, P8960, DOI 10.1073/pnas.91.19.8960; IBA H, 1988, ONCOGENE RES, V2, P121; Iba H, 2000, DEV GROWTH DIFFER, V42, P213; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Kameda T, 1997, CELL GROWTH DIFFER, V8, P495; Koike T, 1999, DIFFERENTIATION, V65, P13, DOI 10.1046/j.1432-0436.1999.6510013.x; Matsumoto K, 1998, ONCOGENE, V16, P1611, DOI 10.1038/sj.onc.1201675; Murakami M, 1999, CELL GROWTH DIFFER, V10, P333; Murakami M, 1997, GENE, V202, P23, DOI 10.1016/S0378-1119(97)00468-X; Murakami M, 1997, ONCOGENE, V14, P2435, DOI 10.1038/sj.onc.1201077; Narita T, 2000, DEVELOPMENT, V127, P981; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; Roberts DJ, 1998, DEVELOPMENT, V125, P2791; Rosenberg N., 1997, P475; SORKIN BC, 1988, P NATL ACAD SCI USA, V85, P7617, DOI 10.1073/pnas.85.20.7617; STOKER AW, 1990, J CELL BIOL, V111, P217, DOI 10.1083/jcb.111.1.217; Sukegawa A, 2000, DEVELOPMENT, V127, P1971; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; SUZUKI T, 1991, JPN J CANCER RES, V82, P58, DOI 10.1111/j.1349-7006.1991.tb01746.x; Tabata H, 1998, DEV GROWTH DIFFER, V40, P519; TAKIGUCHI K, 1988, DEV GROWTH DIFFER, V30, P241; Watanabe H, 1997, P NATL ACAD SCI USA, V94, P3994, DOI 10.1073/pnas.94.8.3994; WEBSTER MA, 1995, P NATL ACAD SCI USA, V92, P7849, DOI 10.1073/pnas.92.17.7849; YASUGI S, 1993, DEV GROWTH DIFFER, V35, P1; Zhang Y, 2000, J BIOL CHEM, V275, P24935, DOI 10.1074/jbc.M002383200	40	16	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 13	2003	22	6					884	893		10.1038/sj.onc.1206174	http://dx.doi.org/10.1038/sj.onc.1206174			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584568				2022-12-28	WOS:000180864300011
J	Bilsland, AE; Anderson, CJ; Fletcher-Monaghan, AJ; McGregor, F; Evans, TRJ; Ganly, I; Knox, RJ; Plumb, JA; Keith, WN				Bilsland, AE; Anderson, CJ; Fletcher-Monaghan, AJ; McGregor, F; Evans, TRJ; Ganly, I; Knox, RJ; Plumb, JA; Keith, WN			Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase	ONCOGENE			English	Article						telomerase; hTERT; hTR; gene therapy; nitroreductase; GDEPT; adenovirus	THYMIDYLATE SYNTHASE PROMOTER; REVERSE-TRANSCRIPTASE GENE; ENZYME PRODRUG THERAPY; TUMOR-CELLS; RNA GENE; TATA-LESS; HMLH1 EXPRESSION; IMMORTAL CELLS; HTERT; ACTIVATION	Reactivation of telomerase maintains telomere function and is considered critical to immortalization in most human cancer cells. Elevation of telomerase expression in cancer cells is highly specific: transcription of both RNA (hTR) and protein (hTERT) components is strongly upregulated in cancer cells relative to normal cells. Therefore, telomerase promoters may be useful in cancer gene therapy by selectively expressing suicide genes in cancer cells and not normal cells. One example of suicide gene therapy is the bacterial nitroreductase (NTR) gene, which bioactivates the prodrug CB1954 into an active cytotoxic alkylating agent. We describe construction of adenovirus vectors harbouring the bacterial NTR gene under control of the hTR or hTERT promoters. Western blot analysis of NTR expression in normal and cancer cells infected with adenoviral vectors showed cancer cell-specific nitroreductase expression. Infection with adenoviral telomerase-NTR constructs in a panel of seven cancer cell lines resulted in up to 18-fold sensitization to the prodrug CB1954, an effect that was retained in two drug-resistant ovarian lines. Importantly, no sensitization was observed with either promoter in any of the four normal cell strains. Finally, an efficacious effect was observed in cervical and ovarian xenograft models following single intratumoural injection with low doses of vector, followed by injection with CB1954.	Univ Glasgow, Canc Res UK, Dept Med Oncol, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Enact Pharma Plc, Salisbury SP4 0JQ, Wilts, England	Beatson Institute; Cancer Research UK; University of Glasgow	Keith, WN (corresponding author), Univ Glasgow, Canc Res UK, Dept Med Oncol, Beatson Labs, Alexander Stone Bldg,Garscube Estate,Switchback R, Glasgow G61 1BD, Lanark, Scotland.		Bilsland, Alan/G-2629-2010; Cairney, Claire/H-6989-2012; Keith, Nicol/D-3325-2009	Keith, Nicol/0000-0001-7862-3580; Cairney, Claire/0000-0001-6531-245X; Bilsland, Alan/0000-0003-0957-3908				Abdul-Ghani R, 2000, MOL THER, V2, P539, DOI 10.1006/mthe.2000.0196; Aghi M, 2000, J GENE MED, V2, P148, DOI 10.1002/(SICI)1521-2254(200005/06)2:3<148::AID-JGM105>3.0.CO;2-Q; ANLEZARK GM, 1992, BIOCHEM PHARMACOL, V44, P2289, DOI 10.1016/0006-2952(92)90671-5; Anthoney DA, 1996, CANCER RES, V56, P1374; Boyd M, 2001, J GENE MED, V3, P165, DOI 10.1002/1521-2254(2000)9999:9999<::AID-JGM158>3.0.CO;2-C; Brown R, 1997, ONCOGENE, V15, P45, DOI 10.1038/sj.onc.1201167; Chung-Faye G, 2001, CLIN CANCER RES, V7, P2662; Clark MP, 1998, NUCLEIC ACIDS RES, V26, P1801, DOI 10.1093/nar/26.7.1801; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Cui W, 1999, GENE THER, V6, P764, DOI 10.1038/sj.gt.3300873; Damm K, 2001, EMBO J, V20, P6958, DOI 10.1093/emboj/20.24.6958; Dong S, 2000, J CELL BIOCHEM, V77, P50, DOI 10.1002/(SICI)1097-4644(20000401)77:1<50::AID-JCB6>3.0.CO;2-C; Downey MG, 2001, J ORAL PATHOL MED, V30, P577, DOI 10.1034/j.1600-0714.2001.301001.x; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Garrett MD, 1999, EUR J CANCER, V35, P2010, DOI 10.1016/S0959-8049(99)00280-4; Gu J, 2002, GENE THER, V9, P30, DOI 10.1038/sj.gt.3301619; Gu J, 2000, CANCER RES, V60, P5359; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hiyama E, 2001, NEOPLASIA, V3, P17, DOI 10.1038/sj.neo.7900134; Holt SE, 1999, J CELL PHYSIOL, V180, P10, DOI 10.1002/(SICI)1097-4652(199907)180:1<10::AID-JCP2>3.0.CO;2-D; Horikawa I, 1999, CANCER RES, V59, P826; Karamouzis MV, 2002, CLIN CANCER RES, V8, P949; KEITH WN, 2002, EXP REV MOL MED; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Koga S, 2000, HUM GENE THER, V11, P1397, DOI 10.1089/10430340050057477; Koga S, 2001, ANTICANCER RES, V21, P1937; Komata T, 2001, CANCER RES, V61, P5796; Majumdar AS, 2001, GENE THER, V8, P568, DOI 10.1038/sj.gt.3301421; Mergny JL, 2002, NUCLEIC ACIDS RES, V30, P839, DOI 10.1093/nar/30.4.839; Naasani I, 1999, CANCER RES, V59, P4004; Pascolo E, 2002, J BIOL CHEM, V277, P15566, DOI 10.1074/jbc.M201266200; Plumb JA, 2001, ONCOGENE, V20, P7797, DOI 10.1038/sj.onc.1204954; Ring CJA, 1996, GENE THER, V3, P1094; Rudge TL, 1999, J CELL BIOCHEM, V73, P90, DOI 10.1002/(SICI)1097-4644(19990401)73:1<90::AID-JCB10>3.0.CO;2-W; Sarvesvaran J, 1999, CARCINOGENESIS, V20, P1649, DOI 10.1093/carcin/20.8.1649; Scapin G, 2002, DRUG DISCOV TODAY, V7, P601, DOI 10.1016/S1359-6446(02)02290-0; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Shi QW, 1997, HUM GENE THER, V8, P403, DOI 10.1089/hum.1997.8.4-403; Soder AI, 1997, ONCOGENE, V14, P1013, DOI 10.1038/sj.onc.1201066; Soder AI, 1998, ONCOGENE, V16, P979, DOI 10.1038/sj.onc.1201620; Strathdee G, 1999, ONCOGENE, V18, P2335, DOI 10.1038/sj.onc.1202540; Takakura M, 1999, CANCER RES, V59, P551; Vassaux G, 1999, GENE THER, V6, P1192, DOI 10.1038/sj.gt.3300910; White LK, 2001, TRENDS BIOTECHNOL, V19, P114, DOI 10.1016/S0167-7799(00)01541-9; Wick M, 1999, GENE, V232, P97, DOI 10.1016/S0378-1119(99)00108-0; Wisman GBA, 2000, HUM PATHOL, V31, P1304, DOI 10.1053/hupa.2000.19299; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zhao JQ, 1998, ONCOGENE, V16, P1345, DOI 10.1038/sj.onc.1201892; Zhao JQ, 2000, NEOPLASIA, V2, P531, DOI 10.1038/sj.neo.7900114	51	72	79	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 23	2003	22	3					370	380		10.1038/sj.onc.1206168	http://dx.doi.org/10.1038/sj.onc.1206168			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545158				2022-12-28	WOS:000180379100006
J	Sharma, GG; Gupta, A; Wang, H; Scherthan, H; Dhar, S; Gandhi, V; Iliakis, G; Shay, JW; Young, CSH; Pandita, TK				Sharma, GG; Gupta, A; Wang, H; Scherthan, H; Dhar, S; Gandhi, V; Iliakis, G; Shay, JW; Young, CSH; Pandita, TK			HTERT associates with human telomeres and enhances genomic stability and DNA repair	ONCOGENE			English	Article						hTERT; telomeres; transcription; DNA repair; ionizing radiation	ATAXIA-TELANGIECTASIA CELLS; EXTENDED-LIFE-SPAN; IONIZING-RADIATION; HUMAN FIBROBLASTS; RNA COMPONENT; IMMUNOHISTOCHEMICAL DETECTION; SACCHAROMYCES-CEREVISIAE; CHROMOSOME INSTABILITY; REVERSE-TRANSCRIPTASE; CATALYTIC SUBUNIT	Ectopic expression of telomerase in telomerase-silent cells is sufficient to overcome senescence and to extend cellular lifespan. We show here that the catalytic subunit of human telomerase (hTERT) crosslinks telomeres. This interaction is blocked by the telomere repeat binding factor 1, but not by a dominant negative form of this protein. It is also abolished by destruction of the RNA component of telomerase as well as by mutations in the hTERT protein. Ectopic expression of hTERT leads to transcriptional alterations of a subset of genes and changes in the interaction of the telomeres with the nuclear matrix. This is associated with reduction of spontaneous chromosome damage in G, cells, enhancement of the kinetics of DNA repair and an increase in NTP levels. The effect on DNA repair is likely indirect as TERT does not directly affect DNA end rejoining in vitro or meiotic recombination in vivo. The observed effects of hTERT occurred rapidly before any significant lengthening of telomeres was observed. Our findings establish an intimate relationship between hTERT-telomere interactions and alteration in transcription of a subset of genes that may lead to increased genomic stability and enhanced repair of genetic damage. These novel functions of telomerase are distinct from its known effect on telomere length and have potentially important biological consequences.	Washington Univ, Sch Med, Radiat & Canc Biol Div, St Louis, MO 63108 USA; Columbia Univ, Coll Phys & Surg, New York, NY 10032 USA; Thomas Jefferson Univ, Philadelphia, PA 19107 USA; Max Planck Inst Mol Genet, D-14195 Berlin, Germany; Univ Texas, MDACC, Houston, TX 77030 USA; Univ Texas, SW Med Ctr, Dallas, TX 75390 USA	Washington University (WUSTL); Columbia University; Jefferson University; Max Planck Society; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Pandita, TK (corresponding author), 4511 Forest Pk,Suite 411, St Louis, MO 63108 USA.		Pandita, Tej K/AAM-9188-2020; Shay, Jerry W/F-7878-2011		NATIONAL CANCER INSTITUTE [P30CA013696] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034746] Funding Source: NIH RePORTER; NCI NIH HHS [CA13696, CN-15015] Funding Source: Medline; NINDS NIH HHS [NS34746] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Baur JA, 2001, SCIENCE, V292, P2075, DOI 10.1126/science.1062329; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Chan SWL, 2002, ONCOGENE, V21, P553, DOI 10.1038/sj.onc.1205082; Choi DH, 2001, FASEB J, V15, P1014, DOI 10.1096/fj.00-0104com; Constantinou A, 2001, CELL, V104, P259, DOI 10.1016/S0092-8674(01)00210-0; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Dhar S, 2000, MOL CELL BIOL, V20, P7764, DOI 10.1128/MCB.20.20.7764-7772.2000; Etheridge KT, 2002, J BIOL CHEM, V277, P24764, DOI 10.1074/jbc.M201227200; Fan ZH, 2000, CANCER GENE THER, V7, P1307, DOI 10.1038/sj.cgt.0243; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Ford LP, 2000, MOL CELL BIOL, V20, P9084, DOI 10.1128/MCB.20.23.9084-9091.2000; Fu WM, 2000, J MOL NEUROSCI, V14, P3, DOI 10.1385/JMN:14:1-2:003; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Goytisolo FA, 2000, J EXP MED, V192, P1625, DOI 10.1084/jem.192.11.1625; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P12454, DOI 10.1073/pnas.96.22.12454; Iliakis G, 1999, METH MOL B, V113, P543; JOHNSON RT, 1970, NATURE, V226, P717, DOI 10.1038/226717a0; Kawakami Y, 2000, ONCOGENE, V19, P3888, DOI 10.1038/sj.onc.1203733; Kharbanda S, 2000, CURR BIOL, V10, P568, DOI 10.1016/S0960-9822(00)00483-8; Kondo S, 1998, ONCOGENE, V16, P3323, DOI 10.1038/sj.onc.1201885; Krude T, 2001, CELL MOL LIFE SCI, V58, P665, DOI 10.1007/PL00000890; KYRION G, 1993, GENE DEV, V7, P1146, DOI 10.1101/gad.7.7a.1146; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; Liu Y, 2000, CURR BIOL, V10, P1459, DOI 10.1016/S0960-9822(00)00805-8; Luderus ME, 1996, J CELL BIOL, V135, P867, DOI 10.1083/jcb.135.4.867; Martin-Rivera L, 1998, P NATL ACAD SCI USA, V95, P10471, DOI 10.1073/pnas.95.18.10471; Ng P, 2000, BIOTECHNIQUES, V29, P524, DOI 10.2144/00293st04; NISHIKAWA K, 1992, CANCER RES, V52, P4758; OLOVNIKOV AM, 1992, IZV AN SSSR BIOL+, P641; Ouellette MM, 2000, HUM MOL GENET, V9, P403, DOI 10.1093/hmg/9.3.403; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; PANDITA TK, 1994, CYTOGENET CELL GENET, V67, P94, DOI 10.1159/000133807; PANDITA TK, 1992, RADIAT RES, V130, P94, DOI 10.2307/3578485; Pandita TK, 2002, ONCOGENE, V21, P611, DOI 10.1038/sj.onc.1205060; Pandita TK, 1999, MOL CELL BIOL, V19, P5096; PLUNKETT W, 1980, CANCER RES, V40, P588; POMMIER Y, 1985, BIOCHEMISTRY-US, V24, P6406, DOI 10.1021/bi00344a014; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; ROBERTS JJ, 1978, ADV RADIAT BIOL, V7, P211; Rodriguez CO, 2000, J CHROMATOGR B, V745, P421, DOI 10.1016/S0378-4347(00)00303-0; RUDD GN, 1995, CANCER CHEMOTH PHARM, V35, P323, DOI 10.1007/BF00689452; Sawant SG, 1999, FASEB J, V13, P1047, DOI 10.1096/fasebj.13.9.1047; Scherthan H, 2000, MOL CELL BIOL, V20, P7773, DOI 10.1128/MCB.20.20.7773-7783.2000; Scherthan H, 2001, NAT REV MOL CELL BIO, V2, P621, DOI 10.1038/35085086; SHERMAN PA, 1989, ANAL BIOCHEM, V180, P222, DOI 10.1016/0003-2697(89)90420-X; Smilenov LB, 1999, MOL CELL BIOL, V19, P6963; Smith S, 1997, TRENDS GENET, V13, P21, DOI 10.1016/S0168-9525(96)10052-4; Steinert S, 2000, BIOCHEM BIOPH RES CO, V273, P1095, DOI 10.1006/bbrc.2000.3080; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Tahara H, 1999, ONCOGENE, V18, P1561, DOI 10.1038/sj.onc.1202458; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Van Komen S, 2000, MOL CELL, V6, P563, DOI 10.1016/S1097-2765(00)00055-1; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Vaziri H, 1999, MOL CELL BIOL, V19, P2373; VAZIRI H, 1994, P NATL ACAD SCI USA, V91, P9857, DOI 10.1073/pnas.91.21.9857; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wong KK, 2000, NAT GENET, V26, P85, DOI 10.1038/79232; Wood LD, 2001, ONCOGENE, V20, P278, DOI 10.1038/sj.onc.1204072; WRIGHT WE, 1992, TRENDS GENET, V8, P193, DOI 10.1016/0168-9525(92)90232-S; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	67	208	224	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 9	2003	22	1					131	146		10.1038/sj.onc.1206063	http://dx.doi.org/10.1038/sj.onc.1206063			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527915				2022-12-28	WOS:000180166900014
J	Osterod, M; Larsen, E; Le Page, F; Hengstler, JG; van der Horst, GT; Boiteux, S; Klungland, A; Epe, B				Osterod, M; Larsen, E; Le Page, F; Hengstler, JG; van der Horst, GT; Boiteux, S; Klungland, A; Epe, B			A global DNA repair mechanism involving the Cockayne syndrome B (CSB) gene product can prevent the in vivo accumulation of endogenous, oxidative DNA base damage	ONCOGENE			English	Article						OGG1; CSB; DNA repair; 7,8-dihydro-8oxoguanine (8-oxoG)	TRANSCRIPTION-COUPLED REPAIR; MAMMALIAN-CELLS; EXCISION-REPAIR; 8-OXOGUANINE; CANCER; 8-HYDROXYGUANINE; OGG1; MICE; MUTAGENESIS; GENOME	The Cockayne syndrome B (CSB) gene product is involved in the repair of various types of base modifications in actively transcribed DNA sequences. To investigate its significance for the repair of endogenous oxidative DNA damage, homozygous csb(-/-)/ogg1(-/-) double knockout mice were generated. These combine the deficiency of CSB with that of OGG1, a gene coding for the mammalian repair glycosylase that initiates the base excision repair of 7,8-dihydro-8-oxoguanine (8-oxoG). Compared to ogg1(-/-) mice, csb(-/-)/ogg1(-/-) mice were found to accumulate with age severalfold higher levels of oxidited purine modifications in hepatocytes, splenocytes and kidney cells. In contrast, the basal (steady-state) levels of oxidative DNA modifications in cells from csb(-/-) mice were not different from those in wild-type mice and did not increase with age. The analysis of the repair rates of additional oxidative DNA base modifications induced by photosensitization in immortalized embryonic fibroblasts was in accordance with these findings: compared to wild-type cells, the global repair was only slightly affected in csb(-/-) cells, more compromised in ogg1(-/-) cells, but virtually absent in csb(-/-)/ogg1(-/-) cells. An inhibition of transcription by a-amanitin did not block the Csb-dependent repair in ogg1(-/-) fibroblasts. The influence of Csb on the global repair of 8-oxoG was not detectable in assays with total protein extracts and in a shuttle vector system. The data indicate a role for Csb in the removal of 8-oxoG from the overall genome that is independent of both Ogg1-mediated base excision repair and regular transcription.	Univ Mainz, Inst Pharm, D-55099 Mainz, Germany; Univ Oslo, Ctr Mol Biol & Neurosci, Natl Hosp, N-0027 Oslo, Norway; Univ Oslo, Inst Med Microbiol, Natl Hosp, N-0027 Oslo, Norway; CEA, UMR 217 CNRS, Dept Radiobiol & Radiopathol, F-92265 Fontenay Aux Roses, France; Univ Mainz, Inst Toxicol, D-55099 Mainz, Germany; Erasmus Univ, Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands	Johannes Gutenberg University of Mainz; University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway; CEA; Johannes Gutenberg University of Mainz; Erasmus University Rotterdam	Epe, B (corresponding author), Univ Mainz, Inst Pharm, Staudingerweg 5, D-55099 Mainz, Germany.		Klungland, Arne/X-1233-2019; van der Horst, Gijsbertus TJ/E-3661-2015; Hengstler, Jan G./O-1415-2013	van der Horst, Gijsbertus TJ/0000-0002-7773-6396; Hengstler, Jan/0000-0002-1427-5246; Klungland, Arne/0000-0001-7274-3661				AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; Boiteux S, 2000, ARCH BIOCHEM BIOPHYS, V377, P1, DOI 10.1006/abbi.2000.1773; BOITEUX S, 1990, J BIOL CHEM, V265, P3916; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; CHENG KC, 1992, J BIOL CHEM, V267, P166; Citterio E, 2000, MOL CELL BIOL, V20, P7643, DOI 10.1128/MCB.20.20.7643-7653.2000; Dianov G, 1999, NUCLEIC ACIDS RES, V27, P1365, DOI 10.1093/nar/27.5.1365; DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; Friedberg EC, 1996, ANNU REV BIOCHEM, V65, P15; Hazra TK, 2002, P NATL ACAD SCI USA, V99, P3523, DOI 10.1073/pnas.062053799; HAZRA TK, 1998, NUCLEIC ACIDS RES, V27, P4001; Hengstler JG, 2000, DRUG METAB REV, V32, P81, DOI 10.1081/DMR-100100564; Hollenbach S, 1999, CARCINOGENESIS, V20, P1863, DOI 10.1093/carcin/20.9.1863; Kapranov P, 2002, SCIENCE, V296, P916, DOI 10.1126/science.1068597; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; KOHN KW, 1976, BIOCHEMISTRY-US, V15, P4629, DOI 10.1021/bi00666a013; Le Page F, 2000, P NATL ACAD SCI USA, V97, P8397, DOI 10.1073/pnas.140137297; Le Page F, 2000, CANCER RES, V60, P5548; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; Le Page F, 1998, NUCLEIC ACIDS RES, V26, P1276, DOI 10.1093/nar/26.5.1276; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; Minowa O, 2000, P NATL ACAD SCI USA, V97, P4156, DOI 10.1073/pnas.050404497; MORIYA M, 1993, P NATL ACAD SCI USA, V90, P1122, DOI 10.1073/pnas.90.3.1122; Osterod M, 2001, CARCINOGENESIS, V22, P1459, DOI 10.1093/carcin/22.9.1459; Pflaum M, 1997, CARCINOGENESIS, V18, P2225, DOI 10.1093/carcin/18.11.2225; Risch N, 2001, CANCER EPIDEM BIOMAR, V10, P733; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; Sunesen M, 2002, ONCOGENE, V21, P3571, DOI 10.1038/sj.onc.1205443; Thomas D, 1997, MOL GEN GENET, V254, P171, DOI 10.1007/s004380050405; Thorslund T, 2002, DNA REPAIR, V1, P261, DOI 10.1016/S1568-7864(02)00003-4; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Tomatis L., 1990, IARC SCI PUBLICATION; Tornaletti S, 1999, BIOCHIMIE, V81, P139, DOI 10.1016/S0300-9084(99)80046-7; Tuo J, 2001, J BIOL CHEM, V276, P45772, DOI 10.1074/jbc.M107888200; vanderHorst GTJ, 1997, CELL, V89, P425, DOI 10.1016/S0092-8674(00)80223-8; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; Will O, 1999, MUTAT RES-DNA REPAIR, V435, P89, DOI 10.1016/S0921-8777(99)00039-7; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; Ye QN, 2001, J CELL BIOL, V155, P911, DOI 10.1083/jcb.200108049	44	120	124	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 28	2002	21	54					8232	8239		10.1038/sj.onc.1206027	http://dx.doi.org/10.1038/sj.onc.1206027			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447686				2022-12-28	WOS:000179323900001
J	Biggs, PJ; Vogel, H; Sage, M; Martin, LA; Donehower, LA; Bradley, A				Biggs, PJ; Vogel, H; Sage, M; Martin, LA; Donehower, LA; Bradley, A			Allelic phasing of a mouse chromosome 11 deficiency influences p53 tumorigenicity	ONCOGENE			English	Article						p53; tumorigenicity; chromosome 11 deletion; loss of heterozygosity; mouse cancer model	CANCER; BREAST; GENE; SUSCEPTIBILITY; MICE; MUTATIONS; DELETIONS; GENOME; TUMORS; BRCA1	Most tumour suppressor genes (TSGs) have been found through linkage studies in cancer predisposed families where the mutations have a high penetrance, for example, the breast cancer genes BRCA1 and BRCA2. Loss of heterozygosity (LOH) analyses of sporadic breast tumours indicate that there are many other putative TSGs yet to be identified. One such locus is proximal to BRCA1 on human chromosome 17q21. In an attempt to isolate this putative TSG, we have assessed a portion of the orthologous region on mouse chromosome 11 for its tumorigenic potential using segmental haploidy in combination with a p53 mutation. Two populations of animals were studied, with the deleted region being either on the same (cis) or on the homologous chromosome (trans) to a targeted mutant p53 allele. The deficiency elevated the tumour susceptibility of p53 heterozygous mice and modified the tumour spectrum, but only when the deficiency was in trans with the p53 mutation. Even though the genotype of these mice is identical, allelic phasing affects both the tumour spectrum and progression.	Wellcome Trust Sanger Inst, Hinxton CB10 1SA, Cambs, England; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Div Mol Virol, Houston, TX 77030 USA	Wellcome Trust Sanger Institute; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Bradley, A (corresponding author), Wellcome Trust Sanger Inst, Wellcome Trust Genome Campus, Hinxton CB10 1SA, Cambs, England.	abradley@sanger.ac.uk	Biggs, Patrick Jon/H-3355-2014	Biggs, Patrick Jon/0000-0002-0285-4101; Bradley, Allan/0000-0002-2349-8839; Vogel, Otto Hannes/0000-0002-0960-3508				Balmain A, 2002, CELL, V108, P145, DOI 10.1016/S0092-8674(02)00622-0; Balmain A, 2002, NATURE, V417, P235, DOI 10.1038/417235a; Bradley A, 1998, INT J DEV BIOL, V42, P943; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, MOL CARCINOGEN, V14, P16, DOI 10.1002/mc.2940140105; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; Liu PT, 1998, GENETICS, V150, P1155; Luo GB, 2000, NAT GENET, V26, P424, DOI 10.1038/82548; MACCOLLIN M, 1993, JAMA-J AM MED ASSOC, V270, P2316, DOI 10.1001/jama.270.19.2316; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Osborne RJ, 2000, CANCER RES, V60, P3706; Ponder BAJ, 2000, BRIT J CANCER, V83, P1301; Ponder BAJ, 2001, NATURE, V411, P336, DOI 10.1038/35077207; RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0; Staff S, 2000, GENE CHROMOSOME CANC, V28, P432, DOI 10.1002/1098-2264(200008)28:4<432::AID-GCC9>3.0.CO;2-J; Su H, 2000, NAT GENET, V24, P92, DOI 10.1038/71756; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; Vogel KS, 1999, SCIENCE, V286, P2176, DOI 10.1126/science.286.5447.2176; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Zheng BH, 1999, NUCLEIC ACIDS RES, V27, P2354, DOI 10.1093/nar/27.11.2354; Zheng BH, 1999, NAT GENET, V22, P375, DOI 10.1038/11949	27	11	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2003	22	21					3288	3296		10.1038/sj.onc.1206384	http://dx.doi.org/10.1038/sj.onc.1206384			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681MM	12761499				2022-12-28	WOS:000183040000011
J	Merle, P; Barraud, L; Lefrancois, L; Chevallier, M; Guerret, S; Maisonnas, M; Bordes, I; Savre-Train, I; Trepo, C; Vitvitski-Trepo, L				Merle, P; Barraud, L; Lefrancois, L; Chevallier, M; Guerret, S; Maisonnas, M; Bordes, I; Savre-Train, I; Trepo, C; Vitvitski-Trepo, L			Long-term high-dose interferon-alpha therapy delays Hepadnavirus-related hepatocarcinogenesis in X/myc transgenic mice	ONCOGENE			English	Article						hepatocellular carcinoma; interferon; c-myc; proliferation	HEPATITIS-B-VIRUS; TELOMERASE REVERSE-TRANSCRIPTASE; C-MYC; HEPATOCELLULAR-CARCINOMA; NUCLEOTIDE-SEQUENCE; EXPRESSION; GENE; ACTIVATION; GROWTH; CANCER	The role of interferon-alpha (IFN-alpha) remains unclear in prevention of virus-induced hepatocellular carcinoma in humans. We have investigated it herewith in the X/myc transgenic mouse model of Hepadnavirus-related hepatocarcinogenesis because of upregulation of c-myc oncogene in the liver. We have demonstrated that IFN-alpha can downregulate dose-dependently hepatocyte proliferation and c-myc overexpression at early premalignant stages, while it does not affect either hepatocyte apoptosis or telomerase activity at these steps. However, continuous and long-term administration of IFN-alpha dose-dependently delays tumor onset in dysplastic livers and increases overall survival of animals, more efficiently whether started before the onset of dysplasia. The present study therefore highlights that early preventive administration of IFN-alpha can slow down evolution towards hepatocellular carcinoma via repression of c-myc and hepatocyte proliferation at premalignant steps in experimental c-myc-induced hepatocarcinogenesis. However, the transient effect observed in this study emphasizes a need to clarify the possible mechanisms of acquired resistance and subsequent therapeutic escape. Our experimental model may be a pertinent toot to explore antioncogenic properties of IFN-alpha in human cirrhotic livers showing c-myc upregulation.	INSERM, U271, F-69424 Lyon 03, France; Labs Marcel Merieux, Dept Anat Pathol, F-69365 Lyon 07, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Trepo, C (corresponding author), INSERM, U271, 151 Cours Albert Thomas, F-69003 Lyon, France.	trepo@lyon151.inserm.fr						BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; CHAOUCHI N, 1994, CLIN IMMUNOL IMMUNOP, V73, P197, DOI 10.1006/clin.1994.1188; Cheng J, 2000, CANCER GENE THER, V7, P407, DOI 10.1038/sj.cgt.7700127; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Ebinuma H, 1999, INT J ONCOL, V15, P991; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; Einhorn S, 1996, J INTERF CYTOK RES, V16, P275, DOI 10.1089/jir.1996.16.275; ETIEMBLE J, 1994, ONCOGENE, V9, P727; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; FARSHID M, 1993, J MED VIROL, V39, P177; Fausto N, 1999, SEMIN LIVER DIS, V19, P243, DOI 10.1055/s-2007-1007114; FERRANTINI M, 1994, J IMMUNOL, V153, P4604; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; GALIBERT F, 1982, J VIROL, V41, P51, DOI 10.1128/JVI.41.1.51-65.1982; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; HIMENO Y, 1988, LIVER, V8, P208; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; HSU TY, 1988, CELL, V55, P627, DOI 10.1016/0092-8674(88)90221-8; IKEDA K, 1993, HEPATOLOGY, V18, P47, DOI 10.1016/0270-9139(93)90505-H; Ikeda K, 1998, CANCER-AM CANCER SOC, V82, P827, DOI 10.1002/(SICI)1097-0142(19980301)82:5<827::AID-CNCR5>3.0.CO;2-G; Kawate S, 1999, ONCOLOGY-BASEL, V57, P157, DOI 10.1159/000012024; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kojima H, 1997, GASTROENTEROLOGY, V112, P493, DOI 10.1053/gast.1997.v112.pm9024303; Komine F, 2000, J HEPATOL, V32, P235, DOI 10.1016/S0168-8278(00)80068-9; Kondoh N, 2001, INT J ONCOL, V18, P1271; Kumada T, 1997, HEPATOLOGY, V25, P87, DOI 10.1053/jhep.1997.v25.pm0008985270; Liu P, 1997, HEPATOLOGY, V25, P874, DOI 10.1002/hep.510250415; Llovet JM, 2000, HEPATOLOGY, V31, P54, DOI 10.1002/hep.510310111; Lundberg AS, 1999, EUR J CANCER, V35, P1886, DOI 10.1016/S0959-8049(99)00292-0; Merle P, 2001, J HEPATOL, V34, P562, DOI 10.1016/S0168-8278(00)00054-4; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; Nishiguchi S, 2001, LANCET, V357, P196, DOI 10.1016/S0140-6736(00)03595-9; Qin XQ, 1998, P NATL ACAD SCI USA, V95, P14411, DOI 10.1073/pnas.95.24.14411; Shen LL, 1998, HEPATO-GASTROENTEROL, V45, P1753; SHOUVAL D, 1983, J CLIN INVEST, V72, P707, DOI 10.1172/JCI111020; SU TS, 1985, BIOCHEM BIOPH RES CO, V132, P264, DOI 10.1016/0006-291X(85)91017-4; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; VORAVUD N, 1989, HUM PATHOL, V20, P1163, DOI 10.1016/S0046-8177(89)80006-1; WADLER S, 1990, CANCER RES, V50, P3473; Wang L, 2000, HEPATOLOGY, V32, P43, DOI 10.1053/jhep.2000.8525; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Xu DW, 2000, BLOOD, V96, P4313, DOI 10.1182/blood.V96.13.4313.h8004313_4313_4318; Yano H, 1999, HEPATOLOGY, V29, P1708, DOI 10.1002/hep.510290624; Yuen MF, 2001, CANCER, V91, P106, DOI 10.1002/1097-0142(20010101)91:1<106::AID-CNCR14>3.0.CO;2-2; ZHANG XK, 1990, ONCOGENE, V5, P909	47	16	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2003	22	18					2762	2771		10.1038/sj.onc.1206375	http://dx.doi.org/10.1038/sj.onc.1206375			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ	12743599				2022-12-28	WOS:000182569300007
J	Krona, C; Ejeskar, K; Abel, F; Kogner, P; Bjelke, J; Bjork, E; Sjoberg, RM; Martinsson, T				Krona, C; Ejeskar, K; Abel, F; Kogner, P; Bjelke, J; Bjork, E; Sjoberg, RM; Martinsson, T			Screening for gene mutations in a 500 kb neuroblastoma tumor suppressor candidate region in chromosome 1p; mutation and stage-specific expression in UBE4B/UFD2	ONCOGENE			English	Article						1p36.2-3; neuroblastoma; mutation analysis; embryonal tumors	CASPASE-ACTIVATED DNASE; ARM 17Q; INTERNATIONAL CRITERIA; SPLICE SITES; DELETION; PROTEIN; GAIN; LOCI; FRAGMENTATION; DIAGNOSIS	Deletion of a part of the short arm of chromosome 1 is one of the most common chromosomal rearrangements observed in neuroblastoma (NBL) tumors and it is associated with a poor prognosis. No NBL tumor suppressor gene has yet been identified in the region. Our shortest region of overlap of deletions, ranging from marker D1S80 to D1S244, was shown to partly overlap a 500 kb region that was homozygously deleted in a NBL cell line. We have screened seven genes known to reside in or very close to this overlap consensus region, UBE4B/UFD2, KIF1B, DFFA, PGD, CORT, PEX14, and ICAT, for coding mutations in NBL tumor DNA. A few deviations from the reference sequences were identified; most interestingly being a splice site mutation that was detected in UBE4B/UFD2 in a stage 3 NBL with a fatal outcome. This mutation was neither present in the patients constitutional DNA nor in any of 192 control chromosomes analysed. Also, the expression of UBE4B/UFD2 was markedly diminished in the high-stage/poor-outcome tumors as compared to the low-stage/favorable-outcome tumors. Overall, the number of amino-acid changes in the genes of the region was low, which shows that mutations in these genes are rare events in NBL development. Given the data presented here, UBE4B/UFD2 stands out as the strongest candidate NBL tumor suppressor gene in the region at this stage.	Univ Gothenburg, Sahlgrens Univ Hosp E, Inst Hlth Women & Children, Dept Clin Genet, SE-41685 Gothenburg, Sweden; Royal Childrens Hosp, Murdoch childrens Res Inst, Cell & Gene Therapy Grp, Parkville, Vic 3052, Australia; Karolinska Inst, Karolinska Hosp, Childhood Canc Res Unit, SE-17176 Stockholm, Sweden	Sahlgrenska University Hospital; University of Gothenburg; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; Karolinska Institutet; Karolinska University Hospital	Martinsson, T (corresponding author), Univ Gothenburg, Sahlgrens Univ Hosp E, Inst Hlth Women & Children, Dept Clin Genet, SE-41685 Gothenburg, Sweden.		Martinsson, Tommy/J-4140-2013	Martinsson, Tommy/0000-0002-9403-3123; Kogner, Per/0000-0002-2202-9694; Ejeskar, Katarina/0000-0001-8962-0860				Abel F, 1999, BRIT J CANCER, V81, P1402, DOI 10.1038/sj.bjc.6692231; Abel F, 2002, BRIT J CANCER, V86, P596, DOI 10.1038/sj.bjc.6600111; Antonarakis SE, 1998, HUM MUTAT, V11, P1; Bauer A, 2001, GENE CHROMOSOME CANC, V31, P228, DOI 10.1002/gcc.1139; Bown N, 1999, NEW ENGL J MED, V340, P1954, DOI 10.1056/NEJM199906243402504; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; BRODEUR GM, 1990, CANCER SURV, V9, P673; BRODEUR GM, 1988, J CLIN ONCOL, V6, P1874, DOI 10.1200/JCO.1988.6.12.1874; Burset M, 2000, NUCLEIC ACIDS RES, V28, P4364, DOI 10.1093/nar/28.21.4364; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CARON H, 1995, HUM MOL GENET, V4, P535, DOI 10.1093/hmg/4.4.535; Caron H, 2001, GENE CHROMOSOME CANC, V30, P168, DOI 10.1002/1098-2264(200102)30:2<168::AID-GCC1072>3.0.CO;2-E; Clark F, 2002, HUM MOL GENET, V11, P451, DOI 10.1093/hmg/11.4.451; Ejeskar K, 2000, CYTOGENET CELL GENET, V89, P62, DOI 10.1159/000015566; Ejeskar K, 2001, MED PEDIATR ONCOL, V36, P61, DOI 10.1002/1096-911X(20010101)36:1<61::AID-MPO1016>3.0.CO;2-0; Guo C, 1999, ONCOGENE, V18, P4948, DOI 10.1038/sj.onc.1202887; Guo C, 2000, MED PEDIATR ONCOL, V35, P544, DOI 10.1002/1096-911X(20001201)35:6<544::AID-MPO10>3.0.CO;2-2; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Ichimiya S, 1999, ONCOGENE, V18, P1061, DOI 10.1038/sj.onc.1202390; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Lal SL, 1999, PLANT PHYSIOL, V121, P411, DOI 10.1104/pp.121.2.411; Lastowska M, 1997, EUR J CANCER, V33, P1627, DOI 10.1016/S0959-8049(97)00282-7; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; MARIS JM, 1995, CANCER RES, V55, P4664; Maris JM, 2001, MED PEDIATR ONCOL, V36, P32, DOI 10.1002/1096-911X(20010101)36:1<32::AID-MPO1009>3.0.CO;2-0; Martinsson T, 1997, EUR J CANCER, V33, P1997, DOI 10.1016/S0959-8049(97)00278-5; MARTINSSON T, 1995, CANCER RES, V55, P5681; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Ohira M, 2000, ONCOGENE, V19, P4302, DOI 10.1038/sj.onc.1203786; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Sakahira H, 2000, J BIOL CHEM, V275, P8091, DOI 10.1074/jbc.275.11.8091; Sakahira H, 1999, J BIOL CHEM, V274, P15740, DOI 10.1074/jbc.274.22.15740; Spieker N, 2001, GENE CHROMOSOME CANC, V31, P172, DOI 10.1002/gcc.1130.abs; Tago K, 2000, GENE DEV, V14, P1741; Thanaraj TA, 2001, NUCLEIC ACIDS RES, V29, P2581, DOI 10.1093/nar/29.12.2581; White PS, 2001, MED PEDIATR ONCOL, V36, P37, DOI 10.1002/1096-911X(20010101)36:1<37::AID-MPO1010>3.0.CO;2-L; WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520	39	43	45	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 17	2003	22	15					2343	2351		10.1038/sj.onc.1206324	http://dx.doi.org/10.1038/sj.onc.1206324			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	667KV	12700669				2022-12-28	WOS:000182231500012
J	Mulherkar, R; Kirtane, BM; Ranichandani, A; Mansukhani, NP; Kannan, S; Naresh, KN				Mulherkar, R; Kirtane, BM; Ranichandani, A; Mansukhani, NP; Kannan, S; Naresh, KN			Expression of enhancing factor/phospholipase A(2) in skin results in abnormal epidermis and increased sensitivity to chemical carcinogenesis	ONCOGENE			English	Article						enhancing factor; secretory phospholipase A(2); transgenic mice; epidermal growth factor; squamous cell carcinoma; hair follicle	MOUSE SMALL-INTESTINES; GROWTH-FACTOR RECEPTOR; TRANSGENIC MICE; PHOSPHOLIPASE A(2); HAIR-FOLLICLES; KERATIN GENE; STEM-CELLS; DIFFERENTIATION; LOCALIZATION; PROTEIN	Enhancing factor (EF), a growth factor modulator, is the mouse homologue of human secretory group 11 phospholipase A(2). EF exhibits growth-promoting activity in vitro, in the presence of epidermal growth factor, and also brings about phenotypic transformation of normal cells. In order to ascertain the role of EF in vivo, a human keratin-14 promoter was used to drive the expression of EF ectopically to squamous epithelial cells. The founder mouse and its progeny showed abnormal whiskers and a scaly, beaded tail. In these mice, keratinization pattern of the epidermis was disturbed and parakeratosis and acanthosis were noted. The transgenic mice, TgK14-EF, expressed EF in the suprabasal layers of tail epidermis as well as in the epithelial cells of hair follicle and sebaceous glands of skin. Expression of EF along with hyperplasia was also observed in other squamous epithelia such as buccal mucosa, tongue and oesophagus. TgK14-EF mice homozygous for the transgene showed delayed and scanty hair growth although the mice were healthy and fertile. The hemizygous TgK14-EF mice were sensitive to a two-stage chemical carcinogenesis and developed a higher number of papillomas than their normal littermates over the course of the experiment. The conversion rate of papilloma to carcinoma was two fold higher in the transgenic mice.	Tata Mem Hosp, Adv Ctr Treatment Res & Educ Canc, ACTREC, Genet Engn Lab,Canc Res Inst, Kharghar 410208, Navi Mumbai, India; Tata Mem Hosp, Tata Mem Ctr, Dept Pathol, Bombay 400012, Maharashtra, India	Tata Memorial Centre (TMC); Advance Centre for Treatment, Research & Education in Cancer (ACTREC); Tata Memorial Hospital; Tata Memorial Centre (TMC); Tata Memorial Hospital	Mulherkar, R (corresponding author), Tata Mem Hosp, Adv Ctr Treatment Res & Educ Canc, ACTREC, Genet Engn Lab,Canc Res Inst, Kharghar 410208, Navi Mumbai, India.			Naresh, Kikkeri N/0000-0003-3807-3638				COHEN S, 1963, J INVEST DERMATOL, V40, P1; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; DEO MG, 1983, INDIAN J BIOCHEM BIO, V20, P228; Gelb MH, 2000, J BIOL CHEM, V275, P39823, DOI 10.1074/jbc.C000671200; Grass DS, 1996, J CLIN INVEST, V97, P2233, DOI 10.1172/JCI118664; GREEN MR, 1983, DEV BIOL, V100, P506, DOI 10.1016/0012-1606(83)90243-9; JIANG CK, 1991, J INVEST DERMATOL, V96, P162, DOI 10.1111/1523-1747.ep12460939; Kadam S, 1999, BIOCHEM J, V340, P237, DOI 10.1042/0264-6021:3400237; KAISER E, 1990, CLIN BIOCHEM, V23, P349, DOI 10.1016/0009-9120(90)90051-U; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; Kiguchi K, 2000, ONCOGENE, V19, P4243, DOI 10.1038/sj.onc.1203778; LAVKER RM, 1993, J INVEST DERMATOL, V101, P16; MORRIS RJ, 1986, CANCER RES, V46, P3061; MULHERKAR R, 1993, BIOCHEM BIOPH RES CO, V195, P1254, DOI 10.1006/bbrc.1993.2179; MULHERKAR R, 1991, HISTOCHEMISTRY, V96, P367, DOI 10.1007/BF00271358; MULHERKAR R, 1986, J CELL PHYSIOL, V127, P183, DOI 10.1002/jcp.1041270122; MULHERKAR R, 1993, FEBS LETT, V317, P263, DOI 10.1016/0014-5793(93)81289-C; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; MURILLAS R, 1995, EMBO J, V14, P5216, DOI 10.1002/j.1460-2075.1995.tb00206.x; Oshima H, 2001, CELL, V104, P233, DOI 10.1016/S0092-8674(01)00208-2; ROOP DR, 1988, CANCER RES, V48, P3245; Shibata MA, 1997, MOL CARCINOGEN, V18, P160, DOI 10.1002/(SICI)1098-2744(199703)18:3<160::AID-MC5>3.0.CO;2-J; Taylor G, 2000, CELL, V102, P451, DOI 10.1016/S0092-8674(00)00050-7; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; WAGLE A, 1989, CELL BIOL INT REP, V13, P309, DOI 10.1016/0309-1651(89)90154-9; Xie W, 1998, CELL GROWTH DIFFER, V9, P313	27	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 3	2003	22	13					1936	1944		10.1038/sj.onc.1206229	http://dx.doi.org/10.1038/sj.onc.1206229			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	662UR	12673199				2022-12-28	WOS:000181967700004
J	Jia, L; Patwari, Y; Kelsey, SM; Srinivasula, SM; Agrawal, SG; Alnemri, ES; Newland, AC				Jia, L; Patwari, Y; Kelsey, SM; Srinivasula, SM; Agrawal, SG; Alnemri, ES; Newland, AC			Role of Smac in human leukaemic cell apoptosis and proliferation	ONCOGENE			English	Article						apoptosis; apaf-1; caspases; IAPs; smac	TRAIL-INDUCED APOPTOSIS; DRUG-INDUCED APOPTOSIS; CYTOCHROME-C; PROMOTES APOPTOSIS; SMAC/DIABLO; PROTEIN; MITOCHONDRIA; DEATH; OVEREXPRESSION; IDENTIFICATION	Smac (or DIABLO) is a recently identified, novel proapoptotic molecule, which is released from mitochondria into the cytosol during apoptosis. Smac functions by eliminating the caspase-inhibitory properties of the inhibitors of apoptosis proteins (IAP), particularly XIAP. In this study, we stably transfected both full-length (FL) and mature (NIT) Smac genes into the K562 and CEM leukaemic cell lines. Both FL and NIT Smac transfectants increased the sensitivity of leukaemic cells to UV light-induced apoptosis and the activation of caspase-9 and caspase-3. Purified cytosol from the mature Smac transfectants, or the addition of human recombinant Smac protein or N-7 peptide into nontransfected cytosol, showed an increased sensitivity to cytochrome c-induced activation of caspase-3. The mature Smac enhanced the susceptibility of both K562 and CEM cells to TRAIL-induced apoptosis. Overexpression of the mature Smac protein also inhibited proliferation, as detected by reduced colony formation and Ki-67 expression in leukaemic cells. Cell cycle analysis revealed that Smac transfectants displayed significant G0/G1 arrest and reduction in 5-bromo-2'-deoxyuridine (BrdU) incorporation. Smac sensitized human acute myeloid leukaemia blasts to cytochrome c-induced activation of caspase-3. However, Smac failed to overcome Apaf-l-deficiency-mediated resistance to cytochrome c in primary leukaemic blasts. In summary, this study reveals that Smac/DIABLO exhibits a potential role in increasing apoptosis and suppressing proliferation in human leukaemic cells. Importantly, it also indicates that it is crucial to evaluate the levels of Apaf-1 and XIAP proteins in patient samples before using Smac peptide therapy in the treatment of human leukaemia.	St Bartholomews & Royal London Sch Med & Dent, Dept Hematol Oncol, London E1 2AD, England; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	University of London; Queen Mary University London; Jefferson University	Jia, L (corresponding author), St Bartholomews & Royal London Sch Med & Dent, Dept Hematol Oncol, Turner St, London E1 2AD, England.	L.jia@qmul.ac.uk	Alnemri, Emad S/B-4526-2010	Jia, Li/0000-0002-6076-8455				Altieri DC, 2001, TRENDS MOL MED, V7, P542, DOI 10.1016/S1471-4914(01)02243-2; Carson JP, 2002, CANCER RES, V62, P18; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Ekert PG, 2001, J CELL BIOL, V152, P483, DOI 10.1083/jcb.152.3.483; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Gerlach C, 1998, LAB INVEST, V78, P129; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Guo F, 2002, BLOOD, V99, P3419, DOI 10.1182/blood.V99.9.3419; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Jia L, 2001, ONCOGENE, V20, P4817, DOI 10.1038/sj.onc.1204628; Jia L, 2001, BIOCHEM BIOPH RES CO, V283, P1037, DOI 10.1006/bbrc.2001.4895; Jia L, 2001, BLOOD, V98, P414, DOI 10.1182/blood.V98.2.414; Jia L, 1999, BLOOD, V93, P2353, DOI 10.1182/blood.V93.7.2353.407k20_2353_2359; Kabra NH, 2001, P NATL ACAD SCI USA, V98, P6307, DOI 10.1073/pnas.111158698; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Liu FT, 2002, BRIT J HAEMATOL, V117, P333, DOI 10.1046/j.1365-2141.2002.03418.x; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; Partheniou F, 2001, BIOCHEM BIOPH RES CO, V287, P181, DOI 10.1006/bbrc.2001.5582; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Suliman A, 2001, ONCOGENE, V20, P2122, DOI 10.1038/sj.onc.1204282; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tamm I, 2000, CLIN CANCER RES, V6, P1796; Terry NHA, 2001, METHOD CELL BIOL, V63, P355; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Zang DY, 2001, BLOOD, V98, P3058, DOI 10.1182/blood.V98.10.3058; Zhang XD, 2001, CANCER RES, V61, P7339	33	48	63	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	2003	22	11					1589	1599		10.1038/sj.onc.1206322	http://dx.doi.org/10.1038/sj.onc.1206322			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642862				2022-12-28	WOS:000181580500001
J	Rabbitt, E; Ayuk, J; Boelaert, K; Sheppard, MC; Hewison, M; Stewart, PM; Gittoes, NJL				Rabbitt, E; Ayuk, J; Boelaert, K; Sheppard, MC; Hewison, M; Stewart, PM; Gittoes, NJL			Abnormal expression of 11 beta-hydroxysteroid dehydrogenase type 2 in human pituitary adenomas: a prereceptor determinant of pituitary cell proliferation	ONCOGENE			English	Article						pituitary adenoma; 11 beta-hydroxysteroid dehydrogenase; proliferation	APPARENT MINERALOCORTICOID EXCESS; CYCLE INHIBITOR P27(KIP1); RECEPTOR EXPRESSION; MICE LACKING; TUMORS; ARREST; GROWTH; TUMORIGENESIS; HYPERPLASIA; PROGRESSION	The physiological effects of glucocorticoids (GCs) are, at least in part, mediated by inhibition of cell proliferation. Two isozymes of 11beta-hydroxysteroid dehydrogenase (11beta-HSD) interconvert cortisol (F) and inactive cortisone (E), and are thus able to modulate GC action at an autocrine level. Previously, we have demonstrated absent expression of 11beta-HSD2 in normal pituitaries; however, in a small number of pituitary tumors analysed, 11beta-HSD2 was readily demonstrable. Here we have used real-time RT-PCR to quantify expression of mRNA for 11beta-HSD1 and 2 in 105 human pituitary tumors and have performed enzyme expression and activity studies in primary pituitary cultures. Overall, pituitary tumors expressed lower levels of 11beta-HSD1 mRNA compared with normals (0.2-fold, P<0.05). In contrast, expression of 11beta-HSD2 mRNA was 9.8-fold greater in tumors than in normals (P < 0.001). Enzyme assays showed significant 11beta-HSD2 activity (71.9+/-22.3pmol/h/mg protein (mean+/-s.d.)) but no detectable 11beta-HSD1 activity. Proliferation assays showed that addition of glycyrrhetinic acid (an 11beta-HSD2 inhibitor) resulted in a 30.3+/-7.7% inhibition of cell proliferation. In summary, we describe a switch in expression from 11beta-HSD1 to 11beta-HSD2 in neoplastic pituitary tissue. We propose that abnormal expression of 11beta-HSD2 acts as a proproliferative prereceptor determinant of pituitary cell growth, and may provide a novel target for future tumor therapy.	Univ Birmingham, Queen Elizabeth Hosp, Div Med Sci, Birmingham B15 2TH, W Midlands, England	University of Birmingham	Stewart, PM (corresponding author), Univ Birmingham, Queen Elizabeth Hosp, Div Med Sci, Birmingham B15 2TH, W Midlands, England.							Bamberger CM, 1999, EUR J ENDOCRINOL, V140, P250, DOI 10.1530/eje.0.1400250; Bland R, 1999, J ENDOCRINOL, V161, P455, DOI 10.1677/joe.0.1610455; Cooper MS, 2000, BONE, V27, P375, DOI 10.1016/S8756-3282(00)00344-6; Croxtall JD, 2000, BRIT J PHARMACOL, V130, P289, DOI 10.1038/sj.bjp.0703272; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Franklin DS, 1998, GENE DEV, V12, P2899, DOI 10.1101/gad.12.18.2899; Gingras MC, 2000, EXP HEMATOL, V28, P350, DOI 10.1016/S0301-472X(00)00149-1; Gittoes NJL, 1997, J CLIN ENDOCR METAB, V82, P1960, DOI 10.1210/jc.82.6.1960; Hundertmark S, 1997, J ENDOCRINOL, V155, P171, DOI 10.1677/joe.0.1550171; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Korbonits M, 2001, J CLIN ENDOCR METAB, V86, P2728, DOI 10.1210/jc.86.6.2728; Koyama K, 2001, J STEROID BIOCHEM, V76, P153, DOI 10.1016/S0960-0760(00)00157-6; Labrie F, 2000, TRENDS ENDOCRIN MET, V11, P421, DOI 10.1016/S1043-2760(00)00342-8; Lidhar K, 1999, J CLIN ENDOCR METAB, V84, P3823, DOI 10.1210/jc.84.10.3823; McKay LI, 1999, ENDOCR REV, V20, P435, DOI 10.1210/er.20.4.435; McTernan CL, 2001, J CLIN ENDOCR METAB, V86, P4979, DOI 10.1210/jc.86.10.4979; MOTOO Y, 1994, CANCER LETT, V86, P91, DOI 10.1016/0304-3835(94)90184-8; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nawrocki AR, 2002, J BIOL CHEM, V277, P14647, DOI 10.1074/jbc.M111549200; Rabbitt EH, 2002, FASEB J, V16, P36, DOI 10.1096/fj.01-0582com; Robson AC, 1998, MOL BRAIN RES, V61, P1, DOI 10.1016/S0169-328X(98)00161-2; Rogatsky I, 1997, MOL CELL BIOL, V17, P3181, DOI 10.1128/MCB.17.6.3181; Samuelsson MKR, 1999, MOL ENDOCRINOL, V13, P1811, DOI 10.1210/me.13.11.1811; SANCHEZ I, 1993, CELL GROWTH DIFFER, V4, P215; Shiota G, 1999, CARCINOGENESIS, V20, P59, DOI 10.1093/carcin/20.1.59; Stewart PM, 1999, VITAM HORM, V57, P249; Stewart PM, 1996, LANCET, V347, P88, DOI 10.1016/S0140-6736(96)90211-1; STEWART PM, 1987, LANCET, V2, P821; Stewart PM, 2002, TRENDS ENDOCRIN MET, V13, P94, DOI 10.1016/S1043-2760(02)00566-0; White PC, 1997, ENDOCR REV, V18, P135, DOI 10.1210/er.18.1.135; WHORWOOD CB, 1993, ENDOCRINOLOGY, V132, P2287, DOI 10.1210/en.132.6.2287	32	45	47	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 20	2003	22	11					1663	1667		10.1038/sj.onc.1206293	http://dx.doi.org/10.1038/sj.onc.1206293			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642869				2022-12-28	WOS:000181580500008
J	Yamashita, H; Iwase, H; Toyama, T; Fujii, Y				Yamashita, H; Iwase, H; Toyama, T; Fujii, Y			Naturally occurring dominant-negative Stat5 suppresses transcriptional activity of estrogen receptors and induces apoptosis in T47D breast cancer cells	ONCOGENE			English	Article						Stat5; estrogen receptor; signal transduction; recombinant adenovirus; breast cancer	MAMMARY-GLAND DEVELOPMENT; SIGNAL TRANSDUCER; SERINE PHOSPHORYLATION; CROSS-TALK; PHOSPHATIDYLINOSITOL 3-KINASE; GLUCOCORTICOID RECEPTOR; EPITHELIAL-CELLS; GENE-EXPRESSION; DNA-BINDING; ER-ALPHA	Signal transducer and activator of transcription (Stat) 5 regulates growth, differentiation, and survival of mammary and hematopoietic cells. The role of Stat5 in breast cancer has not been established, although Stat5 is critical for some hematopoietic malignancies. We detected for the first time that Stat5b is constitutively activated in human breast cancer cell lines, and analysed the role of Stat5 in estrogen receptor(ER)-positive breast cancer cell lines using dominant-negative variants of Stat5. Two distinct carboxyl-truncated Stat5a derivatives were generated. Stat5aDelta740 corresponded to a naturally occurring alternative splice variant, and Stat5aDelta713 was analogous to an 80 kDa Stat5a product of a nuclear protease. Stat5aDelta740 and Stat5aDelta713 displayed comparable dominant-negative properties and suppressed transcriptional activity of wildtype Stat5a and Stat5b equally well. Cotransfection experiments revealed that Stat5aDelta740 completely blocked transcriptional activity of endogenous estrogen receptor in T47D and MCF7 cells, and of both ERalpha and ERbeta in COS-7 cells. Stat5aDelta740 was selected for adenoviral delivery, and high-efficiency expression of tyrosine phosphorylated Stat5aDelta740 was achieved in infected cells. Adenoviral-mediated Stat5aDelta740 induced apoptosis in T47D cells but not in caspase-3-negative MCF7 cells. The present study indicates that overexpression of a dominant-negative variant of Stat5 suppresses ER transcriptional activity and induces apoptosis in estrogen-responsive breast cancer tissue culture cells.	Nagoya City Univ, Sch Med Sci, Dept Surg 2, Mizuho Ku, Nagoya, Aichi 4678601, Japan	Nagoya City University	Yamashita, H (corresponding author), Nagoya City Univ, Sch Med Sci, Dept Surg 2, Mizuho Ku, Kawasumi 1, Nagoya, Aichi 4678601, Japan.		Yamashita, Hiroko/D-5102-2012	Yamashita, Hiroko/0000-0003-4281-8727; Toyama, Tatsuya/0000-0003-4713-7795				Beuvink I, 2000, J BIOL CHEM, V275, P10247, DOI 10.1074/jbc.275.14.10247; Bittorf T, 2000, CELL SIGNAL, V12, P23, DOI 10.1016/S0898-6568(99)00063-7; Bjornstrom L, 2001, J MOL ENDOCRINOL, V27, P93, DOI 10.1677/jme.0.0270093; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Buettner R, 2002, CLIN CANCER RES, V8, P945; Cowley SM, 1999, J STEROID BIOCHEM, V69, P165, DOI 10.1016/S0960-0760(99)00055-2; DaSilva L, 1996, MOL CELL ENDOCRINOL, V117, P131, DOI 10.1016/0303-7207(95)03738-1; Dong F, 1998, J IMMUNOL, V161, P6503; Doppler W, 2001, MOL CELL BIOL, V21, P3266, DOI 10.1128/MCB.21.9.3266-3279.2001; Faulds MH, 2001, MOL ENDOCRINOL, V15, P1929, DOI 10.1210/me.15.11.1929; Favre-Young H, 2000, MOL ENDOCRINOL, V14, P1411, DOI 10.1210/me.14.9.1411; Frank DA, 1997, J CLIN INVEST, V100, P3140, DOI 10.1172/JCI119869; Frasor J, 2001, MOL ENDOCRINOL, V15, P2172, DOI 10.1210/me.15.12.2172; Grimley PM, 1999, CYTOKINE GROWTH F R, V10, P131, DOI 10.1016/S1359-6101(99)00011-8; Hennighausen L, 1997, J BIOL CHEM, V272, P7567, DOI 10.1074/jbc.272.12.7567; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KAZANSKY AV, 1995, MOL ENDOCRINOL, V9, P1598, DOI 10.1210/me.9.11.1598; Kirken RA, 1997, J BIOL CHEM, V272, P15459, DOI 10.1074/jbc.272.24.15459; Kirken RA, 1997, J BIOL CHEM, V272, P14098, DOI 10.1074/jbc.272.22.14098; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Meyer J, 1998, BLOOD, V91, P1901, DOI 10.1182/blood.V91.6.1901.1901_1901_1908; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Park SH, 2001, MOL ENDOCRINOL, V15, P2157, DOI 10.1210/me.15.12.2157; Petersen H, 1998, EXP CELL RES, V243, P347, DOI 10.1006/excr.1998.4160; Saji S, 2000, P NATL ACAD SCI USA, V97, P337, DOI 10.1073/pnas.97.1.337; Santos SCR, 2000, ONCOGENE, V19, P1164, DOI 10.1038/sj.onc.1203418; Schaber JD, 1998, CANCER RES, V58, P1914; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Sonoyama J, 2002, J BIOL CHEM, V277, P8076, DOI 10.1074/jbc.M111501200; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Stoecklin E, 1999, J STEROID BIOCHEM, V69, P195, DOI 10.1016/S0960-0760(99)00052-7; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Wang DM, 1996, MOL CELL BIOL, V16, P6141; WATSON CJ, 1995, BRIT J CANCER, V71, P840, DOI 10.1038/bjc.1995.162; Watson CJ, 2001, J MAMMARY GLAND BIOL, V6, P115, DOI 10.1023/A:1009524817155; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yamashita H, 1998, J BIOL CHEM, V273, P30218, DOI 10.1074/jbc.273.46.30218; Yamashita H, 2001, MOL CELL ENDOCRINOL, V183, P151, DOI 10.1016/S0303-7207(01)00546-9	45	62	67	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 20	2003	22	11					1638	1652		10.1038/sj.onc.1206277	http://dx.doi.org/10.1038/sj.onc.1206277			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642867				2022-12-28	WOS:000181580500006
J	Wells, J; Yan, PS; Cechvala, M; Huang, T; Farnham, PJ				Wells, J; Yan, PS; Cechvala, M; Huang, T; Farnham, PJ			Identification of novel pRb binding sites using CpG microarrays suggests that E2F recruits pRb to specific genomic sites during S phase	ONCOGENE			English	Article						pRb; E2F1; CpG island; chromatin immunoprecipitation	TARGET GENE SPECIFICITY; DNA-REPLICATION; RETINOBLASTOMA PROTEIN; CELL-CYCLE; CHROMATIN IMMUNOPRECIPITATION; EXPRESSION; COMPLEX; CLONING; FAMILY; REPAIR	The retinoblastoma (Rb) tumor suppressor protein is an important regulator of cell proliferation and differentiation. Many studies have shown that pRb can negatively regulate the activity of the E2F family of transcription factors during Go and G, phases of the cell cycle, perhaps by serving as a bridge between the E2Fs and transcriptional repressors such as histone deacetylases and methylases. However, pRb has also been shown to localize to discrete DNA foci during S phase, a time at which pRb is thought to be dissociated from E2F. Numerous other DNA binding proteins have been shown to interact with pRb, suggesting that pRb may control progression through S phase by binding to sites in the genome distinct from E2F target gene promoters. To test this hypothesis, we have identified novel pRb binding sites within the human genome using an unbiased approach which relies upon a combination of chromatin immunoprecipitation and CpG microarray analysis. To provide the greatest opportunity of finding distinct sets of pRb binding sites, we examined pRb binding in chromatin obtained from human Raji cells synchronized in either G(0)/G(1) phase or S phase. These experiments have allowed us to identify a large set of new genomic binding sites for the pRb protein. We found that some sites are occupied by pRb only during G(0)/G(1) phase, as would be predicted from previous models of pRb function. We also identified sites to which pRb bound only during S phase and other sites which were bound constitutively by pRb. Surprisingly, we found that E2F1 was present at most of the CpG islands bound by pRb, independent of the phase of the cell cycle. Thus, although pRb has the potential to interact with numerous transcription factors, our data suggest that the majority of DNA-bound pRb is recruited to E2F target promoters during both G(0)/G(1) and S phases.	Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Madison, WI 53706 USA; Univ Missouri, Ellis Fischel Canc Ctr, Dept Pathol & Anat Sci, Columbia, MO 65203 USA	University of Wisconsin System; University of Wisconsin Madison; University of Missouri System; University of Missouri Columbia	Farnham, PJ (corresponding author), Univ Wisconsin, Sch Med, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.	farnham@oncology.wisc.edu	Yan, Pearlly S/E-4339-2011	Yan, Pearlly S/0000-0003-1965-4920; Farnham, Peggy/0000-0003-4469-7914	NATIONAL CANCER INSTITUTE [P01CA022484, P30CA014520, R33CA084701, R29CA045240, R01CA045240] Funding Source: NIH RePORTER; NCI NIH HHS [CA14520-29, CA22484, R33CA84701, CA45240, CA1452] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albert T, 2001, J BIOL CHEM, V276, P20482, DOI 10.1074/jbc.M100265200; Antequera F, 1999, CURR BIOL, V9, pR661, DOI 10.1016/S0960-9822(99)80418-7; Bosco G, 2001, NAT CELL BIOL, V3, P289, DOI 10.1038/35060086; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kennedy BK, 2000, GENE DEV, V14, P2855, DOI 10.1101/gad.842600; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Ma YH, 2002, ARCH BIOCHEM BIOPHYS, V399, P212, DOI 10.1006/abbi.2002.2761; Maser RS, 2001, MOL CELL BIOL, V21, P6006, DOI 10.1128/MCB.21.17.6006-6016.2001; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Polager S, 2002, ONCOGENE, V21, P437, DOI 10.1038/sj.onc.1205102; Ponzio G, 1998, ONCOGENE, V17, P1159, DOI 10.1038/sj.onc.1202040; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Royzman I, 1999, GENE DEV, V13, P827, DOI 10.1101/gad.13.7.827; SAWAI M, 1990, EXP CELL RES, V187, P4, DOI 10.1016/0014-4827(90)90108-M; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; Takahashi Y, 2000, GENE DEV, V14, P804; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Turner WJ, 2001, J VIROL, V75, P5638, DOI 10.1128/JVI.75.12.5638-5645.2001; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Wells J, 2002, P NATL ACAD SCI USA, V99, P3890, DOI 10.1073/pnas.062047499; Wells J, 2002, METHODS, V26, P48, DOI 10.1016/S1046-2023(02)00007-5; Yan PS, 2001, CANCER RES, V61, P8375; Zhang HS, 2001, ONCOGENE, V20, P3134, DOI 10.1038/sj.onc.1204338; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	39	108	112	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2003	22	10					1445	1460		10.1038/sj.onc.1206264	http://dx.doi.org/10.1038/sj.onc.1206264			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652ZZ	12629508				2022-12-28	WOS:000181411900002
J	Oo, ML; Senga, T; Thant, AA; Amin, AR; Huang, PY; Mon, NN; Hamaguchi, M				Oo, ML; Senga, T; Thant, AA; Amin, AR; Huang, PY; Mon, NN; Hamaguchi, M			Cysteine residues in the C-terminal lobe of Src: their role in the suppression of the Src kinase	ONCOGENE			English	Article						Src; SH-alkylating agents; inactivation; cysteine; redox	HERBIMYCIN-A; TYROSINE; TRANSFORMATION; MECHANISM	To evaluate the function of cysteine residues of the Src kinase, we constructed a series of Src mutants in which some of cyteines were replaced to alanines. With these mutants, we studied the effect of SH-alkylating agents, N[p-(2-benzimidazolyl)phenyll maleimide (BIPM) and N(9-acridinyl) maleimide (NAM), on their kinase activity. Of 10 cysteine residues scattered over v-Src, either a single mutation at Cys520 or multiple mutations at the four clustered cyteines, Cys483, Cys487, Cys496 and Cys498, yielded clear resistance to the treatment with 10 muM BIPM or 1 mum NAM. In contrast, other cysteines including those in the SH2 domain and those in the catalytic cleft of the kinase domain were dispensable for the inactivation by BIPM and NAM. Similarly, deletion of SH2 and SH3 did not confer the resistance to v-Src, suggesting the inactivation by the SH-alkylating agents is SH2/SH3-independent. Although Cys520-mutated v-Src was resistant to 1 mum NAM, it was inactivated by 5 mum NAM. However, combined mutation including all of Cys483, Cys487, Cys496, Cys498 and Cys520 yielded clear resistance to 5 mum NAM. Among these mutants, those with double mutations in the four clustered cysteines yielded a temperature sensitive phenotype in the transfected cells, whereas Cys520 did not, suggesting that Cys520 has, at least in part, a discrete function. In contrast to v-Src, c-Src, which lacks cysteine at position 520, was resistant to 1 mum NAM but sensitive to 5 mum NAM. While replacement of Phe520 of c-Src to cysteine made it sensitive to 1 mum NAM, double mutation in clustered cysteines again yielded resistance to 5 mum NAM. Taken together, our results strongly suggest that the multiple cysteine residues clustered at the end of the G terminal lobe are critical for the inhibition by the SH-alkylating agents and, thereby, have an allosteric repressor effect on the catalytic activity of Src in a SH2-phosphoTyr527 independent manner.	Nagoya Univ, Sch Med, Lab Mol Pathogenesis, Showa Ku, Nagoya, Aichi 4668550, Japan	Nagoya University	Hamaguchi, M (corresponding author), Nagoya Univ, Sch Med, Lab Mol Pathogenesis, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.			AMIN, ARM/0000-0001-9144-2960; Mon, Naing Naing/0000-0001-6178-0176				Akhand AK, 1999, J BIOL CHEM, V274, P25821, DOI 10.1074/jbc.274.36.25821; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Chiarugi P, 2001, J BIOL CHEM, V276, P33478, DOI 10.1074/jbc.M102302200; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; FUKAZAWA H, 1990, BIOCHEM BIOPH RES CO, V173, P276, DOI 10.1016/S0006-291X(05)81053-8; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pu MY, 1996, ONCOGENE, V13, P2615; Senga T, 2000, ONCOGENE, V19, P273, DOI 10.1038/sj.onc.1203296; Sicheri F, 1997, CURR OPIN STRUC BIOL, V7, P777, DOI 10.1016/S0959-440X(97)80146-7; SIMPSON RB, 1961, J AM CHEM SOC, V83, P4711, DOI 10.1021/ja01484a005; STRICKS W, 1953, J AM CHEM SOC, V75, P5673, DOI 10.1021/ja01118a060; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; VEILLETTE A, 1993, J BIOL CHEM, V268, P17547; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	18	22	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2003	22	9					1411	1417		10.1038/sj.onc.1206286	http://dx.doi.org/10.1038/sj.onc.1206286			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618767				2022-12-28	WOS:000181360900016
J	Greenblatt, MS; Beaudet, JG; Gump, JR; Godin, KS; Trombley, L; Koh, J; Bond, JP				Greenblatt, MS; Beaudet, JG; Gump, JR; Godin, KS; Trombley, L; Koh, J; Bond, JP			Detailed computational study of p53 and p16: using evolutionary sequence analysis and disease-associated mutations to predict the functional consequences of allelic variants	ONCOGENE			English	Article						missense mutation; database; cell cycle; structural biology; SNP	MISSENSE MUTATIONS; HUMAN CANCERS; GENE; SUBSTITUTION; CONSERVATION; SPECTRUM	Deciding whether a missense allelic variant affects protein function is important in many contexts. We previously demonstrated that a detailed analysis of p53 intragenic conservation correlates with somatic mutation hotspots. Here we refine these evolutionary studies and expand them to the p16/Ink4a gene. We calculated that in order for 'absolute conservation' of a codon across multiple species to achieve P < 0.05, the evolutionary substitution database must contain at least 3(M) variants, where M equals the number of codons in the gene. Codons in p53 were divided into high (73% of codons), intermediate (29% of codons), and low (0 codons) likelihood of being mutation hotspots. From a database of 263 somatic missense p16 mutations, we identified only four codons that are mutational hotspots at P < 0.05 ( > 8 mutations). However, data on function, structure, and disease association support the conclusion that 11 other codons with greater than or equal to5 somatic mutations also likely indicate functionally critical residues, even though P > 0.05. We calculated p16 evolution using amino acid substitution matrices and nucleotide substitution distances. We looked for evolutionary parameters at each codon that would predict whether missense mutations were disease associated or disrupted function. The current p16 evolutionary substitution database is too small to determine whether observations of 'absolute conservation' are statistically significant. Increasing the number of sequences from three to seven significantly improved the predictive value of evolutionary computations. The sensitivity and specificity for conservation scores in predicting disease association of P16 codons is 70-80%. Despite the small p16 sequence database, our calculations of high conservation correctly predicted loss of cell cycle arrest function in 75% of tested codons, and low conservation correctly predicted wild-type function in 80-90% of codons. These data validate our hypothesis that detailed evolutionary analyses help predict the consequences of missense amino-acid variants.	Univ Vermont, Vermont Canc Ctr, Dept Med, Burlington, VT 05401 USA; Univ Vermont, Vermont Canc Ctr, Dept Pathol, Burlington, VT 05401 USA; Univ Vermont, Vermont Canc Ctr, Dept Microbiol & Med Genet, Burlington, VT 05401 USA	University of Vermont; University of Vermont; University of Vermont	Greenblatt, MS (corresponding author), IV VT, Hematol Oncol Unit, UHC Campus,St Joseph 3210, Burlington, VT 05401 USA.	marc.greenblatt@vtmednet.org			NATIONAL CANCER INSTITUTE [P30CA022435] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA22435] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOTTEMA CDK, 1991, AM J HUM GENET, V49, P820; Ciotti P, 2000, AM J HUM GENET, V67, P311, DOI 10.1086/303001; FITCH WM, 1971, SYST ZOOL, V20, P406, DOI 10.2307/2412116; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Greenblatt MS, 2001, CANCER RES, V61, P4092; Greenblatt MS, 1996, CANCER RES, V56, P2130; HENIKOFF S, 1993, PROTEINS, V17, P49, DOI 10.1002/prot.340170108; INA Y, 1995, J MOL EVOL, V40, P190, DOI 10.1007/BF00167113; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Li W. H, 1997, MOL EVOLUTION; Makalowski W, 1998, P NATL ACAD SCI USA, V95, P9407, DOI 10.1073/pnas.95.16.9407; Miller MP, 2001, HUM MOL GENET, V10, P2319, DOI 10.1093/hmg/10.21.2319; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; Ruas M, 1999, ONCOGENE, V18, P5423, DOI 10.1038/sj.onc.1202918; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; SmithSorensen B, 1996, HUM MUTAT, V7, P294, DOI 10.1002/(SICI)1098-1004(1996)7:4<294::AID-HUMU2>3.0.CO;2-9; WACEY AI, 1994, HUM GENET, V94, P594; Walker DR, 1999, ONCOGENE, V18, P211, DOI 10.1038/sj.onc.1202298; Walker GJ, 1999, INT J CANCER, V82, P305, DOI 10.1002/(SICI)1097-0215(19990719)82:2<305::AID-IJC24>3.0.CO;2-Z; Yang ZH, 1996, MOL BIOL EVOL, V13, P650, DOI 10.1093/oxfordjournals.molbev.a025625; Yang ZH, 1997, COMPUT APPL BIOSCI, V13, P555; Yarbrough WG, 1999, J NATL CANCER I, V91, P1569, DOI 10.1093/jnci/91.18.1569	25	65	65	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2003	22	8					1150	1163		10.1038/sj.onc.1206101	http://dx.doi.org/10.1038/sj.onc.1206101			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650EK	12606942				2022-12-28	WOS:000181249700004
J	Clarke, ID; Dirks, PB				Clarke, ID; Dirks, PB			Human brain tumor-derived PDGFR-alpha deletion mutant is transforming	ONCOGENE			English	Article						PDGFR-alpha; extracellular deletion; brain tumor; transformation	GROWTH-FACTOR RECEPTOR; SIMIAN SARCOMA-VIRUS; GLIOMA CELL-LINES; BETA-RECEPTOR; IN-VIVO; C-JUN; SIGNAL-TRANSDUCTION; HUMAN GLIOBLASTOMAS; V-SIS; MICE	Aberrant receptor tyrosine kinase signaling plays an important role in the molecular pathogenesis of brain tumors. We have been studying a previously identified human glioblastoma-derived PDGFR-alpha mutant that has an in-frame deletion in the extracellular domain, causing loss of exons 8 and 9 (PDGFR-alpha(Delta8,9)). In the primary tumor, this deletion mutant receptor was shown to be amplified and overexpressed. The purpose of this study was to determine the expression, activity, localization, and transformation properties of this deletion mutant. In the absence of serum, or PDGF-AA, PDGFR-alpha(Delta8,9) was phosphorylated on tyrosine residues, indicating ligand-independent autoactivation. Localization by staining and cell surface biotinylation studies revealed expression of the deletion mutant predominantly in the cytoplasm, with very little present on the cell surface. To determine if PDGFR-alpha(Delta8,9) was oncogenic, we transfected wild-type and mutant receptors into Rat1 cells and performed analyses of cell growth, in vitro transformation, and subcutaneous growth in the nude mouse. PDGFR-alpha(Delta8,9)-expressing cells displayed enhanced cell growth and survival in low serum, and formed foci in monolayer cultures. PDGFR-alpha(Delta8,9)-expressing Rat1 cells were also tumorigenic when injected subcutaneously into nude mice. Expression of PDGFR-alpha(Delta8,9) was also associated with increased c-Jun phosphorylation in the absence of PDGF ligand, demonstrating also that the mutant receptor is associated with altered intracellular signaling. These data demonstrate that PDGFR-alpha(Delta8,9) is transforming, and it is the first demonstration of a naturally occurring tumor-derived mutant PDGFR-alpha with oncogenic properties.	Univ Toronto, Div Neurosurg, Hosp Sick Children, Toronto, ON M5G 1X8, Canada; Univ Toronto, Program Dev Biol, Hosp Sick Children, Arthur & Sonia Labatt Brain Tumor Res Lab, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Dirks, PB (corresponding author), Univ Toronto, Div Neurosurg, Hosp Sick Children, 555 Univ Ave,Suite 1504, Toronto, ON M5G 1X8, Canada.							Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; BATRA SK, 1995, CELL GROWTH DIFFER, V6, P1251; Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; BEJCEK BE, 1992, J BIOL CHEM, V267, P3289; BEJECK BE, 1989, SCIENCE, V245, P1496; Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588; Bostrom H, 1996, CELL, V85, P863, DOI 10.1016/S0092-8674(00)81270-2; Calver AR, 1998, NEURON, V20, P869, DOI 10.1016/S0896-6273(00)80469-9; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; CLARKE MF, 1984, NATURE, V308, P464, DOI 10.1038/308464a0; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; DeMali KA, 1997, J BIOL CHEM, V272, P9011; Di Rocco F, 1998, NEUROSURGERY, V42, P341, DOI 10.1097/00006123-199802000-00080; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; Feldkamp MM, 1999, NEUROSURGERY, V45, P1442, DOI 10.1097/00006123-199912000-00034; FLEMING TP, 1992, CANCER RES, V52, P4550; Fruttiger M, 1999, DEVELOPMENT, V126, P457; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; KIM HRC, 1994, J BIOL CHEM, V269, P30604; Kirsch M, 1997, J NEURO-ONCOL, V35, P289, DOI 10.1023/A:1005872718547; Klinghoffer RA, 2002, DEV CELL, V2, P103, DOI 10.1016/S1534-5807(01)00103-4; KUMABE T, 1992, ONCOGENE, V7, P627; LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; Lindahl P, 1997, DEVELOPMENT, V124, P3943; Lokker NA, 1997, J BIOL CHEM, V272, P33037, DOI 10.1074/jbc.272.52.33037; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; NISTER M, 1988, CANCER RES, V48, P3910; NISTER M, 1991, J BIOL CHEM, V266, P16755; Omura T, 1997, J BIOL CHEM, V272, P12676, DOI 10.1074/jbc.272.19.12676; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PETTI L, 1994, J VIROL, V68, P3582, DOI 10.1128/JVI.68.6.3582-3592.1994; PETTI L, 1992, P NATL ACAD SCI USA, V89, P6736, DOI 10.1073/pnas.89.15.6736; Petti LM, 1997, J VIROL, V71, P7318, DOI 10.1128/JVI.71.10.7318-7327.1997; Shoshan Y, 1999, P NATL ACAD SCI USA, V96, P10361, DOI 10.1073/pnas.96.18.10361; Soriano P, 1997, DEVELOPMENT, V124, P2691; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; Uhrbom L, 1998, CANCER RES, V58, P5275; Uren A, 1996, J BIOL CHEM, V271, P11051, DOI 10.1074/jbc.271.19.11051; VALGEIRSDOTTIR S, 1995, J BIOL CHEM, V270, P10161, DOI 10.1074/jbc.270.17.10161; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WESTERMARK B, 1995, GLIA, V15, P257, DOI 10.1002/glia.440150307; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; YU JC, 1994, J BIOL CHEM, V269, P10668; YU JC, 1994, J CELL BIOL, V127, P479, DOI 10.1083/jcb.127.2.479	55	78	80	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 6	2003	22	5					722	733		10.1038/sj.onc.1206160	http://dx.doi.org/10.1038/sj.onc.1206160			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569364				2022-12-28	WOS:000180642100009
J	Tauchi, H; Matsuura, S; Kobayashi, J; Sakamoto, S; Komatsu, K				Tauchi, H; Matsuura, S; Kobayashi, J; Sakamoto, S; Komatsu, K			Nijmegen breakage syndrome gene, NBS1, and molecular links to factors for genome stability	ONCOGENE			English	Review						Nijmegen breakage syndrome; NBS1; Mre11; histone H2AX; double-strand break; two-step binding model	DOUBLE-STRAND BREAKS; DNA-DAMAGE RESPONSE; ATAXIA-TELANGIECTASIA GENE; VERTEBRATE CELLS; MRE11 COMPLEX; NO EVIDENCE; S-PHASE; HOMOLOGOUS RECOMBINATION; CHROMOSOMAL INSTABILITY; V(D)J RECOMBINATION	DNA double-strand breaks represent the most potentially serious damage to a genome and hence, at least two pathways of DNA repair have evolved; namely, homologous recombination repair and non-homologous end joining. Defects in both rejoining processes result in genomic instability including chromosome rearrangements, LOH and gene mutations, which may lead to development of malignancies. Nijmegen breakage syndrome is a recessive genetic disorder, characterized by elevated sensitivity to ionizing radiation that induces double-strand breaks, and high frequency of malignancies. NBS1, the product of the gene underlying the disease, forms a multimeric complex with hMRE11/ hRAD50 nuclease and recruits them to the vicinity of sites of DNA damage by direct binding to phosphorylated histone H2AX. The combination of the highly-conserved NBS1 forkhead associated domain and BRCA1 C-terminus domain has a crucial role for recognition of damaged sites. Thereafter, the NBS1-complex proceeds to rejoin double-strand breaks predominantly by homologous recombination repair in vertebrates. This process collaborates with cell-cycle checkpoints at S and G2 phase to facilitate DNA repair. NBS1 is also associated with telomere maintenance and DNA replication. Based on recent knowledge regarding NBS1, we propose here a two-step binding mechanism for damage recognition by repair proteins, and describe the molecular links to factors for genome stability.	Kyoto Univ, Ctr Radiat Biol, Kyoto 6068501, Japan; Ibaraki Univ, Dept Environm Sci, Mito, Ibaraki 3108512, Japan; Hiroshima Univ, Res Inst Radiat Biol & Med, Hiroshima 7348553, Japan; Hiroshima Univ, Dept Oral & Maxillo Facial Radiol, Hiroshima 7348553, Japan	Kyoto University; Ibaraki University; Hiroshima University; Hiroshima University	Komatsu, K (corresponding author), Kyoto Univ, Ctr Radiat Biol, Kyoto 6068501, Japan.	komatsu@house.rbc.kyoto-u.ac.jp	Matsuura, Shinya/U-4182-2017; Kobayashi, Junya/AAX-6390-2021	Matsuura, Shinya/0000-0001-5294-081X; Kobayashi, Junya/0000-0003-4645-7500; Sakamoto, Shuichi/0000-0001-9396-9475				Antoccia A, 1999, INT J RADIAT BIOL, V75, P583; Bassing CH, 2002, P NATL ACAD SCI USA, V99, P8173, DOI 10.1073/pnas.122228699; Beamish H, 2002, J BIOL CHEM, V277, P30515, DOI 10.1074/jbc.M203801200; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; Bullrich F, 1999, CANCER RES, V59, P24; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Buscemi G, 2001, MOL CELL BIOL, V21, P5214, DOI 10.1128/MCB.21.15.5214-5222.2001; Carlomagno F, 1999, GENE CHROMOSOME CANC, V25, P393, DOI 10.1002/(SICI)1098-2264(199908)25:4<393::AID-GCC12>3.0.CO;2-8; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Cerosaletti KM, 1998, AM J HUM GENET, V63, P125, DOI 10.1086/301927; Chen C, 1999, NAT GENET, V23, P81, DOI 10.1038/12687; Chen HT, 2000, SCIENCE, V290, P1962, DOI 10.1126/science.290.5498.1962; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; D'Amours D, 2001, GENE DEV, V15, P2238, DOI 10.1101/gad.208701; Daoudal-Cotterell S, 2002, FEBS LETT, V516, P164, DOI 10.1016/S0014-5793(02)02536-X; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; de Jager M, 2001, NUCLEIC ACIDS RES, V29, P1317, DOI 10.1093/nar/29.6.1317; De Lange T, 2000, COLD SPRING HARB SYM, V65, P265, DOI 10.1101/sqb.2000.65.265; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Desai-Mehta A, 2001, MOL CELL BIOL, V21, P2184, DOI 10.1128/MCB.21.6.2184-2191.2001; Dong ZW, 1999, J BIOL CHEM, V274, P19513, DOI 10.1074/jbc.274.28.19513; Downs JA, 2000, NATURE, V408, P1001, DOI 10.1038/35050000; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; Ehrenstein MR, 2001, P NATL ACAD SCI USA, V98, P14553, DOI 10.1073/pnas.241525998; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Ferguson DO, 2001, ONCOGENE, V20, P5572, DOI 10.1038/sj.onc.1204767; Franchitto A, 2002, J CELL BIOL, V157, P19, DOI 10.1083/jcb.200110009; Giannini G, 2002, EMBO REP, V3, P248, DOI 10.1093/embo-reports/kvf044; Girard PM, 2002, ONCOGENE, V21, P4191, DOI 10.1038/sj.onc.1205596; Grenon M, 2001, NAT CELL BIOL, V3, P844, DOI 10.1038/ncb0901-844; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; Hall E.J, 1978, RADIOBIOLOGY RADIOLO, V1st; Hama S, 2000, ANTICANCER RES, V20, P1897; Harfst E, 2000, MOL IMMUNOL, V37, P915, DOI 10.1016/S0161-5890(01)00008-6; HERNANDEZ D, 1993, J MED GENET, V30, P135, DOI 10.1136/jmg.30.2.135; Hiel JA, 2000, ARCH DIS CHILD, V82, P400; Hopfner KP, 2000, J BACTERIOL, V182, P6036, DOI 10.1128/JB.182.21.6036-6041.2000; Hopfner KP, 2002, NATURE, V418, P562, DOI 10.1038/nature00922; Huang JR, 2002, NUCLEIC ACIDS RES, V30, P667, DOI 10.1093/nar/30.3.667; Ito A, 1999, BIOCHEM BIOPH RES CO, V265, P716, DOI 10.1006/bbrc.1999.1737; Johnson RD, 2000, EMBO J, V19, P3398, DOI 10.1093/emboj/19.13.3398; Kang J, 2002, EMBO J, V21, P1447, DOI 10.1093/emboj/21.6.1447; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; KIM J, 2002, IN PRESS J BIOL CHEM; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Klein C, 1996, MOVEMENT DISORD, V11, P217, DOI 10.1002/mds.870110217; Kobayashi J, 2002, CURR BIOL, V12, P1846, DOI 10.1016/S0960-9822(02)01259-9; KOMATSU K, 1995, CANCER RES, V55, P1774; KOMATSU K, 1989, INT J RADIAT BIOL, V56, P863, DOI 10.1080/09553008914552331; Komatsu K, 1996, AM J HUM GENET, V58, P885; KOMATSU K, 1993, INT J RADIAT BIOL, V63, P725, DOI 10.1080/09553009314552121; Kraakman-van der Zwet M, 2001, MUTAT RES-DNA REPAIR, V485, P177, DOI 10.1016/S0921-8777(00)00078-1; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Limoli CL, 2002, P NATL ACAD SCI USA, V99, P233, DOI 10.1073/pnas.231611798; Lo AWI, 2002, MOL CELL BIOL, V22, P4836, DOI 10.1128/MCB.22.13.4836-4850.2002; Mahadevaiah SK, 2001, NAT GENET, V27, P271, DOI 10.1038/85830; Manis JP, 2002, IMMUNITY, V16, P607, DOI 10.1016/S1074-7613(02)00306-0; Maraschio P, 2001, J MED GENET, V38, P113, DOI 10.1136/jmg.38.2.113; Maser RS, 2001, MOL CELL BIOL, V21, P6006, DOI 10.1128/MCB.21.17.6006-6016.2001; Maser RS, 2001, NAT GENET, V27, P417, DOI 10.1038/86920; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuura K, 1998, BIOCHEM BIOPH RES CO, V242, P602, DOI 10.1006/bbrc.1997.7924; Matsuura S, 1998, NAT GENET, V19, P179, DOI 10.1038/549; Matsuura S, 1997, AM J HUM GENET, V60, P1487, DOI 10.1086/515461; Metcalfe JA, 1996, NAT GENET, V13, P350, DOI 10.1038/ng0796-350; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Modesti M, 2001, CURR BIOL, V11, pR229, DOI 10.1016/S0960-9822(01)00112-9; Neubauer S, 2002, RADIAT RES, V157, P312, DOI 10.1667/0033-7587(2002)157[0312:ROATAN]2.0.CO;2; Ohta K, 1998, P NATL ACAD SCI USA, V95, P646, DOI 10.1073/pnas.95.2.646; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; Pan Q, 2002, EUR J IMMUNOL, V32, P1300, DOI 10.1002/1521-4141(200205)32:5<1300::AID-IMMU1300>3.0.CO;2-L; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Petersen S, 2001, NATURE, V414, P660, DOI 10.1038/414660a; Petrini JHJ, 2000, CURR OPIN CELL BIOL, V12, P293, DOI 10.1016/S0955-0674(00)00091-0; Ranganathan V, 2001, CURR BIOL, V11, P962, DOI 10.1016/S0960-9822(01)00267-6; Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4; Resnick IB, 2002, J PEDIATR-US, V140, P355, DOI 10.1067/mpd.2002.122724; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Saar K, 1997, AM J HUM GENET, V60, P605; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; SEEMANOVA E, 1990, MUTAT RES, V238, P321, DOI 10.1016/0165-1110(90)90024-6; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; Stanulla M, 2000, BRIT J HAEMATOL, V109, P117, DOI 10.1046/j.1365-2141.2000.01973.x; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Stilgenbauer S, 1997, NAT MED, V3, P1155, DOI 10.1038/nm1097-1155; Stumm P, 2001, CANCER GENET CYTOGEN, V126, P60, DOI 10.1016/S0165-4608(00)00390-3; Takata M, 2000, MOL CELL BIOL, V20, P6476, DOI 10.1128/MCB.20.17.6476-6482.2000; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Taniguchi T, 2002, CELL, V109, P459, DOI 10.1016/S0092-8674(02)00747-X; Tauchi H, 2002, NATURE, V420, P93, DOI 10.1038/nature01125; Tauchi H, 2001, J BIOL CHEM, V276, P12, DOI 10.1074/jbc.C000578200; Tauchi H, 1999, GENOMICS, V55, P242, DOI 10.1006/geno.1998.5657; van Engelen BGM, 2001, HUM IMMUNOL, V62, P1324, DOI 10.1016/S0198-8859(01)00345-7; vanderBurgt I, 1996, J MED GENET, V33, P153, DOI 10.1136/jmg.33.2.153; Varon R, 2000, EUR J HUM GENET, V8, P900, DOI 10.1038/sj.ejhg.5200554; Varon R, 2001, CANCER RES, V61, P3570; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Vorechovsky I, 1997, NAT GENET, V17, P96, DOI 10.1038/ng0997-96; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; WEEMAES CMR, 1981, ACTA PAEDIATR SCAND, V70, P557, DOI 10.1111/j.1651-2227.1981.tb05740.x; Wilda M, 2000, HUM MOL GENET, V9, P1739, DOI 10.1093/hmg/9.12.1739; Williams BR, 2002, CURR BIOL, V12, P648, DOI 10.1016/S0960-9822(02)00763-7; Wim JM, 1997, MOL CELL BIOL, V17, P5016, DOI 10.1128/MCB.17.9.5016; Wu GK, 2000, J BIOL CHEM, V275, P30618, DOI 10.1074/jbc.C000390200; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Yamaguchi-Iwai Y, 1999, EMBO J, V18, P6619, DOI 10.1093/emboj/18.23.6619; Yamane K, 2002, MOL CELL BIOL, V22, P555, DOI 10.1128/MCB.22.2.555-566.2002; Yamazaki V, 1998, CANCER RES, V58, P2316; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747; Zhu J, 2001, CURR BIOL, V11, P105, DOI 10.1016/S0960-9822(01)00019-7; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139	116	144	154	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2002	21	58					8967	8980		10.1038/sj.onc.1206136	http://dx.doi.org/10.1038/sj.onc.1206136			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	626TP	12483513				2022-12-28	WOS:000179889500008
J	Astrinidis, A; Cash, TP; Hunter, DS; Walker, CL; Chernoff, J; Henske, EP				Astrinidis, A; Cash, TP; Hunter, DS; Walker, CL; Chernoff, J; Henske, EP			Tuberin, the tuberous sclerosis complex 2 tumor suppressor gene product, regulates Rho activation, cell adhesion and migration	ONCOGENE			English	Article						tuberous sclerosis complex; TSC2; tuberin; RhoA; cell migration; cell attachment	TSC1 GENE; EKER RAT; TYROSINE PHOSPHORYLATION; GROWTH-FACTOR; KINASE GENE; GTPASE-RHO; HAMARTIN; PROLIFERATION; EXPRESSION; CANCER	Tuberous sclerosis complex (TSC) is a tumor suppressor gene syndrome characterized by seizures, mental retardation, autism, and tumors of the brain, kidney, heart, retina, and skin. TSC is caused by mutations in either TSC1 or TSC2, both of which are tumor suppressor genes. Hamartin, the protein product of TSC1, was found to interact with the ezrin-radixin-moesin family of cytoskeletal proteins and to activate the small GTPase Rho. To determine whether tuberin, the TSC2 product, can also activate Rho, we stably expressed full-length human tuberin in two cell types: MDCK cells and ELT3 cells. ELT3 cells lack endogenous tuberin expression. We found that expression of human tuberin in both MDCK and ELT3 cells was associated with an increase in the amount of Rho-GTP, but not in Rac1-GTP or cdc42-GTP. Tuberin expression increased cell adhesion in both cell types, and decreased chemotactic cell migration in ELT3 cells. In MDCK cells, there was a decrease in the amount of total Focal Adhesion Kinase (FAK) and an increase in the fraction of phosphorylated FAK. These findings demonstrate for the first time that tuberin activates Rho and regulates cell adhesion and migration. Pathways involving Rho activation may have relevance to the clinical manifestations of TSC, including pulmonary lymphangioleiomyomatosis.	Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; Univ Texas, MD Anderson Canc Ctr, Smithville, TX 78957 USA	Fox Chase Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Henske, EP (corresponding author), Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA.		Astreinidis, Aristotelis/AAK-5137-2020; Chernoff, Jonathan/I-7631-2014; Astreinidis, Aristotelis/ABA-6715-2021; Astrinidis, Aristotelis/A-1396-2010	Chernoff, Jonathan/0000-0002-4803-7836; Astrinidis, Aristotelis/0000-0001-7098-1391	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK051052, R01DK051052] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 60746] Funding Source: Medline; NIDDK NIH HHS [DK 51052] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agochiya M, 1999, ONCOGENE, V18, P5646, DOI 10.1038/sj.onc.1202957; Benvenuto G, 2000, ONCOGENE, V19, P6306, DOI 10.1038/sj.onc.1204009; Bobak D, 1997, ONCOGENE, V15, P2179, DOI 10.1038/sj.onc.1201396; BONIFACINO JS, 2001, CURRENT PROTOCOLS CE; Cance WG, 2000, CLIN CANCER RES, V6, P2417; Carsillo T, 2000, P NATL ACAD SCI USA, V97, P6085, DOI 10.1073/pnas.97.11.6085; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Dabora SL, 2001, AM J HUM GENET, V68, P64, DOI 10.1086/316951; Evers EE, 2000, EUR J CANCER, V36, P1269, DOI 10.1016/S0959-8049(00)00091-5; Flinn HM, 1996, J CELL SCI, V109, P1133; Gomez M. R., 1999, TUBEROUS SCLEROSIS C; Henry KW, 1998, J BIOL CHEM, V273, P20535, DOI 10.1074/jbc.273.32.20535; Hodges AK, 2001, HUM MOL GENET, V10, P2899, DOI 10.1093/hmg/10.25.2899; HOWE SR, 1995, AM J PATHOL, V146, P1568; Ilic D, 1997, J CELL SCI, V110, P401; Irani C, 2002, AM J PHYSIOL-LUNG C, V282, pL854, DOI 10.1152/ajplung.00291.2001; Ito N, 1999, CELL, V96, P529, DOI 10.1016/S0092-8674(00)80657-1; Judson PL, 1999, CANCER, V86, P1551, DOI 10.1002/(SICI)1097-0142(19991015)86:6<1551::AID-CNCR23>3.0.CO;2-P; KOBAYASHI T, 1995, NAT GENET, V9, P70, DOI 10.1038/ng0195-70; Kornberg LJ, 1998, HEAD NECK-J SCI SPEC, V20, P745, DOI 10.1002/(SICI)1097-0347(199812)20:8<745::AID-HED14>3.0.CO;2-Z; Lamb RF, 2000, NAT CELL BIOL, V2, P281, DOI 10.1038/35010550; Miloloza A, 2000, HUM MOL GENET, V9, P1721, DOI 10.1093/hmg/9.12.1721; Nellist M, 2001, HUM MOL GENET, V10, P2889, DOI 10.1093/hmg/10.25.2889; NELLIST M, 1993, CELL, V75, P1305; Plank TL, 1998, CANCER RES, V58, P4766; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; Sastry SK, 2000, EXP CELL RES, V261, P25, DOI 10.1006/excr.2000.5043; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Sinnett-Smith J, 2001, EXP CELL RES, V266, P292, DOI 10.1006/excr.2001.5219; Soucek T, 1997, J BIOL CHEM, V272, P29301, DOI 10.1074/jbc.272.46.29301; Sullivan EJ, 1998, CHEST, V114, P1689, DOI 10.1378/chest.114.6.1689; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Timpson P, 2001, CURR BIOL, V11, P1836, DOI 10.1016/S0960-9822(01)00583-8; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413; YEUNG RS, 1995, MOL CARCINOGEN, V14, P28, DOI 10.1002/mc.2940140107; Yu J, 2001, AM J RESP CRIT CARE, V164, P1537, DOI 10.1164/ajrccm.164.8.2104095	44	116	117	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 5	2002	21	55					8470	8476		10.1038/sj.onc.1205962	http://dx.doi.org/10.1038/sj.onc.1205962			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466966				2022-12-28	WOS:000179480100009
J	Sugimoto, M; Martin, N; Wilks, DP; Tamai, K; Huot, TJG; Pantoja, C; Okumura, K; Serrano, M; Hara, E				Sugimoto, M; Martin, N; Wilks, DP; Tamai, K; Huot, TJG; Pantoja, C; Okumura, K; Serrano, M; Hara, E			Activation of cyclin DI-kinase in murine fibroblasts lacking both p21(Cip1) and P27(Kip1)	ONCOGENE			English	Article						cyclin D1; CDK4; p21(Cip1); p27(Kip1); cell cycle	D-DEPENDENT KINASES; POTENTIAL MEDIATOR; DIRECT INHIBITION; CDK4; PROTEIN; P21; PHOSPHORYLATION; EXPRESSION; P16(INK4A); CELLS	Deregulation of D-type cyclin-dependent kinases (CDK4 and 6) is widely observed in various human cancers, illustrating their importance in cell cycle control. Like other cyclin-dependent kinases (CDKs), assembly with cyclins is the most critical step for activation of CDK4/6. As previously reported elsewhere, we observed that the level of cyclinD1-CDK4 complex and its associated kinase activity were significantly low in asynchronously proliferating mouse embryo fibroblasts lacking both p21(Cip1) and p27(Kip1) (p21/p27-null MEFs). These evidences imply, that p21(Cip1) and p27(Kip1) CDK inhibitors are 'essential activators' of cyclin D-kinases. We, however, discovered here that both the assembly and activation of cyclin D1-CDK4 complex occur when quiescent p21/p27-null MEFs were stimulated to re-enter the cell cycle. This mitogen-induced cyclin D1-kinase activity was blocked by overexpression of p16(INK4a) and resulted in the inhibition of S phase entry in p21/p27-null MEFs. Furthermore, ectopic expression of p34(SEI-1), a mitogen-induced CDK4 binding protein, increased the levels of active cyclinD1-CDK4 complex in asynchronously proliferating p21/p27-null MEFs. Together, our results suggest that there are several independent ways to stimulate the assembly of cyclin D1-CDK4 kinases. Although p21(Cip1) and p27(Kip1) play a role in this process, our results demonstrate that additional mechanisms must occur in G0 to S phase transition.	Christie Hosp NHS Trust, Paterson Inst Canc Res, Canc Res UK, Manchester M20 4BX, Lancs, England; Med & Biol Labs Co Ltd, Nagano 3960002, Japan; London Res Inst, Canc Res UK, London WC2A 3PX, England; Natl Biotechnol Ctr, Dept Immunol & Oncol, E-28049 Madrid, Spain; Juntendo Univ, Sch Med, Dept Immunol, Tokyo 1138421, Japan; Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Manchester M60 1QD, Lancs, England	Cancer Research UK; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; University of Manchester; Cancer Research UK; Juntendo University; University of Manchester	Hara, E (corresponding author), Christie Hosp NHS Trust, Paterson Inst Canc Res, Canc Res UK, Manchester M20 4BX, Lancs, England.	Ehara@pier.man.ac.uk	Tamai, Katsuyuki/F-4743-2013; Serrano, Manuel/H-2634-2015	Tamai, Katsuyuki/0000-0003-4094-3911; Serrano, Manuel/0000-0001-7177-9312; Sugimoto, Masataka/0000-0001-8737-8097; Pantoja, Cristina/0000-0003-0180-5823				Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Bagui TK, 2000, MOL CELL BIOL, V20, P8748, DOI 10.1128/MCB.20.23.8748-8757.2000; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; Bruce JL, 2000, MOL CELL, V6, P737, DOI 10.1016/S1097-2765(00)00072-1; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Dong F, 1998, MOL BIOL CELL, V9, P2081, DOI 10.1091/mbc.9.8.2081; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Hansen K, 2001, EMBO J, V20, P422, DOI 10.1093/emboj/20.3.422; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HARPER JW, 1993, CELL, V75, P805; Hsu SIH, 2001, EMBO J, V20, P2273, DOI 10.1093/emboj/20.9.2273; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Latella L, 2001, MOL CELL BIOL, V21, P5631, DOI 10.1128/MCB.21.16.5631-5643.2001; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; Mitra J, 1999, MOL CELL BIOL, V19, P3916; Morisaki H, 1999, EXP CELL RES, V253, P503, DOI 10.1006/excr.1999.4698; Muraoka RS, 2002, MOL CELL BIOL, V22, P2204, DOI 10.1128/MCB.22.7.2204-2219.2002; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; Parry D, 1999, MOL CELL BIOL, V19, P1775; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Rane SG, 2002, MOL CELL BIOL, V22, P644, DOI 10.1128/MCB.22.2.644-656.2002; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Schreiber M, 1999, ONCOGENE, V18, P1663, DOI 10.1038/sj.onc.1202466; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; Sotillo R, 2001, P NATL ACAD SCI USA, V98, P13312, DOI 10.1073/pnas.241338598; Sotillo R, 2001, EMBO J, V20, P6637, DOI 10.1093/emboj/20.23.6637; Sugimoto M, 1999, GENE DEV, V13, P3027, DOI 10.1101/gad.13.22.3027; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; Wang HM, 2002, EMBO J, V21, P930, DOI 10.1093/emboj/21.5.930; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zhang JM, 1999, EMBO J, V18, P6983, DOI 10.1093/emboj/18.24.6983	45	62	68	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2002	21	53					8067	8074		10.1038/sj.onc.1206019	http://dx.doi.org/10.1038/sj.onc.1206019			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615DW	12444543				2022-12-28	WOS:000179231400001
J	Klein, A; Guhl, E; Tzeng, YJ; Fuhrhop, J; Levrero, M; Graessmann, M; Graessmann, A				Klein, A; Guhl, E; Tzeng, YJ; Fuhrhop, J; Levrero, M; Graessmann, M; Graessmann, A			HBX causes cyclin D1 overexpression and development of breast cancer in transgenic animals that are heterozygous for p53	ONCOGENE			English	Article						HBX; transgenic animals; ME-cell immortalization; cyclin D1; differentiation; tumor formation	HEPATITIS-B VIRUS; CELLULAR DNA-REPAIR; X-PROTEIN; HEPATOCELLULAR-CARCINOMA; P53-INDUCED APOPTOSIS; GENE; MICE; ANTIGEN; LIVER; HEPATOCARCINOGENESIS	Transgenic mice, which selectively express the WAP-HBX transgene in mammary gland epithelial cells (ME-cells), were established in order to elucidate the consequences of HBX gene expression on organ differentiation, cell death program and tumor development. Transgene expression was demonstrable by RT-PCR, Northern and Western blot analysis during pregnancy, lactation and after weaning. HBX synthesis neither affect mammary gland differentiation nor apoptosis in ME-cells. Although breast cancer formation was rare in WAP-HBX animals (<1%), WAP-HBX.p53+/- hybrid animals developed breast tumors at an increased rate (12/85) after a latency period of 8-18 months. We also show here for the first time that HBX can immortalize ME-cells generated from mammary gland tissue segments in a p53-independent fashion. HBX causes cyclin D1 gene overexpression during early pregnancy, and this is maintained in ME-cells isolated either from mammary gland or from breast tumors. Intranuclear cyclin D1 accumulation also occurs in the absence of external growth factors and the BrdU incorporation rate remains high under serum starvation conditions. Finally, both cyclin D1 induction and HBX mitotic activity are dependent on p38 and c-Jun N-terminal kinase, but not on MEK-1 kinase activity.	Free Univ Berlin, Inst Mol Biol & Biochem, D-14195 Berlin, Germany; Tzu Chi Univ, Grad Inst Mol & Cell Biol, Hualien 970, Taiwan; Univ Roma La Sapienza, Fdn A Cesalpino, Gene Express Lab, I-00161 Rome, Italy	Free University of Berlin; Tzu Chi University; Sapienza University Rome	Graessmann, A (corresponding author), Free Univ Berlin, Inst Mol Biol & Biochem, Arnimallee 22, D-14195 Berlin, Germany.		Klein, Andreas/AAG-4506-2021; Levrero, Massimo/G-5680-2016	Klein, Andreas/0000-0002-3496-7215; Levrero, Massimo/0000-0002-4978-0875				Arbuthnot P, 2000, J GASTROEN HEPATOL, V15, P357, DOI 10.1046/j.1440-1746.2000.02069.x; BEASLEY RP, 1981, LANCET, V2, P1129; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; BRISON O, 1993, BIOCHIM BIOPHYS ACTA, V1155, P25, DOI 10.1016/0304-419X(93)90020-D; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; Diao JY, 2001, CYTOKINE GROWTH F R, V12, P189, DOI 10.1016/S1359-6101(00)00034-4; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DRAGANI TA, 1990, CARCINOGENESIS, V11, P953, DOI 10.1093/carcin/11.6.953; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; FEITELSON MA, 1993, ONCOGENE, V8, P1109; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Goetz F, 2001, ONCOGENE, V20, P2325, DOI 10.1038/sj.onc.1204355; Gottlob K, 1998, CANCER RES, V58, P3566; Gottlob K, 1998, J BIOL CHEM, V273, P33347, DOI 10.1074/jbc.273.50.33347; GRAESSMANN M, 1983, METHOD ENZYMOL, V101, P482; Huo TI, 2001, ONCOGENE, V20, P3620, DOI 10.1038/sj.onc.1204495; JEHN B, 1992, MOL CELL BIOL, V12, P3890, DOI 10.1128/MCB.12.9.3890; Joo M, 2001, LIVER, V21, P89, DOI 10.1034/j.1600-0676.2001.021002089.x; Kim YC, 1998, WATER SCI TECHNOL, V38, P1, DOI 10.1016/S0273-1223(98)00671-4; Kohzato N, 2001, HEPATOL RES, V21, P27, DOI 10.1016/S1386-6346(00)00150-9; Krause D, 2001, J BIOL CHEM, V276, P19244, DOI 10.1074/jbc.M008186200; Kumar V, 1996, P NATL ACAD SCI USA, V93, P5647, DOI 10.1073/pnas.93.11.5647; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; Madden CR, 2000, J VIROL, V74, P5266, DOI 10.1128/JVI.74.11.5266-5272.2000; Murakami S, 1999, INTERVIROLOGY, V42, P81, DOI 10.1159/000024969; NATOLI G, 1994, ONCOGENE, V9, P2837; Pollicino T, 1998, BIOMED PHARMACOTHER, V52, P363, DOI 10.1016/S0753-3322(99)80003-1; Sambrook J., 2002, MOL CLONING LAB MANU; Santarelli R, 1996, ONCOGENE, V12, P495; Siegel PM, 2000, BIOESSAYS, V22, P554, DOI 10.1002/(SICI)1521-1878(200006)22:6<554::AID-BIES8>3.0.CO;2-A; Sirma H, 1999, ONCOGENE, V18, P4848, DOI 10.1038/sj.onc.1202867; Slagle BL, 1996, MOL CARCINOGEN, V15, P261, DOI 10.1002/(SICI)1098-2744(199604)15:4<261::AID-MC3>3.0.CO;2-J; Su F, 2001, J VIROL, V75, P215, DOI 10.1128/JVI.75.1.215-225.2001; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; Terradillos O, 1998, ONCOGENE, V17, P2115, DOI 10.1038/sj.onc.1202432; Terradillos O, 2002, ONCOGENE, V21, P377, DOI 10.1038/sj.onc.1205110; Tzeng YJ, 1998, ONCOGENE, V16, P2103, DOI 10.1038/sj.onc.1201733; TZENG YJ, 1993, ONCOGENE, V8, P1965; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; WANG XW, 1995, CANCER RES, V55, P6012	45	35	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 15	2003	22	19					2910	2919		10.1038/sj.onc.1206539	http://dx.doi.org/10.1038/sj.onc.1206539			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771941				2022-12-28	WOS:000182824800005
J	Zhang, SL; Qian, XL; Redman, C; Bliskovski, V; Ramsay, ES; Lowy, DR; Mock, BA				Zhang, SL; Qian, XL; Redman, C; Bliskovski, V; Ramsay, ES; Lowy, DR; Mock, BA			p16(INK4a) gene promoter variation and differential binding of a repressor, the ras-responsive zinc-finger transcription factor, RREB	ONCOGENE			English	Article						p16 promoter; RREB; plasmacytoma; NIH 3T3	SUSCEPTIBILITY; PROTEIN; INDUCTION; P19(ARF); REGION; CDKN2A; PROLIFERATION; PLASMACYTOMAS; INTERLEUKIN-6; METHYLATION	BALB/c mice are susceptible to the development of pristane-induced plasma cell tumors, and have a rare allelic variant in the coding region of the p16(INK4a) (p16) tumor suppressor gene that produces a protein with impaired activity. We have now found that the BALB/c p16 promoter has an allelic variant that may also compromise p16 activity. Following pristane treatment, BALB/c p16 mRNA levels in B cells were lower than that in DBA/2 or C.D2-Petr1, a resistant BALB/c congenic strain that harbors DBA/2 chromatin surrounding the p16 locus. Four sequence variants were found between BALB/c and DBA/2 in the p16 promoter region. In reporter assays, the DBA promoter was at least four times more active in driving luciferase expression than the BALB/c promoter. Most of the difference in activity was localized to a single nucleotide deletion in BALB/c. This deletion created a consensus binding site for RREB, a ras-responsive transcriptional element with zinc-finger binding motifs. Transient transfections with RREB confirmed that the p16 promoter can be downregulated by RREB, in a Ras- or Mek-dependent manner, and that the BALB/c promoter is more sensitive than DBA/2 to regulation by RREB. BALB/c mice have both regulatory and coding region defects that may contribute to the impairment of p16 gene function.	NCI, Ctr Canc Res, Genet Lab, NIH, Bethesda, MD 20892 USA; NCI, Ctr Canc Res, Cellular Oncol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Mock, BA (corresponding author), NCI, Ctr Canc Res, Genet Lab, NIH, 37 COnvent Dr,MSC 4255,Bldg 37,Rm 2B-08, Bethesda, MD 20892 USA.	bev@helix.nih.gov	Mock, Beverly A/B-3110-2015	Mock, Beverly A/0000-0003-2479-4549	NATIONAL CANCER INSTITUTE [Z01BC008905, Z01BC010008, ZIABC008905, ZIABC010008] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; Anborgh PH, 1999, MOL CELL BIOL, V19, P4611; Baylin S, 2002, CANCER CELL, V1, P299, DOI 10.1016/S1535-6108(02)00061-2; BOTTORFF D, 1995, MOL CELL BIOL, V15, P5113; Brown RT, 1995, J BIOL CHEM, V270, P31129, DOI 10.1074/jbc.270.52.31129; Dilworth D, 2000, BLOOD, V95, P1869, DOI 10.1182/blood.V95.5.1869.005k09_1869_1871; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; Herzog CR, 1999, MOL CARCINOGEN, V25, P92, DOI 10.1002/(SICI)1098-2744(199906)25:2<92::AID-MC3>3.0.CO;2-2; HILBERT DM, 1995, J EXP MED, V182, P243, DOI 10.1084/jem.182.1.243; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kaneko S, 1999, BIOCHEM MOL BIOL INT, V47, P205; KATO J, 1993, GENE DEV, V7, P331; Klangby U, 1998, BLOOD, V91, P1680, DOI 10.1182/blood.V91.5.1680.1680_1680_1687; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Mock BA, 1997, BLOOD, V90, P4092, DOI 10.1182/blood.V90.10.4092; MOCK BA, 1993, P NATL ACAD SCI USA, V90, P9499, DOI 10.1073/pnas.90.20.9499; Morse HC, 1980, PROGR MYELOMA, P263; Myohanen S, 2001, J BIOL CHEM, V276, P1634, DOI 10.1074/jbc.M004481200; NORDAN RP, 1986, SCIENCE, V233, P566, DOI 10.1126/science.3726549; Ogata A, 1997, J IMMUNOL, V159, P2212; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; POTTER M, 1994, J NATL CANCER I, V86, P1058, DOI 10.1093/jnci/86.14.1058; POTTER M, 1962, NATURE, V193, P1086, DOI 10.1038/1931086a0; POTTER M, 1994, CANCER RES, V54, P969; POTTER M, 1984, CANCER SURV, V3, P247; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Soloff EV, 1996, GENE, V180, P213, DOI 10.1016/S0378-1119(96)00410-6; Taniai M, 2002, GASTROENTEROLOGY, V123, P1090, DOI 10.1053/gast.2002.36021; Thiagalingam A, 1996, MOL CELL BIOL, V16, P5335; Wang W, 2001, J BIOL CHEM, V276, P48655, DOI 10.1074/jbc.M108278200; Zhang SL, 1999, CURR TOP MICROBIOL, V246, P363; Zhang SL, 1998, P NATL ACAD SCI USA, V95, P2429, DOI 10.1073/pnas.95.5.2429; Zhang SL, 2001, MOL CELL BIOL, V21, P310, DOI 10.1128/MCB.21.1.310-318.2001	39	69	71	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2003	22	15					2285	2295		10.1038/sj.onc.1206257	http://dx.doi.org/10.1038/sj.onc.1206257			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	667KV	12700664				2022-12-28	WOS:000182231500007
J	Franchitto, A; Pichierri, P; Piergentili, R; Crescenzi, M; Bignami, M; Palitti, F				Franchitto, A; Pichierri, P; Piergentili, R; Crescenzi, M; Bignami, M; Palitti, F			The mammalian mismatch repair protein MSH2 is required for correct MRE11 and RAD51 relocalization and for efficient cell cycle arrest induced by ionizing radiation in G2 phase	ONCOGENE			English	Article						MSH2; mismatch repair; cell cycle arrest; DSB repair	STRAND BREAK REPAIR; SACCHAROMYCES-CEREVISIAE MSH2; DNA-DAMAGE; HOMOLOGOUS RECOMBINATION; VERTEBRATE CELLS; GENETIC-RECOMBINATION; NUCLEAR FOCI; HISTONE H2AX; IN-VITRO; S-PHASE	In yeast, MSH2 plays an important role in mismatch repair (MMR) and recombination, whereas the function of the mammalian MSH2 protein in recombinational repair is not completely established. We examined the cellular responses of MSH2-deficient mouse cells to X-rays to clarify the role of MSH2 in recombinational repair. Cell survival, checkpoint functions and relocalization of the recombination-related proteins MRE11 and RAD51 were analysed in embryonic fibroblasts derived from MSH2(+/+) and MSH2(-/-) mice, and in MSH2-proficient and deficient mouse colorectal carcinoma cells. Loss of MSH2 function was found to be associated with reduction in cell survival following radiation, absence of either MRE11 or RAD51 relocalization and a higher level of X-ray-induced chromosomal damage specifically in G2-phase cells. Finally, MSH2(-/-) cells showed an inefficient early G2/M checkpoint, being arrested only transiently after irradiation before progressing into mitosis. Consistent with the premature release from the G2-phase arrest, activation of CHK1 was transient and CHK2 was not phosphorylated in synchronized MSH2-null cells. Our data suggest that an active MSH2 is required for a correct response to ionizing radiation-induced DNA damage in the G2 phase of the cell cycle, possibly connecting DSB repair to checkpoint signalling.	Univ Tuscia, DABAC, Lab Citogenet Mol & Mutagenesi, I-01100 Viterbo, Italy; Ist Super Sanita, Tossicol Comparata & Ecotossicol Lab, I-00161 Rome, Italy	Tuscia University; Istituto Superiore di Sanita (ISS)	Palitti, F (corresponding author), Univ Tuscia, DABAC, Lab Citogenet Mol & Mutagenesi, Via S Camillo Lellis, I-01100 Viterbo, Italy.	palitti@unitus.it	Pichierri, Pietro/AAA-5476-2021; Crescenzi, Marco/J-3603-2018; Franchitto, Annapaola/K-7564-2016	Pichierri, Pietro/0000-0002-2702-3523; Crescenzi, Marco/0000-0003-0156-1494; Franchitto, Annapaola/0000-0003-4232-4727				Aebi S, 1996, CANCER RES, V56, P3087; ALANI E, 1994, GENETICS, V137, P19; Anthoney DA, 1996, CANCER RES, V56, P1374; Aquilina G, 1999, CARCINOGENESIS, V20, P2317, DOI 10.1093/carcin/20.12.2317; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Bellacosa A, 2001, CELL DEATH DIFFER, V8, P1076, DOI 10.1038/sj.cdd.4400948; Berry SE, 2001, SEMIN RADIAT ONCOL, V11, P300, DOI 10.1053/S1053-4296(01)80067-9; Boersma AWM, 1996, CYTOMETRY, V24, P123, DOI 10.1002/(SICI)1097-0320(19960601)24:2<123::AID-CYTO4>3.0.CO;2-K; BRADLEY MO, 1979, NUCLEIC ACIDS RES, V7, P793, DOI 10.1093/nar/7.3.793; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Chen WL, 1999, GENETICS, V151, P1299; Chen WL, 1998, MOL CELL BIOL, V18, P6525, DOI 10.1128/MCB.18.11.6525; Ciotta C, 1998, J MOL BIOL, V276, P705, DOI 10.1006/jmbi.1997.1559; Colussi C, 2002, CURR BIOL, V12, P912, DOI 10.1016/S0960-9822(02)00863-1; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; Datta A, 1996, MOL CELL BIOL, V16, P1085; Davis TW, 1998, CANCER RES, V58, P767; DeWeese TL, 1998, P NATL ACAD SCI USA, V95, P11915, DOI 10.1073/pnas.95.20.11915; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Elliott B, 2001, MOL CELL BIOL, V21, P2671, DOI 10.1128/MCB.21.8.2671-2682.2001; Evans E, 2000, MOL CELL, V5, P789, DOI 10.1016/S1097-2765(00)80319-6; Fiumicino S, 2000, INT J CANCER, V85, P590, DOI 10.1002/(SICI)1097-0215(20000215)85:4<590::AID-IJC23>3.0.CO;2-O; Franchitto A, 1998, MUTAGENESIS, V13, P499, DOI 10.1093/mutage/13.5.499; Fritzell JA, 1997, CANCER RES, V57, P5143; Fukushima T, 2001, J BIOL CHEM, V276, P44413, DOI 10.1074/jbc.M106295200; Furnari B, 1999, MOL BIOL CELL, V10, P833, DOI 10.1091/mbc.10.4.833; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Humbert O, 1999, CARCINOGENESIS, V20, P205, DOI 10.1093/carcin/20.2.205; HUTCHINSON F, 1985, PROG NUCLEIC ACID RE, V32, P115, DOI 10.1016/S0079-6603(08)60347-5; Jiricny J, 2000, CURR OPIN GENET DEV, V10, P157, DOI 10.1016/S0959-437X(00)00066-6; Jiricny J, 1998, MUTAT RES-DNA REPAIR, V409, P107, DOI 10.1016/S0921-8777(98)00056-1; Kaina B, 2001, PROG NUCLEIC ACID RE, V68, P41; Kanaar R, 1998, TRENDS CELL BIOL, V8, P483, DOI 10.1016/S0962-8924(98)01383-X; KARRAN P, 1994, BIOESSAYS, V16, P833, DOI 10.1002/bies.950161110; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Lowndes NF, 2000, CURR OPIN GENET DEV, V10, P17, DOI 10.1016/S0959-437X(99)00050-7; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Palitti F, 1999, INT J RADIAT BIOL, V75, P621, DOI 10.1080/095530099140267; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Pichierri P, 2001, CARCINOGENESIS, V22, P1781, DOI 10.1093/carcin/22.11.1781; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SAVAGE JRK, 1976, J MED GENET, V13, P103, DOI 10.1136/jmg.13.2.103; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sugawara N, 1997, P NATL ACAD SCI USA, V94, P9214, DOI 10.1073/pnas.94.17.9214; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Trujillo KM, 1998, J BIOL CHEM, V273, P21447, DOI 10.1074/jbc.273.34.21447; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; WORTH L, 1994, P NATL ACAD SCI USA, V91, P3238, DOI 10.1073/pnas.91.8.3238; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XXS, 2001, CANCER RES, V61, P3775; Yamaguchi-Iwai Y, 1999, EMBO J, V18, P6619, DOI 10.1093/emboj/18.23.6619; Yan T, 2001, CANCER RES, V61, P8290; Zeng M, 2000, CANCER RES, V60, P4889; Zhang H, 2000, CARCINOGENESIS, V21, P1639, DOI 10.1093/carcin/21.9.1639; Zink D, 2002, ONCOGENE, V21, P4788, DOI 10.1038/sj.onc.1205614	64	79	79	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2003	22	14					2110	2120		10.1038/sj.onc.1206254	http://dx.doi.org/10.1038/sj.onc.1206254			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664NJ	12687013				2022-12-28	WOS:000182066900005
J	Yamazaki, K; Sakamoto, M; Ohta, T; Kanai, Y; Ohki, M; Hirohashi, S				Yamazaki, K; Sakamoto, M; Ohta, T; Kanai, Y; Ohki, M; Hirohashi, S			Overexpression of KIT in chromophobe renal cell carcinoma	ONCOGENE			English	Article						gene-expression profiling; KIT; renal cell carcinoma	GASTROINTESTINAL STROMAL TUMORS; GROWTH-FACTOR RECEPTOR; C-KIT; TYROSINE KINASE; LUNG-CANCER; SUPPRESSOR PROTEIN; MET PROTOONCOGENE; CLASSIFICATION; MUTATIONS; GENE	We analysed gene-expression profiles in 15 surgical specimens of conventional, papillary, and chromophobe renal cell carcinomas (RCCs) using high-density oligonucleotide arrays. From about 12 000 genes targeted by the array, 67 were upregulated specifically in each histological type of RCC. The oncogene KIT was one of the genes whose expression was upregulated specifically in chromophobe RCCs. Immunohistochemical analysis demonstrated the KIT gene product on the cell membrane of chromophobe RCC in all cases, although it was not detected in conventional RCCs or non-neoplastic kidneys except for weak staining in the cytoplasm of renal tubules. These results suggest that each histological subtype of RCC has a unique gene-expression profile, and in particular indicates for the first time that KIT could be a useful marker for chromophobe RCC. As overexpression of KIT might be involved in tumor growth, KIT could be a new therapeutic target in this special type of RCC.	Keio Univ, Sch Med, Dept Pathol, Shinjuku Ku, Tokyo 1600016, Japan; Natl Canc Ctr, Res Inst, Canc Genom Div, Chuou Ku, Tokyo 1040045, Japan; Org Pharmaceut Safety & Res, Chiyoda Ku, Tokyo 1000013, Japan; Natl Canc Ctr, Res Inst, Div Pathol, Chuou Ku, Tokyo 1040045, Japan	Keio University; National Cancer Center - Japan; National Cancer Center - Japan	Sakamoto, M (corresponding author), Keio Univ, Sch Med, Dept Pathol, Shinjuku Ku, 35 Shinaimachi, Tokyo 1600016, Japan.		Kanai, Yae/AAE-6987-2019; Sakamoto, Michiie/N-2917-2015	Yamazaki, Ken/0000-0002-7220-7479				Caruana G, 1998, ONCOGENE, V16, P179, DOI 10.1038/sj.onc.1201494; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Dijkhuizen T, 1996, INT J CANCER, V68, P47, DOI 10.1002/(SICI)1097-0215(19960927)68:1<47::AID-IJC9>3.0.CO;2-X; FREEMAN MR, 1989, CANCER RES, V49, P6221; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; GNERRA JR, 1994, NAT GENET, V7, P85; HIBI K, 1991, ONCOGENE, V6, P2291; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; ISHIKAWA J, 1990, INT J CANCER, V45, P1018, DOI 10.1002/ijc.2910450606; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kenck C, 1996, J PATHOL, V179, P157, DOI 10.1002/(SICI)1096-9896(199606)179:2<157::AID-PATH557>3.0.CO;2-S; KOVACS A, 1992, GENE CHROMOSOME CANC, V4, P267, DOI 10.1002/gcc.2870040313; Kovacs G, 1997, J PATHOL, V183, P131, DOI 10.1002/(SICI)1096-9896(199710)183:2<131::AID-PATH931>3.0.CO;2-G; Krystal GW, 2000, CLIN CANCER RES, V6, P3319; Nakopoulou L, 1997, PATHOL RES PRACT, V193, P299; Natali PG, 1996, INT J CANCER, V69, P212, DOI 10.1002/(SICI)1097-0215(19960621)69:3<212::AID-IJC11>3.0.CO;2-9; Nishida T, 1998, NAT GENET, V19, P323, DOI 10.1038/1209; Rubin BP, 2001, CANCER RES, V61, P8118; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schmidt L, 1999, ONCOGENE, V18, P2343, DOI 10.1038/sj.onc.1202547; Semenza GL, 2000, CRIT REV BIOCHEM MOL, V35, P71, DOI 10.1080/10409230091169186; SPEICHER MR, 1994, AM J PATHOL, V145, P356; Storkel S, 1997, CANCER, V80, P987, DOI 10.1002/(SICI)1097-0142(19970901)80:5<987::AID-CNCR24>3.0.CO;2-R; Takahashi M, 2001, P NATL ACAD SCI USA, V98, P9754, DOI 10.1073/pnas.171209998; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; THOENES W, 1986, PATHOL RES PRACT, V181, P125, DOI 10.1016/S0344-0338(86)80001-2; Tuveson DA, 2001, ONCOGENE, V20, P5054, DOI 10.1038/sj.onc.1204704; Wang WL, 2000, ONCOGENE, V19, P3521, DOI 10.1038/sj.onc.1203698; Young AN, 2001, AM J PATHOL, V158, P1639, DOI 10.1016/S0002-9440(10)64120-X	29	131	139	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 13	2003	22	6					847	852		10.1038/sj.onc.1206153	http://dx.doi.org/10.1038/sj.onc.1206153			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584564				2022-12-28	WOS:000180864300007
J	Heinrichs, S; Deppert, W				Heinrichs, S; Deppert, W			Apoptosis or growth arrest: modulation of the cellular response to p53 by proliferative signals	ONCOGENE			English	Article						p53; p21; apoptosis; growth arrest; lymphoid tumors	NF-KAPPA-B; WILD-TYPE P53; MITOCHONDRIAL PERMEABILITY TRANSITION; KINASE C-THETA; P53-MEDIATED APOPTOSIS; BCL-X; P53-DEPENDENT APOPTOSIS; CALCIUM IONOPHORES; PHORBOL ESTER; CYCLE ARREST	Activation of the tumor suppressor p53 after genotoxic insults may result in two different responses: growth arrest or apoptosis. In this study, we analysed how mitogenic stimulation of primary mouse lymphocytes influences p53 signaling upon gamma-irradiation. We found that Go lymphocytes rapidly went into p53-dependent apoptosis, whereas stimulated lymphocytes went into a p53-dependent, p21-mediated growth arrest. The switch in p53 response upon stimulation did neither result from a switch in transcriptional activation of major p53 target genes, nor from the high level of p21 expressed in stimulated, irradiated cells. Growth stimulation, however, led to the upregulation of the antiapoptotic factors Bcl-x(L) and Bfl-1. In resting cells, p53 induced apoptosis after gamma-irradiation was accompanied by a breakdown of the mitochondrial membrane potential (Psi(m)) that was counteracted by growth stimulation. We propose that growth stimulation intercepted p53 proapoptotic signaling at the level of mitochondrial integrity, most likely by upregulating the antiapoptotic factors Bcl-x(L) and Bfl-1. Upregulation of Bcl-x(L) and of Bfl-1 upon growth stimulation was mediated by the PKC-dependent activation of NF-kappaB. Consequently, blocking PKC activity restored apoptosis in stimulated, irradiated splenocytes. The inherent coupling of growth stimulation with antiapoptotic signaling in primary lymphocytes might provide hints as to how precancerous lymphocytes bypass the need for mutational inactivation of p53. Thus, our findings might explain the relatively low frequency of p53 mutations in lymphomas in comparison to other tumor entities.	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany	Heinrich Pette Institute; University of Hamburg	Deppert, W (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.							ABRAHAMSON JLA, 1995, MOL CELL BIOL, V15, P6953; Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Bissonnette N, 1998, ONCOGENE, V16, P3461, DOI 10.1038/sj.onc.1201899; BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; BROOME HE, 1995, J IMMUNOL, V155, P2311; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; Castedo M, 1996, J IMMUNOL, V157, P512; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chattopadhyay D, 2001, J VIROL, V75, P9844, DOI 10.1128/JVI.75.20.9844-9856.2001; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CHOI MSK, 1995, EUR J IMMUNOL, V25, P1352, DOI 10.1002/eji.1830250533; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coudronniere N, 2000, P NATL ACAD SCI USA, V97, P3394, DOI 10.1073/pnas.060028097; DOSCH HM, 1980, J IMMUNOL, V125, P827; Drexler HG, 2000, LEUKEMIA, V14, P198, DOI 10.1038/sj.leu.2401604; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ferri KF, 2001, BIOESSAYS, V23, P111, DOI 10.1002/1521-1878(200102)23:2<111::AID-BIES1016>3.3.CO;2-P; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Grillot DAM, 1996, J EXP MED, V183, P381, DOI 10.1084/jem.183.2.381; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAWRYLOWICZ CM, 1984, IMMUNOLOGY, V53, P703; Henry H, 2002, ONCOGENE, V21, P748, DOI 10.1038/sj.onc.1205125; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; KASTAN MB, 1991, CANCER RES, V51, P6304; KLAUS GGB, 1986, EUR J IMMUNOL, V16, P92, DOI 10.1002/eji.1830160118; Krappmann D, 2001, MOL CELL BIOL, V21, P6640, DOI 10.1128/MCB.21.19.6640-6650.2001; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Lee JM, 1998, ONCOGENE, V17, P1653, DOI 10.1038/sj.onc.1202102; LI YS, 1989, EUR J IMMUNOL, V19, P1721, DOI 10.1002/eji.1830190929; Lin X, 2000, MOL CELL BIOL, V20, P2933, DOI 10.1128/MCB.20.8.2933-2940.2000; LIN YP, 1995, MOL CELL BIOL, V15, P6045; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Mahyar-Roemer M, 2001, ONCOGENE, V20, P3387, DOI 10.1038/sj.onc.1204440; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; MIYASHITA T, 1995, CELL, V80, P293; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; NOVOGRODSKY A, 1971, BIOCHIM BIOPHYS ACTA, V228, P579, DOI 10.1016/0005-2787(71)90064-5; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; OPPENHEIM JJ, 1976, PROG ALLERGY, V20, P65; Samuel T, 2001, J BIOL CHEM, V276, P45201, DOI 10.1074/jbc.M106427200; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Silva M, 1999, J BIOL CHEM, V274, P22165, DOI 10.1074/jbc.274.32.22165; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Su F, 2002, GENE DEV, V16, P46, DOI 10.1101/gad.942902; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Thornborrow EC, 2002, ONCOGENE, V21, P990, DOI 10.1038/sj.onc.1205069; Tian H, 2000, CANCER RES, V60, P679; TRUNEH A, 1985, NATURE, V313, P318, DOI 10.1038/313318a0; Tymms M J, 1995, Methods Mol Biol, V37, P31; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; WEDNER HJ, 1976, PROG ALLERGY, V20, P195; Werner AB, 2002, J BIOL CHEM, V277, P22781, DOI 10.1074/jbc.M201469200; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	73	29	30	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 30	2003	22	4					555	571		10.1038/sj.onc.1206138	http://dx.doi.org/10.1038/sj.onc.1206138			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555069				2022-12-28	WOS:000180538200009
J	Freund, A; Chauveau, C; Brouillet, JP; Lucas, A; Lacroix, M; Licznar, A; Vignon, F; Lazennec, G				Freund, A; Chauveau, C; Brouillet, JP; Lucas, A; Lacroix, M; Licznar, A; Vignon, F; Lazennec, G			IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells	ONCOGENE			English	Article						estrogen receptor; breast; cancer; interleukin-8; invasion	AUTOCRINE GROWTH-FACTOR; HUMAN OVARIAN-CANCER; PROSTATE-CANCER; CARCINOMA-CELLS; ER-BETA; ENDOTHELIAL INTERLEUKIN-8; REDUCED TUMORIGENICITY; LEUKEMIC-CELLS; MESSENGER-RNA; NUDE-MICE	Estrogen-receptor (ER) status is an important parameter in breast cancer management as ER-positive breast cancers have a better prognosis than ER-negative tumors. This difference comes essentially from the lower aggressiveness and invasiveness of ER-positive tumors. Here, we demonstrate, that interleukin-8 (IL-8) was clearly over-expressed in most ER-negative breast, ovary cell lines and breast tumor samples tested, whereas no significant IL-8 level could be detected in ER-positive breast or ovarian cell tines. We have also cloned human IL-8 from ER-negative MDA-MB-231 cells, and we show that IL-8 produced by breast cancer cells is identical to monocyte-derived IL-8. Interestingly, the invasion potential of ER-negative breast cancer cells is associated at least in part with expression of IL-8, but not with IL-8 receptor levels. Moreover, IL-8 increases the invasiveness of ER-positive breast cancer cells by two fold, thus confirming the invasion-promoting role of IL-8. On the other hand, exogenous expression of estrogen receptors in ER-negative cells led to a decrease of IL-8 levels. In summary, our data show that IL-8 expression is negatively linked to ER status of breast and ovarian cancer cells. We also support the idea that IL-8 expression is associated with a higher invasiveness potential of cancer cells in vitro, which suggests that IL-8 could be a novel marker of tumor aggressiveness.	INSERM, U540, F-34090 Montpellier, France; Hop Arnaud de Villeneuve, Lab Biol Cellulaire & Hormonale, F-34295 Montpellier 5, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; CHU de Montpellier	Lazennec, G (corresponding author), INSERM, U540, 60 Rue Navacelles, F-34090 Montpellier, France.		Lacroix, Matthieu/O-1928-2018	Lacroix, Matthieu/0000-0002-1268-9058; Lazennec, Gwendal/0000-0002-8522-1763				BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; Balbay MD, 1999, CLIN CANCER RES, V5, P783; BASOLO F, 1993, INT J CANCER, V55, P926, DOI 10.1002/ijc.2910550609; Brew R, 1997, BIOCHEM SOC T, V25, pS264, DOI 10.1042/bst025264s; Brouillet JP, 2001, INT J CANCER, V95, P205, DOI 10.1002/1097-0215(20010720)95:4<205::AID-IJC1035>3.0.CO;2-Y; De Larco JE, 2001, AM J PATHOL, V158, P639, DOI 10.1016/S0002-9440(10)64005-9; Fontanini G, 1999, BRIT J CANCER, V80, P579, DOI 10.1038/sj.bjc.6690394; GARCIA M, 1992, P NATL ACAD SCI USA, V89, P11538, DOI 10.1073/pnas.89.23.11538; Green AR, 1997, INT J CANCER, V72, P937; GREEN S, 1986, NATURE, V324, P615, DOI 10.1038/324615a0; Greene GF, 1997, AM J PATHOL, V150, P1571; Inoue K, 2000, CLIN CANCER RES, V6, P2104; Ivarsson K, 1998, GYNECOL ONCOL, V71, P420, DOI 10.1006/gyno.1998.5198; Lazennec G, 1997, MOL CELL BIOL, V17, P5053, DOI 10.1128/MCB.17.9.5053; Lazennec G, 2001, ENDOCRINOLOGY, V142, P4120, DOI 10.1210/en.142.9.4120; Lee LF, 2000, J IMMUNOL, V164, P2769, DOI 10.4049/jimmunol.164.5.2769; Luca M, 1997, AM J PATHOL, V151, P1105; MADSEN MW, 1990, EUR J CANCER, V26, P793, DOI 10.1016/0277-5379(90)90154-L; Matsushima K, 1989, Cytokine, V1, P2, DOI 10.1016/1043-4666(89)91043-0; MCGUIRE WL, 1975, CANCER, V36, P638; Merogi AJ, 1997, HUM PATHOL, V28, P321, DOI 10.1016/S0046-8177(97)90131-3; Miller LJ, 1998, ANTICANCER RES, V18, P77; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nakashima E, 1996, PHARMACEUT RES, V13, P1896, DOI 10.1023/A:1016057830271; Pisani Paola, 1992, Journal of Environmental Pathology Toxicology and Oncology, V11, P313; Platet Nadine, 1998, Invasion and Metastasis, V18, P198, DOI 10.1159/000024513; Pujol P, 1998, CANCER RES, V58, P5367; Roger P, 2001, CANCER RES, V61, P2537; SCHADENDORF D, 1993, J IMMUNOL, V151, P2667; SKOOG L, 1987, ACTA ONCOL, V26, P95, DOI 10.3109/02841868709091747; SOMMERS CL, 1994, BREAST CANCER RES TR, V31, P325, DOI 10.1007/BF00666165; Speirs V, 1996, INT J CANCER, V66, P551, DOI 10.1002/(SICI)1097-0215(19960516)66:4<551::AID-IJC21>3.0.CO;2-9; SPRENGER H, 1994, J IMMUNOL, V153, P2524; SPRENGER H, 1994, J BIOL CHEM, V269, P11065; Terui Y, 1998, BLOOD, V92, P2672, DOI 10.1182/blood.V92.8.2672.420k40_2672_2680; Terui Y, 1999, CANCER RES, V59, P5651; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; Veltri RW, 1999, UROLOGY, V53, P139, DOI 10.1016/S0090-4295(98)00455-5; Xu L, 2000, ONCOL RES, V12, P97, DOI 10.3727/096504001108747567; Yoneda J, 1998, JNCI-J NATL CANCER I, V90, P447, DOI 10.1093/jnci/90.6.447; Youngs SJ, 1997, INT J CANCER, V71, P257, DOI 10.1002/(SICI)1097-0215(19970410)71:2<257::AID-IJC22>3.0.CO;2-D	42	171	185	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 16	2003	22	2					256	265		10.1038/sj.onc.1206113	http://dx.doi.org/10.1038/sj.onc.1206113			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527894	Green Submitted, Green Accepted			2022-12-28	WOS:000180322400010
J	Nakayama, H				Nakayama, H			RecQ family helicases: roles as tumor suppressor proteins	ONCOGENE			English	Review						RecQ helicase; Bloom's syndrome; Werner's syndrome; Rothmund-Thomson syndrome; hyper-recombination; cancer predisposition	WERNER-SYNDROME PROTEIN; SYNDROME GENE-PRODUCT; BLOOMS-SYNDROME GENE; ROTHMUND-THOMSON-SYNDROME; ESCHERICHIA-COLI RECQ; SGS1 DNA HELICASE; ARRESTED REPLICATION FORKS; TOPOISOMERASE III-ALPHA; SACCHAROMYCES-CEREVISIAE; HOMOLOGOUS RECOMBINATION	RecQ family DNA helicases are defined as proteins sharing a homologous region with Escherichia coli RecQ and are basically regarded as enzymes involved in recombination. Humans have five RecQ family members, and deficiencies in three of them, BLM, WRN, and RTS, cause Bloom's, Werner's, and Rothmund-Thomson syndromes, respectively, each characterized by genomic instability and cancer predisposition. In this context, an important function of the RecQ homologs appears to be the unwinding of intermediates of recombination, thereby preventing its uncontrolled execution. As a consequence, their deficiencies give rise to elevated levels of recombination (the hyper-recombination phenotype), which result in chromosomal aberrations including loss of heterozygosity, a common chromosomal change associated with malignancies. Thus, those helicases qualify as caretaker-type tumor suppressor proteins. In addition, BLM and WRN deficiencies have been shown to attenuate p53-mediated apoptosis, suggesting that they also belong to the gatekeeper class of tumor suppressor proteins.	Kyushu Univ, Higashi Ku, Fukuoka 8128581, Japan	Kyushu University	Nakayama, H (corresponding author), 4395-2 Fukuma Machi, Fukuoka 8113213, Japan.	nakh@ruby.ocn.ne.jp						Ababou M, 2002, ONCOGENE, V21, P2079, DOI 10.1038/sj.onc.1205246; Ababou M, 2000, ONCOGENE, V19, P5955, DOI 10.1038/sj.onc.1204003; AJIMA J, 2002, MUTAT RES, V9336, P1; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barre FX, 2001, P NATL ACAD SCI USA, V98, P8189, DOI 10.1073/pnas.111008998; Bennett RJ, 2000, J BIOL CHEM, V275, P26898; Bennett RJ, 1999, J MOL BIOL, V289, P235, DOI 10.1006/jmbi.1999.2739; Bennett RJ, 1998, J BIOL CHEM, V273, P9644, DOI 10.1074/jbc.273.16.9644; Bernstein C, 2002, MUTAT RES-REV MUTAT, V511, P145, DOI 10.1016/S1383-5742(02)00009-1; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Blander G, 1999, J BIOL CHEM, V274, P29463, DOI 10.1074/jbc.274.41.29463; Brosh RM, 2000, J BIOL CHEM, V275, P23500, DOI 10.1074/jbc.M001557200; Brosh RM, 2001, EMBO J, V20, P5791; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Brosh RM, 2001, J BIOL CHEM, V276, P35093, DOI 10.1074/jbc.M103332200; Brosh RM, 2001, J BIOL CHEM, V276, P3024, DOI 10.1074/jbc.M006784200; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Cohen H, 2001, P NATL ACAD SCI USA, V98, P3174, DOI 10.1073/pnas.061579598; Collister M, 1998, CARCINOGENESIS, V19, P2115, DOI 10.1093/carcin/19.12.2115; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Cooper MP, 2000, GENE DEV, V14, P907; Courcelle J, 1999, MOL GEN GENET, V262, P543, DOI 10.1007/s004380051116; Courcelle J, 2001, P NATL ACAD SCI USA, V98, P8196, DOI 10.1073/pnas.121008898; Courcelle J, 2001, BIOESSAYS, V23, P463, DOI 10.1002/bies.1065; Cox MM, 2001, P NATL ACAD SCI USA, V98, P8173, DOI 10.1073/pnas.131004998; Doe CL, 2000, EMBO J, V19, P2751, DOI 10.1093/emboj/19.11.2751; Duckett DR, 1999, P NATL ACAD SCI USA, V96, P12384, DOI 10.1073/pnas.96.22.12384; Dutertre S, 2000, ONCOGENE, V19, P2731, DOI 10.1038/sj.onc.1203595; Ellis NA, 1996, HUM MOL GENET, V5, P1457, DOI 10.1093/hmg/5.Supplement_1.1457; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; FARAGHER RGA, 1993, P NATL ACAD SCI USA, V90, P12030, DOI 10.1073/pnas.90.24.12030; Featherstone C, 1999, MUTAT RES-DNA REPAIR, V434, P3, DOI 10.1016/S0921-8777(99)00006-3; Fernandez S, 1998, J BACTERIOL, V180, P3405; Frei C, 2000, J CELL SCI, V113, P2641; Frei C, 2000, GENE DEV, V14, P81; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Fry M, 1999, J BIOL CHEM, V274, P12797, DOI 10.1074/jbc.274.18.12797; FUKUCHI K, 1990, HUM GENET, V84, P249; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; Gangloff S, 2000, NAT GENET, V25, P192, DOI 10.1038/76055; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; Garkavtsev IV, 2001, ONCOGENE, V20, P8276, DOI 10.1038/sj.onc.1205120; GEBHART E, 1988, HUM GENET, V80, P135, DOI 10.1007/BF00702855; German J, 1997, CANCER GENET CYTOGEN, V93, P100, DOI 10.1016/S0165-4608(96)00336-6; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GOTO M, 1982, SCAND J IMMUNOL, V15, P389, DOI 10.1111/j.1365-3083.1982.tb00663.x; GOTO M, 1979, J CLIN INVEST, V64, P695, DOI 10.1172/JCI109511; Goto M, 2000, CLIN EXP RHEUMATOL, V18, P760; Goto M, 1996, CANCER EPIDEM BIOMAR, V5, P239; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; GRODEN J, 1992, HUM GENET, V90, P360; Hakem R, 2001, ANNU REV GENET, V35, P209, DOI 10.1146/annurev.genet.35.102401.090432; Hammond EM, 2002, MOL CELL BIOL, V22, P1834, DOI 10.1128/MCB.22.6.1834-1843.2002; Hanada K, 1997, P NATL ACAD SCI USA, V94, P3860, DOI 10.1073/pnas.94.8.3860; Harmon FG, 1999, MOL CELL, V3, P611, DOI 10.1016/S1097-2765(00)80354-8; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; Harmon FG, 2001, J BIOL CHEM, V276, P232, DOI 10.1074/jbc.M006555200; Hartung F, 2000, NUCLEIC ACIDS RES, V28, P4275, DOI 10.1093/nar/28.21.4275; Hu P, 2001, HUM MOL GENET, V10, P1287, DOI 10.1093/hmg/10.12.1287; Huang PH, 2001, CURR BIOL, V11, P125, DOI 10.1016/S0960-9822(01)00021-5; Imamura O, 2001, ONCOGENE, V20, P1143, DOI 10.1038/sj.onc.1204195; IRINO N, 1986, MOL GEN GENET, V205, P298, DOI 10.1007/BF00430442; Jeong SM, 2000, MOL GEN GENET, V263, P183, DOI 10.1007/s004380051159; Johnson FB, 2000, CANCER RES, V60, P1162; Johnson FB, 2001, EMBO J, V20, P905, DOI 10.1093/emboj/20.4.905; Kamath-Loeb AS, 2000, P NATL ACAD SCI USA, V97, P4603, DOI 10.1073/pnas.97.9.4603; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Kamath-Loeb AS, 2001, J BIOL CHEM, V276, P16439, DOI 10.1074/jbc.M100253200; Karmakar P, 2002, J BIOL CHEM, V277, P18291, DOI 10.1074/jbc.M111523200; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; Kawabe T, 2000, ONCOGENE, V19, P4764, DOI 10.1038/sj.onc.1203841; Kim S, 2002, ONCOGENE, V21, P503, DOI 10.1038/sj.onc.1205077; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; Kitao S, 1998, GENOMICS, V54, P443, DOI 10.1006/geno.1998.5595; Kogoma T, 1997, MICROBIOL MOL BIOL R, V61, P212, DOI 10.1128/.61.2.212-238.1997; Kusano K, 2001, SCIENCE, V291, P2600, DOI 10.1126/science.291.5513.2600; Langland G, 2001, J BIOL CHEM, V276, P30031, DOI 10.1074/jbc.M009664200; LARNER JM, 1994, MOL CELL BIOL, V14, P1901, DOI 10.1128/MCB.14.3.1901; Le S, 1999, GENETICS, V152, P143; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; Lebel M, 1998, P NATL ACAD SCI USA, V95, P13097, DOI 10.1073/pnas.95.22.13097; Lebel M, 2001, CANCER RES, V61, P1816; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li BM, 2000, J BIOL CHEM, V275, P28349, DOI 10.1074/jbc.C000289200; Li BM, 2001, J BIOL CHEM, V276, P9896, DOI 10.1074/jbc.M008575200; Liao SR, 2000, GENE DEV, V14, P2570, DOI 10.1101/gad.822400; Lindor NM, 2000, AM J MED GENET, V90, P223, DOI 10.1002/(SICI)1096-8628(20000131)90:3<223::AID-AJMG7>3.0.CO;2-Z; Lu JA, 1996, NATURE, V383, P678, DOI 10.1038/383678a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Luo GB, 2000, NAT GENET, V26, P424, DOI 10.1038/82548; Michel B, 2001, P NATL ACAD SCI USA, V98, P8181, DOI 10.1073/pnas.111008798; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; MONNAT RJ, 1992, GENOMICS, V13, P777, DOI 10.1016/0888-7543(92)90153-J; Morozov V, 1997, TRENDS BIOCHEM SCI, V22, P417, DOI 10.1016/S0968-0004(97)01128-6; Mullen JR, 2000, GENETICS, V154, P1101; Murray JM, 1997, MOL CELL BIOL, V17, P6868, DOI 10.1128/MCB.17.12.6868; Myung K, 2001, NAT GENET, V27, P113, DOI 10.1038/83673; NAKAYAMA H, 1984, MOL GEN GENET, V195, P474, DOI 10.1007/BF00341449; NAKAYAMA K, 1985, MOL GEN GENET, V200, P266, DOI 10.1007/BF00425434; Oakley TJ, 2002, DNA REPAIR, V1, P175, DOI 10.1016/S1568-7864(02)00002-2; Ogburn CE, 1997, HUM GENET, V101, P121, DOI 10.1007/s004390050599; Onoda F, 2000, MUTAT RES-DNA REPAIR, V459, P203, DOI 10.1016/S0921-8777(99)00071-3; Onoda F, 2001, MOL GEN GENET, V264, P702, DOI 10.1007/s004380000358; Oshima J, 2002, CANCER RES, V62, P547; Pedrazzi G, 2001, NUCLEIC ACIDS RES, V29, P4378, DOI 10.1093/nar/29.21.4378; POOT M, 1992, EXP CELL RES, V202, P267, DOI 10.1016/0014-4827(92)90074-I; Prince PR, 2001, GENE DEV, V15, P933, DOI 10.1101/gad.877001; PURANAM KL, 1994, J BIOL CHEM, V269, P29838; Sakamoto S, 2001, GENES CELLS, V6, P421, DOI 10.1046/j.1365-2443.2001.00433.x; SALK D, 1981, CYTOGENET CELL GENET, V30, P92, DOI 10.1159/000131596; Sanchez-Alonso P, 1998, GENETICS, V148, P1043; Sekelsky JJ, 1999, NUCLEIC ACIDS RES, V27, P3762, DOI 10.1093/nar/27.18.3762; SEKI M, 1994, NUCLEIC ACIDS RES, V22, P4566, DOI 10.1093/nar/22.22.4566; SEKI M, 1994, J BIOCHEM-TOKYO, V115, P523, DOI 10.1093/oxfordjournals.jbchem.a124369; Shen JC, 2000, NUCLEIC ACIDS RES, V28, P3260, DOI 10.1093/nar/28.17.3260; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; Shen JC, 1998, NUCLEIC ACIDS RES, V26, P2879, DOI 10.1093/nar/26.12.2879; Shimamoto A, 2000, NUCLEIC ACIDS RES, V28, P1647, DOI 10.1093/nar/28.7.1647; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; Spillare EA, 1999, GENE DEV, V13, P1355, DOI 10.1101/gad.13.11.1355; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; Sun H, 1998, J BIOL CHEM, V273, P27587, DOI 10.1074/jbc.273.42.27587; Sun H, 1999, NUCLEIC ACIDS RES, V27, P1978, DOI 10.1093/nar/27.9.1978; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; Tachibana A, 1996, MOL CARCINOGEN, V17, P41, DOI 10.1002/(SICI)1098-2744(199609)17:1<41::AID-MC6>3.3.CO;2-Z; Teng SC, 1999, MOL CELL BIOL, V19, P8083; Thompson LH, 1999, BIOCHIMIE, V81, P87, DOI 10.1016/S0300-9084(99)80042-X; Ui A, 2001, MOL GENET GENOMICS, V265, P837, DOI 10.1007/s004380100479; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; UMEZU K, 1993, J MOL BIOL, V230, P1145, DOI 10.1006/jmbi.1993.1231; VANKERCKHOVE CW, 1988, AM J DIS CHILD, V142, P1089, DOI 10.1001/archpedi.1988.02150100083032; VENNOS EM, 1992, J AM ACAD DERMATOL, V27, P750, DOI 10.1016/0190-9622(92)70249-F; Wang WS, 2000, EMBO J, V19, P3428, DOI 10.1093/emboj/19.13.3428; Wang XW, 2001, J BIOL CHEM, V276, P32948, DOI 10.1074/jbc.M103298200; Wang Y, 2000, GENE DEV, V14, P927; Watt PM, 1996, GENETICS, V144, P935; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; Woo RA, 2002, EMBO J, V21, P3000, DOI 10.1093/emboj/cdf307; Wu L, 2001, J BIOL CHEM, V276, P19375, DOI 10.1074/jbc.M009471200; Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636; Wyllie FS, 2000, NAT GENET, V24, P16, DOI 10.1038/71630; Yan H, 1998, NAT GENET, V19, P375, DOI 10.1038/1263; Yannone SM, 2001, J BIOL CHEM, V276, P38242; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	147	67	70	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2002	21	58					9008	9021		10.1038/sj.onc.1205959	http://dx.doi.org/10.1038/sj.onc.1205959			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	626TP	12483516				2022-12-28	WOS:000179889500011
J	Jackson, RJ; Adnane, J; Coppola, D; Cantor, A; Sebti, SM; Pledger, WJ				Jackson, RJ; Adnane, J; Coppola, D; Cantor, A; Sebti, SM; Pledger, WJ			Loss of the cell cycle inhibitors p21(Cip1) and p27(Kip1) enhances tumorigenesis in knockout mouse models	ONCOGENE			English	Article						p21(Cip1); p27(Kip1); urethane; tumors; MMTV/v-Ha-ras mice	MAMMARY-CANCER MODEL; TRANSGENIC MICE; HA-RAS; BREAST-CANCER; GROWTH-FACTOR; SKIN CARCINOGENESIS; LACKING P27(KIP1); TUMOR SUPPRESSION; ONCOGENIC RAS; DIFFERENTIATION	Events that contribute to tumor formation include mutations in the ras gene and loss or inactivation of cell cycle inhibitors such as p21(Cip1) and p27(Kip1). In our previous publication, we showed that mice expressing the MMTV/v-Ha-ras transgene developed tumors earlier and at higher multiplicities in the absence than in the presence of p21(Cip1). To further evaluate the combinatorial role of genetic alterations and loss of cell cycle inhibitors in tumorigenesis, we performed two companion studies. In the first study, wild type and p21(Cip1)-null mice were exposed to the chemical carcinogen, urethane. Similar to its effects in v-Ha-ras mice, loss of p21(Cip1) accelerated tumor onset and increased tumor multiplicity in urethane-treated mice. Lung tumors were the predominant tumor type in urethane-treated mice regardless of p21(Cip1) status. In the second study, tumor formation was monitored in v-Ha-ras mice expressing or lacking p27(Kip1). Unlike p21(Cip1), the absence of p27(Kip1) had no effect on the timing or multiplicity of tumor formation, which was largely restricted to mammary and salivary glands. However, once tumors appeared, they grew faster in p27(Kip1)-null mice than in p27(Kip1)-wild type mice. Increases in growth rate were particularly striking for salivary tumors in ras/p27(-/-) mice. Loss of p21(Cip1) on the other hand, had no effect on tumor growth rate in v-Ha-ras mice. Collectively, our data suggest that p21(Cip1) suppresses tumor formation elicited by multiple agents and that p21(Cip1) and p27(Kip1) suppress tumor formation in different ways.	H Lee Moffit Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; H Lee Moffit Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; H Lee Moffit Canc Ctr & Res Inst, Pathol Serv, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Pledger, WJ (corresponding author), H Lee Moffit Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.				NCI NIH HHS [CA78038, CA67771, CA67360] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U19CA067771, R01CA067360, P01CA078038] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; Adnane J, 2000, ONCOGENE, V19, P5338, DOI 10.1038/sj.onc.1203956; Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ANDRES AC, 1988, GENE DEV, V2, P1486, DOI 10.1101/gad.2.11.1486; Bagui TK, 2000, MOL CELL BIOL, V20, P8748, DOI 10.1128/MCB.20.23.8748-8757.2000; BOS JL, 1989, CANCER RES, V49, P4682; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Davis R W, 1980, Methods Enzymol, V65, P404; Della Ragione F, 1999, ADV EXP MED BIOL, V472, P73; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; DRAGANI TA, 1991, ONCOGENE, V6, P333; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; Frame S, 2000, CURR OPIN GENET DEV, V10, P106, DOI 10.1016/S0959-437X(99)00052-0; Hauser PJ, 1997, CELL GROWTH DIFFER, V8, P203; Johnson DG, 1999, ANNU REV PHARMACOL, V39, P295, DOI 10.1146/annurev.pharmtox.39.1.295; Jones JM, 1999, CELL GROWTH DIFFER, V10, P213; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; Kawana H, 1998, AM J PATHOL, V153, P505, DOI 10.1016/S0002-9440(10)65593-9; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KUMAR R, 1990, SCIENCE, V248, P1101, DOI 10.1126/science.2188364; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; MALKINSON AM, 1983, J NATL CANCER I, V70, P931; Martin-Caballero J, 2001, CANCER RES, V61, P6234; Mirvish S S, 1968, Adv Cancer Res, V11, P1; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NUZUM EO, 1990, MOL CARCINOGEN, V3, P287, DOI 10.1002/mc.2940030509; Paramio JM, 2001, J BIOL CHEM, V276, P44203, DOI 10.1074/jbc.M105650200; Philipp J, 1999, ONCOGENE, V18, P4689, DOI 10.1038/sj.onc.1202840; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Quaroni A, 2000, AM J PHYSIOL-CELL PH, V279, pC1045, DOI 10.1152/ajpcell.2000.279.4.C1045; SANDGREN EP, 1989, ONCOGENE, V4, P715; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Shiohara M, 1997, LEUKEMIA LYMPHOMA, V26, P35, DOI 10.3109/10428199709109155; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SMITH GS, 1973, J NATL CANCER I, V50, P1195, DOI 10.1093/jnci/50.5.1195; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Weinberg WC, 1997, ONCOGENE, V15, P685, DOI 10.1038/sj.onc.1201230; Winston JT, 1996, ONCOGENE, V12, P127; WISEMAN RW, 1986, P NATL ACAD SCI USA, V83, P5825, DOI 10.1073/pnas.83.16.5825; Yang WC, 2001, CANCER RES, V61, P565; Zezula J, 2001, EMBO REP, V2, P27, DOI 10.1093/embo-reports/kve008; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zirbes TK, 2000, INT J CANCER, V89, P14, DOI 10.1002/(SICI)1097-0215(20000120)89:1<14::AID-IJC3>3.0.CO;2-L	56	67	69	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 5	2002	21	55					8486	8497		10.1038/sj.onc.1205946	http://dx.doi.org/10.1038/sj.onc.1205946			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466968				2022-12-28	WOS:000179480100011
J	Duan, WR; Ding, HM; Subler, MA; Zhu, WG; Zhang, HM; Stoner, GD; Windle, JJ; Otterson, GA; Villalona-Calero, MA				Duan, WR; Ding, HM; Subler, MA; Zhu, WG; Zhang, HM; Stoner, GD; Windle, JJ; Otterson, GA; Villalona-Calero, MA			Lung-specific expression of human mutant p53-273H is associated with a high frequency of lung adenocarcinoma in transgenic mice	ONCOGENE			English	Article						lung; adenocarcinoma; p53; SP-C; transgenic mice	TUMOR-SUPPRESSOR GENE; CANCER CELL-LINES; WILD-TYPE; T-ANTIGEN; P53 MUTATIONS; DNA-BINDING; IMMUNOCHEMICAL ANALYSIS; SV40-TRANSFORMED CELLS; TERMINAL DOMAIN; RAS MUTATIONS	To investigate the tumorigenic potential of mutant p53 when selectively expressed in lung tissue, a transgenic mouse model was developed in which a mutant form of p53 (p53-273H) was placed under the transcriptional control of the lung-specific human surfactant protein C (SP-C) promoter. Two founder mice were identified, and a line of SP-C/p53-273H transgenic mice was established from one of the founders. Human p53-273H protein was detected specifically in lung tissue from transgenic mice. Malignant tumors, which were histologically characterized as adenocarcinomas, were observed in transgenic mice, with the earliest onset documented at 4 months of age. To further evaluate incidence and onset of tumor formation, transgenic mice (n = 113) were sacrificed at age intervals ranging from 4-15 months. At 13-15 months of age, transgenic mice were significantly more likely to have lung tumors at necropsy than age-matched non-transgenic littermates (9 out of 39 (23%) versus 2 out of 35 (5.7%), chi(2) test, P = 0.036). The SP-C/p53-273H transgenic mice described here thus represent a genetically defined model with which to study the role of p53 mutations in lung tumorigenesis, as well as the potential complementary contributions of other genetic alterations or environmental carcinogens to lung tumor development.	Ohio State Univ, Arthur G James Canc Hosp, Columbus, OH 43210 USA; Ohio State Univ, Richard J Solove Res Inst, Coll Med & Publ Hlth, Ctr Comprehens Canc, Columbus, OH 43210 USA; Ohio State Univ, Dept Internal Med, Coll Med & Publ Hlth, Columbus, OH 43210 USA; Ohio State Univ, Dept Publ Hlth, Coll Med & Publ Hlth, Columbus, OH 43210 USA; Ohio State Univ, Dept Pathol, Coll Med & Publ Hlth, Columbus, OH 43210 USA; Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Human Genet, Richmond, VA 23298 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Virginia Commonwealth University; Virginia Commonwealth University	Villalona-Calero, MA (corresponding author), Ohio State Univ, Arthur G James Canc Hosp, 320 W 10th Ave,B406 Starling Loving Hall, Columbus, OH 43210 USA.		zhu, wei-guo/E-1334-2012	Windle, Jolene/0000-0001-6690-385X; Zhu, Wei-Guo/0000-0001-8385-6581; duan, wenrui/0000-0001-6512-7350	NATIONAL CANCER INSTITUTE [K01CA076970, P30CA016058] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA16058, K01 CA76970] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albor A, 1998, CANCER RES, V58, P2091; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARTEK J, 1990, ONCOGENE, V5, P893; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Chao HHA, 2000, MOL CELL BIOL, V20, P7624, DOI 10.1128/MCB.20.20.7624-7633.2000; CHEN JY, 1993, ONCOGENE, V8, P2159; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHUMAKOV AM, 1993, ONCOGENE, V8, P3005; DAMICO D, 1992, ONCOGENE, V7, P339; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEMAYO FJ, 1991, AM J PHYSIOL, V261, pL70, DOI 10.1152/ajplung.1991.261.2.L70; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Duan W, 2002, BIOTECHNIQUES, V33, P58, DOI 10.2144/02331st02; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Glasser SW, 2000, AM J PHYSIOL-LUNG C, V278, pL933, DOI 10.1152/ajplung.2000.278.5.L933; GLASSER SW, 1991, AM J PHYSIOL, V261, pL349, DOI 10.1152/ajplung.1991.261.4.L349; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; Hernandez-Boussard T, 1999, HUM MUTAT, V14, P1; Hernandez-Boussard TM, 1998, ENVIRON HEALTH PERSP, V106, P385, DOI 10.2307/3434065; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; Hogan B, 1994, MANIPULATING MOUSE E; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Kawamura M, 1996, ONCOGENE, V12, P2361; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko JL, 1996, GENE DEV, V10, P1054; KORFHAGEN TR, 1990, P NATL ACAD SCI USA, V87, P6122, DOI 10.1073/pnas.87.16.6122; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Liu G, 2000, P NATL ACAD SCI USA, V97, P4174, DOI 10.1073/pnas.97.8.4174; MALKIN D, 1993, CANCER GENET CYTOGEN, V66, P83, DOI 10.1016/0165-4608(93)90233-C; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MITSUDOMI T, 1992, ONCOGENE, V7, P171; OHARE K, 1981, P NATL ACAD SCI-BIOL, V78, P1527, DOI 10.1073/pnas.78.3.1527; PARK DJ, 1994, ONCOGENE, V9, P1899; PURDIE CA, 1994, ONCOGENE, V9, P603; Roemer K, 1999, BIOL CHEM, V380, P879, DOI 10.1515/BC.1999.108; Sambrook J., 2002, MOL CLONING LAB MANU; Shafarenko M, 1997, CARCINOGENESIS, V18, P1423, DOI 10.1093/carcin/18.7.1423; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; TIMME TL, 1994, BIOTECHNIQUES, V17, P461; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; van Oijen MGCT, 2000, CLIN CANCER RES, V6, P2138; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WIKENHEISER KA, 1992, CANCER RES, V52, P5342; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; YonishRouach E, 1996, EXPERIENTIA, V52, P1001, DOI 10.1007/BF01920109; ZHANG W, 1993, ONCOGENE, V8, P2555	58	19	19	2	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 7	2002	21	51					7831	7838		10.1038/sj.onc.1205909	http://dx.doi.org/10.1038/sj.onc.1205909			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	610DT	12420220				2022-12-28	WOS:000178946000008
J	Bhattacharya, S; Garriga, J; Calbo, J; Yong, T; Haines, DS; Grana, X				Bhattacharya, S; Garriga, J; Calbo, J; Yong, T; Haines, DS; Grana, X			SKP2 associates with p130 and accelerates p130 ubiquitylation and degradation in human cells	ONCOGENE			English	Article						adenoviruses; cyclin D1; cyclin E; CDK; E2F1	DEPENDENT KINASE INHIBITORS; HUMAN PROSTATE-CANCER; LIGASE SUBUNIT SKP2; BOX PROTEIN SKP2; RETINOBLASTOMA PROTEIN; S-PHASE; ADIPOCYTE DIFFERENTIATION; CYCLIN-E; PHOSPHORYLATION; P107	p130 is a member of the retinoblastoma family of pocket proteins, which includes pRB and p107. Unlike pRB and p107, p130 protein levels decrease dramatically following its hyperphosphorylation starting in the mid-G1 phase of the cell cycle. However, the mechanism leading to p130 downregulation is unknown. We have found that the proteasome inhibitor, lactacystin, inhibited p130 downregulation in T98G cells progressing through the G1/S transition and S phase and that p130 is multiubiquitylated in 293 cells. We have previously shown that ectopic expression of both cyclin D and E induces phosphorylation and downregulation of p130. Since the SKP1/Cul1/SKP2 E3 ubiquitin ligase complex mediates ubiquitylation of substrates previously phosphorylated by cyclin-dependent kinases, we investigated the potential role of this ubiquitin ligase in mediating p130 downregulation. We found that p130 interacts with SKP1, Cul-1 and SKP2 in human 293 cells. We also found that ectopic coexpression of SKP2 and p130 leads to dose-dependent downregulation of p130, reduces p130 protein half-life and induces p130 ubiquitylation in these cells. Moreover, adenoviral-mediated expression of SKP2 accelerates downregulation of endogenous hyperphosphorylated p130 in mitogen-stimulated T98G cells and primary W138 fibroblasts. We conclude that p130 is a substrate of the SCFSKP2 ubiquitin ligase and this E3 ligase regulates p130 abundance during the cell cycle.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Univ Barcelona, Dept Biochem & Mol Biol, Barcelona, Spain	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Barcelona	Grana, X (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, AHP Bldg,Room 308,3307 N Broad St, Philadelphia, PA 19140 USA.			Grana, Xavier/0000-0001-7134-0473	NATIONAL CANCER INSTITUTE [R24CA088261] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045450, K02AI001823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054894] Funding Source: NIH RePORTER; NCI NIH HHS [R24 CA88261-01] Funding Source: Medline; NIAID NIH HHS [R01 AI45450, K02 AI01823] Funding Source: Medline; NIGMS NIH HHS [R29 GM54894] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams PD, 1996, MOL CELL BIOL, V16, P6623; Ausubel FM., 1988, CURRENT PROTOCOLS MO; Calbo J, 2002, J BIOL CHEM, V277, P50263, DOI 10.1074/jbc.M209181200; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Castano E, 1998, MOL CELL BIOL, V18, P5380, DOI 10.1128/MCB.18.9.5380; Cheng LY, 2000, J BIOL CHEM, V275, P30317, DOI 10.1074/jbc.M005707200; Chiarle R, 2002, AM J PATHOL, V160, P1457, DOI 10.1016/S0002-9440(10)62571-0; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Coats S, 1999, CURR BIOL, V9, P163, DOI 10.1016/S0960-9822(99)80086-4; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; DeSalle LM, 2001, FEBS LETT, V490, P179, DOI 10.1016/S0014-5793(01)02121-4; Garriga J, 1996, BIOCHEM J, V319, P293, DOI 10.1042/bj3190293; Garriga J, 1998, BIOCHEM J, V333, P645, DOI 10.1042/bj3330645; GRANA X, 1995, ONCOGENE, V11, P211; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Hansen K, 2001, EMBO J, V20, P422, DOI 10.1093/emboj/20.3.422; Harper JW, 2001, CURR BIOL, V11, pR431, DOI 10.1016/S0960-9822(01)00253-6; Hershko D, 2001, CANCER, V91, P1745, DOI 10.1002/1097-0142(20010501)91:9<1745::AID-CNCR1193>3.0.CO;2-H; KIESS M, 1995, CELL GROWTH DIFFER, V6, P1287; Krek W, 1998, CURR OPIN GENET DEV, V8, P36, DOI 10.1016/S0959-437X(98)80059-2; Lacy S, 1997, ONCOGENE, V14, P2395, DOI 10.1038/sj.onc.1201085; Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098; Lim MS, 2002, BLOOD, V100, P2950, DOI 10.1182/blood.V100.8.2950; Lu LF, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-22; Masuda T, 2002, CANCER RES, V62, P3819; Mayol X, 1996, ONCOGENE, V13, P237; MAYOL X, 1995, ONCOGENE, V11, P801; MAYOL X, 1998, FRONT BIOSCI, V3, P11; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Parreno M, 2000, J VIROL, V74, P3166, DOI 10.1128/JVI.74.7.3166-3176.2000; Parreno M, 2001, ONCOGENE, V20, P4793, DOI 10.1038/sj.onc.1204644; Penin RM, 2002, MODERN PATHOL, V15, P1227, DOI 10.1097/01.MP.0000036589.99516.D6; Prince AM, 2002, BIOCHEM BIOPH RES CO, V290, P1066, DOI 10.1006/bbrc.2001.6291; Richon VM, 1997, J BIOL CHEM, V272, P10117, DOI 10.1074/jbc.272.15.10117; Signoretti S, 2002, J CLIN INVEST, V110, P633, DOI 10.1172/JCI200215795; Smith EJ, 1998, CELL GROWTH DIFFER, V9, P297; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; Yang G, 2002, CLIN CANCER RES, V8, P3419; Yew PR, 2001, J CELL PHYSIOL, V187, P1, DOI 10.1002/1097-4652(2001)9999:9999<1::AID-JCP1049>3.0.CO;2-O; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408	43	85	86	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 24	2003	22	16					2443	2451		10.1038/sj.onc.1206339	http://dx.doi.org/10.1038/sj.onc.1206339			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	670AD	12717421				2022-12-28	WOS:000182383500007
J	Bartunek, P; Kralova, J; Blendinger, G; Dvorak, M; Zenke, M				Bartunek, P; Kralova, J; Blendinger, G; Dvorak, M; Zenke, M			GATA-1 and c-myb crosstalk during red blood cell differentiation through GATA-1 binding sites in the c-myb promoter	ONCOGENE			English	Article						c-myb; proto-oncogene; GATA-1; GATA factor; erythropoiesis; red blood cell	TRANSCRIPTION FACTOR GATA-1; EMBRYONIC STEM-CELLS; ZINC-FINGER PROTEIN; ERYTHROID PROGENITORS; HEMATOPOIETIC-CELLS; IN-VITRO; DNA-BINDING; TERMINAL DIFFERENTIATION; ERYTHROPOIETIN RECEPTOR; GLUCOCORTICOID RECEPTOR	GATA-1 and c-Myb transcription factors represent key regulators of red blood cell development. GATA-1 is upregulated and c-myh proto-oncogene expression is downregulated when red cell progenitors differentiate into erythrocytes. Here we have employed a culture system, that faithfully recapitulates red blood cell differentiation in vitro, to follow the kinetics of GATA-1 and c-myb expression. We show that c-myb proto-oncogene expression is high in progenitors and effectively downregulated at the time when nuclear GATA-1 accumulates and cells differentiate into erythrocytes. Additionally, we identified two GATA-1 binding sites within the c-myb promoter and demonstrate that GATA-I protein binds to these sites in vitro. Furthermore, GATA-1 represses c-myb expression through one of the GATA-1 binding sites in transient transfection experiments and this requires FOG-1. Thus, our study provides evidence for a direct molecular link between GATA-1 activity and c-myb proto-oncogene expression during terminal red cell differentiation.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Inst Mol Genet, Prague 16637 6, Czech Republic	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences	Zenke, M (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.		Dvořák, Michal/I-9939-2014; Bartunek, Petr/J-3897-2014; Kralova, Jarmila/G-3834-2014; Dvorak, Michal/G-5861-2014	Bartunek, Petr/0000-0002-6202-7650; Kralova, Jarmila/0000-0002-4735-8857; 				AIRD WC, 1994, J BIOL CHEM, V269, P883; Bartunek P, 1996, CYTOKINE, V8, P14, DOI 10.1006/cyto.1996.0003; Bartunek P, 2002, ONCOGENE, V21, P400, DOI 10.1038/sj/onc/1205103; Bartunek P, 1997, ONCOGENE, V15, P2939, DOI 10.1038/sj.onc.1201457; Bartunek P, 1998, MOL ENDOCRINOL, V12, P1269, DOI 10.1210/mend.12.9.0173; BARTUNEK P, 1992, VIROLOGY, V190, P882, DOI 10.1016/0042-6822(92)90930-N; Bauer A, 1998, EMBO J, V17, P4291, DOI 10.1093/emboj/17.15.4291; Bellon T, 1997, BLOOD, V90, P1828, DOI 10.1182/blood.V90.5.1828; BEUG H, 1995, METHOD ENZYMOL, V254, P41; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Briegel K, 1996, DEVELOPMENT, V122, P3839; BRIEGEL K, 1993, GENE DEV, V7, P1097, DOI 10.1101/gad.7.6.1097; Campanero MR, 1999, MOL CELL BIOL, V19, P8442; CHIBA T, 1991, NUCLEIC ACIDS RES, V19, P3843, DOI 10.1093/nar/19.14.3843; CROSSLEY M, 1994, J BIOL CHEM, V269, P16589; CUDDIHY AE, 1993, MOL CELL BIOL, V13, P3505, DOI 10.1128/MCB.13.6.3505; Deconinck AE, 2000, DEVELOPMENT, V127, P2031; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; DOLZNIG H, 1995, CELL GROWTH DIFFER, V6, P1341; Dolznig H, 2002, CURR BIOL, V12, P1076, DOI 10.1016/S0960-9822(02)00930-2; Dolznig H, 2001, FASEB J, V15, P1442, DOI 10.1096/fj.00-0705fje; DVORAK M, 1989, NUCLEIC ACIDS RES, V17, P5651; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FIBACH E, 1991, INT J CELL CLONING, V9, P57, DOI 10.1002/stem.5530090108; FONG TC, 1992, GENE DEV, V6, P521, DOI 10.1101/gad.6.4.521; Graf T, 2002, BLOOD, V99, P3089, DOI 10.1182/blood.V99.9.3089; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; KOZMIK Z, 1990, GENE, V90, P287, DOI 10.1016/0378-1119(90)90192-T; LYON JJ, 1995, DIFFERENTIATION, V59, P171, DOI 10.1046/j.1432-0436.1995.5930171.x; MCCANN S, 1995, J BIOL CHEM, V270, P23785, DOI 10.1074/jbc.270.40.23785; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1994, CURR OPIN GENET DEV, V4, P718, DOI 10.1016/0959-437X(94)90139-T; NICOLAIDES NC, 1991, MOL CELL BIOL, V11, P6166, DOI 10.1128/MCB.11.12.6166; NICOLAIDES NC, 1992, J BIOL CHEM, V267, P19665; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; ORKIN SH, 1995, CURR OPIN CELL BIOL, V7, P870, DOI 10.1016/0955-0674(95)80072-7; Panzenbock B, 1998, BLOOD, V92, P3658, DOI 10.1182/blood.V92.10.3658.422k18_3658_3668; PERROTTI D, 1995, MOL CELL BIOL, V15, P6075; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PEVNY L, 1995, DEVELOPMENT, V121, P163; SIMON MC, 1992, NAT GENET, V1, P92, DOI 10.1038/ng0592-92; SOBIESZCZUK PW, 1989, NUCLEIC ACIDS RES, V17, P9593, DOI 10.1093/nar/17.23.9593; Sullivan J, 1997, J BIOL CHEM, V272, P1943, DOI 10.1074/jbc.272.3.1943; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; Tsang AP, 1998, GENE DEV, V12, P1176, DOI 10.1101/gad.12.8.1176; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; URBANEK P, 1988, NUCLEIC ACIDS RES, V16, P11521, DOI 10.1093/nar/16.24.11521; von Lindern M, 1999, BLOOD, V94, P550, DOI 10.1182/blood.V94.2.550.414k39_550_559; WEISS MJ, 1995, EXP HEMATOL, V23, P99; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; Wessely O, 1997, EMBO J, V16, P267, DOI 10.1093/emboj/16.2.267; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; Zhang DY, 2001, EXP HEMATOL, V29, P1278, DOI 10.1016/S0301-472X(01)00725-1	56	53	57	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 3	2003	22	13					1927	1935		10.1038/sj.onc.1206281	http://dx.doi.org/10.1038/sj.onc.1206281			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	662UR	12673198				2022-12-28	WOS:000181967700003
J	Kim, YC; Yamaguchi, Y; Kondo, N; Masutani, H; Yodoi, J				Kim, YC; Yamaguchi, Y; Kondo, N; Masutani, H; Yodoi, J			Thioredoxin-dependent redox regulation of the antioxidant responsive element (ARE) in electrophile response	ONCOGENE			English	Article						thioredoxin; Nrf2; antioxidant responsive element (ARE); tert-butylhydroquinone (tBHQ); redox regulation; electrophile	SITE-DIRECTED MUTAGENESIS; MEDIATED EXPRESSION; ACTIVATION; TRANSCRIPTION; NRF2; BINDING; GENE; PROTEINS; DIFFERENTIATION; ASSOCIATION	Thioredoxin is a redox-regulating protein, the expression of which is induced by various forms of oxidative stress. Thioredoxin controls the interactions of various transcription factors through redox regulation. In K562 cells, we have previously reported that hemin induces activation of the thioredoxin gene by regulating NF-E2-related factor (Nrf2) through the antioxidant responsive element (ARE). We showed here that tert-butylhydroquinone (tBHQ), an electrophile stressor, activates the thioredoxin gene through the ARE. In an electrophoretic mobility shift assay, a specific Nrf2/small Maf binding complex was induced by tBHQ and bound to the ARE. Overexpression of Nrf2 increased the tBHQ-induced thioredoxin gene activation through the ARE, whereas that of Jun and Fos suppressed the activation. The tBHQ-induced ARE binding activity was completely abrogated by an oxidizing agent, diamide, whereas 2-mereaptoethanol (2-ME) reversibly recovered the inhibitory effects of diamide, suggesting that ARE binding activity is redox-dependent. Moreover, overexpression of thioredoxin enhanced the ARE-mediated thioredoxin gene activation by tBHQ. Therefore, ARE-mediated induction of thioredoxin expression is a mechanism of enhancing signal transduction through the ARE in electrophile-induced stress responses.	Kyoto Univ, Inst Virus Res, Dept Biol Responses, Sakyo Ku, Kyoto 6068507, Japan; Natl Inst Adv Ind Sci & Technol, Human Stress Signal Res Ctr, Biomed Special Res Unit, AIST, Osaka 5638577, Japan	Kyoto University; National Institute of Advanced Industrial Science & Technology (AIST)	Masutani, H (corresponding author), Kyoto Univ, Inst Virus Res, Dept Biol Responses, Sakyo Ku, 53 Shogoin,Kawahara Cho, Kyoto 6068507, Japan.	hmasutan@virus.kyoto-u.ac.jp	Masutani, Hiroshi/B-5114-2014	Masutani, Hiroshi/0000-0001-7633-2827				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Blank V, 1997, TRENDS BIOCHEM SCI, V22, P437, DOI 10.1016/S0968-0004(97)01105-5; Bloom D, 2002, ONCOGENE, V21, P2191, DOI 10.1038/sj.onc.1205288; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; IGARASHI K, 1995, P NATL ACAD SCI USA, V92, P7445, DOI 10.1073/pnas.92.16.7445; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; ITOH K, 1995, MOL CELL BIOL, V15, P4184, DOI 10.1128/mcb.15.8.4184; Kim YC, 2001, J BIOL CHEM, V276, P18399, DOI 10.1074/jbc.M100103200; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MILLER EC, 1981, CANCER-AM CANCER SOC, V47, P2327, DOI 10.1002/1097-0142(19810515)47:10<2327::AID-CNCR2820471003>3.0.CO;2-Z; NAKABEPPU Y, 1993, MOL CELL BIOL, V13, P4157, DOI 10.1128/MCB.13.7.4157; NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604; OBLONG JE, 1994, J BIOL CHEM, V269, P11714; PACKER L, 1999, REDOX REGULATION CEL, P251; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; TSUJI Y, 1995, MOL CELL BIOL, V15, P5152; Ueno M, 1999, J BIOL CHEM, V274, P35809, DOI 10.1074/jbc.274.50.35809; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; VERHAGEN H, 1989, CARCINOGENESIS, V10, P1947, DOI 10.1093/carcin/10.10.1947	23	103	111	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2003	22	12					1860	1865		10.1038/sj.onc.1206369	http://dx.doi.org/10.1038/sj.onc.1206369			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660821				2022-12-28	WOS:000181678200012
J	Pichierri, P; Rosselli, F; Franchitto, A				Pichierri, P; Rosselli, F; Franchitto, A			Werner's syndrome protein is phosphorylated in an ATR/ATM-dependent manner following replication arrest and DNA damage induced during the S phase of the cell cycle	ONCOGENE			English	Article						Werner's syndrome protein; RecQ helicases; ATR; replication arrest; DNA damage response	SYNDROME LYMPHOBLASTOID-CELLS; BLOOMS-SYNDROME PROTEIN; ATAXIA-TELANGIECTASIA; FUNCTIONAL INTERACTION; IONIZING-RADIATION; CHECKPOINT PATHWAY; FORK ARREST; ATM KINASE; RECOMBINATION; EXONUCLEASE	Werner's syndrome (WS) is an autosomal recessive disorder, characterized at the cellular level by genomic instability in the form of variegated translocation mosaicism and extensive deletions. Individuals with WS prematurely develop multiple age-related pathologies and exhibit increased incidence of cancer. WRN, the gene defective in WS, encodes a 160-kDa protein (WRN), which has 3'-5' exonuclease, DNA helicase and DNA-dependent ATPase activities. WRN-defective cells are hypersensitive to certain genotoxic agents that cause replication arrest and/or double-strand breaks at the replication fork, suggesting a pivotal role for WRN in the protection of the integrity of the genoma during the DNA replication process. Here, we show that WRN is phosphorylated through an ATR/ATM dependent pathway in response to replication blockage. However, we provide evidence that WRN phosphorylation is not essential for its subnuclear relocalization after replication arrest. Finally, we show that WRN and ATR colocalize after replication fork arrest, suggesting that WRN and the ATR kinase collaborate to prevent genome instability during the S phase.	Inst Gustave Roussy, CNRS, UPR2169, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Franchitto, A (corresponding author), Inst Gustave Roussy, CNRS, UPR2169, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.		Franchitto, Annapaola/K-7564-2016; Filippo, Rosselli/AAO-6393-2020; Pichierri, Pietro/AAA-5476-2021	Franchitto, Annapaola/0000-0003-4232-4727; Filippo, Rosselli/0000-0003-1080-5745; Pichierri, Pietro/0000-0002-2702-3523				Ababou M, 2002, ONCOGENE, V21, P2079, DOI 10.1038/sj.onc.1205246; Ababou M, 2000, ONCOGENE, V19, P5955, DOI 10.1038/sj.onc.1204003; Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; BIERNE H, 1994, MOL MICROBIOL, V13, P17, DOI 10.1111/j.1365-2958.1994.tb00398.x; Bohr VA, 2001, ENVIRON MOL MUTAGEN, V38, P227, DOI 10.1002/em.1076; Brosh RM, 2002, EXP GERONTOL, V37, P491, DOI 10.1016/S0531-5565(01)00227-3; CAO G, 1991, EXP CELL RES, V193, P405, DOI 10.1016/0014-4827(91)90113-9; Cliby WA, 2002, J BIOL CHEM, V277, P1599, DOI 10.1074/jbc.M106287200; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Cooper MP, 2000, GENE DEV, V14, P907; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; FOTEDAR R, 1992, EMBO J, V11, P2177, DOI 10.1002/j.1460-2075.1992.tb05277.x; Franchitto A, 2002, J CELL BIOL, V157, P19, DOI 10.1083/jcb.200110009; Frei C, 2000, J CELL SCI, V113, P2641; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; Gatei M, 2000, CANCER RES, V60, P3299; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; GEBHART E, 1988, HUM GENET, V80, P135, DOI 10.1007/BF00702855; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Imamura O, 2002, ONCOGENE, V21, P954, DOI 10.1038/sj.onc.1205143; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; KARMAKAR P, 2002, J BIOL CHEM, V11, P11; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; KREPINSKY AB, 1979, HUM GENET, V50, P151, DOI 10.1007/BF00390236; Li BM, 2000, J BIOL CHEM, V275, P28349, DOI 10.1074/jbc.C000289200; Marciniak RA, 1998, P NATL ACAD SCI USA, V95, P6887, DOI 10.1073/pnas.95.12.6887; Michel B, 2000, TRENDS BIOCHEM SCI, V25, P173, DOI 10.1016/S0968-0004(00)01560-7; Michel B, 1997, EMBO J, V16, P430, DOI 10.1093/emboj/16.2.430; Michel B, 2001, P NATL ACAD SCI USA, V98, P8181, DOI 10.1073/pnas.111008798; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Mohaghegh P, 2001, HUM MOL GENET, V10, P741, DOI 10.1093/hmg/10.7.741; Orren DK, 2001, NUCLEIC ACIDS RES, V29, P1926, DOI 10.1093/nar/29.9.1926; Pichierri P, 2000, MUTAT RES-DNA REPAIR, V459, P123, DOI 10.1016/S0921-8777(99)00065-8; Pichierri P, 2001, MOL BIOL CELL, V12, P2412, DOI 10.1091/mbc.12.8.2412; Pichierri P, 2000, MUTAT RES-FUND MOL M, V456, P45, DOI 10.1016/S0027-5107(00)00109-3; POOT M, 1992, EXP CELL RES, V202, P267, DOI 10.1016/0014-4827(92)90074-I; Poot M, 1999, HUM GENET, V104, P10, DOI 10.1007/s004390050903; Poot M, 2001, FASEB J, V15, P1224, DOI 10.1096/fj.00-0611fje; Rothstein R, 2000, GENE DEV, V14, P1; Sakamoto S, 2001, GENES CELLS, V6, P421, DOI 10.1046/j.1365-2443.2001.00433.x; SALK D, 1981, CYTOGENET CELL GENET, V30, P92, DOI 10.1159/000131596; Salk D, 1985, Basic Life Sci, V35, P419; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sarkaria JN, 1999, CANCER RES, V59, P4375; SCAPPATICCI S, 1982, HUM GENET, V62, P16, DOI 10.1007/BF00295599; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 2000, ONCOGENE, V19, P6176, DOI 10.1038/sj.onc.1203971; Shao RG, 1999, EMBO J, V18, P1397, DOI 10.1093/emboj/18.5.1397; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Wang HY, 2001, CANCER RES, V61, P8554; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445; Yannone SM, 2001, J BIOL CHEM, V276, P38242; ZernikKobak M, 1997, J BIOL CHEM, V272, P23896, DOI 10.1074/jbc.272.38.23896; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083	61	101	102	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 13	2003	22	10					1491	1500		10.1038/sj.onc.1206169	http://dx.doi.org/10.1038/sj.onc.1206169			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652ZZ	12629512				2022-12-28	WOS:000181411900006
J	Wang, XD; Rosales, JL; Magliocco, A; Gnanakumar, R; Lee, KY				Wang, XD; Rosales, JL; Magliocco, A; Gnanakumar, R; Lee, KY			Cyclin E in breast tumors is cleaved into its low molecular weight forms by calpain	ONCOGENE			English	Article						cyclin E; calpain; breast cancer	CANCER; OVEREXPRESSION; CELLS; AMPLIFICATION; EXPRESSION; SYSTEM	Abundant levels of the hyperactive low molecular weight (LMW) forms of cyclin E contribute to deregulation of Cdk2 in breast tumors, but the mechanism through which they arise is not fully understood. Here, we explored the hypothesis that post-translational processing by a protease generates the LMW forms of cyclin E in breast tumors. In ZR75 tumor cell lysates, calcium-induced cyclin E truncation into peptides corresponding in size with LMW forms of cyclin E in tumor tissues. Calpeptin inhibited calcium-stimulated cyclin E truncation, indicating that cleavage resulted from activity of the calcium-dependent protease, calpain. Consistently, calcium + calpain caused truncation of cyclin E immunoprecipitated from tumor cells and tissues. Calcium also caused truncation of the calpain regulatory subunit in tumor cell lysates, indicating that elevated calpain activity accompanies cyclin E truncation. Increased levels of the calpain small subunit were also observed in breast tumors, and significant amounts of its proteolyzed forms indicated increased calpain activity. While elastase also caused cyclin E truncation, the cleavage pattern was distinct from that generated by calpain, suggesting discrete mechanisms in regulating the formation of LMW cyclin E in breast tumors. Treatment of ZR75 cultures with calcium + A23187 recapitulated the formation of the calcium/calpain/induced LMW forms of cyclin E. Altered calcium homeostasis and/or inability of the endogenous calpain inhibitor to control the activity of high levels of the calpain small subunit may contribute to increased calpain activity in breast tumors, causing abundant levels of LMW cyclin E.	Univ Calgary, Fac Med, Dept Cell Biol & Anat, Canc Biol & Neurosci Res Grp, Calgary, AB T2N 4N1, Canada	University of Calgary	Lee, KY (corresponding author), Univ Calgary, Fac Med, Dept Cell Biol & Anat, Canc Biol & Neurosci Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.		Magliocco, Anthony M/E-5723-2010	Rosales, Jesusa/0000-0002-2543-3801				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; Dou QP, 1996, NAT MED, V2, P254, DOI 10.1038/nm0396-254a; Ford HL, 1998, P NATL ACAD SCI USA, V95, P12608, DOI 10.1073/pnas.95.21.12608; Harwell RM, 2000, CANCER RES, V60, P481; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Kawasaki H, 1996, MOL MEMBR BIOL, V13, P217, DOI 10.3109/09687689609160599; Keyomarsi K, 1997, Prog Cell Cycle Res, V3, P171; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KEYOMARSI K, 1995, ONCOGENE, V11, P941; LEE SW, 1992, P NATL ACAD SCI USA, V89, P2504, DOI 10.1073/pnas.89.6.2504; Lelekakis M, 1999, CLIN EXP METASTAS, V17, P163, DOI 10.1023/A:1006689719505; Nielsen NH, 1996, BRIT J CANCER, V74, P874, DOI 10.1038/bjc.1996.451; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Porter DC, 2001, MOL CELL BIOL, V21, P6254, DOI 10.1128/MCB.21.18.6254-6269.2001; SAID TK, 1995, CARCINOGENESIS, V16, P823, DOI 10.1093/carcin/16.4.823; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SEWING A, 1994, J CELL SCI, V107, P581; Shiba, 1996, Breast Cancer, V3, P13, DOI 10.1007/BF02966957; Steeg PS, 1998, BREAST CANCER RES TR, V52, P17, DOI 10.1023/A:1006102916060	21	44	53	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 6	2003	22	5					769	774		10.1038/sj.onc.1206166	http://dx.doi.org/10.1038/sj.onc.1206166			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569370	Bronze			2022-12-28	WOS:000180642100015
J	Bocchetta, M; Miele, L; Pass, HI; Carbone, M				Bocchetta, M; Miele, L; Pass, HI; Carbone, M			Notch-1 induction, a novel activity of SV40 required for growth of SV40-transformed human mesothelial cells	ONCOGENE			English	Article						SV40; DNA tumor viruses; carcinogenicity; mesothelioma; notch-1	SMALL-T-ANTIGEN; SIMIAN-VIRUS-40; TRANSFORMATION; DIFFERENTIATION; EXPRESSION; ASBESTOS; PROTEIN; SEL-10; TRANSACTIVATION; PATHOGENESIS	We show that SV40 infection of human mesothelial cells directly causes overexpression of Notch-1, a key cell regulatory gene. Notch-1 induction is achieved at the transcriptional level and requires both the SV40 large T-antigen and the small t-antigen. Notch-1 upregulation is maintained in SV40-transformed human mesothelial clones and in SV40-positive mesotheliomas and derived cell lines. Activation of Notch-1 promotes cell cycle progression and it is required for the growth of SV40-transformed mesothelial cells. Our finding is relevant to the process of SV40-mediated human cell transformation, an effect that cannot be accounted for solely by SV40-Tag inhibition of Rb and p53.	Loyola Univ, Cardinal Bernardin Canc Ctr, Canc Immunol Program, Dept Pathol, Maywood, IL 60153 USA; Univ Illinois, Dept Pharmacodynam & Pharmaceut, Chicago, IL USA; Univ Illinois, Ctr Canc, Chicago, IL USA; Wayne State Univ, Aerodigest Program, Karmanos Ctr Inst, Detroit, MI 48201 USA	Loyola University Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Wayne State University	Carbone, M (corresponding author), Loyola Univ, Cardinal Bernardin Canc Ctr, Canc Immunol Program, Dept Pathol, Room 205,2160 S 1st Ave, Maywood, IL 60153 USA.	mcarbon@orion.it.luc.edu		Pass, Harvey/0000-0003-3222-3471; Miele, Lucio/0000-0002-5853-7287	NCI NIH HHS [R0-1 CA92657, R0-1 CA84065] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092657, R01CA084065] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Aster JC, 2000, MOL CELL BIOL, V20, P7505, DOI 10.1128/MCB.20.20.7505-7515.2000; Bocchetta M, 2000, P NATL ACAD SCI USA, V97, P10214, DOI 10.1073/pnas.170207097; Butel JS, 1999, JNCI-J NATL CANCER I, V91, P119, DOI 10.1093/jnci/91.2.119; Cacciotti P, 2001, P NATL ACAD SCI USA, V98, P12032, DOI 10.1073/pnas.211026798; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; CARBONE M, 1994, ONCOGENE, V9, P1781; Carbone M, 2002, SEMIN ONCOL, V29, P2, DOI 10.1053/sonc.2002.30227; Carbone M, 1997, NAT MED, V3, P908, DOI 10.1038/nm0897-908; Carlesso N, 1999, BLOOD, V93, P838, DOI 10.1182/blood.V93.3.838.403k29_838_848; DeLuca A, 1997, NAT MED, V3, P913, DOI 10.1038/nm0897-913; Foddis R, 2002, ONCOGENE, V21, P1434, DOI 10.1038/sj.onc.1205203; FROST JA, 1994, MOL CELL BIOL, V14, P6244, DOI 10.1128/MCB.14.9.6244; Grammatikakis N, 2001, J BIOL CHEM, V276, P27840, DOI 10.1074/jbc.M101987200; Gupta-Rossi N, 2001, J BIOL CHEM, V276, P34371, DOI 10.1074/jbc.M101343200; Hsieh JJD, 1997, J VIROL, V71, P1938, DOI 10.1128/JVI.71.3.1938-1945.1997; Imperiale MJ, 2001, SEMIN CANCER BIOL, V11, P81, DOI 10.1006/scbi.2000.0349; Jang MS, 2000, CURR OPIN MOL THER, V2, P55; Jasani B, 2001, SEMIN CANCER BIOL, V11, P49, DOI 10.1006/scbi.2000.0346; Klein G, 2002, ONCOGENE, V21, P1141, DOI 10.1038/sj.onc.1205173; KLEIN G, 2000, P NATL ACTA SCI US, V97, P10214; Krynska B, 1999, P NATL ACAD SCI USA, V96, P11519, DOI 10.1073/pnas.96.20.11519; MATTHEWS BJ, 1987, J VIROL, V61, P1282, DOI 10.1128/JVI.61.4.1282-1285.1987; McLendon C, 2000, FASEB J, V14, P2383; Miele L, 1999, J CELL PHYSIOL, V181, P393, DOI 10.1002/(SICI)1097-4652(199912)181:3<393::AID-JCP3>3.0.CO;2-6; Mossman BT, 2002, AM J RESP CELL MOL, V26, P167, DOI 10.1165/ajrcmb.26.2.f229; MOSSMAN BT, 1990, SCIENCE, V247, P294, DOI 10.1126/science.2153315; MYERS RM, 1985, SCIENCE, V230, P1242, DOI 10.1126/science.4071043; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; Osborne B, 1999, IMMUNITY, V11, P653, DOI 10.1016/S1074-7613(00)80140-5; Pass HI, 1996, CANCER RES, V56, P4044; Pass HI, 1998, J THORAC CARDIOV SUR, V116, P854, DOI 10.1016/S0022-5223(98)00438-3; Porras A, 1996, J VIROL, V70, P6902; Powers A, 2002, CANCER BIOL THER, V1, P348; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Rangarajan A, 2001, VIROLOGY, V286, P23, DOI 10.1006/viro.2001.0867; Rizzo P, 2001, SEMIN CANCER BIOL, V11, P63, DOI 10.1006/scbi.2000.0347; Robledo R, 1999, J CELL PHYSIOL, V180, P158, DOI 10.1002/(SICI)1097-4652(199908)180:2<158::AID-JCP3>3.0.CO;2-R; Rundell K, 2001, SEMIN CANCER BIOL, V11, P5, DOI 10.1006/scbi.2000.0341; SCHILLING LJ, 1994, NUCLEIC ACIDS RES, V22, P3061, DOI 10.1093/nar/22.15.3061; Schrump DS, 2001, SEMIN CANCER BIOL, V11, P73, DOI 10.1006/scbi.2000.0348; Shelly LL, 1999, J CELL BIOCHEM, V73, P164, DOI 10.1002/(SICI)1097-4644(19990501)73:2<164::AID-JCB3>3.0.CO;2-0; Shivapurkar N, 2000, J CELL BIOCHEM, V76, P181; Testa JR, 2001, SEMIN CANCER BIOL, V11, P31, DOI 10.1006/scbi.2000.0344; TESTA JR, 2001, CANC PRINCIPLES PRAC, V6, P1937; Toyooka S, 2001, CANCER RES, V61, P5727; Wiman KG, 1997, NAT MED, V3, P839, DOI 10.1038/nm0897-839; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001; Yu J, 2001, VIROLOGY, V290, P192, DOI 10.1006/viro.2001.1204; Zhou SF, 2001, MOL CELL BIOL, V21, P6222, DOI 10.1128/MCB.21.18.6222-6232.2001	52	79	84	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	2003	22	1					81	89		10.1038/sj.onc.1206097	http://dx.doi.org/10.1038/sj.onc.1206097			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527910				2022-12-28	WOS:000180166900009
J	Gros, L; Saparbaev, MK; Laval, J				Gros, L; Saparbaev, MK; Laval, J			Enzymology of the repair of free radicals-induced DNA damage	ONCOGENE			English	Review						oxygen free radicals; oxidative DNA damage; DNA glycosylase; base excision; 8-oxoguanine; AP endonuclease	BASE-EXCISION-REPAIR; COLI ENDONUCLEASE-III; HUMAN APURINIC/APYRIMIDINIC ENDONUCLEASE; HUMAN APURINIC ENDONUCLEASE; CELL NUCLEAR ANTIGEN; TRANSCRIPTION-COUPLED REPAIR; DOUBLE-STRAND BREAKS; HUMAN MUTT HOMOLOG; HUMAN ALKYLADENINE GLYCOSYLASE; RING FRAGMENTATION PRODUCT	A number of intrinsic and extrinsic mutagens induce structural damage in cellular DNA. These DNA damages are cytotoxic, miscoding or both and are believed to be at the origin of cell lethality, tissue degeneration, ageing and cancer. In order to counteract immediately the deleterious effects of such lesions, leading to genomic instability, cells have evolved a number of DNA repair mechanisms including the direct reversal of the lesion, sanitation of the dNTPs pools, mismatch repair and several DNA excision pathways including the base excision repair (BER) nucleotide excision repair (NER) and the nucleotide incision repair (NIR). These repair pathways are universally present in living cells and extremely well conserved. This review is focused on the repair of lesions induced by free radicals and ionising radiation. The BER pathway removes most of these DNA lesions, although recently it was shown that other pathways would also be efficient in the removal of oxidised bases. In the BER pathway the process is initiated by a DNA glycosylase excising the modified and mismatched base by hydrolysis of the glycosidic bond between the base and the deoxyribose of the DNA, generating a free base and an abasic site (AP-site) which in turn is repaired since it is cytotoxic and mutagenic.	Inst Gustave Roussy, UMR 8532 CNRS, ENS Cachan, LBPA,Grp Reparat ADN, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy	Laval, J (corresponding author), Inst Gustave Roussy, UMR 8532 CNRS, ENS Cachan, LBPA,Grp Reparat ADN, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	jlaval@igr.fr	Saparbaev, Murat K/N-3225-2015; Saparbaev, Murat/AAC-5478-2020	Saparbaev, Murat K/0000-0002-4630-1074; Saparbaev, Murat/0000-0002-4630-1074				AHNSTROM G, 1982, INT J RADIAT BIOL, V41, P671, DOI 10.1080/09553008214550761; Al-Tassan N, 2002, NAT GENET, V30, P227, DOI 10.1038/ng828; Allinson SL, 2001, EMBO J, V20, P6919, DOI 10.1093/emboj/20.23.6919; Alseth I, 1999, MOL CELL BIOL, V19, P3779; Aravind L, 2000, GENOME BIOL, V1, P1, DOI DOI 10.1186/GB-2000-1-4-RESEARCH0007; ASAHARA H, 1989, BIOCHEMISTRY-US, V28, P4444, DOI 10.1021/bi00436a048; Aspinwall R, 1997, P NATL ACAD SCI USA, V94, P109, DOI 10.1073/pnas.94.1.109; Augeri L, 1997, BIOCHEMISTRY-US, V36, P721, DOI 10.1021/bi9625511; Baeuerle PA, 1996, PATHOL BIOL, V44, P29; BAILLY V, 1987, BIOCHEM J, V242, P565, DOI 10.1042/bj2420565; BAILLY V, 1989, BIOCHEM J, V262, P581, DOI 10.1042/bj2620581; Barrett TE, 1998, CELL, V92, P117, DOI 10.1016/S0092-8674(00)80904-6; BARZILAY G, 1995, NUCLEIC ACIDS RES, V23, P1544, DOI 10.1093/nar/23.9.1544; BARZILAY G, 1995, BIOESSAYS, V17, P713, DOI 10.1002/bies.950170808; Bauche C, 1999, J BACTERIOL, V181, P262, DOI 10.1128/JB.181.1.262-269.1999; Bennett RAO, 1999, MOL CELL BIOL, V19, P1800; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Bessho T, 1999, NUCLEIC ACIDS RES, V27, P979, DOI 10.1093/nar/27.4.979; Bhagwat M, 1996, BIOCHEMISTRY-US, V35, P659, DOI 10.1021/bi9522662; BJELLAND S, 1993, NUCLEIC ACIDS RES, V21, P2045, DOI 10.1093/nar/21.9.2045; BJELLAND S, 1995, BIOCHEMISTRY-US, V34, P14758, DOI 10.1021/bi00045a017; BJELLAND S, 1994, J BIOL CHEM, V269, P30489; Blaisdell JO, 1999, J BACTERIOL, V181, P6396, DOI 10.1128/JB.181.20.6396-6402.1999; Blaisdell JO, 2001, RADIAT PROT DOSIM, V97, P25, DOI 10.1093/oxfordjournals.rpd.a006634; Blaisdell JO, 2001, P NATL ACAD SCI USA, V98, P7426, DOI 10.1073/pnas.131077798; BOITEUX S, 1992, BIOCHEMISTRY-US, V31, P106, DOI 10.1021/bi00116a016; Boiteux S, 2000, ARCH BIOCHEM BIOPHYS, V377, P1, DOI 10.1006/abbi.2000.1773; BOITEUX S, 1987, EMBO J, V6, P3177, DOI 10.1002/j.1460-2075.1987.tb02629.x; BOITEUX S, 1993, J PHOTOCH PHOTOBIO B, V19, P87, DOI 10.1016/1011-1344(93)87101-R; BOITEUX S, 1982, BIOCHEMISTRY-US, V21, P6746, DOI 10.1021/bi00269a020; BOITEUX S, 1990, J BIOL CHEM, V265, P3916; Boldogh I, 2001, NUCLEIC ACIDS RES, V29, P2802, DOI 10.1093/nar/29.13.2802; BONURA T, 1975, P NATL ACAD SCI USA, V72, P4265, DOI 10.1073/pnas.72.11.4265; BOORSTEIN RJ, 1992, MOL CELL BIOL, V12, P5536, DOI 10.1128/MCB.12.12.5536; Boorstein RJ, 2001, J BIOL CHEM, V276, P41991, DOI 10.1074/jbc.M106953200; Brooks PJ, 2000, J BIOL CHEM, V275, P22355, DOI 10.1074/jbc.M002259200; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; Budworth H, 2002, J BIOL CHEM, V277, P21300, DOI 10.1074/jbc.M201918200; Burgess S, 2002, J BIOL CHEM, V277, P2938, DOI 10.1074/jbc.M110499200; Cadet J, 1999, MUTAT RES-FUND MOL M, V424, P9, DOI 10.1016/S0027-5107(99)00004-4; Cerda SR, 1998, FEBS LETT, V431, P12, DOI 10.1016/S0014-5793(98)00697-8; CHAN E, 1987, P NATL ACAD SCI USA, V84, P3189, DOI 10.1073/pnas.84.10.3189; Chang DY, 2002, J BIOL CHEM, V277, P11853, DOI 10.1074/jbc.M111739200; Chang DY, 2001, MOL GENET GENOMICS, V266, P336, DOI 10.1007/s004380100567; CHARKOV DO, 2002, EMBO J, V21, P789; Chaudhry MA, 1997, J BIOL CHEM, V272, P15650, DOI 10.1074/jbc.272.25.15650; CHAUDHRY MA, 1995, J MOL BIOL, V249, P914; Chen LW, 2002, CHEM BIOL, V9, P345, DOI 10.1016/S1074-5521(02)00120-5; Chevillard S, 1998, ONCOGENE, V16, P3083, DOI 10.1038/sj.onc.1202096; Chmiel NH, 2001, NUCLEIC ACIDS RES, V29, P553, DOI 10.1093/nar/29.2.553; Chou KM, 2000, J BIOL CHEM, V275, P31009, DOI 10.1074/jbc.M004082200; Chou KM, 2002, NATURE, V415, P655, DOI 10.1038/415655a; Colussi C, 2002, CURR BIOL, V12, P912, DOI 10.1016/S0960-9822(02)00863-1; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Cunniffe S, 1999, RADIAT RES, V152, P421, DOI 10.2307/3580227; CUNNINGHAM RP, 1985, P NATL ACAD SCI USA, V82, P474, DOI 10.1073/pnas.82.2.474; CUNNINGHAM RP, 1986, J BACTERIOL, V168, P1120, DOI 10.1128/jb.168.3.1120-1127.1986; CZECZOT H, 1991, J BACTERIOL, V173, P3419, DOI 10.1128/jb.173.11.3419-3424.1991; D'Ham C, 1999, BIOCHEMISTRY-US, V38, P3335, DOI 10.1021/bi981982b; Dantzer F, 2002, NUCLEIC ACIDS RES, V30, P2349, DOI 10.1093/nar/30.11.2349; David SS, 1998, CHEM REV, V98, P1221, DOI 10.1021/cr980321h; David-Cordonnier MH, 2000, J BIOL CHEM, V275, P11865, DOI 10.1074/jbc.275.16.11865; David-Cordonnier MH, 2002, BIOCHEMISTRY-US, V41, P634, DOI 10.1021/bi011682l; David-Cordonnier MH, 2001, BIOCHEMISTRY-US, V40, P11811, DOI 10.1021/bi0112356; David-Cordonnier MH, 2001, NUCLEIC ACIDS RES, V29, P1107, DOI 10.1093/nar/29.5.1107; de Souza-Pinto NC, 2001, CANCER RES, V61, P5378; DEMPLE B, 1983, J BACTERIOL, V153, P1079, DOI 10.1128/JB.153.2.1079-1082.1983; DEMPLE B, 1986, P NATL ACAD SCI USA, V83, P7731, DOI 10.1073/pnas.83.20.7731; DEMPLE B, 1991, ANNU REV GENET, V25, P315, DOI 10.1146/annurev.ge.25.120191.001531; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; DEMPLE B, 1980, NATURE, V287, P203, DOI 10.1038/287203a0; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; DEUTSCH WA, 1982, J BIOL CHEM, V257, P3366; DEVASAGAYAM TPA, 1991, BIOCHEMISTRY-US, V30, P6283, DOI 10.1021/bi00239a029; Dherin C, 1999, NUCLEIC ACIDS RES, V27, P4001, DOI 10.1093/nar/27.20.4001; Dherin C, 2000, NUCLEIC ACIDS RES, V28, P4583, DOI 10.1093/nar/28.23.4583; Dianov GL, 1999, J BIOL CHEM, V274, P13741, DOI 10.1074/jbc.274.20.13741; Dianova II, 2001, BIOCHEMISTRY-US, V40, P12639, DOI 10.1021/bi011117i; DIRKSEN ML, 1988, INT J RADIAT BIOL, V54, P195, DOI 10.1080/09553008814551631; Dizdaroglu M, 1999, BIOCHEMISTRY-US, V38, P243, DOI 10.1021/bi9819071; DIZDAROGLU M, 1977, INT J RADIAT BIOL, V32, P481, DOI 10.1080/09553007714551241; Dizdaroglu M, 2001, BIOCHEMISTRY-US, V40, P12150, DOI 10.1021/bi015552o; DIZDAROGLU M, 1993, BIOCHEMISTRY-US, V32, P12105, DOI 10.1021/bi00096a022; DODSON ML, 1994, J BIOL CHEM, V269, P32709; Doherty AJ, 1996, NUCLEIC ACIDS RES, V24, P2488, DOI 10.1093/nar/24.13.2488; Dotto GP, 2000, BBA-REV CANCER, V1471, pM43, DOI 10.1016/S0304-419X(00)00019-6; DUGLE DL, 1976, P NATL ACAD SCI USA, V73, P809, DOI 10.1073/pnas.73.3.809; DUWAT P, 1995, MICROBIOL-UK, V141, P411, DOI 10.1099/13500872-141-2-411; Eide L, 1996, P NATL ACAD SCI USA, V93, P10735, DOI 10.1073/pnas.93.20.10735; Eide L, 2001, BIOCHEMISTRY-US, V40, P6653, DOI 10.1021/bi0028901; Elder RH, 1998, MOL CELL BIOL, V18, P5828, DOI 10.1128/MCB.18.10.5828; ELGHISSASSI F, 1995, CHEM RES TOXICOL, V8, P278, DOI 10.1021/tx00044a013; Engelward BP, 1997, P NATL ACAD SCI USA, V94, P13087, DOI 10.1073/pnas.94.24.13087; Fink SP, 1997, P NATL ACAD SCI USA, V94, P8652, DOI 10.1073/pnas.94.16.8652; Fortini P, 1999, J BIOL CHEM, V274, P15230, DOI 10.1074/jbc.274.21.15230; Frenkel K, 1998, CANCER EPIDEM BIOMAR, V7, P49; Friedberg EC, 2002, SCIENCE, V296, P1627, DOI 10.1126/science.1070236; Fromme JC, 2002, NAT STRUCT BIOL, V9, P544, DOI 10.1038/nsb809; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Fujii Y, 1999, J BIOL CHEM, V274, P38251, DOI 10.1074/jbc.274.53.38251; Fujikawa K, 1999, J BIOL CHEM, V274, P18201, DOI 10.1074/jbc.274.26.18201; Fujikawa K, 2001, NUCLEIC ACIDS RES, V29, P449, DOI 10.1093/nar/29.2.449; FURUICHI M, 1994, GENOMICS, V24, P485, DOI 10.1006/geno.1994.1657; Gallinari P, 1996, NATURE, V383, P735, DOI 10.1038/383735a0; Garcia-Ortiz MV, 2001, PLANT MOL BIOL, V47, P795, DOI 10.1023/A:1013644026132; GELLON L, 2002, J BIOL CHEM; Georgakilas AG, 2002, NUCLEIC ACIDS RES, V30, P2800, DOI 10.1093/nar/gkf393; Gilboa R, 2002, J BIOL CHEM, V277, P19811, DOI 10.1074/jbc.M202058200; GILONI L, 1981, J BIOL CHEM, V256, P8608; Girard PM, 1997, NUCLEIC ACIDS RES, V25, P3204, DOI 10.1093/nar/25.16.3204; Girard PM, 1997, BIOCHIMIE, V79, P559, DOI 10.1016/S0300-9084(97)82004-4; GONG Z, 2002, IN PRESS CELL, V111; GOODHEAD DT, 1994, INT J RADIAT BIOL, V65, P7, DOI 10.1080/09553009414550021; GRAVES RJ, 1992, J BIOL CHEM, V267, P14429; Greenberg RB, 2001, J BIOL CHEM, V276, P31551, DOI 10.1074/jbc.M103588200; Gu YS, 2002, J BIOL CHEM, V277, P11135, DOI 10.1074/jbc.M108618200; Guan Y, 1998, NAT STRUCT BIOL, V5, P1058, DOI 10.1038/4168; HABRAKEN Y, 1991, CARCINOGENESIS, V12, P1971, DOI 10.1093/carcin/12.10.1971; Hadi MZ, 2000, ENVIRON MOL MUTAGEN, V36, P312, DOI 10.1002/1098-2280(2000)36:4<312::AID-EM7>3.0.CO;2-K; HALLIWELL B, 1982, CELL BIOL INT REP, V6, P529, DOI 10.1016/0309-1651(82)90175-8; Hanawalt PC, 2000, NATURE, V405, P415, DOI 10.1038/35013197; Hang B, 1998, P NATL ACAD SCI USA, V95, P13561, DOI 10.1073/pnas.95.23.13561; Hang B, 1997, P NATL ACAD SCI USA, V94, P12869, DOI 10.1073/pnas.94.24.12869; Hang B, 2002, BIOCHEMISTRY-US, V41, P2158, DOI 10.1021/bi011542b; Haracska L, 2000, NAT GENET, V25, P458, DOI 10.1038/78169; Hardeland U, 2002, EMBO J, V21, P1456, DOI 10.1093/emboj/21.6.1456; Harrison L, 1998, NUCLEIC ACIDS RES, V26, P932, DOI 10.1093/nar/26.4.932; HATAHET Z, 1994, J BIOL CHEM, V269, P18814; Haushalter KA, 1999, CURR BIOL, V9, P174, DOI 10.1016/S0960-9822(99)80087-6; Hayakawa H, 1999, BIOCHEMISTRY-US, V38, P3610, DOI 10.1021/bi982361l; Hayashi H, 2002, CURR BIOL, V12, P335, DOI 10.1016/S0960-9822(02)00686-3; Hazra TK, 2002, P NATL ACAD SCI USA, V99, P3523, DOI 10.1073/pnas.062053799; Hazra TK, 2001, PROG NUCLEIC ACID RE, V68, P193; Hazra TK, 2000, J BIOL CHEM, V275, P27762; HENNER WD, 1983, J BIOL CHEM, V258, P711; Hilbert TP, 1997, J BIOL CHEM, V272, P6733, DOI 10.1074/jbc.272.10.6733; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Holley WR, 1996, RADIAT RES, V145, P188, DOI 10.2307/3579174; Hollis T, 2000, MUTAT RES-DNA REPAIR, V460, P201, DOI 10.1016/S0921-8777(00)00027-6; Hosfield DJ, 1999, CELL, V98, P397, DOI 10.1016/S0092-8674(00)81968-6; Ikeda S, 1998, J BIOL CHEM, V273, P21585, DOI 10.1074/jbc.273.34.21585; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; Ischenko AA, 2002, NATURE, V415, P183, DOI 10.1038/415183a; Ishikawa T, 2001, MUTAT RES-FUND MOL M, V477, P41, DOI 10.1016/S0027-5107(01)00094-X; Janssen K, 2001, MUTAT RES-DNA REPAIR, V486, P207, DOI 10.1016/S0921-8777(01)00096-9; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Jelinsky SA, 2000, MOL CELL BIOL, V20, P8157, DOI 10.1128/MCB.20.21.8157-8167.2000; Jiang DY, 1997, J BACTERIOL, V179, P3773, DOI 10.1128/jb.179.11.3773-3782.1997; JOHNSON AW, 1988, J BIOL CHEM, V263, P18017; JOHNSON AW, 1988, J BIOL CHEM, V263, P18009; Johnson RE, 1998, GENE DEV, V12, P3137, DOI 10.1101/gad.12.19.3137; Jurado J, 1998, BIOCHEMISTRY-US, V37, P7757, DOI 10.1021/bi972982z; KAKUMA T, 1995, J BIOL CHEM, V270, P25942, DOI 10.1074/jbc.270.43.25942; KAMIYA H, 1995, NUCL ACIDS S SER, V34, P233; KANG D, 1995, J BIOL CHEM, V270, P14659, DOI 10.1074/jbc.270.24.14659; Karahalil B, 1998, NUCLEIC ACIDS RES, V26, P1228, DOI 10.1093/nar/26.5.1228; KASAI H, 1990, MUTAT RES, V243, P249, DOI 10.1016/0165-7992(90)90139-B; KIM J, 1988, NUCLEIC ACIDS RES, V16, P1135, DOI 10.1093/nar/16.3.1135; Kim JE, 2001, BIOCHEM BIOPH RES CO, V285, P1186, DOI 10.1006/bbrc.2001.5305; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Klungland A, 1999, MOL CELL, V3, P33, DOI 10.1016/S1097-2765(00)80172-0; Koukourakis MI, 2001, INT J RADIAT ONCOL, V50, P27, DOI 10.1016/S0360-3016(00)01561-3; KOW YW, 1987, BIOCHEMISTRY-US, V26, P8200, DOI 10.1021/bi00399a027; Krokan HE, 1997, BIOCHEM J, V325, P1; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; Kuninger DT, 2002, NUCLEIC ACIDS RES, V30, P823, DOI 10.1093/nar/30.3.823; KUNZ BA, 1994, P NATL ACAD SCI USA, V91, P8165, DOI 10.1073/pnas.91.17.8165; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; Kuraoka I, 2000, P NATL ACAD SCI USA, V97, P3832, DOI 10.1073/pnas.070471597; Labahn J, 1996, CELL, V86, P321, DOI 10.1016/S0092-8674(00)80103-8; Lau AY, 1998, CELL, V95, P249, DOI 10.1016/S0092-8674(00)81755-9; Lau AY, 2000, P NATL ACAD SCI USA, V97, P13573, DOI 10.1073/pnas.97.25.13573; LAVAL F, 1994, NUCLEIC ACIDS RES, V22, P4943, DOI 10.1093/nar/22.23.4943; Laval J, 1998, MUTAT RES-FUND MOL M, V402, P93, DOI 10.1016/S0027-5107(97)00286-8; LAVAL J, 1977, NATURE, V269, P829, DOI 10.1038/269829a0; Lavrukhin OV, 2000, BIOCHEMISTRY-US, V39, P15266, DOI 10.1021/bi001587x; Le Marchand L, 2002, CANCER EPIDEM BIOMAR, V11, P409; Le Page F, 2000, P NATL ACAD SCI USA, V97, P8397, DOI 10.1073/pnas.140137297; Le Page F, 2000, CANCER RES, V60, P5548; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; LEVIN JD, 1988, J BIOL CHEM, V263, P8066; Levine RL, 2001, J BIOL CHEM, V276, P18717, DOI 10.1074/jbc.M102158200; Lim DS, 1996, MOL CELL BIOL, V16, P7133; LIN JJ, 1989, BIOCHEMISTRY-US, V28, P7979, DOI 10.1021/bi00446a002; LINDAHL T, 1974, P NATL ACAD SCI USA, V71, P3649, DOI 10.1073/pnas.71.9.3649; LINDAHL T, 1976, NATURE, V259, P64, DOI 10.1038/259064a0; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINDAHL T, 1988, ANNU REV BIOCHEM, V57, P133, DOI 10.1146/annurev.bi.57.070188.001025; Lindahl T., 2001, PROG NUCL ACID RES M, V68, P27; LJUNGQUIST S, 1977, J BIOL CHEM, V252, P2808; Lu AL, 1998, J BIOL CHEM, V273, P25098, DOI 10.1074/jbc.273.39.25098; Luna L, 2000, MUTAT RES-DNA REPAIR, V460, P95, DOI 10.1016/S0921-8777(00)00015-X; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; Marenstein DR, 2001, J BIOL CHEM, V276, P21242, DOI 10.1074/jbc.M101594200; Marnett LJ, 1999, MUTAT RES-FUND MOL M, V424, P83, DOI 10.1016/S0027-5107(99)00010-X; Marnett LJ, 2001, TRENDS GENET, V17, P214, DOI 10.1016/S0168-9525(01)02239-9; MARNETT LJ, 1994, DNA ADDUCTS IDENTIFI, P151; Matsumoto Y, 1999, J BIOL CHEM, V274, P33703, DOI 10.1074/jbc.274.47.33703; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; Matsumoto Y, 2001, NUCLEIC ACIDS RES, V29, P1975, DOI 10.1093/nar/29.9.1975; MAZUMDER A, 1991, BIOCHEMISTRY-US, V30, P1119, DOI 10.1021/bi00218a033; MCCORD JM, 1987, FASEB J, V46, P2402; MCGOLDRICK JP, 1995, MOL CELL BIOL, V15, P989; Mckenzie JA, 2001, BIOCHEMISTRY-US, V40, P13254, DOI 10.1021/bi015587o; Meira LB, 2001, CANCER RES, V61, P5552; MELAMEDE RJ, 1994, BIOCHEMISTRY-US, V33, P1255, DOI 10.1021/bi00171a028; Miao F, 2000, J BIOL CHEM, V275, P28433, DOI 10.1074/jbc.M001064200; MICHAELS ML, 1990, NUCLEIC ACIDS RES, V18, P3841, DOI 10.1093/nar/18.13.3841; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; Milligan JR, 2000, INT J RADIAT BIOL, V76, P1475; Missero C, 2001, J BIOL CHEM, V276, P33569, DOI 10.1074/jbc.M104963200; MO JY, 1992, P NATL ACAD SCI USA, V89, P11021, DOI 10.1073/pnas.89.22.11021; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; Nakabeppu Y, 2001, PROG NUCLEIC ACID RE, V68, P75; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Nash HM, 1997, CHEM BIOL, V4, P693, DOI 10.1016/S1074-5521(97)90225-8; NEDDERMANN P, 1993, J BIOL CHEM, V268, P21218; NEDDERMANN P, 1994, P NATL ACAD SCI USA, V91, P1642, DOI 10.1073/pnas.91.5.1642; Neddermann P, 1996, J BIOL CHEM, V271, P12767, DOI 10.1074/jbc.271.22.12767; Ni TT, 1999, MOL CELL, V4, P439, DOI 10.1016/S1097-2765(00)80346-9; Nilsen H, 2000, MOL CELL, V5, P1059, DOI 10.1016/S1097-2765(00)80271-3; Nilsen H, 2001, EMBO J, V20, P4278, DOI 10.1093/emboj/20.15.4278; Nishioka K, 1999, MOL BIOL CELL, V10, P1637, DOI 10.1091/mbc.10.5.1637; NUNOSHIBA T, 1993, J BACTERIOL, V175, P7492, DOI 10.1128/JB.175.22.7492-7494.1993; OCONNOR TR, 1993, J BIOL CHEM, V268, P9063; OCONNOR TR, 1991, BIOCHEM BIOPH RES CO, V176, P1170, DOI 10.1016/0006-291X(91)90408-Y; OCONNOR TR, 1989, P NATL ACAD SCI USA, V86, P5222, DOI 10.1073/pnas.86.14.5222; OCONNOR TR, 1993, NUCLEIC ACIDS RES, V21, P5561; Oda H, 1997, J BIOL CHEM, V272, P17843, DOI 10.1074/jbc.272.28.17843; Oda H, 1999, NUCLEIC ACIDS RES, V27, P4335, DOI 10.1093/nar/27.22.4335; Ohtsubo T, 2000, NUCLEIC ACIDS RES, V28, P1355, DOI 10.1093/nar/28.6.1355; Okochi E, 2002, JPN J CANCER RES, V93, P501, DOI 10.1111/j.1349-7006.2002.tb01284.x; Olive PL, 1998, RADIAT RES, V150, pS42, DOI 10.2307/3579807; Osterod M, 2001, CARCINOGENESIS, V22, P1459, DOI 10.1093/carcin/22.9.1459; Otterlei M, 2000, EMBO J, V19, P5542, DOI 10.1093/emboj/19.20.5542; Parker A, 2001, J BIOL CHEM, V276, P5547, DOI 10.1074/jbc.M008463200; Parlanti E, 2002, ONCOGENE, V21, P5204, DOI 10.1038/sj.onc.1205561; Pascucci B, 2002, NUCLEIC ACIDS RES, V30, P2124, DOI 10.1093/nar/30.10.2124; Pascucci B, 1999, J BIOL CHEM, V274, P33696, DOI 10.1074/jbc.274.47.33696; PENDLEBURY A, 1994, CARCINOGENESIS, V15, P2957, DOI 10.1093/carcin/15.12.2957; Pope MA, 2002, J BIOL CHEM, V277, P22605, DOI 10.1074/jbc.M203037200; POPOFF SC, 1990, P NATL ACAD SCI USA, V87, P4193, DOI 10.1073/pnas.87.11.4193; Prasad R, 2000, J BIOL CHEM, V275, P4460, DOI 10.1074/jbc.275.6.4460; Privezentzev CV, 2001, MUTAT RES-FUND MOL M, V480, P277, DOI 10.1016/S0027-5107(01)00186-5; Privezentzev CV, 2000, BIOCHEMISTRY-US, V39, P14263, DOI 10.1021/bi001337g; Rabow LE, 1997, BIOCHEMISTRY-US, V36, P5084, DOI 10.1021/bi963005a; RADMAN M, 1976, J BIOL CHEM, V251, P1438; RAMOTAR D, 1991, MOL CELL BIOL, V11, P4537, DOI 10.1128/MCB.11.9.4537; RASOULINIA A, 2001, MICROS 2001; Reardon JT, 1997, P NATL ACAD SCI USA, V94, P9463, DOI 10.1073/pnas.94.17.9463; REITER RJ, 1995, FASEB J, V9, P526, DOI 10.1096/fasebj.9.7.7737461; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P5519, DOI 10.1093/nar/19.20.5519; ROGERS SG, 1980, GENE, V11, P187, DOI 10.1016/0378-1119(80)90059-1; Roldan-Arjona T, 2000, PLANT MOL BIOL, V44, P43, DOI 10.1023/A:1006429114451; Roth RB, 2002, CANCER RES, V62, P656; Rothwell DG, 1997, ONCOL RES, V9, P275; Roy R, 1998, BIOCHEMISTRY-US, V37, P580, DOI 10.1021/bi972313l; Roy R, 1996, CARCINOGENESIS, V17, P2177, DOI 10.1093/carcin/17.10.2177; SAMSON L, 1991, P NATL ACAD SCI USA, V88, P9127, DOI 10.1073/pnas.88.20.9127; Sandigursky M, 1999, CURR BIOL, V9, P531, DOI 10.1016/S0960-9822(99)80237-1; Sandigursky M, 2000, J BIOL CHEM, V275, P19146, DOI 10.1074/jbc.M001995200; Saparbaev M, 1998, P NATL ACAD SCI USA, V95, P8508, DOI 10.1073/pnas.95.15.8508; SAPARBAEV M, 1995, NUCLEIC ACIDS RES, V23, P3750, DOI 10.1093/nar/23.18.3750; Saparbaev M, 2002, J BIOL CHEM, V277, P26987, DOI 10.1074/jbc.M111100200; Saparbaev M, 2002, ENVIRON MOL MUTAGEN, V39, P10, DOI 10.1002/em.10041; SAPARBAEV M, 1994, P NATL ACAD SCI USA, V91, P5873, DOI 10.1073/pnas.91.13.5873; Sard L, 1997, GENOMICS, V44, P222, DOI 10.1006/geno.1997.4843; Sartori AA, 2002, EMBO J, V21, P3182, DOI 10.1093/emboj/cdf309; Scharer OD, 1997, CURR OPIN CHEM BIOL, V1, P526, DOI 10.1016/S1367-5931(97)80048-8; Scharer OD, 2001, BIOESSAYS, V23, P270, DOI 10.1002/1521-1878(200103)23:3<270::AID-BIES1037>3.0.CO;2-J; SCHUCHMANN MN, 1984, INT J RADIAT BIOL, V46, P225, DOI 10.1080/09553008414551341; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; Senturker S, 1998, NUCLEIC ACIDS RES, V26, P5270, DOI 10.1093/nar/26.23.5270; Senturker S, 1999, BIOCHEMISTRY-US, V38, P9435, DOI 10.1021/bi990680m; Serre L, 2002, EMBO J, V21, P2854, DOI 10.1093/emboj/cdf304; Shida T, 1996, NUCLEIC ACIDS RES, V24, P4572, DOI 10.1093/nar/24.22.4572; Sidorkina OM, 1998, NUCLEIC ACIDS RES, V26, P5351, DOI 10.1093/nar/26.23.5351; Sidorkina OM, 2000, J BIOL CHEM, V275, P9924, DOI 10.1074/jbc.275.14.9924; SINGER B, 1992, P NATL ACAD SCI USA, V89, P9386, DOI 10.1073/pnas.89.20.9386; Slupska MM, 1996, J BACTERIOL, V178, P3885, DOI 10.1128/jb.178.13.3885-3892.1996; Slupska MM, 1999, J BACTERIOL, V181, P6210, DOI 10.1128/JB.181.19.6210-6213.1999; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; STRAUSS BS, 1991, BIOESSAYS, V13, P79, DOI 10.1002/bies.950130206; Sugahara M, 2000, EMBO J, V19, P3857, DOI 10.1093/emboj/19.15.3857; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; Sung JS, 2000, BIOCHEMISTRY-US, V39, P10224, DOI 10.1021/bi0007066; Sutherland BM, 2001, ENVIRON MOL MUTAGEN, V38, P159, DOI 10.1002/em.1067; Sutherland BM, 2001, RADIAT PROT DOSIM, V97, P33, DOI 10.1093/oxfordjournals.rpd.a006635; Sutherland BM, 2000, P NATL ACAD SCI USA, V97, P103, DOI 10.1073/pnas.97.1.103; Sutherland BM, 2000, BIOCHEMISTRY-US, V39, P8026, DOI 10.1021/bi9927989; Sutton MD, 2000, ANNU REV GENET, V34, P479, DOI 10.1146/annurev.genet.34.1.479; Taddei F, 1997, SCIENCE, V278, P128, DOI 10.1126/science.278.5335.128; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; Takama F, 2000, INT J ONCOL, V17, P467; Takao M, 1998, NUCLEIC ACIDS RES, V26, P2917, DOI 10.1093/nar/26.12.2917; Takao M, 2002, EMBO J, V21, P3486, DOI 10.1093/emboj/cdf350; Takezaki T, 2002, INT J CANCER, V99, P624, DOI 10.1002/ijc.10400; TCHOU J, 1995, J BIOL CHEM, V270, P11671, DOI 10.1074/jbc.270.19.11671; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; TERASHIMA I, 1998, MOL GEN GENET, V259, P577; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; Thomas D, 1997, MOL GEN GENET, V254, P171, DOI 10.1007/s004380050405; THOMAS L, 1982, BIOCHEMISTRY-US, V21, P1162, DOI 10.1021/bi00535a009; Tini M, 2002, MOL CELL, V9, P265, DOI 10.1016/S1097-2765(02)00453-7; Tom S, 2001, J BIOL CHEM, V276, P48781, DOI 10.1074/jbc.M109626200; TRUSH MA, 1991, FREE RADICAL BIO MED, V10, P201, DOI 10.1016/0891-5849(91)90077-G; TSAIWU JJ, 1992, P NATL ACAD SCI USA, V89, P8779, DOI 10.1073/pnas.89.18.8779; TSAIWU JYYJ, 1991, J BACTERIOL, V173, P1902, DOI 10.1128/jb.173.6.1902-1910.1991; TSANEVA IR, 1990, J BACTERIOL, V172, P4197, DOI 10.1128/jb.172.8.4197-4205.1990; Tsuchimoto D, 2001, NUCLEIC ACIDS RES, V29, P2349, DOI 10.1093/nar/29.11.2349; Tsuzuki T, 2001, P NATL ACAD SCI USA, V98, P11456, DOI 10.1073/pnas.191086798; Um S, 1998, J BIOL CHEM, V273, P20728, DOI 10.1074/jbc.273.33.20728; Unk I, 2000, J BIOL CHEM, V275, P22427, DOI 10.1074/jbc.M002845200; Unk I, 2001, MOL CELL BIOL, V21, P1656, DOI 10.1128/MCB.21.5.1656-1661.2001; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Vaisman A, 2001, EMBO J, V20, P6520, DOI 10.1093/emboj/20.22.6520; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; VERLY WG, 1972, CAN J BIOCHEM CELL B, V50, P217, DOI 10.1139/o72-029; VICKERS MA, 1993, P NATL ACAD SCI USA, V90, P3437, DOI 10.1073/pnas.90.8.3437; Vidal AE, 2001, EMBO J, V20, P6530, DOI 10.1093/emboj/20.22.6530; Vidal AE, 2001, NUCLEIC ACIDS RES, V29, P1285, DOI 10.1093/nar/29.6.1285; VONSONNTAG C, 1994, METHOD ENZYMOL, V233, P47; WARD JF, 1995, RADIAT RES, V142, P362, DOI 10.2307/3579145; WARD JF, 1981, RADIAT RES, V86, P185, DOI 10.2307/3575500; Waters TR, 1999, J BIOL CHEM, V274, P67, DOI 10.1074/jbc.274.1.67; Weinfeld M, 2001, RADIAT RES, V156, P584, DOI 10.1667/0033-7587(2001)156[0584:ROBERE]2.0.CO;2; WEISS B, 1987, ADV ENZYMOL RAMB, V60, P1; WILSON DM, 1995, J BIOL CHEM, V270, P16002, DOI 10.1074/jbc.270.27.16002; Wilson DM, 1995, NUCLEIC ACIDS RES, V23, P5027; Wilson DM, 1997, P NATL ACAD SCI USA, V94, P12754, DOI 10.1073/pnas.94.24.12754; WINK DA, 1994, ANN NY ACAD SCI, V738, P265; WU C, 1995, BIOCHEM BIOPH RES CO, V214, P1239, DOI 10.1006/bbrc.1995.2419; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; Xanthoudakis S, 1996, P NATL ACAD SCI USA, V93, P8919, DOI 10.1073/pnas.93.17.8919; Yamagata Y, 1996, CELL, V86, P311, DOI 10.1016/S0092-8674(00)80102-6; Yang HJ, 2001, NUCLEIC ACIDS RES, V29, P743, DOI 10.1093/nar/29.3.743; You HJ, 1999, BIOCHEMISTRY-US, V38, P11298, DOI 10.1021/bi991121i; Zharkov DO, 2000, J BIOL CHEM, V275, P28607, DOI 10.1074/jbc.M002441200; Zharkov DO, 1998, BIOCHEMISTRY-US, V37, P12384, DOI 10.1021/bi981066y; Zharkov DO, 1997, J BIOL CHEM, V272, P5335, DOI 10.1074/jbc.272.8.5335	343	158	169	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2002	21	58					8905	8925		10.1038/sj.onc.1206005	http://dx.doi.org/10.1038/sj.onc.1206005			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	626TP	12483508				2022-12-28	WOS:000179889500003
J	Nishino, T; Morikawa, K				Nishino, T; Morikawa, K			Structure and function of nucleases in DNA repair: shape, grip and blade of the DNA scissors	ONCOGENE			English	Article						DNA repair; nuclease; metal-dependent cleavage; protein-DNA interaction; structure-function relationships	NUCLEOTIDE EXCISION-REPAIR; X-RAY-STRUCTURE; COLI RNASE HI; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; MISMATCH REPAIR; APURINIC/APYRIMIDINIC ENDONUCLEASE; PROTEIN MUTS; ACTIVE-SITE; METAL-IONS	DNA nucleases catalyze the cleavage of phosphodiester bonds. These enzymes play crucial roles in various DNA repair processes, which involve DNA replication, base excision repair, nucleotide excision repair, mismatch repair, and double strand break repair. In recent years, new nucleases involved in various DNA repair processes have been reported, including the Mus81 : Mms4 (Eme1) complex, which functions during the meiotic phase and the Artemis: DNA-PK complex, which processes a V(D)J recombination intermediate. Defects of these nucleases cause genetic instability or severe immunodeficiency. Thus, structural biology on various nuclease actions is essential for the elucidation of the molecular mechanism of complex DNA repair machinery. Three-dimensional structural information of nucleases is also rapidly accumulating, thus providing important insights into the molecular architectures, as well as the DNA recognition and cleavage mechanisms. This review focuses on the three-dimensional structure-function relationships of nucleases crucial for DNA repair processes.	BERI, Dept Biol Struct, Suita, Osaka 5650874, Japan		Morikawa, K (corresponding author), BERI, Dept Biol Struct, 6-2-3 Furuedai, Suita, Osaka 5650874, Japan.	morikawa@beri.or.jp		nishino, tatsuya/0000-0001-8017-8762				Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P17, DOI 10.1016/S0968-0004(97)01162-6; Aravind L, 1998, NUCLEIC ACIDS RES, V26, P3746, DOI 10.1093/nar/26.16.3746; Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; Beernink PT, 2001, J MOL BIOL, V307, P1023, DOI 10.1006/jmbi.2001.4529; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; Boddy MN, 2000, MOL CELL BIOL, V20, P8758, DOI 10.1128/MCB.20.23.8758-8766.2000; Boddy MN, 2001, CELL, V107, P537, DOI 10.1016/S0092-8674(01)00536-0; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; de Boer J, 2000, CARCINOGENESIS, V21, P453, DOI 10.1093/carcin/21.3.453; FARBER GK, 1990, TRENDS BIOCHEM SCI, V15, P228, DOI 10.1016/0968-0004(90)90035-A; Fijalkowska IJ, 1996, P NATL ACAD SCI USA, V93, P2856, DOI 10.1073/pnas.93.7.2856; Galburt EA, 1999, NAT STRUCT BIOL, V6, P1096, DOI 10.1038/70027; Goedken ER, 2001, J BIOL CHEM, V276, P7266, DOI 10.1074/jbc.M009626200; Goldsby RE, 2001, NAT MED, V7, P638, DOI 10.1038/88963; Gorman MA, 1997, EMBO J, V16, P6548, DOI 10.1093/emboj/16.21.6548; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Hadden JM, 2002, EMBO J, V21, P3505, DOI 10.1093/emboj/cdf337; Hamdan S, 2002, STRUCTURE, V10, P535, DOI 10.1016/S0969-2126(02)00738-4; Hopfner KP, 2001, CELL, V105, P473, DOI 10.1016/S0092-8674(01)00335-X; Hosfield DJ, 1999, CELL, V98, P397, DOI 10.1016/S0092-8674(00)81968-6; Hosfield DJ, 1998, CELL, V95, P135, DOI 10.1016/S0092-8674(00)81789-4; Hwang KY, 1998, NAT STRUCT BIOL, V5, P707, DOI 10.1038/1406; Interthal H, 2000, MOL GEN GENET, V263, P812, DOI 10.1007/s004380000241; JENCKS WP, 1969, CATALYSIS CHEM ENZYM, P111; Kaliraman V, 2001, GENE DEV, V15, P2730, DOI 10.1101/gad.932201; KATAYANAGI K, 1993, PROTEINS, V17, P337, DOI 10.1002/prot.340170402; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; Lamers MH, 2000, NATURE, V407, P711, DOI 10.1038/35037523; LEVIN JD, 1991, J BIOL CHEM, V266, P22893; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Mol CD, 2000, NATURE, V403, P451, DOI 10.1038/35000249; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; Mol CD, 2000, MUTAT RES-DNA REPAIR, V460, P211, DOI 10.1016/S0921-8777(00)00028-8; MORRISON A, 1993, EMBO J, V12, P1467, DOI 10.1002/j.1460-2075.1993.tb05790.x; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Mullen JR, 2001, GENETICS, V157, P103; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Obmolova G, 2000, NATURE, V407, P703, DOI 10.1038/35037509; Parikh SS, 2000, MUTAT RES-DNA REPAIR, V460, P183, DOI 10.1016/S0921-8777(00)00026-4; Petit C, 1999, BIOCHIMIE, V81, P15, DOI 10.1016/S0300-9084(99)80034-0; Pingoud A, 2001, NUCLEIC ACIDS RES, V29, P3705, DOI 10.1093/nar/29.18.3705; Prakash S, 2000, MUTAT RES-FUND MOL M, V451, P13, DOI 10.1016/S0027-5107(00)00037-3; Raaijmakers H, 1999, EMBO J, V18, P1447, DOI 10.1093/emboj/18.6.1447; RAMOTAR D, 1991, MOL CELL BIOL, V11, P4537, DOI 10.1128/MCB.11.9.4537; Roberts RJ, 1998, ANNU REV BIOCHEM, V67, P181, DOI 10.1146/annurev.biochem.67.1.181; Shamoo Y, 1999, CELL, V99, P155, DOI 10.1016/S0092-8674(00)81647-5; Sharples GJ, 2001, MOL MICROBIOL, V39, P823, DOI 10.1046/j.1365-2958.2001.02284.x; Shevelev IV, 2002, NAT REV MOL CELL BIO, V3, P364, DOI 10.1038/nrm804; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; SUCK D, 1988, NATURE, V332, P464, DOI 10.1038/332464a0; Tsutakawa SE, 1999, MOL CELL, V3, P621, DOI 10.1016/S1097-2765(00)80355-X; Tsutakawa SE, 1999, CELL, V99, P615, DOI 10.1016/S0092-8674(00)81550-0; Tsutakawa SE, 2001, NUCLEIC ACIDS RES, V29, P3775, DOI 10.1093/nar/29.18.3775; Vassylyev DG, 1997, CURR OPIN STRUC BIOL, V7, P103, DOI 10.1016/S0959-440X(97)80013-9; Wilson DM, 1997, P NATL ACAD SCI USA, V94, P12754, DOI 10.1073/pnas.94.24.12754; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; Yamagata A, 2002, P NATL ACAD SCI USA, V99, P5908, DOI 10.1073/pnas.092547099; Yang W, 2000, MUTAT RES-DNA REPAIR, V460, P245, DOI 10.1016/S0921-8777(00)00030-6; Yoshikawa M, 2001, J BIOL CHEM, V276, P10432, DOI 10.1074/jbc.M010138200	62	86	88	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2002	21	58					9022	9032		10.1038/sj.onc.1206135	http://dx.doi.org/10.1038/sj.onc.1206135			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	626TP	12483517				2022-12-28	WOS:000179889500012
J	Kalaitzidis, D; Davis, RE; Rosenwald, A; Staudt, LM; Gilmore, TD				Kalaitzidis, D; Davis, RE; Rosenwald, A; Staudt, LM; Gilmore, TD			The human B-cell lymphoma cell line RC-K8 has multiple genetic alterations that dysregulate the Rel/NF-kappa B signal transduction pathway	ONCOGENE			English	Article						RC-K8; c-Rel; Rel; Rel-nrg; NF-kappa B; I kappa B	C-REL; GASTROINTESTINAL-TRACT; TRANSCRIPTION FACTORS; HODGKINS-DISEASE; ALPHA-GENE; V-REL; MUTATIONS; EXPRESSION; PHOSPHORYLATION; TRANSFORMATION	The human large B-cell lymphoma cell line RC-K8 has a rearranged REL locus that directs the production of a chimeric protein, termed REL-NRG (Non-Rel Gene). In this study, we show that RC-K8 cells have constitutively nuclear heterodimeric and homodimeric DNA-binding complexes that consist of p50, REL, and REL-NRG. In vitro, IkappaBalpha can block the DNA-binding activity of wildtype REL homodimers but not REL-NRG homodimers. In vivo, REL-NRG cannot activate transcription of a kappaB site reporter plasmid, suggesting that it is a transcription repressing or blocking REL protein. By Western blotting, no IkappaBalpha protein can be detected in extracts of RC-K8 cells. The absence of IkappaBalpha protein in RC-K8 cells appears to be due to mutations that cause premature termination of translation in three of the four copies of the IKBA gene in RC-K8 cells. Re-expression of wild-type IkappaBalpha or a super-repressor form of IkappaBalpha in RC-K8 cells is cytotoxic; in contrast, expression of a dominant-negative form of IkappaB kinase does not affect the growth of RC-K8 cells. By cDNA microarray analysis, a number of previously identified Rel/NF-kappaB target genes are overexpressed in RC-K8 cells, consistent with there being transcriptionally active REL complexes. Taken together, our results suggest that the growth of RC-K8 cells is dependent on the activity of nuclear wild-type REL dimers, while the contribution of REL-NRG to the transformed state of RC-K8 cells is less clear. Nevertheless, the RC-K8 cell line is the first tumor cell line identified with mutations in genes encoding multiple proteins in the Rel/NF-kappaB signal transduction pathway.	Boston Univ, Dept Biol, Boston, MA 02215 USA; NCI, Metab Branch, Canc Res Ctr, NIH, Bethesda, MD 20892 USA	Boston University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Gilmore, TD (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.		Staudt, Louis/AAC-5324-2019		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007387] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R29CA047763, R01CA047763] Funding Source: NIH RePORTER; NCI NIH HHS [CA47763] Funding Source: Medline; NICHD NIH HHS [T32-HD07387] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alizadeh A, 1999, COLD SPRING HARB SYM, V64, P71, DOI 10.1101/sqb.1999.64.71; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; Barkett M, 1997, J BIOL CHEM, V272, P29419, DOI 10.1074/jbc.272.47.29419; Barkett M, 2001, BBA-GEN SUBJECTS, V1526, P25, DOI 10.1016/S0304-4165(01)00092-7; Barth TFE, 1998, BLOOD, V91, P4321, DOI 10.1182/blood.V91.11.4321.411k08_4321_4330; Barth TFE, 2001, GENE CHROMOSOME CANC, V31, P316, DOI 10.1002/gcc.1150; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Cabannes E, 1999, ONCOGENE, V18, P3063, DOI 10.1038/sj.onc.1202893; Cahir-McFarland ED, 2000, P NATL ACAD SCI USA, V97, P6055, DOI 10.1073/pnas.100119497; CAPOBIANCO AJ, 1991, ONCOGENE, V6, P2203; Davis RE, 2001, J EXP MED, V194, P1861, DOI 10.1084/jem.194.12.1861; Den Dunnen JT, 1999, HUM MUTAT, V14, P95, DOI 10.1002/(SICI)1098-1004(1999)14:2<95::AID-HUMU1>3.0.CO;2-G; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Emmerich F, 1999, BLOOD, V94, P3129, DOI 10.1182/blood.V94.9.3129.421k03_3129_3134; Gerondakis S, 1996, P NATL ACAD SCI USA, V93, P3405, DOI 10.1073/pnas.93.8.3405; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gilmore T, 2002, CANCER LETT, V181, P1, DOI 10.1016/S0304-3835(01)00795-9; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; GILMORE TD, 1995, DNA PROVIRUS, P109; Gilmore TD, 2001, ONCOGENE, V20, P7098, DOI 10.1038/sj.onc.1204898; Grigoriadis G, 1996, EMBO J, V15, P7099, DOI 10.1002/j.1460-2075.1996.tb01101.x; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; Houldsworth J, 1996, BLOOD, V87, P25; Joos S, 1996, BLOOD, V87, P1571, DOI 10.1182/blood.V87.4.1571.bloodjournal8741571; Joos S, 2002, BLOOD, V99, P1381, DOI 10.1182/blood.V99.4.1381; Jungnickel B, 2000, J EXP MED, V191, P395, DOI 10.1084/jem.191.2.395; Kalaitzidis D, 2002, GENE CHROMOSOME CANC, V34, P129, DOI 10.1002/gcc.10051; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; KRALOVA J, 1994, J VIROL, V68, P2073, DOI 10.1128/JVI.68.4.2073-2083.1994; KUBONISHI I, 1986, CANCER, V58, P1453, DOI 10.1002/1097-0142(19861001)58:7<1453::AID-CNCR2820580713>3.0.CO;2-B; LEBEAU MM, 1992, GENOMICS, V14, P529, DOI 10.1016/S0888-7543(05)80261-7; LU D, 1991, ONCOGENE, V6, P1235; Malek S, 2001, J BIOL CHEM, V276, P45225, DOI 10.1074/jbc.M105865200; Martin-Subero JI, 2002, BLOOD, V99, P1474, DOI 10.1182/blood.V99.4.1474; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Palanisamy N, 2002, GENE CHROMOSOME CANC, V33, P114, DOI 10.1002/gcc.10016; Quong MW, 1999, EMBO J, V18, P6307, DOI 10.1093/emboj/18.22.6307; Rao PH, 1998, BLOOD, V92, P234, DOI 10.1182/blood.V92.1.234.413k22_234_240; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; Sambrook J., 2002, MOL CLONING LAB MANU; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Staudt LM, 2000, J EXP MED, V191, P207, DOI 10.1084/jem.191.2.207; Sylla BS, 1998, P NATL ACAD SCI USA, V95, P10106, DOI 10.1073/pnas.95.17.10106	45	44	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 12	2002	21	57					8759	8768		10.1038/sj.onc.1206033	http://dx.doi.org/10.1038/sj.onc.1206033			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483529				2022-12-28	WOS:000179734400010
J	Kraus, AC; Ferber, I; Bachmann, SO; Specht, H; Wimmel, A; Gross, MW; Schlegel, J; Suske, G; Schuermann, M				Kraus, AC; Ferber, I; Bachmann, SO; Specht, H; Wimmel, A; Gross, MW; Schlegel, J; Suske, G; Schuermann, M			In vitro chemo- and radio-resistance in small cell lung cancer correlates with cell adhesion and constitutive activation of AKT and MAP kinase pathways	ONCOGENE			English	Article						lung cancer; Akt; chemoresistance; radioresistance; adhesion	NF-KAPPA-B; INDUCED APOPTOSIS; MULTIDRUG-RESISTANCE; TUMOR-CELLS; IN-VIVO; EXPRESSION; PROTEIN; GROWTH; CARCINOMA; LINES	Most small cell lung cancer (SCLC) patients relapse within 12 months of starting combination chemotherapy plus radio-therapy, due to the development of acquired chemo- and radio-resistance. This phenomenon relates to the induction of tumour differentiation, resulting in apoptosis-resistant, morphologically variant (v-SCLC) cells, which lack the neuroendocrine expression of classic (c-) SCLC cells. In this study spontaneously adherent SCLC sublines were shown by differential gene expression analysis to provide an in vitro model of variant differentiation in SCLC, with down-regulation of neuroendocrine markers and up-regulation of epithelial differentiation markers cyclin D1, endothelin, the cell adhesion molecules CD 44 and integrin subunits alpha2, beta3 and beta4. The sensitivity of adherent SCLC sublines to etoposide, cyclophosphamide and gamma radiation was significantly diminished relative to parent suspension cell lines. Western blot analysis using phosphorylation-specific antibodies to Akt and MAP kinase revealed markedly elevated activation in adherent SCLC sublines, paralleled by increased levels of phosphorylated Bad protein and activated NF-kappaB. Subcultivation of the adherent sublines on uncoated surfaces reversed their adherent phenotype immediately and under these conditions Akt activity reverted to low levels. These results suggest that c-SCLC cells can differentiate spontaneously to v-SCLC and that the associated cellular adhesion may trigger Akt-dependent inhibition of apoptosis in SCLC cells, thus leading to acquired chemo-and radio-resistance.	Univ Marburg, Univ Hosp, Inst Mol Biol & Tumour Res, D-35033 Marburg, Germany; Univ Marburg, Univ Hosp, Dept Neuropathol, D-35033 Marburg, Germany; Univ Marburg, Univ Hosp, Dept Radiotherapy & Radio Oncol, D-35033 Marburg, Germany; Univ Marburg, Univ Hosp, Ctr Internal Med, Dept Haematol & Oncol, D-35033 Marburg, Germany	Philipps University Marburg; Philipps University Marburg; Philipps University Marburg; Philipps University Marburg	Schuermann, M (corresponding author), Univ Marburg, Klinikum, Zentrum Innere Med, Baldingerstr, D-35033 Marburg, Germany.	schuermann@mailer.uni-marburg.de		Suske, Guntram/0000-0002-4807-0513; Schlegel, Jurgen/0000-0002-5544-2717				Abe Y, 1996, BRIT J CANCER, V74, P1929, DOI 10.1038/bjc.1996.655; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Basu S, 1998, BIOCHEM BIOPH RES CO, V247, P79, DOI 10.1006/bbrc.1998.8741; BRAMBILLA E, 1991, J CLIN ONCOL, V9, P50, DOI 10.1200/JCO.1991.9.1.50; BRODIN O, 1995, LUNG CANCER-J IASLC, V12, P183, DOI 10.1016/0169-5002(95)00444-6; CARNEY DN, 1985, CANCER RES, V45, P2913; Cheng QW, 2000, ONCOGENE, V19, P4936, DOI 10.1038/sj.onc.1203861; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dingemans AMC, 1996, ANN ONCOL, V7, P625; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; Fushimi H, 1996, CANCER, V77, P278, DOI 10.1002/(SICI)1097-0142(19960115)77:2<278::AID-CNCR9>3.0.CO;2-I; GAZDAR AF, 1985, CANCER RES, V45, P2924; Gazdar AF, 1996, J CELL BIOCHEM, P1; Grossi F, 2001, CRIT REV ONCOL HEMAT, V37, P61, DOI 10.1016/S1040-8428(00)00098-6; Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782; KLUG J, 1994, MOL CELL BIOL, V14, P6208, DOI 10.1128/MCB.14.9.6208; Moore SM, 1998, CANCER RES, V58, P5239; Nakashio A, 2000, CANCER RES, V60, P5303; Okada S, 2001, INT J RADIAT ONCOL, V49, P1149, DOI 10.1016/S0360-3016(00)01429-2; Ozes ON, 1999, NATURE, V401, P82; Pianetti S, 2001, ONCOGENE, V20, P1287, DOI 10.1038/sj.onc.1204257; RADICE PA, 1982, CANCER-AM CANCER SOC, V50, P2894, DOI 10.1002/1097-0142(19821215)50:12<2894::AID-CNCR2820501232>3.0.CO;2-G; Risse-Hackl G, 1998, ONCOGENE, V16, P3057, DOI 10.1038/sj.onc.1201845; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Salge U, 2001, J CANCER RES CLIN, V127, P139, DOI 10.1007/s004320000210; Savaraj N, 1997, AM J CLIN ONCOL-CANC, V20, P398, DOI 10.1097/00000421-199708000-00016; SCHAUER IE, 1994, P NATL ACAD SCI USA, V91, P7827, DOI 10.1073/pnas.91.16.7827; Schlegel J, 2000, CANCER LETT, V158, P103, DOI 10.1016/S0304-3835(00)00515-2; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; SHTIVELMAN E, 1995, P NATL ACAD SCI USA, V92, P4661, DOI 10.1073/pnas.92.10.4661; SUPINO R, 1993, INT J CANCER, V54, P309, DOI 10.1002/ijc.2910540224; Thiede C, 2001, LEUKEMIA, V15, P293, DOI 10.1038/sj.leu.2401953; Uhm JH, 1999, CLIN CANCER RES, V5, P1587; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wimmel A, 1997, LUNG CANCER, V16, P151, DOI 10.1016/S0169-5002(96)00625-3; Wimmel A, 2001, EUR J CANCER, V37, P2264, DOI 10.1016/S0959-8049(01)00271-4; Worden FP, 2000, EXPERT OPIN INV DRUG, V9, P565, DOI 10.1517/13543784.9.3.565; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	40	110	117	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2002	21	57					8683	8695		10.1038/sj.onc.1205939	http://dx.doi.org/10.1038/sj.onc.1205939			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483521				2022-12-28	WOS:000179734400002
J	Garcia, MA; Guerra, S; Gil, JS; Jimenez, V; Esteban, M				Garcia, MA; Guerra, S; Gil, JS; Jimenez, V; Esteban, M			Anti-apoptotic and oncogenic properties of the dsRNA-binding protein of vaccinia virus, E3L	ONCOGENE			English	Article						E3L; vaccinia virus; dsRNA; PKR; tumor apoptosis	DOUBLE-STRANDED-RNA; NF-KAPPA-B; TETRATRICOPEPTIDE REPEAT PROTEIN; BROAD SPECIES-SPECIFICITY; TUMOR-SUPPRESSOR P53; KINASE PKR; INFECTED CELLS; INTERFERON RESISTANCE; ACTIVATION; GENE	The vaccinia virus (VV) E3L gene encodes a dsRNA binding protein that inhibits activation of the IFN-induced, dsRNA-dependent protein kinase, (PKR), the 2-5A synthetases/RNase L system and other dsRNA dependent pathways, thus leading to efficient VV replication. To analyse E3L effects over cellular metabolism in a virus-free system, we have generated stable mouse 3T3 cell lines expressing E3L. Expression of E3L in NIH3T3 cells results in inhibition of eIF-2alpha phosphorylation and IkappaBalpha degradation in response to dsRNA. Antiviral responses induced by IFN-alpha/beta were partially impaired in 3T3-E3L cells, as determined by a viability assay upon VSV infection. E3L expression also confers resistance to dsRNA-triggered apoptosis. Interestingly, cells expressing E3L grew faster than control cells, and showed increased expression of cyclin A and decreased levels of P27(Kip1). E3L cooperated with H-ras in a focus formation assay, and NIH3T3 E3L cells formed solid tumors when injected in nude mice. Overall, our findings reveal that interference of E3L protein with several cellular pathways, results in promotion of cellular growth, impairment of antiviral activity and resistance to apoptosis.	CSIC, Ctr Nacl Biotecnol, Dept Mol & Cellular Biol, Madrid 28049, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Esteban, M (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Mol & Cellular Biol, Campus Univ Autonoma, Madrid 28049, Spain.		Garcia, Maria Angel MA/I-5116-2016; Gil, Jesus/C-7739-2012; guerra, susana/K-5972-2014	Garcia, Maria Angel MA/0000-0003-2003-3769; Gil, Jesus/0000-0002-4303-6260; guerra, susana/0000-0001-9067-2991; ESTEBAN, MARIANO/0000-0003-0846-2827				ALCAMI A, 1995, J VIROL, V69, P4633; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; BARBER GN, 1994, P NATL ACAD SCI USA, V91, P4278, DOI 10.1073/pnas.91.10.4278; BEATTIE E, 1995, J VIROL, V69, P499, DOI 10.1128/JVI.69.1.499-505.1995; Beattie E, 1996, VIRUS GENES, V12, P89, DOI 10.1007/BF00370005; Benkirane M, 1997, EMBO J, V16, P611, DOI 10.1093/emboj/16.3.611; Brandt TA, 2001, J VIROL, V75, P850, DOI 10.1128/JVI.75.2.850-856.2001; Castelli JC, 1997, J EXP MED, V186, P967, DOI 10.1084/jem.186.6.967; CHANG HW, 1992, P NATL ACAD SCI USA, V89, P4825, DOI 10.1073/pnas.89.11.4825; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; Cuddihy AR, 1999, MOL CELL BIOL, V19, P2475; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; DAVIES MV, 1993, J VIROL, V67, P1688, DOI 10.1128/JVI.67.3.1688-1692.1993; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; DiazGuerra M, 1997, VIROLOGY, V236, P354, DOI 10.1006/viro.1997.8719; Gale M, 1999, J VIROL, V73, P6506, DOI 10.1128/JVI.73.8.6506-6516.1999; Geiss G, 2001, J BIOL CHEM, V276, P30178, DOI 10.1074/jbc.C100137200; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Guo JJ, 2000, VIROLOGY, V267, P209, DOI 10.1006/viro.1999.0135; Heylbroeck C, 2000, J VIROL, V74, P3781, DOI 10.1128/JVI.74.8.3781-3792.2000; Jacobs BL, 1996, VIROLOGY, V219, P339, DOI 10.1006/viro.1996.0259; Kibler KV, 1997, J VIROL, V71, P1992, DOI 10.1128/JVI.71.3.1992-2003.1997; Kim T, 1999, J BIOL CHEM, V274, P30686, DOI 10.1074/jbc.274.43.30686; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; Lee SB, 1996, J INTERF CYTOK RES, V16, P1073, DOI 10.1089/jir.1996.16.1073; LEE SB, 1993, VIROLOGY, V193, P1037, DOI 10.1006/viro.1993.1223; LEE SB, 1994, VIROLOGY, V199, P491, DOI 10.1006/viro.1994.1151; LEVIN D, 1978, P NATL ACAD SCI USA, V75, P1121, DOI 10.1073/pnas.75.3.1121; LU Y, 1995, VIROLOGY, V214, P222, DOI 10.1006/viro.1995.9937; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MEURS EF, 1993, CELL, V62, P379; Murcia-Nicolas A, 1999, VIRUS RES, V59, P1, DOI 10.1016/S0168-1702(98)00114-2; PAEZ E, 1984, VIROLOGY, V134, P12, DOI 10.1016/0042-6822(84)90268-X; PARK H, 1994, P NATL ACAD SCI USA, V11, P4713; PETRYSHYN R, 1984, J BIOL CHEM, V259, P4736; Rebouillat D, 1999, J INTERF CYTOK RES, V19, P295, DOI 10.1089/107999099313992; Rivas C, 1998, VIROLOGY, V243, P406, DOI 10.1006/viro.1998.9072; Romano PR, 1998, MOL CELL BIOL, V18, P7304, DOI 10.1128/MCB.18.12.7304; Sangfelt O, 1999, ONCOGENE, V18, P2798, DOI 10.1038/sj.onc.1202609; Savinova O, 1999, INT J BIOCHEM CELL B, V31, P175, DOI 10.1016/S1357-2725(98)00140-X; SEN GC, 1992, J BIOL CHEM, V267, P5017; Sharp TV, 1998, VIROLOGY, V250, P302, DOI 10.1006/viro.1998.9365; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Smith EJ, 2001, J BIOL CHEM, V276, P8951, DOI 10.1074/jbc.M008717200; Smith Geoffrey L., 1994, Trends in Microbiology, V2, P81, DOI 10.1016/0966-842X(94)90539-8; Smith GL, 1997, IMMUNOL REV, V159, P137, DOI 10.1111/j.1600-065X.1997.tb01012.x; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; SYMONS JA, 1995, CELL, V81, P551, DOI 10.1016/0092-8674(95)90076-4; Tan SL, 1999, J INTERF CYTOK RES, V19, P543, DOI 10.1089/107999099313677; Tang NM, 1999, MOL CELL BIOL, V19, P4757; WATSON JC, 1991, VIROLOGY, V185, P206, DOI 10.1016/0042-6822(91)90768-7; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Xiang Y, 2002, J VIROL, V76, P5251, DOI 10.1128/JVI.76.10.5251-5259.2002; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; YUWEN H, 1993, VIROLOGY, V195, P732, DOI 10.1006/viro.1993.1424; Zhou AM, 1997, EMBO J, V16, P6355, DOI 10.1093/emboj/16.21.6355; Zhou AM, 1999, VIROLOGY, V258, P435, DOI 10.1006/viro.1999.9738	64	48	51	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 5	2002	21	55					8379	8387		10.1038/sj.onc.1206036	http://dx.doi.org/10.1038/sj.onc.1206036			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466958	Bronze			2022-12-28	WOS:000179480100001
J	Span, PN; Manders, P; Heuvel, JJ; Thomas, CMG; Bosch, RR; Beex, LV; Sweep, CGJ				Span, PN; Manders, P; Heuvel, JJ; Thomas, CMG; Bosch, RR; Beex, LV; Sweep, CGJ			Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer	ONCOGENE			English	Article						breast neoplasms; quantitative real-time RT-PCR; gene expression regulation; oncogene; angiogenesis; extracellular matrix	PLASMINOGEN-ACTIVATOR; ENDOTHELIAL-CELLS; TRANSFORMING GENE; MESSENGER-RNA; MATRIX; UROKINASE; CARCINOMA; PHENOTYPE	The transcription factor Ets-1 regulates the expression of several angiogenic and extracellular matrix remodeling factors, and might be implicated in disease progression of breast cancer. In the present study, the prognostic value of Ets-1 expression was assessed by quantitative real-time fluorescence RT-PCR in 123 sporadic primary breast cancer samples of patients with a median follow-up time of 62 months. Ets-1 expression levels correlated significantly with VEGF and PAI-1 in the same tissue. In univariate (P = 0.0011) and multivariate (P = 0.005) analyses, Ets-1 expression showed significant prognostic value for relapse-free survival. Ets-1 is a strong, independent predictor of poor prognosis in breast cancer. This seems - at least in part - to be attributable to its role in transcriptional regulation of factors involved in angiogenesis (VEGF), and extracellular matrix remodeling (PAI-1).	Univ Nijmegen, Med Ctr, Dept Chem Endocrinol 530, NL-6500 HB Nijmegen, Netherlands; Univ Nijmegen, Med Ctr, Dept Med Oncol, Nijmegen, Netherlands; Univ Nijmegen, Med Ctr, Dept Obstet & Gynecol, Nijmegen, Netherlands; Univ Nijmegen, Med Ctr, Dept Endocrinol, Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen	Span, PN (corresponding author), Univ Nijmegen, Med Ctr, Dept Chem Endocrinol 530, POB 9101, NL-6500 HB Nijmegen, Netherlands.		Manders, P./L-4501-2015; Span, Paul/G-4710-2012; Sweep, C.G.J./H-8096-2014; Span, Paul N./A-3143-2009; Thomas, C.M.G./L-4687-2015	Span, Paul/0000-0002-1930-6638; Sweep, C.G.J./0000-0003-1103-3070; 				Behrens P, 2001, J PATHOL, V194, P43, DOI 10.1002/path.844; Benz CC, 1998, ENDOCR-RELAT CANCER, V5, P271, DOI 10.1677/erc.0.0050271; COX DR, 1972, J R STAT SOC B, V34, P187; Davidson B, 2001, CLIN CANCER RES, V7, P551; Gilles C, 1997, CLIN EXP METASTAS, V15, P519, DOI 10.1023/A:1018427027270; Himelstein BP, 1998, CLIN EXP METASTAS, V16, P169; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; Janicke F, 2001, J NATL CANCER I, V93, P913, DOI 10.1093/jnci/93.12.913; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Look MP, 2002, JNCI-J NATL CANCER I, V94, P116, DOI 10.1093/jnci/94.2.116; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; Oda N, 1999, J CELL PHYSIOL, V178, P121, DOI 10.1002/(SICI)1097-4652(199902)178:2<121::AID-JCP1>3.3.CO;2-6; PERSYN JP, 1980, EUR J CANCER, V16, P1513; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Trojanowska M, 2000, ONCOGENE, V19, P6464, DOI 10.1038/sj.onc.1204043; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Watabe T, 1998, INT J CANCER, V77, P128, DOI 10.1002/(SICI)1097-0215(19980703)77:1<128::AID-IJC20>3.0.CO;2-9; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294	18	108	110	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 5	2002	21	55					8506	8509		10.1038/sj.onc.1206040	http://dx.doi.org/10.1038/sj.onc.1206040			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466970				2022-12-28	WOS:000179480100013
J	Blondel, D; Regad, T; Poisson, N; Pavie, B; Harper, F; Pandolfi, PP; de The, H; Chelbi-Alix, MK				Blondel, D; Regad, T; Poisson, N; Pavie, B; Harper, F; Pandolfi, PP; de The, H; Chelbi-Alix, MK			Rabies virus P and small P products interact directly with PML and reorganize PML nuclear bodies	ONCOGENE			English	Article						interferon; PML; RING finger; SUMO; rabies virus; P protein	ACUTE PROMYELOCYTIC LEUKEMIA; EPSTEIN-BARR-VIRUS; PROTEIN PML; RAR-ALPHA; ADENOVIRUS INFECTION; SP100 PROTEINS; MESSENGER-RNA; PHOSPHOPROTEIN; CELLS; INTERFERONS	The interferon-induced promyelocytic leukaemia (PML) protein localizes both in the nucleoplasm and in matrix-associated multi-protein complexes known as nuclear bodies (NBs). NBs are disorganized in acute promyelocytic leukaemia or during some viral infections, suggesting that PML NBs could be a part of cellular defense mechanism. Rabies virus, a member of the rhabdoviridae family, replicates in the cytoplasm. Rabies phosphoprotein P and four other amino-terminally truncated products (P2, P3, P4, P5) are all translated from P mRNA. P and P2 are located in the cytoplasm, whereas P3, P4 and P5 are found mostly in the nucleus. Infection with rabies virus reorganized PML NBs. PML NBs became larger and appeared as dense aggregates when analysed by confocal or electron microscopy, respectively. The expression of P sequesters PML in the cytoplasm where both proteins colocalize, whereas that of P3 results in an increase in PML body size, as observed in infected cells. The P and P3 interacted directly in vivo and in vitro with PML. The C-terminal domain of P and the PML RING finger seem to be involved in this binding. Moreover, PML -/- primary mouse embryonic fibroblasts expressed viral proteins at a higher level and produced 20 times more virus than wild-type cells, suggesting that the absence of all PML isoforms resulted in an increase in rabies virus replication.	Inst Lwoff, CNRS, UPR 9045, F-94801 Villejuif, France; CNRS, UMR 2472, F-91198 Gif Sur Yvette, France; Inst Lwoff, CNRS, UPR 1983, F-94801 Villejuif, France; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Hop St Louis, CNRS, UPR 9051, F-75475 Paris, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Memorial Sloan Kettering Cancer Center; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Chelbi-Alix, MK (corresponding author), Inst Lwoff, CNRS, UPR 9045, 7 Rue Guy Moquet, F-94801 Villejuif, France.	mchelbi@infobiogen.fr	Regad, Tarik/A-6095-2012	Regad, Tarik/0000-0003-4028-6368; Pavie, Benjamin/0000-0002-0249-3844				Ahn JH, 1999, J VIROL, V73, P10458, DOI 10.1128/JVI.73.12.10458-10471.1999; Bell P, 2000, J VIROL, V74, P11800, DOI 10.1128/JVI.74.24.11800-11810.2000; Bonilla WV, 2002, J VIROL, V76, P3810, DOI 10.1128/JVI.76.8.3810-3818.2002; Borden KLB, 1998, J VIROL, V72, P758, DOI 10.1128/JVI.72.1.758-766.1998; BOURHY H, 1993, VIROLOGY, V194, P70, DOI 10.1006/viro.1993.1236; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; Chelbi-Alix MK, 1998, J VIROL, V72, P1043, DOI 10.1128/JVI.72.2.1043-1051.1998; Chelbi-Alix MK, 1999, ONCOGENE, V18, P935, DOI 10.1038/sj.onc.1202366; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; CHENIK M, 1995, J VIROL, V69, P707, DOI 10.1128/JVI.69.2.707-712.1995; Chenik M, 1998, J VIROL, V72, P1925, DOI 10.1128/JVI.72.3.1925-1930.1998; CHENIK M, 1994, J GEN VIROL, V75, P2889, DOI 10.1099/0022-1317-75-11-2889; DANIEL MT, 1993, BLOOD, V82, P1858; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Djavani M, 2001, J VIROL, V75, P6204, DOI 10.1128/JVI.75.13.6204-6208.2001; Duprez E, 1999, J CELL SCI, V112, P381; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Everett RD, 1998, J VIROL, V72, P6581, DOI 10.1128/JVI.72.8.6581-6591.1998; Everett RD, 2001, ONCOGENE, V20, P7266, DOI 10.1038/sj.onc.1204759; GAUDIN Y, 1992, VIROLOGY, V187, P627, DOI 10.1016/0042-6822(92)90465-2; Gaudin Y, 1999, J GEN VIROL, V80, P1647, DOI 10.1099/0022-1317-80-7-1647; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Goodbourn S, 2000, J GEN VIROL, V81, P2341, DOI 10.1099/0022-1317-81-10-2341; Gupta AK, 2000, J VIROL, V74, P91, DOI 10.1128/JVI.74.1.91-98.2000; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Jacob Y, 2001, J VIROL, V75, P9613, DOI 10.1128/JVI.75.20.9613-9622.2001; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Muller S, 1999, J VIROL, V73, P5137; Negorev D, 2001, ONCOGENE, V20, P7234, DOI 10.1038/sj.onc.1204764; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; Puvion-Dutilleul F, 1999, BIOL CELL, V91, P617, DOI 10.1016/S0248-4900(00)88526-3; PUVIONDUTILLEUL F, 1995, EXP CELL RES, V218, P9, DOI 10.1006/excr.1995.1125; Raux H, 1997, J GEN VIROL, V78, P119, DOI 10.1099/0022-1317-78-1-119; Regad T, 2001, EMBO J, V20, P3495, DOI 10.1093/emboj/20.13.3495; Regad T, 2001, ONCOGENE, V20, P7274, DOI 10.1038/sj.onc.1204854; Rose JK, 2001, FIELDS VIROLOGY, P1221; Seeler JS, 2001, ONCOGENE, V20, P7243, DOI 10.1038/sj.onc.1204758; Stadler M, 1995, ONCOGENE, V11, P2565; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Szekely L, 1996, J VIROL, V70, P2562, DOI 10.1128/JVI.70.4.2562-2568.1996; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7	46	129	138	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2002	21	52					7957	7970		10.1038/sj.onc.1205931	http://dx.doi.org/10.1038/sj.onc.1205931			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	612VY	12439746				2022-12-28	WOS:000179097200005
J	Marziali, G; Perrotti, E; Ilari, R; Lulli, V; Coccia, EM; Moret, R; Kuhn, LC; Testa, U; Battistini, A				Marziali, G; Perrotti, E; Ilari, R; Lulli, V; Coccia, EM; Moret, R; Kuhn, LC; Testa, U; Battistini, A			Role of Ets-1 in transcriptional regulation of transferrin receptor and erythroid differentiation	ONCOGENE			English	Article						Friend leukemia cells; transferrin receptor; Ets-1; transcription; differentiation	ERYTHROLEUKEMIC CELL-LINES; HEMATOPOIETIC PROGENITORS; IRON-METABOLISM; MESSENGER-RNA; PROMOTER REGION; HEME-SYNTHESIS; DNA-BINDING; MYB-ETS; T-CELLS; GENE	High expression of transferrin receptor (TfR) on the membrane of erythroid cells accounts for the high level of iron required to sustain heme synthesis. Several studies indicate that during erythroid differentiation TfR expression is highly dependent on transcriptional regulation. In this study we characterized the minimal region able to confer transcriptional regulation during erythroid differentiation in Friend leukemia cells (FLC). This region of 120 bp, upstream the transcription start site, contains an overlapping consensus recognition sequence for AP1/CREB/ATF transcription factors and for proteins of the Ets family and a GC rich region. Here, we report that both the Ets and the Ap1/CRE like sites are essential for promoter activity during erythroid differentiation. We showed that Ets-1 binds to the EBS-TfR and its binding activity decreases in FLC induced to differentiate and during normal erythroid differentiation. Consistent with this, FLC constitutively expressing Ets-1 show a decrease in TfR gene expression, globin mRNA and hemoglobin synthesis. We conclude that Ets-1 binding activity is modulated during erythroid maturation and that a deregulated expression of this transcription factor interferes with terminal erythroid differentiation.	Ist Super Sanita, Virol Lab, I-00161 Rome, Italy; Ist Super Sanita, Lab Hematol & Oncol, I-00161 Rome, Italy; Ist Super Sanita, Immunol Lab, I-00161 Rome, Italy; Swiss Inst Expt Canc Res, ISREC, CH-1066 Epalinges, Switzerland	Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS); Swiss Institute Experimental Cancer Research	Battistini, A (corresponding author), Ist Super Sanita, Virol Lab, Viale Regina Elena 299, I-00161 Rome, Italy.		Lulli, Valentina/J-9189-2016; Coccia, Eliana M/B-4752-2013; Marziali, Giovanna/J-9808-2016; BATTISTINI, ANGELA/C-2944-2016; Testa, Ugo/J-6472-2016; PERROTTI, EDVIGE/C-2956-2016	Lulli, Valentina/0000-0002-2143-4436; Coccia, Eliana M/0000-0002-1606-2949; Marziali, Giovanna/0000-0001-7450-1017; Testa, Ugo/0000-0001-7900-8942; Ilari, Ramona/0000-0001-7380-522X; PERROTTI, EDVIGE/0000-0002-4041-2910				Bartelsman EJ, 1998, J PROD ANAL, V9, P5, DOI 10.1023/A:1018383629341; BATTISTINI A, 1991, J BIOL CHEM, V266, P528; BEARD P, 1991, NUCLEIC ACIDS RES, V19, P7117, DOI 10.1093/nar/19.25.7117; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; Busfield SJ, 1997, EUR J BIOCHEM, V249, P77, DOI 10.1111/j.1432-1033.1997.t01-1-00077.x; CASEY JL, 1988, NUCLEIC ACIDS RES, V16, P629, DOI 10.1093/nar/16.2.629; CHAN RYY, 1994, EUR J BIOCHEM, V220, P683, DOI 10.1111/j.1432-1033.1994.tb18669.x; Clausen PA, 1997, LEUKEMIA, V11, P1224, DOI 10.1038/sj.leu.2400735; Cowley DO, 2000, GENE DEV, V14, P366; GABBIANELLI M, 1990, SCIENCE, V249, P1561, DOI 10.1126/science.2218497; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; Grignani F, 1998, CANCER RES, V58, P14; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; HIRSCH S, 1995, CELL GROWTH DIFFER, V6, P719; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KRAUT N, 1994, GENE DEV, V8, P33, DOI 10.1101/gad.8.1.33; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; Lok CN, 1999, J BIOL CHEM, V274, P24147, DOI 10.1074/jbc.274.34.24147; Lok CN, 2000, J BIOL CHEM, V275, P24185, DOI 10.1074/jbc.M000944200; Marziali G, 1997, MOL CELL BIOL, V17, P1387, DOI 10.1128/MCB.17.3.1387; MARZIALI G, 1999, MOL BIOL HEMATOPOIES, V6, P391; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; ORKIN SH, 1975, J BIOL CHEM, V250, P8753; OUYANG Q, 1993, MOL CELL BIOL, V13, P1796, DOI 10.1128/MCB.13.3.1796; Pereira R, 1999, ONCOGENE, V18, P1597, DOI 10.1038/sj.onc.1202534; Ponka P, 1999, INT J BIOCHEM CELL B, V31, P1111, DOI 10.1016/S1357-2725(99)00070-9; Ponka P, 1997, BLOOD, V89, P1; QUEVA C, 1993, ONCOGENE, V8, P2511; Rameil P, 2000, ONCOGENE, V19, P2086, DOI 10.1038/sj.onc.1203542; Rao G, 1997, ONCOGENE, V14, P123, DOI 10.1038/sj.onc.1200807; Rossi F, 1996, CURR BIOL, V6, P866, DOI 10.1016/S0960-9822(02)00610-3; SETH A, 1993, ONCOGENE, V8, P1783; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; Sieweke MH, 1998, CURR OPIN GENET DEV, V8, P545, DOI 10.1016/S0959-437X(98)80009-9; SPOSI NM, 1992, P NATL ACAD SCI USA, V89, P6353, DOI 10.1073/pnas.89.14.6353; Starck J, 1999, MOL CELL BIOL, V19, P121; Tacchini L, 1999, J BIOL CHEM, V274, P24142, DOI 10.1074/jbc.274.34.24142; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1997, TRANSCRIPTION FACTOR, P253; WATSON DK, 2000, ETS GENE FAMILY ONCO; Weiss G, 1997, BLOOD, V89, P680, DOI 10.1182/blood.V89.2.680; WERNERT N, 1992, AM J PATHOL, V140, P119; Yamada T, 1997, BLOOD, V89, P1383, DOI 10.1182/blood.V89.4.1383	43	23	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 14	2002	21	52					7933	7944		10.1038/sj.onc.1205925	http://dx.doi.org/10.1038/sj.onc.1205925			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	612VY	12439744				2022-12-28	WOS:000179097200003
J	Moreno-Bueno, G; Hardisson, D; Sanchez, C; Sarrio, D; Cassia, R; Garcia-Rostan, G; Prat, J; Guo, MZ; Herman, JG; Matias-Guiu, X; Esteller, M; Palacios, J				Moreno-Bueno, G; Hardisson, D; Sanchez, C; Sarrio, D; Cassia, R; Garcia-Rostan, G; Prat, J; Guo, MZ; Herman, JG; Matias-Guiu, X; Esteller, M; Palacios, J			Abnormalities of the APC/beta-catenin pathway in endometrial cancer	ONCOGENE			English	Article						endometrial cancer; APC promoter hypermethylation; beta catenin mutations; gamma-catenin; AXIN1; AXIN2	MONONUCLEOTIDE REPEAT MICROSATELLITES; ABERRANT NUCLEAR EXPRESSION; BETA-CATENIN; PROMOTER HYPERMETHYLATION; OVARIAN CARCINOMAS; GAMMA-CATENIN; COLORECTAL-CANCER; CLINICOPATHOLOGICAL FEATURES; MUTATIONAL ANALYSIS; TUMOR-SUPPRESSOR	The activation of the APC/beta-catenin signalling pathway due to beta-catenin mutations has been implicated in the development of a subset of endometrial carcinomas (ECs). However, up to 25% of ECs have beta-catenin nuclear accumulation without evidence of beta-catenin mutations, suggesting alterations of other molecules that can modulate the Wnt pathway, such as APC, gamma-catenin, AXIN1 and AXIN2. We investigated the expression pattern of beta- and gamma-catenin in a group of 128 endometrial carcinomas, including 95 endometrioid endometrial carcinomas (EECs) and 33 non-endometrioid endometrial carcinomas (NEECs). In addition, we evaluated the presence of loss of heterozygosity and promoter hypermethylation of the APC gene and mutations in the APC, beta- and gamma-catenin, AXIN1, AXIN2, and RAS genes, and phospho-Akt expression. No APC mutations were detected but LOH at the APC locus was found in 24.3% of informative cases. APC promoter 1A hypermethylation was observed in 46.6% of ECs, and was associated with the endometrioid phenotype (P=0.034) and microsatellite instability (P=0.008). Neither LOH nor promoter hypermethylation of APC was associated with nuclear catenin expression. Nuclear beta-catenin expression was found in 31.2% of EECs and 3% of NEECs (P=0.002), and was significantly associated with beta-catenin gene exon 3 mutations (P<0.0001). beta-catenin gene exon 3 mutations were associated with the endometrioid phenotype, and were detected in 14 (14.9%) EECs, but in none of the NEECs (P = 0.02). gamma-catenin nuclear expression was found in 10 ECs; it was not associated with the histological type but was associated with more advanced stages (P=0.042). No mutations in gamma-catenin, AXIN1 and 2 genes were detected in this series. Neither RAS mutations nor phospho-Akt expression, which were found in 16 and 27.6% of the cases, respectively, were associated with beta-catenin nuclear expression. Our results demonstrated a high prevalence of alterations in molecules of the APC/beta-catenin pathway, but only mutations in beta-catenin gene are associated with aberrant nuclear localization of beta-catenin.	Ctr Nacl Invest Oncol, CNIO, Lab Breast & Gynaecol Canc, Mol Pathol Programme, Madrid 28029, Spain; Hosp Univ La Paz, Dept Pathol, Madrid 28029, Spain; Hosp Santa Cruz & San Pablo, Dept Pathol, E-08025 Barcelona, Spain; Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA; Hosp Univ Arnau Vilanova, Serv Pathol, Lleida 25198, Spain; Ctr Nacl Invest Oncol, CNIO, Lab Canc Epigenet, Mol Pathol Programme, Madrid 28029, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Hospital Universitario La Paz; Johns Hopkins University; Johns Hopkins Medicine; University Hospital Arnau de Vilanova; Centro Nacional de Investigaciones Oncologicas (CNIO)	Palacios, J (corresponding author), Ctr Nacl Invest Oncol, CNIO, Lab Breast & Gynaecol Canc, Mol Pathol Programme, Melchor Fernandez Almagro 3, Madrid 28029, Spain.		Rostan, Ginesa Garcia/E-4093-2018; Esteller, Manel/L-5956-2014; Prat, Jaime/G-4679-2011; Moreno-Bueno, Gema/K-9354-2016; Hardisson, David/A-6259-2011; SARRIO, DAVID/Y-8903-2019; Corominas, Joan Prat/C-6420-2011; Hardisson, David/AAN-3833-2020; Palacios, Jose/AAV-3765-2020; Hardisson, David/E-2832-2010; Rostan, Ginesa Maria Garcia -/B-6062-2008; matias-guiu, xavier/C-3039-2009	Rostan, Ginesa Garcia/0000-0002-9238-1263; Esteller, Manel/0000-0003-4490-6093; Moreno-Bueno, Gema/0000-0002-5030-6687; Hardisson, David/0000-0002-2183-3699; matias-guiu, xavier/0000-0002-7201-6605; Sarrio, David/0000-0003-4886-8290				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Bailey T, 1998, AM J PATHOL, V152, P135; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Boland CR, 1998, CANCER RES, V58, P5248; Caca K, 1999, CELL GROWTH DIFFER, V10, P369; Chesire DR, 2002, ONCOGENE, V21, P2679, DOI 10.1038/sj.onc.1205352; Dahmen RP, 2001, CANCER RES, V61, P7039; Desbois-Mouthon C, 2001, ONCOGENE, V20, P252, DOI 10.1038/sj.onc.1204064; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; Dong SM, 2001, CLIN CANCER RES, V7, P1982; Duval A, 1999, ONCOGENE, V18, P6806, DOI 10.1038/sj.onc.1203287; Espada J, 1999, J CELL BIOL, V146, P967, DOI 10.1083/jcb.146.5.967; Esteller M, 2000, CANCER RES, V60, P4366; Esteller M, 1998, ONCOGENE, V17, P2413, DOI 10.1038/sj.onc.1202178; Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721; FUJINO T, 1994, CANCER RES, V54, P4294; Fukuchi T, 1998, CANCER RES, V58, P3526; Gamallo C, 1999, AM J PATHOL, V155, P527, DOI 10.1016/S0002-9440(10)65148-6; Garcia-Rostan G, 2001, AM J PATHOL, V158, P987, DOI 10.1016/S0002-9440(10)64045-X; Gras E, 2001, CANCER-AM CANCER SOC, V92, P2829, DOI 10.1002/1097-0142(20011201)92:11<2829::AID-CNCR10094>3.0.CO;2-3; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Ikeda T, 2000, ONCOL REP, V7, P323; Jin Z, 2001, BRIT J CANCER, V85, P69, DOI 10.1054/bjoc.2001.1853; JONES MH, 1994, GENE CHROMOSOME CANC, V9, P119, DOI 10.1002/gcc.2870090207; Kawakami K, 2000, J NATL CANCER I, V92, P1805, DOI 10.1093/jnci/92.22.1805; Kirchner T, 2000, AM J PATHOL, V157, P1113, DOI 10.1016/S0002-9440(10)64626-3; Kobayashi K, 1999, JPN J CANCER RES, V90, P55, DOI 10.1111/j.1349-7006.1999.tb00665.x; Kolligs FT, 2000, GENE DEV, V14, P1319; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lin YM, 2000, J HUM GENET, V45, P254, DOI 10.1007/s100380070036; Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859; Matias-Guiu X, 2001, HUM PATHOL, V32, P569, DOI 10.1053/hupa.2001.25929; Mirabelli-Primdahl L, 1999, CANCER RES, V59, P3346; Moreno-Bueno G, 2001, DIAGN MOL PATHOL, V10, P116, DOI 10.1097/00019606-200106000-00008; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nei H, 1999, MOL CARCINOGEN, V25, P207, DOI 10.1002/(SICI)1098-2744(199907)25:3<207::AID-MC7>3.3.CO;2-W; Palacios J, 1998, CANCER RES, V58, P1344; Palacios J, 2001, VIRCHOWS ARCH, V438, P464, DOI 10.1007/s004280000371; Perucho M, 1999, CANCER RES, V59, P249; Reinacher-Schick A, 2001, J CELL BIOL, V152, P491, DOI 10.1083/jcb.152.3.491; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Saegusa M, 2001, J PATHOL, V194, P59, DOI 10.1002/path.856; Saegusa M, 2001, BRIT J CANCER, V84, P209, DOI 10.1054/bjoc.2000.1581; Samowitz WS, 2001, AM J PATHOL, V158, P1517, DOI 10.1016/S0002-9440(10)64102-8; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Satyamoorthy K, 2001, CANCER RES, V61, P7318; SCHOSSHAUER PW, 2000, MODERN PATHOL, V13, P1066; Sharpe C, 2001, BIOESSAYS, V23, P311, DOI 10.1002/bies.1045; Sparks AB, 1998, CANCER RES, V58, P1130; Staal FJT, 1999, INT IMMUNOL, V11, P317, DOI 10.1093/intimm/11.3.317; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tsuchiya T, 2000, ONCOGENE, V19, P3642, DOI 10.1038/sj.onc.1203704; Ueda M, 2001, BRIT J CANCER, V85, P64, DOI 10.1054/bjoc.2001.1863; Valizadeh A, 1997, AM J PATHOL, V150, P1977; Virmani AK, 2001, CLIN CANCER RES, V7, P1998; Voeller HJ, 1998, CANCER RES, V58, P2520; Webster MT, 2000, GENE CHROMOSOME CANC, V28, P443; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Wu R, 2001, CANCER RES, V61, P8247; Yuan HD, 1999, J BIOL CHEM, V274, P30419, DOI 10.1074/jbc.274.43.30419; Zhou XP, 1998, GENE CHROMOSOME CANC, V21, P101, DOI 10.1002/(SICI)1098-2264(199802)21:2<101::AID-GCC4>3.0.CO;2-4; Zysman M, 2002, CANCER RES, V62, P3663	63	189	193	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 14	2002	21	52					7981	7990		10.1038/sj.onc.1205924	http://dx.doi.org/10.1038/sj.onc.1205924			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	612VY	12439748				2022-12-28	WOS:000179097200007
J	Baba, M; Hirai, S; Yamada-Okabe, H; Hamada, K; Tabuchi, H; Kobayashi, K; Kondo, K; Yoshida, M; Yamashita, A; Kishida, T; Nakaigawa, N; Nagashima, Y; Kubota, Y; Yao, M; Ohno, S				Baba, M; Hirai, S; Yamada-Okabe, H; Hamada, K; Tabuchi, H; Kobayashi, K; Kondo, K; Yoshida, M; Yamashita, A; Kishida, T; Nakaigawa, N; Nagashima, Y; Kubota, Y; Yao, M; Ohno, S			Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through Hypoxia-inducible factor	ONCOGENE			English	Article						VHL; tumor suppressor; contact inhibition; renal cell carcinoma; cyclinDl; HIF	TUMOR-SUPPRESSOR GENE; TRANSFORMING-GROWTH-FACTOR; RENAL-CARCINOMA CELLS; UBIQUITIN LIGASE; HIF-ALPHA; G1 PHASE; VHL; CYCLE; COMPLEX; FIBROBLASTS	Loss of the von Hippel-Lindau gene (VHL) expression causes deregulation of contact inhibition of cell growth, which might be one of the bases of the tumor suppressor function of VHL. Here we show that this function of the VHL gene product (pVHL) depends on cell autonomous events. To identify the target gene of pVHL, which is directly involved in the contact inhibition, we compared the gene expression profile between VHL-deficient renal carcinoma 786-O cells and those infected with an adenovirus vector encoding VHL. In addition to known pVHL-regulated genes, such as vascular endothelial growth factor and carbonic anhydrase, we found cyclinD1 as a new target of pVHL at a high cell density. In VHL-expressing cells (VHL (+) cells), the cyclinD1 mRNA expression level diminishes at a high cell density, while it remains at a relatively high level in VHL-deficient cells (VHL (-) cells). The cyclinD1 expression level was also abnormally high in VHL (-) cells at a high cell density. Consequently, the phosporylation level of the retinoblastoma (Rb) protein remained high in these cells, whereas there was no phosporylated Rb in VHL (+) cells under the contact inhibition. The abnormal expression of cyctinD1 at a high cell density was observed even in VHL (+) cells under the hypoxic state. Moreover, ectopic expression of a HIF mutant resistant to pVHL-mediated proteolysis causes the abnormal cyclinD1 expression in VHL (+) cells. Taken together, these observations indicate that VHL is required for the downregulation of cyclinD1 at a high cell density through HIF.	Yokohama City Univ, Sch Med, Dept Mol Biol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Yokohama City Univ, Sch Med, Dept Urol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Yokohama City Univ, Sch Med, Dept Pathol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Chugai Res Ctr, Pharmacol Res Dept 4, Kamakura, Kanagawa 2473590, Japan	Yokohama City University; Yokohama City University; Yokohama City University; Chugai Pharmaceutical Co., Ltd.	Hirai, S (corresponding author), Yokohama City Univ, Sch Med, Dept Mol Biol, Kanazawa Ku, 3-9 Fuko Ura, Yokohama, Kanagawa 2360004, Japan.		Baba, Masaya/ABE-4893-2020; Baba, Masaya/L-7490-2013; Ohno, Shigeo/B-1768-2010; Nagashima, Yoji/AAA-2591-2021	Baba, Masaya/0000-0002-5308-6683; Ohno, Shigeo/0000-0002-1294-5269; 				Baba M, 2001, ONCOGENE, V20, P2727, DOI 10.1038/sj.onc.1204397; Bindra RS, 2002, CANCER RES, V62, P3014; de Paulsen N, 2001, P NATL ACAD SCI USA, V98, P1387, DOI 10.1073/pnas.031587498; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; Iizuka N, 2002, CANCER RES, V62, P3939; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Ivanov SV, 1998, P NATL ACAD SCI USA, V95, P12596, DOI 10.1073/pnas.95.21.12596; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Izumi Y, 1997, J BIOL CHEM, V272, P7381, DOI 10.1074/jbc.272.11.7381; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jacobsen K, 2002, ONCOGENE, V21, P3058, DOI 10.1038/sj.onc.1205423; JIANG W, 1993, ONCOGENE, V8, P3447; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Knebelmann B, 1998, CANCER RES, V58, P226; Kondo K, 2001, EXP CELL RES, V264, P117, DOI 10.1006/excr.2000.5139; Kondo K, 2002, GENE CHROMOSOME CANC, V34, P58, DOI 10.1002/gcc.10054; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Maher ER, 1997, MEDICINE, V76, P381, DOI 10.1097/00005792-199711000-00001; Mandriota SJ, 2002, CANCER CELL, V1, P459, DOI 10.1016/S1535-6108(02)00071-5; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; PAPADIMITRIOU E, 1993, J IMMUNOL METHODS, V162, P41, DOI 10.1016/0022-1759(93)90405-V; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Sellers WR, 1996, BBA-REV CANCER, V1288, pM1, DOI 10.1016/0304-419X(96)00014-5; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHUIN T, 1994, CANCER RES, V54, P2852; Siemeister G, 1996, CANCER RES, V56, P2299; Vinals F, 1999, MOL CELL BIOL, V19, P2763; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; Yao M, 2002, JNCI-J NATL CANCER I, V94, P1569; Zatyka M, 2002, CANCER RES, V62, P3803	43	77	80	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2003	22	18					2728	2738		10.1038/sj.onc.1206373	http://dx.doi.org/10.1038/sj.onc.1206373			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ	12743597				2022-12-28	WOS:000182569300004
J	Kamsteeg, M; Rutherford, T; Sapi, E; Hanczaruk, B; Shahabi, S; Flick, M; Brown, D; Mor, G				Kamsteeg, M; Rutherford, T; Sapi, E; Hanczaruk, B; Shahabi, S; Flick, M; Brown, D; Mor, G			Phenoxodiol - an isoflavone analog - induces apoptosis in chemoresistant ovarian cancer cells	ONCOGENE			English	Article						phenoxodiol; apoptosis; XIAP; ovarian cancer; Fas	FAS/FAS-LIGAND SYSTEM; FAS-MEDIATED APOPTOSIS; CD95-MEDIATED APOPTOSIS; SIGNALING COMPLEX; TUMOR-CELLS; C-FLIP; DEATH; EXPRESSION; ESTROGEN; INHIBITION	Interference with the innate apoptotic activity is a hallmark of neoplastic transformation and tumor formation. In this study we characterize the cytotoxic effect of phenoxodiol, a synthetic anticancer drug analog of genestein, and demonstrate the mechanism of action by which phenoxodiol affects the components of the Fas apoptotic pathway on ovarian cancer cells. Primary ovarian cancer cells, isolated from ascitic fluids of ovarian cancer patients, resistant to conventional chemotherapy, undergo apoptosis following phenoxodiol treatment. This effect is dependent upon the activation of the caspase system, inhibiting XIAP, an inhibitor of apoptosis, and disrupting FLICE inhibitory protein (FLIP) expression through the Akt signal transduction pathway. We suggest that phenoxodiol is an efficient inducer of cell death in ovarian cancer cells and sensitizes the cancer cells to Fas-mediated apoptosis. We identified FLIP and XIAP signalling pathways as key factors regulating the survival of ovarian cancer cells. These findings demonstrate a novel nontoxic drug that controls FLIP/XIAP function and has the potential to eliminate tumor cells through Fas-mediated apoptosis.	Yale Univ, Sch Med, Dept Obstet & Gynecol, New Haven, CT 06520 USA	Yale University	Mor, G (corresponding author), Yale Univ, Sch Med, Dept Obstet & Gynecol, 333 Cedar St, New Haven, CT 06520 USA.		Kamsteeg, M./L-4422-2015		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD037137] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA092435] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA92435-01] Funding Source: Medline; NICHD NIH HHS [R01 HD37137-01A2] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aschkenazi S, 2002, BIOL REPROD, V66, P1853, DOI 10.1095/biolreprod66.6.1853; Baldwin RL, 1999, GYNECOL ONCOL, V74, P265, DOI 10.1006/gyno.1999.5448; BERCHUCK A, 1994, J SOC GYNECOL INVEST, V1, P181, DOI 10.1177/107155769400100302; Constantinou AI, 2002, ANTICANCER RES, V22, P2581; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; FLICK M, UNPUB; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; GREENE MH, 1984, SEMIN ONCOL, V11, P209; Gutierrez LS, 1999, BREAST CANCER RES TR, V54, P245, DOI 10.1023/A:1006102601215; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HUGHES FM, 1991, ENDOCRINOLOGY, V129, P2415, DOI 10.1210/endo-129-5-2415; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Kirchhoff S, 2000, J IMMUNOL, V165, P6293, DOI 10.4049/jimmunol.165.11.6293; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Lamartiniere CA, 1998, P SOC EXP BIOL MED, V217, P358, DOI 10.3181/00379727-217-44245; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; Mor G, 2002, BIOCHEM PHARMACOL, V64, P1305, DOI 10.1016/S0006-2952(02)01267-4; Mor G, 2001, AM J REPROD IMMUNOL, V46, P298, DOI 10.1034/j.1600-0897.2001.d01-16.x; Mori T, 1997, HORM RES, V48, P11, DOI 10.1159/000191295; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; ODWYER PJ, 1994, CANCER RES, V54, P724; Panka DJ, 2001, J BIOL CHEM, V276, P6893, DOI 10.1074/jbc.C000569200; Peter M E, 1999, Results Probl Cell Differ, V23, P25; Quirk SM, 1997, ENDOCRINOLOGY, V138, P4558, DOI 10.1210/en.138.11.4558; Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726; Rohn JL, 1998, ONCOGENE, V17, P2811, DOI 10.1038/sj.onc.1202393; Roughton SA, 1999, BIOL REPROD, V60, P797, DOI 10.1095/biolreprod60.4.797; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Sapi E, 2002, J SOC GYNECOL INVEST, V9, P243, DOI 10.1016/S1071-5576(02)00162-4; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Song J, 2000, J CLIN INVEST, V106, P1209, DOI 10.1172/JCI10411; Song J, 2002, MOL HUM REPROD, V8, P447, DOI 10.1093/molehr/8.5.447; Song RXD, 2001, J NATL CANCER I, V93, P1714, DOI 10.1093/jnci/93.22.1714; Suhara T, 2001, CIRC RES, V89, P13, DOI 10.1161/hh1301.092506; Tilly J L, 1996, Rev Reprod, V1, P162, DOI 10.1530/revreprod/1.3.162; Tilly JL, 2001, NAT REV MOL CELL BIO, V2, P838, DOI 10.1038/35099086; Weber G, 2000, EUR J GYNAECOL ONCOL, V21, P231; Xerri L, 1997, J CLIN PATHOL-MOL PA, V50, P87, DOI 10.1136/mp.50.2.87	42	160	174	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2003	22	17					2611	2620		10.1038/sj.onc.1206422	http://dx.doi.org/10.1038/sj.onc.1206422			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730675				2022-12-28	WOS:000182569000009
J	Ahonen, M; Poukkula, M; Baker, AH; Kashiwagi, M; Nagase, H; Eriksson, JE; Kahari, VM				Ahonen, M; Poukkula, M; Baker, AH; Kashiwagi, M; Nagase, H; Eriksson, JE; Kahari, VM			Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors	ONCOGENE			English	Article						TIMP-3; death receptor; apoptosis; caspase; melanoma	FAS-LIGAND EXPRESSION; MATRIX-METALLOPROTEINASE; TNF RECEPTOR; IN-VITRO; TIMP-3; GENE; INVASION; PROTEASE; CANCER; DOMAIN	Tissue inhibitors of metalloproteinases (TIMPs) are important regulators of matrix metalloproteinase (MMP) and adamalysin (ADAM) activity. We have previously shown that adenovirally expressed tissue inhibitor of metalloproteinases-3 (TIMP-3) induces apoptosis in melanoma cells and inhibits growth of human melanoma xenografts. Here, we have studied the role of death receptors in apoptosis of melanoma cells induced by TIMP-3. Our results show, that the exposure of three metastatic melanoma cell lines (A2058, SK-Mel-5, and WM-266-4) to recombinant TIMP-3, N-terminal MMP inhibitory domain of TIMP-3, as well as to adenovirally expressed TIMP-3 results in stabilization of tumor necrosis factor receptor-1 (TNF-RI), FAS, and TNF-related apoptosis inducing ligand receptor-1 (TRAIL-RI) on melanoma cell surface and sensitizes these cells to apoptosis induced by TNF-alpha, anti-Fas-antibody and TRAIL. Stabilization of death receptors by TIMP-3 results in activation of caspase-8 and caspase-3, and subsequent apoptosis is blocked by specific caspase-8 inhibitor (Z-IETD-FMK) and by pan-caspase inhibitor (Z-DEVD-FMK). Adenovirus-mediated expression of TIMP-3 in human melanoma xenografts in vivo resulted in increased immunostaining for TNF-RI, FAS, and cleaved caspase-3, and in apoptosis of melanoma cells. Taken together, these results show that TIMP-3 promotes apoptosis in melanoma cells through stabilization of three distinct death receptors and activation of their apoptotic signaling cascade through caspase-8.	Univ Turku, Ctr Biotechnol, FIN-20520 Turku, Finland; Abo Akad Univ, FIN-20520 Turku, Finland; Univ Turku, Dept Med Biochem, FIN-20520 Turku, Finland; Univ Turku, Dept Dermatol, FIN-20520 Turku, Finland; Univ Turku, Dept Biol, FIN-20014 Turku, Finland; Univ Glasgow, Dept Med & Therapeut, Glasgow G11 6NT, Lanark, Scotland; Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Rheumatol, Kennedy Inst, London W6 8LH, England	University of Turku; Abo Akademi University; University of Turku; University of Turku; University of Turku; University of Glasgow; Imperial College London; University of Oxford	Kahari, VM (corresponding author), Univ Turku, Ctr Biotechnol, Tykistokatu 6B, FIN-20520 Turku, Finland.	veli-matti.kahari@utu.fi	Baker, Andy/AAO-5250-2021; Kahari, Veli-Matti/E-5144-2011	Baker, Andy/0000-0003-1441-5576; Poukkula, Minna Karoliina/0000-0003-4192-2899; Kahari, Veli-Matti/0000-0003-2421-9368	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040994] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR40994] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahonen M, 2002, MOL THER, V5, P705, DOI 10.1006/mthe.2002.0606; Ahonen M, 1998, CANCER RES, V58, P2310; Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Bachman KE, 1999, CANCER RES, V59, P798; Baker AH, 1996, MATRIX BIOL, V15, P383, DOI 10.1016/S0945-053X(96)90158-4; Baker AH, 1999, BRIT J CANCER, V79, P1347, DOI 10.1038/sj.bjc.6690217; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bond M, 2002, J BIOL CHEM, V277, P13787, DOI 10.1074/jbc.M111507200; Bond M, 2000, J BIOL CHEM, V275, P41358, DOI 10.1074/jbc.M007929200; Borland G, 1999, J BIOL CHEM, V274, P2810, DOI 10.1074/jbc.274.5.2810; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; CHIRIVI RGS, 1994, INT J CANCER, V58, P460, DOI 10.1002/ijc.2910580326; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Ekmekcioglu S, 1999, MELANOMA RES, V9, P261, DOI 10.1097/00008390-199906000-00008; Fariss RN, 1997, AM J PATHOL, V150, P323; Fata JE, 2001, J CLIN INVEST, V108, P831, DOI 10.1172/JCI13171; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; Hargreaves PG, 1998, BRIT J HAEMATOL, V101, P694, DOI 10.1046/j.1365-2141.1998.00754.x; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Kashiwagi M, 2001, J BIOL CHEM, V276, P12501, DOI 10.1074/jbc.C000848200; Killar L, 1999, ANN NY ACAD SCI, V878, P442, DOI 10.1111/j.1749-6632.1999.tb07701.x; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Langton KP, 1998, J BIOL CHEM, V273, P16778, DOI 10.1074/jbc.273.27.16778; LECO KJ, 1994, J BIOL CHEM, V269, P9352; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; Loging WT, 1999, ONCOGENE, V18, P7608, DOI 10.1038/sj.onc.1203135; Mitsiades N, 1999, J NATL CANCER I, V91, P1678, DOI 10.1093/jnci/91.19.1678; Mitsiades N, 2001, CANCER RES, V61, P577; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; O'Connell J, 1999, IMMUNOL TODAY, V20, P46, DOI 10.1016/S0167-5699(98)01382-6; Owen-Schaub LB, 1998, J EXP MED, V188, P1717, DOI 10.1084/jem.188.9.1717; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; Pennie WD, 1999, CELL GROWTH DIFFER, V10, P279; Schlondorff J, 1999, J CELL SCI, V112, P3603; Smith MR, 1997, CYTOKINE, V9, P770, DOI 10.1006/cyto.1997.0233; Solomon KA, 1999, J IMMUNOL, V163, P4105; Soubrane C, 2000, BRIT J DERMATOL, V143, P307, DOI 10.1046/j.1365-2133.2000.03655.x; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Terheyden P, 1999, J INVEST DERMATOL, V112, P899, DOI 10.1046/j.1523-1747.1999.00607.x; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Ueki T, 2000, CANCER RES, V60, P1835; UGUREL S, 2001, CLIN CANCER RES, V7, P1108; Wehrli P, 2000, J INVEST DERMATOL, V115, P141, DOI 10.1046/j.1523-1747.2000.00037.x; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; WILKINSON GWG, 1992, NUCLEIC ACIDS RES, V20, P2233, DOI 10.1093/nar/20.9.2233; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yu WH, 2000, J BIOL CHEM, V275, P31226, DOI 10.1074/jbc.M000907200	54	152	168	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2003	22	14					2121	2134		10.1038/sj.onc.1206292	http://dx.doi.org/10.1038/sj.onc.1206292			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664NJ	12687014				2022-12-28	WOS:000182066900006
J	Kikuchi, T; Daigo, Y; Katagiri, T; Tsunoda, T; Okada, K; Kakiuchi, S; Zembutsu, H; Furukawa, Y; Kawamura, M; Kobayashi, K; Imai, K; Nakamura, Y				Kikuchi, T; Daigo, Y; Katagiri, T; Tsunoda, T; Okada, K; Kakiuchi, S; Zembutsu, H; Furukawa, Y; Kawamura, M; Kobayashi, K; Imai, K; Nakamura, Y			Expression profiles of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs	ONCOGENE			English	Article						non-small cell lung cancer; gene-expression profile; chemosensitivity; lymph-node metastasis	LASER-CAPTURE MICRODISSECTION; COLORECTAL TUMORS; CARCINOMAS; CLASSIFICATION; ADENOCARCINOMA; CARCINOGENESIS; RESISTANCE; ADHESION; P53	To investigate genes involved in pulmonary carcinogenesis and those related to sensitivity of nonsmall cell lung cancers (NSCLCs) to therapeutic drugs, we performed cDNA microarray analysis of 37 NSCLCs after laser-capture microdissection of cancer cells from primary tumors. A clustering algorithm applied to the expression data easily distinguished two major histological types of non-small cell lung cancer, adenocarcinoma and squamous cell carcinoma. Subsequent analysis of the 18 adenocarcinomas identified 40 genes whose expression levels could separate cases with lymph-node metastasis from those without metastasis. In addition, we compared the expression data with measurements of the sensitivity of surgically dissected NSCLC specimens to six anti-cancer drugs (docetaxel, paclitaxel, irinotecan, cisplatin, gemcitabine, and vinorelbine), as measured by the CD-DST (collagen gel droplet embedded culture-drug sensitivity test) method. We found significant associations between expression levels of dozens of genes and chemosensitivity of NSCLCs. Our results provide valuable information for eventually identifying predictive markers and novel therapeutic target molecules for this type of cancer.	Univ Tokyo, Inst Med Sci, Ctr Human Genome, Lab Mol Med,Minato Ku, Tokyo 1088639, Japan; Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido 0608543, Japan; RIKEN, Inst Phys & Chem Res, SNP Res Ctr, Lab Med Informat, Kanagawa 2300045, Japan; Keio Univ, Sch Med, Dept Surg, Div Gen Thorac Surg, Tokyo 1608582, Japan	University of Tokyo; Sapporo Medical University; RIKEN; Keio University	Nakamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Lab Mol Med,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	yusuke@ims.u-tokyo.ac.jp	Tsunoda, Tatsuhiko/K-2061-2014	Tsunoda, Tatsuhiko/0000-0002-5439-7918; Daigo, Yataro/0000-0002-0915-3025				Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; FRANKLIN WA, 1994, INT J CANCER, P89; Fukata M, 2001, NAT REV MOL CELL BIO, V2, P887, DOI 10.1038/35103068; Furuhata T, 1996, ONCOGENE, V13, P1965; FURUKAWA T, 1995, CLIN CANCER RES, V1, P305; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Ichigotani Y, 2002, CANCER RES, V62, P2215; Kawano N, 1997, HUM PATHOL, V28, P613, DOI 10.1016/S0046-8177(97)90085-X; Kitahara O, 2001, CANCER RES, V61, P3544; Kondoh N, 2001, ANTICANCER RES, V21, P2429; Lin YM, 2002, ONCOGENE, V21, P4120, DOI 10.1038/sj.onc.1205518; Luo XL, 2002, MOL CELL, V9, P59, DOI 10.1016/S1097-2765(01)00435-X; Makino K, 2001, ONCOGENE, V20, P2537, DOI 10.1038/sj.onc.1204366; McDoniels-Silvers AL, 2002, CLIN CANCER RES, V8, P1127; Meyaard L, 2001, J EXP MED, V194, P107, DOI 10.1084/jem.194.1.107; Mitsudomi T, 2000, CLIN CANCER RES, V6, P4055; Niklinski J, 2001, LUNG CANCER, V34, pS53, DOI 10.1016/S0169-5002(01)00345-2; Okabe H, 2001, CANCER RES, V61, P2129; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Salonga D, 2000, CLIN CANCER RES, V6, P1322; Sozzi G, 2001, EUR J CANCER, V37, pS63; Turton NJ, 2001, ONCOGENE, V20, P1300, DOI 10.1038/sj.onc.1204235; UEDA K, 1987, J BIOL CHEM, V262, P505; VAMVAKOPOULOS NC, 1995, CYTOGENET CELL GENET, V68, P8, DOI 10.1159/000133878; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Watine J, 2000, BRIT MED J, V320, P379; Wieland I, 1999, ONCOGENE, V18, P4530, DOI 10.1038/sj.onc.1202806; Yanagawa R, 2001, NEOPLASIA, V3, P395, DOI 10.1038/sj.neo.7900185; Zembutsu H, 2002, CANCER RES, V62, P518	33	273	314	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2003	22	14					2192	2205		10.1038/sj.onc.1206288	http://dx.doi.org/10.1038/sj.onc.1206288			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664NJ	12687021				2022-12-28	WOS:000182066900013
J	Laiho, P; Hienonen, T; Karhu, A; Lipton, L; Aalto, Y; Thomas, HJW; Birkenkamp-Demtroder, K; Hodgson, S; Salovaara, R; Mecklin, JP; Jarvinen, H; Knuutila, S; Halford, S; Orntoft, TF; Tomlinson, I; Launonen, V; Houlston, R; Aaltonen, LA				Laiho, P; Hienonen, T; Karhu, A; Lipton, L; Aalto, Y; Thomas, HJW; Birkenkamp-Demtroder, K; Hodgson, S; Salovaara, R; Mecklin, JP; Jarvinen, H; Knuutila, S; Halford, S; Orntoft, TF; Tomlinson, I; Launonen, V; Houlston, R; Aaltonen, LA			Genome-wide allelotyping of 104 Finnish colorectal cancers reveals an excess of allelic imbalance in chromosome 20q in familial cases	ONCOGENE			English	Article						colorectal cancer; familial; hereditary; allelic imbalance; loss of heterozygosity	HERITABLE FACTORS; HETEROZYGOSITY; HYBRIDIZATION; GAINS; SUSCEPTIBILITY; CARCINOMAS; LOSSES; SWEDEN; GENES	We have allelotyped a series of 104 Finnish colorectal cancers (CRCs) using 372 polymorphic markers spaced, on average, at 10 cM intervals, and have made a comparison of the differences in the frequency of allelic imbalance (AI) between familial and sporadic cases. Differences in the frequency of allelic imbalance (loss of heterozygosity or amplification) at a number of loci were detected and these were evaluated through analysis of additional series of cancers using specific markers. The most consistent difference was observed at chromosome 20q13.1-13.3 characterized by a two fold difference between familial and nonfamilial disease in a total of 99 familial and 186 sporadic Finnish cases. This difference was not observed in a UK set of 67 familial and 96 sporadic CRCs. The genome-wide effort resulted in a large data set giving clues to the location of putative CRC predisposition genes in the genome. The approach provides an alternative strategy for detecting cancer predisposition genes solely reliant on the molecular analysis of single cases obviating the requirement to collect multiple samples from families.	Univ Helsinki, Biomedicum, Dept Med Genet, FIN-00014 Helsinki, Finland; Canc Res UK, Mol & Populat Genet Lab, London WC2A 3PX, England; St Marks Hosp, Cancres Res UK, Colorectal Unit, Harrow HA1 3UJ, Middx, England; Univ Helsinki, Haartman Inst, Dept Med Genet, FIN-00029 Helsinki, Finland; Univ Helsinki, Cent Hosp, FIN-00029 Helsinki, Finland; Aarhus Univ Hosp, Dept Clin Biochem, Mol Diagnost Lab, DK-8200 Aarhus, N Skejby, Denmark; Guys Hosp, Dept Clin Genet, Canc Res UK, London SE1 9RT, England; Univ Helsinki, Haartman Inst, Dept Pathol, FIN-00014 Helsinki, Finland; Cent Hosp Jyvaskyla, Dept Surg, FIN-40620 Jyvaskyla, Finland; Univ Helsinki, Cent Hosp, Dept Surg 2, FIN-00029 Helsinki, Finland; Inst Canc Res, Sect Canc Genet, Sutton SM2 5NG, Surrey, England; Univ Helsinki, Cent Hosp, Dept Oncol, FIN-00029 Helsinki, Finland	University of Helsinki; Cancer Research UK; Imperial College London; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Aarhus University; Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust; University of Helsinki; Central Finland Central Hospital; University of Helsinki; Helsinki University Central Hospital; University of London; Institute of Cancer Research - UK; University of Helsinki; Helsinki University Central Hospital	Aaltonen, LA (corresponding author), Univ Helsinki, Biomedicum, Dept Med Genet, POB 63, FIN-00014 Helsinki, Finland.	lauri.aaltonen@helsinki.fi	Mecklin, Jukka-Pekka/AAC-9650-2019; Mecklin, Jukka-Pekka/AAB-5378-2020; Birkenkamp-Demtröder, Karin/C-1981-2017; Aaltonen, Lauri/A-5375-2010; Birkenkamp-Demtröder, Karin/AAN-1764-2021	Mecklin, Jukka-Pekka/0000-0003-4895-2249; Aaltonen, Lauri/0000-0001-6839-4286; Birkenkamp-Demtröder, Karin/0000-0001-8057-6277; Houlston, Richard/0000-0002-5268-0242; Karhu, Auli/0000-0002-7927-0796				Aaltonen LA, 1998, NEW ENGL J MED, V338, P1481, DOI 10.1056/NEJM199805213382101; Aust DE, 2000, HUM PATHOL, V31, P109, DOI 10.1016/S0046-8177(00)80206-3; Bonaiti-Pellie C, 1999, EUR J CANCER PREV, V8, pS27; BURT RW, 1990, B WORLD HEALTH ORGAN, V68, P655; Canzian F, 1996, CANCER RES, V56, P3331; CUZICK J, 1999, METABOLIC POLYMORPHI, P109; De Angelis PM, 1999, BRIT J CANCER, V80, P526; De Angelis PM, 2001, INT J COLORECTAL DIS, V16, P38, DOI 10.1007/s003840000275; Dong C, 2001, INT J CANCER, V93, P155, DOI 10.1002/ijc.1317; Fischer J, 1998, ONCOGENE, V17, P733, DOI 10.1038/sj.onc.1201983; Ginzinger DG, 2000, CANCER RES, V60, P5405; Hemminki A, 1997, NAT GENET, V15, P87, DOI 10.1038/ng0197-87; HOULSTON RS, 1992, ANN HUM GENET, V56, P99, DOI 10.1111/j.1469-1809.1992.tb01136.x; Lewis CM, 1996, CANCER RES, V56, P1382; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; Meijer GA, 1998, J CLIN PATHOL, V51, P901, DOI 10.1136/jcp.51.12.901; Mertens F, 1997, CANCER RES, V57, P2765; Perneger TV, 1998, BRIT MED J, V316, P1236, DOI 10.1136/bmj.316.7139.1236; Peto J, 2001, EUR J CANCER, V37, pS88; Reich DE, 2001, NATURE, V411, P199, DOI 10.1038/35075590; Ried T, 1996, GENE CHROMOSOME CANC, V15, P234, DOI 10.1002/(SICI)1098-2264(199604)15:4<234::AID-GCC5>3.0.CO;2-2; Salovaara R, 2000, J CLIN ONCOL, V18, P2193, DOI 10.1200/JCO.2000.18.11.2193; Teh BT, 1998, AM J HUM GENET, V63, P1544, DOI 10.1086/302097; THORLACIUS S, 1991, ANTICANCER RES, V11, P1501; Tomlinson I, 1999, GASTROENTEROLOGY, V116, P789, DOI 10.1016/S0016-5085(99)70061-2; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; Weber TK, 1999, CYTOGENET CELL GENET, V86, P142, DOI 10.1159/000015368	27	13	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2003	22	14					2206	2214		10.1038/sj.onc.1206294	http://dx.doi.org/10.1038/sj.onc.1206294			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664NJ	12687022				2022-12-28	WOS:000182066900014
J	Wang, HM; Chakrabarty, S				Wang, HM; Chakrabarty, S			Platelet-activating factor activates mitogen-activated protein kinases, inhibits proliferation, induces differentiation and suppresses the malignant phenotype of human colon carcinoma cells	ONCOGENE			English	Article						PAF; colon; carcinomas	METHOXY HEXADECYL GLYCEROL; EPIDERMAL GROWTH-FACTOR; FACTOR-RECEPTOR; C-ALPHA; EXPRESSION; PAF; SECRETION	Recent studies suggest that the action of platelet-activating factor (PAF), a potent phospholipid modulator of allergic and inflammatory reactions, is diverse and functions as a modulator of a variety of physiological and pathological events in many cell types and tissues. Its role (if any) in modulating the proliferation, transformation and/or differentiation of epithelial colonic cells, however, is not known. In this study, we showed that PAF is biologically active in epithelial-derived human colon carcinoma cells with different phenotypic properties. These cells expressed the PAF receptor. PAF activated three prominent mitogen-activated protein kinase modules (ERK, p38MAPK and Jun N-terminal kinases) in these cells, inhibited proliferation and induced differentiation (measured by the induction of Waf1/p21 and the induction of the differentiation-related marker CEA). The net effect of PAF treatment was the suppression of malignant cell behavior (measured by anchorage-independent growth and cellular invasion). It is concluded that PAF is a modulator of proliferation and differentiation in human epithelial-derived colon carcinoma cells.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, DIv Pathol & Lab Med, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Chakrabarty, S (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, DIv Pathol & Lab Med, 1515 Holcombe Blvd, Houston, TX 77030 USA.							Bazan HEP, 1997, J OCUL PHARMACOL TH, V13, P277, DOI 10.1089/jop.1997.13.277; BRATTAIN MG, 1984, CANCER METAST REV, V3, P177, DOI 10.1007/BF00048384; Chakrabarty S, 1998, LAB INVEST, V78, P413; CHAKRABARTY S, 1988, CANCER RES, V48, P4059; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; GUADAGNI F, 1990, CANCER RES, V50, P6248; HONDA Z, 1994, J BIOL CHEM, V269, P2307; HUANG S, 1992, INT J CANCER, V52, P978, DOI 10.1002/ijc.2910520625; Kume K, 1997, J BIOL CHEM, V272, P22898, DOI 10.1074/jbc.272.36.22898; KUNZ D, 1992, J BIOL CHEM, V267, P9101; Marques SA, 2002, J PHARMACOL EXP THER, V300, P1026, DOI 10.1124/jpet.300.3.1026; Mukherjee PK, 1999, J BIOL CHEM, V274, P6493, DOI 10.1074/jbc.274.10.6493; Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419; Reynolds S, 1998, CANCER LETT, V134, P53, DOI 10.1016/S0304-3835(98)00242-0; Reynolds S, 2000, CLIN EXP METASTAS, V18, P309, DOI 10.1023/A:1011071907047; SAITO H, 1992, J LIPID MEDIATOR, V5, P135; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SCHROY PC, 1994, J CELL PHYSIOL, V161, P111, DOI 10.1002/jcp.1041610114; Shimada A, 1998, J INVEST DERMATOL, V110, P889, DOI 10.1046/j.1523-1747.1998.00202.x; SMITH CS, 1994, CELL IMMUNOL, V155, P292, DOI 10.1006/cimm.1994.1123; Sperber K, 1998, INFLAMM BOWEL DIS, V4, P12, DOI 10.1097/00054725-199802000-00003; STOLL LL, 1991, J CELL SCI, V100, P145; Sugano T, 2001, MOL HUM REPROD, V7, P475, DOI 10.1093/molehr/7.5.475; Tokutomi T, 2001, NEUROL RES, V23, P605, DOI 10.1179/016164101101199081; Wang H, 1999, J CELL PHYSIOL, V178, P173, DOI 10.1002/(SICI)1097-4652(199902)178:2<173::AID-JCP6>3.3.CO;2-H; Wang HM, 2001, J CELL PHYSIOL, V187, P188, DOI 10.1002/jcp.1068	26	24	25	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2003	22	14					2186	2191		10.1038/sj.onc.1206348	http://dx.doi.org/10.1038/sj.onc.1206348			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664NJ	12687020				2022-12-28	WOS:000182066900012
J	Weiss, MM; Kuipers, EJ; Postma, C; Snijders, AM; Siccama, I; Pinkel, D; Westerga, J; Meuwissen, SGM; Albertson, DG; Meijer, GA				Weiss, MM; Kuipers, EJ; Postma, C; Snijders, AM; Siccama, I; Pinkel, D; Westerga, J; Meuwissen, SGM; Albertson, DG; Meijer, GA			Genomic profiling of gastric cancer predicts lymph node status and survival	ONCOGENE			English	Article						gastric cancer; genomic profiling; survival; microarray CGH	DNA COPY NUMBER; HELICOBACTER-PYLORI; GENETIC ALTERATIONS; INTESTINAL-TYPE; CARCINOMA; HYBRIDIZATION; DISSECTION; AMPLICON; SUBTYPES; GAINS	Gastric carcinogenesis is driven by an accumulation of genetic changes that to a large extent occur at the chromosomal level. We analysed the patterns of chromosomal instability in 35 gastric carcinomas and their clinical correlations. With microarray competitive genomic hybridization, genomewide chromosomal copy number changes can be studied with high resolution and sensitivity. A genomewide scanning array with 2275 BAC and PI clones spotted in triplicate was used. This array provided an average resolution of 1.4 Mb across the genome. Patterns of chromosomal aberrations were analysed by hierarchical cluster analysis of the normalized 1092 tumour to normal fluorescence ratios of all clones, and cluster membership was correlated to clinicopathological data including survival. Hierarchical cluster analysis revealed three groups with different genomic profiles that correlated significantly with lymph node status (P = 0.02). Moreover, gastric cancer cases from cluster 3 showed a significantly better prognosis than those from clusters I and 2 (P = 0.02). Genomic profiling of gastric adenocarcinomas based on microarray analysis of chromosomal copy number changes predicted lymph node status and survival. The possibility to discriminate between patients with a high risk of lymph node metastasis could clinically be helpful for selecting patients for extended lymph node resection.	Vrije Univ Amsterdam, Med Ctr, Dept Pathol, NL-1007 MB Amsterdam, Netherlands; Vrije Univ Amsterdam, Med Ctr, Dept Gastroenterol, NL-1007 MB Amsterdam, Netherlands; Erasmus Univ, Med Ctr, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands; Univ Calif San Francisco, Ctr Canc, San Francisco, CA 94143 USA; KiQ Ltd, Amsterdam, Netherlands; Slotervaart Hosp, Dept Pathol, Amsterdam, Netherlands	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Erasmus University Rotterdam; Erasmus MC; University of California System; University of California San Francisco; Slotervaart Hospital	Meijer, GA (corresponding author), Vrije Univ Amsterdam, Med Ctr, Dept Pathol, POB 7057, NL-1007 MB Amsterdam, Netherlands.	ga.meijer@vumc.nl	Kuipers, Ernst J/H-3293-2019	Kuipers, Ernst J/0000-0002-0633-3098; Meijer, Gerrit/0000-0003-0330-3130; Weiss, Marjan M./0000-0002-0936-1406				Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985; Alizadeh AA, 2001, J PATHOL, V195, P41, DOI 10.1002/path.889; Bonenkamp JJ, 1999, NEW ENGL J MED, V340, P908, DOI 10.1056/NEJM199903253401202; Cuschieri A, 1999, BRIT J CANCER, V79, P1522, DOI 10.1038/sj.bjc.6690243; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Ekstrom AM, 2001, GASTROENTEROLOGY, V121, P784, DOI 10.1053/gast.2001.27999; Guan XY, 2000, CANCER GENET CYTOGEN, V123, P27, DOI 10.1016/S0165-4608(00)00306-X; HAUSEN AZ, 2001, GASTROENTEROLOGY, V121, P612; Hermsen M, 2002, GASTROENTEROLOGY, V123, P1109, DOI 10.1053/gast.2002.36051; Hermsen MAJA, 1998, J PATHOL, V186, P356; Jain AN, 2002, GENOME RES, V12, P325, DOI 10.1101/gr.210902; Koizumi Y, 1997, CLIN CANCER RES, V3, P1067; Kokkola A, 1998, CANCER GENET CYTOGEN, V107, P32, DOI 10.1016/S0165-4608(98)00092-2; Kokkola A, 1997, GENE CHROMOSOME CANC, V20, P38, DOI 10.1002/(SICI)1098-2264(199709)20:1<38::AID-GCC6>3.0.CO;2-A; Koo SH, 2000, CANCER GENET CYTOGEN, V117, P97, DOI 10.1016/S0165-4608(99)00152-1; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Parkin DM, 2001, LANCET ONCOL, V2, P533, DOI 10.1016/S1470-2045(01)00486-7; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Sakakura C, 1999, GENE CHROMOSOME CANC, V24, P299, DOI 10.1002/(SICI)1098-2264(199904)24:4<299::AID-GCC2>3.0.CO;2-U; SASAKO M, 1995, BRIT J SURG, V82, P346, DOI 10.1002/bjs.1800820321; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Sipponen P, 1998, ALIMENT PHARM THER, V12, P61, DOI 10.1111/j.1365-2036.1998.00005.x; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; SUDBERY P, 2002, HUMAN MOL GENETICS; van Dekken H, 2001, AM J PATHOL, V158, P1961, DOI 10.1016/S0002-9440(10)64666-4; van Grieken NCT, 2000, J PATHOL, V192, P301, DOI 10.1002/1096-9896(2000)9999:9999&lt;::AID-PATH697&gt;3.0.CO;2-F; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Varis A, 2002, CANCER RES, V62, P2625; VISSER O, 2001, INCIDENCE CANC NETHE; Weiss MM, 1999, J CLIN PATHOL-MOL PA, V52, P243; WEISS MM, 2003, IN PRESS J PATHOL; Wu MS, 2001, GENE CHROMOSOME CANC, V30, P80, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1062>3.0.CO;2-R; Wu MS, 1997, GASTROENTEROLOGY, V112, P1457, DOI 10.1016/S0016-5085(97)70071-4	34	90	94	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2003	22	12					1872	1879		10.1038/sj.onc.1206350	http://dx.doi.org/10.1038/sj.onc.1206350			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660823				2022-12-28	WOS:000181678200014
J	Graveel, CR; Harkins-Perry, SR; Acevedo, LG; Farnham, PJ				Graveel, CR; Harkins-Perry, SR; Acevedo, LG; Farnham, PJ			Identification and characterization of CRG-L2, a new marker for liver tumor development	ONCOGENE			English	Article						hepatocellular carcinoma; cancer testis antigen; olfactomedin domain; tumor marker; rapid amplification of cDNA ends	EXPRESSION; PROTEIN; GENE; DIETHYLNITROSAMINE; C57BL/6J; LESIONS; FAMILY; TESTIS; MEMBER; FOCI	Liver cancer is very common worldwide and the rates of hepatocellular carcinoma (HCC) have increased by over 70% in the last 2 decades in the US. Late diagnosis, because of the lack of clinical symptoms, and decreased hepatic function, because of underlying hepatic disease, lead to the extremely high mortality rates associated with HCC. Clearly, the identification of markers that are expressed early in the development of HCC and that are easily detected in high-risk patients would aid in early diagnosis and increased survival. We present the cloning and characterization of a novel gene, CRG-L2 (Cancer related gene-Liver 2), which displays high expression in murine and human hepatocellular carcinomas. Using in situ hybridization, we show that CRG-L2 mRNA levels are increased early during the development of liver tumors in C3H/HeJ mice, and that in normal tissues CRG-L2 mRNA is restricted to the murine testis and human placenta. Its restricted expression in normal tissues and unique early upregulation during tumor development make CRG-L2 an excellent candidate as a new clinical marker of HCC.	Univ Wisconsin, McArdle Lab Canc Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Farnham, PJ (corresponding author), Univ Wisconsin, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.	farnham@oncology.wisc.edu		Farnham, Peggy/0000-0003-4469-7914	NCI NIH HHS [CA22484, CA14520] Funding Source: Medline; NIGMS NIH HHS [GM08349] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA022484, P30CA014520] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*AM CANC SOC, 2002, CANC FACTS FIG 2002, P1; Borscheri N, 2001, AM J SURG PATHOL, V25, P1297, DOI 10.1097/00000478-200110000-00011; Bosch FX, 1999, SEMIN LIVER DIS, V19, P271, DOI 10.1055/s-2007-1007117; Brinkmann U, 1998, P NATL ACAD SCI USA, V95, P10757, DOI 10.1073/pnas.95.18.10757; El-Serag HB, 1999, NEW ENGL J MED, V340, P745, DOI 10.1056/NEJM199903113401001; Gilboa E, 1999, IMMUNITY, V11, P263, DOI 10.1016/S1074-7613(00)80101-6; Graveel CR, 2001, ONCOGENE, V20, P2704, DOI 10.1038/sj.onc.1204391; HANIGAN MH, 1988, CARCINOGENESIS, V9, P885, DOI 10.1093/carcin/9.6.885; KOEN H, 1983, CANCER RES, V43, P702; Kulkarni NH, 2000, GENET RES, V76, P41, DOI 10.1017/S0016672300004584; Lukas ER, 1999, MOL CARCINOGEN, V25, P295, DOI 10.1002/(SICI)1098-2744(199908)25:4<295::AID-MC8>3.0.CO;2-9; Micales BK, 2001, METHODS, V23, P313, DOI 10.1006/meth.2000.1143; MOORE MR, 1981, CANCER RES, V41, P1585; Ono T, 2001, P NATL ACAD SCI USA, V98, P3282, DOI 10.1073/pnas.041625098; Rainov NG, 1995, CLIN CANCER RES, V1, P775; Richards JE, 1998, OPHTHALMOLOGY, V105, P1698, DOI 10.1016/S0161-6420(98)99041-8; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; Scanlan MJ, 2000, CANCER LETT, V150, P155, DOI 10.1016/S0304-3835(99)00385-7; Scanlan MJ, 2002, INT J CANCER, V98, P485, DOI 10.1002/ijc.10276; Song BC, 2002, CANCER-AM CANCER SOC, V94, P175, DOI 10.1002/cncr.10170; Struss AK, 2001, ONCOGENE, V20, P4107, DOI 10.1038/sj.onc.1204552; Tureci O, 1998, P NATL ACAD SCI USA, V95, P5211, DOI 10.1073/pnas.95.9.5211; VESSELINOVITCH SD, 1985, CANCER RES, V45, P2774; Zhang JC, 2002, GENE, V283, P83, DOI 10.1016/S0378-1119(01)00763-6	24	16	19	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	2003	22	11					1730	1736		10.1038/sj.onc.1206309	http://dx.doi.org/10.1038/sj.onc.1206309			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642876				2022-12-28	WOS:000181580500015
J	Tarsounas, M; Davies, D; West, SC				Tarsounas, M; Davies, D; West, SC			BRCA2-dependent and independent formation of RAD51 nuclear foci	ONCOGENE			English	Article						recombination; DNA repair; genome stability; breast cancer	DNA-DAMAGE; HOMOLOGOUS RECOMBINATION; CANCER SUSCEPTIBILITY; CELL-CYCLE; BRCA2; PROTEIN; REPAIR; GENE; ASSOCIATION; DEFICIENCY	The formation of RAD51 foci in response to ionizing radiation (IR) represents an important step in the repair of DNA double-strand breaks. RAD51 foci also appear during S phase and are thought to be required for the restart of stalled or broken replication forks. The RAD51 recombinase interacts directly with the breast cancer-associated tumour suppressor BRCA2, an interaction that is required for normal recombination proficiency, radiation resistance and genome stability. In CAPAN-1 cells, which express a truncated form of BRCA2 that is cytoplasmic because of loss of the nuclear localization signal, the formation of IR-induced RAD51 foci is impaired. In this work, we show that S-phase RAD51 foci form normally in CAPAN-1 cells expressing truncated BRCA2. Moreover, we find that RAD51 specifically associates with chromatin at S phase in a reaction that is BRCA2-independent. The observed BRCA2-dependent and independent formation of RAD51 foci shows that intact BRCA2 is not required for RAD51 focus formation per se, leading us to suggest that S phase and IR-induced RAD51 foci assemble by distinct pathways with defined protein requirements.	Canc Res UK, London Res Inst, Clare Hall Labs, S Mimms EN6 3LD, Herts, England	Cancer Research UK	West, SC (corresponding author), Canc Res UK, London Res Inst, Clare Hall Labs, S Mimms EN6 3LD, Herts, England.	stephen.west@cancer.org.uk		West, Stephen/0000-0001-8848-9418; Davies, Derek/0000-0002-6977-4181				Barlow AL, 1997, EMBO J, V16, P5207, DOI 10.1093/emboj/16.17.5207; Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200; Bishop DK, 1998, J BIOL CHEM, V273, P21482, DOI 10.1074/jbc.273.34.21482; Chen FQ, 1997, MUTAT RES-DNA REPAIR, V384, P205, DOI 10.1016/S0921-8777(97)00020-7; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Darzynkiewicz Z, 1999, EXP CELL RES, V249, P1, DOI 10.1006/excr.1999.4477; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Dimitrova DS, 1999, J CELL BIOL, V146, P709, DOI 10.1083/jcb.146.4.709; Essers J, 2002, EMBO J, V21, P2030, DOI 10.1093/emboj/21.8.2030; Flygare J, 1996, BBA-MOL CELL RES, V1312, P231, DOI 10.1016/0167-4889(96)00040-7; Godthelp BC, 2002, ONCOGENE, V21, P5002, DOI 10.1038/sj.onc.1205656; Goggins M, 1996, CANCER RES, V56, P5360; Golub EI, 1998, NUCLEIC ACIDS RES, V26, P5388, DOI 10.1093/nar/26.23.5388; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Huber LJ, 2001, MOL CELL BIOL, V21, P4005, DOI 10.1128/MCB.21.12.4005-4015.2001; Kerr P, 2001, CURR BIOL, V11, pR668, DOI 10.1016/S0960-9822(01)00389-X; Kraakman-van der Zwet M, 2002, MOL CELL BIOL, V22, P669, DOI 10.1128/MCB.22.2.669-679.2002; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Moens PB, 1997, CHROMOSOMA, V106, P207, DOI 10.1007/s004120050241; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; O'Regan P, 2001, J BIOL CHEM, V276, P22148, DOI 10.1074/jbc.M102396200; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Plug AW, 1996, P NATL ACAD SCI USA, V93, P5920, DOI 10.1073/pnas.93.12.5920; Raderschall E, 1999, P NATL ACAD SCI USA, V96, P1921, DOI 10.1073/pnas.96.5.1921; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Spain BH, 1999, P NATL ACAD SCI USA, V96, P13920, DOI 10.1073/pnas.96.24.13920; Takei Y, 2001, EMBO REP, V2, P119, DOI 10.1093/embo-reports/kve026; Tan TLR, 1999, CURR BIOL, V9, P325, DOI 10.1016/S0960-9822(99)80142-0; Tashiro S, 2000, J CELL BIOL, V150, P283, DOI 10.1083/jcb.150.2.283; Tashiro S, 1996, ONCOGENE, V12, P2165; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233; Welcsh PL, 2000, TRENDS GENET, V16, P69, DOI 10.1016/S0168-9525(99)01930-7; Xia F, 2001, P NATL ACAD SCI USA, V98, P8644, DOI 10.1073/pnas.151253498; Yu VPCC, 2000, GENE DEV, V14, P1400; Yuan SSF, 1999, CANCER RES, V59, P3547	44	152	163	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2003	22	8					1115	1123		10.1038/sj.onc.1206263	http://dx.doi.org/10.1038/sj.onc.1206263			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650EK	12606939				2022-12-28	WOS:000181249700001
J	Arguello, M; Sgarbanti, M; Hernandez, E; Mamane, Y; Sharma, S; Servant, M; Lin, RT; Hiscott, J				Arguello, M; Sgarbanti, M; Hernandez, E; Mamane, Y; Sharma, S; Servant, M; Lin, RT; Hiscott, J			Disruption of the B-cell specific transcriptional program in HHV-8 associated primary effusion lymphoma cell lines	ONCOGENE			English	Article						primary effusion lymphoma (PEL); IRF-4; PU.1; Oct-2; HHV-8	CLASSICAL HODGKINS-DISEASE; CAVITY-BASED LYMPHOMAS; REED-STERNBERG CELLS; CHAIN GENE ENHANCER; KAPOSIS-SARCOMA; FACTOR PU.1; NUCLEAR FACTOR; DNA-SEQUENCES; EXPRESSION; OCT-2	Primary effusion lymphoma (PEL) is a lymphoproliferative disease of B-cell origin that is associated with HHV-8 infection. PEL cells harbor a non-B, non-T phenotype and lack significant surface immunoglobulin (Ig) expression, a characteristic that has not been fully explained. In the present study, we demonstrate that PEL cells constitutively express interferon regulatory factor (IRF)-4, a transcription factor that regulates the activity of the immunoglobulin light-chain enhancer elements 13 and KEY through binding to a composite Ets-IRF site. IRF-4 activity requires its physical interaction with PU.1, an Ets family member involved in the activation of genes essential for B-cell development. However, in PEL-derived B-cell lines, PU.1 expression was completely abrogated; expression of the B cell specific transcription factor Oct-2, which is known to regulate PU.1 expression, was also abolished. Moreover, the B-cell-specific coactivator of octamer factors, BOB-1/OcaB, was expressed at very decreased levels in PEL cells. Ectopic expression of Oct-2 was able to fully restore PU.1 promoter activity in the PEL cell line BCBL-1, while PU.1 expression also reconstituted the activity of the lambdaB Ets-IRF site. In addition, protein levels of BSAP/Pax-5 and IRF-8/ICSBP were undetectable in PEL cells. The pattern of transcription factor ablation observed in PEL was found to be comparable to that observed in classical Hodgkin's disease-derived cell lines, which also lack B-cell-specific surface markers. These observations indicate that disruption of the B-cell-specific transcriptional program is likely to contribute to the incomplete B-cell phenotype characteristic of PEL cells.	Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University; McGill University	Hiscott, J (corresponding author), Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, 3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.		SGARBANTI, MARCO/C-2962-2016; Lin, Rongtuan/A-1442-2008	SGARBANTI, MARCO/0000-0002-0433-5110; Lin, Rongtuan/0000-0002-2238-3503				Brass AL, 1999, EMBO J, V18, P977, DOI 10.1093/emboj/18.4.977; Brass AL, 1996, GENE DEV, V10, P2335, DOI 10.1101/gad.10.18.2335; Carbone A, 2001, BLOOD, V97, P744, DOI 10.1182/blood.V97.3.744; Carbone A, 2000, LEUKEMIA, V14, P1301, DOI 10.1038/sj.leu.2401802; Carbone A, 2000, BRIT J HAEMATOL, V111, P247, DOI 10.1046/j.1365-2141.2000.02329.x; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; Chan WC, 2001, HEMATOL ONCOL, V19, P1; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chen HM, 1996, J BIOL CHEM, V271, P15743, DOI 10.1074/jbc.271.26.15743; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; Dolcetti R, 2001, EUR J CANCER, V37, P1276, DOI 10.1016/S0959-8049(01)00105-8; DREXLER HG, 1993, LEUKEMIA LYMPHOMA, V9, P1, DOI 10.3109/10428199309148499; Drexler HG, 1998, LEUKEMIA, V12, P1507, DOI 10.1038/sj.leu.2401160; EHLINHENRIKSSON B, 1987, INT J CANCER, V39, P211, DOI 10.1002/ijc.2910390215; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Falini B, 2000, BLOOD, V95, P2084, DOI 10.1182/blood.V95.6.2084; FELDHAUS AL, 1992, MOL CELL BIOL, V12, P1126, DOI 10.1128/MCB.12.3.1126; Gaidano G, 1997, BLOOD, V89, P3755; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; Hecht JL, 2000, J CLIN ONCOL, V18, P3707, DOI 10.1200/JCO.2000.18.21.3707; Hertel CB, 2002, ONCOGENE, V21, P4908, DOI 10.1038/sj.onc.1205629; Himmelmann A, 1997, BLOOD, V90, P3984, DOI 10.1182/blood.V90.10.3984; JUNKER S, 1990, CELL, V61, P467, DOI 10.1016/0092-8674(90)90528-M; LIEBERMAN SA, 1993, J IMMUNOL, V151, P2588; Mamane Y, 2002, J INTERF CYTOK RES, V22, P135, DOI 10.1089/107999002753452746; Mamane Y, 2002, ONCOGENE, V21, P6751, DOI 10.1038/sj.onc.1205843; Marecki S, 2002, J INTERF CYTOK RES, V22, P121, DOI 10.1089/107999002753452737; Matolcsy A, 1998, AM J PATHOL, V153, P1609, DOI 10.1016/S0002-9440(10)65749-5; Muller S, 1996, ONCOGENE, V13, P1955; Nador RG, 1996, BLOOD, V88, P645, DOI 10.1182/blood.V88.2.645.bloodjournal882645; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; OMORI SA, 1993, P NATL ACAD SCI USA, V90, P11723, DOI 10.1073/pnas.90.24.11723; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Pernis AB, 2002, J INTERF CYTOK RES, V22, P111, DOI 10.1089/107999002753452728; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; RADOMSKA HS, 1994, IMMUNITY, V1, P623, DOI 10.1016/1074-7613(94)90034-5; Rao E, 1997, J BIOL CHEM, V272, P6722, DOI 10.1074/jbc.272.10.6722; Re D, 2001, CANCER RES, V61, P2080; Reya T, 1998, CURR OPIN IMMUNOL, V10, P158, DOI 10.1016/S0952-7915(98)80244-6; Schubart K, 2001, NAT IMMUNOL, V2, P69, DOI 10.1038/83190; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Servant MJ, 2001, J BIOL CHEM, V276, P355, DOI 10.1074/jbc.M007790200; Sharif MN, 2001, J IMMUNOL, V167, P4421, DOI 10.4049/jimmunol.167.8.4421; Sharma S, 2002, J IMMUNOL, V169, P3120, DOI 10.4049/jimmunol.169.6.3120; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; SINGH H, 1994, IMMUNOL RES, V13, P280, DOI 10.1007/BF02935619; Stein H, 2001, BLOOD, V97, P496, DOI 10.1182/blood.V97.2.496; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; Torlakovic E, 2001, AM J PATHOL, V159, P1807, DOI 10.1016/S0002-9440(10)63027-1	51	44	48	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 20	2003	22	7					964	973		10.1038/sj.onc.1206270	http://dx.doi.org/10.1038/sj.onc.1206270			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	644PB	12592383				2022-12-28	WOS:000180926100002
J	Roccato, E; Pagliardini, S; Cleris, L; Canevari, S; Formelli, F; Pierotti, MA; Greco, A				Roccato, E; Pagliardini, S; Cleris, L; Canevari, S; Formelli, F; Pierotti, MA; Greco, A			Role of TFG sequences outside the coiled-coil domain in TRK-T3 oncogenic activation	ONCOGENE			English	Article						TRK-T3; coiled-coil domain; TFG; NTRK1; oncogenic activation	NERVE GROWTH-FACTOR; TYROSINE KINASE; OLIGOMERIZATION DOMAIN; PROMOTER REGION; PC MOTIF; PROTEIN; DIMERIZATION; RECEPTOR; TERMINUS; MEMBRANE	The TRK-T3 oncoprotein, isolated from a human papillary thyroid tumor, arises from the fusion between the N-terminal domain of the TFG gene and the tyrosine kinase domain of the NTRK1 receptor. The 68 kDa TRKT3 oncoprotein displays a constitutive tyrosine kinase activity resulting in its capability to transform NIH3T3 cells. The TFG portion of TRK-T3 contains a coiled-coil domain, which mediates protein oligomerization essential for the oncogene constitutive activation, and several consensus sites for protein interaction. In this study, we investigate the role of TFG sequences outside the coiled-coil domain on TRK-T3 activation, We constructed four mutants carrying different deletions of TFG sequences and expressed them in mammalian cells. By performing biochemical and biological assays we demonstrated that all the deleted regions are required for TRK-T3 activation, as they are involved in different mechanisms such as protein processing, formation of stable and/or functional complexes, and possible interaction with other proteins. By constructing site-specific mutants, we demonstrated a crucial role for a PB1 domain and a considerable contribution of an SH2-binding motif in TRK-T3 oncogenic activation. This work establishes an important role for TFG sequences outside the coiled-coil domain in the activation of the thyroid TRK-T3 oncogene.	Ist Nazl Tumori, Operat Unit 3, Dept Expt Oncol, I-20133 Milan, Italy; Ist Nazl Tumori, Operat Unit 13, Dept Expt Oncol, I-20133 Milan, Italy; Ist Nazl Tumori, Operat Unit 11, Dept Expt Oncol, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan	Greco, A (corresponding author), Ist Nazl Tumori, Operat Unit 3, Dept Expt Oncol, Via Venezian 1, I-20133 Milan, Italy.	angela.greco@istitutotumori.mi.it	Pierotti, Marco Alessandro/AAC-4728-2022; Greco, Angela/C-1953-2017; Cleris, Loredana/T-3144-2018	Pierotti, Marco Alessandro/0000-0002-7431-8332; Greco, Angela/0000-0003-2994-0349; Cleris, Loredana/0000-0001-8778-7931				BORRELLO MG, 1994, ONCOGENE, V9, P1661; BYRD DA, 1994, J CELL BIOL, V127, P1515, DOI 10.1083/jcb.127.6.1515; Canu N, 1997, J NEUROCHEM, V68, P1390; DURICK K, 1995, J BIOL CHEM, V270, P24642, DOI 10.1074/jbc.270.42.24642; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; GRECO A, 1995, MOL CELL BIOL, V15, P6118; Greco A, 1998, ONCOGENE, V16, P809, DOI 10.1038/sj.onc.1201596; Grignani F, 1999, ONCOGENE, V18, P6313, DOI 10.1038/sj.onc.1203029; Ito T, 2001, EMBO J, V20, P3938, DOI 10.1093/emboj/20.15.3938; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; Mathews JM, 2000, J VIROL, V74, P5911, DOI 10.1128/JVI.74.13.5911-5920.2000; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; Mencinger M, 1999, BIOCHEM BIOPH RES CO, V257, P67, DOI 10.1006/bbrc.1999.0417; Mencinger M, 1997, GENOMICS, V41, P327, DOI 10.1006/geno.1997.4625; Miranda C, 2001, J CELL PHYSIOL, V186, P35; Monaco C, 2001, ONCOGENE, V20, P599, DOI 10.1038/sj.onc.1204127; Pierotti MA, 1996, GENE CHROMOSOME CANC, V16, P1; POSSENTI R, 1992, P NATL ACAD SCI USA, V89, P3815, DOI 10.1073/pnas.89.9.3815; Roccato E, 2002, BRIT J CANCER, V87, P645, DOI 10.1038/sj.bjc.6600544; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RODRIGUES GA, 1994, CURR OPIN GENE DEV, V13, P6711; Terasawa H, 2001, EMBO J, V20, P3947, DOI 10.1093/emboj/20.15.3947; Tong Q, 1997, J BIOL CHEM, V272, P9043	28	22	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2003	22	6					807	818		10.1038/sj.onc.1206189	http://dx.doi.org/10.1038/sj.onc.1206189			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584559				2022-12-28	WOS:000180864300002
J	Karnauskas, R; Niu, Q; Talapatra, S; Plas, DR; Greene, ME; Crispino, JD; Rudin, CM				Karnauskas, R; Niu, Q; Talapatra, S; Plas, DR; Greene, ME; Crispino, JD; Rudin, CM			Bcl-X-L and Akt cooperate to promote leukemogenesis in vivo	ONCOGENE			English	Article						leukemia; Akt; Bcl-X-L; p53; interleukin-3	CHROMOSOMAL TRANSLOCATIONS; SURVIVAL; BCL-X(L); EXPRESSION; LYMPHOMA; GROWTH; CANCER; CELLS; GENE; HAPLOINSUFFICIENCY	To analyse individual factors that may contribute to leukemic transformation in vivo, we have developed a murine model of leukemogenesis based on the early hematopoietic precursor cell FL5.12. FL5.12 cells are interleukin-3 (IL-3) dependent for growth, proliferation, and survival. Relative resistance to cell death following IL-3 withdrawal can be conferred by either overexpression of the Bcl-x(L) apoptotic inhibitor, or constitutive activation of the serine/threonine kinase Akt. The ability of Bcl-x(L) or a constitutively active myristylated Akt to promote leukemic transformation of FL5.12 cells was compared in athymic nu(+)/nu(+) mice. Bcl-x(L) alone could not promote leukemic transformation, but mice injected with FL5.12 cells overexpressing Bcl-x(L), and a dominant-negative p53 construct developed leukocytosis and blastic infiltration of lymph nodes, spleen, and liver with features of a high-grade lymphoid malignancy. In contrast to the cells injected into these animals, cell lines derived from the mice were able to proliferate in the absence of IL-3, and were found to have constitutively activated Akt. This constitutive activation was associated with a variety of alterations of the signaling pathway regulating Akt activity, including alterations of PTEN mRNA and protein expression. In addition, some of these leukemic clones demonstrated concurrent constitutive upregulation of ERK activity. A constitutively active Akt construct introduced into FL5.12 cells promoted similar clonal expansion in vivo, with emergence of clonal IL-3-independent proliferation. Bcl-x(L) and Akt appeared to function cooperatively in this model, enhancing rapid clonal outgrowth in vivo relative to Akt alone. These results implicate activated Akt and growth-factor independence in leukemogenic transformation, and demonstrate the potential for in vivo analysis of genetic determinants of leukemogenesis.	Univ Chicago, Med Ctr, Hematol Oncol Sect, Dept Med, Chicago, IL 60637 USA; Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA	University of Chicago; University of Chicago Medical Center; University of Pennsylvania; Pennsylvania Medicine; University of Chicago	Rudin, CM (corresponding author), Univ Chicago, Med Ctr, Hematol Oncol Sect, Dept Med, 5841 S Maryland Ave,MC 2115, Chicago, IL 60637 USA.	crudin@medicine.bsd.uchicago.edu	Rudin, Charles/R-2530-2019	Rudin, Charles/0000-0001-5204-3465; Crispino, John/0000-0002-8182-8306	NCI NIH HHS [CA81138] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K23CA081138] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Barlow C, 1999, NAT GENET, V21, P359, DOI 10.1038/7684; Barthel A, 1999, J BIOL CHEM, V274, P20281, DOI 10.1074/jbc.274.29.20281; BELLACOSA A, 1993, ONCOGENE, V8, P745; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Cross DAE, 1997, FEBS LETT, V406, P211, DOI 10.1016/S0014-5793(97)00240-8; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DellaRagione F, 1995, HAEMATOLOGICA, V80, P557; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; DREXLER HG, 1995, LEUKEMIA, V9, P480; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Huang ZW, 2000, ONCOGENE, V19, P6627, DOI 10.1038/sj.onc.1204087; ISSA JP, 1997, LEUKEMIA S1, V11, P7; Klein G, 2000, BIOESSAYS, V22, P414, DOI 10.1002/(SICI)1521-1878(200005)22:5<414::AID-BIES3>3.0.CO;2-5; Komuro Hiroaki, 1999, Neoplasia (New York), V1, P253, DOI 10.1038/sj.neo.7900033; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; Lawlor MA, 2001, J CELL SCI, V114, P2903; Lund AH, 2002, NAT GENET, V32, P160, DOI 10.1038/ng956; MCKEARN JP, 1985, P NATL ACAD SCI USA, V82, P7414, DOI 10.1073/pnas.82.21.7414; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Minn AJ, 1999, EMBO J, V18, P632, DOI 10.1093/emboj/18.3.632; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; Plas DR, 2002, TRENDS ENDOCRIN MET, V13, P74; Rowley JD, 2000, SEMIN HEMATOL, V37, P315; RUDIN CM, 2001, METABOLIC MOL BASES, P631; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Talapatra S, 2001, J PHARMACOL EXP THER, V298, P873; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Veldman T, 1997, NAT GENET, V15, P406, DOI 10.1038/ng0497-406; Weissman IL, 2001, ANNU REV CELL DEV BI, V17, P387, DOI 10.1146/annurev.cellbio.17.1.387; Xerri L, 1998, LEUKEMIA LYMPHOMA, V28, P451, DOI 10.3109/10428199809058352	37	30	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2003	22	5					688	698		10.1038/sj.onc.1206159	http://dx.doi.org/10.1038/sj.onc.1206159			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569361				2022-12-28	WOS:000180642100006
J	Bachelier, R; Xu, XL; Wang, XY; Li, WM; Naramura, M; Gu, H; Deng, CX				Bachelier, R; Xu, XL; Wang, XY; Li, WM; Naramura, M; Gu, H; Deng, CX			Normal lymphocyte development and thymic lymphoma formation in Brca1 exon-11-deficient mice	ONCOGENE			English	Article						T-lymphoma; Brca1; p53; tumorigenesis	DNA-DAMAGE RESPONSE; DOUBLE-STRAND BREAKS; MAMMARY EPITHELIAL-CELLS; MURINE BRCA1; CANCER SUSCEPTIBILITY; SUBCELLULAR-LOCALIZATION; ATAXIA-TELANGIECTASIA; CHROMOSOME STABILITY; GENETIC INSTABILITY; REPAIR	Breast-cancer-associated gene 1 (BRCA1) is highly expressed in thymus and spleen. In this paper, we have studied lymphocyte development and tumorigenesis in mice carrying mutations in Brca1 and p53. We show that the deletion of Brca1 exon 11 (Brca1-Delta11), which disrupts the full-length isoform, but not the short isoform of Brcal, does not interfere with lymphocyte development. This is true irrespective of p53 status, that is, whether it is wild type, heterozygous or homozygous for a null mutation. These data suggest that the expression of Brcal short isoform alone is enough to maintain normal development of lymphocytes. However, it cannot suppress tumorigenesis as about 30% of Brca1(Delta11/Delta11)p53(+/-) mice develop thymic lymphoma between 3 and 7 months of age. We demonstrate that p53 plays an essential role in Brca1-associated lymphoma, as all the tumors from Brca1(Delta11/Delta11)p53(+/-) mice exhibit LOH of p53 and Brca1(Delta11/Delta)11p53(-/-) mice exhibited accelerated tumorigenesis. We further demonstrate that the Brca1-Delta11 deficiency does not affect thymocyte proliferation; however, it increases genetic instability and triggers gamma-irradiation-induced apoptosis. The loss of p53 attenuates apoptosis and allows accumulation of further mutations in Brca1-Delta11 thymocytes, eventually leading to thymic lymphoma formation.	NIDDK, Genet Dev & Dis Branch, Lab Immunol, Bethesda, MD 20892 USA; NIAID, Lab Immunol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Deng, CX (corresponding author), NIDDK, Genet Dev & Dis Branch, Lab Immunol, 10-9N105,10 Ctr Dr, Bethesda, MD 20892 USA.		deng, chuxia/N-6713-2016	Naramura, Mayumi/0000-0003-3658-0767	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK056001, ZIADK056001] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; Bachelier R, 2000, INT J CANCER, V88, P519, DOI 10.1002/1097-0215(20001115)88:4<519::AID-IJC2>3.0.CO;2-R; Baldeyron C, 2002, ONCOGENE, V21, P1401, DOI 10.1038/sj.onc.1205200; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; BENNETT LM, 1995, GENOMICS, V29, P576, DOI 10.1006/geno.1995.9963; Bernstein C, 2002, MUTAT RES-REV MUTAT, V511, P145, DOI 10.1016/S1383-5742(02)00009-1; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Brodie S G, 2001, Trends Genet, V17, pS18, DOI 10.1016/S0168-9525(01)02451-9; Brodie SG, 2001, ONCOGENE, V20, P7514, DOI 10.1038/sj.onc.1204929; Brodie SG, 2001, ONCOGENE, V20, P1445, DOI 10.1038/sj.onc.1204222; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chen JJ, 1999, CANCER RES, V59, p1752S; Chen YM, 1996, CANCER RES, V56, P3168; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Deng CX, 2000, BIOESSAYS, V22, P728; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EASTON DF, 1995, AM J HUM GENET, V56, P265; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; Elliott B, 2002, CELL MOL LIFE SCI, V59, P373, DOI 10.1007/s00018-002-8429-3; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Gatei M, 2000, CANCER RES, V60, P3299; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; GRETZULA JC, 1987, J AM ACAD DERMATOL, V17, P479, DOI 10.1016/S0190-9622(87)70233-3; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Hartman AR, 2002, NAT GENET, V32, P180, DOI 10.1038/ng953; Huang JR, 2002, NUCLEIC ACIDS RES, V30, P667, DOI 10.1093/nar/30.3.667; Huber LJ, 2001, MOL CELL BIOL, V21, P4005, DOI 10.1128/MCB.21.12.4005-4015.2001; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kuschel B, 2001, GENE CHROMOSOME CANC, V31, P96, DOI 10.1002/gcc.1122; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Lu ML, 2000, ONCOGENE, V19, P6351, DOI 10.1038/sj.onc.1204025; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Ludwig T, 2001, GENE DEV, V15, P1188, DOI 10.1101/gad.879201; Luo GB, 2000, NAT GENET, V26, P424, DOI 10.1038/82548; Mak TW, 2000, NAT IMMUNOL, V1, P77, DOI 10.1038/76950; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; Meza JE, 1999, J BIOL CHEM, V274, P5659, DOI 10.1074/jbc.274.9.5659; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Moore JK, 1996, MOL CELL BIOL, V16, P2164, DOI 10.1128/mcb.16.5.2164; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Moynahan ME, 2001, CANCER RES, V61, P4842; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; SHARAN SK, 1995, HUM MOL GENET, V4, P2275, DOI 10.1093/hmg/4.12.2275; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Snouwaert JN, 1999, ONCOGENE, V18, P7900, DOI 10.1038/sj.onc.1203334; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Thompson LH, 2001, MUTAT RES-FUND MOL M, V477, P131, DOI 10.1016/S0027-5107(01)00115-4; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wang Q, 2001, ONCOGENE, V20, P4640, DOI 10.1038/sj.onc.1204625; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Zhong Q, 2002, J BIOL CHEM, V277, P28641, DOI 10.1074/jbc.M200748200; Zhong Q, 2002, CANCER RES, V62, P3966; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	66	24	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 30	2003	22	4					528	537		10.1038/sj.onc.1206208	http://dx.doi.org/10.1038/sj.onc.1206208			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555066				2022-12-28	WOS:000180538200006
J	Fu, WN; Bertoni, F; Kelsey, SM; McElwaine, SM; Cotter, FE; Newland, AC; Jia, L				Fu, WN; Bertoni, F; Kelsey, SM; McElwaine, SM; Cotter, FE; Newland, AC; Jia, L			Role of DNA methylation in the suppression of Apaf-1 protein in human leukaemia	ONCOGENE			English	Article						Apaf-1; apoptosis; methylation; CpG island; real-time polymerase chain reaction	CYTOCHROME-C; INDUCED APOPTOSIS; LEUKEMIC-CELLS; CANCER; INACTIVATION; EPIGENETICS; ACTIVATION; CASPASE-9; DEATH	Apaf-1 protein deficiency occurs in human leukaemic blasts and confers resistance to cytochrome-c-dependent apoptosis. Demethylation treatment with 5-aza-2-deoxycytidine (5aza2dc) increased the sensitivity of the K562 leukaemic cell line to UV light-induced apoptosis in association with increased Apaf-1 protein levels. There was no correlation between Apaf-1 protein expression and Apaf-1 mRNA levels after the demethylation treatment. Methylation-specific polymerase chain reaction was used to show that the methylation can occur within the Apaf-1 promoter region in leukaemic blasts. Apaf-1 DNA methylation was demonstrated in acute myeloid leukaemia, chronic myeloid leukaemia and acute lymphoid leukaemia, suggesting that it is not specific to a particular leukaemia subtype. Apaf-1 protein expression did not correlate with Apaf-1 mRNA levels in human leukaemic blasts. Some leukaemic cells expressed high levels of Apaf-1 mRNA but low levels of Apaf-1 protein. This study suggests that Apaf-1 DNA promoter methylation might contribute to the inactivation of Apaf-1 expression. However, Apaf-1 protein levels might also be controlled at post-transcription level.	St Bartholomews & Royal London Sch Med & Dent, Dept Haematol Oncol, London E1 2AD, England; Osped San Giovanni Bellinzona, Oncol Inst So Switzerland, Bellinzona, Switzerland	University of London; Queen Mary University London; Institute of Oncology Research (IOR); Regional Hospital of Bellinzona & Valleys, San Giovanni	Jia, L (corresponding author), St Bartholomews & Royal London Sch Med & Dent, Dept Haematol Oncol, Turner St, London E1 2AD, England.		Bertoni, Francesco/G-6922-2014	Bertoni, Francesco/0000-0001-5637-8983; Jia, Li/0000-0002-6076-8455				Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Chitnis S, 2000, ARTHRITIS RES, V2, P399, DOI 10.1186/ar118; Feinberg AP, 2001, P NATL ACAD SCI USA, V98, P392, DOI 10.1073/pnas.98.2.392; Fu WN, 2001, BIOCHEM BIOPH RES CO, V282, P268, DOI 10.1006/bbrc.2001.4575; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jia L, 2001, ONCOGENE, V20, P4817, DOI 10.1038/sj.onc.1204628; Jia L, 2001, BLOOD, V98, P414, DOI 10.1182/blood.V98.2.414; Jones PA, 2001, NATURE, V409, P141, DOI 10.1038/35051677; LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu FT, 2002, BRIT J HAEMATOL, V117, P333, DOI 10.1046/j.1365-2141.2002.03418.x; Lopatina N, 2002, J CELL BIOCHEM, V84, P324, DOI 10.1002/jcb.10015; Perkins C, 1998, CANCER RES, V58, P4561; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Shinoura N, 2001, INT J CANCER, V93, P252, DOI 10.1002/ijc.1327; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; van Noesel MM, 2002, CANCER RES, V62, P2157; Wolf BB, 2001, J BIOL CHEM, V276, P34244, DOI 10.1074/jbc.M011778200; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	22	77	89	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 23	2003	22	3					451	455		10.1038/sj.onc.1206147	http://dx.doi.org/10.1038/sj.onc.1206147			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545166				2022-12-28	WOS:000180379100014
J	Nagashima, M; Shiseki, M; Pedeux, RM; Okamura, S; Kitahama-Shiseki, M; Miura, K; Yokota, J; Harris, CC				Nagashima, M; Shiseki, M; Pedeux, RM; Okamura, S; Kitahama-Shiseki, M; Miura, K; Yokota, J; Harris, CC			A novel PHD-finger motif protein, p47ING3, modulates p53-mediated transcription, cell cycle control, and apoptosis	ONCOGENE			English	Article						PHD-finger motif; ING1; ING3; p53	CANDIDATE TUMOR-SUPPRESSOR; ALTERNATIVE TRANSCRIPTS; DNA-BINDING; P53; ACETYLATION; P33(ING1); GENE; DEACETYLASE; EXPRESSION; MUTATIONS	A candidate tumor suppressor gene, p33ING1, was previously identified by using the genetic suppressor element methodology. p33ING1 cooperates with p53 and plays a significant role in p53-mediated cellular processes. Recently, we have identified p33ING2, which shows a sequence homology similar to p33ING1 and modulates p53 function. In the present study, we identified and characterized another 'ING family' gene. The estimated molecular weight of the encoded protein is 46.8 kDa, thus, we named it p47ING3. The p47ING3 gene is located at chromosome 7q31.3 and consists of 12 exons that encode 418 amino acids. A computational domain search revealed a C-terminal PHD-finger motif. Such motifs are common in proteins involved in chromatin remodeling. p47ING3 is highly expressed in some normal human tissues or organs, including the spleen, testis, skeletal muscle, and heart. p47ING3 expression levels varied among cancer cell lines. p47ING3 overexpression resulted in a decreased population of cells in S phase, a diminished colony-forming efficiency, and induced apoptosis in RKO cells, but not in RKO-E6 cells with inactivated p53. p47ING3 activates p53-transactivated promoters, including promoters of p21/waf1 and bax. Thus, we have isolated a novel ING family gene, p47ING3, which modulates p53-mediated transcription, cell cycle control, and apoptosis.	NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA; Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, Tokyo 104, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Cancer Center - Japan	Harris, CC (corresponding author), NCI, Human Carcinogenesis Lab, NIH, 37 Convent Dr,Bldg 37,Rm 2C05, Bethesda, MD 20892 USA.	curtis_harris@nih.gov	PEDEUX, Rémy M/I-2603-2014	PEDEUX, Rémy M/0000-0002-2553-7934; Miura, Koh/0000-0001-7303-9430	NATIONAL CANCER INSTITUTE [ZIABC005795, Z01BC005795] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Garkavtsev I, 1997, MOL CELL BIOL, V17, P2014, DOI 10.1128/MCB.17.4.2014; Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; Garkavtsev I, 1999, NAT GENET, V23, P373, DOI 10.1038/15566; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Helbing CC, 1997, CANCER RES, V57, P1255; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hollstein M, 1999, MUTAT RES-FUND MOL M, V431, P199, DOI 10.1016/S0027-5107(99)00162-1; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Kuzmichev A, 2002, MOL CELL BIOL, V22, P835, DOI 10.1128/MCB.22.3.835-848.2002; Liu L, 1999, MOL CELL BIOL, V19, P1202; Loewith R, 2000, MOL CELL BIOL, V20, P3807, DOI 10.1128/MCB.20.11.3807-3816.2000; Loewith R, 2001, J BIOL CHEM, V276, P24068, DOI 10.1074/jbc.M102176200; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; MIYASHITA T, 1995, CELL, V80, P293; Nagashima M, 2001, P NATL ACAD SCI USA, V98, P9671, DOI 10.1073/pnas.161151798; Nourani A, 2001, MOL CELL BIOL, V21, P7629, DOI 10.1128/MCB.21.22.7629-7640.2001; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; Saito A, 2000, J HUM GENET, V45, P177, DOI 10.1007/s100380050206; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Skowyra D, 2001, J BIOL CHEM, V276, P8734, DOI 10.1074/jbc.M007664200; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675	26	129	136	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2003	22	3					343	350		10.1038/sj.onc.1206115	http://dx.doi.org/10.1038/sj.onc.1206115			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545155				2022-12-28	WOS:000180379100003
J	Wang, SN; Mori, Y; Sato, F; Yin, J; Xu, Y; Zou, TT; Olaru, A; Kimos, MC; Perry, K; Selaru, FM; Deacu, E; Sun, MH; Shi, YC; Shibata, D; Abraham, JM; Greenwald, BD; Meltzer, SJ				Wang, SN; Mori, Y; Sato, F; Yin, J; Xu, Y; Zou, TT; Olaru, A; Kimos, MC; Perry, K; Selaru, FM; Deacu, E; Sun, MH; Shi, YC; Shibata, D; Abraham, JM; Greenwald, BD; Meltzer, SJ			An LOH and mutational investigation of the ST7 gene locus in human esophageal carcinoma	ONCOGENE			English	Article						esophageal cancer; ST7; 7q31; LOH; mutation; expression	TUMOR-SUPPRESSOR GENE; SQUAMOUS-CELL CARCINOMA; HETEROZYGOSITY; REGION; 7Q31.1	Frequent loss of heterozygosity (LOH) on human chromosome 7q31 has been reported in numerous malignancies. Suppressor of tumorigenicity 7 (ST7) has been identified as a candidate tumor suppressor gene in this region. To identify whether 7q31 and genetic alterations of ST7 were involved in human esophageal carcinogenesis, we performed LOH mapping of a 5.4cM region at 7q31-q35 in 43 primary esophageal carcinomas, as well as mutational analyses of the ST7 gene in tumors with LOH in this region. Of 43 tumors, 12 (28%) showed LOH at 7q31-q35. These included four (22%) of 18 squamous cell carcinomas and eight (32%) of 25 adenocarcinomas. The peak LOH locus was D7S480, lying 4.2 Mb telomeric to ST7 and showing LOH in eight of 37 informative tumors, or 22%. No mutations were found in the entire coding or flanking intronic regions of the ST7 gene among 12 tumors with 7q-LOH. In addition, quantitative RT-PCR analyses of ST7 mRNA expression levels in 11/13 normal-tumor pairs failed to show more than a 50% decrease in tumor ST7 mRNA relative to matched normal tissues. These data suggest that LOH at 7q31-q35 is involved in the origin or progression of at least a subset of esophageal carcinomas, but that ST7 is not the target gene of this somatic event.	Univ Maryland, Sch Med, Div Gastroenterol, Dept Med, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Univ Maryland, Baltimore VA Hosp, Sch Med,Greenbaum Canc Ctr, Div Surg Oncol,Dept Surg, Baltimore, MD 21201 USA; Fudan Univ, Coll Med, Dept Pathol, Shanghai 200433, Peoples R China	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Fudan University	Meltzer, SJ (corresponding author), Univ Maryland, Sch Med, Div Gastroenterol, Dept Med, 22 S Greene St, Baltimore, MD 21201 USA.			Perry, Kellie/0000-0001-6238-8221; Selaru, Florin/0000-0001-7990-8238	NCI NIH HHS [CA77057, CA95323, CA85069] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095323, U01CA085069, R01CA077057] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Gunduz M, 2002, ONCOGENE, V21, P4462, DOI 10.1038/sj.onc.1205540; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; Hughes KA, 2001, NAT GENET, V29, P380, DOI 10.1038/ng783; Liang H, 1998, P NATL ACAD SCI USA, V95, P3781, DOI 10.1073/pnas.95.7.3781; Miller BA, 1996, NIH PUB, V96-4104; Mori Y, 2001, CANCER RES, V61, P6046; Riegman PHJ, 2001, CANCER RES, V61, P3164; Roth MJ, 2001, CANCER RES, V61, P4098; SHIBAGAKI I, 1994, CANCER RES, V54, P2996; Tatarelli C, 2000, GENOMICS, V68, P1, DOI 10.1006/geno.2000.6272; Thomas NA, 2001, NAT GENET, V29, P379, DOI 10.1038/ng784; Tobias ES, 2001, ONCOGENE, V20, P2844, DOI 10.1038/sj.onc.1204433; van Dekken H, 1999, J PATHOL, V188, P263, DOI 10.1002/(SICI)1096-9896(199907)188:3<263::AID-PATH374>3.0.CO;2-Y; ZENKLUSEN JC, 1994, ONCOGENE, V9, P2817; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; Zenklusen JC, 2001, NAT GENET, V27, P392, DOI 10.1038/86891; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347; Zenklusen Jean C., 1999, Neoplasia (New York), V1, P16, DOI 10.1038/sj.neo.7900011; Zou TT, 2002, ONCOGENE, V21, P4855, DOI 10.1038/sj.onc.1205613	19	11	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 23	2003	22	3					467	470		10.1038/sj.onc.1206125	http://dx.doi.org/10.1038/sj.onc.1206125			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545169				2022-12-28	WOS:000180379100017
J	Yuan, BZ; Zhou, XL; Durkin, ME; Zimonjic, DB; Gumundsdottir, K; Eyfjord, JE; Thorgeirsson, SS; Popescu, NC				Yuan, BZ; Zhou, XL; Durkin, ME; Zimonjic, DB; Gumundsdottir, K; Eyfjord, JE; Thorgeirsson, SS; Popescu, NC			DLC-1 gene inhibits human breast cancer cell growth and in vivo tumorigenicity	ONCOGENE			English	Article						tumor suppressor gene; breast cancer; colon cancer; prostate cancer; tumorigenicity; metastasis	TUMOR-SUPPRESSOR GENE; CHROMOSOME 8P DELETION; HEPATOCELLULAR-CARCINOMA; RHO GTPASES; METASTASIS; IDENTIFICATION; ASSOCIATION; LINKAGE; PROTEIN; CLONING	The human DLC-1 (deleted in liver cancer 1) gene was cloned from a primary human hepatocellular carcinoma (HCC) and mapped to the chromosome 8p21-22 region frequently deleted in common human cancers and suspected to harbor tumor suppressor genes. DLC-1 was found to be deleted or downregulated in a significant number of HCCs. We expanded our investigations to other cancers with recurrent deletions of 8p22, and in this study examined alterations of DLC-1 in primary human breast tumors, human breast, colon, and prostate tumor cell lines. Genomic deletion of DLC-1 was observed in 40% of primary breast tumors, whereas reduced or undetectable levels of DLC-1 mRNA were seen in 70% of breast, 70% of colon, and 50% of prostate tumor cell lines To see whether DLC-1 expression affects cell growth and tumorigenicity, two breast carcinoma cell lines lacking the expression of endogenous gene were transfected with the DLC-1 cDNA. In both cell lines, DLC-1 transfection caused significant growth inhibition and reduction of colony formation. Furthermore, introduction of the DLC-1 cDNA abolished the in vivo tumorigenicity in nude mice, suggesting that the DLC-1 gene plays a role in breast cancer by acting as a bona fide tumor suppressor gene.	NCI, Expt Carcinogenesis Lab, Canc Res Ctr, Bethesda, MD 20892 USA; Iceland Canc Soc, Reykjavik, Iceland	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Popescu, NC (corresponding author), NCI, Expt Carcinogenesis Lab, Canc Res Ctr, Bethesda, MD 20892 USA.	popescun@mail.nih.gov	Zimonjic, Drazen/AAX-7513-2020		NATIONAL CANCER INSTITUTE [Z01BC010038, ZIABC010038] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arbieva ZH, 2000, GENOME RES, V10, P244, DOI 10.1101/gr.10.2.244; Boettner B, 2002, GENE, V286, P155, DOI 10.1016/S0378-1119(02)00426-2; Borkhardt A, 2000, P NATL ACAD SCI USA, V97, P9168, DOI 10.1073/pnas.150079597; Cabeza-Arvelaiz Y, 2001, ONCOGENE, V20, P4169, DOI 10.1038/sj.onc.1204539; Durkin ME, 2002, GENE, V288, P119, DOI 10.1016/S0378-1119(02)00462-6; Euer N, 2002, ANTICANCER RES, V22, P733; Gustafson CE, 1996, CANCER RES, V56, P5238; HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Jenkins R, 1998, GENE CHROMOSOME CANC, V21, P131, DOI 10.1002/(SICI)1098-2264(199802)21:2<131::AID-GCC9>3.0.CO;2-1; Martinez-Climent JA, 2001, BLOOD, V98, P3479, DOI 10.1182/blood.V98.12.3479; Nagase T, 1996, DNA Res, V3, P17, DOI 10.1093/dnares/3.1.17; Ng IOL, 2000, CANCER RES, V60, P6581; Ponting CP, 1999, TRENDS BIOCHEM SCI, V24, P130, DOI 10.1016/S0968-0004(99)01362-6; Qin LX, 1999, CANCER RES, V59, P5662; Qin LX, 2001, J CANCER RES CLIN, V127, P482, DOI 10.1007/s004320100236; Sekimata M, 1999, J BIOL CHEM, V274, P17757, DOI 10.1074/jbc.274.25.17757; Tikoo A, 2000, GENE, V257, P23, DOI 10.1016/S0378-1119(00)00387-5; Tirkkonen M, 1998, GENE CHROMOSOME CANC, V21, P177, DOI 10.1002/(SICI)1098-2264(199803)21:3<177::AID-GCC1>3.3.CO;2-C; Wilson PJ, 2000, HUM MUTAT, V15, P156, DOI 10.1002/(SICI)1098-1004(200002)15:2<156::AID-HUMU4>3.0.CO;2-4; Xu JF, 2001, AM J HUM GENET, V69, P341, DOI 10.1086/321967; YAREMKO ML, 1998, GENE CHROMOSOME CANC, V21, P189; Yoshioka K, 1998, J BIOL CHEM, V273, P5146, DOI 10.1074/jbc.273.9.5146; Yuan BZ, 1998, CANCER RES, V58, P2196; Yuan BZ, 1999, CYTOGENET CELL GENET, V87, P189, DOI 10.1159/000015462; YUAN BZ, IN PRESS CANC GENET; YUAN BZ, 2000, P AM ASSOC CANC RES, V41, P105; Zimonjic DB, 2000, INT J ONCOL, V16, P221; Zitzelsberger H, 1997, HISTOCHEM CELL BIOL, V108, P403, DOI 10.1007/s004180050181	29	126	135	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2003	22	3					445	450		10.1038/sj.onc.1206064	http://dx.doi.org/10.1038/sj.onc.1206064			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545165				2022-12-28	WOS:000180379100013
J	Hodgson, L; Henderson, AJ; Dong, C				Hodgson, L; Henderson, AJ; Dong, C			Melanoma cell migration to type IV collagen requires activation of NF-kappa B	ONCOGENE			English	Article						chemotaxis; integrin; GTPase; transactivation; A2058	FOCAL ADHESION KINASE; ANTIINFLAMMATORY SESQUITERPENE LACTONE; ACTIN STRESS FIBERS; SIGNAL-TRANSDUCTION; TRANSCRIPTIONAL ACTIVITY; EXTRACELLULAR-MATRIX; RHO; CDC42; GTPASES; RAC	Chemotaxis is the consequence of environmental factors engaging their receptors to initiate signaling cascades. However, the biochemical mechanisms controlling this phenomenon are not clear. We employed an in vitro modified Boyden 48-well chemotaxis migration system to characterize the role of signal transducers in type IV collagen (CIV) induced A2058 human melanoma cell migration. Using specific pharmacological inhibitors and a series of dominant-negative and constitutively active signaling proteins, we show that Ras and Rac GTPases, PI-3K, and PKC participate in cell migration mediated by beta1 integrins. Collagen also induces a time-dependent degradation of IkappaB-alpha and an increase in nuclear translocation of NF-kappaB which is dependent on PKC pathway. More importantly, collagen-stimulated melanoma cell migration directly correlated with an increase in NF-kappaB transactivation. Furthermore, CIV induced an increase in beta1 integrin mRNA levels. Specific NF-kappaB inhibitors Helenalin and SN-50 inhibited melanoma cell migration to collagen, indicating a novel requirement for NF-kappaB transactivation in cell chemotaxis mediated by beta1 integrin signals. These results describe signal transduction events that are initiated by type IV collagen through beta1 integrins and demonstrate an important role for NF-kappaB in regulating melanoma chemotaxis.	Penn State Univ, Dept Bioengn, University Pk, PA 16802 USA; Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Dong, C (corresponding author), Penn State Univ, Dept Bioengn, 229 Hallowell, University Pk, PA 16802 USA.	exd23@psu.edu		Henderson, Andrew/0000-0002-9299-5302; Hodgson, Louis/0000-0001-9188-7580	NATIONAL CANCER INSTITUTE [R29CA076434, R01CA097306] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR010732] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046261] Funding Source: NIH RePORTER; NCI NIH HHS [CA76434, R01 CA097306, R01 CA097306-01A1, R01 CA097306-02] Funding Source: Medline; NCRR NIH HHS [M01 RR010732-110202, M01 RR010732-090202, M01 RR010732, M01 RR010732-080202, M01 RR010732-070202, M01 RR010732-100202, M01 RR010732-060202] Funding Source: Medline; NIAID NIH HHS [AI46261] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anrather J, 1999, J BIOL CHEM, V274, P13594, DOI 10.1074/jbc.274.19.13594; Aspenstrom P, 1999, EXP CELL RES, V246, P20, DOI 10.1006/excr.1998.4300; AZNAVOORIAN S, 1990, J CELL BIOL, V110, P1427, DOI 10.1083/jcb.110.4.1427; Benoliel AM, 1997, J CELL SCI, V110, P2089; Boukerche H, 2000, CANCER RES, V60, P5848; Burow ME, 2000, BIOCHEM BIOPH RES CO, V271, P342, DOI 10.1006/bbrc.2000.2626; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONDEELIS J, 1993, ANNU REV CELL BIOL, V9, P411, DOI 10.1146/annurev.cb.09.110193.002211; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; HARVATH L, 1980, J IMMUNOL METHODS, V37, P39, DOI 10.1016/0022-1759(80)90179-9; Hodgson L, 2001, AM J PHYSIOL-CELL PH, V281, pC106, DOI 10.1152/ajpcell.2001.281.1.C106; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; Keely P, 1998, TRENDS CELL BIOL, V8, P101, DOI 10.1016/S0962-8924(97)01219-1; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Khoshnan A, 2000, J IMMUNOL, V165, P6933, DOI 10.4049/jimmunol.165.12.6933; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; LEAVESLEY DI, 1993, J CELL BIOL, V121, P163, DOI 10.1083/jcb.121.1.163; LESTER BR, 1992, CANCER METAST REV, V11, P31, DOI 10.1007/BF00047601; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; LIOTTA LA, 1986, P NATL ACAD SCI USA, V83, P3302, DOI 10.1073/pnas.83.10.3302; LU C, 1993, J CELL BIOL, V120, P1281, DOI 10.1083/jcb.120.5.1281; Lyss G, 1998, J BIOL CHEM, V273, P33508, DOI 10.1074/jbc.273.50.33508; Lyss G, 1997, BIOL CHEM, V378, P951, DOI 10.1515/bchm.1997.378.9.951; Machesky LM, 1997, J CELL BIOL, V138, P913, DOI 10.1083/jcb.138.4.913; Meredith JE, 1996, ENDOCR REV, V17, P207, DOI 10.1210/er.17.3.207; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Palmantier R, 2001, CANCER RES, V61, P2445; Paolucci L, 2000, AM J PHYSIOL-CELL PH, V278, pC33, DOI 10.1152/ajpcell.2000.278.1.C33; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Pasco S, 2000, CANCER RES, V60, P467; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; POWIS G, 1994, CANCER CHEMOTH PHARM, V34, P344, DOI 10.1007/BF00686043; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Renshaw MW, 1996, J BIOL CHEM, V271, P21691, DOI 10.1074/jbc.271.36.21691; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rong R, 2002, ONCOGENE, V21, P1062, DOI 10.1038/sj.onc.1205154; Salazar EP, 2001, J BIOL CHEM, V276, P17788, DOI 10.1074/jbc.M100984200; Sarner S, 2000, MOL CELL BIOL, V20, P158, DOI 10.1128/MCB.20.1.158-172.2000; SAVARESE DMF, 1992, J BIOL CHEM, V267, P21928; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHNAPER HW, 1993, PEDIATR NEPHROL, V7, P96, DOI 10.1007/BF00861587; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SCHWARTZ MA, 1994, MOL BIOL CELL, V5, P389, DOI 10.1091/mbc.5.4.389; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; Stracke M L, 1994, In Vivo, V8, P49; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Trushin SA, 1999, J BIOL CHEM, V274, P22923, DOI 10.1074/jbc.274.33.22923; VAN AL, 1997, GENE DEV, V11, P2295; YEBRA M, 1995, MOL BIOL CELL, V6, P841, DOI 10.1091/mbc.6.7.841; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0	55	34	37	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	2003	22	1					98	108		10.1038/sj.onc.1206059	http://dx.doi.org/10.1038/sj.onc.1206059			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527912	Green Accepted			2022-12-28	WOS:000180166900011
J	Mukai, T; Sekiguchi, M				Mukai, T; Sekiguchi, M			Gene silencing in phenomena related to DNA repair	ONCOGENE			English	Article						DNA methylation; histone methylation; cancer; Mgmt; Mlh1; animal model	HUMAN O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; CHEMOTHERAPEUTIC ALKYLATING-AGENTS; HMLH1 PROMOTER HYPERMETHYLATION; NONPOLYPOSIS COLORECTAL-CANCER; SYNDROME IMPRINTING-CENTER; MISMATCH REPAIR; HISTONE H3; CPG-ISLAND; O6-METHYLGUANINE-DNA METHYLTRANSFERASE; MICROSATELLITE INSTABILITY	DNA methylation is essential for embryonic development and important for transcriptional repression, as observed in several biological phenomena. These include genomic imprinting, X-inactivation and carcinogenesis. The basic mechanism by which DNA methlyation silences transcription is generally understood, but there is still much to be learned about how DNA methyltransferase is targeted to a specific region of the gene. Silencing by DNA methylation occurs at an early stage of carcinogenesis, when the DNA repair genes, MGMT and hMLH1, are frequently inactivated, resulting in mutations in key cancer-related genes in cells. Mice defective in Mgmt and/or Mlh1 gave clear evidence of the significant roles of these proteins in carcinogenesis. Recently, it has been demonstrated that DNA methylation is linked to histone methylation in fungi and plants, although it remains unknown whether this mechanism occurs in mammalian systems.	Saga Med Sch, Dept Biomol Sci, Div Mol Biol & Genet, Saga 8498501, Japan; Biomol Engn Res Inst, Suita, Osaka 5650874, Japan	Saga University	Mukai, T (corresponding author), Saga Med Sch, Dept Biomol Sci, Div Mol Biol & Genet, 5-1-1 Nabeshima, Saga 8498501, Japan.							ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; Avner P, 2001, NAT REV GENET, V2, P59, DOI 10.1038/35047580; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Ben-Porath I, 2000, CURR OPIN GENET DEV, V10, P550, DOI 10.1016/S0959-437X(00)00126-X; Boggs BA, 2002, NAT GENET, V30, P73, DOI 10.1038/ng787; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; Brockdorff N, 2002, TRENDS GENET, V18, P352, DOI 10.1016/S0168-9525(02)02717-8; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CHEN B, 1994, CARCINOGENESIS, V15, P2031, DOI 10.1093/carcin/15.9.2031; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Danam RP, 1999, MOL CARCINOGEN, V24, P85, DOI 10.1002/(SICI)1098-2744(199902)24:2<85::AID-MC2>3.0.CO;2-C; DAY RS, 1979, NATURE, V279, P797, DOI 10.1038/279797a0; De Smet C, 1999, MOL CELL BIOL, V19, P7327; de Wind N, 1998, CANCER RES, V58, P248; Deng GR, 1999, CANCER RES, V59, P2029; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; El-Maarri O, 2001, NAT GENET, V27, P341, DOI 10.1038/85927; Esteller M, 2000, CANCER RES, V60, P4366; Esteller M, 2001, CANCER RES, V61, P4689; Esteller M, 1998, ONCOGENE, V17, P2413, DOI 10.1038/sj.onc.1202178; Esteller M, 2001, CANCER RES, V61, P3225; Esteller M, 1999, AM J PATHOL, V155, P1767, DOI 10.1016/S0002-9440(10)65492-2; Esteller M, 2000, CANCER RES, V60, P2368; Fleisher AS, 2000, CANCER RES, V60, P4864; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; Glassner BJ, 1999, MUTAGENESIS, V14, P339, DOI 10.1093/mutage/14.3.339; HARRIS LC, 1991, NUCLEIC ACIDS RES, V19, P6163, DOI 10.1093/nar/19.22.6163; HATADA I, 1991, P NATL ACAD SCI USA, V88, P9523, DOI 10.1073/pnas.88.21.9523; Heard E, 2001, CELL, V107, P727, DOI 10.1016/S0092-8674(01)00598-0; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; HERMAN JG, 1995, CANCER RES, V55, P4525; Iwakuma T, 1997, CARCINOGENESIS, V18, P1631, DOI 10.1093/carcin/18.8.1631; Jackson JP, 2002, NATURE, V416, P556, DOI 10.1038/nature731; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jiricny J, 1998, MUTAT RES-DNA REPAIR, V409, P107, DOI 10.1016/S0921-8777(98)00056-1; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; JONES PA, 1985, CELL, V40, P485, DOI 10.1016/0092-8674(85)90192-8; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kane MF, 1997, CANCER RES, V57, P808; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; Kawate H, 2000, CARCINOGENESIS, V21, P301, DOI 10.1093/carcin/21.2.301; Kawate H, 1998, P NATL ACAD SCI USA, V95, P5116, DOI 10.1073/pnas.95.9.5116; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOIKE G, 1990, J BIOL CHEM, V265, P14754; KOLODNER RD, 1995, CANCER RES, V55, P242; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; MATSUKARA S, 2003, IN PRESS BRIT J CANC; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Nakamura M, 2001, CARCINOGENESIS, V22, P1715, DOI 10.1093/carcin/22.10.1715; NAKATSU Y, 1993, MUTAT RES, V293, P119, DOI 10.1016/0921-8777(93)90063-M; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; Papadopoulos N, 1997, HUM MUTAT, V10, P89, DOI 10.1002/(SICI)1098-1004(1997)10:2<89::AID-HUMU1>3.3.CO;2-K; Peters AHFM, 2002, NAT GENET, V30, P77, DOI 10.1038/ng789; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Qian XLC, 1997, CANCER RES, V57, P3672; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; Riggs A. D., 1996, EPIGENETIC MECH GENE, P29; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Sakumi K, 1997, CANCER RES, V57, P2415; Santini V, 2001, ANN INTERN MED, V134, P573, DOI 10.7326/0003-4819-134-7-200104030-00011; Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302; Shiraishi A, 2000, CARCINOGENESIS, V21, P1879, DOI 10.1093/carcin/21.10.1879; SKLAR R, 1981, NATURE, V289, P417, DOI 10.1038/289417a0; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Thorvaldsen JL, 1998, GENE DEV, V12, P3693, DOI 10.1101/gad.12.23.3693; Tsuzuki T, 1996, CARCINOGENESIS, V17, P1215, DOI 10.1093/carcin/17.6.1215; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Walsh CP, 1999, GENE DEV, V13, P26, DOI 10.1101/gad.13.1.26; Watts GS, 1997, MOL CELL BIOL, V17, P5612, DOI 10.1128/MCB.17.9.5612; Wolf P, 2001, CANCER RES, V61, P8113; Wutz A, 1997, NATURE, V389, P745, DOI 10.1038/39631; Xin ZH, 2001, AM J HUM GENET, V69, P1389, DOI 10.1086/324469; Yang L, 2002, ONCOGENE, V21, P148, DOI 10.1038/sj.onc.1204998; Yang T, 1998, NAT GENET, V19, P25, DOI 10.1038/ng0598-25; YOU M, 1989, P NATL ACAD SCI USA, V86, P3070, DOI 10.1073/pnas.86.9.3070; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	97	18	19	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 16	2002	21	58					9033	9042		10.1038/sj.onc.1206095	http://dx.doi.org/10.1038/sj.onc.1206095			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	626TP	12483518				2022-12-28	WOS:000179889500013
J	Pane, F; Intrieri, M; Quintarelli, C; Izzo, B; Muccioli, GC; Salvatore, F				Pane, F; Intrieri, M; Quintarelli, C; Izzo, B; Muccioli, GC; Salvatore, F			BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations	ONCOGENE			English	Review						Philadelphia chromosome; Ph positive leukemias; molecular pathogenesis; phenotype of leukemia	CHRONIC MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; ABL TYROSINE KINASE; CHRONIC MYELOCYTIC-LEUKEMIA; POLYMERASE CHAIN-REACTION; HYBRID MESSENGER-RNA; CHRONIC MYELOMONOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC-LEUKEMIA; IN-SITU HYBRIDIZATION	The Philadelphia chromosome (Ph), a minute chromosome that derives from the balanced translocation between chromosomes 9 and 22, was first described in 1960 and was for a long time the only genetic lesion consistently associated with human cancer. This chromosomal translocation results in the fusion between the 5' part of BCR gene, normally located on chromosome 22, and the 3' part of the ABL gene on chromosome 9 giving origin to a BCR/ABL fusion gene which is transcribed and then translated into a hybrid protein. Three main variants of the BCR/ABL gene have been described, that, depending on the length of the sequence of the BCR gene included, encode for the p190(BCR/ABL), P210(BCR/ABL), and P230(BCR/ABL) proteins. These three main variants are associated with distinct clinical types of human leukemias. Herein we review the data on the correlations between the type of BCR/ABL gene and the corresponding leukemic clinical features. Lastly, drawing on experimental data, we provide insight into the different transforming power of the three hybrid BCR/ABL proteins.	Univ Naples Federico II, CEINGE Biotechnol Avanzate, I-80131 Naples, Italy; Univ Naples Federico II, Fac Med, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy; Univ Molise, Fac Sci MFN, Dipartimento STAT, Isernia, Italy	CEINGE Biotecnologie Avanzate; University of Naples Federico II; University of Naples Federico II; University of Molise	Pane, F (corresponding author), Univ Naples Federico II, CEINGE Biotechnol Avanzate, Via 5 Pansini 5, I-80131 Naples, Italy.		Schepis, Filippo/H-9417-2014; Quintarelli, Concetta/K-6056-2016; Pierantoni, Giovanna Maria/O-7527-2015; Salvatore, Francesco/A-1966-2011	Schepis, Filippo/0000-0001-6549-5102; Quintarelli, Concetta/0000-0002-4343-9705; Pierantoni, Giovanna Maria/0000-0003-4078-8528; Salvatore, Francesco/0000-0002-2346-3564				AHMED S, 1994, J BIOL CHEM, V269, P17642; ALIMENA G, 1995, LEUKEMIA, V9, P1483; ANNINO L, 1994, LEUKEMIA, V8, P664; Arico M, 2000, NEW ENGL J MED, V342, P998, DOI 10.1056/NEJM200004063421402; BACCARANI M, 1995, LEUKEMIA, V9, P1648; BENNETT JM, 1994, BRIT J HAEMATOL, V87, P746, DOI 10.1111/j.1365-2141.1994.tb06734.x; Blickstein D, 1997, BLOOD, V90, P2768, DOI 10.1182/blood.V90.7.2768.2768_2768_2771; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Briz M, 1997, BLOOD, V90, P5024, DOI 10.1182/blood.V90.12.5024.5024_5024_5024; Cervantes F, 1996, LEUKEMIA, V10, P1241; CHISSOE SL, 1995, GENOMICS, V27, P67, DOI 10.1006/geno.1995.1008; Chopra R, 1999, BLOOD REV, V13, P211, DOI 10.1054/blre.1999.0119; CHUANG TH, 1995, P NATL ACAD SCI USA, V92, P10282, DOI 10.1073/pnas.92.22.10282; CLARK SS, 1987, SCIENCE, V235, P85, DOI 10.1126/science.3541203; CLARKSON B, 1993, LEUKEMIA, V7, P1683; Cobaleda C, 2000, BLOOD, V95, P1007, DOI 10.1182/blood.V95.3.1007.003k35_1007_1013; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DAVIS RL, 1985, MOL CELL BIOL, V5, P204, DOI 10.1128/MCB.5.1.204; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; Delforge M, 1999, BLOOD, V93, P284, DOI 10.1182/blood.V93.1.284.401k31_284_292; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; DHINGRA K, 1991, LEUKEMIA, V5, P191; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; EISENBERG A, 1988, LEUKEMIA, V2, P642; ERIKSON J, 1986, P NATL ACAD SCI USA, V83, P1807, DOI 10.1073/pnas.83.6.1807; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; FAINSTEIN E, 1987, NATURE, V330, P386, DOI 10.1038/330386a0; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FIALKOW PJ, 1977, AM J MED, V63, P125, DOI 10.1016/0002-9343(77)90124-3; Fioretos T, 1999, BLOOD, V94, P225, DOI 10.1182/blood.V94.1.225.413k24_225_232; FIORETOS T, 1993, LEUKEMIA, V7, P1225; FUTAKI M, 1992, LEUKEMIA RES, V16, P1071, DOI 10.1016/0145-2126(92)90045-9; GALE RP, 1984, P NATL ACAD SCI-BIOL, V81, P5648, DOI 10.1073/pnas.81.18.5648; Gleissner B, 2002, BLOOD, V99, P1536, DOI 10.1182/blood.V99.5.1536; Goldman JM, 2001, BLOOD, V98, P2039, DOI 10.1182/blood.V98.7.2039; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; GROFFEN J, 1983, J EXP MED, V158, P9, DOI 10.1084/jem.158.1.9; Gross AW, 1999, MOL CELL BIOL, V19, P6918; Gross AW, 2000, ONCOGENE, V19, P6286, DOI 10.1038/sj.onc.1204023; Haferlach T, 1997, BRIT J HAEMATOL, V99, P452, DOI 10.1046/j.1365-2141.1997.4203237.x; Haskovec C, 1998, BRIT J HAEMATOL, V103, P1104, DOI 10.1046/j.1365-2141.1998.01098.x; HEISTERKAMP N, 1982, NATURE, V299, P747, DOI 10.1038/299747a0; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hochhaus A, 2000, BLOOD, V95, P62; Hochhaus A, 1996, BLOOD, V88, P2236, DOI 10.1182/blood.V88.6.2236.bloodjournal8862236; Holyoake T, 1999, BLOOD, V94, P2056, DOI 10.1182/blood.V94.6.2056; Holyoake TL, 2001, BLOOD, V97, P720, DOI 10.1182/blood.V97.3.720; Holyoake TL, 2001, BRIT J HAEMATOL, V113, P11, DOI 10.1046/j.1365-2141.2001.02558.x; Honda H, 1998, BLOOD, V91, P2067, DOI 10.1182/blood.V91.6.2067.2067_2067_2075; How GF, 1999, BRIT J HAEMATOL, V105, P434, DOI 10.1111/j.1365-2141.1999.01372.x; How GF, 1998, LEUKEMIA, V12, P1166, DOI 10.1038/sj.leu.2401055; Huettner CS, 2000, NAT GENET, V24, P57, DOI 10.1038/71691; Huntly BJP, 2002, BLOOD, V99, P4547, DOI 10.1182/blood.V99.12.4547; Huntly BJP, 2001, BLOOD, V98, P1732, DOI 10.1182/blood.V98.6.1732; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; INOKUCHI K, 1991, BLOOD, V78, P3125; INUKAI T, 1993, BRIT J HAEMATOL, V85, P823; IWATA S, 1994, LEUKEMIA, V8, P1696; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JAUBERT J, 1990, BRIT J HAEMATOL, V74, P30, DOI 10.1111/j.1365-2141.1990.tb02534.x; JONAS D, 1992, BLOOD, V79, P1017; KANTARJIAN HM, 1991, BLOOD, V78, P2411, DOI 10.1182/blood.V78.9.2411.bloodjournal7892411; Kasprzyk A, 1999, LEUKEMIA, V13, P2000, DOI 10.1038/sj.leu.2401580; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; Kin Y, 2001, J BIOL CHEM, V276, P39462, DOI 10.1074/jbc.M105484200; Kojima K, 1999, BRIT J HAEMATOL, V106, P720, DOI 10.1046/j.1365-2141.1999.01588.x; Kolomietz E, 2001, BLOOD, V97, P3581, DOI 10.1182/blood.V97.11.3581; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; KURZROCK R, 1987, BLOOD, V70, P1584; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; Lee SJ, 2000, BRIT J HAEMATOL, V111, P993, DOI 10.1046/j.1365-2141.2000.02216.x; Lewis JM, 1998, J BIOL CHEM, V273, P14225, DOI 10.1074/jbc.273.23.14225; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Ma GZ, 1997, ONCOGENE, V14, P2367, DOI 10.1038/sj.onc.1201053; MaguerSatta V, 1996, BLOOD, V88, P1796; Mancini M, 2001, Hematol J, V2, P54, DOI 10.1038/sj.thj.6200079; Martinelli G, 2002, HAEMATOLOGICA, V87, P688; Martinelli G, 2000, BONE MARROW TRANSPL, V25, P729, DOI 10.1038/sj.bmt.1702207; Martinez-Mancilla M, 2002, HAEMATOLOGICA, V87, P666; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MAURER J, 1991, LANCET, V337, P1055, DOI 10.1016/0140-6736(91)91706-Z; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; McWhirter JR, 1997, ONCOGENE, V15, P1625, DOI 10.1038/sj.onc.1201342; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MELO JV, 1994, LEUKEMIA, V8, P208; MELO JV, 1993, BLOOD, V81, P2488; MELO JV, 1993, BLOOD, V81, P158; Melo JV, 1996, BLOOD, V88, P2375, DOI 10.1182/blood.V88.7.2375.bloodjournal8872375; Miao YJ, 1996, J BIOL CHEM, V271, P22823, DOI 10.1074/jbc.271.37.22823; MILLS KI, 1991, LEUKEMIA, V5, P731; Mittre H, 1997, BLOOD, V89, P4239, DOI 10.1182/blood.V89.11.4239; Moreno MD, 2001, BLOOD, V97, P3668; MORRIS CM, 1991, BLOOD, V78, P1078; NEGRINI M, 1992, CANCER GENET CYTOGEN, V61, P11, DOI 10.1016/0165-4608(92)90363-D; NOWELL PC, 1960, SCIENCE, V132, P1497; NUCIFORA G, 1995, BLOOD, V86, P1; Okamoto K, 1997, BRIT J HAEMATOL, V96, P611, DOI 10.1046/j.1365-2141.1997.d01-2066.x; Olson MF, 1996, J MOL MED-JMM, V74, P563, DOI 10.1007/s001090050060; OPALKA B, 1992, BLOOD, V80, P1854; Pajor L, 2000, LEUKEMIA, V14, P1122, DOI 10.1038/sj.leu.2401794; Pane F, 1999, BLOOD, V94, P2200, DOI 10.1182/blood.V94.7.2200.419a33_2200_2207; Pane F, 1996, LEUKEMIA, V10, P741; Pane F, 1996, BLOOD, V88, P2410, DOI 10.1182/blood.V88.7.2410.bloodjournal8872410; Paulsson K, 2001, CANCER GENET CYTOGEN, V130, P160, DOI 10.1016/S0165-4608(01)00486-1; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; Pluk H, 2002, CELL, V108, P247, DOI 10.1016/S0092-8674(02)00623-2; Polak J, 2000, BONE MARROW TRANSPL, V25, P1109, DOI 10.1038/sj.bmt.1702412; PREUDHOMME C, 1992, BRIT J HAEMATOL, V82, P623, DOI 10.1111/j.1365-2141.1992.tb06480.x; Pui CH, 1998, NEW ENGL J MED, V339, P605, DOI 10.1056/NEJM199808273390907; Quackenbush RC, 2000, BLOOD, V95, P2913, DOI 10.1182/blood.V95.9.2913.009k32_2913_2921; Radich J, 1997, BLOOD, V89, P2602, DOI 10.1182/blood.V89.7.2602; RADICH JP, 1994, LEUKEMIA, V8, P1688; Rotoli B, 2000, BRIT J HAEMATOL, V110, P493; Roumier C, 1999, HAEMATOLOGICA, V84, P1075; ROWLEY JD, 1973, NEW ENGL J MED, V289, P220; Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495; Saglio G, 1997, LEUKEMIA LYMPHOMA, V26, P281, DOI 10.3109/10428199709051777; SAGLIO G, 1988, BLOOD, V72, P1203; Saglio G, 1996, BLOOD, V87, P1075, DOI 10.1182/blood.V87.3.1075.bloodjournal8731075; SAGLIO G, 1990, BLOOD, V76, P1819; Saglio G, 1999, LEUKEMIA, V13, pS96, DOI 10.1038/sj.leu.2401321; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHAEFERREGO K, 1987, BLOOD, V70, P448; Schenk TM, 1998, LEUKEMIA, V12, P666, DOI 10.1038/sj.leu.2400986; Schoch C, 1997, BRIT J HAEMATOL, V99, P605, DOI 10.1046/j.1365-2141.1997.4473257.x; Schrappe M, 1998, BLOOD, V92, P2730; SECKERWALKER LM, 1992, CANCER GENET CYTOGEN, V58, P29, DOI 10.1016/0165-4608(92)90129-V; SHEPHERD P, 1995, BRIT J HAEMATOL, V89, P546, DOI 10.1111/j.1365-2141.1995.tb08362.x; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Sinclair PB, 2000, BLOOD, V95, P738, DOI 10.1182/blood.V95.3.738.003k21_738_743; SOEKARMAN D, 1990, LEUKEMIA, V4, P397; STAM K, 1985, NEW ENGL J MED, V313, P1429, DOI 10.1056/NEJM198512053132301; STEWART MJ, 1994, J BIOL CHEM, V269, P10820; SURYANARAYAN K, 1991, BLOOD, V77, P324; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Takahashi N, 1998, BLOOD, V92, P4758, DOI 10.1182/blood.V92.12.4758; Takeda N, 1999, P NATL ACAD SCI USA, V96, P203, DOI 10.1073/pnas.96.1.203; TUSZYNSKI A, 1993, LEUKEMIA, V7, P1504; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; VANDERPLAS DC, 1991, LEUKEMIA, V5, P457; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; vanRhee F, 1996, BLOOD, V87, P5213, DOI 10.1182/blood.V87.12.5213.bloodjournal87125213; VERSCHRAEGEN CF, 1995, CANCER-AM CANCER SOC, V76, P992, DOI 10.1002/1097-0142(19950915)76:6<992::AID-CNCR2820760612>3.0.CO;2-L; Verstovsek S, 2002, CANCER, V94, P2416, DOI 10.1002/cncr.10490; WADA H, 1995, CANCER RES, V55, P3192; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WESTBROOK CA, 1992, BLOOD, V80, P2983; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Wilson G, 1997, BLOOD, V89, P3064, DOI 10.1182/blood.V89.8.3064; Wilson GA, 2000, BRIT J HAEMATOL, V111, P1109, DOI 10.1046/j.1365-2141.2000.02471.x; WITTE ON, 1980, NATURE, V283, P826, DOI 10.1038/283826a0; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yamagata T, 1996, BRIT J HAEMATOL, V94, P370, DOI 10.1046/j.1365-2141.1996.d01-1798.x; ZACCARIA A, 1993, LEUKEMIA LYMPHOMA, V11, P81, DOI 10.3109/10428199309047869; ZACCARIA A, 1993, BRIT J HAEMATOL, V84, P265, DOI 10.1111/j.1365-2141.1993.tb03062.x	164	85	98	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	2002	21	56					8652	8667		10.1038/sj.onc.1206094	http://dx.doi.org/10.1038/sj.onc.1206094			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZF	12476311				2022-12-28	WOS:000179734300014
J	Cagatay, T; Ozturk, M				Cagatay, T; Ozturk, M			p53 mutation as a source of aberrant beta-catenin accumulation in cancer cells	ONCOGENE			English	Article						beta-catenin; p53; mutation; hepatocellular carcinoma; wnt pathway	HUMAN HEPATOCELLULAR CARCINOMAS; TRANSGENIC MICE; COLORECTAL-CANCER; GENE-MUTATIONS; BREAST-CANCER; CYCLIN D1; PROTEIN; FREQUENT; PATHWAY; ACTIVATION	b-catenin is involved in both cell-cell interactions and wnt pathway-dependent cell fate determination through its interactions with E-cadherin and TCF/LEF transcription factors, respectively. Cytoplasmic/nuclear levels of beta-catenin are important in regulated transcriptional activation of TCF/LEF target genes. Normally, these levels are kept low by proteosomal degradation of beta-catenin through Axin1- and APC-dependent phosphorylation by CKI and GSK-3beta. Deregulation of beta-catenin degradation results in its aberrant accumulation, often leading to cancer. Accordingly, aberrant accumulation of beta-catenin is observed at high frequency in many cancers. This accumulation correlates with either mutational activation of CTNNB1 (beta-catenin) or mutational inactivation of APC and Axin1 genes in some tumors. However, there are many tumors that display beta-catenin accumulation in the absence of a mutation in these genes. Thus, there must be additional sources for aberrant beta-catenin accumulation in cancer cells. Here, we provide experimental evidence that wild-type beta-catenin accumulates in hepatocellular carcinoma (HCC) cells in association with mutational inactivation of p53 gene. We also show that worldwide p53 and beta-catenin mutation rates are inversely correlated in HCC. These data suggest that inactivation of p53 is an important cause of aberrant accumulation of beta-catenin in cancer cells.	Bilkent Univ, Dept Mol Biol & Genet, TR-06533 Bilkent, Turkey	Ihsan Dogramaci Bilkent University	Ozturk, M (corresponding author), Bilkent Univ, Dept Mol Biol & Genet, TR-06533 Bilkent, Turkey.	ozturk@fen.bilkent.edu.tr	OZTURK, MEHMET/AAS-7241-2021; ozturk, mehmet/G-3330-2014	OZTURK, MEHMET/0000-0002-6092-9706; 				Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; Barker N, 2000, ADV CANCER RES, V77, P1; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; Cadoret A, 2001, CANCER RES, V61, P3245; Calvisi DF, 2001, CANCER RES, V61, P2085; Candidus S, 1996, CANCER RES, V56, P49; Chung DC, 2000, GASTROENTEROLOGY, V119, P854, DOI 10.1053/gast.2000.16507; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Devereux TR, 2001, MOL CARCINOGEN, V31, P68, DOI 10.1002/mc.1041; FREBOURG T, 1992, CANCER RES, V52, P6976; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Fujie H, 2001, HEPATOL RES, V20, P39, DOI 10.1016/S1386-6346(00)00116-9; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Hommura F, 2002, CANCER-AM CANCER SOC, V94, P752, DOI 10.1002/cncr.10213; Hsu HC, 2000, AM J PATHOL, V157, P763, DOI 10.1016/S0002-9440(10)64590-7; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; Huang H, 1999, AM J PATHOL, V155, P1795, DOI 10.1016/S0002-9440(10)65496-X; Inagawa S, 2002, CLIN CANCER RES, V8, P450; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; Jonsson M, 2000, EUR J CANCER, V36, P242, DOI 10.1016/S0959-8049(99)00276-2; Kinzler KW, 1998, GENETIC BASIS HUMAN, P565; Koch A, 1999, CANCER RES, V59, P269; Kondo Y, 1999, JPN J CANCER RES, V90, P1301, DOI 10.1111/j.1349-7006.1999.tb00712.x; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Miyoshi Y, 1998, CANCER RES, V58, P2524; Monga SPS, 2001, HEPATOLOGY, V33, P1098, DOI 10.1053/jhep.2001.23786; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Ozdag H, 2000, EUR J CANCER, V36, P2076, DOI 10.1016/S0959-8049(00)00277-X; Ozturk M, 1999, SEMIN LIVER DIS, V19, P235, DOI 10.1055/s-2007-1007113; OZTURK M, 1991, LANCET, V338, P1356, DOI 10.1016/0140-6736(91)92236-U; Park WS, 2001, J PATHOL, V193, P483; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; Polakis P, 2000, GENE DEV, V14, P1837; PONCHEL F, 1994, CANCER RES, V54, P2064; Renard CA, 2000, ONCOGENE, V19, P2678, DOI 10.1038/sj.onc.1203617; Rimm DL, 1999, AM J PATHOL, V154, P325, DOI 10.1016/S0002-9440(10)65278-9; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Sadot E, 2001, MOL CELL BIOL, V21, P6768, DOI 10.1128/MCB.21.20.6768-6781.2001; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Sayan AE, 2001, ONCOGENE, V20, P5111, DOI 10.1038/sj.onc.1204669; Sayan BS, 2001, J CELL BIOL, V155, P719, DOI 10.1083/jcb.200106044; Shinohara A, 2001, GYNECOL ONCOL, V82, P450, DOI 10.1006/gyno.2001.6298; Sparks AB, 1998, CANCER RES, V58, P1130; Terris B, 1999, ONCOGENE, V18, P6583, DOI 10.1038/sj.onc.1203051; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Ueda M, 2001, BRIT J CANCER, V85, P64, DOI 10.1054/bjoc.2001.1863; Umeda T, 2000, INT J ONCOL, V16, P1133; UNSAL H, 1994, P NATL ACAD SCI USA, V91, P822, DOI 10.1073/pnas.91.2.822; Van Nhieu JT, 1999, AM J PATHOL, V155, P703, DOI 10.1016/S0002-9440(10)65168-1; Wei Y, 2000, ONCOGENE, V19, P498, DOI 10.1038/sj.onc.1203356; Wong CM, 2001, CANCER-AM CANCER SOC, V92, P136, DOI 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R; Yakicier MC, 1999, ONCOGENE, V18, P4879, DOI 10.1038/sj.onc.1202866; Yolcu E, 2001, ONCOGENE, V20, P1398, DOI 10.1038/sj.onc.1204240	61	82	86	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2002	21	52					7971	7980		10.1038/sj.onc.1205919	http://dx.doi.org/10.1038/sj.onc.1205919			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	612VY	12439747	Green Published			2022-12-28	WOS:000179097200006
J	Yabana, N; Shibuya, M				Yabana, N; Shibuya, M			Adaptor protein APS binds the NH2-terminal autoinhibitory domain of guanine nucleotide exchange factor Vav3 and augments its activity	ONCOGENE			English	Article						Vav; guanine nucleotide; exchange factor; calponin; homology domain	SH2 DOMAINS; PROTOONCOGENE PRODUCT; PLECKSTRIN HOMOLOGY; SIGNALING PATHWAYS; C-CBL; FAMILY; ACTIVATION; RHO; DBL; MEMBER	The N-terminal calponin homology (CH) domain of Vav guanine nucleotide exchange factor is thought to serve a regulatory role in the autoinhibition, however, its precise function is not entirely clear. We found that the adaptor molecule APS could bind the CH domain of Vav3, a member of the vav proto-oncogene family. The binding of Vav3 and APS was apparently stabilized by the tyrosine phosphorylation of Vav3 by Lck, and the association of APS with Vav3 in turn enhanced the Lck-mediated phosphorylation of Vav3. Focus formation assays demonstrated that APS could increase the transforming activity of proto-Vav3. Further analyses revealed that the Vav3 CH domain could bind the pleckstrin homology (PH) domain of APS and that this binding was indispensable to enhance the transforming activity of Vav3. We present here a novel stimulatory mechanism of Vav3 in which APS directly relieves the autoinhibitory CH domain and furthermore enhances its tyrosine phosphorylation by Lck.	Univ Tokyo, Inst Med Sci, Div Genet, Minato Ku, Tokyo, Japan	University of Tokyo	Shibuya, M (corresponding author), Univ Tokyo, Inst Med Sci, Div Genet, Minato Ku, Shirokanedai 4-6-1, Tokyo, Japan.	shibuya@ims.u-tokyo.ac.jp						Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Abe R, 1999, J BIOL CHEM, V274, P30410, DOI 10.1074/jbc.274.43.30410; ADAMS JM, 1992, ONCOGENE, V7, P611; Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Alberts AS, 1998, EMBO J, V17, P4075, DOI 10.1093/emboj/17.14.4075; Bhattacharyya R, 2000, J BIOL CHEM, V275, P14992, DOI 10.1074/jbc.M000415200; Bi F, 2001, MOL CELL BIOL, V21, P1463, DOI 10.1128/MCB.21.5.1463-1474.2001; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Bustelo XR, 1997, ONCOGENE, V15, P2511, DOI 10.1038/sj.onc.1201430; CASTRESANA J, 1995, FEBS LETT, V374, P149, DOI 10.1016/0014-5793(95)01098-Y; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; Doody GM, 2001, NAT IMMUNOL, V2, P542, DOI 10.1038/88748; Gimona M, 1998, CURR BIOL, V8, pR674; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hobert O, 1996, MOL CELL BIOL, V16, P3066; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; Inabe K, 2002, J EXP MED, V195, P189, DOI 10.1084/jem.20011571; Iseki M, 2000, BIOCHEM BIOPH RES CO, V272, P45, DOI 10.1006/bbrc.2000.2736; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1994, J BIOL CHEM, V269, P32579; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; Kawasaki Y, 2000, SCIENCE, V289, P1194, DOI 10.1126/science.289.5482.1194; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; Moores SL, 2000, MOL CELL BIOL, V20, P6364, DOI 10.1128/MCB.20.17.6364-6373.2000; Movilla N, 1999, MOL CELL BIOL, V19, P7870; OSBORNE MA, 1995, BIO-TECHNOL, V13, P1474, DOI 10.1038/nbt1295-1474; RON D, 1989, ONCOGENE, V4, P1067; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Schuebel KE, 1996, ONCOGENE, V13, P363; Stradal T, 1998, FEBS LETT, V431, P134, DOI 10.1016/S0014-5793(98)00751-0; Takaki S, 2000, IMMUNITY, V13, P599, DOI 10.1016/S1074-7613(00)00060-1; Tedford K, 2001, NAT IMMUNOL, V2, P548, DOI 10.1038/88756; VAN AL, 1997, GENE DEV, V11, P2295; Wakioka T, 1999, LEUKEMIA, V13, P760, DOI 10.1038/sj.leu.2401397; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Yokouchi M, 1997, ONCOGENE, V15, P7, DOI 10.1038/sj.onc.1201163; Yokouchi M, 1999, ONCOGENE, V18, P759, DOI 10.1038/sj.onc.1202326; Zeng LY, 2000, MOL CELL BIOL, V20, P9212, DOI 10.1128/MCB.20.24.9212-9224.2000	48	20	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 31	2002	21	50					7720	7729		10.1038/sj.onc.1205927	http://dx.doi.org/10.1038/sj.onc.1205927			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	606VW	12400014				2022-12-28	WOS:000178756200011
J	She, QB; Ma, WY; Wang, MF; Kaji, A; Ho, CT; Dong, ZG				She, QB; Ma, WY; Wang, MF; Kaji, A; Ho, CT; Dong, ZG			Inhibition of cell transformation by resveratrol and its derivatives: differential effects and mechanisms involved	ONCOGENE			English	Article						resveratrol; resveratrol derivatives; cell transformation; p53; PI-3K/Akt; chemoprevention	ACTIVATOR PROTEIN-1 ACTIVATION; PHOSPHATIDYLINOSITOL KINASE; APOPTOSIS; GROWTH; CHEMOPREVENTION; P53; PRODUCT; PATHWAY; ARREST; PHOSPHORYLATION	Resveratrol, a constituent of grapes and other foods, has been reported to be a potential cancer chemopreventive agent. Our previous study showed that the antitumor activity of resveratrol occurs through mitogen-activated protein kinases-mediated p53 activation and induction of apoptosis. To develop more effective agents with fewer side effects for the chemoprevention of cancer, we investigated the effect of resveratrol and its structurally related derivatives on epidermal growth factor (EGF)-induced cell transformation. Our results provided the first evidence that one of the resveratrol derivatives exerted a more potent inhibitory effect than resveratrol on EGF-induced cell transformation, but had less cytotoxic effects on normal nontransformed cells. Compared to resveratrol, this compound also caused cell cycle arrest in the G1 phase, but did not induce p53 activation and apoptosis. Furthermore, this compound, but not resveratrol, markedly inhibited EGF-induced phosphatidylinositol-3 kinase (PI-3K) and Akt activation. Collectively, these data suggested that the higher antitumor effect of the compound compared to resveratrol, may act through a different mechanism by mainly targeting PI-3K/Akt signaling pathways.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; Rutgers State Univ, Dept Food Sci, New Brunswick, NJ 08901 USA	University of Minnesota System; Rutgers State University New Brunswick	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	zgdong@hi.umn.edu	Wang, Mingfu/AAT-3292-2021	Wang, Mingfu/0000-0003-1469-3963; She, Qing-Bai/0000-0002-7207-0599	NATIONAL CANCER INSTITUTE [R01CA077646, R37CA081064, R01CA081064] Funding Source: NIH RePORTER; NCI NIH HHS [CA77646, CA81064] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adhami VM, 2001, BIOCHEM BIOPH RES CO, V288, P579, DOI 10.1006/bbrc.2001.5819; Ahmad N, 2001, CLIN CANCER RES, V7, P1466; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; Clement MV, 1998, BLOOD, V92, P996; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; COUGHLIN SR, 1989, SCIENCE, V243, P1191; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Della Ragione F, 1998, BIOCHEM BIOPH RES CO, V250, P53, DOI 10.1006/bbrc.1998.9263; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dong ZG, 1999, ANTICANCER RES, V19, P3743; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; Edinger AL, 2002, MOL BIOL CELL, V13, P2276, DOI 10.1091/mbc.01-12-0584; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Hong WK, 1997, SCIENCE, V278, P1073, DOI 10.1126/science.278.5340.1073; Hsieh TC, 1999, EXP CELL RES, V249, P109, DOI 10.1006/excr.1999.4471; Huang CS, 1999, CARCINOGENESIS, V20, P237, DOI 10.1093/carcin/20.2.237; Huang CS, 1999, J BIOL CHEM, V274, P29672, DOI 10.1074/jbc.274.42.29672; Huang CS, 1997, CANCER RES, V57, P2873; Huang CS, 1997, P NATL ACAD SCI USA, V94, P11957, DOI 10.1073/pnas.94.22.11957; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; Kelloff GJ, 2000, J NUTR, V130, p467S, DOI 10.1093/jn/130.2.467S; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Park JW, 2001, CARCINOGENESIS, V22, P1633, DOI 10.1093/carcin/22.10.1633; Prives C, 1999, J PATHOL, V187, P112; SERUNIAN LA, 1990, J VIROL, V64, P4718, DOI 10.1128/JVI.64.10.4718-4725.1990; She QB, 2000, FEBS LETT, V469, P163, DOI 10.1016/S0014-5793(00)01273-4; She QB, 2002, MOL CARCINOGEN, V33, P244, DOI 10.1002/mc.10041; She QB, 2001, CANCER RES, V61, P1604; Sporn MB, 2000, CARCINOGENESIS, V21, P525, DOI 10.1093/carcin/21.3.525; Stein RC, 2000, MOL MED TODAY, V6, P347, DOI 10.1016/S1357-4310(00)01770-6; Subbaramaiah K, 1998, J BIOL CHEM, V273, P21875, DOI 10.1074/jbc.273.34.21875; Surh YJ, 1999, CANCER LETT, V140, P1, DOI 10.1016/S0304-3835(99)00039-7; Tsai SH, 1999, BRIT J PHARMACOL, V126, P673, DOI 10.1038/sj.bjp.0702357; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Wang MF, 1999, J AGR FOOD CHEM, V47, P3974, DOI 10.1021/jf990382w; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	38	49	53	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2003	22	14					2143	2150		10.1038/sj.onc.1206370	http://dx.doi.org/10.1038/sj.onc.1206370			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664NJ	12687016				2022-12-28	WOS:000182066900008
J	Visconti, R; Schepis', F; Iuliano, R; Pierantoni, GM; Zhang, L; Carlomagno, F; Battaglia, C; Martelli, ML; Trapasso, F; Santoro, M; Fusco, A				Visconti, R; Schepis', F; Iuliano, R; Pierantoni, GM; Zhang, L; Carlomagno, F; Battaglia, C; Martelli, ML; Trapasso, F; Santoro, M; Fusco, A			Cloning and molecular characterization of a novel gene strongly induced by the adenovirus E1A gene in rat thyroid cells	ONCOGENE			English	Article						thyroid; carcinoma; E1A; transformation	NUCLEAR TRANSLOCATION; ENDOTHELIAL-CELLS; EPITHELIAL-CELLS; EARLY REGION-1A; LINE; ONCOGENES; PROTEIN; GROWTH; TRANSFORMATION; LOCALIZATION	Expression of the adenovirus E1A gene in the rat thyroid differentiated cell line PC CI 3 induces thyrotropin-independent cell growth and impairs differentiation. However, the malignant phenotype is achieved only when the PC E1A cells are infected with other murine retroviruses carrying the v-abl, v-raf or polyoma middle-T genes. To determine through which genes E1A affects thyroid cells, we differentially screened PC Cl 3 and PC E1A cells. Here we report a new gene, named CL2, that is upregulated in PC E1A cells. The CL2 transcript is 4.4 kb long and encodes a 949 amino-acid protein. Conceptual translation of the open reading frame showed one product with a signal peptide, multiple nuclear localization signals and three newly described domains. Furthermore, in vivo, this protein was located juxtanuclear, which is suggestive of Golgian localization, and also in cytoplasm and nucleus/nucleolus. Finally, CL2 gene expression was drastically downregulated in human thyroid neoplastic cell lines and tissues.	Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol L Calif, I-80131 Naples, Italy; CNR, Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Univ Catanzaro Magna Graecia, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); Magna Graecia University of Catanzaro	Fusco, A (corresponding author), Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol L Calif, Via Pansini 5, I-80131 Naples, Italy.		Visconti, Roberta/C-5299-2009; schepis, filippo/H-9417-2014	schepis, filippo/0000-0001-6549-5102; Pierantoni, Giovanna Maria/0000-0003-4078-8528; Fusco, Alfredo/0000-0003-3332-5197; Visconti, Roberta/0000-0001-7613-3801				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Antoine M, 1997, J BIOL CHEM, V272, P29475, DOI 10.1074/jbc.272.47.29475; Bailey TL, 1998, J COMPUT BIOL, V5, P211, DOI 10.1089/cmb.1998.5.211; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; Basolo F, 2002, INT J CANCER, V97, P608, DOI 10.1002/ijc.10116; BERLINGIERI MT, 1993, ONCOGENE, V8, P249; BERLINGIERI MT, 1988, MOL CELL BIOL, V8, P2261, DOI 10.1128/MCB.8.5.2261; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; CHINNADURAI G, 1992, ONCOGENE, V7, P1255; CONE RD, 1988, MOL CELL BIOL, V8, P1036, DOI 10.1128/MCB.8.3.1036; DRY KL, 1995, HUM MOL GENET, V4, P2347, DOI 10.1093/hmg/4.12.2347; ESTOUR B, 1989, VIRCHOWS ARCH B, V57, P167, DOI 10.1007/BF02899078; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; FABIEN N, 1994, CANCER, V73, P2206, DOI 10.1002/1097-0142(19940415)73:8<2206::AID-CNCR2820730828>3.0.CO;2-M; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; Fearnhead HO, 1997, GENE DEV, V11, P1266, DOI 10.1101/gad.11.10.1266; Fiore L, 1997, J CLIN ENDOCR METAB, V82, P4094, DOI 10.1210/jc.82.12.4094; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; Gallimore PH, 2001, ONCOGENE, V20, P7824, DOI 10.1038/sj.onc.1204913; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HENDERSON JE, 1995, MOL CELL BIOL, V15, P4064; Hill DJ, 1992, GROWTH FACTORS, V6, P277, DOI 10.3109/08977199209021540; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; Kurosawa H, 1999, BLOOD, V93, P321, DOI 10.1182/blood.V93.1.321.401k05_321_332; LYNCH MJ, 1989, CANCER RES, V49, P5429; MAHER DW, 1989, MOL CELL BIOL, V9, P2251, DOI 10.1128/MCB.9.5.2251; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Melillo RM, 2001, MOL CELL BIOL, V21, P4177, DOI 10.1128/MCB.21.13.4177-4187.2001; MOROIANU J, 1994, P NATL ACAD SCI USA, V91, P1677, DOI 10.1073/pnas.91.5.1677; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Pan J, 1996, FEBS LETT, V383, P21; PANG XP, 1989, ENDOCRINOLOGY, V125, P1783, DOI 10.1210/endo-125-4-1783; PARASKEVA C, 1980, INT J CANCER, V25, P631, DOI 10.1002/ijc.2910250513; ROSSINI M, 1983, VIROLOGY, V131, P49, DOI 10.1016/0042-6822(83)90532-9; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Sambrook J., 2002, MOL CLONING LAB MANU; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; STOW ND, 1982, NUCLEIC ACIDS RES, V10, P5105, DOI 10.1093/nar/10.17.5105; TANAKA J, 1987, VIROLOGY, V161, P62, DOI 10.1016/0042-6822(87)90171-1; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; White E, 2001, ONCOGENE, V20, P7836, DOI 10.1038/sj.onc.1204861; WHITE E, 1995, CURR TOP MICROBIOL, V199, P33; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; ZEKI K, 1991, ACTA ENDOCRINOL-COP, V124, P60, DOI 10.1530/acta.0.1240060	48	15	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 20	2003	22	7					1087	1097		10.1038/sj.onc.1206194	http://dx.doi.org/10.1038/sj.onc.1206194			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	644PB	12592395				2022-12-28	WOS:000180926100014
J	Vigorito, E; Billadeu, DD; Savoy, D; McAdam, S; Doody, G; Fort, P; Turner, M				Vigorito, E; Billadeu, DD; Savoy, D; McAdam, S; Doody, G; Fort, P; Turner, M			RhoG regulates gene expression and the actin cytoskeleton in lymphocytes	ONCOGENE			English	Article						RhoG; Vav; lymphocytes; signalling; NFAT	ACTIVATED T-CELLS; VAV FAMILY; GTPASE-RHO; THYMOCYTE DEVELOPMENT; INDEPENDENT PATHWAYS; ADP-RIBOSYLATION; EXCHANGE FACTOR; WILD-TYPE; RAC; EFFECTOR	RhoG, a member of the Rho family of GTPases, has been implicated as a regulator of the actin cytoskeleton. In this study, we show a novel function for the small GTPase RhoG on the regulation of the interferon-gamma promoter and nuclear factor of activated T cells (NFAT) gene transcription in lymphocytes. Optimal function of RhoG for the expression of these genes requires a calcium signal, normally provided by the antigen receptor. In addition, RhoG potentiation of NFAT requires the indirect activity of Rac and Cdc42; however, pathways distinct from those activated by Rac and Cdc42 mediate RhoG activation of NFAT-dependent transcription. Using effector domain mutants of RhoG we found that its ability to potentiate NFAT-dependent transcription correlates with its capacity to increase actin polymerization, supporting the suggestion that NFAT-dependent transcription is an actin-dependent process. RhoG also promotes T-cell spreading on fibronectin, a property that is independent of its ability to enhance NFAT-dependent transcription. Hence, these results implicate RhoG in leukocyte trafficking and the control of gene expression induced in response to antigen encounter.	Babraham Inst, Mol Immunol Programme, Lab Lymphocyte Signalling & Dev, Cambridge CB2 4AT, England; Mayo Clin & Mayo Grad Sch Med, Dept Immunol, Rochester, MN 55905 USA; CNRS, Ctr Rech Biochim Macromol, IFR24,UPR 1086, Dept Immunol, F-34293 Montpellier, France	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Mayo Clinic; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Vigorito, E (corresponding author), Babraham Inst, Mol Immunol Programme, Lab Lymphocyte Signalling & Dev, Cambridge CB2 4AT, England.		Turner, Martin/N-9976-2014; Doody, Gina/AAN-8246-2021; Fort, Philippe/M-9498-2015	Turner, Martin/0000-0002-3801-9896; Doody, Gina/0000-0003-0665-6759; Fort, Philippe/0000-0001-5997-8722				Angkachatchai V, 1999, J IMMUNOL, V163, P3819; Arrieumerlou C, 2000, J IMMUNOL, V165, P3182, DOI 10.4049/jimmunol.165.6.3182; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Billadeau DD, 1998, J EXP MED, V188, P549, DOI 10.1084/jem.188.3.549; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Blangy A, 2000, J CELL SCI, V113, P729; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Corre I, 2001, J EXP MED, V194, P903, DOI 10.1084/jem.194.7.903; Costello PS, 2000, J EXP MED, V192, P77, DOI 10.1084/jem.192.1.77; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; Croker BA, 2002, J IMMUNOL, V168, P3376, DOI 10.4049/jimmunol.168.7.3376; D'Souza-Schorey C, 1998, MOL CELL BIOL, V18, P3936, DOI 10.1128/MCB.18.7.3936; Estrach S, 2002, CURR BIOL, V12, P307, DOI 10.1016/S0960-9822(02)00658-9; FAULL RJ, 1994, J EXP MED, V179, P1307, DOI 10.1084/jem.179.4.1307; GABIG TG, 1995, BLOOD, V85, P804, DOI 10.1182/blood.V85.3.804.bloodjournal853804; Galandrini R, 1997, IMMUNITY, V7, P163, DOI 10.1016/S1074-7613(00)80519-1; Gauthier-Rouviere C, 1998, MOL BIOL CELL, V9, P1379, DOI 10.1091/mbc.9.6.1379; Genot E, 1996, EMBO J, V15, P3923, DOI 10.1002/j.1460-2075.1996.tb00766.x; Gomez M, 2000, NAT IMMUNOL, V1, P348, DOI 10.1038/79808; Gomez M, 2001, IMMUNITY, V15, P703, DOI 10.1016/S1074-7613(01)00235-7; Hashimoto A, 1998, J EXP MED, V188, P1287, DOI 10.1084/jem.188.7.1287; Henning SW, 1998, J EXP MED, V188, P931, DOI 10.1084/jem.188.5.931; Henning SW, 1997, EMBO J, V16, P2397, DOI 10.1093/emboj/16.9.2397; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; Jacinto E, 1998, IMMUNITY, V8, P31, DOI 10.1016/S1074-7613(00)80456-2; Katoh H, 2000, MOL CELL BIOL, V20, P7378, DOI 10.1128/MCB.20.19.7378-7387.2000; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; Krawczyk C, 2000, IMMUNITY, V13, P463, DOI 10.1016/S1074-7613(00)00046-7; Kuhne MR, 2000, J BIOL CHEM, V275, P2185, DOI 10.1074/jbc.275.3.2185; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LANG P, 1992, J BIOL CHEM, V267, P11677; Li BY, 2000, SCIENCE, V288, P2219, DOI 10.1126/science.288.5474.2219; Lores P, 1997, ONCOGENE, V15, P601, DOI 10.1038/sj.onc.1201378; MALY FE, 1994, J BIOL CHEM, V269, P18743; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Na SQ, 1999, ONCOGENE, V18, P7966, DOI 10.1038/sj.onc.1203122; Reynolds LF, 2002, J EXP MED, V195, P1103, DOI 10.1084/jem.20011663; Rincon M, 1998, EMBO J, V17, P2817, DOI 10.1093/emboj/17.10.2817; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Schuebel KE, 1996, ONCOGENE, V13, P363; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Tapon N, 1998, EMBO J, V17, P1395, DOI 10.1093/emboj/17.5.1395; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; Vignal E, 2001, MOL CELL BIOL, V21, P8022, DOI 10.1128/MCB.21.23.8022-8034.2001; Villalba M, 2000, IMMUNITY, V12, P151, DOI 10.1016/S1074-7613(00)80168-5; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; Wardenburg JB, 1998, IMMUNITY, V9, P607, DOI 10.1016/S1074-7613(00)80658-5; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Wielowieyski PA, 2000, J BIOL CHEM, V275, P38474, DOI 10.1074/jbc.M007682200; Yablonski D, 1998, EMBO J, V17, P5647, DOI 10.1093/emboj/17.19.5647	52	42	42	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 23	2003	22	3					330	342		10.1038/sj.onc.1206116	http://dx.doi.org/10.1038/sj.onc.1206116			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545154				2022-12-28	WOS:000180379100002
J	Castellone, MD; Cirafici, AM; De Vita, G; De Falco, V; Malorni, L; Tallini, G; Fagin, JA; Fusco, A; Melillo, RM; Santoro, M				Castellone, MD; Cirafici, AM; De Vita, G; De Falco, V; Malorni, L; Tallini, G; Fagin, JA; Fusco, A; Melillo, RM; Santoro, M			Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes	ONCOGENE			English	Article						kinase; carcinoma; survival; ras; tyrosine; thyroid; oncogene; TUNEL	EPIDERMAL GROWTH-FACTOR; PAPILLARY CARCINOMAS; RET PROTOONCOGENE; PATHWAY; REARRANGEMENTS; PROLIFERATION; ONCOPROTEIN; ACTIVATION; RECEPTOR; KINASES	RET gene rearrangements, which generate chimeric RET/ PTC oncogenes, are early events in the evolution of thyroid papillary carcinomas. Expression of RET/PTC oncogenes promotes neoplastic transformation of cultured thyroid cells and of thyroid glands in transgenic mice. Notwithstanding these oncogenic effects, we have found that the expression of two RET/PTC oncogenes (H4-RET and RFG-RET) induces apoptosis of rat thyroid PC CL 3 cells. Promotion of thyroid cell death depends on the kinase activity of RET/PTC and on the phosphorylation of a tyrosine residue (tyrosine 1062) that maps in the carboxy-terminus of the RET protein. Tyrosine 1062 is essential for RET/PTC-mediated activation of the Ras/ ERK pathway. Inhibition of Ras/ERK by a dominant negative Ras or by the MEKI inhibitor, PD98059, obstructed RET/PTC-mediated apoptosis. We also show that signals transmitted by tyrosine 1062 mediate proapoptotic events like Bcl-2 down regulation and Bax upregulation, and that adoptive overexpression of Bcl-2 overcomes RET/PTC-induced apoptosis. Thus, gene rearrangements that generate RET/PTC oncogenes subvert RET function by converting it into a chronically active kinase that is constitutively phosphorylated on tyrosine 1062. In turn, Y1062 phosphorylation transmits not only mitogenic but also proapoptotic signals to thyroid cells.	Univ Naples Federico II, Ist Endocrinol & Oncol Sperimentale, CNR, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Yale Univ, Dept Pathol, New Haven, CT 06520 USA; Univ Cincinnati, Coll Med, Div Endocrinol, Cincinnati, OH 45267 USA	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; Yale University; University System of Ohio; University of Cincinnati	Santoro, M (corresponding author), Univ Naples Federico II, Ist Endocrinol & Oncol Sperimentale, CNR, Dipartimento Biol & Patol Cellulare & Mol, Via S Pansini 5, I-80131 Naples, Italy.		DE FALCO, VALENTINA/C-2061-2015; De Vita, Gabriella/H-4422-2011; Tallini, Giovanni/F-7850-2013; Malorni, Luca/J-1973-2019; melillo, rosa marina/O-5255-2015	DE FALCO, VALENTINA/0000-0002-8972-7921; De Vita, Gabriella/0000-0002-7302-1174; Tallini, Giovanni/0000-0003-0113-6682; Malorni, Luca/0000-0002-4297-2997; MELILLO, Rosa Marina/0000-0002-9233-5275; Fusco, Alfredo/0000-0003-3332-5197; CASTELLONE, MARIADOMENICA/0000-0003-0507-8037				Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Cheng GJ, 2001, ONCOGENE, V20, P7334, DOI 10.1038/sj.onc.1204928; Corvi R, 2001, LAB INVEST, V81, P1639, DOI 10.1038/labinvest.3780377; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; DREMIER S, 1994, ENDOCRINOLOGY, V135, P135, DOI 10.1210/en.135.1.135; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; Gimm O, 2001, CANCER LETT, V163, P143, DOI 10.1016/S0304-3835(00)00697-2; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; Jhiang SM, 2000, ONCOGENE, V19, P5590, DOI 10.1038/sj.onc.1203857; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kimura T, 2001, ENDOCR REV, V22, P631, DOI 10.1210/er.22.5.631; LAMY F, 1993, J BIOL CHEM, V268, P8398; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Manie S, 2001, TRENDS GENET, V17, P580, DOI 10.1016/S0168-9525(01)02420-9; Melillo RM, 2001, MOL CELL BIOL, V21, P4177, DOI 10.1128/MCB.21.13.4177-4187.2001; Mercalli E, 2001, ONCOGENE, V20, P3475, DOI 10.1038/sj.onc.1204462; Monaco C, 2001, ONCOGENE, V20, P599, DOI 10.1038/sj.onc.1204127; Pierotti MA, 2001, CANCER LETT, V166, P1, DOI 10.1016/S0304-3835(01)00439-6; ROGER PP, 1982, FEBS LETT, V144, P209, DOI 10.1016/0014-5793(82)80639-X; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SANTORO M, 1994, ONCOGENE, V9, P509; Shirokawa JM, 2000, MOL ENDOCRINOL, V14, P1725, DOI 10.1210/me.14.11.1725; Sugg SL, 1998, J CLIN ENDOCR METAB, V83, P4116, DOI 10.1210/jc.83.11.4116; Tong Q, 1997, J BIOL CHEM, V272, P9043; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	30	38	38	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 16	2003	22	2					246	255		10.1038/sj.onc.1206112	http://dx.doi.org/10.1038/sj.onc.1206112			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527893				2022-12-28	WOS:000180322400009
J	Ma, YX; Fan, SJ; Xiong, JB; Yuan, RQ; Meng, QH; Gao, M; Goldberg, ID; Fuqua, SA; Pestell, RG; Rosen, EM				Ma, YX; Fan, SJ; Xiong, JB; Yuan, RQ; Meng, QH; Gao, M; Goldberg, ID; Fuqua, SA; Pestell, RG; Rosen, EM			Role of BRCA1 in heat shock response	ONCOGENE			English	Article						BRCA1; prostate cancer; breast cancer; DU-145; MCF-7; heat shock; HSP27; HSP70; HSP90	BREAST-CANCER CELLS; HUMAN PROSTATE-CANCER; DNA-DAMAGE RESPONSE; TUMOR-SUPPRESSOR; DIFFERENTIAL REGULATION; ACTIN POLYMERIZATION; ANTISENSE INHIBITION; PROTEIN-DEGRADATION; NEGATIVE REGULATION; THERMAL PROTECTION	The heat shock response is an evolutionarily conserved response to heat and other stresses that promotes the maintenance of key metabolic functions and cell survival. We report that exposure of human prostate (DU-145) and breast (MCF-7) cancer cells to heat (42degreesC caused a rapid disappearance of the breast cancer susceptibility gene-1 (BRCA1) protein, starting at 1 h after the onset of heating and slightly lagging behind the increase in heat shock protein 70 (HSP70) levels. The heat-induced loss of BRCA1 occurred at the protein level, since: (1) BRCA1 mRNA expression was unaffected; and (2) the BRCA1 protein loss was also observed in DU-145 cells that expressed exogenous wild-type BRCA1 (wtBRCA1). In addition to heat regulation of BRCA1 protein levels, we also found that BRCA1 could modulate the heat shock response. Thus, wtBRCA1 overexpressing DU-145 cell clones showed significantly decreased sensitivity to heat-induced cytotoxicity; and Brca1 mutant mouse embryo fibroblasts showed increased sensitivity to heat. The DU-145 wtBRCA1 clones also showed increased expression of the small heat shock protein HSP27; and reporter assays revealed that wtBRCA1 stimulated a two to four-fold increase in HSP27 promoter activity, consistent with its ability to upregulate HSP27 mRNA and protein levels. In studies using epitope-tagged truncated BRCA1 proteins, the ability to stimulate the HSP27 promoter and to mediate heat-induced degradation required the amino-terminus but not the carboxyl-terminus of BRCA1 Although the heat-induced loss of BRCA1 appeared to be due to protein degradation, various protein metabolic agents (or combinations) failed to block this event, including: MG132 (a 26S proteasomal inhibitor), N-Wacetyl-leucyl-leucyl-norleucinal (a calpain inhibitor), z-VAD-fmk (a pan-caspase inhibitor), and ammonium chloride and chloroquine (which stabilize lysosomes). These findings suggest that in addition to its other functions, BRCA1 may participate in mammalian heat shock response pathways.	Albert Einstein Coll Med, Dept Radiat Oncol, Long Isl Jewish Med Ctr, New Hyde Pk, NY 11040 USA; Albert Einstein Coll Med, Dept Radiat Oncol, Bronx, NY 10461 USA; Baylor Coll Med, Breast Ctr, Houston, TX 77030 USA; Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Albert Einstein Coll Med, Div Hormone Dependent Tumor Biol, Bronx, NY 10461 USA	Northwell Health; Yeshiva University; Yeshiva University; Albert Einstein College of Medicine; Baylor College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Rosen, EM (corresponding author), Albert Einstein Coll Med, Dept Radiat Oncol, Long Isl Jewish Med Ctr, Long Isl Campus,270-05 76th Ave, New Hyde Pk, NY 11040 USA.		Meng, Q./GSI-6185-2022		NATIONAL CANCER INSTITUTE [R01CA080000, R01CA082599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009169] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA80000, R01-CA82599] Funding Source: Medline; NIEHS NIH HHS [R01-ES09169] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALLEY MC, 1988, CANCER RES, V48, P589; Andres JL, 1998, ONCOGENE, V16, P2229, DOI 10.1038/sj.onc.1201752; AOYAMA A, 1993, MOL CELL BIOL, V13, P1824, DOI 10.1128/MCB.13.3.1824; BATES PJ, 1982, BIOCHIM BIOPHYS ACTA, V719, P377, DOI 10.1016/0304-4165(82)90113-1; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; Blagosklonny MV, 1999, ONCOGENE, V18, P6460, DOI 10.1038/sj.onc.1203068; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Bruey JM, 2000, ONCOGENE, V19, P4855, DOI 10.1038/sj.onc.1203850; Brzovic PS, 1998, J BIOL CHEM, V273, P7795, DOI 10.1074/jbc.273.14.7795; Bubendorf L, 1999, J NATL CANCER I, V91, P1758, DOI 10.1093/jnci/91.20.1758; Chen YM, 1996, CANCER RES, V56, P3168; Cornford PA, 2000, CANCER RES, V60, P7099; Creagh EM, 2000, LEUKEMIA, V14, P1161, DOI 10.1038/sj.leu.2401841; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fan SJ, 1998, INT J CANCER, V77, P600, DOI 10.1002/(SICI)1097-0215(19980812)77:4<600::AID-IJC21>3.0.CO;2-8; Fan SJ, 2001, ONCOGENE, V20, P77, DOI 10.1038/sj.onc.1204073; Fan SJ, 2001, ONCOGENE, V20, P8215, DOI 10.1038/sj.onc.1205033; Fan SJ, 1998, ONCOGENE, V16, P3069, DOI 10.1038/sj.onc.1202116; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; Forsythe HL, 2001, J BIOL CHEM, V276, P15571, DOI 10.1074/jbc.C100055200; Fung TK, 2002, J BIOL CHEM, V277, P35140, DOI 10.1074/jbc.M205503200; Gao B, 2001, FEBS LETT, V488, P179, DOI 10.1016/S0014-5793(00)02430-3; Garrido C, 1999, FASEB J, V13, P2061, DOI 10.1096/fasebj.13.14.2061; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Guenal I, 1997, ONCOGENE, V15, P347, DOI 10.1038/sj.onc.1201182; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506; Horman S, 1999, INT J CANCER, V82, P574, DOI 10.1002/(SICI)1097-0215(19990812)82:4<574::AID-IJC17>3.0.CO;2-L; Huber LJ, 2001, MOL CELL BIOL, V21, P4005, DOI 10.1128/MCB.21.12.4005-4015.2001; INOUE S, 1991, J BIOL CHEM, V266, P13311; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Kamradt MC, 2001, J BIOL CHEM, V276, P16059, DOI 10.1074/jbc.C100107200; Lee DH, 1996, J BIOL CHEM, V271, P27280, DOI 10.1074/jbc.271.44.27280; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Mairesse N, 1996, CELL BIOL INT, V20, P205, DOI 10.1006/cbir.1996.0025; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Nakamoto H, 2000, FEBS LETT, V483, P169, DOI 10.1016/S0014-5793(00)02097-4; Newton EM, 1996, MOL CELL BIOL, V16, P839; Nylandsted J, 2000, ANN NY ACAD SCI, V926, P122; Nylandsted J, 2000, P NATL ACAD SCI USA, V97, P7871, DOI 10.1073/pnas.97.14.7871; Oesterreich S, 1997, J CELL BIOCHEM, V67, P275, DOI 10.1002/(SICI)1097-4644(19971101)67:2<275::AID-JCB13>3.0.CO;2-E; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Pandey P, 2000, EMBO J, V19, P4310, DOI 10.1093/emboj/19.16.4310; Payne J, 2000, INT J HYPERTHER, V16, P492, DOI 10.1080/02656730050199340; Pfleger CM, 2000, GENE DEV, V14, P655; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; POOLE B, 1997, ACTA BIOL MED GER, V36, P1777; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RUBIN SJ, 1991, J SURG ONCOL, V46, P31, DOI 10.1002/jso.2930460108; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Shao NS, 1996, ONCOGENE, V13, P1; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; STREUWING JP, 1997, NEW ENGL J MED, V336, P1401; Thomas JE, 1997, CELL GROWTH DIFFER, V8, P801; Tirkkonen M, 1997, CANCER RES, V57, P1222; Trautinger F, 1997, J PHOTOCH PHOTOBIO B, V39, P90, DOI 10.1016/S1011-1344(96)00010-3; Wang JA, 1999, INT J RADIAT BIOL, V75, P301, DOI 10.1080/095530099140483; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Waterhouse NJ, 2001, J CELL BIOL, V153, P319, DOI 10.1083/jcb.153.2.319; WOSIKOWSKI K, 1995, CELL GROWTH DIFFER, V6, P1395; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Yuan RQ, 1999, PROSTATE, V40, P37; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; ZHU HJ, 1995, FEBS LETT, V374, P303, DOI 10.1016/0014-5793(95)01116-V	76	19	20	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 9	2003	22	1					10	27		10.1038/sj.onc.1206061	http://dx.doi.org/10.1038/sj.onc.1206061			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527903				2022-12-28	WOS:000180166900002
J	Debatin, KM; Poncet, D; Kroemer, G				Debatin, KM; Poncet, D; Kroemer, G			Chemotherapy: targeting the mitochondrial cell death pathway	ONCOGENE			English	Review						anti-cancer therapy; drug targets; mitochondria	ADENINE-NUCLEOTIDE TRANSLOCATOR; CYTOCHROME-C RELEASE; PERMEABILITY TRANSITION PORE; DEPENDENT ANION CHANNEL; BCL-2 FAMILY MEMBERS; ARSENITE INDUCES APOPTOSIS; SYNTHETIC RETINOID CD437; OVARIAN-CANCER; MEMBRANE PERMEABILIZATION; BENZODIAZEPINE RECEPTOR	One of the mechanisms by which chemotherapeutics destroy cancer cells is by inducing apoptosis. Apoptosis can be activated through several different signalling pathways, but these all appear to converge at a single event - mitochondrial membrane permeabilization (MMP). This 'point-of-no-return' in the cell death program is a complex process that is regulated by the composition of the mitochondrial membrane and pre-mitochondrial signal-transduction events. MMP is subject to a complex regulation, and local alterations in the composition of mitochondrial membranes, as well as alterations in pre-mitochondrial signal-transducing events, can determine chemotherapy resistance in cancer cells. Detecting MMP might thus be useful for detecting chemotherapy responses in vivo. Several cytotoxic drugs induce MMP by a direct action on mitochondria. This type of agents can enforce death in cells in which upstream signals normally leading to apoptosis have been disabled. Cytotoxic components acting on mitochondria can specifically target proteins from the Bcl-2 family, the peripheral benzodiazepin receptor, or the adenine nucleotide translocase, and/or act by virtue of their physicochemical properties as steroid analogues, cationic ampholytes, redox-active compounds or photosensitizers. Some compounds acting on mitochondria can overcome the cytoprotective effect of Bcl-2-like proteins. Several agents which are already used in anti-cancer chemotherapy can induce MMP, and new drugs specifically designed to target mitochondria are being developed.	Inst Gustave Roussy, CNRS, UMR1599, F-94805 Villejuif, France; Univ Ulm, Childrens Hosp, D-89075 Ulm, Germany	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Ulm University	Debatin, KM (corresponding author), Inst Gustave Roussy, CNRS, UMR1599, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	klaus-michael.debatin@medizin.uni-ulm.de; kroemer@igr.fr	Debatin, Klaus-Michael/J-9704-2014; KROEMER, Guido/B-4263-2013; Poncet, Delphine A/A-7190-2016; Kroemer, Guido/AAY-9859-2020	Debatin, Klaus-Michael/0000-0002-8397-1886; KROEMER, Guido/0000-0002-9334-4405; Poncet, Delphine A/0000-0003-0446-5262; 				Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Angioli R, 1997, INT J ONCOL, V11, P777; Aoki H, 2002, J BIOL CHEM, V277, P10244, DOI 10.1074/jbc.M112355200; Aqeilan R, 1999, FEBS LETT, V457, P271, DOI 10.1016/S0014-5793(99)01050-9; Aranha O, 2002, J UROLOGY, V167, P1288, DOI 10.1016/S0022-5347(05)65283-4; Arap W, 2002, NAT MED, V8, P121, DOI 10.1038/nm0202-121; Arap W, 2002, P NATL ACAD SCI USA, V99, P1527, DOI 10.1073/pnas.241655998; Banker DE, 2002, LEUKEMIA RES, V26, P91, DOI 10.1016/S0145-2126(01)00112-6; Barry M, 2002, NAT REV IMMUNOL, V2, P401, DOI 10.1038/nri819; Basanez G, 2001, J BIOL CHEM, V276, P31083, DOI 10.1074/jbc.M103879200; Basanez G, 1999, P NATL ACAD SCI USA, V96, P5492, DOI 10.1073/pnas.96.10.5492; Belostotsky R, 2001, J IMMUNOL, V167, P4719, DOI 10.4049/jimmunol.167.8.4719; Belzacq AS, 2001, ONCOGENE, V20, P7579, DOI 10.1038/sj.onc.1204953; Belzacq AS, 2001, CANCER RES, V61, P1260; Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; Beutner G, 1998, BBA-BIOMEMBRANES, V1368, P7, DOI 10.1016/S0005-2736(97)00175-2; Birbes H, 2001, FASEB J, V15, P2669, DOI 10.1096/fj.01-0539com; Bottero V, 2001, J BIOL CHEM, V276, P21317, DOI 10.1074/jbc.M005850200; BOYA P, 2002, IN PRESS CELL DEATH; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; Britten CD, 2000, CLIN CANCER RES, V6, P42; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; CARRE M, 2002, J BIOL CHEM, V26, P26; Casellas P, 2002, NEUROCHEM INT, V40, P475, DOI 10.1016/S0197-0186(01)00118-8; Chandra J, 2002, BLOOD, V99, P655, DOI 10.1182/blood.V99.2.655; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; CHEN LB, 1988, ANNU REV CELL BIOL, V4, P155, DOI 10.1146/annurev.cb.04.110188.001103; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Chi KN, 2001, CLIN CANCER RES, V7, P3920; CLARKE SJ, 2002, J BIOL CHEM, V2, P2; Coller HA, 2001, NAT GENET, V28, P147, DOI 10.1038/88859; Costantini P, 2000, ONCOGENE, V19, P307, DOI 10.1038/sj.onc.1203299; Costantini P, 2000, J NATL CANCER I, V92, P1042, DOI 10.1093/jnci/92.13.1042; Crompton M, 2000, J PHYSIOL-LONDON, V529, P11, DOI 10.1111/j.1469-7793.2000.00011.x; Danielson SR, 2002, J BIOL CHEM, V277, P5810, DOI 10.1074/jbc.M110119200; De Lena M, 2001, EUR J CANCER, V37, P364, DOI 10.1016/S0959-8049(00)00400-7; de Pablo MA, 1999, APOPTOSIS, V4, P81, DOI 10.1023/A:1009694124241; Decaudin D, 2002, CANCER RES, V62, P1388; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; Donald SP, 2001, CANCER RES, V61, P1810; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Ellerby HM, 1999, NAT MED, V5, P1032, DOI 10.1038/12469; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Fernandez-Salas E, 2002, MOL CELL BIOL, V22, P3610, DOI 10.1128/MCB.22.11.3610-3620.2002; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Ferri KF, 2000, J EXP MED, V192, P1081, DOI 10.1084/jem.192.8.1081; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Fulda S, 1998, CANCER RES, V58, P4453; Fulda S, 1998, J BIOL CHEM, V273, P33942, DOI 10.1074/jbc.273.51.33942; Fulda S, 2001, ONCOGENE, V20, P1063, DOI 10.1038/sj.onc.1204141; Fulda S, 2000, MED PEDIATR ONCOL, V35, P616, DOI 10.1002/1096-911X(20001201)35:6<616::AID-MPO27>3.0.CO;2-N; Gajate C, 2001, BLOOD, V98, P3860, DOI 10.1182/blood.V98.13.3860; Genini D, 2000, BLOOD, V96, P3537; Gincel D, 2001, BIOCHEM J, V358, P147, DOI 10.1042/0264-6021:3580147; Giraud S, 1998, J MOL BIOL, V281, P409, DOI 10.1006/jmbi.1998.1955; Gogvadze V, 2001, J BIOL CHEM, V276, P19066, DOI 10.1074/jbc.M100614200; GolshaniHebroni SG, 1997, J BIOENERG BIOMEMBR, V29, P331, DOI 10.1023/A:1022442629543; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Grinberg M, 2002, J BIOL CHEM, V277, P12237, DOI 10.1074/jbc.M104893200; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; GUO Y, 2002, J BIOL CHEM, V6, P6; Hail N, 2001, CANCER RES, V61, P6698; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Haridas V, 2001, P NATL ACAD SCI USA, V98, P11557, DOI 10.1073/pnas.191363498; Heiden MGV, 2001, J BIOL CHEM, V276, P19414, DOI 10.1074/jbc.M101590200; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Hirsch T, 1998, EXP CELL RES, V241, P426, DOI 10.1006/excr.1998.4084; Hossain K, 2000, J IMMUNOL, V165, P4290, DOI 10.4049/jimmunol.165.8.4290; Huang CS, 1999, CANCER RES, V59, P3053; Hwang PM, 2001, NAT MED, V7, P1111, DOI 10.1038/nm1001-1111; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; Ionov Y, 2000, P NATL ACAD SCI USA, V97, P10872, DOI 10.1073/pnas.190210897; Jacotot E, 2001, J EXP MED, V193, P509, DOI 10.1084/jem.193.4.509; Jan G, 2002, CELL DEATH DIFFER, V9, P179, DOI 10.1038/sj.cdd.4400935; Jansen B, 2000, LANCET, V356, P1728, DOI 10.1016/S0140-6736(00)03207-4; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Joza N, 2002, TRENDS GENET, V18, P142, DOI 10.1016/S0168-9525(01)02618-X; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; Kessel D, 2001, PHOTOCHEM PHOTOBIOL, V74, P346, DOI 10.1562/0031-8655(2001)074<0346:TROTPB>2.0.CO;2; Khaled AR, 2001, MOL CELL BIOL, V21, P7545, DOI 10.1128/MCB.21.22.7545-7557.2001; Kidd JF, 2002, J BIOL CHEM, V277, P6504, DOI 10.1074/jbc.M106802200; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kudla G, 2000, J BIOL CHEM, V275, P22713, DOI 10.1074/jbc.M003807200; Kumar S, 2001, J BIOL CHEM, V276, P17281, DOI 10.1074/jbc.M101414200; Larisch S, 2000, NAT CELL BIOL, V2, P915, DOI 10.1038/35046566; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Lehenkari PP, 2002, MOL PHARMACOL, V61, P1255, DOI 10.1124/mol.61.5.1255; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Li LW, 1999, MOL CELL BIOL, V19, P8547; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; LIN DT, 2002, J BIOL CHEM, V19, P19; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; MACHIDA K, 2002, J BIOL CHEM, V12, P12; MACHO A, 1995, BLOOD, V86, P2481; Madesh M, 2001, J CELL BIOL, V155, P1003, DOI 10.1083/jcb.200105057; Mannick JB, 2001, J CELL BIOL, V154, P1111, DOI 10.1083/jcb.200104008; Marchetti P, 1999, CANCER RES, V59, P6257; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Matsko CM, 2001, BIOCHEM BIOPH RES CO, V287, P1112, DOI 10.1006/bbrc.2001.5696; McClintock DS, 2002, MOL CELL BIOL, V22, P94, DOI 10.1128/MCB.22.1.94-104.2002; Miccoli L, 1998, J NATL CANCER I, V90, P1400, DOI 10.1093/jnci/90.18.1400; Miccoli L, 1998, CANCER RES, V58, P5777; ModicaNapolitano JS, 1996, CANCER RES, V56, P544; Motoori S, 2001, CANCER RES, V61, P5382; Muthumani K, 2002, ONCOGENE, V21, P4613, DOI 10.1038/sj.onc.1205549; Nagahara Y, 2000, J IMMUNOL, V165, P3250, DOI 10.4049/jimmunol.165.6.3250; Nakamura Y, 2002, J BIOL CHEM, V277, P8492, DOI 10.1074/jbc.M109760200; Nomura K, 1999, J BIOL CHEM, V274, P29294, DOI 10.1074/jbc.274.41.29294; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; Paradiso A, 2001, BRIT J CANCER, V84, P651, DOI 10.1054/bjoc.2000.1658; Pardo J, 2001, J IMMUNOL, V167, P1222, DOI 10.4049/jimmunol.167.3.1222; Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200; Pervaiz S, 1999, BLOOD, V93, P4096, DOI 10.1182/blood.V93.12.4096.412k44_4096_4108; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Qin ZH, 2001, J BIOL CHEM, V276, P8079, DOI 10.1074/jbc.M007028200; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Ravagnan L, 1999, ONCOGENE, V18, P2537, DOI 10.1038/sj.onc.1202625; Rippo MR, 2000, FASEB J, V14, P2047, DOI 10.1096/fj.99-1028com; Robertson JD, 2000, J BIOL CHEM, V275, P32438, DOI 10.1074/jbc.C000518200; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Sakurai K, 2001, J BIOL CHEM, V276, P26942, DOI 10.1074/jbc.M102029200; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schempp CM, 2002, ONCOGENE, V21, P1242, DOI 10.1038/sj.onc.1205190; Schendel SL, 1999, J BIOL CHEM, V274, P21932, DOI 10.1074/jbc.274.31.21932; Schlattner U, 2001, J BIOL CHEM, V276, P48027, DOI 10.1074/jbc.M106524200; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Scorrano L, 2001, J BIOL CHEM, V276, P12035, DOI 10.1074/jbc.M010603200; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Singh KK, 1999, ONCOGENE, V18, P6641, DOI 10.1038/sj.onc.1203056; Smith TAD, 2000, BRIT J BIOMED SCI, V57, P170; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Sordet O, 2001, BLOOD, V97, P3931, DOI 10.1182/blood.V97.12.3931; Sowter HM, 2001, CANCER RES, V61, P6669; Stahnke K, 2001, BLOOD, V98, P3066, DOI 10.1182/blood.V98.10.3066; Stoebner PE, 2001, CELL DEATH DIFFER, V8, P747, DOI 10.1038/sj.cdd.4400861; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Sturm I, 2001, J CLIN ONCOL, V19, P2272, DOI 10.1200/JCO.2001.19.8.2272; Sun SY, 1999, ONCOGENE, V18, P2357, DOI 10.1038/sj.onc.1202543; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Tai YT, 1998, J CLIN ONCOL, V16, P2583, DOI 10.1200/JCO.1998.16.8.2583; Takuma K, 2001, J BIOL CHEM, V276, P48093, DOI 10.1074/jbc.M108622200; Thomas DA, 2001, P NATL ACAD SCI USA, V98, P14985, DOI 10.1073/pnas.261581498; Tinhofer I, 2001, FASEB J, V15, P1613, DOI 10.1096/fj.00-0675fje; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vieira Helena L. A., 2002, Oncogene, V21, P1963, DOI 10.1038/sj.onc.1205270; Vieira HLA, 2001, ONCOGENE, V20, P4305, DOI 10.1038/sj.onc.1204575; Vieira HLA, 2000, CELL DEATH DIFFER, V7, P1146, DOI 10.1038/sj.cdd.4400778; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang JL, 2000, CANCER RES, V60, P1498; Wang JM, 2001, P NATL ACAD SCI USA, V98, P4038, DOI 10.1073/pnas.061038798; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Watabe M, 2000, CANCER RES, V60, P5214; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Williams SD, 2002, BIOCHEM J, V362, P23, DOI 10.1042/bj3620023; Xue L, 2002, P NATL ACAD SCI USA, V99, P6925, DOI 10.1073/pnas.102182299; Xue LY, 2001, ONCOGENE, V20, P3420, DOI 10.1038/sj.onc.1204441; Yu R, 2000, MOL PHARMACOL, V58, P431, DOI 10.1124/mol.58.2.431; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zamzami N, 2000, ONCOGENE, V19, P6342, DOI 10.1038/sj.onc.1204030; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761; Zhao M, 2001, NAT MED, V7, P1241, DOI 10.1038/nm1101-1241; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A; Zorov DB, 2000, J EXP MED, V192, P1001, DOI 10.1084/jem.192.7.1001	186	350	361	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2002	21	57					8786	8803		10.1038/sj.onc.1206039	http://dx.doi.org/10.1038/sj.onc.1206039			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483532				2022-12-28	WOS:000179734400013
J	Rowley, M; Van Ness, B				Rowley, M; Van Ness, B			Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: implications for disease progression and therapeutic response	ONCOGENE			English	Article						Ras; myeloma; therapeutic response	MULTIPLE-MYELOMA; GROWTH-FACTOR; APOPTOSIS; DEXAMETHASONE; MUTATIONS; DIFFERENTIATION; ONCOGENES; PROTEINS; COMPLEX; ANBL6	Ras is a major signaling molecule activated by interleukin-6. There have been no published reports, however, that specifically examine the kinetics and percentage of Ras activation in response to IL-6. Model cell lines were used to study activation of N- and K-ras induced by IL-6. All of the myeloma cell lines we tested express both N-ras and K-ras, but not H-ras. GTP-bound Ras was measured and the percentage of the total Ras pool that was activated in response to IL-6 was calculated. IL-6 is able to transiently activate both Nand K-ras in the ANBL6 cell tine. In addition, increasing concentrations of IL-6 are able to activate increasing levels of both N- and K-ras. One ng/ml of IL-6 is able to activate approximately 10% of the N-ras pool and 18% of the K-ras pool. The amount of Ras-GTP in the cells correlates with the level of proliferation at low levels, but proliferation plateaus when higher levels of Ras-GTP are present. Protection from dexamethasone-induced apoptosis correlates with IL-6 concentration and Ras activation. However, IL-6 enhances apoptosis induced by doxorubicin. Interestingly, the ANBL6 cell line transfected with an N-ras12 or a K-ras12 gene is protected from doxorubicin-induced apoptosis.	Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA; Univ Minnesota, Grad Program Mol Cellular Dev Biol & Genet, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Van Ness, B (corresponding author), Canc Ctr Res Bldg,Mayo Mail Code 806, Minneapolis, MN 55455 USA.				NCI NIH HHS [P01CA62242] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA062242] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATAILLE R, 1989, J CLIN INVEST, V84, P2008, DOI 10.1172/JCI114392; Billadeau D, 1997, CANCER RES, V57, P2268; BILLADEAU D, 1995, CANCER RES, V55, P3640; Brownell HL, 1997, DNA CELL BIOL, V16, P103, DOI 10.1089/dna.1997.16.103; Chauhan D, 1997, J BIOL CHEM, V272, P29995, DOI 10.1074/jbc.272.48.29995; Chauhan D, 1997, ONCOGENE, V15, P837, DOI 10.1038/sj.onc.1201253; CORRADINI P, 1993, EMBO J, V16, P6439; Hall A, 1998, SCIENCE, V280, P2074, DOI 10.1126/science.280.5372.2074; HARDIN J, 1994, BLOOD, V84, P3063; HATA Y, 1993, ONCOL RES, V5, P161; Hirano Toshio, 1997, Cytokine and Growth Factor Reviews, V8, P241, DOI 10.1016/S1359-6101(98)80005-1; Jones MK, 1998, J BIOL CHEM, V273, P1782, DOI 10.1074/jbc.273.3.1782; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KLEIN B, 1989, BLOOD, V73, P517; LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076; Liu PC, 1996, BLOOD, V88, P2699, DOI 10.1182/blood.V88.7.2699.bloodjournal8872699; MCCLOSKEY TW, 1994, CLIN IMMUNOL IMMUNOP, V71, P14, DOI 10.1006/clin.1994.1045; McCormick F, 1996, NAT STRUCT BIOL, V3, P653, DOI 10.1038/nsb0896-653; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; NERI A, 1989, J EXP MED, V170, P1715, DOI 10.1084/jem.170.5.1715; PAQUETTE RL, 1990, ONCOGENE, V5, P1659; PORTIER M, 1992, ONCOGENE, V7, P2539; Rowley M, 2000, BLOOD, V96, P3175, DOI 10.1182/blood.V96.9.3175.h8003175_3175_3180; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9	25	26	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 12	2002	21	57					8769	8775		10.1038/sj.onc.1205387	http://dx.doi.org/10.1038/sj.onc.1205387			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483530				2022-12-28	WOS:000179734400011
J	Miranda, C; Zanotti, G; Pagliardinil, S; Ponzetto, C; Pierotti, MA; Greco, A				Miranda, C; Zanotti, G; Pagliardinil, S; Ponzetto, C; Pierotti, MA; Greco, A			Gain of function mutations of RTK conserved residues display differential effects on NTRK1 kinase activity	ONCOGENE			English	Article						tyrosine kinase receptors; NTRK1; oncogenic; activation	RECEPTOR TYROSINE KINASE; NERVE GROWTH-FACTOR; LIGAND-INDEPENDENT ACTIVATION; PROTOONCOGENE C-KIT; CONGENITAL INSENSITIVITY; POINT MUTATION; DOMAIN; CELLS; TRK; IDENTIFICATION	Activation of tyrosine kinase receptors is associated with human tumors. Tumorigenic versions of several RTKs, such as Ret, Kit and Met carry activating mutations at highly conserved residues of the tyrosine kinase domain. We have investigated the effect of some of these mutations on the NTRK1/NGF receptor, for which no naturally occurring activating point mutations have been so far detected. We introduced the following mutations in NTRK1 tyrosine kinase domain: (i) D668N equivalent to Met D1246N associated to HPRC; (ii) D668V modelled on Kit D816V found in mastocytosis; (iii) M688T corresponding to Ret M918T associated to the cancer syndrome MEN2B. The Met-like mutation rendered the NTRK1 receptor more responsive to ligand, as observed for the corresponding mutation in Met. On the contrary the Kit-like D668V resulted as neutral mutation. Surprisingly, the MEN213-like M688T completely abrogated NTRK1 receptor activity, resulting as a loss of function mutation. Our results show that the mutations tested, although involving conserved amino acids in highly homologous regions, exert distinct effects in different receptors, and suggest a very peculiar auto-inhibitory mechanism for NTRK1.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Univ Padua, Dept Organ Chem, I-35131 Padua, Italy; Univ Turin, Dept Anat & Pharmacol, I-10126 Turin, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Padua; University of Turin	Greco, A (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via G Venezian 1, I-20133 Milan, Italy.		Pierotti, Marco Alessandro/AAC-4728-2022; Greco, Angela/C-1953-2017	Pierotti, Marco Alessandro/0000-0002-7431-8332; Greco, Angela/0000-0003-2994-0349; Zanotti, Giuseppe/0000-0002-0945-6501				CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; Cunningham ME, 1998, EMBO J, V17, P7282, DOI 10.1093/emboj/17.24.7282; Descamps S, 1998, J BIOL CHEM, V273, P16659, DOI 10.1074/jbc.273.27.16659; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; GRECO A, 1995, MOL CELL BIOL, V15, P6118; Greco A, 2000, J CELL PHYSIOL, V182, P127, DOI 10.1002/(SICI)1097-4652(200001)182:1<127::AID-JCP14>3.0.CO;2-0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; Indo Y, 2001, HUM MUTAT, V18, P462, DOI 10.1002/humu.1224; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Maritano D, 2000, ONCOGENE, V19, P1354, DOI 10.1038/sj.onc.1203431; Miknyoczki SJ, 1999, INT J CANCER, V81, P417, DOI 10.1002/(SICI)1097-0215(19990505)81:3<417::AID-IJC16>3.0.CO;2-6; Miranda C, 2002, J BIOL CHEM, V277, P6455, DOI 10.1074/jbc.M110016200; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; Pierotti MA, 1996, GENE CHROMOSOME CANC, V16, P1; Reuther GW, 2000, MOL CELL BIOL, V20, P8655, DOI 10.1128/MCB.20.23.8655-8666.2000; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Tagliabue E, 1999, INT J BIOL MARKER, V14, P68, DOI 10.1177/172460089901400203; Till JH, 2001, J BIOL CHEM, V276, P10049, DOI 10.1074/jbc.M010161200; TSUJIMURA T, 1994, BLOOD, V83, P2619; VANHEYNINGEN V, 1994, NATURE, V367, P319, DOI 10.1038/367319a0; Weeraratna AT, 2001, CLIN CANCER RES, V7, P2237	24	5	5	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 28	2002	21	54					8334	8339		10.1038/sj.onc.1206052	http://dx.doi.org/10.1038/sj.onc.1206052			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447696				2022-12-28	WOS:000179323900011
J	Robinson, SJ; Healy, E				Robinson, SJ; Healy, E			Human melanocortin 1 receptor (MC1R) gene variants alter melanoma cell growth and adhesion to extracellular matrix	ONCOGENE			English	Article						melanocortin 1 receptor; melanoma; proliferation; fibronectin	STIMULATING HORMONE IMMUNOREACTIVITY; INHIBITS EXPERIMENTAL METASTASIS; 1 RECEPTOR MC1R; MSH RECEPTOR; HUMAN MELANOCYTES; COAT COLOR; ALPHA-MELANOTROPIN; FAIR SKIN; RISK; EXPRESSION	Pigmentation is a significant determinant of individual susceptibility to cutaneous melanoma, with fair skinned subjects at highest risk of developing this neoplasm. Melanocortin 1 receptor (MC1R) gene variants alter pigment synthesis in vivo, and are causally associated with red hair and fair skin in humans. MC1R variants are more frequent in subjects with melanoma, and increase the risk of developing this tumour in sporadic and familial cases. MC1R variants may predispose to melanoma as a result of alterations in skin pigmentation (which affords less protection against incident ultraviolet radiation). However, melanoma cells synthesize and release alpha-melanocyte stimulating hormone (alphaMSH, the ligand for MC1R), therefore MC1R variants could alter the autocrine effects of alphaMSH on melanoma cell behaviour, thereby affecting early melanoma development and progression via non-pigmentary mechanisms. B16G4F melanoma cells, which are functionally null at Mc1r, were stably transfected with wild type and variant (Arg151Cys, Arg160Trp, and Asp294His) human MC1R. At similar MO receptor numbers per cell, aMSH increased intracellular cAMP in wild type MC1R transfected melanoma cells, but the cAMP response was compromised in the variant MCIR transfected clones. In growth inhibition experiments, alphaMSH significantly reduced growth of wild type MC1R transfected cells, but had no effect on cells transfected with variant MC1R. In addition, binding to fibronectin was significantly reduced by alphaMSH in the wild type transfectants whereas this was not observed in the variant transfected clones; binding to laminin was not affected by aMSH in this cell tine. These results provide evidence for differences in melanoma cell behaviour secondary to MC1R variants, and suggest an alternative non-pigmentary mechanism whereby MC1R variants could modify melanoma susceptibility or progression.	Univ Southampton, Southampton Gen Hosp, Sch Med, Southampton SO16 6YD, Hants, England	University of Southampton	Healy, E (corresponding author), Univ Southampton, Southampton Gen Hosp, Sch Med, Mailpoint 825, Southampton SO16 6YD, Hants, England.	ehealy@soton.ac.uk		Healy, Eugene/0000-0001-5591-6970	MRC [G116/122] Funding Source: UKRI; Medical Research Council [G116/122] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abdel-Malek ZA, 2001, CELL MOL LIFE SCI, V58, P434, DOI 10.1007/PL00000868; Andersen GN, 2001, CLIN EXP IMMUNOL, V126, P441, DOI 10.1046/j.1365-2249.2001.01604.x; Bastiaens MT, 2001, AM J HUM GENET, V68, P884, DOI 10.1086/319500; Box NF, 2001, AM J HUM GENET, V69, P765, DOI 10.1086/323412; Box NF, 2001, J INVEST DERMATOL, V116, P224, DOI 10.1046/j.1523-1747.2001.01224.x; Box NF, 1997, HUM MOL GENET, V6, P1891, DOI 10.1093/hmg/6.11.1891; Chluba-de Tapia J, 1996, J CELL SCI, V109, P2023; CHLUBADETAPIA J, 1995, J RECEPT SIGNAL TR R, V15, P43; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Corbin JD, 1999, J BIOL CHEM, V274, P13729, DOI 10.1074/jbc.274.20.13729; CROMBIE IK, 1979, BRIT J CANCER, V40, P185, DOI 10.1038/bjc.1979.165; Flanagan N, 2000, HUM MOL GENET, V9, P2531, DOI 10.1093/hmg/9.17.2531; GHANEM G, 1989, PIGM CELL RES, V2, P519, DOI 10.1111/j.1600-0749.1989.tb00248.x; HAAKE AR, 1999, DERMATOLOGY GEN MED, P70; Harding RM, 2000, AM J HUM GENET, V66, P1351, DOI 10.1086/302863; Haycock JW, 1999, J INVEST DERMATOL, V113, P560, DOI 10.1046/j.1523-1747.1999.00739.x; Healy E, 2001, HUM MOL GENET, V10, P2397, DOI 10.1093/hmg/10.21.2397; Healy E, 2000, LANCET, V355, P1072, DOI 10.1016/S0140-6736(00)02042-0; Hedley SJ, 1998, BRIT J DERMATOL, V138, P536; HUMPHRIES MJ, 1986, SCIENCE, V233, P467, DOI 10.1126/science.3726541; IWAMOTO Y, 1987, SCIENCE, V238, P1132, DOI 10.1126/science.2961059; Jiang JW, 1995, PIGM CELL RES, V8, P314, DOI 10.1111/j.1600-0749.1995.tb00680.x; Jimenez-Cervantes C, 2001, J INVEST DERMATOL, V117, P156, DOI 10.1046/j.0022-202x.2001.01393.x; KAIDBEY KH, 1979, J AM ACAD DERMATOL, V1, P249, DOI 10.1016/S0190-9622(79)70018-1; Karjalainen JM, 1998, BRIT J CANCER, V77, P1917, DOI 10.1038/bjc.1998.318; Kennedy C, 2001, J INVEST DERMATOL, V117, P294, DOI 10.1046/j.0022-202x.2001.01421.x; Kijas JMH, 2001, GENETICS, V158, P779; KLUNGLAND H, 1995, MAMM GENOME, V6, P636, DOI 10.1007/BF00352371; LEGROS F, 1981, CANCER RES, V41, P1539; Loir B, 1998, EUR J CANCER, V34, P424, DOI 10.1016/S0959-8049(97)10016-8; Luger TA, 2000, ANN NY ACAD SCI, V917, P232; LUNEC J, 1990, PATHOBIOLOGY, V58, P193, DOI 10.1159/000163583; Marklund L, 1996, MAMM GENOME, V7, P895, DOI 10.1007/s003359900264; Morandini R, 1998, J CELL PHYSIOL, V175, P276, DOI 10.1002/(SICI)1097-4652(199806)175:3<276::AID-JCP5>3.0.CO;2-L; MORETTI S, 1990, J INVEST DERMATOL, V95, P320, DOI 10.1111/1523-1747.ep12485060; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; Murata J, 1997, INVAS METAST, V17, P82; NESBIT M, 1994, INVAS METAST, V14, P131; Newton JM, 2000, MAMM GENOME, V11, P24, DOI 10.1007/s003350010005; Palmer JS, 2000, AM J HUM GENET, V66, P176, DOI 10.1086/302711; RAMPEN FHJ, 1988, ARCH DERMATOL, V124, P885, DOI 10.1001/archderm.124.6.885; RAMSAY JA, 1995, J INVEST DERMATOL, V105, P22, DOI 10.1111/1523-1747.ep12312431; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; RomeroGraillet C, 1996, J BIOL CHEM, V271, P28052, DOI 10.1074/jbc.271.45.28052; SAWYER TK, 1980, P NATL ACAD SCI-BIOL, V77, P5754, DOI 10.1073/pnas.77.10.5754; Schioth HB, 1999, BIOCHEM BIOPH RES CO, V260, P488, DOI 10.1006/bbrc.1999.0935; Smalley K, 2000, FEBS LETT, V476, P198, DOI 10.1016/S0014-5793(00)01726-9; Smith R, 1998, J INVEST DERMATOL, V111, P119, DOI 10.1046/j.1523-1747.1998.00252.x; SOLCA FF, 1993, FEBS LETT, V322, P177, DOI 10.1016/0014-5793(93)81563-F; Takeuchi S, 1996, BBA-GENE STRUCT EXPR, V1308, P164, DOI 10.1016/0167-4781(96)00100-5; TERRANOVA VP, 1984, SCIENCE, V226, P982, DOI 10.1126/science.6505678; THODY AJ, 1993, ANN NY ACAD SCI, V680, P381, DOI 10.1111/j.1749-6632.1993.tb19696.x; Vage DI, 1997, NAT GENET, V15, P311, DOI 10.1038/ng0397-311; Vage DI, 1999, MAMM GENOME, V10, P39, DOI 10.1007/s003359900939; Valverde P, 1996, HUM MOL GENET, V5, P1663, DOI 10.1093/hmg/5.10.1663; VALVERDE P, 1995, NAT GENET, V11, P328, DOI 10.1038/ng1195-328; van der Velden PA, 2001, AM J HUM GENET, V69, P774, DOI 10.1086/323411; WEINSTOCK MA, 1991, AM J EPIDEMIOL, V133, P240, DOI 10.1093/oxfordjournals.aje.a115868	58	51	51	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2002	21	52					8037	8046		10.1038/sj.onc.1205913	http://dx.doi.org/10.1038/sj.onc.1205913			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	612VY	12439754				2022-12-28	WOS:000179097200013
J	Budunova, IV; Kowalczyk, D; Perez, P; Yao, YJ; Jorcano, JL; Slaga, TJ				Budunova, IV; Kowalczyk, D; Perez, P; Yao, YJ; Jorcano, JL; Slaga, TJ			Glucocorticoid receptor functions as a potent suppressor of mouse skin carcinogenesis	ONCOGENE			English	Article						glucocorticoid receptor; transgenic mice; skin carcinogenesis; NF-kappa B	NF-KAPPA-B; TRANSGENIC TG.AC MICE; CELL-CYCLE; TRANSCRIPTION FACTORS; TUMOR PROMOTION; ONCOGENIC RAS; ORNITHINE DECARBOXYLASE; PAPILLOMA DEVELOPMENT; DNA-BINDING; EXPRESSION	Glucocorticoids are effective inhibitors of epidermal proliferation and skin tumorigenesis. Glucocorticoids affect cellular functions via glucocorticoid receptor (GR), a well-known transcription factor. Recently, we generated skin-targeted transgenic mice overexpressing GR under control of the keratin5 promoter (K5-GR mice). To test the hypothesis that GR plays a role as a tumor suppressor in skin, we bred K5-GR transgenic mice with Tg.AC transgenic mice, which express v-Ha-ras oncogene in the skin, and compared the susceptibility of F1 offspring to TPA-induced skin carcinogenesis. GR overexpression in the epidermis dramatically inhibited skin tumor development. In K5-GR/ras+ double transgenic mice papillomas developed later and the average number of tumors per animal was 15% (in males) and 40% (in females) of the number seen in wild type (w.t./ras+) littermates. In addition, the papillomas in w.t./ras+ animals were eight to nine times larger. GR overexpression resulted in a decrease in keratinocyte proliferation combined with a modest increase in apoptosis and differentiation of keratinocytes in K5-GR/ras+ papillomas. Our data clearly indicate that interference of GR transgenic protein with nuclear factor kappa B (NF-kappaB) transcription factor had resulted in NF-kappaB blockage in K5-GR/ras + tumors. We discuss the role of NF-kappaB blockage in tumor-suppressor effect of GR.	AMC Canc Res Ctr, Denver, CO 80214 USA; CSIC, Inst Biomed Valencia, E-46010 Valencia, Spain; CIEMAT, Project Cell & Mol Biol & Gene Therapy, E-28040 Madrid, Spain	AMC Cancer Research Center; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biomedicina de Valencia (IBV); Centro de Investigaciones Energeticas, Medioambientales Tecnologicas	Budunova, IV (corresponding author), AMC Canc Res Ctr, 1600 Pierce St, Denver, CO 80214 USA.	budunovai@amc.org	Perez, Paloma/K-8841-2017	Perez, Paloma/0000-0002-7166-2824	NATIONAL CANCER INSTITUTE [R01CA079065] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA-79065-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adcock IM, 2001, PULM PHARMACOL THER, V14, P211, DOI 10.1006/pupt.2001.0283; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Battalora MS, 2001, CARCINOGENESIS, V22, P651, DOI 10.1093/carcin/22.4.651; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Binder RL, 1998, CANCER RES, V58, P4314; Budunova IV, 1997, MOL CARCINOGEN, V18, P177, DOI 10.1002/(SICI)1098-2744(199703)18:3<177::AID-MC7>3.3.CO;2-U; Budunova IV, 1999, ONCOGENE, V18, P7423, DOI 10.1038/sj.onc.1203104; Cannon RE, 1997, MOL CARCINOGEN, V20, P108, DOI 10.1002/(SICI)1098-2744(199709)20:1<108::AID-MC12>3.0.CO;2-5; Cannon RE, 1998, MOL CARCINOGEN, V21, P244, DOI 10.1002/(SICI)1098-2744(199804)21:4<244::AID-MC3>3.0.CO;2-K; Cha HH, 1998, J BIOL CHEM, V273, P1998, DOI 10.1074/jbc.273.4.1998; DIGIOVANNI J, 1992, CARCINOGENESIS, V13, P525, DOI 10.1093/carcin/13.4.525; DIGIOVANNI J, 1988, CARCINOGENESIS, V9, P1445, DOI 10.1093/carcin/9.8.1445; Distelhorst CW, 2002, CELL DEATH DIFFER, V9, P6, DOI 10.1038/sj.cdd.4400969; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; FISCHER SM, 1989, CANCER RES, V49, P6693; Greenstein S, 2002, CLIN CANCER RES, V8, P1681; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; HANSEN LA, 1994, MOL CARCINOGEN, V9, P143, DOI 10.1002/mc.2940090306; HENNINGS H, 1987, MULTISTEP MODELS CAR, P59; Honchel R, 2001, MOL CARCINOGEN, V30, P99, DOI 10.1002/1098-2744(200102)30:2<99::AID-MC1018>3.3.CO;2-Z; Jehn BM, 1997, CRIT REV EUKAR GENE, V7, P179, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.100; Jol H, 2000, ONCOGENE, V19, P841, DOI 10.1038/sj.onc.1203392; Larcher F, 1998, ONCOGENE, V17, P303, DOI 10.1038/sj.onc.1201928; Ma SH, 1997, GENE EXPRESSION, V6, P361; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Mayo MW, 2001, METHOD ENZYMOL, V333, P73; Morris RJ, 2000, J CLIN INVEST, V106, P3, DOI 10.1172/JCI10508; NAITO M, 1988, CARCINOGENESIS, V9, P639, DOI 10.1093/carcin/9.4.639; Nalca A, 1999, J BIOL CHEM, V274, P29976, DOI 10.1074/jbc.274.42.29976; NESNOW S, 1986, ENVIRON HEALTH PERSP, V68, P19, DOI 10.1289/ehp.866819; Park JH, 2001, INT J ONCOL, V18, P997; Perez P, 2000, MOL CARCINOGEN, V27, P272, DOI 10.1002/(SICI)1098-2744(200004)27:4<272::AID-MC5>3.0.CO;2-P; Perez P, 2001, FASEB J, V15, P2030, DOI 10.1096/fj.00-0772fje; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; Radoja N, 2000, MOL CELL BIOL, V20, P4328, DOI 10.1128/MCB.20.12.4328-4339.2000; Ramalingam A, 1997, MOL ENDOCRINOL, V11, P577, DOI 10.1210/me.11.5.577; Reichardt HM, 2001, EMBO J, V20, P7168, DOI 10.1093/emboj/20.24.7168; ROBELS AI, 1995, CARCINOGENESIS, V16, P781, DOI 10.1093/carcin/16.4.781; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Rogatsky I, 1999, MOL CELL BIOL, V19, P5036; Rogatsky I, 1997, MOL CELL BIOL, V17, P3181, DOI 10.1128/MCB.17.6.3181; Samuelsson MKR, 1999, MOL ENDOCRINOL, V13, P1811, DOI 10.1210/me.13.11.1811; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHWARZ JA, 1977, CHEM-BIOL INTERACT, V17, P331, DOI 10.1016/0009-2797(77)90096-5; SLAGA TJ, 1984, MODELS MECH ETIOLOGY, P497; Smith E, 2000, J BIOL CHEM, V275, P19992, DOI 10.1074/jbc.M001758200; Smith MK, 1998, CARCINOGENESIS, V19, P1409, DOI 10.1093/carcin/19.8.1409; SPALDING JW, 1993, CARCINOGENESIS, V14, P1335, DOI 10.1093/carcin/14.7.1335; Spiegelman VS, 1997, MOL CARCINOGEN, V20, P99, DOI 10.1002/(SICI)1098-2744(199709)20:1<99::AID-MC11>3.0.CO;2-4; STRAWHECKER JM, 1992, CARCINOGENESIS, V13, P2075, DOI 10.1093/carcin/13.11.2075; Takuwa N, 2001, MOL CELL ENDOCRINOL, V177, P25, DOI 10.1016/S0303-7207(01)00439-7; Terada Y, 2001, KIDNEY INT, V59, P1706, DOI 10.1046/j.1523-1755.2001.0590051706.x; Thompson KL, 1998, TOXICOL PATHOL, V26, P548, DOI 10.1177/019262339802600411; Tuckermann JP, 1999, J CELL BIOL, V147, P1365, DOI 10.1083/jcb.147.7.1365; VERMA AK, 1983, CANCER RES, V43, P3045	56	28	29	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2003	22	21					3279	3287		10.1038/sj.onc.1206383	http://dx.doi.org/10.1038/sj.onc.1206383			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681MM	12761498				2022-12-28	WOS:000183040000010
J	Bianco, R; Shin, I; Ritter, CA; Yakes, FM; Basso, A; Rosen, N; Tsurutani, J; Dennis, PA; Mills, GB; Arteaga, CL				Bianco, R; Shin, I; Ritter, CA; Yakes, FM; Basso, A; Rosen, N; Tsurutani, J; Dennis, PA; Mills, GB; Arteaga, CL			Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors	ONCOGENE			English	Article						epidermal growth factor receptor; ZD1839; PTEN; tyrosine kinase inhibitors; Akt	GROWTH-FACTOR RECEPTOR; BREAST-CANCER; PHOSPHATIDYLINOSITOL 3-KINASE; ZD1839 IRESSA; CELLULAR-SURVIVAL; REGULATED KINASES; CYCLE PROGRESSION; UP-REGULATION; AKT; GENE	We have examined the possible mechanisms of resistance to the epidermal growth factor receptor (EGFR) inhibitors in tumor cells with variable levels of EGFR. ZD1839 (Iressa) is a small-molecular-weight, ATP-mimetic that specifically inhibits the EGFR tyrosine kinase. A431 cell growth was markedly inhibited by ZD1839 (IC(50)less than or equal to0.1 muM) whereas the MDA-468 cells were relatively resistant (IC50>2 muM). Low doses of ZD1839 delayed cell cycle progression and induced apoptosis in A431 cells but not in MDA-468 cells. In both cell tines, 0.1 muM ZD1839 eliminated EGFR phosphorylation. However, the basal activity of the phosphatidytinositol-3 kinase (PI3 K) target Akt was eliminated in A431 but not in MDA-468 cells, implying that their Akt activity is independent of EGFR signals. A431 cells express PTEN/MMAC1/TEP, a phosphatase that can dephosphorylate position D3 of phosphatidytinositol-3,4,5 trisphosphate, the site that recruits the plecstrin-homology domain of Akt to the cell membrane. On the contrary, MDA-468 cells lack the phosphatase and tensin homolog (PTEN), potentially setting Akt activity at a high threshold that is unresponsive to EGFR inhibition alone. Therefore, we reintroduced (PTEN) by retroviral infection in MDA-468 cells. In MDA-468/PTEN but not in vector controls, treatment with ZD1839 inhibited P-Akt levels, induced relocalization of the Forkbead factor FKHRL1 to the cell nucleus, and increased FKHRL1-dependent transcriptional activity. ZD1839 induced a greater degree of apoptosis and cell cycle delay in PTEN-reconstituted than in control cells. These data suggest that loss of PTEN, by permitting a high level of Akt activity independent of receptor tyrosine kinase inputs, can temporally dissociate the inhibition of the EGFR with that of Akt induced by EGFR inhibitors. Thus, in EGFR-expressing tumor cells with concomitant amplification(s) of PI3K-Akt signaling, combined blockade of the EGFR tyrosine kinase and Akt should be considered as a therapeutic approach.	Vanderbilt Univ, Sch Med, Dept Med, Div Oncol, Nashville, TN 37232 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Cell Biol & Genet, New York, NY 10021 USA; NCI, Ctr Canc Res, Bethesda, MD 20892 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77030 USA; Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA	Vanderbilt University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Texas System; UTMD Anderson Cancer Center; Vanderbilt University; Vanderbilt University	Arteaga, CL (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, Div Oncol, 2220 Pierce Ave,777 Preston Res Bldg, Nashville, TN 37232 USA.	carlos.arteaga@vanderbilt.edu	Rosen, Neal/ABF-2677-2020		NATIONAL CANCER INSTITUTE [R01CA080195, P30CA068485, Z01SC010292] Funding Source: NIH RePORTER; NCI NIH HHS [CA68485, R01 CA80195] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albanell J, 2001, CANCER RES, V61, P6500; Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; Arteaga CL, 2001, J CLIN ONCOL, V19, p32S; Baselga J, 2002, J CLIN ONCOL, V20, P4292, DOI 10.1200/JCO.2002.03.100; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; Brognard J, 2001, CANCER RES, V61, P3986; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Busse D, 2000, J BIOL CHEM, V275, P6987, DOI 10.1074/jbc.275.10.6987; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; Chakravarti A, 2002, CANCER RES, V62, P200; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; D'Cruz CM, 2001, NAT MED, V7, P235, DOI 10.1038/84691; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; ENNIS BW, 1989, MOL ENDOCRINOL, V3, P1830, DOI 10.1210/mend-3-11-1830; Fan Z, 1997, CLIN CANCER RES, V3, P1943; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; Forgacs E, 1998, ONCOGENE, V17, P1557, DOI 10.1038/sj.onc.1202070; Fry MJ, 2001, BREAST CANCER RES, V3, P304, DOI 10.1186/bcr312; Goldstein NI, 1995, CLIN CANCER RES, V1, P1311; Grignani F, 1998, CANCER RES, V58, P14; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Hermanto U, 2001, ONCOGENE, V20, P7551, DOI 10.1038/sj.onc.1204964; Kohno T, 1998, GENE CHROMOSOME CANC, V22, P152, DOI 10.1002/(SICI)1098-2264(199806)22:2<152::AID-GCC10>3.0.CO;2-S; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; Lenferink AEG, 2000, P NATL ACAD SCI USA, V97, P9609, DOI 10.1073/pnas.160564197; Lenferink AEG, 2001, CANCER RES, V61, P6583; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Lu YH, 2001, JNCI-J NATL CANCER I, V93, P1852, DOI 10.1093/jnci/93.24.1852; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Moasser MM, 2001, CANCER RES, V61, P7184; Moulder SL, 2001, CANCER RES, V61, P8887; Moyer JD, 1997, CANCER RES, V57, P4838; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; Nelson JM, 2001, J BIOL CHEM, V276, P14842, DOI 10.1074/jbc.M008786200; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Perren A, 1999, AM J PATHOL, V155, P1253, DOI 10.1016/S0002-9440(10)65227-3; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Shin I, 2001, MOL BIOL CELL, V12, P3328, DOI 10.1091/mbc.12.11.3328; Simpson SJ, 2000, ADV STUD BEHAV, V29, P1, DOI 10.1016/S0065-3454(08)60102-3; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Sun M, 2001, CANCER RES, V61, P5985; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Teng DHF, 1997, CANCER RES, V57, P5221; VANDEVIJVER MJ, 1991, J BIOL CHEM, V266, P7503; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719; Wakeling AE, 2002, CANCER RES, V62, P5749; Yakes FM, 2002, CANCER RES, V62, P4132; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	58	384	417	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2003	22	18					2812	2822		10.1038/sj.onc.1206388	http://dx.doi.org/10.1038/sj.onc.1206388			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ	12743604				2022-12-28	WOS:000182569300012
J	Bowers, AJ; Scully, S; Boylan, JF				Bowers, AJ; Scully, S; Boylan, JF			SKIP3, a novel Drosophila tribbles ortholog, is overexpressed in human tumors and is regulated by hypoxia	ONCOGENE			English	Article						SKIP3; ATF4; hypoxia; tumor; gene expression	ACTIVATING TRANSCRIPTION FACTOR-4; LEUCINE-ZIPPER PROTEINS; CAMP RESPONSE ELEMENT; DNA-BINDING; GENE; ATF4; IDENTIFICATION; MORPHOGENESIS; EXPRESSION; INTERACT	Regions of hypoxia are a hallmark of solid tumors. Tumor cells modulate the regulation of specific genes allowing adaptation and survival in the harsh hypoxic environment. We have identified SKIP3, a novel human kinase-like gene, which is overexpressed in multiple human tumors and is regulated by hypoxia. SKIP3 is an ortholog of the Drosophila tribbles, rat NIPK, dog C5FW, and human C8FW genes. Drosophila tribbles is involved in slowing cell-cycle progression during Drosophila development, but little is known regarding the function or tissue distribution of the vertebrate orthologs. We show that the normal tissue expression of SKIP3 is confined to human liver, while multiple primary human lung, colon, and breast tumors express high levels of SKIP3 transcript. Endogenous SKIP3 protein accumulates within 48 h under hypoxic growth conditions in HT-29 and PC-3 cells, with upregulation of the SKIP3 mRNA transcript by 72 h. We identified activating transcription factor 4 (ATF4) as a SKIP3-binding partner using the yeast-two-hybrid assay. Coexpression of SKIP3 and ATF4 showed that SKIP3 is associated with the proteolysis of ATF4, which can be blocked using a proteosome inhibitor. These results indicate that SKIP3 may be an important participant in tumor cell growth.	Amgen Inc, Dept Canc Biol, Thousand Oaks, CA 91320 USA; Amgen Inc, Dept Pathol, Thousand Oaks, CA 91320 USA	Amgen; Amgen	Boylan, JF (corresponding author), Amgen Inc, Dept Canc Biol, 1 Amgen Ctr Dr, Thousand Oaks, CA 91320 USA.		Bowers, Alex J./C-1557-2013	Bowers, Alex J./0000-0002-5140-6428				AUSSERER WA, 1994, MOL CELL BIOL, V14, P5032, DOI 10.1128/MCB.14.8.5032; Butscher WG, 1998, J BIOL CHEM, V273, P552, DOI 10.1074/jbc.273.1.552; Eddy SR, 1996, CURR OPIN STRUC BIOL, V6, P361, DOI 10.1016/S0959-440X(96)80056-X; ESTES SD, 1995, EXP CELL RES, V220, P47, DOI 10.1006/excr.1995.1290; Fafournoux P, 2000, BIOCHEM J, V351, P1, DOI 10.1042/0264-6021:3510001; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; Gachon F, 2001, FEBS LETT, V502, P57, DOI 10.1016/S0014-5793(01)02646-1; Grosshans J, 2000, CELL, V101, P523, DOI 10.1016/S0092-8674(00)80862-4; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; He CH, 2001, J BIOL CHEM, V276, P20858, DOI 10.1074/jbc.M101198200; Hewes RS, 2000, GENETICS, V155, P1711; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; Kato Y, 1999, MOL CELL ENDOCRINOL, V154, P151, DOI 10.1016/S0303-7207(99)00078-7; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; Lal A, 2001, JNCI-J NATL CANCER I, V93, P1337, DOI 10.1093/jnci/93.17.1337; Lassot I, 2001, MOL CELL BIOL, V21, P2192, DOI 10.1128/MCB.21.6.2192-2202.2001; Liang GS, 1997, J BIOL CHEM, V272, P24088, DOI 10.1074/jbc.272.38.24088; Masuoka HC, 2002, BLOOD, V99, P736, DOI 10.1182/blood.V99.3.736; Mata J, 2000, CELL, V101, P511, DOI 10.1016/S0092-8674(00)80861-2; Mayumi-Matsuda K, 1999, BIOCHEM BIOPH RES CO, V258, P260, DOI 10.1006/bbrc.1999.0576; NISHIZAWA M, 1992, FEBS LETT, V299, P36, DOI 10.1016/0014-5793(92)80094-W; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; Reddy TR, 1997, ONCOGENE, V14, P2785, DOI 10.1038/sj.onc.1201119; Rorth P, 2000, MOL CELL, V6, P23; Saramaki OR, 2001, CANCER GENET CYTOGEN, V128, P31, DOI 10.1016/S0165-4608(01)00396-X; Seher TC, 2000, CURR BIOL, V10, P623, DOI 10.1016/S0960-9822(00)00502-9; Semenza GL, 2000, GENE DEV, V14, P1983; Tang KQ, 2000, BIOCHEMISTRY-US, V39, P3185, DOI 10.1021/bi992664v; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; Wadle A, 2001, ONCOGENE, V20, P5920, DOI 10.1038/sj.onc.1204797; WILCOX JN, 1993, J HISTOCHEM CYTOCHEM, V41, P1725, DOI 10.1177/41.12.8245419; Wilkin F, 1997, EUR J BIOCHEM, V248, P660, DOI 10.1111/j.1432-1033.1997.t01-1-00660.x; YAO KS, 1994, MOL CELL BIOL, V14, P5997, DOI 10.1128/MCB.14.9.5997; YAO KS, 1995, J NATL CANCER I, V87, P117, DOI 10.1093/jnci/87.2.117	38	120	128	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2003	22	18					2823	2835		10.1038/sj.onc.1206367	http://dx.doi.org/10.1038/sj.onc.1206367			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ	12743605				2022-12-28	WOS:000182569300013
J	Gery, S; Yin, D; Xie, D; Black, KL; Koeffler, HP				Gery, S; Yin, D; Xie, D; Black, KL; Koeffler, HP			TMEFF1 and brain tumors	ONCOGENE			English	Article						brain cancer; epidermal growth factor and follistatin	EPIDERMAL GROWTH-FACTOR; PROSTATE-CANCER; FOLLISTATIN; CELLS	TMEFF1 is a novel transmembrane protein, containing two follisatin domains and an epidermal growth factor-like region. These structural domains suggest a role for TMEFF1 in growth factor signaling. TMEFF1 fused to enhanced green fluorescent protein revealed that TMEFF1 is expressed on the cell membrane. Northern analysis of normal human tissue showed that TMEFF1 is predominantly expressed in the brain. Study of cancer cell lines from different tissues including the brain, demonstrated moderate to low levels of TMEFF1 in most of these transformed cell lines. Furthermore, quantitative real-time RT-PCR analysis of 54 brain tumors showed that most of these tumors (96%) had lower levels of TMEFF1 expression than normal brain tissue. Interestingly, ectopic expression of TMEFF1 in brain cancer cells resulted in their growth inhibition. These data suggest that TMEFF1 may behave as a tumor suppressor gene in brain cancers.	Cedars Sinai Med Ctr, Div Hematol Oncol, Los Angeles, CA 90048 USA; Cedars Sinai Med Ctr, Maxine Dunitz Neurosurg Inst, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; Cedars Sinai Medical Center	Gery, S (corresponding author), Cedars Sinai Med Ctr, Div Hematol Oncol, Los Angeles, CA 90048 USA.			Black, Keith/0000-0002-0546-4934				Eib DW, 1996, J NEUROCHEM, V67, P1047; Eib DW, 1998, CYTOGENET CELL GENET, V81, P180, DOI 10.1159/000015023; EIB DW, 2000, MECH DEVELOP, V97, P67; ENGLER DA, 1990, FEBS LETT, V271, P47, DOI 10.1016/0014-5793(90)80368-S; Gery S, 2002, ONCOGENE, V21, P4739, DOI 10.1038/sj.onc.1205142; Glynne-Jones E, 2001, INT J CANCER, V94, P178, DOI 10.1002/ijc.1450; Horie M, 2000, GENOMICS, V67, P146, DOI 10.1006/geno.2000.6228; Kupprion C, 1998, J BIOL CHEM, V273, P29635, DOI 10.1074/jbc.273.45.29635; Patel K, 1998, INT J BIOCHEM CELL B, V30, P1087, DOI 10.1016/S1357-2725(98)00064-8; PATTHY L, 1993, TRENDS NEUROSCI, V16, P76, DOI 10.1016/0166-2236(93)90021-D; Westermark Bengt, 1995, Current Opinion in Oncology, V7, P220, DOI 10.1097/00001622-199505000-00005	11	21	23	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2003	22	18					2723	2727		10.1038/sj.onc.1206351	http://dx.doi.org/10.1038/sj.onc.1206351			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ	12743596				2022-12-28	WOS:000182569300003
J	Konishi, H; Sugiyama, M; Mizuno, K; Saito, H; Yatabe, Y; Takahashi, T; Osada, H; Takahashi, T				Konishi, H; Sugiyama, M; Mizuno, K; Saito, H; Yatabe, Y; Takahashi, T; Osada, H; Takahashi, T			Detailed characterization of a homozygously deleted region corresponding to a candidate tumor suppressor locus at distal 17p13.3 in human lung cancer	ONCOGENE			English	Article						homozygous deletion; 17p13.3; tumor suppressor gene; lung cancer; LOST1	HUMAN-CHROMOSOME 3P21.3; HEPATOCELLULAR-CARCINOMA; EPIGENETIC INACTIVATION; MITOTIC CHECKPOINT; BREAST-CANCER; CELL-LINES; IN-VIVO; GENE; IDENTIFICATION; P53	17p13.3 is one of the chromosomal regions most frequently affected by allelic loss in a variety of human neoplasms including lung cancer. A number of loss of heterozygosity (LOH) analyses have suggested the existence of a tumor suppressor gene at 17p13.3, distal to the p53 locus at 17p13.1. In the present study, we characterized a homozygous deletion at 17p13.3 in a small cell lung cancer cell line by constructing a bacterial artificial chromosome (BAC) contig and a restriction map surrounding the region, as well as by utilizing publicly available draft sequences. We defined the breakpoint, assigned and analysed two known genes, 14-3-3epsilon. and CRK, and a novel gene LOST1 within or at the end of the homozygous deletion of about 170 kb in size. Marked reduction of LOST1 expression was detected in 69% (11/16) of lung cancer specimens by quantitative real-time RT-PCR, while significant DNA hypermethylation was observed at the 5' end of the LOST1 gene in four of six lung cancer cell lines with negligible LOST1 expression. We also show here that a polymorphic marker D17S1174, which resides within the homozygous deletion, was apparently located in the middle of the minimum LOH region, providing further supportive evidence for the presence of a tumor suppressor gene(s) in this region.	Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr Hosp, Dept Anat & Mol Diagnost Pathol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr, Res Inst, Div Immunol, Chikusa Ku, Nagoya, Aichi 4648681, Japan	Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center	Takahashi, T (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.		YATABE, Yasushi/J-6461-2014; Takahashi, Takashi/I-7262-2014; Osada, Hiroyuki/AAY-6254-2020	YATABE, Yasushi/0000-0003-1788-559X; Takahashi, Takashi/0000-0003-0615-7001; Konishi, Hiroyuki/0000-0003-1131-4905				BIEGEL JA, 1992, CANCER RES, V52, P3391; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; CAIRNS P, 1994, CANCER RES, V54, P1422; CANNING S, 1989, P NATL ACAD SCI USA, V86, P5044, DOI 10.1073/pnas.86.13.5044; Chen C, 1999, NAT GENET, V23, P81, DOI 10.1038/12687; COGEN PH, 1992, AM J HUM GENET, V50, P584; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; FUJIMORI M, 1991, CANCER RES, V51, P89; Haataja L, 1997, CANCER RES, V57, P32; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Inoue H, 1997, P NATL ACAD SCI USA, V94, P14584, DOI 10.1073/pnas.94.26.14584; Ji L, 2002, CANCER RES, V62, P2715; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kohno T, 1996, DNA Res, V3, P421, DOI 10.1093/dnares/3.6.421; Kondo M, 2001, ONCOGENE, V20, P6258, DOI 10.1038/sj.onc.1204832; Konishi H, 1998, ONCOGENE, V17, P2095, DOI 10.1038/sj.onc.1202128; Konishi H, 2002, CANCER RES, V62, P271; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; Lerman MI, 2000, CANCER RES, V60, P6116; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; McHale JC, 2000, CYTOGENET CELL GENET, V88, P225, DOI 10.1159/000015556; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; MINNA JD, 1997, CANC PRINCIPLES PRAC, V1, P849; MURATA Y, 1994, HUM MOL GENET, V3, P1341, DOI 10.1093/hmg/3.8.1341; Nishioka M, 2000, ONCOGENE, V19, P6251, DOI 10.1038/sj.onc.1204031; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Nomoto S, 1999, ONCOGENE, V18, P7180, DOI 10.1038/sj.onc.1203141; Oh JJ, 2002, CANCER RES, V62, P3207; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Osada H, 2001, CANCER RES, V61, P8331; Phillips NJ, 1996, CANCER RES, V56, P606; POMYKALA HM, 1994, MOL CELL BIOL, V14, P7604, DOI 10.1128/MCB.14.11.7604; SAXENA A, 1992, CANCER RES, V52, P6716; Schultz DC, 1996, CANCER RES, V56, P1997; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Shigemitsu K, 2001, ONCOGENE, V20, P4249, DOI 10.1038/sj.onc.1204557; STACK M, 1995, HUM MOL GENET, V4, P2047, DOI 10.1093/hmg/4.11.2047; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; TADOKORO K, 1992, ONCOGENE, V7, P1215; TAKAHASHI T, 1992, CANCER RES, V52, P2340; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; Tamura K, 2002, J HUM GENET, V47, P348, DOI 10.1007/s100380200048; Tomizawa Y, 2001, P NATL ACAD SCI USA, V98, P13954, DOI 10.1073/pnas.231490898; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; Yatabe Y, 2000, AM J PATHOL, V157, P985, DOI 10.1016/S0002-9440(10)64611-1; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; Zhao XT, 2001, CANCER RES, V61, P7383	53	29	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 27	2003	22	12					1892	1905		10.1038/sj.onc.1206304	http://dx.doi.org/10.1038/sj.onc.1206304			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660825				2022-12-28	WOS:000181678200016
J	Vernon, EG; Malik, K; Reynolds, P; Powlesland, R; Dallosso, AR; Jackson, S; Henthorn, K; Green, ED; Brown, KW				Vernon, EG; Malik, K; Reynolds, P; Powlesland, R; Dallosso, AR; Jackson, S; Henthorn, K; Green, ED; Brown, KW			The parathyroid hormone-responsive B1 gene is interrupted by a t(1;7)(q42;p15) breakpoint associated with Wilms' tumour	ONCOGENE			English	Article						Wilms' tumour; chromosome 7; PTH-B1 gene	SHORT ARM; HETEROZYGOSITY; TRANSLOCATION; CHROMOSOME-7; CELLS; LOCUS; IDENTIFICATION; ABNORMALITIES; MUTATIONS; ALLELES	Wilms' tumour (WT) has a diverse and complex molecular aetiology, with several different loci identified by cytogenetic and molecular analyses. One such locus is on chromosome 7p, where cytogenetic abnormalities and loss of heterozygosity (LOH) indicate the presence of a Wilms' tumour suppressor gene. In order to isolate a candidate gene for this locus, we have characterized the breakpoint regions at a novel constitutional chromosome translocation (t(1;7)(q42;p15)), found in a child with WT and skeletal abnormalities. We identified two genes that were interrupted by the translocation: the parathyroid hormone-responsive B1 gene (PTH-B1) at 7p and obscurin at 1q. With no evidence for LOH at 1q42, we focused on the characterization of PTH-B1. We detected novel alternately spliced isoforms of PTH-B1, which were expressed in a wide range of adult and foetal tissues. Importantly, expression of two isoforms were disrupted in the WT of the t(1;7) patient. We also identified an additional splice isoform expressed only in 7p LOH tumours. The disruption of PTH-B1 by the t(1;7), together with aberrant splicing in sporadic WTs, suggests that PTH-B1 is a candidate for the 7p Wilms' tumour suppressor gene.	Univ Bristol, Sch Med Sci, Dept Pathol & Microbiol, CLIC Res Unit, Bristol BS8 1TD, Avon, England; MGH Canc Ctr, Boston, MA USA; NHGRI, Genome Technol Branch, NIH, Bethesda, MD 20892 USA	University of Bristol; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Brown, KW (corresponding author), Univ Bristol, Sch Med Sci, Dept Pathol & Microbiol, CLIC Res Unit, Bristol BS8 1TD, Avon, England.		dallosso, anthony/A-8335-2008; Brown, Keith/C-3355-2009	Brown, Keith/0000-0002-4258-5129; Vernon, Ellen/0000-0002-8344-1025; Dallosso, Anthony/0000-0002-1460-2550; Malik, Karim/0000-0002-8965-200X				Adams AE, 1999, BONE, V24, P305, DOI 10.1016/S8756-3282(98)00188-4; Balmain A, 2002, NATURE, V417, P235, DOI 10.1038/417235a; Baudry D, 2000, CLIN CANCER RES, V6, P3957; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BROWN KW, 1993, GENE CHROMOSOME CANC, V8, P74, DOI 10.1002/gcc.2870080203; BROWN KW, 1989, BRIT J CANCER, V60, P25, DOI 10.1038/bjc.1989.213; BROWN KW, 2001, EXP REV MOL MED, V14; DEKRAKER J, 1979, HELV PAEDIATR ACTA, V34, P459; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GRUNDY PE, 1994, CANCER RES, V54, P2331; Grundy RG, 1998, ONCOGENE, V17, P395, DOI 10.1038/sj.onc.1201927; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; HEWITT M, 1991, J MED GENET, V28, P411, DOI 10.1136/jmg.28.6.411; KOUFOS A, 1989, AM J HUM GENET, V44, P711; Little M, 1997, HUM MUTAT, V9, P209, DOI 10.1002/(SICI)1098-1004(1997)9:3<209::AID-HUMU2>3.0.CO;2-2; Lobbert RW, 1998, GENE CHROMOSOME CANC, V21, P347, DOI 10.1002/(SICI)1098-2264(199804)21:4<347::AID-GCC9>3.0.CO;2-Z; Miozzo M, 1996, GENOMICS, V37, P310, DOI 10.1006/geno.1996.0565; Nissim-Rafinia M, 2002, TRENDS GENET, V18, P123, DOI 10.1016/S0168-9525(01)02619-1; Perotti D, 2001, GENE CHROMOSOME CANC, V31, P42, DOI 10.1002/gcc.1116; PING AJ, 1989, AM J HUM GENET, V44, P720; Powlesland RM, 2000, BRIT J CANCER, V82, P323, DOI 10.1054/bjoc.1999.0922; RADICE P, 1995, GENOMICS, V27, P497, DOI 10.1006/geno.1995.1082; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; Reynolds PA, 1996, GENE CHROMOSOME CANC, V17, P151, DOI 10.1002/(SICI)1098-2264(199611)17:3<151::AID-GCC2>3.0.CO;2-3; RIVERA H, 1995, CANCER GENET CYTOGEN, V81, P97, DOI 10.1016/S0165-4608(94)00199-5; Sambrook J., 2002, MOL CLONING LAB MANU; SAWYER JR, 1993, CANCER GENET CYTOGEN, V69, P57, DOI 10.1016/0165-4608(93)90114-2; SMIT AFA, 1993, NUCLEIC ACIDS RES, V21, P1863, DOI 10.1093/nar/21.8.1863; WILMORE HP, 1994, CANCER GENET CYTOGEN, V77, P93, DOI 10.1016/0165-4608(94)90221-6; WILSON K, 1986, BIOL GUIDE PRINCIPLE; Young P, 2001, J CELL BIOL, V154, P123, DOI 10.1083/jcb.200102110	31	29	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2003	22	9					1371	1380		10.1038/sj.onc.1206332	http://dx.doi.org/10.1038/sj.onc.1206332			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618763				2022-12-28	WOS:000181360900012
J	Janknecht, R				Janknecht, R			Regulation of the ER81 transcription factor and its coactivators by mitogen- and stress-activated protein kinase 1 (MSK1)	ONCOGENE			English	Article						CBP; ER81; MSK1; p300; phosphorylation; transcription	RUBINSTEIN-TAYBI-SYNDROME; PROTEIN-KINASE; MAP KINASE; HISTONE H3; INDUCED PHOSPHORYLATION; EXPRESSION PATTERNS; BINDING PROTEIN; ETS-DOMAIN; PEA3 GROUP; GENE	The transcription factor ER81 has been shown to be involved in ontogenesis and breast tumor formation. ER81 is activated by many signals through phosphorylation directly mediated by mitogen-activated protein kinases (MAPKs), but also by an unknown protein kinase(s). Here, mitogen- and stress-activated protein kinase I (MSK1), which itself is directly activated by distinct classes of MAPKs, is identified to regulate ER81 function. MSK1 expression enhances ER81-dependent transcription upon stimulation of especially the p38-MAPK pathway. Two serine residues in ER81 are phosphorylated by MSK1, and mutating these serine residues to alanines dramatically diminishes the ability of MSK1 to stimulate ER81. However, mutation of the MSK1 phosphorylation sites in ER81 does not completely abrogate the ability of MSK1 to activate ER81 function, suggesting that MSK1 may also target cofactors of ER81. Consistently, MSK1 interacts with two homologous coactivators of ER81, CBP and p300, and stimulates the transactivation domains of CBP. Thus, MSK1 may regulate ER81-dependent transcription via direct phosphorylation of ER81 as well as via stimulation of CBP/p300, which might be important for ER81's normal function and during mammary tumor formation.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic	Janknecht, R (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.	janknecht.ralf@mayo.edu		Janknecht, Ralf/0000-0003-1741-1562	NATIONAL CANCER INSTITUTE [R01CA085257] Funding Source: NIH RePORTER; NCI NIH HHS [CA085257, R01 CA085257] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Arber S, 2000, CELL, V101, P485, DOI 10.1016/S0092-8674(00)80859-4; Arthur JSC, 2000, FEBS LETT, V482, P44, DOI 10.1016/S0014-5793(00)02031-7; Baert JL, 2002, J BIOL CHEM, V277, P1002, DOI 10.1074/jbc.M107139200; BARRATT MJ, 1994, EMBO J, V13, P4524, DOI 10.1002/j.1460-2075.1994.tb06774.x; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Blough RI, 2000, AM J MED GENET, V90, P29, DOI 10.1002/(SICI)1096-8628(20000103)90:1<29::AID-AJMG6>3.0.CO;2-Z; Bosc DG, 2002, J CELL BIOCHEM, V86, P174, DOI 10.1002/jcb.10205; Bosc DG, 2001, ONCOGENE, V20, P6215, DOI 10.1038/sj.onc.1204820; BredemeierErnst I, 1997, FEBS LETT, V408, P47, DOI 10.1016/S0014-5793(97)00387-6; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Chotteau-Lelievre A, 2001, MECH DEVELOP, V108, P191, DOI 10.1016/S0925-4773(01)00480-4; ChotteauLelievre A, 1997, ONCOGENE, V15, P937, DOI 10.1038/sj.onc.1201261; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Coutte L, 1999, ONCOGENE, V18, P6278, DOI 10.1038/sj.onc.1203020; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Goodman RH, 2000, GENE DEV, V14, P1553; Goto H, 1999, J BIOL CHEM, V274, P25543, DOI 10.1074/jbc.274.36.25543; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Hung MC, 1999, SEMIN ONCOL, V26, P51; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; Janknecht R, 2002, HISTOL HISTOPATHOL, V17, P657, DOI 10.14670/HH-17.657; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Janknecht R, 2001, J BIOL CHEM, V276, P41856, DOI 10.1074/jbc.M106630200; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; JEON IS, 1995, ONCOGENE, V10, P1229; Kucera J, 2002, DEV DYNAM, V223, P389, DOI 10.1002/dvdy.10066; Kung AL, 2000, GENE DEV, V14, P272; Liu SL, 2000, ONCOGENE, V19, P3352, DOI 10.1038/sj.onc.1203675; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; MILLER RW, 1995, AM J MED GENET, V56, P112, DOI 10.1002/ajmg.1320560125; MONTE D, 1995, ONCOGENE, V11, P771; New L, 1999, J BIOL CHEM, V274, P1026, DOI 10.1074/jbc.274.2.1026; Nomura M, 2001, J BIOL CHEM, V276, P25558, DOI 10.1074/jbc.M101164200; Papoutsopoulou S, 2000, MOL CELL BIOL, V20, P7300, DOI 10.1128/MCB.20.19.7300-7310.2000; Pearson KL, 1999, BBA-GENE STRUCT EXPR, V1489, P354, DOI 10.1016/S0167-4781(99)00166-9; Pierrat B, 1998, J BIOL CHEM, V273, P29661, DOI 10.1074/jbc.273.45.29661; Rubin I, 2001, ANN ONCOL, V12, P3, DOI 10.1023/A:1011195320446; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Shepherd TG, 2001, CURR BIOL, V11, P1739, DOI 10.1016/S0960-9822(01)00536-X; Smits PHM, 1996, ONCOGENE, V12, P1529; Stein B, 1997, J BIOL CHEM, V272, P19509, DOI 10.1074/jbc.272.31.19509; Strelkov IS, 2002, CANCER RES, V62, P75; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Tomas-Zuber M, 2001, J BIOL CHEM, V276, P5892, DOI 10.1074/jbc.M005822200; VANDERGEER P, 1994, ELECTROPHORESIS, V15, P544, DOI 10.1002/elps.1150150173; Wiggin GR, 2002, MOL CELL BIOL, V22, P2871, DOI 10.1128/MCB.22.8.2871-2881.2002; Zhang YG, 2001, J BIOL CHEM, V276, P42534, DOI 10.1074/jbc.M106044200; Zhong SP, 2001, J BIOL CHEM, V276, P33213, DOI 10.1074/jbc.M103973200	54	81	85	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 6	2003	22	5					746	755		10.1038/sj.onc.1206185	http://dx.doi.org/10.1038/sj.onc.1206185			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569367				2022-12-28	WOS:000180642100012
J	Rossow, KL; Janknecht, R				Rossow, KL; Janknecht, R			Synergism between p68 RNA helicase and the transcriptional coactivators CBP and p300	ONCOGENE			English	Article						CBP; E1A; p300; p68 RNA helicase; RNA polymerase II; transcription	ESTROGEN-RECEPTOR-ALPHA; DEAD BOX PROTEIN; COLORECTAL TUMORS; POLYMERASE-II; GENE; ACTIVATION; COAMPLIFICATION; OVEREXPRESSION; IDENTIFICATION; NEUROBLASTOMA	p68 RNA helicase has been implicated in a variety of processes, including rearrangement of RNA secondary structures, RNA splicing, gene transcription and tumor development, yet its mechanisms of action are not well understood. In this study, we show that p68 is predominantly localized to the cell nucleus, where it partially colocalizes with the transcriptional coactivator p300. Accordingly, p68 and p300, or the paralogous CREB-binding protein (CBP), coimmunoprecipitate. Similarly, p68 and RNA polymerase II (Pol II) are able to interact in vivo. GST pull-down assays confirmed these interactions in vitro, demonstrating that p68 can interact with several domains of CBP, while CBP/p300 bind to amino acids 176-388 of p68 and RNA Pol II binds to the N-terminal 80 amino acids of p68. Furthermore, p68 stimulates transcription mediated by the C-terminal transactivation domain of CBP. p68 is also able to stimulate TPA oncogene responsive unit (TORU) promoter activity, and p300 acts in synergy with p68. On the other hand, suppression of CBP/p300 function by the adenoviral protein E1A abolishes TORU promoter activation by p68. Altogether, our results suggest the existence of a multiprotein complex in which p68 RNA helicase, CBP/p300 and RNA Pol II jointly promote gene expression.	Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic	Janknecht, R (corresponding author), Mayo Clin, Dept Biochem & Mol Biol, 200 1st St,SW,Guggenheim Bldg 1501A, Rochester, MN 55905 USA.			Janknecht, Ralf/0000-0003-1741-1562				AKAO Y, 1995, CANCER RES, V55, P3444; Akileswaran L, 2001, J BIOL CHEM, V276, P17448, DOI 10.1074/jbc.M101171200; Causevic M, 2001, ONCOGENE, V20, P7734, DOI 10.1038/sj.onc.1204976; Eisen A, 1998, BIOESSAYS, V20, P634, DOI 10.1002/(SICI)1521-1878(199808)20:8<634::AID-BIES6>3.0.CO;2-I; Endoh H, 1999, MOL CELL BIOL, V19, P5363; FORD MJ, 1988, NATURE, V332, P736, DOI 10.1038/332736a0; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; George RE, 1996, ONCOGENE, V12, P1583; GODBOUT R, 1993, P NATL ACAD SCI USA, V90, P7578, DOI 10.1073/pnas.90.16.7578; Goodman RH, 2000, GENE DEV, V14, P1553; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; IGGO RD, 1989, EMBO J, V8, P1827, DOI 10.1002/j.1460-2075.1989.tb03577.x; IGGO RD, 1991, MOL CELL BIOL, V11, P1326, DOI 10.1128/MCB.11.3.1326; Janknecht R, 2002, HISTOL HISTOPATHOL, V17, P657, DOI 10.14670/HH-17.657; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LEE CG, 1993, J BIOL CHEM, V268, P16822; Liu SL, 2000, ONCOGENE, V19, P3352, DOI 10.1038/sj.onc.1203675; MONTE D, 1995, ONCOGENE, V11, P771; Muraoka M, 1996, ONCOGENE, V12, P1565; Nakagawa Y, 1999, BRIT J CANCER, V80, P914, DOI 10.1038/sj.bjc.6690441; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nicol SM, 2000, EXP CELL RES, V257, P272, DOI 10.1006/excr.2000.4886; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; Pearson KL, 1999, BBA-GENE STRUCT EXPR, V1489, P354, DOI 10.1016/S0167-4781(99)00166-9; Rossler OG, 2001, NUCLEIC ACIDS RES, V29, P2088, DOI 10.1093/nar/29.10.2088; Rossow KL, 2001, CANCER RES, V61, P2690; SQUIRE JA, 1995, ONCOGENE, V10, P1417; Stevenson RJ, 1998, J PATHOL, V184, P351, DOI 10.1002/(SICI)1096-9896(199804)184:4<351::AID-PATH1235>3.0.CO;2-C; Tang HL, 1997, SCIENCE, V276, P1412, DOI 10.1126/science.276.5317.1412; Tanner NK, 2001, MOL CELL, V8, P251, DOI 10.1016/S1097-2765(01)00329-X; von Mikecz A, 2000, J CELL BIOL, V150, P265, DOI 10.1083/jcb.150.1.265; Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341	33	89	95	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 9	2003	22	1					151	156		10.1038/sj.onc.1206067	http://dx.doi.org/10.1038/sj.onc.1206067			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527917				2022-12-28	WOS:000180166900016
J	Hanawalt, PC				Hanawalt, PC			Subpathways of nucleotide excision repair and their regulation	ONCOGENE			English	Article						nucleotide excision-repair; transcription-coupled repair; global genomic repair; SOS response; p53; xeroderma pigmentosum; cockayne syndrome; UV sensitive syndrome; Li-Fraumeni syndrome	GLOBAL GENOMIC REPAIR; CYCLOBUTANE PYRIMIDINE DIMERS; TRANSCRIPTION-COUPLED REPAIR; DNA-REPAIR; ESCHERICHIA-COLI; DAMAGED-DNA; P53 MUTATIONS; WILD-TYPE; GENE; CELLS	Nucleotide excision repair provides an important cellular defense against a large variety of structurally unrelated DNA alterations. Most of these alterations, if unrepaired, may contribute to mutagenesis, oncogenesis, and developmental abnormalities, as well as cellular lethality. There are two subpathways of nucleotide excision repair; global genomic repair (GGR) and transcription coupled repair (TCR), that is selective for the transcribed DNA strand in expressed genes. Some of the proteins involved in the recognition of DNA damage (including RNA polymerase) are also responsive to natural variations in the secondary structural features of DNA. Gratuitous repair events in undamaged DNA might then contribute to genomic instability. However, damage recognition enzymes for GGR are normally maintained at very low levels unless the cells are genomically stressed. GGR is controlled through the SOS stress response in E. coli and through the activated p53 tumor suppressor in human cells. These inducible responses in human cells are important, as they have been shown to operate upon chemical carcinogen DNA damage at levels to which humans are environmentally exposed. Interestingly, most rodent tissues are deficient in the p53-dependent GGR pathway. Since rodents are used as surrogates for environmental cancer risk assessment, it is essential that we understand how they differ from humans with respect to DNA repair and oncogenic responses to environmental genotoxins. In the case of terminally differentiated mammalian cells, a new paradigm has appeared in which GGR is attenuated but both strands of expressed genes are repaired efficiently.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	Stanford University	Hanawalt, PC (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.	hanawalt@stanford.edu			NCI NIH HHS [CA77712, R01 CA077712, CA 44349, CA90915, CA91456] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA091456, R35CA044349, R56CA077712, R01CA090915, R01CA077712] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adimoolam S, 2002, P NATL ACAD SCI USA, V99, P12985, DOI 10.1073/pnas.202485699; Batty D, 2000, J MOL BIOL, V300, P275, DOI 10.1006/jmbi.2000.3857; BEACH AC, 1992, CARCINOGENESIS, V13, P1053, DOI 10.1093/carcin/13.7.1053; Ben-Ishai R., 1975, MOL MECH REPAIR DNA, P607; Birrell GW, 2002, P NATL ACAD SCI USA, V99, P8778, DOI 10.1073/pnas.132275199; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; Bowman KK, 2000, MOL CARCINOGEN, V29, P17, DOI 10.1002/1098-2744(200009)29:1<17::AID-MC3>3.3.CO;2-5; Branum ME, 2001, J BIOL CHEM, V276, P25421, DOI 10.1074/jbc.M101032200; COUCH J, 1967, BIOCHEM BIOPH RES CO, V29, P779, DOI 10.1016/0006-291X(67)90287-2; Courcelle J, 2001, GENETICS, V158, P41; Crowley DJ, 2001, MUTAT RES-DNA REPAIR, V485, P319, DOI 10.1016/S0921-8777(01)00068-4; Crowley DJ, 1998, J BACTERIOL, V180, P3345, DOI 10.1128/JB.180.13.3345-3352.1998; Dumaz N, 1997, CARCINOGENESIS, V18, P897, DOI 10.1093/carcin/18.5.897; Dunkern TR, 2002, MOL BIOL CELL, V13, P348, DOI 10.1091/mbc.01-05-0225; Eisen JA, 1999, MUTAT RES-DNA REPAIR, V435, P171, DOI 10.1016/S0921-8777(99)00050-6; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; Ford JM, 1998, CANCER RES, V58, P599; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; GRIVELL AR, 1975, J MOL BIOL, V98, P219, DOI 10.1016/S0022-2836(75)80110-0; Hanawalt P. C., 1983, MANIPULATION EXPRESS, P45; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HANAWALT PC, 1968, COLD SPRING HARB SYM, V33, P187, DOI 10.1101/SQB.1968.033.01.022; Hanawalt PC, 2000, COLD SPRING HARB SYM, V65, P183, DOI 10.1101/sqb.2000.65.183; Hanawalt PC, 2001, ENVIRON MOL MUTAGEN, V38, P89, DOI 10.1002/em.1057; HANAWALT PC, 1987, PROCESSES CUTANEOUS, P217; Hwang BJ, 1998, MOL CELL BIOL, V18, P4391, DOI 10.1128/MCB.18.7.4391; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; KLIMEK K, 1965, NEOPLASMA, V12, P459; LEADON SA, 1993, P NATL ACAD SCI USA, V90, P10499, DOI 10.1073/pnas.90.22.10499; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; Ljungman M, 1996, ONCOGENE, V13, P823; Lloyd DR, 2000, CANCER RES, V60, P517; LOHMAN PHM, 1977, MUTAT RES, V46, P138; McKay Bruce C., 1999, Neoplasia (New York), V1, P276, DOI 10.1038/sj.neo.7900028; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; Moolenaar GF, 2002, P NATL ACAD SCI USA, V99, P1467, DOI 10.1073/pnas.032584099; MULLAART E, 1988, J INVEST DERMATOL, V90, P346, DOI 10.1111/1523-1747.ep12456316; Nouspikel T, 2000, MOL CELL BIOL, V20, P1562, DOI 10.1128/MCB.20.5.1562-1570.2000; Nouspikel T, 2002, DNA REPAIR, V1, P59, DOI 10.1016/S1568-7864(01)00005-2; NOUSPIKEL T, 2003, IN PRESS BIOESSAYS; PAINTER RB, 1969, RADIAT RES, V37, P451, DOI 10.2307/3572686; PAULING C, 1965, P NATL ACAD SCI USA, V54, P1728, DOI 10.1073/pnas.54.6.1728; PELEG L, 1977, EXP CELL RES, V104, P301, DOI 10.1016/0014-4827(77)90095-7; Petit C, 1999, BIOCHIMIE, V81, P15, DOI 10.1016/S0300-9084(99)80034-0; PETTIJOHN DE, 1964, J MOL BIOL, V9, P395, DOI 10.1016/S0022-2836(64)80216-3; Plosky B, 2002, DNA REPAIR, V1, P683, DOI 10.1016/S1568-7864(02)00075-7; Prost S, 1998, J BIOL CHEM, V273, P33327, DOI 10.1074/jbc.273.50.33327; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Spivak G., 2002, DNA REPAIR, V50, P1; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X; Tang J, 2002, DNA REPAIR, V1, P601, DOI 10.1016/S1568-7864(02)00052-6; Tang JY, 2000, MOL CELL, V5, P737, DOI 10.1016/S1097-2765(00)80252-X; Therrien JP, 1999, P NATL ACAD SCI USA, V96, P15038, DOI 10.1073/pnas.96.26.15038; TROSKO JE, 1965, RADIAT RES, V24, P667, DOI 10.2307/3571885; Van Houten B, 2002, P NATL ACAD SCI USA, V99, P2581, DOI 10.1073/pnas.062062599; VANZEELAND AA, 1981, MUTAT RES, V82, P173, DOI 10.1016/0027-5107(81)90148-2; VIJG J, 1984, MUTAT RES, V132, P129, DOI 10.1016/0167-8817(84)90007-5; Wakasugi M, 2002, J BIOL CHEM, V277, P1637, DOI 10.1074/jbc.C100610200; Wani MA, 2000, CANCER RES, V60, P2273; Zou Y, 1999, EMBO J, V18, P4889, DOI 10.1093/emboj/18.17.4889; Zou Y, 2001, BIOCHEMISTRY-US, V40, P2923, DOI 10.1021/bi001504c	64	341	346	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2002	21	58					8949	8956		10.1038/sj.onc.1206096	http://dx.doi.org/10.1038/sj.onc.1206096			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	626TP	12483511				2022-12-28	WOS:000179889500006
J	Segawa, T; Nau, ME; Xu, LL; Chilukuri, RN; Makarem, M; Zhang, W; Petrovics, G; Sesterhenn, IA; McLeod, DG; Moul, JW; Vahey, M; Srivastava, S				Segawa, T; Nau, ME; Xu, LL; Chilukuri, RN; Makarem, M; Zhang, W; Petrovics, G; Sesterhenn, IA; McLeod, DG; Moul, JW; Vahey, M; Srivastava, S			Androgen-induced expression of endoplasmic reticulum (ER) stress response genes in prostate cancer cells	ONCOGENE			English	Article						prostate cancer; androgen regulated genes; gene chip; endoplasmic reticulum stress response	UNFOLDED PROTEIN RESPONSE; FATTY-ACID SYNTHASE; RECEPTOR GENE; ORNITHINE DECARBOXYLASE; POLYAMINE LEVELS; CARCINOMA-CELLS; GROWTH-FACTOR; IN-VIVO; PROGRESSION; MODEL	Evaluations of androgen regulated gene (ARG) repertoire provide new insights into the androgen receptor (AR) mediated signaling at the transcriptional level. Definition of ARGs having critical functions in the biology of normal and malignant prostate should aid in identifying new bio-markers and therapeutic targets for prostate cancer (CaP). Using Affymetrix HuGene FL oligonucleotide arrays, temporal expression profiles of ARGs in widely used hormone responsive LNCaP cells, were analysed by hierarchical clustering methods and functional classification. ARGs in response to different androgen concentrations showed temporal co-regulation of genes involved in specific biochemical pathways. This study focuses on our new observations of the coordinated androgen induction of genes (NDRG1, PDIR, HERPUD1, ORP150) involved in the endoplasmic reticulum (ER) stress response pathway. Expression analysis of the two selected ER stress responsive genes, NDRG1 and HERPUD1 in primary CaPs revealed a significantly reduced tumor associated expression. Intriguing linkage of the androgen signaling to ER stress responsive genes, a protective response to protein unfolding or protein damage resulting from cellular stress signals, suggests that androgens may induce such stress signals in CaP cells. Decreased CaP associated expression of two ER stress responsive genes also suggests that possible abrogation of this pathway in prostate tumorigenesis.	Uniformed Serv Univ Hlth Sci, Ctr Prostrate Dis Res, Dept Surg, Rockville, MD 20852 USA; Walter Reed Army Med Ctr, Urol Serv, Washington, DC 20307 USA; Armed Forces Inst Pathol, Dept Genitourinary Pathol, Washington, DC 20307 USA; Walter Reed Army Inst Res, Div Retrovirol, Affymetrix Gene Array Lab, Rockville, MD 20850 USA	Uniformed Services University of the Health Sciences - USA; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; United States Department of Defense; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)	Srivastava, S (corresponding author), Uniformed Serv Univ Hlth Sci, Ctr Prostrate Dis Res, Dept Surg, 1530 E Jefferson St, Rockville, MD 20852 USA.	ssrivastava@cpdr.org		Petrovics, Gyorgy/0000-0003-3732-284X				Amler LC, 2000, CANCER RES, V60, P6134; Augustus M, 1999, MOLECULAR PATHOLOGY OF EARLY CANCER, P321; Bettuzzi S, 2000, CANCER RES, V60, P1472; Brewer JW, 1997, EMBO J, V16, P7207, DOI 10.1093/emboj/16.23.7207; Claessens F, 2001, J STEROID BIOCHEM, V76, P23, DOI 10.1016/S0960-0760(00)00154-0; COFFEY DS, 1992, CAMPBELLS UROLOGY, V1, P221; CROZAT A, 1992, ENDOCRINOLOGY, V130, P1131, DOI 10.1210/en.130.3.1131; CULIG Z, 1994, CANCER RES, V54, P5474; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; EPSTEIN JI, 1995, UROLOGY, V45, P81, DOI 10.1016/S0090-4295(95)96904-7; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; FJOSNE HE, 1990, PROSTATE, V17, P1, DOI 10.1002/pros.2990170102; Graumann PL, 1998, TRENDS BIOCHEM SCI, V23, P286, DOI 10.1016/S0968-0004(98)01255-9; Greeve I, 2000, J NEUROSCI, V20, P7345; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; Guang RJ, 2000, CANCER RES, V60, P749; Hakimi JM, 1996, WORLD J UROL, V14, P329; Hardy DO, 1996, J CLIN ENDOCR METAB, V81, P4400, DOI 10.1210/jc.81.12.4400; Heemers H, 2001, MOL ENDOCRINOL, V15, P1817, DOI 10.1210/me.15.10.1817; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Huggins C, 1941, CANCER RES, V1, P293; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Kanai S, 1998, J MOL EVOL, V47, P200, DOI 10.1007/PL00006377; Koike C, 1999, CANCER RES, V59, P6109; Kokame K, 2000, J BIOL CHEM, V275, P32846, DOI 10.1074/jbc.M002063200; Kokame K, 1996, J BIOL CHEM, V271, P29659, DOI 10.1074/jbc.271.47.29659; Kurdistani SK, 1998, CANCER RES, V58, P4439; Lin BY, 2000, CANCER RES, V60, P858; Lin BY, 2001, CANCER RES, V61, P1611; Messing EM, 1999, J NATL CANCER I, V91, P1416, DOI 10.1093/jnci/91.16.1416; Mohan RR, 1999, CLIN CANCER RES, V5, P143; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Mousses S, 2002, CANCER RES, V62, P1256; Myers RB, 2001, J UROLOGY, V165, P1027, DOI 10.1016/S0022-5347(05)66596-2; Nagabhushan M, 1996, CANCER RES, V56, P3042; Nau ME, 2000, J CLIN MICROBIOL, V38, P1901, DOI 10.1128/JCM.38.5.1901-1908.2000; NOBLE RL, 1977, CANCER RES, V37, P1929; Ozawa K, 1999, J BIOL CHEM, V274, P6397, DOI 10.1074/jbc.274.10.6397; Park H, 2000, BIOCHEM BIOPH RES CO, V276, P321, DOI 10.1006/bbrc.2000.3475; Pizer ES, 2001, PROSTATE, V47, P102, DOI 10.1002/pros.1052; Pollard M, 1998, PROSTATE, V37, P1, DOI 10.1002/(SICI)1097-0045(19980915)37:1<1::AID-PROS1>3.0.CO;2-L; Ripple MO, 1997, JNCI-J NATL CANCER I, V89, P40, DOI 10.1093/jnci/89.1.40; ROSS R, 1986, JNCI-J NATL CANCER I, V76, P45; Segawa T, 1998, CANCER RES, V58, P2282; Simoneau AR, 2001, JNCI-J NATL CANCER I, V93, P57, DOI 10.1093/jnci/93.1.57; SMITH RC, 1995, NAT MED, V1, P1040, DOI 10.1038/nm1095-1040; Stanford JL, 1997, CANCER RES, V57, P1194; Swinnen JV, 1997, P NATL ACAD SCI USA, V94, P12975, DOI 10.1073/pnas.94.24.12975; Tilley WD, 1996, CLIN CANCER RES, V2, P277; Tindall DJ, 1999, PROSTATE, V38, P166, DOI 10.1002/(SICI)1097-0045(19990201)38:2<166::AID-PROS11>3.0.CO;2-A; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Ulrix W, 1999, FEBS LETT, V455, P23, DOI 10.1016/S0014-5793(99)00845-5; Vaarala MH, 2000, LAB INVEST, V80, P1259, DOI 10.1038/labinvest.3780134; van Laar T, 2000, FEBS LETT, V469, P123, DOI 10.1016/S0014-5793(00)01253-9; vanBelzen N, 1997, LAB INVEST, V77, P85; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Xu LL, 2000, GENOMICS, V66, P257, DOI 10.1006/geno.2000.6214; Xu LL, 2000, CANCER RES, V60, P6568; Xu LL, 2001, INT J CANCER, V92, P322, DOI 10.1002/ijc.1196	59	115	116	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2002	21	57					8749	8758		10.1038/sj.onc.1205992	http://dx.doi.org/10.1038/sj.onc.1205992			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483528				2022-12-28	WOS:000179734400009
J	Senga, T; Iwamoto, T; Humphrey, SE; Yokota, T; Taparowsky, EJ; Hamaguchi, M				Senga, T; Iwamoto, T; Humphrey, SE; Yokota, T; Taparowsky, EJ; Hamaguchi, M			Stat3-dependent induction of BATF in M1 mouse myeloid leukemia cells	ONCOGENE			English	Article						IL-6/LIF; gp130; Stat3; BATF; AP-1	CYTOKINE RECEPTOR GP130; C-MYC; B-ATF; STAT3; SIGNALS; DIFFERENTIATION; TRANSCRIPTION; ACTIVATION; PROTEIN; FAMILY	Stat3 mediates cellular responses associated with proliferation, survival and differentiation, but the mechanisms underlying the diverse effects of this signaling molecule remain unknown. M1 mouse myeloid leukemia cells arrest growth and differentiate into macrophages following treatment with interleukin 6 (IL-6) or leukemia inhibitory factor (LIF), and recent studies have shown that Stat3 plays a central role in this process. Utilizing representational difference analysis, we demonstrate that expression of the mouse BATF gene is upregulated as an early response to IL-6/LIF stimulation and Stat3 activation in this cell system. Immunoblots using antibodies to BATF detected an increase in BATF protein in response to LIF/IL-6 stimulation. BATF is a member of the AP-1 family of basic leucine zipper transcription factors and functions to inhibit the transcriptional and biological functions of AP-1 activity in mammalian cells. BATF forms complexes with c-Jun in M1. cells and forced expression of BATF in the absence of Stat3 signaling results in a reduced rate of cellular growth. These results indicate that Stat3 mediates cellular growth by modulating AP-1 activity through the induction of BATF.	Nagoya Univ, Sch Med, Dept Mol Pathogenesis, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Radioisotope Res Ctr, Med Div,Showa Ku, Nagoya, Aichi 4668550, Japan; Kanazawa Univ, Grad Sch Med Sci, Div Stem Cell Biol, Kanazawa, Ishikawa 9208640, Japan; Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA	Nagoya University; Nagoya University; Kanazawa University; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Hamaguchi, M (corresponding author), Nagoya Univ, Sch Med, Dept Mol Pathogenesis, Showa Ku, 65 Tsurumai, Nagoya, Aichi 4668550, Japan.	mhamagu@tsuru.med.nagoya-u.ac.jp	Yokota, Takashi/J-8483-2015; Yokota, Takashi/F-6021-2011		NATIONAL CANCER INSTITUTE [R01CA078264] Funding Source: NIH RePORTER; NCI NIH HHS [CA78264] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; Bellido T, 1998, J BIOL CHEM, V273, P21137, DOI 10.1074/jbc.273.33.21137; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Dorsey MJ, 1995, ONCOGENE, V11, P2255; Echlin DR, 2000, ONCOGENE, V19, P1752, DOI 10.1038/sj.onc.1203491; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Fukada T, 1998, EMBO J, V17, P6670, DOI 10.1093/emboj/17.22.6670; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Kitamura T, 2000, METH MOL B, V134, P143; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; Masuhara M, 1997, BIOCHEM BIOPH RES CO, V239, P439, DOI 10.1006/bbrc.1997.7484; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; O'Farrell AM, 2000, J IMMUNOL, V164, P4607, DOI 10.4049/jimmunol.164.9.4607; Ohtani T, 2000, IMMUNITY, V12, P95, DOI 10.1016/S1074-7613(00)80162-4; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; Senga T, 2001, J BIOL CHEM, V276, P32678, DOI 10.1074/jbc.M105749200; Shimozaki K, 1997, J BIOL CHEM, V272, P25184, DOI 10.1074/jbc.272.40.25184; Shirogane T, 1999, IMMUNITY, V11, P709, DOI 10.1016/S1074-7613(00)80145-4; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Williams KL, 2001, EUR J IMMUNOL, V31, P1620, DOI 10.1002/1521-4141(200105)31:5<1620::AID-IMMU1620>3.0.CO;2-3	22	31	32	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2002	21	53					8186	8191		10.1038/sj.onc.1205918	http://dx.doi.org/10.1038/sj.onc.1205918			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615DW	12444555				2022-12-28	WOS:000179231400013
J	Pandey, A; Blagoev, B; Kratchmarova, I; Fernandez, M; Nielsen, M; Kristiansen, TZ; Ohara, O; Podtelejnikov, AV; Roche, S; Lodish, HF; Mann, M				Pandey, A; Blagoev, B; Kratchmarova, I; Fernandez, M; Nielsen, M; Kristiansen, TZ; Ohara, O; Podtelejnikov, AV; Roche, S; Lodish, HF; Mann, M			Cloning of a novel phosphotyrosine binding domain containing molecule, Odin, involved in signaling by receptor tyrosine kinases	ONCOGENE			English	Article						proteomics; mass spectrometry; bioinformatics	MASS-SPECTROMETRY; C-FOS; PROTEIN; IDENTIFICATION; SCAFFOLD; GENE; TRANSDUCTION; SHC; ACTIVATION; INDUCTION	We have used a proteomic approach using mass spectrometry to identify signaling molecules involved in receptor tyrosine kinase signaling pathways. Using affinity purification by anti-phosphotyrosine antibodies to enrich for tyrosine phosphorylated proteins, we have identified a novel signaling molecule in the epidermal growth factor receptor signaling pathway. This molecule, designated Odin, contains several ankyrin repeats, two sterile alpha motifs and a phosphotyrosine binding domain and is ubiquitously expressed. Using antibodies against endogenous Odin, we show that it undergoes tyrosine phosphorylation upon addition of growth factors such as EGF or PDGF but not by cytokines such as IL-3 or erythropoietin. Immunofluorescence experiments as well as Western blot analysis on subcellular fractions demonstrated that Odin is localized to the cytoplasm both before and after growth factor treatment. Deletion analysis showed that the phosphotyrosine binding domain of Odin is not required for its tyrosine phosphorylation. Overexpression of Odin, but not an unrelated adapter protein, Grb2, inhibited EGF-induced activation of c-Fos promoter. Microinjection of wild-type or a mutant version lacking the PTB domain into NIH3T3 fibroblasts inhibited PDGF-induced mitogenesis. Taken together, our results indicate that Odin may play a negative role in growth factor receptor signaling pathways.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Univ So Denmark, Ctr Expt Bioinformat, DK-5230 Odense M, Denmark; Kazusa DNA Res Inst, Chiba 2920812, Japan; RIKEN, Res Ctr Allergy & Immunol, Chiba 2920812, Japan; Ctr Rech Biochim Macromol, F-34293 Montpellier, France	Massachusetts Institute of Technology (MIT); Whitehead Institute; University of Southern Denmark; Kazusa DNA Research Institute; RIKEN; Universite de Montpellier	Pandey, A (corresponding author), Univ So Denmark, Ctr Expt Bioinformat, DK-5230 Odense M, Denmark.	Pandey@cebi.sdu.dk; mann@bmb.sdu.dk	Ohara, Osamu/G-5448-2015; Mann, Matthias/A-3454-2013; Pandey, Akhilesh/B-4127-2009; Ohara, Osamu/A-9119-2012; Podtelejnikov, Alexandre/B-6120-2017	Ohara, Osamu/0000-0002-3328-9571; Mann, Matthias/0000-0003-1292-4799; Pandey, Akhilesh/0000-0001-9943-6127; Podtelejnikov, Alexandre/0000-0002-8124-6584; Blagoev, Blagoy/0000-0002-3596-0066; roche, serge/0000-0003-3413-3859; Kratchmarova, Irina/0000-0001-6613-7315	NCI NIH HHS [K01 CA75447] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA075447] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Burack WR, 2000, CURR OPIN CELL BIOL, V12, P211, DOI 10.1016/S0955-0674(99)00078-2; CURRAN T, 1985, CANCER SURV, V4, P655; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; Ito M, 1999, MOL CELL BIOL, V19, P7539; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; LAVERY DJ, 1993, GENE DEV, V7, P1871, DOI 10.1101/gad.7.10.1871; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Manes G, 2000, MOL CELL BIOL, V20, P3396, DOI 10.1128/MCB.20.10.3396-3406.2000; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; Margolis B, 1999, TRENDS ENDOCRIN MET, V10, P262, DOI 10.1016/S1043-2760(99)00168-X; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Pandey A, 2000, J BIOL CHEM, V275, P38633, DOI 10.1074/jbc.M007849200; Pandey A, 2000, P NATL ACAD SCI USA, V97, P179, DOI 10.1073/pnas.97.1.179; PANDEY A, 2000, SCI STKE, pPL1; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pawson T, 1994, Princess Takamatsu Symp, V24, P303; PONTING CP, 1995, PROTEIN SCI, V4, P1928, DOI 10.1002/pro.5560040927; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Smalla M, 1999, PROTEIN SCI, V8, P1954, DOI 10.1110/ps.8.10.1954; Steen H, 2002, J BIOL CHEM, V277, P1031, DOI 10.1074/jbc.M109992200; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Yaich L, 1998, J BIOL CHEM, V273, P10381, DOI 10.1074/jbc.273.17.10381; Yasuda J, 1999, MOL CELL BIOL, V19, P7245	42	40	45	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2002	21	52					8029	8036		10.1038/sj.onc.1205988	http://dx.doi.org/10.1038/sj.onc.1205988			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	612VY	12439753				2022-12-28	WOS:000179097200012
J	Russo, M; Palumbo, R; Mupo, A; Tosto, M; Iacomino, G; Scognamiglio, A; Tedesco, I; Galano, G; Russo, GL				Russo, M; Palumbo, R; Mupo, A; Tosto, M; Iacomino, G; Scognamiglio, A; Tedesco, I; Galano, G; Russo, GL			Flavonoid quercetin sensitizes a CD95-resistant cell line to apoptosis by activating protein kinase C alpha	ONCOGENE			English	Article						quercetin; PKC alpha; CD95/Fas/Apol; flavonoids; HPB-ALL; apoptosis	PHOSPHOINOSITIDE 3-KINASE; DOWN-REGULATION; DNA-SYNTHESIS; DEATH DOMAIN; COLON-CANCER; IN-VITRO; FAS; INHIBITION; GROWTH; PKC	We previously demonstrated that quercetin, a naturally occurring flavonoid with strong antioxidant properties, was able to enhance programmed cell death in HPB-acute lymphoblastic leukemia (ALL) cell line, derived from a human tymoma, when associated with the agonistic antiCD95 monoclonal antibody. Here, we report that HPBALL cells are normally resistant to Cd95-mediated apoptosis, and quercetin is able to sensitize this cell line through a mechanism independent of its antioxidant properties. In fact, other compounds structurally and functionally similar to quercetin, when associated with anti-CD95 antibody did not induce any CD95-mediated apoptosis, still maintaining their antioxidant capacity. We found that quercetin effects are mediated by the activation of PKCalpha. Treatment of HPB-ALL cells with quercetin slightly decreased PKCa activity, but when the flavonoid was associated with anti-CD95, the kinase activity increased by 12-fold with respect to the treatment with quercetin. In addition, overexpression of PKCalpha induced programmed cell death in the absence of any additional stimulus, while a kinase-defective mutant of PKCalpha was ineffective. Our data confirm the involvement of specific PKC isoforms in CD95 signaling and suggest, for the first time, that quercetin targets this pathway increasing apoptogenic response in a cell line resistant to CD95-mediated apoptosis.	CNR, Ist Sci Alimentaz, I-83100 Avellino, Italy; Staz Zool Anton Dohrn, I-80121 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Scienze dell' Alimentazione (ISA-CNR); Stazione Zoologica Anton Dohrn di Napoli	Russo, GL (corresponding author), CNR, Ist Sci Alimentaz, Via Roma 52 A-C, I-83100 Avellino, Italy.	russogl@inwind.it	Russo, Maria/AAJ-9424-2020; russo, maria/E-8585-2011; RUSSO, GIAN LUIGI/GQB-0962-2022; Iacomino, Giuseppe/AAV-2456-2021	russo, maria/0000-0001-8385-9184; IACOMINO, GIUSEPPE/0000-0001-5231-2231; PALUMBO, ROSANNA/0000-0002-3858-4529; Mupo, Annalisa/0000-0002-2771-0462; RUSSO, GIAN LUIGI/0000-0001-9321-1613				Agullo G, 1997, BIOCHEM PHARMACOL, V53, P1649, DOI 10.1016/S0006-2952(97)82453-7; Alberts DS, 1999, CANCER RES, V59, P4743; ALDERSON MR, 1994, INT IMMUNOL, V6, P1799, DOI 10.1093/intimm/6.11.1799; AVILA MA, 1994, CANCER RES, V54, P2424; Avila MA, 1996, ADV EXP MED BIOL, V401, P101; BORS W, 1990, METHOD ENZYMOL, V186, P343; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Caltagirone S, 2000, INT J CANCER, V87, P595, DOI 10.1002/1097-0215(20000815)87:4&lt;595::AID-IJC21&gt;3.0.CO;2-5; Casagrande F, 2001, BIOCHEM PHARMACOL, V61, P1205, DOI 10.1016/S0006-2952(01)00583-4; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Clement MV, 1996, EMBO J, V15, P216, DOI 10.1002/j.1460-2075.1996.tb00352.x; Cuvillier O, 1998, J BIOL CHEM, V273, P2910, DOI 10.1074/jbc.273.5.2910; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DEBATIN KM, 1995, LEUKEMIA, V9, P815; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; FAUTZ R, 1991, MUTAT RES, V253, P173, DOI 10.1016/0165-1161(91)90130-Z; Ferrandina G, 1998, INT J CANCER, V77, P747, DOI 10.1002/(SICI)1097-0215(19980831)77:5<747::AID-IJC14>3.0.CO;2-Z; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; Frutos S, 1999, J BIOL CHEM, V274, P10765, DOI 10.1074/jbc.274.16.10765; Galati G, 2000, Drug Metabol Drug Interact, V17, P311; Gamet-Payrastre L, 1999, GEN PHARMACOL-VASC S, V32, P279, DOI 10.1016/S0306-3623(98)00220-1; GILLIS S, 1980, J EXP MED, V152, P1709, DOI 10.1084/jem.152.6.1709; Goldberg DM, 1996, ANAL CHEM, V68, P1688, DOI 10.1021/ac951083i; Gomez-Angelats M, 2000, J BIOL CHEM, V275, P19609, DOI 10.1074/jbc.M909563199; Gomez-Angelats M, 2001, J BIOL CHEM, V276, P44944, DOI 10.1074/jbc.M104919200; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; HAGIWARA M, 1988, BIOCHEM PHARMACOL, V37, P2987; Hausler P, 1998, EUR J IMMUNOL, V28, P57, DOI 10.1002/(SICI)1521-4141(199801)28:01<57::AID-IMMU57>3.0.CO;2-8; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Ishikawa Y, 2000, BIOCHEM BIOPH RES CO, V279, P629, DOI 10.1006/bbrc.2000.4016; Iwao K, 1999, BBA-GEN SUBJECTS, V1427, P112, DOI 10.1016/S0304-4165(99)00007-0; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jamieson L, 1999, J BIOL CHEM, V274, P3927, DOI 10.1074/jbc.274.7.3927; JARVIS WD, 1994, CANCER RES, V54, P1707; Kang TB, 1997, BIOCHEM PHARMACOL, V54, P1013, DOI 10.1016/S0006-2952(97)00260-8; Kang ZC, 1999, NUTR CANCER, V35, P175, DOI 10.1207/S15327914NC352_12; KLAS C, 1993, INT IMMUNOL, V5, P625, DOI 10.1093/intimm/5.6.625; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Krammer PH, 1998, ADV CANCER RES, V75, P251, DOI 10.1016/S0065-230X(08)60744-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larocca LM, 1997, INT J CANCER, V73, P75, DOI 10.1002/(SICI)1097-0215(19970926)73:1<75::AID-IJC13>3.0.CO;2-4; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Le Marchand L, 2000, JNCI-J NATL CANCER I, V92, P154, DOI 10.1093/jnci/92.2.154; Li WQ, 1999, ONCOGENE, V18, P6564, DOI 10.1038/sj.onc.1203065; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; Mahmoud NN, 2000, CARCINOGENESIS, V21, P921, DOI 10.1093/carcin/21.5.921; Mandil R, 2001, CANCER RES, V61, P4612; Middleton E, 1986, FLAVONOIDS ADV RES 1, V1993, P619; Mizuno K, 1997, EUR J BIOCHEM, V250, P7, DOI 10.1111/j.1432-1033.1997.00007.x; MORIKAWA S, 1978, INT J CANCER, V21, P166, DOI 10.1002/ijc.2910210207; Mouria M, 2002, INT J CANCER, V98, P761, DOI 10.1002/ijc.10202; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Noroozi M, 2000, EUR J CLIN NUTR, V54, P143, DOI 10.1038/sj.ejcn.1600908; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Plaumann B, 1996, ONCOGENE, V13, P1605; Ranelletti FO, 2000, INT J CANCER, V85, P438, DOI 10.1002/(SICI)1097-0215(20000201)85:3&lt;438::AID-IJC22&gt;3.0.CO;2-F; Reddy BS, 2000, CANCER EPIDEM BIOMAR, V9, P239; Rong Y, 2000, ANTICANCER RES, V20, P4339; Ruiz-Ruiz C, 1999, J IMMUNOL, V163, P4737; Russo M, 1999, FEBS LETT, V462, P322, DOI 10.1016/S0014-5793(99)01544-6; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Shao RG, 1997, J BIOL CHEM, V272, P31321, DOI 10.1074/jbc.272.50.31321; Shimizu T, 1998, J BIOL CHEM, V273, P8669, DOI 10.1074/jbc.273.15.8669; STAVRIC B, 1994, CLIN BIOCHEM, V27, P319, DOI 10.1016/0009-9120(94)00039-5; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Wajant H, 2000, J BIOL CHEM, V275, P24357, DOI 10.1074/jbc.M000811200; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(05)00089-4; Wang IK, 1999, EUR J CANCER, V35, P1517, DOI 10.1016/S0959-8049(99)00168-9; Weber G, 1999, ADV ENZYME REGUL, V39, P51, DOI 10.1016/S0065-2571(98)00027-2; Weisburger JH, 2000, AM J CLIN NUTR, V71, p1710S, DOI 10.1093/ajcn/71.6.1710S; Yang CS, 2001, ANNU REV NUTR, V21, P381, DOI 10.1146/annurev.nutr.21.1.381	73	58	60	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2003	22	21					3330	3342		10.1038/sj.onc.1206493	http://dx.doi.org/10.1038/sj.onc.1206493			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681MM	12761503				2022-12-28	WOS:000183040000015
J	Zada, AAP; Singh, SM; Reddy, VA; Elsasser, A; Meisel, A; Haferlach, T; Tenen, DG; Hiddemann, W; Behre, G				Zada, AAP; Singh, SM; Reddy, VA; Elsasser, A; Meisel, A; Haferlach, T; Tenen, DG; Hiddemann, W; Behre, G			Downregulation of c-Jun expression and cell cycle regulatory molecules in acute myeloid leukemia cells upon CD44 ligation	ONCOGENE			English	Article						CD44; c-Jun; AML; differentiation; proliferation; cell cycle	TRANS-RETINOIC ACID; ADHESION MOLECULE; C/EBP-ALPHA; TRANSCRIPTIONAL ACTIVITY; RETINOBLASTOMA PROTEIN; KINASE-ACTIVITY; DIFFERENTIATION; PHOSPHORYLATION; AP-1; P21	In the present study, we investigated the mechanism of CD44 ligation with the anti-CD44 monoclonal antibody A3D8 to inhibit the proliferation of human acute myeloid leukemia (AML) cells. The effects of A3D8 on myeloid cells were associated with specific disruption of cell cycle events and induction of G0/G1 arrest. Induction of G0/G1 arrest was accompanied by an increase in the expression of p21, attenuation of pRb phosphorylation and associated with decreased Cdk2 and Cdk4 kinase activities. Since c-Jun is an important regulator of proliferation and cell cycle progression, we analysed its role in A3D8-mediated growth arrest. We observed that A3D8 treatment of AML patient blasts and HL60/U937 cells led to the down-regulation of c-Jun expression at mRNA and protein level. Transient transfection studies showed the inhibition of c-jun promoter activity by A3D8, involving both AP-1 sites. Furthermore, A3D8 treatment caused a decrease in JNK protein expression and a decrease in the level of phosphorylated c-Jun. Ectopic overexpression of c-Jun in HL60 cells was able to induce proliferation and prevent the antiproliferative effects of A3D8. In summary, these data identify an important functional role of c-Jun in the induction of cell cycle arrest and proliferation arrest of myeloid leukemia cells because of the ligation of the cell surface adhesion receptor CD44 by anti-CD44 antibody. Moreover, targeting of G1 regulatory proteins and the resulting induction of G I arrest by A3D8 may provide new insights into antiproliferative and differentiation therapy of AML.	Univ Munich, Klinikum Grosshadern, D-81377 Munich, Germany; GSF Munich, Hematologikum, D-81377 Munich, Germany; Harvard Univ, Sch Med, Harvard Inst Med, Boston, MA 02115 USA	University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Harvard University; Harvard Medical School	Behre, G (corresponding author), Univ Munich, Klinikum Grosshadern, Marchioninistr 15, D-81377 Munich, Germany.	gerdbehre@aol.com		Tenen, Daniel/0000-0002-6423-3888				Allouche M, 2000, BLOOD, V96, P1187, DOI 10.1182/blood.V96.3.1187.015k01_1187_1190; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; BATES S, 1994, ONCOGENE, V9, P1633; Behre G, 1999, METHODS, V17, P231, DOI 10.1006/meth.1998.0733; Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; Behre G, 1999, BIOTECHNIQUES, V26, P24, DOI 10.2144/99261bm03; Behre G, 2002, J BIOL CHEM, V277, P26293, DOI 10.1074/jbc.M202301200; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; Charrad RS, 2002, BLOOD, V99, P290, DOI 10.1182/blood.V99.1.290; Charrad RS, 1999, NAT MED, V5, P669, DOI 10.1038/9518; CHOU SY, 1992, MOL BIOL CELL, V3, P1117, DOI 10.1091/mbc.3.10.1117; DANOVA M, 1990, LEUKEMIA RES, V14, P417, DOI 10.1016/0145-2126(90)90027-7; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; ELSASSER A, 2002, ASH, V100, P200; Emig M, 1999, LEUKEMIA, V13, P1825, DOI 10.1038/sj.leu.2401566; Gitig DM, 2000, METH MOL B, V142, P109; HARPER JW, 1993, CELL, V75, P805; HILBERG F, 1992, ONCOGENE, V7, P2371; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; HORIGUCHIYAMADA J, 1994, MOL CELL BIOCHEM, V132, P31, DOI 10.1007/BF00925672; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG HP, 1994, ONCOGENE, V9, P3397; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kantarjian H, 1999, SEMIN HEMATOL, V36, P16; Kiaris H, 1999, ONCOGENE, V18, P7168, DOI 10.1038/sj.onc.1203213; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KUHN LC, 1994, BAILLIERE CLIN HAEM, V7, P763, DOI 10.1016/S0950-3536(05)80123-4; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LIESVELD JL, 1994, LEUKEMIA LYMPHOMA, V14, P19, DOI 10.3109/10428199409049647; Lowell CA, 1999, J LEUKOCYTE BIOL, V65, P313, DOI 10.1002/jlb.65.3.313; Lowenberg B, 1999, NEW ENGL J MED, V341, P1051, DOI 10.1056/NEJM199909303411407; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Milde-Langosch K, 2000, INT J CANCER, V87, P468, DOI 10.1002/1097-0215(20000815)87:4<468::AID-IJC2>3.0.CO;2-R; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MIYAKE K, 1990, J EXP MED, V172, P69, DOI 10.1084/jem.172.1.69; Moll J, 1998, J CLIN INVEST, V102, P1024, DOI 10.1172/JCI2494; MULLER R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P151, DOI 10.1016/0304-419X(93)90003-U; Nead MA, 1998, EMBO J, V17, P2342, DOI 10.1093/emboj/17.8.2342; Nishitani J, 1999, J BIOL CHEM, V274, P5454, DOI 10.1074/jbc.274.9.5454; Patel R, 1998, J CELL SCI, V111, P2247; Pisani F, 1997, ANN HEMATOL, V75, P145, DOI 10.1007/s002770050332; Rangatia J, 2002, MOL CELL BIOL, V22, P8681, DOI 10.1128/MCB.22.24.8681-8694.2002; Reddy VA, 2002, BLOOD, V100, P483, DOI 10.1182/blood.V100.2.483; REUSSBORST MA, 1992, ANN HEMATOL, V65, P169, DOI 10.1007/BF01703110; SANFORD JS, 1998, BLOOD, V91, P2645; SAVATIER P, 1994, ONCOGENE, V9, P809; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SHERR CJ, 1994, STEM CELLS, V12, P47; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; Sievers EL, 2000, CURR OPIN ONCOL, V12, P30, DOI 10.1097/00001622-200001000-00005; SLACK RS, 1993, ONCOGENE, V8, P1585; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMITH MJ, 1992, BLOOD, V79, P2107; Steinman RA, 1998, BLOOD, V91, P4531, DOI 10.1182/blood.V91.12.4531.412k10_4531_4542; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; THEIL EC, 1990, J BIOL CHEM, V265, P4771; Trayner ID, 1998, LEUKEMIA RES, V22, P537, DOI 10.1016/S0145-2126(98)00041-1; Vangala RK, 2003, BLOOD, V101, P270, DOI 10.1182/blood-2002-04-1288; Verfaillie CM, 1998, BLOOD, V92, P2609, DOI 10.1182/blood.V92.8.2609; Waxman S, 2000, LEUKEMIA, V14, P491, DOI 10.1038/sj.leu.2401714; Wei P, 1998, MOL ENDOCRINOL, V12, P1322, DOI 10.1210/me.12.9.1322; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188	67	37	47	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2003	22	15					2296	2308		10.1038/sj.onc.1206330	http://dx.doi.org/10.1038/sj.onc.1206330			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	667KV	12700665				2022-12-28	WOS:000182231500008
J	Falahatpisheh, MH; Ramos, KS				Falahatpisheh, MH; Ramos, KS			Ligand-activated Ahr signaling leads to disruption of nephrogenesis and altered Wilms' tumor suppressor mRNA splicing	ONCOGENE			English	Article						Ahr; WT1 splicing; nephrogenesis	ARYL-HYDROCARBON RECEPTOR; GENE-EXPRESSION; EMBRYONAL CARCINOMA; KIDNEY DEVELOPMENT; DEFICIENT MICE; WT1 GENE; GROWTH; CELLS; TRANSCRIPTION; INVOLVEMENT	The aryl hydrocarbon receptor (Ahr), a member of the large basic helix-loop-helix (bHLH) and PAS homology domain superfamily, is a highly conserved transcriptional regulator involved in mammalian development. In the present study, a murine metanephros organ culture system was employed to evaluate the role of the Ahr signaling in nephrogenesis in vitro. Ahr and Wilms' tumor suppressor (wt1) mRNAs were detected by in situ hybridization and RT-PCR during the course of renal development. Treatment with 3 pm BaP, a hydrocarbon ligand of Ahr, inhibited glomerulogenesis and branching morphogenesis of metanephric kidneys. Deficits in the epithelialization of mesenchymal cells were evidenced by inhibition of the formation of podocyte foot processes and glomerular basement membranes. Hydrocarbon treatment markedly induced -KTS wt1 splice variants, although total wt1 mRNA levels remained unchanged. A significant decrease in total WT1 protein was observed by both immunocytochemistry and Western analysis in cultures challenged with BaP compared to controls. Comparison of metanephric cultures from Ahr+/+ and Ahr-/- mice showed that Ahr is involved in kidney development, and required for BaP-induced deficits in nephrogenesis. These results indicate that ligand activation of Ahr signaling disrupts nephrogenesis in vitro, and that this response involves modulation of wt1 alternative splicing and post-transcriptional control.	Texas A&M Univ, Ctr Environm & Rural Hlth, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station	Ramos, KS (corresponding author), Texas A&M Univ, Ctr Environm & Rural Hlth, College Stn, TX 77843 USA.				NIEHS NIH HHS [ES09106, ES04917] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009106, P42ES004917] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abbott BD, 1995, TOXICOLOGY, V105, P365, DOI 10.1016/0300-483X(95)03234-7; ASWIN M, 1998, KIDNEY INT, V53, P1512; AVNER ED, 1990, PEDIATR NEPHROL, V4, P372, DOI 10.1007/BF00862522; AVNER ED, 1993, SEMIN NEPHROL, V13, P427; Barbaux S, 1997, NAT GENET, V17, P467, DOI 10.1038/ng1297-467; Bowes RC, 1996, BIOCHEM PHARMACOL, V52, P587, DOI 10.1016/0006-2952(96)00310-3; BOWES RC, 1994, TOXICOL IN VITRO, V8, P1151, DOI 10.1016/0887-2333(94)90104-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruening W, 1996, J BIOL CHEM, V271, P8646, DOI 10.1074/jbc.271.15.8646; Cantrell SM, 1998, TOXICOL APPL PHARM, V148, P24, DOI 10.1006/taap.1997.8309; Carver LA, 1997, J BIOL CHEM, V272, P11452; Crews ST, 1999, CURR OPIN GENET DEV, V9, P580, DOI 10.1016/S0959-437X(99)00003-9; Dressler G R, 1997, Adv Nephrol Necker Hosp, V26, P1; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; GESSLER M, 1992, GENOMICS, V12, P807, DOI 10.1016/0888-7543(92)90313-H; Gutierrez A, 1997, MOL BRAIN RES, V45, P59, DOI 10.1016/S0169-328X(96)00237-9; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HABIB R, 1985, CLIN NEPHROL, V24, P269; Hammes A, 2001, CELL, V106, P319, DOI 10.1016/S0092-8674(01)00453-6; Hewitt SM, 1996, ANTICANCER RES, V16, P621; Hida M, 2002, KIDNEY INT, V61, P1252, DOI 10.1046/j.1523-1755.2002.00273.x; Hundeiker C, 1999, INT J IMMUNOPHARMACO, V21, P841, DOI 10.1016/S0192-0561(99)00053-3; Hushka LJ, 1998, TOXICOL APPL PHARM, V152, P200, DOI 10.1006/taap.1998.8508; KAFAFI SA, 1993, CHEM RES TOXICOL, V6, P328, DOI 10.1021/tx00033a012; Kim DW, 2000, ONCOGENE, V19, P5498, DOI 10.1038/sj.onc.1203945; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Kudoh T, 1996, ONCOGENE, V13, P1431; Lahvis GP, 2000, P NATL ACAD SCI USA, V97, P10442, DOI 10.1073/pnas.190256997; Laity JH, 2000, BIOCHEMISTRY-US, V39, P5341, DOI 10.1021/bi9926678; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; NEBERT DW, 1994, BIOCHEM PHARMACOL, V47, P25, DOI 10.1016/0006-2952(94)90434-0; Peters JM, 1999, TOXICOL SCI, V47, P86, DOI 10.1093/toxsci/47.1.86; PETERSON RE, 1993, CRIT REV TOXICOL, V23, P283, DOI 10.3109/10408449309105013; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; Renshaw J, 1997, GENE CHROMOSOME CANC, V19, P256, DOI 10.1002/(SICI)1098-2264(199708)19:4<256::AID-GCC8>3.0.CO;2-W; RYAN G, 1995, DEVELOPMENT, V121, P867; SAXON L, 1987, ORGANOGENESIS KIDNEY; Scharnhorst V, 1997, CELL GROWTH DIFFER, V8, P133; Scharnhorst V, 1999, J BIOL CHEM, V274, P23456, DOI 10.1074/jbc.274.33.23456; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; SHARMA PM, 1994, GENE DEV, V8, P720, DOI 10.1101/gad.8.6.720; Toth T, 1996, NEPHRON, V74, P64, DOI 10.1159/000189283; WALKER C, 1994, CANCER RES, V54, P3101; WANG ZY, 1992, J BIOL CHEM, V267, P21999; Winn LM, 1997, FREE RADICAL BIO MED, V22, P607, DOI 10.1016/S0891-5849(96)00340-1; Yeger H, 1996, IN VITRO CELL DEV-AN, V32, P496; Zaher H, 1998, MOL PHARMACOL, V54, P313, DOI 10.1124/mol.54.2.313	47	29	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 10	2003	22	14					2160	2171		10.1038/sj.onc.1206238	http://dx.doi.org/10.1038/sj.onc.1206238			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664NJ	12687018	Bronze			2022-12-28	WOS:000182066900010
J	Murray, SA; Zheng, HW; Gu, L; Xiao, ZXJ				Murray, SA; Zheng, HW; Gu, L; Xiao, ZXJ			IGF-1 activates p21 to inhibit UV-induced cell death	ONCOGENE			English	Article						IGF-1; Akt; p53; p21; UV and apoptosis	SERINE-THREONINE KINASE; MYC-INDUCED APOPTOSIS; NF-KAPPA-B; P53-INDUCED APOPTOSIS; TUMOR-SUPPRESSOR; CANCER-CELLS; TRANSCRIPTION FACTOR; GROWTH-FACTORS; DNA-DAMAGE; P53	The insulin-like growth factor-1 (IGF-1) and its downstream effector Akt have been documented as survival factors in response to a variety of stress signals. In this study, we show that IGF-1 activates p21 protein expression in a p53-dependent manner. Inhibition of PI-3 kinase or ectopic expression of a dominant-negative Akt blocks the effect of IGF-1 on the upregulation of p21 expression. In addition, IGF-1 prevents the UV irradiation-mediated suppression of p21 and MDM2 expression. Furthermore, p21 is important for IGF-1-mediated cell survival upon UV irradiation. Taken together, these data indicate that IGF-1 may activate p21 in executing its survival function upon genotoxic insults.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA	Boston University; Boston University	Xiao, ZXJ (corresponding author), Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA.	jxiao@bu.edu		Zheng, Hongwu/0000-0002-5823-4913	NATIONAL CANCER INSTITUTE [R01CA079804] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA79804] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Carter CS, 2002, TRENDS GENET, V18, P295, DOI 10.1016/S0168-9525(02)02696-3; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; GEIER A, 1995, CANCER INVEST, V13, P480, DOI 10.3109/07357909509024911; Gooch JL, 1999, BREAST CANCER RES TR, V56, P1, DOI 10.1023/A:1006208721167; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; Grimberg A, 2000, J CELL PHYSIOL, V183, P1, DOI 10.1002/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO;2-J; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lawlor MA, 2000, MOL CELL BIOL, V20, P8983, DOI 10.1128/MCB.20.23.8983-8995.2000; Lawlor MA, 2000, J CELL BIOL, V151, P1131, DOI 10.1083/jcb.151.6.1131; Lawrence JW, 2001, J BIOL CHEM, V276, P31521, DOI 10.1074/jbc.M103306200; Lu X, 1996, ONCOGENE, V13, P413; Matsui T, 1999, CIRCULATION, V100, P2373, DOI 10.1161/01.CIR.100.23.2373; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; McKay BC, 1998, ONCOGENE, V17, P545, DOI 10.1038/sj.onc.1201963; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; Mitsuuchi Y, 2000, CANCER RES, V60, P5390; MIYASHITA T, 1995, CELL, V80, P293; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nghiem P, 2001, P NATL ACAD SCI USA, V98, P9092, DOI 10.1073/pnas.161281798; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okubo Y, 1998, J BIOL CHEM, V273, P25961, DOI 10.1074/jbc.273.40.25961; Ozes ON, 1999, NATURE, V401, P82; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Rossig L, 2001, MOL CELL BIOL, V21, P5644, DOI 10.1128/MCB.21.16.5644-5657.2001; ROSSIG L, 2002, J BIOL CHEM, V4, P4; Sandhu MS, 2002, J NATL CANCER I, V94, P972; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Shimoke K, 1999, DEV BRAIN RES, V112, P245, DOI 10.1016/S0165-3806(98)00172-2; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang JA, 1999, INT J RADIAT BIOL, V75, P301, DOI 10.1080/095530099140483; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; Xu SQ, 2000, BIOCHEM BIOPH RES CO, V269, P179, DOI 10.1006/bbrc.2000.2247; Zeng XY, 2000, CANCER RES, V60, P6184; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	67	24	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	2003	22	11					1703	1711		10.1038/sj.onc.1206327	http://dx.doi.org/10.1038/sj.onc.1206327			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642873				2022-12-28	WOS:000181580500012
J	Ferrara, P; Andermarcher, E; Bossis, G; Acquaviva, C; Brockly, F; Jariel-Encontre, I; Piechaczyk, M				Ferrara, P; Andermarcher, E; Bossis, G; Acquaviva, C; Brockly, F; Jariel-Encontre, I; Piechaczyk, M			The structural determinants responsible for c-Fos protein proteasomal degradation differ according to the conditions of expression	ONCOGENE			English	Article						c-Fos; protein degradation; proteasome	IN-VITRO; PROTOONCOGENE PRODUCT; G0-TO-G1 TRANSITION; MOUSE FIBROBLASTS; V-FOS; JUN; AP-1; PHOSPHORYLATION; TRANSCRIPTION; KINASE	c-fos gene is expressed constitutively in a number of tissues as well as in certain tumor cells and is inducible, in general rapidly and transiently, in virtually all other cell types by a variety of stimuli. Its protein product, c-Fos, is a short-lived transcription factor that heterodimerizes with various protein partners within the AP-1 transcription complex via leucine zipper/leucine zipper interactions for binding to specific DNA sequences. It is mostly, if not exclusively, degraded by the proteasome. To localize the determinant(s) responsible for its instability, we have conducted a genetic analysis in which the half-lives of c-Fos mutants and chimeras made with the stable EGFP reporter protein were compared under two experimental conditions taken as example of continous and inducible expression. Those were constitutive expression in asynchronously growing Balb/C 3T3 mouse embryo fibroblasts and transient induction in the same cells undergoing the G0/G1 phase transition upon stimulation by serum. Our work shows that c-Fos is degraded faster in synchronous-than in asynchronous cells. This difference in turnover is primarily accounted for by several mechanisms. First, in asynchronous cells, a unique C-terminal destabilizer is active whereas, in serum-stimulated cells two destabilizers located at both extremities of the protein are functional. Second, heterodimerization and/or binding to DNA accelerates protein degradation only during the G0/G1 phase transition. Adding another level of complexity to turnover control, phosphorylation at serines 362 and 374, which are c-Fos phosphorylation sites largely modified during the G0/G1 phase transition, stabilizes c-Fos much more efficiently in asynchronous than in serum-stimulated cells. In both cases, the reduced degradation rate is due to inhibition of the activity of the C-terminal destabilizer. However, in serum-stimulated cells, this effect is partially masked by the activation of the N-terminal destabilizer and basic domain/leucine zipper-dependent mechanisms. Taken together, our data show that multiple degradation mechanisms, differing according to the conditions of expression, may operate on c-Fos to ensure a proper level and/or timing of expression. Moreover, they also indicate that the half-life of c-Fos during the G0/G1 phase transition is determined by a delicate balance between opposing stabilizing and destabilizing mechanisms operating at the same time.	CNRS, UMR 5535, Inst Mol Genet, IFR24, F-34293 Montpellier 05, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Piechaczyk, M (corresponding author), CNRS, UMR 5535, Inst Mol Genet, IFR24, 1919 Route Mende, F-34293 Montpellier 05, France.	piechaczyk@igm.cnrs-mop.fr	PIECHACZYK, Marc/E-7896-2013; Acquaviva, Claire/N-4306-2017; Bossis, Guillaume/C-7172-2012	PIECHACZYK, Marc/0000-0003-1367-2597; Acquaviva, Claire/0000-0002-0227-9813; bossis, guillaume/0000-0002-3349-8250				ABATE C, 1990, CELL GROWTH DIFFER, V1, P455; Acquaviva C, 2001, ONCOGENE, V20, P7563, DOI 10.1038/sj.onc.1204880; Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; Bakiri L, 2002, MOL CELL BIOL, V22, P4952, DOI 10.1128/MCB.22.13.4952-4964.2002; Chaussepied M, 1998, MOL BIOCHEM PARASIT, V94, P215, DOI 10.1016/S0166-6851(98)00070-X; Chen JS, 1997, J NEUROSCI, V17, P4933; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; Chen RH, 1996, ONCOGENE, V12, P1493; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Coux Olivier, 2002, Prog Mol Subcell Biol, V29, P85; Curran T, 1988, ONCOGENE HDB, P307; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; DOBRZANSKI P, 1991, MOL CELL BIOL, V11, P5470, DOI 10.1128/MCB.11.11.5470; EIBL B, 1995, CYTOKINES MOL THER, V1, P29; Ferdous A, 2001, MOL CELL, V7, P981, DOI 10.1016/S1097-2765(01)00250-7; FUJII M, 1991, ONCOGENE, V6, P1023; Gamberi G, 1998, ONCOLOGY-BASEL, V55, P556, DOI 10.1159/000011912; Gianni M, 2002, EMBO J, V21, P3760, DOI 10.1093/emboj/cdf374; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gonzalez F, 2002, SCIENCE, V296, P548, DOI 10.1126/science.1069490; GRUDA MC, 1994, ONCOGENE, V9, P2537; Hafezi F, 1997, NAT MED, V3, P346, DOI 10.1038/nm0397-346; He HL, 1998, J BIOL CHEM, V273, P25015, DOI 10.1074/jbc.273.39.25015; Herdegen T, 2001, ONCOGENE, V20, P2424, DOI 10.1038/sj.onc.1204387; HermidaMatsumoto ML, 1996, J BIOL CHEM, V271, P4930; HUANG TS, 1995, CANCER LETT, V96, P1, DOI 10.1016/0304-3835(95)03918-M; IWAHASHI M, 1994, BRIT J HAEMATOL, V86, P193, DOI 10.1111/j.1365-2141.1994.tb03275.x; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KANAITSUKA T, 1988, ACTA PATHOL JAPON, V38, P1523; Kanaitsuka T, 1987, Nihon Naika Gakkai Zasshi, V76, P1595; Kim YH, 2000, BRAIN RES, V872, P227, DOI 10.1016/S0006-8993(00)02477-X; Kisselev AF, 2001, CHEM BIOL, V8, P739, DOI 10.1016/S1074-5521(01)00056-4; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; Krappmann D, 1996, EMBO J, V15, P6716, DOI 10.1002/j.1460-2075.1996.tb01061.x; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; Li XQ, 1998, J BIOL CHEM, V273, P34970, DOI 10.1074/jbc.273.52.34970; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Masuyama H, 1998, J CELL BIOCHEM, V71, P429, DOI 10.1002/(SICI)1097-4644(19981201)71:3<429::AID-JCB11>3.0.CO;2-P; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; Navon A, 2001, MOL CELL, V8, P1339, DOI 10.1016/S1097-2765(01)00407-5; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; PAPAVASSILIOU AG, 1992, SCIENCE, V258, P1941, DOI 10.1126/science.1470918; Perkins G, 2001, EMBO J, V20, P4836, DOI 10.1093/emboj/20.17.4836; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; PIECHACZYK M, 1994, CRIT REV ONCOL HEMAT, V17, P93, DOI 10.1016/1040-8428(94)90021-3; RANSONE LJ, 1990, P NATL ACAD SCI USA, V87, P3806, DOI 10.1073/pnas.87.10.3806; RECH J, 1989, NUCLEIC ACIDS RES, V17, P2874, DOI 10.1093/nar/17.7.2874; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; Rubio N, 1996, J NEUROVIROL, V2, P167, DOI 10.3109/13550289609146879; Salvat C, 1998, ONCOGENE, V17, P327, DOI 10.1038/sj.onc.1201922; Sambrook J, 1989, MOL CLONING; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106; Su KH, 2000, BIOCHEM J, V348, P281, DOI 10.1042/0264-6021:3480281; Tajima S, 2002, J VIROL, V76, P2557, DOI 10.1128/JVI.76.5.2557-2562.2002; Tansey WP, 2001, GENE DEV, V15, P1045, DOI 10.1101/gad.896501; Thomas D, 2000, CURR BIOL, V10, pR341, DOI 10.1016/S0960-9822(00)00462-0; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Wang WL, 1996, P NATL ACAD SCI USA, V93, P8236, DOI 10.1073/pnas.93.16.8236; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; Zhang JH, 2002, NAT GENET, V30, P416, DOI 10.1038/ng859	70	53	53	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2003	22	10					1461	1474		10.1038/sj.onc.1206266	http://dx.doi.org/10.1038/sj.onc.1206266			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652ZZ	12629509				2022-12-28	WOS:000181411900003
J	Weston, CR; Balmanno, K; Chalmers, C; Hadfield, K; Molton, SA; Ley, R; Wagner, EF; Cook, SJ				Weston, CR; Balmanno, K; Chalmers, C; Hadfield, K; Molton, SA; Ley, R; Wagner, EF; Cook, SJ			Activation of ERK1/2 by Delta Raf-1 : ER* represses bim expression independently of the JNK or PI3K pathways	ONCOGENE			English	Article						apoptosis; bim; ERK; Raf; JNK; PI3K	PROGRAMMED CELL-DEATH; BCL-2 FAMILY-MEMBER; C-JUN; BH3 DOMAIN; MOLECULAR-CLONING; CYCLE ARREST; PROTEIN BIM; APOPTOSIS; SURVIVAL; GENE	CC139 fibroblasts are one of several model systems in which the Raf --> MEK --> ERK1/2 pathway can inhibit apoptosis independently of the PI3K pathway; however, the precise mechanism for this protective effect is not known. Serum withdrawal from CC139 fibroblasts resulted in the rapid onset of apoptosis, which was prevented by actinomycin D or cycloheximide. Serum withdrawal promoted the rapid, de novo accumulation of BiMEL, a proapoptotic 'BH3-only' member of the Bcl-2 protein family. BiMEL expression was an early event, occurring several hours prior to caspase activation. In contrast to studies in neurons, activation of the JNK - cJun pathway was neither necessary nor sufficient to induce BiMEL expression. Selective inhibition of either the ERK pathway (with U0126) or the PI3K pathway (with LY294002) caused an increase in the expression of BiMEL. Furthermore, selective activation of the ERK1/2 pathway by DeltaRaf-1:ER*:ER* substantially reduced BiMEL expression, abolished conformational changes in Bax and blocked the appearance of apoptotic cells. The ability of DeltaRaf-1:ER* to repress Bim(EL) expression required the ERK pathway but was independent of the PI3K --> PDK --> PKB pathway. Thus, serum withdrawal-induced expression of BiMEL occurs independently of the JNK --> c-Jun pathway and can be repressed by the ERK pathway independently of the PI3K pathway. This may contribute to Raf- and Ras-induced cell survival at low serum concentrations.	Babraham Inst, Signalling Programme, Cambridge CB2 4AT, England; Res IMP, A-1030 Vienna, Austria; Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Worcester, MA 01605 USA	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester	Cook, SJ (corresponding author), Babraham Inst, Signalling Programme, Cambridge CB2 4AT, England.	simon.cook@bbsrc.ac.uk		Wagner, Erwin F/0000-0001-7872-0196; Balmanno, Kathryn/0000-0002-6417-3889	Biotechnology and Biological Sciences Research Council [BBS/E/B/0000H457, BBS/E/B/0000C199] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bouillet P, 2001, MAMM GENOME, V12, P163, DOI 10.1007/s003350010242; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cook SJ, 1999, MOL CELL BIOL, V19, P330; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Garner AP, 2002, ONCOGENE, V21, P8089, DOI 10.1038/sj.onc.1206000; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Harris CA, 2001, J BIOL CHEM, V276, P37754; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; HILBERG F, 1992, ONCOGENE, V7, P2371; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1432, DOI 10.1210/me.12.9.1432; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Imaizumi K, 1999, J BIOL CHEM, V274, P7975, DOI 10.1074/jbc.274.12.7975; Imaizumi K, 1997, J BIOL CHEM, V272, P18842, DOI 10.1074/jbc.272.30.18842; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; Le Gall M, 2000, MOL BIOL CELL, V11, P1103, DOI 10.1091/mbc.11.3.1103; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Makin GWJ, 2001, EMBO J, V20, P6306, DOI 10.1093/emboj/20.22.6306; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; Miyashita MUT, 2001, FEBS LETT, V509, P135, DOI 10.1016/S0014-5793(01)03145-3; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; O'Reilly LA, 2000, AM J PATHOL, V157, P449, DOI 10.1016/S0002-9440(10)64557-9; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Shinjyo T, 2001, MOL CELL BIOL, V21, P854, DOI 10.1128/MCB.21.3.854-864.2001; Talapatra S, 2001, J PHARMACOL EXP THER, V298, P873; VASQUEZ F, 2000, BIOCHIM BIOPHYS ACTA, V1470, pM21; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	52	154	159	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2003	22	9					1281	1293		10.1038/sj.onc.1206261	http://dx.doi.org/10.1038/sj.onc.1206261			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618753				2022-12-28	WOS:000181360900002
J	Kroger, A; Dallugge, A; Kirchhoff, S; Hauser, H				Kroger, A; Dallugge, A; Kirchhoff, S; Hauser, H			IRF-1 reverts the transformed phenotype of oncogenically transformed cells in vitro and in vivo	ONCOGENE			English	Article						interferon regulatory factor-1 (IRF-1); cell proliferation; reversion of tumorigenicity; interferon	REGULATORY FACTOR-I; TRANSCRIPTION FACTOR IRF-1; HIGHER EUKARYOTIC CELLS; NATURAL-KILLER-CELLS; GROWTH INHIBITION; PROTEIN-KINASE; LYSYL OXIDASE; DNA-DAMAGE; INTERFERON; GENE	The expression of the transcriptional activator and tumor suppressor IRF-1 induces multiple effects that counteract the growth of tumor cells in vitro and in vivo. These include the inhibition of cell proliferation, the secretion of interferon-beta (IFN-beta), the induction of apoptosis specifically in certain cell types and the induction of a strong T-cell response. Here, we show that apart from its immune-activating properties, IRF-1 expression leads to a reversion of the tumorigenic phenotype of NIH3T3 cells transformed by different oncogenes. This was analysed in detail in a cell line in which the expression of c-Ha-ras and c-myc is under the control of a doxycycline-regulated promoter allowing to switch between the normal and oncogenic cell status. In the same cells, a beta-estradiol activatable IRF-1 fusion protein is expressed. After IRF-1 activation the oncogene-mediated acceleration of the cell cycle is reverted. Further, a complete IRF-1-mediated reversion of the oncogenic phenotype is observed in soft-agar growth assays. IRF-1 activation induces IFN-beta secretion; however, the observed effects are not mediated by IFN-beta. Inhibition of tumor growth is observed in nude mice as long as IRF-1 is active, indicating that neither B-nor T-cells must become activated for tumor growth suppression.	GBF, German Res Ctr Biotechnol, Dept Gene Regulat & Differentiat, D-38124 Braunschweig, Germany	Helmholtz Association; Helmholtz-Center for Infection Research	Hauser, H (corresponding author), GBF, German Res Ctr Biotechnol, Dept Gene Regulat & Differentiat, Mascheroder Weg 1, D-38124 Braunschweig, Germany.							Andoh A, 2002, J IMMUNOL, V169, P1683, DOI 10.4049/jimmunol.169.4.1683; Baasner S, 1996, ONCOGENE, V13, P901; BARON U, 1995, NUCLEIC ACIDS RES, V23, P3605, DOI 10.1093/nar/23.17.3605; BENECH P, 1987, MOL CELL BIOL, V7, P4498, DOI 10.1128/MCB.7.12.4498; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BRIKEN V, 1995, MOL CELL BIOL, V15, P975; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; COLBEREGARAPIN F, 1981, J MOL BIOL, V150, P1, DOI 10.1016/0022-2836(81)90321-1; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; DINTER H, 1987, EUR J BIOCHEM, V166, P103, DOI 10.1111/j.1432-1033.1987.tb13488.x; Futaki M, 1996, LEUKEMIA RES, V20, P601, DOI 10.1016/0145-2126(96)00013-6; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRESSER I, 1989, ACTA ONCOL, V28, P347, DOI 10.3109/02841868909111205; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; Hobart M, 1996, TRANSPLANTATION, V62, P1895, DOI 10.1097/00007890-199612270-00037; Horiuchi M, 1997, J BIOL CHEM, V272, P11952, DOI 10.1074/jbc.272.18.11952; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; KIRCHHOFF S, 1995, TRENDS GENET, V11, P219, DOI 10.1016/S0168-9525(00)89053-8; Kirchhoff S, 1999, ONCOGENE, V18, P3725, DOI 10.1038/sj.onc.1202704; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; KIRCHHOFF S, 1995, ONCOGENE, V11, P439; Kirchhoff S, 1999, EUR J BIOCHEM, V261, P546, DOI 10.1046/j.1432-1327.1999.00308.x; Kroger A, 2002, J INTERF CYTOK RES, V22, P5, DOI 10.1089/107999002753452610; Kroger A, 2001, CANCER RES, V61, P2609; Kwissa M, 2000, J MOL MED-JMM, V78, P495, DOI 10.1007/s001090000135; LENGYEL P, 1982, ANNU REV BIOCHEM, V51, P251, DOI 10.1146/annurev.bi.51.070182.001343; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; Nguyen H, 1997, ONCOGENE, V15, P1425, DOI 10.1038/sj.onc.1201318; Ogasawara K, 1998, NATURE, V391, P700, DOI 10.1038/35636; Ohteki T, 1998, J EXP MED, V187, P967, DOI 10.1084/jem.187.6.967; Park JS, 2000, J BIOL CHEM, V275, P6764, DOI 10.1074/jbc.275.10.6764; Qin XQ, 2001, MOL THER, V4, P356, DOI 10.1006/mthe.2001.0464; Salkowski CA, 1996, J IMMUNOL, V156, P3107; Sambrook J., 2002, MOL CLONING LAB MANU; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; TAKIKAWA O, 1988, J BIOL CHEM, V263, P2041; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tamura Tomohiko, 1997, Leukemia (Basingstoke), V11, P439; Tan RSP, 1996, CANCER RES, V56, P2417; TANAKA H, 1994, P NATL ACAD SCI USA, V91, P7995, DOI 10.1073/pnas.91.17.7995; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANAKA N, 1994, CANCER LETT, V83, P191, DOI 10.1016/0304-3835(94)90318-2; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TANIGUCHI T, 1997, BIOCHIM BIOPHYS ACTA, V1333, P9; Unsinger J, 2001, MOL THER, V4, P484, DOI 10.1006/mthe.2001.0480; Yim JH, 1997, J IMMUNOL, V158, P1284	50	47	49	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 20	2003	22	7					1045	1056		10.1038/sj.onc.1206260	http://dx.doi.org/10.1038/sj.onc.1206260			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	644PB	12592391				2022-12-28	WOS:000180926100010
J	Tsai, MS; Shamon-Taylor, LA; Mehmi, I; Tang, CK; Lupu, R				Tsai, MS; Shamon-Taylor, LA; Mehmi, I; Tang, CK; Lupu, R			Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer	ONCOGENE			English	Article						HRG antisense; tumorigenicity; metastasis; breast cancer	MATRIX-METALLOPROTEINASE-9 EXPRESSION; SIGNAL-TRANSDUCTION; ONCOGENE PRODUCT; GROWTH-FACTOR; RECEPTOR; ERBB-2; DIFFERENTIATION; ACTIVATION; PATHWAYS; LIGAND	The growth factor heregulin (HRG), expressed in about 30% of breast cancer tumors, activates the erbB-2 receptor via induction of heterodimeric complexes of erbB-2 with erbB-3 or erB-4. HRG induces tumorigenicity and metastasis of breast cancer cells. Our investigation into whether HRG is a factor likely to promote tumor formation independently of erbB-2 overexpression concludes that blockage of HRG expression suppresses the aggressive phenotype of MDA-MB-231 breast cancer cells by inhibiting cell proliferation, preventing anchorage-independent growth, and suppressing the invasive potential of the cells in vitro. More importantly, we observed a marked reduction in tumor formation, tumor size, and a lack of metastasis in vivo. These studies were achieved by blocking HRG expression in MDA-MB-231 cells using an HRG antisense cDNA. In the search for the mechanism by which blockage of HRG reverts this aggressive phenotype, we discovered that the cells in which HRG is blocked exhibit a marked decrease in erbB activation and a significant reduction in MMP-9 activity, demonstrating a direct causal role in HRG induction of tumorigenicity. Our study is the first report and serves as a proof of the concept that HRG is a key promoter of breast cancer tumorigenicity and metastasis independently of erbB-2 overexpression and should be deemed a potential target in developing therapies for breast cancer.	Northwestern Univ, Evanston NW Healthcare Res Inst, Sch Med, Evanston, IL 60201 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA; Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA	Northwestern University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Georgetown University	Lupu, R (corresponding author), Northwestern Univ, Evanston NW Healthcare Res Inst, Sch Med, 1001 Univ Pl, Evanston, IL 60201 USA.	rlupu@enh.org			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049049] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49049] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALIMANDI M, 1995, ONCOGENE, V10, P1813; ATLAS E, 2003, IN PRESS MOL CANC RE; BACUS SS, 1992, CELL GROWTH DIFFER, V3, P401; CARDILLO M, 1995, HEREGULIN INDUCES ME; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; Curran S, 1999, J PATHOL, V189, P300, DOI 10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C; GRUNT TW, 1995, INT J CANCER, V63, P560, DOI 10.1002/ijc.2910630417; Guerra-Vladusic FK, 1999, INT J ONCOL, V15, P883; Hijazi MM, 2000, INT J ONCOL, V17, P629; Himelstein BP, 1997, ONCOGENE, V14, P1995, DOI 10.1038/sj.onc.1201012; Hua J, 1996, CANCER RES, V56, P5279; Lee KS, 1996, CLIN EXP METASTAS, V14, P512; Lim SJ, 2000, ONCOGENE, V19, P6271, DOI 10.1038/sj.onc.1204014; Liu WM, 1999, CANCER RES, V59, P5695; LUPU R, 1995, SEMIN CANCER BIOL, V6, P135, DOI 10.1006/scbi.1995.0016; LUPU R, 1992, BIOCHEMISTRY-US, V31, P7330, DOI 10.1021/bi00147a018; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; LUPU R, 1992, P NATL ACAD SCI USA, V89, P2287, DOI 10.1073/pnas.89.6.2287; PAIK S, 1990, J CLIN ONCOL, V8, P103, DOI 10.1200/JCO.1990.8.1.103; PIERCE JH, 1991, ONCOGENE, V6, P1189; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; Reese DM, 1997, STEM CELLS, V15, P1, DOI 10.1002/stem.150001; SeppLorenzino L, 1996, ONCOGENE, V12, P1679; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOMMERS CL, 1994, BREAST CANCER RES TR, V31, P325, DOI 10.1007/BF00666165; Stern DF, 2000, BREAST CANCER RES, V2, P176, DOI 10.1186/bcr51; Tang CK, 1996, CANCER RES, V56, P3350; Tripathy D, 1992, Cancer Treat Res, V63, P15; Tsai MS, 2002, ONCOGENE, V21, P8178, DOI 10.1038/sj.onc.1205682; Tsai MS, 2000, CANCER RES, V60, P5603; Tsang KJ, 2001, INT J ONCOL, V18, P369; Yao J, 2001, ONCOGENE, V20, P8066, DOI 10.1038/sj.onc.1204944	33	105	113	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2003	22	5					761	768		10.1038/sj.onc.1206130	http://dx.doi.org/10.1038/sj.onc.1206130			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569369				2022-12-28	WOS:000180642100014
J	Isaksson, A; Berggren, M; Ricksten, A				Isaksson, A; Berggren, M; Ricksten, A			Epstein-Barr virus U leader exon contains an internal ribosome entry site	ONCOGENE			English	Article						Epstein-Barr virus; internal ribosome entry site; U leader exon; luciferase expression; chloramphenicol transferase expression	SARCOMA-ASSOCIATED HERPESVIRUS; LYMPHOMA CELL-LINES; C-MYC IRES; MESSENGER-RNA; EBNA-1 GENE; ENCEPHALOMYOCARDITIS VIRUS; 5'-UNTRANSLATED REGION; INITIATION SITE; F-PROMOTER; TRANSLATION	Eukaryotic translation can be initiated either by a cap-dependent mechanism or by internal ribosome entry, a process by which ribosomes are directly recruited to structured regions of mRNA upstream of the initiation codon. Here we report the finding of an internal ribosome entry site (IRES) in the untranslated region of the Epstein-Barr nuclear antigen 1 (EBNA1) gene. EBNA1 is the only nuclear protein expressed in all known states of Epstein-Barr virus (EBV) latency and in the virus lytic cycle, and is required for the maintenance of the EBV episome. Using cDNA reporter constructs and in vitro transfection assays, we found that sequences contained in the 5' untranslated region (UTR) of the Fp and Qp initiated EBNA1 mRNA increased the expression level 4-14- fold in different Burkitt lymphoma cell lines. The U leader exon, located within the 5' UTR, included in all known EBNA1 transcripts and also contained in the EBNA3, 4 and 6 mRNAs, was demonstrated by bicistronic expression analyses to contain an IRES. The EBNA IRES initiates translation more efficiently than the encephalomyocarditis virus IRES in EBV-positive lymphoma cells. We propose that the EBNA IRES constitute a novel mechanism, whereby EBV regulates latent gene expression.	Sahlgrens Univ Hosp, Inst Lab Med, Dept Clin Chem & Transfus Med, S-41345 Gothenburg, Sweden	Sahlgrenska University Hospital	Ricksten, A (corresponding author), Sahlgrens Univ Hosp, Inst Lab Med, Dept Clin Chem & Transfus Med, S-41345 Gothenburg, Sweden.	anne.ricksten@clinchem.gu.se						Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019; BENBASSAT H, 1977, INT J CANCER, V19, P27, DOI 10.1002/ijc.2910190105; Bieleski L, 2001, J VIROL, V75, P1864, DOI 10.1128/JVI.75.4.1864-1869.2001; Creancier L, 2001, MOL CELL BIOL, V21, P1833, DOI 10.1128/MCB.21.5.1833-1840.2001; Davenport MG, 1999, J VIROL, V73, P3154, DOI 10.1128/JVI.73.4.3154-3161.1999; deQuinto SL, 1997, J VIROL, V71, P4171; Dufva M, 2002, NUCLEIC ACIDS RES, V30, P2131, DOI 10.1093/nar/30.10.2131; Grundhoff A, 2001, J VIROL, V75, P1857, DOI 10.1128/JVI.75.4.1857-1863.2001; Hinton TM, 2001, J GEN VIROL, V82, P2257, DOI 10.1099/0022-1317-82-9-2257; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; KERR BM, 1992, VIROLOGY, V187, P189, DOI 10.1016/0042-6822(92)90307-B; KIEFF E, 2001, FIELDS VIROLOGY, P2511; KLEIN G, 1972, INT J CANCER, V10, P44, DOI 10.1002/ijc.2910100108; KLEIN G, 1978, INT J CANCER, V21, P552, DOI 10.1002/ijc.2910210504; Le Quesne JPC, 2001, J MOL BIOL, V310, P111, DOI 10.1006/jmbi.2001.4745; Low W, 2001, J VIROL, V75, P2938, DOI 10.1128/JVI.75.6.2938-2945.2001; Marechal V, 1999, J VIROL, V73, P4385, DOI 10.1128/JVI.73.5.4385-4392.1999; MILLER G, 1973, P NATL ACAD SCI USA, V70, P190, DOI 10.1073/pnas.70.1.190; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; Nateri AS, 2000, J VIROL, V74, P6269, DOI 10.1128/JVI.74.14.6269-6277.2000; Nonkwelo C, 1996, J VIROL, V70, P623, DOI 10.1128/JVI.70.1.623-627.1996; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; REYNOLDS JE, 1995, EMBO J, V14, P6010, DOI 10.1002/j.1460-2075.1995.tb00289.x; RICKSTEN A, 1988, NUCLEIC ACIDS RES, V16, P8391, DOI 10.1093/nar/16.17.8391; Rowe David T., 1999, Frontiers in Bioscience, V4, pD346, DOI 10.2741/Rowe; Sambrook J., 2001, MOL CLONING; SAMPLE J, 1986, P NATL ACAD SCI USA, V83, P5096, DOI 10.1073/pnas.83.14.5096; SAWADA K, 1989, VIROLOGY, V168, P22, DOI 10.1016/0042-6822(89)90399-1; SCHAEFER BC, 1995, P NATL ACAD SCI USA, V92, P10565, DOI 10.1073/pnas.92.23.10565; SCHAEFER BC, 1995, J VIROL, V69, P5039, DOI 10.1128/JVI.69.8.5039-5047.1995; Sjoblom A, 1998, J VIROL, V72, P1365; Stoneley M, 2000, NUCLEIC ACIDS RES, V28, P687, DOI 10.1093/nar/28.3.687; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; TSAI CN, 1995, DNA CELL BIOL, V14, P767, DOI 10.1089/dna.1995.14.767; TSUKIYAMAKOHARA K, 1992, J VIROL, V66, P1476, DOI 10.1128/JVI.66.3.1476-1483.1992; Vagner S, 2001, EMBO REP, V2, P893, DOI 10.1093/embo-reports/kve208; van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4; WOISETSCHLAEGER M, 1990, P NATL ACAD SCI USA, V87, P1725, DOI 10.1073/pnas.87.5.1725; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; Zetterberg H, 1999, J GEN VIROL, V80, P457, DOI 10.1099/0022-1317-80-2-457; ZUKER M, 1989, METHOD ENZYMOL, P262	41	26	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2003	22	4					572	581		10.1038/sj.onc.1206149	http://dx.doi.org/10.1038/sj.onc.1206149			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555070				2022-12-28	WOS:000180538200010
J	Carneiro, C; Jiao, MS; Hu, M; Shaffer, D; Park, M; Pandolfi, PP; Cordon-Cardo, C; Koff, A				Carneiro, C; Jiao, MS; Hu, M; Shaffer, D; Park, M; Pandolfi, PP; Cordon-Cardo, C; Koff, A			p27 deficiency desensitizes Rb-/- cells to signals that trigger apoptosis during pituitary tumor development	ONCOGENE			English	Article						tumorigenesis; p27kip1; Rb; Arf	DEPENDENT KINASE INHIBITOR; PROGNOSTIC-SIGNIFICANCE; GENE-EXPRESSION; GROWTH ARREST; MICE LACKING; P27(KIP1); CANCER; CYCLE; P53; DIFFERENTIATION	Low p27 expression in many human cancers is a prognostic indicator for poor outcome. While analysing the mechanism by which p27 deficiency contributed to tumor development in the Rb+/- mouse model, we identified a role for p27 as a proapoptotic tumor suppressor. We examined the cell cycle and apoptotic response of these pituitary tumor cells to the dopamine analog bromocriptine as well as the expression of Arf and other cell cycle and apoptotic regulators in these tumors. We also examined the expression of Arf and its function in mouse embryo fibroblasts either singly or doubly deficient for Rb and p27. From these studies, we concluded that the absence of p27 disabled the trigger for an Arf-dependent apoptotic response in Rb-/- tumor cells. This suggests a novel mechanism by which the loss of p27 may impact on tumor development.	Mem Sloan Kettering Canc Ctr, Dept Mol Biol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Koff, A (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Mol Biol, RRL917D,Box 207,1275 York Ave, New York, NY 10021 USA.			Koff, Andrew/0000-0003-3271-3067				Arita J, 1998, NEUROENDOCRINOLOGY, V68, P163, DOI 10.1159/000054362; CasacciaBonnefil P, 1997, GENE DEV, V11, P2335, DOI 10.1101/gad.11.18.2335; CHRONWALL BM, 1987, ENDOCRINOLOGY, V120, P1201, DOI 10.1210/endo-120-3-1201; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Drissi H, 1999, CANCER RES, V59, P3705; Durand B, 1998, CURR BIOL, V8, P431, DOI 10.1016/S0960-9822(98)70177-0; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Franklin DS, 1998, GENE DEV, V12, P2899, DOI 10.1101/gad.12.18.2899; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Ho A, 2002, CURR OPIN GENET DEV, V12, P47, DOI 10.1016/S0959-437X(01)00263-5; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Lloyd RV, 1999, AM J PATHOL, V154, P313, DOI 10.1016/S0002-9440(10)65277-7; Lowenheim H, 1999, P NATL ACAD SCI USA, V96, P4084, DOI 10.1073/pnas.96.7.4084; Millard SS, 1997, J BIOL CHEM, V272, P7093, DOI 10.1074/jbc.272.11.7093; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nikitin AY, 1996, GENE DEV, V10, P1870, DOI 10.1101/gad.10.15.1870; Palmqvist R, 1999, J PATHOL, V188, P18, DOI 10.1002/(SICI)1096-9896(199905)188:1<18::AID-PATH311>3.0.CO;2-T; Parisi T, 2002, BIOCHEM BIOPH RES CO, V291, P1138, DOI 10.1006/bbrc.2002.6591; Park MS, 1999, P NATL ACAD SCI USA, V96, P6382, DOI 10.1073/pnas.96.11.6382; Philipp-Staheli J, 2002, CANCER CELL, V1, P355, DOI 10.1016/S1535-6108(02)00054-5; Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Swerdlow RH, 1998, DRUG AGING, V13, P263, DOI 10.2165/00002512-199813040-00002; Tong W, 1998, CELL GROWTH DIFFER, V9, P787; Tsihlias J, 1999, ANNU REV MED, V50, P401; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; Yin DL, 1999, J CLIN NEUROSCI, V6, P326, DOI 10.1016/S0967-5868(99)90057-7; Zezula J, 2001, EMBO REP, V2, P27, DOI 10.1093/embo-reports/kve008; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	39	22	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 23	2003	22	3					361	369		10.1038/sj.onc.1206163	http://dx.doi.org/10.1038/sj.onc.1206163			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545157				2022-12-28	WOS:000180379100005
J	Chandrasekar, N; Mohanam, S; Gujrati, M; Olivero, WC; Dinh, DH; Rao, JS				Chandrasekar, N; Mohanam, S; Gujrati, M; Olivero, WC; Dinh, DH; Rao, JS			Downregulation of uPA inhibits migration and PI3k/Akt signaling in glioblastoma cells	ONCOGENE			English	Article						migration; invasion; glioblastoma; antisense uPA	PLASMINOGEN-ACTIVATOR; UROKINASE RECEPTOR; MELANOMA-CELLS; INVASION; SYSTEM; STAUROSPORINE; BIOCHEMISTRY; METASTASIS; EXPRESSION; ADHESION	The ability of glioma cells to migrate great distances from a primary tumor mass is the primary cause of tumor recurrence. The urokinase-type plasminogen activator (uPA) is a serine protease that can initiate proteolytic cascades, which result in remodeling of extracellular matrix and basement membrane, allowing cells to move across and through these barriers. The binding between uPA and its receptor uPAR also mediates several signaling events that seem to contribute to the evolution of a migratory phenotype. In this study, we determined how the downregulation of uPA affects the signaling pathways leading to cell migration. Stably transfecting human glioblastoma cells with antisense uPA decreased the amount of cell-bound uPA and disrupted actin cytoskeleton formation and cell migration. The phosphatidylinositol 3-kinase (PI3k) and Akt signaling pathway has been suggested to mediate migration in various cancer cells. The antisense-uPA clones also had less phosphorylated PI3k and Akt than control cells, a finding associated with decreased cell migration, G2/M-phase arrest, and decreased clonogenic survival. Decreased activation of PI3k and the antiapoptotic factor Akt was not sufficient to induce apoptosis in the antisense-uPA clones, but staurosporine sensitized them to apoptosis to a greater extent than control cells. These results indicate that PI3k/Akt pathway is involved in the signaling cascade required to induce cell migration and that uPA has a direct role in regulating migration.	UIC, Coll Med, Dept Biomed, Div Canc Biol, Peoria, IL 61656 USA; UIC, Coll Med, Dept Therapeut Sci, Div Canc Biol, Peoria, IL 61656 USA; UIC, Coll Med, Dept Neuropathol, Peoria, IL USA; UIC, Coll Med, Dept Neurosurg, Peoria, IL USA	University of Illinois System; University of Illinois Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois System; University of Illinois Chicago	Rao, JS (corresponding author), UIC, Coll Med, Dept Biomed, Div Canc Biol, 1 Illini Dr,Box 1649, Peoria, IL 61656 USA.	jsrao@uic.edu			NATIONAL CANCER INSTITUTE [R01CA075557, R01CA085216] Funding Source: NIH RePORTER; NCI NIH HHS [CA 75557, CA 85216] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Berens M E, 1990, Neurosurg Clin N Am, V1, P1; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Carriero MV, 1999, CANCER RES, V59, P5307; DANO K, 1994, FIBRINOLYSIS, V8, P189, DOI 10.1016/0268-9499(94)90717-X; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dear AE, 1998, EUR J BIOCHEM, V252, P185, DOI 10.1046/j.1432-1327.1998.2520185.x; Ganju N, 2002, BIOCHEM BIOPH RES CO, V291, P1258, DOI 10.1006/bbrc.2002.6584; GOODMAN SL, 1985, CELL, V41, P1029, DOI 10.1016/S0092-8674(85)80083-0; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; Haeckel C, 1998, INT J CANCER, V77, P153, DOI 10.1002/(SICI)1097-0215(19980703)77:1<153::AID-IJC23>3.3.CO;2-2; HARSH GR, 1990, NEUROLOGICAL SURGERY, P3040; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Jimenez C, 2000, J CELL BIOL, V151, P249, DOI 10.1083/jcb.151.2.249; Kim EJ, 2001, INT J ONCOL, V18, P187; Koopman JL, 1998, J BIOL CHEM, V273, P33267, DOI 10.1074/jbc.273.50.33267; Kusch A, 2000, J BIOL CHEM, V275, P39466, DOI 10.1074/jbc.M003626200; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Longstaff C, 1999, BLOOD, V93, P3839, DOI 10.1182/blood.V93.11.3839.411k08_3839_3846; MacDonald TJ, 1998, J NEURO-ONCOL, V40, P215, DOI 10.1023/A:1006150506789; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MEGGIO F, 1995, EUR J BIOCHEM, V234, P317, DOI 10.1111/j.1432-1033.1995.317_c.x; Metzner B, 1996, J INVEST DERMATOL, V107, P597, DOI 10.1111/1523-1747.ep12583096; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; Mohanam S, 2001, CLIN CANCER RES, V7, P2519; Mohanam S, 1997, ONCOGENE, V14, P1351, DOI 10.1038/sj.onc.1200963; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; PYKE C, 1991, AM J PATHOL, V138, P1059; Renz A, 2001, BLOOD, V98, P1542, DOI 10.1182/blood.V98.5.1542; Sachdev P, 2002, J BIOL CHEM, V277, P17638, DOI 10.1074/jbc.M111575200; Schmitt M, 1997, THROMB HAEMOSTASIS, V78, P285; Sliva D, 2002, J BIOL CHEM, V277, P3150, DOI 10.1074/jbc.M109579200; STAHL A, 1994, CANCER RES, V54, P3066; Stepanova V, 1999, MOL CELL BIOCHEM, V195, P199, DOI 10.1023/A:1006936623106; Sturge J, 2002, J CELL SCI, V115, P699; Takahashi A, 1997, ONCOGENE, V14, P2741, DOI 10.1038/sj.onc.1201131; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; WEI Y, 1994, J BIOL CHEM, V269, P32380; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Wild-Bode C, 2001, J NEUROSURG, V94, P976, DOI 10.3171/jns.2001.94.6.0978; YAMAMOTO M, 1994, CANCER RES, V54, P3656; Yebra M, 1999, EXP CELL RES, V250, P231, DOI 10.1006/excr.1999.4510	46	87	91	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2003	22	3					392	400		10.1038/sj.onc.1206164	http://dx.doi.org/10.1038/sj.onc.1206164			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545160				2022-12-28	WOS:000180379100008
J	Wei, DY; Le, XD; Zheng, LZ; Wang, LW; Frey, JA; Gao, AC; Peng, ZH; Huang, SY; Xiong, HQ; Abbruzzese, JL; Xie, KP				Wei, DY; Le, XD; Zheng, LZ; Wang, LW; Frey, JA; Gao, AC; Peng, ZH; Huang, SY; Xiong, HQ; Abbruzzese, JL; Xie, KP			Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis	ONCOGENE			English	Article						Stat3; angiogenesis; metastasis; tumor; pancreas	FACTOR GENE-EXPRESSION; FACTOR MESSENGER-RNA; CONSTITUTIVE ACTIVATION; TRANSCRIPTION FACTORS; ENHANCED EXPRESSION; PERMEABILITY FACTOR; CARDIAC MYOCYTES; UP-REGULATION; FACTOR-I; CELLS	Expression of vascular endothelial growth factor (VEGF), a key angiogenic protein, has been linked with pancreatic cancer progression. However, the molecular basis for VEGF overexpression remains unclear. Immunohistochemical studies have indicated that VEGF overexpression coincides with elevated Stat3 activation in human pancreatic cancer specimens. In our study, more than 80% of the human pancreatic cancer cell lines used exhibited constitutively activated Stat3, with Stat3 activation correlated with the VEGF expression level. Blockade of activated Stat3 via ectopic expression of dominant-negative Stat3 significantly suppressed VEGF expression, angiogenesis, tumor growth, and metastasis in vivo. Furthermore, constitutively activated Stat3 directly activated the VEGF promoter, whereas dominant-negative Stat3 inhibited the VEGF promoter. A putative Stat3-responsive element on the VEGF promoter was identified using a protein-DNA binding assay and confirmed using a promoter mutagenesis assay. These results indicate that Stat3 directly regulates VEGF expression and hence angiogenesis, growth, and metastasis of human pancreatic cancer, suggesting that Stat3 signaling may be targeted for treatment of pancreatic cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA; Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Inst Canc, Pittsburgh, PA 15213 USA; Fudan Univ, Affiliated Shanghai Peoples Hosp 1, Dept Gen Surg, Shanghai 200080, Peoples R China; Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Fudan University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Xie, KP (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Box 426,1515 Holcombe Blvd, Houston, TX 77030 USA.	kepxie@mail.mdanderson.org			NCI NIH HHS [CA 16672-23] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; BROWN LF, 1993, CANCER RES, V53, P4727; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; CHRISTOFORI G, 1995, MOL ENDOCRINOL, V9, P1760, DOI 10.1210/me.9.12.1760; Claffey KP, 1998, MOL BIOL CELL, V9, P469, DOI 10.1091/mbc.9.2.469; Clarke K, 2001, BRIT J CANCER, V84, P1322, DOI 10.1054/bjoc.2001.1805; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; Damert A, 1997, CANCER RES, V57, P3860; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Deroanne CF, 1997, CANCER RES, V57, P5590; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Evans Douglas B., 1997, P1054; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; Flamme I, 1997, MECH DEVELOP, V63, P51, DOI 10.1016/S0925-4773(97)00674-6; Folkman J, 1997, EXS, V79, P1; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; Funamoto M, 2000, J BIOL CHEM, V275, P10561, DOI 10.1074/jbc.275.14.10561; Goad DL, 1996, ENDOCRINOLOGY, V137, P2262, DOI 10.1210/en.137.6.2262; GouilleuxGruart V, 1996, BLOOD, V87, P1692; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; Hishinuma S, 1999, BIOCHEM BIOPH RES CO, V264, P436, DOI 10.1006/bbrc.1999.1535; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Itakura J, 1997, CLIN CANCER RES, V3, P1309; Jiang BH, 1997, CANCER RES, V57, P5328; KAMOHARA H, 1994, RES COMMUN MOL PATH, V85, P131; Kern SE, 2000, MED CLIN N AM, V84, P691, DOI 10.1016/S0025-7125(05)70251-0; KIESER A, 1994, ONCOGENE, V9, P963; Korc M, 1998, Surg Oncol Clin N Am, V7, P25; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; LI J, 1995, J BIOL CHEM, V270, P308, DOI 10.1074/jbc.270.1.308; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; MORGAN RT, 1980, INT J CANCER, V25, P591, DOI 10.1002/ijc.2910250507; Ni Z, 2000, CANCER RES, V60, P1225; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; RAK J, 1995, CANCER RES, V55, P4575; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Shi Q, 2001, ONCOGENE, V20, P3751, DOI 10.1038/sj.onc.1204500; Shi Q, 2001, CANCER RES, V61, P4143; SHI Q, 1999, CLIN CANCER RES, V5, P7234; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; STEIN I, 1995, MOL CELL BIOL, V15, P5363; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; VEZERIDIS MP, 1990, J SURG RES, V48, P51, DOI 10.1016/0022-4804(90)90145-R; Wang BL, 2001, INT J PANCREATOL, V29, P37, DOI 10.1385/IJGC:29:1:37; Wang DG, 1999, CANCER RES, V59, P1464; WATSON CJ, 1995, BRIT J CANCER, V71, P840, DOI 10.1038/bjc.1995.162; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	58	438	481	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2003	22	3					319	329		10.1038/sj.onc.1206122	http://dx.doi.org/10.1038/sj.onc.1206122			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545153				2022-12-28	WOS:000180379100001
J	Alcivar, A; Hu, SM; Tang, J; Yang, XL				Alcivar, A; Hu, SM; Tang, J; Yang, XL			DEDD and DEDD2 associate with caspase-8/10 and signal cell death	ONCOGENE			English	Article						DEDD; DEDD2; caspase-8/10; apoptosis	ACTIVATION; OLIGOMERIZATION; APOPTOSIS	An apoptotic signal triggered by cell surface death receptors is disseminated to intracellular compartments through protein-protein interactions mediated by conserved domains such as the death effector domain (DED). A unique family of single DED-containing proteins, including DEDD and DEDD2, is targeted to the nucleolus. However, the role of DEDD/DEDD2 in apoptosis remains less understood. Here we show that DEDD and DEDD2 are highly conserved in diverse species, and that they are potent inducers of apoptosis in various cell types. Deletion analysis indicates that both the N-terminal DED domain and the C-terminal region of DEDD2 can induce apoptosis. The cell death activity of this family appears to be related to their nuclear localization. DEDD and DEDD2 bind to two tandem DED-containing caspases, caspase -8 and -10, that are engaged by death receptors. Consistent with the nuclear localization of this family, caspase-8 translocates to the nucleus during CD95-induced apoptosis. DEDD and DEDD2 also readily associate with themselves and with each other. These results suggest that DEDD and DEDD2 may be important mediators for death receptors and that they may target caspases to the nucleus.	Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Yang, XL (corresponding author), 421 Curie Blvd,Rm 610 BRB2-3, Philadelphia, PA 19104 USA.		Hu, Shimin/H-3427-2019	Hu, Shimin/0000-0001-7110-3814	NATIONAL CANCER INSTITUTE [R01CA088868] Funding Source: NIH RePORTER; NCI NIH HHS [CA88868] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Chang HY, 2000, MICROBIOL MOL BIOL R, V64, P821, DOI 10.1128/MMBR.64.4.821-846.2000; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Roth W, 2002, J BIOL CHEM, V277, P7501, DOI 10.1074/jbc.M110749200; Schickling O, 2001, CELL DEATH DIFFER, V8, P1157, DOI 10.1038/sj.cdd.4400928; Stegh AH, 1998, EMBO J, V17, P5974, DOI 10.1093/emboj/17.20.5974; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355; Zhan Y, 2002, CELL DEATH DIFFER, V9, P439, DOI 10.1038/sj.cdd.4401038; Zhou BB, 1998, P NATL ACAD SCI USA, V95, P6785, DOI 10.1073/pnas.95.12.6785	11	54	59	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 16	2003	22	2					291	297		10.1038/sj.onc.1206099	http://dx.doi.org/10.1038/sj.onc.1206099			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527898				2022-12-28	WOS:000180322400014
J	Gila, L; Elena, N; Yechezkel, S; Mary, B				Gila, L; Elena, N; Yechezkel, S; Mary, B			p53-associated 3 '-> 5 ' exonuclease activity in nuclear and cytoplasmic compartments of cells	ONCOGENE			English	Article						p53; 3 ' -> 5 ' exonuclease; cytoplasmic p53; nuclear p53; DNA replication fidelity	IMMUNODEFICIENCY-VIRUS TYPE-1; P53 PROTEIN; DNA-SYNTHESIS; SUBSTRATE-SPECIFICITY; REVERSE-TRANSCRIPTASE; 3 TERMINI; FIDELITY; ACCUMULATION; EXCISION; IDENTIFICATION	The tumor suppressor protein p53 plays an important role in maintenance of the genomic integrity of cells. p53 possesses an intrinsic 3' --> 5' exonuclease activity. p53 was found in the nucleus and in the cytoplasm of the cell. In order to evaluate the subcellular location and extent of p53-associated 3'--> 5' exonuclease activity, we established an in vitro experimental system of cell lines with different nuclear/cytoplasmic distribution of p53. Nuclear and cytoplasmic extracts obtained from LCC2 cells (expressing a high level of cytoplasmic wild-type p53), MCF-7 cells (expressing a high level of wild-type nuclear p53), MDA cells (expressing mutant p53) and H1299 cells (p53-null) were subjected to the analysis of exonuclease activity. Interestingly, 3' --> 5' exonuclease was predominantly cytoplasmic; the nuclear extracts derived from all cell lines tested, exerted a low level of exonuclease activity. Cytoplasmic extracts of LCC2 cells, with a high level of wild-type p53, showed an enhanced exonuclease activity in comparison to those expressing either a low level of wild-type p53 (in MCF-7 cells) or the mutant p53 (in NIDA cells). Evidence that exonuclease function detected in cytoplasmic extracts is attributed to the p53 is supported by several facts: First, this activity closely parallels with levels and status of endogenous cytoplasmic p53. Second, immunoprecipitation of p53 from cytoplasmic extracts of LCC2 cells markedly reduced the exonuclease activity. Third, the observed 3' --> 5' exonuclease in cytoplasmic fraction of LCC2 cells displays identical biochemical properties characteristic of recombinant wild-type p53. The biochemical functions include: (a) substrate specificity; exonuclease hydrolyzes single-stranded DNA in preference to double-stranded DNA and RNA/DNA template-primers, (b) efficient excision of 3'-terminal mispairs from DNA/DNA and RNA/DNA substrates, (c) the preferential excision of purine-purine mispairs over purine-pyrimidine mispairs and (d) functional interaction with exonuclease-deficient DNA polymerase, for example, murine leukemia virus reverse transcriptase (representing a relatively low fidelity enzyme), thus enhancing the fidelity of DNA synthesis by excision of mismatched nucleotides from the nascent DNA strand. Taken together, the data demonstrate that wildtype p53 in cytoplasm, in its noninduced state, is functional; it displays intrinsic 3' --> 5' exonuclease activity. The possible role of p53-associated 3' --> 5' exonuclease activity in DNA repair in nucleus and cytoplasm is discussed.	Chaim Sheba Med Ctr, Infect Dis Unit, IL-52621 Tel Hashomer, Israel; Chaim Sheba Med Ctr, Dept Med C, IL-52621 Tel Hashomer, Israel; Chaim Sheba Med Ctr, Lab Expt Chemotherapy, IL-52621 Tel Hashomer, Israel	Chaim Sheba Medical Center; Chaim Sheba Medical Center; Chaim Sheba Medical Center	Mary, B (corresponding author), Chaim Sheba Med Ctr, Infect Dis Unit, IL-52621 Tel Hashomer, Israel.	bakhanus@yahoo.com						Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BAKHANASHVILI M, 1992, FEBS LETT, V306, P151, DOI 10.1016/0014-5793(92)80988-S; BAKHANASHVILI M, 1992, BIOCHEMISTRY-US, V31, P9393, DOI 10.1021/bi00154a010; Bakhanashvili M, 2001, EUR J BIOCHEM, V268, P2047, DOI 10.1046/j.1432-1327.2001.02075.x; BAKHANASHVILI M, 1993, BIOCHEMISTRY-US, V32, P7559, DOI 10.1021/bi00080a030; Bakhanashvili M, 2001, ONCOGENE, V20, P7635, DOI 10.1038/sj.onc.1204956; Ballal K, 2002, J MOL MED-JMM, V80, P25, DOI 10.1007/s00109-001-0290-6; BOGENHAGEN D, 1974, J BIOL CHEM, V249, P7991; BOSARI S, 1995, AM J PATHOL, V147, P790; BUTCHER S, 1994, BIOCHEM J, V298, P513, DOI 10.1042/bj2980513; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FONTOURA BMA, 1992, MOL CELL BIOL, V12, P5145, DOI 10.1128/MCB.12.11.5145; FOORD O, 1993, MOL CELL BIOL, V13, P1378, DOI 10.1128/MCB.13.3.1378; Gaitonde SV, 2000, ONCOGENE, V19, P4042, DOI 10.1038/sj.onc.1203756; Genini D, 2001, FASEB J, V15, P5; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; GRAY H, 1992, J BIOL CHEM, V267, P5835; HARRINGTON JA, 1993, ANTIMICROB AGENTS CH, V37, P918, DOI 10.1128/AAC.37.4.918; Hoss M, 1999, EMBO J, V18, P3868, DOI 10.1093/emboj/18.13.3868; Huang P, 1998, ONCOGENE, V17, P261, DOI 10.1038/sj.onc.1201946; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Janus F, 1999, MOL CELL BIOL, V19, P2155; Janz C, 2002, ONCOGENE, V21, P2130, DOI 10.1038/sj.onc.1205292; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, ONCOGENE, V6, P131; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Lilling G, 2002, CANCER INVEST, V20, P509, DOI 10.1081/CNV-120002151; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; Meek DW, 1998, INT J RADIAT BIOL, V74, P729, DOI 10.1080/095530098141005; Melle C, 2002, NUCLEIC ACIDS RES, V30, P1493, DOI 10.1093/nar/30.7.1493; MILNER J, 1990, ONCOGENE, V5, P1683; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; Offer H, 1999, FEBS LETT, V450, P197, DOI 10.1016/S0014-5793(99)00505-0; Okorokov AL, 2002, ONCOGENE, V21, P356, DOI 10.1038/sj.onc.1205112; OLSON MW, 1992, J BIOL CHEM, V267, P23136; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; PERRINO FW, 1994, J BIOL CHEM, V269, P16357; PERRINO FW, 1989, P NATL ACAD SCI USA, V86, P8343, DOI 10.1073/pnas.86.21.8343; Prives C, 1999, J PATHOL, V187, P112; Sabapathy K, 1997, EMBO J, V16, P6217, DOI 10.1093/emboj/16.20.6217; Shevelev IV, 2002, NAT REV MOL CELL BIO, V3, P364, DOI 10.1038/nrm804; Skalski V, 2000, ONCOGENE, V19, P3321, DOI 10.1038/sj.onc.1203649; SKALSKI V, 1995, BIOCHEM PHARMACOL, V50, P815, DOI 10.1016/0006-2952(95)00205-E; SOUSSI T, 1995, MOL GENETICS CANC, P135; STEINMEYER K, 1988, ONCOGENE, V3, P501; STENMARKASKMALM M, 1994, EUR J CANCER, V30A, P175, DOI 10.1016/0959-8049(94)90082-5; SUN XF, 1992, LANCET, V340, P1369, DOI 10.1016/0140-6736(92)92558-W; VAZQUEZPADUA MA, 1990, CANCER COMMUN, V2, P55, DOI 10.3727/095535490820874740; Wang ZJ, 2002, J BIOL CHEM, V277, P4446, DOI 10.1074/jbc.M110006200; Wickens M, 1997, CURR OPIN GENET DEV, V7, P220, DOI 10.1016/S0959-437X(97)80132-3; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	59	36	37	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2003	22	2					233	245		10.1038/sj.onc.1206111	http://dx.doi.org/10.1038/sj.onc.1206111			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527892				2022-12-28	WOS:000180322400008
J	Nimmanapalli, R; Bhalla, K				Nimmanapalli, R; Bhalla, K			Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571	ONCOGENE			English	Article						Bcr-Abl protein; tyrosine kinase; imatinib; CML	TYROSINE KINASE INHIBITOR; CHRONIC MYELOGENOUS LEUKEMIA; ACUTE PROMYELOCYTIC LEUKEMIA; RIBOZYME-MEDIATED CLEAVAGE; DNA-BINDING ACTIVITY; ARSENIC TRIOXIDE; CELL-LINES; IN-VITRO; C-ABL; SELECTIVE-INHIBITION	In the pathophysiology of CML, the constitutive activity of the Ber-Abl tyrosine kinase (TK) is, most likely, the sole molecular abnormality of the chronic phase. It also remains a critical molecular determinant of malignant behavior of the leukemic progenitors in the accelerated and blastic phase of CML. Therefore, downregulation of the levels and activity of Bcr-Abl is clearly the lynchpin of a rational therapeutic strategy against all phases of CML. Support for this has only been strengthened by the observations that resistance to imatinib mesylate (imatinib) commonly involves a breakthrough and the persistent activity of Bcr-Abl TK. This is due to either mutations that inhibit imatinib action on Bcr-Abl TK or amplification of the bcr-abl gene. Recent studies have demonstrated that other small molecule tyrosine kinase inhibitors that also inhibit Bcr-Abl TK may be highly active in inducing differentiation and apoptosis of CML progenitors, regardless of their sensitivity to imatinib. Small molecule inhibitors that downregulate the levels of Bcr - Abl by inhibiting its translation, e.g., arsenic trioxide, or promoting its proteasomal degradation, e.g., geldanamycin analogues, have also been identified. Finally the identification of other potent survival and antiapoptotic signaling pathways in imatinib-resistant CML progenitors indicates that inhibitors of these pathways will eventually be treatment strategies for advanced phases of CML.	Univ S Florida, Dept Interdisciplinary Oncol, Tampa, FL 33620 USA; H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA	State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute	Bhalla, K (corresponding author), Univ S Florida, Dept Interdisciplinary Oncol, Tampa, FL 33620 USA.	bhallakn@moffitt.usf.edu		Bhalla, Kapil/0000-0001-5209-5126				AFAR DEH, 1994, COLD SPRING HARB SYM, V59, P589, DOI 10.1101/SQB.1994.059.01.067; An WG, 2000, CELL GROWTH DIFFER, V11, P355; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Barthe C, 2001, SCIENCE, V293; Bayever E, 1993, Antisense Res Dev, V3, P383; BEDI A, 1994, BLOOD, V83, P2038; Beran M, 1998, CLIN CANCER RES, V4, P1661; Blagosklonny MV, 2002, LEUKEMIA, V16, P455, DOI 10.1038/sj.leu.2402415; Blagosklonny MV, 2001, LEUKEMIA, V15, P1537, DOI 10.1038/sj.leu.2402257; Cai X, 2000, LEUKEMIA, V14, P262, DOI 10.1038/sj.leu.2401650; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; Chen YC, 1998, J CELL PHYSIOL, V177, P324, DOI 10.1002/(SICI)1097-4652(199811)177:2<324::AID-JCP14>3.0.CO;2-9; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; Creagh EM, 2000, LEUKEMIA, V14, P1161, DOI 10.1038/sj.leu.2401841; Dai J, 1999, BLOOD, V93, P268, DOI 10.1182/blood.V93.1.268.401a21_268_277; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1992, MOL CELL BIOL, V12, P1864, DOI 10.1128/MCB.12.4.1864; de Fabritiis P, 1998, BLOOD, V91, P3156, DOI 10.1182/blood.V91.9.3156; Deininger MWN, 1997, BLOOD, V90, P3691, DOI 10.1182/blood.V90.9.3691; Deininger MWN, 2000, CANCER RES, V60, P2049; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; DeLong RK, 1997, ANTISENSE NUCLEIC A, V7, P71, DOI 10.1089/oli.1.1997.7.71; DHUT S, 1990, LEUKEMIA, V4, P745; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; DONATO NJ, 2001, ASH; Dorsey JF, 2000, CANCER RES, V60, P3127; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2002, TRENDS MOL MED, V8, pS14, DOI 10.1016/S1471-4914(02)02305-5; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; EVANS CA, 1993, CANCER RES, V53, P1735; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; Fang GF, 2000, BLOOD, V96, P2246, DOI 10.1182/blood.V96.6.2246.h8002246_2246_2253; Gambacorti-Passerini C, 2000, JNCI-J NATL CANCER I, V92, P1641, DOI 10.1093/jnci/92.20.1641; Gong JG, 1999, NATURE, V399, P806; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Hamdane M, 1997, ONCOGENE, V15, P2267, DOI 10.1038/sj.onc.1201411; Hochhaus A, 2001, SCIENCE, V293, P2163; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; James HA, 1998, BLOOD, V91, P371, DOI 10.1182/blood.V91.2.371.371_371_382; Jing YK, 1999, BLOOD, V94, P2102, DOI 10.1182/blood.V94.6.2102; KANO Y, 2001, LEUKEMIA, V15, P772; Kraker AJ, 2000, BIOCHEM PHARMACOL, V60, P885, DOI 10.1016/S0006-2952(00)00405-6; LANGE W, 1994, FEBS LETT, V338, P175, DOI 10.1016/0014-5793(94)80359-5; LANGE W, 1993, LEUKEMIA, V7, P1786; LAROSEE P, 2001, ASH; le Coutre P, 2000, BLOOD, V95, P1758, DOI 10.1182/blood.V95.5.1758.005a41_1758_1766; Mahon FX, 2000, BLOOD, V96, P1070, DOI 10.1182/blood.V96.3.1070.015k17_1070_1079; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MCGAHON AJ, 1995, J BIOL CHEM, V270, P22625, DOI 10.1074/jbc.270.38.22625; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; Mills K. I., 1996, Blood, V88, p577A; NAKAJIMA A, 2002, P AM ASSOC CANC RES, V43, P4235; Nimmanapalli R, 2001, BLOOD, V98, p618A; Nimmanapalli R, 2001, CLIN CANCER RES, V7, P350; Nimmanapalli R, 2001, CANCER RES, V61, P1799; NIMMANAPALLI R, 2001, P AM ASSOC CANC RES, V42, P4293; Nishii K, 1996, ONCOGENE, V13, P2225; NOWELL PC, 1960, SCIENCE, V132, P1497; Perkins C, 2000, BLOOD, V95, P1014, DOI 10.1182/blood.V95.3.1014.003k04_1014_1022; Porosnicu M, 2001, LEUKEMIA, V15, P772, DOI 10.1038/sj.leu.2402104; Raitano A. B., 1997, BIOCHIM BIOPHYS ACTA, V1333, P201, DOI 10.1016/S0304-419X(97)00023-1; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Savage DG, 2002, NEW ENGL J MED, V346, P683, DOI 10.1056/NEJMra013339; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; Sawyers CL, 1999, CANCER J SCI AM, V5, P63; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; Sawyers CL, 2001, J CLIN ONCOL, V19, p13S; SAWYERS CL, 1991, NEW ENGL J MED, V340, P1330; SHORE SK, 1993, ONCOGENE, V8, P3183; Shuai K, 1996, ONCOGENE, V13, P247; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; SKORSKI T, 1994, P NATL ACAD SCI USA, V91, P4504, DOI 10.1073/pnas.91.10.4504; SKORSKI T, 1991, FOLIA HISTOCHEM CYTO, V29, P85; Soignet SL, 2001, J CLIN ONCOL, V19, P3852, DOI 10.1200/JCO.2001.19.18.3852; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; SZCZYLIK C, 1991, SCIENCE, V253, P562, DOI 10.1126/science.1857987; Thiesing JT, 2000, BLOOD, V96, P3195, DOI 10.1182/blood.V96.9.3195.h8003195_3195_3199; Vigneri P, 2001, NAT MED, V7, P228, DOI 10.1038/84683; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; Wang ZG, 1998, BLOOD, V92, P1497, DOI 10.1182/blood.V92.5.1497.417k41_1497_1504; Weisberg E, 2000, BLOOD, V95, P3498, DOI 10.1182/blood.V95.11.3498.011k27_3498_3505; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; WRIGHT L, 1993, EXP HEMATOL, V21, P1714; Wu YP, 1999, HUM GENE THER, V10, P2847, DOI 10.1089/10430349950016573; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079; Yu CR, 2002, CANCER RES, V62, P188; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; ZHANG RW, 1995, CLIN PHARMACOL THER, V58, P44, DOI 10.1016/0009-9236(95)90071-3; Zhu XH, 1999, J NATL CANCER I, V91, P772, DOI 10.1093/jnci/91.9.772	95	29	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2002	21	56					8584	8590		10.1038/sj.onc.1206086	http://dx.doi.org/10.1038/sj.onc.1206086			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZF	12476305				2022-12-28	WOS:000179734300008
J	Wertheim, JA; Miller, JP; Xu, LW; He, YP; Pear, WS				Wertheim, JA; Miller, JP; Xu, LW; He, YP; Pear, WS			The biology of chronic myelogenous leukemia: mouse models and cell adhesion	ONCOGENE			English	Article						CML; mouse model; cell adhesion; Philadelphia chromosome; BCR-ABL	CHRONIC MYELOID-LEUKEMIA; ABL TYROSINE KINASE; ACUTE LYMPHOBLASTIC-LEUKEMIA; BONE-MARROW STROMA; BCR-ABL; C-ABL; PHILADELPHIA-CHROMOSOME; TRANSGENIC MICE; MYELOPROLIFERATIVE DISEASE; HEMATOPOIETIC-CELLS	Chronic myelogenous leukemia (CML) is a biphasic neoplasm of the bone marrow that is precipitated by the Philadelphia chromosome, a t(9;22) balanced translocation that encodes a constitutively activated nonreceptor tyrosine kinase termed P210(BCR-ABL). This oncoprotein has several intracellular functions; however, the most important effect of P210(BCR-ABL) leading to cell transformation is phosphorylation of signaling molecules through a constitutively active tyrosine kinase domain. Despite extensive knowledge of the structure and functional domains of BCR-ABL, its precise function in transformation is not known. Progress has been hampered, in part, by the lack of relevant CML models, as cell culture and in vitro assays do not mimic the pathogenesis of CML. Recently, there has been significant progress toward improving murine models that closely resemble human CML. This has allowed researchers to evaluate critical functions of BCR-ABL and has provided a model to test the efficacy of therapeutic medications that block these pathways. Our laboratory has developed two intersecting research programs to better understand the functioning of P210(BCR-ABL) in leukemogenesis. In one approach, we have developed a murine CML model by transferring HSCs that express BCR-ABL from a retroviral vector. All recipients develop a rapidly fatal MPD that shares several important features with CML. This model has been extremely useful for studying the function of BCR-ABL in the pathogenesis of CML. A second approach utilizes a quantitative cell detachment apparatus capable of measuring small changes in cell adhesion to investigate the mechanism by which P210(BCR-ABL) causes abnormal cell binding. Altered cell adhesion may contribute to the imbalance between proliferation and self-renewal in the hematopoietic progenitor compartment. To better understand the role abnormal adhesion may play in the development of leukemia, we have attempted to correlate the effects of functional P210(BCR-ABL) mutants in regulating adhesion and oncogenicity.	Univ Penn, Inst Med & Engn, Philadelphia, PA 19104 USA; Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania	Pear, WS (corresponding author), Univ Penn, Inst Med & Engn, 611 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.		Wertheim, Jason/H-1275-2014	Wertheim, Jason/0000-0001-5680-1067	NCI NIH HHS [CA77570] Funding Source: Medline; NIDDK NIH HHS [P30-DK50306] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077570] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK050306] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andreasson P, 1997, GENE CHROMOSOME CANC, V20, P299; Bashaw GJ, 2000, CELL, V101, P703, DOI 10.1016/S0092-8674(00)80883-1; Bazzoni G, 1996, J CLIN INVEST, V98, P521, DOI 10.1172/JCI118820; Bernasconi P, 2001, HAEMATOLOGICA, V86, P320; Bhatia R, 1999, EXP HEMATOL, V27, P1384, DOI 10.1016/S0301-472X(99)00084-3; Boettiger D, 2001, MOL BIOL CELL, V12, P1227, DOI 10.1091/mbc.12.5.1227; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Castillo DA, 2001, CR-NEW CENTEN REV, V1, P283, DOI 10.1353/ncr.2003.0033; Cobaleda C, 2000, BLOOD, V95, P1007, DOI 10.1182/blood.V95.3.1007.003k35_1007_1013; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; COZENSROBERTS C, 1990, BIOPHYS J, V58, P841, DOI 10.1016/S0006-3495(90)82430-9; COZENSROBERTS C, 1990, BIOPHYS J, V58, P857, DOI 10.1016/S0006-3495(90)82431-0; Cuenco GM, 2001, ONCOGENE, V20, P8236, DOI 10.1038/sj.onc.1205095; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1991, P NATL ACAD SCI USA, V88, P11335, DOI 10.1073/pnas.88.24.11335; Dash AB, 2002, P NATL ACAD SCI USA, V99, P7622, DOI 10.1073/pnas.102583199; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Garcia AJ, 1999, BIOMATERIALS, V20, P2427, DOI 10.1016/S0142-9612(99)00170-2; Garcia AJ, 1998, J BIOL CHEM, V273, P10988, DOI 10.1074/jbc.273.18.10988; GISHIZKY ML, 1993, P NATL ACAD SCI USA, V90, P3755, DOI 10.1073/pnas.90.8.3755; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; Golub TR, 1997, CURR TOP MICROBIOL, V220, P67; Golub TR, 1996, MOL CELL BIOL, V16, P4107; Gordon MY, 1996, BRIT J HAEMATOL, V95, P10; Haskovec C, 1998, BRIT J HAEMATOL, V103, P1104, DOI 10.1046/j.1365-2141.1998.01098.x; HAWLEY RG, 1994, GENE THER, V1, P136; HAWLEY RG, 1993, J EXP MED, V178, P1175, DOI 10.1084/jem.178.4.1175; He YP, 2002, BLOOD, V99, P2957, DOI 10.1182/blood.V99.8.2957; Heaney C, 1997, BLOOD, V89, P297, DOI 10.1182/blood.V89.1.297.297_297_306; Heisterkamp N, 2000, BLOOD, V96, P2226; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; Honda H, 2000, BLOOD, V95, P1144, DOI 10.1182/blood.V95.4.1144.004k04_1144_1150; HONDA H, 1995, BLOOD, V85, P2853, DOI 10.1182/blood.V85.10.2853.bloodjournal85102853; Honda H, 1998, BLOOD, V91, P2067, DOI 10.1182/blood.V91.6.2067.2067_2067_2075; HURLEY RW, 1995, J CLIN INVEST, V96, P511, DOI 10.1172/JCI118063; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; Kramer A, 1999, P NATL ACAD SCI USA, V96, P2087, DOI 10.1073/pnas.96.5.2087; KRUH GD, 1986, SCIENCE, V234, P1545, DOI 10.1126/science.3787260; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Lewis ID, 1998, BLOOD, V91, P630, DOI 10.1182/blood.V91.2.630.630_630_640; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MCWHIRTER JR, MOL CELL BIOL, V13, P1553; Melo JV, 1996, BLOOD, V88, P2375, DOI 10.1182/blood.V88.7.2375.bloodjournal8872375; Melo JV, 1996, LEUKEMIA, V10, P751; Million RP, 2002, BLOOD, V99, P4568, DOI 10.1182/blood-2001-12-0244; Million RP, 2000, BLOOD, V96, P664; NOWELL PC, 1960, SCIENCE, V132, P1497; ODA T, 1994, J BIOL CHEM, V269, P22925; Okuda K, 1996, ONCOGENE, V13, P1147; Pane F, 1996, BLOOD, V88, P2410, DOI 10.1182/blood.V88.7.2410.bloodjournal8872410; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PEREGO R, 1991, ONCOGENE, V6, P1899; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SALGIA R, 1995, ONCOGENE, V11, P1149; Sattler M, 2002, CANCER CELL, V1, P479, DOI 10.1016/S1535-6108(02)00074-0; Schott B, 1996, SOMAT CELL MOLEC GEN, V22, P291, DOI 10.1007/BF02369568; Skourides PA, 1999, ONCOGENE, V18, P1165, DOI 10.1038/sj.onc.1202407; SPANGRUDE GJ, 1995, BLOOD, V85, P1006, DOI 10.1182/blood.V85.4.1006.bloodjournal8541006; Sparrow E.M., 1960, J HEAT TRANS-T ASME, V82, P294, DOI [10.1115/1.3679937, DOI 10.1115/1.3679937]; TACHIBANA N, 1987, BLOOD, V70, P1458; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; Tauchi T, 1997, J BIOL CHEM, V272, P1389, DOI 10.1074/jbc.272.2.1389; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; Van Limbergen H, 2001, GENE CHROMOSOME CANC, V30, P274, DOI 10.1002/1098-2264(2000)9999:9999<1::AID-GCC1089>3.3.CO;2-T; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; VERFAILLIE C, 1994, CRIT REV ONCOL HEMAT, V16, P201, DOI 10.1016/1040-8428(94)90071-X; Verfaillie CM, 1997, ACTA HAEMATOL-BASEL, V97, P40; Verfaillie CM, 1997, J LAB CLIN MED, V129, P584, DOI 10.1016/S0022-2143(97)90192-X; VERFAILLIE CM, 1992, J CLIN INVEST, V90, P1232, DOI 10.1172/JCI115985; VERFAILLIE CM, 1992, BLOOD, V79, P2821; Verstovsek S, 2002, CANCER, V94, P2416, DOI 10.1002/cncr.10490; VONCKEN JW, 1995, CELL, V80, P719, DOI 10.1016/0092-8674(95)90350-X; VONCKEN JW, 1995, BLOOD, V86, P4603, DOI 10.1182/blood.V86.12.4603.bloodjournal86124603; WADA H, 1995, CANCER RES, V55, P3192; Wertheim JA, 2002, BLOOD, V99, P4122, DOI 10.1182/blood.V99.11.4122; Wolff NC, 2001, BLOOD, V98, P2808, DOI 10.1182/blood.V98.9.2808; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Zhang XW, 1998, BLOOD, V92, P3829, DOI 10.1182/blood.V92.10.3829; Zhang XW, 2001, BLOOD, V97, P277, DOI 10.1182/blood.V97.1.277; Zhang XW, 2001, MOL CELL BIOL, V21, P840, DOI 10.1128/MCB.21.3.840-853.2001; ZHAO X, 2002, NAT STRUCT BIOL, V7, P7	94	21	24	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	2002	21	56					8612	8628		10.1038/sj.onc.1206089	http://dx.doi.org/10.1038/sj.onc.1206089			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZF	12476308				2022-12-28	WOS:000179734300011
J	Horie, K; Tomida, A; Sugimoto, Y; Yasugi, T; Yoshikawa, H; Taketani, Y; Tsuruo, T				Horie, K; Tomida, A; Sugimoto, Y; Yasugi, T; Yoshikawa, H; Taketani, Y; Tsuruo, T			SUMO-1 conjugation to intact DNA topoisomerase I amplifies cleavable complex formation induced by camptothecin	ONCOGENE			English	Article						SUMO-1; topoisomerase I; camptothecin	UBIQUITIN-LIKE PROTEINS; COVALENT MODIFICATION; SUBCELLULAR-LOCALIZATION; MECHANISM; IDENTIFICATION; EXPRESSION; REPLICATION; INVOLVEMENT; SUMOYLATION; ACTIVATION	DNA topoisomerase I (Topo1) manages the topological state of DNA. Cleavable complexes, the covalent Topo1-DNA intermediates, become DNA damaged when the catalytic cycles are inhibited by the anti-tumor drug camptothecin (CPT). Intriguingly, Topo1 is modified rapidly and extensively with SUMO-1, a ubiquitin-like protein, in response to CPT. This study shows that the sumoylation enhances the cleavable complex formation and apoptosis induced by CPT. Indeed, substitutions of Lys117 and Lys153, identified as Topo1 sumoylation sites, reduced the CPT-induced cleavable complexes without influencing its in vitro catalytic activity. Consistent with this observation, CPT-induced cleavable complexes of wild-type Topo1 increased in a sumoylation-dependent manner. We also found that Topo1 sumoylation occurred independently of CPT when Topo1 was inactivated by mutation of the catalytic Tyr723. These findings suggested that Topo1 inactivation by CPT treatment can trigger Topo1 sumoylation, leading to enhanced cleavable complex formation.	Univ Tokyo, Inst Mol & Cellular Biosci, Lab Cell Growth & Regulat, Bunkyo Ku, Tokyo 1130032, Japan; Univ Tokyo, Fac Med, Dept Obstet & Gynecol, Bunkyo Ku, Tokyo 1130033, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Toshima Ku, Tokyo 1708455, Japan; Univ Tsukuba, Inst Clin Med, Dept Obstet & Gynecol, Tsukuba, Ibaraki 3058575, Japan	University of Tokyo; University of Tokyo; Japanese Foundation for Cancer Research; University of Tsukuba	Tsuruo, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Lab Cell Growth & Regulat, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	ttsuruo@iam.u-tokyo.ac.jp						ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BJORNSTI MA, 1989, CANCER RES, V49, P6318; Chakrabarti SR, 2000, P NATL ACAD SCI USA, V97, P13281, DOI 10.1073/pnas.240315897; DARPA P, 1990, CANCER RES, V50, P6919; Desai SD, 1997, J BIOL CHEM, V272, P24159, DOI 10.1074/jbc.272.39.24159; Desai SD, 2001, CANCER RES, V61, P5926; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Duprez E, 1999, J CELL SCI, V112, P381; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Haas AL, 1997, FASEB J, V11, P1257; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; HOLM C, 1989, CANCER RES, V49, P6365; HSIANG YH, 1988, CANCER RES, V48, P1722; HSIANG YH, 1989, CANCER RES, V49, P5077; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; Liu LF, 2000, ANN NY ACAD SCI, V922, P1; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mao Y, 2000, J BIOL CHEM, V275, P26066, DOI 10.1074/jbc.M001831200; Mao Y, 2000, P NATL ACAD SCI USA, V97, P4046, DOI 10.1073/pnas.080536597; Mashima T, 1999, ONCOGENE, V18, P2423, DOI 10.1038/sj.onc.1202558; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Mo YY, 2002, J BIOL CHEM, V277, P2958, DOI 10.1074/jbc.M108263200; Mo YY, 2000, J BIOL CHEM, V275, P41107, DOI 10.1074/jbc.M003135200; Mo YY, 2000, EXP CELL RES, V256, P480, DOI 10.1006/excr.2000.4864; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Pommier Y, 1999, DRUG RESIST UPDATE, V2, P307, DOI 10.1054/drup.1999.0102; POMMIER Y, 1995, P NATL ACAD SCI USA, V92, P8861, DOI 10.1073/pnas.92.19.8861; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; ROCA J, 1995, TRENDS BIOCHEM SCI, V20, P156, DOI 10.1016/S0968-0004(00)88993-8; Saitoh H, 1997, TRENDS BIOCHEM SCI, V22, P374, DOI 10.1016/S0968-0004(97)01102-X; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; Shen ZY, 1996, GENOMICS, V36, P271, DOI 10.1006/geno.1996.0462; SQUIRES S, 1993, CANCER RES, V53, P2012; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; Stewart L, 1997, J MOL BIOL, V269, P355, DOI 10.1006/jmbi.1997.1056; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Stewart L, 1996, J BIOL CHEM, V271, P7602, DOI 10.1074/jbc.271.13.7602; Stewart L, 1996, J BIOL CHEM, V271, P7593, DOI 10.1074/jbc.271.13.7593; Subramanian D, 2000, METH MOL B, V95, P137; SUBRAMANIAN D, 1995, CANCER RES, V55, P2097; Subramanian D, 1998, CANCER RES, V58, P976; SUBRAMANIAN D, 1995, ONCOL RES, V7, P461; SUGIMOTO Y, 1990, CANCER RES, V50, P6925; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6	59	47	48	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2002	21	52					7913	7922		10.1038/sj.onc.1205917	http://dx.doi.org/10.1038/sj.onc.1205917			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	612VY	12439742				2022-12-28	WOS:000179097200001
J	Yu, JS; Tsai, HC; Wu, CC; Weng, LP; Li, HP; Chung, PJ; Chang, YS				Yu, JS; Tsai, HC; Wu, CC; Weng, LP; Li, HP; Chung, PJ; Chang, YS			Induction of inducible nitric oxide synthase by Epstein-Barr virus B95-8-derived LMP1 in Balb/3T3 cells promotes stress-induced cell death and impairs LMP1-mediated transformation	ONCOGENE			English	Article						LMP1; iNOS; nitric oxide; caspase-3; JNK	NF-KAPPA-B; LATENT MEMBRANE-PROTEIN; HUMAN EPITHELIAL-CELLS; TERMINAL KINASE JNK; NASOPHARYNGEAL CARCINOMA; INDUCED APOPTOSIS; TUMOR-GROWTH; A431 CELLS; FUNCTIONAL DIFFERENCES; BNLF-1 GENE	The latent membrane protein 1 (LMP1) of Epstein-Barr virus (EBV) causes cellular transformation and activation of several intracellular signaling events. In this report, we show that BLMP1 (encoded by the LMP1 gene derived from the B95-8 strain of EBV) triggers the expression of inducible nitric oxide synthase (iNOS) in Balb/3T3 fibroblasts. Intriguingly, NLMP1, a natural sequence variant of LMP1 identified in EBV-positive nasopharyngeal carcinoma biopsy, does not similarly induce iNOS expression. BLMP1-induced iNOS in Balb/3T3 cells is active to produce nitric oxide (NO), and NO production can be blocked by several iNOS inhibitors. When subjected to environmental stress, Balb/3T3 cells that produce NO lose viability more rapidly than non NO-producing cells. Blockage of NO generation by iNOS inhibitors enhances the viability of NO-producing cells under stress conditions. The activities of caspase-3 and c-Jun N-terminal kinase, two important regulators mediating stress-induced apoptosis, are significantly potentiated following heat shock treatment of BLMPl-expressing/NO-producing cells, compared to parental and NLMP1-expressing cells. Furthermore, treatment with iNOS inhibitor augmented the cloning efficiency (in culture) and tumor growth (in nude mice) of BLMP1-expressing/NO-producing cells. Collectively, the results demonstrate that BLMP1 induces iNOS expression and NO production in Balb/3T3 cells, which leads to the alteration of cell functions, including sensitivity to environmental stress, capability to colonize independent of anchorage and tumorigenicity in nude mice. Our data additionally implicate that the differential iNOS induction potential of the two LMP1 forms may represent the basis of a functional difference between the two LMP1 proteins.	Chang Gung Univ, Coll Med, Inst Basic Med Sci, Dept Cell & Mol Biol, Tao Yuan, Taiwan; Chang Gung Univ, Coll Med, Inst Basic Med Sci, Dept Microbiol & Immunol, Tao Yuan, Taiwan	Chang Gung University; Chang Gung University	Yu, JS (corresponding author), Chang Gung Univ, Coll Med, Inst Basic Med Sci, Dept Cell & Mol Biol, Tao Yuan, Taiwan.	yusong@mail.cgu.edu.tw	Li, Hsin-Pai/C-7305-2014	Chang, Yu-Sun/0000-0002-6457-3890; Wu, Chih-Ching/0000-0002-7264-9672; Yu, Jau-Song/0000-0002-4295-983X				Aaltomaa SH, 2001, ANTICANCER RES, V21, P3101; Ambs S, 1998, NAT MED, V4, P1371, DOI 10.1038/3957; Ambs S, 1998, CANCER RES, V58, P334; ARVANITAKIS L, 1995, J IMMUNOL, V155, P1047; ASANO K, 1994, P NATL ACAD SCI USA, V91, P10089, DOI 10.1073/pnas.91.21.10089; BAICHWAL VR, 1988, ONCOGENE, V2, P461; BIRKENBACH M, 1989, J VIROL, V63, P4079, DOI 10.1128/JVI.63.9.4079-4084.1989; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; Campbell IL, 1996, J NEUROIMMUNOL, V71, P31, DOI 10.1016/S0165-5728(96)00129-4; Chan WH, 2000, BIOCHEM J, V351, P221, DOI 10.1042/0264-6021:3510221; Chan WH, 1998, J PROTEIN CHEM, V17, P485, DOI 10.1023/A:1022578820147; CHEN ML, 1992, ONCOGENE, V7, P2131; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; COBBS CS, 1995, CANCER RES, V55, P727; Dawson CW, 2000, VIROLOGY, V272, P204, DOI 10.1006/viro.2000.0344; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Dimmeler S, 1997, NITRIC OXIDE-BIOL CH, V1, P275, DOI 10.1006/niox.1997.0133; Eliopoulos AG, 1998, CURR BIOL, V8, pR196, DOI 10.1016/S0960-9822(98)70123-X; Eliopoulos AG, 1998, ONCOGENE, V16, P1731, DOI 10.1038/sj.onc.1201694; ESPTEIN MA, 1964, LANCET, V1, P702; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; FAIRBAIRN LJ, 1993, J GEN VIROL, V74, P247, DOI 10.1099/0022-1317-74-2-247; Fielding CA, 2001, J VIROL, V75, P9129, DOI 10.1128/JVI.75.19.9129-9141.2001; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Gao XR, 1999, VIROLOGY, V258, P375, DOI 10.1006/viro.1999.9748; Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131; HAMMERSCHMIDT W, 1989, J VIROL, V63, P2469, DOI 10.1128/JVI.63.6.2469-2475.1989; HANTO DW, 1985, TRANSPLANT P, V17, P89; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HENLE G, 1968, P NATL ACAD SCI USA, V59, P94, DOI 10.1073/pnas.59.1.94; HU LF, 1991, J GEN VIROL, V72, P2399, DOI 10.1099/0022-1317-72-10-2399; HU LF, 1993, ONCOGENE, V8, P1575; Iwasaki Y, 1998, J VIROL, V72, P8321, DOI 10.1128/JVI.72.10.8321-8326.1998; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; JENKINS DC, 1995, P NATL ACAD SCI USA, V92, P4392, DOI 10.1073/pnas.92.10.4392; Johnson RJ, 1998, J VIROL, V72, P4038, DOI 10.1128/JVI.72.5.4038-4048.1998; Kawanishi M, 1995, INTERVIROLOGY, V38, P206, DOI 10.1159/000150434; KIEFF E, 1990, VIROLOGY, P1889; Kieser A, 1999, EMBO J, V18, P2511, DOI 10.1093/emboj/18.9.2511; Kieser A, 1997, EMBO J, V16, P6478, DOI 10.1093/emboj/16.21.6478; KLEIN G, 1974, P NATL ACAD SCI USA, V71, P4737, DOI 10.1073/pnas.71.12.4737; Kleinert H, 1996, J BIOL CHEM, V271, P6039, DOI 10.1074/jbc.271.11.6039; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Li SN, 1996, ONCOGENE, V12, P2129; LIEBOWITZ D, 1986, J VIROL, V58, P233, DOI 10.1128/JVI.58.1.233-237.1986; Lu JJY, 1996, J GEN VIROL, V77, P1883, DOI 10.1099/0022-1317-77-8-1883; MacFarlane M, 2000, BIOCHEM J, V348, P93, DOI 10.1042/0264-6021:3480093; MANN KP, 1985, J VIROL, V55, P710, DOI 10.1128/JVI.55.3.710-720.1985; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; Martins LM, 1997, TRENDS CELL BIOL, V7, P111; Massi D, 2001, J PATHOL, V194, P194, DOI 10.1002/1096-9896(200106)194:2<194::AID-PATH851>3.0.CO;2-S; Miller WE, 1998, ONCOGENE, V16, P1869, DOI 10.1038/sj.onc.1201696; MONCADA S, 1991, PHARMACOL REV, V43, P109; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; MOSIALOS G, 1994, J VIROL, V68, P1697, DOI 10.1128/JVI.68.3.1697-1705.1994; Murono S, 2001, P NATL ACAD SCI USA, V98, P6905, DOI 10.1073/pnas.121016998; Muschel RJ, 1998, ONCOGENE, V17, P3359, DOI 10.1038/sj.onc.1202580; NAKAGOMI H, 1994, INT J CANCER, V57, P240, DOI 10.1002/ijc.2910570218; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nilsson BO, 1999, INFLAMM RES, V48, P509, DOI 10.1007/s000110050495; PATHMANATHAN R, 1995, NEW ENGL J MED, V333, P693, DOI 10.1056/NEJM199509143331103; PENG M, 1992, ONCOGENE, V7, P1775; Riches DWH, 1998, J BIOL CHEM, V273, P22800, DOI 10.1074/jbc.273.35.22800; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; SU IJ, 1992, LEUKEMIA LYMPHOMA, V7, P47, DOI 10.3109/10428199209053601; Sylla BS, 1998, P NATL ACAD SCI USA, V95, P10106, DOI 10.1073/pnas.95.17.10106; Tang TK, 1998, J CELL BIOCHEM, V70, P442, DOI 10.1002/(SICI)1097-4644(19980915)70:4<442::AID-JCB2>3.3.CO;2-N; Thomsen LL, 1997, CANCER RES, V57, P3300; THOMSEN LL, 1994, CANCER RES, V54, P1352; THOMSEN LL, 1995, BRIT J CANCER, V72, P41, DOI 10.1038/bjc.1995.274; TRIVEDI P, 1994, EUR J CANCER, V30A, P84, DOI 10.1016/S0959-8049(05)80024-3; Valentinis B, 1999, ONCOGENE, V18, P1827, DOI 10.1038/sj.onc.1202471; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; Wilson KT, 1998, CANCER RES, V58, P2929; Xie KP, 1998, CANCER METAST REV, V17, P55, DOI 10.1023/A:1005956721457; Yeh TS, 1997, DNA CELL BIOL, V16, P1311, DOI 10.1089/dna.1997.16.1311; YU JS, 1994, J CELL BIOCHEM, V56, P131, DOI 10.1002/jcb.240560117	89	20	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2002	21	52					8047	8061		10.1038/sj.onc.1205990	http://dx.doi.org/10.1038/sj.onc.1205990			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	612VY	12439755				2022-12-28	WOS:000179097200014
J	Windham, TC; Parikh, NU; Siwak, DR; Summy, JM; McConkey, DJ; Kraker, AJ; Gallick, GE				Windham, TC; Parikh, NU; Siwak, DR; Summy, JM; McConkey, DJ; Kraker, AJ; Gallick, GE			Src activation regulates anoikis in human colon tumor cell lines	ONCOGENE			English	Article						Src; protein tyrosine kinases; anoikis; colon cancer; Akt	FOCAL ADHESION KINASE; ENDOTHELIAL GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; DOWN-REGULATION; C-SRC; EXTRACELLULAR-MATRIX; INDUCED RESISTANCE; PP60C-SRC ACTIVITY; CODON 531; IN-SITU	Src is a non-receptor protein tyrosine kinase, the expression and activity of which is increased in >80% of human colon cancers with respect to normal colonic epithelium. Previous studies from this and other laboratories have demonstrated that Src activity contributes to tumorigenicity of established colon adenocarcinoma cell lines. Src participates in the regulation of many signal transduction pathways, among which are those leading to cellular survival. In this study, we addressed the potential role of Src activation to a specific aspect of tumor cell survival, resistance to detachment-induced apoptosis (anoikis). Using five colon tumor cell lines with different biologic properties and genetic alterations, we demonstrate that expression and activity of Src corresponds with resistance to anoikis. Enforced expression of activated Src in subclones of SW480 cells (of low intrinsic Src expression and activity) increases resistance to anoikis; whereas decreased Src expression in HT29 cells (of high Src expression and activity) by transfection with anti-sense Src expression vectors increases susceptibility to anoikis. In contrast, increasing or decreasing Src expression had no effect on susceptibility to staurosporine-induced apoptosis in attached cells. PD173955, a Src family-specific tyrosine kinase inhibitor, increases the susceptibility of HT29 cells to anoikis in a dose- and time-dependent manner. Increasing Src expression and activity led to increased phosphorylation of Akt, a mediator of cellular survival pathways, whereas decreasing Src activity led to decreased Akt phosphorylation. In colon tumor cells with high Src activity, the PI3 kinase inhibitor LY 294002 sensitized cells to anoikis. These results suggest that Src activation may contribute to colon tumor progression and metastasis in part by activating Akt-mediated survival pathways that decrease sensitivity of detached cells to anoikis.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Pfizer Global Res & Dev, Dept Canc Res, Ann Arbor, MI 48105 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Pfizer	Gallick, GE (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	ggallick@mdanderson.org			NCI NIH HHS [T32CA09599, CA53617, CA65527] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009599, U19CA053617, R01CA065527, U01CA053617] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allgayer H, 2002, CANCER, V94, P344, DOI 10.1002/cncr.10221; Allgayer H, 1999, J BIOL CHEM, V274, P18428, DOI 10.1074/jbc.274.26.18428; Barvian M. R., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P176; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CARTWRIGHT CA, 1993, ONCOGENE, V8, P1033; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; Chen RY, 2001, J BIOL CHEM, V276, P31858, DOI 10.1074/jbc.C100271200; Coll ML, 2002, ONCOGENE, V21, P2908, DOI 10.1038/sj.onc.1205388; Daigo Y, 1999, CANCER RES, V59, P4222; DEFILIPPI P, 1994, CELL ADHES COMMUN, V2, P75, DOI 10.3109/15419069409014203; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Ellis LM, 1998, J BIOL CHEM, V273, P1052, DOI 10.1074/jbc.273.2.1052; Fincham VJ, 2000, MOL CELL BIOL, V20, P6518, DOI 10.1128/MCB.20.17.6518-6536.2000; Fleming RYD, 1997, SURGERY, V122, P501, DOI 10.1016/S0039-6060(97)90044-1; FOSS FM, 1989, ONCOGENE RES, V5, P13; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; GARCIA R, 1991, ONCOGENE, V6, P1983; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gervais FG, 1998, J BIOL CHEM, V273, P17102, DOI 10.1074/jbc.273.27.17102; Grossmann J, 2001, CELL GROWTH DIFFER, V12, P147; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; HALL PA, 1994, J CELL SCI, V107, P3569; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; HUANG MM, 1993, J CELL BIOL, V122, P473, DOI 10.1083/jcb.122.2.473; Irby R, 1997, CELL GROWTH DIFFER, V8, P1287; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; JESSUP JM, 1992, CURR PROB CANCER, V16, P265; Jost M, 2001, MOL BIOL CELL, V12, P1519, DOI 10.1091/mbc.12.5.1519; Karni R, 1999, ONCOGENE, V18, P4654, DOI 10.1038/sj.onc.1202835; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Moasser MM, 1999, CANCER RES, V59, P6145; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Paul R, 2001, NAT MED, V7, P222, DOI 10.1038/84675; Rosen K, 1998, CURR BIOL, V8, P1331, DOI 10.1016/S0960-9822(07)00564-7; Rosen K, 2000, J CELL BIOL, V149, P447, DOI 10.1083/jcb.149.2.447; Rosen K, 2001, J BIOL CHEM, V276, P37273, DOI 10.1074/jbc.M106424200; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlessinger J, 2000, CELL, V100, P293, DOI 10.1016/S0092-8674(00)80664-9; Schmidt R, 1998, INT J CANCER, V76, P91, DOI 10.1002/(SICI)1097-0215(19980330)76:1<91::AID-IJC15>3.0.CO;2-J; Staley CA, 1997, CELL GROWTH DIFFER, V8, P269; STRATER J, 1995, GUT, V37, P819, DOI 10.1136/gut.37.6.819; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; TERMUHLEN PM, 1993, J SURG RES, V54, P293, DOI 10.1006/jsre.1993.1046; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Wang NM, 2000, CANCER LETT, V150, P201, DOI 10.1016/S0304-3835(99)00398-5; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S; Weng ZG, 2002, J BIOL CHEM, V277, P18677, DOI 10.1074/jbc.M105331200; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Xing LP, 2001, GENE DEV, V15, P241, DOI 10.1101/gad.840301; Zhong MH, 2002, ONCOGENE, V21, P1071, DOI 10.1038/sj/onc/1205165	58	171	175	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2002	21	51					7797	7807		10.1038/sj.onc.1205989	http://dx.doi.org/10.1038/sj.onc.1205989			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	610DT	12420216				2022-12-28	WOS:000178946000004
J	Luo, RZ; Fang, XJ; Marquez, R; Liu, SY; Mills, GB; Liao, WSL; Yu, YH; Bast, RC				Luo, RZ; Fang, XJ; Marquez, R; Liu, SY; Mills, GB; Liao, WSL; Yu, YH; Bast, RC			ARHI is a Ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers	ONCOGENE			English	Article						ARHI; tumor suppressor gene; GTP-binding protein; GTPase; mutagenesis; protein function; Ras superfamily	TUMOR-SUPPRESSOR GENE; GTPASE-ACTIVATING PROTEIN; BIOCHEMICAL-PROPERTIES; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; RHO-FAMILY; DOMAIN; FARNESYLATION; ASSOCIATION; MEMBRANE	Our group recently identified Ras homolog member I (ARHI), a novel maternally imprinted tumor suppressor gene that encodes a 26kDa GTP-binding protein with high homology to Ras and Rap. Unlike other Ras family members, ARHI exhibits several unusual structural and functional properties. ARHI contains a unique 34 amino-acid extension at the N-terminus, and differs from Ras in residues critical for GTPase activity and in its putative effector domain. Like Ras, ARHI can bind to GTP with high affinity but has low intrinsic GTPase activity. In addition, while Ras is an oncogene, ARHI functions as an inhibitor for cell growth. 12 Phosphorus labeling showed that ARHI is maintained in a constitutively activated GTP-bound state in resting cells, possibly because of impaired GTPase activity. ARHI is associated at the cell membrane through its prenylation at the C-terminal cysteine residue. Mutation of the conserved CAAX box at the C-terminus led to a loss of its membrane association and a decreased ability to inhibit cell growth. Conversion of Ser(51) to Asn decreased GTP binding and reduced ARHI's biological activity. Mutation of Ala(46) to Val increased the ability of ARHI to inhibit cell growth, associated with a further decrease of its intrinsic GTPase activity. Moreover, conversion of residues in ARHI that are conserved in the Ras family for GTPase activity partially restored the GTPase activity in ARHI. Most strikingly, deletion of ARHI's unique N-terminal extension nearly abolished its inhibitory effect on cell growth, suggesting its importance in ARHI's inhibitory function. Thus, ARHI is a unique Ras family member that retains basic small GTPase function, but exhibits many unusual features. In contrast to most other Ras family members, ARHI has a long N-terminal extension, modest GTPase activity, and constitutive GTP binding in resting cells. Furthermore, unlike the Ras oncogene, ARHI inhibits cell growth, and loss of its expression in cells may contribute to the development of breast and ovarian cancers.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Bast, RC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, 1515 Holcombe Blvd,Rm Y7-5821,Box 355, Houston, TX 77030 USA.	rbast@mdanderson.org	Bast, Robert C/E-6585-2011	Bast, Robert C/0000-0003-4621-8462	NATIONAL CANCER INSTITUTE [P01CA064602] Funding Source: NIH RePORTER; NCI NIH HHS [CA80957, CA64602] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashar HR, 2000, J BIOL CHEM, V275, P30451, DOI 10.1074/jbc.M003469200; BHULLAR RP, 1987, BIOCHEM J, V245, P617, DOI 10.1042/bj2450617; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOLLAG G, 1995, METHOD ENZYMOL, V225, P161; BOUNE HR, 1991, NATURE, V349, P117; Chen JM, 1996, J PROTEIN CHEM, V15, P511, DOI 10.1007/BF01908532; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; CLARK GJ, 1995, BREAST CANCER RES TR, V35, P133, DOI 10.1007/BF00694753; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; Ellis CA, 2002, P NATL ACAD SCI USA, V99, P9876, DOI 10.1073/pnas.142193799; Fiegen D, 2002, FEBS LETT, V525, P100, DOI 10.1016/S0014-5793(02)03094-6; Finlin BS, 2001, J BIOL CHEM, V276, P42259, DOI 10.1074/jbc.M105888200; Foster R, 1996, MOL CELL BIOL, V16, P2689; Garavini H, 2002, BIOCHEMISTRY-US, V41, P6303, DOI 10.1021/bi025651h; Gotoh T, 2000, J BIOL CHEM, V275, P30118, DOI 10.1074/jbc.M003074200; HALL A, 1986, J BIOL CHEM, V261, P963; Hofemeister H, 2000, MOL BIOL CELL, V11, P3233, DOI 10.1091/mbc.11.9.3233; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Luo RZ, 2001, BBA-GENE STRUCT EXPR, V1519, P216, DOI 10.1016/S0167-4781(01)00226-3; MAGUIRE J, 1994, SCIENCE, V265, P241, DOI 10.1126/science.7912851; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; Muller JM, 2002, EMBO J, V21, P736, DOI 10.1093/emboj/21.4.736; Murphy GA, 1999, ONCOGENE, V18, P3831, DOI 10.1038/sj.onc.1202758; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Nobes CD, 1998, J CELL BIOL, V141, P187, DOI 10.1083/jcb.141.1.187; PARK HO, 1993, NATURE, V365, P269, DOI 10.1038/365269a0; Patton SE, 1998, CANCER RES, V58, P2253; Peng HQ, 2000, INT J CANCER, V86, P690, DOI 10.1002/(SICI)1097-0215(20000601)86:5<690::AID-IJC14>3.0.CO;2-K; Piddini E, 2001, EMBO J, V20, P4076, DOI 10.1093/emboj/20.15.4076; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SUNYER T, 1984, J BIOL CHEM, V259, P5447; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; Xu FJ, 2000, CANCER RES, V60, P4913; Yu YH, 1999, P NATL ACAD SCI USA, V96, P214, DOI 10.1073/pnas.96.1.214; ZHENG Y, 1995, METHOD ENZYMOL, V256, P77; ZHU JH, 1995, J BIOL CHEM, V270, P4805, DOI 10.1074/jbc.270.9.4805	41	83	89	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2003	22	19					2897	2909		10.1038/sj.onc.1206380	http://dx.doi.org/10.1038/sj.onc.1206380			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771940				2022-12-28	WOS:000182824800004
J	Pei, HP; Yordy, JS; Leng, QX; Zhao, QH; Watson, DK; Li, RZ				Pei, HP; Yordy, JS; Leng, QX; Zhao, QH; Watson, DK; Li, RZ			EAPII interacts with ETS1 and modulates its transcriptional function	ONCOGENE			English	Article						ETS1; EAPII; transcriptional control; migration	LONG TERMINAL REPEAT; NF-KAPPA-B; MATRIX METALLOPROTEINASE-1; HEPATOCELLULAR-CARCINOMA; PROTEIN INTERACTIONS; TERNARY COMPLEXES; ENDOTHELIAL-CELLS; FAMILY PROTEINS; EXPRESSION; PROMOTER	Ets proteins constitute a family of conserved sequence-specific DNA-binding proteins and function as transcription factors. ETS1 plays important roles in differentiation, lymphoid cell development, invasiveness and angiogenesis. Such diverse roles of ETS1 are likely to be dependent on its associated proteins. A yeast two-hybrid screen was conducted and here we describe a novel ETS1 interacting protein designated as ETS1-associated protein II (EAPII). EAPII protein interacts with ETS1 and other Ets proteins (ETS2 and FLI1) both in vitro and in vivo. Indirect immunofluorescence demonstrated that EAPII is predominately localized to the nucleus of mammalian cells. EAPII negatively modulates ETS1 transcriptional activity and attenuates synergistic transactivation by ETS1 and AP-1. Significantly, re-expression of EAPII inhibits the migration of epithelial cancer cells, but does not affect cell viability. Therefore, EAPII is a novel ETS1 modulator that regulates specific aspects of the ETS1 functions.	Med Univ S Carolina, Hollings Canc Ctr, Lab Canc Genom, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina	Li, RZ (corresponding author), Med Univ S Carolina, Hollings Canc Ctr, Lab Canc Genom, Room 315,86 Jonathan Lucas St, Charleston, SC 29425 USA.				NATIONAL CANCER INSTITUTE [P01CA078582] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA78582] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; Chen ZQ, 1997, CANCER RES, V57, P2013; Davidson B, 2001, CLIN CANCER RES, V7, P551; de Nigris F, 2001, CANCER RES, V61, P2267; Delannoy-Courdent A, 1998, J CELL SCI, V111, P1521; FISHER RJ, 1991, ONCOGENE, V6, P2249; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; GHYSDAEL J, 1997, ETS FAMILY TRANSCRIP; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Gri G, 1998, J BIOL CHEM, V273, P6431, DOI 10.1074/jbc.273.11.6431; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HOLZMEISTER J, 1993, BIOCHEM BIOPH RES CO, V197, P1229, DOI 10.1006/bbrc.1993.2608; Ito Y, 2000, AM J CLIN PATHOL, V114, P719, DOI 10.1309/RAVV-8NM1-CJB7-GJFR; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; KOIZUMI S, 1990, ONCOGENE, V5, P675; KRAMER B, 1995, J BIOL CHEM, V270, P6577; Li RH, 1999, P NATL ACAD SCI USA, V96, P3876, DOI 10.1073/pnas.96.7.3876; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; Li RZ, 2000, ONCOGENE, V19, P6514, DOI 10.1038/sj.onc.1204035; Maroulakou IG, 2000, ONCOGENE, V19, P6432, DOI 10.1038/sj.onc.1204039; Narayan VA, 1997, J BIOL CHEM, V272, P7801, DOI 10.1074/jbc.272.12.7801; Nimer S, 1996, BLOOD, V88, P66, DOI 10.1182/blood.V88.1.66.bloodjournal88166; Oda N, 1999, J CELL PHYSIOL, V178, P121, DOI 10.1002/(SICI)1097-4652(199902)178:2<121::AID-JCP1>3.3.CO;2-6; Ozaki I, 2000, CANCER RES, V60, P6519; Pype S, 2000, J BIOL CHEM, V275, P18586, DOI 10.1074/jbc.M000531200; Remy P, 2000, ONCOGENE, V19, P6417, DOI 10.1038/sj.onc.1204044; Rutter JL, 1998, CANCER RES, V58, P5321; Seidel JJ, 2002, GENE DEV, V16, P127, DOI 10.1101/gad.950902; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Sementchenko VI, 1998, ONCOGENE, V17, P2883, DOI 10.1038/sj.onc.1202220; SETH A, 1993, AIDS RES HUM RETROV, V9, P1017, DOI 10.1089/aid.1993.9.1017; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Skalicky JJ, 1996, PROTEIN SCI, V5, P296; Thomas RS, 1997, ONCOGENE, V14, P2845, DOI 10.1038/sj.onc.1201125; Verger A, 2002, BIOESSAYS, V24, P362, DOI 10.1002/bies.10068; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 2002, ENCY CANC, V2, P751; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Wheat W, 1999, MOL CELL BIOL, V19, P2231; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9	41	56	59	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2003	22	18					2699	2709		10.1038/sj.onc.1206374	http://dx.doi.org/10.1038/sj.onc.1206374			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ	12743594				2022-12-28	WOS:000182569300001
J	Jendrossek, V; Muller, I; Eibl, H; Belka, C				Jendrossek, V; Muller, I; Eibl, H; Belka, C			Intracellular mediators of erucylphosphocholine-induced apoptosis	ONCOGENE			English	Article						apoptosis; erucylphosphocholine; caspases; mitochondria; Bcl-2; FADD	DRUG-INDUCED APOPTOSIS; HEMATOPOIETIC PROGENITOR CELLS; RADIATION-INDUCED APOPTOSIS; BREAST-CANCER PATIENTS; HUMAN CARCINOMA-CELLS; HUMAN LEUKEMIC-CELLS; ETHER LIPID ANALOGS; PROTEIN-KINASE-C; CYTOCHROME-C; CASPASE ACTIVATION	Induction of apoptosis contributes to the cytotoxic action of the intravenously applicable alkylphosphocholine erucylphosphocholine (ErPC). To define molecular requirements for ErPC-induced apoptosis, activation of caspases-8, -9 and -3 and cleavage of the caspase-3 substrates PARP and ICAD were tested in normal Jurkat T cells, Jurkat cells resistant to death receptor (CD95 or TNFalpha-related apoptosis inducing ligand (TRAIL)-induced apoptosis, Jurkat cells lacking caspase-8 or Fas-associated death domain (FADD) Jurkat cells expressing a dominant-negative caspase-9 or overexpressing Bcl-2 as well as BJAB B-lymphoma cells expressing a dominant-negative FADD (FADD-DN). ErPC induced a time- and dose-dependent apoptotic cell death in Jurkat and BJAB cells, which was characterized by breakdown of the phosphatidylserine asymmetry, depolarization of the mitochondrial membrane potential, release of cytochrome c, activation of caspases-9, -8 and -3, cleavage of PARP and ICAD, as well as chromatin condensation. ErPC-induced apoptosis was independent from CD95-receptor signaling and FADD since CD95- and TRAIL-resistant, caspase-8- and FADD-negative Jurkat cells, as well as BJAB cells expressing FADD-DN were sensitive to ErPC-induced apoptosis. In contrast, inhibition of caspase-9 and overexpression of Bcl-2 significantly reduced ErPC-induced caspase activation and apoptosis. Thus, ErPC triggers apoptosis via a Bcl-2-dependent mitochondrial but death receptor-independent pathway.	Univ Tubingen, Dept Radiat Oncol, D-72076 Tubingen, Germany; Max Planck Inst Biophys Chem, D-37075 Gottingen, Germany	Eberhard Karls University of Tubingen; Max Planck Society	Jendrossek, V (corresponding author), Univ Tubingen, Dept Radiat Oncol, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.		Jendrossek, Verena/AAH-4967-2019	Jendrossek, Verena/0000-0003-1058-2107				Belka C, 2002, INT J RADIAT BIOL, V78, P643, DOI 10.1080/09553000210137680; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; BERGER MR, 1993, J CANCER RES CLIN, V119, P541, DOI 10.1007/BF01686464; BERGGREN MI, 1993, CANCER RES, V53, P4297; BERGMANN J, 1994, ANTICANCER RES, V14, P1549; Berkovic D, 1995, EUR J CANCER, V31A, P2080, DOI 10.1016/0959-8049(95)00350-9; Berkovic D, 1997, RADIOTHER ONCOL, V43, P293, DOI 10.1016/S0167-8140(97)01909-9; Berkovic D, 2001, EUR J CANCER, V37, P503, DOI 10.1016/S0959-8049(00)00394-4; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cabaner C, 1999, BRIT J PHARMACOL, V127, P813, DOI 10.1038/sj.bjp.0702606; Chen M, 2002, APOPTOSIS, V7, P313, DOI 10.1023/A:1016167228059; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CINEK T, 1995, IMMUNOGENETICS, V41, P110, DOI 10.1007/BF00182321; Clive S, 1999, CANCER CHEMOTH PHARM, V44, pS29, DOI 10.1007/s002800051114; Cuvillier O, 1999, BLOOD, V94, P3583, DOI 10.1182/blood.V94.10.3583.422k31_3583_3592; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; Engelmann J, 1996, ANTICANCER RES, V16, P1429; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Erdlenbruch B, 1999, CANCER CHEMOTH PHARM, V44, P484, DOI 10.1007/s002800051122; Ergezinger K, 1999, ANTICANCER RES, V19, P3213; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Friesen C, 1997, LEUKEMIA, V11, P1833, DOI 10.1038/sj.leu.2400827; Fulda S, 1997, CANCER RES, V57, P4956; Gajate C, 2000, INT J CANCER, V85, P674, DOI 10.1002/(SICI)1097-0215(20000301)85:5<674::AID-IJC13>3.0.CO;2-Z; Gajate C, 2001, BLOOD, V98, P3860, DOI 10.1182/blood.V98.13.3860; Gajate C, 1998, MOL PHARMACOL, V53, P602, DOI 10.1124/mol.53.4.602; Georgieva MC, 2002, CANCER LETT, V182, P163, DOI 10.1016/S0304-3835(02)00088-5; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Huang HW, 1999, BIOPHYS J, V77, P1489, DOI 10.1016/S0006-3495(99)76996-1; Jendrossek V, 2001, ANTICANCER RES, V21, P3389; Jendrossek V, 1999, INT J ONCOL, V14, P15; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Konstantinov SM, 1998, CANCER CHEMOTH PHARM, V41, P210; Konstantinov SM, 1999, CANCER LETT, V144, P153, DOI 10.1016/S0304-3835(99)00219-0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li XY, 2001, CANCER RES, V61, P1699; Lucas L, 2001, ONCOGENE, V20, P1110, DOI 10.1038/sj.onc.1204216; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Matzke A, 2001, EUR J CELL BIOL, V80, P1, DOI 10.1078/0171-9335-00130; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; MIYASHITA T, 1993, BLOOD, V81, P151; Mollinedo F, 1997, CANCER RES, V57, P1320; MOLLINEDO F, 1994, BIOCHEM J, V302, P325, DOI 10.1042/bj3020325; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; Nomura Y, 2000, LEUKEMIA, V14, P299, DOI 10.1038/sj.leu.2401649; NOSEDA A, 1989, EXP MOL PATHOL, V50, P69, DOI 10.1016/0014-4800(89)90057-9; NOSEDA A, 1988, CANCER RES, V48, P1788; Raisova M, 2001, J INVEST DERMATOL, V117, P333, DOI 10.1046/j.0022-202x.2001.01409.x; Raisova M, 2002, FEBS LETT, V516, P47, DOI 10.1016/S0014-5793(02)02472-9; Rudner J, 2002, APOPTOSIS, V7, P441, DOI 10.1023/A:1020087108926; Rudner J, 2001, J CELL SCI, V114, P4161; Rudner J, 2001, INT J RADIAT BIOL, V77, P1, DOI 10.1080/095530001453069; Ruiter GA, 2001, INT J RADIAT ONCOL, V49, P415, DOI 10.1016/S0360-3016(00)01476-0; Ruiter GA, 1999, CANCER RES, V59, P2457; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Smorenburg CH, 2000, ANTI-CANCER DRUG, V11, P825, DOI 10.1097/00001813-200011000-00006; STEKAR J, 1995, EUR J CANCER, V31A, P372, DOI 10.1016/0959-8049(94)00495-Q; Stepczynska A, 2001, ONCOGENE, V20, P1193, DOI 10.1038/sj.onc.1204221; Stroh C, 1998, CELL DEATH DIFFER, V5, P997, DOI 10.1038/sj.cdd.4400451; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; UNGER C, 1992, PROG EXP TUMOR RES, V34, P153; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; VEHMEYER K, 1992, EXP HEMATOL, V20, P1; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VERWEIJ J, 1992, J CANCER RES CLIN, V118, P606, DOI 10.1007/BF01211805; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Wieder T, 1998, J BIOL CHEM, V273, P11025, DOI 10.1074/jbc.273.18.11025; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; ZHENG B, 1990, CANCER RES, V50, P3025; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	81	57	57	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2003	22	17					2621	2632		10.1038/sj.onc.1206355	http://dx.doi.org/10.1038/sj.onc.1206355			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730676				2022-12-28	WOS:000182569000010
J	Glassford, J; Soeiro, I; Skarell, SM; Banerji, L; Holman, M; Klaus, GGB; Kadowaki, T; Koyasu, S; Lam, EWF				Glassford, J; Soeiro, I; Skarell, SM; Banerji, L; Holman, M; Klaus, GGB; Kadowaki, T; Koyasu, S; Lam, EWF			BCR targets cyclin D2 via Btk and the p85 alpha subunit of PI3-K to induce cell cycle progression in primary mouse B cells	ONCOGENE			English	Article						BCR; Btk; p85 alpha; cyclin D2; PKC beta; Ca2+ flux; cell cycle	BRUTONS-TYROSINE-KINASE; XID-LIKE IMMUNODEFICIENCY; FACTOR-KAPPA-B; ANTIGEN RECEPTOR; PHOSPHOLIPASE C-GAMMA-2; T-CELL; PHOSPHATIDYLINOSITOL 3-KINASE; MEDIATED PROLIFERATION; ADAPTER PROTEIN; ACTIVATION	The p85alpha subunit of PI3-K and Btk are two crucial components of the B-cell receptor (BCR) signalling pathway. In the present study, we showed that primary splenic B cells from p85alpha null and xid (Btk-deficient) mice fail to induce cyclin D2 expression and enter early G1, but not S phase of the cell cycle in response to BCR engagement. Furthermore, these Btk or p85alpha null B cells displayed increased cell death compared with wild type following BCR engagement. These findings are further confirmed by studies showing that specific pharmacological inhibitors of Btk (LFM-A13), PI3-K (LY294002 and Wortmannin) and PLCgamma (U73122) also block cyclin D2 expression and S phase entry following BCR stimulation, as well as triggering apoptosis. Collectively, these data provide evidence for the concept that the B-cell signalosome (p85alpha, Btk, BLNK and PLCgamma) is involved in regulating cyclin D2 expression in response to BCR engagement. PKC and intracellular calcium are two major downstream effectors of the B-cell signalosome and can be activated by PMA and ionomycin, respectively. In small resting (GO) B cells, costimulation with PMA and ionomycin, but not PMA or ionomycin alone, induces cyclin D2 expression and cell-cycle progression. Consistent with this, we also showed that the BCR-mediated cyclin D2 induction could be abolished by pretreatment of resting B cells with specific inhibitors of capacitative Ca2+ entry (SK&F 96365) or PKC (Go6850). Our present results lead us to propose a model in which the B-cell signalosome targets cyclin D2 via the Ca2+ and PKC-dependent signalling cascades to mediate cell-cycle progression in response to BCR engagement.	Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Sch Med, Canc Re UK Labs, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Sch Med, Sect Canc Cell Biol,Dept Canc Med, London W12 0NN, England; Natl Inst Med Res, Div Cellular Immunol, London NW7 1AA, England; Univ Tokyo, Grad Sch Med, Dept Metab Dis, Bunkyo Ku, Tokyo 1138655, Japan; Keio Univ, Sch Med, Dept Microbiol & Immunol, Shinjuku Ku, Tokyo 1608582, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi 3320012, Japan	Imperial College London; Imperial College London; MRC National Institute for Medical Research; University of Tokyo; Keio University; Japan Science & Technology Agency (JST)	Lam, EWF (corresponding author), Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Sch Med, Canc Re UK Labs, Du Cane Rd, London W12 0NN, England.	eric.lam@ic.ac.uk	Lam, Eric W-F/AAW-8566-2020; Koyasu, Shigeo/J-5583-2015	Lam, Eric W-F/0000-0003-1274-3576; Koyasu, Shigeo/0000-0001-9585-3038				ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Baba Y, 2001, P NATL ACAD SCI USA, V98, P2582, DOI 10.1073/pnas.051626198; Banerji L, 2001, ONCOGENE, V20, P7352, DOI 10.1038/sj.onc.1204951; Brorson K, 1997, J IMMUNOL, V159, P135; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cariappa A, 2002, CURR OPIN IMMUNOL, V14, P241, DOI 10.1016/S0952-7915(02)00328-X; Clayton E, 2002, J EXP MED, V196, P753, DOI 10.1084/jem.20020805; DeFranco AL, 2001, NAT IMMUNOL, V2, P482, DOI 10.1038/88669; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Downward J, 1999, NAT CELL BIOL, V1, pE33, DOI 10.1038/10026; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; FASOLATO C, 1990, J BIOL CHEM, V265, P20351; Fruman DA, 2000, IMMUNITY, V13, P1, DOI 10.1016/S1074-7613(00)00002-9; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Fu C, 1997, J BIOL CHEM, V272, P27362, DOI 10.1074/jbc.272.43.27362; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Glassford J, 2001, J BIOL CHEM, V276, P41040, DOI 10.1074/jbc.M105305200; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Gulbranson-Judge A, 1999, EUR J IMMUNOL, V29, P477, DOI 10.1002/(SICI)1521-4141(199902)29:02&lt;477::AID-IMMU477&gt;3.0.CO;2-V; HAHNER L, 1991, FASEB J, V5, P2466, DOI 10.1096/fasebj.5.10.1648524; Hayashi K, 2000, P NATL ACAD SCI USA, V97, P2755, DOI 10.1073/pnas.040575697; Johnson-Leger C, 1998, J IMMUNOL, V161, P4618; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; King LB, 1999, J IMMUNOL, V162, P2655; KLAUS GGB, 1986, EUR J IMMUNOL, V16, P92, DOI 10.1002/eji.1830160118; Klaus GGB, 1997, EUR J IMMUNOL, V27, P2749, DOI 10.1002/eji.1830271102; Kurosaki T, 2000, IMMUNOL REV, V176, P19; Kurosaki T, 2000, CURR OPIN IMMUNOL, V12, P276, DOI 10.1016/S0952-7915(00)00087-X; Kurosaki T, 1999, ANNU REV IMMUNOL, V17, P555, DOI 10.1146/annurev.immunol.17.1.555; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; Lam EWF, 1999, EUR J IMMUNOL, V29, P3380, DOI 10.1002/(SICI)1521-4141(199910)29:10<3380::AID-IMMU3380>3.0.CO;2-C; Lam EWF, 1998, J BIOL CHEM, V273, P10051, DOI 10.1074/jbc.273.16.10051; Lam EWF, 2000, J BIOL CHEM, V275, P3479, DOI 10.1074/jbc.275.5.3479; Lam KP, 1997, CELL, V90, P1073, DOI 10.1016/S0092-8674(00)80373-6; Lauper N, 1998, ONCOGENE, V17, P2637, DOI 10.1038/sj.onc.1202477; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Leitges M, 1996, SCIENCE, V273, P788, DOI 10.1126/science.273.5276.788; Mahajan S, 1999, J BIOL CHEM, V274, P9587, DOI 10.1074/jbc.274.14.9587; Mahajan S, 2001, J BIOL CHEM, V276, P31216, DOI 10.1074/jbc.M104874200; Martino A, 2001, J IMMUNOL, V166, P1723, DOI 10.4049/jimmunol.166.3.1723; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; MUTHUKKUMAR S, 1993, EUR J IMMUNOL, V23, P2419, DOI 10.1002/eji.1830231007; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; O'Rourke LM, 1998, IMMUNITY, V8, P635, DOI 10.1016/S1074-7613(00)80568-3; Okkenhaug K, 2002, SCIENCE, V297, P1031; Petro JB, 2002, FEBS LETT, V532, P57, DOI 10.1016/S0014-5793(02)03623-2; Qiu Y, 2000, ONCOGENE, V19, P5651, DOI 10.1038/sj.onc.1203958; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; Saijo K, 2002, J EXP MED, V195, P1647, DOI 10.1084/jem.20020408; SARDET C, 1997, ONCOGENES TRANSCRIPT, V2, P1; Satterthwaite AB, 1998, SEMIN IMMUNOL, V10, P309, DOI 10.1006/smim.1998.0123; Scharenberg AM, 1998, CELL, V94, P5, DOI 10.1016/S0092-8674(00)81214-3; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Solvason N, 2000, INT IMMUNOL, V12, P631, DOI 10.1093/intimm/12.5.631; Solvason N, 1998, J EXP MED, V187, P1081, DOI 10.1084/jem.187.7.1081; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; Tan JEL, 2001, J BIOL CHEM, V276, P20055, DOI 10.1074/jbc.M010800200; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; THOMPSON AK, 1991, J BIOL CHEM, V266, P23856; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TSUKADA S, 1994, CURR OPIN IMMUNOL, V6, P623, DOI 10.1016/0952-7915(94)90151-1; Tsukada S, 2001, ADV IMMUNOL, V77, P123, DOI 10.1016/S0065-2776(01)77016-2; VIHINEN M, 1995, IMMUNOL TODAY, V16, P460, DOI 10.1016/0167-5699(95)80027-1; Vihinen M, 1997, NUCLEIC ACIDS RES, V25, P166, DOI 10.1093/nar/25.1.166; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wang DM, 2000, IMMUNITY, V13, P25, DOI 10.1016/S1074-7613(00)00005-4; Williams CD, 1997, BLOOD, V90, P194; Xu SL, 2000, INT IMMUNOL, V12, P397, DOI 10.1093/intimm/12.3.397; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	71	54	58	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2003	22	15					2248	2259		10.1038/sj.onc.1206425	http://dx.doi.org/10.1038/sj.onc.1206425			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	667KV	12700661				2022-12-28	WOS:000182231500004
J	Stoica, GE; Franke, TF; Wellstein, A; Morgan, E; Czubayko, F; List, HJ; Reiter, R; Martin, MB; Stoica, A				Stoica, GE; Franke, TF; Wellstein, A; Morgan, E; Czubayko, F; List, HJ; Reiter, R; Martin, MB; Stoica, A			RETRACTED: Heregulin-beta 1 regulates the estrogen receptor-alpha gene expression and activity via the ErbB2/PI 3-K/Akt pathway (Retracted Article. See vol 24, pg 1964, 2005)	ONCOGENE			English	Review; Retracted Publication						estrogen receptor; HRG-beta 1; ErbB2; Akt	BREAST-CANCER CELLS; EPIDERMAL-GROWTH-FACTOR; PROTEIN-KINASE-B; SIGNAL-TRANSDUCTION PATHWAYS; MESSENGER-RIBONUCLEIC-ACID; STEROID-HORMONE RECEPTORS; MAMMARY-TUMOR CELLS; ATHYMIC NUDE-MICE; PHOSPHATIDYLINOSITOL 3-KINASE; BINDING-SITES	This study examines whether the serine/threonine protein kinase, Akt, is involved in the crosstalk between the ErbB2 and estrogen receptor-alpha (ER-alpha) pathways. Treatment of MCF-7 cells with 10(-9) M heregulin-beta1 (HRG-beta) resulted in a rapid phosphorylation of Akt and a 15-fold increase in Akt activity. Akt phosphorylation was blocked by inhibitors of phosphatidylinositol 3-kinase (PI 3-K), by antiestrogens, the protein tyrosine kinase inhibitor, genistein, and by AG825, a selective ErbB2 inhibitor; but not by AG30, a selective EGFR inhibitor. Akt phosphorylation by HRG-beta1 was abrogated by an arginine to cysteine mutation (R25C) in the pleckstrin homology (PH) domain of Akt, and HRG-beta1 did not induce Akt phosphorylation in the ER-negative variant of MCF-7, MCF-7/ADR. Transient transfection of ER-alpha into these cells restored Akt phosphorylation by HRG-beta1, suggesting the requirement of ER-alpha. HRG-beta1 did not activate Akt in MCF-7 cells stably transfected with an anti-ErbB2-targeted ribozyme, further confirming a role for ErbB2. Stable transfection of the cells with a dominant negative Akt or with the R25C-Akt mutant, as well as PI 3-K inhibitors, blocked the effect of HRG-beta1 on ER-alpha expression and activity and on the growth of MCF-7 cells. Stable transfection of MCF-7 cells with a constitutively active Akt mimicked the effect of HRG-beta1. Experiments employing selective ErbB inhibitors demonstrate that the effect of HRG-beta1 on ER-alpha expression and activity is also mediated by ErbB2 and not by EGFR, demonstrating that ErbB2 is the primary mediator of the effects of HRG-beta1 on ER-a regulation. Taken together, our data suggest that HRG-beta1, bound to the ErbB2 ErbB3 heterodimer, in the presence of membrane ER-alpha, interacts with and activates PI 3-K/Akt. Akt leads to nuclear ER-alpha phosphorylation, thereby altering its expression and transcriptional activity.	Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Dept Oncol, Washington, DC 20007 USA; Columbia Univ, Dept Pharmacol, New York, NY 10032 USA; Georgetown Univ, Sch Nursing & Hlth Studies, Washington, DC 20007 USA; Univ Marburg, Sch Med, Dept Pharmacol & Toxicol, D-35033 Marburg, Germany	Georgetown University; Columbia University; Georgetown University; Philipps University Marburg	Stoica, A (corresponding author), E411 Res Bldg,3970 Reservoir Rd NW, Washington, DC 20007 USA.	stoicaa@georgetown.edu		Wellstein, Anton/0000-0002-0570-4950	NCI NIH HHS [P50-CA-58185, P30-CA-51008] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058185, P30CA051008] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguilar Z, 1999, ONCOGENE, V18, P6050, DOI 10.1038/sj.onc.1202993; AHMED NN, 1993, ONCOGENE, V8, P1957; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ALLRED DC, 1992, HUM PATHOL, V23, P974, DOI 10.1016/0046-8177(92)90257-4; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Angus WGR, 2000, MOL CELL ENDOCRINOL, V170, P1, DOI 10.1016/S0303-7207(00)00337-3; ANTONIOTTI S, 1992, EUR J CANCER, V28A, P318, DOI 10.1016/S0959-8049(05)80045-0; Bates NP, 1997, ONCOGENE, V15, P473, DOI 10.1038/sj.onc.1201368; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BENCHAIBI M, 1989, VIROLOGY, V169, P15, DOI 10.1016/0042-6822(89)90036-6; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; BERNS EMJJ, 1992, J STEROID BIOCHEM, V43, P13, DOI 10.1016/0960-0760(92)90182-I; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BERTHOIS Y, 1986, J STEROID BIOCHEM, V25, P963, DOI 10.1016/0022-4731(86)90330-4; Brockhoff G, 2001, CYTOMETRY, V44, P338, DOI 10.1002/1097-0320(20010801)44:4<338::AID-CYTO1125>3.0.CO;2-V; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Chen XM, 2000, BIOCHEM BIOPH RES CO, V277, P757, DOI 10.1006/bbrc.2000.3731; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1997, ONCOGENE, V14, P2793, DOI 10.1038/sj.onc.1201121; Chung YL, 2002, INT J CANCER, V97, P306, DOI 10.1002/ijc.1614; Daly RJ, 1999, GROWTH FACTORS, V16, P255, DOI 10.3109/08977199909069144; DAUVOIS S, 1993, J CELL SCI, V106, P1377; DEPOTTER CR, 1990, INT J CANCER, V45, P55, DOI 10.1002/ijc.2910450112; DOUGALL WC, 1994, ONCOGENE, V9, P2109; DOWNWARD J, 1995, NATURE, V376, P553, DOI 10.1038/376553a0; ElTanani MKK, 1997, MOL ENDOCRINOL, V11, P928, DOI 10.1210/me.11.7.928; ElTanani MKK, 1997, J STEROID BIOCHEM, V60, P269, DOI 10.1016/S0960-0760(96)00226-9; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GARCIAMORALES P, 1994, J BIOL CHEM, V269, P16896; GRUNT TW, 1995, INT J CANCER, V63, P560, DOI 10.1002/ijc.2910630417; GULLICK W J, 1990, Progress in Growth Factor Research, V2, P1, DOI 10.1016/0955-2235(90)90006-6; GULLICK WJ, 1991, HUM EXP TOXICOL, V10, P398, DOI 10.1177/096032719101000604; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; HARRIS JR, 1992, NEW ENGL J MED, V327, P473, DOI 10.1056/NEJM199208133270706; Hemmings BA, 1997, SCIENCE, V277, P534, DOI 10.1126/science.277.5325.534; HODA K, 2000, J NEUROSCI RES, V60, P321; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Houston SJ, 1999, BRIT J CANCER, V79, P1220, DOI 10.1038/sj.bjc.6690196; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; Improta-Brears T, 1999, P NATL ACAD SCI USA, V96, P4686, DOI 10.1073/pnas.96.8.4686; Juhl H, 1997, J BIOL CHEM, V272, P29482, DOI 10.1074/jbc.272.47.29482; Kato  S, 2001, Breast Cancer, V8, P3, DOI 10.1007/BF02967472; Keshamouni VG, 2002, J BIOL CHEM, V277, P22558, DOI 10.1074/jbc.M202351200; KIM HH, 1994, J BIOL CHEM, V269, P24747; Kim HP, 1999, BIOCHEM BIOPH RES CO, V263, P257; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; Kurokawa H, 2000, CANCER RES, V60, P5887; Lichtner RB, 1999, J STEROID BIOCHEM, V71, P181, DOI 10.1016/S0960-0760(99)00136-3; Liu W, 1999, BIOCHEM BIOPH RES CO, V261, P897, DOI 10.1006/bbrc.1999.1144; LIU YL, 1995, BREAST CANCER RES TR, V34, P97, DOI 10.1007/BF00665783; LUPU R, 1992, BIOCHEMISTRY-US, V31, P7330, DOI 10.1021/bi00147a018; Lupu R, 1996, BREAST CANCER RES TR, V38, P57, DOI 10.1007/BF01803784; LUPU R, 1993, BREAST CANCER RES TR, V27, P83, DOI 10.1007/BF00683195; Marquez DC, 2001, ONCOGENE, V20, P5420, DOI 10.1038/sj.onc.1204729; Martin MB, 2000, ENDOCRINOLOGY, V141, P4503, DOI 10.1210/en.141.12.4503; MATSUDA S, 1993, P NATL ACAD SCI USA, V90, P10803, DOI 10.1073/pnas.90.22.10803; MCLESKEY SW, 1993, CANCER RES, V53, P2168; Menard S, 2000, J NATL CANCER I, V92, P943; Mermelstein PG, 1996, J NEUROSCI, V16, P595; METZGER D, 1995, MOL ENDOCRINOL, V9, P579, DOI 10.1210/me.9.5.579; MIMNAUGH EG, 1991, BIOCHEM PHARMACOL, V42, P391, DOI 10.1016/0006-2952(91)90727-M; Miwa W, 1996, BIOCHEM BIOPH RES CO, V225, P968, DOI 10.1006/bbrc.1996.1280; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; NICHOLSON RI, 1993, EUR J CANCER, V29A, P1018, DOI 10.1016/S0959-8049(05)80215-1; NORMANNO N, 1995, BREAST CANCER RES TR, V35, P293, DOI 10.1007/BF00665981; ORTI E, 1992, ENDOCR REV, V13, P105, DOI 10.1210/er.13.1.105; PAIK S, 1990, J CLIN ONCOL, V8, P103, DOI 10.1200/JCO.1990.8.1.103; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PIERCE JH, 1991, ONCOGENE, V6, P1189; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; Puricelli L, 2002, INT J CANCER, V100, P642, DOI 10.1002/ijc.10533; QUENEL N, 1995, BREAST CANCER RES TR, V35, P283, DOI 10.1007/BF00665980; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; READ LD, 1989, MOL ENDOCRINOL, V3, P295, DOI 10.1210/mend-3-2-295; READ LD, 1990, CANCER RES, V50, P3947; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; RUSSELL KS, 1992, CANCER RES, V52, P6624; SACEDA M, 1988, MOL ENDOCRINOL, V2, P1157, DOI 10.1210/mend-2-12-1157; Saceda M, 1996, ENDOCRINOLOGY, V137, P4322, DOI 10.1210/en.137.10.4322; SeppLorenzino L, 1996, ONCOGENE, V12, P1679; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Stevis PE, 1999, ENDOCRINOLOGY, V140, P5455, DOI 10.1210/en.140.11.5455; Stoica A, 2000, J CELL BIOCHEM, V76, P605, DOI 10.1002/(SICI)1097-4644(20000315)76:4<605::AID-JCB9>3.0.CO;2-T; Stoica A, 2000, J ENDOCRINOL, V165, P371, DOI 10.1677/joe.0.1650371; Stoica A, 1997, ENDOCRINOLOGY, V138, P1498, DOI 10.1210/en.138.4.1498; STOICA GE, 2003, UNPUB ONCOGENE; STOICA GE, 2003, IN PRESS MOL ENDOCRI; Sweeney C, 2001, J BIOL CHEM, V276, P22685, DOI 10.1074/jbc.M100602200; Tan M, 1999, CANCER RES, V59, P1620; Tang CK, 1996, CANCER RES, V56, P3350; TAUCHI K, 1989, VIRCHOWS ARCH A, V416, P65, DOI 10.1007/BF01606471; TAVERNA D, 1994, INT J CANCER, V56, P522, DOI 10.1002/ijc.2910560411; Tsutsui S, 2002, J SURG ONCOL, V79, P216, DOI 10.1002/jso.10079; TZAHAR E, 1998, BIOCHIM BIOPHYS ACTA, V1377, P25; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; Watters JJ, 1997, ENDOCRINOLOGY, V138, P4030, DOI 10.1210/en.138.9.4030; Weigel NL, 1996, BIOCHEM J, V319, P657, DOI 10.1042/bj3190657; Wosikowski K, 1997, CLIN CANCER RES, V3, P2405; WRIGHT C, 1992, BRIT J CANCER, V65, P271, DOI 10.1038/bjc.1992.54; Yamamoto T, 1986, Princess Takamatsu Symp, V17, P203; Yoo JY, 1998, BREAST CANCER RES TR, V51, P71, DOI 10.1023/A:1006035603635; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	118	41	41	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2003	22	14					2073	2087		10.1038/sj.onc.1206311	http://dx.doi.org/10.1038/sj.onc.1206311			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664NJ	12687010				2022-12-28	WOS:000182066900002
J	Flinterman, M; Gaken, J; Farzaneh, F; Tavassoli, M				Flinterman, M; Gaken, J; Farzaneh, F; Tavassoli, M			E1A-mediated suppression of EGFR expression and induction of apoptosis in head and neck squamous carcinoma cell lines	ONCOGENE			English	Article						E1A; EGFR; PML; apoptosis; head and neck cancer; gene therapy	GROWTH-FACTOR RECEPTOR; PROMYELOCYTIC LEUKEMIA PROTEIN; TUMOR SUPPRESSION; ADENOVIRUS-5 E1A; NUCLEAR-BODIES; CANCER CELLS; IN-VIVO; P53; PML; TRANSCRIPTION	Previous studies have shown early region 1A (E1A) gene to inhibit the proliferation of tumour cells with wild-type, but not mutant, p53. E1A has also been shown to downregulate c-erb-B-2/neu expression, resulting in inhibition of growth in c-erb-B-2/neu overexpressing tumour cells. In this study, we have investigated the effect of E1A expression on four head and neck squamous cell carcinoma (HNSCC) cell lines that do not overexpress c-erb-B-2/neu. Cell cycle and Western blot analysis show E1A-mediated induction of apoptosis in all cell lines examined. This induction of apoptosis was independent of the p53 status as it occurred in the cell lines with wildtype, mutated or deleted p53. However, there was no evidence of E1A-induced apoptosis in a p53(+ve) normal human fibroblast cell line, 1BR3. Analysis of apoptosis in the SCC cell lines demonstrated E1A-mediated downregulation of EGFR, which was overexpressed in each of these cell lines. Overexpression of an exogenously introduced EGFR, under the control of an E1A-insensitive heterologous promoter, blocked E1A induction of apoptosis in these cells. Therefore, E1A-mediated downregulation of EGFR expression appears to be the cause, rather than a consequence of E1A-induced apoptosis in these SCC cell lines. Previous studies have shown downregulation of EGFR expression by PML. Interestingly, E1A expression in the HNSCC cells altered the pattern of PML distribution and induced the level of PML protein, thus suggesting that E1A-mediated downregulation of EGFR may occur via direct or indirect interactions with PML. These findings demonstrate a novel pathway by which E1A can induce apoptosis and identify EGFR as a potential target for the development of therapeutic strategies against epithelial malignancies, the majority of which have abnormal EGFR expression.	Kings Coll London, Dept Oral Med & Pathol, Head & Neck Oncol Grp, Rayne Inst, London SE5 9NU, England; Kings Coll London, Guys Kings & St Thomas Sch Med, Rayne Inst, Dept Mol Med, London SE5 9NU, England	University of London; King's College London; University of London; King's College London	Tavassoli, M (corresponding author), Kings Coll London, Dept Oral Med & Pathol, Head & Neck Oncol Grp, Rayne Inst, 123 Coldharbour Lane, London SE5 9NU, England.	mahvash.tavassoli@kcl.ac.uk	Farzaneh, Farzin/B-4902-2009	Farzaneh, Farzin/0000-0002-9275-2415				AKUSJARVI G, 1979, J MOL BIOL, V134, P143, DOI 10.1016/0022-2836(79)90417-0; Alcalay M, 1998, MOL CELL BIOL, V18, P1084, DOI 10.1128/MCB.18.2.1084; Averbuch SD, 2002, CLIN CANCER RES, V8, P1; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; BRANTON PE, 1984, BIOCHIM BIOPHYS ACTA, V780, P67, DOI 10.1016/0304-419X(84)90007-6; Chang JY, 1996, ONCOGENE, V13, P1405; Chang JY, 1997, ONCOGENE, V14, P561, DOI 10.1038/sj.onc.1200861; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; Davies DE, 1996, BIOCHEM PHARMACOL, V51, P1101, DOI 10.1016/0006-2952(95)02232-5; de Melker AA, 2001, J CELL SCI, V114, P2167; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DEGROOT R, 1991, MOL CELL BIOL, V11, P192, DOI 10.1128/MCB.11.1.192; Duque PM, 1999, CANCER GENE THER, V6, P554, DOI 10.1038/sj.cgt.7700077; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FAHA B, 1993, J VIROL, V67, P2456, DOI 10.1128/JVI.67.5.2456-2465.1993; FERGUSON B, 1985, MOL CELL BIOL, V5, P2653, DOI 10.1128/MCB.5.10.2653; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; FRISCH SM, 1995, CANCER RES, V55, P5551; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; He YK, 1998, JNCI-J NATL CANCER I, V90, P1080, DOI 10.1093/jnci/90.14.1080; IMPERIALE MJ, 1984, MOL CELL BIOL, V4, P867, DOI 10.1128/MCB.4.5.867; IRISH JC, 1993, LARYNGOSCOPE, V103, P42; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Lee WP, 1999, MOL CELL BIOL, V19, P8075; Lill NL, 2000, J BIOL CHEM, V275, P367, DOI 10.1074/jbc.275.1.367; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; Maul GG, 1995, J CELL BIOCHEM, V59, P498, DOI 10.1002/jcb.240590410; Mymryk JS, 1996, ONCOGENE, V13, P1581; Nishi H, 2001, J BIOL CHEM, V276, P41717, DOI 10.1074/jbc.M101241200; Prudenziati M, 2000, INT J CANCER, V88, P943, DOI 10.1002/1097-0215(20001215)88:6<943::AID-IJC17>3.0.CO;2-F; RUSCH V, 1993, CANCER RES, V53, P2379; Saha V, 1998, J CELL BIOCHEM, P264, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<264::AID-JCB32>3.0.CO;2-U; SALOMON DS, 1995, BREAST CANCER RES TR, V33, P103, DOI 10.1007/BF00682718; Sartor M, 1999, BRIT J CANCER, V80, P79, DOI 10.1038/sj.bjc.6690505; SASSONECORSI P, 1987, P NATL ACAD SCI USA, V84, P6430, DOI 10.1073/pnas.84.18.6430; Sheikh MS, 1997, ONCOGENE, V15, P1095, DOI 10.1038/sj.onc.1201264; STEIN R, 1984, MOL CELL BIOL, V4, P2792, DOI 10.1128/MCB.4.12.2792; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; Tavassoli M, 2002, CARCINOGENESIS, V23, P1569, DOI 10.1093/carcin/23.10.1569; TEODORO JG, 1995, ONCOGENE, V11, P467; Thomas A, 1998, GENE DEV, V12, P1975, DOI 10.1101/gad.12.13.1975; Tian XX, 1999, BRIT J CANCER, V81, P994, DOI 10.1038/sj.bjc.6690798; Vallian S, 1997, EXP CELL RES, V237, P371, DOI 10.1006/excr.1997.3801; Vallian S, 1998, MOL CELL BIOL, V18, P7147, DOI 10.1128/MCB.18.12.7147; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Woodburn JR, 1999, PHARMACOL THERAPEUT, V82, P241, DOI 10.1016/S0163-7258(98)00045-X; Wu WS, 2001, MOL CELL BIOL, V21, P2259, DOI 10.1128/MCB.21.7.2259-2268.2001; YAN DH, 1991, ONCOGENE, V6, P343; Yeudall WA, 1997, MOL CARCINOGEN, V18, P89, DOI 10.1002/(SICI)1098-2744(199702)18:2<89::AID-MC4>3.0.CO;2-L; YU DH, 1995, ONCOGENE, V11, P1383	58	31	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2003	22	13					1965	1977		10.1038/sj.onc.1206190	http://dx.doi.org/10.1038/sj.onc.1206190			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	662UR	12673202	Bronze			2022-12-28	WOS:000181967700007
J	Rodriguez, S; Jafer, O; Goker, H; Summersgill, BM; Zafarana, G; Gillis, AJM; van Gurp, RJHLM; Oosterhuis, JW; Lu, YJ; Huddart, R; Cooper, CS; Clark, J; Looijenga, LHJ; Shipley, JM				Rodriguez, S; Jafer, O; Goker, H; Summersgill, BM; Zafarana, G; Gillis, AJM; van Gurp, RJHLM; Oosterhuis, JW; Lu, YJ; Huddart, R; Cooper, CS; Clark, J; Looijenga, LHJ; Shipley, JM			Expression profile of genes from 12p in testicular germ cell tumors of adolescents and adults associated with i(12p) and amplification at 12p11.2-p12.1	ONCOGENE			English	Article						testicular germ cell tumors of adolescents and adults; isochromosome 12p; amplification; microarray expression profiling; comparative expressed sequence hybridization; candidate genes	COMPARATIVE GENOMIC HYBRIDIZATION; BREAST-CANCER; IN-SITU; C-MYC; IDENTIFICATION; TESTIS; OVERREPRESENTATION; CHROMOSOME-12; TUMORIGENESIS; MICROARRAYS	Gain of 12p material is invariably associated with testicular germ cell tumors (TGCTs) of adolescents and adults, most usually as an isochromosome 12p. We analyzed TGCTs with i(12p) using a global approach to expression profiling targeting chromosomes (comparative expressed sequence hybridization, CESH). This indicated overexpression of genes from 12p11.2-p12.1 relative to testis tissue and fibroblasts. The nonseminoma subtype showed higher levels of expression than seminomas. Notably, 12p11.2-p12.1 is amplified in about 10% of TGCTs and CESH analysis of such amplicon cases showed high levels of overexpression from this region. Microarray analysis, including cDNA clones representing most UniGene clusters from 12p11.2-p12.1, was applied to DNA and RNA from 5 TGCTs with amplification of 12p11.2-p12.1 and seven TGCTs with gain of the entire short arm of chromosome 12. Expression profiles were consistent with the CESH data and overexpression of EST595078, MRPS35 and LDHB at 12p11.2-p12.1 was detected in most TGCTs. High-level overexpression of BCAT1 was specific to nonseminomas and overexpression of genes such as CMAS, EKI1, KRAS2, SURB7 and various ESTs correlated with their amplification. Genes such as CCND2, GLU3, LRP6 and HPH1 at 12p13 were also overexpressed. The overexpressed sequences identified, particularly those in the region amplified, represent candidate genes for involvement in TGCT development.	Inst Canc Res, Male Urol Canc Res Ctr, Sutton SM2 5NG, Surrey, England; Erasmus MC Univ, Med Ctr, Dr Daniel Den Hoed Canc Ctr, Josephine Nefkens Inst,Pathol Lab Expt Pathooncol, NL-3000 DR Rotterdam, Netherlands; Inst Canc Res, Sect Paediat Oncol, Sutton SM2 5NG, Surrey, England; Royal Marsden Natl Hlth Serv Trust, Acad Dept Urol, Surrey, England; Inst Canc Res, Sect Mol Carcinogenesis, Sutton SM2 5NG, Surrey, England	University of London; Institute of Cancer Research - UK; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Shipley, JM (corresponding author), Inst Canc Res, Male Urol Canc Res Ctr, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.	shipley@icr.ac.uk	Looijenga, Leendert/B-8145-2019; Zafarana, Gaetano/L-8352-2017	Looijenga, Leendert/0000-0002-8146-1911; huddart, robert/0000-0003-3604-1990; Lu, Yong-Jie/0000-0001-6174-6621; Shipley, Janet/0000-0001-6748-8678; Zafarana, Gaetano/0000-0003-1391-4488				ATKIN NB, 1982, LANCET, V2, P1349; BALDINI A, 1990, AM J HUM GENET, V46, P784; Ben-Yosef T, 1998, ONCOGENE, V17, P165, DOI 10.1038/sj.onc.1201939; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; Bosl GJ, 1997, NEW ENGL J MED, V337, P242, DOI 10.1056/NEJM199707243370406; Bourdon V, 2002, CANCER RES, V62, P6218; Clark J, 2002, GENE CHROMOSOME CANC, V34, P104, DOI 10.1002/gcc.10039; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; Hayes DF, 2002, SEMIN ONCOL, V29, P231, DOI 10.1053/sonc.2002.32899; Hinoi E, 2002, BIOCHEM BIOPH RES CO, V294, P1177, DOI 10.1016/S0006-291X(02)00578-8; Houldsworth J, 1997, CELL GROWTH DIFFER, V8, P293; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; Korn WM, 1996, GENE CHROMOSOME CANC, V17, P78, DOI 10.1002/(SICI)1098-2264(199610)17:2<78::AID-GCC2>3.0.CO;2-Y; Lu YJ, 2001, P NATL ACAD SCI USA, V98, P9197, DOI 10.1073/pnas.161272798; Mostert MMC, 1996, CANCER GENET CYTOGEN, V89, P146, DOI 10.1016/0165-4608(96)00043-X; Olie RA, 1996, BRIT J CANCER, V74, P133, DOI 10.1038/bjc.1996.328; OLIE RA, 1995, GENE CHROMOSOME CANC, V12, P110, DOI 10.1002/gcc.2870120205; OOSTERHUIS JW, 1989, LAB INVEST, V60, P14; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Rao PH, 1998, CANCER RES, V58, P4260; Roelofs H, 2000, AM J PATHOL, V157, P1155, DOI 10.1016/S0002-9440(10)64631-7; Rorth M, 2000, SCAND J UROL NEPHROL, V34, P166, DOI 10.1080/00365590050509896; Rosenberg C, 2000, ONCOGENE, V19, P5858, DOI 10.1038/sj.onc.1203950; Sambrook J, 2001, MOL CLONING LAB MANU; Skotheim RI, 2002, CANCER RES, V62, P2359; SUIJKERBUIJK RF, 1993, CANCER GENET CYTOGEN, V70, P85, DOI 10.1016/0165-4608(93)90173-J; Summersgill B, 1998, DIAGN MOL PATHOL, V7, P260, DOI 10.1097/00019606-199810000-00005; Summersgill B, 2001, BRIT J CANCER, V85, P213, DOI 10.1054/bjoc.2001.1889; Summersgill B, 1998, BRIT J CANCER, V77, P305, DOI 10.1038/bjc.1998.47; Summersgill BM, 2001, CANCER GENET CYTOGEN, V128, P120, DOI 10.1016/S0165-4608(01)00414-9; von Eyben FE, 2000, ACTA ONCOL, V39, P509, DOI 10.1080/028418600750013438; Windstetter D, 1997, Eur J Med Res, V2, P431; Zafarana G, 2002, CANCER RES, V62, P1822	34	125	130	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2003	22	12					1880	1891		10.1038/sj.onc.1206302	http://dx.doi.org/10.1038/sj.onc.1206302			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660824				2022-12-28	WOS:000181678200015
J	Zeisig, BB; Garcia-Cuellar, MP; Winkler, TH; Slany, RK				Zeisig, BB; Garcia-Cuellar, MP; Winkler, TH; Slany, RK			The oncoprotein MLL-ENL disturbs hematopoietic lineage determination and transforms a biphenotypic lymphoid/myeloid cell	ONCOGENE			English	Article						leukemia; MLL; fusion protein; mixed-lineage leukemia	ACUTE LYMPHOBLASTIC-LEUKEMIA; INTERNAL TANDEM DUPLICATION; ACUTE MYELOID LEUKEMIAS; BONE-MARROW; HEMATOLOGICAL MALIGNANCIES; 11Q23 TRANSLOCATIONS; DROSOPHILA-TRITHORAX; MAMMALIAN TRITHORAX; FETAL LIVER; MUTANT MICE	Mixed-lineage leukemia (MLL) fusion proteins are associated with a unique class of leukemia that is characterized by the simultaneous expression of lymphoid-specific as well as myeloid-specific genes. Here we report the first experimental model of MLL. Murine bone marrow cells were retrovirally transduced to express the MLL-eleven nineteen leukemia (MLL-ENL) fusion protein. When cultivated in flt-3 ligand, stem cell factor and interleukin-7 (IL-7) in a stroma-free culture system MLL-ENL-transduced as well as control cells showed a wave of B-lymphopoiesis. Whereas the controls exhausted their proliferative capacity in a CD19+/B220+ state, a continuously proliferating CD19-/B220+ cell population emerged in the MLL-ENL-transduced cultures. Despite the lymphoid surface marker, these cells were of monocytoid morphology. The immortalized cells contained unrearranged retrovirus, expressed MLL-ENL mRNA and were able to grow in syngenic recipients. From the diseased animals an MLL-ENL positive, B220+/CD19-cell type could be reisolated and cultivated in vitro. In analogy to human MLL, MLL-ENL-transformed cells not only coexpressed lymphocyte-specific (rag1, rag2, pax5, Tdt) and monocyte-specific genes (lysozyme, c-fms), but also showed rearrangements of the genomic immunoglobulin locus. This model shows that MLL-ENL influences events of early lineage determination and it will enable the investigation of the underlying molecular processes.	Univ Erlangen Nurnberg, Dept Genet, D-91058 Erlangen, Germany	University of Erlangen Nuremberg	Slany, RK (corresponding author), Univ Erlangen Nurnberg, Dept Genet, Staudtstr 5, D-91058 Erlangen, Germany.							Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Behm FG, 1996, BLOOD, V87, P2870, DOI 10.1182/blood.V87.7.2870.bloodjournal8772870; Butler LH, 1997, BLOOD, V89, P3361, DOI 10.1182/blood.V89.9.3361; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; CUMANO A, 1992, NATURE, V356, P612, DOI 10.1038/356612a0; Dannaeus K, 1999, EXP HEMATOL, V27, P1646, DOI 10.1016/S0301-472X(99)00106-X; DiMartino JF, 1999, BRIT J HAEMATOL, V106, P614, DOI 10.1046/j.1365-2141.1999.01439.x; DiMartino JF, 2000, BLOOD, V96, P3887, DOI 10.1182/blood.V96.12.3887.h8003887_3887_3893; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; Dobson CL, 2000, EMBO J, V19, P843, DOI 10.1093/emboj/19.5.843; Dobson CL, 1999, EMBO J, V18, P3564, DOI 10.1093/emboj/18.13.3564; Eberhard D, 2000, EMBO J, V19, P2292, DOI 10.1093/emboj/19.10.2292; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Hanson RD, 1999, P NATL ACAD SCI USA, V96, P14372, DOI 10.1073/pnas.96.25.14372; Hess JL, 1997, BLOOD, V90, P1799, DOI 10.1182/blood.V90.5.1799; Huret JL, 2001, LEUKEMIA, V15, P987, DOI 10.1038/sj.leu.2402135; Kelly LM, 2002, BLOOD, V99, P310, DOI 10.1182/blood.V99.1.310; Kottaridis PD, 2001, BLOOD, V98, P1752, DOI 10.1182/blood.V98.6.1752; Lavau C, 2000, P NATL ACAD SCI USA, V97, P10984, DOI 10.1073/pnas.190167297; Lavau C, 2000, EMBO J, V19, P4655, DOI 10.1093/emboj/19.17.4655; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Mahmoudi T, 2001, ONCOGENE, V20, P3055, DOI 10.1038/sj.onc.1204330; Martensson IL, 1997, J EXP MED, V185, P653, DOI 10.1084/jem.185.4.653; Montecino-Rodriguez E, 2001, NAT IMMUNOL, V2, P83, DOI 10.1038/83210; Nutt S L, 2001, Int Rev Immunol, V20, P65, DOI 10.3109/08830180109056723; Nutt SL, 1998, EMBO J, V17, P2319, DOI 10.1093/emboj/17.8.2319; Nutt SL, 1999, NATURE, V401, P556, DOI 10.1038/44076; PUI CH, 1991, BLOOD, V77, P440; Schreiner S, 2001, CANCER RES, V61, P6480; Schreiner SA, 1999, LEUKEMIA, V13, P1525, DOI 10.1038/sj.leu.2401534; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Yagi H, 1998, BLOOD, V92, P108, DOI 10.1182/blood.V92.1.108.413k11_108_117; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6; Yu BD, 1998, P NATL ACAD SCI USA, V95, P10632, DOI 10.1073/pnas.95.18.10632; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	38	44	45	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 20	2003	22	11					1629	1637		10.1038/sj.onc.1206104	http://dx.doi.org/10.1038/sj.onc.1206104			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642866				2022-12-28	WOS:000181580500005
J	Hattori, T; Ohoka, N; Inoue, Y; Hayashi, H; Onozaki, K				Hattori, T; Ohoka, N; Inoue, Y; Hayashi, H; Onozaki, K			C/EBP family transcription factors are degraded by the proteasome but stabilized by forming dimer	ONCOGENE			English	Article						C/EBP; degradation; proteasome; ubiquitination; dimer; leucine zipper	ENHANCER-BINDING-PROTEIN; NUCLEAR-PROTEIN; ADIPOCYTE DIFFERENTIATION; NEGATIVE INHIBITOR; MESSENGER-RNA; FACTOR CHOP; GENE; DNA; EXPRESSION; ACTIVATION	CCAAT/enhancer-binding protein (C/EBP) family transcription factors are critical for transcription of several genes involved in tissue development and cellular function, proliferation, and differentiation. Here we show that inhibitory/regulatory C/EBP family proteins, Ig/EBP (C/EBPgamma) and CHOP (C/EBPxi), but not positively functioning NF-IL6 (C/EBPbeta), are constitutively multiubiquitinated and subsequently degraded by the proteasome. In addition, ubiquitination and degradation of these proteins are suppressed by forming dimer through their leucine zipper domains. Deletion of leucine zipper domain in NF-IL6 caused the loss of its homodimerization activity and the degradation of protein by the ubiquitin-proteasome system. In addition, Ig/EBP with its leucine zipper domain substituted for that of NF-IL6 formed homodimer and was stabilized. These observations suggest that mammalian cells equip a novel regulatory system abrogating the excess C/EBP family transcription factors bereft of dimerizing partner.	Nagoya City Univ, Grad Sch Pharmaceut Sci, Dept Mol Hlth Sci, Nagoya, Aichi 4678603, Japan	Nagoya City University	Onozaki, K (corresponding author), Nagoya City Univ, Grad Sch Pharmaceut Sci, Dept Mol Hlth Sci, Nagoya, Aichi 4678603, Japan.							CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COOPER C, 1995, NUCLEIC ACIDS RES, V23, P4371, DOI 10.1093/nar/23.21.4371; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Hattori T, 2001, J INTERF CYTOK RES, V21, P323, DOI 10.1089/107999001300177510; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; Pahl HL, 1996, CURR OPIN CELL BIOL, V8, P340, DOI 10.1016/S0955-0674(96)80007-X; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; ROMAN C, 1990, GENE DEV, V4, P1404, DOI 10.1101/gad.4.8.1404; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Ubeda M, 1996, MOL CELL BIOL, V16, P1479; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347	18	99	102	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2003	22	9					1273	1280		10.1038/sj.onc.1206204	http://dx.doi.org/10.1038/sj.onc.1206204			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618752				2022-12-28	WOS:000181360900001
J	Majumdar, S; Aggarwal, BB				Majumdar, S; Aggarwal, BB			Adenosine suppresses activation of nuclear factor-kappa B selectively induced by tumor necrosis factor in different cell types	ONCOGENE			English	Article						HIV; NF-kappa B; TNF; rheumatoid arthritis; inflammation; purines	FACTOR-ALPHA PRODUCTION; TRANSCRIPTION FACTOR; RECEPTOR AGONISTS; TNF-ALPHA; CARBOCYCLIC NUCLEOSIDE; MEDIATED CYTOTOXICITY; INDUCED ARTHRITIS; A(2) RECEPTORS; KINASE; MACROPHAGES	Adenosine is an endogenous immunomodulator that has been shown to exhibit anti-inflammatory and immunosuppressive properties through a mechanism that is not fully established. Owing to the pivotal role of nuclear factor (NF)-kappaB in these responses, we tested the hypothesis that adenosine mediates its effects through suppression of NF-kappaB activation. We investigated the effects of adenosine on NF-kappaB activation induced by various inflammatory agents in human myeloid KBM-5 cells. The treatment of these cells with adenosine suppressed TNF-induced NF-kappaB activation, but had no effect on activation of another redox-sensitive transcription factor, AP-1. These effects were not restricted to myeloid cells, as NF-kappaB activation in other lymphocytic and epithelial cell types was also inhibited. The effect on TNF-induced NF-kappaB activation was selective as adenosine had minimal effect on NF-kappaB activation induced by H2O2, PMA, LPS, okadaic acid, or ceramide, suggesting differences in the pathway leading to NF-kappaB activation by different agents. Adenosine also suppressed NF-kappaB-dependent reporter gene expression activated by TNF or by overexpression of TNFR1, TRAIT 2, NIK, and P65 subunit of NF-kappaB. The suppression of TNF-induced NF-kappaB activation by adenosine was found not to be because of inhibition of TNF-induced IkappaBalpha phosphorylation and degradation or IkappaBalpha kinase activation. The suppression of TNF-induced NF-kappaB activation was unique to adenosine, as neither its metabolites (inosine, AMP, and ATP) nor pyrimidines (thymidine and uridine) had any effect. Overall, our results clearly demonstrate that adenosine selectively suppresses TNF-induced NF-kappaB activation, which may contribute to its role in suppression of inflammation and of the immune system.	Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Lab, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Lab, Box 143,1515 Holcombe Blvd, Houston, TX 77030 USA.		Aggarwal, Bharat B/G-3388-2013					ALBRECHT H, 1995, J INFLAMM, V45, P64; BERGMANN S, 1994, J IMMUNOL, V153, P1736; Bonizzi G, 1997, J IMMUNOL, V159, P5264; Bouma MG, 1997, SHOCK, V8, P313, DOI 10.1097/00024382-199711000-00001; BOUMA MG, 1994, J IMMUNOL, V153, P4159; Bouma MG, 1996, AM J PHYSIOL-CELL PH, V270, pC522, DOI 10.1152/ajpcell.1996.270.2.C522; Bowlin TL, 1997, CELL MOL BIOL, V43, P345; Chaturvedi MM, 2000, METHOD ENZYMOL, V319, P585; CRONSTEIN BN, 1994, J APPL PHYSIOL, V76, P5, DOI 10.1152/jappl.1994.76.1.5; Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724; DAVAL JL, 1991, LIFE SCI, V49, P1435, DOI 10.1016/0024-3205(91)90043-B; Daval JL, 1996, PHARMACOL THERAPEUT, V71, P325, DOI 10.1016/S0163-7258(96)00094-0; DELAHARPE J, 1989, J IMMUNOL, V143, P596; Ferrari D, 1997, J CELL BIOL, V139, P1635, DOI 10.1083/jcb.139.7.1635; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; GREEN PG, 1991, P NATL ACAD SCI USA, V88, P4162, DOI 10.1073/pnas.88.10.4162; Guo Y, 2001, J MOL CELL CARDIOL, V33, P825, DOI 10.1006/jmcc.2001.1338; Hajra L, 2000, P NATL ACAD SCI USA, V97, P9052, DOI 10.1073/pnas.97.16.9052; Hasko G, 2000, BRIT J PHARMACOL, V129, P909, DOI 10.1038/sj.bjp.0703134; Hasko G, 1996, J IMMUNOL, V157, P4634; Hasko G, 2000, FASEB J, V14, P2065, DOI 10.1096/fj.99-0508com; JANIER MF, 1993, AM J PHYSIOL, V264, pH163, DOI 10.1152/ajpheart.1993.264.1.H163; Jeong SY, 1999, J BIOL CHEM, V274, P18981, DOI 10.1074/jbc.274.27.18981; John GR, 2001, J NEUROSCI, V21, P4134, DOI 10.1523/JNEUROSCI.21-12-04134.2001; LI C, 2001, AM J PHYSIOL, V28, pH1264; Li CF, 2000, SURGERY, V127, P161, DOI 10.1067/msy.2000.101582; Li CF, 1999, AM J PHYSIOL-HEART C, V276, pH543, DOI 10.1152/ajpheart.1999.276.2.H543; Liu JSH, 2000, J NEUROSCI, V20, P5292, DOI 10.1523/JNEUROSCI.20-14-05292.2000; MAHON TM, 1995, J BIOL CHEM, V270, P28557, DOI 10.1074/jbc.270.48.28557; Majumdar S, 2001, J IMMUNOL, V167, P2911, DOI 10.4049/jimmunol.167.5.2911; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Manna SK, 2000, J IMMUNOL, V165, P4927, DOI 10.4049/jimmunol.165.9.4927; Manna SK, 2000, J BIOL CHEM, V275, P13297, DOI 10.1074/jbc.275.18.13297; MARANGOS PJ, 1990, PROG CLIN BIOL RES, V361, P331; McWhinney CD, 1996, EUR J PHARMACOL, V310, P209, DOI 10.1016/0014-2999(96)00272-5; Miagkov AV, 1998, P NATL ACAD SCI USA, V95, P13859, DOI 10.1073/pnas.95.23.13859; Nasuhara Y, 1999, J BIOL CHEM, V274, P19965, DOI 10.1074/jbc.274.28.19965; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Nie ZZ, 1998, MOL PHARMACOL, V53, P663, DOI 10.1124/mol.53.4.663; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; PARMELY MJ, 1993, J IMMUNOL, V151, P389; REINSTEIN LJ, 1994, HEPATOLOGY, V19, P1445, DOI 10.1002/hep.1840190620; Salvatore CA, 2000, J BIOL CHEM, V275, P4429, DOI 10.1074/jbc.275.6.4429; SCHRIER DJ, 1990, J IMMUNOL, V145, P1874; SULLIVAN GW, 1990, J IMMUNOL, V145, P1537; Szabo C, 1998, BRIT J PHARMACOL, V125, P379, DOI 10.1038/sj.bjp.0702040; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; Wagner DR, 1998, CIRCULATION, V97, P521; Wagner DR, 1998, CIRC RES, V82, P47; Xia DX, 2000, BIOCHEM PHARMACOL, V60, P717, DOI 10.1016/S0006-2952(00)00367-1; Yin YZ, 2001, LEUKEMIA RES, V25, P423, DOI 10.1016/S0145-2126(00)00147-8; Zwacka RM, 1998, HEPATOLOGY, V28, P1022, DOI 10.1002/hep.510280417	52	83	89	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 27	2003	22	8					1206	1218		10.1038/sj.onc.1206184	http://dx.doi.org/10.1038/sj.onc.1206184			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650EK	12606947				2022-12-28	WOS:000181249700009
J	Neiman, PE; Grbic, JJ; Polony, TS; Kimmel, R; Bowers, SJ; Delrow, J; Beemon, KL				Neiman, PE; Grbic, JJ; Polony, TS; Kimmel, R; Bowers, SJ; Delrow, J; Beemon, KL			Functional genomic analysis reveals distinct neoplastic phenotypes associated with c-myb mutation in the bursa of Fabricius	ONCOGENE			English	Article						c-myb; c-myc; bursa of farbricius; lymphomas; cDNA microarray	AVIAN-LEUKOSIS VIRUS; B-CELL LYMPHOMA; GENE-EXPRESSION; PROMOTER INSERTION; RAPID INDUCTION; MYELOID TUMORS; BALB/C MICE; ACTIVATION; ONCOGENE; PROTEINS	Avian retroviral integration into the c-myb locus is casually associated with the development of lymphomas in the bursa of Farbricius of chickens; these arise with a shorter latency than bursal lymphomas caused by deregulation of c-myc. This study indicates that c-myb mutation in embryonic bursal precursors leads to an oligoclonal population of developing bursal follicles, showing a variable propensity to form a novel lesion, the neoplastic follicle (NF). About half of such bursas rapidly developed lymphomas. Detection of changes in gene expression, during the development of neoplasms, was carried out by cDNA microarray analysis. The transcriptional signature of lymphomas with mutant c-myb was more limited than, and only partially shared with, those of bursal lymphomas caused by Myc or Rel oncogenes. The c-myb-associated lymphomas frequently showed overexpression of c-myc and altered expression of other genes involved in cell cycle control and proliferation-related signal transduction. Oligoclonal, NF-containing bursas lacked detectable c-myc overexpression and demonstrated a pattern of gene expression distinct from that of normal bursa and partially shared with the short-latency lymphomas. This functional genomic analysis uncovered several different pathways of lymphomagenesis by oncogenic transcription factors acting in a B-cell lineage.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Johns Hopkins University	Neiman, PE (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1124 Columbia St, Seattle, WA 98109 USA.				NCI NIH HHS [R01 CA20068, R01 CA48746] Funding Source: Medline; NIGMS NIH HHS [T32 GM007231] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA020068, R01CA048746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007231] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abdrakhmanov I, 2000, GENOME RES, V10, P2062, DOI 10.1101/gr.10.12.2062; BABA TW, 1985, P NATL ACAD SCI USA, V82, P213, DOI 10.1073/pnas.82.1.213; BARTH CF, 1988, MOL CELL BIOL, V8, P5358, DOI 10.1128/MCB.8.12.5358; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Brandvold KA, 2000, ONCOGENE, V19, P2780, DOI 10.1038/sj.onc.1203589; Brandvold KA, 2001, ONCOGENE, V20, P3226, DOI 10.1038/sj.onc.1204431; Clurman BE, 1998, P NATL ACAD SCI USA, V95, P15158, DOI 10.1073/pnas.95.26.15158; CLURMAN BE, 1989, MOL CELL BIOL, V9, P2657, DOI 10.1128/MCB.9.6.2657; COOPER MD, 1960, HISTOGENESIS J NATT, V41, P373; ECKERT EA, 1951, J NATL CANCER I, V12, P447; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Goitsuka R, 1997, J IMMUNOL, V159, P3126; GONDA TJ, 1987, J VIROL, V61, P2754, DOI 10.1128/JVI.61.9.2754-2763.1987; Gong M, 1998, J VIROL, V72, P5517, DOI 10.1128/JVI.72.7.5517-5525.1998; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Guarguaglini G, 2000, CELL GROWTH DIFFER, V11, P455; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; Irwin MS, 2001, APOPTOSIS, V6, P17, DOI 10.1023/A:1009663809458; Jackers P, 1996, ONCOGENE, V13, P495; Jiang WP, 1997, J VIROL, V71, P6526, DOI 10.1128/JVI.71.9.6526-6533.1997; KANTER MR, 1988, J VIROL, V62, P1423, DOI 10.1128/JVI.62.4.1423-1432.1988; Kramer ER, 2000, MOL BIOL CELL, V11, P1555, DOI 10.1091/mbc.11.5.1555; Kuersten S, 2001, TRENDS CELL BIOL, V11, P497, DOI 10.1016/S0962-8924(01)02144-4; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; Marshall AJ, 2000, J EXP MED, V191, P1319, DOI 10.1084/jem.191.8.1319; MuziFalconi M, 1995, P NATL ACAD SCI USA, V92, P12475, DOI 10.1073/pnas.92.26.12475; NASONBURCHENAL K, 1993, P NATL ACAD SCI USA, V90, P1619, DOI 10.1073/pnas.90.4.1619; NEEL BG, 1981, CELL, V23, P323, DOI 10.1016/0092-8674(81)90128-8; NEIMAN P, 1985, P NATL ACAD SCI USA, V82, P222, DOI 10.1073/pnas.82.1.222; NEIMAN P, 1980, J VIROL, V34, P178, DOI 10.1128/JVI.34.1.178-186.1980; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5857, DOI 10.1073/pnas.88.13.5857; NEIMAN PE, 1994, ADV IMMUNOL, V56, P467, DOI 10.1016/S0065-2776(08)60457-5; Neiman PE, 2001, P NATL ACAD SCI USA, V98, P6378, DOI 10.1073/pnas.111144898; Ness SA, 1996, BBA-REV CANCER, V1288, pF123, DOI 10.1016/S0304-419X(96)00027-3; Ouspenski II, 1998, EXP CELL RES, V244, P171, DOI 10.1006/excr.1998.4174; PAYNE GS, 1981, CELL, V23, P311, DOI 10.1016/0092-8674(81)90127-6; Petersen BO, 2000, GENE DEV, V14, P2330, DOI 10.1101/gad.832500; Pfleger CM, 2001, GENE DEV, V15, P2396, DOI 10.1101/gad.918201; PIZER E, 1989, J VIROL, V63, P1630, DOI 10.1128/JVI.63.4.1630-1640.1989; PIZER ES, 1992, J VIROL, V66, P512, DOI 10.1128/JVI.66.1.512-523.1992; PRICHARD CC, 2001, P NATL ACAD SCI USA, V98, P13266; Sauer K, 2001, J BIOL CHEM, V276, P45207, DOI 10.1074/jbc.M106811200; Schmidt M, 2000, MOL CELL BIOL, V20, P1970, DOI 10.1128/MCB.20.6.1970-1981.2000; SHENONG GL, 1986, IN PRESS MOL CELL BI, V6, P2756; SHENONG GLC, 1986, MOL CELL BIOL, V6, P380, DOI 10.1128/MCB.6.2.380; SHENONG GLC, 1987, J VIROL, V61, P3721, DOI 10.1128/JVI.61.12.3721-3725.1987; Smith MR, 1997, J VIROL, V71, P6534, DOI 10.1128/JVI.71.9.6534-6540.1997; Sudo T, 2001, EMBO J, V20, P6499, DOI 10.1093/emboj/20.22.6499; THOMPSON CB, 1987, CELL, V51, P371, DOI 10.1016/0092-8674(87)90633-7; Tirunagaru VG, 2000, GENOMICS, V66, P144, DOI 10.1006/geno.2000.6189; WOLFF L, 1988, J IMMUNOL, V141, P681	51	32	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 20	2003	22	7					1073	1086		10.1038/sj.onc.1206070	http://dx.doi.org/10.1038/sj.onc.1206070			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	644PB	12592394				2022-12-28	WOS:000180926100013
J	Xiao, Z; Latek, R; Lodish, HF				Xiao, Z; Latek, R; Lodish, HF			An extended bipartite nuclear localization signal in Smad4 is required for its nuclear import and transcriptional activity	ONCOGENE			English	Article						nuclear localization signal (NLS); nucleocytoplasmic shuttling; R-Smads; Co-Smad; importin alpha	CRYSTAL-STRUCTURE; DNA-BINDING; DOMAIN; TRANSLOCATION; MUTATIONS; ALPHA; RICH	Smad proteins are a class of tumor suppressors that play critical roles in inhibiting the proliferation of a variety of cell types by modulating the transcriptions of target genes. Despite recent advances, the mechanism of their nuclear import is not completely understood. Smad proteins contain a conserved basic motif in their N-terminal MH1 domains that resembles a nuclear localization signal (NLS). Previous studies indicate that in receptor-regulated Smads such as Smad1 and Smad3 this motif determines their interactions with nuclear import receptors and mediates their ligand-induced nuclear translocation. Common-Smads such as Smad4 display constant nucleocytoplasmic shuttling and are capable of autonomous nuclear import and export. Mutations of the basic motif in Smad4 disrupted its nuclear accumulation. However, this motif is not sufficient to confer nuclear translocation to a fused heterologous protein, suggesting that it is only part of the bona fide Smad4 NLS. We mapped the Smad4 NLS by fusing various segments of Smad4 sequence covering the basic motif to GFP and tested the localization of the fusion proteins. We identified an extended NLS, starting from the basic motif and extending into the DNA-binding region (AA 45-110), that is sufficient to confer nuclear localization to GFP. Among the 14 basic residues in the NLS, only four (K45, K46, K48 and R81) are critical for import. This NLS is critical not only for autonomous nuclear import of Smad4, but also for its nuclear translocation in the presence of activated R-Smads, further confirming the functional relevance of the Smad4 NLS in TGF-beta signal transduction. Structural modeling demonstrated that the four critical basic residues are all solvent exposed and map to a single localized segment on one surface of the Smad4 MH1 domain. Their distribution and spacing resemble a classical bipartite NLS. Smad4 displays specific binding to importin alpha through its MR1 domain, which was abrogated by loss-of-function mutations in Smad4 NLS. Finally, the Smad4 NLS is essential for its transcriptional activity since loss-of-function NLS mutants are also transcriptionally inactive.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Lodish, HF (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.		Gung, Amber/D-9842-2011		NATIONAL CANCER INSTITUTE [R01CA063260] Funding Source: NIH RePORTER; NCI NIH HHS [CA63260] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; de Caestecker MP, 2000, J BIOL CHEM, V275, P2115, DOI 10.1074/jbc.275.3.2115; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Hanyu A, 2001, J CELL BIOL, V155, P1017, DOI 10.1083/jcb.200106023; Jones JB, 2000, NUCLEIC ACIDS RES, V28, P2363, DOI 10.1093/nar/28.12.2363; Kobe B, 1999, NAT STRUCT BIOL, V6, P388, DOI 10.1038/7625; Kurisaki A, 2001, MOL BIOL CELL, V12, P1079, DOI 10.1091/mbc.12.4.1079; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Moren A, 2000, ONCOGENE, V19, P4396, DOI 10.1038/sj.onc.1203798; NICOLS A, 1991, PROTEINS, V11, P140; Pierreux CE, 2000, MOL CELL BIOL, V20, P9041, DOI 10.1128/MCB.20.23.9041-9054.2000; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Watanabe M, 2000, EMBO REP, V1, P176, DOI 10.1093/embo-reports/kvd029; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Xiao Z, 2000, P NATL ACAD SCI USA, V97, P7853, DOI 10.1073/pnas.97.14.7853; Xiao Z, 2000, J BIOL CHEM, V275, P23425, DOI 10.1074/jbc.C000345200; Xu J, 2000, P NATL ACAD SCI USA, V97, P4820, DOI 10.1073/pnas.97.9.4820; YING X, 2000, PROTEIN-STRUCT FUNCT, V40, P343	21	78	81	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 20	2003	22	7					1057	1069		10.1038/sj.onc.1206212	http://dx.doi.org/10.1038/sj.onc.1206212			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	644PB	12592392				2022-12-28	WOS:000180926100011
J	Millan, O; Ballester, A; Castrillo, A; de la Oliva, JL; Traves, PG; Rojas, JM; Bosca, L				Millan, O; Ballester, A; Castrillo, A; de la Oliva, JL; Traves, PG; Rojas, JM; Bosca, L			H-Ras-specific activation of NF-kappa B protects NIH 3T3 cells against stimulus-dependent apoptosis	ONCOGENE			English	Article						survival; nuclear factor kappa B; apoptosis; TNF alpha; staurosporine	NITRIC-OXIDE SYNTHASE; ONCOGENIC RAS; TRANSCRIPTIONAL ACTIVITY; KINASE; INDUCTION; EXPRESSION; TRANSFORMATION; INHIBITION; PROTEINS; SUBUNIT	Ras signaling involves the activation of several downstream pathways that exhibit isoform specificity. In this study, the basal and tumor necrosis factor alpha (TNFalpha)-induced activation. of NF-kappaB has been examined in cells overexpressing H-Ras, K-Ras or N-Ras. Cells expressing H-Ras exhibited a basal kappaB activity that correlated with sustained IkappaB kinase activation and lower steady-state levels of IkappaBalpha in the cytosol. Upon activation with TNFalpha, the cells expressing the distinct Ras. isoforms behaved similarly in terms of binding of nuclear proteins to a kappaB sequence and induction of a kappaB-dependent reporter gene. The basal activation of NF-kappaB in cells expressing H-Ras impaired staurosporine-induced apoptosis in these cells, through a mechanism that was NF-kappaB-dependent and inhibitable in the presence of z-VAD. Moreover, titration of caspase activation in response to staurosporine showed a significant resistance in cells expressing H-Ras when compared with the void vector or the N-Ras counterparts. These results indicate that the distinct Ras proteins have specific effects on the NF-kappaB pathway and that this action contributes to protect cells against apoptosis.	Univ Complutense, Fac Farm, Inst Bioquim, Ctr Mixto CSIC UCM, Madrid 28040, Spain; Univ Complutense, Fac Farm, Inst Bioquim, Ctr Nacl Invest Cardiovasc, Madrid 28040, Spain; Inst Salud Carlos III, Ctr Nacl Microbiol, Unidad Biol Celular, Majadahonda, Spain	Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Centro Nacional de Investigaciones Cardiovasculares (CNIC); Complutense University of Madrid; Instituto de Salud Carlos III; Centro Nacional de Microbiologa (CNM)	Bosca, L (corresponding author), Univ Complutense, Fac Farm, Inst Bioquim, Ctr Mixto CSIC UCM, Madrid 28040, Spain.	boscal@farm.ucm.es	Rojas, José M/D-3718-2018; Bosca, Lisardo/A-2059-2008; G. Traves, Paqui/L-5693-2014; Rojas, José M./AAA-3354-2021	Rojas, José M/0000-0002-5383-3482; Bosca, Lisardo/0000-0002-0253-5469; G. Traves, Paqui/0000-0001-5749-8426; Rojas, José M./0000-0002-7547-2825; Ballester Jareno, Alicia/0000-0002-6474-7248				Arsura M, 2000, MOL CELL BIOL, V20, P5381, DOI 10.1128/MCB.20.15.5381-5391.2000; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Cadoret A, 1997, ONCOGENE, V14, P1589, DOI 10.1038/sj.onc.1200992; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Castrillo A, 2000, MOL CELL BIOL, V20, P1692, DOI 10.1128/MCB.20.5.1692-1698.2000; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiazGuerra MJM, 1996, J BIOL CHEM, V271, P30114, DOI 10.1074/jbc.271.47.30114; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Downward J, 1996, CANCER SURV, V27, P87; Fenwick C, 2000, SCIENCE, V287, P869, DOI 10.1126/science.287.5454.869; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; FINCO TS, 1993, J BIOL CHEM, V268, P17676; Folgueira L, 1996, J VIROL, V70, P2332, DOI 10.1128/JVI.70.4.2332-2338.1996; Fritz G, 2001, J BIOL CHEM, V276, P3115, DOI 10.1074/jbc.M005058200; Grana TM, 2002, CANCER RES, V62, P4142; Henry DO, 2000, MOL CELL BIOL, V20, P8084, DOI 10.1128/MCB.20.21.8084-8092.2000; Hortelano S, 2002, CELL DEATH DIFFER, V9, P643, DOI 10.1038/sj.cdd.4401017; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Jol H, 2000, ONCOGENE, V19, P841, DOI 10.1038/sj.onc.1203392; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Ludwig L, 2001, CANCER RES, V61, P4526; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Maeno E, 2000, P NATL ACAD SCI USA, V97, P9487, DOI 10.1073/pnas.140216197; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Mayo MW, 2001, METHOD ENZYMOL, V333, P73; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; McFall A, 2001, MOL CELL BIOL, V21, P5488, DOI 10.1128/MCB.21.16.5488-5499.2001; Norris JL, 1999, J BIOL CHEM, V274, P13841, DOI 10.1074/jbc.274.20.13841; Olson MF, 2000, SEMIN IMMUNOL, V12, P63, DOI 10.1006/smim.2000.0208; Pahan K, 2000, J NEUROCHEM, V74, P2288, DOI 10.1046/j.1471-4159.2000.0742288.x; Prior IA, 2001, J CELL SCI, V114, P1603; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; Yan F, 2001, CANCER RES, V61, P8668; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052	44	23	23	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2003	22	4					477	483		10.1038/sj.onc.1206179	http://dx.doi.org/10.1038/sj.onc.1206179			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555061				2022-12-28	WOS:000180538200001
J	Loreto, MP; McGlade, CJ				Loreto, MP; McGlade, CJ			Cloning and characterization of human Src-like adaptor protein 2 and a novel splice isoform, SLAP-2-v	ONCOGENE			English	Article						adaptor protein; SLAP-2; SLAP; splice variant; TCR; myeloid; chromosome 20q	T-CELL RECEPTOR; TYROSINE KINASE; C-CBL; PHOSPHORYLATION SITE; NEGATIVE REGULATOR; MYELOID-LEUKEMIA; ZAP-70; LAT; IDENTIFICATION; THYMOCYTES	Src-like adaptor protein 2 (SLAP-2) is a recently characterized adaptor protein bearing sequence and structural similarity to the Src-like adaptor protein (SLAP). SLAP-2 expression is hematopoietic-specific, and it has been demonstrated to function as a negative regulator of T-cell antigen receptor (TCR)-mediated signalling by virtue of its interaction with c-Cbl. Here we report the cloning of a cDNA encoding the human homologue of SLAP-2, as well as the genomic structure of the human SLAP-2 gene. Similar to its murine counterpart, two human SLAP-2 protein isoforms exist because of alternative translation initiation, and SLAP-2 protein expression is observed in a variety of hernatopoietic cell tines of both lymphoid and myeloid lineages. The human SLAP-2 gene is located on chromosome 20q, and the SLAP-2 coding region consists of seven exons. Concurrent with the cloning of the full-length SLAP-2 cDNA, a unique cDNA encoding an alternatively spliced SLAP-2 isoform has been identified, and designated as SLAP-2-v. The SLAP-2-v transcript encodes a putative protein of 210 amino acids that lacks the c-Cbl interaction region, and consequently is impaired in its ability to both bind to c-Cbl, and inhibit TCR signalling relative to SLAP-2.	Hosp Sick Children, Arthur & Sonia Labatt Brain Tumour Res Ctr, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	McGlade, CJ (corresponding author), Hosp Sick Children, Arthur & Sonia Labatt Brain Tumour Res Ctr, 555 Univ Ave,Rm 3020B, Toronto, ON M5G 1X8, Canada.							Berry DM, 2001, ONCOGENE, V20, P1203, DOI 10.1038/sj.onc.1204218; Clements JL, 1999, ANNU REV IMMUNOL, V17, P89, DOI 10.1146/annurev.immunol.17.1.89; Holland SJ, 2001, J EXP MED, V194, P1263, DOI 10.1084/jem.194.9.1263; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kratchmarova I, 2001, GENE, V262, P267, DOI 10.1016/S0378-1119(00)00516-3; Latour S, 2001, CURR OPIN IMMUNOL, V13, P299, DOI 10.1016/S0952-7915(00)00219-3; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Loreto MP, 2002, MOL CELL BIOL, V22, P4241, DOI 10.1128/MCB.22.12.4241-4255.2002; Lupher ML, 1998, J BIOL CHEM, V273, P35273, DOI 10.1074/jbc.273.52.35273; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; MacGrogan D, 2001, ONCOGENE, V20, P4150, DOI 10.1038/sj.onc.1204540; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Pandey A, 2002, J BIOL CHEM, V277, P19131, DOI 10.1074/jbc.M110318200; Rao N, 2001, EMBO J, V20, P7085, DOI 10.1093/emboj/20.24.7085; Rao N, 2000, J IMMUNOL, V164, P4616, DOI 10.4049/jimmunol.164.9.4616; ROULSTON D, 1993, BLOOD, V82, P3424; Rudd CE, 1999, CELL, V96, P5, DOI 10.1016/S0092-8674(00)80953-8; Sosinowski T, 2000, J EXP MED, V191, P463, DOI 10.1084/jem.191.3.463; Sosinowski T, 2001, IMMUNITY, V15, P457, DOI 10.1016/S1074-7613(01)00195-9; Thien CBF, 1999, J IMMUNOL, V162, P7133; Wang HY, 2001, J BIOL CHEM, V276, P26004, DOI 10.1074/jbc.M010738200; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	23	10	12	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 16	2003	22	2					266	273		10.1038/sj.onc.1206114	http://dx.doi.org/10.1038/sj.onc.1206114			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527895				2022-12-28	WOS:000180322400011
J	Fukuma, M; Okita, H; Hata, J; Umezawa, A				Fukuma, M; Okita, H; Hata, J; Umezawa, A			Upregulation of Id2, an oncogenic helix-loop-helix protein, is mediated by the chimeric EWS/ets protein in Ewing sarcoma	ONCOGENE			English	Article						Ewing sarcoma; Id2; EWS/ets; chimeric protein	DNA-BINDING; EWS GENE; TRANSCRIPTIONAL ACTIVATION; FUSION PROTEIN; CELL-CYCLE; ETS; EXPRESSION; FAMILY; TRANSLOCATION; EWS-FLI1	The chromosomal translocation specifically linked to the Ewing sarcoma family results in the generation of fusion proteins comprising the amino terminal portion of EWS and the DNA-binding domain of ets transcription factors. The EWS/ets chimeric proteins act as aberrant transcription factors leading to tumorigenic processes. We searched for genes specifically activated in Ewing sarcoma cells but not in other tumor cell lines using the gene array technique, and found significantly enhanced expression of the Id2 gene. High levels of Id2 transcripts were detected in Ewing sarcoma cell lines and tumor tissues. The EWS/ ets chimeric proteins activated the Id2 gene via the 5'-upstream promoter sequence. Chromatin-immunoprecipitation revealed a direct interaction of EWS/Fli-1 with the promoter regions of the 142, TGF-beta type 11 receptor, cyclin D1, and c-myc genes. Since EWS/Fti-1 transactivates c-myc, a cooperative action of the chimeric protein and c-myc leads to overexpression of Id2. In the present study, we suggest that Id2 is a target of the chimeric proteins and that the c-myc/Id2 pathway plays a pivotal role in the tumorigenic processes provoked by EWS/ets proteins.	Keio Univ, Dept Pathol, Sch Med, Shinjuku Ku, Tokyo 1608582, Japan	Keio University	Umezawa, A (corresponding author), Keio Univ, Dept Pathol, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	umezawa@1985.jukuin.keio.ac.jp						BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; Dauphinot L, 2001, ONCOGENE, V20, P3258, DOI 10.1038/sj.onc.1204437; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; Edelman GM, 2000, P NATL ACAD SCI USA, V97, P3038, DOI 10.1073/pnas.040569897; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Im YH, 2000, CANCER RES, V60, P1536; JEON IS, 1995, ONCOGENE, V10, P1229; Langlands K, 1997, J BIOL CHEM, V272, P19785, DOI 10.1074/jbc.272.32.19785; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; Martinsen BJ, 1998, SCIENCE, V281, P988, DOI 10.1126/science.281.5379.988; Matsumoto Y, 2001, BRIT J CANCER, V84, P768, DOI 10.1054/bjoc.2000.1652; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; Moreno CS, 1999, IMMUNITY, V10, P143, DOI 10.1016/S1074-7613(00)80015-1; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; NEUMAN T, 1993, DEV BIOL, V160, P186, DOI 10.1006/dbio.1993.1297; NOGUERA R, 1992, LAB INVEST, V66, P143; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; OHNO T, 1994, ONCOGENE, V9, P3087; PANKOV R, 1994, MOL CELL BIOL, V14, P7744, DOI 10.1128/MCB.14.12.7744; Paulussen M, 2001, J CLIN ONCOL, V19, P1818, DOI 10.1200/JCO.2001.19.6.1818; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; SETH A, 1993, AIDS RES HUM RETROV, V9, P1017, DOI 10.1089/aid.1993.9.1017; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Sugimoto T, 1997, VIRCHOWS ARCH, V430, P41, DOI 10.1007/BF01008015; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; Thompson AD, 1996, ONCOGENE, V13, P2649; Toretsky JA, 1997, J BIOL CHEM, V272, P30822, DOI 10.1074/jbc.272.49.30822; Urano F, 1998, JPN J CANCER RES, V89, P703, DOI 10.1111/j.1349-7006.1998.tb03274.x; Urano F, 1996, BIOCHEM BIOPH RES CO, V219, P608, DOI 10.1006/bbrc.1996.0281; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; Yokota Y, 1999, NATURE, V397, P702, DOI 10.1038/17812	37	83	90	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	2003	22	1					1	9		10.1038/sj.onc.1206055	http://dx.doi.org/10.1038/sj.onc.1206055			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527902				2022-12-28	WOS:000180166900001
J	Honorio, S; Agathanggelou, A; Schuermann, M; Pankow, W; Viacava, P; Maher, ER; Latif, F				Honorio, S; Agathanggelou, A; Schuermann, M; Pankow, W; Viacava, P; Maher, ER; Latif, F			Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients	ONCOGENE			English	Article						methylation; RASSF1A; sputum; ductal carcinoma in situ	FREQUENT EPIGENETIC INACTIVATION; TUMOR-SUPPRESSOR GENE; LUNG-CANCER; CPG ISLAND; 3P21.3; REGION; METHYLATION; LOCUS	The newly identified 3p21.3 tumour suppressor gene RASSF1A is methylated in the majority of primary lung tumours, lung tumour cell lines and in a variable percentage of breast tumours. To determine the extent of RASSF1A promoter hypermethylation in early lung tumorigenesis, we analysed sputum samples from lung cancer patients and from current and former smokers using a sensitive methylation-specific PCR (MSP) technique. We also analysed RASSF1A promoter region hypermethylation in trios of normal breast/invasive ductal breast carcinoma/ductal carcinoma in situ (DCIS) from breast cancer patients and DCIS without invasive cancer. We found that 50% of small cell lung cancer (SCLC) and 21% of non-small cell lung cancer (NSCLC) patients had RASSF1A methylation, while one of two former smokers and four of 13 current smokers demonstrated RASSF1A methylation in sputum. Furthermore, two of the four current smokers and one former smoker showing RASSF1A methylation in their sputum developed cancer within 12-14 months of bronchoscopy. In our breast cancer trios, RASSF1A promoter hypermethylation was detected in 65% of invasive cancers, in 42% of corresponding DCIS but in none of the normal breast samples. In addition, we found that three out of 10 DCIS without invasive breast cancer also underwent RASSF1A promoter hypermethylation. Our findings suggest that RASSF1A promoter region hypermethylation may be a useful molecular marker for early detection of lung cancer. Furthermore, since RASSF1A promoter hypermethylation was detected in ductal carcinoma in situ, inactivation of RASSF1A may be an early event in breast tumorigenesis.	Univ Birmingham, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Sch Med, Birmingham B15 2TT, W Midlands, England; Univ Marburg, D-35033 Marburg, Germany; Krankenhaus Neukolln, Abt Innere Med 3, Schwerpunkt Pneumonol Infektiol, Berlin, Germany; Univ Pisa, Dept Oncol, Div Pathol, Pisa, Italy	University of Birmingham; Philipps University Marburg; University of Pisa	Latif, F (corresponding author), Univ Birmingham, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Sch Med, Birmingham B15 2TT, W Midlands, England.	flatif@hgmp.mrc.ac.uk	Caligo, Adelaide Maria/K-4289-2018; MAHER, EAMONN R/A-9507-2008	Caligo, Adelaide Maria/0000-0003-0589-1829; MAHER, EAMONN R/0000-0002-6226-6918				Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968; Belinsky SA, 2002, CANCER RES, V62, P2370; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Byun DS, 2001, CANCER RES, V61, P7034; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kersting M, 2000, J CLIN ONCOL, V18, P3221, DOI 10.1200/JCO.2000.18.18.3221; Kuzmin I, 2002, CANCER RES, V62, P3498; Lee MG, 2001, CANCER RES, V61, P6688; Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8; Lerman MI, 2000, CANCER RES, V60, P6116; Lo KW, 2001, CANCER RES, V61, P3877; Morrissey C, 2001, CANCER RES, V61, P7277; Palmisano WA, 2000, CANCER RES, V60, P5954; Vlacava P, 1999, J PATHOL, V188, P245	17	94	104	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	2003	22	1					147	150		10.1038/sj.onc.1206057	http://dx.doi.org/10.1038/sj.onc.1206057			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527916				2022-12-28	WOS:000180166900015
J	Thompson, CL; Sancar, A				Thompson, CL; Sancar, A			Photolyase/cryptochrome blue-light photoreceptors use photon energy to repair DNA and reset the circadian clock	ONCOGENE			English	Article						pyrimidine dimers; DNA photorepair; circadian clock; photosensory pigment	NUCLEOTIDE EXCISION-REPAIR; ESCHERICHIA-COLI; PHOTOREACTIVATING ENZYME; CRYSTAL-STRUCTURE; ARABIDOPSIS-THALIANA; ANACYSTIS-NIDULANS; 2ND CHROMOPHORE; MAMMALIAN-CELLS; FOWLPOX VIRUS; PHYTOCHROME-B	Blue light governs a number of cellular responses in bacteria, plants, and animals, including photoreactivation, plant development, and circadian photoentrainment. These activities are mediated by a family of highly conserved flavoproteins, the photolyase/cryptochrome family. Photolyase binds to UV photoproducts in DNA and repairs them in a process called photoreactivation in which blue light is used to initiate a cyclic electron transfer to break bonds and restore the integrity of DNA. Cryptochrome, which has a high degree of sequence identity to photolyase, works as the main circadian photoreceptor and as a component of the molecular clock in animals, including mammals, and regulates growth and development in plants.	Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Sancar, A (corresponding author), Univ N Carolina, Sch Med, Dept Biochem & Biophys, CB 7260, Chapel Hill, NC 27599 USA.	aziz_sancar@med.unc.edu						ADAMS MD, 1995, NATURE, V377, P3; Afonso CL, 2000, J VIROL, V74, P3815, DOI 10.1128/JVI.74.8.3815-3831.2000; Afonso CL, 1999, J VIROL, V73, P533, DOI 10.1128/JVI.73.1.533-552.1999; Ahmad M, 1998, MOL CELL, V1, P939, DOI 10.1016/S1097-2765(00)80094-5; AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; Akashi M, 2002, MOL CELL BIOL, V22, P1693, DOI 10.1128/MCB.22.6.1693-1703.2002; Anderson LE, 2000, CANCER LETT, V148, P121, DOI 10.1016/S0304-3835(99)00320-1; BAER ME, 1993, J BIOL CHEM, V268, P16717; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Berson DM, 2002, SCIENCE, V295, P1070, DOI 10.1126/science.1067262; Briggs WR, 1999, ANNU REV CELL DEV BI, V15, P33, DOI 10.1146/annurev.cellbio.15.1.33; Camacho F, 2001, FEBS LETT, V489, P159, DOI 10.1016/S0014-5793(00)02434-0; Ceriani MF, 1999, SCIENCE, V285, P553, DOI 10.1126/science.285.5427.553; Deisenhofer J, 2000, MUTAT RES-DNA REPAIR, V460, P143, DOI 10.1016/S0921-8777(00)00023-9; Egan ES, 1999, J NEUROSCI, V19, P3665; Eide EJ, 2002, J BIOL CHEM, V277, P17248, DOI 10.1074/jbc.M111466200; EKER AP, 1988, BIOCHEMISTRY-US, V27, P1758, DOI 10.1021/bi00405a056; EKER APM, 1981, PHOTOCHEM PHOTOBIOL, V33, P65, DOI 10.1111/j.1751-1097.1981.tb04298.x; Elich TD, 1997, PLANT CELL, V9, P2271, DOI 10.1105/tpc.9.12.2271; Emery P, 2000, NATURE, V404, P456, DOI 10.1038/35006558; Griffin EA, 1999, SCIENCE, V286, P768, DOI 10.1126/science.286.5440.768; Guo HW, 1998, SCIENCE, V279, P1360, DOI 10.1126/science.279.5355.1360; HAHN RA, 1991, EPIDEMIOLOGY, V2, P459, DOI 10.1097/00001648-199111000-00015; Hattar S, 2002, SCIENCE, V295, P1065, DOI 10.1126/science.1069609; HAYS JB, 1985, J BACTERIOL, V161, P602, DOI 10.1128/JB.161.2.602-608.1985; Helfrich-Forster C, 2001, NEURON, V30, P249, DOI 10.1016/S0896-6273(01)00277-X; Hitomi K, 2000, NUCLEIC ACIDS RES, V28, P2353, DOI 10.1093/nar/28.12.2353; Hoffman PD, 1996, MOL GEN GENET, V253, P259, DOI 10.1007/s004380050321; Hsu DS, 1996, BIOCHEMISTRY-US, V35, P13871, DOI 10.1021/bi962209o; Ishikawa T, 1999, GENES CELLS, V4, P57, DOI 10.1046/j.1365-2443.1999.00237.x; JOCHLE W, 1964, ANN NY ACAD SCI, V117, P88, DOI 10.1111/j.1749-6632.1964.tb48164.x; JOHNSON JL, 1988, P NATL ACAD SCI USA, V85, P2046, DOI 10.1073/pnas.85.7.2046; JORNS MS, 1984, BIOCHEMISTRY-US, V23, P2673, DOI 10.1021/bi00307a021; Kanai S, 1997, J MOL EVOL, V45, P535, DOI 10.1007/PL00006258; KATO T, 1994, NUCLEIC ACIDS RES, V22, P4119, DOI 10.1093/nar/22.20.4119; KIENER A, 1989, J BIOL CHEM, V264, P13880; KIM ST, 1994, J BIOL CHEM, V269, P8535; Kobayashi Y, 2000, GENES CELLS, V5, P725, DOI 10.1046/j.1365-2443.2000.00364.x; Komori H, 2001, P NATL ACAD SCI USA, V98, P13560, DOI 10.1073/pnas.241371398; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; LI YF, 1993, P NATL ACAD SCI USA, V90, P4389, DOI 10.1073/pnas.90.10.4389; Lin CT, 1998, P NATL ACAD SCI USA, V95, P2686, DOI 10.1073/pnas.95.5.2686; Lin CT, 1996, PLANT J, V10, P893, DOI 10.1046/j.1365-313X.1996.10050893.x; LIN CT, 1995, SCIENCE, V269, P968, DOI 10.1126/science.7638620; Lin FJ, 2001, MOL CELL BIOL, V21, P7287, DOI 10.1128/MCB.21.21.7287-7294.2001; MALHOTRA K, 1992, J BIOL CHEM, V267, P15406; MALHOTRA K, 1994, BIOCHEMISTRY-US, V33, P8712, DOI 10.1021/bi00195a012; MALHOTRA K, 1995, BIOCHEMISTRY-US, V34, P6892, DOI 10.1021/bi00020a037; Mas P, 2000, NATURE, V408, P207, DOI 10.1038/35041583; Miyamoto Y, 1998, P NATL ACAD SCI USA, V95, P6097, DOI 10.1073/pnas.95.11.6097; Miyamoto Y, 1999, MOL BRAIN RES, V71, P238, DOI 10.1016/S0169-328X(99)00192-8; Ng WO, 2001, MOL GEN GENET, V264, P924, DOI 10.1007/s004380000383; Ozer Z, 1995, BIOCHEMISTRY-US, V34, P15886, DOI 10.1021/bi00049a002; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; PAYNE G, 1990, BIOCHEMISTRY-US, V29, P7715, DOI 10.1021/bi00485a021; PAYNE G, 1987, BIOCHEMISTRY-US, V26, P7121, DOI 10.1021/bi00396a038; Petit C, 1999, M S-MED SCI, V15, P1411, DOI 10.4267/10608/1284; Provencio I, 2002, NATURE, V415, P493, DOI 10.1038/415493a; Provencio I, 2000, J NEUROSCI, V20, P600, DOI 10.1523/JNEUROSCI.20-02-00600.2000; Roenneberg T, 1997, PHOTOCHEM PHOTOBIOL, V66, P549, DOI 10.1111/j.1751-1097.1997.tb03188.x; Rosato E, 2001, CURR BIOL, V11, P909, DOI 10.1016/S0960-9822(01)00259-7; Sancar A, 2000, ANNU REV BIOCHEM, V69, P31, DOI 10.1146/annurev.biochem.69.1.31; SANCAR A, 1994, BIOCHEMISTRY-US, V33, P2, DOI 10.1021/bi00167a001; SANCAR A, 1984, P NATL ACAD SCI-BIOL, V81, P7397, DOI 10.1073/pnas.81.23.7397; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SANCAR GB, 1987, TRENDS BIOCHEM SCI, V12, P259, DOI 10.1016/0968-0004(87)90130-7; SANCAR GB, 1987, J BIOL CHEM, V262, P15457; SANCAR GB, 1989, MOL CELL BIOL, V9, P4767, DOI 10.1128/MCB.9.11.4767; Selby CP, 1999, PHOTOCHEM PHOTOBIOL, V69, P105, DOI 10.1562/0031-8655(1999)069<0105:ATMOTP>2.3.CO;2; Selby CP, 2000, P NATL ACAD SCI USA, V97, P14697, DOI 10.1073/pnas.260498597; Shalitin D, 2002, NATURE, V417, P763, DOI 10.1038/nature00815; Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013; Shigeyoshi Y, 1997, CELL, V91, P1043, DOI 10.1016/S0092-8674(00)80494-8; Somers DE, 1998, SCIENCE, V282, P1488, DOI 10.1126/science.282.5393.1488; Srinivasan V, 2001, J VIROL, V75, P1681, DOI 10.1128/JVI.75.4.1681-1688.2001; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; Stevens RG, 2001, CANCER CAUSE CONTROL, V12, P279, DOI 10.1023/A:1011237000609; Tamada T, 1997, NAT STRUCT BIOL, V4, P887, DOI 10.1038/nsb1197-887; TAMARKIN L, 1982, SCIENCE, V216, P1003, DOI 10.1126/science.7079745; TAMARKIN L, 1981, CANCER RES, V41, P4432; Thompson CL, 2001, P NATL ACAD SCI USA, V98, P11708, DOI 10.1073/pnas.201301498; Thresher RJ, 1998, SCIENCE, V282, P1490, DOI 10.1126/science.282.5393.1490; Todo T, 1999, MUTAT RES-DNA REPAIR, V434, P89, DOI 10.1016/S0921-8777(99)00013-0; Todo T, 1997, MUTAT RES-DNA REPAIR, V384, P195, DOI 10.1016/S0921-8777(97)00032-3; Todo T, 1996, SCIENCE, V272, P109, DOI 10.1126/science.272.5258.109; TODO T, 1993, NATURE, V361, P371, DOI 10.1038/361371a0; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; Vielhaber E, 2000, MOL CELL BIOL, V20, P4888, DOI 10.1128/MCB.20.13.4888-4899.2000; Vielhaber EL, 2001, J BIOL CHEM, V276, P45921, DOI 10.1074/jbc.M107726200; Vitaterna MH, 1999, P NATL ACAD SCI USA, V96, P12114, DOI 10.1073/pnas.96.21.12114; Willer DO, 1999, VIROLOGY, V264, P319, DOI 10.1006/viro.1999.0002; Wood RD, 1997, J BIOL CHEM, V272, P23465, DOI 10.1074/jbc.272.38.23465; Yagita K, 2000, GENE DEV, V14, P1353; Yang HQ, 2000, CELL, V103, P815, DOI 10.1016/S0092-8674(00)00184-7; YASUI A, 1994, EMBO J, V13, P6143, DOI 10.1002/j.1460-2075.1994.tb06961.x; Yu WJ, 2002, BIOCHEM BIOPH RES CO, V290, P933, DOI 10.1006/bbrc.2001.6300; Zhao SY, 1997, PHOTOCHEM PHOTOBIOL, V66, P727, DOI 10.1111/j.1751-1097.1997.tb03214.x; Zhao XD, 1997, J BIOL CHEM, V272, P32580, DOI 10.1074/jbc.272.51.32580	99	83	85	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2002	21	58					9043	9056		10.1038/sj.onc.1205958	http://dx.doi.org/10.1038/sj.onc.1205958			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	626TP	12483519				2022-12-28	WOS:000179889500014
J	Zhu, GH; Lenzi, M; Schwartz, EL				Zhu, GH; Lenzi, M; Schwartz, EL			The Sp1 transcription factor contributes to the tumor necrosis factor-induced expression of the angiogenic factor thymidine phosphorylase in human colon carcinoma cells	ONCOGENE			English	Article						thymidine phosphorylase; angiogenic factor; transcription regulation; colorectal cancer	ENDOTHELIAL GROWTH-FACTOR; MURINE URIDINE PHOSPHORYLASE; HUMAN COLORECTAL-CARCINOMA; NF-KAPPA-B; FACTOR-ALPHA; FACTOR GENE; DEPENDENT INDUCTION; GASTRIC-CARCINOMA; INTERFERON-GAMMA; LUNG-CANCER	Thymidine phosphorylase (TP; also known as platelet-derived endothelial cell growth factor, PD-ECGF) is an angiogenic factor that is chemotactic for endothelial cells and has been found to induce neovascularization in vivo. TP is frequently overexpressed in human solid tumors, where its expression has been correlated with increased tumor microvessel density, invasion, and metastasis, and shorter patient survival. In this report, TP activity in the WiDr colon carcinoma cell line was found to be induced 100-fold by tumor necrosis factor (TNFalpha), a secretory product of activated macrophages that has indirect angiogenic activities. Increased TP activity was accompanied by increased TP mRNA levels and without an increase in mRNA stability. TNFalpha-induced TP mRNA levels were reduced by mithramycin, a DNA-binding transcription inhibitor specific for GC-rich sequences. Transcriptional regulation by TNFa was confirmed by transient transfection of WiDr with upstream TP sequences in a luciferase reporter construct. Deletion analysis of the reporter pinpointed two regions of the TP promoter with regulatory elements for both TNFalpha-inducible and basal expression, and they contained, respectively, three and one consensus binding sites for the Sp1-family of transcription factors. One additional region contributed only to basal TP expression, and it contained three Sp1 sites. TNFalpha-induced TP expression decreased when point mutations were made in three of the four Sp1 sites postulated to contribute to both basal and TNFalpha-inducible expression. Electrophoretic mobility shift assays further demonstrated binding of nuclear Sp1 to these three sites. Sp1-binding activity was also increased in cells treated with TNFalpha. These studies establish a role for Sp1 in the regulation of expression of the angiogenic factor TP in colon cancer WiDr cells.	Montefiore Med Ctr, Albert Einstein Coll Med, Dept Oncol, Bronx, NY 10467 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Schwartz, EL (corresponding author), Montefiore Med Ctr, Albert Einstein Coll Med, Dept Oncol, 111 E 210th St, Bronx, NY 10467 USA.				NATIONAL CANCER INSTITUTE [R01CA054422, R01CA089352] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA89352, P01-CA13330, R01-CA54422] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; BLUME SW, 1991, J CLIN INVEST, V88, P1613, DOI 10.1172/JCI115474; BUSSOLINO F, 1988, J BIOL CHEM, V263, P11856; Cakouros D, 2001, J IMMUNOL, V167, P302, DOI 10.4049/jimmunol.167.1.302; Cao DL, 1999, CANCER RES, V59, P4997; Cheng N, 2001, J BIOL CHEM, V276, P13771, DOI 10.1074/jbc.M009147200; EDA H, 1993, JPN J CANCER RES, V84, P341, DOI 10.1111/j.1349-7006.1993.tb02876.x; EDA H, 1993, CANCER CHEMOTH PHARM, V32, P333, DOI 10.1007/BF00735915; Engels K, 1997, J PATHOL, V182, P414, DOI 10.1002/(SICI)1096-9896(199708)182:4<414::AID-PATH897>3.0.CO;2-Q; FINKENZELLER G, 1995, BIOCHEM BIOPH RES CO, V208, P432, DOI 10.1006/bbrc.1995.1356; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; FINNIS C, 1993, EUR J BIOCHEM, V212, P201, DOI 10.1111/j.1432-1033.1993.tb17651.x; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FRATERSCHRODER M, 1987, P NATL ACAD SCI USA, V84, P5277, DOI 10.1073/pnas.84.15.5277; Giraudo E, 1998, J BIOL CHEM, V273, P22128, DOI 10.1074/jbc.273.34.22128; Goto H, 2001, CANCER RES, V61, P469; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; Griffiths L, 1997, CANCER RES, V57, P570; HAGIWARA K, 1991, MOL CELL BIOL, V11, P2125, DOI 10.1128/MCB.11.4.2125; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; ISHIKAWA F, 1989, NATURE, V338, P557, DOI 10.1038/338557a0; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; Kim I, 2000, BIOCHEM BIOPH RES CO, V269, P361, DOI 10.1006/bbrc.2000.2296; Koukourakis MI, 1998, BRIT J CANCER, V77, P1696, DOI 10.1038/bjc.1998.280; Krehan A, 2000, J BIOL CHEM, V275, P18327, DOI 10.1074/jbc.M909736199; Lee AHS, 1999, J PATHOL, V187, P285; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; Maeda K, 1996, BRIT J CANCER, V73, P884, DOI 10.1038/bjc.1996.177; MIYAZONO K, 1987, J BIOL CHEM, V262, P4098; Naar AM, 1998, COLD SPRING HARB SYM, V63, P189, DOI 10.1101/sqb.1998.63.189; O'Byrne KJ, 2000, BRIT J CANCER, V82, P1427, DOI 10.1054/bjoc.1999.1129; OKAMURA K, 1991, J BIOL CHEM, V266, P19162; POLVERINI PJ, 1984, LAB INVEST, V51, P635; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; ROSENBAUM JT, 1988, AM J PATHOL, V133, P47; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; SATO N, 1986, JNCI-J NATL CANCER I, V76, P1113; SATO N, 1987, J NATL CANCER I, V79, P1383; Sawada N, 1998, CLIN CANCER RES, V4, P1013; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schwartz EL, 1998, CANCER RES, V58, P1551; SCHWARTZ EL, 1995, J BIOL CHEM, V270, P19073, DOI 10.1074/jbc.270.32.19073; Seki N, 2000, EUR J CANCER, V36, P68, DOI 10.1016/S0959-8049(99)00201-4; Shimaoka S, 2000, CANCER, V88, P2220, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2220::AID-CNCR4>3.3.CO;2-3; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; SUMIZAWA T, 1993, J BIOCHEM-TOKYO, V114, P9, DOI 10.1093/oxfordjournals.jbchem.a124146; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Takahashi Y, 1998, CLIN CANCER RES, V4, P429; Takahashi Y, 1996, J NATL CANCER I, V88, P1146, DOI 10.1093/jnci/88.16.1146; TAKEBAYASHI Y, 1995, CANCER LETT, V95, P57, DOI 10.1016/0304-3835(95)03865-T; Takebayashi Y, 1996, JNCI-J NATL CANCER I, V88, P1110, DOI 10.1093/jnci/88.16.1110; TEVAEARAI HT, 1992, EUR J CANCER, V28A, P368, DOI 10.1016/S0959-8049(05)80055-3; van Triest B, 2000, CLIN CANCER RES, V6, P1063; WATANABE SI, 1995, J BIOL CHEM, V270, P12191, DOI 10.1074/jbc.270.20.12191; WATANABE SI, 1995, BIOCHEM BIOPH RES CO, V216, P265, DOI 10.1006/bbrc.1995.2619; Zhang DK, 2001, CANCER RES, V61, P6899; ZIMMERMAN M, 1964, J BIOL CHEM, V239, P2618	58	62	65	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 5	2002	21	55					8477	8485		10.1038/sj.onc.1206030	http://dx.doi.org/10.1038/sj.onc.1206030			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466967				2022-12-28	WOS:000179480100010
J	Sciacca, L; Mineo, R; Pandini, G; Murabito, A; Vigneri, R; Belfiore, A				Sciacca, L; Mineo, R; Pandini, G; Murabito, A; Vigneri, R; Belfiore, A			In IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A	ONCOGENE			English	Article						insulin; isoforms; IGF-I receptor; IGF-II; cell invasion; apoptosis	GROWTH-FACTOR-II; BREAST-CANCER CELLS; MONOCLONAL-ANTIBODIES; AUTOPHOSPHORYLATION; ACTIVATION; MECHANISM; MIGRATION; PATHWAYS; TUMORS	One of the two isoforms of the human insulin receptor (isoform A or IR-A) binds IGF-II with high affinity and is predominantly expressed in fetal tissues and malignant cells. We evaluated the biological relevance of IR-A in human myosarcoma cells. Six myosarcoma cell lines were studied. All produced high amounts of IGF-II and five of them predominantly expressed IR-A. SKUT-1 leiomyosarcoma cells, that do not express the IGF-IR, were identified as a suitable model to study the effects of IR-A in the absence of the interference of IGF-IR. In these cells, which express high levels of IR with an IR-A relative abundance of approximate to95%, IGF-II elicits biological effects exclusively via IR-A activation and IGF-I is almost ineffective. Blockade of autocrine IGF-II reduced unstimulated cell viability and migration. Although both insulin and IGF-II activate IR-A, these two ligands showed a different ability to activate different intracellular signaling pathways and to elicit different biological effects. Insulin was more potent than IGF-II in activating the PI3-K/Akt pathway and in protecting cells from apoptosis. In contrast, IGF-II was more potent than insulin in activating the Shc/ERK pathway and in stimulating cell migration. These data indicate that IGF-II sensitive IR-A is the predominant IR isoform in a variety of myosarcoma cells. In SKUT-1 leiomyoma cells this fetal IR isoform may vicariate the IGF-IR for cell response to both insulin and IGF-II. Acting on the same IR-A receptor IGF-II is more potent than insulin in stimulating cancer cell migration.	Univ Catanzaro, Cattedra Endocrinol, Dipartimento Med Clin & Sperimentale, Policlin Mater Domini, I-88100 Catanzaro, Italy; Univ Catania, Dipartimento Med Interna & Med Specialist, Osped Garibaldi, I-95123 Catania, Italy; Ist Mediterraneo Oncol, IMO, Catania, Italy	Magna Graecia University of Catanzaro; University of Catania; Mediterranean Institute of Oncology	Belfiore, A (corresponding author), Univ Catanzaro, Cattedra Endocrinol, Dipartimento Med Clin & Sperimentale, Policlin Mater Domini, Via T Campanella 115, I-88100 Catanzaro, Italy.		Pandini, Giuseppe/AAB-9650-2019; Sciacca, Laura/B-9368-2014; SCIACCA, Laura/AAS-2896-2020; Belfiore, Antonino/B-4652-2011; Vigneri, Riccardo/M-3968-2017	Pandini, Giuseppe/0000-0003-3747-7649; Sciacca, Laura/0000-0002-3258-7200; SCIACCA, Laura/0000-0002-3258-7200; Belfiore, Antonino/0000-0002-6181-4193; Vigneri, Riccardo/0000-0002-4401-3140				BACH LA, 1994, ENDOCRINOLOGY, V135, P2168, DOI 10.1210/en.135.5.2168; BALTENSPERGER K, 1992, P NATL ACAD SCI USA, V89, P7885, DOI 10.1073/pnas.89.17.7885; Barber AJ, 2001, J BIOL CHEM, V276, P32814, DOI 10.1074/jbc.M104738200; Bartucci M, 2001, CANCER RES, V61, P6747; Belfiore A, 1996, MOL ENDOCRINOL, V10, P1318, DOI 10.1210/me.10.11.1318; Cullen K J, 1992, Cancer Treat Res, V61, P413; CULLEN KJ, 1992, BREAST CANCER RES TR, V22, P21, DOI 10.1007/BF01833330; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ELBADRY OM, 1990, CELL GROWTH DIFFER, V1, P325; FORSAYETH JR, 1987, J BIOL CHEM, V262, P4134; Frasca F, 1999, MOL CELL BIOL, V19, P3278, DOI 10.1128/mcb.19.5.3278; GANDERTON RH, 1992, BIOCHEM J, V288, P195, DOI 10.1042/bj2880195; HEO DS, 1990, CANCER RES, V50, P3681; Hiromura K, 2002, KIDNEY INT, V61, P1312, DOI 10.1046/j.1523-1755.2002.00257.x; Imai Y, 1999, ENDOCRINOLOGY, V140, P4228, DOI 10.1210/en.140.9.4228; KULL FC, 1983, J BIOL CHEM, V258, P6561; Leibiger B, 2001, MOL CELL, V7, P559, DOI 10.1016/S1097-2765(01)00203-9; OSBORNE CK, 1989, MOL ENDOCRINOL, V3, P1701, DOI 10.1210/mend-3-11-1701; Pandini G, 2002, J BIOL CHEM, V277, P39684, DOI 10.1074/jbc.M202766200; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; ROTH RA, 1982, P NATL ACAD SCI-BIOL, V79, P7312, DOI 10.1073/pnas.79.23.7312; RUBIN R, 1995, LAB INVEST, V73, P311; Sciacca L, 1999, ONCOGENE, V18, P2471, DOI 10.1038/sj.onc.1202600; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; STRAUSS G, 1994, J INTERN MED, V236, P97, DOI 10.1111/j.1365-2796.1994.tb01127.x; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; Vella V, 2002, J CLIN ENDOCR METAB, V87, P245, DOI 10.1210/jc.87.1.245; VU TH, 1995, J CLIN ENDOCR METAB, V80, P1670, DOI 10.1210/jc.80.5.1670	28	130	140	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 28	2002	21	54					8240	8250		10.1038/sj.onc.1206058	http://dx.doi.org/10.1038/sj.onc.1206058			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447687				2022-12-28	WOS:000179323900002
J	Saez, C; Pereda, T; Borrero, JJ; Espina, A; Romero, F; Tortolero, M; Pintor-Toro, JA; Segura, DI; Japon, MA				Saez, C; Pereda, T; Borrero, JJ; Espina, A; Romero, F; Tortolero, M; Pintor-Toro, JA; Segura, DI; Japon, MA			Expression of hpttg proto-oneogene in lymphoid neoplasias	ONCOGENE			English	Article						hpttg proto-oncogene; B-cell lymphoma; T-cell; lymphoma; Hodgkin's disease; immunohistochemistry	TUMOR-TRANSFORMING GENE; TRANSCRIPTIONAL ACTIVATION FUNCTION; STRAND BREAK REPAIR; PITUITARY-ADENOMAS; CELL LYMPHOMA; HUMAN CANCERS; PTTG; CHECKPOINT; MYC; IDENTIFICATION	Pituitary tumor-transforming gene (pttg) is a distinct proto-oncogene which is expressed in certain normal tissues with high proliferation rate and in a variety of tumors. PTTG is the vertebrate analog of yeast securins Pds1 and Cut2 with a key role in the regulation of sister chromatid separation during mitosis. Impairment of PTTG regulated functions is expected to lead to chromosomal instability and aneuploidy. Human pttg (hpttg) is abundantly expressed in Jurkat T lymphoblastic lymphoma cells but not in normal peripheral blood leukocytes. To obtain additional data on the potential role of hpttg in lymphomagenesis we selected 150 cases of lymphoid tumors for the assessment of hpttg expression in tumor tissues. Immunohistochemical studies on formalin-fixed, paraffin-em bedded tissues revealed hPTTG in 38.8% of B-cell lymphomas, 70.2% of T-cell lymphomas, and 73.1% of Hodgkin's lymphomas. Among B-cell lymphomas, the most frequently immunostained tumors were plasma cell tumors, diffuse large cell lymphomas, and follicle center cell lymphomas. In Hodgkin's disease, immunoreactivity was mainly noted in Reed-Sternberg cells. In conclusion, the frequent overexpression of hpttg in many histological subtypes of lymphoma suggests the involvement of this protooncogene in lymphomagenesis.	Hosp Univ Virgen Rocio, Dept Pathol, Seville 41013, Spain; CSIC, Inst Recursos Nat & Agrobiol, E-41080 Seville, Spain; Univ Seville, Dept Microbiol, Fac Biol, Seville 41080, Spain	Virgen del Rocio University Hospital; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Recursos Naturales y Agrobiologia de Sevilla (IRNAS); University of Sevilla	Japon, MA (corresponding author), Hosp Univ Virgen Rocio, Dept Pathol, Avenida Manuel Siurot SN, Seville 41013, Spain.		Sáez, Carmen/B-9468-2015; Romero, Francisco/K-2101-2014; Espina Zambrano, Águeda Gema/AAB-2657-2021; IBIS, TUMORIGENESIS/P-3506-2015; Japón, Miguel A/L-2555-2017; Tortolero, Maria/K-5744-2014; Pintor-Toro, Jose/L-4737-2014	Sáez, Carmen/0000-0002-8600-0508; Romero, Francisco/0000-0002-9588-6881; Espina Zambrano, Águeda Gema/0000-0003-1962-0990; Japón, Miguel A/0000-0002-5980-5044; Tortolero, Maria/0000-0003-1797-9940; Pintor-Toro, Jose/0000-0002-9060-5243; Borrero, Juan Jose/0000-0003-4776-1061				Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chien WW, 2000, J BIOL CHEM, V275, P19422, DOI 10.1074/jbc.M910105199; Cohen-Fix O, 1997, P NATL ACAD SCI USA, V94, P14361, DOI 10.1073/pnas.94.26.14361; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; Davies J, 1999, ONCOGENE, V18, P3643, DOI 10.1038/sj.onc.1202956; Dominguez A, 1998, ONCOGENE, V17, P2187, DOI 10.1038/sj.onc.1202140; Hardwick KG, 1998, TRENDS GENET, V14, P1, DOI 10.1016/S0168-9525(97)01340-1; HARRIS NL, 1994, BLOOD, V84, P1361; Heaney AP, 2000, LANCET, V355, P716, DOI 10.1016/S0140-6736(99)10238-1; Hecht JL, 2000, J CLIN ONCOL, V18, P3707, DOI 10.1200/JCO.2000.18.21.3707; Jallepalli PV, 2001, CELL, V105, P445, DOI 10.1016/S0092-8674(01)00340-3; Jin SF, 1997, EMBO J, V16, P6874, DOI 10.1093/emboj/16.22.6874; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; LANDANYI M, 1991, BLOOD, V77, P1057; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li GC, 1998, MOL CELL, V2, P1, DOI 10.1016/S1097-2765(00)80108-2; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; Pei L, 2001, J BIOL CHEM, V276, P8484, DOI 10.1074/jbc.M009654200; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Ramos-Morales F, 2000, ONCOGENE, V19, P403, DOI 10.1038/sj.onc.1203320; Rao PH, 1998, BLOOD, V92, P234, DOI 10.1182/blood.V92.1.234.413k22_234_240; Romero F, 2001, NUCLEIC ACIDS RES, V29, P1300, DOI 10.1093/nar/29.6.1300; Saez C, 1999, ONCOGENE, V18, P5473, DOI 10.1038/sj.onc.1202914; Strausberg RL, 1997, NAT GENET, V15, P415, DOI 10.1038/ng0497supp-415; Werner CA, 1997, AM J PATHOL, V151, P335; Zhang X, 1999, MOL ENDOCRINOL, V13, P156, DOI 10.1210/me.13.1.156; Zhang X, 1999, J CLIN ENDOCR METAB, V84, P761, DOI 10.1210/jc.84.2.761; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	30	38	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 21	2002	21	53					8173	8177		10.1038/sj.onc.1205954	http://dx.doi.org/10.1038/sj.onc.1205954			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615DW	12444553				2022-12-28	WOS:000179231400011
J	Tsai, MS; Bogart, DF; Castaneda, JM; Li, P; Lupu, R				Tsai, MS; Bogart, DF; Castaneda, JM; Li, P; Lupu, R			Cyr61 promotes breast tumorigenesis and cancer progression	ONCOGENE			English	Article						Cyr61; invasiveness; estrogen-dependence; antiestrogen-resistance; breast cancer	IMMEDIATE-EARLY GENE; TISSUE GROWTH-FACTOR; MESSENGER RIBONUCLEIC-ACID; CELL-LINES; ESTROGEN-RECEPTOR; INTEGRIN ALPHA(V)BETA(3); TUMOR PROGRESSION; DRUG-RESISTANCE; PROTEIN-LEVELS; EXPRESSION	Cyr61, a member of the CCN family of genes, is an angiogenic factor. We have shown that it is over-expressed in invasive and metastatic human breast cancer cells and tissues. Here, we investigated whether Cyr61 is necessary and/or sufficient to bypass the 'normal' estrogen (E2) requirements for breast cancer cell growth. Our results demonstrate that Cyr61 is sufficient to induce MCF-7 cells to grow in the absence of E2. Cyr61-transfected MCF-7 cells (MCF-7/Cyr61) became E2-independent but still E2-responsive. On the other hand, MCF-7 cells transfected with the vector DNA (MCF-7/V) remain E2-dependent. MCF-7/Cyr61 cells acquire an antiestrogen-resistant phenotype, one of the most common clinical occurrences during breast cancer progression. MCF-7/Cyr61 cells are anchorage-independent and capable of forming Matrigel outgrowth patterns in the absence of E2. ERalpha expression in MCF7/Cyr61 cells is decreased although still functional. Moreover, MCF-7/Cyr61 cells are tumorigenic in ovariectomized athymic nude mice. The tumors resemble human invasive carcinomas with increased vascularization and overexpression of vascular endothelial growth factor (VEGF). Our results demonstrate that Cyr61 is a tumor-promoting factor and a key regulator of breast cancer progression. This study provides evidence that Cyr61. is sufficient to induce E2-independence and antiestrogen-resistance, and to promote invasiveness in vitro, and to induce tumorigenesis in vivo, all of which are characteristics of an aggressive breast cancer phenotype.	Univ Calif Berkeley, Ernest Orlando Lawrence Berkely Natl Lab, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Lupu, R (corresponding author), Evanston NW Healthcare Res Inst, 1001 Univ Pl, Evanston, IL 60201 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049049] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49049] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Babic AM, 1999, MOL CELL BIOL, V19, P2958; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; BROWER ST, 1999, BREAST CANC, P273; Cardillo M., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P262; CAVAILLES V, 1988, NUCLEIC ACIDS RES, V16, P1903, DOI 10.1093/nar/16.5.1903; Chen CC, 2001, J BIOL CHEM, V276, P47329, DOI 10.1074/jbc.M107666200; Chen NY, 2000, J BIOL CHEM, V275, P24953, DOI 10.1074/jbc.M003040200; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Gasparini G, 1998, CLIN CANCER RES, V4, P2625; Govind AP, 2001, J CELL BIOCHEM, V80, P571, DOI 10.1002/1097-4644(20010315)80:4<571::AID-JCB1011>3.0.CO;2-H; Guerra-Vladusic FK, 1999, INT J ONCOL, V15, P883; Hijazi MM, 2000, INT J ONCOL, V17, P629; Jedsadayanmata A, 1999, J BIOL CHEM, V274, P24321, DOI 10.1074/jbc.274.34.24321; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Kireeva ML, 1998, J BIOL CHEM, V273, P3090, DOI 10.1074/jbc.273.5.3090; Kireeva ML, 1997, EXP CELL RES, V233, P63, DOI 10.1006/excr.1997.3548; Kolesnikova TV, 1998, ONCOGENE, V16, P747, DOI 10.1038/sj.onc.1201572; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; LUPU R, 1995, SEMIN CANCER BIOL, V6, P135, DOI 10.1006/scbi.1995.0016; Lupu R, 1996, BREAST CANCER RES TR, V38, P57, DOI 10.1007/BF01803784; MacGregor JI, 1998, PHARMACOL REV, V50, P151; Meyer T, 1998, BRIT J CANCER, V77, P530, DOI 10.1038/bjc.1998.86; NARDULLI AM, 1988, ENDOCRINOLOGY, V122, P935, DOI 10.1210/endo-122-3-935; OBRIEN TP, 1992, CELL GROWTH DIFFER, V3, P645; PRATT SE, 1993, CANCER RES, V53, P5193; READ LD, 1989, MOL ENDOCRINOL, V3, P295, DOI 10.1210/mend-3-2-295; Saceda M, 1996, ENDOCRINOLOGY, V137, P4322, DOI 10.1210/en.137.10.4322; Sampath D, 2001, ENDOCRINOLOGY, V142, P2540, DOI 10.1210/en.142.6.2540; SOMMERS CL, 1991, CELL GROWTH DIFFER, V2, P365; Tang CK, 1996, CANCER RES, V56, P3350; Tsai MS, 2002, ONCOGENE, V21, P964, DOI 10.1038/sj/onc/1205131; Tsai MS, 2000, CANCER RES, V60, P5603; Vladusic EA, 2000, ONCOL REP, V7, P157; WEAVER CA, 1988, MOL ENDOCRINOL, V2, P936, DOI 10.1210/mend-2-10-936; Xie D, 2001, J BIOL CHEM, V276, P14187, DOI 10.1074/jbc.M009755200; YANG GP, 1991, CELL GROWTH DIFFER, V2, P351	36	158	164	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 21	2002	21	53					8178	8185		10.1038/sj.onc.1205682	http://dx.doi.org/10.1038/sj.onc.1205682			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615DW	12444554	Green Submitted			2022-12-28	WOS:000179231400012
J	Wang, WS; Chen, PM; Hsiao, HL; Ju, SY; Su, Y				Wang, WS; Chen, PM; Hsiao, HL; Ju, SY; Su, Y			Overexpression of the thymosin beta-4 gene is associated with malignant progression of SW480 colon cancer cells	ONCOGENE			English	Article						thymosin beta-4; SW480; E-cadherin; beta-catenin; c-Myc; malignancy	ACTIN-SEQUESTERING PEPTIDE; EXTRACELLULAR-MATRIX; CYCLE PROGRESSION; EPITHELIAL-CELLS; PROSTATE-CANCER; CATENIN COMPLEX; BREAST-CANCER; E-CADHERIN; EXPRESSION; CYTOSKELETON	Thymosin beta-4 (Tbeta-4), a small peptide originally isolated from calf thymus, modulates the formation of F-actin microfilaments by sequestering the monomeric G-actin. Recent studies have shown that overexpression of the Tbeta-4 gene occurs not only in many human carcinomas but also in the highly metastatic melanomas and fibrosarcomas. However, little is known about the specific growth advantages acquired by different tumors from this genetic abnormality. To address the above questions, Tbeta-4-overexpressing human colon carcinoma (SW480) cells were established by stable transfection and their phenotypic changes were monitored. We found that both the morphology and the cortical actin cytoskeleton of SW480 cells were altered by Tbeta-4 overexpression. Moreover, both cellular level and that distributed over the intercellular junctions of the E-cadherin were decreased in the Tbeta-4 overexpressers, which were accompanied by a twofold increase in their saturation densities. Meanwhile, these cells also exhibited an increased ability to form colonies in soft agar. Interestingly, a dramatic increase of growth rate was detected in the Tbeta-4 overexpressers, which might be attributed to an accelerated proliferation induced by c-Myc that was activated by nuclear beta-catenin. Finally, a motility increase of these cells was demonstrated by two independent migration assays, which was accompanied by an enhanced focal contact. Taken together, our data suggest that the drastic growth property and motility changes of the SW480 cells overexpressing Tbeta-4 gene are due mainly to a deregulated cell-cell adhesion arisen from the downregulation of E-cadherin, plus uncontrolled cell proliferation owing to the upregulation of beta-catenin, both resulted from a breakdown of actin microfilaments caused by the overexpression of this G-actin sequestering peptide.	Natl Yang Ming Univ, Coll Life Sci, Inst Biopharmaceut Sci, Taipei 112, Taiwan; Natl Yang Ming Univ, Sch Med, Inst Clin Med, Taipei 112, Taiwan; Vet Gen Hosp, Dept Med, Div Med Oncol, Taipei, Taiwan; Natl Yang Ming Univ, Coll Life Sci, Inst Pharmacol, Taipei 112, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	Su, Y (corresponding author), Natl Yang Ming Univ, Coll Life Sci, Inst Biopharmaceut Sci, Taipei 112, Taiwan.	yeusu@ym.edu.tv						Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Angres B, 1996, J CELL BIOL, V134, P549, DOI 10.1083/jcb.134.2.549; Assoian RK, 2001, CURR OPIN GENET DEV, V11, P48, DOI 10.1016/S0959-437X(00)00155-6; Bao LR, 1996, NAT MED, V2, P1322, DOI 10.1038/nm1296-1322; Barker N, 2000, BIOESSAYS, V22, P961; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; Califano D, 1998, CANCER RES, V58, P823; CASSIMERIS L, 1992, J CELL BIOL, V119, P1261, DOI 10.1083/jcb.119.5.1261; Chakravarti A, 2000, UROLOGY, V55, P635, DOI 10.1016/S0090-4295(00)00462-3; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Ezzell RM, 1997, EXP CELL RES, V231, P14, DOI 10.1006/excr.1996.3451; FERNANDEZ JLR, 1993, J CELL BIOL, V122, P1285, DOI 10.1083/jcb.122.6.1285; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gold JS, 1997, MODERN PATHOL, V10, P1106; Golla R, 1997, CELL MOTIL CYTOSKEL, V38, P187, DOI 10.1002/(SICI)1097-0169(1997)38:2<187::AID-CM7>3.0.CO;2-4; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HALL AK, 1991, INT J CANCER, V48, P672, DOI 10.1002/ijc.2910480507; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Kobayashi T, 2002, AM J PATHOL, V160, P869, DOI 10.1016/S0002-9440(10)64910-3; Lee SH, 2001, ONCOGENE, V20, P6700, DOI 10.1038/sj.onc.1204683; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; LOW TLK, 1982, J BIOL CHEM, V257, P1000; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nakanishi K, 2002, CANCER RES, V62, P2971; NEWELL KJ, 1994, MOL CARCINOGEN, V10, P199, DOI 10.1002/mc.2940100404; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; Quigley JP, 1998, CELL, V94, P281, DOI 10.1016/S0092-8674(00)81470-1; Quinlan MP, 1999, CELL GROWTH DIFFER, V10, P839; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; SAFER D, 1991, J BIOL CHEM, V266, P4029; SAFER D, 1990, P NATL ACAD SCI USA, V87, P2536, DOI 10.1073/pnas.87.7.2536; SANGER JM, 1995, CELL MOTIL CYTOSKEL, V31, P307, DOI 10.1002/cm.970310407; Santelli G, 1999, AM J PATHOL, V155, P799, DOI 10.1016/S0002-9440(10)65178-4; Sardi I, 2002, INT J MOL MED, V9, P541; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sellin JH, 2001, CANCER RES, V61, P2899; Sosne G, 2002, CURR EYE RES, V24, P268, DOI 10.1076/ceyr.24.4.268.8414; Su Y, 2000, MOL CELL BIOCHEM, V203, P163, DOI 10.1023/A:1007020619788; Sun HQ, 1996, J BIOL CHEM, V271, P9223, DOI 10.1074/jbc.271.16.9223; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tang RY, 1997, J VIROL METHODS, V65, P153, DOI 10.1016/S0166-0934(97)02176-9; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; VARNUMFINNEY B, 1994, J CELL BIOL, V127, P1071, DOI 10.1083/jcb.127.4.1071; VergheseNikolakaki S, 1996, BRIT J CANCER, V74, P1441, DOI 10.1038/bjc.1996.562; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WETERMAN MAJ, 1993, INT J CANCER, V53, P278, DOI 10.1002/ijc.2910530218; Xie D, 2002, INT J ONCOL, V21, P499; YAMAMOTO T, 1993, BIOCHEM BIOPH RES CO, V193, P706, DOI 10.1006/bbrc.1993.1682; YU FX, 1994, CELL MOTIL CYTOSKEL, V27, P13, DOI 10.1002/cm.970270103	57	71	79	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2003	22	21					3297	3306		10.1038/sj.onc.1206404	http://dx.doi.org/10.1038/sj.onc.1206404			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681MM	12761500				2022-12-28	WOS:000183040000012
J	Zhang, XW; Chen, Z; Chen, YL; Tong, TJ				Zhang, XW; Chen, Z; Chen, YL; Tong, TJ			Delivering antisense telomerase RNA by a hybrid adenovirus/adeno-associated virus significantly suppresses the malignant phenotype and enhances cell apoptosis of human breast cancer cells	ONCOGENE			English	Article						telomerase RNA; antisense; adenovirus; adeno-associated virus; gene therapy; breast cancer	SITE-SPECIFIC INTEGRATION; CATALYTIC SUBUNIT; IMMORTAL CELLS; HIGH-CAPACITY; GENE-TRANSFER; TUMOR-CELLS; DNA; INDUCTION; VECTORS; INHIBITION	Activated tetomerase is frequently detected in cancer cells and is able to maintain and stabilize the integrity of telomeres; it also contributes to unlimited divisions in cancer cells. Recently, a new generation of selective anticancer strategies is under development targeting the blockage of telomerase activity either at the protein level or telomerase RNA. Here, we report suppression of the malignant phenotype by the expression of the full-length antisense human telomerase RNA (hTR) delivered by a novel hybrid vector recombining adenovirus and adenoassociated virus (vAd-AAV). The hybrid vector vAd-AAV retained the unique traits from two parental viruses, such as high efficiency of gene transfer in mammalian cells and the ability to integrate into the genomic DNA of host cells. The stable expression of antisense hTR in MCF-7, cells significantly suppressed telomerase activity and progressively shortened telomere length for 30 population doublings (PD30). Expression of antisense hTR leads to a telomere-based growth arrest and the induction of spontaneous apoptosis. Antisense hTR decreased soft agar colony formation and reduced the cell proliferation, leading to exit from the cell cycle at G1 at PD15. The expression of antisense hTR also sensitized MCF-7 cells to apoptosis induced by sodium butyrate or serum starvation. Our study demonstrates that delivering antisense hTR by the hybrid Ad/AAV vector is an effective antineoplastic gene therapeutic strategy, which significantly suppresses the malignant phenotype and enhances apoptosis of human breast cancer cells.	Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Beijing 100083, Peoples R China; Natl Inst Deafness & Commun Disorders, Head & Neck Surg Branch, Tumor Biol Sect, NIH, Bethesda, MD 20892 USA	Peking University; National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD)	Tong, TJ (corresponding author), Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Beijing 100083, Peoples R China.							ALI M, 1994, GENE THER, V1, P367; ANDREW NS, 1994, CANCER GENE THER, V1, P165; Avilion AA, 1996, CANCER RES, V56, P645; BERNS KI, 1995, BIOESSAYS, V17, P237, DOI 10.1002/bies.950170310; Bisoffi M, 1998, EUR J CANCER, V34, P1242, DOI 10.1016/S0959-8049(98)00049-5; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1996, EXP CELL RES, V228, P58, DOI 10.1006/excr.1996.0299; Campisi J, 1999, MOLECULAR BASIS OF CELL CYCLE AND GROWTH CONTROL, P348; Campisi Judith, 1996, P121; Chiu CP, 1997, P SOC EXP BIOL MED, V214, P99; Collins K, 2002, ONCOGENE, V21, P564, DOI 10.1038/sj.onc.1205083; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DOUGLAS J, 1994, CANCER GENE THER, V1, P51; Ducrest AL, 2002, ONCOGENE, V21, P541, DOI 10.1038/sj.onc.1205081; Elenitoba-Johnson KSJ, 2001, AM J PATHOL, V159, P405, DOI 10.1016/S0002-9440(10)61710-5; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Ferrari FK, 1996, J VIROL, V70, P3227, DOI 10.1128/JVI.70.5.3227-3234.1996; Gonzalez-Suarez E, 2001, EMBO J, V20, P2619, DOI 10.1093/emboj/20.11.2619; GUILBAUD NF, 1990, J CELL PHYSIOL, V145, P162, DOI 10.1002/jcp.1041450122; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hahn WC, 2001, CLIN CANCER RES, V7, P2953; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Helbing CC, 1998, ONCOGENE, V17, P1491, DOI 10.1038/sj.onc.1202241; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; Hiyama E, 2002, ONCOGENE, V21, P643, DOI 10.1038/sj.onc.1205070; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Holt SE, 1997, EUR J CANCER, V33, P761, DOI 10.1016/S0959-8049(97)00066-X; Hsiao RS, 1997, ANTICANCER RES, V17, P827; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Kim MM, 2001, P NATL ACAD SCI USA, V98, P7982, DOI 10.1073/pnas.131211098; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim S, 2002, ONCOGENE, V21, P503, DOI 10.1038/sj.onc.1205077; Kochanek S, 1999, HUM GENE THER, V10, P2451, DOI 10.1089/10430349950016807; Kondo S, 1998, FASEB J, V12, P801, DOI 10.1096/fasebj.12.10.801; KOTIN RM, 1991, GENOMICS, V10, P831, DOI 10.1016/0888-7543(91)90470-Y; KOTIN RM, 1990, P NATL ACAD SCI USA, V87, P2211, DOI 10.1073/pnas.87.6.2211; KOTIN RM, 1992, EMBO J, V11, P5071, DOI 10.1002/j.1460-2075.1992.tb05614.x; Kyo S, 1997, CANCER RES, V57, P610; Lee KH, 2001, P NATL ACAD SCI USA, V98, P3381, DOI 10.1073/pnas.051629198; Li ZD, 2000, ACTA BIOCH BIOPH SIN, V32, P383; Lieber A, 1999, J VIROL, V73, P9314, DOI 10.1128/JVI.73.11.9314-9324.1999; Lu MS, 1996, J VIROL, V70, P8850, DOI 10.1128/JVI.70.12.8850-8857.1996; Mitchell JR, 2000, MOL CELL, V6, P361, DOI 10.1016/S1097-2765(00)00036-8; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Niida H, 1998, NAT GENET, V19, P203, DOI 10.1038/580; Philpott NJ, 2002, J VIROL, V76, P5411, DOI 10.1128/JVI.76.11.5411-5421.2002; Poole JC, 2001, GENE, V269, P1, DOI 10.1016/S0378-1119(01)00440-1; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; Recchia A, 1999, P NATL ACAD SCI USA, V96, P2615, DOI 10.1073/pnas.96.6.2615; RICHARD JS, 1989, J VIROL, V63, P3822; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; Schulick AH, 1997, J CLIN INVEST, V99, P209, DOI 10.1172/JCI119149; Shay J W, 2001, Novartis Found Symp, V235, P116; Shayakhmetov DM, 2002, J VIROL, V76, P1135, DOI 10.1128/JVI.76.3.1135-1143.2002; Shin I, 2001, MOL BIOL CELL, V12, P3328, DOI 10.1091/mbc.12.11.3328; Smith R. H., 2002, MOBILE DNA, P905; SRIVASTAVA A, 1983, J VIROL, V45, P555, DOI 10.1128/JVI.45.2.555-564.1983; Strahl C, 1996, MOL CELL BIOL, V16, P53; Tsao JI, 1997, CLIN CANCER RES, V3, P627; WANG FS, 1997, J BEIJING MED U, V29, P295; WANG WG, 1999, CHIN J BIOCH MOL BIO, V15, P655; Wright WE, 1996, EMBO J, V15, P1734, DOI 10.1002/j.1460-2075.1996.tb00519.x; Wright Woodring E., 1996, V16, P153; Yamamoto I, 1996, J BIOCHEM-TOKYO, V119, P1056; 王文恭, 1997, 北京医科大学学报, V29, P490; 张新庆, 2001, 中华神经外科杂志, V17, P395	70	27	30	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2003	22	16					2405	2416		10.1038/sj.onc.1206317	http://dx.doi.org/10.1038/sj.onc.1206317			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	670AD	12717417				2022-12-28	WOS:000182383500003
J	Mischel, PS; Shai, R; Shi, T; Horvath, S; Lu, KV; Choe, G; Seligson, D; Kremen, TJ; Palotie, A; Liau, LM; Cloughesy, TF; Nelson, SF				Mischel, PS; Shai, R; Shi, T; Horvath, S; Lu, KV; Choe, G; Seligson, D; Kremen, TJ; Palotie, A; Liau, LM; Cloughesy, TF; Nelson, SF			Identification of molecular subtypes of glioblastoma by gene expression profiling	ONCOGENE			English	Article						glioblastoma; EGFR; microarray; 12q13-15	ENDOTHELIAL GROWTH-FACTOR; HUMAN-MALIGNANT GLIOMAS; FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; CLINICAL-SIGNIFICANCE; TUMOR GRADE; CELL; AMPLIFICATION; INHIBITION; OVEREXPRESSION	Epidermal growth factor receptor (EGFR) overexpression occurs in nearly 50% of cases of glioblastoma (GBM), but its clinical and biological implications are not well understood. We have used Affymetrix high-density oligonucleotide arrays to demonstrate that EGFR-over-expressing GBMs (EGFR +) have a distinct global gene transcriptional profile. We show that the expression of 90 genes can distinguish EGFR + from EGFR nonexpressing (EGFR-) GBMs, including a number of genes known to act as growth/survival factors for GBMs. We have also uncovered two additional novel molecular subtypes of GBMs, one of which is characterized by coordinate upregulation of contiguous genes on chromosome 12q13-15 and expression of both astrocytic and oligodendroglial genes. These results define distinct molecular subtypes of GBMs that may be important in disease stratification, and in the discovery and assessment of GBM treatment strategies.	Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Biostat, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Henry E Singleton Brain Tumor Program, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Mischel, PS (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90095 USA.	pmischel@mednet.ucla.edu	Cloughesy, Timothy Francis/AGV-1013-2022; Nelson, Stanley F/D-4771-2009	Nelson, Stanley F/0000-0002-2082-3114; Liau, Linda/0000-0002-4053-0052; , Tao/0000-0001-5489-2655; Kremen, Thomas/0000-0003-1643-4869	NATIONAL CANCER INSTITUTE [T32CA009056, U01CA088127] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS043147] Funding Source: NIH RePORTER; NCI NIH HHS [U01 CA88127, T32 CA 09056] Funding Source: Medline; NINDS NIH HHS [K08NS43147-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; Barker FG, 2001, INT J RADIAT ONCOL, V51, P410, DOI 10.1016/S0360-3016(01)01609-1; BATRA SK, 1995, CELL GROWTH DIFFER, V6, P1251; BERKMAN RA, 1993, J CLIN INVEST, V91, P153, DOI 10.1172/JCI116165; Brat DJ, 2001, AM J PATHOL, V158, P789, DOI 10.1016/S0002-9440(10)64025-4; Chan ASY, 1998, AM J SURG PATHOL, V22, P816, DOI 10.1097/00000478-199807000-00004; Chaudhry IH, 2001, HISTOPATHOLOGY, V39, P409, DOI 10.1046/j.1365-2559.2001.01230.x; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; Cheng SY, 1996, P NATL ACAD SCI USA, V93, P8502, DOI 10.1073/pnas.93.16.8502; Chin LS, 2001, J BIOL CHEM, V276, P7069, DOI 10.1074/jbc.M004129200; Choe GY, 2002, CLIN CANCER RES, V8, P2894; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Egidy G, 2000, LAB INVEST, V80, P1681, DOI 10.1038/labinvest.3780178; Fischer U, 1996, HUM GENET, V98, P625, DOI 10.1007/s004390050271; Fu H, 2002, DEVELOPMENT, V129, P681; Galanis E, 1998, INT J ONCOL, V13, P717; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Griffin J, 2001, SEMIN ONCOL, V28, P3, DOI 10.1016/S0093-7754(01)90097-1; Hajihosseini M, 1996, J NEUROSCI, V16, P7981; HAMADA H, 1988, CANCER RES, V48, P3173; Hastie T., 2009, ELEMENTS STAT LEARNI, DOI 10.1007/978-0-387-84858-7_7; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; Herold-Mende C, 2002, INT J CANCER, V98, P362, DOI 10.1002/ijc.10233; Holland EC, 2001, CURR OPIN NEUROL, V14, P683, DOI 10.1097/00019052-200112000-00002; Holland EC, 2000, AM J PATHOL, V157, P1031, DOI 10.1016/S0002-9440(10)64615-9; Hoos A, 2002, AM J PATHOL, V160, P175, DOI 10.1016/S0002-9440(10)64361-1; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Hui ABY, 2001, LAB INVEST, V81, P717, DOI 10.1038/labinvest.3780280; Kaufman L., 1990, FINDING GROUPS DATA, DOI 10.1002/9780470316801; Kilic T, 2000, CANCER RES, V60, P5143; KLEIHUES P, 1999, NEURO-ONCOLOGY, V1, P4; Kleihues P., 2000, PATHOLOGY GENETICS T, P29; Kuan C T, 2000, Brain Tumor Pathol, V17, P71, DOI 10.1007/BF02482738; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; Lal A, 2002, CANCER RES, V62, P3335; Landry CF, 1997, CANCER RES, V57, P4098; Leegwater PAJ, 2002, HUM GENET, V110, P279, DOI 10.1007/s00439-002-0682-x; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Ljubimova JY, 2001, CANCER RES, V61, P5601; MacDonald TJ, 2001, NAT GENET, V29, P143, DOI 10.1038/ng731; Maity A, 2000, CANCER RES, V60, P5879; Meng K, 2000, P NATL ACAD SCI USA, V97, P2603, DOI 10.1073/pnas.020487997; NAGANE M, 2001, CANC LETT, V161, pS17; Nam SW, 2000, ONCOGENE, V19, P241, DOI 10.1038/sj.onc.1203263; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; O'Rourke DM, 1998, P NATL ACAD SCI USA, V95, P10842, DOI 10.1073/pnas.95.18.10842; Ohnishi T, 1998, CLIN EXP METASTAS, V16, P729, DOI 10.1023/A:1006532812408; Pauletti G, 2000, J CLIN ONCOL, V18, P3651, DOI 10.1200/JCO.2000.18.21.3651; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Powers C, 2002, J BIOL CHEM, V277, P14153, DOI 10.1074/jbc.M112354200; PRESTONMARTIN S, 1999, GLIOMAS, P2; REIFENBERGER G, 1995, CANCER RES, V55, P731; Reifenberger G, 1996, CANCER RES, V56, P5141; REIFENBERGER G, 1994, CANCER RES, V54, P4299; Rickman DS, 2001, CANCER RES, V61, P6885; Sallinen SL, 2000, CANCER RES, V60, P6617; Sawyers CL, 2002, CURR OPIN GENET DEV, V12, P111, DOI 10.1016/S0959-437X(01)00273-8; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Smith JS, 2001, JNCI-J NATL CANCER I, V93, P1246, DOI 10.1093/jnci/93.16.1246; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; Venables W., 2013, MODERN APPL STAT S, V53, P86; Watanabe K, 1996, BRAIN PATHOL, V6, P217, DOI 10.1111/j.1750-3639.1996.tb00848.x; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; Ye KQ, 2000, CELL, V103, P919, DOI 10.1016/S0092-8674(00)00195-1; Yuan F, 1996, P NATL ACAD SCI USA, V93, P14765, DOI 10.1073/pnas.93.25.14765; Zhou Q, 2001, NEURON, V31, P791, DOI 10.1016/S0896-6273(01)00414-7	70	200	206	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2003	22	15					2361	2373		10.1038/sj.onc.1206344	http://dx.doi.org/10.1038/sj.onc.1206344			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	667KV	12700671				2022-12-28	WOS:000182231500014
J	Thompson, HGR; Harris, JW; Wold, BJ; Lin, F; Brody, JP				Thompson, HGR; Harris, JW; Wold, BJ; Lin, F; Brody, JP			p62 overexpression in breast tumors and regulation by prostate-derived Ets factor in breast cancer cells	ONCOGENE			English	Article						breast cancer; P62; PDEF; promoter; proteasome inhibitor; SQSTM1	PHOSPHOTYROSINE-INDEPENDENT LIGAND; CHAIN BINDING-PROTEIN; KAPPA-B ACTIVATION; TRANSCRIPTION FACTOR; DNA-BINDING; SH2 DOMAIN; GENE; PEA3; PROTEASOME; EXPRESSION	p62 is a multifunctional cytoplasmic protein able to noncovalently bind ubiquitin and several signaling proteins, suggesting a regulatory role connected to the ubiquitin-proteasome pathway. No studies to date have linked p62 protein expression with pathological states. Here we demonstrate the overabundance of p62 protein in malignant breast tissue relative to normal breast tissue. The proteasome inhibitor PSI increased p62 mRNA and protein; however, PSI treatment of breast epithelial cells transfected with the p62 promoter did not affect promoter activity. High levels of prostate-derived Ets factor (PDEF) mRNA have been identified in breast cancer compared to normal breast. Only the PSA and maspin promoters have been identified as targets of this transcription factor. Here we show that PDEF stimulates the p62 promoter through at least two sites, and likely acts as a coactivator. PSI treatment abrogates the PDEF-stimulated increase of p62 promoter activity by 50%. Thus, multiple mechanisms for the induction of p62 exist. We conclude that (1) p62 protein is overexpressed in breast cancer; (2) p62 mRNA and protein increase in response to PSI, with no change of basal promoter activity; (3) PDEF upregulates p62 promoter activity through at least two sites; and (4) PSI downregulates PDEF-induced p62 promoter activation through one of these sites.	Univ Calif Irvine, Dept Biomed Engn, Rockwell Engn Ctr 204, Irvine, CA 92697 USA; CALTECH, Dept Biol, Pasadena, CA 91125 USA; Univ Calif Irvine, Irvine Med Ctr, Orange, CA 92868 USA	University of California System; University of California Irvine; California Institute of Technology; University of California System; University of California Irvine	Brody, JP (corresponding author), Univ Calif Irvine, Dept Biomed Engn, Rockwell Engn Ctr 204, Irvine, CA 92697 USA.			Brody, James/0000-0002-7995-5197	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [K22HG000047] Funding Source: NIH RePORTER; NHGRI NIH HHS [1K22HG00047-01, K22 HG000047, K22 HG000047-01, K22 HG000047-03, K22 HG000047-02] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Adams J, 2001, SEMIN ONCOL, V28, P613, DOI 10.1053/sonc.2001.28609; Afrikanova I, 2002, ONCOGENE, V21, P1272, DOI 10.1038/sj.onc.1205183; An B, 1998, CELL DEATH DIFFER, V5, P1062, DOI 10.1038/sj.cdd.4400436; Benz CC, 1997, ONCOGENE, V15, P1513, DOI 10.1038/sj.onc.1201331; Bojovic BB, 2001, J BIOL CHEM, V276, P4509, DOI 10.1074/jbc.M005509200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen H, 2002, CANCER RES, V62, P338; de Launoit Y, 2000, ADV EXP MED BIOL, V480, P107; DeSalle LM, 2001, FEBS LETT, V490, P179, DOI 10.1016/S0014-5793(01)02121-4; Dittmer J, 1998, BBA-REV CANCER, V1377, pF1, DOI 10.1016/S0304-419X(97)00039-5; Fan XM, 2001, INT J CANCER, V93, P481, DOI 10.1002/ijc.1373; Geetha T, 2002, FEBS LETT, V512, P19, DOI 10.1016/S0014-5793(02)02286-X; Ghadersohi A, 2001, CLIN CANCER RES, V7, P2731; Gong JP, 1999, SCIENCE, V285, P1565, DOI 10.1126/science.285.5433.1565; Greenall A, 2001, J BIOL CHEM, V276, P16207, DOI 10.1074/jbc.M011582200; HIGASHINO F, 1995, ONCOGENE, V10, P1461; Hiroumi H, 2001, INT J CANCER, V93, P786, DOI 10.1002/ijc.1410; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Joung I, 1996, P NATL ACAD SCI USA, V93, P5991, DOI 10.1073/pnas.93.12.5991; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; Kornitzer D, 2000, J CELL PHYSIOL, V182, P1, DOI 10.1002/(SICI)1097-4652(200001)182:1<1::AID-JCP1>3.0.CO;2-V; Kuusisto E, 2001, BIOCHEM BIOPH RES CO, V280, P223, DOI 10.1006/bbrc.2000.4107; Lee YH, 1998, FEBS LETT, V438, P297, DOI 10.1016/S0014-5793(98)01323-4; Nagamura-Inoue T, 2001, Int Rev Immunol, V20, P83, DOI 10.3109/08830180109056724; Nozawa M, 2000, CANCER RES, V60, P1348; Oettgen P, 2000, J BIOL CHEM, V275, P1216, DOI 10.1074/jbc.275.2.1216; Owa T, 2001, CURR MED CHEM, V8, P1487, DOI 10.2174/0929867013371996; Pasquini LA, 2000, J NEUROSCI RES, V59, P601, DOI 10.1002/(SICI)1097-4547(20000301)59:5<601::AID-JNR3>3.0.CO;2-1; Rachubinski RA, 1999, J BIOL CHEM, V274, P18278, DOI 10.1074/jbc.274.26.18278; Sanz L, 2000, EMBO J, V19, P1576, DOI 10.1093/emboj/19.7.1576; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Shin J, 1998, ARCH PHARM RES, V21, P629, DOI 10.1007/BF02976748; Spataro V, 1998, BRIT J CANCER, V77, P448, DOI 10.1038/bjc.1998.71; Su ZZ, 2000, ONCOGENE, V19, P3411, DOI 10.1038/sj.onc.1203666; Sudo T, 2000, BIOCHEM BIOPH RES CO, V269, P521, DOI 10.1006/bbrc.2000.2333; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; Vadlamudi RK, 1996, J BIOL CHEM, V271, P20235, DOI 10.1074/jbc.271.34.20235; Vadlamudi RK, 1998, FEBS LETT, V435, P138, DOI 10.1016/S0014-5793(98)01021-7; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; Xing XM, 2000, NAT MED, V6, P189, DOI 10.1038/72294; Yamada N, 2000, GENE, V241, P267, DOI 10.1016/S0378-1119(99)00484-9; Yamada T, 2001, BLOOD, V97, P2300, DOI 10.1182/blood.V97.8.2300	44	142	148	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 17	2003	22	15					2322	2333		10.1038/sj.onc.1206325	http://dx.doi.org/10.1038/sj.onc.1206325			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	667KV	12700667				2022-12-28	WOS:000182231500010
J	Zhang, H; Morisaki, T; Nakahara, C; Matsunaga, H; Sato, N; Nagumo, F; Tadano, J; Katano, M				Zhang, H; Morisaki, T; Nakahara, C; Matsunaga, H; Sato, N; Nagumo, F; Tadano, J; Katano, M			PSK-mediated NF-kappa B inhibition augments docetaxel-induced apoptosis in human pancreatic cancer cells NOR-P1	ONCOGENE			English	Article						pancreatic cancer; docetaxel; PSK; apoptosis; NF-kappa B	PHASE-II; TUMOR-CELLS; ACTIVATION; CHEMOTHERAPY; AGENTS; LINE; PHOSPHORYLATION; SUPPRESSION; EXPERIENCE; EXPRESSION	Docetaxel, a member of the taxane family, has been shown to induce apoptosis in a variety of cancer cells. However, toxicity at therapeutic doses has precluded the use of docetaxel alone for the management of cancer patients. PSK, a protein-bound polysaccharide, is widely used in Japan as an immunopotentiating biological response modifier for cancer patients. Our previous study showed that PSK induced downregulation of several invasion-related factors, suggesting an interaction of PSK with transcriptional factors. In this study, we showed that PSK dose dependently enhanced apoptosis induced by 1 nM of docetaxel in a human pancreatic cancer cell line NOR-P1. Furthermore, PSK inhibited docetaxel-induced nuclear factor kappa B (NF-kappaB) activation. Moreover, the expression of cellular inhibitor of apoptosis protein (cIAP-1), which is transcriptionally regulated by NF-kappaB and functions as an antiapoptotic molecule through interrupting the caspase pathway, was also inhibited by treatment with PSK plus docetaxel. As a result, PSK enhanced the docetaxel-induced caspase-3 activation. In addition, treatment by transfection of NF-kappaB decoy oligodeoxynucleotides (ODNs), but not scramble ones, inhibited the expression of cIAP-1 in NOR-P1 cells and induced a significant increase in docetaxel-induced apoptosis. Our data indicate that PSK suppresses the docetaxel-induced NF-kappaB activation pathway. Combination of PSK with a low dose of docetaxel may be a new therapeutic strategy to treat patients with pancreatic cancer.	Kyushu Univ, Grad Sch Med Sci, Dept Canc Therapy & Res, Higashi Ku, Fukuoka 8128582, Japan; Saga Med Sch, Dept Hosp Clin Lab, Saga 8498501, Japan; Saga Med Sch, Dept Hosp Pharm, Saga 8498501, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Clin Oncol, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University; Saga University; Saga University; Kyushu University	Morisaki, T (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Canc Therapy & Res, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.							ANAI H, 1991, ANTI-CANCER DRUG, V2, P275; Aota K, 2000, BIOCHEM BIOPH RES CO, V273, P1168, DOI 10.1006/bbrc.2000.3072; Arlt A, 2001, ONCOGENE, V20, P859, DOI 10.1038/sj.onc.1204168; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; BISSERY MC, 1995, ANTI-CANCER DRUG, V6, P339, DOI 10.1097/00001813-199506000-00001; Cascinu S, 1999, ANN ONCOL, V10, P1377, DOI 10.1023/A:1008394111533; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; CORTES JE, 1995, J CLIN ONCOL, V13, P2643, DOI 10.1200/JCO.1995.13.10.2643; Cui XF, 2000, BBA-GEN SUBJECTS, V1524, P178, DOI 10.1016/S0304-4165(00)00155-0; EBINA T, 1992, JPN J CANCER RES, V83, P775, DOI 10.1111/j.1349-7006.1992.tb01979.x; Fisher M, 2002, ANTICANCER RES, V22, P1737; Fukushima M, 1996, SEMIN ONCOL, V23, P369; Haldar S, 1997, CANCER RES, V57, P229; Huang Y, 2000, CANCER RES, V60, P4426; IINO Y, 1992, ANTICANCER RES, V12, P2101; Ishiyama M, 1996, BIOL PHARM BULL, V19, P1518; IWAGUCHI T, 1989, J BIOCHEM BIOPH METH, V18, P157, DOI 10.1016/0165-022X(89)90077-8; KAYE SB, 1995, SEMIN ONCOL, V22, P30; Kojima M, 2000, ONCOGENE, V19, P1225, DOI 10.1038/sj.onc.1203427; Kolfschoten GM, 2002, BIOCHEM PHARMACOL, V63, P733, DOI 10.1016/S0006-2952(01)00895-4; Lenzi R, 2002, CANCER INVEST, V20, P464, DOI 10.1081/CNV-120002146; MORI H, 1987, INT J IMMUNOPHARMACO, V9, P881, DOI 10.1016/0192-0561(87)90004-X; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Okada S, 1999, BRIT J CANCER, V80, P438, DOI 10.1038/sj.bjc.6690375; Rougier P, 2000, EUR J CANCER, V36, P1016, DOI 10.1016/S0959-8049(00)00072-1; Rowinsky EK, 1997, ANNU REV MED, V48, P353; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Sato N, 2000, CANCER LETT, V155, P153, DOI 10.1016/S0304-3835(00)00421-3; Shibata M, 2002, CANCER INVEST, V20, P166, DOI 10.1081/CNV-120001142; Spencer W, 1999, ONCOGENE, V18, P495, DOI 10.1038/sj.onc.1202335; Stathopoulos GP, 2001, ANN ONCOL, V12, P101, DOI 10.1023/A:1008310106171; Takahashi Y, 2001, Gan To Kagaku Ryoho, V28, P531; TSUKAGOSHI S, 1984, CANCER TREAT REV, V11, P131, DOI 10.1016/0305-7372(84)90005-7; Vos IHC, 2000, FASEB J, V14, P815, DOI 10.1096/fasebj.14.5.815; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang WX, 1999, CLIN CANCER RES, V5, P119; Wright ME, 2000, FEBS LETT, V481, P13, DOI 10.1016/S0014-5793(00)01962-1; Zhang H, 2000, CLIN EXP METASTAS, V18, P343	38	57	60	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 10	2003	22	14					2088	2096		10.1038/sj.onc.1206310	http://dx.doi.org/10.1038/sj.onc.1206310			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664NJ	12687011				2022-12-28	WOS:000182066900003
J	Do, TN; Rosal, RV; Drew, L; Raffo, AJ; Michl, J; Pincus, MR; Friedman, FK; Petrylak, DP; Cassai, N; Szmulewicz, J; Sidhu, G; Fine, RL; Brandt-Rauf, PW				Do, TN; Rosal, RV; Drew, L; Raffo, AJ; Michl, J; Pincus, MR; Friedman, FK; Petrylak, DP; Cassai, N; Szmulewicz, J; Sidhu, G; Fine, RL; Brandt-Rauf, PW			Preferential induction of necrosis in human breast cancer cells by a p53 peptide derived from the MDM2 binding site	ONCOGENE			English	Article						breast cancer; p53; MDM2; necrosis	TUMOR-SUPPRESSOR GENE; C-TERMINAL PEPTIDE; IN-VIVO; INTRACELLULAR DELIVERY; MUTANT P53; ANTENNAPEDIA HOMEODOMAIN; PROTEIN TRANSDUCTION; CIRCULAR-DICHROISM; 3RD HELIX; DOMAIN	p53 is the most frequently altered gene in human cancer and therefore represents an ideal target for cancer therapy. Several amino terminal p53-derived synthetic peptides were tested for their antiproliferative effects on breast cancer cell lines MDA-MB-468 (mutant p53), MCF-7 (overexpressed wild-type p53), and MDA-MB-157 (null p53). p53(15)Ant peptide representing the majority of the mouse double minute clone 2 binding site on p53 (amino acids 12-26) fused to the Drosophila carrier protein Antennapedia was the most effective. p53(15)Ant peptide induced rapid, nonapoptotic cell death resembling necrosis in all breast cancer cells; however, minimal cytotoxicity was observed in the nonmalignant breast epithelial cells MCF-10-2A and MCF-10F. Bioinformatic/biophysical analysis utilizing hydrophobic moment and secondary structure predictions as well as circular dichroism spectroscopy revealed an alpha-helical hydrophobic peptide structure with membrane disruptive potential. Based on these findings, p53(15)Ant peptide may be a novel peptide cancer therapeutic because it induces necrotic cell death and not apoptosis, which is uncommon in traditional cancer therapy.	Columbia Univ, Dept Environm Hlth Sci, Mailman Sch Publ Hlth, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Div Med Oncol, Expt Therapeut Program, New York, NY 10032 USA; Harbor VA Med Ctr, Dept Pathol & Lab Med, Manhasset, NY 10010 USA; Harbor VA Med Ctr, Dept Pathol & Lab Med, Brooklyn, NY 11209 USA; Suny Downstate Med Ctr, Dept Pathol, Brooklyn, NY 11203 USA; NIH, Lab Metab, Bethesda, MD 20892 USA	Columbia University; Columbia University; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; National Institutes of Health (NIH) - USA	Brandt-Rauf, PW (corresponding author), Columbia Univ, Dept Environm Hlth Sci, Mailman Sch Publ Hlth, New York, NY 10032 USA.		Friedman, Fred/O-6173-2019; Friedman, Fred K/D-4208-2016	Friedman, Fred/0000-0002-0284-7067; 	NATIONAL CANCER INSTITUTE [R01CA042500, R01CA082528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH [R01OH004192] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 42500, CA 82528] Funding Source: Medline; NIOSH CDC HHS [OH 04192] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIOSH CDC HHS		Berlose JP, 1996, EUR J BIOCHEM, V242, P372, DOI 10.1111/j.1432-1033.1996.0372r.x; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; BRUGIDOU J, 1995, BIOCHEM BIOPH RES CO, V214, P685, DOI 10.1006/bbrc.1995.2340; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; DEKROON AIP, 1993, LIPID PEPTIDE INTERA; DELACONSTANTINO.G, 1987, ANTICANCER RES, V7, P1011; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; EISENBERG D, 1984, P NATL ACAD SCI-BIOL, V81, P140, DOI 10.1073/pnas.81.1.140; Fahraeus R, 1999, J PATHOL, V187, P138; FINE RL, 1996, ONCOLOGIST, V1, P261; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; GARNIER JG, 1996, METHOD ENZYMOL, P540; Harris CC, 1996, JNCI-J NATL CANCER I, V88, P1442, DOI 10.1093/jnci/88.20.1442; Kanovsky M, 2001, P NATL ACAD SCI USA, V98, P12438, DOI 10.1073/pnas.211280698; Kim AL, 1999, J BIOL CHEM, V274, P34924, DOI 10.1074/jbc.274.49.34924; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LOFTS FJ, 1993, ONCOGENE, V8, P2813; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OZBUN MA, 1995, ADV CANCER RES, V66, P71, DOI 10.1016/S0065-230X(08)60252-3; PERCZEL A, 1991, PROTEIN ENG, V4, P669, DOI 10.1093/protein/4.6.669; Prives C, 1999, J PATHOL, V187, P112; Prochiantz A, 1999, ANN NY ACAD SCI, V886, P172, DOI 10.1111/j.1749-6632.1999.tb09410.x; Rousselle C, 2000, MOL PHARMACOL, V57, P679, DOI 10.1124/mol.57.4.679; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; Selivanova G, 1999, MOL CELL BIOL, V19, P3395; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; SHERBET GV, 1989, EXP CELL BIOL, V57, P198; Soussi T, 2000, Bull Cancer, V87, P689; SOUSSI T, 1990, ONCOGENE, V5, P945; Soussi T, 2000, ANN NY ACAD SCI, V910, P121; SPECTOR AA, 1987, CANCER RES, V47, P4529; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Velculescu VE, 1996, CLIN CHEM, V42, P858; Wang JL, 2000, CANCER RES, V60, P1498; Wasylyk C, 1999, ONCOGENE, V18, P1921, DOI 10.1038/sj.onc.1202528; Yeung TK, 1999, BIOCHEM BIOPH RES CO, V263, P398, DOI 10.1006/bbrc.1999.1375; Zhang RW, 2000, CURR PHARM DESIGN, V6, P393, DOI 10.2174/1381612003400911	43	72	86	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 13	2003	22	10					1431	1444		10.1038/sj.onc.1206258	http://dx.doi.org/10.1038/sj.onc.1206258			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652ZZ	12629507				2022-12-28	WOS:000181411900001
J	Murakami, D; Okamoto, I; Nagano, O; Kawano, Y; Tomita, T; Iwatsubo, T; De Strooper, B; Yumoto, E; Saya, H				Murakami, D; Okamoto, I; Nagano, O; Kawano, Y; Tomita, T; Iwatsubo, T; De Strooper, B; Yumoto, E; Saya, H			Presenilin-dependent gamma-secretase activity mediates the intramembranous cleavage of CD44	ONCOGENE			English	Article						CD44; gamma-secretase; presenilin; intramembranous cleavage	FAMILIAL ALZHEIMERS-DISEASE; AMYLOID PRECURSOR PROTEIN; INTRACELLULAR DOMAIN; E-CADHERIN; MISSENSE MUTATIONS; CALCIUM INFLUX; BETA-CATENIN; RHO-FAMILY; GENE; RECEPTOR	CD44 is the major adhesion molecule for the extracellular matrix components and is implicated in a wide variety of physiological and pathological processes including the regulation of tumor cell growth and metastasis. Our previous studies have shown that CD44 undergoes sequential proteolytic cleavages in the extracellular and transmembrane domains and the cleavage product derived from CD44 intramembranous cleavage acts as a signal transduction molecule. However, the underlying mechanism of the intramembranous cleavage of CD44 remains to be elucidated. In the present study, we report for the first time that CD44 is a substrate of the presenilin (PS)-dependent gamma-secretase. We demonstrate that the intramembranous cleavage of CD44 induced by 12-O-tetradecanoylphorbol 13-acetate (TPA) treatment or mechanical scraping is blocked by gamma-secretase inhibitors in U251MG cells and that this cleavage is also inhibited in PS-deficient mouse embryonic fibroblasts. Furthermore, we showed that PSI is redistributed to ruffling areas of the plasma membrane similarly to CD44 after TPA treatment, supporting our biochemical observation that PSI is involved in the intramembranous cleavage of CD44. Our present findings suggest important implications for understanding CD44-dependent signal transduction and a potential role of PS/gamma-secretase activity in the functional regulation of adhesion molecules.	Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 8600811, Japan; Kumamoto Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Kumamoto 8608556, Japan; Kumamoto Univ, Sch Med, Dept Internal Med 1, Kumamoto 8608556, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Bunkyo Ku, Tokyo 1130033, Japan; Katholieke Univ Leuven, Ctr Human Genet, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol VIB, B-3000 Louvain, Belgium	Kumamoto University; Kumamoto University; Kumamoto University; University of Tokyo; KU Leuven; Flanders Institute for Biotechnology (VIB)	Saya, H (corresponding author), Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, 2-2-1 Honjo, Kumamoto 8600811, Japan.	hsaya@gpo.kumamoto-u.ac.jp	de+Strooper, Bart/Z-1638-2019; Tomita, Taisuke/L-5427-2015; Saya, Hideyuki/J-4325-2013; Nagano, Osamu/J-5874-2013; De Strooper, Bart/F-6507-2012	Tomita, Taisuke/0000-0002-0075-5943; Nagano, Osamu/0000-0002-7630-142X; De Strooper, Bart/0000-0001-5455-5819; Murakami, Daizo/0000-0001-8668-800X				ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; De Strooper B, 2001, NAT CELL BIOL, V3, pE221, DOI 10.1038/ncb1001-e221; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; EVIN G, 1995, BIOCHEMISTRY-US, V34, P14185, DOI 10.1021/bi00043a024; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Ito K, 1999, ONCOGENE, V18, P7080, DOI 10.1038/sj.onc.1203191; Kaether C, 2002, J CELL BIOL, V158, P551, DOI 10.1083/jcb.200201123; Kawano Y, 2000, J BIOL CHEM, V275, P29628, DOI 10.1074/jbc.M002440200; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; LESLEY J, 1998, FRONT BIOSCI, V3, P616; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Noe V, 2001, J CELL SCI, V114, P111; Okamoto I, 1999, J BIOL CHEM, V274, P25525, DOI 10.1074/jbc.274.36.25525; Okamoto I, 2001, J CELL BIOL, V155, P755, DOI 10.1083/jcb.200108159; Okamoto I, 1999, ONCOGENE, V18, P1435, DOI 10.1038/sj.onc.1202447; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Sadot E, 1998, P NATL ACAD SCI USA, V95, P15339, DOI 10.1073/pnas.95.26.15339; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Weber GF, 2002, CANCER RES, V62, P2281	34	119	124	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 13	2003	22	10					1511	1516		10.1038/sj.onc.1206298	http://dx.doi.org/10.1038/sj.onc.1206298			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652ZZ	12629514				2022-12-28	WOS:000181411900008
J	Fujioka, S; Sclabas, GM; Schmidt, C; Niu, JG; Frederick, WA; Dong, QG; Abbruzzese, JL; Evans, DB; Baker, C; Chiao, PJ				Fujioka, S; Sclabas, GM; Schmidt, C; Niu, JG; Frederick, WA; Dong, QG; Abbruzzese, JL; Evans, DB; Baker, C; Chiao, PJ			Inhibition of constitutive NF-kappa B activity by I kappa B alpha M suppresses tumorigenesis	ONCOGENE			English	Article						I kappa B alpha; NF-kappa B; tumorigenesis; angiogenesis; pancreatic cancer	ENDOTHELIAL GROWTH-FACTOR; PANCREATIC-CANCER CELLS; ANGIOGENESIS; EXPRESSION; INTERLEUKIN-8; APOPTOSIS; ADENOCARCINOMA; METASTASIS; INDUCTION; PROTEINS	We have demonstrated that nuclear factor-kappaB (NF-kappaB) is constitutively activated in human pancreatic adenocarcinoma and human pancreatic cancer cell lines but not in normal pancreatic tissues or in immortalized, nontumorigenic pancreatic epithelial cells, suggesting that NF-kappaB plays a critical role in the development of pancreatic adenocarcinoma. To elucidate the role of constitutive NF- kappaB activity in human pancreatic cancer cells, we generated pancreatic tumor cell lines that express a phosphorylation defective IkappaBalpha (S32, 36A) (IkappaBalphaM) that blocks NF-kappaB, activity. In this study, we showed that inhibiting constitutive NF-kappaB activity by expressing IkappaBalphaM suppressed the tumorigenicity of a nonmetastatic human pancreatic cancer cell line, PANC-1, in an orthotopic nude mouse model. Immunohistochemical analysis showed that PANC-1-derived tumors expressed vascular endothelial growth factor (VEGF) and induced angiogenesis. Inhibiting NF-kappaB signaling by expressing licBaM significantly reduced expression of Bcl-x(L) and Bcl-2. The cytokine-induced expression of VEGF and Interleukin-8 in PANC-1 cells is also decreased. Taken together, these results suggest that the inhibition of NF-kappaB signaling can suppress tumorigenesis of pancreatic cancer cells and that the NF-kappaB signaling pathway is a potential target for anticancer agents.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Unit 107, Houston, TX 77030 USA; Univ Texas, Dept Surg Oncol, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Houston, TX 77030 USA; Univ Texas, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA; Univ Texas, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas System; University of Texas System; University of Texas System	Chiao, PJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Unit 107, 1515 Holcombe Blvd, Houston, TX 77030 USA.			Schmidt, Christian/0000-0002-1260-9732	NATIONAL CANCER INSTITUTE [R01CA075517, R29CA073675, P01CA078778] Funding Source: NIH RePORTER; NCI NIH HHS [CA78778, CA73675, CA 75517] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BRAMHALL SR, 1995, BRIT J SURG, V82, P111, DOI 10.1002/bjs.1800820137; Breslin TM, 2001, ANN SURG ONCOL, V8, P123, DOI 10.1007/s10434-001-0123-4; Chang TC, 1997, FEBS LETT, V415, P11, DOI 10.1016/S0014-5793(97)01083-1; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; DEJARDIN E, 1995, ONCOGENE, V11, P1835; Dong QG, 2002, ONCOGENE, V21, P6510, DOI 10.1038/sj.onc.1205848; FERRARA N, 1995, BREAST CANCER RES TR, V36, P127, DOI 10.1007/BF00666035; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; Folkman J, 1992, Semin Cancer Biol, V3, P65; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Fujioka S, 2003, CLIN CANCER RES, V9, P346; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Gilmore TD, 1996, ONCOGENE, V13, P1367; Grau AM, 1997, CANCER RES, V57, P3929; Grisham MB, 1999, METHOD ENZYMOL, V300, P345; HU DE, 1993, INFLAMMATION, V17, P135, DOI 10.1007/BF00916100; Huang S, 2000, CANCER RES, V60, P5334; Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; Klingler K, 1997, INFECT IMMUN, V65, P5272, DOI 10.1128/IAI.65.12.5272-5278.1997; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Lee TH, 2002, J BIOL CHEM, V277, P10445, DOI 10.1074/jbc.M107348200; Leek RD, 1996, CANCER RES, V56, P4625; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LU D, 1991, ONCOGENE, V6, P1235; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Mohammad RM, 2001, ANTI-CANCER DRUG, V12, P735, DOI 10.1097/00001813-200110000-00005; MOORE BE, 1988, VIROLOGY, V162, P377, DOI 10.1016/0042-6822(88)90478-3; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; Parborell F, 2002, BIOL REPROD, V67, P481, DOI 10.1095/biolreprod67.2.481; PASSANITI A, 1992, LAB INVEST, V67, P519; Sawai H, 2001, PANCREAS, V23, P399, DOI 10.1097/00006676-200111000-00011; Schwarte-Waldhoff I, 2000, P NATL ACAD SCI USA, V97, P9624, DOI 10.1073/pnas.97.17.9624; Shono T, 1996, MOL CELL BIOL, V16, P4231; STRIETER RM, 1992, AM J PATHOL, V141, P1279; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; Teraoka H, 2001, BRIT J CANCER, V85, P612, DOI 10.1054/bjoc.2001.1941; Tsai LC, 2000, ANTICANCER RES, V20, P2441; Tsuzuki Y, 2001, LAB INVEST, V81, P1439, DOI 10.1038/labinvest.3780357; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang WX, 1999, ONCOGENE, V18, P4554, DOI 10.1038/sj.onc.1202833; Wang WX, 1999, CLIN CANCER RES, V5, P119; Xu ZW, 2001, INT J CANCER, V94, P268, DOI 10.1002/ijc.1447; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yoshida A, 1999, INVEST OPHTH VIS SCI, V40, P1624; YOSHIMURA T, 1987, J IMMUNOL, V139, P788	52	138	152	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2003	22	9					1365	1370		10.1038/sj.onc.1206323	http://dx.doi.org/10.1038/sj.onc.1206323			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618762				2022-12-28	WOS:000181360900011
J	Wong, BCY; Jiang, XH; Fan, XM; Lin, MCM; Jiang, SH; Lam, SK; Kung, HF				Wong, BCY; Jiang, XH; Fan, XM; Lin, MCM; Jiang, SH; Lam, SK; Kung, HF			Suppression of RelA/p65 nuclear translocation independent of I kappa B-alpha degradation by cyclooxygenase-2 inhibitor in gastric cancer	ONCOGENE			English	Article						COX-2 inhibitor; NSAIDs; NF-kappa B; p65 (RelA) and gastric cancer	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TRANSCRIPTION FACTOR; ACTIVATOR PROTEIN-1; SODIUM-SALICYLATE; INDUCED APOPTOSIS; KINASE-BETA; CELL-DEATH; ASPIRIN; INDUCTION; PATHWAY	Selective cyclooxygenase-2 (COX-2) inhibitors are promising anti-inflammatory drugs with potential antitumor activities. The nuclear factor-kappa B (NF-kappaB) family of proteins is important transcriptional regulators of genes involved in immunity, inflammation, and carcinogenesis. In the present study, we investigated whether and by which molecular mechanism the selective COX-2 inhibitors inhibit NF-kappaB activation in gastric cancer. The effects of SC236 and its derivative, but devoid of COX-2 enzyme inhibition activity on NF-kappaB signaling, were evaluated using electromobility shift, transfection, and reporter gene assay. The translocation of RelA/p65 was investigated using Western blotting and immunocytochemistry. We showed that SC236 suppressed NF-kappaB-mediated gene transcription and binding activity in gastric cancer. This effect occurred through a mechanism independent of cyclooxygenase activity and prostaglandin synthesis. Furthermore, unlike aspirin, SC236 affected neither the phosphorylation, degradation, nor expression of IkappaB-alpha, suggesting that the effects of SC236 are independent of IKK activity and IkappaB-alpha gene transcription. Instead, SC236 worked directly through suppressing nuclear translocation of RelA/p65. It is possible that SC236 directly targets proteins that facilitate the nuclear translocation of NF-kappaB. Our study suggests an important molecular mechanism by which COX-2 inhibitors reduce inflammation and suppress carcinogenesis in gastrointestinal tract.	Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China; RuiJin Hosp, Dept Gastroenterol, Shanghai, Peoples R China; Univ Hong Kong, Inst Mol Biol, Hong Kong, Hong Kong, Peoples R China; Fudan Univ, Affiliated Jinshan Hosp, Dept Med, Shanghai 200433, Peoples R China	University of Hong Kong; Shanghai Jiao Tong University; University of Hong Kong; Fudan University	Wong, BCY (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China.		Wong, Benjamin Chun Yu/ABB-1962-2020; jiang, cynthia xiaohua/F-7580-2017; Wong, Benjamin Chun Yu/C-4436-2009	jiang, cynthia xiaohua/0000-0002-7372-4961; 				Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Connolly EM, 2002, BRIT J CANCER, V87, P231, DOI 10.1038/sj.bjc.6600462; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DuBois RN, 1996, J GASTROENTEROL, V31, P898, DOI 10.1007/BF02358623; Elder DJE, 1997, CLIN CANCER RES, V3, P1679; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Grosch S, 2001, FASEB J, V15, P2742, DOI 10.1096/fj.01-0299fje; Gupta RA, 1998, GASTROENTEROLOGY, V114, P1095, DOI 10.1016/S0016-5085(98)70330-0; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397; Jiang XH, 2002, ONCOGENE, V21, P6113, DOI 10.1038/sj.onc.1205778; KARGMAN SL, 1995, CANCER RES, V55, P3785; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Li JJ, 1997, CANCER RES, V57, P3569; Manna SK, 2000, J IMMUNOL, V164, P6509, DOI 10.4049/jimmunol.164.12.6509; Masferrer JL, 2000, CANCER RES, V60, P1306; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; PARETT ML, 1997, INT J ONCOL, V10, P503; Penning TD, 1997, J MED CHEM, V40, P1347, DOI 10.1021/jm960803q; Reddy BS, 1996, CANCER RES, V56, P4566; Richter M, 2001, CARCINOGENESIS, V22, P17, DOI 10.1093/carcin/22.1.17; Ristimaki A, 1997, CANCER RES, V57, P1276; Sawaoka H, 1998, AM J PHYSIOL-GASTR L, V274, pG1061, DOI 10.1152/ajpgi.1998.274.6.G1061; Sheng HM, 1998, CANCER RES, V58, P362; Stark LA, 2001, FASEB J, V15, P1273, DOI 10.1096/fj.00-0529fje; Tegeder I, 2001, FASEB J, V15, P2, DOI 10.1096/fasebj.15.1.2; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; Wahl C, 1998, J CLIN INVEST, V101, P1163, DOI 10.1172/JCI992; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Weber CK, 2000, GASTROENTEROLOGY, V119, P1209, DOI 10.1053/gast.2000.19458; Wulczyn FG, 1996, J MOL MED, V74, P749, DOI 10.1007/s001090050078; Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Zhou XM, 2001, CARCINOGENESIS, V22, P1393, DOI 10.1093/carcin/22.9.1393; Zhu GH, 2000, GASTROENTEROLOGY, V118, P507, DOI 10.1016/S0016-5085(00)70256-3; Zhu GH, 1999, BRIT J CANCER, V79, P393, DOI 10.1038/sj.bjc.6690062	40	66	75	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 27	2003	22	8					1189	1197		10.1038/sj.onc.1206234	http://dx.doi.org/10.1038/sj.onc.1206234			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650EK	12606945				2022-12-28	WOS:000181249700007
J	Cariati, R; Zancai, P; Righetti, E; Rizzo, S; De Rossi, A; Boiocchi, M; Dolcetti, R				Cariati, R; Zancai, P; Righetti, E; Rizzo, S; De Rossi, A; Boiocchi, M; Dolcetti, R			Inhibition of oxidative phosphorylation underlies the antiproliferative and proapoptotic effects of mofarotene (Ro 40-8757) in Burkitt's lymphoma cells	ONCOGENE			English	Article						Burkitt's lymphoma; retinoids; Ro 40-8757; Epstein-Barr virus; reactive oxygen species; oxidative phosphorylation	COMPLEX I; AROTINOID RO-40-8757; APOPTOSIS; CANCER; BIOLOGY; BCL-2; EXPRESSION; INDUCTION; THERAPY; VITRO	In the search for retinoids active against Burkitt's lymphoma (BL), we found that the arotinoid mofarotene (Ro 40-8757) induced strong antiproliferative and apoptotic responses in most established BL cell lines as well as in primary BL cells. Ro 40-8757-induced apoptosis is associated with mitochondrial membrane depolarization, activation of caspase-3 and -9, and enhanced production of reactive oxygen species. These effects were related to a transient drop in intracellular ATP content, probably favored by a downregulation of NADH dehydrogenase subunit-1, a component of the mitochondrial respiratory chain (MRC) Complex I. Inhibition of MRC with thenoyltrifluoroacetone suppressed both the ATP recovery and apoptosis, confirming that the effects of Ro 40-8757 are mediated by changes in mitochondrial function. Compared to EBV-negative lines, EBV-carrying BLs were more resistant to Ro 40-8757-induced apoptosis. EBV infection and ectopic LMP-1 expression increased the resistance of BL cells to Ro 40-8757-induced apoptosis, probably through bcl-2 upregulation. Finally, we also show that 2-methoxyoestradiol, an inhibitor of the scavenger enzymes superoxide dismutases, enhanced Ro 40-8757-mediated apoptosis. These findings provide the rationale for evaluating the clinical efficacy of Ro 40-8757 in BL patients and suggest that the combination of Ro 40-8757 with inhibitors of scavenger enzymes may be a promising therapeutic approach for this aggressive lymphoma.	Ctr Riferimento Oncol, Div Expt Oncol 1, IRCCS, Natl Canc Inst,Dept Pre Clin & Epidemiol Res, I-33081 Aviano, PN, Italy; AIDS Reference Ctr, Dept Oncol & Surg Sci, Padua, Italy	IRCCS Aviano (CRO); IRCCS Istituto Oncologico Veneto (IOV)	Boiocchi, M (corresponding author), Ctr Riferimento Oncol, Div Expt Oncol 1, IRCCS, Natl Canc Inst,Dept Pre Clin & Epidemiol Res, Via Pedemontana Occidentale 12, I-33081 Aviano, PN, Italy.	mboiocchi@cro.it	Rizzo, Silvana/AAW-1132-2020; Dolcetti, Riccardo/O-3832-2015; De Rossi, Anita/Q-4845-2019; De Rossi, A./L-3128-2015	Rizzo, Silvana/0000-0002-7156-1783; Dolcetti, Riccardo/0000-0003-1625-9853; De Rossi, Anita/0000-0001-6435-7509; De Rossi, A./0000-0001-6435-7509				Barrientos A, 1999, J BIOL CHEM, V274, P16188, DOI 10.1074/jbc.274.23.16188; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; Cariati R, 2000, INT J CANCER, V86, P375, DOI 10.1002/(SICI)1097-0215(20000501)86:3<375::AID-IJC12>3.0.CO;2-Z; CASTLEBERRY RP, 1994, NEW ENGL J MED, V331, P1680, DOI 10.1056/NEJM199412223312503; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ELIASON JF, 1993, BRIT J CANCER, V67, P1293, DOI 10.1038/bjc.1993.240; ELIASON JF, 1995, BLOOD, V86, P4516, DOI 10.1182/blood.V86.12.4516.bloodjournal86124516; ELIASON JF, 1994, INT J CANCER, V57, P192, DOI 10.1002/ijc.2910570211; FalK MH, 1998, INT J CANCER, V75, P620, DOI 10.1002/(SICI)1097-0215(19980209)75:4<620::AID-IJC21>3.0.CO;2-B; Fenaux P, 1997, SEMIN ONCOL, V24, P92; FRENCH LE, 1994, LANCET, V344, P686, DOI 10.1016/S0140-6736(94)92122-9; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; HARTMANN D, 1993, RETINOIDS PROGR RES, P491; Hecht JL, 2000, J CLIN ONCOL, V18, P3707, DOI 10.1200/JCO.2000.18.21.3707; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Higuchi M, 1998, ONCOGENE, V17, P2515, DOI 10.1038/sj.onc.1202485; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; KNOWLES DM, 1988, ANN INTERN MED, V108, P744, DOI 10.7326/0003-4819-108-5-744; Komano J, 1999, J VIROL, V73, P9827, DOI 10.1128/JVI.73.12.9827-9831.1999; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Louvet C, 1996, BRIT J CANCER, V74, P394, DOI 10.1038/bjc.1996.371; Marton A, 1997, EUR J BIOCHEM, V250, P467, DOI 10.1111/j.1432-1033.1997.0467a.x; Morrison VA, 1999, SEMIN ONCOL, V26, P84; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; OHNO R, 1994, LEUKEMIA LYMPHOMA, V14, P401, DOI 10.3109/10428199409049696; Pettus EH, 2000, J NEUROCHEM, V75, P383, DOI 10.1046/j.1471-4159.2000.0750383.x; Pitkanen S, 1996, J CLIN INVEST, V98, P345, DOI 10.1172/JCI118798; Pomponi F, 1996, BLOOD, V88, P3147, DOI 10.1182/blood.V88.8.3147.bloodjournal8883147; PRYOR WA, 1982, ANN NY ACAD SCI, V393, P1, DOI 10.1111/j.1749-6632.1982.tb31228.x; Richter C, 1996, FEBS LETT, V378, P107, DOI 10.1016/0014-5793(95)01431-4; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; Ruf IK, 2000, J VIROL, V74, P10223, DOI 10.1128/JVI.74.21.10223-10228.2000; Schweizer M., 1997, OXIDATIVE STRESS MOL, P169; Seaton TA, 1998, BRAIN RES, V809, P12, DOI 10.1016/S0006-8993(98)00790-2; SLATER AFG, 1995, BBA-MOL BASIS DIS, V1271, P59, DOI 10.1016/0925-4439(95)00010-2; TEELMANN K, 1993, CANCER RES, V53, P2319; UCHIDA T, 1994, INT J CANCER, V58, P891, DOI 10.1002/ijc.2910580624; WHITE L, 1992, CRIT REV ONCOL HEMAT, V13, P55, DOI 10.1016/1040-8428(92)90016-J; Xu JW, 2000, J IMMUNOL, V164, P2815, DOI 10.4049/jimmunol.164.5.2815	40	5	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2003	22	6					906	918		10.1038/sj.onc.1206060	http://dx.doi.org/10.1038/sj.onc.1206060			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584570				2022-12-28	WOS:000180864300013
J	Funakoshi, T; Tachibana, I; Hoshida, Y; Kimura, H; Takeda, Y; Kijima, T; Nishino, K; Goto, H; Yoneda, T; Kumagai, T; Osaki, T; Hayashi, S; Aozasa, K; Kawase, I				Funakoshi, T; Tachibana, I; Hoshida, Y; Kimura, H; Takeda, Y; Kijima, T; Nishino, K; Goto, H; Yoneda, T; Kumagai, T; Osaki, T; Hayashi, S; Aozasa, K; Kawase, I			Expression of tetraspanins in human lung cancer cells: frequent downregulation of CD9 and its contribution to cell motility in small cell lung cancer	ONCOGENE			English	Article						small cell lung cancer (SCLC); tetraspanin; CD9; motility	KAI1/CD82 GENE-EXPRESSION; TRANSMEMBRANE-4 SUPERFAMILY; BREAST-CANCER; MONOCLONAL-ANTIBODY; TM4SF PROTEINS; TYROSINE PHOSPHORYLATION; INTEGRIN ALPHA-3-BETA-1; MOLECULAR-CLONING; PANCREATIC-CANCER; TUMOR PROGRESSION	Small cell lung cancer (SCLC) invades locally and metastasizes distantly extremely early when compared with nonsmall cell lung cancer (NSCLC). The underlying molecular mechanisms, however, have not been elucidated. Accumulating evidence suggests that downregulation of several members of tetraspanins is associated with progression of solid tumors, thus indicating poor prognosis. Here we screened 30 lung cancer cell lines for expression of tetraspanins, CD9, CD63, CD81, CD82, CD151, and NAG-2. Flow cytometry revealed that, among these proteins, CD9 is broadly expressed in NSCLC lines, but is absent or highly reduced in most SCLC lines (P < 0.0001). Using the Boyden chamber and videomicroscopic cell motility assays, we showed that stable transfection of CD9 into an SCLC line, OS3-R5, reduced cell motility on fibronectin. Furthermore, by transient transfection of green fluorescent protein (GFP)-tagged CD9 into three other SCLC lines, we observed that SCLC cells expressing GFP-CD9 were uniformly less motile than untransfected cells. CD9 or GFP-CD9 was associated with beta1 integrins and distributed at the tumor cell periphery and cell-cell contacts, suggesting that CD9 modifies beta1 integrin function to reduce motility. These findings suggest that low expression of CD9 may contribute to the highly invasive and metastatic phenotype of SCLC.	Osaka Univ, Grad Sch Med, Dept Mol Med, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Pathol, Suita, Osaka 5650871, Japan; Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Thorac & Adult Oncol, Boston, MA 02115 USA	Osaka University; Osaka University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Tachibana, I (corresponding author), Osaka Univ, Grad Sch Med, Dept Mol Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Hoshida, Yujin/R-7513-2019	Hoshida, Yoshihiko/0000-0003-3166-9754				Adachi M, 1996, CANCER RES, V56, P1751; Adachi M, 1998, J CLIN ONCOL, V16, P1397, DOI 10.1200/JCO.1998.16.4.1397; ATKINSON B, 1985, HYBRIDOMA, V4, P243, DOI 10.1089/hyb.1985.4.243; Berditchevski F, 1997, J BIOL CHEM, V272, P2595, DOI 10.1074/jbc.272.5.2595; Berditchevski F, 1999, J CELL BIOL, V146, P477, DOI 10.1083/jcb.146.2.477; BOUCHEIX C, 1985, ANN GENET-PARIS, V28, P19; Bredin CG, 1998, EUR RESPIR J, V11, P400, DOI 10.1183/09031936.98.11020400; Cajot JF, 1997, CANCER RES, V57, P2593; CARNEY DN, 1985, CANCER RES, V45, P2913; Claas C, 1998, J CELL BIOL, V141, P267, DOI 10.1083/jcb.141.1.267; DOYLE A, 1985, J EXP MED, V161, P1135, DOI 10.1084/jem.161.5.1135; FELDMAN LE, 1991, CANCER RES, V51, P1065; FITTER S, 1995, BLOOD, V86, P1348, DOI 10.1182/blood.V86.4.1348.bloodjournal8641348; Guo XZ, 1996, CANCER RES, V56, P4876; Hemler ME, 1996, BBA-REV CANCER, V1287, P67, DOI 10.1016/0304-419X(96)00007-8; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; HIGASHIYAMA M, 1995, CANCER RES, V55, P6040; HOTTA H, 1988, CANCER RES, V48, P2955; HSU SM, 1981, AM J CLIN PATHOL, V75, P816, DOI 10.1093/ajcp/75.6.816; Huang CI, 1998, AM J PATHOL, V153, P973, DOI 10.1016/S0002-9440(10)65639-8; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; Inoue G, 2001, INT J MOL MED, V7, P67; KAPRIELIAN Z, 1995, J NEUROSCI, V15, P562; KASHII T, 1992, ANTICANCER RES, V12, P621; Lagaudriere-Gesbert C, 1997, J IMMUNOL, V158, P2790; Lantuejoul S, 1998, AM J SURG PATHOL, V22, P1267, DOI 10.1097/00000478-199810000-00012; Le Naour F, 2000, SCIENCE, V287, P319, DOI 10.1126/science.287.5451.319; Li J, 1996, ONCOGENE, V13, P2379; Lombardi DP, 1999, CANCER RES, V59, P5724; MABRY M, 1991, CANCER CELL-MON REV, V3, P53; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Mashimo T, 2000, BIOCHEM BIOPH RES CO, V274, P370, DOI 10.1006/bbrc.2000.3139; Miyado K, 2000, SCIENCE, V287, P321, DOI 10.1126/science.287.5451.321; Miyake M, 2000, ONCOGENE, V19, P5221, DOI 10.1038/sj.onc.1203919; MIYAKE M, 1995, CANCER RES, V55, P4127; Miyake M, 1996, CANCER RES, V56, P1244; MOUNTAIN CF, 1978, SEMIN ONCOL, V5, P272; NAGIRA M, 1994, CELL IMMUNOL, V157, P144, DOI 10.1006/cimm.1994.1212; NAKAMURA K, 1995, J CELL BIOL, V129, P1691, DOI 10.1083/jcb.129.6.1691; Oritani K, 1996, BLOOD, V87, P2252, DOI 10.1182/blood.V87.6.2252.bloodjournal8762252; Rubinstein E, 1996, EUR J IMMUNOL, V26, P2657, DOI 10.1002/eji.1830261117; SAITO S, 1994, LUNG CANCER-J IASLC, V10, P307, DOI 10.1016/0169-5002(94)90660-2; SAITO S, 1991, CANCER IMMUNOL IMMUN, V33, P165, DOI 10.1007/BF01756137; Salgia R, 1998, J CLIN ONCOL, V16, P1207, DOI 10.1200/JCO.1998.16.3.1207; SCHEIDEGGER EP, 1994, LAB INVEST, V70, P95; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; SHAW ARE, 1995, J BIOL CHEM, V270, P24092, DOI 10.1074/jbc.270.41.24092; Sho M, 1998, INT J CANCER, V79, P509, DOI 10.1002/(SICI)1097-0215(19981023)79:5<509::AID-IJC11>3.0.CO;2-X; Shtivelman E, 1997, ONCOGENE, V14, P2167, DOI 10.1038/sj.onc.1201059; SOUHAMI RL, 1987, LANCET, V2, P325; Tachibana I, 1997, J BIOL CHEM, V272, P29181, DOI 10.1074/jbc.272.46.29181; Tachibana I, 1996, EXP CELL RES, V227, P230, DOI 10.1006/excr.1996.0272; Tachibana I, 1999, J CELL BIOL, V146, P893, DOI 10.1083/jcb.146.4.893; TANIO Y, 1992, JPN J CANCER RES, V83, P736, DOI 10.1111/j.1349-7006.1992.tb01974.x; Testa JE, 1999, CANCER RES, V59, P3812; Uchida S, 1999, BRIT J CANCER, V79, P1168, DOI 10.1038/sj.bjc.6690186; White A, 1998, ONCOGENE, V16, P3143, DOI 10.1038/sj.onc.1201852; Yang XH, 2000, CLIN CANCER RES, V6, P3424; Yauch RL, 1998, MOL BIOL CELL, V9, P2751, DOI 10.1091/mbc.9.10.2751	59	69	82	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 6	2003	22	5					674	687		10.1038/sj.onc.1206106	http://dx.doi.org/10.1038/sj.onc.1206106			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569360				2022-12-28	WOS:000180642100005
J	Waga, K; Nakamura, Y; Maki, K; Arai, H; Yamagata, T; Sasaki, K; Kurokawa, M; Hirai, H; Mitani, K				Waga, K; Nakamura, Y; Maki, K; Arai, H; Yamagata, T; Sasaki, K; Kurokawa, M; Hirai, H; Mitani, K			Leukemia-related transcription factor TEL accelerates differentiation of Friend erythroleukemia cells	ONCOGENE			English	Article						erythroid differentiation; FLI-1; MEL; TEL	LONG TERMINAL REPEAT; ERYTHROID-DIFFERENTIATION; MYELOID-LEUKEMIA; FUSION PROTEIN; HISTONE DEACETYLASE; CO-REPRESSORS; GENE; FLI-1; VIRUS; ACTIVATION	TEL belongs to a member of the ETS family transcription factors that represses transcription of target genes such as FLI-1. Although TEL is essential for establishing hematopoiesis in neonatal bone marrow, its role in erythroid lineage is not understood. To investigate a role for TEL in erythroid differentiation, we introduced TEL into mouse erythroleukemia (MEL) cells. Overexpressing wild-type-TEL in MEL cells enhanced differentiation induced by hexamethylene bisacetamide or dimethylsulfoxide, as judged by the increased levels of erythroid-specific delta-aminolevulinate synthase and beta-globin mRNAs. TEL bound to a corepressor mSin3A through the helix-loop-helix domain. A TEL mutant lacking this domain still bound to the ETS binding site, but lost its transrepressional effect. This mutant completely blocked erythroid differentiation in MEL cells. Moreover, it showed dominant-negative effects over TEL-mediated transcriptional repression and acceleration of erythroid differentiation. Endogenous TEL mRNA was found to increase during the first 3 days in differentiating MEL cells and drastically decrease thereafter. All these data suggest that TEL might play some role in erythroid cell differentiation.	Dokkyo Univ, Sch Med, Dept Hematol, Mibu, Tochigi 3210293, Japan; Univ Tokyo, Dept Hematol & Oncol, Grad Sch Med, Tokyo 1138655, Japan	Dokkyo Medical University; University of Tokyo	Mitani, K (corresponding author), Dokkyo Univ, Sch Med, Dept Hematol, 880 Kitakobayashi, Mibu, Tochigi 3210293, Japan.							Athanasiou M, 2000, LEUKEMIA, V14, P439, DOI 10.1038/sj.leu.2401689; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; Buijs A, 2000, MOL CELL BIOL, V20, P9281, DOI 10.1128/MCB.20.24.9281-9293.2000; Fenrick R, 2000, MOL CELL BIOL, V20, P5828, DOI 10.1128/MCB.20.16.5828-5839.2000; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; Gu XS, 2001, J BIOL CHEM, V276, P9421, DOI 10.1074/jbc.M010070200; Guidez F, 2000, BLOOD, V96, P2557; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Kim CA, 2001, EMBO J, V20, P4173, DOI 10.1093/emboj/20.15.4173; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Kuno Y, 2001, BLOOD, V97, P1050, DOI 10.1182/blood.V97.4.1050; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; Maki K, 1999, BLOOD, V93, P3216, DOI 10.1182/blood.V93.10.3216.410k45_3216_3224; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; Martinez R, 2000, BLOOD, V96, p453A; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nicol R, 1998, J BIOL CHEM, V273, P3588, DOI 10.1074/jbc.273.6.3588; Pereira R, 1999, ONCOGENE, V18, P1597, DOI 10.1038/sj.onc.1202534; Poirel H, 1997, ONCOGENE, V14, P349, DOI 10.1038/sj.onc.1200829; Potter MD, 2000, BLOOD, V95, P3341, DOI 10.1182/blood.V95.11.3341.011k44_3341_3348; Spyropoulos DD, 2000, MOL CELL BIOL, V20, P5643, DOI 10.1128/MCB.20.15.5643-5652.2000; Starck J, 1999, MOL CELL BIOL, V19, P121; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; TANAKA T, 1994, J BIOL CHEM, V269, P24020; Turner J, 2001, BIOESSAYS, V23, P683, DOI 10.1002/bies.1097; Van Rompaey L, 2000, ONCOGENE, V19, P5244, DOI 10.1038/sj.onc.1203899; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; Wang LL, 2001, ONCOGENE, V20, P3716, DOI 10.1038/sj.onc.1204479	40	25	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 9	2003	22	1					59	68		10.1038/sj.onc.1206072	http://dx.doi.org/10.1038/sj.onc.1206072			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527908				2022-12-28	WOS:000180166900007
J	Jasin, M				Jasin, M			Homologous repair of DNA damage and tumorigenesis: the BRCA connection	ONCOGENE			English	Review						BRCA1; BRCA2; DNA repair; homologous recombination; RAD51	DOUBLE-STRAND BREAKS; EMBRYONIC CELLULAR PROLIFERATION; CANCER-PREDISPOSING MUTATIONS; RETRACTED ARTICLE. SEE; NUCLEAR-LOCALIZATION; RING DOMAIN; IN-VIVO; RADIATION HYPERSENSITIVITY; GENOMIC INSTABILITY; FUNCTIONAL DOMAINS	Homologous recombination has been recognized in recent years to be an important DNA repair pathway in mammalian cells, for such damage as chromosomal double-strand breaks. Cells mutated for the genes involved in the hereditary breast and ovarian cancer susceptibility syndromes, i.e. BRCAJ and BRCA2, show defects in DNA repair by homologous recombination, implicating this repair pathway in protecting individuals against tumorigenesis. This review summarizes recent advances in our understanding of BRCA1 and BRCA2 in DNA repair, as well as insight into these proteins gleaned from structure determination of domains of these proteins and the broader evolutionary conservation than previously appreciated.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Jasin, M (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave, New York, NY 10021 USA.	m-jasin@ski.mskcc.org			NATIONAL CANCER INSTITUTE [P01CA094060] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA94060] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldeyron C, 2002, ONCOGENE, V21, P1401, DOI 10.1038/sj.onc.1205200; Bassing CH, 2002, P NATL ACAD SCI USA, V99, P8173, DOI 10.1073/pnas.122228699; Baumann P, 1997, EMBO J, V16, P5198, DOI 10.1093/emboj/16.17.5198; Baumann P, 1998, P NATL ACAD SCI USA, V95, P14066, DOI 10.1073/pnas.95.24.14066; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Begg CB, 2002, J NATL CANCER I, V94, P1221; Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200; Bignell G, 1997, HUM MOL GENET, V6, P53, DOI 10.1093/hmg/6.1.53; Bork P, 1996, NAT GENET, V13, P22, DOI 10.1038/ng0596-22; Brzovic PS, 2001, J BIOL CHEM, V276, P41399, DOI 10.1074/jbc.M106551200; Brzovic PS, 2001, NAT STRUCT BIOL, V8, P833, DOI 10.1038/nsb1001-833; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Caspari T, 2002, GENE DEV, V16, P1195, DOI 10.1101/gad.221402; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chandler J, 2001, GENESIS, V29, P72, DOI 10.1002/1526-968X(200102)29:2<72::AID-GENE1007>3.0.CO;2-B; Chen A, 2002, J BIOL CHEM, V277, P22085, DOI 10.1074/jbc.M201252200; Chen CF, 1999, J BIOL CHEM, V274, P32931, DOI 10.1074/jbc.274.46.32931; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Cressman VL, 1999, MOL CELL BIOL, V19, P7061; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Fabbro M, 2002, J BIOL CHEM, V277, P21315, DOI 10.1074/jbc.M200769200; Feldmann E, 2000, NUCLEIC ACIDS RES, V28, P2585, DOI 10.1093/nar/28.13.2585; Ganesan S, 2002, CELL, V111, P393, DOI 10.1016/S0092-8674(02)01052-8; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Gasior SL, 2001, P NATL ACAD SCI USA, V98, P8411, DOI 10.1073/pnas.121046198; Gatei M, 2000, CANCER RES, V60, P3299; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; Goggins M, 1996, CANCER RES, V56, P5360; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Huber LJ, 2001, MOL CELL BIOL, V21, P4005, DOI 10.1128/MCB.21.12.4005-4015.2001; Jasin M., 2001, CONT CANC RES, VIII, P207; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Johnson RD, 2000, EMBO J, V19, P3398, DOI 10.1093/emboj/19.13.3398; Johnson RD, 2001, BIOCHEM SOC T, V29, P196, DOI 10.1042/BST0290196; Joo WS, 2002, GENE DEV, V16, P583, DOI 10.1101/gad.959202; Joukov V, 2001, P NATL ACAD SCI USA, V98, P12078, DOI 10.1073/pnas.211427098; Kojic M, 2002, MOL CELL, V10, P683, DOI 10.1016/S1097-2765(02)00632-9; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Kraakman-van der Zwet M, 2002, MOL CELL BIOL, V22, P669, DOI 10.1128/MCB.22.2.669-679.2002; Lane TF, 2000, ONCOGENE, V19, P4085, DOI 10.1038/sj.onc.1203760; Larminat F, 2002, ONCOGENE, V21, P5188, DOI 10.1038/sj.onc.1205659; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; Ludwig T, 2001, GENE DEV, V15, P1188, DOI 10.1101/gad.879201; Mak TW, 2000, NAT IMMUNOL, V1, P77, DOI 10.1038/76950; Marston NJ, 1999, MOL CELL BIOL, V19, P4633; McAllister KA, 1997, CANCER RES, V57, P3121; McAllister KA, 2002, CANCER RES, V62, P990; Merel P, 2002, ONCOGENE, V21, P5654, DOI 10.1038/sj.onc.1205742; Meza JE, 1999, J BIOL CHEM, V274, P5659, DOI 10.1074/jbc.274.9.5659; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Monteiro ANA, 2000, TRENDS BIOCHEM SCI, V25, P469, DOI 10.1016/S0968-0004(00)01632-7; Morimatsu M, 1998, CANCER RES, V58, P3441; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Moynahan ME, 2001, CANCER RES, V61, P4842; MOYNAHAN ME, 2002, IN PRESS ONCOGENE RE; Orelli BJ, 2001, ONCOGENE, V20, P4433, DOI 10.1038/sj.onc.1204485; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Paull TT, 2001, CELL, V107, P563, DOI 10.1016/S0092-8674(01)00591-8; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; Pellegrini L, 2002, NATURE, V420, P287, DOI 10.1038/nature01230; Pierce AJ, 2001, TRENDS CELL BIOL, V11, pS52, DOI 10.1016/S0962-8924(01)02149-3; Rodriguez JA, 2000, J BIOL CHEM, V275, P38589, DOI 10.1074/jbc.M003851200; ROUET P, 1994, MOL CELL BIOL, V14, P8096, DOI 10.1128/MCB.14.12.8096; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Sarkisian CJ, 2001, J BIOL CHEM, V276, P37640, DOI 10.1074/jbc.M106281200; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Sharan SK, 1997, GENOMICS, V40, P234, DOI 10.1006/geno.1996.4573; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Snouwaert JN, 1999, ONCOGENE, V18, P7900, DOI 10.1038/sj.onc.1203334; Spain BH, 1999, P NATL ACAD SCI USA, V96, P13920, DOI 10.1073/pnas.96.24.13920; Stark JM, 2002, J BIOL CHEM, V277, P20185, DOI 10.1074/jbc.M112132200; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Takata M, 2002, ONCOGENE, V21, P1130, DOI 10.1038/sj.onc.1205168; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Thai TH, 1998, HUM MOL GENET, V7, P195, DOI 10.1093/hmg/7.2.195; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Tirkkonen M, 1997, CANCER RES, V57, P1222; Turner BC, 2002, CANCER RES, V62, P4054; Tutt A, 2001, EMBO J, V20, P4704, DOI 10.1093/emboj/20.17.4704; Tutt ANJ, 2002, EMBO REP, V3, P255, DOI 10.1093/embo-reports/kvf037; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Vogelstein B., 1998, GENETIC BASIS HUMAN; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Wang HC, 2001, CANCER RES, V61, P270; Wang Y, 2000, GENE DEV, V14, P927; Warren M, 2002, HUM MOL GENET, V11, P841, DOI 10.1093/hmg/11.7.841; Welcsh PL, 2000, TRENDS GENET, V16, P69, DOI 10.1016/S0168-9525(99)01930-7; Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705; Williams RS, 2001, NAT STRUCT BIOL, V8, P838, DOI 10.1038/nsb1001-838; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xia F, 2001, P NATL ACAD SCI USA, V98, P8644, DOI 10.1073/pnas.151253498; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Yamane K, 2000, BIOCHEM BIOPH RES CO, V279, P678, DOI 10.1006/bbrc.2000.3983; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837; Yano K, 2000, BIOCHEM BIOPH RES CO, V270, P171, DOI 10.1006/bbrc.2000.2392; Ye QN, 2001, J CELL BIOL, V155, P911, DOI 10.1083/jcb.200108049; Yu VPCC, 2000, GENE DEV, V14, P1400; Yu X, 2000, J BIOL CHEM, V275, P18541, DOI 10.1074/jbc.M909494199; Yuan SSF, 1999, CANCER RES, V59, P3547; Zhong Q, 2002, J BIOL CHEM, V277, P28641, DOI 10.1074/jbc.M200748200; Zhong Q, 2002, CANCER RES, V62, P3966; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	124	269	289	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2002	21	58					8981	8993		10.1038/sj.onc.1206176	http://dx.doi.org/10.1038/sj.onc.1206176			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	626TP	12483514				2022-12-28	WOS:000179889500009
J	Benhar, M; Engelberg, D; Levitzki, A				Benhar, M; Engelberg, D; Levitzki, A			Cisplatin-induced activation of the EGF receptor	ONCOGENE			English	Article						cisplatin; EGF receptor; Src; glioblastoma; DNA damage	GROWTH-FACTOR RECEPTOR; N-TERMINAL KINASE; BCL-X-L; C-SRC; INDUCED APOPTOSIS; TYROSINE KINASES; PROTEIN-KINASE; HYDROGEN-PEROXIDE; EPITHELIAL-CELLS; PHOSPHORYLATION	Cisplatin (CDDP) is an efficient DNA-damaging antitumor agent employed for the treatment of various human cancers. CDDP activates nuclear as well as cytoplasmatic signaling pathways involved in regulation of the cell cycle, damage repair and programmed cell death. Here we report that CDDP also activates a membrane-integrated protein, the epidermal growth factor receptor (EGFR). We show that EGFR is activated in response to CDDP in various types of cells that overexpress the receptor, including transformed human glioma cells and human breast tumor cells. CDDP-induced EGFR activation requires its kinase activity, as it can be blocked by an EGFR kinase inhibitor or by expression of a kinase dead receptor. We also show that CDDP-induced EGFR activation is independent of receptor ligand. CDDP induces the activation of c-Src, and EGFR activation is blocked by Src-family inhibitor PP1, suggesting that Src kinases mediate CDDP-induced EGFR activation. We propose that EGFR activation in response to CDDP is a survival response, since inhibition of EGFR activation enhances CDDP-induced death. These findings show that signals generated by DNA damage can modulate EGFR activity, and argue that interfering with CDDP-induced EGFR activation in tumor cells might be a useful approach to sensitize these cells to genotoxic agents.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Levitzki, A (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel.	levitzki@vms.huji.ac.il	Benhar, Moran/AAV-5764-2020	Benhar, Moran/0000-0002-7094-3456				Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Benhar M, 2002, EMBO REP, V3, P420, DOI 10.1093/embo-reports/kvf094; Benhar M, 2001, MOL CELL BIOL, V21, P6913, DOI 10.1128/MCB.21.20.6913-6926.2001; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Chen K, 2001, J BIOL CHEM, V276, P16045, DOI 10.1074/jbc.M011766200; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Deschesnes RG, 2001, MOL BIOL CELL, V12, P1569, DOI 10.1091/mbc.12.6.1569; Fang L, 2001, EMBO J, V20, P1931, DOI 10.1093/emboj/20.8.1931; Gebauer G, 2000, INT J ONCOL, V16, P321; Gibson S, 1999, J BIOL CHEM, V274, P17612, DOI 10.1074/jbc.274.25.17612; Haas A, 2002, J BIOL CHEM, V277, P18694, DOI 10.1074/jbc.M111357200; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; JOHNSON GR, 1993, J BIOL CHEM, V268, P2924; Jordan P, 2000, CELL MOL LIFE SCI, V57, P1229, DOI 10.1007/PL00000762; Kartalou M, 2001, MUTAT RES-FUND MOL M, V478, P23, DOI 10.1016/S0027-5107(01)00141-5; KITAGAWA D, 2001, J BIOL CHEM, V2, P2; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Leu CM, 2000, ONCOGENE, V19, P1665, DOI 10.1038/sj.onc.1203452; Lin RZ, 1997, J BIOL CHEM, V272, P31196, DOI 10.1074/jbc.272.49.31196; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; Miyajima A, 1997, BRIT J CANCER, V76, P206, DOI 10.1038/bjc.1997.363; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; Nagane M, 1998, P NATL ACAD SCI USA, V95, P5724, DOI 10.1073/pnas.95.10.5724; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; Pearce AK, 2001, TRENDS CELL BIOL, V11, P426, DOI 10.1016/S0962-8924(01)02119-5; Persons DL, 1999, CLIN CANCER RES, V5, P1007; SATO KI, 1995, BIOCHEM BIOPH RES CO, V215, P1078, DOI 10.1006/bbrc.1995.2574; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Simizu S, 1998, J BIOL CHEM, V273, P26900, DOI 10.1074/jbc.273.41.26900; Stoll SW, 1998, ONCOGENE, V16, P1493, DOI 10.1038/sj.onc.1201657; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Wu WD, 2002, J BIOL CHEM, V277, P24252, DOI 10.1074/jbc.M200437200; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706; Young MA, 2001, CELL, V105, P115, DOI 10.1016/S0092-8674(01)00301-4; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	43	116	121	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2002	21	57					8723	8731		10.1038/sj.onc.1205980	http://dx.doi.org/10.1038/sj.onc.1205980			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483525				2022-12-28	WOS:000179734400006
J	Jin, SQ; Tong, T; Fan, WH; Fan, FY; Antinore, MJ; Zhu, XC; Mazzacurati, L; Li, XX; Petrik, KL; Rajasekaran, B; Wu, M; Zhan, QM				Jin, SQ; Tong, T; Fan, WH; Fan, FY; Antinore, MJ; Zhu, XC; Mazzacurati, L; Li, XX; Petrik, KL; Rajasekaran, B; Wu, M; Zhan, QM			GADD45-induced cell cycle G2-M arrest associates with altered subcellular distribution of cyclin B1 and is independent of p38 kinase activity	ONCOGENE			English	Article						p53; GADD45; G2-M arrest; cyclin B1	P53-REGULATED PROTEIN GADD45; HUMAN CANCER-CELLS; DNA-DAMAGE; IONIZING-RADIATION; DEPENDENT KINASES; MAMMALIAN G(1); GROWTH ARREST; HELA-CELLS; P53; CHECKPOINTS	In response to DNA damage, the cell cycle checkpoint is an important biological event in maintaining genomic fidelity. Gadd45, a p53-regulated and DNA damage inducible protein, has recently been demonstrated to play a role in the G2-M checkpoint in response to DNA damage. In the current study, we further investigated the biochemical mechanism(s) involved in the GADD45-activated cell cycle G2-M arrest. Using the tetracycline-controlled system (tet-off), we established GADD45-inducible lines in HCT116 (wild-type p53) and Hela (inactivated p53 status) cells. Following inducible expression of the Gadd45 protein, cell growth was strongly suppressed in both HCT116 and Hela cells. Interestingly, HCT116 cells revealed a significant G2-M arrest but Hela cells failed to arrest at the G2-M phases, indicating that the GADD45-activated G2-M arrest requires normal p53 function. The GADD45-induced G2-M arrest was observed independent of p38 kinase activity. Importantly, induction of Gadd45 protein resulted in a reduction of nuclear cyclin B1 protein, whose nuclear localization is critical for the completion of G2-M transition. The reduced nuclear cyclin B1 levels correlated with inhibition of Cdc2/cyclin 131 kinase activity. Additionally, overexpression of cyclin B1 substantially abrogated the GADD45-induced cell growth suppression. Therefore, GADD45 inhibition of Cdc2 kinase activity through alteration of cyclin B1 subcellular localization may be an essential step in the GADD45-induced cell cycle G2-M arrest and growth suppression.	Univ Pittsburgh, Sch Med, Inst Canc, Dept Radiat Oncol, Pittsburgh, PA 15213 USA; Chinese Acad Med Sci, Inst Canc, Natl Lab Mol Oncol, Beijing 100021, Peoples R China; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Chinese Academy of Medical Sciences - Peking Union Medical College; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zhan, QM (corresponding author), Univ Pittsburgh, Sch Med, Inst Canc, Dept Radiat Oncol, BST W-945,200 Lothrop St, Pittsburgh, PA 15213 USA.			mazzacurati, lucia/0000-0002-8336-8032	NATIONAL CANCER INSTITUTE [R01CA083874] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA-83874] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; BERNHARD EJ, 1995, RADIAT ENVIRON BIOPH, V34, P79, DOI 10.1007/BF01275210; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Carrier F, 1999, MOL CELL BIOL, V19, P1673; Chen IT, 1996, ONCOGENE, V12, P595; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; HALL PA, 1995, ONCOGENE, V10, P2427; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KEARSEY JM, 1995, ONCOGENE, V11, P1675; KOHN KW, 1994, J CELL BIOCHEM, V54, P440, DOI 10.1002/jcb.240540411; MUSCHEL RJ, 1992, RADIAT RES, V132, P153, DOI 10.2307/3578520; MUSCHEL RJ, 1991, CANCER RES, V51, P5113; O'Connor P M, 1992, Semin Cancer Biol, V3, P409; O'Connor P M, 1996, Prog Cell Cycle Res, V2, P165; OConnor PM, 1997, CANCER SURV, V29, P151; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Soria JC, 2000, CANCER RES, V60, P4000; STEWART N, 1995, ONCOGENE, V10, P109; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Thompson DA, 1997, ONCOGENE, V15, P3025, DOI 10.1038/sj.onc.1201495; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yu M, 2002, MOL IMMUNOL, V38, P981, DOI 10.1016/S0161-5890(02)00026-3; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; ZHANG H, 1994, COLD SPRING HARB SYM, V59, P21, DOI 10.1101/SQB.1994.059.01.005; Zhao HC, 2000, EXP CELL RES, V258, P92, DOI 10.1006/excr.2000.4906	48	154	165	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 12	2002	21	57					8696	8704		10.1038/sj.onc.1206034	http://dx.doi.org/10.1038/sj.onc.1206034			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483522				2022-12-28	WOS:000179734400003
J	Chesire, DR; Isaacs, WB				Chesire, DR; Isaacs, WB			Ligand-dependent inhibition of beta-catenin/TCF signaling by androgen receptor	ONCOGENE			English	Article						androgen receptor; beta-catenin; TCF/LEF; prostate; nuclear signaling	HUMAN-PROSTATE-CANCER; GROWTH-FACTOR-BETA; CREB-BINDING-PROTEIN; TRANSCRIPTIONAL ACTIVATION; WNT/BETA-CATENIN; CARCINOMA-CELLS; TUMOR-SUPPRESSOR; MAMMARY-GLAND; TARGET GENES; CYCLIN D1	beta-catenin signaling may contribute to prostate cancer (CaP) progression. Although beta-catenin is known to upregulate T cell factor (TCF) target gene expression in CaP cells, recent evidence demonstrates its capacity to enhance ligand-dependent androgen receptor (AR) function. Thus, we wished to further understand the interaction between these two pathways. We find in both CaP cells (CWR22-Rv1, LAPC-4, DU145) and non-CaP cells (HEK-293, TSU, SW480, HCT-116) that beta-catenin/TCF-related transcription (CRT), as measured by activation of a synthetic promoter and that of cyclin D1, is inhibited by androgen treatment. This inhibition is AR-dependent, as it only occurs in cells expressing AR endogenously or transiently, and is abrogated by AR antagonists. Additional analyses convey that the ligand-dependent nature of CRT suppression depends on transactivation-competent AR in the nucleus, but not on indirect effects stemming from AR target gene expression. Given the recent work identifying an AR/beta-catenin interaction, and from our finding that liganded AR does not prompt gross changes in the constitutive nuclear localization of TCF4 or mutant beta-catenin, we hypothesized that transcription factor (i.e. AR and TCF) competition for beta-catenin recruitment may explain, in part, androgen-induced suppression of CRT. To address this idea, we expressed an AR mutant lacking its DNA-binding domain (DBD). This receptor could not orchestrate ligand-dependent CRT repression, thereby providing support for those recent data implicating the AR DBD/LBD as necessary for beta-catenin interaction. Further supporting this hypothesis, TCF/LEF overexpression counteracts androgen-induced suppression of CRT, and requires beta-catenin binding activity to do so. Interestingly, TCF4 over-expression potently antagonizes AR function; however, this inhibition may occur independently of beta-catenin/TCF4 interaction. These results from TCF4 over-expression analyses, taken together, provide further evidence that AR-mediated suppression of CRT is a consequence of limiting amounts of beta-catenin, and not AR target gene expression. Our analyses point to a reciprocal balance between AR and CRT function that may shape critical processes during normal prostate development and tumor progression.	Johns Hopkins Med Inst, Brady Urol Inst, Res Labs, Baltimore, MD 21287 USA; Johns Hopkins Med Inst, Johns Hopkins Oncol Ctr, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Isaacs, WB (corresponding author), Johns Hopkins Univ Hosp, Dept Urol, Marburg 115,600 N Wolfe St, Baltimore, MD 21287 USA.	wisaacs@jhmi.edu			NCI NIH HHS [CA58236] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058236] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aarnisalo P, 1998, P NATL ACAD SCI USA, V95, P2122, DOI 10.1073/pnas.95.5.2122; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Brisken C, 2000, GENE DEV, V14, P650; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Chesire DR, 2002, ONCOGENE, V21, P2679, DOI 10.1038/sj.onc.1205352; Chesire DR, 2000, PROSTATE, V45, P323, DOI 10.1002/1097-0045(20001201)45:4<323::AID-PROS7>3.0.CO;2-W; Chipuk JE, 2002, J BIOL CHEM, V277, P1240, DOI 10.1074/jbc.M108855200; Cude KJ, 1999, J MOL MED, V77, P419, DOI 10.1007/s001090050372; Culig Z, 1998, PROSTATE, V35, P63, DOI 10.1002/(SICI)1097-0045(19980401)35:1<63::AID-PROS9>3.0.CO;2-I; CULIG Z, 1994, CANCER RES, V54, P5474; DasGupta R, 1999, DEVELOPMENT, V126, P4557; Dotzlaw H, 2002, MOL ENDOCRINOL, V16, P661, DOI 10.1210/me.16.4.661; Dyer BW, 2000, ANAL BIOCHEM, V282, P158, DOI 10.1006/abio.2000.4605; Easwaran V, 1999, CURR BIOL, V9, P1415, DOI 10.1016/S0960-9822(00)80088-3; Elo JP, 2001, ANN MED, V33, P130, DOI 10.3109/07853890109002068; Fronsdal K, 1998, J BIOL CHEM, V273, P31853, DOI 10.1074/jbc.273.48.31853; Galbiati F, 2000, J BIOL CHEM, V275, P23368, DOI 10.1074/jbc.M002020200; GAVIN BJ, 1992, MOL CELL BIOL, V12, P2418, DOI 10.1128/MCB.12.5.2418; Gerstein AV, 2002, GENE CHROMOSOME CANC, V34, P9, DOI 10.1002/gcc.10037; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hecht A, 1999, J BIOL CHEM, V274, P18017, DOI 10.1074/jbc.274.25.18017; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Hobisch A, 1998, CANCER RES, V58, P4640; HOBISCH A, 1995, CANCER RES, V55, P3068; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/88264; Hsu W, 2001, J CELL BIOL, V155, P1055, DOI 10.1083/jcb.200107066; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; HUSMANN DA, 1990, ENDOCRINOLOGY, V126, P2359, DOI 10.1210/endo-126-5-2359; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497-402; Knudsen KE, 1999, CANCER RES, V59, P2297; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Leung JY, 2002, J BIOL CHEM, V277, P21657, DOI 10.1074/jbc.M200139200; Linja MJ, 2001, CANCER RES, V61, P3550; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859; Lu ML, 2001, J BIOL CHEM, V276, P13442, DOI 10.1074/jbc.M006598200; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; MacLean HE, 1997, J STEROID BIOCHEM, V62, P233, DOI 10.1016/S0960-0760(97)00049-6; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Masiello D, 2002, J BIOL CHEM, V277, P26321, DOI 10.1074/jbc.M203310200; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; McDonald S, 2000, CANCER RES, V60, P2317; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Mulholland DJ, 2002, J BIOL CHEM, V277, P17933, DOI 10.1074/jbc.M200135200; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028; Park JJ, 2000, CANCER RES, V60, P5946; Pawlowski JE, 2002, J BIOL CHEM, V277, P20702, DOI 10.1074/jbc.M200545200; Petre CE, 2002, J BIOL CHEM, V277, P2207, DOI 10.1074/jbc.M106399200; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Sadot E, 1998, P NATL ACAD SCI USA, V95, P15339, DOI 10.1073/pnas.95.26.15339; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Samowitz WS, 1999, CANCER RES, V59, P1442; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Schuur ER, 1996, J BIOL CHEM, V271, P7043, DOI 10.1074/jbc.271.12.7043; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; Song CZ, 1999, P NATL ACAD SCI USA, V96, P11776, DOI 10.1073/pnas.96.21.11776; SONNENSCHEIN C, 1989, CANCER RES, V49, P3474; Spiegelman VS, 2000, MOL CELL, V5, P877, DOI 10.1016/S1097-2765(00)80327-5; Sun YN, 2000, P NATL ACAD SCI USA, V97, P12613, DOI 10.1073/pnas.220158597; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tan J, 1997, MOL ENDOCRINOL, V11, P450, DOI 10.1210/me.11.4.450; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tindall DJ, 1999, PROSTATE, V38, P166, DOI 10.1002/(SICI)1097-0045(19990201)38:2<166::AID-PROS11>3.0.CO;2-A; Tomura A, 2001, J BIOL CHEM, V276, P28395, DOI 10.1074/jbc.M101755200; Truica CI, 2000, CANCER RES, V60, P4709; Tyagi RK, 2000, MOL ENDOCRINOL, V14, P1162, DOI 10.1210/me.14.8.1162; Vainio S, 1999, NATURE, V397, P405, DOI 10.1038/17068; van Bokhoven A, 2001, CANCER RES, V61, P6340; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Voeller HJ, 1998, CANCER RES, V58, P2520; WEBERHALL SJ, 1994, DIFFERENTIATION, V57, P205, DOI 10.1046/j.1432-0436.1994.5730205.x; Wen Y, 2000, CANCER RES, V60, P6841; Yan D, 2001, P NATL ACAD SCI USA, V98, P14973, DOI 10.1073/pnas.261574498; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; Yu DC, 1999, CANCER RES, V59, P1498; Yuan X, 2001, J BIOL CHEM, V276, P46647, DOI 10.1074/jbc.M108404200; Zegarra-Moro OL, 2002, CANCER RES, V62, P1008; Zorn AM, 1999, MOL CELL, V4, P487, DOI 10.1016/S1097-2765(00)80200-2	95	129	133	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	2002	21	55					8453	8469		10.1038/sj.onc.1206049	http://dx.doi.org/10.1038/sj.onc.1206049			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466965				2022-12-28	WOS:000179480100008
J	Park, WY; Hwang, CI; Im, CN; Kang, MJ; Woo, JH; Kim, JH; Kim, YS; Kim, JH; Kim, H; Kim, KA; Yu, HJ; Lee, SJ; Lee, YS; Seo, JS				Park, WY; Hwang, CI; Im, CN; Kang, MJ; Woo, JH; Kim, JH; Kim, YS; Kim, JH; Kim, H; Kim, KA; Yu, HJ; Lee, SJ; Lee, YS; Seo, JS			Identification of radiation-specific responses from gene expression profile	ONCOGENE			English	Article						gamma-irradiation; cDNA microarray; p53; cytoplasmic epoxide hydrolase; phospholipase C gamma 2	T-CELL RECEPTOR; IONIZING-RADIATION; GENOTOXIC STRESS; DNA-DAMAGE; KAPPA-B; IN-VITRO; P53; APOPTOSIS; IRRADIATION; CANCER	The responses to ionizing radiation (IR) in tumors are dependent on cellular context. We investigated radiation-related expression patterns in Jurkat T cells with nonsense mutation in p53 using cDNA microarray. Expression of 2400 genes in gamma-irradiated cells was distinct from other stimulations like anti-CD3, phetohemagglutinin (PHA) and concanavalin A (ConA) in unsupervised clustering analysis. Among them, 384 genes were selected for their IR-specific changes to make 'RadChip'. In spite of p53 status, every type of cells showed similar patterns in expression of these genes upon gamma-radiation. Moreover, radiation-induced responses were clearly separated from the responses to other genotoxic stress like UV radiation, cisplatin and doxorubicin. We focused on two IR-related genes, phospholipase Cgamma2 (PLCG2) and cytosolic epoxide hydrolase (EPHX2), which were increased at 12 h after gamma-radiation in RT-PCR. TPCK could suppress the induction of these two genes in either of Jurkat T cells and PBMCs, which might suggest the transcriptional regulation of PLCG2 and EPHX2 by NF-gammaB upon gamma-radiation. From these results, we could identify the IR-specific genes from expression profiling, which can be used as radiation biomarkers to screen radiation exposure as well as probing the mechanism of cellular responses to ionizing radiation.	Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, Chongnogu, Seoul 110799, South Korea; Seoul Natl Univ, Ilchun Mol Med Inst, Seoul, South Korea; Seoul Natl Univ, Dept Internal Med, Seoul, South Korea; Seoul Natl Univ, Coll Med, Dept Prevent Med, Seoul, South Korea; Seoul Natl Univ, Grad Sch Publ Hlth, Dept Biostat, Seoul, South Korea; Macrogen Inc, Seoul, South Korea; Korea Canc Ctr Hosp, Lab Radiat Effect, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Macrogen, Inc.; National Cancer Center - Korea (NCC)	Seo, JS (corresponding author), Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, Chongnogu, 28 Yongondong, Seoul 110799, South Korea.		Kim, Ho/AAS-2402-2021; park, woongyang/D-5727-2012; Kim, Ju Han/E-5983-2012; Seo, Jeong-Sun/J-2763-2012; Kim, Yon Su/J-2743-2012	Kim, Ho/0000-0001-7472-3752; Hwang, Chang-il/0000-0002-5710-7672; Im, Chang-Nim/0000-0002-7566-7075				Abraham RT, 2000, IMMUNOL RES, V22, P95, DOI 10.1385/IR:22:2-3:95; Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; Amundson SA, 2001, COMP BIOCHEM PHYS B, V129, P703, DOI 10.1016/S1096-4959(01)00389-X; Backlund MG, 2001, CANCER RES, V61, P6577; Cemerski S, 2002, J BIOL CHEM, V277, P19585, DOI 10.1074/jbc.M111451200; DENEKAMP J, 1973, BRIT J RADIOL, V46, P381, DOI 10.1259/0007-1285-46-545-381; DENT P, 1995, MOL CELL BIOL, V15, P4125; Dysvik B, 2001, BIOINFORMATICS, V17, P369, DOI 10.1093/bioinformatics/17.4.369; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; FUKS Z, 1993, RADIAT ONCOL INVEST, V1, P81; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; Gong BD, 2000, CANCER RES, V60, P5754; Green JA, 2001, LANCET, V358, P781, DOI 10.1016/S0140-6736(01)05965-7; Iwamoto KS, 1996, CANCER RES, V56, P3862; Kang JS, 1996, FEBS LETT, V399, P14, DOI 10.1016/S0014-5793(96)01276-8; Kavanagh BD, 1995, CLIN CANCER RES, V1, P1557; Kawabe T, 2002, ONCOGENE, V21, P1717, DOI 10.1038/sj.onc.1205229; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kim SG, 1997, MOL PHARMACOL, V51, P225, DOI 10.1124/mol.51.2.225; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; LuHesselmann J, 1997, RADIAT RES, V148, P531, DOI 10.2307/3579728; Madden SL, 1997, ONCOGENE, V15, P1079, DOI 10.1038/sj.onc.1201091; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MIYAMOTO S, 1994, MOL CELL BIOL, V14, P3276, DOI 10.1128/MCB.14.5.3276; MORETTA A, 1987, P NATL ACAD SCI USA, V84, P1654, DOI 10.1073/pnas.84.6.1654; NOGAMI M, 1994, RADIAT RES, V139, P47, DOI 10.2307/3578731; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Park WY, 2001, BIOCHEM BIOPH RES CO, V282, P934, DOI 10.1006/bbrc.2001.4632; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Quackenbush J, 2001, NAT REV GENET, V2, P418, DOI 10.1038/35076576; Roth JA, 2001, ACTA ONCOL, V40, P739; Safwat A, 2000, RADIAT RES, V153, P599, DOI 10.1667/0033-7587(2000)153[0599:TIOLDT]2.0.CO;2; SALLY AA, 1999, ONCOGENE, V18, P3666; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; Seidegard J, 1997, ENVIRON HEALTH PERSP, V105, P791, DOI 10.2307/3433285; Smith ML, 1996, MUTAT RES-REV GENET, V340, P109, DOI 10.1016/S0165-1110(96)90043-3; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Vigorito E, 1999, HEMATOL CELL THER, V41, P153, DOI 10.1007/s00282-999-0153-0; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Zhan QM, 1996, ONCOGENE, V13, P2287	41	96	104	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 5	2002	21	55					8521	8528		10.1038/sj.onc.1205977	http://dx.doi.org/10.1038/sj.onc.1205977			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466973				2022-12-28	WOS:000179480100016
J	Joaquin, M; Bessa, M; Saville, MK; Watson, RJ				Joaquin, M; Bessa, M; Saville, MK; Watson, RJ			B-Myb overcomes a p107-mediated cell proliferation block by interacting with an N-terminal domain of p107	ONCOGENE			English	Article						B-Myb; p107 pocket protein; cell cycle; cyclin E/Cdk2; cyclin A2/Cdk2	CYCLIN A/CDK2; S-PHASE; REGULATED EXPRESSION; DEPENDENT KINASE; C-MYB; PROTEIN; PHOSPHORYLATION; TRANSCRIPTION; TRANSACTIVATION; INHIBITION	B-Myb is a cell-cycle regulated transcription factor which is implicated in cell proliferation and has an essential role in early embryonic development. In this study we examined the functions of B-Myb required to overcome G1 arrest in Saos-2 cells induced by the retinoblastoma-related p107 protein. Our results demonstrated that this activity was independent of B-Myb transactivation function, but correlated with its capacity to form an in vivo complex with p107. A large proportion of B-Myb formed complexes with p107 in cotransfected cells, however, B-Myb bound weakly to the related p130 protein and not at all to pRb. In contrast to the E2F transcription factors, which bind the p107 C-terminal pocket domain, B-Myb recognizes an N-terminal p107 region which overlaps the larger cyclin-binding domain. B-Myb and cyclin A2 formed mutually exclusive complexes with p107, and B-Myb enhanced the activity of co-transfected cyclin E kinase activity, implying that B-Myb affects the cell cycle by preventing sequestration of active cyclin/cdk2 complexes. This study defines a novel function of B-Myb and further suggests that the p107 N-terminus provides an interaction domain for transcription factors involved in cell cycle control.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Ludwig Inst Canc Res, Sect Virol & Cell Biol, London W2 1PG, England	Imperial College London; Ludwig Institute for Cancer Research	Watson, RJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Ludwig Inst Canc Res, Sect Virol & Cell Biol, St Marys Campus,Norfolk Pl, London W2 1PG, England.		Joaquin, Manel/O-6533-2019; Joaquin, Manel/E-2216-2015	Joaquin, Manel/0000-0001-8973-5916; Joaquin, Manel/0000-0001-8973-5916				Ansieau S, 1997, J MOL MED-JMM, V75, P815, DOI 10.1007/s001090050170; ARSURA M, 1992, BLOOD, V79, P2708; Bartsch O, 1999, EUR J BIOCHEM, V260, P384, DOI 10.1046/j.1432-1327.1999.00191.x; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; Bessa M, 2001, BLOOD CELL MOL DIS, V27, P416, DOI 10.1006/bcmd.2001.0399; Bessa M, 2001, ONCOGENE, V20, P3376, DOI 10.1038/sj.onc.1204439; Bies J, 1996, ONCOGENE, V12, P355; Castano E, 1998, MOL CELL BIOL, V18, P5380, DOI 10.1128/MCB.18.9.5380; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; Engelhard A, 2000, EXP CELL RES, V254, P153, DOI 10.1006/excr.1999.4742; Golay J, 1997, CELL GROWTH DIFFER, V8, P1305; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; JAULT FM, 1995, J VIROL, V69, P6697, DOI 10.1128/JVI.69.11.6697-6704.1995; Johnson RA, 1999, J GEN VIROL, V80, P1293, DOI 10.1099/0022-1317-80-5-1293; Johnson TK, 1999, J BIOL CHEM, V274, P36741, DOI 10.1074/jbc.274.51.36741; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; RASCHELLA G, 1995, J BIOL CHEM, V270, P8540, DOI 10.1074/jbc.270.15.8540; Robinson C, 1996, ONCOGENE, V12, P1855; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sala A, 1996, J BIOL CHEM, V271, P9363, DOI 10.1074/jbc.271.16.9363; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Sala A, 1996, J BIOL CHEM, V271, P28738, DOI 10.1074/jbc.271.46.28738; Sala A, 1999, J CELL PHYSIOL, V179, P245; Saville MK, 1998, ONCOGENE, V17, P2679, DOI 10.1038/sj.onc.1202503; Saville MK, 1998, ADV CANCER RES, V72, P109; Sitzmann J, 1996, ONCOGENE, V12, P1889; Tanaka Y, 1999, J BIOL CHEM, V274, P28067, DOI 10.1074/jbc.274.40.28067; Timchenko NA, 1999, MOL CELL BIOL, V19, P2936; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; ZHU LG, 1995, MOL CELL BIOL, V15, P3552; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7	42	21	21	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 14	2002	21	52					7923	7932		10.1038/sj.onc.1206001	http://dx.doi.org/10.1038/sj.onc.1206001			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	612VY	12439743				2022-12-28	WOS:000179097200002
J	Kawai, H; Li, HC; Chun, P; Avraham, S; Avraham, HK				Kawai, H; Li, HC; Chun, P; Avraham, S; Avraham, HK			Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells	ONCOGENE			English	Article						VEGF; BRCA1; estrogen; estrogen receptors; breast cancer cells; transcriptional regulation	MAMMARY-CARCINOMA CELLS; EXON 7-ENCODED DOMAIN; TYROSINE KINASE; FACTOR GENE; MITOGENIC STIMULATION; EXTRACELLULAR-MATRIX; CYCLE PROGRESSION; OVARIAN-CANCER; TUMOR-CELLS; ANGIOGENESIS	Mutational inactivation of BRCA1 confers increased risk for breast cancer. However, the underlying basis for the breast tissue-restricted, tumor-suppressive properties of BRCA1 remains poorly defined. Here, we show that BRCA1 and the estrogen receptor alpha (ER-alpha) modulated vascular endothelial growth factor (VEGF) gene transcription and secretion in breast cancer cells. ER-alpha interacted in vitro and in vivo with BRCA1, and this interaction was mediated by the AF-2 domain of ER-alpha and two domains of BRCA1, the amino-acid residues 1-306 and 428-683. Endogenous interaction of ER-alpha with BRCA1 was observed in normal MCF-10A breast epithelial cells and in breast cancer cells (MCF-7 and T47D), and this interaction was significantly reduced in the presence of estrogen. Furthermore, ER-alpha induced activation of VEGF gene transcription, using human VEGF promoter-luciferase reporter constructs. The AF-2 domain of ER-alpha was also shown to induce VEGF gene transcription activation similar to that obtained with the full-length ER-alpha. However, in the presence of BRCA1, VEGF gene transcription activation and VEGF protein secretion were significantly inhibited in a dose-dependent manner. The BRCA1 domain of 1-683 amino acid residues was required for this inhibition of VEGF gene transcription activation. Three mutated forms of BRCA1 (A1708E, M1775R and Y1853X), that have been identified in familial breast cancers, failed to associate with ER-alpha and to suppress VEGF promoter activity and VEGF protein secretion. Overexpression of wild-type BRCA1 in HCC-1937 breast cancer cells that lack endogenous functional BRCA1 significantly reduced VEGF secretion in these cells. These results demonstrate a novel pathogenic mechanism whereby mutations in BRCA1, via their interaction with ER-alpha, could promote tumorigenesis through the hormonal regulation of mammary epithelial cell proliferation and impaired VEGF function, which may lead to cancer growth and angiogenesis.	Beth Israel Deaconess Med Ctr, Div Expt Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Avraham, HK (corresponding author), Beth Israel Deaconess Med Ctr, Div Expt Med, 4 Blackfan Circle, Boston, MA 02115 USA.	havraham@caregroup.harvard.edu		Avraham, Hava/0000-0002-7545-3640	NATIONAL CANCER INSTITUTE [R01CA076226, R21CA087290] Funding Source: NIH RePORTER; NCI NIH HHS [R21 CA87290, CA76226] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ali SH, 2000, CANCER RES, V60, P7094; Altiok S, 1999, J BIOL CHEM, V274, P32274, DOI 10.1074/jbc.274.45.32274; Altucci L, 1996, ONCOGENE, V12, P2315; Bachelder RE, 2001, CANCER RES, V61, P5736; BATTEGAY EJ, 1995, J MOL MED, V73, P333; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; BROWN LF, 1995, HUM PATHOL, V26, P86, DOI 10.1016/0046-8177(95)90119-1; Chen YM, 1999, J CELL PHYSIOL, V181, P385, DOI 10.1002/(SICI)1097-4652(199912)181:3<385::AID-JCP2>3.0.CO;2-4; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fan SJ, 2001, ONCOGENE, V20, P77, DOI 10.1038/sj.onc.1204073; Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488; GARRIDO C, 1993, GROWTH FACTORS, V8, P109, DOI 10.3109/08977199309046931; Gasparini G, 1997, ENDOCR-RELAT CANCER, V4, P423, DOI 10.1677/erc.0.0040423; Grunstein J, 1999, CANCER RES, V59, P1592; GUIDI AJ, 1995, J NATL CANCER I, V87, P1237, DOI 10.1093/jnci/87.16.1237; Hilakivi-Clarke L, 2000, CANCER RES, V60, P4993; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; Hyder SM, 2000, CANCER RES, V60, P3183; Jordan VC, 2001, CANCER RES, V61, P5683; JORDAN VC, 1990, ENDOCR REV, V11, P578, DOI 10.1210/edrv-11-4-578; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; Kim KJ, 1992, GROWTH FACTORS, V7, P53, DOI 10.3109/08977199209023937; Kranz A, 1999, INT J CANCER, V84, P293, DOI 10.1002/(SICI)1097-0215(19990621)84:3<293::AID-IJC16>3.0.CO;2-T; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Levine AC, 1998, ENDOCRINOLOGY, V139, P4672, DOI 10.1210/en.139.11.4672; LIPPMAN M, 1976, CANCER RES, V36, P4595; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MINCHENKO A, 1994, CELL MOL BIOL RES, V40, P35; Miralem T, 2001, ONCOGENE, V20, P5511, DOI 10.1038/sj.onc.1204753; Mueller MD, 2000, P NATL ACAD SCI USA, V97, P10972, DOI 10.1073/pnas.200377097; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; OSBORNE CK, 1983, CANCER RES, V43, P3583; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; Prall OWJ, 1998, J STEROID BIOCHEM, V65, P169, DOI 10.1016/S0960-0760(98)00021-1; Price DJ, 2001, CELL GROWTH DIFFER, V12, P129; Santin AD, 1999, EUR J GYNAECOL ONCOL, V20, P177; SHIBUYA M, 1990, ONCOGENE, V5, P519; Soker S, 1997, J BIOL CHEM, V272, P31582, DOI 10.1074/jbc.272.50.31582; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; SUTHERLAND RL, 1983, CANCER RES, V43, P3998; TAYLOR IW, 1983, CANCER RES, V43, P4007; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TISCHER E, 1989, BIOCHEM BIOPH RES CO, V165, P1198, DOI 10.1016/0006-291X(89)92729-0; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Tomlinson GE, 1998, CANCER RES, V58, P3237; VANDERBURG B, 1988, J CELL PHYSIOL, V134, P101, DOI 10.1002/jcp.1041340112; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Weidner Noel, 1996, P167; Yoshida A, 1996, GROWTH FACTORS, V13, P57, DOI 10.3109/08977199609034566; Yoshiji H, 1997, CANCER RES, V57, P3924; Yoshiji H, 1996, CANCER RES, V56, P2013; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298	61	97	108	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 31	2002	21	50					7730	7739		10.1038/sj.onc.1205971	http://dx.doi.org/10.1038/sj.onc.1205971			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	606VW	12400015	Bronze			2022-12-28	WOS:000178756200012
J	Mikola, M; Kero, J; Nilson, JH; Keri, RA; Poutanen, M; Huhtaniemi, I				Mikola, M; Kero, J; Nilson, JH; Keri, RA; Poutanen, M; Huhtaniemi, I			High levels of luteinizing hormone analog stimulate gonadal and adrenal tumorigenesis in mice transgenic for the mouse inhibin-alpha-subunit promoter Simian virus 40 T-antigen fusion gene	ONCOGENE			English	Article						LH; adrenal and gonadal tumorigenesis; inhibin	IMMUNOREACTIVE INHIBIN; POSTMENOPAUSAL WOMEN; ACTIVATING MUTATION; OVARIAN-TUMORS; SERUM INHIBIN; CELL TUMORS; GONADOTROPIN; RECEPTOR; PROTEIN; CANCER	Transgenic (TG) mice expressing the Simian virus 40 T-antigen under the control of the murine inhibin-a promoter (Inhalpha/Tag) develop granulosa and Leydig cell tumors at the age of 5-6 months, with 100% penetrance. When these mice are gonadectomized, they develop adrenocortical tumors. Suppression of gonadotropin secretion inhibits the tumorigenesis in the gonads of intact animals and in the adrenals after gonadectomy. To study further the role of luteinizing hormone (LH) in gonadal and adrenal tumorigenesis, a double TG mouse model was generated by crossing the Inha/Tag mice with mice producing constitutively elevated levels of LH (bLHbeta-CTP mice). Our results show that in double TG mice (bLHbeta-CTP/Inhalpha/Tag), gonadal tumorigenesis starts earlier and progresses faster than in Inha/Tag mice. Both ovarian and testicular tumors were histologically comparable with the tumors found in Inhalpha/Tag mice. In addition, adrenal tumorigenesis was found in intact double TG females, but not in Inha/Tag females. Inhibin-a and LH receptor (LHR) were highly expressed in tumorigenic gonadal tissues, and the elevated LH levels were shown to be associated with ectopic LHR and high inhibin-a expression in the female adrenals. We conclude that in the Inhalpha/Tag tumor mouse model, elevated LH levels act as a tumor promoter, advancing gonadal and adrenal tumorigenesis.	Univ Turku, Dept Physiol, FIN-20520 Turku, Finland; Univ Turku, Dept Pediat, FIN-20520 Turku, Finland; Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA	University of Turku; University of Turku; Case Western Reserve University	Huhtaniemi, I (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Inst Reprod & Dev Biol, Du Cane Rd, London W12 0NN, England.	ilpo.huhtaniemi@ic.ac.uk	Keri, Ruth/ABF-2209-2021; kero, jukka/G-3448-2014; Poutanen, Matti/I-1700-2018	Keri, Ruth/0000-0002-1640-3088; kero, jukka/0000-0001-8767-7222; Poutanen, Matti/0000-0002-8953-1734; Ahtiainen, Maarit/0000-0002-3263-2307				ADELSON MD, 1993, CLIN OBSTET GYNECOL, V36, P690, DOI 10.1097/00003081-199309000-00025; Ala-Fossi SL, 2000, EUR J GYNAECOL ONCOL, V21, P187; ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEJONG FH, 1990, J STEROID BIOCHEM, V37, P863, DOI 10.1016/0960-0760(90)90433-L; DING YQ, 1989, ACTA ENDOCRINOL-COP, V121, P46, DOI 10.1530/acta.0.1210046; Dufau ML, 1998, ANNU REV PHYSIOL, V60, P461, DOI 10.1146/annurev.physiol.60.1.461; GAYTAN F, 1994, J ENDOCRINOL, V142, P527, DOI 10.1677/joe.0.1420527; Gocze PM, 1997, GYNECOL ONCOL, V65, P143, DOI 10.1006/gyno.1997.4635; HEALY DL, 1993, NEW ENGL J MED, V329, P1539, DOI 10.1056/NEJM199311183292104; Herath CB, 2001, J ANDROL, V22, P838; Hogan B, 1994, MANIPULATING MOUSE E; HUHTANIEMI I, 1994, EUR J ENDOCRINOL, V130, P25, DOI 10.1530/eje.0.1300025; HUHTANIEMI I, 1985, J CLIN ENDOCR METAB, V61, P698, DOI 10.1210/jcem-61-4-698; HUHTANIEMI IT, 1981, ENDOCRINOLOGY, V109, P588, DOI 10.1210/endo-109-2-588; Iczkowski KA, 1998, MODERN PATHOL, V11, P774; Illingworth PJ, 1996, J CLIN ENDOCR METAB, V81, P1321, DOI 10.1210/jc.81.4.1321; Kananen K, 1997, ENDOCRINOLOGY, V138, P3521, DOI 10.1210/en.138.8.3521; Kananen K, 1996, MOL CELL ENDOCRINOL, V119, P135, DOI 10.1016/0303-7207(96)03802-6; KANANEN K, 1995, MOL ENDOCRINOL, V9, P616, DOI 10.1210/me.9.5.616; Kananen K, 1996, MOL ENDOCRINOL, V10, P1667, DOI 10.1210/me.10.12.1667; Keri RA, 2000, P NATL ACAD SCI USA, V97, P383, DOI 10.1073/pnas.97.1.383; Kero J, 2000, J CLIN INVEST, V105, P633, DOI 10.1172/JCI7716; Kuhn B, 1999, BIOCHEMISTRY-US, V38, P12490, DOI 10.1021/bi990755m; Kumar TR, 1999, MOL ENDOCRINOL, V13, P851, DOI 10.1210/me.13.6.851; Kumar TR, 1996, ENDOCRINOLOGY, V137, P4210, DOI 10.1210/en.137.10.4210; LambertMesserlian GM, 1997, GYNECOL ONCOL, V65, P512, DOI 10.1006/gyno.1997.4719; LAPPOHN RE, 1989, NEW ENGL J MED, V321, P790, DOI 10.1056/NEJM198909213211204; Liu G, 1999, NEW ENGL J MED, V341, P1731, DOI 10.1056/NEJM199912023412304; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MATZUK MM, 1994, P NATL ACAD SCI USA, V91, P8817, DOI 10.1073/pnas.91.19.8817; Matzuk MM, 1996, RECENT PROG HORM RES, V51, P123; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; Mikola MK, 2001, J ENDOCRINOL, V170, P79, DOI 10.1677/joe.0.1700079; Mukherjee A, 1996, ENDOCRINOLOGY, V137, P3234, DOI 10.1210/en.137.8.3234; NEUMANN F, 1991, MUTAT RES, V248, P341, DOI 10.1016/0027-5107(91)90067-X; NISWENDER GD, 1968, P SOC EXP BIOL MED, V128, P807; Owens GE, 2002, MOL ENDOCRINOL, V16, P1230, DOI 10.1210/me.16.6.1230; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; PEI L, 1991, MOL ENDOCRINOL, V5, P521, DOI 10.1210/mend-5-4-521; Rahman NA, 2001, BIOL REPROD, V64, P1122, DOI 10.1095/biolreprod64.4.1122; Rilianawati, 2000, J ENDOCRINOL, V166, P77, DOI 10.1677/joe.0.1660077; Rilianawati, 1998, MOL ENDOCRINOL, V12, P801, DOI 10.1210/me.12.6.801; RISMA KA, 1995, P NATL ACAD SCI USA, V92, P1322, DOI 10.1073/pnas.92.5.1322; Rulli SB, 2002, ENDOCRINOLOGY, V143, P4084, DOI 10.1210/en.2002-220490; SIMON WE, 1983, J NATL CANCER I, V70, P839; Toppari J, 1998, APMIS, V106, P101, DOI 10.1111/j.1699-0463.1998.tb01325.x; van Casteren JIJ, 2000, BIOL REPROD, V62, P886, DOI 10.1095/biolreprod62.4.886; VUORENTO T, 1989, SCAND J CLIN LAB INV, V49, P395, DOI 10.3109/00365518909089113; WILLEMSEN W, 1993, LANCET, V341, P986, DOI 10.1016/0140-6736(93)91071-S; WIMALASENA J, 1992, GYNECOL ONCOL, V46, P345, DOI 10.1016/0090-8258(92)90230-G; Wise PM, 1996, SCIENCE, V273, P67, DOI 10.1126/science.273.5271.67	52	33	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2003	22	21					3269	3278		10.1038/sj.onc.1206518	http://dx.doi.org/10.1038/sj.onc.1206518			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681MM	12761497				2022-12-28	WOS:000183040000009
J	Unoki, M; Nakamura, Y				Unoki, M; Nakamura, Y			EGR2 induces apoptosis in various cancer cell lines by direct transactivation of BNIP3L and BAK	ONCOGENE			English	Article						EGR2; BNIP3L; BAK; apoptosis; PTEN	BCL-2 HOMOLOG; GROWTH SUPPRESSION; MEDIATED TRANSFER; GENE; MUTATIONS; PROTEIN; DEATH; PTEN; IDENTIFICATION; MODULATION	EGR2 plays a key role in the PTEN-induced apoptotic pathway. Using adenovirus-mediated gene transfer to 39 cancer cell lines, we found that EGR2 could induce apoptosis in a large proportion of these lines by altering the permeability of mitochondrial membranes, releasing cytochrome c and activating caspase-3, -8, and -9. Analysis by cDNA microarray and subsequent functional studies revealed that EGR2 directly transactivates expression of BNIP3L and BAK. Our results helped to clarify the molecular mechanism of the apoptotic pathway induced by PTEN-EGR2, and suggested that EGR2 may be an excellent target molecule for gene therapy to treat a variety of cancers.	Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Nakamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	yusuke@ims.u-tokyo.ac.jp	Unoki, Motoko/X-3285-2019	Unoki, Motoko/0000-0002-9629-3818				Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; Chen G, 1999, J BIOL CHEM, V274, P7, DOI 10.1074/jbc.274.1.7; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; HOLLAND PM, 1991, P NATL ACAD SCI USA, V88, P7276, DOI 10.1073/pnas.88.16.7276; Imazu T, 1999, ONCOGENE, V18, P4523, DOI 10.1038/sj.onc.1202722; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; Kruidering M, 2000, IUBMB LIFE, V50, P85, DOI 10.1080/15216540050212088; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MacEwan DJ, 1996, FEBS LETT, V379, P77, DOI 10.1016/0014-5793(95)01495-0; Matsushima M, 1998, GENE CHROMOSOME CANC, V21, P230, DOI 10.1002/(SICI)1098-2264(199803)21:3<230::AID-GCC7>3.0.CO;2-0; Matsushima-Nishiu M, 2001, CANCER RES, V61, P3741; Minaguchi T, 1999, CANCER RES, V59, P6063; Mittelstadt PR, 1999, J BIOL CHEM, V274, P3222, DOI 10.1074/jbc.274.5.3222; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; Obata K, 1998, CANCER RES, V58, P2095; Ono K, 2000, CANCER RES, V60, P5007; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; Risinger JI, 1997, CANCER RES, V57, P4736; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; TOPILKO P, 1994, NATURE, V371, P796, DOI 10.1038/371796a0; Unoki M, 2001, ONCOGENE, V20, P4457, DOI 10.1038/sj.onc.1204608; Warner LE, 1998, NAT GENET, V18, P382, DOI 10.1038/ng0498-382; Wei MC, 2000, GENE DEV, V14, P2060; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zorick TS, 1996, MOL CELL NEUROSCI, V8, P129, DOI 10.1006/mcne.1996.0052	36	85	89	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2003	22	14					2172	2185		10.1038/sj.onc.1206222	http://dx.doi.org/10.1038/sj.onc.1206222			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664NJ	12687019				2022-12-28	WOS:000182066900011
J	Olivier, A; Lucie, K; Jean-Francois, R; Christian-Jacques, L; Paule, S				Olivier, A; Lucie, K; Jean-Francois, R; Christian-Jacques, L; Paule, S			Delineation of the domains required for physical and functional interaction of p14(ARF) with human topoisomerase I	ONCOGENE			English	Article						p14(ARF); topoisomerase I; protein interactions; cell cycle	NUCLEOLAR LOCALIZATION; TUMOR-SUPPRESSOR; BETA-TRANSCRIPT; NUCLEAR EXPORT; CELL-LINES; P19(ARF); PROTEIN; MDM2; P53; ARF	We recently reported an interaction between the p14(ARF). protein and human topoisomerase I (Topo 1) resulting in the stimulation of the relaxation activity of Topo 1. Our data showed that the complex between the two proteins was located within the nucleolus. In the present work, we have investigated the regions of p14(ARF). involved in this interaction by using targeted point mutagenesis and deletion mutants. A region encompassing exon 2-encoded sequence was required for physical binding of p14(ARF) to Topo I as well as for stimulatory activity of the enzyme. Exon 1beta-encoded segment was not implicated in the interaction. Moreover, among p14(ARF) point mutants selected for their high conservation among different mammalian species, mutant p14(ARF) (RR87, 88AA) did not stimulate Topo I in spite of its association with the enzyme, suggesting its direct implication in the functional activity of ARE In contrast, one mutant,p14(ARF) (R71A), was more efficient than wild-type protein to activate Topo 1, suggesting that this residue is a key element to modulate Topo I activity. Finally, only ARF-Topo I complexes containing p14(ARF) exon 2 segment were found to be localized in the nucleolus, suggesting that this sulmuclear location is linked to the biological function of the ARF-Topo I complex.	Inst Biol Mol & Ingn Genet, IBMIG, F-86022 Poitiers, France; UFR Pharm, F-51096 Reims, France	Universite de Poitiers; Universite de Reims Champagne-Ardenne	Paule, S (corresponding author), Inst Biol Mol & Ingn Genet, IBMIG, 40 Ave Recteur Pineau, F-86022 Poitiers, France.			Seite, Paule/0000-0002-7809-7610; riou, jean-francois/0000-0002-0055-6506				Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; DellaValle V, 1997, ONCOGENE, V15, P2475, DOI 10.1038/sj.onc.1201417; Gazzeri S, 1998, CANCER RES, V58, P3926; GULDNER HH, 1986, CHROMOSOMA, V94, P132, DOI 10.1007/BF00286991; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Karayan L, 2001, ONCOGENE, V20, P836, DOI 10.1038/sj.onc.1204170; KUBBUTAT MH, 1997, NATURE, V6630, P299; Kurokawa K, 1999, ONCOGENE, V18, P2718, DOI 10.1038/sj.onc.1202628; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Rizos H, 2000, ONCOGENE, V19, P2978, DOI 10.1038/sj.onc.1203629; Rossi F, 1996, NATURE, V381, P80, DOI 10.1038/381080a0; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; VAUGHN JL, 1977, IN VITRO CELL DEV B, V13, P213; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; Zhang YP, 2001, CELL GROWTH DIFFER, V12, P175; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	22	22	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 3	2003	22	13					1945	1954		10.1038/sj.onc.1206214	http://dx.doi.org/10.1038/sj.onc.1206214			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	662UR	12673200				2022-12-28	WOS:000181967700005
J	Demoulin, JB; Louahed, J; Dumoutier, L; Stevens, M; Renauld, JC				Demoulin, JB; Louahed, J; Dumoutier, L; Stevens, M; Renauld, JC			MAP kinase activation by interleukin-9 in lymphoid and mast cell lines	ONCOGENE			English	Article						cytokines; ERK; proliferation	INSULIN-RECEPTOR SUBSTRATE-1; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; GAMMA-CHAIN; HEMATOPOIETIC-CELLS; TRANSGENIC MICE; IL-9 RECEPTOR; PROLIFERATION; PROTEIN; RAS	Interleukin-9 (IL-9) stimulates the proliferation of mast cells and lymphocytes. In the present study, we showed that IL-9 induced a transient phosphorylation of MEK, ERK2 and p90/RSK in murine lymphoid and mast cell lines. ERK2 in vitro kinase activity was also increased upon IL-9 stimulation. Similar results were obtained with IL-4, which had not been previously reported to activate these kinases in hematopoietic cells. Analysis of IL-9 receptor mutants showed that activation of the pathway was correlated with proliferation and with phosphorylation of the adaptor protein SHC, but not IRS2 or GAB2. The MEK inhibitor PD98059 reduced the mitogenic response to IL-4 and IL-9. In addition, expression of a dominant-negative RAS variant blocked ERK phosphorylation and significantly decreased Ba/F3 cell growth in the presence of IL-9, but did not affect expression of pim-1, a STAT target gene. In summary, these results indicate that IL-9 can transiently activate the mitogen-activated protein kinase pathway, which contributes to growth stimulation of hematopoietic cell tines.	Univ Catholique Louvain, Ludwig Inst Canc Res, B-1200 Brussels, Belgium; Univ Catholique Louvain, Expt Med Univ, B-1200 Brussels, Belgium	Ludwig Institute for Cancer Research; Universite Catholique Louvain; Universite Catholique Louvain	Renauld, JC (corresponding author), Univ Catholique Louvain, Ludwig Inst Canc Res, Ave Hippocrate 74, B-1200 Brussels, Belgium.	Jean-Christophe.Renauld@bru.licr.org	Demoulin, Jean-Baptiste/E-5847-2010; Renauld, Jean-Christophe/B-7268-2012	Renauld, Jean-Christophe/0000-0003-1736-2131; Demoulin, Jean-Baptiste/0000-0002-8016-6689; Dumoutier, Laure/0000-0002-6645-684X				Crowley MT, 1996, J BIOL CHEM, V271, P1145, DOI 10.1074/jbc.271.2.1145; Demoulin JB, 2000, FEBS LETT, V482, P200, DOI 10.1016/S0014-5793(00)02059-7; Demoulin JB, 1999, J BIOL CHEM, V274, P25855, DOI 10.1074/jbc.274.36.25855; Demoulin JB, 1998, CYTOKINES CELL MOL T, V4, P243; Demoulin JB, 2000, CANCER RES, V60, P3971; Demoulin JB, 1996, MOL CELL BIOL, V16, P4710; Demoulin JB, 2001, CELL GROWTH DIFFER, V12, P169; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Gadina M, 2000, J BIOL CHEM, V275, P26959; Gingras S, 2000, MOL ENDOCRINOL, V14, P229, DOI 10.1210/me.14.2.229; Gomez J, 1996, J IMMUNOL, V157, P2272; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; Lemoli RM, 1996, BLOOD, V87, P3852, DOI 10.1182/blood.V87.9.3852.bloodjournal8793852; Louahed J, 2001, BLOOD, V97, P1035, DOI 10.1182/blood.V97.4.1035; Louahed J, 1999, BLOOD, V94, P1701, DOI 10.1182/blood.V94.5.1701.417k29_1701_1710; Miyata Y, 1999, BIOCHEM BIOPH RES CO, V266, P291, DOI 10.1006/bbrc.1999.1705; MIYAZAWA K, 1992, BLOOD, V80, P1685; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; Nicolaides NC, 1997, P NATL ACAD SCI USA, V94, P13175, DOI 10.1073/pnas.94.24.13175; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; PRUETT W, 1995, MOL CELL BIOL, V15, P1778; RENAULD JC, 1994, ONCOGENE, V9, P1327; RENAULD JC, 1995, J LEUKOCYTE BIOL, V57, P353, DOI 10.1002/jlb.57.3.353; Renauld Jean-Christophe, 1998, P313; Richard M, 2000, P NATL ACAD SCI USA, V97, P767, DOI 10.1073/pnas.97.2.767; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rohrschneider LR, 2000, GENE DEV, V14, P505; Rolling C, 1996, FEBS LETT, V393, P53, DOI 10.1016/0014-5793(96)00835-6; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; Vink A, 1999, J EXP MED, V189, P1413, DOI 10.1084/jem.189.9.1413; WELHAM MJ, 1994, J BIOL CHEM, V269, P5865; WELHAM MJ, 1995, J BIOL CHEM, V270, P12286, DOI 10.1074/jbc.270.20.12286; Xiao H, 2002, J BIOL CHEM, V277, P8091, DOI 10.1074/jbc.M106650200; YIN TG, 1995, J BIOL CHEM, V270, P20497, DOI 10.1074/jbc.270.35.20497; Zamorano J, 1998, J IMMUNOL, V161, P859; Zhu YX, 1997, J BIOL CHEM, V272, P21334, DOI 10.1074/jbc.272.34.21334	43	28	28	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2003	22	12					1763	1770		10.1038/sj.onc.1206253	http://dx.doi.org/10.1038/sj.onc.1206253			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660812	Bronze			2022-12-28	WOS:000181678200003
J	Zhang, B; Potyagaylo, V; Fenton, RG				Zhang, B; Potyagaylo, V; Fenton, RG			IL-6-independent expression of Mcl-1 in human multiple myeloma	ONCOGENE			English	Article						Mcl-1; apoptosis; multiple myeloma; gene expression; IL-6	CHRONIC LYMPHOCYTIC-LEUKEMIA; ACTIVATED PROTEIN-KINASES; IN-VIVO; PLASMA-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; DRUG-RESISTANCE; BCL2 FAMILY; APOPTOSIS; SURVIVAL; GENE	Mcl-1 is a critical antiapoptotic survival factor for human multiple myeloma (MM). We examined the importance of IL-6 for Mcl-1 expression in five MM cell lines and in primary MM cells from 14 patients. While culture of MM.1S cells in IL-6 did induce Mcl-1 expression, four other MM cell lines exhibited high levels of Mcl-1 expression that were unaffected by IL-6. Similarly, Mcl-1 expression in 10 of 14 primary MM isolates was found to be IL-6-independent. An analysis of the mechanisms responsible for IL-6-independent Mcl-1 expression was undertaken. ERK1/2 activity did not influence Mcl-1 expression, distinct from Mcl-1 regulation that occurs during myeloid differentiation from hematopoietic progenitor cells. Inhibition of the PI3K pathway led to growth inhibition of 8226 and ANBL-6 cells without reduction of Mcl-1 levels, and high level Mcl-1 expression was maintained in the absence of activated STAT3. Analysis of the transcriptional activity of 5-regulatory sequences from the human Mcl-1 gene in MM cells demonstrated high levels of IL-6-independent indicator gene activation as predicted. These data demonstrate that the mechanisms regulating Mcl-1 levels in MM cells are heterogeneous, and are often independent from IL-6 signaling pathways.	Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Fenton, RG (corresponding author), Univ Maryland, Greenebaum Canc Ctr, Bressler Res Bldg,Rm 7-023,655 W Baltimore St, Baltimore, MD 21201 USA.	rfent001@umaryland.edu						Akgul C, 2000, FEBS LETT, V478, P72, DOI 10.1016/S0014-5793(00)01809-3; Akgul C, 2000, CELL MOL LIFE SCI, V57, P684, DOI 10.1007/PL00000728; Alcalay M, 2001, ONCOGENE, V20, P5680, DOI 10.1038/sj.onc.1204642; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bergsagel PL, 2001, ONCOGENE, V20, P5611, DOI 10.1038/sj.onc.1204641; Bergsagel PL, 1996, P NATL ACAD SCI USA, V93, P13931, DOI 10.1073/pnas.93.24.13931; Bright JJ, 1999, J IMMUNOL, V162, P6255; Calame KL, 2001, NAT IMMUNOL, V2, P1103, DOI 10.1038/ni1201-1103; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chao JR, 1998, MOL CELL BIOL, V18, P4883, DOI 10.1128/MCB.18.8.4883; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Craig RW, 2002, LEUKEMIA, V16, P444, DOI 10.1038/sj.leu.2402416; Derenne S, 2002, BLOOD, V100, P194, DOI 10.1182/blood.V100.1.194; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Epling-Burnette PK, 2001, J IMMUNOL, V166, P7486, DOI 10.4049/jimmunol.166.12.7486; Fonseca R, 1999, HEMATOL ONCOL CLIN N, V13, P1169, DOI 10.1016/S0889-8588(05)70119-2; Gauthier ER, 1996, CANCER RES, V56, P1451; Ge NL, 2000, ONCOGENE, V19, P4091, DOI 10.1038/sj.onc.1203801; Gojo I, 2002, CLIN CANCER RES, V8, P3527; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hallek M, 1998, BLOOD, V91, P3, DOI 10.1182/blood.V91.1.3.3_3_21; Halloran PJ, 1998, CANCER RES, V58, P3855; HANADA M, 1993, BLOOD, V82, P1820; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Huang HM, 2000, BLOOD, V96, P1764, DOI 10.1182/blood.V96.5.1764.h8001764_1764_1771; Hyun T, 2000, BLOOD, V96, P3560, DOI 10.1182/blood.V96.10.3560.h8003560_3560_3568; Jelinek DF, 1997, J IMMUNOL, V159, P487; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Jourdan M, 2000, CELL DEATH DIFFER, V7, P1244, DOI 10.1038/sj.cdd.4400758; Kaufmann SH, 1998, BLOOD, V91, P991, DOI 10.1182/blood.V91.3.991.991_991_1000; Kitada S, 1998, BLOOD, V91, P3379, DOI 10.1182/blood.V91.9.3379; Kitada S, 2000, BLOOD, V96, P393; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Liu HT, 2001, J EXP MED, V194, P113, DOI 10.1084/jem.194.2.113; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; McConkey DJ, 1996, J IMMUNOL, V156, P2624; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; Metcalf D, 1998, STEM CELLS, V16, P314, DOI 10.1002/stem.160314; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Miguel-Garcia A, 1998, HAEMATOLOGICA, V83, P298; Moulding DA, 2000, BLOOD, V96, P1756, DOI 10.1182/blood.V96.5.1756.h8001756_1756_1763; ONG F, 1995, LEUKEMIA, V9, P1282; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Pepper C, 1996, BRIT J HAEMATOL, V95, P513, DOI 10.1046/j.1365-2141.1996.d01-1927.x; Puthier D, 1999, LEUKEMIA, V13, P289, DOI 10.1038/sj.leu.2401302; Puthier D, 1999, BRIT J HAEMATOL, V107, P392, DOI 10.1046/j.1365-2141.1999.01705.x; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAGHOEBIER S, 1991, BLOOD, V77, P1560; Rajkumar SV, 1999, HEMATOL ONCOL CLIN N, V13, P1295, DOI 10.1016/S0889-8588(05)70128-3; REED JC, 1995, HEMATOL ONCOL CLIN N, V9, P451, DOI 10.1016/S0889-8588(18)30104-7; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; ROWLEY JD, 1988, J CLIN ONCOL, V6, P919, DOI 10.1200/JCO.1988.6.5.919; Schimmer AD, 2001, BLOOD, V98, P3541, DOI 10.1182/blood.V98.13.3541; Schubert KM, 2001, BIOCHEM J, V356, P473, DOI 10.1042/0264-6021:3560473; Slifka MK, 1998, IMMUNITY, V8, P363, DOI 10.1016/S1074-7613(00)80541-5; Sordet O, 1999, CELL DEATH DIFFER, V6, P351, DOI 10.1038/sj.cdd.4400499; Thomas A, 1996, ONCOGENE, V12, P1055; Townsend KJ, 1999, J BIOL CHEM, V274, P1801, DOI 10.1074/jbc.274.3.1801; Tricot G, 1997, J CLIN ONCOL, V15, P2659, DOI 10.1200/JCO.1997.15.7.2659; Tu YP, 1998, CANCER RES, V58, P256; Zhan FH, 2002, BLOOD, V99, P1745, DOI 10.1182/blood.V99.5.1745; Zhang B, 2002, J CELL PHYSIOL, V193, P42, DOI 10.1002/jcp.10148; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885; Zhou P, 2001, BLOOD, V97, P3902, DOI 10.1182/blood.V97.12.3902	68	36	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2003	22	12					1848	1859		10.1038/sj.onc.1206358	http://dx.doi.org/10.1038/sj.onc.1206358			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660820				2022-12-28	WOS:000181678200011
J	Wessendorf, S; Schwaenen, C; Kohlhammer, H; Kienle, D; Wrobel, G; Barth, TFE; Nessling, M; Moller, P; Dohner, H; Lichter, P; Bentz, M				Wessendorf, S; Schwaenen, C; Kohlhammer, H; Kienle, D; Wrobel, G; Barth, TFE; Nessling, M; Moller, P; Dohner, H; Lichter, P; Bentz, M			Hidden gene amplifications in aggressive B-cell non-Hodgkin lymphomas detected by microarray-based comparative genomic hybridization	ONCOGENE			English	Article						CGH; microarray; gene amplification; lymphoma	DNA COPY-NUMBER; ABERRATIONS; IMBALANCES; DELETIONS; NEOPLASMS; SURVIVAL; STAGE; GAINS	DNA amplifications are important mechanisms for protooncogene activation. Comparative genomic hybridization (CGH) to metaphase chromosome preparations has revealed amplifications in 10-20% of B-cell lymphomas (B-NHL). We analysed a series of 16 aggressive non-Hodgkin lymphomas by the new approach termed Matrix-CGH (M-CGH) using genomic DNA microarrays as hybridization target. For M-CGH, a dedicated B-cell lymphoma chip was constructed containing 496 genomic targets covering oncogenes, tumor suppressor genes as well as chromosome regions frequently altered in B-NHL. In 10 of 16 samples a total of 15 DNA amplifications were identified. The amplicons included BCL2, REL, CCND1, CCND2, JAK2, FGF4 and MDM2. Four of the 15 amplifications remained undetected by chromosomal CGH. The respective amplicons mapped to bands 2p13, 9p13-p21 and 12q24 and, were confirmed by fluorescence in situ hybridization. Furthermore, for four genomically amplified genes real-time quantitative reverse transcription polymerase chain reaction revealed elevated mRNA expression levels. These data show the superior diagnostic sensitivity of the newly developed diagnostic tool. As only a small portion of the genome (approximately 1.5%) has been analysed by the present DNA array, it is likely that gene amplifications are much more common in aggressive lymphomas than previously assumed.	Univ Ulm, Med Klin, Abt Innere Med 3, D-89081 Ulm, Germany; Deutsch Krebsforschungszentrum, Abt Mol Genet, D-69120 Heidelberg, Germany; Univ Ulm, Abt Pathol, D-89081 Ulm, Germany	Ulm University; Helmholtz Association; German Cancer Research Center (DKFZ); Ulm University	Bentz, M (corresponding author), Univ Ulm, Med Klin, Abt Innere Med 3, Robert Koch Str 8, D-89081 Ulm, Germany.		Döhner, Hartmut/C-8933-2016	Döhner, Hartmut/0000-0003-2116-5536				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Barth TFE, 2001, GENE CHROMOSOME CANC, V31, P316, DOI 10.1002/gcc.1150; Bentz M, 1998, GENE CHROMOSOME CANC, V21, P172, DOI 10.1002/(SICI)1098-2264(199802)21:2<172::AID-GCC14>3.0.CO;2-T; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; DUMANOIR S, 1993, HUM GENET, V90, P590, DOI 10.1007/BF00202476; GRIBBEN JG, 1991, BLOOD, V78, P3275; Houldsworth J, 1996, BLOOD, V87, P25; Jaffe ES, 2001, WORLD HLTH ORG CLASS; Joos S, 1996, BLOOD, V87, P1571, DOI 10.1182/blood.V87.4.1571.bloodjournal8741571; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Kirchhoff M, 1999, GENE CHROMOSOME CANC, V25, P410, DOI 10.1002/(SICI)1098-2264(199908)25:4<410::AID-GCC17>3.0.CO;2-J; Klein CA, 1999, P NATL ACAD SCI USA, V96, P4494, DOI 10.1073/pnas.96.8.4494; Knuutila S, 1998, AM J PATHOL, V152, P1107; Korz C, 2002, BLOOD, V99, P4554, DOI 10.1182/blood.V99.12.4554; LICHTER P, 1995, METHOD ENZYMOL, V254, P334; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Rao PH, 1998, BLOOD, V92, P234, DOI 10.1182/blood.V92.1.234.413k22_234_240; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; SolinasToldo S, 1997, GENE CHROMOSOME CANC, V20, P399, DOI 10.1002/(SICI)1098-2264(199712)20:4<399::AID-GCC12>3.0.CO;2-I; Werner CA, 1997, AM J PATHOL, V151, P335; Wessendorf S, 2002, LAB INVEST, V82, P47, DOI 10.1038/labinvest.3780394	24	74	76	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2003	22	9					1425	1429		10.1038/sj.onc.1206297	http://dx.doi.org/10.1038/sj.onc.1206297			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618769				2022-12-28	WOS:000181360900018
J	Tuck, AB; Hota, C; Wilson, SM; Chambers, AF				Tuck, AB; Hota, C; Wilson, SM; Chambers, AF			Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways	ONCOGENE			English	Article						osteopontin (OPN); migration; mammary epithelial cells; breast cancer; EGFR; signal transduction	EPIDERMAL GROWTH-FACTOR; BREAST-CANCER; ALPHA(V)BETA(3) INTEGRIN; CARCINOMA-CELLS; EXPRESSION; PHOSPHORYLATION; KINASE; SURVIVAL; BETA-1-INTEGRIN; TUMORIGENICITY	Osteopontin (OPN) is a secreted, integrin-binding glycophosphoprotein that has been implicated in breast cancer. We previously showed that OPN-induced cell migration of mammary epithelial cells (MEC) depends on binding to cell surface integrins and involves activation of the hepatocyte growth factor (HGF) receptor, Met. Here, we show that OPN-induced migration of MEC also requires activation of the epidermal growth factor (EGF) pathway. Synergism was seen between EGF and OPN in inducing cell migration. Furthermore, incubation of cells with exogenous OPN increased ligand (TGFalpha > EGF) and EGF receptor (EGFR) mRNA expression, as well as EGFR kinase activity. Treatment of cells with anti-TGFalpha or anti-EGFR antibody, or with tyrphostin-25 (EGFR inhibitor), significantly impaired the cell migration response to OPN. Other more broad-spectrum tyrosine kinase inhibitors and the growth factor/receptor interaction inhibitor, suramin, also inhibited OPN-induced migration. Using specific signal transduction pathway inhibitors, we have screened for involvement of MEK (MAP kinase kinase), phosphatidylinositol 3-kinase, phospholipase C (PLC), and protein kinase C (PKC). Results implicated all of these pathways in OPN-induced cell migration, the most pronounced effect being seen with PLC and PKC inhibitors. These results suggest that induction of MEC migration by OPN involves a cascade of events including at least two growth factor/receptor pathways and multiple downstream signal transduction pathways. A number of potential targets are thus provided for strategies aimed at blocking the malignancy-promoting effects of OPN.	Univ Western Ontario, London Hlth Sci Ctr, Dept Pathol, London, ON N6A 5A5, Canada; Univ Western Ontario, London Hlth Sci Ctr, Dept Oncol, London, ON N6A 5A5, Canada; London Reg Canc Ctr, London, ON N6A 4L6, Canada	London Health Sciences Centre; Western University (University of Western Ontario); London Health Sciences Centre; Western University (University of Western Ontario); Western University (University of Western Ontario)	Tuck, AB (corresponding author), Univ Western Ontario, London Hlth Sci Ctr, Dept Pathol, Univ Campus,POB 5339,Stn B, London, ON N6A 5A5, Canada.		Chambers, Ann F/L-6285-2015	Chambers, Ann F/0000-0002-9509-5123				Adelsman MA, 1999, MOL BIOL CELL, V10, P2861, DOI 10.1091/mbc.10.9.2861; BAND V, 1990, CANCER RES, V50, P7351; BELLAHCENE A, 1995, AM J PATHOL, V146, P95; BROWN LF, 1994, AM J PATHOL, V145, P610; Comoglio P M, 1993, EXS, V65, P131; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DONATO NJ, 1989, J BIOL CHEM, V264, P20474; Furger Kara A., 2001, Current Molecular Medicine (Hilversum), V1, P621, DOI 10.2174/1566524013363339; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; HIROTA S, 1995, LAB INVEST, V72, P64; Jones PL, 1997, J CELL BIOL, V139, P279, DOI 10.1083/jcb.139.1.279; Kassis J, 1999, CLIN CANCER RES, V5, P2251; Kermorgant S, 2001, CARCINOGENESIS, V22, P1035, DOI 10.1093/carcin/22.7.1035; Lee JW, 2002, BBA-MOL CELL RES, V1542, P23, DOI 10.1016/S0167-4889(01)00161-6; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; MURRAY JC, 1986, NUCLEIC ACIDS RES, V14, P5117, DOI 10.1093/nar/14.12.5117; PRICE JE, 1990, CANCER RES, V50, P717; Price JT, 1999, CANCER RES, V59, P5475; Qiao H, 2000, CELL GROWTH DIFFER, V11, P123; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; SENGER DR, 1988, CANCER RES, V48, P5770; Singhal H, 1997, CLIN CANCER RES, V3, P605; Sodek J, 2000, CRIT REV ORAL BIOL M, V11, P279, DOI 10.1177/10454411000110030101; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Tuck AB, 2000, J CELL BIOCHEM, V78, P465, DOI 10.1002/1097-4644(20000901)78:3<465::AID-JCB11>3.0.CO;2-C; Tuck AB, 1999, ONCOGENE, V18, P4237, DOI 10.1038/sj.onc.1202799; Tuck AB, 1998, INT J CANCER, V79, P502, DOI 10.1002/(SICI)1097-0215(19981023)79:5<502::AID-IJC10>3.0.CO;2-3; Tuck AB, 2001, J MAMMARY GLAND BIOL, V6, P419, DOI 10.1023/A:1014734930781; TUCK AB, 1991, J NATL CANCER I, V83, P485; TUCK AB, 1990, CLIN EXP METASTAS, V8, P417, DOI 10.1007/BF00058153; Wang F, 1998, P NATL ACAD SCI USA, V95, P14821, DOI 10.1073/pnas.95.25.14821; Wang R, 1996, P NATL ACAD SCI USA, V93, P8425, DOI 10.1073/pnas.93.16.8425; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; Wells A, 2000, ADV CANCER RES, V78, P31; XU YH, 1984, NATURE, V309, P806, DOI 10.1038/309806a0; XUAN JW, 1995, J CELL BIOCHEM, V57, P680, DOI 10.1002/jcb.240570413; XUAN JW, 1994, J CELL BIOCHEM, V54, P247, DOI 10.1002/jcb.240540213	40	109	127	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 27	2003	22	8					1198	1205		10.1038/sj.onc.1206209	http://dx.doi.org/10.1038/sj.onc.1206209			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650EK	12606946				2022-12-28	WOS:000181249700008
J	Moorehead, RA; Sanchez, OH; Baldwin, RM; Khokha, R				Moorehead, RA; Sanchez, OH; Baldwin, RM; Khokha, R			Transgenic overexpression of IGF-II induces spontaneous lung tumors: a model for human lung adenocarcinoma	ONCOGENE			English	Article						IGF-II; lung cancer; CREB; transgenic model	GROWTH-FACTOR-I; CANCER CELL-LINES; ELEMENT-BINDING PROTEIN; TRANSCRIPTION FACTOR-I; NF-KAPPA-B; PULMONARY ADENOCARCINOMA; GENE-EXPRESSION; MOUSE; PROLIFERATION; ENDOTOXEMIA	Elevated levels of insulin-like growth factor (IGF)-II are associated with a poor prognosis in human pulmonary adenocarcinoma; however, a causal role for IGF-II in pulmonary adenocarcinoma has not been demonstrated. Here, we show that transgenic overexpression of IGF-II in lung epithelium induces lung tumors in 69% of mice older than 18 months of age. These tumors displayed morphological characteristics of human pulmonary adenocarcinoma such as their epithelial origin, tubulo-acinar architecture and expression of TTF-1, SP-B and proSP-C. Examination of signaling molecules downstream of the IGF-IR showed the activation of either the Erk1/Erk2 or p38 MAPK pathways, but not both, within the lung tumors. Notably, all lung tumors contained high levels of phosphorylated CREB, suggesting that both the Erk1/ Erk2 and p38 MAPK pathways converged on this transcription factor. Moreover, IGF-II induced proliferation and CREB phosphorylation in human lung cancer cell lines, suggesting that IGF-II and CREB also contribute to the growth of human lung tumors. Thus, IGF-II is an important genetic factor in the development of lung tumorigenesis, in which activation of CREB is a ubiquitous event. The MMTV-IGF-II transgenic mice provide a critical model for elucidating the role of IGF-II in this fatal human disease.	Univ Toronto, Dept Med Biophys, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto	Khokha, R (corresponding author), Univ Toronto, Dept Med Biophys, Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	rkhokha@oci.utoronto.ca		, Roger/0000-0001-9539-6295; Khokha, Rama/0000-0002-6028-1524				Abraham E, 2001, J IMMUNOL, V166, P522, DOI 10.4049/jimmunol.166.1.522; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Chailley-Heu B, 2001, J PATHOL, V195, P482, DOI 10.1002/path.960; Clark JC, 2001, AM J PHYSIOL-LUNG C, V280, pL705, DOI 10.1152/ajplung.2001.280.4.L705; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DiLoreto C, 1997, J CLIN PATHOL, V50, P30, DOI 10.1136/jcp.50.1.30; Fata JE, 1999, DEV BIOL, V211, P238, DOI 10.1006/dbio.1999.9313; George CLS, 1999, AM J PHYSIOL-LUNG C, V276, pL776, DOI 10.1152/ajplung.1999.276.5.L776; Grimberg A, 2000, J CELL PHYSIOL, V183, P1, DOI 10.1002/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO;2-J; HARVEY MB, 1995, DEVELOPMENT, V121, P1005; Inderdeo DS, 1996, BIOL REPROD, V55, P498, DOI 10.1095/biolreprod55.3.498; JAQUES G, 1988, EXP CELL RES, V176, P336, DOI 10.1016/0014-4827(88)90335-7; KAISER U, 1993, J CANCER RES CLIN, V119, P665, DOI 10.1007/BF01215985; Kaufmann O, 2000, HISTOPATHOLOGY, V36, P8; Lawlor MA, 2001, J CELL SCI, V114, P2903; Lee CT, 1996, CANCER RES, V56, P3038; London SJ, 2002, JNCI-J NATL CANCER I, V94, P749, DOI 10.1093/jnci/94.10.749; Lukanova A, 2001, INT J CANCER, V92, P888, DOI 10.1002/ijc.1265; Mendelson CR, 2000, ANNU REV PHYSIOL, V62, P875, DOI 10.1146/annurev.physiol.62.1.875; MINUTO F, 1988, CANCER RES, V48, P3716; MINUTO F, 1986, CANCER RES, V46, P985; Moorehead RA, 2001, CELL DEATH DIFFER, V8, P16, DOI 10.1038/sj.cdd.4400762; NAKANISHI Y, 1988, J CLIN INVEST, V82, P354, DOI 10.1172/JCI113594; Nguyen LQ, 2000, MOL ENDOCRINOL, V14, P1448, DOI 10.1210/me.14.9.1448; Ordonez NG, 2000, AM J SURG PATHOL, V24, P1217, DOI 10.1097/00000478-200009000-00004; REHM S, 1994, TUMOURS MOUSE, V2, P325; ROTSCH M, 1992, J CANCER RES CLIN, V118, P502, DOI 10.1007/BF01225264; Rudolph D, 1998, P NATL ACAD SCI USA, V95, P4481, DOI 10.1073/pnas.95.8.4481; Samet JM, 1998, AM J PHYSIOL-LUNG C, V275, pL551, DOI 10.1152/ajplung.1998.275.3.L551; SCHARDT C, 1993, EXP CELL RES, V204, P22, DOI 10.1006/excr.1993.1004; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Schneider MR, 2000, FASEB J, V14, P629, DOI 10.1096/fasebj.14.5.629; Shenkar R, 1999, J IMMUNOL, V163, P954; Shenkar R, 2001, AM J PHYSIOL-LUNG C, V281, pL418, DOI 10.1152/ajplung.2001.281.2.L418; Takanami I, 1996, J SURG ONCOL, V61, P205, DOI 10.1002/(SICI)1096-9098(199603)61:3<205::AID-JSO8>3.0.CO;2-F; Toretsky JA, 1996, J ENDOCRINOL, V149, P367, DOI 10.1677/joe.0.1490367; Wetterau LA, 1999, MOL GENET METAB, V68, P161, DOI 10.1006/mgme.1999.2920; Yan C, 1997, J BIOL CHEM, V272, P17327, DOI 10.1074/jbc.272.28.17327; Yu H, 1999, JNCI-J NATL CANCER I, V91, P151, DOI 10.1093/jnci/91.2.151; Zia F, 1996, J CELL BIOCHEM, P269	40	69	86	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2003	22	6					853	857		10.1038/sj.onc.1206188	http://dx.doi.org/10.1038/sj.onc.1206188			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584565				2022-12-28	WOS:000180864300008
J	Strehl, S; Borkhardt, A; Slany, R; Fuchs, UE; Konig, M; Haas, OA				Strehl, S; Borkhardt, A; Slany, R; Fuchs, UE; Konig, M; Haas, OA			The human LASP1 gene is fused to MLL in an acute myeloid leukemia with t(11;17)(q23;q21)	ONCOGENE			English	Article						MLL gene; LASP1 gene; fusion transcript; t(11 ; 17)(q23 ; q21); retroviral transduction	HEMATOLOGICAL MALIGNANCIES; FUSION PARTNER; HRX-ENL; PROTEIN; LEUKEMOGENESIS; LIM	The MLL gene at chromosome 11q23 is frequently rearranged in acute leukemia. Here we report the identification of a new MLL fusion partner in the case of an infant with AML-M4 and a t(11;17)(q23;q21) translocation. Fluorescence in situ hybridization (FISH) and RT-PCR analyses indicated a rearrangement of the MLL gene, but no fusion with previously identified MLL fusion partners at 17q, such as AF17 or MSF. Rapid amplification of cDNA ends (RACE) revealed an in-frame fusion of MLL to LASP1, a gene that is amplified and overexpressed in breast cancer. Retroviral transduction of myeloid progenitors demonstrated that MLL/LASP1 is the fourth known fusion of MLL with a cytoplasmic protein that has no in vitro transformation capability, thus establishing a potential subgroup among the MLL fusion proteins.	St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria; Univ Giessen, Dept Pediat Hematol & Oncol, D-35392 Giessen, Germany; Univ Erlangen Nurnberg, Dept Genet, D-91058 Erlangen, Germany	Saint Anna Children's Hospital; Justus Liebig University Giessen; University of Erlangen Nuremberg	Haas, OA (corresponding author), St Anna Childrens Hosp, Childrens Canc Res Inst, Kinderspitalgasse 6, A-1090 Vienna, Austria.	oskar.haas@ccri.univie.ac.at	Haas, Oskar/AAM-5794-2020	Strehl, Sabine/0000-0002-0179-0628				Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Borkhardt A, 2001, GENE CHROMOSOME CANC, V32, P82, DOI 10.1002/gcc.1169; Butler LH, 1997, BLOOD, V89, P3361, DOI 10.1182/blood.V89.9.3361; Chew CS, 2000, J CELL SCI, V113, P2035; Chew CS, 1998, AM J PHYSIOL-CELL PH, V275, pC56, DOI 10.1152/ajpcell.1998.275.1.C56; Daheron L, 2001, GENE CHROMOSOME CANC, V31, P382, DOI 10.1002/gcc.1157; DiMartino JF, 1999, BRIT J HAEMATOL, V106, P614, DOI 10.1046/j.1365-2141.1999.01439.x; DiMartino JF, 2002, BLOOD, V99, P3780, DOI 10.1182/blood.V99.10.3780; Ernst P, 2002, CURR OPIN HEMATOL, V9, P282, DOI 10.1097/00062752-200207000-00004; Felix C A, 1999, Oncologist, V4, P225; Fuchs U, 2001, P NATL ACAD SCI USA, V98, P8756, DOI 10.1073/pnas.121433898; GREIL J, 1994, BRIT J HAEMATOL, V86, P275, DOI 10.1111/j.1365-2141.1994.tb04726.x; Huret JL, 2001, LEUKEMIA, V15, P987, DOI 10.1038/sj.leu.2402135; Lavau C, 2000, P NATL ACAD SCI USA, V97, P10984, DOI 10.1073/pnas.190167297; Lavau C, 2000, EMBO J, V19, P4655, DOI 10.1093/emboj/19.17.4655; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Megonigal MD, 2000, P NATL ACAD SCI USA, V97, P2814, DOI 10.1073/pnas.050397097; Osaka M, 1999, P NATL ACAD SCI USA, V96, P6428, DOI 10.1073/pnas.96.11.6428; PRASAD R, 1994, P NATL ACAD SCI USA, V91, P8107, DOI 10.1073/pnas.91.17.8107; Rowley JD, 1999, SEMIN HEMATOL, V36, P59; Schreiber V, 1998, GENE, V207, P171, DOI 10.1016/S0378-1119(97)00622-7; Schreiber VR, 1998, MOL MED, V4, P675, DOI 10.1007/BF03401929; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; Taki T, 1999, CANCER RES, V59, P4261; TOMASETTO C, 1995, FEBS LETT, V373, P245, DOI 10.1016/0014-5793(95)01040-L; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; von Bergh A, 2000, GENE CHROMOSOME CANC, V28, P14, DOI 10.1002/(SICI)1098-2264(200005)28:1<14::AID-GCC2>3.3.CO;2-O	27	44	46	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	2003	22	1					157	160		10.1038/sj.onc.1206042	http://dx.doi.org/10.1038/sj.onc.1206042			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527918				2022-12-28	WOS:000180166900017
J	Devarajan, E; Sahin, AA; Chen, JS; Krishnamurthy, RR; Aggarwal, N; Brun, AM; Sapino, A; Zhang, F; Sharma, D; Yang, XH; Tora, AD; Mehta, K				Devarajan, E; Sahin, AA; Chen, JS; Krishnamurthy, RR; Aggarwal, N; Brun, AM; Sapino, A; Zhang, F; Sharma, D; Yang, XH; Tora, AD; Mehta, K			Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance	ONCOGENE			English	Article						apoptosis; cyteine-proteases; drug-resistance; caspases; breast cancer	FAS-MEDIATED APOPTOSIS; TUMOR-SUPPRESSOR GENE; DRUG-RESISTANCE; CELL-LINES; P53; PROTEASES; DNA; AMPLIFICATION; EXPRESSION; INHIBITION	Caspase-3 is a member of the cysteine protease family, which plays a crucial role in apoptotic pathways by cleaving a variety of key cellular proteins. Caspase-3 can be activated by diverse death-inducing signals, including the chemotherapeutic agents. The purpose of this study was to determine the levels of caspase-3 expression in breast tumor samples and to determine whether alterations in its expression can affect their ability to undergo apoptosis. Primary breast tumor and normal breast parenchyma samples were obtained from patients undergoing breast surgery and the expression of caspases-3 was studied. Similarly, normal mammary epithelial cells and several established mammary cancer cell lines were studied for caspases-3 expression by reverse transcriptase-polymerase chain reaction, Northern blot analysis, and Western blot analysis. Approximately 75% of the tumor as well as morphologically normal peritumoral tissue samples lacked the caspase-3 transcript and caspase-3 protein expression. In addition, the caspases-3 mRNA levels in commercially available total RNA samples from breast, ovarian, and cervical tumors were either undetectable (breast and cervical) or substantially decreased (ovarian). Despite the complete loss of caspase-3, the expression levels of other caspases, such as caspase-8 and caspase-9, were normal in all of the tumor samples studied. The sensitivity of caspase-3-deficient breast cancer (MCF-7) cells to undergo apoptosis in response to doxorubicin and other apoptotic stimuli could be augmented by reconstituting caspase-3 expression. These results suggest that the loss of caspases-3 expression may represent an important cell survival mechanism in breast cancer patients.	Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ N Texas, Hlth Sci Ctr, Dept Pathol, Ft Worth, TX 76107 USA; Univ Turin, Dept Biomed Sci & Human Oncol, I-10124 Turin, Italy; Northwestern Univ, Sch Med, Dept Pathol, Evanston, IL 60201 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of North Texas System; University of North Texas Health Science Center; University of Turin; Northwestern University	Mehta, K (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Yang, Jim/B-3776-2010; Sapino, Anna/J-4113-2018; Sapino, Anna/AGY-9901-2022	Sapino, Anna/0000-0003-3542-9571; Sapino, Anna/0000-0003-3542-9571				Ahmad M, 1998, CANCER RES, V58, P5201; BAGASRA O, 1993, J IMMUNOL METHODS, V158, P131, DOI 10.1016/0022-1759(93)90265-9; Cande C, 2002, BIOCHIMIE, V84, P215, DOI 10.1016/S0300-9084(02)01374-3; Chen XM, 2000, JNCI-J NATL CANCER I, V92, P1999, DOI 10.1093/jnci/92.24.1999; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; Clynes M, 1998, CRIT REV ONCOL HEMAT, V28, P181, DOI 10.1016/S1040-8428(98)00018-3; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Devarajan E, 2002, INT J ONCOL, V20, P913; Eck-Enriquez K, 2000, BREAST CANCER RES TR, V61, P229, DOI 10.1023/A:1006442017658; Eckhart L, 2000, BIOCHEM BIOPH RES CO, V277, P655, DOI 10.1006/bbrc.2000.3698; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Friedrich K, 2001, ONCOGENE, V20, P2749, DOI 10.1038/sj.onc.1204342; Guo YP, 1999, CANCER RES, V59, P1366; Haidar MA, 2000, INT J ONCOL, V16, P561; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harris CC, 1996, CARCINOGENESIS, V17, P1187, DOI 10.1093/carcin/17.6.1187; Hasegawa J, 1996, CANCER RES, V56, P1713; Hickman JA, 1996, EUR J CANCER, V32A, P921, DOI 10.1016/0959-8049(96)00080-9; Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459; Huang YH, 2001, BIOCHEM BIOPH RES CO, V283, P762, DOI 10.1006/bbrc.2001.4871; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Liang Y, 2001, ONCOGENE, V20, P6570, DOI 10.1038/sj.onc.1204815; MARTIN SJ, 1995, CRIT REV ONCOL HEMAT, V18, P137, DOI 10.1016/1040-8428(94)00124-C; Nakopoulou L, 2001, PATHOBIOLOGY, V69, P266, DOI 10.1159/000064337; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Pirnia F, 2000, J NATL CANCER I, V92, P1535, DOI 10.1093/jnci/92.18.1535; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Silke J, 2001, EMBO J, V20, P3114, DOI 10.1093/emboj/20.12.3114; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Ueki T, 2001, INT J CANCER, V91, P673, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1113>3.0.CO;2-U; Wallace-Brodeur RR, 1999, CELL MOL LIFE SCI, V55, P64, DOI 10.1007/s000180050270; Winter RN, 2001, CANCER RES, V61, P1227; Yang XH, 2001, CANCER RES, V61, P348; Yuan YF, 2001, CANCER RES, V61, P5558	40	333	346	2	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 12	2002	21	57					8843	8851		10.1038/sj.onc.1206044	http://dx.doi.org/10.1038/sj.onc.1206044			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483536				2022-12-28	WOS:000179734400017
J	Kim, SH; Gunnery, S; Choe, JK; Mathews, MB				Kim, SH; Gunnery, S; Choe, JK; Mathews, MB			Neoplastic progression in melanoma and colon cancer is associated with increased expression and activity of the interferon-inducible protein kinase, PKR	ONCOGENE			English	Article						PKR; interferon; melanoma; colon; cancer	SQUAMOUS-CELL CARCINOMA; NF-KAPPA-B; MALIGNANT TRANSFORMATION; HEPATOCELLULAR-CARCINOMA; CUTANEOUS MELANOMA; CATALYTIC DOMAIN; TUMOR-SUPPRESSOR; C-MYC; ACTIVATION; P68	The interferon-inducible, double-stranded RNA (dsRNA)-activated protein kinase, PKR, plays key roles in regulation of cell growth and differentiation, and has been postulated as a tumor suppressor. Downstream effectors of PKR include the translation initiation factor, eIF2alpha, and the transcription factor, NF-kappaB. We found elevated levels of PKR protein, dsRNA-dependent PKR autophosphorylation activity, and phosphorylated eIF2a in melanoma cells compared to nontransformed melanocytes in culture. Treatment with interferon-alpha2b further induced PKR expression and activity. Immunohistochemical analysis of primary melanomas demonstrated minimal PKR immunoreactivity, but melanoma lymph node metastases expressed a high level of PKR protein. Furthermore, analysis of colon cancer specimens revealed that transformation from normal mucosa to adenomas and carcinomas was coincident with an increase in PKR expression. These data do not support the concept of PKR as a classic tumor suppressor but instead suggest that PKR upregulation occurs at defined steps in cancer progression, probably as a cellular response to neoplasia.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Surg, Newark, NJ 07103 USA; VA New Jersey Healthcare Syst, Pathol & Lab Med Serv, E Orange, NJ 07018 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA; VA New Jersey Healthcare Syst, Surg Serv, E Orange, NJ 07018 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; New Jersey Department of Health & Senior Services; Rutgers State University New Brunswick; Rutgers State University Medical Center; New Jersey Department of Health & Senior Services	Kim, SH (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Surg, 185 S Orange Ave, Newark, NJ 07103 USA.				NIAID NIH HHS [AI34552] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034552] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abraham N, 1999, J BIOL CHEM, V274, P5953, DOI 10.1074/jbc.274.9.5953; Barber GN, 2001, CELL DEATH DIFFER, V8, P113, DOI 10.1038/sj.cdd.4400823; BARBER GN, 1995, J BIOL CHEM, V270, P17423, DOI 10.1074/jbc.270.29.17423; Bonnet MC, 2000, MOL CELL BIOL, V20, P4532, DOI 10.1128/MCB.20.13.4532-4542.2000; CAREY TE, 1976, P NATL ACAD SCI USA, V73, P3278, DOI 10.1073/pnas.73.9.3278; Clemens MJ, 1999, INT J BIOCHEM CELL B, V31, P1, DOI 10.1016/S1357-2725(98)00127-7; Delhem N, 2001, ONCOGENE, V20, P5836, DOI 10.1038/sj.onc.1204744; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; Gil J, 2000, ONCOGENE, V19, P1369, DOI 10.1038/sj.onc.1203448; Gil J, 2000, APOPTOSIS, V5, P107, DOI 10.1023/A:1009664109241; Gil J, 2001, ONCOGENE, V20, P385, DOI 10.1038/sj.onc.1204109; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; HAINES GK, 1993, VIRCHOWS ARCH B, V63, P289, DOI 10.1007/BF02899275; HAINES GK, 1992, VIRCHOWS ARCH B, V62, P151, DOI 10.1007/BF02899677; Haines GK, 1996, TUMOR BIOL, V17, P5, DOI 10.1159/000217961; Haines GK, 1998, TUMOR BIOL, V19, P52, DOI 10.1159/000029974; HAINES GK, 1993, ARCH OTOLARYNGOL, V119, P1142; Ishii T, 2001, ONCOGENE, V20, P1900, DOI 10.1038/sj.onc.1204267; Jagus R, 1999, INT J BIOCHEM CELL B, V31, P123, DOI 10.1016/S1357-2725(98)00136-8; JARAMILLO ML, 1995, CANCER INVEST, V13, P327, DOI 10.3109/07357909509094468; Kim SH, 2000, ONCOGENE, V19, P3086, DOI 10.1038/sj.onc.1203632; KIM SH, 1998, CUTANEOUS ONCOLOGY, P303; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kirkwood JM, 1996, J CLIN ONCOL, V14, P7, DOI 10.1200/JCO.1996.14.1.7; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mathews Michael B., 2001, Trends in Biochemical Sciences, V26, P585, DOI 10.1016/S0968-0004(01)01971-5; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; OFFERMANN MK, 1995, EUR J BIOCHEM, V232, P28, DOI 10.1111/j.1432-1033.1995.tb20777.x; OLDFIELD S, 1994, EUR J BIOCHEM, V221, P399, DOI 10.1111/j.1432-1033.1994.tb18752.x; Pataer A, 2002, CANCER RES, V62, P2239; Pehamberger H, 1998, J CLIN ONCOL, V16, P1425, DOI 10.1200/JCO.1998.16.4.1425; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; Raveh T, 1996, J BIOL CHEM, V271, P25479, DOI 10.1074/jbc.271.41.25479; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Savinova O, 1999, INT J BIOCHEM CELL B, V31, P175, DOI 10.1016/S1357-2725(98)00140-X; Shang YF, 1998, J BIOL CHEM, V273, P30608, DOI 10.1074/jbc.273.46.30608; Shimada A, 1998, CANCER RES, V58, P4434; Sieber OM, 2000, MOL MED TODAY, V6, P462; SINGH C, 1995, TUMOR BIOL, V16, P281, DOI 10.1159/000217945; Sudhakar A, 2000, BIOCHEMISTRY-US, V39, P12929, DOI 10.1021/bi0008682; Terada T, 2000, HUM PATHOL, V31, P817, DOI 10.1053/hupa.2000.8443; Terada W, 2000, LIVER, V20, P450, DOI 10.1034/j.1600-0676.2000.020006450.x; WILLIAMS BR, 2001, SCI STKE RE, V2; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Zamanian-Daryoush M, 2000, MOL CELL BIOL, V20, P1278, DOI 10.1128/MCB.20.4.1278-1290.2000; Zamanian-Daryoush M, 1999, ONCOGENE, V18, P315, DOI 10.1038/sj.onc.1202293; Zhou U, 1998, EUR J CANCER, V34, P2046, DOI 10.1016/S0959-8049(98)00292-5	50	76	80	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 12	2002	21	57					8741	8748		10.1038/sj.onc.1205987	http://dx.doi.org/10.1038/sj.onc.1205987			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483527				2022-12-28	WOS:000179734400008
J	Chadee, DN; Peltier, CP; Davie, JR				Chadee, DN; Peltier, CP; Davie, JR			Histone H1(S)-3 phosphorylation in Ha-ras oncogene-transformed mouse fibroblasts	ONCOGENE			English	Article						histone Hl; ras oncogene; Cdk2	NIH 3T3 CELLS; G1 PHASE; SER-10 PHOSPHORYLATION; MAMMALIAN-CELLS; GENE-EXPRESSION; H1; KINASE; PROGRESSION; CHROMATIN; CYCLE	Phosphorylation of linker histone H1(S)-3 (previously named H1b) and core histone H3 is elevated in mouse fibroblasts transformed with oncogenes or constitutively active mitogen-activated protein kinase (MAPK) kinase (MEK). H1(S)-3 phosphorylation is the only histone modification known to be dependent upon transcription and replication. Our results show that the increased amounts of phosphorylated H1(S)-3 in the oncogene Ha-ras-transformed mouse fibroblasts was a consequence of an elevated Cdk2 activity rather than the reduced activity of a H1 phosphatase, which our studies suggest is PP1. Induction of oncogenic ras expression results in an increase in H1(S)-3 and H3 phosphorylation. However, in contrast to the phosphorylation of H3, which occurred immediately following the onset of Ras expression, there was a lag of several hours before H1(S)-3 phosphorylation levels increased. We found that there was a transient increase in the levels of P21(cip1), which inhibited the HI kinase activity of Cdk2. Cdk2 activity and H1(S)-3 phosphorylated levels increased after p21(cip1) levels declined. Our studies suggest that persistent activation of the Ras-MAPK signal transduction pathway in oncogene-transformed cells results in deregulated activity of kinases phosphorylating H3 and H1(S)-3 associated with transcribed genes. The chromatin remodelling actions of these modified histones may result in aberrant gene expression.	Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada		Davie, JR (corresponding author), Manitoba Inst Cell Biol, 675 McDeermot Ave, Winnipeg, MB R3E 0V9, Canada.	Davie@cc.umanitoba.ca		Davie, James/0000-0002-0420-6888				Bottazzi ME, 1999, J CELL BIOL, V146, P1255, DOI 10.1083/jcb.146.6.1255; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Chadee DN, 1997, J BIOL CHEM, V272, P8113, DOI 10.1074/jbc.272.13.8113; CHADEE DN, 1995, J BIOL CHEM, V270, P20098, DOI 10.1074/jbc.270.34.20098; CRISSMAN HA, 1991, P NATL ACAD SCI USA, V88, P7580, DOI 10.1073/pnas.88.17.7580; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; GADBOIS DM, 1992, BIOCHEM BIOPH RES CO, V184, P80, DOI 10.1016/0006-291X(92)91160-R; GADBOIS DM, 1992, P NATL ACAD SCI USA, V89, P8626, DOI 10.1073/pnas.89.18.8626; HALIOTIS T, 1990, INT J CANCER, V45, P1177, DOI 10.1002/ijc.2910450631; Herrera RE, 1996, P NATL ACAD SCI USA, V93, P11510, DOI 10.1073/pnas.93.21.11510; Kivinen L, 1999, ONCOGENE, V18, P6252, DOI 10.1038/sj.onc.1203000; KRAEMER PM, 1993, EXP CELL RES, V207, P206, DOI 10.1006/excr.1993.1183; LAITINEN J, 1990, J CELL BIOL, V111, P9, DOI 10.1083/jcb.111.1.9; LAITINEN J, 1995, J CELL BIOCHEM, V57, P1, DOI 10.1002/jcb.240570102; Lee HL, 1998, EMBO J, V17, P1454, DOI 10.1093/emboj/17.5.1454; LENNOX RW, 1982, J BIOL CHEM, V257, P5183; LU MJ, 1994, CHROMOSOMA, V103, P111; Maharizi M, 1999, J OPTOELECTRON ADV M, V1, P65; MELLO MLS, 1994, ANAL QUANT CYTOL, V16, P113; Parseghian MH, 2000, CHROMOSOME RES, V8, P405, DOI 10.1023/A:1009262819961; Parseghian MH, 2001, BIOCHEM CELL BIOL, V79, P289; Paulson JR, 1996, J CELL SCI, V109, P1437; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; Strelkov IS, 2002, CANCER RES, V62, P75; TAN KB, 1982, J BIOL CHEM, V257, P5337; Taylor WR, 1995, FEBS LETT, V377, P51, DOI 10.1016/0014-5793(95)01314-8; TUCK AB, 1991, J NATL CANCER I, V83, P485; WRIGHT JA, 1990, ANTICANCER RES, V10, P1247	29	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 5	2002	21	55					8397	8403		10.1038/sj.onc.1206029	http://dx.doi.org/10.1038/sj.onc.1206029			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466960				2022-12-28	WOS:000179480100003
J	Payton, M; Scully, S; Chung, G; Coats, S				Payton, M; Scully, S; Chung, G; Coats, S			Deregulation of Cyclin E2 expression and associated kinase activity in primary breast tumors	ONCOGENE			English	Article						Cyclin E2; Cyclin E1; Cdk2; breast tumor	CANCER; SURVIVAL; CDK2	The increased expression of G, cyclins has been associated with the many types of human tumors. In primary solid tumors however, the expression and activity of cyclin E2, the newest member of the G, cyclin family, is largely unknown. In this study we have analysed the expression of the E-type cyclins in primary solid tumors from breast, lung, uterus, ovary, colon, and rectal tissues. Relative gene expression was analysed by quantitative real-time reverse transcription polymerase chain reaction (Taqman). The levels of cyclin El and cyclin E2 were significantly elevated (23 vs 38%, respectively) in primary breast tumor samples relative to normal breast tissue controls. We also observed an inverse correlation between the expression of cyclin E1/E2 and estrogen receptor in breast tumors. Our results demonstrate that the expression and associated catalytic activity for both cyclin El and cyclin E2 is elevated in primary breast tumors when compared to normal breast tissue. The increased level of cyclin E2 in breast tumors suggests that, similar to cyclin El, it may contribute to the pathogenesis of breast cancer.	Amgen Inc, Dept Canc Biol, Thousand Oaks, CA 91320 USA; Amgen Inc, Dept Pathol, Thousand Oaks, CA 91320 USA	Amgen; Amgen	Coats, S (corresponding author), Amgen Inc, Dept Canc Biol, 1 Amgen Ctr Dr,Mailstop 5-2A, Thousand Oaks, CA 91320 USA.							BORTNER DM, 1997, MOL CELL BIOL, V17, P435; DUTTA A, 1995, P NATL ACAD SCI USA, V92, P5386, DOI 10.1073/pnas.92.12.5386; Geng Y, 2001, P NATL ACAD SCI USA, V98, P13138, DOI 10.1073/pnas.231487798; GrayBablin J, 1996, P NATL ACAD SCI USA, V93, P15215, DOI 10.1073/pnas.93.26.15215; Gudas JM, 1999, MOL CELL BIOL, V19, P612; KEYOMARSI K, 1994, CANCER RES, V54, P380; Loden M, 1999, ONCOGENE, V18, P2557, DOI 10.1038/sj.onc.1202488; Miracco C, 2000, INT J CANCER, V88, P411, DOI 10.1002/1097-0215(20001101)88:3<411::AID-IJC13>3.3.CO;2-G; Muller-Tidow C, 2001, CANCER RES, V61, P647; Nielsen NH, 1996, BRIT J CANCER, V74, P874, DOI 10.1038/bjc.1996.451; Payton M, 2002, INT J BIOCHEM CELL B, V34, P315, DOI 10.1016/S1357-2725(01)00137-6; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Shaaban AM, 2002, AM J PATHOL, V160, P597, DOI 10.1016/S0002-9440(10)64879-1; Zariwala M, 1998, ONCOGENE, V17, P2787, DOI 10.1038/sj.onc.1202505	14	47	61	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 5	2002	21	55					8529	8534		10.1038/sj.onc.1206035	http://dx.doi.org/10.1038/sj.onc.1206035			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466974	Bronze			2022-12-28	WOS:000179480100017
J	Makris, C; Voisin, L; Giasson, E; Tudan, C; Kaplan, DR; Meloche, S				Makris, C; Voisin, L; Giasson, E; Tudan, C; Kaplan, DR; Meloche, S			The Rb-family protein p107 inhibits translation by a PDK1-dependent mechanism	ONCOGENE			English	Article						p107; cell growth; translation; PDK1; PI 3-kinase signaling	RNA-POLYMERASE-III; PHOSPHOINOSITIDE 3-KINASE; KINASE B; RETINOBLASTOMA PROTEIN; S6 KINASE; TARGET; PHOSPHORYLATION; GROWTH; SIZE; E2F	The Rb family of proteins, which consists of Rb, p107 and p130, are critical regulators of cell proliferation. In addition to their inhibitory effects on cell cycle progression, Rb-family proteins repress transcription by RNA polymerases I and 111, and may therefore restrain cell growth. However, it is not known if Rb, p107 or p130 have direct effects on protein synthesis. Here we report that ectopic expression of p107 in rat fibroblasts markedly attenuates the stimulation of mRNA translation and global protein synthesis by serum growth factors. This effect is associated with a reduction in the phosphorylation and activation of the serine-threonine kinases Akt1 and p70 S6 kinase (S6K1), two downstream targets of phosphoinositide-dependent kinase 1 (PDK1). We show that overexpression of p107 interferes with the recruitment of PDK1 to the plasma membrane in response to growth factors. Overexpression of PDK1 restores the defect in translation elicited by p107. These results suggest that p107 restricts cell growth by interfering with the phosphoinositide 3-kinase (PI3K) signaling pathway.	Univ Montreal, Inst Rech Clin, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Dept Pharmacol, Montreal, PQ H2W 1R7, Canada; Montreal Neurol Inst, Brain Tumor Res Ctr, Montreal, PQ H3A 3B4, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; McGill University	Meloche, S (corresponding author), Univ Montreal, Inst Rech Clin, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.	melochs@ircm.qc.ca						Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; Coffer PJ, 1998, BIOCHEM J, V335, P1; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Edgar BA, 1999, NAT CELL BIOL, V1, pE191, DOI 10.1038/70217; Filippa N, 2000, MOL CELL BIOL, V20, P5712, DOI 10.1128/MCB.20.15.5712-5721.2000; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GIASSON E, 1995, J BIOL CHEM, V270, P5225, DOI 10.1074/jbc.270.10.5225; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Koh H, 1999, ONCOGENE, V18, P5115, DOI 10.1038/sj.onc.1202895; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; Martin KA, 2001, J BIOL CHEM, V276, P7884, DOI 10.1074/jbc.M006969200; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Oldham S, 2000, GENE DEV, V14, P2689, DOI 10.1101/gad.845700; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; Servant MJ, 2000, J CELL BIOL, V148, P543, DOI 10.1083/jcb.148.3.543; Shioi T, 2000, EMBO J, V19, P2537, DOI 10.1093/emboj/19.11.2537; Sutcliffe JE, 1999, MOL CELL BIOL, V19, P4255; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; Volarevic S, 2001, PROG NUCLEIC ACID RE, V65, P101; Weinkove D, 1999, CURR BIOL, V9, P1019, DOI 10.1016/S0960-9822(99)80450-3; White RJ, 1997, TRENDS BIOCHEM SCI, V22, P77, DOI 10.1016/S0968-0004(96)10067-0; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; Zini N, 2001, J CELL PHYSIOL, V189, P34, DOI 10.1002/jcp.1135	38	9	9	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2002	21	51					7891	7896		10.1038/sj.onc.1205964	http://dx.doi.org/10.1038/sj.onc.1205964			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	610DT	12420226				2022-12-28	WOS:000178946000014
J	Arlt, A; Gehrz, A; Muerkoster, S; Vorndamm, J; Kruse, ML; Folsch, UR; Schafer, H				Arlt, A; Gehrz, A; Muerkoster, S; Vorndamm, J; Kruse, ML; Folsch, UR; Schafer, H			Role of NF-kappa B and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death	ONCOGENE			English	Article						programmed cell death; DNA damage; transcription factor; chemotherapy; protein kinase	CANCER-CELLS; INDUCED APOPTOSIS; DIRECT INHIBITION; MAMMALIAN TARGET; PROTEIN-KINASE; SOLID TUMORS; K-RAS; ACTIVATION; P53; EXPRESSION	Pancreatic cancer is resistant to almost all cytotoxic drugs. Currently, gemcitabine appears to be the only clinically active drug but, because of pre-existing or acquired chemoresistance of most of the tumor cells, it failed to significantly improve the outcome of pancreatic carcinoma patients. The current study examined the relevance of nuclear factor kappaB (NF-kappaB) and PI3K/Akt in the resistance of five pancreatic carcinoma cell lines towards gemcitabine. Treatment for 24 h with gemcitabine (0.04-20 muM) led to a strong induction of apoptosis in PT45-P1 and T3M4 cells but not in BxPc-3, Capan-1 and PancTu-1 cells. These resistant cell lines exhibited a high basal NF-kappaB activity in contrast to the sensitive cell lines. Furthermore, gemcitabine showed a dose-dependent induction of NF-kappaB. At a dose of 0.04 muM, gemcitabine still induced apoptosis in the sensitive cell lines, but did not induce NF-kappaB. In addition, NF-kappaB inhibition by MG132, sulfasalazine or the IkappaBalpha super-repressor strongly diminished the resistance against gemcitabine (0.04-20 muM). In contrast to this obvious correlation between basal NF-kappaB activity and gemcitabine resistance, PI3K/Akt seems not to be involved in gemcitabine resistance of these cell lines. Neither did the basal Akt activity correlate with the sensitivity towards gemcitabine treatment, nor did the inhibition of PI3K/Akt by LY294002 alter gemcitabine-induced apoptosis. These results indicate that constitutive NF-kappaB activity confers resistance against gemcitabine and that modulation of this activity by pharmacological or genetic approaches may have therapeutical potential when combined with gemcitabine in the treatment of pancreatic carcinoma.	Univ Kiel, Dept Med 1, Lab Mol Gastroenterol, D-24105 Kiel, Germany	University of Kiel	Schafer, H (corresponding author), Univ Kiel, Dept Med 1, Lab Mol Gastroenterol, Schittenhelmstr 12, D-24105 Kiel, Germany.		Sebens, Susanne/C-1222-2010; Schäfer, Heiner/C-1055-2011; Arlt, Alexander/G-7308-2019	Arlt, Alexander/0000-0002-6160-1059				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Arlt A, 2002, CANCER RES, V62, P910; Arlt A, 2002, INT J CLIN PHARM TH, V40, P336; Arlt A, 2001, ONCOGENE, V20, P859, DOI 10.1038/sj.onc.1204168; Bian X, 2001, J BIOL CHEM, V276, P48921, DOI 10.1074/jbc.M108674200; BIAN X, 2002, J BIOL CHEM, V26, P26; Brognard J, 2001, CANCER RES, V61, P3986; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Crnogorac-Jurcevic T, 2002, ONCOGENE, V21, P4587, DOI 10.1038/sj.onc.1205570; Dong QG, 2002, ONCOGENE, V21, P6510, DOI 10.1038/sj.onc.1205848; Dumontet C, 1999, BRIT J HAEMATOL, V106, P78, DOI 10.1046/j.1365-2141.1999.01509.x; Galmarini CM, 2002, INT J CANCER, V97, P439, DOI 10.1002/ijc.1628; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Goan YG, 1999, CANCER RES, V59, P4204; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Grisham MB, 1999, METHOD ENZYMOL, V300, P345; Hui YF, 1997, AM J HEALTH-SYST PH, V54, P162, DOI 10.1093/ajhp/54.2.162; KALTHOFF H, 1993, ONCOGENE, V8, P289; Kaltschmidt B, 2000, EUR J BIOCHEM, V267, P3828, DOI 10.1046/j.1432-1327.2000.01421.x; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Moore PS, 2001, VIRCHOWS ARCH, V439, P798, DOI 10.1007/s004280100474; Ng SSW, 2000, CANCER RES, V60, P5451; Ng SSW, 2001, CLIN CANCER RES, V7, P3269; Oya M, 2001, ONCOGENE, V20, P3888, DOI 10.1038/sj.onc.1204525; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Reddy SAG, 2000, J IMMUNOL, V164, P1355, DOI 10.4049/jimmunol.164.3.1355; Rosenberg L, 1997, INT J PANCREATOL, V22, P81; Rosewicz S, 1997, LANCET, V349, P485; Schafer H, 1998, FEBS LETT, V436, P139, DOI 10.1016/S0014-5793(98)01109-0; Sekulic A, 2000, CANCER RES, V60, P3504; Trauzold A, 2001, ONCOGENE, V20, P4258, DOI 10.1038/sj.onc.1204559; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; VANHAPEREN VWTR, 1995, SEMIN ONCOL, V22, P35; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang WX, 1999, ONCOGENE, V18, P4554, DOI 10.1038/sj.onc.1202833; Wang WX, 1999, CLIN CANCER RES, V5, P119; WARSHAW AL, 1990, ARCH SURG-CHICAGO, V125, P230; Weber CK, 2000, GASTROENTEROLOGY, V119, P1209, DOI 10.1053/gast.2000.19458	42	435	452	1	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 22	2003	22	21					3243	3251		10.1038/sj.onc.1206390	http://dx.doi.org/10.1038/sj.onc.1206390			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681MM	12761494				2022-12-28	WOS:000183040000006
J	Sarna, MK; Ingley, E; Busfield, SJ; Cull, VS; Lepere, W; McCarthy, DJ; Wright, MJ; Palmer, GA; Chappell, D; Sayer, MS; Alexander, WS; Hilton, DJ; Starr, R; Watowich, SS; Bittorf, T; Klinken, SP; Tilbrook, PA				Sarna, MK; Ingley, E; Busfield, SJ; Cull, VS; Lepere, W; McCarthy, DJ; Wright, MJ; Palmer, GA; Chappell, D; Sayer, MS; Alexander, WS; Hilton, DJ; Starr, R; Watowich, SS; Bittorf, T; Klinken, SP; Tilbrook, PA			Differential regulation of SOCS genes in normal and transformed erythroid cells	ONCOGENE			English	Article							PHENYLHYDRAZINE-TREATED MICE; PROTEIN-TYROSINE KINASE; ERYTHROPOIETIN RECEPTOR; C-KIT; SIGNAL-TRANSDUCTION; PROGENITOR CELLS; IN-VIVO; ERYTHROLEUKEMIA DEVELOPMENT; TRANSLATIONAL REPRESSION; TRANSCRIPTION FACTOR	The SOCS family of genes are negative regulators of cytokine signalling with SOCS-1 displaying tumor suppressor activity. SOCS-1, CIS and SOCS-3 have been implicated in the regulation of red blood cell production. In this study, a detailed examination was conducted on the expression patterns of these three SOCS family members in normal erythroid progenitors and a panel of erythroleukemic cell lines. Unexpectedly, differences in SOCS gene expression were observed during maturation of normal red cell progenitors, viz changes to CIS were inversely related to the alterations of SOCS-1 and SOCS-3. Similarly, these SOCS genes were differentially expressed in transformed erythoid cells erythroleukemic cells immortalized at an immature stage of differentiation expressed SOCS-1 and SOCS-3 mRNA constitutively, whereas in more mature cell lines SOCS-1 and CIS were induced only after exposure to erythropoietin (Epo). Significantly, when ectopic expression of the tyrosine kinase Lyn was used to promote differentiation of immature cell lines, constitutive expression of SOCS-1 and SOCS-3 was completely suppressed. Modulation of intracellular signalling via mutated Epo receptors in mature erythroleukemic lines also highlighted different responses by the three SOCS family members. Close scrutiny of SOCS-1 revealed that, despite large increases in mRNA levels, the activity of the promoter did not alter after erythropoietin stimulation; in addition, erythroid cells from SOCS-1-/- mice displayed increased sensitivity to Epo. These observations indicate complex, stage-specific regulation of SOCS genes during normal erythroid maturation and in erythroleukemic cells.	Univ Western Australia, Royal Perth Hosp, Western Australian Inst Med Res, Lab Canc Med, Perth, WA 6009, Australia; Univ Western Australia, Med Res Ctr, Perth, WA 6009, Australia; Royal Perth Hosp, Western Australian Inst Med Res, Neurotrauma Lab, Perth, WA 6000, Australia; PO Box Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic, Australia; PO Box Royal Melbourne Hosp, Cooperat Res Ctr Cellular Growth Factors, Melbourne, Vic, Australia; Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; Univ Rostock, Inst Med Biochem, D-2500 Rostock 1, Germany	Royal Perth Hospital; University of Western Australia; University of Western Australia; Royal Perth Hospital; University of Western Australia; Royal Melbourne Hospital; Walter & Eliza Hall Institute; Royal Melbourne Hospital; University of Texas System; UTMD Anderson Cancer Center; University of Rostock	Klinken, SP (corresponding author), Western Australian Inst Med Res, Lab Canc Med, 6th Floor MRF Bldg,Rear,50 Murray St, Perth, WA 6000, Australia.	pklinken@waimr.uwa.edu.au	Fear, Vanessa/A-6876-2013; Fear, Vanessa S/AAF-9805-2020; Hilton, Douglas J/C-7250-2013; Sarna, Mohinder/Q-7834-2016; Sarna, Mohinder/AAO-9343-2020; Ingley, Evan/C-2401-2013; Sarna, Mohinder/GYR-3271-2022; Fear, Vanessa/O-5618-2019	Fear, Vanessa S/0000-0001-8363-6685; Hilton, Douglas J/0000-0002-7698-2392; Sarna, Mohinder/0000-0002-2448-1588; Sarna, Mohinder/0000-0002-2448-1588; Ingley, Evan/0000-0002-8112-9134; Watowich, Stephanie/0000-0003-1969-659X	NATIONAL CANCER INSTITUTE [R01CA022556, R01CA077447, R37CA022556] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA022556, R37 CA022556, R01 CA077447-03, CA-77447, CA-22556, R01 CA077447-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; BIEKER JJ, 1995, MOL CELL BIOL, V15, P852; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Brysha M, 2001, J BIOL CHEM, V276, P22086, DOI 10.1074/jbc.M102737200; BUSFIELD SJ, 1992, BLOOD, V80, P412; Cacalano NA, 2001, NAT CELL BIOL, V3, P460, DOI 10.1038/35074525; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cohney SJ, 1999, MOL CELL BIOL, V19, P4980; Constantinescu SN, 1999, TRENDS ENDOCRIN MET, V10, P18, DOI 10.1016/S1043-2760(98)00101-5; COOPER MC, 1974, P NATL ACAD SCI USA, V71, P1677, DOI 10.1073/pnas.71.5.1677; CORY S, 1991, CELL GROWTH DIFFER, V2, P165; Cull V, 2000, ONCOGENE, V19, P953, DOI 10.1038/sj.onc.1203370; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; De Sepulveda P, 1999, EMBO J, V18, P904; DEJONG MO, 1995, BLOOD, V86, P4076, DOI 10.1182/blood.V86.11.4076.bloodjournal86114076; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Gregorieff A, 2000, J BIOL CHEM, V275, P21596, DOI 10.1074/jbc.M910087199; HAWLEY RG, 1994, GENE THER, V1, P136; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Hodges VM, 1999, BRIT J HAEMATOL, V106, P325, DOI 10.1046/j.1365-2141.1999.01535.x; IACOPETTA BJ, 1982, BIOCHIM BIOPHYS ACTA, V687, P204, DOI 10.1016/0005-2736(82)90547-8; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Klingmuller U, 1997, EUR J BIOCHEM, V249, P637, DOI 10.1111/j.1432-1033.1997.t01-1-00637.x; KLINKEN SP, 1988, P NATL ACAD SCI USA, V85, P8506, DOI 10.1073/pnas.85.22.8506; KLINKEN SP, 1990, LEUKEMIA, V4, P24; KOURY MJ, 1992, EUR J BIOCHEM, V210, P649, DOI 10.1111/j.1432-1033.1992.tb17466.x; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; LANDSCHULZ KT, 1989, BLOOD, V73, P1476; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; MARSHALL CJ, 1988, J CELL SCI, P157; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Metcalf D, 1999, LEUKEMIA, V13, P926, DOI 10.1038/sj.leu.2401440; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MIURA O, 1994, BLOOD, V84, P1501; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; Ohya K, 1997, J BIOL CHEM, V272, P27178, DOI 10.1074/jbc.272.43.27178; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; Pircher TJ, 2001, J BIOL CHEM, V276, P8995, DOI 10.1074/jbc.M007473200; RAYNER JR, 1994, MOL CELL BIOL, V14, P880, DOI 10.1128/MCB.14.2.880; Roberts AW, 2001, P NATL ACAD SCI USA, V98, P9324, DOI 10.1073/pnas.161271798; Rottapel R, 2002, ONCOGENE, V21, P4351, DOI 10.1038/sj.onc.1205537; Saito H, 2000, J IMMUNOL, V164, P5833, DOI 10.4049/jimmunol.164.11.5833; Sasaki A, 2000, J BIOL CHEM, V275, P29338, DOI 10.1074/jbc.M003456200; Schluter G, 2000, BIOCHEM BIOPH RES CO, V268, P255, DOI 10.1006/bbrc.2000.2109; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Tilbrook PA, 1999, GROWTH FACTORS, V17, P25, DOI 10.3109/08977199909001060; Tilbrook PA, 1996, J BIOL CHEM, V271, P3453; Tilbrook PA, 1996, CELL GROWTH DIFFER, V7, P511; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; Tilbrook PA, 2001, ARCH BIOCHEM BIOPHYS, V396, P128, DOI 10.1006/abbi.2001.2577; Tilbrook PA, 2001, CANCER RES, V61, P2453; TROWBRIDGE IS, 1982, J CELL PHYSIOL, V112, P403, DOI 10.1002/jcp.1041120314; UOSHIMA N, 1995, BRIT J HAEMATOL, V91, P30, DOI 10.1111/j.1365-2141.1995.tb05240.x; Vannucchi AM, 2000, BLOOD, V95, P2559; Verdier F, 1998, J BIOL CHEM, V273, P28185, DOI 10.1074/jbc.273.43.28185; Verdier F, 1998, MOL CELL BIOL, V18, P5852, DOI 10.1128/MCB.18.10.5852; Waldmann V, 1996, PATHOL RES PRACT, V192, P883, DOI 10.1016/S0344-0338(96)80067-7; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071	66	25	26	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2003	22	21					3221	3230		10.1038/sj.onc.1206381	http://dx.doi.org/10.1038/sj.onc.1206381			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681MM	12761492	Green Accepted			2022-12-28	WOS:000183040000004
J	Hiwatari, M; Taki, T; Taketani, T; Taniwaki, M; Sugita, K; Okuya, M; Eguchi, M; Ida, K; Hayashi, Y				Hiwatari, M; Taki, T; Taketani, T; Taniwaki, M; Sugita, K; Okuya, M; Eguchi, M; Ida, K; Hayashi, Y			Fusion of an AF4-related gene, LAF4, to MLL in childhood acute lymphoblastic leukemia with t(2;11)(q11;q23)	ONCOGENE			English	Article						LAF4; AF4; AF5Q31; MLL; t(2;11)	ACUTE MYELOID-LEUKEMIA; DROSOPHILA-TRITHORAX; ABNORMALITIES; REARRANGEMENTS; T(4-11); 11Q23; IDENTIFICATION; TRANSLOCATIONS; INVOLVEMENT; FREQUENCY	We showed that the LAF4 gene on 2q11.2-12 was fused to the MLL gene on 11q23 in a pediatric patient with CD10 positive acute lymphoblastic leukemia (ALL) having t(2;11)(q11;q23). The LAF4 gene, which encodes a lymphoid nuclear protein of 1227 amino acids with transactivation potential, is thought to have a role in early lymphoid development. The LAF4 protein was homologous to AF4 and AF5q31 proteins that are fused to MLL in infant early pre-B ALL and the breakpoint of LAF4 was located within the region homologous to the transactivation domain of AF4 and AF5q31. Expression of the 8.5-kb LAF4 transcript was detected in the adult heart, brain, and placenta and in the fetal brain. LAF4 expression was found to be higher in ALL cell lines than in AML and Epstein-Barr virus-transformed B-lymphocyte cell lines. These findings suggest that LAF4, AF4 and AF5q31 might define a new family particularly involved in the pathogenesis of 11q23-associated ALL.	Univ Tokyo, Grad Sch Med, Dept Pediat, Bunkyo Ku, Tokyo 1138655, Japan; Kyoto Prefectural Univ Med, Dept Internal Med 3, Kamigyo Ku, Kyoto 6028655, Japan; Dokkyo Univ, Sch Med, Dept Pediat, Mibu, Tochigi 3210293, Japan	University of Tokyo; Kyoto Prefectural University of Medicine; Dokkyo Medical University	Hayashi, Y (corresponding author), Univ Tokyo, Grad Sch Med, Dept Pediat, Bunkyo Ku, Hongo 7-3-1, Tokyo 1138655, Japan.		HIWATARI, Mitsuteru/HDM-0869-2022	Hiwatari, Mitsuteru/0000-0003-3683-4472				Ferrando AA, 2000, SEMIN HEMATOL, V37, P381, DOI 10.1016/S0037-1963(00)90018-0; Gecz J, 1996, NAT GENET, V13, P105, DOI 10.1038/ng0596-105; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Gu YH, 1996, NAT GENET, V13, P109, DOI 10.1038/ng0596-109; Hayashi Y, 2000, SEMIN HEMATOL, V37, P368, DOI 10.1016/S0037-1963(00)90017-9; Hayashi Y, 2000, CANCER RES, V60, P1139; Heerema NA, 1999, LEUKEMIA, V13, P679, DOI 10.1038/sj.leu.2401413; HUNGER SP, 1993, BLOOD, V81, P3197; Isnard P, 2000, BLOOD, V96, P705; Ma C, 1996, BLOOD, V87, P734, DOI 10.1182/blood.V87.2.734.bloodjournal872734; Niitsu N, 2001, BRIT J HAEMATOL, V112, P315, DOI 10.1046/j.1365-2141.2001.02523.x; Ono R, 2002, CANCER RES, V62, P333; Pui CH, 2002, LANCET, V359, P1909, DOI 10.1016/S0140-6736(02)08782-2; PUI CH, 1995, NEW ENGL J MED, V332, P1618, DOI 10.1056/NEJM199506153322407; Reichel M, 2001, ONCOGENE, V20, P2900, DOI 10.1038/sj.onc.1204401; Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495; RUBNITZ JE, 1994, BLOOD, V84, P570; Shibuya N, 2001, GENE CHROMOSOME CANC, V32, P1, DOI 10.1002/gcc.1160; SUPER HJG, 1993, BLOOD, V82, P3705; Taketani T, 2002, CANCER RES, V62, P33; Taki T, 1999, P NATL ACAD SCI USA, V96, P14535, DOI 10.1073/pnas.96.25.14535; Taki T, 1996, LEUKEMIA, V10, P1303; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9	23	36	36	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2003	22	18					2851	2855		10.1038/sj.onc.1206389	http://dx.doi.org/10.1038/sj.onc.1206389			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ	12743608				2022-12-28	WOS:000182569300016
J	Colombo, R; Draetta, GF; Chiocca, S				Colombo, R; Draetta, GF; Chiocca, S			Modulation of p120(E4F) transcriptional activity by the Gam1 adenoviral early protein	ONCOGENE			English	Article						HDAC1; Gam1; adenoviral protein; P120(E4F) transcriptional activity	MOUSE HISTONE DEACETYLASE-1; FACTOR E4F; GENE; IDENTIFICATION; GROWTH; CELO; ARREST	Gam1, an early adenoviral CELO protein, is required for viral replication. Consistent with its ability to inhibit histone deacetylation by HDAC1, Gam1 activates transcription. In this report, we identify the cellular transcription factor p120(E4F) as a Gam1 interaction partner. p120(E4F) is a low-abundance transcription factor that represses the adenovirus E4 promoter. Here we demonstrate that p120(E4F) interacts with HDAC1 in vivo and in vitro, and that E4F-mediated transcriptional repression is alleviated by the HDAC inhibitor trichostatin A or by overexpressing Gam1. A mutant E4 promoter unresponsive to E4F-mediated transcriptional repression is also not stimulated by Gam1. Moreover, our cofractionation experiments demonstrate that p120(E4F), HDAC1 and Gam1 may be concomitantly present in protein complexes. We conclude that Gam1 activates E4-dependent transcription possibly by inactivating HDAC1.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy	IRCCS European Institute of Oncology (IEO)	Chiocca, S (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Ripamonti 435, I-20141 Milan, Italy.		Chiocca, Susanna/AAC-8863-2019; Chiocca, Susanna/K-5233-2016	Chiocca, Susanna/0000-0002-9721-0850	Telethon [E.0865] Funding Source: Medline	Telethon(Fondazione Telethon)		Ahringer J, 2000, TRENDS GENET, V16, P351, DOI 10.1016/S0168-9525(00)02066-7; Bartl S, 1997, MOL CELL BIOL, V17, P5033, DOI 10.1128/MCB.17.9.5033; Chiocca S, 1997, J VIROL, V71, P3168, DOI 10.1128/JVI.71.4.3168-3177.1997; Chiocca S, 1996, J VIROL, V70, P2939, DOI 10.1128/JVI.70.5.2939-2949.1996; Chiocca S, 2002, CURR BIOL, V12, P594, DOI 10.1016/S0960-9822(02)00720-0; Colombo R, 2002, EMBO REP, V3, P1062, DOI 10.1093/embo-reports/kvf213; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Fajas L, 2001, MOL CELL BIOL, V21, P2956, DOI 10.1128/MCB.21.8.2956-2966.2001; Fajas L, 2000, P NATL ACAD SCI USA, V97, P7738, DOI 10.1073/pnas.130198397; Fernandes ER, 1997, MOL CELL BIOL, V17, P1890, DOI 10.1128/MCB.17.4.1890; Fernandes ER, 1998, MOL CELL BIOL, V18, P459, DOI 10.1128/MCB.18.1.459; FOGNANI C, 1993, EMBO J, V12, P4985, DOI 10.1002/j.1460-2075.1993.tb06192.x; Glotzer JB, 2000, NATURE, V407, P207, DOI 10.1038/35025102; Johnson CA, 1999, SEMIN CELL DEV BIOL, V10, P179, DOI 10.1006/scdb.1999.0299; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Lehrmann H, 1999, J VIROL, V73, P6517, DOI 10.1128/JVI.73.8.6517-6525.1999; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; RAYCHAUDHURI P, 1987, EMBO J, V6, P4073, DOI 10.1002/j.1460-2075.1987.tb02753.x; RAYCHAUDHURI P, 1989, GENE DEV, V3, P620, DOI 10.1101/gad.3.5.620; RIZOS H, 2002, J BIOL CHEM, V21, P21; Rooney RJ, 2001, CELL GROWTH DIFFER, V12, P505; Rooney RJ, 1998, MAMM GENOME, V9, P320, DOI 10.1007/s003359900758; Sandy P, 2000, ONCOGENE, V19, P188, DOI 10.1038/sj.onc.1203250; Taplick J, 2001, J MOL BIOL, V308, P27, DOI 10.1006/jmbi.2001.4569; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	26	10	14	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2003	22	17					2541	2547		10.1038/sj.onc.1206379	http://dx.doi.org/10.1038/sj.onc.1206379			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730668				2022-12-28	WOS:000182569000001
J	Lacour, S; Micheau, O; Hammann, A; Drouineaud, V; Tschopp, J; Solary, E; Dimanche-Boitrel, MT				Lacour, S; Micheau, O; Hammann, A; Drouineaud, V; Tschopp, J; Solary, E; Dimanche-Boitrel, MT			Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells	ONCOGENE			English	Article							TUMOR-NECROSIS-FACTOR; TRAIL-INDUCED APOPTOSIS; FADD-DEPENDENT APOPTOSIS; UP-REGULATION; APO-2 LIGAND; FAS LIGAND; DEATH; RECEPTOR; EXPRESSION; CASPASE-8	Cytokines such as Fas-ligand (Fas-L) and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) can induce human colon cancer cell apoptosis through engagement of their death domain receptors. All the cancer cells are not sensitive to these cytokines. We have shown recently that low doses of cytotoxic drugs could restore TRAIL-induced cell death in resistant colon cancer cell lines. The present work further explores the death pathway triggered by the cytotoxic drug/TRAIL combination in HT-29 colon cancer cells (www.alexiscorp.com). Clinically relevant concentrations of cisplatin, doxorubicin and 5-fluorouracil synergize with TRAIL to trigger HT-29 cell death. Activation of this pathway leads to apoptosis that involves both caspases and the mitochondria. An increased recruitment of Fas-associated death domain (FADD) and procaspase-8 to the TRAIL-induced death-inducing signaling complex (DISC) was shown in cells exposed to anticancer drugs. Following caspase-8 activation at the DISC level, the mitochondria-dependent death pathway is activated, as demonstrated by the cleavage of Bid, the dissipation of DeltaPsi(m), the release of mitochondrial proteins in the cytosol and the inhibitory effect of Bcl-2 expression. Importantly, besides mitochondrial potentiation, we show here that cytotoxic drugs sensitize HT-29 colon cancer cells to TRAIL-induced cell death by enhancing FADD and procaspase-8 recruitment to the DISC, a novel mechanism whose efficacy could depend partly on Bcl-2 expression level.	Fac Med & Pharm Dijon, INSERM, IFR 100, U517, F-21033 Dijon, France; Univ Lausanne, Inst Biochem, BIL Biomed Res Ctr, CH-1066 Epalinges, Switzerland	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; University of Lausanne	Dimanche-Boitrel, MT (corresponding author), Fac Med & Pharm Dijon, INSERM, IFR 100, U517, 7 Blvd Jeanne Arc, F-21033 Dijon, France.	marie-therese.boitrel@rennes.inserm.fr	micheau, olivier/C-3574-2011; Dimanche-Boitrel, Marie-Therese M/I-4642-2015	micheau, olivier/0000-0001-8499-7984; Dimanche-Boitrel, Marie-Therese/0000-0002-8038-7780; Solary, Eric/0000-0002-8629-1341				Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; BISIAU H, 1995, NOUV REV FR HEMATOL, V37, P241; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Buglioni S, 1999, INT J CANCER, V84, P545, DOI 10.1002/(SICI)1097-0215(19991222)84:6<545::AID-IJC1>3.0.CO;2-2; Burns TF, 2001, J BIOL CHEM, V276, P37879; CHAPMAN PB, 1987, J CLIN ONCOL, V5, P1942, DOI 10.1200/JCO.1987.5.12.1942; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Droin N, 1998, ONCOGENE, V16, P2885, DOI 10.1038/sj.onc.1201821; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Golstein P, 1997, CURR BIOL, V7, pR750, DOI 10.1016/S0960-9822(06)90000-1; Gorlick R, 1999, SEMIN ONCOL, V26, P606; Gottlieb RA, 2001, BIOL SIGNAL RECEPT, V10, P147; Hueber AO, 2002, EMBO REP, V3, P190, DOI 10.1093/embo-reports/kvf022; Ikonen E, 2001, CURR OPIN CELL BIOL, V13, P470, DOI 10.1016/S0955-0674(00)00238-6; Keane MM, 1999, CANCER RES, V59, P734; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lacour S, 2001, CANCER RES, V61, P1645; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Micheau O, 1997, J NATL CANCER I, V89, P783, DOI 10.1093/jnci/89.11.783; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Micheau O, 1999, BIOCHEM BIOPH RES CO, V256, P603, DOI 10.1006/bbrc.1999.0391; Mizutani Y, 1999, CLIN CANCER RES, V5, P2605; Munshi A, 2001, ONCOGENE, V20, P3757, DOI 10.1038/sj.onc.1204504; Nagane M, 2001, APOPTOSIS, V6, P191, DOI 10.1023/A:1011336726649; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Rohn TA, 2001, ONCOGENE, V20, P4128, DOI 10.1038/sj.onc.1204534; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Seol DW, 2001, CANCER RES, V61, P1138; Sheikh MS, 1998, CANCER RES, V58, P1593; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Suliman A, 2001, ONCOGENE, V20, P2122, DOI 10.1038/sj.onc.1204282; Sun SY, 2001, BIOCHEM BIOPH RES CO, V280, P788, DOI 10.1006/bbrc.2000.4218; Tanaka M, 1997, J IMMUNOL, V158, P2303; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yamada H, 1999, BIOCHEM BIOPH RES CO, V265, P130, DOI 10.1006/bbrc.1999.1641; Yamanaka T, 2000, HEPATOLOGY, V32, P482, DOI 10.1053/jhep.2000.16266; Zhang XD, 1999, CANCER RES, V59, P2747	46	111	118	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2003	22	12					1807	1816		10.1038/sj.onc.1206127	http://dx.doi.org/10.1038/sj.onc.1206127			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660816				2022-12-28	WOS:000181678200007
J	Wang, B; Wei, DY; Crum, VE; Richardson, EL; Xiong, HH; Luo, Y; Huang, S; Abbruzzese, JL; Xie, KP				Wang, B; Wei, DY; Crum, VE; Richardson, EL; Xiong, HH; Luo, Y; Huang, S; Abbruzzese, JL; Xie, KP			A novel model system for studying the double-edged roles of nitric oxide production in pancreatic cancer growth and metastasis	ONCOGENE			English	Article						nitric oxide; angiogenesis; metastasis; tumor; pancreas	SYNTHASE-II GENE; EXPRESSION; CELLS; ADENOCARCINOMA; ANGIOGENESIS; APOPTOSIS; DISRUPTION; BIOLOGY; ABILITY; MICE	In the present study, a model system for studying the role of nitric oxide (NO) in tumor growth and metastasis was reported. Incubation of Panc02 murine pancreatic adenocarcinoma cells in vitro with cytokines and interferon led to heterogeneous expression of NO synthase 11 (NOS 11) protein. Clonal sublines expressing different levels of NOS 11 were then established using a limited dilution technique. After orthotopical implantation into the pancreas of syngeneic C57BL/6 mice, clones with a low level of NOS 11 expression produced tumors in pancreas, metastasized to the liver, and formed ascites, whereas those having a high level of NOS 11 expression did not. Liver-metastasis variants having low to high metastatic ability were also established using in vivo/in vitro passage. Compared with parental Panc02 cells exhibiting a high level of NOS 11 expression, these variants had a decreased level of NOS 11 expression. Furthermore, the heterogeneous Panc02 cells were injected intravenously into a large number of syngeneic mice. Variants that metastasized to the liver, lung, skin, peritoneum, ovary, and lymph nodes were established. All of the metastatic variants exhibited a lower level of NOS 11 expression than the parental Panc02 cell line did. However, the phenotypes of NOS 11 induction and metastatic ability were unstable. Multiple in vitrolin vivo selection led to stable low NOS 11 expression and high metastatic potential. Finally, to further confirm the role of NOS 11 expression derived from tumor cells in metastasis, poorly metastatic Panc02-H0 and highly metastatic Panc02-H7 cells were injected into the pancreas of syngeneic NOS II-/- mice, and groups of mice received i.p. injections of either phosphate-buffered saline or L-N-6-(I-iminoethyl) lysine. Inhibition of NOS 11 activity in vivo significantly promoted distant liver metastasis. Collectively, these data show that NOS 11 expression is highly heterogeneous and dynamically regulated, which can directly influence tumor growth and metastasis.	Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Xie, KP (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Box 426,1515 Holcombe Blvd, Houston, TX 77030 USA.	kepxie@mail.mdanderson.org			NCI NIH HHS [1R01-CA093829] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093829] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambs S, 1998, NAT MED, V4, P1371, DOI 10.1038/3957; Ambs S, 1997, FASEB J, V11, P443, DOI 10.1096/fasebj.11.6.9194524; Ambs S, 1998, CANCER RES, V58, P334; COBBS CS, 1995, CANCER RES, V55, P727; CORBETT TH, 1984, CANCER RES, V44, P717; DiNapoli MR, 1996, J EXP MED, V183, P1323, DOI 10.1084/jem.183.4.1323; DONG ZY, 1994, CANCER RES, V54, P789; FIDLER IJ, 1987, CURR PROB SURG, V24, P137, DOI 10.1016/0011-3840(87)90002-5; Fukumura D, 1998, CANCER METAST REV, V17, P77, DOI 10.1023/A:1005908805527; Gansauge S, 1998, CELL GROWTH DIFFER, V9, P611; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; Jaffrey SR, 1995, ANNU REV CELL DEV BI, V11, P417; JENKINS DC, 1995, P NATL ACAD SCI USA, V92, P4392, DOI 10.1073/pnas.92.10.4392; JUANG SH, 1998, CANCER BIOTHERAPY, V12, P167; Jurasz P, 2001, CANCER RES, V61, P376; Kong G, 2001, INT J PANCREATOL, V29, P133, DOI 10.1385/IJGC:29:3:133; Lala PK, 2001, LANCET ONCOL, V2, P149, DOI 10.1016/S1470-2045(00)00256-4; Lala PK, 1998, CANCER METAST REV, V17, P91, DOI 10.1023/A:1005960822365; Martinez A, 2001, Med Sci Monit, V7, P646; Moncada S, 1999, J ROY SOC MED, V92, P164, DOI 10.1177/014107689909200402; Moochhala S, 1996, CARCINOGENESIS, V17, P1171, DOI 10.1093/carcin/17.5.1171; MOORE WM, 1994, J MED CHEM, V37, P3886, DOI 10.1021/jm00049a007; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Nussler AK, 1998, LANGENBECK ARCH SURG, V383, P474, DOI 10.1007/s004230050163; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; RADOMSKI MW, 1991, CANCER RES, V51, P6073; Shi Q, 2000, CANCER RES, V60, P2579; Shi Q, 1999, CANCER RES, V59, P2072; THOMSEN LL, 1994, BRIT J CANCER, V72, P41; Wang BL, 2001, INT J PANCREATOL, V29, P37, DOI 10.1385/IJGC:29:1:37; Wang BL, 2001, ONCOGENE, V20, P6930, DOI 10.1038/sj.onc.1204871; Wang BL, 2001, INT J CANCER, V91, P607, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1109>3.0.CO;2-D; Wang BL, 2001, CANCER RES, V61, P71; Wink DA, 1998, CARCINOGENESIS, V19, P711, DOI 10.1093/carcin/19.5.711; XIE K, 2003, IN PRESS FREE RAD BI; XIE K, 1997, CLIN CANCER RES, V3, P2189; Xie KP, 1997, J NATL CANCER I, V89, P421, DOI 10.1093/jnci/89.6.421; XIE KP, 1995, CANCER RES, V55, P3123; Xie KP, 1997, ONCOGENE, V15, P771, DOI 10.1038/sj.onc.1201239; Xie KP, 2001, INT J PANCREATOL, V29, P25, DOI 10.1385/IJGC:29:1:25; XIE KP, 1993, INT J ONCOL, V3, P1043; Xie KP, 1998, CANCER METAST REV, V17, P55, DOI 10.1023/A:1005956721457; XIE KP, 1995, J EXP MED, V181, P1333, DOI 10.1084/jem.181.4.1333	43	38	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2003	22	12					1771	1782		10.1038/sj.onc.1206386	http://dx.doi.org/10.1038/sj.onc.1206386			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660813				2022-12-28	WOS:000181678200004
J	Liu, JW; Shen, JJ; Tanzillo-Swarts, A; Bhatia, B; Maldonado, CM; Person, MD; Lau, SS; Tang, DG				Liu, JW; Shen, JJ; Tanzillo-Swarts, A; Bhatia, B; Maldonado, CM; Person, MD; Lau, SS; Tang, DG			Annexin II expression is reduced or lost in prostate cancer cells and its re-expression inhibits prostate cancer cell migration	ONCOGENE			English	Article						annexins; prostate cancer; cell migration; proteomics; progression	ENHANCED EXPRESSION; CARCINOMA CELLS; DOWN-REGULATION; GENE FAMILY; CALPACTIN-I; IDENTIFICATION; RECEPTOR; PROTEIN; LOCALIZATION; APOPTOSIS	While studying Bim, a BH3-only proapoptotic protein, we identified an similar to36kDa protein, which was abundantly expressed in all five strains of primary normal human prostate (NHP) epithelial cells but significantly reduced or lost in seven prostate cancer cell lines. The similar to36kDa protein was subsequently identified as annexin II by proteomic approach and confirmed by Western blotting using an annexin II-specific antibody. Conventional and 2D SDS-PAGE, together with Western blotting, also revealed reduced or lost expression of annexin I in prostate cancer cells. Subcellular localization studies revealed that in NHP cells, annexin II was distributed both in the cytosol and underneath the plasma membrane, but not on the cell surface. Prostate cancer cells showed reduced levels as well as altered expression patterns of annexin II. Since annexins play important roles in maintaining Ca2+ homeostasis and regulating the cytoskeleton and cell motility, we hypothesized that the reduced or lost expression of annexin I/II might promote certain aggressive phenotypes of prostate cancer cells. In subsequent experiments, we indeed observed that restoration of annexin II expression inhibited the migration of the transfected prostate cancer cells without affecting cell proliferation or apoptosis. Hence, our results suggest that annexin II, and, likely, annexin I, may be endogenous suppressors of prostate cancer cell migration and their reduced or lost expression may contribute to prostate cancer development and progression.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Smithville, TX 78957 USA; Univ Texas, Coll Pharm, Ctr Mol & Cellular Toxicol, Div Pharmacol & Toxicol, Austin, TX 78712 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Austin	Tang, DG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Pk Rd,1C, Smithville, TX 78957 USA.	dtang@sprd1.mdacc.tmc.edu	Tang, Dean/AAI-3457-2020	Tang, Dean/0000-0001-5029-1174; Tanzillo-Swarts, Angela/0000-0001-9277-3761	NCI NIH HHS [CA-90297] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline; NIGMS NIH HHS [GM39338] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039338, R01GM039338] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aarli A, 1997, AM J REPROD IMMUNOL, V38, P313; Ahn SH, 1997, CLIN EXP METASTAS, V15, P151, DOI 10.1023/A:1018452810915; Balch C, 1997, EXP CELL RES, V237, P259, DOI 10.1006/excr.1997.3817; BIANCHI R, 1995, BIOCHEM BIOPH RES CO, V208, P910, DOI 10.1006/bbrc.1995.1421; Chetcuti A, 2001, CANCER RES, V61, P6331; Chiang YP, 1999, MOL CELL BIOCHEM, V199, P139, DOI 10.1023/A:1006942128672; Chiang YP, 1996, BBA-MOL CELL RES, V1313, P295, DOI 10.1016/0167-4889(96)00103-6; CHUNG CY, 1994, J CELL BIOL, V126, P539, DOI 10.1083/jcb.126.2.539; COLE SPC, 1992, BRIT J CANCER, V65, P498, DOI 10.1038/bjc.1992.103; ELKSO E, 1980, CELL, V21, P829; FROHLICH M, 1990, MOL CELL BIOL, V10, P3216, DOI 10.1128/MCB.10.6.3216; GUPTA S, 2002, P AACR, V43, pA5; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; Hajjar KA, 2000, ANN NY ACAD SCI, V902, P265; HUANG KS, 1986, CELL, V46, P191, DOI 10.1016/0092-8674(86)90736-1; IKEBUCHI NW, 1990, J BIOL CHEM, V265, P3392; LEE SW, 1992, P NATL ACAD SCI USA, V89, P2504, DOI 10.1073/pnas.89.6.2504; Liu JW, 2002, CANCER RES, V62, P2976; Ma ASP, 1996, ARCH DERMATOL RES, V288, P596, DOI 10.1007/s004030050109; MA ASP, 1994, J CELL SCI, V107, P1973; Mai JX, 2000, BBA-PROTEIN STRUCT M, V1477, P215, DOI 10.1016/S0167-4838(99)00274-5; Menaa C, 1999, J CLIN INVEST, V103, P1605, DOI 10.1172/JCI6374; Morgan RO, 1997, CELL MOL LIFE SCI, V53, P508, DOI 10.1007/s000180050064; Navone NM, 1997, CLIN CANCER RES, V3, P2493; Paweletz CP, 2000, CANCER RES, V60, P6293; Pencil SD, 1998, CLIN EXP METASTAS, V16, P113, DOI 10.1023/A:1021917017109; Pol A, 1997, BIOCHEM J, V327, P741, DOI 10.1042/bj3270741; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; REEVES SA, 1992, CANCER RES, V52, P6871; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; Solito E, 2001, BRIT J PHARMACOL, V133, P217, DOI 10.1038/sj.bjp.0704054; Srivastava M, 2001, P NATL ACAD SCI USA, V98, P4575, DOI 10.1073/pnas.071055798; TAKAHASHI S, 1994, J BIOL CHEM, V269, P28696; Tang DG, 1998, CANCER RES, V58, P3466; Tang SH, 2002, J BIOL CHEM, V277, P16189, DOI 10.1074/jbc.M111936200; THIEL C, 1992, J CELL SCI, V103, P733; VISHWANATHA JK, 1993, CARCINOGENESIS, V14, P2575, DOI 10.1093/carcin/14.12.2575; Zobiack N, 2001, FEBS LETT, V500, P137, DOI 10.1016/S0014-5793(01)02604-7; ZOKAS L, 1987, J CELL BIOL, V105, P2111, DOI 10.1083/jcb.105.5.2111	39	118	129	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2003	22	10					1475	1485		10.1038/sj.onc.1206196	http://dx.doi.org/10.1038/sj.onc.1206196			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652ZZ	12629510				2022-12-28	WOS:000181411900004
J	Masuda, Y; Nishida, A; Hori, K; Hirabayashi, T; Kajimoto, S; Nakajo, S; Kondo, T; Asaka, M; Nakaya, K				Masuda, Y; Nishida, A; Hori, K; Hirabayashi, T; Kajimoto, S; Nakajo, S; Kondo, T; Asaka, M; Nakaya, K			beta-hydroxyisovalerylshikonin induces apoptosis in human leukemia cells by inhibiting the activity of a polo-like kinase 1 (PLK1)	ONCOGENE			English	Article						beta-hydroxyisovalerylshikonin; apoptosis; DNA fragmentation; PLK1	CHRONIC MYELOGENOUS LEUKEMIA; ABL TYROSINE KINASE; PROTEIN-KINASE; POTENT INDUCER; ANTICANCER DRUGS; DNA-DAMAGE; ACTIVATION; GENE; EXPRESSION; INDUCTION	beta-Hydroxyisovalerylshikonin (beta-HIVS), which was isolated from the plant, Lithospermum radix, induces apoptosis in various lines of human tumor cells. To identify genes involved in beta-HIVS-induced apoptotic process, we performed cDNA array analysis and found that beta-HIVS suppresses the expression of the gene for a polo-like kinase 1 (PLK1) that is involved in control of the cell cycle. When U937 and HL60 cells were treated with 10(-6) m beta-HIVS for 0.5 h, both the amount of PLK1 itself and the kinase activity of this enzyme were decreased. By contrast, Bcr-Abl-positive K562 cells were resistant to the induction of apoptosis by beta-HIVS and this compound did not suppress the kinase activity of PLK1 in these cells. However, simultaneous treatment of K562 cells with both beta-HIVS and STI571, which selectively inhibits the protein tyrosine kinase (PTK) activity of Bcr-Abl, strongly induced apoptosis. Moreover, beta-HIVS increased the inhibitory effect of STI571 on PTK activity. Treatment of K562 cells with antisense oligodeoxynucleotides (ODNs) specific for PLK1 sensitized these cells to the beta-HIVS-induced fragmentation of DNA. These results suggest that suppression of the activity of PLK1 via inhibition of tyrosine kinase activity by beta-HIVS might play a critical role in the induction of apoptosis.	Showa Univ, Sch Pharmaceut Sci, Biol Chem Lab, Shinagawa Ku, Tokyo 1428555, Japan; Hokkaido Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sapporo, Hokkaido 0600815, Japan	Showa University; Hokkaido University	Nakaya, K (corresponding author), Showa Univ, Sch Pharmaceut Sci, Biol Chem Lab, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.	nakaya@pharm.showa-u.ac.jp	堀, 孝一/K-5102-2019; 堀, 孝一/AAU-8506-2021; Kondo, Takeshi/G-2103-2012; Asaka, Masahiro/A-5948-2012	堀, 孝一/0000-0002-0530-181X; 堀, 孝一/0000-0002-0530-181X; Kondo, Takeshi/0000-0001-7455-5824; 				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; BHALLA K, 1993, LEUKEMIA, V7, P563; BRUNK CF, 1979, ANAL BIOCHEM, V92, P497, DOI 10.1016/0003-2697(79)90690-0; CHALIFOUR LE, 1994, ANAL BIOCHEM, V216, P299, DOI 10.1006/abio.1994.1045; Cheng L, 1998, MOL CELL BIOL, V18, P7360, DOI 10.1128/MCB.18.12.7360; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAY FJ, 1993, P NATL ACAD SCI USA, V90, P4882, DOI 10.1073/pnas.90.11.4882; Cogswell JP, 2000, CELL GROWTH DIFFER, V11, P615; Conn CW, 2000, CANCER RES, V60, P6826; Dai W, 2000, GENE CHROMOSOME CANC, V27, P332, DOI 10.1002/(SICI)1098-2264(200003)27:3<332::AID-GCC15>3.0.CO;2-K; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Deininger MWN, 1997, BLOOD, V90, P3691, DOI 10.1182/blood.V90.9.3691; DONOHUE PJ, 1995, J BIOL CHEM, V270, P10351, DOI 10.1074/jbc.270.17.10351; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 1999, BLOOD, V94, p697A; Elez R, 2000, BIOCHEM BIOPH RES CO, V269, P352, DOI 10.1006/bbrc.2000.2291; EVANS DL, 1993, CANCER RES, V53, P2133; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Feng Y, 1999, BIOCHEM J, V339, P435, DOI 10.1042/0264-6021:3390435; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Glover DM, 1996, J CELL BIOL, V135, P1681, DOI 10.1083/jcb.135.6.1681; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; Hamdane M, 1997, ONCOGENE, V15, P2267, DOI 10.1038/sj.onc.1201411; Hashimoto S, 1999, J BIOCHEM-TOKYO, V125, P17, DOI 10.1093/oxfordjournals.jbchem.a022255; Hashimoto S, 2002, JPN J CANCER RES, V93, P944, DOI 10.1111/j.1349-7006.2002.tb01341.x; HURLE JM, 1981, EXP CELL RES, V133, P465, DOI 10.1016/0014-4827(81)90343-8; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; LAURENTCRAWFORD AG, 1991, VIROLOGY, V185, P829, DOI 10.1016/0042-6822(91)90554-O; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; Li B, 1996, J BIOL CHEM, V271, P19402, DOI 10.1074/jbc.271.32.19402; MASUDA Y, 1995, LEUKEMIA RES, V19, P549, DOI 10.1016/0145-2126(95)00031-I; Masuda Y, 1997, INT J CANCER, V71, P691, DOI 10.1002/(SICI)1097-0215(19970516)71:4<691::AID-IJC29>3.0.CO;2-D; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; OHIZUMI H, 1995, J BIOCHEM-TOKYO, V117, P11, DOI 10.1093/oxfordjournals.jbchem.a124695; Perkins C, 1998, CANCER RES, V58, P4561; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Qian YW, 1998, SCIENCE, V282, P1701, DOI 10.1126/science.282.5394.1701; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; SAKAI I, 1993, BIOCHEM BIOPH RES CO, V191, P873, DOI 10.1006/bbrc.1993.1298; SAKAI I, 1994, BIOCHEM BIOPH RES CO, V205, P1305, DOI 10.1006/bbrc.1994.2807; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; SUNKEL CE, 1988, J CELL SCI, V89, P25; Thiesing JT, 2000, BLOOD, V96, P3195, DOI 10.1182/blood.V96.9.3195.h8003195_3195_3199; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; UCKER DS, 1987, NATURE, V327, P62, DOI 10.1038/327062a0; Watabe M, 1996, J BIOL CHEM, V271, P14067, DOI 10.1074/jbc.271.24.14067; Watabe M, 1997, CANCER RES, V57, P3097; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	62	50	74	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2003	22	7					1012	1023		10.1038/sj.onc.1206200	http://dx.doi.org/10.1038/sj.onc.1206200			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	644PB	12592388				2022-12-28	WOS:000180926100007
J	Thompson, PM; Gotoh, T; Kok, M; White, PS; Brodeur, GM				Thompson, PM; Gotoh, T; Kok, M; White, PS; Brodeur, GM			CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system	ONCOGENE			English	Article						chromodomain; chromatin; remodeling; neural development	ACUTE PROMYELOCYTIC LEUKEMIA; HISTONE DEACETYLASE COMPLEX; DNA-BINDING PROTEIN; MOLECULAR ANALYSIS; TRANSCRIPTIONAL REPRESSION; MI-2 AUTOANTIGEN; RETINOIC ACID; NEUROBLASTOMA; SIN3; 1P36	Chromatin remodeling is one of the mechanisms by which gene expression is regulated developmentally. Chromatin structure is controlled at least in part by post-translational modification of histones, as well as by chromodomain proteins. We have identified a novel gene encoding a protein with chromatin remodeling, helicase and DNA-binding motifs. This gene, called CHD5, is the fifth member of the CHD gene family identified in humans. This gene is most homologous to CHD3 and CHD4, which encode proteins that are part of the nucleosome remodeling and histone deacetylation (NuRD) complex. CHD5 is preferentially expressed in total brain, fetal brain, and cerebellum. It is also moderately expressed in the adrenal gland, but expression is undetectable in almost all other tissues examined. CHD5 maps within a small region of deletion on 1p36.3 in human neuroblastomas, a common pediatric tumor. We examined a panel of neuroblastoma cell lines for CHD5 expression, which was consistently low or undetectable in all these lines. Expression was also examined in a panel of 137 primary neuroblastomas, and low expression was highly correlated with 1p deletion, MYCN amplification, advanced stage, and unfavorable histology. These findings suggest that this gene may play a role in the development of the nervous system, and it may also play a role in the pathogenesis of neural tumors.	Childrens Hosp Philadelphia, Div Oncol, Abramson Res Ctr, Philadelphia, PA 19104 USA; Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Brodeur, GM (corresponding author), Childrens Hosp Philadelphia, Div Oncol, Abramson Res Ctr, Rm 902-D,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.				NCI NIH HHS [CA-39771] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039771] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahringer J, 2000, TRENDS GENET, V16, P351, DOI 10.1016/S0168-9525(00)02066-7; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bentley DR, 2001, NATURE, V409, P942, DOI 10.1038/35057165; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Brodeur GM, 1997, J PEDIAT HEMATOL ONC, V19, P93, DOI 10.1097/00043426-199703000-00001; DELMAS V, 1993, P NATL ACAD SCI USA, V90, P2414, DOI 10.1073/pnas.90.6.2414; Eggert A, 2000, BIOTECHNIQUES, V28, P681, DOI 10.2144/00284st04; GE Q, 1995, J CLIN INVEST, V96, P1730, DOI 10.1172/JCI118218; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Harper SE, 1996, P NATL ACAD SCI USA, V93, P8536, DOI 10.1073/pnas.93.16.8536; Hogarty MD, 2000, MED PEDIATR ONCOL, V35, P512, DOI 10.1002/1096-911X(20001201)35:6<512::AID-MPO2>3.0.CO;2-D; Kasten MM, 1996, MOL CELL BIOL, V16, P4215; Kehle J, 1998, SCIENCE, V282, P1897, DOI 10.1126/science.282.5395.1897; Kitamura K, 2000, BRIT J HAEMATOL, V108, P696, DOI 10.1046/j.1365-2141.2000.01933.x; Kozak M, 2000, GENOMICS, V70, P396, DOI 10.1006/geno.2000.6412; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Maris JM, 2001, MED PEDIATR ONCOL, V36, P32, DOI 10.1002/1096-911X(20010101)36:1<32::AID-MPO1009>3.0.CO;2-0; Maris JM, 1996, GENOMICS, V35, P289, DOI 10.1006/geno.1996.0359; MULLER J, 1995, EMBO J, V14, P1209, DOI 10.1002/j.1460-2075.1995.tb07104.x; Reese MG, 2000, GENOME RES, V10, P483, DOI 10.1101/gr.10.4.483; Schmidt DR, 1999, BIOCHEMISTRY-US, V38, P14711, DOI 10.1021/bi991614n; Schreiber-Agus N, 1998, BIOESSAYS, V20, P808, DOI 10.1002/(SICI)1521-1878(199810)20:10<808::AID-BIES6>3.0.CO;2-U; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SEELIG HP, 1995, ARTHRITIS RHEUM-US, V38, P1389, DOI 10.1002/art.1780381006; Slavotinek A, 1999, J MED GENET, V36, P657; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1016/S0378-1097(99)00149-4; Thompson PM, 2001, CANCER RES, V61, P679; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; White PS, 1997, EUR J CANCER, V33, P1957, DOI 10.1016/S0959-8049(97)00311-0; White PS, 2001, MED PEDIATR ONCOL, V36, P37, DOI 10.1002/1096-911X(20010101)36:1<37::AID-MPO1010>3.0.CO;2-L; Wong AKC, 2000, CANCER RES, V60, P6171; Woodage T, 1997, P NATL ACAD SCI USA, V94, P11472, DOI 10.1073/pnas.94.21.11472; Wu YQ, 1999, HUM MOL GENET, V8, P313, DOI 10.1093/hmg/8.2.313; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	42	132	142	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 20	2003	22	7					1002	1011		10.1038/sj.onc.1206211	http://dx.doi.org/10.1038/sj.onc.1206211			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	644PB	12592387				2022-12-28	WOS:000180926100006
J	Wu, WS				Wu, WS			ERK signaling pathway is involved in p15(INK4b)/p16(INK4a) expression and HepG2 growth inhibition triggered by TPA and Saikosaponin a	ONCOGENE			English	Article						ERK; p15(INK4b); p16(INK4a); growth inhibition	CELL-CYCLE ARREST; ACTIVATED PROTEIN-KINASES; BREAST-CANCER CELLS; TUMOR SUPPRESSION; RETINOIC ACID; ONCOGENIC RAS; PROLIFERATION; P15(INK4B); AP-1; SENESCENCE	The signal pathway mediating induction of p15(INK4b) and p16(INK4)a during HepG2 growth inhibition triggered by the phorbol ester tumor promoter TPA (12-O-tetradecanoyl-phorbol 13-acetate) and the Chinese herb Saikosaponin a was investigated. Western blot of three activated forms of mitogen-activated protein kinase (MAPK) (p-ERK, p-JNK and p-p38) demonstrated that phosphorylation of ERK is dramatically induced (11.6-fold) by TPA during 15 min to 1 h and significantly induced (2.5-fold) by Saikosaponin alpha at 30 min, whereas phosphorylation of JNK was induced only by TPA during 30 min to I h. Phosphorylation of p38 was not induced by either drug. During this period, phosphorylation of one of the downstream transcriptional factors of MAPK cascade, ATF2, was 3.2- and 2.0-fold induced by TPA and Saikosaponin a, respectively, whereas that of another transcriptional factor, c-jun, was induced by TPA only. On the other hand, expressions of proto-oncogene c-jun, junB and c-fos were induced by TPA and Saikosaponin a during 30 min to 6 h of treatment. Pretreatment of 20 mug/ml PD98059, an inhibitor of MEK which is the upstream kinase of ERK, prevents the TPA- and Saikosaponin a-triggered HepG2 growth inhibition by 50 and 30%, respectively, accompanied by a 50 - 85% decrease of the P15(INK4b)/ p16(INK4a) RNAs and proteins induced by both drugs. Inductions of c-fos RNA by both drugs and c-jun phosphorylation by TPA were also significantly reduced by PD98059 pretreatment. In addition, AP-1 DNA-binding assay using nonisotopic capillary electrophoresis and laser-induced fluorescence (CE/LIF) demonstrated that the AP-1-related DNA-binding activity was significantly induced by TPA and Saikosaponin a, which can be reduced by PD98059 pretreatment. These results suggested that activation of ERK together with its downstream transcriptional machinery mediated p15(INK4b) and p16(INK4a) expression that led to HepG2 growth inhibition.	TZU CHI Univ, Dept Med Technol, Hualien 970, Taiwan	Tzu Chi University	Wu, WS (corresponding author), TZU CHI Univ, Dept Med Technol, 701,Chung Yang Rd,Sec 3, Hualien 970, Taiwan.	wuws@mail.tcu.edu.tw	Wu, Wen-Sheng/AAN-9078-2020					Agadir A, 1999, J BIOL CHEM, V274, P29779, DOI 10.1074/jbc.274.42.29779; Baek MJ, 2000, CANCER, V89, P60, DOI 10.1002/1097-0142(20000701)89:1<60::AID-CNCR9>3.0.CO;2-3; Bosch M, 1998, J BIOL CHEM, V273, P22145, DOI 10.1074/jbc.273.34.22145; Campbell I, 2000, CANCER GENE THER, V7, P1270, DOI 10.1038/sj.cgt.7700226; Cocolakis E, 2001, J BIOL CHEM, V276, P18430, DOI 10.1074/jbc.M010768200; DAM HV, 2001, ONCOGENE, V20, P2453; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; FATIMA MG, 2001, ONCOGENE, V20, P2378; FOULDS GJ, 1998, NUCLEIC ACIDS RES, V26, P4404; Franklin CC, 1995, ONCOGENE, V11, P2365; Fuxe J, 2000, CELL GROWTH DIFFER, V11, P373; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; Halfter H, 1999, Mol Cell Biol Res Commun, V1, P109, DOI 10.1006/mcbr.1999.0117; Hartsough MT, 1996, J BIOL CHEM, V271, P22368, DOI 10.1074/jbc.271.37.22368; Hochholdinger F, 1999, MOL CELL BIOL, V19, P8052; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kavanagh KT, 2001, J CELL BIOCHEM, V82, P387, DOI 10.1002/jcb.1164; Kimura A, 1999, CANCER RES, V59, P5133; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lloyd AC, 1998, CURR OPIN GENET DEV, V8, P43, DOI 10.1016/S0959-437X(98)80060-9; Malumbres M, 2000, MOL CELL BIOL, V20, P2915, DOI 10.1128/MCB.20.8.2915-2925.2000; Onishi T, 2000, ANTICANCER RES, V20, P3075; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; Robson CN, 1999, J ENDOCRINOL, V160, P257, DOI 10.1677/joe.0.1600257; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Verlinden L, 2000, CANCER RES, V60, P2673; Wang JH, 2000, SEP PURIF TECHNOL, V19, P11, DOI 10.1016/S1383-5866(99)00078-7; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Weber E, 1999, INT J CANCER, V80, P935, DOI 10.1002/(SICI)1097-0215(19990315)80:6<935::AID-IJC21>3.0.CO;2-E; WONG H, 1994, ANAL BIOCHEM, V223, P251, DOI 10.1006/abio.1994.1581; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Wu WS, 2001, BIOCHEM BIOPH RES CO, V285, P183, DOI 10.1006/bbrc.2001.5152; Yang XY, 1999, J BIOL CHEM, V274, P27981, DOI 10.1074/jbc.274.39.27981; Zauberman A, 1997, ONCOGENE, V15, P1705, DOI 10.1038/sj.onc.1201348	44	49	59	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2003	22	7					955	963		10.1038/sj.onc.1206237	http://dx.doi.org/10.1038/sj.onc.1206237			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	644PB	12592382				2022-12-28	WOS:000180926100001
J	Callahan, G; Denison, SR; Phillips, LA; Shridhar, V; Smith, DI				Callahan, G; Denison, SR; Phillips, LA; Shridhar, V; Smith, DI			Characterization of the common fragile site FRA9E and its potential role in ovarian cancer	ONCOGENE			English	Article						common fragile sites; FRA9E; chromosomal deletions; ovarian cancer; PAPPA	PLASMA PROTEIN-A; MOLECULAR CHARACTERIZATION; REPEAT EXPANSION; INTEGRATION SITE; BREAST-CANCER; BROAD REGION; X-SYNDROME; PREGNANCY; CELLS; GENE	Common fragile sites (CFSs) are regions of profound genomic instability that have been hypothesized to play a role in cancer. The major aim of this study was to locate a fragile region associated with ovarian cancer. Differential display (DD)-PCR analysis comparing normal ovarian epithelial cultures and ovarian cancer cell tines identified pregnancy-associated plasma protein-A (PAPPA) because of its frequent loss of expression (LOE) in ovarian cancer cell lines. PAPPA is localized to human chromosome 9q32-33.1, a region associated with significant loss of heterozygosity (LOH) in ovarian tumors (> 50%) and in close proximity to the FRA9E CFS. FISH analysis determined that PAPPA was contained within the distal end of FRA9E. Characterization of FRA9E determined that aphidicolin-induced instability extended over 9 Mb, identifying FRA9E as the largest CFS characterized to date. Comprehensive LOH analysis revealed several distinct peaks of LOH within FRA9E. Semiquantitative RT-PCR analysis of 16 genes contained within FRA9E indicated that genes showing LOE in ovarian tumors coincided with regions of high LOH. PAPPA displayed the most significant loss (72%). This study provides evidence to suggest that instability within FRA9E may play an important role in the development of ovarian cancer and lends further support for the hypothesis that CFSs may be causally related to cancer.	Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Expt Pathol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Grad Sch, Tumor Biol Program, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Smith, DI (corresponding author), Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Expt Pathol, 200 1st St SW, Rochester, MN 55905 USA.		Seal, Sudipta/A-7698-2012; Lomberk, Gwen/AAL-8490-2020	Lomberk, Gwen/0000-0001-5463-789X	NCI NIH HHS [CA48031, CA 75926] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA075926, R01CA048031] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arlt MF, 2002, GENE CHROMOSOME CANC, V33, P82, DOI 10.1002/gcc.10000; BECKER NA, 2002, IN PRESS ONCOGENE; Bednarek AK, 2000, CANCER RES, V60, P2140; Chen BK, 2002, ENDOCRINOLOGY, V143, P1199, DOI 10.1210/en.143.4.1199; Conover CA, 1998, EXP CELL RES, V238, P439, DOI 10.1006/excr.1997.3861; Denison SR, 2002, GENE CHROMOSOME CANC, V34, P406, DOI 10.1002/gcc.10084; DURHAM SK, 1995, ENDOCRINOLOGY, V136, P1374, DOI 10.1210/en.136.4.1374; GABRA H, 1997, BIOL FEMALE CANC, P93; GLOVER TW, 1984, HUM GENET, V67, P136, DOI 10.1007/BF00272988; HAMILTON TC, 1984, SEMIN ONCOL, V11, P285; Hewett DR, 1998, MOL CELL, V1, P773, DOI 10.1016/S1097-2765(00)80077-5; Huang HJ, 1998, GENE CHROMOSOME CANC, V21, P152, DOI 10.1002/(SICI)1098-2264(199802)21:2<152::AID-GCC11>3.0.CO;2-T; Huang HJ, 1998, ONCOGENE, V16, P2311, DOI 10.1038/sj.onc.1200202; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; JONES C, 1994, HUM MOL GENET, V3, P2123, DOI 10.1093/hmg/3.12.2123; JONES C, 1995, NATURE, V376, P145, DOI 10.1038/376145a0; Kirschner LS, 1999, BIOTECHNIQUES, V27, P72; KNIGHT SJL, 1993, CELL, V74, P127, DOI 10.1016/0092-8674(93)90300-F; KRUK PA, 1990, LAB INVEST, V63, P132; Krummel KA, 2000, GENOMICS, V69, P37, DOI 10.1006/geno.2000.6321; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; Lawrence JB, 1999, P NATL ACAD SCI USA, V96, P3149, DOI 10.1073/pnas.96.6.3149; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; LIN TM, 1974, AM J OBSTET GYNECOL, V118, P223, DOI 10.1016/0002-9378(74)90553-5; Mangelsdorf M, 2000, CANCER RES, V60, P1683; Mishmar D, 1998, P NATL ACAD SCI USA, V95, P8141, DOI 10.1073/pnas.95.14.8141; NANCARROW JK, 1994, SCIENCE, V264, P1938, DOI 10.1126/science.8009225; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; Paige AJW, 2001, P NATL ACAD SCI USA, V98, P11417, DOI 10.1073/pnas.191175898; Paige AJW, 2000, CANCER RES, V60, P1690; Paradee W, 1996, GENOMICS, V35, P87, DOI 10.1006/geno.1996.0326; Rassool FV, 1996, GENOMICS, V35, P109, DOI 10.1006/geno.1996.0329; RITCHIE RJ, 1994, HUM MOL GENET, V3, P2115, DOI 10.1093/hmg/3.12.2115; SCHULTZ DC, 1995, CANCER RES, V55, P2150; SILAHTAROGLU AN, 1993, CYTOGENET CELL GENET, V62, P214, DOI 10.1159/000133479; Smith DI, 1998, INT J ONCOL, V12, P187; Sonoda G, 1997, GENE CHROMOSOME CANC, V20, P320; Stabile I, 1988, Obstet Gynecol Surv, V43, P73; Sutherland GR, 1998, TRENDS GENET, V14, P501, DOI 10.1016/S0168-9525(98)01628-X; Tatarelli C, 2000, GENOMICS, V68, P1, DOI 10.1006/geno.2000.6272; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; Verma R.S., 1989, HUMAN CHROMOSOMES MA, P240; Wald NJ, 1996, BRIT J OBSTET GYNAEC, V103, P407, DOI 10.1111/j.1471-0528.1996.tb09765.x; Wilke CM, 1996, HUM MOL GENET, V5, P187, DOI 10.1093/hmg/5.2.187; Yu S, 1997, CELL, V88, P367, DOI 10.1016/S0092-8674(00)81875-9; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375	46	59	62	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 30	2003	22	4					590	601		10.1038/sj.onc.1206171	http://dx.doi.org/10.1038/sj.onc.1206171			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555072				2022-12-28	WOS:000180538200012
J	Mamay, CL; Mingo-Sion, AM; Wolf, DM; Molina, MD; Van Den Berg, CL				Mamay, CL; Mingo-Sion, AM; Wolf, DM; Molina, MD; Van Den Berg, CL			An inhibitory function for JNK in the regulation of IGF-I signaling in breast cancer	ONCOGENE			English	Article						IGF-I; JNK; IRS-1; breast cancer; apoptosis	ACTIVATED PROTEIN-KINASE; N-TERMINAL KINASE; GROWTH-FACTOR; INSULIN-RECEPTOR; CELLULAR STRESSES; MAP KINASE; PHOSPHORYLATION; EXPRESSION; TRANSDUCTION; PATHWAY	Insulin-like growth factor-I receptor (IGF-IR) is frequently overexpressed in a variety of cancer types. Since many breast tumors and cancer cell lines overexpress IGF-IR, we tested IGF-I effects on chemotherapy-treated breast cancer cells. IGF-I protects from chemotherapy-induced apoptosis, suggesting that overlapping signaling pathways modulate IGF-I and chemotherapy treatment outcomes. Taxol and other chemotherapy drugs induce c-Jun N-terminal kinase (JNK), a kinase that conveys cellular stress and death signals. Notably, in this paper we show that IGF-I alone induces a potent JNK response and this activity is reversed by inhibition of phosphatidylinositol 3-kinase (PI3-kinase) with LY294002 in MCF-7 but not T47D cells. Cotreatment of cells with chemotherapy and IGF-I leads to additive JNK responses. Using cells overexpressing Akt, we confirm that IGF-I-mediated survival is Akt dependent. In contrast, overexpression of JNK significantly enhances Taxol-induced apoptosis and inhibits IGF-I survival effects. Further, JNK attenuates anchorage-independent growth of MCF-7 cells. The inhibitory effect of JNK appears to be mediated by serine phosphorylation of IRS-1 (insulin receptor substrate) since both Taxol and IGF-I treatment enhanced Ser(312) IRS-1 phosphorylation, while LY294002 blocked IGF-I-mediated phosphorylation. Taken together, these data provide a mechanism whereby stress or growth factors activate JNK to reduce proliferation and/or survival in breast cancer cells.	Univ Calif Davis, Dept Biol Chem, Davis, CA 95616 USA; Univ Colorado, Hlth Sci Ctr, Sch Pharm, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Sch Med, Dept Obstet & Gynecol, Denver, CO 80262 USA	University of California System; University of California Davis; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Van Den Berg, CL (corresponding author), Univ Calif Davis, Dept Biol Chem, Davis, CA 95616 USA.	carla.vandenberg@UCHSC.edu			NATIONAL CANCER INSTITUTE [R01CA089288] Funding Source: NIH RePORTER; NCI NIH HHS [CA89288A] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200; Alblas J, 1998, ONCOGENE, V16, P131, DOI 10.1038/sj.onc.1201485; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Butler AA, 1998, CANCER RES, V58, P3021; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chen NY, 2001, CANCER RES, V61, P3908; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; CULLEN KJ, 1990, CANCER RES, V50, P48; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; Desbois-Mouthon C, 1998, BIOCHEM BIOPH RES CO, V243, P765, DOI 10.1006/bbrc.1998.8181; Dunn SE, 1998, CANCER RES, V58, P3353; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; Gooch JL, 1999, BREAST CANCER RES TR, V56, P1, DOI 10.1023/A:1006208721167; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Hemi R, 2002, J BIOL CHEM, V277, P8961, DOI 10.1074/jbc.M109391200; Hermanto U, 2000, CELL GROWTH DIFFER, V11, P655; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lee AV, 2000, MOL CELL BIOL, V20, P1489, DOI 10.1128/MCB.20.5.1489-1496.2000; Logan SK, 1997, MOL CELL BIOL, V17, P5784, DOI 10.1128/MCB.17.10.5784; LopezIlasaca M, 1997, BIOCHEM BIOPH RES CO, V232, P273, DOI 10.1006/bbrc.1997.6289; Miller BS, 1996, BIOCHEMISTRY-US, V35, P8769, DOI 10.1021/bi952651r; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; Mitsuuchi Y, 2000, CANCER RES, V60, P5390; Monno S, 2000, ENDOCRINOLOGY, V141, P544, DOI 10.1210/en.141.2.544; Okubo Y, 1998, J BIOL CHEM, V273, P25961, DOI 10.1074/jbc.273.40.25961; Paz K, 1999, J BIOL CHEM, V274, P28816, DOI 10.1074/jbc.274.40.28816; PEYRAT JP, 1990, J STEROID BIOCHEM, V37, P823, DOI 10.1016/0960-0760(90)90426-L; Potapova O, 2000, MOL CELL BIOL, V20, P1713, DOI 10.1128/MCB.20.5.1713-1722.2000; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; Resnik JL, 1998, CANCER RES, V58, P1159; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; She QB, 2002, CANCER RES, V62, P1343; SINGER C, 1995, CANCER RES, V55, P2448; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; VandenBerg CL, 1997, EUR J CANCER, V33, P1108, DOI 10.1016/S0959-8049(97)00071-3; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106	48	35	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2003	22	4					602	614		10.1038/sj.onc.1206186	http://dx.doi.org/10.1038/sj.onc.1206186			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555073				2022-12-28	WOS:000180538200013
J	Delhommeau, FO; Thierry, A; Feneux, D; Lauret, E; Leclercq, E; Courtier, MH; Sainteny, F; Vainchenker, W; Bennaceur-Griscelli, A				Delhommeau, FO; Thierry, A; Feneux, D; Lauret, E; Leclercq, E; Courtier, MH; Sainteny, F; Vainchenker, W; Bennaceur-Griscelli, A			Telomere dysfunction and telomerase reactivation in human leukemia cell lines after telomerase inhibition by the expression of a dominant-negative hTERT mutant	ONCOGENE			English	Article						telomere; telomerase; leukemia; retrovirus; cell death; therapy	REVERSE-TRANSCRIPTASE GENE; HUMAN TUMOR-CELLS; IONIZING-RADIATION; CATALYTIC SUBUNIT; HUMAN-CHROMOSOMES; TTAGGG REPEATS; LIFE-SPAN; LENGTH; APOPTOSIS; ENDS	As activation of telomerase represents a key step in the malignant transformation process, experimental models to develop anti-telomerase drugs provide a rational basis for anticancer strategies. We analysed the short and longterm efficacy of a stably expressed dominant-negative mutant (DN) of the telomerase catalytic unit (hTERT) in UT-7 and U937 human leukemia cell lines by using an IRES-e-GFP retrovirus. As expected, telomerase inactivation resulted in drastic telomere shortening, cytogenetic instability and cell growth inhibition in all e-GFP positive DN clones after 15-35 days of culture. However, despite this initial response, 50% of e-GFP positive DN clones with short telomeres escaped from crisis after 35 days of culture and recovered a proliferation rate similar to the control cells. This rescue was associated with a telomerase reactivation inducing telomere lengthening. We identified two pathways, one involving the loss of the DN transgene expression and the other the transcriptional up-regulation of endogenous hTERT with persistence of the DN transgene expression. Although this second mechanism appears to be a very rare event (one clone), these findings suggest that genomic instability induced by short telomeres after telomerase inhibition might enhance the probability of activation or selection of telomere maintenance mechanisms dependent on hTERT transcription.	Inst Gustave Roussy, INSERM, U362, F-94805 Villejuif, France; Hop Bicetre, Serv Hematol & Cytogenet, F-94270 Le Kremlin Bicetre, France; Inst Gustave Roussy, Dept Clin Biol, Serv Hematol Biol, F-94805 Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy	Bennaceur-Griscelli, A (corresponding author), Inst Gustave Roussy, INSERM, U362, PR-1,39-53 Rue Camille Desmoulins, F-94805 Villejuif, France.	abenna@igr.fr	LAURET, Evelyne/P-4929-2017	LAURET, Evelyne/0000-0003-4643-6857; bennaceur griscelli, annelise/0000-0002-3557-4499; Vainchenker, William/0000-0003-4705-202X; Delhommeau, Francois/0000-0002-4915-0734				Arai K, 2002, J BIOL CHEM, V277, P8538, DOI 10.1074/jbc.M111068200; Bailey SM, 1999, P NATL ACAD SCI USA, V96, P14899, DOI 10.1073/pnas.96.26.14899; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Bryce LA, 2000, NEOPLASIA, V2, P197, DOI 10.1038/sj.neo.7900092; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Chiu CP, 1996, STEM CELLS, V14, P239, DOI 10.1002/stem.140239; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Colgin LM, 1999, CURR OPIN GENET DEV, V9, P97, DOI 10.1016/S0959-437X(99)80014-8; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; Counter CM, 1998, ONCOGENE, V16, P1217, DOI 10.1038/sj.onc.1201882; Damm K, 2001, EMBO J, V20, P6958, DOI 10.1093/emboj/20.24.6958; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; di Fagagna FD, 1999, NAT GENET, V23, P76; DOU QP, 1995, P NATL ACAD SCI USA, V92, P9019, DOI 10.1073/pnas.92.20.9019; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Gisselsson D, 2001, P NATL ACAD SCI USA, V98, P12683, DOI 10.1073/pnas.211357798; Goytisolo FA, 2000, J EXP MED, V192, P1625, DOI 10.1084/jem.192.11.1625; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Hou M, 2001, CLIN CHEM, V47, P519; Kim MM, 2001, P NATL ACAD SCI USA, V98, P7982, DOI 10.1073/pnas.131211098; KOMATSU N, 1991, CANCER RES, V51, P341; Kondo Y, 1998, ONCOGENE, V16, P2243, DOI 10.1038/sj.onc.1201754; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; Lee KH, 2001, P NATL ACAD SCI USA, V98, P3381, DOI 10.1073/pnas.051629198; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Morin GB, 1997, EXP GERONTOL, V32, P375, DOI 10.1016/S0531-5565(96)00164-7; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Morrison SJ, 1996, IMMUNITY, V5, P207, DOI 10.1016/S1074-7613(00)80316-7; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; Pendino F, 2002, LEUKEMIA, V16, P826, DOI 10.1038/sj.leu.2402470; Pendino F, 2001, P NATL ACAD SCI USA, V98, P6662, DOI 10.1073/pnas.111464998; Raymond E, 1996, CURR OPIN BIOTECH, V7, P583, DOI 10.1016/S0958-1669(96)80068-1; Riou JF, 2002, P NATL ACAD SCI USA, V99, P2672, DOI 10.1073/pnas.052698099; Sachsinger J, 2001, CANCER RES, V61, P5580; Samper E, 2000, EMBO REP, V1, P244, DOI 10.1093/embo-reports/kvd051; Wong KK, 2000, NAT GENET, V26, P85, DOI 10.1038/79232; Wright WE, 1996, DEV GENET, V18, P173; Zhang AJ, 2000, CANCER RES, V60, P6230; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	51	38	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 28	2002	21	54					8262	8271		10.1038/sj.onc.1206054	http://dx.doi.org/10.1038/sj.onc.1206054			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447689				2022-12-28	WOS:000179323900004
J	El-Naggar, AK; Kim, HW; Clayman, GL; Coombes, MM; Le, B; Lai, S; Zhan, F; Luna, MA; Hong, WK; Lee, JJ				El-Naggar, AK; Kim, HW; Clayman, GL; Coombes, MM; Le, B; Lai, S; Zhan, F; Luna, MA; Hong, WK; Lee, JJ			Differential expression profiling of head and neck squamous carcinoma: significance in their phenotypic and biological classification	ONCOGENE			English	Article						gene expression; microarray analysis; head and neck squamous carcinoma; biological classification; squamous carcinoma subtypes	LASER CAPTURE MICRODISSECTION; NUCLEAR RIBONUCLEOPROTEIN B1; CELL CARCINOMA; CDNA MICROARRAY; EPITHELIAL DIFFERENTIATION; AERODIGESTIVE TRACT; KERATIN GENES; CANCER; IDENTIFICATION; GENOME	The genetic events associated with the development and progression of head and neck squamous carcinoma (HNSC) are largely unknown. We analysed 12 matched pairs of histologically normal squamous mucosa and tumor specimens from six conventional and six phenotypic variants HNSC to define the differentially expressed genes in these tumors. Parallel expression analysis of 8055 unique genes was performed, and the level of the hybridization signal for each gene was measured after normalization. Hierarchical cluster analysis of the expressed genes showed distinct inter-and intra-tumoral patterns in and between conventional squamous carcinoma and squamous carcinoma variants. We also identified 26 (0.32%) differentially expressed genes that were consistently different between matched pairs of normal and tumor specimens; a selected set of the overexpressed genes was validated using real-time quantitative RT-PCR. The majority of the genes were associated with differentiation and proliferation. Our study defines a set of genes that could form the basis for the construction of limited HNSC targeted expression array band indepth studies and further highlights gene profile differences that may be useful in pathobiologic classification of HNSC.	Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	El-Naggar, AK (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Pathol, 1515 Holcombe Blvd,Box 85, Houston, TX 77030 USA.	anaggar@mdanderson.org	Center, Univ of Texas-M D Anderson Cancer/AAE-8182-2019; Lee, Jack/P-7331-2019	Center, Univ of Texas-M D Anderson Cancer/0000-0001-5469-9214; Lee, Jack/0000-0002-4584-929X	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE011906] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Abraham JM, 1996, CELL GROWTH DIFFER, V7, P855; Alevizos I, 2001, ONCOGENE, V20, P6196, DOI 10.1038/sj.onc.1204685; Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; Anbazhagan R, 1999, CANCER RES, V59, P5119; Austin SJ, 1996, J BIOL CHEM, V271, P3737, DOI 10.1074/jbc.271.7.3737; Balm AJM, 1996, EUR ARCH OTO-RHINO-L, V253, P227, DOI 10.1007/BF00171132; BANKS ER, 1992, AM J SURG PATHOL, V16, P939, DOI 10.1097/00000478-199210000-00003; Bertucci F, 2000, HUM MOL GENET, V9, P2981, DOI 10.1093/hmg/9.20.2981; Bockmuhl U, 2000, AM J PATHOL, V157, P369, DOI 10.1016/S0002-9440(10)64549-X; Califano J, 1996, CANCER RES, V56, P2488; Chaib H, 2001, NEOPLASIA, V3, P43, DOI 10.1038/sj.neo.7900126; Chu PG, 2001, HISTOPATHOLOGY, V39, P9, DOI 10.1046/j.1365-2559.2001.01105.x; De Benedetti VMG, 2000, INT J BIOL MARKER, V15, P1; Diehn M, 2000, NAT GENET, V25, P58, DOI 10.1038/75603; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; ELLIS GL, 1987, AM J SURG PATHOL, V11, P335, DOI 10.1097/00000478-198705000-00001; ELNAGGAR AK, 1995, CANCER RES, V55, P2656; ElNaggar AK, 1997, AM J PATHOL, V151, P1767; Emmert-Buck MR, 2000, J MOL DIAGN, V2, P60, DOI 10.1016/S1525-1578(10)60617-4; Freedberg IM, 2001, J INVEST DERMATOL, V116, P633, DOI 10.1046/j.1523-1747.2001.01327.x; Fujimoto W, 1997, J INVEST DERMATOL, V108, P200, DOI 10.1111/1523-1747.ep12334240; Goto Y, 1999, JPN J CANCER RES, V90, P1358, DOI 10.1111/j.1349-7006.1999.tb00720.x; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; HARVAT BL, 1997, J DERMATOL, V24, P711; Helliwell TR, 2001, J PATHOL, V194, P289, DOI 10.1002/1096-9896(200107)194:3<289::AID-PATH912>3.0.CO;2-L; Hesse M, 2001, J CELL SCI, V114, P2569; HEYDEN A, 1992, J ORAL PATHOL MED, V21, P7, DOI 10.1111/j.1600-0714.1992.tb00960.x; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Huang HT, 2000, CANCER RES, V60, P6868; IVANYI D, 1990, CANCER RES, V50, P5143; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; KLIJANIENKO J, 1993, ANAL QUANT CYTOL, V15, P335; LAI SL, 1995, ONCOL REP, V2, P1115; Leethanakul C, 2000, ONCOGENE, V19, P3220, DOI 10.1038/sj.onc.1203703; MEDINA JE, 1984, ARCH OTOLARYNGOL, V110, P437; Mischke D, 1998, Subcell Biochem, V31, P71; OGDEN GR, 1993, J CLIN PATHOL, V46, P352, DOI 10.1136/jcp.46.4.352; Ono K, 2000, CANCER RES, V60, P5007; Petersen S, 2000, INT J CANCER, V86, P512, DOI 10.1002/(SICI)1097-0215(20000515)86:4<512::AID-IJC11>3.0.CO;2-6; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Sallinen SL, 2000, CANCER RES, V60, P6617; Sgroi DC, 1999, CANCER RES, V59, P5656; Shim C, 1998, CLIN CANCER RES, V4, P3045; Suarez PA, 2000, HEAD NECK-J SCI SPEC, V22, P360; Sueoka E, 1999, CANCER RES, V59, P1404; TANAKA M, 1995, CANCER LETT, V89, P195, DOI 10.1016/0304-3835(94)03687-E; Villaret DB, 2000, LARYNGOSCOPE, V110, P374, DOI 10.1097/00005537-200003000-00008; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; WAIN SL, 1986, HUM PATHOL, V17, P1158, DOI 10.1016/S0046-8177(86)80422-1; Wang T, 2000, ONCOGENE, V19, P1519, DOI 10.1038/sj.onc.1203457; Weinstein LB, 1999, CURR OPIN CELL BIOL, V11, P378, DOI 10.1016/S0955-0674(99)80053-2; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	53	43	44	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2002	21	53					8206	8219		10.1038/sj.onc.1206021	http://dx.doi.org/10.1038/sj.onc.1206021			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615DW	12444558				2022-12-28	WOS:000179231400016
J	Humar, B; Graziano, F; Cascinu, S; Catalano, V; Ruzzo, AM; Magnani, M; Toro, T; Burchill, T; Futschik, ME; Merriman, T; Guilford, P				Humar, B; Graziano, F; Cascinu, S; Catalano, V; Ruzzo, AM; Magnani, M; Toro, T; Burchill, T; Futschik, ME; Merriman, T; Guilford, P			Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer	ONCOGENE			English	Article						diffuse gastric cancer; E-cadherin; CDH1; polymorphism; genetics	E-CADHERIN GENE; LINKAGE DISEQUILIBRIUM; EPIDEMIOLOGY; CARCINOMA; MUTATIONS	Truncating mutations in the gene for the cell to cell adhesion protein E-cadherin are the most consistent genetic alterations observed in sporadic and hereditary diffuse gastric cancer (DGC). In addition to these inactivating mutations, a CDH1 promoter polymorphism at position -160 has been reported to lead to transcriptional downregulation of the gene in vitro. We therefore performed a case-control study to investigate whether this variant is associated with an increased susceptibility to DGC. The frequency of the - 160A allele was significantly higher (P < 0.005) in 53 diffuse gastric cancer cases compared to 70 matched controls. The odds ratio associated with the A-allele was 2.27 for CA-heterozygotes (95% CI 1.16-4.44) and 7.84 for AA-homozygotes (95% CI 2.89-21.24). Two additional polymorphisms (the 48+6T-->C and the 2076C-->T variant) were genotyped and shown to be equally distributed among cases and controls. Haplotype analysis with the three polymorphisms confirmed an association with disease (P < 0.004). However, this analysis suggested the -160C --> A CDH1 promoter polymorphism may be in linkage disequilibrium with a distinct aetiological locus or acts in combination with other functional variants in or near the C-DH1 region.	Univ Otago, Dept Biochem, Canc Genet Lab, Dunedin, Aotearoa, New Zealand; Hosp Urbino, Div Med Oncol, I-61029 Urbino, Italy; Hosp Parma, I-43100 Parma, Italy; Hosp Pesaro, I-61100 Pesaro, Italy; Univ Urbino, G Fornaini Inst Biochem & Mol Biol, I-61029 Urbino, Italy; Univ Otago, Knowledge Engn Lab, Dunedin, Aotearoa, New Zealand; Univ Otago, Biochem Lab, Dunedin, Aotearoa, New Zealand	University of Otago; University of Parma; University Hospital of Parma; University of Urbino; University of Otago; University of Otago	Guilford, P (corresponding author), Univ Otago, Dept Biochem, Canc Genet Lab, POB 56, Dunedin, Aotearoa, New Zealand.		Ruzzo, Annamaria/Q-2155-2016; Magnani, Mauro/A-1919-2008; Futschik, Matthias/AAK-8837-2020; Cascinu, Stefano/AAN-1923-2020; Cascinu, Stefano/G-2399-2017	Ruzzo, Annamaria/0000-0003-2815-1890; Futschik, Matthias/0000-0002-6245-8071; Cascinu, Stefano/0000-0003-2215-0731; Guilford, Parry/0000-0002-7256-9576; Merriman, Tony/0000-0003-0844-8726; Magnani, Mauro/0000-0001-6456-6626				Avizienyte E, 2001, J MED GENET, V38, P49, DOI 10.1136/jmg.38.1.49; Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D; Borch K, 2000, BRIT J SURG, V87, P618, DOI 10.1046/j.1365-2168.2000.01425.x; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; DEVLIN B, 1995, GENOMICS, V29, P311, DOI 10.1006/geno.1995.9003; Dunbier A, 2001, ADV CANCER RES, V83, P55, DOI 10.1016/S0065-230X(01)83002-5; FISHER RA, 1951, DESIGN EXPT, P1; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; HOWSON CP, 1986, EPIDEMIOL REV, V8, P1; Humar B, 2002, HUM MUTAT, V19, P518, DOI 10.1002/humu.10067; Koeleman BPC, 2000, ANN HUM GENET, V64, P207, DOI 10.1017/S0003480000008095; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; LAUREN PA, 1993, CANCER-AM CANCER SOC, V71, P2926, DOI 10.1002/1097-0142(19930515)71:10<2926::AID-CNCR2820711007>3.0.CO;2-X; Lei HX, 2002, INT J CANCER, V98, P199, DOI 10.1002/ijc.10176; Li LC, 2000, CANCER RES, V60, P873; Porter TR, 2002, ONCOGENE, V21, P1928, DOI 10.1038/sj.onc.1205245; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; Wu MS, 2002, CANCER-AM CANCER SOC, V94, P1443, DOI 10.1002/cncr.10371	19	85	93	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 21	2002	21	53					8192	8195		10.1038/sj.onc.1205921	http://dx.doi.org/10.1038/sj.onc.1205921			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615DW	12444556				2022-12-28	WOS:000179231400014
J	Shchepina, LA; Pletjushkina, OY; Avetisyan, AV; Bakeeva, LE; Fetisova, EK; Izyumov, DS; Saprunova, VB; Vyssokikh, MY; Chernyak, BV; Skulachev, VP				Shchepina, LA; Pletjushkina, OY; Avetisyan, AV; Bakeeva, LE; Fetisova, EK; Izyumov, DS; Saprunova, VB; Vyssokikh, MY; Chernyak, BV; Skulachev, VP			Oligomycin, inhibitor of the F-0 part of H+-ATP-synthase, suppresses the TNF-induced apoptosis	ONCOGENE			English	Article						apoptosis; Bcl-2; mitochondria; ultrastructure; membrane potential; permeability transition; oligomycin; tumor necrosis factor	MITOCHONDRIAL PERMEABILITY TRANSITION; CYTOCHROME-C RELEASE; OLIGOMERIZES BAK; BCL-2; ACTIVATION; INDUCTION; MECHANISM; COMPLEX; PROTEIN; PORES	The release of cytochrome c from the intermembrane space of mitochondria into the cytosol is one of the critical events in apoptotic cell death. In the present study, it is shown that release of cytochrome c and apoptosis induced by tumor necrosis factor alpha (TNF) in HeLa cells can be inhibited by (i) overexpression of an oncoprotein Bcl-2, (ii) Cyclosporin A, an inhibitor of the mitochondrial permeability transition pore (PTP) or (iii) oligomycin, an inhibitor of H+- ATP-synthase. Staurosporine-induced apoptosis is sensitive to Bcl-2 but insensitive to Cyclosporin A and oligomycin. The effect of oligomycin is not due to changes in mitochondrial membrane potential or to inhibition of ATP synthesis/hydrolysis since (a) uncouplers (CCCP, DNP) which discharge the membrane potential fail to abolish the protective action of oligomycin and (b) aurovertin B (another inhibitor of H+-ATP-synthase, affecting its F-1 component) do not affect apoptosis. A role of oligomycin-sensitive F-0 component of H+-ATP-synthase in the TNF-induced PTP opening and apoptosis is suggested.	Moscow MV Lomonosov State Univ, AN Belozersky Inst, Moscow 119992, Russia	Lomonosov Moscow State University	Chernyak, BV (corresponding author), Moscow MV Lomonosov State Univ, AN Belozersky Inst, 4 Khokhlova Str,Bldg A, Moscow 119992, Russia.	bchernyak@yahoo.com	Avetisyan, Armine/O-2426-2014; Fetisova, Elena/D-3250-2018; Skulachev, Vladimir P/J-4164-2012; Chernyak, Boris V/D-9917-2012; Pletjushkina, Olga G/J-8476-2012; Vyssokikh, Mikhail/H-4744-2014	Fetisova, Elena/0000-0002-7305-8102; Skulachev, Vladimir P/0000-0003-4886-2243; Chernyak, Boris V/0000-0003-1523-0864; Vyssokikh, Mikhail/0000-0002-4047-6201; Skulachev, Vladimir/0000-0001-5141-7517; Avetisyan, Armine/0000-0002-3882-2013				Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; Broekemeier KM, 1995, BIOCHEMISTRY-US, V34, P16440, DOI 10.1021/bi00050a027; Domnina LV, 2002, BIOCHEMISTRY-MOSCOW+, V67, P737, DOI 10.1023/A:1016336421582; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Eguchi Y, 1997, CANCER RES, V57, P1835; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Ikemoto H, 2000, CELL DEATH DIFFER, V7, P511, DOI 10.1038/sj.cdd.4400682; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Liu YB, 1997, J NEUROCHEM, V69, P581, DOI 10.1046/j.1471-4159.1997.69020581.x; Matsuyama S, 1998, MOL CELL, V1, P327, DOI 10.1016/S1097-2765(00)80033-7; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; NOVGORODOV SA, 1989, FEBS LETT, V247, P255, DOI 10.1016/0014-5793(89)81347-X; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; Peachman KK, 2001, P NATL ACAD SCI USA, V98, P1717, DOI 10.1073/pnas.98.4.1717; Salomon AR, 2000, P NATL ACAD SCI USA, V97, P14766, DOI 10.1073/pnas.97.26.14766; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Shchepina LA, 2002, BIOCHEMISTRY-MOSCOW+, V67, P222, DOI 10.1023/A:1014418231692; Sidoti-de Fraisse C, 1998, ONCOGENE, V17, P1639, DOI 10.1038/sj.onc.1202094; Skulachev Vladimir P., 1999, Molecular Aspects of Medicine, V20, P139, DOI 10.1016/S0098-2997(99)00008-4; Skulachev VP, 1996, FEBS LETT, V397, P7, DOI 10.1016/0014-5793(96)00989-1; Skulachev VP, 1998, FEBS LETT, V423, P275, DOI 10.1016/S0014-5793(98)00061-1; Skulachev VP, 1996, Q REV BIOPHYS, V29, P169, DOI 10.1017/S0033583500005795; Tafani M, 2000, AM J PATHOL, V156, P2111, DOI 10.1016/S0002-9440(10)65082-1; Tafani M, 2001, CANCER RES, V61, P2459; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wei MC, 2000, GENE DEV, V14, P2060; WOLVETANG EJ, 1994, FEBS LETT, V339, P40, DOI 10.1016/0014-5793(94)80380-3; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhuang JG, 1998, CELL DEATH DIFFER, V5, P953, DOI 10.1038/sj.cdd.4400440	38	120	130	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2002	21	53					8149	8157		10.1038/sj.onc.1206053	http://dx.doi.org/10.1038/sj.onc.1206053			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615DW	12444550				2022-12-28	WOS:000179231400008
J	Greider, C; Chattopadhyay, A; Parkhurst, C; Yang, E				Greider, C; Chattopadhyay, A; Parkhurst, C; Yang, E			BCL-x(L) and BCL2 delay Myc-induced cell cycle entry through elevation of p27 and inhibition of G1 cyclin-dependent kinases	ONCOGENE			English	Article						BCL2; BCL-x(L); cell cycle; p27; cdk; Myc	C-MYC; S-PHASE; EXPRESSION; APOPTOSIS; P27(KIP1); TRANSCRIPTION; GENE; PROGRESSION; DEATH; INDUCTION	The anti-apoptotic molecules BCL-X-L and BCL2 delay cell cycle entry from quiescence. We used serum induction and induction of a Myc-estrogen receptor fusion protein (MycER) in quiescent fibroblasts to investigate the mechanisms underlying the cell cycle activity of BCL-X-L and BCL2. We demonstrate for the first time that BCL-x(L) and BCL2 delayed serum-induced and Myc-induced, but not E2F-induced, cell cycle entry. The cyclin-dependent kinase inhibitor p27 was elevated during serum deprivation and cell cycle entry in BCL-X-L or BCL2-expressing NIH3T3 cells and a Rat1MycER cell line. Activation of cyclin-dependent kinase 2 (cdk2) and cyclin-dependent kinase 4 (cdk4) were delayed during progression to S phase, while the induction of cyclin 131 protein, as well as the levels of cyclin E, cdk2, and cdk4 were unaltered by BCL-X-L or BCL2. Inhibition of cyclin/cdk activities in BCL-X-L or BCL2 expressing cells was associated with excess p27 in the cyclin/cdk complexes. Neither BCL-X-L nor BCL2 delayed S phase entry in cells deficient in p27, thus p27 is required for the cell cycle function of BCL-X-L and BCL2. The cell cycle effects of BCL-X-L and BCL2 were more profound in Myc-induced than in serum-induced cell cycle entry. Our results suggest that one possible mechanism by which BCL-X-L and BCL2 delay cell cycle entry may be the inhibition of Myc activity through the elevation of p27.	Vanderbilt Univ, Ctr Med, Sch Med, Dept Pediat,Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Canc Biol, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Yang, E (corresponding author), Vanderbilt Univ, Ctr Med, Sch Med, Dept Pediat,Vanderbilt Ingram Canc Ctr, 397 PRB, Nashville, TN 37232 USA.	elizabeth.yang@vanderbilt.edu		Sansam, Courtney/0000-0002-0253-8643	NATIONAL CANCER INSTITUTE [T32CA009385, R01CA078443] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA78443, T32CA09385, CA58485] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams MR, 2000, MOL CELL BIOL, V20, P3633, DOI 10.1128/MCB.20.10.3633-3639.2000; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Brady HJM, 1996, EMBO J, V15, P6991, DOI 10.1002/j.1460-2075.1996.tb01091.x; Chattopadhyay A, 2001, ONCOGENE, V20, P4507, DOI 10.1038/sj.onc.1204584; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cory S, 1999, CANCER RES, V59, p1685S; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Eischen CM, 2001, ONCOGENE, V20, P6983, DOI 10.1038/sj.onc.1204892; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Hengstschlager M, 1999, ONCOGENE, V18, P843, DOI 10.1038/sj.onc.1202342; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; Hueber AO, 1998, TRENDS GENET, V14, P364, DOI 10.1016/S0168-9525(98)01520-0; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; Lind EF, 1999, J IMMUNOL, V162, P5374; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; MARIN MC, 1995, EXP CELL RES, V217, P240, DOI 10.1006/excr.1995.1083; Mazel S, 1996, J EXP MED, V183, P2219, DOI 10.1084/jem.183.5.2219; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; O'Hagan RC, 2000, GENE DEV, V14, P2185, DOI 10.1101/gad.827200; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; PERSSON H, 1985, MOL CELL BIOL, V5, P2903, DOI 10.1128/MCB.5.11.2903; Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; TOMODA K, 2001, J BIOL CHEM, V9, P9; Vairo G, 2000, MOL CELL BIOL, V20, P4745, DOI 10.1128/MCB.20.13.4745-4753.2000; Vairo G, 1996, ONCOGENE, V13, P1511; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245	42	97	100	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2002	21	51					7765	7775		10.1038/sj.onc.1205928	http://dx.doi.org/10.1038/sj.onc.1205928			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	610DT	12420213				2022-12-28	WOS:000178946000001
J	Kovalchuk, AL; Kim, JS; Janz, S				Kovalchuk, AL; Kim, JS; Janz, S			E mu/S mu transposition into Myc is sometimes a precursor for T(12;15) translocation in mouse B cells	ONCOGENE			English	Article						genetic transposition; immunoglobulin heavy-chain locus; intronic heavy-chain enhancer; immunoglobulin switch region; chromosomal translocation	CLASS-SWITCH RECOMBINATION; HEAVY-CHAIN GENE; VISIBLE CHROMOSOMAL TRANSLOCATIONS; C-MYC; MURINE PLASMACYTOMA; MULTIPLE-MYELOMA; ABERRANT REARRANGEMENT; IMMUNOGLOBULIN; REGION; ENHANCER	Misguided immunoglobulin (Ig) class switch recombination (CSR) has been implicated in the origin of Myc-activating chromosomal translocations, T(12;15), in BALB/c mouse plasmacytomas (PCTs). CSR has also been involved in the progression of T(12;15); for example, the approximation of Myc to the 3'-Calpha enhancer. This study provides evidence for an additional mechanism by which aberrant CSR may facilitate T(12;15): transposition of Ig heavy-chain (IgH) sequences to Myc. Five IgH transposons containing the intronic heavy-chain enhancer, Emu, and a truncated switch mu region, Smu, were found in the first intron of Myc in lymph node cells of IL-6 transgenic BALB/c mice. In two cases Emu/Smu transposition primed Myc to get involved in apparent trans-chromosomal CSR to Cgamma1, presumably leading to T(12;15). Translocations preceded by Emu/Smu transposition can sometimes be distinguished from de novo translocations by molecular fingerprints in translocation breakpoint regions (Ig switch region [S] inversions and unusual gene orders in composite S regions). The presence of such fingerprints in some PCTs suggests that the tumors sometimes evolve from transposition-bearing precursors. We propose that Emu/Smu transposition to Myc may facilitate plasmacytomagenesis by sensitizing Myc to undergo T(12;15) translocation. T(12;15), in turn, juxtaposes Myc to the 3'-Calpha enhancer, which appears to be required for deregulating Myc in a manner that is conducive to PCT development.	NCI, Genet Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Janz, S (corresponding author), NCI, Genet Lab, Ctr Canc Res, NIH, Bldg 37,Room 2B10, Bethesda, MD 20892 USA.			Kovalchuk, Alexander/0000-0003-2761-0442	DIVISION OF BASIC SCIENCES - NCI [Z01BC010024] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGUILERA RJ, 1985, EMBO J, V4, P3689, DOI 10.1002/j.1460-2075.1985.tb04136.x; AXELSON H, 1991, ONCOGENE, V6, P2263; Bakkus MHC, 2001, LEUKEMIA, V15, P1127, DOI 10.1038/sj.leu.2402164; Bergsagel PL, 2001, ONCOGENE, V20, P5611, DOI 10.1038/sj.onc.1204641; Chaganti SR, 1998, GENE CHROMOSOME CANC, V23, P328, DOI 10.1002/(SICI)1098-2264(199812)23:4<328::AID-GCC8>3.0.CO;2-M; Chen C, 1995, IMMUNITY, V3, P747, DOI 10.1016/1074-7613(95)90064-0; CORCORAN LM, 1985, CELL, V40, P71, DOI 10.1016/0092-8674(85)90310-1; Crossen PE, 1998, LEUKEMIA LYMPHOMA, V31, P559, DOI 10.3109/10428199809057615; DUNNICK W, 1993, NUCLEIC ACIDS RES, V21, P365, DOI 10.1093/nar/21.3.365; ESSER C, 1990, ANNU REV IMMUNOL, V8, P717, DOI 10.1146/annurev.iy.08.040190.003441; FAHRLANDER PD, 1985, P NATL ACAD SCI USA, V82, P3746, DOI 10.1073/pnas.82.11.3746; Gabrea A, 1999, MOL CELL, V3, P119, DOI 10.1016/S1097-2765(00)80180-X; Geltinger C, 1996, GENE EXPRESSION, V6, P113; GERSTEIN RM, 1990, CELL, V63, P537, DOI 10.1016/0092-8674(90)90450-S; GREENBERG R, 1982, NUCLEIC ACIDS RES, V10, P7751, DOI 10.1093/nar/10.23.7751; HORTNAGEL K, 1995, ONCOGENE, V10, P1393; JANZ S, 1993, P NATL ACAD SCI USA, V90, P7361, DOI 10.1073/pnas.90.15.7361; Janz S, 1995, Curr Top Microbiol Immunol, V194, P373; Kovalchuk AL, 2000, LEUKEMIA, V14, P1127, DOI 10.1038/sj.leu.2401767; Kovalchuk AL, 1997, ONCOGENE, V15, P2369, DOI 10.1038/sj.onc.1201409; Kovalchuk AL, 2000, LEUKEMIA, V14, P909, DOI 10.1038/sj.leu.2401676; Kovalchuk AL, 2002, P NATL ACAD SCI USA, V99, P1509, DOI 10.1073/pnas.022643999; Kovalchuk AL, 2001, GENE CHROMOSOME CANC, V30, P283, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1094>3.0.CO;2-I; Kuppers R, 2001, ONCOGENE, V20, P5580, DOI 10.1038/sj.onc.1204640; LAFFAN M, 1992, J CLIN INVEST, V90, P2299, DOI 10.1172/JCI116117; Lee CG, 1998, CURR BIOL, V8, P227, DOI 10.1016/S0960-9822(98)70087-9; Luby TM, 2001, J EXP MED, V193, P159, DOI 10.1084/jem.193.2.159; MADISEN L, 1994, GENE DEV, V8, P2212, DOI 10.1101/gad.8.18.2212; Manis JP, 2002, TRENDS IMMUNOL, V23, P31, DOI 10.1016/S1471-4906(01)02111-1; Muller JR, 1996, CANCER RES, V56, P419; Muller JR, 1997, BLOOD, V89, P291, DOI 10.1182/blood.V89.1.291.291_291_296; MULLER JR, 1995, CANCER RES, V55, P5012; MULLER JR, 1994, P NATL ACAD SCI USA, V91, P12066, DOI 10.1073/pnas.91.25.12066; MURAMATSU M, 2000, CELL, DOI UNSP 102553; Nardini E, 2000, BLOOD, V95, P1032, DOI 10.1182/blood.V95.3.1032.003k38_1032_1038; OHNO S, 1989, ONCOGENE, V4, P1513; OHNO S, 1991, INT J CANCER, V49, P102, DOI 10.1002/ijc.2910490119; Papavasiliou FN, 2000, NATURE, V408, P216, DOI 10.1038/35041599; Papavasiliou FN, 2002, CELL, V109, pS35, DOI 10.1016/S0092-8674(02)00706-7; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; PEAR WS, 1986, IMMUNOGENETICS, P23393; POTTER M, 1992, CARCINOGENESIS, V13, P1681, DOI 10.1093/carcin/13.10.1681; Pratt G, 2001, BRIT J HAEMATOL, V112, P388, DOI 10.1046/j.1365-2141.2001.02588.x; Proffitt J, 1999, LEUKEMIA, V13, P1100, DOI 10.1038/sj.leu.2401465; RAYNAL MC, 1989, P NATL ACAD SCI USA, V86, P8024, DOI 10.1073/pnas.86.20.8024; Roschke V, 1997, ONCOGENE, V14, P3011, DOI 10.1038/sj.onc.1201156; SHAPIRO MA, 1987, MOL CELL BIOL, V7, P4130, DOI 10.1128/MCB.7.11.4130; SHAUGHNESSY JD, 1993, ONCOGENE, V8, P3111; SUEMATSU S, 1992, P NATL ACAD SCI USA, V89, P232, DOI 10.1073/pnas.89.1.232; Vaandrager JW, 2000, BLOOD, V96, P1947, DOI 10.1182/blood.V96.5.1947.h8001947_1947_1952; VANNESS BG, 1983, NATURE, V301, P425, DOI 10.1038/301425a0; Willis TG, 2000, BLOOD, V96, P808, DOI 10.1182/blood.V96.3.808.015k30_808_822; ZHANG K, 1995, J IMMUNOL, V154, P2237	53	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2003	22	18					2842	2850		10.1038/sj.onc.1206345	http://dx.doi.org/10.1038/sj.onc.1206345			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ	12743607				2022-12-28	WOS:000182569300015
J	Marchese, C; Maresca, V; Cardinali, G; Belleudi, F; Ceccarelli, S; Bellocci, M; Frati, L; Torrisi, MR; Picardo, M				Marchese, C; Maresca, V; Cardinali, G; Belleudi, F; Ceccarelli, S; Bellocci, M; Frati, L; Torrisi, MR; Picardo, M			UVB-induced activation and internalization of keratinocyte growth factor receptor	ONCOGENE			English	Article						UVB; keratinocyte growth factor receptor; oxidative stress; tyrosine phosphorylation	CULTURED HUMAN KERATINOCYTES; INDUCED EGF-RECEPTOR; HYDROGEN-PEROXIDE; ULTRAVIOLET-LIGHT; INDUCED APOPTOSIS; EXPRESSION; CELLS; KGF; INVOLVEMENT; MODULATION	Ultraviolet irradiation of mammalian cells induces several events that include activation of growth factor receptors and triggering of signal transduction pathway. Most of the UV responses are mediated by the production of reactive oxygen species (ROS) and can be blocked by antioxidants. In this study, we analysed the effect of UVB irradiation at physiologic doses and that of the prooxidant agent cumene hydroperoxide (CUH) on the activation of the receptor for keratinocyte growth factor (KGF), a key mediator of epithelial growth and differentiation. Exposure to both UVB (30-150 mJ/cm(2)) and CUH (200 muM of NIH3T3 KGFR (KGF receptors) transfectants caused a rapid tyrosine phosphorylation and activation of KGFR similar to that induced by KGF, and internalization of the activated receptor. The KGFR expression appeared unmodified by the treatments. Ultrastructural observations of both UVB- and CUH-treated cells showed a normal morphology of the plasma membranes and intracellular organelles. The antioxidant N-acetylcysteine inhibited UVB-induced receptor phosphorylation. The generation of an intracellular oxidative stress was detected as a decrease of catalase activity and of vitamin E, and reduced glutathione levels, whereas superoxide dismutase activity was not significantly modified. A peroxidation of polyunsaturated fatty acids of cell membranes was observed after both treatments, associated with the intracellular oxidative stress. Similar biochemical events were observed on NIH3T3 untransfected control cells, suggesting that KGFR activation follows intracellular generation of ROS and is not associated with a scavenging effect. Taken together our results demonstrate that exposure to UVB and to oxidant stimuli induces a rapid intracellular production of ROS, which in turn are capable of triggering KGFR activation and internalization, similar to those induced by KGF.	Univ Roma La Sapienza, Dipartimento Med Sperimentale & Patol, I-00161 Rome, Italy; IRCCS, Ist Dermatol Santa Maria & San Gallicano, Rome, Italy	Sapienza University Rome; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS San Gallicano Dermatological Institute (ISG)	Marchese, C (corresponding author), Univ Roma La Sapienza, Dipartimento Med Sperimentale & Patol, Viale Regina Elena 324, I-00161 Rome, Italy.		Picardo, Mauro/A-6978-2011; maresca, vittoria/J-3272-2016; Frati, Luigi/ABI-7437-2020; Cardinali, Giorgia/H-1814-2016; Ceccarelli, Simona/J-4086-2018; Marchese, Cinzia/J-1323-2018	Picardo, Mauro/0000-0003-4899-6639; maresca, vittoria/0000-0001-9239-6978; Cardinali, Giorgia/0000-0002-7527-9451; Ceccarelli, Simona/0000-0001-8789-7719; MARCHESE, CINZIA/0000-0002-9280-8917				Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Capone A, 2000, CELL GROWTH DIFFER, V11, P607; Claiborne A., 1985, CRC HDB METHODS OXYG, P283; COFFER PJ, 1995, ONCOGENE, V11, P561; de Gruijl FR, 2000, METHOD ENZYMOL, V319, P359; Dimon-Gadal S, 1998, J BIOL CHEM, V273, P22833, DOI 10.1074/jbc.273.35.22833; Finch PW, 1997, AM J PATHOL, V151, P1619; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; Fisher GJ, 1997, NEW ENGL J MED, V337, P1419, DOI 10.1056/NEJM199711133372003; FUCHS J, 1990, PHOTODERMATOL PHOTO, V7, P920; Hadari YR, 2001, P NATL ACAD SCI USA, V98, P8578, DOI 10.1073/pnas.161259898; Hines MD, 1996, J BIOL CHEM, V271, P6245, DOI 10.1074/jbc.271.11.6245; Huang RP, 1996, J CELL BIOL, V133, P211, DOI 10.1083/jcb.133.1.211; HUANG RP, 1995, ONCOGENE, V10, P467; Kayanoki Y, 1996, J BIOCHEM-TOKYO, V119, P817; LAROCHELLE WJ, 1995, J CELL BIOL, V129, P357, DOI 10.1083/jcb.129.2.357; Marchese C, 1997, CELL GROWTH DIFFER, V8, P989; Marchese C, 1998, J CELL SCI, V111, P3517; MARCHESE C, 1995, J EXP MED, V182, P1369, DOI 10.1084/jem.182.5.1369; MARCHESE C, 1990, J CELL PHYSIOL, V144, P326, DOI 10.1002/jcp.1041440219; McGregor WG, 1999, J INVEST DERM SYMP P, V4, P1, DOI 10.1038/sj.jidsp.5640172; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; ONEIL P, 1998, J BIOCH, V24, P41; Peus D, 1998, J INVEST DERMATOL, V110, P966, DOI 10.1046/j.1523-1747.1998.00210.x; Peus D, 1999, FREE RADICAL BIO MED, V27, P1197, DOI 10.1016/S0891-5849(99)00198-7; Picardo M, 1996, J INVEST DERMATOL, V107, P322, DOI 10.1111/1523-1747.ep12363163; PICCOLI G, 1994, J CHROMATOGR A, V676, P239, DOI 10.1016/0021-9673(94)80465-6; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SCHWARZ A, 1995, J INVEST DERMATOL, V104, P922, DOI 10.1111/1523-1747.ep12606202; SHAOUL E, 1995, ONCOGENE, V10, P357; Sheikh MS, 1998, ONCOGENE, V17, P2555, DOI 10.1038/sj.onc.1202292; STAIANOCOICO L, 1993, J EXP MED, V178, P865, DOI 10.1084/jem.178.3.865; VESSEY DA, 1995, J INVEST DERMATOL, V104, P355, DOI 10.1111/1523-1747.ep12665382; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; Wikonkal NM, 1999, J INVEST DERM SYMP P, V4, P6, DOI 10.1038/sj.jidsp.5640173; Zhou Y, 1996, Exp Dermatol, V5, P138, DOI 10.1111/j.1600-0625.1996.tb00108.x	41	52	57	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 24	2003	22	16					2422	2431		10.1038/sj.onc.1206301	http://dx.doi.org/10.1038/sj.onc.1206301			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	670AD	12717419				2022-12-28	WOS:000182383500005
J	Shelton, JG; Steelman, LS; Lee, JT; Knapp, SL; Blalock, WL; Moye, PW; Franklin, RA; Pohnert, SC; Mirza, AM; McMahon, M; McCubrey, JA				Shelton, JG; Steelman, LS; Lee, JT; Knapp, SL; Blalock, WL; Moye, PW; Franklin, RA; Pohnert, SC; Mirza, AM; McMahon, M; McCubrey, JA			Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells	ONCOGENE			English	Article						Raf; PI3K; Akt; apoptosis; signal transduction; hematopoietic cells; cytokine dependence; annexin V binding; autocrine transformation	ACTIVATED PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; B-RAF; DIFFERENTIAL ABILITIES; NEGATIVE REGULATION; DEREGULATED RAF; PHOSPHORYLATION; TRANSFORMATION; EXPRESSION; BAD	The Raf/MEK/ERK kinase cascade is pivotal in transmitting signals from membrane receptors to transcription factors that control gene expression culminating in the regulation of cell cycle progression. This cascade can prevent cell death through ERK2 and p90(Rsk) activation and phosphorylation of apoptotic and cell cycle regulatory proteins. The PI3K/Akt kinase cascade also controls apoptosis and can phosphorylate many apoptotic and cell cycle regulatory proteins. These pathways are interwoven as Akt can phosphorylate Raf and result in its inactivation, and Raf can be required for the antiapoptotic effects of Akt. In this study, the effects of activated Raf (Raf-1, A-Raf and B-Raf) and PI3K/Akt proteins on abrogation of cytokine dependence in FL5.12 hematopoietic cells were examined. Activated Raf, PI3K or Akt expression, by themselves, did not readily relieve cytokine dependence. The presence of activated Raf and PI3K/Akt increased the isolation of factor-independent cells from 400- to 2506-fold depending upon the particular combination examined. The individual effects of activated Raf and Akt on proliferation, apoptosis and autocrine growth factor synthesis were further examined with hormone-inducible constructs (DeltaRaf-1:AR and DeltaAkt:ER*(Myr(+)). Activation of either Raf or Akt hindered cell death; however, both proliferation and maximal synthesis of autocrine cytokines were dependent upon activation of both signaling' pathways. The effects of small molecular weight inhibitors on DNA synthesis and cytokine gene expression were also examined. The PI3K inhibitor, LY294002, inhibited growth and cytokine gene expression. This effect could be synergistically increased by addition of the MEK inhibitor UO126. These cells will be useful in elucidating the interactions between Raf/MEK/ ERK and PI3K/Akt cascades in proliferation, apoptosis, and leukernogenesis, as well as evaluating the efficacy of signal transduction inhibitors that target these cascades.	E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Greenville, NC 27858 USA; E Carolina Univ, Brody Sch Med, Leo Jenkins Canc Ctr, Greenville, NC 27858 USA; E Carolina Univ, Brody Sch Med, Dept Biochem, Greenville, NC 27858 USA; Univ Calif San Francisco, Mt Zion Med Ctr, San Francisco, CA 94115 USA	University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Medical Center at Mount Zion	McCubrey, JA (corresponding author), E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Brody Bldg 5N98C, Greenville, NC 27858 USA.	mccubreyj@mail.ecu.edu	Blalock, William L/C-6959-2019	Blalock, William L/0000-0002-8045-4840; Franklin, Richard A./0000-0003-0299-9578; McCubrey, James/0000-0001-6027-3156				Blalock WL, 1999, LEUKEMIA, V13, P1109, DOI 10.1038/sj.leu.2401493; Blalock WL, 2001, LEUKEMIA, V15, P794, DOI 10.1038/sj.leu.2402109; Blalock WL, 2000, LEUKEMIA, V14, P1080, DOI 10.1038/sj.leu.2401793; Blalock WL, 2000, ONCOGENE, V19, P526, DOI 10.1038/sj.onc.1203337; Bosch E, 1997, ONCOGENE, V15, P1021, DOI 10.1038/sj.onc.1201270; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; Chang FM, 2001, ONCOGENE, V20, P4354, DOI 10.1038/sj.onc.1204564; Chang FM, 2002, CELL CYCLE, V1, P220, DOI 10.4161/cc.1.3.128; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; Craddock BL, 1997, J BIOL CHEM, V272, P29281, DOI 10.1074/jbc.272.46.29281; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0; EYCHENE A, 1995, ONCOGENE, V10, P1159; Gelfanov VM, 2001, BLOOD, V98, P2508, DOI 10.1182/blood.V98.8.2508; Guan KL, 2000, J BIOL CHEM, V275, P27354; Hoyle PE, 2000, LEUKEMIA, V14, P642, DOI 10.1038/sj.leu.2401720; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kubota Y, 1998, CELL GROWTH DIFFER, V9, P247; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; Majewski M, 1999, CANCER RES, V59, P2815; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL M, 1995, MOL REPROD DEV, V42, P493, DOI 10.1002/mrd.1080420418; MCCUBREY J, 1989, ONCOGENE RES, V4, P97; McCubrey JA, 2001, ADV ENZYME REGUL, V41, P289, DOI 10.1016/S0065-2571(00)00021-2; McCubrey JA, 1998, LEUKEMIA, V12, P1903, DOI 10.1038/sj.leu.2401215; McCubrey JA, 2001, CANCER DETECT PREV, V25, P375; McCubrey JA, 2000, ADV ENZYME REGUL, V40, P305, DOI 10.1016/S0065-2571(99)00033-3; McCubrey JA, 2000, LEUKEMIA, V14, P9, DOI 10.1038/sj.leu.2401657; MCCUBREY JA, 2001, CELL CYCLE CHECKPOIN, P17; MCCUBREY JA, 2001, CELL CYCLE CHECKPOIN, P1; MCCUE JL, 1991, BRIT J SURG, V78, P921, DOI 10.1002/bjs.1800780808; McIlroy J, 1997, MOL CELL BIOL, V17, P248, DOI 10.1128/MCB.17.1.248; MCKEARN JP, 1985, P NATL ACAD SCI USA, V82, P7414, DOI 10.1073/pnas.82.21.7414; McMahon M, 2001, METHOD ENZYMOL, V332, P401; Minshall C, 1996, J IMMUNOL, V156, P939; Mirza AM, 2000, CELL GROWTH DIFFER, V11, P279; Mischak H, 1996, MOL CELL BIOL, V16, P5409; Mizutani S, 2001, FEBS LETT, V507, P295, DOI 10.1016/S0014-5793(01)02992-1; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Moye PW, 2000, LEUKEMIA, V14, P1060, DOI 10.1038/sj.leu.2401792; RAPP UR, 1988, LUNG CANCER, V4, P162; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RodriguezViciana P, 1996, PHILOS T ROY SOC B, V351, P225, DOI 10.1098/rstb.1996.0020; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; STORM SM, 1993, TOXICOL LETT, V67, P201, DOI 10.1016/0378-4274(93)90056-4; Sutor SL, 1999, J BIOL CHEM, V274, P7002, DOI 10.1074/jbc.274.11.7002; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; von Gise A, 2001, MOL CELL BIOL, V21, P2324, DOI 10.1128/MCB.21.7.2324-2336.2001; Weber CK, 2001, CANCER RES, V61, P3595; Weinstein-Oppenheimer C, 2000, LEUKEMIA, V14, P1921, DOI 10.1038/sj.leu.2401926; WEINSTEINOPPENH.CR, 2000, PHARMACOL THERAPEUT, V88, P230; Wick MJ, 2000, J BIOL CHEM, V275, P40400, DOI 10.1074/jbc.M003937200; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052; Zhang BH, 2001, J BIOL CHEM, V276, P31620, DOI 10.1074/jbc.M102808200; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	68	87	94	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2003	22	16					2478	2492		10.1038/sj.onc.1206321	http://dx.doi.org/10.1038/sj.onc.1206321			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	670AD	12717425				2022-12-28	WOS:000182383500011
J	Kanaya, T; Kyo, S; Maida, Y; Yatabe, N; Tanaka, M; Nakamura, M; Inoue, M				Kanaya, T; Kyo, S; Maida, Y; Yatabe, N; Tanaka, M; Nakamura, M; Inoue, M			Frequent hypermethylation of MLH1 promoter in normal endometrium of patients with endometrial cancers	ONCOGENE			English	Article						MLH1; methylation; promoter; endometrial cancer; microsatellite instability	NONPOLYPOSIS COLON-CANCER; ISLAND METHYLATOR PHENOTYPE; MICROSATELLITE INSTABILITY; COLORECTAL-CANCER; CARCINOMA; MUTATIONS; HMLH1; PTEN; CARCINOGENESIS; CONSEQUENCES	Silencing of the MLH1 gene by promoter hypermethylation is the mechanism underlying the microsatellite instability (MSI) phenotype in endometrial cancers. However, the profile of CpG methylation in a wide range of MLH1 promoters in endometrial cancers and in the normal endometrium is largely unknown. The present study investigates the region 700 bp upstream of MLH1 covering 48 CpG sites using bisulfite sequencing. Methylation status was classified as full (over 80% of CpGs are methylated), partial (10-80%) or nonmethylation (less than 10%). Of 56 endometrioid endometrial cancers, 16 (29%) were fully methylated, 14 (25%) were partially methylated and 26 (46%) were not methylated. Analyses of MLH1 by immunohistochemical means and of MSI revealed that the degree, rather than region-specific methylation of CpG islands is critical for decreased MLH1 expression and the MSI phenotype. Among 12 patients with methylated cancers, five (42%) patients contained methylated promoters in their normal endometria with profiles similar to those of cancer lesions, and these were associated with the MSI phenotype. In contrast, only one of 31 (3%) normal endometria from patients without endometrial malignancies harbored methylated promoters. These findings suggest that hypermethylation of the MLH1 promoter is frequent in the histologically normal endometrium adjacent to cancers, supporting the notion that hypermethylation of mismatch repair genes is the initial step that triggers various genetic events in endometrial carcinogenesis.	Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, Kanazawa, Ishikawa 9208641, Japan	Kanazawa University	Kyo, S (corresponding author), Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, 13-1 Takaramachi, Kanazawa, Ishikawa 9208641, Japan.							BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BURKS RT, 1994, ONCOGENE, V9, P1163; Deng GR, 1999, CANCER RES, V59, P2029; Deng GR, 2001, ONCOGENE, V20, P7120, DOI 10.1038/sj.onc.1204891; DUGGAN BD, 1994, J NATL CANCER I, V86, P1216, DOI 10.1093/jnci/86.16.1216; Esteller M, 1998, ONCOGENE, V17, P2413, DOI 10.1038/sj.onc.1202178; Esteller M, 2001, CANCER RES, V61, P3225; Esteller M, 1999, AM J PATHOL, V155, P1767, DOI 10.1016/S0002-9440(10)65492-2; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Gurin CC, 1999, CANCER RES, V59, P462; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Inoue M, 2001, INT J GYNECOL CANCER, V11, P339, DOI 10.1046/j.1525-1438.2001.01046.x; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KATABUCHI H, 1995, CANCER RES, V55, P5556; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Mutter GL, 2001, CANCER RES, V61, P4311; Mutter GL, 2000, JNCI-J NATL CANCER I, V92, P924, DOI 10.1093/jnci/92.11.924; Nakagawa H, 2001, CANCER RES, V61, P6991; Papadopoulos N, 1997, HUM MUTAT, V10, P89, DOI 10.1002/(SICI)1098-1004(1997)10:2<89::AID-HUMU1>3.3.CO;2-K; Peltomaki P, 1997, ADV CANCER RES, V71, P93, DOI 10.1016/S0065-230X(08)60097-4; Simpkins SB, 1999, HUM MOL GENET, V8, P661, DOI 10.1093/hmg/8.4.661; Tashiro H, 1997, CANCER RES, V57, P3935; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Toyota M, 1999, CANCER RES, V59, P5438; Zhou XP, 2002, HUM MOL GENET, V11, P445, DOI 10.1093/hmg/11.4.445	27	69	72	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 17	2003	22	15					2352	2360		10.1038/sj.onc.1206365	http://dx.doi.org/10.1038/sj.onc.1206365			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	667KV	12700670	Green Submitted			2022-12-28	WOS:000182231500013
J	von Haefen, C; Wieder, T; Essmann, F; Schulze-Osthoff, K; Dorken, B; Daniel, PT				von Haefen, C; Wieder, T; Essmann, F; Schulze-Osthoff, K; Dorken, B; Daniel, PT			Paclitaxel-induced apoptosis in BJAB cells proceeds via a death receptor-independent, caspases-3/-8-driven mitochondrial amplification loop	ONCOGENE			English	Article						chemotherapy; apoptosis; mitochondria; amplification loop; BJAB cells; caspase-3; caspase-8; cytochrome c; Bcl-x(L); taxol; paclitaxel	DRUG-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; CANCER CELLS; CASPASE-8 ACTIVATION; SIGNAL-TRANSDUCTION; OCCURS DOWNSTREAM; CARCINOMA-CELLS; PATHWAYS; BCL-2; RADIATION	Caspase-8 is a key effector of death-receptor-triggered apoptosis. In a previous study, we demonstrated, however, that caspase-8 can also be activated in a death receptor-independent manner via the mitochondrial apoptosis pathway, downstream of caspase-3. Here, we show that caspases-3 and -8 mediate a mitochondrial amplification loop that is required for the optimal release of cytochrome c, mitochondrial permeability shift transition, and cell death during apoptosis induced by treatment with the microtubule-damaging agent paclitaxel (Taxol). In contrast, Smac release from mitochondria followed a different pattern, and therefore seems to be regulated independently from cytochrome c release. Taxol-induced cell death was inhibited by the use of synthetic, cell-permeable caspase-3- (zDEVD-fmk) or caspase-8-specific (zIETD-fmk) inhibitors. Apoptosis signaling was not affected by a dominant-negative FADD mutant (FADD-DN), thereby excluding a role of death receptor signaling in the amplification loop and drug-induced apoptosis. The inhibitor experiments were corroborated by the use of BJAB cells overexpressing the natural serpin protease inhibitor, cytokine response modifier A. These data demonstrate that the complete activation of mitochondria, release of cytochrome c, and execution of drug-induced apoptosis require a mitochondrial amplification loop that depends on caspases-3 and -8 activation. In addition, this is the first report to demonstrate death receptor-independent caspase-8 autoprocessing in vivo.	Humboldt Univ, Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany; Univ Dusseldorf, Inst Mol Med, D-4000 Dusseldorf, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Heinrich Heine University Dusseldorf	Daniel, PT (corresponding author), Humboldt Univ, Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, Campus Berlin Buch,Lindenberger Weg 80, D-13125 Berlin, Germany.		Essmann, Frank/ABG-7409-2020; Schulze-Osthoff, Klaus/N-9025-2013	Essmann, Frank/0000-0003-4369-8456; Schulze-Osthoff, Klaus/0000-0003-1443-2720				Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Biswas RS, 2001, MOL CELL BIOCHEM, V225, P7, DOI 10.1023/A:1012203110027; Bricker K.S., 1978, Kasetsart University Fisheries Research Bulletin, V10, P1; Calastretti A, 2001, ONCOGENE, V20, P6172, DOI 10.1038/sj.onc.1204751; Charles AG, 2001, CANCER CHEMOTH PHARM, V47, P444, DOI 10.1007/s002800000265; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; Daniel PT, 2000, LEUKEMIA, V14, P2035, DOI 10.1038/sj.leu.2401940; Das GC, 2001, CANCER LETT, V165, P147, DOI 10.1016/S0304-3835(01)00404-9; DHEIN J, 1992, J IMMUNOL, V149, P3166; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Essmann F, 2000, BIOCHEM J, V346, P777, DOI 10.1042/0264-6021:3460777; Fadeel B, 2000, LEUKEMIA, V14, P1514, DOI 10.1038/sj.leu.2401871; Friedrich K, 2001, ONCOGENE, V20, P2749, DOI 10.1038/sj.onc.1204342; Friesen C, 1999, LEUKEMIA, V13, P1854, DOI 10.1038/sj.leu.2401333; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Fulda S, 2001, ONCOGENE, V20, P1063, DOI 10.1038/sj.onc.1204141; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Huang Y, 1999, ONCOGENE, V18, P3431, DOI 10.1038/sj.onc.1202685; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Kitamura K, 2000, LEUKEMIA, V14, P1743, DOI 10.1038/sj.leu.2401900; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; LAMBERT IH, 1989, J MEMBRANE BIOL, V111, P113, DOI 10.1007/BF01871776; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Madesh M, 2002, J BIOL CHEM, V277, P5651, DOI 10.1074/jbc.M108171200; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Nomura Y, 2000, LEUKEMIA, V14, P299, DOI 10.1038/sj.leu.2401649; Oyaizu H, 1999, Mol Cell Biol Res Commun, V2, P36, DOI 10.1006/mcbr.1999.0146; Pan JX, 2001, J CLIN ENDOCR METAB, V86, P4731, DOI 10.1210/jc.86.10.4731; Perkins CL, 2000, CANCER RES, V60, P1645; Prokop A, 2000, LEUKEMIA, V14, P1606, DOI 10.1038/sj.leu.2401866; Radetzki S, 2002, ONCOGENE, V21, P227, DOI 10.1038/sj/onc/1205010; Reers M, 1995, METHOD ENZYMOL, V260, P406, DOI 10.1016/0076-6879(95)60154-6; Rokhlin OW, 2001, ONCOGENE, V20, P2836, DOI 10.1038/sj.onc.1204410; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stepczynska A, 2001, ONCOGENE, V20, P1193, DOI 10.1038/sj.onc.1204221; Sugiyama T, 2002, ONCOGENE, V21, P4944, DOI 10.1038/sj.onc.1205621; Suliman A, 2001, ONCOGENE, V20, P2122, DOI 10.1038/sj.onc.1204282; Suzuki A, 1998, EUR J PHARMACOL, V343, P87, DOI 10.1016/S0014-2999(97)01520-3; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Wang LG, 1999, CANCER CHEMOTH PHARM, V44, P355, DOI 10.1007/s002800050989; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Zamzami N, 2000, ONCOGENE, V19, P6342, DOI 10.1038/sj.onc.1204030; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	52	149	153	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 17	2003	22	15					2236	2247		10.1038/sj.onc.1206280	http://dx.doi.org/10.1038/sj.onc.1206280			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	667KV	12700660				2022-12-28	WOS:000182231500003
J	Zhang, F; Li, C; Halfter, H; Liu, JW				Zhang, F; Li, C; Halfter, H; Liu, JW			Delineating an oncostatin M-activated STAT3 signaling pathway that coordinates the expression of genes involved in cell cycle regulation and extracellular matrix deposition of MCF-7 cells	ONCOGENE			English	Article						oncostatin M; STAT3; cell growth; cell migration; extracellular matrix	C-MYC-GENE; INDUCED GROWTH-INHIBITION; P53 TUMOR-SUPPRESSOR; BREAST-CANCER CELLS; INTERFERON-GAMMA; TRANSDUCER; INDUCTION; TRANSCRIPTION; BINDING; DIFFERENTIATION	A number of studies have demonstrated that the STAT pathway is an important signaling cascade utilized by the IL-6 cytokine family to regulate a variety of cell functions. However, the downstream target genes of STAT activation that mediate the cytokine-induced cellular responses are largely uncharacterized. The aims of the current study are to determine whether the STAT signaling pathway is critically involved in the oncostatin M (OM)-induced growth inhibition and morphological changes of MCF-7 cells and to identify STAT3-target genes that are utilized by OM to regulate cell growth and morphology. We show that expression of a dominant negative (DN) mutant of STAT3 in MCF-7 cells completely eliminated the antiproliferative activity of OM, whereas expression of DN STAT1 had no effect. The growth inhibition of breast cancer cells was achieved through a concerted action of OM on cell cycle components. We have identified four cell cycle regulators including c-myc, cyclin D1, c/EBPdelta, and p53 as downstream effectors of the OM-activated STAT3 signaling cascade. The expression of these genes is differentially regulated by OM in MCF-7 cells, but is unaffected by OM in MCF-7-dnStat3 stable clones. We also demonstrate that the OM-induced morphological changes are correlated with increased cell motility in a STAT3-dependent manner. Expression analysis of extracellular matrix (ECM) proteins leads to the identification of fibronectin as a novel OM-regulated ECM component. Our studies further reveal that STAT3 plays a key role in the robust induction of fibronectin expression by OM in MCF-7 and T47D cells. These new findings provide a molecular basis for the mechanistic understanding of the effects of OM on cell growth and migration.	VA Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA; Univ Munster, Dept Neurol & Internal Med A Oncol, D-4400 Munster, Germany	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; University of Munster	Liu, JW (corresponding author), VA Palo Alto Hlth Care Syst, 154P,3801 Miranda Ave, Palo Alto, CA 94304 USA.	jingwen.liu@med.va.gov			NCI NIH HHS [1R01CA83648-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083648] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Badache A, 2001, CANCER RES, V61, P383; Bamber B, 1998, J MOL MED-JMM, V76, P61, DOI 10.1007/s109-1998-8105-3; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; BROWN TJ, 1987, J IMMUNOL, V139, P2977; Carroll JS, 2002, CANCER RES, V62, P3126; Catterall JB, 2001, ARTHRITIS RHEUM-US, V44, P2296, DOI 10.1002/1529-0131(200110)44:10<2296::AID-ART392>3.0.CO;2-9; Chang TLY, 2000, J BIOL CHEM, V275, P10212, DOI 10.1074/jbc.275.14.10212; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Douglas AM, 1998, INT J CANCER, V75, P64, DOI 10.1002/(SICI)1097-0215(19980105)75:1<64::AID-IJC11>3.0.CO;2-D; Douglas AM, 1997, ONCOGENE, V14, P661, DOI 10.1038/sj.onc.1200882; DUNCAN MR, 1995, J INVEST DERMATOL, V104, P128, DOI 10.1111/1523-1747.ep12613623; Grant SL, 2002, ONCOGENE, V21, P460, DOI 10.1038/sj.onc.1205100; GROVE RI, 1993, P NATL ACAD SCI USA, V90, P823, DOI 10.1073/pnas.90.3.823; GROVE RI, 1991, J LIPID RES, V32, P1889; Halfter H, 2000, J NEUROCHEM, V75, P973, DOI 10.1046/j.1471-4159.2000.0750973.x; Halfter H, 1998, GROWTH FACTORS, V15, P135, DOI 10.3109/08977199809117189; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Hirano Toshio, 1997, Cytokine and Growth Factor Reviews, V8, P241, DOI 10.1016/S1359-6101(98)80005-1; Horn D, 1990, GROWTH FACTORS, V2, P157, DOI 10.3109/08977199009071502; Hutt JA, 2000, J BIOL CHEM, V275, P29123, DOI 10.1074/jbc.M004476200; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; Kerr C, 1999, J INTERF CYTOK RES, V19, P1195, DOI 10.1089/107999099313145; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Kortylewski M, 1999, ONCOGENE, V18, P3742, DOI 10.1038/sj.onc.1202708; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; Li C, 2001, BREAST CANCER RES TR, V66, P111, DOI 10.1023/A:1010614724664; Li C, 2001, ONCOGENE, V20, P8193, DOI 10.1038/sj.onc.1205046; LI W, 2002, J BIOL CHEM, V1, P1; Li WQ, 2001, J IMMUNOL, V166, P3491, DOI 10.4049/jimmunol.166.5.3491; Lin JY, 2002, CANCER RES, V62, P376; Liu HF, 1999, WORLD J GASTROENTERO, V5, P15; Liu JW, 1997, CELL GROWTH DIFFER, V8, P667; LIU JW, 1992, CELL GROWTH DIFFER, V3, P307; Mahboubi K, 2002, J BIOL CHEM, V277, P8012, DOI 10.1074/jbc.M107542200; Makogonenko E, 2002, BIOCHEMISTRY-US, V41, P7907, DOI 10.1021/bi025770x; MARSTERS P, 2002, BIOCHEM J, V1, P1; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Noda A, 2000, ONCOGENE, V19, P21, DOI 10.1038/sj.onc.1203230; Rayanade RJ, 1997, J BIOL CHEM, V272, P4659, DOI 10.1074/jbc.272.8.4659; Rayanade RJ, 1998, J IMMUNOL, V161, P325; Sauter ER, 2002, CANCER RES, V62, P3200; Schaefer LK, 2000, CYTOKINE, V12, P1647, DOI 10.1006/cyto.2000.0774; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Spence MJ, 1997, CANCER RES, V57, P2223; Strand K, 2000, J CELL BIOCHEM, V79, P239, DOI 10.1002/1097-4644(20001101)79:2<239::AID-JCB70>3.0.CO;2-2; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Wahl AF, 2001, ANN RHEUM DIS, V60, pIII75; Yamada T, 1997, J BIOCHEM-TOKYO, V121, P731; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739; Zhang DX, 1996, J BIOL CHEM, V271, P9503, DOI 10.1074/jbc.271.16.9503; ZHANG XG, 1994, J EXP MED, V179, P1337, DOI 10.1084/jem.179.4.1337	53	97	103	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2003	22	6					894	905		10.1038/sj.onc.1206158	http://dx.doi.org/10.1038/sj.onc.1206158			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584569				2022-12-28	WOS:000180864300012
J	Crowder, C; Kopantzev, E; Williams, K; Lengel, C; Miki, T; Rudikoff, S				Crowder, C; Kopantzev, E; Williams, K; Lengel, C; Miki, T; Rudikoff, S			An unusual H-Ras mutant isolated from a human multiple myeloma line leads to transformation and factor-independent cell growth	ONCOGENE			English	Article						Ras; mutation; transformation; growth factor independence	GUANINE-NUCLEOTIDE-BINDING; N-RAS; K-RAS; ACTIVATING MUTATIONS; STRUCTURAL DIFFERENCES; TRANSDUCTION PATHWAY; SIGNAL-TRANSDUCTION; FACTOR RECEPTOR-3; LIVER-TUMORS; PRODUCT P21	Multiple myeloma (MM) is an incurable plasma cell malignancy. To investigate biochemical lesions associated,with MM, we constructed an expression cDNA library from the OPM-2 human myeloma line. A highly transforming H-Ras mutant was identified by transfection analysis using NIH 3T3 cells. DNA sequencing demonstrated a single-point mutation at position 117 located in the guanine nucleotide-binding site resulting in a lysine-to-glutamic acid substitution. This mutant, H-Ras (K117E), was found to be constitutively activated in terms of GTP binding. We compared the biological effects of H-Ras (K117E) and H-Ras (G12V) in 32D murine hematopoietic progenitor cells. Whereas both Ras proteins are constitutively activated, 32D cells expressing H-Ras (G12V) are still dependent on IL-3 for survival and proliferation while cells carrying H-Ras (K117E) become IL-3 independent. Similar experiments conducted with the B9 line, an IL-6-dependent hybridoma, also demonstrated that B9/H-Ras (KI17E) became IL-6-independent. Expression of H-Ras (K117E) in the human IL-6-dependent ANBL-6 myeloma line resulted in enhanced proliferation at suboptimal concentrations of IL-6. These observations suggest that H-Ras mutations at the binding site for the GTP nucleotide ring structure may also represent activating lesions and have additional biological effects when compared to previously described Ras mutants.	NCI, Lab Cellular & Mol Biol, NIH, Bethesda, MD 20892 USA; NCI, Mol Tumor Biol Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rudikoff, S (corresponding author), NCI, Lab Cellular & Mol Biol, NIH, Bethesda, MD 20892 USA.	rudikoff@helix.nih.gov			DIVISION OF BASIC SCIENCES - NCI [Z01BC005553] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANNA CH, 1994, CARCINOGENESIS, V15, P2255, DOI 10.1093/carcin/15.10.2255; Bergsagel PL, 1996, P NATL ACAD SCI USA, V93, P13931, DOI 10.1073/pnas.93.24.13931; BERGUI L, 1989, J EXP MED, V170, P613, DOI 10.1084/jem.170.2.613; Bezieau S, 2001, HUM MUTAT, V18, P212, DOI 10.1002/humu.1177; Billadeau D, 1997, CANCER RES, V57, P2268; BILLADEAU D, 1995, CANCER RES, V55, P3640; BOS JL, 1987, BLOOD, V69, P1237; Chesi M, 2000, ANN ONCOL, V11, P131, DOI 10.1023/A:1008300325610; Chesi M, 2001, BLOOD, V97, P729, DOI 10.1182/blood.V97.3.729; CLANTON DJ, 1986, P NATL ACAD SCI USA, V83, P5076, DOI 10.1073/pnas.83.14.5076; Cool RH, 1999, MOL CELL BIOL, V19, P6297; CORRADINI P, 1994, LEUKEMIA LYMPHOMA, V15, P17, DOI 10.3109/10428199409051673; Cristofanelli B, 2000, ONCOGENE, V19, P3245, DOI 10.1038/sj.onc.1203664; DER CJ, 1986, MOL CELL BIOL, V6, P3291, DOI 10.1128/MCB.6.9.3291; DIAMANT M, 1994, J IMMUNOL METHODS, V173, P229, DOI 10.1016/0022-1759(94)90301-8; Drach J, 2000, J CANCER RES CLIN, V126, P441, DOI 10.1007/s004320050011; Ferlin M, 2000, BRIT J HAEMATOL, V111, P626, DOI 10.1046/j.1365-2141.2000.02364.x; FREUND GG, 1993, J IMMUNOL, V151, P1811; Ge NL, 2000, BLOOD, V96, P2856; GeorgiiHemming P, 1996, BLOOD, V88, P2250, DOI 10.1182/blood.V88.6.2250.bloodjournal8862250; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HILBERT DM, 1995, J EXP MED, V182, P243, DOI 10.1084/jem.182.1.243; Hilbert DM, 1996, IMMUNITY, V5, P81, DOI 10.1016/S1074-7613(00)80312-X; Ho PJ, 2001, BLOOD, V97, P490, DOI 10.1182/blood.V97.2.490; HONGYO T, 1993, NUCLEIC ACIDS RES, V21, P3637, DOI 10.1093/nar/21.16.3637; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Kalakonda N, 2001, BLOOD, V98, P1555, DOI 10.1182/blood.V98.5.1555; Kastrinakis NG, 2000, ANN ONCOL, V11, P1217, DOI 10.1023/A:1008331714186; KATAGIRI S, 1985, INT J CANCER, V36, P241, DOI 10.1002/ijc.2910360217; KLEIN B, 1992, HEMATOL ONCOL CLIN N, V6, P273, DOI 10.1016/S0889-8588(18)30344-7; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; Kuehl WM, 2002, NAT REV CANCER, V2, P175, DOI 10.1038/nrc746; Lattanzio G, 1997, AM J PATHOL, V151, P689; LIDA S, 1997, NAT GENET, V17, P226; LIOTTA LA, 1988, J NATL CANCER I, V80, P468, DOI 10.1093/jnci/80.7.468; Liu PC, 1996, BLOOD, V88, P2699, DOI 10.1182/blood.V88.7.2699.bloodjournal8872699; Liu Q, 2001, EXP HEMATOL, V29, P962, DOI 10.1016/S0301-472X(01)00677-4; MATOZAKI S, 1991, Kobe Journal of Medical Sciences, V37, P35; MIKI T, 1995, METHOD ENZYMOL, V254, P196; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; NERI A, 1989, J EXP MED, V170, P1715, DOI 10.1084/jem.170.5.1715; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAQUETTE RL, 1990, ONCOGENE, V5, P1659; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Rawat R, 2000, BLOOD, V96, P3514; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; Rowley M, 2000, BLOOD, V96, P3175, DOI 10.1182/blood.V96.9.3175.h8003175_3175_3180; Sebti SM, 2000, ONCOGENE, V19, P6584, DOI 10.1038/sj.onc.1204146; Shou YP, 2000, P NATL ACAD SCI USA, V97, P228, DOI 10.1073/pnas.97.1.228; STANLEY LA, 1994, CARCINOGENESIS, V15, P1125, DOI 10.1093/carcin/15.6.1125; TAKAHASHI M, 1994, HEMATOL ONCOL, V12, P53, DOI 10.1002/hon.2900120202; TONG L, 1989, NATURE, V337, P90, DOI 10.1038/337090a0; TSUCHIYA H, 1988, BLOOD, V72, P796; WALTER M, 1986, SCIENCE, V233, P649, DOI 10.1126/science.3487832	56	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2003	22	5					649	659		10.1038/sj.onc.1206180	http://dx.doi.org/10.1038/sj.onc.1206180			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569357				2022-12-28	WOS:000180642100002
J	Li, JX; Ma, CL; Huang, Y; Luo, H; Huang, CS				Li, JX; Ma, CL; Huang, Y; Luo, H; Huang, CS			Differential requirement of EGF receptor and its tyrosine kinase for AP-1 transactivation induced by EGF and TPA	ONCOGENE			English	Article						EGF; TPA; AP-1; kinase and signal transduction	GROWTH-FACTOR RECEPTOR; ACTIVATED PROTEIN-KINASE; CELL-TRANSFORMATION; MECHANISMS; EXPRESSION; BINDING; FAMILY; CANCER; DOMAIN; RAF	The transcription factor activator protein-1 (AP-1) has been implicated in a large variety of biological processes including cell differentiation, proliferation, apoptosis and oncogenic transformation. It is thought that the 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced AP-1 activity is because of the activation of the PKC/MAPK/AP-1 pathway, although the detailed molecular mechanism has not been fully characterized. The tyrosine kinases of epidermal growth factor receptor (EGFR) lie at the head of a complex of signal transduction cascade that modulates cell proliferation, survival, adhesion, migration and differentiation. Currently, little is known about whether EGFR or its tyrosine kinase is necessary for TPA-induced AP-1 activation. In the present study, we investigated this issue using a well-characterized mouse fibroblast B82 cell line, which is devoid of the EGFR, and its stable transfectants with either wild-type EGFR (B82L) or tyrosine kinase-deficient EGFR (mutation at Lys-721) (B82M721). We demonstrated that the TPA or epidermal growth factor (EGF) induced AP-1 activation in the B82L cells that express wild-type EGFR, but not in the B82 cell, whereas autophosphorylation at tyrosine(1173) of EGFR in B82L cells was only induced by EGF, but not TPA. The expression of tyrosine kinase-deficient EGFR (mutation at Lys-721) (B82M721) resulted in deficiency of AP-1 induction in cellular response to EGF, while TPA treatment led to fully AP-1 activation. Furthermore, the mutation at Lys-721 of EGFR resulted in impairing of EGFR autophosphorylation at tyrosinell(1173) induced by EGF. Based on these results, we conclude that TPA-induced AP-1 activation requires the basal level-EGFR protein, but not EGFR tyrosine kinase and EGFR autophosphorylation at tyrosine(1173), whereas both EGFR tyrosine kinase and EGFR autophosphorylation at Y-1173 play a critical role in EGF-induced AP-1 activation.	NYU, Sch Med, Nelson Inst Environm Med, Tuxedo Pk, NY 10987 USA; W Virginia Univ, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA	New York University; West Virginia University	Huang, CS (corresponding author), NYU, Sch Med, Nelson Inst Environm Med, 57 Old Forge Rd, Tuxedo Pk, NY 10987 USA.	chuanshu@env.med.nyu.edu		Huang, Chuanshu/0000-0003-4133-5096; Luo, Jia/0000-0002-6968-3618	NCI NIH HHS [CA 16087] Funding Source: Medline; NIEHS NIH HHS [ES 00260] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000260] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Baker VL, 1998, PLACENTA, V19, P475, DOI 10.1016/S0143-4004(98)91040-2; BLUMBERG PM, 1991, MOL CARCINOGEN, V4, P339, DOI 10.1002/mc.2940040502; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; Chen NY, 2001, J BIOL CHEM, V276, P46722, DOI 10.1074/jbc.M107156200; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; Ciardiello F, 2000, DRUGS, V60, P25, DOI 10.2165/00003495-200060001-00003; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Gulliford T, 1999, CELL SIGNAL, V11, P245, DOI 10.1016/S0898-6568(98)00058-8; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; Huang CS, 1999, J BIOL CHEM, V274, P29672, DOI 10.1074/jbc.274.42.29672; Huang CS, 1997, CANCER RES, V57, P2873; Huang CS, 1997, J BIOL CHEM, V272, P4187, DOI 10.1074/jbc.272.7.4187; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Huang CS, 1997, J BIOL CHEM, V272, P26325, DOI 10.1074/jbc.272.42.26325; Huang CS, 1997, ONCOGENE, V14, P1945, DOI 10.1038/sj.onc.1201056; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; Huang CS, 1999, ONCOGENE, V18, P2828, DOI 10.1038/sj.onc.1202639; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Kong ANT, 2001, MUTAT RES-FUND MOL M, V480, P231, DOI 10.1016/S0027-5107(01)00182-8; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; PRYWES R, 1986, EMBO J, V5, P2179, DOI 10.1002/j.1460-2075.1986.tb04482.x; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schwartz MA, 1999, CURR OPIN CELL BIOL, V11, P197, DOI 10.1016/S0955-0674(99)80026-X; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Simon MA, 2000, CELL, V103, P13, DOI 10.1016/S0092-8674(00)00100-8; SLAGA TJ, 1982, J CELL BIOCHEM, V18, P99, DOI 10.1002/jcb.1982.240180109; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; Watts RG, 1998, ONCOGENE, V17, P3493, DOI 10.1038/sj.onc.1202259; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; XIAN WJ, 1995, CELL GROWTH DIFFER, V6, P1447; Yarden Y, 2001, EUR J CANCER, V37, pS3; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827	38	32	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2003	22	2					211	219		10.1038/sj.onc.1206102	http://dx.doi.org/10.1038/sj.onc.1206102			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527890				2022-12-28	WOS:000180322400006
J	Van Etten, RA				Van Etten, RA			Studying the pathogenesis of BCR-ABL(+) leukemia in mice	ONCOGENE			English	Article						CML; tyrosine kinase; retrovirus; Philadelphia chromosome	CHRONIC MYELOGENOUS LEUKEMIA; BCR-ABL ONCOGENE; CHRONIC MYELOID-LEUKEMIA; COLONY-STIMULATING FACTOR; HEMATOPOIETIC-CELL LINES; GROWTH-FACTOR INDEPENDENCE; SERINE THREONINE KINASE; DNA-BINDING ACTIVITY; TYROSINE KINASE; C-ABL	Animal models of BCR-ABL(+) leukemias have provided important new knowledge about the molecular pathophysiology of these diseases, and answered questions that are difficult or impossible to address using BCR-ABL-expressing cell lines or primary Ph+ leukemia samples from patients. The power of mouse models lies in their ability to recapitulate precisely the phenotypes of BCR-ABL(+) leukemias in vivo, but this comes at the price of significant complexity. Here I review recent studies of leukemias induced in mice by BCR-ABL with an emphasis on the intricate nature of these diseases and the need for careful pathological and molecular analysis.	Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School	Van Etten, RA (corresponding author), Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA.				NCI NIH HHS [CA90576] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090576] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson SM, 1996, BLOOD, V87, P238; Andreasson P, 1997, GENE CHROMOSOME CANC, V20, P299; BRUNEL V, 1996, LEUKEMIA, V10, P2003; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; CHUNG SW, 1991, P NATL ACAD SCI USA, V88, P1585, DOI 10.1073/pnas.88.4.1585; Cortez D, 1997, ONCOGENE, V15, P2333, DOI 10.1038/sj.onc.1201400; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1991, P NATL ACAD SCI USA, V88, P11335, DOI 10.1073/pnas.88.24.11335; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; ELEFANTY AG, 1992, MOL CELL BIOL, V12, P1755, DOI 10.1128/MCB.12.4.1755; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; Era T, 2000, P NATL ACAD SCI USA, V97, P1737, DOI 10.1073/pnas.97.4.1737; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GROOPMAN JE, 1981, ANN INTERN MED, V94, P95, DOI 10.7326/0003-4819-94-1-95; Gross AW, 2000, ONCOGENE, V19, P6286, DOI 10.1038/sj.onc.1204023; HAN XD, 1991, P NATL ACAD SCI USA, V88, P10129, DOI 10.1073/pnas.88.22.10129; Hannemann JR, 1998, BRIT J HAEMATOL, V102, P475, DOI 10.1046/j.1365-2141.1998.00803.x; Hariharan I K, 1988, Oncogene Res, V3, P387; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; ILARIA RL, 1995, BLOOD, V86, P3897, DOI 10.1182/blood.V86.10.3897.bloodjournal86103897; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; Jiang XY, 1999, P NATL ACAD SCI USA, V96, P12804, DOI 10.1073/pnas.96.22.12804; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; Kelly LM, 2002, BLOOD, V99, P310, DOI 10.1182/blood.V99.1.310; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; LANEUVILLE P, 1991, ONCOGENE, V6, P275; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Li SG, 2001, BLOOD, V97, P1442, DOI 10.1182/blood.V97.5.1442; Liu JX, 1996, MOL CELL BIOL, V16, P998; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; Million RP, 2002, BLOOD, V99, P4568, DOI 10.1182/blood-2001-12-0244; Million RP, 2000, BLOOD, V96, P664; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Okuda K, 1996, ONCOGENE, V13, P1147; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; Perlingeiro RCR, 2001, DEVELOPMENT, V128, P4597; Peters DG, 2001, ONCOGENE, V20, P2636, DOI 10.1038/sj.onc.1204374; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Roumiantsev S, 2001, BLOOD, V97, P4, DOI 10.1182/blood.V97.1.4; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; Schwaller J, 1998, EMBO J, V17, P5321, DOI 10.1093/emboj/17.18.5321; SCOTT ML, 1991, P NATL ACAD SCI USA, V88, P6506, DOI 10.1073/pnas.88.15.6506; Shuai K, 1996, ONCOGENE, V13, P247; SKORSKI T, 1995, CANCER RES, V55, P2275; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Tomasson MH, 2000, J CLIN INVEST, V105, P423, DOI 10.1172/JCI8902; Tomasson MH, 2001, BLOOD, V97, P1435, DOI 10.1182/blood.V97.5.1435; Van Etten R A, 2001, Curr Oncol Rep, V3, P228; Van Limbergen H, 2001, GENE CHROMOSOME CANC, V30, P274, DOI 10.1002/1098-2264(2000)9999:9999<1::AID-GCC1089>3.3.CO;2-T; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; VANETTEN RA, 1995, ONCOGENE, V10, P1977; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; Voss J, 2000, ONCOGENE, V19, P1684, DOI 10.1038/sj.onc.1203467; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Wu Y, 1998, ONCOGENE, V16, P141, DOI 10.1038/sj.onc.1201524; Zhang XW, 1998, BLOOD, V92, P3829, DOI 10.1182/blood.V92.10.3829	74	39	40	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	2002	21	56					8643	8651		10.1038/sj.onc.1206091	http://dx.doi.org/10.1038/sj.onc.1206091			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZF	12476310	Green Published			2022-12-28	WOS:000179734300013
J	Bindels, EMJ; Lallemand, F; Balkenende, A; Verwoerd, D; Michalides, R				Bindels, EMJ; Lallemand, F; Balkenende, A; Verwoerd, D; Michalides, R			Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells	ONCOGENE			English	Article						antiestrogens; Gl/S cyclins; breast cancer; cell cycle; estrogen receptor	RETINOBLASTOMA PROTEIN; DEPENDENT KINASES; TRANSCRIPTIONAL ACTIVATION; ECTOPIC EXPRESSION; TRANSGENIC MICE; GENE-EXPRESSION; CDK INHIBITORS; D1; PHOSPHORYLATION; PROGRESSION	Estrogen receptor-mediated transcription is enhanced by overexpression of G1/S cyclins D1, E or A in the presence as well in the absence of estradiol. Excess of G1/S cyclins also prevents the inhibition of transactivation of estrogen receptor (ER) by the pure antiestrogen ICI 182780. Cyclin D1 mediates this transactivation independent of complex formation to its CDK4/6 partner. This raises the possibility that overexpression of G1/S cyclins renders growth of ER-positive breast cancer hormone-independent and resistant to treatment with antiestrogens. Transient transfection of ER-positive breast cancer cell lines T47D and MCF7 with G1/S cyclins could overcome the growth arrest induced by ICI 182780 treatment. The ability of various cyclin D1 mutants to overcome the ICI 182780 mediated growth arrest corresponded with their ability to stimulate cyclin A- and E2F- promoter based reporter activities in the presence of ICI 182780. Transfection of a mutant cyclin D1 (cyclin D1-KE) that was unable to bind CDK4 and was reported to transactivate ER in the presence of ICI 182780, could not stimulate proliferation in ICI 182780 treated cells. On the other hand, cyclin D1-LALA, which is unable to stimulate ERE transactivation, could overcome the ICI 182780 cell cycle arrest. Furthermore, transient transfection of T47D cells using cyclin D1 together with a catalytic inactive mutant of CDK4 (CDK4-DN) indicated that the observed effect is due to binding to CDK inhibitors. However, a moderate, sixfold overexpression of cyclin D1 in stably transfected MCF7 cells did not overcome the ICI 182780 mediated growth arrest. These results indicate that CDK-independent transactivation of the estrogen receptor by cyclin D1 is by itself, not sufficient to result in estradiol-independent growth of breast cancer cells, whereas a vast overexpression of G1/S cyclins is able to do so, most likely by capturing of CDK inhibitors.	Netherlands Canc Inst, Div Tumor Biol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Michalides, R (corresponding author), Netherlands Canc Inst, Div Tumor Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	r.michalides@nki.nl						Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Anderson JJ, 1996, J PATHOL, V180, P65, DOI 10.1002/(SICI)1096-9896(199609)180:1<65::AID-PATH607>3.0.CO;2-C; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; Cangi MG, 2000, J CLIN INVEST, V106, P753, DOI 10.1172/JCI9174; Cariou S, 2000, P NATL ACAD SCI USA, V97, P9042, DOI 10.1073/pnas.160016897; Carroll JS, 2000, J BIOL CHEM, V275, P38221, DOI 10.1074/jbc.M004424200; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Favoni RE, 1998, TRENDS PHARMACOL SCI, V19, P406, DOI 10.1016/S0165-6147(98)01252-8; Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488; Foster JS, 2001, MOL CELL BIOL, V21, P794, DOI 10.1128/MCB.21.3.794-810.2001; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Haas K, 1997, ONCOGENE, V15, P179, DOI 10.1038/sj.onc.1201171; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; Hiyama H, 1997, ONCOGENE, V14, P2533, DOI 10.1038/sj.onc.1201080; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; KEYOMARSI K, 1994, CANCER RES, V54, P380; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamb J, 2000, MOL CELL BIOL, V20, P8667, DOI 10.1128/MCB.20.23.8667-8675.2000; Latella L, 2001, MOL CELL BIOL, V21, P5631, DOI 10.1128/MCB.21.16.5631-5643.2001; Latham KM, 1996, MOL CELL BIOL, V16, P4445; LIPPMAN M, 1976, CANCER RES, V36, P4595; Michalides R, 2002, BRIT J CANCER, V86, P402, DOI 10.1038/sj.bjc.6600072; Michalides R, 1996, BRIT J CANCER, V73, P728, DOI 10.1038/bjc.1996.128; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; NIELSEN NH, 1999, BREAST CANC RES TREA, V74, P874; Pacilio C, 1998, CANCER RES, V58, P871; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Rogatsky I, 1999, J BIOL CHEM, V274, P22296, DOI 10.1074/jbc.274.32.22296; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SoferLevi Y, 1996, ONCOGENE, V13, P2431; Strobeck MW, 2000, ONCOGENE, V19, P1857, DOI 10.1038/sj.onc.1203510; SUTHERLAND RL, 1983, EUR J CANCER CLIN ON, V19, P307, DOI 10.1016/0277-5379(83)90127-X; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Varma H, 2000, ONCOGENE, V19, P4746, DOI 10.1038/sj.onc.1203827; WAKELING AE, 1991, CANCER RES, V51, P3867; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488; Zwijsen RML, 1996, MOL CELL BIOL, V16, P2554	45	41	45	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2002	21	53					8158	8165		10.1038/sj.onc.1206012	http://dx.doi.org/10.1038/sj.onc.1206012			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615DW	12444551				2022-12-28	WOS:000179231400009
J	Peschiaroli, A; Figliola, R; Coltella, L; Strom, A; Valentini, A; D'Agnano, I; Maione, R				Peschiaroli, A; Figliola, R; Coltella, L; Strom, A; Valentini, A; D'Agnano, I; Maione, R			MyoD induces apoptosis in the absence of RB function through a p21(WAF1)-dependent re-localization of cyclin/cdk complexes to the nucleus	ONCOGENE			English	Article						apoptosis; cyclin-cdk; MyoD; p21; retinoblastoma	CELL-CYCLE ARREST; T-EXPRESSING MYOBLASTS; SKELETAL-MUSCLE CELLS; TERMINAL DIFFERENTIATION; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; KINASE-ACTIVITY; CDK INHIBITORS; MYOGENIC DIFFERENTIATION; MYOCYTE DIFFERENTIATION	During differentiation of skeletal myoblasts, MyoD promotes growth arrest through the induction of the cdk inhibitor p21 and the accumulation of hypophosphorylated RB protein. Myoblasts lacking RB function fail to accomplish full differentiation and undergo apoptosis. Here we show that exogenous MyoD induces apoptosis in several cell backgrounds sharing RB inactivation. This process is associated with increased levels of cell cycle-driving proteins and aberrant cell cycle progression. The inability of MyoD to induce apoptosis in a p21-null background, highlights a requirement of p21 in RB-regulated apoptosis during myogenesis. This pro-apoptotic function of p21 cannot be exerted by simple p21 over-expression, but requires the co-operation of MyoD. We also suggest that the essential aspect of p21 activity involved in such a process is related to its ability to induce the nuclear accumulation and aberrant activity of cyclin/cdk complexes. These results establish a novel link between MyoD, p21 and RB during myogenesis, providing new insights into the antagonism between muscle differentiation and loss of RB function.	Univ Roma La Sapienza, Ist Pasteur, Fdn Cenci Bolognetti,Sez Genet Mol, Dipartimento Biotecnol Cellulari & Ematol, I-00161 Rome, Italy; CNR, Ist Tecnol Biomed, I-00137 Rome, Italy	Fondazione Cenci Bolognetti; Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR)	Maione, R (corresponding author), Univ Roma La Sapienza, Ist Pasteur, Fdn Cenci Bolognetti,Sez Genet Mol, Dipartimento Biotecnol Cellulari & Ematol, Piazzale Aldo Moro 5, I-00161 Rome, Italy.		Coltella, Luana/AAA-5263-2020; D'Agnano, Igea/AAR-7282-2020	PESCHIAROLI, ANGELO/0000-0001-6311-2382; D'Agnano, Igea/0000-0002-2646-9224				Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cenciarelli C, 1999, MOL CELL BIOL, V19, P5203; Chen YNP, 1999, P NATL ACAD SCI USA, V96, P4325, DOI 10.1073/pnas.96.8.4325; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Cho SY, 2001, J BIOL CHEM, V276, P33533, DOI 10.1074/jbc.M102906200; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; D'Agnano I, 1998, ENVIRON MOL MUTAGEN, V32, P56, DOI 10.1002/(SICI)1098-2280(1998)32:1<56::AID-EM7>3.0.CO;2-9; D'Agnano I, 2001, ONCOGENE, V20, P2814, DOI 10.1038/sj.onc.1204392; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; de la Serna IL, 2001, J BIOL CHEM, V276, P41486, DOI 10.1074/jbc.M107281200; Dotto GP, 2000, BBA-REV CANCER, V1471, pM43, DOI 10.1016/S0304-419X(00)00019-6; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Fimia GM, 1998, MOL BIOL CELL, V9, P1449, DOI 10.1091/mbc.9.6.1449; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Gottifredi V, 1999, J CELL SCI, V112, P2397; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; Guo K, 1997, J BIOL CHEM, V272, P791, DOI 10.1074/jbc.272.2.791; GUO K, 1995, MOL CELL BIOL, V15, P3823; Guo M, 1999, CURR OPIN CELL BIOL, V11, P745, DOI 10.1016/S0955-0674(99)00046-0; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HU JS, 1990, J BIOL CHEM, V265, P7914; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jiang Z, 2000, DEV BIOL, V227, P28, DOI 10.1006/dbio.2000.9892; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lawlor MA, 2000, MOL CELL BIOL, V20, P8983, DOI 10.1128/MCB.20.23.8983-8995.2000; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MAIONE R, 1994, CELL GROWTH DIFFER, V5, P231; Maione R, 1997, BBA-REV CANCER, V1332, pM19, DOI 10.1016/S0304-419X(96)00036-4; MARTELLI F, 1994, ONCOGENE, V9, P3579; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Naya FJ, 1999, CURR OPIN CELL BIOL, V11, P683, DOI 10.1016/S0955-0674(99)00036-8; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Novitch BG, 1999, CURR BIOL, V9, P449, DOI 10.1016/S0960-9822(99)80210-3; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Poluha W, 1996, MOL CELL BIOL, V16, P1335; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Schreiber M, 1999, ONCOGENE, V18, P1663, DOI 10.1038/sj.onc.1202466; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Tedesco D, 2001, EXP CELL RES, V269, P301, DOI 10.1006/excr.2001.5318; Tsao YP, 1999, J VIROL, V73, P4983, DOI 10.1128/JVI.73.6.4983-4990.1999; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wang J, 1997, CANCER RES, V57, P351; Wei Q, 2001, FEBS LETT, V490, P171, DOI 10.1016/S0014-5793(01)02120-2; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; Yang J, 1999, TRENDS CELL BIOL, V9, P207, DOI 10.1016/S0962-8924(99)01577-9; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; Zhang JM, 1999, EMBO J, V18, P6983, DOI 10.1093/emboj/18.24.6983; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213	66	32	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 21	2002	21	53					8114	8127		10.1038/sj.onc.1206010	http://dx.doi.org/10.1038/sj.onc.1206010			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615DW	12444547				2022-12-28	WOS:000179231400005
J	Arlt, A; Kruse, ML; Breitenbroich, M; Gehrz, A; Koc, B; Minkenberg, J; Folsch, UR; Schafer, H				Arlt, A; Kruse, ML; Breitenbroich, M; Gehrz, A; Koc, B; Minkenberg, J; Folsch, UR; Schafer, H			The early response gene IEX-1 attenuates NF-kappa B activation in 293 cells, a possible counter-regulatory process leading to enhanced cell death	ONCOGENE			English	Article						programmed cell death; cytokines; transcription factor; ribozyme	IMMEDIATE-EARLY GENE; TARGET GENE; IMMUNE-RESPONSES; IN-VIVO; APOPTOSIS; GROWTH; IDENTIFICATION; EXPRESSION; P53; KERATINOCYTES	The early response gene IEX-1 is involved in the regulation of cellular growth and survival, and its expression is related to stress-, growth- and death-inducing signals. Addressing the role of IEX-1 in the promotion of apoptosis, we investigated the effect of IEX-1 on nuclear factor-kappaB (NF-kappaB) activation. Stably transfected HEK-293 cells conditionally overexpressing IEX-1 exhibit decreased levels of NF-kappaB activity, either basal or TNFalpha induced, as shown by gel-shift and luciferase reporter gene assay. Furthermore, activated p65 accumulated in the nuclei of 293 cells to a lower degree, if IEX-1 expression was increased. This inhibited NF-kappaB activation was preceded by an altered turnover of IkappaBalpha and phospho-IkappaBalpha. In addition, IEX-1 expression also inhibited the activity of the 26S-proteasome, as shown by a fluorometric proteasome assay. Conversely, disruption of IEX-1 expression in 293 cells by stable transfection with specific anti-IEX-1 hammerhead ribozymes increased NF-kappaB activity, and accelerated the degradation of IkappaBalpha. Along with these opposite effects of IEX-1 expression and IEX-1 disruption on NF-kappaB activation, the sensitivity of 293 cells towards various apoptotic stimuli also changed. In contrast to ribozyme-transduced 293 cells that were significantly less sensitive to apoptosis, this sensitivity was enhanced if IEX-1 expression was increased. Our data suggest that IEX-1 itself an NF-kappaB target gene - inhibits the activation of this transcription factor, and hereby may counteract the antiapoptodc potential of NF-kappaB.	Univ Kiel, Dept Med 1, Lab Mol Gastroenterol & Hepatol, D-24105 Kiel, Germany	University of Kiel	Schafer, H (corresponding author), Univ Kiel, Dept Med 1, Lab Mol Gastroenterol & Hepatol, Schittenhelmstr 12, D-24105 Kiel, Germany.		Schäfer, Heiner/C-1055-2011; Arlt, Alexander/G-7308-2019	Arlt, Alexander/0000-0002-6160-1059				Arlt A, 2001, ONCOGENE, V20, P69, DOI 10.1038/sj.onc.1204061; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; CHARLES CH, 1993, ONCOGENE, V8, P797; Chen BC, 2002, J BIOL CHEM, V277, P24169, DOI 10.1074/jbc.M106014200; Chen DY, 2002, J BIOL CHEM, V277, P15985, DOI 10.1074/jbc.M108675200; De Keulenaer GW, 2002, CIRC RES, V90, P690, DOI 10.1161/01.RES.0000012922.40318.05; Garcia J, 2002, EMBO J, V21, P5151, DOI 10.1093/emboj/cdf488; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Grobe O, 2001, FEBS LETT, V494, P196, DOI 10.1016/S0014-5793(01)02344-4; Huang YH, 2002, ONCOGENE, V21, P6819, DOI 10.1038/sj.onc.1205854; IM HJ, 2002, J BIOL CHEM, V21, P3706; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kobayashi T, 1998, BIOCHEM BIOPH RES CO, V251, P868, DOI 10.1006/bbrc.1998.9556; Kondratyev AD, 1996, CANCER RES, V56, P1498; Kumar R, 1998, BIOCHEM BIOPH RES CO, V253, P336, DOI 10.1006/bbrc.1998.9692; Masdehors P, 2000, BLOOD, V96, P269, DOI 10.1182/blood.V96.1.269.013k10_269_274; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Ohki R, 2002, J HYPERTENS, V20, P685, DOI 10.1097/00004872-200204000-00026; Pietzsch A, 1997, BIOCHEM BIOPH RES CO, V235, P4, DOI 10.1006/bbrc.1997.6715; Pietzsch A, 1998, BIOCHEM BIOPH RES CO, V245, P651, DOI 10.1006/bbrc.1998.8500; Schafer H, 1999, BIOCHEM BIOPH RES CO, V262, P139, DOI 10.1006/bbrc.1999.1131; Schafer H, 1998, FEBS LETT, V436, P139, DOI 10.1016/S0014-5793(98)01109-0; Schafer H, 1996, CANCER RES, V56, P2641; Schafer H, 1999, PANCREAS, V18, P378, DOI 10.1097/00006676-199905000-00008; Schafer H, 1998, ONCOGENE, V16, P2479, DOI 10.1038/sj.onc.1201788; Schilling D, 2001, ONCOGENE, V20, P7992, DOI 10.1038/sj.onc.1204965; Segev DL, 2000, J BIOL CHEM, V275, P28371, DOI 10.1074/jbc.M004554200; Segev DL, 2001, J BIOL CHEM, V276, P26799, DOI 10.1074/jbc.M103092200; Seitz CS, 2000, CANCER RES, V60, P4085; Spitkovsky D, 2002, J BIOL CHEM, V277, P25576, DOI 10.1074/jbc.M201884200; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Tone Y, 2002, GENE DEV, V16, P3142, DOI 10.1101/gad.1025602; Um JH, 2001, ONCOGENE, V20, P6048, DOI 10.1038/sj.onc.1204732; VAN AD, 1996, SCIENCE, V274, P787; van Hogerlinden M, 2002, ONCOGENE, V21, P4969, DOI 10.1038/sj.onc.1205620; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Zhang Y, 2002, P NATL ACAD SCI USA, V99, P878, DOI 10.1073/pnas.022326699	40	37	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 22	2003	22	21					3343	3351		10.1038/sj.onc.1206524	http://dx.doi.org/10.1038/sj.onc.1206524			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681MM	12761504				2022-12-28	WOS:000183040000016
J	Beghini, A; Magnani, I; Roversi, G; Piepoli, T; Di Terlizzi, S; Moroni, RF; Pollo, B; Conti, AMF; Cowell, JK; Finocchiaro, G; Larizza, L				Beghini, A; Magnani, I; Roversi, G; Piepoli, T; Di Terlizzi, S; Moroni, RF; Pollo, B; Conti, AMF; Cowell, JK; Finocchiaro, G; Larizza, L			The neural progenitor-restricted isoform of the MARK4 gene in 19q13.2 is upregulated in human gliomas and overexpressed in a subset of glioblastoma cell lines	ONCOGENE			English	Article						glioma; MARK4; neural progenitor; upregulation and overexpression; intrachromosomal amplification; Wnt pathway	HUMAN-MALIGNANT GLIOMAS; EPIDERMAL-GROWTH-FACTOR; CENTRAL-NERVOUS-SYSTEM; TUMOR-SUPPRESSOR GENE; BRAIN-TUMORS; HUMAN ASTROCYTOMAS; FACTOR RECEPTOR; FRAGILE SITES; EXPRESSION; AMPLIFICATION	Alterations of 19q13 are frequently observed in glial neoplasms, suggesting that this region harbors at least one gene involved in gliomagenesis. Following our previous studies on structural 19q chromosome rearrangements in gliomas, we have undertaken a detailed FISH analysis of the breakpoints and identified a 19q13.2 intrachromosomal amplification of the MAP/microtubule affinity-regulating kinase 4 (MARK4) gene in three primary glioblastoma cell lines. Recent data suggest that this gene is involved in the Wnt-signating pathway. We observed that the expression of the alternatively spliced MARK4L isoform is upregulated in both fresh and cultured gliomas and overexpressed in all of the above three glioblastoma cell lines. Interestingly, we also found that MARK4L expression is restricted to undifferentiated neural progenitor cells or proliferating glial precursor cells, whereas its expression is downregulated during glial differentiation. Perturbation of expression using antisense oligonucleotides against MARK4 in glioblastoma cell tines, consistently induced a decreased proliferation of tumor cells. Taken together, these data show that MARK4, which is normally expressed in neural progenitors, is re-expressed in gliomas and may become a key target of intrachromosomal amplification upon 19q rearrangements.	Univ Milan, Dept Biol & Genet, I-20133 Milan, Italy; Ist Nazl Neurol Carlo Besta, I-20133 Milan, Italy; Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	University of Milan; IRCCS Istituto Neurologico Besta; Roswell Park Cancer Institute	Beghini, A (corresponding author), Univ Milan, Dept Biol & Genet, Via Viotti 3-5, I-20133 Milan, Italy.	alessandro.beghini@unimi.it	Beghini, Alessandro/F-7306-2012; Finocchiaro, Gaetano/AAG-6791-2020; Pollo, Bianca/K-5347-2018	Pollo, Bianca/0000-0002-5523-4256; Cowell, John/0000-0002-2079-5950; Finocchiaro, Gaetano/0000-0003-3583-4040; Beghini, Alessandro/0000-0002-8234-3474; Moroni, Ramona Frida/0000-0002-0461-3213	NCI NIH HHS [CA76457] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076457] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLO MJ, 1995, INT J CANCER, V64, P207; BIGNER SH, 1988, CANCER RES, V48, P405; Chernova O, 1998, CANCER GENET CYTOGEN, V105, P60, DOI 10.1016/S0165-4608(97)00479-2; Chernova OB, 1998, ONCOGENE, V17, P2873, DOI 10.1038/sj.onc.1202481; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; ELAZOUZI M, 1989, P NATL ACAD SCI USA, V86, P7186, DOI 10.1073/pnas.86.18.7186; Fan SJ, 1998, ONCOGENE, V16, P3069, DOI 10.1038/sj.onc.1202116; GUHA A, 1995, INT J CANCER, V60, P168, DOI 10.1002/ijc.2910600206; Hartmann C, 2002, CANCER RES, V62, P4100; Hellman A, 2002, CANCER CELL, V1, P89, DOI 10.1016/S1535-6108(02)00017-X; HENSON JW, 1994, ANN NEUROL, V36, P714, DOI 10.1002/ana.410360505; Holland EC, 2001, NAT REV GENET, V2, P120, DOI 10.1038/35052535; JEN J, 1994, CANCER RES, V54, P6353; Kato T, 2001, NEOPLASIA, V3, P4, DOI 10.1038/sj.neo.7900132; Koch A, 2001, INT J CANCER, V93, P445, DOI 10.1002/ijc.1342; Lee JC, 2000, GLIA, V30, P105, DOI 10.1002/(SICI)1098-1136(200004)30:2<105::AID-GLIA1>3.0.CO;2-H; Louis DN, 2002, CANCER CELL, V1, P125, DOI 10.1016/S1535-6108(02)00040-5; Magnani I, 1999, CANCER GENET CYTOGEN, V110, P82, DOI 10.1016/S0165-4608(98)00190-3; MAGNANI I, 1994, CANCER GENET CYTOGEN, V75, P77, DOI 10.1016/0165-4608(94)90157-0; MARSDEN HB, 1983, INT J CANCER, V31, P439, DOI 10.1002/ijc.2910310408; Megason SG, 2002, DEVELOPMENT, V129, P2087; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Nagase T, 2001, DNA RES, V8, P85, DOI 10.1093/dnares/8.2.85; NOBEL M, 1997, J NEUROONCOL, V35, P193; PEREGO P, 1994, J CANCER RES CLIN, V120, P585, DOI 10.1007/BF01212812; REIFENBERGER G, 1995, CANCER RES, V55, P731; REIFENBERGER G, 1994, CANCER RES, V54, P4299; RITLAND SR, 1995, GENE CHROMOSOME CANC, V12, P277, DOI 10.1002/gcc.2870120407; Rosenberg JE, 1996, ONCOGENE, V13, P2483; Roth W, 2000, ONCOGENE, V19, P4210, DOI 10.1038/sj.onc.1203783; Sano T, 1999, CANCER RES, V59, P1820; Satoh J, 2000, NEUROPATHOLOGY, V20, P113, DOI 10.1046/j.1440-1789.2000.00293.x; SCHROCK E, 1994, AM J PATHOL, V144, P1203; Smith JS, 2000, GENE CHROMOSOME CANC, V29, P16, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1007>3.3.CO;2-9; SUTHERLAND GR, 1995, CURR OPIN GENET DEV, V5, P323, DOI 10.1016/0959-437X(95)80046-8; Svendsen CN, 1998, J NEUROSCI METH, V85, P141, DOI 10.1016/S0165-0270(98)00126-5; TAKAHASHI JA, 1992, J NEUROSURG, V76, P792, DOI 10.3171/jns.1992.76.5.0792; VONDEIMLING A, 1992, CANCER RES, V52, P4277; Vrieling H, 2001, NAT GENET, V28, P101, DOI 10.1038/88794; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; Zurawel RH, 1998, CANCER RES, V58, P896	42	61	65	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2003	22	17					2581	2591		10.1038/sj.onc.1206336	http://dx.doi.org/10.1038/sj.onc.1206336			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12735302				2022-12-28	WOS:000182569000006
J	Graham, LJ; Veri, MC; DeBell, KE; Noviello, C; Rawat, R; Jen, S; Bonvini, E; Rellahan, B				Graham, LJ; Veri, MC; DeBell, KE; Noviello, C; Rawat, R; Jen, S; Bonvini, E; Rellahan, B			70Z/3 Cbl induces PLC gamma 1 activation in T lymphocytes via an alternate Lat- and Slp-76-independent signaling mechanism	ONCOGENE			English	Article						T lymphocytes; T-cell receptor; signal transduction; PLC gamma 1; c-Cbl	PHOSPHOTYROSINE-BINDING DOMAIN; EPIDERMAL GROWTH-FACTOR; PHOSPHOLIPASE C-GAMMA-1 PLC-GAMMA-1; TEC FAMILY KINASES; CELL RECEPTOR; C-CBL; TYROSINE PHOSPHORYLATION; NEGATIVE REGULATOR; SH2 DOMAIN; ZAP-70	The oncoprotein 70Z/3 Cbl signals in an autonomous fashion or through blockade of endogenous c-Cbl, a negative regulator of signaling. The mechanism of 70Z/3 Cbl-induced signaling was investigated by comparing the molecular requirements for 70Z/3 Cbl- and TCR-induced phospholipase Cgamma1 (PLCgamma1) activation. 70Z/3 Cbl-induced PLCgamma1 tyrosine phosphorylation required, in addition to the PLCgamma1 N-terminal SH2 domain, the C-terminal SH2 and SH3 domains that were dispensable for TCR-induced phosphorylation. Deletion of the leucine zipper of 70Z/3 Cbl did not eliminate 70Z/3 Cbl-induced PLCgamma1 phosphorylation, suggesting that blockage of c-Cbl via dimerization with 70Z/3 Cbl cannot fully explain 70Z/3 Cbl activating characteristics. The complete elimination of PLCgamma1 phosphorylation required deleting the SH3 domain-binding region of 70Z/3 Cbl, consistent with 70Z/3 Cbl binding the PLCgamma1 SH3 domain. 70Z/3 Cbl-induced PLCgamma1 phosphorylation required Zap-70, as for the TCR, and the tyrosine kinase binding domain of 70Z/3 Cbl, which binds Zap-70, but did not require PLCgamma1 binding to Lat, a crucial interaction in TCR-induced PLCgamma1 phosphorylation. Furthermore, 70Z/3 Cbl-induced activation of NFAT, a PLCgamma1/Ca2+-dependent transcriptional event, required Zap-70, but was independent of Slp-76, an adapter required for TCR-induced NFAT activation. These results suggest that 70Z/3 Cbl and PLCgamma1 form a TCR-, Lat- and Slp-76-independent complex that leads to PLCgamma1 phosphorylation and activation.	US FDA, Ctr Biol Evaluat & Res, Div Monoc Antibodies, Immunobiol Lab, Bethesda, MD 20892 USA	US Food & Drug Administration (FDA)	Bonvini, E (corresponding author), HFM-564,29B-3NN10,8800 Rockville Pike, Bethesda, MD 20892 USA.							ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; Bartkiewicz M, 1999, J BIOL CHEM, V274, P30887, DOI 10.1074/jbc.274.43.30887; Boerth NJ, 2000, J EXP MED, V192, P1047, DOI 10.1084/jem.192.7.1047; Bunnell SC, 1996, J BIOL CHEM, V271, P25646, DOI 10.1074/jbc.271.41.25646; Chang JS, 1997, CANCER RES, V57, P5465; DeBell KE, 1999, MOL CELL BIOL, V19, P7388; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; Graham LJ, 1998, BIOCHEM BIOPH RES CO, V249, P537, DOI 10.1006/bbrc.1998.9177; Graham LJ, 2000, FEBS LETT, V470, P273, DOI 10.1016/S0014-5793(00)01341-7; Irvin BJ, 2000, MOL CELL BIOL, V20, P9149, DOI 10.1128/MCB.20.24.9149-9161.2000; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; JOHNSON MD, 1994, HUM PATHOL, V25, P146, DOI 10.1016/0046-8177(94)90270-4; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; LEE SJ, 1995, J BIOL CHEM, V270, P16378, DOI 10.1074/jbc.270.27.16378; Liu YC, 1998, CELL SIGNAL, V10, P377, DOI 10.1016/S0898-6568(97)00179-4; Lupher ML, 1999, IMMUNOL TODAY, V20, P375, DOI 10.1016/S0167-5699(99)01484-X; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; NEUMEISTER EN, 1995, MOL CELL BIOL, V15, P3171; NOH DY, 1994, CANCER, V73, P36, DOI 10.1002/1097-0142(19940101)73:1<36::AID-CNCR2820730108>3.0.CO;2-5; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Rellahan BL, 1997, J BIOL CHEM, V272, P30806, DOI 10.1074/jbc.272.49.30806; RELLAHAN BL, 1994, J EXP MED, V180, P1529, DOI 10.1084/jem.180.4.1529; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Sawasdikosol S, 2000, BBA-REV CANCER, V1471, pM1, DOI 10.1016/S0304-419X(00)00013-5; Schaeffer EM, 2000, CURR OPIN IMMUNOL, V12, P282, DOI 10.1016/S0952-7915(00)00088-1; Shan XC, 2000, MOL CELL BIOL, V20, P6945, DOI 10.1128/MCB.20.18.6945-6957.2000; Shan XC, 1999, J BIOL CHEM, V274, P29323, DOI 10.1074/jbc.274.41.29323; Smith MR, 1998, CARCINOGENESIS, V19, P177, DOI 10.1093/carcin/19.1.177; Stoica B, 1998, J IMMUNOL, V160, P1059; Su YW, 1999, EUR J IMMUNOL, V29, P3702, DOI 10.1002/(SICI)1521-4141(199911)29:11<3702::AID-IMMU3702>3.0.CO;2-R; Thien CBF, 2001, MOL CELL, V7, P355, DOI 10.1016/S1097-2765(01)00183-6; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; TODDERUD G, 1990, SCIENCE, V249, P296, DOI 10.1126/science.2374928; Tsygankov AY, 2001, ONCOGENE, V20, P6382, DOI 10.1038/sj.onc.1204781; van Leeuwen JEM, 1999, MOL CELL BIOL, V19, P6652; van Leeuwen JEM, 1999, J BIOL CHEM, V274, P5153, DOI 10.1074/jbc.274.8.5153; Veri MC, 2001, MOL CELL BIOL, V21, P6939, DOI 10.1128/MCB.21.20.6939-6950.2001; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; Williams BL, 1999, EMBO J, V18, P1832, DOI 10.1093/emboj/18.7.1832; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; Yablonski D, 2001, MOL CELL BIOL, V21, P4208, DOI 10.1128/MCB.21.13.4208-4218.2001; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Yasuda T, 2000, J EXP MED, V191, P641, DOI 10.1084/jem.191.4.641; Zhang WG, 2000, J BIOL CHEM, V275, P23355, DOI 10.1074/jbc.M000404200; Zhang WG, 1999, INT IMMUNOL, V11, P943, DOI 10.1093/intimm/11.6.943; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zhang ZH, 1999, J BIOL CHEM, V274, P4883, DOI 10.1074/jbc.274.8.4883; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	50	5	6	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 24	2003	22	16					2493	2503		10.1038/sj.onc.1206318	http://dx.doi.org/10.1038/sj.onc.1206318			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	670AD	12717426				2022-12-28	WOS:000182383500012
J	Sugano, Y; Matsuzaki, K; Tahashi, Y; Furukawa, F; Mori, S; Yamagata, H; Yoshida, K; Matsushita, M; Nishizawa, M; Fujisawa, J; Inoue, K				Sugano, Y; Matsuzaki, K; Tahashi, Y; Furukawa, F; Mori, S; Yamagata, H; Yoshida, K; Matsushita, M; Nishizawa, M; Fujisawa, J; Inoue, K			Distortion of autocrine transforming growth factor beta signal accelerates malignant potential by enhancing cell growth as well as PAI-1 and VEGF production in human hepatocellular carcinoma cells	ONCOGENE			English	Article						TGF-beta; Smad; HCC; PAI-1; VEGF	PLASMINOGEN-ACTIVATOR INHIBITOR-1; TGF-BETA; HEPATOMA-CELLS; GENE-MUTATIONS; CANCER; UROKINASE; EXPRESSION; RECEPTOR; LIVER; SMAD2	Resistance to growth inhibitory effects of transforming growth factor (TGF)-beta is a frequent consequence of malignant transformation. On the other hand, serum concentrations of TGF-beta, plasminogen activator inhibitor type 1 (PAI-1), and vascular endothelial growth factor (VEGF) are elevated as tumor progresses. The molecular mechanism of autocrine TGF-beta signaling and its effects on PAI-1 and VEGF production in human hepatocellular carcinoma (HCC) is unknown. TGF-beta signaling involves TGF-beta type I receptor-mediated phosphorylation of serine residues within the conserved SSXS motif at the C-terminus of Smad2 and Smad3. To investigate the involvement of autocrine TGF-beta signal in cell growth, PAI-1 and VEGF production of HCC, we made stable transfectants of human HCC line (HuH-7 cells) to express a mutant Smad2(3S-A), in which serine residues of SSXS motif were changed to alanine. The transfectants demonstrated an impaired Smad2 signaling. Along with the resistance to growth inhibition by TGF-beta, forced expression of Smad2(3S-A) induced endogenous TGF-beta secretion. Moreover, this increased TGF-beta enhanced ligand-dependent signaling through the activated Smad3 and Smad4 complex, and transcriptional activities of PAI-1 and VEGF genes. In conclusion, distortion of autocrine TGF-beta signals in human HCC accelerates their malignant potential by enhancing cell growth as well as PAI-1 and VEGF production.	Dept Internal Med 3, Moriguchi, Osaka 5708507, Japan; Dept Med Chem, Moriguchi, Osaka 5708507, Japan; Kansai Med Univ, Dept Microbiol, Moriguchi, Osaka 5708507, Japan	Kansai Medical University	Matsuzaki, K (corresponding author), Dept Internal Med 3, 10-15 Fumizonocho, Moriguchi, Osaka 5708507, Japan.	matsuzak@takii.kmu.ac.jp						Abelev G I, 1971, Adv Cancer Res, V14, P295, DOI 10.1016/S0065-230X(08)60523-0; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; Date M, 1998, J HEPATOL, V28, P572, DOI 10.1016/S0168-8278(98)80280-8; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; DVORAK HF, 1991, J EXP MED, V174, P1275, DOI 10.1084/jem.174.5.1275; Engel ME, 1998, J CELL BIOCHEM, P111; Fan GS, 1996, ONCOGENE, V12, P1909; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1; Gutierrez LS, 2000, CANCER RES, V60, P5839; HEALY AM, 1994, J BIOL CHEM, V269, P19095; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Matsuzaki K, 2000, CANCER RES, V60, P1394; Matsuzaki K, 2000, HEPATOLOGY, V32, P218, DOI 10.1053/jhep.2000.9145; MATSUZAKI K, 1990, JPN J CANCER RES, V81, P345, DOI 10.1111/j.1349-7006.1990.tb02574.x; Mise M, 1996, HEPATOLOGY, V23, P455; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Miyazono K, 2001, J CELL PHYSIOL, V187, P265, DOI 10.1002/jcp.1080; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; PEDERSEN H, 1994, CANCER RES, V54, P120; PEDERSEN H, 1994, CANCER RES, V54, P4671; Piek E, 2001, ADV CANCER RES, V83, P1, DOI 10.1016/S0065-230X(01)83001-3; Prunier C, 2001, MOL CELL BIOL, V21, P3302, DOI 10.1128/MCB.21.10.3302-3313.2001; Riggins GJ, 1997, CANCER RES, V57, P2578; Schwarte-Waldhoff I, 2000, P NATL ACAD SCI USA, V97, P9624, DOI 10.1073/pnas.97.17.9624; SHIRAI Y, 1994, CANCER, V73, P2275, DOI 10.1002/1097-0142(19940501)73:9<2275::AID-CNCR2820730907>3.0.CO;2-T; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Yakicier MC, 1999, ONCOGENE, V18, P4879, DOI 10.1038/sj.onc.1202866; YAMANAKA N, 1990, CANCER, V65, P1104, DOI 10.1002/1097-0142(19900301)65:5<1104::AID-CNCR2820650511>3.0.CO;2-G; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2; Zhou L, 2000, PATHOL INT, V50, P392, DOI 10.1046/j.1440-1827.2000.01059.x	36	36	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2003	22	15					2309	2321		10.1038/sj.onc.1206305	http://dx.doi.org/10.1038/sj.onc.1206305			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	667KV	12700666				2022-12-28	WOS:000182231500009
J	Gautam, A; Li, ZR; Bepler, G				Gautam, A; Li, ZR; Bepler, G			RRM1-induced metastasis suppression through PTEN-regulated pathways	ONCOGENE			English	Article						ribonucleotide reductase; PTEN; focal adhesion kinase; lung cancer; chromosome 11; metastasis suppression; tumor suppression	FOCAL ADHESION KINASE; MAMMALIAN RIBONUCLEOTIDE REDUCTASE; CHROMOSOME SEGMENT 11P15.5; TUMOR-SUPPRESSOR; LUNG-CANCER; CELL MOTILITY; MESSENGER-RNA; GENE; INHIBITION; PROTEIN	Lung cancer is the leading cause of cancer-related mortality in the United States. Only 15% of patients with this disease survive 5 years or longer. Early metastatic spread is the single most important reason for this poor outcome. The survival of patients with pathological stage I disease, that is, no evidence for metastatic spread, and molecular aberrations on chromosome 11p15.5 is equal to that of patients with stage II disease, that is, metastatic spread to hilar lymph nodes. RRM1 is a gene in this region, and it is haploinsufficient in at least 34% stage I patients. Here, we show that overexpression of RRM1 in human and mouse lung cancer cell lines induced PTEN expression, reduced phosphorylation of focal adhesion kinase (FAK), suppressed migration, invasion, and metastasis formation, and increased survival in an animal model. Increased PTEN expression was required for the RRM1-induced suppression of cell motility and FAK phosphorylation. We conclude that RRM1 functions as a metastasis suppressor gene through induction of PTEN expression.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Thorac Oncol Program ,MRC,MOLONC, Tampa, FL 33612 USA; Roswell Pk Canc Inst, Lung Canc Program, Buffalo, NY 14263 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Roswell Park Cancer Institute	Bepler, G (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Thorac Oncol Program ,MRC,MOLONC, Tampa, FL 33612 USA.	beplerg@moffitt.usf.edu			NATIONAL CANCER INSTITUTE [P30CA016056, R01CA070317] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA70317, P30-CA16056] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; Amara FM, 1996, J BIOL CHEM, V271, P20126, DOI 10.1074/jbc.271.33.20126; Bepler G, 1998, CANCER DETECT PREV, V22, P14; BEPLER G, 1994, P NATL ACAD SCI USA, V91, P5513, DOI 10.1073/pnas.91.12.5513; Bepler G, 2002, J CLIN ONCOL, V20, P1353, DOI 10.1200/JCO.20.5.1353; CARNEY DN, 1985, CANCER RES, V45, P2913; Cary LA, 1996, J CELL SCI, V109, P1787; CHEN FY, 1993, EMBO J, V12, P3977, DOI 10.1002/j.1460-2075.1993.tb06075.x; CORY JG, 1983, MOL CELL BIOCHEM, V53-4, P257; Desany BA, 1998, GENE DEV, V12, P2956, DOI 10.1101/gad.12.18.2956; ELLEDGE SJ, 1992, TRENDS BIOCHEM SCI, V17, P119, DOI 10.1016/0968-0004(92)90249-9; Fan HZ, 1997, P NATL ACAD SCI USA, V94, P13181, DOI 10.1073/pnas.94.24.13181; Forgacs E, 1998, ONCOGENE, V17, P1557, DOI 10.1038/sj.onc.1202070; GATES RE, 1994, CELL GROWTH DIFFER, V5, P891; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Hall A, 1998, SCIENCE, V280, P2074, DOI 10.1126/science.280.5372.2074; Hong TM, 2000, AM J RESP CELL MOL, V23, P355, DOI 10.1165/ajrcmb.23.3.4002; ILLC D, 1995, NATURE, V377, P539; JAKLITSCH MT, 1995, LUNG CANCER, V12, pS17, DOI 10.1016/S0169-5002(10)80003-0; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Kang YH, 2002, LAB INVEST, V82, P285, DOI 10.1038/labinvest.3780422; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; NYHOLM S, 1993, BIOCHEMISTRY-US, V32, P11569, DOI 10.1021/bi00094a013; OBriant K, 1997, ANTICANCER RES, V17, P3243; Pitterle DM, 1999, MAMM GENOME, V10, P916, DOI 10.1007/s003359901114; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; ROMER LH, 1994, MOL BIOL CELL, V5, P349, DOI 10.1091/mbc.5.3.349; SATOH H, 1993, MOL CARCINOGEN, V7, P157, DOI 10.1002/mc.2940070306; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Schrock E, 1996, SCIENCE, V273, P494, DOI 10.1126/science.273.5274.494; Soria JC, 2002, CLIN CANCER RES, V8, P1178; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stubbe J, 1998, P NATL ACAD SCI USA, V95, P2723, DOI 10.1073/pnas.95.6.2723; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Tamura M, 1999, CANCER RES, V59, P442; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Virmani AK, 1998, GENE CHROMOSOME CANC, V21, P308, DOI 10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2; Weng LP, 2001, HUM MOL GENET, V10, P237, DOI 10.1093/hmg/10.3.237; WHANGPENG J, 1991, GENE CHROMOSOME CANC, V3, P168, DOI 10.1002/gcc.2870030303; YUHAS JM, 1975, CANCER RES, V35, P242; Zhao BH, 2001, ONCOGENE, V20, P8154, DOI 10.1038/sj.onc.1205027; Zhou BS, 1998, CLIN EXP METASTAS, V16, P43	49	118	135	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2003	22	14					2135	2142		10.1038/sj.onc.1206232	http://dx.doi.org/10.1038/sj.onc.1206232			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664NJ	12687015	Bronze			2022-12-28	WOS:000182066900007
J	Nasr, AF; Nutini, M; Palombo, B; Guerra, E; Alberti, S				Nasr, AF; Nutini, M; Palombo, B; Guerra, E; Alberti, S			Mutations of TP53 induce loss of DNA methylation and amplification of the TROP1 gene	ONCOGENE			English	Article						DNA methylation; gene amplification; genome instability; p53; Trop-1	WILD-TYPE P53; CHROMOSOME INSTABILITY; COLON-CANCER; MUTANT P53; HOMOLOGOUS RECOMBINATION; METHYLTRANSFERASE GENE; RETINOBLASTOMA GENE; COLORECTAL-CANCER; CELLS; EXPRESSION	p53 and DNA methylation play key roles in the maintenance of genome stability. In this work, we demonstrate that the two mechanisms are linked and that p53 plays a role in the maintenance of the DNA methylation levels. The loss of p53 was shown to induce loss of DNA methylation in the TROP1 gene, a human cancer-expressed locus that undergoes amplification when hypomethylated. This demethylation was reverted by the reintroduction of a wild-type TP53 (wt TP53) in the TP53-null cells. Using a gene-amplification assay in vivo, we demonstrate that the loss of p53 leads to a demethylation-dependent TROP1 gene amplification. The induction of gene amplification was reverted by the expression of a wtTP53 gene or by in vitro methylation of the transfected DNA with the Sss I DNA methylase. Taken together, these findings demonstrate that the inactivation of TP53 induces loss of DNA methylation and DNA methylation-dependent gene amplification.	Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, Expt Oncol Lab, I-66030 Santa Maria Imbaro, Chieti, Italy	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Alberti, S (corresponding author), Univ G DAnnunzio, Sch Med, Inst Med & Aging, Chieti, Italy.		Alberti, Saverio/M-4511-2014	Alberti, Saverio/0000-0002-4647-6042; Guerra, Emanuela/0000-0002-7091-8621				Ahuja N, 1997, CANCER RES, V57, P3370; ALBERTI S, 1994, P NATL ACAD SCI USA, V91, P5833, DOI 10.1073/pnas.91.13.5833; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BLANDINO G, 1995, ONCOGENE, V10, P731; Blobel GA, 2000, BLOOD, V95, P745, DOI 10.1182/blood.V95.3.745.003k05_745_755; Calabrese G, 2001, CYTOGENET CELL GENET, V92, P164, DOI 10.1159/000056891; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; Esteller M, 2001, CANCER RES, V61, P3225; FEINBERG AP, 1988, CANCER RES, V48, P1159; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; GIULOTTO E, 1987, CELL, V48, P837, DOI 10.1016/0092-8674(87)90080-8; GOETZ SE, 1985, SCIENCE, V228, P187; HARE JT, 1985, P NATL ACAD SCI USA, V82, P7350, DOI 10.1073/pnas.82.21.7350; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORI T, 1983, MUTAT RES, V121, P47, DOI 10.1016/0165-7992(83)90085-4; HSIEH CL, 1992, EMBO J, V11, P315, DOI 10.1002/j.1460-2075.1992.tb05054.x; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; Jones PA, 1997, P NATL ACAD SCI USA, V94, P2103, DOI 10.1073/pnas.94.6.2103; LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MAKOS M, 1992, P NATL ACAD SCI USA, V89, P1929, DOI 10.1073/pnas.89.5.1929; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Mitelman F, 2000, MUTAT RES-REV MUTAT, V462, P247, DOI 10.1016/S1383-5742(00)00006-5; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Patra SK, 2001, BIOCHEM BIOPH RES CO, V287, P705, DOI 10.1006/bbrc.2001.5639; PERRY ME, 1992, MUTAT RES, V276, P189, DOI 10.1016/0165-1110(92)90008-W; Pradhan S, 2002, EMBO J, V21, P779, DOI 10.1093/emboj/21.4.779; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; Saintigny Y, 2002, ONCOGENE, V21, P488, DOI 10.1038/sj.onc.1205040; Sambrook J., 2002, MOL CLONING LAB MANU; Soares J, 1999, CANCER, V85, P112, DOI 10.1002/(SICI)1097-0142(19990101)85:1<112::AID-CNCR16>3.3.CO;2-K; STEIN R, 1982, P NATL ACAD SCI-BIOL, V79, P61, DOI 10.1073/pnas.79.1.61; STRNAD J, 1989, CANCER RES, V49, P314; Tuck-Muller CM, 2000, CYTOGENET CELL GENET, V89, P121, DOI 10.1159/000015590; WAHL GM, 1984, NATURE, V307, P516, DOI 10.1038/307516a0; WRIGHT JA, 1990, P NATL ACAD SCI USA, V87, P1791, DOI 10.1073/pnas.87.5.1791; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; Zheng L, 2002, CANCER RES, V62, P2498	49	28	28	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 20	2003	22	11					1668	1677		10.1038/sj.onc.1206248	http://dx.doi.org/10.1038/sj.onc.1206248			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642870				2022-12-28	WOS:000181580500009
J	Presneau, N; Mes-Masson, AM; Ge, B; Provencher, D; Hudson, TJ; Tonin, PN				Presneau, N; Mes-Masson, AM; Ge, B; Provencher, D; Hudson, TJ; Tonin, PN			Patterns of expression of chromosome 17 genes in primary cultures of normal ovarian surface epithelia and epithelial ovarian cancer cell lines	ONCOGENE			English	Article						ovarian cancer; cell lines; DNA microarray; chromosome 17; gene expression	ALLELIC LOSS; MICROARRAY ANALYSIS; DELETION UNIT; TUMORS DISTAL; FREQUENT LOSS; P53 GENE; BREAST; REGION; CANDIDATE; HETEROZYGOSITY	Oligonucleotide microarray analysis was applied to assess the expression profile of 332 probe sets representing 308 genes or expressed sequence tags (ESTs) that map to chromosome 17 in order to address epigenetic events that result in alterations in gene expression in epithelial ovarian cancer (EOC). Expression profiles were generated from 12 primary cultures derived from normal ovarian surface epithelium (NOSE) and four long-term cultures (TOV-81D, TOV-112D, TOV-21G and OV-90) derived from EOCs that have been previously characterized and shown to mimic features of the tumoral cells from which they were derived. The expression values of all 332 probe sets is highly correlated across the 12 NOSEs (89% correlation coefficients > 0.90). In two-way comparisons, differential patterns of gene expression were observed for 157 probe sets for which the expression value of at least one EOC cell tine fell outside the limits of the range of expression of the 12 NOSEs. When compared to NOSEs, four genes displayed similar differential patterns of gene expression across all four EOC cell lines, and 26 genes displayed similar differential patterns of gene expression across the three EOC cell lines (TOV-112D, TOV-21G and OV-90) representing tumoral cells derived from the most aggressive disease. A total of 17 genes displayed differential patterns of gene expression greater than threefold in at least one EOC cell line in comparison to NOSE, and three genes were differentially expressed greater than threefold across all aggressive cell lines. The analysis of a selected number of genes by RT-PCR revealed patterns of gene expression comparable to those observed by microarray analysis in the majority of samples tested. Comparison of expression profiles of differentially expressed genes identified by microarray analysis in two-way comparisons of the EOC cell lines and the NOSEs with published reports revealed 10 genes previously implicated in ovarian tumorigenesis and 18 in tumorigenesis of other types of cancer. The differential pattern of gene expression of genes that map to both the p and q arm of chromosome 17 is consistent with the hypothesis that a number of genes that map to this chromosome are implicated in the etiology of ovarian cancer.	McGill Univ, Ctr Hlth, Res Inst, Montreal, PQ H3G 1A4, Canada; McGill Univ, Ctr Hlth, Montreal Genome Ctr, Montreal, PQ H3G 1A4, Canada; McGill Univ, Dept Human Genet, Montreal, PQ H3A 1B1, Canada; CHU Montreal, Notre Dame Hosp, Ctr Rech, Inst Canc Montreal, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Dept Obstet Gynecol, Montreal, PQ H3C 3J7, Canada; McGill Univ, Dept Med, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University; McGill University; Universite de Montreal; Universite de Montreal; Universite de Montreal; McGill University	Tonin, PN (corresponding author), Montreal Gen Hosp, Room L10-120,1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.	patricia.tonin@mcgill.ca	Pillay, Nischalan/F-9536-2012	Mes-Masson, Anne-Marie/0000-0002-6498-266X				Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; CLIBY W, 1993, CANCER RES, V53, P2393; Davidson B, 1999, CLIN EXP METASTAS, V17, P799, DOI 10.1023/A:1006723011835; Davidson B, 2001, EUR J CANCER, V37, P2040, DOI 10.1016/S0959-8049(01)00235-0; Dion F, 2000, ONCOGENE, V19, P1466, DOI 10.1038/sj.onc.1203463; ECCLES DM, 1990, ONCOGENE, V5, P1599; ECCLES DM, 1992, BRIT J CANCER, V65, P40, DOI 10.1038/bjc.1992.8; FOULKES WD, 1993, INT J CANCER, V54, P220, DOI 10.1002/ijc.2910540210; GODWIN AK, 1994, AM J HUM GENET, V55, P666; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Hoff C, 2000, GENOMICS, V70, P26, DOI 10.1006/geno.2000.6353; JACOBS IJ, 1993, CANCER RES, V53, P1218; Kalikin LM, 1997, ONCOGENE, V14, P1991, DOI 10.1038/sj.onc.1201013; Kauraniemi P, 2001, CANCER RES, V61, P8235; Kikkawa F, 1997, CANCER LETT, V120, P109, DOI 10.1016/S0304-3835(97)00295-4; Konishi H, 1998, ONCOGENE, V17, P2095, DOI 10.1038/sj.onc.1202128; KRUK PA, 1990, LAB INVEST, V63, P132; LEARY JA, 1995, INT J CANCER, V64, P189, DOI 10.1002/ijc.2910640308; LEE JH, 1990, CANCER RES, V50, P2724; LOUNIS H, 1994, EXP CELL RES, V215, P303, DOI 10.1006/excr.1994.1346; Lucito R, 2000, GENOME RES, V10, P1726, DOI 10.1101/gr.138300; MANDAI M, 1994, CANCER RES, V54, P1825; Manderson EN, 2002, GENOME RES, V12, P112, DOI 10.1101/gr.174202; Merajver SD, 1995, CLIN CANCER RES, V1, P539; Mertens F, 1997, CANCER RES, V57, P2765; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; OKAMOTO A, 1991, CANCER RES, V51, P5171; Papp J, 1996, BRIT J CANCER, V74, P1592, DOI 10.1038/bjc.1996.594; Phelan CM, 1998, CANCER RES, V58, P1004; PHILLIPS N, 1993, INT J CANCER, V54, P85, DOI 10.1002/ijc.2910540115; Pieretti M, 1995, INT J CANCER, V64, P434, DOI 10.1002/ijc.2910640614; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Provencher DM, 2000, IN VITRO CELL DEV-AN, V36, P357; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; RUSSELL SEH, 1990, ONCOGENE, V5, P1581; SATO T, 1991, CANCER RES, V51, P5118; Schneider J, 1996, ANTICANCER RES, V16, P1197; Schneider J, 2000, BRIT J CANCER, V82, P1662; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Tangir J, 1996, ONCOGENE, V12, P735; TAVASSOLI M, 1993, GENE CHROMOSOME CANC, V8, P195, DOI 10.1002/gcc.2870080310; Teng DHF, 2001, GENOMICS, V74, P352, DOI 10.1006/geno.2001.6551; Tonin PN, 2001, ONCOGENE, V20, P6617, DOI 10.1038/sj.onc.1204804; TSAO SW, 1991, ANTICANCER RES, V11, P1975; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; YANGFENG TL, 1993, INT J CANCER, V54, P546, DOI 10.1002/ijc.2910540405	46	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2003	22	10					1568	1579		10.1038/sj.onc.1206219	http://dx.doi.org/10.1038/sj.onc.1206219			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652ZZ	12629520	Bronze			2022-12-28	WOS:000181411900014
J	Frese, KK; Lee, SS; Thomas, DL; Latorre, IJ; Weiss, RS; Glaunsinger, BA; Javier, RT				Frese, KK; Lee, SS; Thomas, DL; Latorre, IJ; Weiss, RS; Glaunsinger, BA; Javier, RT			Selective PDZ protein-dependent stimulation of phosphatidylinositol 3-kinase by the adenovirus E4-ORF1 oncoprotein	ONCOGENE			English	Article						adenovirus; E4-ORF1; PDZ; PI3K; oncoprotein	TUMOR-SUPPRESSOR PROTEIN; PAPILLOMAVIRUS E6 ONCOPROTEINS; READING FRAME-1 ENCODES; GUANYLATE KINASE; S6 KINASE; ONCOGENIC TRANSFORMATION; MAMMARY TUMORIGENESIS; SIGNALING PATHWAY; DOMAIN PROTEIN; HUMAN HOMOLOG	While PDZ domain-containing proteins represent cellular targets for several different viral oncoproteins, including human papillomavirus E6, human T-cell leukemia virus type 1 Tax, and human adenovirus E4-ORF1, the functional consequences for such interactions have not been elucidated. Here we report that, at the plasma membrane of cells, the adenovirus E4-ORF1 oncoprotein selectively and potently stimulates phosphatidylinositol 3-kinase (PI3K), triggering a downstream cascade of events that includes activation of both protein kinase B and p70S6-kinase. This activity of E4-ORF1 could be abrogated by overexpression of its PDZ-protein targets or by disruption of its PDZ domain-binding motif, which was shown to mediate complex formation between E4-ORF1 and PDZ proteins at the plasma membrane of cells. Furthermore, E4-ORF1 mutants unable to activate the PI3K pathway failed to transform cells in culture or to promote tumors in animals, and drugs that block either PI3K or p70S6-kinase inhibited E4-ORF1-induced transformation of cells. From these results, we propose that the transforming and tumorigenic potentials of the adenovirus E4-ORF1 oncoprotein depend on its capacity to activate PI3K through a novel PDZ protein-dependent mechanism of action.	Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA	Baylor College of Medicine	Javier, RT (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, 1 Baylor Plaza, Houston, TX 77030 USA.	rjavier@bcm.tmc.edu		Latorre, Isabel/0000-0003-0638-1783	NCI NIH HHS [R01 CA058541, T32 CA009197, R01 CA58541, T32 CA09197] Funding Source: Medline; NIAID NIH HHS [T32 AI07471, T32 AI007471] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009197, R01CA058541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007471] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cantrell DA, 2001, J CELL SCI, V114, P1439; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; Glaunsinger BA, 2001, EMBO J, V20, P5578, DOI 10.1093/emboj/20.20.5578; Gottardi CJ, 1996, P NATL ACAD SCI USA, V93, P10779, DOI 10.1073/pnas.93.20.10779; Hsueh YP, 2000, NATURE, V404, P298, DOI 10.1038/35005118; Islas S, 2002, EXP CELL RES, V274, P138, DOI 10.1006/excr.2001.5457; JAVIER R, 1991, J VIROL, V65, P3192, DOI 10.1128/JVI.65.6.3192-3202.1991; JAVIER RT, 1994, J VIROL, V68, P3917, DOI 10.1128/JVI.68.6.3917-3924.1994; Kimble J, 1997, ANNU REV CELL DEV BI, V13, P333, DOI 10.1146/annurev.cellbio.13.1.333; KINGSTON RE, 1989, CURRENT PROTOCOLS MO; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; Lou XJ, 2001, MOL BIOL CELL, V12, P615, DOI 10.1091/mbc.12.3.615; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Mills GB, 2001, SEMIN ONCOL, V28, P125, DOI 10.1053/sonc.2001.28554; Mirza AM, 2000, CELL GROWTH DIFFER, V11, P279; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Nishimura W, 2000, J CELL PHYSIOL, V185, P358, DOI 10.1002/1097-4652(200012)185:3<358::AID-JCP6>3.3.CO;2-R; PELECH SL, 1987, J BIOL CHEM, V262, P11598; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; SUSA M, 1992, J BIOL CHEM, V267, P22951; Suzuki T, 1999, ONCOGENE, V18, P5967, DOI 10.1038/sj.onc.1203008; Thomas DL, 1999, J VIROL, V73, P3071, DOI 10.1128/JVI.73.4.3071-3079.1999; Thomas DL, 2001, J VIROL, V75, P557, DOI 10.1128/JVI.75.2.557-568.2001; Tsatsanis C, 2000, INT J MOL MED, V5, P583; Tsunoda S, 1999, CELL CALCIUM, V26, P165, DOI 10.1054/ceca.1999.0070; Uthoff SMS, 2001, MOL CARCINOGEN, V31, P56, DOI 10.1002/mc.1039; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Weiss RS, 1997, J VIROL, V71, P4385, DOI 10.1128/JVI.71.6.4385-4394.1997; Weiss RS, 1996, J VIROL, V70, P862, DOI 10.1128/JVI.70.2.862-872.1996; Weiss RS, 1997, J VIROL, V71, P7873, DOI 10.1128/JVI.71.10.7873-7880.1997; Weiss RS, 1997, J VIROL, V71, P1857, DOI 10.1128/JVI.71.3.1857-1870.1997; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199; Yamada KM, 2001, J CELL SCI, V114, P2375; Yu Y, 1999, J CELL PHYSIOL, V178, P235, DOI 10.1002/(SICI)1097-4652(199902)178:2<235::AID-JCP13>3.3.CO;2-J	51	71	76	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2003	22	5					710	721		10.1038/sj.onc.1206151	http://dx.doi.org/10.1038/sj.onc.1206151			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569363	Green Accepted			2022-12-28	WOS:000180642100008
J	Lee, MS; Igawa, T; Yuan, TC; Zhang, XQ; Lin, FF; Lin, MF				Lee, MS; Igawa, T; Yuan, TC; Zhang, XQ; Lin, FF; Lin, MF			ErbB-2 signaling is involved in regulating PSA secretion in androgen-independent human prostate cancer LNCaP C-81 cells	ONCOGENE			English	Article						prostate cancer; androgen independence; prostatic acid phosphatase; protein tyrosine phosphatase; ErbB-2; protein tvrosine kinase; PSA secretion; MAP kinases	IN-SITU HYBRIDIZATION; ANTIGEN MESSENGER-RNA; TUMOR-NECROSIS-FACTOR; ACID-PHOSPHATASE; GROWTH-FACTOR; TYROSINE KINASE; RECEPTOR ACTIVATION; PROTEIN EXPRESSION; GENE-EXPRESSION; EGF RECEPTOR	The expression and secretion of prostate-specific antigen (PSA) are regulated by androgens in normal prostate secretory epithelial cells. In prostate cancer patients, the serum PSA level is usually elevated and cancer cells are initially responsive to androgens. However, those cancer cells become androgen-independent after androgen ablation therapy. In hormone-refractory, cancer patients, even in an androgen-deprived environment, the circulation level of PSA rebounds and is constitutively elevated through a yet unknown mechanism. Tyrosine phosphorylation of ErbB-2 is involved in regulating the androgen-responsive phenotype of prostate cancer cells, and it is at least partly regulated by the cellular form of prostatic acid phosphatase (PAc6) a prostate-unique protein tyrosine phosphatase. We investigated the ErbB-2 signal pathway in androgen-independent PSA secretion. LNCaP C-81 cells, which are androgen-independent LNCaP cells lacking endogenous PAcP expression with a hypertyrosine phosphorylated ErbB-2, secreted a higher level of PSA in conditioned media than did androgen-sensitive LNCaP C-33 parental cells. A restored expression of cellular PAcP in C-81 cells was concurrent with a decrease in tyrophosphorylation of ErbB-2 and reduction of PSA secretion. Moreover, transient transfection of C-33 cells with the wild-type ErbB-2 or a constitutively active mutant of MEK1 cDNA resulted in an increased level of secreted PSA. The elevation of secreted PSA level by the forced expression of ErbB-2 was inhibited by an MEK inhibitor, PD98059. In C-81 cells, the expression of a dominant negative mutant of ErbB-2 reduced the secreted level of PSA. The inhibition of ErbB-2 or mitogen-activated protein (MAP) kinases by specific inhibitors AG879, AG825, or PD98059 led to a decrease in PSA secretion. Taken together, our data clearly indicate that the ErbB-2 signal pathway via MAP kinases (ERK1/2) is involved in regulating the secretion of PSA by androgen-independent human prostate cancer LNCaP C-81 cells in an androgen-depleted environment.	Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Sect Urol Surg, Coll Med, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Eppley Inst Res Canc, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Lin, MF (corresponding author), Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, 9845255 Nebraska Med Ctr, Omaha, NE 68198 USA.	mlin@.unmc.edu		LEE, MING-SHYUE/0000-0002-8673-5088; LEE, MING-SHYUE/0000-0002-5884-4535	NATIONAL CANCER INSTITUTE [R01CA088184] Funding Source: NIH RePORTER; NCI NIH HHS [CA88184] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Auclerc G, 2000, Oncologist, V5, P36, DOI 10.1634/theoncologist.5-1-36; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BEERLI RR, 1994, J BIOL CHEM, V269, P23931; BERCHUCK A, 1990, CANCER RES, V50, P4087; Bubendorf L, 1999, CANCER RES, V59, P803; Chu TM, 1998, J CLIN LIGAND ASSAY, V21, P24; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; CULIG Z, 1994, CANCER RES, V54, P5474; de Medina SGD, 1998, HUM PATHOL, V29, P1005, DOI 10.1016/S0046-8177(98)90208-8; Denis LJ, 2000, SEMIN SURG ONCOL, V18, P52, DOI 10.1002/(SICI)1098-2388(200001/02)18:1<52::AID-SSU8>3.0.CO;2-6; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Gioeli D, 2002, J BIOL CHEM, V277, P29304, DOI 10.1074/jbc.M204131200; Gioeli D, 1999, CANCER RES, V59, P279; Grasso AW, 1997, ONCOGENE, V15, P2705, DOI 10.1038/sj.onc.1201447; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Gu KF, 1996, CANCER LETT, V99, P185, DOI 10.1016/0304-3835(95)04061-7; GULLICK WJ, 1987, INT J CANCER, V40, P246, DOI 10.1002/ijc.2910400221; Hobisch A, 1998, CANCER RES, V58, P4640; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; HUNG MC, 1992, CANCER LETT, V61, P95, DOI 10.1016/0304-3835(92)90166-S; Igawa T, 2002, PROSTATE, V50, P222, DOI 10.1002/pros.10054; Johannessen LE, 2001, BIOCHEM J, V356, P87, DOI 10.1042/0264-6021:3560087; Karan D, 2001, CLIN CANCER RES, V7, P3472; Kimmelman AC, 2002, MOL CELL BIOL, V22, P5946, DOI 10.1128/MCB.22.16.5946-5961.2002; KURIYAMA M, 1982, J NATL CANCER I, V68, P99; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LICHTENSTEIN A, 1990, CANCER RES, V50, P7364; Lin DL, 2001, CLIN CANCER RES, V7, P1773; Lin MF, 1996, BIOCHEM BIOPH RES CO, V226, P206, DOI 10.1006/bbrc.1996.1334; LIN MF, 1993, ARCH BIOCHEM BIOPHYS, V300, P384, DOI 10.1006/abbi.1993.1052; Lin MF, 1998, J BIOL CHEM, V273, P5939, DOI 10.1074/jbc.273.10.5939; LIN MF, 1994, DIFFERENTIATION, V57, P143, DOI 10.1046/j.1432-0436.1994.5720143.x; Lin MF, 2001, J UROLOGY, V166, P1943, DOI 10.1016/S0022-5347(05)65725-4; Lin MF, 2000, CELL BIOL INT, V24, P681, DOI 10.1006/cbir.2000.0433; LOOR R, 1981, CANCER LETT, V14, P63, DOI 10.1016/0304-3835(81)90010-0; Mark HFL, 1999, EXP MOL PATHOL, V66, P170, DOI 10.1006/exmp.1999.2242; MAUCHER A, 1993, J CANCER RES CLIN, V119, P669, DOI 10.1007/BF01215986; MCCANN A, 1990, CANCER, V65, P88, DOI 10.1002/1097-0142(19900101)65:1<88::AID-CNCR2820650119>3.0.CO;2-Z; Meng TC, 2000, ONCOGENE, V19, P2664, DOI 10.1038/sj.onc.1203576; Meng TC, 1998, J BIOL CHEM, V273, P22096, DOI 10.1074/jbc.273.34.22096; MYERS RB, 1994, J NATL CANCER I, V86, P1140, DOI 10.1093/jnci/86.15.1140; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; OESTERLING JE, 1991, J UROLOGY, V145, P907, DOI 10.1016/S0022-5347(17)38491-4; Osman I, 2001, CLIN CANCER RES, V7, P2643; PAPSIDERO LD, 1980, CANCER RES, V40, P2428; PIERCE JH, 1991, ONCOGENE, V6, P1189; Pilat MJP, 1998, CANCER METAST REV, V17, P373, DOI 10.1023/A:1006166511344; PRESS MF, 1990, ONCOGENE, V5, P953; Price DT, 1999, J UROLOGY, V162, P1537, DOI 10.1016/S0022-5347(05)68354-1; Qian XL, 1999, J BIOL CHEM, V274, P574, DOI 10.1074/jbc.274.2.574; QIAN XL, 1994, ONCOGENE, V9, P1507; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; Ross JS, 1997, CANCER-AM CANCER SOC, V79, P2162, DOI 10.1002/(SICI)1097-0142(19970601)79:11<2162::AID-CNCR14>3.0.CO;2-U; Sadar MD, 1999, ENDOCR-RELAT CANCER, V6, P487, DOI 10.1677/erc.0.0060487; Sadar MD, 1999, J BIOL CHEM, V274, P7777, DOI 10.1074/jbc.274.12.7777; SAMANTA A, 1994, P NATL ACAD SCI USA, V91, P1711, DOI 10.1073/pnas.91.5.1711; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; Sherwood ER, 1998, BRIT J CANCER, V77, P855, DOI 10.1038/bjc.1998.142; Signoretti S, 2000, JNCI-J NATL CANCER I, V92, P1918, DOI 10.1093/jnci/92.23.1918; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOLIN T, 1990, BIOCHIM BIOPHYS ACTA, V1048, P72, DOI 10.1016/0167-4781(90)90024-V; Stenman UH, 1999, SEMIN CANCER BIOL, V9, P83, DOI 10.1006/scbi.1998.0086; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; VELDSCHOLTE J, 1994, J STEROID BIOCHEM, V49, P341, DOI 10.1016/0960-0760(94)90277-1; WANG MC, 1981, PROSTATE, V2, P89, DOI 10.1002/pros.2990020109; Wen Y, 2000, CANCER RES, V60, P6841; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; YOUNG CYF, 1991, CANCER RES, V51, P3748; Zegarra-Moro OL, 2002, CANCER RES, V62, P1008; Zelivianski S, 1998, BIOCHEM BIOPH RES CO, V245, P108, DOI 10.1006/bbrc.1998.8386; Zhang XQ, 2001, J BIOL CHEM, V276, P2544, DOI 10.1074/jbc.M006661200; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	74	50	52	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2003	22	5					781	796		10.1038/sj.onc.1206066	http://dx.doi.org/10.1038/sj.onc.1206066			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569372				2022-12-28	WOS:000180642100017
J	Lee, SH; Kim, JW; Lee, HW; Cho, YS; Oh, SH; Kim, YJ; Jung, CH; Zhang, W; Lee, JH				Lee, SH; Kim, JW; Lee, HW; Cho, YS; Oh, SH; Kim, YJ; Jung, CH; Zhang, W; Lee, JH			Interferon regulatory factor-1 (IRF-1) is a mediator for interferon-gamma induced attenuation of telomerase activity and human telomerase reverse transcriptase (hTERT) expression	ONCOGENE			English	Article						telomerase; hTERT; interferon-gamma (INF-gamma); IRF-1	HUMAN-PAPILLOMAVIRUS TYPE-16; TUMOR-SUPPRESSOR GENE; CELL-CYCLE ARREST; MESSENGER-RNA; DAUDI CELLS; APOPTOSIS; CANCER; DEGRADATION; PROTEIN; P53	Constitutive activation of the telomerase is a key step in the development of human cancers. Interferon-gamma (IFN-gamma) signaling induces growth arrest in many tumors through multiple regulatory mechanisms. In this study, we show that IFN-gamma signaling represses telomerase activity and human telomerase reverse transcriptase (hTERT) transcription, and suggest that this signaling is mediated by IRF-1. Ectopic expression of IRF-1 attenuated hTERT promoter activity. Murine embryonic fibroblasts (MEFs) genetically deficient in IRF-1 (IRF-1(-/-)) showed an elevated level (> 15 times) of hTERT promoter activity as compared to the hTERT promoter activity of wild-type MEFs. The telomerase activity and hTERT expression in IRF-1(-/-) MEFs were downregulated by IRF-1 transfection. Interestingly, less extent of telomerase repression was observed in HPV E6 and E7 negative, p53 mutant HT-3 cells than in HPV 18 E6 and E7 positive HeLa cells (intact p53). These findings provide evidence that IRF-1 is a potential mediator of IFN-gamma-induced attenuation of telomerase activity and hTERT expression.	Sungkyunkwan Univ, Coll Med,Mol Therapy Res Ctr, Samsung Med Ctr Annex 8F, Kangnam Gu, Seoul 130710, South Korea; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Sungkyunkwan Univ, Coll Med, Dept Mol Biol, Jangan Gu, Suwon 440746, South Korea; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	Sungkyunkwan University (SKKU); University of Pennsylvania; Sungkyunkwan University (SKKU); University of Texas System; UTMD Anderson Cancer Center	Lee, JH (corresponding author), Sungkyunkwan Univ, Coll Med,Mol Therapy Res Ctr, Samsung Med Ctr Annex 8F, Kangnam Gu, 50 ILwon Dong, Seoul 135710, South Korea.	jeholee@samsung.co.kr		Kim, Jung-whan/0000-0002-7829-1480				Akiyama M, 1999, CANCER LETT, V142, P23, DOI 10.1016/S0304-3835(99)00109-3; ALLSOPP RC, 1995, EXP CELL RES, V219, P130, DOI 10.1006/excr.1995.1213; Baege AC, 2002, AM J PATHOL, V160, P1251, DOI 10.1016/S0002-9440(10)62552-7; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Bosch FX, 2002, J CLIN PATHOL, V55, P244, DOI 10.1136/jcp.55.4.244; Boyer SN, 1996, CANCER RES, V56, P4620; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Chapman RS, 2000, ONCOGENE, V19, P6386, DOI 10.1038/sj.onc.1204016; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; Crowe DL, 2001, BBA-GENE STRUCT EXPR, V1518, P1, DOI 10.1016/S0167-4781(00)00296-7; De Maeyer E, 1998, Int Rev Immunol, V17, P53, DOI 10.3109/08830189809084487; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; DRON M, 1986, MOL CELL BIOL, V6, P1374, DOI 10.1128/MCB.6.5.1374; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FARBER JM, 1992, MOL CELL BIOL, V12, P1535, DOI 10.1128/MCB.12.4.1535; Greider CW, 1998, P NATL ACAD SCI USA, V95, P90, DOI 10.1073/pnas.95.1.90; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; HARADA H, 1994, ONCOGENE, V9, P3313; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; Holt SE, 1999, J CELL PHYSIOL, V180, P10, DOI 10.1002/(SICI)1097-4652(199907)180:1<10::AID-JCP2>3.0.CO;2-D; Horvath CM, 1996, MOL CELL BIOL, V16, P6957; JONAK GJ, 1984, P NATL ACAD SCI-BIOL, V81, P1747, DOI 10.1073/pnas.81.6.1747; Kano A, 1999, BIOCHEM BIOPH RES CO, V257, P672, DOI 10.1006/bbrc.1999.0276; Kim J, 1999, CANCER GENE THER, V6, P172, DOI 10.1038/sj.cgt.7700006; Kim KY, 2000, J GEN VIROL, V81, P695, DOI 10.1099/0022-1317-81-3-695; Kusumoto M, 1999, CLIN CANCER RES, V5, P2140; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; MACIEJEWSKI JP, 1995, J CLIN INVEST, V96, P1085, DOI 10.1172/JCI118094; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nozawa H, 1998, INT J CANCER, V77, P522, DOI 10.1002/(SICI)1097-0215(19980812)77:4<522::AID-IJC8>3.0.CO;2-W; Nozawa H, 1999, GENE DEV, V13, P1240, DOI 10.1101/gad.13.10.1240; Ogasawara S, 1996, GASTROENTEROLOGY, V110, P52, DOI 10.1053/gast.1996.v110.pm8536888; Oh S, 1999, J BIOL CHEM, V274, P37473, DOI 10.1074/jbc.274.52.37473; Ossina NK, 1997, J BIOL CHEM, V272, P16351, DOI 10.1074/jbc.272.26.16351; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHIFFMAN MH, 1992, JNCI-J NATL CANCER I, V84, P394, DOI 10.1093/jnci/84.6.394; Shay JW, 1996, TRENDS GENET, V12, P129, DOI 10.1016/0168-9525(96)30018-8; SHAY JW, 1995, MOL MED TODAY, V1, P378, DOI 10.1016/S1357-4310(95)93872-9; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Shiratsuchi M, 1999, LEUKEMIA LYMPHOMA, V34, P349, DOI 10.3109/10428199909050960; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Veldman T, 2001, J VIROL, V75, P4467, DOI 10.1128/JVI.75.9.4467-4472.2001; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; Wright WE, 1996, DEV GENET, V18, P173; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Xu DW, 2000, BLOOD, V96, P4313, DOI 10.1182/blood.V96.13.4313.h8004313_4313_4318; YASUI W, 1988, JPN J CANCER RES, V89, P1099; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	56	41	47	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2003	22	3					381	391		10.1038/sj.onc.1206133	http://dx.doi.org/10.1038/sj.onc.1206133			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545159				2022-12-28	WOS:000180379100007
J	Wiedemeyer, R; Westermann, F; Wittke, I; Nowock, J; Schwab, M				Wiedemeyer, R; Westermann, F; Wittke, I; Nowock, J; Schwab, M			Ataxin-2 promotes apoptosis of human neuroblastoma cells	ONCOGENE			English	Article						neuroblastoma; ataxin-2; apoptosis; MYCN; amplification; SCA2	DRUG-INDUCED APOPTOSIS; TUMOR-NECROSIS-FACTOR; N-MYC; CHILDHOOD NEUROBLASTOMAS; NUCLEAR-LOCALIZATION; INTERFERON-GAMMA; PROTEIN-KINASE; IFN-GAMMA; S-PHASE; EXPRESSION	Neuroblastoma is a highly heterogeneous tumor of young children. Although many advances have been made towards understanding the molecular mechanisms dictating the phenotypic heterogeneity, the prognosis of children with neuroblastoma, particularly of progressively growing variants, has remained dire. About 10% of neuroblastomas regress spontaneously, probably by apoptosis, while another 20% have amplified the MYCN gene resulting in a poor prognosis. In pursuit of identifying cell death-associated genes in neuroblastoma, we encountered the SCA2 gene, coding for ataxin-2, as an important player. Here, we report that enforced expression of wild-type ataxin-2, but not of mutant ataxin-2, sensitizes neuroblastoma cells for apoptosis. In line with this, higher levels of ataxin-2 were detected in apoptotic cells compared to nonapoptotic cells. Neuroblastoma tumors with amplified MYCN contain significantly less ataxin-2 protein than tumors without amplified MYCN. Collectively, our data suggest that ataxin-2 has an important role in regulating the susceptibility of neuroblastoma cells to apoptotic stimuli in vitro and in vivo.	German Canc Res Ctr, Dept Cytogenet, D-69121 Heidelberg, Germany; Univ Frankfurt, Sect Mol Neurogenet, D-60590 Frankfurt, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Goethe University Frankfurt	Schwab, M (corresponding author), German Canc Res Ctr, Dept Cytogenet, H0400,Neuenheimer Feld 280, D-69121 Heidelberg, Germany.		Westermann, Frank/F-7509-2013					Annicchiarico-Petruzzelli M, 2001, MED PEDIATR ONCOL, V36, P115; Bernassola F, 1999, CELL DEATH DIFFER, V6, P652, DOI 10.1038/sj.cdd.4400537; BERTHOLD F, 1990, KLIN PADIATR, V202, P262, DOI 10.1055/s-2007-1025531; Berthold F, 2000, DRUGS, V59, P1261, DOI 10.2165/00003495-200059060-00006; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Catchpoole DR, 2001, EUR J CANCER, V37, P2217, DOI 10.1016/S0959-8049(01)00273-8; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; De Falco G, 1998, J CELL PHYSIOL, V177, P501, DOI 10.1002/(SICI)1097-4652(199812)177:4<501::AID-JCP1>3.0.CO;2-4; Eggert A, 2001, CANCER RES, V61, P1314; Estrada R, 1999, ACTA NEUROPATHOL, V97, P306, DOI 10.1007/s004010050989; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Fulda S, 1999, ONCOGENE, V18, P1479, DOI 10.1038/sj.onc.1202435; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Gil J, 2000, ONCOGENE, V19, P3665, DOI 10.1038/sj.onc.1203710; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Huynh DP, 2000, NAT GENET, V26, P44, DOI 10.1038/79162; Ikeda H, 1996, AM J SURG PATHOL, V20, P649, DOI 10.1097/00000478-199606000-00001; Imbert G, 1996, NAT GENET, V14, P285, DOI 10.1038/ng1196-285; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; Lutz W, 1998, ONCOGENE, V17, P339, DOI 10.1038/sj.onc.1200201; Lutz W, 1996, ONCOGENE, V13, P803; Mac SM, 2000, MOL CARCINOGEN, V29, P76, DOI 10.1002/1098-2744(200010)29:2<76::AID-MC4>3.0.CO;2-Y; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nakagawara A, 1997, CANCER RES, V57, P4578; Nechiporuk T, 1998, HUM MOL GENET, V7, P1301, DOI 10.1093/hmg/7.8.1301; PRITCHARD J, 1994, LANCET, V344, P869, DOI 10.1016/S0140-6736(94)92834-7; Pulst SM, 1996, NAT GENET, V14, P269, DOI 10.1038/ng1196-269; Sanpei K, 1996, NAT GENET, V14, P277, DOI 10.1038/ng1196-277; Savelyeva L, 2001, CANCER LETT, V167, P115, DOI 10.1016/S0304-3835(01)00472-4; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Teitz T, 2001, J MOL MED, V79, P428, DOI 10.1007/s001090100233; van Golen CM, 2001, CELL GROWTH DIFFER, V12, P371; van Golen CM, 2000, CELL DEATH DIFFER, V7, P654, DOI 10.1038/sj.cdd.4400693; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; WITTKE I, 2002, UNPUB	38	50	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 23	2003	22	3					401	411		10.1038/sj.onc.1206150	http://dx.doi.org/10.1038/sj.onc.1206150			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545161				2022-12-28	WOS:000180379100009
J	Yawata, T; Kamino, H; Kugoh, H; Katoh, M; Nomura, N; Oishi, M; Horikawa, I; Barrett, JC; Oshimura, M				Yawata, T; Kamino, H; Kugoh, H; Katoh, M; Nomura, N; Oishi, M; Horikawa, I; Barrett, JC; Oshimura, M			Identification of a <= 600-kb region on human chromosome 1q42.3 inducing cellular senescence	ONCOGENE			English	Article						cellular senescence; chromosome transfer; chromosome 1; telomerase; mouse melanoma	TELOMERASE REPRESSOR GENE; IMMORTAL CELLS; INDEPENDENT SENESCENCE; SUPPRESSES TELOMERASE; MULTIPLE PATHWAYS; GROWTH ARREST; HETEROZYGOSITY; CARCINOMA; CANCER; ALLELOTYPE	The introduction of a human chromosome 1 via microcell-mediated chromosome transfer (MMCT) induces the cellular senescence in mouse melanoma B16-F10 cells. The senescent cells maintained still the telomerase activity, which is frequently associated with immortal growth of human cells, suggesting that a telomerase-independent mechanism is involved in the senescence observed in this mouse cell line. To map the senescence-inducing gene to a specific chromosomal region, we took two experimental approaches: identification of a minimal region with the senescence-inducing activity via MMCT of a series of subchromosomal transferrable fragments (STFs), each consisting of a different profile of human chromosome 1-derived regions, and identification of a region commonly deleted from the transferred chromosome 1 in the revertant clones that escaped cellular senescence. These approaches identified a 2.7-3.0 Mb of senescence-inducing region shared among the active STFs and a 2.4-3.0 Mb of commonly deleted region in the revertant clones. These two regions overlapped each other to map the responsible gene at the 450 to 600-kb interval between UniSTS93710 and D1S3542 on chromosome 1q42.3. This study provides essential information and materials for cloning and characterization of a novel senescence-inducing gene that functions in a telomerase-independent pathway, which is likely to be conserved between mice and humans.	Tottori Univ, Fac Med, Sch Life Sci, Dept Mol & Cell Genet, Yonago, Tottori 6838503, Japan; NCI, Lab Biosyst & Canc, Canc Res Ctr, NIH, Bethesda, MD 20892 USA; Tottori Univ, Dept Human Genome Sci, Div Life Sci, Grad Sch Med, Yonago, Tottori 6838503, Japan; Kazusa DNA Res Inst, Chiba, Japan	Tottori University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Tottori University; Kazusa DNA Research Institute	Oshimura, M (corresponding author), Tottori Univ, Fac Med, Sch Life Sci, Dept Mol & Cell Genet, 86 Nishimachi, Yonago, Tottori 6838503, Japan.	oshimura@grape.med.tottori-u.ac.jp		KAMINO, HIROKI/0000-0002-2489-0453	DIVISION OF BASIC SCIENCES - NCI [Z01BC010417] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Backsch C, 2001, GENE CHROMOSOME CANC, V31, P196, DOI 10.1002/gcc.1134; Berthon P, 1998, AM J HUM GENET, V62, P1416, DOI 10.1086/301879; BUNN CL, 1980, EXP CELL RES, V127, P385, DOI 10.1016/0014-4827(80)90443-7; Carman TA, 1998, EXP CELL RES, V244, P33, DOI 10.1006/excr.1998.4207; CHEN LC, 1989, P NATL ACAD SCI USA, V86, P7204, DOI 10.1073/pnas.86.18.7204; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DOWDY SF, 1990, GENE CHROMOSOME CANC, V2, P318, DOI 10.1002/gcc.2870020410; DUNCAN EL, 1993, EXP CELL RES, V205, P337, DOI 10.1006/excr.1993.1095; FIDLER IJ, 1976, JNCI-J NATL CANCER I, V57, P1199, DOI 10.1093/jnci/57.5.1199; Groth A, 2000, J BIOL CHEM, V275, P27473; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HENSLER PJ, 1994, MOL CELL BIOL, V14, P2291, DOI 10.1128/MCB.14.4.2291; Horikawa I, 2000, J ANTI-AGING MED, V3, P373, DOI 10.1089/rej.1.2000.3.373; Jones CJ, 2000, MOL CELL BIOL, V20, P5690, DOI 10.1128/MCB.20.15.5690-5699.2000; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kitamura Y, 2000, GENE CHROMOSOME CANC, V27, P244; KOI M, 1986, P NATL ACAD SCI USA, V83, P5992, DOI 10.1073/pnas.83.16.5992; KOI M, 1989, JPN J CANCER RES, V80, P413, DOI 10.1111/j.1349-7006.1989.tb02329.x; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; KUGOH H, 1995, GENOMICS, V27, P207, DOI 10.1006/geno.1995.1028; Kugoh H, 1999, DNA Res, V6, P165, DOI 10.1093/dnares/6.3.165; Li YS, 1995, CANCER GENET CYTOGEN, V84, P46, DOI 10.1016/0165-4608(95)00065-8; LOUPART ML, 1995, GENE CHROMOSOME CANC, V12, P16, DOI 10.1002/gcc.2870120104; Mathon NF, 2001, SCIENCE, V291, P872, DOI 10.1126/science.1056782; Nakabayashi K, 1999, EXP CELL RES, V252, P376, DOI 10.1006/excr.1999.4619; Nishimoto A, 2001, ONCOGENE, V20, P828, DOI 10.1038/sj.onc.1204165; OHMURA H, 1995, JPN J CANCER RES, V86, P899, DOI 10.1111/j.1349-7006.1995.tb02998.x; Oshimura M, 1997, EUR J CANCER, V33, P710, DOI 10.1016/S0959-8049(97)00090-7; PEREIRASMITH OM, 1983, SCIENCE, V221, P964, DOI 10.1126/science.6879195; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; Piao Z, 1998, INT J CANCER, V75, P29, DOI 10.1002/(SICI)1097-0215(19980105)75:1<29::AID-IJC5>3.3.CO;2-#; Polascik TJ, 1996, CANCER RES, V56, P1892; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Russo I, 1998, ONCOGENE, V17, P3417, DOI 10.1038/sj.onc.1202261; SANO T, 1991, CANCER RES, V51, P2926; Sasaki K, 1998, MOL CARCINOGEN, V23, P20; SASAKI M, 1994, CANCER RES, V54, P6090; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Steenbergen RDM, 2001, JNCI-J NATL CANCER I, V93, P865, DOI 10.1093/jnci/93.11.865; SUGAWARA O, 1990, SCIENCE, V247, P707, DOI 10.1126/science.2300822; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Tanaka H, 1999, MOL CARCINOGEN, V25, P249, DOI 10.1002/(SICI)1098-2744(199908)25:4<249::AID-MC3>3.0.CO;2-Z; Tanaka H, 1998, GENE CHROMOSOME CANC, V23, P123, DOI 10.1002/(SICI)1098-2264(199810)23:2<123::AID-GCC5>3.0.CO;2-4; TSUCHIYA E, 1992, CANCER RES, V52, P2478; Uejima H, 1998, MOL CARCINOGEN, V22, P34, DOI 10.1002/(SICI)1098-2744(199805)22:1<34::AID-MC5>3.0.CO;2-L; Vojta PJ, 1996, GENE CHROMOSOME CANC, V16, P55; YAMADA H, 1990, ONCOGENE, V5, P1141	49	7	7	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2003	22	2					281	290		10.1038/sj.onc.1206143	http://dx.doi.org/10.1038/sj.onc.1206143			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527897				2022-12-28	WOS:000180322400013
J	Gunnarsson, C; Ahnstrom, M; Kirschner, K; Olsson, B; Nordenskjold, B; Rutqvist, LE; Skoog, L; Stal, O				Gunnarsson, C; Ahnstrom, M; Kirschner, K; Olsson, B; Nordenskjold, B; Rutqvist, LE; Skoog, L; Stal, O			Amplification of HSD17B1 and ERBB2 in primary breast cancer	ONCOGENE			English	Article						17q; 17 beta-HSD; breast cancer; ERBB2 estrogen; HSD17B1; real-time PCR	17-BETA-HYDROXYSTEROID DEHYDROGENASE; ESTRADIOL LEVELS; EXPRESSION; REGIONS; TYPE-1; TISSUE; TUMORS; CELLS; RECURRENCE; TAMOXIFEN	Estrogens play a crucial role in the development of breast cancer. Estradiol can be produced in the breast tissue in situ, and one of the enzymes involved in this process is 17beta-hydroxysteriod dehydrogenase (17beta-HSD) type 1 that catalyzes the interconversion of estrone (E1) to the biologically more potent estradiol (E2). The gene coding for 17beta-HSD type 1 (HSD17B1) is located at 17q12-21, close to the more studied ERBB2 and BRCA1. The aim of this study was to investigate if HSD17B1 shows an altered gene copy number in breast cancer. We used real-time PCR and examined 221 postmenopausal breast tumors for amplification of HSD17B1 and ERBB2. In all, 32 tumors (14.5%) showed amplification of HSD17B1 and 21% were amplified for ERBB2. Amplification of the two genes was correlated (P = 0.00078) and in 14 tumors (44%) with amplification of HSD17B1, ERBB2 was co amplified. The patients with amplification in at least one of the genes had a significantly worse outcome than patients without (P = 0.0059). For estrogen receptor (ER)-positive patients who received adjuvant tamoxifen, amplification of HSD17B1 was related to decreased breast cancer survival (P=0.017), whereas amplification of ERRB2 was not. Amplification of HSD17B1 might be an indicator of adverse prognosis among ER-positive patients, and possibly a mechanism for decreased benefit from tamoxifen treatment.	Linkoping Univ, Dept Biomed & Surg, Div Oncol, Fac Hlth Sci, SE-58185 Linkoping, Sweden; Huddinge Univ Hosp, Dept Oncol, SE-14186 Stockholm, Sweden; Karolinska Hosp, Div Cytol, SE-10401 Stockholm, Sweden	Linkoping University; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Stal, O (corresponding author), Linkoping Univ Hosp, Dept Oncol, SE-58185 Linkoping, Sweden.		Gunnarsson, Cecilia/ABD-9170-2021	Kirschner, Kristina/0000-0001-7607-8670				Bieche I, 1998, INT J CANCER, V78, P661, DOI 10.1002/(SICI)1097-0215(19981123)78:5<661::AID-IJC22>3.3.CO;2-9; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; Bieche I, 1996, CANCER RES, V56, P3886; Dowsett M, 1997, J STEROID BIOCHEM, V61, P261; Ellis MJ, 2001, J CLIN ONCOL, V19, P3808, DOI 10.1200/JCO.2001.19.18.3808; Feigelson HS, 2001, CANCER RES, V61, P785; Gunnarsson C, 2001, CANCER RES, V61, P8448; Jarvinen TAH, 2000, AM J PATHOL, V156, P839, DOI 10.1016/S0002-9440(10)64952-8; Kauraniemi P, 2001, CANCER RES, V61, P8235; Labrie F, 1997, STEROIDS, V62, P148, DOI 10.1016/S0039-128X(96)00174-2; Latham C, 2001, CANCER GENET CYTOGEN, V127, P16, DOI 10.1016/S0165-4608(00)00427-1; LuuThe V, 1995, J STEROID BIOCHEM, V55, P581, DOI 10.1016/0960-0760(95)00209-X; MANNERMAA A, 1994, HUM GENET, V93, P319, DOI 10.1007/BF00212030; Miettinen MM, 1996, BIOCHEM J, V314, P839, DOI 10.1042/bj3140839; Miyoshi Y, 2001, INT J CANCER, V94, P685, DOI 10.1002/ijc.1525; Osborne RJ, 2000, CANCER RES, V60, P3706; Plummer SJ, 1997, GENE CHROMOSOME CANC, V20, P354; POUTANEN M, 1992, INT J CANCER, V50, P386, DOI 10.1002/ijc.2910500310; Purohit A, 2002, BREAST CANCER RES, V4, P65, DOI 10.1186/bcr425; Revillion F, 1998, EUR J CANCER, V34, P791, DOI 10.1016/S0959-8049(97)10157-5; Sasano H, 1996, J CLIN ENDOCR METAB, V81, P4042, DOI 10.1210/jc.81.11.4042; Speirs V, 1999, BRIT J CANCER, V81, P690, DOI 10.1038/sj.bjc.6690749; Speirs V, 1998, BRIT J CANCER, V78, P1421, DOI 10.1038/bjc.1998.702; Speirs V, 1998, J STEROID BIOCHEM, V67, P267, DOI 10.1016/S0960-0760(98)00119-8; STAL O, 1994, CYTOMETRY, V16, P160, DOI 10.1002/cyto.990160210; Stal O, 2000, ANN ONCOL, V11, P1545, DOI 10.1023/A:1008313310474; Suzuki T, 2000, BRIT J CANCER, V82, P518; Utsumi T, 1999, CANCER RES, V59, P377; Vihko P, 2001, MOL CELL ENDOCRINOL, V171, P71, DOI 10.1016/S0303-7207(00)00389-0; Yue W, 1998, CANCER RES, V58, P927	30	71	72	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 9	2003	22	1					34	40		10.1038/sj.onc.1206078	http://dx.doi.org/10.1038/sj.onc.1206078			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527905				2022-12-28	WOS:000180166900004
J	Becker, NA; Thorland, EC; Denison, SR; Phillips, LA; Smith, DI				Becker, NA; Thorland, EC; Denison, SR; Phillips, LA; Smith, DI			Evidence that instability within the FRA3B region extends four megabases	ONCOGENE			English	Article						common fragile sites; FRA3B; human papillomavirus; cervical cancer; viral integration	COMMON FRAGILE SITE; CELL CARCINOMA; FHIT GENE; VIRAL INTEGRATION; CERVICAL-CANCER; BROAD REGION; EXPRESSION; CLONING; DNA; METHYLATION	FRA3B is the most frequently expressed common fragile site localized within human chromosomal band 3p14.2, which is frequently deleted in many different cancers, including cervical cancer. Previous reports indicate aphidicolin-induced FRA3B instability occurs over similar to500 kb which is spanned by the 1.5 Mb fragile histidine triad (FHIT) gene. Recently an HPV16 cervical tumor integration, 2 Mb centromeric to the published FRA3B region, has been identified. FISH-based analysis with a BAC spanning the integration has demonstrated this integration occurs within the FRA3B region of instability. These data suggest that the unstable FRA3B region is much larger than previously reported. FISH-based analysis of aphidicolin-induced metaphase chromosomes allowed for a complete characterization of instability associated with FRA3B. This analysis indicates that fragility extends for 4 Mb. Within this region are a total of five genes, including FHIT. FRA3B gene expression analysis on a panel of cervical tumor-derived cell lines revealed that three of the five genes within FRA3B were aberrantly regulated. A similar analysis of genes outside of FRA3B indicated that the surrounding genes were not aberrantly expressed. These data provide additional support that regions of instability associated with CFSs and the genes contained within them, may play an important role in cancer development.	Mayo Clin & Mayo Fdn, Dept Expt Pathol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Mol Biol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Smith, DI (corresponding author), Mayo Clin & Mayo Fdn, Dept Expt Pathol, 200 1St St Sw,Hilton 800, Rochester, MN 55905 USA.	smith.david@mayo.edu			NCI NIH HHS [CA 48031] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048031] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boldog F, 1997, HUM MOL GENET, V6, P193, DOI 10.1093/hmg/6.2.193; BOLDOG FL, 1993, P NATL ACAD SCI USA, V90, P8509, DOI 10.1073/pnas.90.18.8509; CHOO KR, 1998, GENETIC BASIS HUMAN, P631; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; Connolly DC, 2000, CLIN CANCER RES, V6, P3505; Cool D E, 1993, Semin Cell Biol, V4, P443, DOI 10.1006/scel.1993.1052; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; Corbin S, 2002, CANCER RES, V62, P3477; Druck T, 1998, ONCOL RES, V10, P341; Fang JM, 2001, GENE CHROMOSOME CANC, V30, P292, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1095>3.0.CO;2-F; Gallego MI, 1997, MOL CARCINOGEN, V19, P114, DOI 10.1002/(SICI)1098-2744(199707)19:2<114::AID-MC6>3.0.CO;2-F; GLOVER TW, 1987, AM J HUM GENET, V41, P882; GLOVER TW, 1988, CANCER GENET CYTOGEN, V31, P69, DOI 10.1016/0165-4608(88)90013-1; GLOVER TW, 1988, AM J HUM GENET, V43, P265; Gonzalez MV, 1998, J CLIN PATHOL, V51, P520, DOI 10.1136/jcp.51.7.520; Gostout BS, 1998, AM J OBSTET GYNECOL, V179, P56, DOI 10.1016/S0002-9378(98)70251-0; Greenspan DL, 1997, CANCER RES, V57, P4692; Hendricks DT, 1997, CANCER RES, V57, P2112; Herzog CR, 2001, MOL CARCINOGEN, V30, P159, DOI 10.1002/mc.1024; Huang HJ, 1998, ONCOGENE, V16, P2311, DOI 10.1038/sj.onc.1200202; Huebner K, 1998, ANNU REV GENET, V32, P7, DOI 10.1146/annurev.genet.32.1.7; KANG SM, 1995, J BIOL CHEM, V270, P27014, DOI 10.1074/jbc.270.45.27014; Kastury K, 1996, GENOMICS, V32, P225, DOI 10.1006/geno.1996.0109; Krummel KA, 2000, GENOMICS, V69, P37, DOI 10.1006/geno.2000.6321; Mishmar D, 1998, P NATL ACAD SCI USA, V95, P8141, DOI 10.1073/pnas.95.14.8141; Paradee W, 1996, GENOMICS, V35, P87, DOI 10.1006/geno.1996.0326; Parniewski P, 1999, NUCLEIC ACIDS RES, V27, P616, DOI 10.1093/nar/27.2.616; POPESCU NC, 1990, HUM GENET, V84, P383; POUMAY Y, 1995, J INVEST DERMATOL, V104, P271, DOI 10.1111/1523-1747.ep12612810; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RASSOOL FV, 1991, P NATL ACAD SCI USA, V88, P6657, DOI 10.1073/pnas.88.15.6657; Rassool FV, 1996, GENOMICS, V35, P109, DOI 10.1006/geno.1996.0329; SANDBERG AA, 1990, CHROMOSOME HUMAN CAN; Sarkar G, 1993, PCR Methods Appl, V2, P318; SMEETS DFCM, 1986, HUM GENET, V72, P215, DOI 10.1007/BF00291880; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; Tanaka H, 1998, CANCER RES, V58, P3429; Tatarelli C, 2000, GENOMICS, V68, P1, DOI 10.1006/geno.2000.6272; Thorland EC, 2000, CANCER RES, V60, P5916; USDIN K, 1995, NUCLEIC ACIDS RES, V23, P4202, DOI 10.1093/nar/23.20.4202; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VERMA RS, 1989, HUMAN CHROMOSOMES MA; VERTINO PM, 1993, CANCER RES, V53, P1684; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Wang L, 1997, GENOMICS, V41, P485, DOI 10.1006/geno.1997.4690; Wilke CM, 1996, HUM MOL GENET, V5, P187, DOI 10.1093/hmg/5.2.187; Zimonjic DB, 1997, CANCER RES, V57, P1166; Zochbauer-Muller S, 2001, CANCER RES, V61, P3581	48	52	53	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2002	21	57					8713	8722		10.1038/sj.onc.1205950	http://dx.doi.org/10.1038/sj.onc.1205950			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483524				2022-12-28	WOS:000179734400005
J	Stevnsner, T; Nyaga, S; de Souza-Pinto, NC; van der Horst, GTJ; Gorgels, TGMF; Hogue, BA; Thorslund, T; Bohr, VA				Stevnsner, T; Nyaga, S; de Souza-Pinto, NC; van der Horst, GTJ; Gorgels, TGMF; Hogue, BA; Thorslund, T; Bohr, VA			Mitochondrial repair of 8-oxoguanine is deficient in Cockayne syndrome group B	ONCOGENE			English	Article						base excision repair; oxidative damage; mitochondria; Cockayne syndrome	RNA-POLYMERASE-II; TRANSCRIPTION-COUPLED REPAIR; OXIDATIVE BASE DAMAGE; HAMSTER OVARY CELLS; INDUCED DNA-DAMAGE; ACTIVE GENES; PREFERENTIAL REPAIR; INDUCED APOPTOSIS; FACTOR CSB/ERCC6; EXCISION-REPAIR	Reactive oxygen species, which are prevalent in mitochondria, cause oxidative DNA damage including the mutagenic DNA lesion 7,8-dihydroxyguanine (8-oxoG). Oxidative damage to mitochondrial DNA has been implicated as a causative factor in a wide variety of degenerative diseases, and in cancer and aging. 8-oxoG is repaired efficiently in mammalian mitochondrial DNA by enzymes in the base excision repair pathway, including the 8-oxoguanine glycosylase (OGG1), which incizes the lesion in the first step of repair. Cockayne syndrome (CS) is a segmental premature aging syndrome in humans that has two complementation groups, CSA and CSB. Previous studies showed that CSB-deficient cells have reduced capacity to repair 8-oxoG. This study examines the role of the CSB gene in regulating repair of 8-oxoG in mitochondrial DNA in human and mouse cells. 8-oxoG repair was measured in liver cells from CSB deficient mice and in human CS-B cells carrying expression vectors for wild type or mutant forms of the human CSB gene. For the first time we report that CSB stimulates repair of 8-oxoG in mammalian mitochondrial DNA. Furthermore, evidence is presented to support the hypothesis that wild type CSB regulates expression of OGG1.	NIA, Lab Mol Gerontol, IRP, NIH, Baltimore, MD 21224 USA; Aarhus Univ, Dept Mol Biol, Danish Ctr Mol Gerontol, DK-8000 Aarhus C, Denmark; Erasmus Univ, Ctr Biomed Genet, Ctr Genet Med, Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Aarhus University; Erasmus University Rotterdam	Bohr, VA (corresponding author), NIA, Lab Mol Gerontol, IRP, NIH, Box 1,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.		Souza-Pinto, Nadja/T-3050-2019; Souza-Pinto, Nadja C./C-3462-2013; Bohr, Vilhelm/AAP-5931-2020; van der Horst, Gijsbertus TJ/E-3661-2015	Souza-Pinto, Nadja/0000-0003-4206-964X; Souza-Pinto, Nadja C./0000-0003-4206-964X; van der Horst, Gijsbertus TJ/0000-0002-7773-6396; Thorslund, Tina/0000-0001-9207-0070; Stevnsner, Tinna/0000-0003-1007-0427	NATIONAL INSTITUTE ON AGING [ZIAAG000733, Z01AG000733, Z01AG000731] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aburatani H, 1997, CANCER RES, V57, P2151; Anson RM, 1998, NUCLEIC ACIDS RES, V26, P662, DOI 10.1093/nar/26.2.662; Balajee AS, 1997, P NATL ACAD SCI USA, V94, P4306, DOI 10.1073/pnas.94.9.4306; Balajee AS, 2000, ONCOGENE, V19, P477, DOI 10.1038/sj.onc.1203372; Bjoras M, 1997, EMBO J, V16, P6314, DOI 10.1093/emboj/16.20.6314; BOHR VA, 1988, NUCLEIC ACIDS RES, V16, P7397, DOI 10.1093/nar/16.15.7397; Brosh RM, 1999, MOL BIOL CELL, V10, P3583, DOI 10.1091/mbc.10.11.3583; Citterio E, 2000, MOL CELL BIOL, V20, P7643, DOI 10.1128/MCB.20.20.7643-7653.2000; CLAYTON DA, 1974, P NATL ACAD SCI USA, V71, P2777, DOI 10.1073/pnas.71.7.2777; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; Croteau DL, 1997, J BIOL CHEM, V272, P27338, DOI 10.1074/jbc.272.43.27338; de Souza-Pinto NC, 2001, CANCER RES, V61, P5378; Dianov G, 1999, NUCLEIC ACIDS RES, V27, P1365, DOI 10.1093/nar/27.5.1365; Dianov G, 1998, J BIOL CHEM, V273, P33811, DOI 10.1074/jbc.273.50.33811; Dianov GL, 1997, NUCLEIC ACIDS RES, V25, P3636, DOI 10.1093/nar/25.18.3636; Dobson AW, 2000, J BIOL CHEM, V275, P37518, DOI 10.1074/jbc.M000831200; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; EVANS MK, 1994, MUTAT RES, V314, P221, DOI 10.1016/0921-8777(94)90067-1; Friedberg EC, 1996, ANNU REV BIOCHEM, V65, P15; HENNING KA, 1995, CELL, V82, P555, DOI 10.1016/0092-8674(95)90028-4; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; LEADON SA, 1993, P NATL ACAD SCI USA, V90, P10499, DOI 10.1073/pnas.90.22.10499; LEDOUX SP, 1992, CARCINOGENESIS, V13, P1967, DOI 10.1093/carcin/13.11.1967; LEHMANN AR, 1982, MUTAT RES, V106, P347, DOI 10.1016/0027-5107(82)90115-4; Ljungman M, 1996, ONCOGENE, V13, P823; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; MAYNE LV, 1982, CANCER RES, V42, P1473; MAYNE LV, 1984, AM J HUM GENET, V36, P311; MAYNE LV, 1982, MUTAT RES, V106, P179, DOI 10.1016/0027-5107(82)90200-7; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; SCHNEIDER JE, 1990, NUCLEIC ACIDS RES, V18, P631, DOI 10.1093/nar/18.3.631; Selby CP, 1997, P NATL ACAD SCI USA, V94, P11205, DOI 10.1073/pnas.94.21.11205; Selby CP, 1997, J BIOL CHEM, V272, P1885, DOI 10.1074/jbc.272.3.1885; Selzer RR, 2002, NUCLEIC ACIDS RES, V30, P782, DOI 10.1093/nar/30.3.782; Souza-Pinto NC, 1999, NUCLEIC ACIDS RES, V27, P1935, DOI 10.1093/nar/27.8.1935; Taffe BG, 1996, MUTAT RES-DNA REPAIR, V364, P183, DOI 10.1016/S0921-8777(96)00031-6; TANAKA K, 1981, SOMAT CELL GENET, V7, P445, DOI 10.1007/BF01542989; Tantin D, 1997, MOL CELL BIOL, V17, P6803, DOI 10.1128/MCB.17.12.6803; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; TUO J, 2002, IN PRESS DNA REPAIR; vanderHorst GTJ, 1997, CELL, V89, P425, DOI 10.1016/S0092-8674(00)80223-8; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; vanOosterwijk MF, 1996, MOL CELL BIOL, V16, P4436; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; WADE MH, 1979, MUTAT RES, V59, P49, DOI 10.1016/0027-5107(79)90194-5; Wallace Douglas C., 1998, Biofactors, V7, P187	48	88	90	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 12	2002	21	57					8675	8682		10.1038/sj.onc.1205994	http://dx.doi.org/10.1038/sj.onc.1205994			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483520				2022-12-28	WOS:000179734400001
J	Ling, MT; Wang, XH; Ouyang, XS; Lee, TK; Fan, TY; Xu, KX; Tsao, SW; Wong, Y				Ling, MT; Wang, XH; Ouyang, XS; Lee, TK; Fan, TY; Xu, KX; Tsao, SW; Wong, Y			Activation of MAPK signaling pathway is essential for Id-1 induced serum independent prostate cancer cell growth	ONCOGENE			English	Article						Id-1; prostate cancer; MAPK; cell growth	LOOP-HELIX PROTEINS; HUMAN KERATINOCYTES; PANCREATIC-CANCER; G(1) PROGRESSION; SENESCENCE; EXPRESSION; GENES; ID1; P16/INK4A; CARCINOMA	The helix-loop-helix protein Id-1 has been suggested to play a positive role in cell proliferation and tumorigenesis of many types of human cancers. However, little is known about the molecular mechanism involved in the function of Id-1. In this study, using four stable Id-1 transfectant clones, we investigated the involvement of MAPK signaling pathway in the Id-1 induced serum independent prostate cancer cell growth. Our results demonstrated that both transient and stable ectopic Id-1 expression in prostate cancer LNCaP cells led to activation of the Raf/MEK1/2 signaling pathway. In addition, inhibition of MEK1/2 phosphorylation by one of its inhibitors, PD098059, resulted in the decreased cell cycle S phase fraction and cell growth rate, suggesting that activation of MAPK signaling pathway is essential for Id-1 induced prostate cancer cell proliferation. Furthermore, treatment with antisense oligonucleotide complementary to Id-1 mRNA in PC-3 and DU145 cells resulted in a decreased Id-1 expression which was accompanied by decreased Egr-1 protein. Our results suggest for the first time that the function of Id-1 is associated with MAPK signaling pathway activation and indicate a possible novel mechanism in which Id-1 regulates prostate cancer cell growth and tumorigenesis.	Univ Hong Kong, Dept Anat, Fac Med, Lab Block,Canc Biol Lab, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Cent Lab, Inst Mol Technol Drug Discovery & Synthesis, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong	Wong, Y (corresponding author), Univ Hong Kong, Dept Anat, Fac Med, Lab Block,Canc Biol Lab, 21 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.		Tsao, George/C-4422-2009	Lee, Kin Wah/0000-0003-0682-322X				Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; Bain G, 2001, NAT IMMUNOL, V2, P165, DOI 10.1038/84273; Benezra R, 2001, ONCOGENE, V20, P8334, DOI 10.1038/sj.onc.1205160; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Eid MA, 1998, CANCER RES, V58, P2461; Fan MY, 2000, CANCER RES, V60, P6403; Gioeli D, 1999, CANCER RES, V59, P279; HARA E, 1994, J BIOL CHEM, V269, P2139; Kawashita Y, 1999, HUM GENE THER, V10, P1509, DOI 10.1089/10430349950017842; Kleeff J, 1998, CANCER RES, V58, P3769; Langlands K, 2000, CANCER RES, V60, P5929; Lin CQ, 2000, CANCER RES, V60, P1332; Ling MT, 2001, J ENDOCRINOL, V170, P287, DOI 10.1677/joe.0.1700287; Maruyama H, 1999, AM J PATHOL, V155, P815, DOI 10.1016/S0002-9440(10)65180-2; Nickoloff BJ, 2000, J BIOL CHEM, V275, P27501; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Ouyang XS, 2001, CARCINOGENESIS, V22, P965, DOI 10.1093/carcin/22.6.965; Ouyang XS, 2002, J UROLOGY, V167, P2598, DOI 10.1016/S0022-5347(05)65044-6; Ouyang XS, 2002, CARCINOGENESIS, V23, P721, DOI 10.1093/carcin/23.5.721; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; Polsky D, 2001, CANCER RES, V61, P6008; Ristow HJ, 1996, GROWTH REGULAT, V6, P96; Sakurai D, 2001, BIOCHEM BIOPH RES CO, V284, P436, DOI 10.1006/bbrc.2001.4974; Schindl M, 2001, CANCER RES, V61, P5703; Tournay O, 1996, MOL CELL BIOL, V16, P2418; Zebedee Z, 2001, ONCOGENE, V20, P8317, DOI 10.1038/sj.onc.1205092	29	89	102	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 5	2002	21	55					8498	8505		10.1038/sj.onc.1206007	http://dx.doi.org/10.1038/sj.onc.1206007			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466969	Green Submitted			2022-12-28	WOS:000179480100012
J	Mangiacasale, R; Pittoggi, C; Sciamanna, I; Careddu, A; Mattei, E; Lorenzini, R; Travaglini, L; Landriscina, M; Barone, C; Nervi, C; Lavia, P; Spadafora, C				Mangiacasale, R; Pittoggi, C; Sciamanna, I; Careddu, A; Mattei, E; Lorenzini, R; Travaglini, L; Landriscina, M; Barone, C; Nervi, C; Lavia, P; Spadafora, C			Exposure of normal and transformed cells to nevirapine, a reverse transcriptase inhibitor, reduces cell growth and promotes differentiation	ONCOGENE			English	Article						reverse transcriptase inhibitor; endogenous reverse transcriptase; proliferation; differentiation; transformation	EMBRYONAL CARCINOMA-CELLS; ENDOGENOUS RETROVIRAL SEQUENCES; TOXIC EPIDERMAL NECROLYSIS; DEPENDENT DNA POLYMERASE; F9 TERATOCARCINOMA CELLS; ACUTE MYELOID-LEUKEMIA; RETINOIC-ACID; PROMYELOCYTIC LEUKEMIA; HISTONE DEACETYLASE; LINE-1 RNA	Endogenous, nontelomeric reverse transcriptase (RT) is encoded by two classes of repeated elements: retrotransposons and endogenous retroviruses. Expression of RT-coding genes is generally repressed in differentiated nonpathological tissues, yet is active in the mammalian germ line, embryonic tissues and tumor cells. Nevirapine is a non-nucleoside RT inhibitor with a well-characterized inhibitory activity on RT enzymes of retroviral origin. Here, we show that nevirapine is also an effective inhibitor of the endogenous RT in murine and human cell lines. In addition, progenitor and transformed cells undergo a significant reduction in the rate of cell growth upon exposure to nevirapine. This is accompanied by the onset of differentiation, as depicted in F9 and C2C7 progenitor cells cultures in which nevirapine triggers the expression of differentiation-specific markers. Consistent with this, an extensive reprogramming of cell cycle gene expression was depicted in nevirapine-treated F9 cultures. Furthermore, nevirapine exposure rescued the differentiation block present in acute myeloid leukemia (AML) cell lines and primary blasts from two AML patients, as indicated by morphological, functional and immunophenotypic assays. The finding that an RT inhibitor can modulate cell proliferation and differentiation suggests that RT may represent a novel target in the development of therapeutical approaches to neoplasia.	Ist Super Sanita, I-00161 Rome, Italy; CNR, Inst Mol Biol & Pathol, Rome, Italy; Univ Siena, Dept Paediat Obstet & Reprod Med, I-53100 Siena, Italy; Univ Roma La Sapienza, Dept Med Histol & Embryol, Rome, Italy; Univ Cattolica Sacro Cuore, Med Oncol Unit, Rome, Italy	Istituto Superiore di Sanita (ISS); Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); University of Siena; Sapienza University Rome; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Spadafora, C (corresponding author), Ist Super Sanita, Viale Regina Elena 299, I-00161 Rome, Italy.		Lavia, Patrizia/J-5793-2019; Landriscina, Matteo/K-1092-2016; Lavia, Patrizia/AAL-3982-2021; Travaglini, Lorena/AAA-6245-2020	Lavia, Patrizia/0000-0003-3310-6701; Spadafora, Corrado/0000-0001-9647-1410; Travaglini, Lorena/0000-0003-0142-6516; Landriscina, Matteo/0000-0003-0591-9799; NERVI, Clara/0000-0001-9341-0188; Spadafora, Corrado/0000-0002-5743-3224; Sciamanna, Ilaria/0000-0002-5629-6184				ASHWORTH A, 1990, EMBO J, V9, P1529, DOI 10.1002/j.1460-2075.1990.tb08271.x; Babich V, 1999, GENE, V239, P341, DOI 10.1016/S0378-1119(99)00391-1; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BALTIMORE D, 1970, NATURE, V226, P1209, DOI 10.1038/2261209a0; Banerjee S, 2000, BBA-PROTEIN STRUCT M, V1480, P1, DOI 10.1016/S0167-4838(00)00080-7; BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; BROSIUS J, 1996, VIRUS GENES, V11, P163; Cattelan AM, 2001, J INFECTION, V43, P246, DOI 10.1053/jinf.2001.0902; Chou HK, 2000, BIOCHEM J, V348, P473, DOI 10.1042/0264-6021:3480473; Ciciarello M, 2001, J BIOL CHEM, V276, P19205, DOI 10.1074/jbc.M009528200; Damm K, 2001, EMBO J, V20, P6958, DOI 10.1093/emboj/20.24.6958; DARROW AL, 1990, METHOD ENZYMOL, V190, P110; DERAGON JM, 1990, EMBO J, V9, P3363, DOI 10.1002/j.1460-2075.1990.tb07537.x; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Fagot JP, 2001, AIDS, V15, P1843, DOI 10.1097/00002030-200109280-00014; Ferrara FF, 2001, CANCER RES, V61, P2; Ferrigno O, 2001, NAT GENET, V28, P77, DOI 10.1038/ng0501-77; FEUCHTERMURTHY AE, 1993, NUCLEIC ACIDS RES, V21, P135, DOI 10.1093/nar/21.1.135; Friedlander A, 1999, CRIT REV ONCOGENESIS, V10, P129; Giordano R, 2000, J CELL BIOL, V148, P1107, DOI 10.1083/jcb.148.6.1107; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; HEWISH DR, 1973, BIOCHEM BIOPH RES CO, V52, P504, DOI 10.1016/0006-291X(73)90740-7; ISLAM TC, 1993, J BIOL CHEM, V268, P3251; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Kazazian HH, 1998, CURR OPIN GENET DEV, V8, P343, DOI 10.1016/S0959-437X(98)80092-0; KIESSLING AA, 1979, CANCER RES, V39, P2062; LANOTTE M, 1991, BLOOD, V77, P1080; Li Y, 1999, EXP CELL RES, V253, P372, DOI 10.1006/excr.1999.4664; LIBERMANN TA, 1987, EMBO J, V6, P1627, DOI 10.1002/j.1460-2075.1987.tb02410.x; MARTIN SL, 1993, MOL CELL BIOL, V13, P5383, DOI 10.1128/MCB.13.9.5383; MARTIN SL, 1991, MOL CELL BIOL, V11, P4804, DOI 10.1128/MCB.11.9.4804; MEDSTRAND P, 1993, J VIROL, V67, P6778, DOI 10.1128/JVI.67.11.6778-6787.1993; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; Mi S, 2000, NATURE, V403, P785, DOI 10.1038/35001608; Miki Y, 1998, J HUM GENET, V43, P77, DOI 10.1007/s100380050045; Morgan HD, 1999, NAT GENET, V23, P314, DOI 10.1038/15490; MWENDA JM, 1993, CELL MOL BIOL, V39, P317; Nekrutenko A, 2001, TRENDS GENET, V17, P619, DOI 10.1016/S0168-9525(01)02445-3; NORRIS J, 1995, J BIOL CHEM, V270, P22777, DOI 10.1074/jbc.270.39.22777; Ostertag EM, 2001, ANNU REV GENET, V35, P501, DOI 10.1146/annurev.genet.35.102401.091032; PACKER AI, 1993, DEV BIOL, V157, P281, DOI 10.1006/dbio.1993.1133; POZNANSKI AA, 1991, DEV BIOL, V143, P271, DOI 10.1016/0012-1606(91)90077-G; ROGERS MB, 1990, J CELL BIOL, V110, P1767, DOI 10.1083/jcb.110.5.1767; ROSS SA, 1994, J CELL PHYSIOL, V159, P263, DOI 10.1002/jcp.1041590210; SALGANIK RI, 1985, BIOCHEM BIOPH RES CO, V131, P492, DOI 10.1016/0006-291X(85)91829-7; Speek M, 2001, MOL CELL BIOL, V21, P1973, DOI 10.1128/MCB.21.6.1973-1985.2001; TEMIN HM, 1970, NATURE, V226, P1211, DOI 10.1038/2261211a0; TEMIN HM, 1971, J NATL CANCER I, V46, P56; TING CN, 1992, GENE DEV, V6, P1457, DOI 10.1101/gad.6.8.1457; Tirelli U, 2001, EUR J CANCER, V37, P1320, DOI 10.1016/S0959-8049(01)00106-X; Tomilin NV, 1999, INT REV CYTOL, V186, P1; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; Whitelaw E, 2001, NAT GENET, V27, P361, DOI 10.1038/86850; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0	57	93	100	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2003	22	18					2750	2761		10.1038/sj.onc.1206354	http://dx.doi.org/10.1038/sj.onc.1206354			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ	12747369				2022-12-28	WOS:000182569300006
J	Teramoto, H; Malek, RL; Behbahani, B; Castellone, MD; Lee, NH; Gutkind, JS				Teramoto, H; Malek, RL; Behbahani, B; Castellone, MD; Lee, NH; Gutkind, JS			Identification of H-Ras, RhoA, Rac1 and Cdc42 responsive genes	ONCOGENE			English	Article						foci formation; small GTPases; microarray	GTP-BINDING PROTEINS; SIGNAL-TRANSDUCTION; CELLS; GTPASES; EXPRESSION; CANCER; TRANSFORMATION; TRANSCRIPTION; ACTIVATION; RECEPTOR	The superfamily of small GTP-binding proteins has expanded dramatically in recent years. The Ras family has long been associated with signaling pathways contributing to normal and aberrant cell growth, while Rho-related protein function is to integrate extracellular signals with specific targets regulating cell morphology, cell aggregation, tissue polarity, cell motility and cytokinesis. Recent findings suggest that certain Rho proteins, including RhoA, Rac1 and Cdc42, can also play a role in signal transduction to the nucleus and cell growth control. However, the nature of the genes regulated by Ras and Rho GTPases, as well as their contribution to their numerous biological effects is still largely unknown. To approach these questions, we investigated the global gene expression pattern induced by activated forms of H-Ras, RhoA, Rac1 and Cdc42 using cDNA microarrays comprising 19 117 unique elements. Using this approach, we identified 1184 genes that were up- or downregulated by at least twofold. Hierarchical cluster analysis revealed the existence of patterns of gene regulation both unique and common to H-Ras V12, RhoA QL, Rac1 QL and Cdc42 QL activation. For example, H-Ras V12 upregulated osteopontin and Akt 1, and H-Ras and RhoA stimulated cyclin G1, cyclin-dependent kinase 8, cyclin A2 and HMGI-C, while Rac1 QL and Cdc42 QL upregulated extracellular matrix and cell adhesion proteins such as alpha-actinin 4, procollagen type I and V and neuropilin. Furthermore, H-Ras V12 downregulated by >eightfold 52 genes compared to only three genes by RhoA QL, Rac1 QL and Cdc42 QL. These results provide key information to begin unraveling the complexity of the molecular mechanisms underlying the transforming potential of Ras and Rho proteins, as well as the numerous morphological and cell cycle effects induced by these small GTPases.	NIDR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; Inst Genom Res, Dept Funct Genom, Rockville, MD 20850 USA; George Washington Univ, Med Ctr, Dept Pharmacol, Washington, DC 20037 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); J. Craig Venter Institute; George Washington University	Gutkind, JS (corresponding author), NIDCR, Oral & Pharyngeal Canc Branch, NIH, 9000 Rockville Pike,Bldg 30,Room 212, Bethesda, MD 20892 USA.		Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016	Gutkind, J. Silvio/0000-0002-5150-4482; CASTELLONE, MARIADOMENICA/0000-0003-0507-8037	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551, ZIADE000558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000558, Z01DE000551] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; BOS JL, 1989, CANCER RES, V49, P4682; Brenner KA, 2000, ONCOGENE, V19, P3156, DOI 10.1038/sj.onc.1203626; Chen H, 1998, NAT NEUROSCI, V1, P436, DOI 10.1038/2154; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Fedele M, 1998, ONCOGENE, V17, P413, DOI 10.1038/sj.onc.1201952; Fukuhara S, 2001, ONCOGENE, V20, P1661, DOI 10.1038/sj.onc.1204182; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Liu CT, 2000, J BIOL CHEM, V275, P20315, DOI 10.1074/jbc.M909046199; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; Malek RL, 2002, ONCOGENE, V21, P7256, DOI 10.1038/sj.onc.1205900; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PERONA R, 1993, ONCOGENE, V8, P1285; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; Prasad MVVSV, 1999, ONCOGENE, V18, P1639, DOI 10.1038/sj.onc.1202461; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tanaka TS, 2000, P NATL ACAD SCI USA, V97, P9127, DOI 10.1073/pnas.97.16.9127; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; vanLeeuwen FN, 1995, ONCOGENE, V11, P2215; YANG IV, 2002, GENOME BIOL, V3; Zentner MD, 2001, J BIOL CHEM, V276, P29805, DOI 10.1074/jbc.M103153200; Zhang J, 2001, CANCER LETT, V171, P215, DOI 10.1016/S0304-3835(01)00607-3	27	45	48	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2003	22	17					2689	2697		10.1038/sj.onc.1206364	http://dx.doi.org/10.1038/sj.onc.1206364			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730683				2022-12-28	WOS:000182569000017
J	Roussigne, M; Cayrol, C; Clouaire, T; Amalric, F; Girard, JP				Roussigne, M; Cayrol, C; Clouaire, T; Amalric, F; Girard, JP			THAP1 is a nuclear proapoptotic factor that links prostate-apoptosis-response-4 (Par-4) to PML nuclear bodies	ONCOGENE			English	Article						PML nuclear bodies; Par-4; apoptosis; nuclear proteins; protein interaction	BINDING-PROTEIN; DOWN-REGULATION; DLK/ZIP KINASE; EXPRESSION; DAXX; APOPTOSIS; LOCALIZATION; PATHWAY; REPRESSOR; ISOFORMS	Promyelocytic leukemia (PML) nuclear bodies (PML NBs) are discrete subnuclear domains organized by the promyelocytic leukemia protein PML, a tumor suppressor essential for multiple apoptotic pathways. We have recently described a novel family of cellular factors, the THAP proteins, characterized by the presence at their amino-terminus of an evolutionary conserved putative DNA-binding motif, designated THAP domain. Here, we report that THAP1 is a novel nuclear proapoptotic factor associated with PML NBs, which potentiates both serum withdrawal- and TNFalpha-induced apoptosis, and interacts with prostate-apoptosis-response-4 (Par-4), a well characterized proapoptotic factor, previously linked to prostate cancer and neurodegenerative diseases. We show that endogenous Par-4 colocatizes with ectopic THAP1 within PML NBs in primary endothelial cells and fibroblasts. In addition, we found that Par-4 is a component of PML NBs in blood vessels, a major site of PML expression in vivo. Finally, we investigated the role of the THAP domain in THAP1 activities and found that this putative DNA-binding domain is not required for Par-4 binding and localization within PML NBs, but is essential for THAP1 proapoptotic activity. Together, our results provide an unexpected link between a nuclear factor of the THAP family, the proapoptotic protein Par-4 and PML nuclear bodies.	CNRS, UMR 5089, Inst Pharmacol & Biol Struct, Lab Biol Vasc, F-31077 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Girard, JP (corresponding author), CNRS, UMR 5089, Inst Pharmacol & Biol Struct, Lab Biol Vasc, 205 Route Narbonne, F-31077 Toulouse, France.	Jean-Philippe.Girard@ipbs.fr	GIRARD, Jean-Philippe/F-5229-2010; CAYROL, Corinne/C-2106-2011; CLOUAIRE, THOMAS/L-7396-2017	GIRARD, Jean-Philippe/0000-0002-9154-1691; CAYROL, Corinne/0000-0002-7813-4397; CLOUAIRE, THOMAS/0000-0003-3238-1496; Roussigne, Myriam/0000-0002-4240-4105				Barradas M, 1999, EMBO J, V18, P6362, DOI 10.1093/emboj/18.22.6362; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Besset S, 2000, FASEB J, V14, P345, DOI 10.1096/fasebj.14.2.345; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Diaz-Meco MT, 1999, J BIOL CHEM, V274, P19606, DOI 10.1074/jbc.274.28.19606; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; Ferbeyre G, 2000, GENE DEV, V14, P2015; FLENGHI L, 1995, BLOOD, V85, P1871, DOI 10.1182/blood.V85.7.1871.bloodjournal8571871; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Gale M, 1998, MOL CELL BIOL, V18, P859, DOI 10.1128/MCB.18.2.859; Girard JP, 1999, P NATL ACAD SCI USA, V96, P12772, DOI 10.1073/pnas.96.22.12772; GIRARD JP, 1995, IMMUNOL TODAY, V16, P449, DOI 10.1016/0167-5699(95)80023-9; GIRARD JP, 1995, IMMUNITY, V2, P113, DOI 10.1016/1074-7613(95)90083-7; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Guo Q, 1998, NAT MED, V4, P957, DOI 10.1038/nm0898-957; Hofmann T.G., 2001, NAT CELL BIOL, V10, P10; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Johnstone RW, 1996, MOL CELL BIOL, V16, P6945; Kogel D, 1999, ONCOGENE, V18, P7212, DOI 10.1038/sj.onc.1203169; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; Lee CC, 1998, EMBO J, V17, P4166, DOI 10.1093/emboj/17.14.4166; Lehembre F, 2001, ONCOGENE, V20, P1, DOI 10.1038/sj.onc.1204063; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Mattson MP, 1999, J MOL NEUROSCI, V13, P17, DOI 10.1385/JMN:13:1-2:17; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Negorev D, 2001, ONCOGENE, V20, P7234, DOI 10.1038/sj.onc.1204764; Page G, 1999, ONCOGENE, V18, P7265, DOI 10.1038/sj.onc.1203170; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Qiu GF, 1999, ONCOGENE, V18, P623, DOI 10.1038/sj.onc.1202344; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Richard DJ, 2001, GENE DEV, V15, P328, DOI 10.1101/gad.185901; ROUSSIGNE M, 2003, IN PRESS TRENDS BIOC; Ruggero D, 2000, BIOESSAYS, V22, P827, DOI 10.1002/1521-1878(200009)22:9<827::AID-BIES8>3.3.CO;2-T; Sells SF, 1997, MOL CELL BIOL, V17, P3823, DOI 10.1128/MCB.17.7.3823; SELLS SF, 1994, CELL GROWTH DIFFER, V5, P457; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; TERRIS B, 1995, CANCER RES, V55, P1590; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752; Zong S, 1999, ONCOGENE, V18, P7941, DOI 10.1038/sj.onc.1203367	49	113	122	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2003	22	16					2432	2442		10.1038/sj.onc.1206271	http://dx.doi.org/10.1038/sj.onc.1206271			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	670AD	12717420				2022-12-28	WOS:000182383500006
J	Zhou, CY; Smith, JL; Liu, JS				Zhou, CY; Smith, JL; Liu, JS			Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1	ONCOGENE			English	Article						ovarian cancer; BRCA1; cell cycle; ionizing radiation; paclitaxel	TUMOR-SUPPRESSOR GENE; MUTATION; CYCLE; CARCINOMA; BREAST; P53; PHOSPHORYLATION; AMPLIFICATION; ASSOCIATION; INHIBITOR	BRCA1, the gene responsible for approximately half of all cases of hereditary breast cancer and almost all cases of combined hereditary breast and ovarian cancer, has been implicated in the maintenance of genomic stability through DNA repair. This function is mediated, at least in part, through two tandem BRCA1 C-terminal (BRCT) repeats. The role of BRCA1 in the develepment of ovarian cancer is poorly understood, partially owing to the lack of ovarian cancer cell lines with defective BRCA1 The purpose of this study was to further characterize an endometrioid ovarian cancer cell line, SNU-251, which was previously reported to carry a nonsense mutation (from G to A) at amino acid 1815 of BRCA1. In addition, we examined the role of BRCA1 in the cell cycle and in the responses to the chemotherapy drug paclitaxel and ionizing radiation. Loss of the C-terminal 49 amino acids due to this point mutation did not affect the expression of the truncated BRCA1 protein, but caused a loss of transcriptional activation of the endogenous p21(WAF1/CIP1) gene, and could not sustain arrest in the G(2)/M phase of the cell cycle. The BRCA1 mutation in SNU-251 cells inhibited BRCA1 subnuclear assembly for DNA-damage repair and increased cellular sensitivity to ionizing radiation and paclitaxel. This sensitivity was reversed by reintroduction of ectopic wild-type BRCA1 Our results suggest that the deletion of the C-terminal 49 amino acids of BRCA1 results in a loss of BRCA1 function in the SNU-251 cell line. BRCA1 helps to mediate the resistance to both radiation and paclitaxel. Therefore, SNU-251 may be a useful model for studying the molecular mechanism of BRCA1 in the resistance of ovarian cancer to ionizing radiation and chemotherapy treatment and in the development of hereditary human ovarian cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Div Pathol & Lab Med,Unit 85, Houston, TX 77030 USA; Dynagene, Houston, TX 77054 USA	University of Texas System; UTMD Anderson Cancer Center	Liu, JS (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Div Pathol & Lab Med,Unit 85, 1515 Holcomber Blvd, Houston, TX 77030 USA.	jliu@mdanderson.org						Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chen JJ, 1999, CANCER RES, V59, p1752S; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Chen YM, 1996, CANCER RES, V56, P3168; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; EASTON DF, 1993, AM J HUM GENET, V52, P678; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARPER JW, 1993, CELL, V75, P805; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; Liu JS, 2000, ONCOGENE, V19, P2767, DOI 10.1038/sj.onc.1203599; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; PARK JG, 2002, J J CANC CHEMOTHE S1, V29, P89; Risinger JI, 1996, NAT GENET, V14, P102, DOI 10.1038/ng0996-102; Sato N, 2000, CANCER RES, V60, P7052; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Somasundaram K, 1999, ONCOGENE, V18, P6605, DOI 10.1038/sj.onc.1203284; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Sun HB, 2001, AM J CLIN PATHOL, V115, P32; To MD, 1998, AM J PATHOL, V153, P47, DOI 10.1016/S0002-9440(10)65544-7; Tomlinson GE, 1998, CANCER RES, V58, P3237; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Yan T, 2001, CANCER RES, V61, P8290; Yuan Y, 1997, GYNECOL ONCOL, V66, P378, DOI 10.1006/gyno.1997.4785; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	34	60	67	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2003	22	16					2396	2404		10.1038/sj.onc.1206319	http://dx.doi.org/10.1038/sj.onc.1206319			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	670AD	12717416				2022-12-28	WOS:000182383500002
J	Eymin, B; Leduc, C; Coll, JL; Brambilla, E; Gazzeri, S				Eymin, B; Leduc, C; Coll, JL; Brambilla, E; Gazzeri, S			P14(ARF) induces G(2) arrest and apoptosis independently of p53 leading to regression of tumours established in nude mice	ONCOGENE			English	Article						apoptosis; G(2) arrest; tumour regression; ARF; p53	DNA-DAMAGE CHECKPOINT; CELL-CYCLE ARREST; INHIBITORY PHOSPHORYLATION; P53-DEPENDENT APOPTOSIS; PROTEIN-KINASE; CDC25 PROTEIN; FEEDBACK LOOP; LUNG-CANCER; SUPPRESSOR; P19(ARF)	Until recently, the ability of ARF (human p14(ARF), murine p19(ARF)) tumour-suppressor protein, encoded by the INK4A/ARF locus, to inhibit cell growth in response to various stimuli was related to its ability to stabilize p53 through the so-called ARF/MDM2/p53 pathway. However, recent data have demonstrated that ARF is not implicated in this unique p53-dependent pathway. By use of transient and stable expression, we show here that human p14(ARF) inhibits the growth of human tumoral cells lacking functional p53 by inducing a transient G(2) arrest and subsequently apoptosis. This p14(ARF)-induced G2 arrest was correlated with inhibition of CDC2 activity, inactivation of CDC25C phosphatase and induction of the CDK inhibitor p21(WAF1). Apoptosis was demonstrated using Hoechst 33352 staining, proteolytic activation of caspase-3 and PARP cleavage. Similar results were obtained in experiments with cells synchronized by hydroxyurea block. Importantly, we were able to reproduce these effects 'in vivo' by showing that p14(ARF) inhibits the growth of p53 nullizygous human tumours in nude mice and induces the regression of p53 -/- established tumours. In these experiments, tumoral regression was associated with inhibition of cell proliferation as well as induction of apoptosis confirming the data obtained in cell lines.	Inst Albert Bonniot, INSERM, Equipe 9924, Grp Rech Canc Poumon,EA 2021, F-38706 La Tronche, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Gazzeri, S (corresponding author), Inst Albert Bonniot, INSERM, Equipe 9924, Grp Rech Canc Poumon,EA 2021, F-38706 La Tronche, France.	Sylvie.Gazzeri@ujf-grenoble.fr	Coll, Jean-Luc/G-2520-2013; eymin, beatrice/U-4670-2019; Eymin, Beatrice/M-1962-2013; gazzeri, sylvie/U-4669-2019; Brambilla, Elisabeth MP/L-8796-2013; gazzeri, sylvie/M-1961-2013	Coll, Jean-Luc/0000-0002-2453-3552; eymin, beatrice/0000-0002-7311-3810; Eymin, Beatrice/0000-0002-7311-3810; gazzeri, sylvie/0000-0001-5817-1839; gazzeri, sylvie/0000-0001-5817-1839				AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Athar M, 2000, BIOCHEM BIOPH RES CO, V277, P107, DOI 10.1006/bbrc.2000.3436; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Blasina A, 1997, MOL BIOL CELL, V8, P1013, DOI 10.1091/mbc.8.6.1013; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; Cong F, 1999, ONCOGENE, V18, P7731, DOI 10.1038/sj.onc.1203290; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Draetta G.F., 1997, CURR BIOL, V7, P50; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Esteller M, 2000, CANCER RES, V60, P129; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; FAN SJ, 1995, CANCER RES, V55, P1649; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Gazzeri S, 1998, CANCER RES, V58, P3926; Goldstone S, 2001, ONCOGENE, V20, P921, DOI 10.1038/sj.onc.1204177; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; Labat-Moleur F, 1998, J HISTOCHEM CYTOCHEM, V46, P327, DOI 10.1177/002215549804600306; LI CY, 1995, ONCOGENE, V11, P1885; LI Y, 1994, ONCOGENE, V9, P2261; Lindstrom MS, 2000, EXP CELL RES, V256, P400, DOI 10.1006/excr.2000.4854; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Poon RYC, 1997, CANCER RES, V57, P5168; POWELL SN, 1995, CANCER RES, V55, P1643; QUELLE DE, 1995, CELL, V83, P993; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Raj K, 2001, NATURE, V412, P914, DOI 10.1038/35091082; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sanchez-Cespedes M, 1999, ONCOGENE, V18, P5843, DOI 10.1038/sj.onc.1203003; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Smits VAJ, 2000, J BIOL CHEM, V275, P30638, DOI 10.1074/jbc.M005437200; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; Takizawa CG, 2000, CURR OPIN CELL BIOL, V12, P658, DOI 10.1016/S0955-0674(00)00149-6; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Walworth NC, 2000, CURR OPIN CELL BIOL, V12, P697, DOI 10.1016/S0955-0674(00)00154-X; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; Weber HO, 2002, ONCOGENE, V21, P3207, DOI 10.1038/sj.onc.1205429; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Weinert T, 1997, SCIENCE, V277, P1450, DOI 10.1126/science.277.5331.1450; Winters ZE, 1998, ONCOGENE, V17, P673, DOI 10.1038/sj.onc.1201991; Yarbrough WG, 2002, CANCER RES, V62, P1171; Ye XS, 1996, EMBO J, V15, P3599, DOI 10.1002/j.1460-2075.1996.tb00729.x; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	69	103	112	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2003	22	12					1822	1835		10.1038/sj.onc.1206303	http://dx.doi.org/10.1038/sj.onc.1206303			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660818	Green Submitted			2022-12-28	WOS:000181678200009
J	Agathanggelou, A; Dallol, A; Zochbauer-Muller, S; Morrissey, C; Honorio, S; Hesson, L; Martinsson, T; Fong, KM; Kuo, MJ; Yuen, PW; Maher, ER; Minna, JD; Latif, F				Agathanggelou, A; Dallol, A; Zochbauer-Muller, S; Morrissey, C; Honorio, S; Hesson, L; Martinsson, T; Fong, KM; Kuo, MJ; Yuen, PW; Maher, ER; Minna, JD; Latif, F			Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers	ONCOGENE			English	Article						epigenetic inactivation; 3p21.3 region; human cancers	SINGLE NUCLEOTIDE POLYMORPHISM; HUMAN-CHROMOSOME 3P21.3; HIPPEL-LINDAU-DISEASE; CHANNEL SUBUNIT GENE; HUMAN LUNG-CANCER; 3P ALLELE LOSS; NEUROBLASTOMA TUMORS; RENAL-CARCINOMA; BREAST-CANCER; IDENTIFICATION	Many distinct regions of 3p show frequent allelic losses in a wide range of tumour types. Previously, the BLU candidate tumour suppressor gene (TSG) encoded by a gene-rich critical deleted region in 3p21.3 was found to be inactivated rarely in lung cancer, although expression was downregulated in a subset of lung tumour cell lines. To elucidate the role of BLU in tumorigenesis, we analysed BLU promoter methylation status in tumour cell lines and detected promoter region hypermethylation in 39% lung, 42% breast, 50% kidney, 86% neuroblastoma and 80% nasopharyngeal (NPC) tumour cell lines. Methylation of the BLU promoter region correlated with the down-regulation of BLU transcript expression in tumour cell lines. Expression was recovered in tumour cell lines treated with 5-aza 2-deoxycytidine. Exogenous expression of BLU in neuroblastoma (SK-N-SH) and NSCLC (NCI-H1299) resulted in reduced colony formation efficiency, in vitro. Furthermore, methylation of the BLU promoter region was detected in primary sporadic SCLC (14%), NSCLC (19%) and neuroblastoma (41%). As frequent methylation of the RASSF1A 3p21.3 TSG has also been reported in these tumour types, we investigated whether BLU and RASSF1A methylation were independent or related events. No correlation was found between hypermethylation of RASSF1A and BLU promoter region CpG islands in SCLC or neuroblastoma. However, there was association between RASSF1A and BLU methylation in NSCLC (P = 0.0031). Our data suggest that in SCLC and neuroblastoma, RASSF1A and BLU methylations are unrelated events and not a manifestation of a regional alteration in epigenetic status, while in NSCLC there may be a regional methylation effect. Together, these data suggest a significant role for epigenetic inactivation of BLU in the pathogenesis of common human cancers and that methylation inactivation of BLU occurs independent of RASSF1A in SCLC and neuroblastoma tumours.	Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX USA; Univ Gothenburg, Sahlgrenska Hosp Ostra, Dept Clin Genet, S-41685 Gothenburg, Sweden; Prince Charles Hosp, Brisbane, Qld 4032, Australia; Birmingham Childrens Hosp, Birmingham B4 6NH, W Midlands, England; Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Univ Birmingham, Sch Med, Canc Res UK, Renal Mol Oncol Res Grp, Birmingham B15 2TT, W Midlands, England	University of Birmingham; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Gothenburg; Prince Charles Hospital; University of Birmingham; University of Hong Kong; Cancer Research UK; University of Birmingham	Latif, F (corresponding author), Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.	flatif@hgmp.mrc.ac.uk	Martinsson, Tommy/J-4140-2013; Fong, Kwun M/G-6369-2010; Dallol, Ashraf/H-8661-2012; Zöchbauer-Müller, Sabine/B-8399-2012; MAHER, EAMONN R/A-9507-2008; Hesson, Luke/HDM-0311-2022	Martinsson, Tommy/0000-0002-9403-3123; Dallol, Ashraf/0000-0002-8803-228X; Zöchbauer-Müller, Sabine/0000-0002-6777-1729; MAHER, EAMONN R/0000-0002-6226-6918; Fong, Kwun/0000-0002-6507-1403	NATIONAL CANCER INSTITUTE [P50CA070907, R01CA071618] Funding Source: NIH RePORTER; NCI NIH HHS [CA71618, P50 CA70907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Angeloni D, 2000, MOL CELL PROBE, V14, P53, DOI 10.1006/mcpr.1999.0277; Angeloni D, 2001, MOL CELL PROBE, V15, P125, DOI 10.1006/mcpr.2000.0341; Ansieau S, 2002, J BIOL CHEM, V277, P4906, DOI 10.1074/jbc.M110078200; Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Clifford SC, 2001, ADV CANCER RES, V82, P85, DOI 10.1016/S0065-230X(01)82003-0; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Ejeskar K, 1998, BRIT J CANCER, V77, P1787, DOI 10.1038/bjc.1998.297; FEINSTEIN PG, 1995, GENETICS, V140, P573; Foster K, 1995, EUR J CANCER, V31A, P2392, DOI 10.1016/0959-8049(95)00437-8; Fullwood P, 1999, CANCER RES, V59, P4662; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Honorio S, 2001, MOL CELL PROBE, V15, P391, DOI 10.1006/mcpr.2001.0382; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LeBoeuf RD, 1998, J BIOL CHEM, V273, P361, DOI 10.1074/jbc.273.1.361; Lerman MI, 2000, CANCER RES, V60, P6116; Lutterbach B, 1998, MOL CELL BIOL, V18, P3604, DOI 10.1128/MCB.18.6.3604; Maitra A, 2001, AM J PATHOL, V159, P119, DOI 10.1016/S0002-9440(10)61679-3; Martinez A, 2000, J CLIN PATHOL-MOL PA, V53, P137, DOI 10.1136/mp.53.3.137; Martinez A, 2001, J CLIN PATHOL-MOL PA, V54, P300, DOI 10.1136/mp.54.5.300; Masselink H, 2000, ONCOGENE, V19, P1538, DOI 10.1038/sj.onc.1203421; Michelson RJ, 1999, J BIOL CHEM, V274, P30510, DOI 10.1074/jbc.274.43.30510; SEKIDO Y, 1994, ONCOGENE, V9, P1599; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Sundaresan V, 1998, ONCOGENE, V17, P1723, DOI 10.1038/sj.onc.1202103; Wei MH, 1996, CANCER RES, V56, P1487; Wistuba II, 2000, CANCER RES, V60, P1949; Wolford JK, 1998, GENE, V212, P103, DOI 10.1016/S0378-1119(98)00141-3; Yan H, 2002, NAT GENET, V30, P25, DOI 10.1038/ng799; Zochbauer-Muller S, 2001, CANCER RES, V61, P249	33	80	90	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2003	22	10					1580	1588		10.1038/sj.onc.1206243	http://dx.doi.org/10.1038/sj.onc.1206243			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652ZZ	12629521				2022-12-28	WOS:000181411900015
J	Wong, JMS; Ionescu, D; Ingles, CJ				Wong, JMS; Ionescu, D; Ingles, CJ			Interaction between BRCA2 and replication protein A is compromised by a cancer-predisposing mutation in BRCA2	ONCOGENE			English	Article						replication protein A; BRCA2; DSB repair; protein-protein interaction	NUCLEOTIDE EXCISION-REPAIR; RNA-POLYMERASE-II; TRANSCRIPTIONAL ACTIVATION DOMAINS; DNA-REPLICATION; RAD51; RPA; P53; BIND; GENE; SUSCEPTIBILITY	Mutations in the BRCA1 and BRCA2 genes predispose women to familial, early-onset breast cancer. Both the BRCA1 and BRCA2 proteins appear to function in the homologous recombination pathway of DNA double-strand break repair. Both BRCA1 and BRCA2 have also been implicated in transcription by RNA polymerase II, for both proteins have domains which, when tethered adjacent to a promoter, can activate transcription. In experiments reported here, we have used protein affinity chromatography and coimmunoprecipitation techniques to show that the putative N-terminal acidic transcriptional activation domain of BRCA2 interacts with replication protein A (RPA), a protein essential for DNA repair, replication and recombination. This interaction was not mediated by DNA and was specific for human RPA but not yeast RPA. Since the cancer-predisposing mutation Y42C in BRCA2 significantly compromised the interaction between RPA and BRCA2, this interaction may be biologically important. That BRCA2 protein in HeLa cell extract also coimmunoprecipitated with RPA suggested that this interaction occurs in vivo. Therefore, the transcriptional activation domains within BRCA2, and perhaps BRCA1, may provide links to RPA and DNA repair processes rather than transcription.	Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1L6, Canada	University of Toronto; University of Toronto	Ingles, CJ (corresponding author), Univ Toronto, Banting & Best Dept Med Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.							BARDWELL AJ, 1994, MOL CELL BIOL, V14, P3569, DOI 10.1128/MCB.14.6.3569; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Choudhary SK, 2002, J CELL BIOCHEM, V84, P666, DOI 10.1002/jcb.10081; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; de Laat WL, 1998, GENE DEV, V12, P2598, DOI 10.1101/gad.12.16.2598; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; Golub EI, 1998, NUCLEIC ACIDS RES, V26, P5388, DOI 10.1093/nar/26.23.5388; Greenblatt J, 1996, METHOD ENZYMOL, V274, P120; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; He ZG, 1996, J BIOL CHEM, V271, P28243, DOI 10.1074/jbc.271.45.28243; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; Hu YF, 1999, GENE DEV, V13, P637, DOI 10.1101/gad.13.6.637; Kerr P, 2001, CURR BIOL, V11, pR668, DOI 10.1016/S0960-9822(01)00389-X; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; Lim DS, 1996, MOL CELL BIOL, V16, P7133; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; McIlwraith MJ, 2000, J MOL BIOL, V304, P151, DOI 10.1006/jmbi.2000.4180; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; Nordling M, 1998, CANCER RES, V58, P1372; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Rahman N, 1998, ANNU REV GENET, V32, P95, DOI 10.1146/annurev.genet.32.1.95; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shinohara A, 1998, GENES CELLS, V3, P145, DOI 10.1046/j.1365-2443.1998.00176.x; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; SOPTA M, 1985, J BIOL CHEM, V260, P353; van Golen K, 1999, J LAB CLIN MED, V134, P11, DOI 10.1016/S0022-2143(99)90049-5; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Warren M, 2002, HUM MOL GENET, V11, P841, DOI 10.1093/hmg/11.7.841; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; Ye QN, 2001, J CELL BIOL, V155, P911, DOI 10.1083/jcb.200108049	39	63	64	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 9	2003	22	1					28	33		10.1038/sj.onc.1206071	http://dx.doi.org/10.1038/sj.onc.1206071			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527904				2022-12-28	WOS:000180166900003
J	Hobbs, SS; Coffing, SL; Le, AT; Cameron, EM; Williams, EE; Andrew, M; Blommel, EN; Hammer, RP; Chang, H; Riese, DJ				Hobbs, SS; Coffing, SL; Le, AT; Cameron, EM; Williams, EE; Andrew, M; Blommel, EN; Hammer, RP; Chang, H; Riese, DJ			Neuregulin isoforms exhibit distinct patterns of ErbB family receptor activation	ONCOGENE			English	Article						heregulins; neuregulins; ErbB3; ErbB4; HER3; HER4	EPIDERMAL GROWTH-FACTOR; NEU DIFFERENTIATION FACTOR; TYROSINE KINASES; SIGNALING NETWORK; CELLULAR-RESPONSE; BETA-RECEPTOR; EGF DOMAIN; HEREGULIN; PROTEIN; LIGAND	During the last decade, several novel members of the Epidermal Growth Factor family of peptide growth factors have been identified. Most prominent among these are the Neuregulins or Heregulins. To date, four different Neuregulin genes have been identified (Neuregulin1-4) and several different splicing isoforms have been identified for :at least two of these genes (Neuregulin1 and Neuregulin2). While Neuregulin1 isoforms have been extensively studied, comparatively little is known about Neuregulin3, Neuregulin4, or the Neuregulin2 isoforms. Indeed, there has been no systematic comparison of the activities of these molecules. Here we demonstrate that Neuregulin2alpha and Neuregulin2beta stimulate ErbB3 tyrosine phosphorylation and coupling to biological responses. In contrast, Neuregulin3 and Neuregulin4 fail to activate ErbB3 signaling. Furthermore, Neuregulin2beta, but not Neuregulin2alpha, stimulates ErbB4 tyrosine phosphorylation and coupling to biological responses. Finally, both Neuregulin3 and Neuregulin4 stimulate modest amounts of ErbB4 tyrosine phosphorylation. However, whereas Neuregulin3 stimulates a modest amount of ErbB4 coupling to biological responses, Neuregulin4 fails to stimulate ErbB4 coupling to biological responses. This suggests that there are qualitative as well as quantitative differences in ErbB family receptor activation by Neuregulin isoforms.	Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA; Louisiana State Univ, Dept Chem, Baton Rouge, LA 70803 USA; Bristol Myers Squibb Co, Pharmaceut Res Inst, Princeton, NJ 08543 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Louisiana State University System; Louisiana State University; Bristol-Myers Squibb	Riese, DJ (corresponding author), Purdue Univ, Dept Med Chem & Mol Pharmacol, 1333 RHPH,Room 224D, W Lafayette, IN 47907 USA.		Riese, David/AAF-3581-2020	Riese, David/0000-0002-8823-5802	NCI NIH HHS [F33CA085049, R21CA080770] Funding Source: Medline; NIGMS NIH HHS [T32GM008737] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F33CA085049, R21CA080770] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008737] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ballinger MD, 1998, J BIOL CHEM, V273, P11675, DOI 10.1074/jbc.273.19.11675; BOONSTRA J, 1995, CELL BIOL INT, V19, P413, DOI 10.1006/cbir.1995.1086; Burke CL, 1998, MOL CELL BIOL, V18, P5371, DOI 10.1128/MCB.18.9.5371; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; DrummondBarbosa D, 1997, BBA-REV CANCER, V1332, pM1, DOI 10.1016/S0304-419X(96)00034-0; Feroz K, 2002, CELL SIGNAL, V14, P793, DOI 10.1016/S0898-6568(02)00019-0; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; Gullick WJ, 2001, ENDOCR-RELAT CANCER, V8, P75, DOI 10.1677/erc.0.0080075; Harari D, 1999, ONCOGENE, V18, P2681, DOI 10.1038/sj.onc.1202631; Hijazi MM, 1998, INT J ONCOL, V13, P1061; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Jones JT, 1998, J BIOL CHEM, V273, P11667, DOI 10.1074/jbc.273.19.11667; Jones JT, 1999, FEBS LETT, V447, P227, DOI 10.1016/S0014-5793(99)00283-5; KITA YA, 1994, FEBS LETT, V349, P139, DOI 10.1016/0014-5793(94)00644-X; Klein O, 1998, J VIROL, V72, P8921, DOI 10.1128/JVI.72.11.8921-8932.1998; Kumar R, 2000, J CLIN LIGAND ASSAY, V23, P233; LU HS, 1995, J BIOL CHEM, V270, P4784, DOI 10.1074/jbc.270.9.4784; NILSON LA, 1995, J VIROL, V69, P5869, DOI 10.1128/JVI.69.9.5869-5874.1995; Normanno N, 2001, FRONT BIOSCI-LANDMRK, V6, pD685, DOI 10.2741/Normano; Ozawa F, 2001, TERATOGEN CARCIN MUT, V21, P27, DOI 10.1002/1520-6866(2001)21:1<27::AID-TCM4>3.0.CO;2-9; Pinkas-Kramarski R, 1998, MOL CELL BIOL, V18, P6090, DOI 10.1128/MCB.18.10.6090; Pinkas-Kramarski R, 1999, MOL CELL BIOL, V19, P8695; PinkasKramarski R, 1996, J BIOL CHEM, V271, P19029, DOI 10.1074/jbc.271.32.19029; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; Riese DJ, 1998, J BIOL CHEM, V273, P11288, DOI 10.1074/jbc.273.18.11288; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, ONCOGENE, V12, P345; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Stern DF, 2000, BREAST CANCER RES, V2, P176, DOI 10.1186/bcr51; Sweeney C, 2000, J BIOL CHEM, V275, P19803, DOI 10.1074/jbc.C901015199; Sweeney C, 2001, J BIOL CHEM, V276, P22685, DOI 10.1074/jbc.M100602200; SWEENEYCROVELLO C, 1998, J BIOL CHEM, V273, P26954; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562	39	71	76	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 5	2002	21	55					8442	8452		10.1038/sj.onc.1205960	http://dx.doi.org/10.1038/sj.onc.1205960			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466964				2022-12-28	WOS:000179480100007
J	Perri, P; Longo, L; Cusano, R; McConville, CM; Rees, SA; Devoto, M; Conte, M; Ferrara, GB; Seri, M; Romeo, G; Tonini, GP				Perri, P; Longo, L; Cusano, R; McConville, CM; Rees, SA; Devoto, M; Conte, M; Ferrara, GB; Seri, M; Romeo, G; Tonini, GP			Weak linkage at 4p16 to predisposition for human neuroblastoma	ONCOGENE			English	Article						neuroblastoma; chromosome 4p; LOH; linkage analysis; tumor suppressor genes	COMPARATIVE GENOMIC HYBRIDIZATION; TUMORS; MUTATION; DELETION; CANCER; REGION; LOCUS; MYC	The most frequent genetic alterations described in neuroblastoma (NB) are amplification of MYCN oncogene and deletion of chromosome 1p, although somatic deletions have been demonstrated at other chromosomal intervals. Since loss of heterozygosity (LOH) at distal 4p has been observed in about 20-29% of neuroblastomas, we have evaluated deletions in 41 Italian NB samples by LOH analysis at loci mapping to 4p as follows: pter-D4S2936-D4S412-D4S2957MS432-D4S3023-MS431-cen. Our analysis showed allele losses in eight out of 41 samples (19.5%) and allowed the identification of a smallest region of overlapping deletion (SRO) of 3.0 cM, delimited by D4S412 and D4S3023. Two of these tumors with 4p LOH are from patients belonging to a family with recurrent NB. Interestingly the genotyping of this family revealed an identical haplotype that includes the nonrecombinant loci D4S412, D4S2957 and D4S432 shared by all affected children and demonstrated that this haplotype is retained in the two tumors carrying somatic deletions from patients of this family. Furthermore linkage analysis was performed in two NB families and yielded an overall lod-score of 3.0 in the interval including the haplotype. This provides a confirmatory indication that the region delimited by D4S2936 and D4S3023, which also includes the new defined SRO, may harbor NB predisposing gene/s.	Natl Inst Canc Res, IST, Lab Populat Genet, I-16132 Genoa, Italy; Adv Biotechnol Ctr, Lab Neuroblastoma Res, I-16132 Genoa, Italy; Gaslini Childrens Hosp, Mol Genet Lab, I-16148 Genoa, Italy; Univ Birmingham, Dept Paediat & Child Hlth, Birmingham B15 2TT, W Midlands, England; Univ Genoa, Dept Oncol Biol & Genet, I-16132 Genoa, Italy; AI duPont Hosp Children, Dept Res, Wilmington, DE 19899 USA; Gaslini Childrens Hosp, Dept Hematol & Oncol, I-16148 Genoa, Italy; Natl Inst Canc Res, IST, Immunogenet Lab, I-16132 Genoa, Italy; Univ Bologna, Dept Internal Med Cardioangiol & Hepatol, I-40138 Bologna, Italy	University of Genoa; IRCCS AOU San Martino IST; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); University of Genoa; IRCCS Istituto Giannina Gaslini; University of Birmingham; University of Genoa; Nemours Alfred I. duPont Hospital for Children; University of Genoa; IRCCS Istituto Giannina Gaslini; University of Genoa; IRCCS AOU San Martino IST; University of Bologna	Tonini, GP (corresponding author), Natl Inst Canc Res, IST, Lab Populat Genet, Lgo R Benzi 10, I-16132 Genoa, Italy.		conte, massimo/K-2049-2016; conte, massimo/AAA-8044-2019; Devoto, Marcella/AAP-7595-2021; Longo, Luca/K-6156-2018; Perri, Patrizia/I-8124-2018; Perri, Patrizia/AFV-5794-2022; Eva, Alessandra/J-8268-2016; Seri, Marco/A-4339-2014	conte, massimo/0000-0001-9405-7339; conte, massimo/0000-0001-9405-7339; Longo, Luca/0000-0002-5153-4243; Perri, Patrizia/0000-0003-2538-8278; Perri, Patrizia/0000-0003-2538-8278; Eva, Alessandra/0000-0003-2949-078X; DEVOTO, MARCELLA/0000-0002-4431-5114; Seri, Marco/0000-0003-2425-2176; Cusano, Roberto/0000-0001-5543-7881				Altura RA, 1997, GENE CHROMOSOME CANC, V19, P176, DOI 10.1002/(SICI)1098-2264(199707)19:3<176::AID-GCC7>3.0.CO;2-V; Bown N, 2001, MED PEDIATR ONCOL, V36, P14, DOI 10.1002/1096-911X(20010101)36:1<14::AID-MPO1005>3.3.CO;2-7; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Caron H, 1996, HUM GENET, V97, P834; KNUDSON AG, 1972, AM J HUM GENET, V24, P514; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; Lo Cunsolo C, 2000, BRIT J CANCER, V83, P1295, DOI 10.1054/bjoc.2000.1432; Luttikhuis MEMO, 2001, BRIT J CANCER, V85, P531, DOI 10.1054/bjoc.2001.1960; Martinsson T, 1997, EUR J CANCER, V33, P1997, DOI 10.1016/S0959-8049(97)00278-5; OCONNELL JR, 1995, NAT GENET, V11, P402, DOI 10.1038/ng1295-402; Perri P, 1997, EUR J CANCER, V33, P1949, DOI 10.1016/S0959-8049(97)00286-4; SCHWAB M, 1984, NATURE, V308, P288, DOI 10.1038/308288a0; Schwab M, 1996, GENE CHROMOSOME CANC, V16, P211, DOI 10.1002/(SICI)1098-2264(199608)16:4<211::AID-GCC1>3.0.CO;2-0; SRIVATSAN ES, 1993, GENE CHROMOSOME CANC, V7, P32, DOI 10.1002/gcc.2870070106; TAKITA J, 1995, ONCOGENE, V11, P1829; Vandesompele J, 2001, MED PEDIATR ONCOL, V36, P5, DOI 10.1002/1096-911X(20010101)36:1<5::AID-MPO1003>3.0.CO;2-E; Vandesompele J, 1998, GENE CHROMOSOME CANC, V23, P141, DOI 10.1002/(SICI)1098-2264(199810)23:2<141::AID-GCC7>3.0.CO;2-2; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520	20	30	30	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 28	2002	21	54					8356	8360		10.1038/sj.onc.1206009	http://dx.doi.org/10.1038/sj.onc.1206009			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447700				2022-12-28	WOS:000179323900015
J	Jiang, MR; Lie, YC; Yang, Y; Wu, JR				Jiang, MR; Lie, YC; Yang, Y; Wu, JR			C-Myc degradation induced by DNA damage results in apoptosis of CHO cells	ONCOGENE			English	Article						c-Myc; apoptosis; DNA damage; CHO cell; tripchlorolide	SISTER-CHROMATID EXCHANGE; STRAND-BREAK REPAIR; PROTEIN-DEGRADATION; TRIPTOLIDE; PROTEASOME; EXPRESSION; GROWTH; CHEMOTHERAPY; SUPPRESSION; INHIBITORS	Although tripchlorolide (TC), a compound purified from a Chinese herb Tripterygium Wilfordii Hook, has been demonstrated to be a potent antitumor agent, its mechanisms of action are unknown. The present study shows that TC induces apoptosis of Chinese Hamster Ovary (CHO) cells. Most strikingly, TC was particularly potent in inducing apoptosis of the UV41 mutant CHO cells, which are deficient in the ERCC4 gene encoding a nucleotide excision repair protein. TC caused a higher level of DNA damage in UV41 cells than those in the wildtype CHO cells or EM9 cells, which are deficient in single-strand break repair. These results provided a critical link between apoptotic hypersensitivity and DNA damage in defective nucleotide excision repair pathway of UV41 cells by TC treatment. Further analysis showed that degradation of the c-Myc protein in TC-treated UV41 cells was much stronger than those in the wild-type CHOAA8 and the EM9. A proteasome inhibitor, MG132, reduced both the degradation of c-Myc and apoptosis in TC-treated UV41 cells. Expression of exogenous c-Myc also inhibited apoptosis of TC-treated UV41 cells. These results indicate that c-Myc degradation induced by DNA damage in the presence of TC contributes to induction of apoptosis of UV41 cells.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Mol Cell Biol Lab, Shanghai 200031, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Mat Med, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Shanghai Institutes for Biological Sciences, CAS	Wu, JR (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Mol Cell Biol Lab, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.		Jiang, Manrong/E-6991-2011					Adachi S, 2001, MOL CELL BIOL, V21, P4929, DOI 10.1128/MCB.21.15.4929-4937.2001; Brookman KW, 1996, MOL CELL BIOL, V16, P6553; Chang WT, 2001, J BIOL CHEM, V276, P2221, DOI 10.1074/jbc.M009713200; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Dang CV, 1999, MOL CELL BIOL, V19, P1; Deroo BJ, 2002, MOL CELL BIOL, V22, P4113, DOI 10.1128/MCB.22.12.4113-4123.2002; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Flinn EM, 1998, MOL CELL BIOL, V18, P5961, DOI 10.1128/MCB.18.10.5961; GIBSON AW, 1995, EXP CELL RES, V218, P351, DOI 10.1006/excr.1995.1166; Gottlieb RA, 2002, METHODS, V26, P341, DOI 10.1016/S1046-2023(02)00040-3; Jiang MR, 2001, BIOCHEM BIOPH RES CO, V287, P775, DOI 10.1006/bbrc.2001.5655; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; Kornitzer D, 2000, J CELL PHYSIOL, V182, P1, DOI 10.1002/(SICI)1097-4652(200001)182:1<1::AID-JCP1>3.0.CO;2-V; KUPCHAN SM, 1972, J AM CHEM SOC, V94, P7194, DOI 10.1021/ja00775a078; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lee HY, 1997, GENE, V184, P177, DOI 10.1016/S0378-1119(96)00592-6; Lee KY, 1999, J BIOL CHEM, V274, P13451, DOI 10.1074/jbc.274.19.13451; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LU XY, 1990, ACTA ACADEMIAE MED S, V12, P157; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Sgonc R, 1998, EXP GERONTOL, V33, P525, DOI 10.1016/S0531-5565(98)00031-X; Sonenshein GE, 1997, J IMMUNOL, V158, P1994; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; Tajima K, 2001, FEBS LETT, V490, P59, DOI 10.1016/S0014-5793(01)02138-X; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; Thompson LH, 1998, BIOESSAYS, V20, P589, DOI 10.1002/(SICI)1521-1878(199807)20:7<589::AID-BIES11>3.0.CO;2-W; THOMPSON LH, 1981, P NATL ACAD SCI-BIOL, V78, P3734, DOI 10.1073/pnas.78.6.3734; THOMPSON LH, 1982, MUTAT RES, V95, P427, DOI 10.1016/0027-5107(82)90276-7; THOMPSON LH, 1990, MOL CELL BIOL, V10, P6160, DOI 10.1128/MCB.10.12.6160; THULASI R, 1993, J BIOL CHEM, V268, P18306; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WOOD AC, 1994, BRIT J CANCER, V69, P663, DOI 10.1038/bjc.1994.128; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZHANG T-M, 1981, Acta Pharmacologica Sinica, V2, P128	39	21	22	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 22	2003	22	21					3252	3259		10.1038/sj.onc.1206501	http://dx.doi.org/10.1038/sj.onc.1206501			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681MM	12761495				2022-12-28	WOS:000183040000007
J	Zhang, YF; Homer, C; Edwards, SJ; Hananeia, L; Lasham, A; Royds, J; Sheard, P; Braithwaite, AW				Zhang, YF; Homer, C; Edwards, SJ; Hananeia, L; Lasham, A; Royds, J; Sheard, P; Braithwaite, AW			Nuclear localization of Y-box factor YB1 requires wild-type p53	ONCOGENE			English	Article						YB1; p53; nuclear localization	MDR1 GENE-EXPRESSION; BINDING-PROTEIN YB-1; TRANSCRIPTIONAL TARGET; MONOCLONAL-ANTIBODY; POTENTIAL MEDIATOR; CELL-PROLIFERATION; APOPTOSIS; DOMAIN; TRANSACTIVATION; ACTIVATION	Nuclear localization and high levels of the Y-box binding protein YB1 appear to be important indicators of drug resistance and tumor prognosis. YB1 also interacts with the p53 tumor suppressor protein. In this paper, we explore a role for p53 in the nuclear localization of YB1. We report that various genotoxic stresses induce nuclear localization of YB1 in a small proportion of treated cells, but only in cells with wild-type p53. We go on to show directly that functional p53 is required for YB1 to translocate to the nucleus. Tumor-associated p53 mutants however are attenuated for YB1 nuclear localization as are mutants mutated in the proline-rich domain of p53. These data link the DNA-damage response of p53 to YB1 nuclear translocation. In addition, we find that YB1 inhibits p53-induced cell death and its ability to transactivate promoters of genes involved in cell death signaling. Together these data suggest that some forms of p53 cause YB1 to accumulate in the nucleus, which in turn inhibits p53 activity. These results provide a possible explanation for the correlation of nuclear YB1 with drug resistance and poor prognosis in some tumor types, and for the first time implicate p53 in the process of nuclear translocation.	Univ Otago, Dunedin Sch Med, Dept Pathol, Dunedin, New Zealand; Genesis Res & Dev Corp Ltd, Auckland, New Zealand; Univ Otago, Sch Med Sci, Dept Physiol, Dunedin, New Zealand	University of Otago; University of Otago	Braithwaite, AW (corresponding author), Univ Otago, Dunedin Sch Med, Dept Pathol, Box 913, Dunedin, New Zealand.	antony.braithwaite@stonebow.otago.ac.nz		Edwards, Sara/0000-0002-3468-1217				Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; ASAKUNO K, 1994, BIOCHEM BIOPH RES CO, V199, P1428, DOI 10.1006/bbrc.1994.1390; Baptiste N, 2002, ONCOGENE, V21, P9, DOI 10.1038/sj/onc/1205015; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; Bissonnette N, 1997, BIOCHEM CELL BIOL, V75, P351, DOI 10.1139/bcb-75-4-351; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; Dix BR, 2000, CANCER RES, V60, P2666; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fortin A, 2001, J CELL BIOL, V155, P207, DOI 10.1083/jcb.200105137; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Holm PS, 2002, J BIOL CHEM, V277, P10427, DOI 10.1074/jbc.M106955200; JACKSON P, 1994, BIOCHEM BIOPH RES CO, V203, P133, DOI 10.1006/bbrc.1994.2159; Janz M, 2002, INT J CANCER, V97, P278, DOI 10.1002/ijc.1610; Kamura T, 1999, CANCER, V85, P2450, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2450::AID-CNCR21>3.0.CO;2-U; Koike K, 1997, FEBS LETT, V417, P390, DOI 10.1016/S0014-5793(97)01296-9; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LADOMERY M, 1995, BIOESSAYS, V17, P9, DOI 10.1002/bies.950170104; Lasham A, 2000, GENE, V252, P1, DOI 10.1016/S0378-1119(00)00220-1; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; Matsumoto K, 1998, TRENDS CELL BIOL, V8, P318, DOI 10.1016/S0962-8924(98)01300-2; Mertens PR, 2002, J BIOL CHEM, V277, P24875, DOI 10.1074/jbc.M200445200; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; O'Carroll SJ, 2000, BIOTECHNIQUES, V28, P408, DOI 10.2144/00283bm03; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Oda Y, 1998, CLIN CANCER RES, V4, P2273; Ohga T, 1998, J BIOL CHEM, V273, P5997, DOI 10.1074/jbc.273.11.5997; Ohga T, 1996, CANCER RES, V56, P4224; Okamoto T, 2000, ONCOGENE, V19, P6194, DOI 10.1038/sj.onc.1204029; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; Prives C, 1999, J PATHOL, V187, P112; Robles AI, 2001, CANCER RES, V61, P6660; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Shibahara K, 2001, CLIN CANCER RES, V7, P3151; Shibao K, 1999, INT J CANCER, V83, P732; Sommerville J, 1999, BIOESSAYS, V21, P319, DOI 10.1002/(SICI)1521-1878(199904)21:4<319::AID-BIES8>3.3.CO;2-V; STEIN U, 2001, J BIOL CHEM, V21, P21; UCHIUMI T, 1993, CELL GROWTH DIFFER, V4, P147; Vater CA, 1996, ONCOGENE, V13, P739; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533	51	51	53	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2003	22	18					2782	2794		10.1038/sj.onc.1206357	http://dx.doi.org/10.1038/sj.onc.1206357			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ	12743601				2022-12-28	WOS:000182569300009
J	Alisi, A; Giambartolomei, S; Cupelli, F; Merlo, P; Fontemaggi, G; Spaziani, A; Balsano, C				Alisi, A; Giambartolomei, S; Cupelli, F; Merlo, P; Fontemaggi, G; Spaziani, A; Balsano, C			Physical and functional interaction between HCV core protein and the different p73 isoforms	ONCOGENE			English	Article						HCV; core p53; p73; p21(WAF1/CIP1); HCC	HEPATITIS-C VIRUS; KAPPA-B ACTIVATION; HEPATOCELLULAR-CARCINOMA; TRANSCRIPTIONAL ACTIVITY; P53-RELATED PROTEIN; HUMAN HEPATOCYTES; RNA HELICASE; DNA-BINDING; P53; APOPTOSIS	Hepatitis C virus (HCV) core protein is a structural viral protein that packages the viral genomic RNA. In addition to this function, HCV core also modulates a number of cellular regulatory functions. In fact, HCV core protein has been found to modulate the expression of the cyclin-dependent inhibitor p21(WAF1/CIP1) and to promote both apoptosis and cell proliferation through its physical interaction with p53. Here, we studied the ability of HCV core to bind the p53-related p73 protein, its isoforms and its deletion mutants. We found that HCV core co-immunoprecipitated with p73 in HepG2 and SAOS-2 cells. Deletion mutational analysis of p73 indicates that the domain involved in HCV core binding is located between amino-acid residues 321-353. We also demonstrate that p73/core interaction results in the nuclear translocation of HCV core protein either in the presence of the p73 or or p73 beta tumor-suppressor proteins. In addition, the interaction with HCV core protein prevents p73 alpha, but not p73 beta dependent cell growth arrest in a p53-dependent manner. Our findings demonstrate that HCV core protein may directly influence the various p73 functions, thus playing a role in HCV pathogenesis.	Fdn Andrea Cesalpino, Med Clin 1, I-00161 Rome, Italy; Univ Aquila, Dip MISP, I-67100 Laquila, Italy; Regina Elena Inst Canc Res, I-00158 Rome, Italy	University of L'Aquila; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Balsano, C (corresponding author), Policlin Umberto 1, Med Clin 1, Viale Policlin 155, I-00161 Rome, Italy.		Balsano, Clara/AAK-9870-2020; Alisi, Anna/A-6469-2010; Merlo, Paola/K-5330-2014; Fontemaggi, Giulia/K-9702-2016	Balsano, Clara/0000-0002-9615-7031; Alisi, Anna/0000-0001-7241-6329; Merlo, Paola/0000-0003-0105-7044; Fontemaggi, Giulia/0000-0001-8332-8842				Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200; Basu A, 2002, VIROLOGY, V298, P53, DOI 10.1006/viro.2002.1460; Colombo M, 1999, J HEPATOL, V31, P25, DOI 10.1016/S0168-8278(99)80370-5; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; De Francesco R, 1999, J HEPATOL, V31, P47, DOI 10.1016/S0168-8278(99)80374-2; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Giambartolomei S, 2001, ONCOGENE, V20, P2606, DOI 10.1038/sj.onc.1204372; Hayashi J, 1999, INTERVIROLOGY, V42, P205, DOI 10.1159/000024962; Higashino F, 1998, P NATL ACAD SCI USA, V95, P15683, DOI 10.1073/pnas.95.26.15683; Jin DY, 2000, EMBO J, V19, P729, DOI 10.1093/emboj/19.4.729; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kaida A, 2000, ONCOGENE, V19, P827, DOI 10.1038/sj.onc.1203387; Koike K, 2002, ONCOLOGY-BASEL, V62, P29, DOI 10.1159/000048273; Levrero M, 1999, CELL DEATH DIFFER, V6, P1146, DOI 10.1038/sj.cdd.4400624; Lu W, 1999, VIROLOGY, V264, P134, DOI 10.1006/viro.1999.9979; Maillard P, 2001, J VIROL, V75, P8240, DOI 10.1128/JVI.75.17.8240-8250.2001; Mamiya N, 1999, J BIOL CHEM, V274, P15751, DOI 10.1074/jbc.274.22.15751; Marusawa H, 1999, J VIROL, V73, P4713, DOI 10.1128/JVI.73.6.4713-4720.1999; Moriya K, 1997, J GEN VIROL, V78, P1527, DOI 10.1099/0022-1317-78-7-1527; Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053; Otsuka M, 2000, J BIOL CHEM, V275, P34122, DOI 10.1074/jbc.M000578200; Park KJ, 2002, J BIOL CHEM, V277, P13122, DOI 10.1074/jbc.M111599200; Prabhu NS, 1998, INT J ONCOL, V13, P5; Ray RB, 1996, VIROLOGY, V226, P176, DOI 10.1006/viro.1996.0644; Ray RB, 1998, GENE, V208, P331, DOI 10.1016/S0378-1119(98)00030-4; Ray RB, 2000, VIROLOGY, V271, P197, DOI 10.1006/viro.2000.0295; Reichelt M, 1999, ARCH VIROL, V144, P621, DOI 10.1007/s007050050530; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shi ST, 2002, VIROLOGY, V292, P198, DOI 10.1006/viro.2001.1225; Stiewe T, 2002, J BIOL CHEM, V277, P14177, DOI 10.1074/jbc.M200480200; Takamatsu Manabu, 2001, Kobe Journal of Medical Sciences, V47, P97; TANNAPFEL A, 1999, J NATL CANCER I, V79, P164; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; Tsutsumi T, 2002, HEPATOLOGY, V35, P937, DOI 10.1053/jhep.2002.32470; Uchida M, 2002, HEPATOL RES, V22, P297, DOI 10.1016/S1386-6346(02)00005-0; Vossio S, 2002, ONCOGENE, V21, P3796, DOI 10.1038/sj.onc.1205465; Wienzek S, 2000, J VIROL, V74, P193, DOI 10.1128/JVI.74.1.193-202.2000; Yamanaka T, 2002, BIOCHEM BIOPH RES CO, V294, P528, DOI 10.1016/S0006-291X(02)00508-9; You LR, 1999, J VIROL, V73, P2841, DOI 10.1128/JVI.73.4.2841-2853.1999; Zemel R, 2002, DIGEST DIS SCI, V47, P716, DOI 10.1023/A:1014767311799; Zeng YX, 1996, ONCOGENE, V12, P1557; Zhu NL, 1998, J VIROL, V72, P3691, DOI 10.1128/JVI.72.5.3691-3697.1998	45	50	55	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2003	22	17					2573	2580		10.1038/sj.onc.1206333	http://dx.doi.org/10.1038/sj.onc.1206333			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730672				2022-12-28	WOS:000182569000005
J	He, Q; Montalbano, J; Corcoran, C; Jin, WX; Huang, Y; Sheikh, MS				He, Q; Montalbano, J; Corcoran, C; Jin, WX; Huang, Y; Sheikh, MS			Effect of Bax deficiency on death receptor 5 and mitochondrial pathways during endoplasmic reticulum calcium pool depletion-induced apoptosis	ONCOGENE			English	Article						thapsigargin; Apo2L/TRAIL; death receptor 5; caspases; Bax; cytochrome c	PROSTATE-CANCER CELLS; CYTOCHROME-C; RELEASE; THAPSIGARGIN; SULINDAC; CYTOSOL; LIGAND; AGENTS; COLON	Thapsigargin (TG), by inducing perturbations in cellular Ca2+ homeostasis, can induce apoptosis, but the molecular mechanisms remain to be fully elucidated. We have recently reported that TG-induced apoptosis appears to involve the DR5-dependent apoptotic pathway that cross talks with the mitochondrial pathway via TG-induced Bid cleavage. In this study, we have utilized Bax-proficient and -deficient HCT116 human colon cancer cells to investigate the effect of Bax deficiency on TG-induced apoptosis and TG regulation of the DR5 and mitochondrial pathways. Our results indicate that Bax-deficient cells are less sensitive to undergo apoptosis following TG treatment. Our results further demonstrate that TG-induced apoptosis is coupled with DR5 upregulation and caspases 8 and 3 activation, as well as Bid cleavage in both Bax-proficient and -deficient cells, although caspase 3 activation was reduced in Bax-deficient cells. TG also promoted the release of cytochrome c into cytosol and caspase 9 activation in Bax-proficient cells but not in Bax-deficient cells. These findings suggest that although Bax is not absolutely required for death receptor (DR)-dependent signals, it appears to be a key molecule in TG-regulated mitochondrial events. Bax-deficient cells were relatively more resistant to Apo2L/TRAIL than the Bax-proficient counterparts. However, the combination of Apo2L/TRAIL and TG was more effective in mediating apoptosis in both Bax-proficient. and -deficient cells and that was coupled with activation of caspases 8 and 3. Although both agents in combination also induced cytochrome c release into cytosol and caspase 9 activation in Bax-proficient cells, these events were abrogated in Bax-deficient cells. Our results thus suggest that the combination of Apo2L/TRAIL and TG appears to bypass the Bax deficiency-induced defects in the mitochondrial (intrinsic) pathway by engaging the DR5-dependent apoptotic signals (extrinsic pathway).	SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Sheikh, MS (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA.				NATIONAL CANCER INSTITUTE [R21CA089043] Funding Source: NIH RePORTER; NCI NIH HHS [CA89043] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Boya P, 2002, CELL DEATH DIFFER, V9, P465, DOI 10.1038/sj.cdd.4401006; Burns TF, 2001, J BIOL CHEM, V276, P37879; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; FURUYA Y, 1994, CANCER RES, V54, P6167; He Q, 2002, ONCOGENE, V21, P6032, DOI 10.1038/sj.onc.1205897; He Q, 2002, ONCOGENE, V21, P2623, DOI 10.1038/sj.onc.1205345; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Huang Y, 2001, CANCER RES, V61, P6918; Jin ZY, 2002, CELL CYCLE, V1, P82, DOI 10.4161/cc.1.1.104; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kim BC, 2002, J BIOL CHEM, V277, P31381, DOI 10.1074/jbc.M203465200; Krebs J, 1998, BIOMETALS, V11, P375, DOI 10.1023/A:1009226316146; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Mikhailov V, 2003, J BIOL CHEM, V278, P5367, DOI 10.1074/jbc.M203392200; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Nutt LK, 2002, J BIOL CHEM, V277, P20301, DOI 10.1074/jbc.M201604200; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Tombal B, 2002, CELL DEATH DIFFER, V9, P561, DOI 10.1038/sj.cdd.4400999; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang XD, 2001, GENE DEV, V15, P2922; Wertz IE, 2000, J BIOL CHEM, V275, P11470, DOI 10.1074/jbc.275.15.11470; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; YANG E, 1996, BLOOD, V88, P368; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	32	32	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2003	22	17					2674	2679		10.1038/sj.onc.1206363	http://dx.doi.org/10.1038/sj.onc.1206363			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730681				2022-12-28	WOS:000182569000015
J	Kominsky, SL; Argani, P; Korz, D; Evron, E; Raman, V; Garrett, E; Rein, A; Sauter, G; Kallioniemi, OP; Sukumar, S				Kominsky, SL; Argani, P; Korz, D; Evron, E; Raman, V; Garrett, E; Rein, A; Sauter, G; Kallioniemi, OP; Sukumar, S			Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast	ONCOGENE			English	Article						breast cancer; tight junction; claudin-7; methylation	GENE-EXPRESSION; CANCER; CELLS; HYPERMETHYLATION; METHYLATION; OCCLUDIN; CADHERIN; STRANDS; TUMORS; ZO-1	Claudius are transmembrane proteins that seal tight junctions, and are critical for maintaining cell-to-cell adhesion in epithelial cell sheets. However, their role in cancer progression remains largely unexplored. Here, we report that Claudin-7 (CLDN-7) expression is lower in invasive ductal carcinomas (IDC) of the breast than in normal breast epithelium, as determined by both RT-PCR (9/10) and Western analysis (6/8). Immunohistochemical (IHC) analysis of ductal carcinoma in situ (IDS) and IDC showed that the loss of CLDN-7 expression correlated with histological grade in both MIS (P<0.001, n=38) and IDC (P=0.014, n=31), occurring predominantly in high-grade (Nuclear and Elston grade 3) lesions. Tissue array analysis of 355 IDC cases further confirmed the inverse correlation between CLDN-7 expression and histological grade (P = 0.03). This pattern of expression is consistent with the biological function of CLDN-7, as greater discohesion is typically observed in high-grade lesions. In line with this observation, by IHC analysis, CLDN-7 expression was lost in the vast majority (13/17) of cases of lobular carcinoma in situ, which is defined by cellular discohesion. In fact, inducing disassociation of MCF-7 and T47D cells in culture by treating with HGF/scatter factor resulted in a loss of CLDN-7 expression within 24h. Silencing of CLDN-7 expression correlated with promoter hypermethylation as determined by methylation-specific PCR (MSP) and nucleotide sequencing in breast cancer cell lines (3/3), but not in IDCs (0/5). In summary, these studies provide insight into the potential role of CLDN-7 in the progression and ability of breast cancer cells to disseminate.	Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Breast Canc Program, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Oncol Biostat, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21231 USA; NCI, HIV Drug Resistance Program, Frederick, MD 21072 USA; NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA; Univ Basel, Inst Pathol, CH-4003 Basel, Switzerland	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Basel	Sukumar, S (corresponding author), Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Breast Canc Program, BBCRB Room 410,1650 Orleans St, Baltimore, MD 21231 USA.		Kallioniemi, Olli P/H-5111-2011	Kallioniemi, Olli P/0000-0002-3231-0332; Evron, Ella/0000-0002-1003-5042	NATIONAL CANCER INSTITUTE [P50CA088843, ZIABC010511, Z01BC010511] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA88843] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balda MS, 2000, EMBO J, V19, P2024, DOI 10.1093/emboj/19.9.2024; BERGSTRAESSER LM, 1993, CANCER RES, V53, P2644; Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3; Evron E, 2001, CANCER RES, V61, P2782; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Fujii T, 2002, CANCER RES, V62, P3340; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; Furuse M, 2002, J CELL BIOL, V156, P1099, DOI 10.1083/jcb.200110122; GOMM JJ, 1995, ANAL BIOCHEM, V226, P91, DOI 10.1006/abio.1995.1196; Iacobuzio-Donahue CA, 2002, AM J PATHOL, V160, P1239, DOI 10.1016/S0002-9440(10)62551-5; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; Jiang W, 1999, CRIT REV ONCOL HEMAT, V29, P209, DOI 10.1016/S1040-8428(98)00019-5; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kramer F, 2000, HUM GENET, V107, P249, DOI 10.1007/s004390000375; Loeb DM, 2001, CANCER RES, V61, P921; Mitic LL, 2000, AM J PHYSIOL-GASTR L, V279, pG250, DOI 10.1152/ajpgi.2000.279.2.G250; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; Nacht M, 1999, CANCER RES, V59, P5464; Simon DB, 1999, SCIENCE, V285, P103, DOI 10.1126/science.285.5424.103; Sirotkin H, 1997, GENOMICS, V42, P245, DOI 10.1006/geno.1997.4734; SOLER AP, 1995, HUM PATHOL, V26, P1363, DOI 10.1016/0046-8177(95)90302-X; Tsukita S, 1999, TRENDS CELL BIOL, V9, P268, DOI 10.1016/S0962-8924(99)01578-0; Wheelock MJ, 2001, J MAMMARY GLAND BIOL, V6, P275, DOI 10.1023/A:1011319507155; Wilcox ER, 2001, CELL, V104, P165, DOI 10.1016/S0092-8674(01)00200-8	25	364	384	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 3	2003	22	13					2021	2033		10.1038/sj.onc.1206199	http://dx.doi.org/10.1038/sj.onc.1206199			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	662UR	12673207				2022-12-28	WOS:000181967700012
J	Wei, LH; Kuo, ML; Chen, CA; Chou, CH; Lai, KB; Lee, CN; Hsieh, CY				Wei, LH; Kuo, ML; Chen, CA; Chou, CH; Lai, KB; Lee, CN; Hsieh, CY			Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway	ONCOGENE			English	Article						angiogenesis; cervical cancer; cytokine; interleukin-6; STAT3; vascular endothelial growth factor	MESSENGER-RNA; KAPOSIS-SARCOMA; IN-VITRO; CERVICOVAGINAL SECRETIONS; FACTOR EXPRESSION; GENE-EXPRESSION; CELL-GROWTH; CANCER; IL-6; CYTOKINE	Interleukin-6 (IL-6) has received particular attention in the pathogenesis of cervical cancer, although the underlying mechanism remains elusive. This study revealed that IL-6 promotes in vivo tumor growth of human cervical cancer C33A cells, but does not substantially alter their in vitro growth kinetics. The in vivo angiogenic assays showed that IL-6 increases angiogenic activity in human cervical cancer cells, an effect that is specifically associated with upregulation of vascular endothelial growth factor (VEGF). Also, using anti-VEGF antibody to block VEGF function significantly inhibited IL-6-mediated angiogenesis and tumor growth in nude mice, strongly supporting the critical role of VEGF in the IL-6-mediated cervical tumorigenesis. Accordingly, the signaling pathway downstream of IL-6/ IL-6R responsible for the regulation of VEGF was investigated. Notably, pharmacological inhibition of PI3-K or MAPK failed to inhibit IL-6-mediated transcriptional upregulation of VEGF. Meanwhile, blocking STAT3 pathway with dominant-negative mutant STAT3D effectively abolished IL-6-induced VEGF mRNA. In transient transfections, a luciferase reporter construct containing the full-length 1.5-kb VEGF promoter or a 1.2-kb fragment lacking the known hypoxic-response element also exhibited the same degree of response to IL-6. Additionally, transient transfection of STAT3D downregulated the 1.2-kb VEGF promoter luciferase reporter stimulated by IL-6. Based on the above phenomenon combined with the concomitant increased tumor expression of IL-6 and VEGF in cervical cancer tissues, we conclude that IL-6 may promote cervical tumorigenesis by activating VEGF-mediated angiogenesis via a STAT3 pathway.	Natl Taiwan Univ Hosp, Coll Med, Dept Obstet & Gynecol, Taipei 100, Taiwan; Natl Taiwan Univ Hosp, Dept Oncol, Taipei 100, Taiwan; Natl Taiwan Univ, Coll Med, Inst Toxicol, Lab Mol & Cellular Toxicol, Taipei 100, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Hsieh, CY (corresponding author), Natl Taiwan Univ Hosp, Coll Med, Dept Obstet & Gynecol, 7 Chung Shan S Rd, Taipei 100, Taiwan.	cyhsieh@ha.mc.ntu.edu.tw	Wei, Lin-Hung/B-1188-2008; Kuo, Min-Liang/C-4872-2009	Lee, Chien-Nan/0000-0002-1725-0407; CHEN, CHI-AN/0000-0001-6670-7939; Wei, Lin-Hung/0000-0001-8789-0859; KUO, MIN-LIANG/0000-0002-7139-0144				Aoki Y, 1999, BLOOD, V93, P4034, DOI 10.1182/blood.V93.12.4034.412k38_4034_4043; BELEC L, 1995, CYTOKINE, V7, P568, DOI 10.1006/cyto.1995.0077; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Castrilli G, 1997, BRIT J CANCER, V75, P855, DOI 10.1038/bjc.1997.152; Chen Z, 1999, CLIN CANCER RES, V5, P1369; Cheng WF, 1999, OBSTET GYNECOL, V93, P761, DOI 10.1016/S0029-7844(98)00505-5; Cheng WF, 2000, OBSTET GYNECOL, V96, P721, DOI 10.1016/S0029-7844(00)01025-5; DANFORTH DN, 1993, CANCER RES, V53, P1538; Dankbar B, 2000, BLOOD, V95, P2630, DOI 10.1182/blood.V95.8.2630; Dobbs SP, 1997, BRIT J CANCER, V76, P1410, DOI 10.1038/bjc.1997.571; EUSTACE D, 1993, GYNECOL ONCOL, V50, P15, DOI 10.1006/gyno.1993.1156; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Fujimoto J, 1999, BRIT J CANCER, V79, P1249, DOI 10.1038/sj.bjc.6690200; Fujimoto J, 1999, BRIT J CANCER, V80, P827, DOI 10.1038/sj.bjc.6690428; Fujimoto J, 1997, CANCER LETT, V111, P21, DOI 10.1016/S0304-3835(96)04485-0; Fujimoto J, 2000, CANCER RES, V60, P2632; GUIDI AJ, 1995, J NATL CANCER I, V87, P1237, DOI 10.1093/jnci/87.16.1237; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Hirano Toshio, 1997, Cytokine and Growth Factor Reviews, V8, P241, DOI 10.1016/S1359-6101(98)80005-1; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; IGLESIAS M, 1995, AM J PATHOL, V146, P944; Jee SH, 2001, ONCOGENE, V20, P198, DOI 10.1038/sj.onc.1204076; Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; Kodama J, 1999, EUR J CANCER, V35, P485, DOI 10.1016/S0959-8049(98)00410-9; Kodama J, 2001, CLIN CANCER RES, V7, P2826; Lee JS, 2002, GYNECOL ONCOL, V85, P469, DOI 10.1006/gyno.2002.6648; Lopez-Ocejo O, 2000, ONCOGENE, V19, P4611, DOI 10.1038/sj.onc.1203817; Mahnke JL, 2000, FERTIL STERIL, V73, P166, DOI 10.1016/S0015-0282(99)00466-5; Masood R, 1999, BLOOD, V93, P1038, DOI 10.1182/blood.V93.3.1038.403a14_1038_1044; MATEO RB, 1994, AM J PHYSIOL, V266, pR1840, DOI 10.1152/ajpregu.1994.266.6.R1840; MOTRO B, 1990, P NATL ACAD SCI USA, V87, P3092, DOI 10.1073/pnas.87.8.3092; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; Nicholas J, 1997, NAT MED, V3, P287, DOI 10.1038/nm0397-287; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Okamoto M, 1997, CANCER RES, V57, P141; Page C, 2000, INT J ONCOL, V17, P23; PASSANITI A, 1992, LAB INVEST, V67, P519; Richter HE, 1999, AM J OBSTET GYNECOL, V181, P940, DOI 10.1016/S0002-9378(99)70329-7; SCHIFFMAN MH, 1995, CANCER-AM CANCER SOC, V76, P1888, DOI 10.1002/1097-0142(19951115)76:10+<1888::AID-CNCR2820761305>3.0.CO;2-H; SILLMAN F, 1981, AM J OBSTET GYNECOL, V139, P154, DOI 10.1016/0002-9378(81)90438-5; SmithMcCune K, 1997, CANCER RES, V57, P1294; SMITHMCCUNE KK, 1994, CANCER RES, V54, P800; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; TAKIZAWA H, 1993, CANCER RES, V53, P4175; TARTOUR E, 1994, CANCER RES, V54, P6243; Tilg H, 1997, IMMUNOL TODAY, V18, P428, DOI 10.1016/S0167-5699(97)01103-1; Tjiong MY, 1999, GYNECOL ONCOL, V73, P285, DOI 10.1006/gyno.1999.5358; Valdembri D, 2001, FASEB J, V15, P225, DOI 10.1096/fj.01-0633fje; Wei LH, 2001, ONCOGENE, V20, P5799, DOI 10.1038/sj.onc.1204733; Wei LH, 2001, GYNECOL ONCOL, V82, P49, DOI 10.1006/gyno.2001.6235; Xu L, 2002, J BIOL CHEM, V277, P11368, DOI 10.1074/jbc.M108347200; YAMAUCHITAKIHARA K, 1995, CIRCULATION, V91, P1520, DOI 10.1161/01.CIR.91.5.1520; YAN SF, 1995, J BIOL CHEM, V270, P11463, DOI 10.1074/jbc.270.19.11463; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	57	405	433	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2003	22	10					1517	1527		10.1038/sj.onc.1206226	http://dx.doi.org/10.1038/sj.onc.1206226			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652ZZ	12629515				2022-12-28	WOS:000181411900009
J	Kobayashi, M; Iwamatsu, A; Shinohara-Kanda, A; Ihara, S; Fukui, Y				Kobayashi, M; Iwamatsu, A; Shinohara-Kanda, A; Ihara, S; Fukui, Y			Activation of ErB3-PI3-kinase pathway is correlated with malignant phenotypes of adenocarcinomas	ONCOGENE			English	Article						ErbB3; phosphatidylinositol 3-kinase; signet-ring cell carcinoma; gastric cancer; mucin	EPIDERMAL GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; GASTRIC-CARCINOMA; CELL-ADHESION; EGF RECEPTOR; KINASE; EXPRESSION; CANCER; ERBB3; PROTEINS	Signet-ring cell carcinomas are malignant dedifferentiated carcinomas, which are frequently found in the stomach. We previously demonstrated that a 200 kDa protein is often constitutively phosphorylated on tyrosine and bound to phosphatidylinositol 3-kinase (PI3-kinase) in signet-ring cell carcinoma cells. In this study, we purified the 200 kDa protein from an extract of NUGC-4 cells, a cell line of signet-ring cell carcinoma, and identified it as ErbB3. ErbB3 was found to be phosphorylated selectively in dedifferentiated adenocarcinoma cell lines among various gastric cancer cell lines. Expression of a constitutively active chimeric receptor consisting of ErbB2 and ErbB3 in HCC2998 cells, a highly differentiated adenocarcinoma cell line, revealed that the signaling triggered by phosphorylation of ErbB3 was important for dedifferentiated phenotypes such as loss of cell-cell interaction and high expression of MUC1/DF3 antigen, a marker of the malignant tumors. Taken together, activation of ErbB3 pathway may contribute to the development of dedifferentiated carcinomas.	Univ Tokyo, Fac Agr & Life Sci, Dept Appl Biol Chem, Biol Chem Lab,Bunkyo Ku, Tokyo 1138657, Japan; Kirin Brewery Co Ltd, Cent Labs Key Technol, Yokohama, Kanagawa 2360004, Japan	University of Tokyo; Kirin Brewery Company Limited	Fukui, Y (corresponding author), Univ Tokyo, Fac Agr & Life Sci, Dept Appl Biol Chem, Biol Chem Lab,Bunkyo Ku, Yayoi 1-1-1, Tokyo 1138657, Japan.		Fukui, Yasuhisa/E-8806-2010					Altiok N, 1997, EMBO J, V16, P717, DOI 10.1093/emboj/16.4.717; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Chen XM, 2000, BIOCHEM BIOPH RES CO, V277, P757, DOI 10.1006/bbrc.2000.3731; Guddo F, 1998, ANTICANCER RES, V18, P1915; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hellyer NJ, 1998, BIOCHEM J, V333, P757, DOI 10.1042/bj3330757; Isogaki J, 1999, CANCER DETECT PREV, V23, P204, DOI 10.1046/j.1525-1500.1999.99020.x; Iwamatsu A, 1996, J BIOCHEM-TOKYO, V120, P29; Jensen ON, 1996, RAPID COMMUN MASS SP, V10, P1371, DOI 10.1002/(SICI)1097-0231(199608)10:11<1371::AID-RCM682>3.0.CO;2-5; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KIM HH, 1994, J BIOL CHEM, V269, P24747; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Kobayashi M, 1999, P NATL ACAD SCI USA, V96, P4874, DOI 10.1073/pnas.96.9.4874; Komatsu M, 1997, J BIOL CHEM, V272, P33245, DOI 10.1074/jbc.272.52.33245; Kondo K, 1998, CANCER RES, V58, P2014; KUFE D, 1984, HYBRIDOMA, V3, P223, DOI 10.1089/hyb.1984.3.223; LAVAN BE, 1992, J BIOL CHEM, V267, P11631; Levkowitz G, 1996, ONCOGENE, V12, P1117; Ma YY, 2000, ONCOGENE, V19, P2739, DOI 10.1038/sj.onc.1203597; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; PETER MS, 1999, EMBO J, V18, P2149; Sakaguchi T, 1998, CANCER-AM CANCER SOC, V82, P1238, DOI 10.1002/(SICI)1097-0142(19980401)82:7<1238::AID-CNCR5>3.0.CO;2-B; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; TAHARA E, 1993, J CANCER RES CLIN, V119, P265, DOI 10.1007/BF01212724; Tanaka K, 1999, BIOSCI BIOTECH BIOCH, V63, P368, DOI 10.1271/bbb.63.368; TANAKA S, 1993, JPN J CANCER RES, V84, P279, DOI 10.1111/j.1349-7006.1993.tb02868.x; TOKUNAGA A, 1995, CANCER, V75, P1418, DOI 10.1002/1097-0142(19950315)75:6+<1418::AID-CNCR2820751505>3.0.CO;2-Y; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Waterman H, 1999, EMBO J, V18, P3348, DOI 10.1093/emboj/18.12.3348; WONGSASANT B, 1991, BIOCHEM BIOPH RES CO, V181, P981, DOI 10.1016/0006-291X(91)92033-G; YANAGIHARA K, 1992, CANCER RES, V52, P4042; Zhang K, 1996, J BIOL CHEM, V271, P3884	36	36	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2003	22	9					1294	1301		10.1038/sj.onc.1206256	http://dx.doi.org/10.1038/sj.onc.1206256			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618754				2022-12-28	WOS:000181360900003
J	Ishikawa, T; Chen, J; Wang, JX; Okada, F; Sugiyama, T; Kobayashi, T; Shindo, M; Higashino, F; Katoh, H; Asaka, M; Kondo, T; Hosokawa, M; Kobayashi, M				Ishikawa, T; Chen, J; Wang, JX; Okada, F; Sugiyama, T; Kobayashi, T; Shindo, M; Higashino, F; Katoh, H; Asaka, M; Kondo, T; Hosokawa, M; Kobayashi, M			Adrenomedullin antagonist suppresses in vivo growth of human pancreatic cancer cells in SCID mice by suppressing angiogenesis	ONCOGENE			English	Article						pancreatic cancer; hypoxia; adrenomedullin; angiogenesis; adrenomedullin antagonist	POSSIBLE PROMOTION MECHANISM; AUTOCRINE GROWTH; EXPRESSION; HYPOXIA; APOPTOSIS; PEPTIDE; LINES; RECEPTORS	Since it is reported that adrenomedullin (AM) upregulated by hypoxia inhibits hypoxic cell death, we examined the effects of AM antagonist (AM C-terminal fragment; AM(22-52)) on the growth of pancreatic cancer cells. We, for the first time, demonstrated that AM antagonist significantly reduced the in vivo growth of the pancreatic cancer cell line. Immunohistochemical. analysis demonstrated that the mean diameter of blood vessels was significantly smaller in the tumor tissues treated with AM antagonist than in those treated with AM N-terminal fragment (AM(1-25)), and that the PCNA-labeling index was lower in the former than in the latter. Then we demonstrated that AM antagonist showed no effect on the in vitro growth of the pancreatic cancer cell line. These results showed that AM played an important role in the growth of pancreatic cancer cells in vivo, suggesting that AM antagonist might be a useful tool for treating pancreatic cancers.	Hokkaido Univ, Inst Med Genet, Div Canc Pathobiol, Kita Ku, Sapporo, Hokkaido 0600815, Japan; Hokkaido Univ, Grad Sch Med, Dept Gastroenterol & Hematol, Sapporo, Hokkaido, Japan; Hokkaido Univ, Grad Sch Med, Dept Surg Oncol, Sapporo, Hokkaido, Japan; Hokkaido Univ, Grad Dent Sch, Dept Oral Pathobiol Sci, Sapporo, Hokkaido, Japan	Hokkaido University; Hokkaido University; Hokkaido University; Hokkaido University	Kobayashi, M (corresponding author), Hokkaido Univ, Inst Med Genet, Div Canc Pathobiol, Kita Ku, Kita 15,Nishi 7, Sapporo, Hokkaido 0600815, Japan.	mkobaya@med.hokudai.ac.jp	Shindoh, Masanobu/A-4799-2012; Asaka, Masahiro/A-5948-2012; Higashino, Fumihiro/F-8510-2012; Kondo, Takeshi/G-2103-2012	Shindoh, Masanobu/0000-0002-7782-5823; Kondo, Takeshi/0000-0001-7455-5824; Okada, Futoshi/0000-0003-4733-1037; Kobayashi, Masanobu/0000-0002-7445-9741				Akakura N, 2001, CANCER RES, V61, P6548; Browder T, 2000, J BIOL CHEM, V275, P1521, DOI 10.1074/jbc.275.3.1521; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Choi S, 2000, CLIN EXP METASTAS, V18, P45, DOI 10.1023/A:1026507713080; Cormier-Regard S, 1998, J BIOL CHEM, V273, P17787, DOI 10.1074/jbc.273.28.17787; DRAKE CJ, 1995, P NATL ACAD SCI USA, V92, P7657, DOI 10.1073/pnas.92.17.7657; EGUCHI S, 1994, ENDOCRINOLOGY, V135, P2454, DOI 10.1210/en.135.6.2454; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Garayoa M, 2000, MOL ENDOCRINOL, V14, P848, DOI 10.1210/me.14.6.848; Hayakawa H, 1999, HYPERTENSION, V33, P689, DOI 10.1161/01.HYP.33.2.689; Kato H, 1997, ENDOCRINOLOGY, V138, P2615, DOI 10.1210/en.138.6.2615; Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505; Miller MJ, 1996, J BIOL CHEM, V271, P23345; Muff R, 2001, PEPTIDES, V22, P1765, DOI 10.1016/S0196-9781(01)00515-0; Nakayama M, 1998, BIOCHEM BIOPH RES CO, V243, P514, DOI 10.1006/bbrc.1998.8131; Niizeki H, 2002, BRIT J CANCER, V86, P1914, DOI 10.1038/sj.bjc.6600331; NUKI C, 1993, BIOCHEM BIOPH RES CO, V196, P245, DOI 10.1006/bbrc.1993.2241; Oehler MK, 2002, ONCOGENE, V21, P2815, DOI 10.1038/sj.onc.1205374; Oehler MK, 2001, ONCOGENE, V20, P2937, DOI 10.1038/sj.onc.1204422; Ouafik L, 2002, AM J PATHOL, V160, P1279, DOI 10.1016/S0002-9440(10)62555-2; Rocchi P, 2001, CANCER RES, V61, P1196; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; Watanabe TX, 1996, BIOCHEM BIOPH RES CO, V219, P59, DOI 10.1006/bbrc.1996.0181; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; ZHAO L, 1996, AM J PHYSIOL, V271, P622	26	75	83	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2003	22	8					1238	1242		10.1038/sj.onc.1206207	http://dx.doi.org/10.1038/sj.onc.1206207			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650EK	12606950	Green Submitted			2022-12-28	WOS:000181249700012
J	Sprowles, A; Wisdom, R				Sprowles, A; Wisdom, R			Oncogenic effect of delta deletion in v-Jun does not result from uncoupling Jun from JNK signaling	ONCOGENE			English	Article						Jun; JNK; transformation	ACTIVATED PROTEIN-KINASES; C-JUN; TRANSCRIPTION FACTORS; MAP KINASES; EMBRYO FIBROBLASTS; DOCKING SITES; HA-RAS; PHOSPHORYLATION; DOMAIN; ONCOPROTEIN	The protein encoded by the v-Jun oncogene shows increased transforming activity compared to c-Jun, its normal cellular counterpart. One major determinant of this increased transforming activity is an in-frame deletion of a region near the amino-terminus of the protein. This region, referred to as the delta domain, functions as a docking site for Jun N-terminal kinase (JNK), the mitogen-activated protein (MAP) kinase that phosphorylates c-Jun to regulate its transcriptional properties. As a consequence of this deletion, v-Jun is unresponsive to JNK signaling, and it is widely believed that it is the uncoupling of v-Jun from JNK signaling that underlies the oncogenic effects of the delta-domain deletion; however, this idea has never been directly tested. Here we use JNK overexpression as well as alanine scanning mutagenesis to test this idea. Point mutants that are uncoupled from JNK signaling do not show enhanced transforming activity, suggesting that disruption of the Jun-JNK interaction is not the mechanism by which the delta-domain deletion enhances transforming activity. Consistent with this idea, we have generated a panel of point mutants that show markedly enhanced transforming activity, despite the fact that they do not perturb the ability of JNK to either dock with or phosphorylate c-Jun in vitro or in vivo. The fact that these mutants cluster in a small region suggests the existence of an additional regulator of Jun function whose activity is disrupted by mutations in this region.	Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA; Univ Calif Davis, Ctr Canc, UC Davis Sch Med, Sacramento, CA 95817 USA	Vanderbilt University; University of California System; University of California Davis	Wisdom, R (corresponding author), Res Bldg 3,Rm 1100 4645 2nd Ave, Sacramento, CA 95817 USA.				NCI NIH HHS [CA64118, T32CA009582] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064118, T32CA009582] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; Akagi T, 2000, P NATL ACAD SCI USA, V97, P7290, DOI 10.1073/pnas.140210297; BAICHWAL VR, 1992, GENE DEV, V6, P1493, DOI 10.1101/gad.6.8.1493; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; Bardwell L, 1998, P NATL ACAD SCI USA, V95, P15400, DOI 10.1073/pnas.95.26.15400; Bardwell L, 1998, GENE DEV, V12, P2887, DOI 10.1101/gad.12.18.2887; BLACK EJ, 1994, ONCOGENE, V9, P2363; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; CAVALIERI F, 1985, VIROLOGY, V143, P680, DOI 10.1016/0042-6822(85)90412-X; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Cook JG, 1997, NATURE, V390, P85, DOI 10.1038/36355; DAI TN, 1995, ONCOGENE, V10, P849; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Fantz DA, 2001, J BIOL CHEM, V276, P27256, DOI 10.1074/jbc.M102512200; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kilbey A, 1996, ONCOGENE, V12, P2409; Madhani HD, 1997, CELL, V91, P673, DOI 10.1016/S0092-8674(00)80454-7; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; May GHW, 1998, CURR BIOL, V8, P117, DOI 10.1016/S0960-9822(98)70043-0; May GHW, 1998, J BIOL CHEM, V273, P33429, DOI 10.1074/jbc.273.50.33429; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PULVERER BJ, 1993, ONCOGENE, V8, P407; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; Ui M, 1998, FEBS LETT, V429, P289, DOI 10.1016/S0014-5793(98)00618-8; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Yang SH, 1999, MOL CELL BIOL, V19, P4028; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740	36	11	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 30	2003	22	4					498	506		10.1038/sj.onc.1206165	http://dx.doi.org/10.1038/sj.onc.1206165			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555063				2022-12-28	WOS:000180538200003
J	Berkovich, E; Ginsberg, D				Berkovich, E; Ginsberg, D			ATM is a target for positive regulation by E2F-1	ONCOGENE			English	Article						E2F; ATM; oncogenic stress	TRANSCRIPTION FACTOR E2F-1; GENE-PRODUCT; DNA-REPLICATION; EXPRESSION; APOPTOSIS; PHOSPHORYLATION; P53; INDUCTION; FAMILY; REPAIR	The E2F-1 transcription factor is a critical downstream target of the tumor suppressor, RB. When activated, E2F-1 induces cell proliferation. In addition, deregulation of E2F-1 constitutes an oncogenic stress that can induce apoptosis. The protein kinase ATM is a pivotal mediator of the response to another type of stress, genotoxic stress. In response to ionizing radiation, ATM activates the tumor suppressor p53, a key player in the control of cell growth and viability. We show here that E2F-1 elevates ATM promoter activity and induces an increase in ATM mRNA and protein levels. This is accompanied by an E2F-nduced increase in p53 phosphorylation. Expression of the E7 protein of HPV16, which dissociates RB/E2F complexes, also induces the elevation of ATM levels and p53 phosphorylation, implicating endogenous E2F in these phenomena. These data demonstrate that ATM is transcriptionally regulated by E2F-1 and suggest that ATM serves as a novel, ARF-independent functional link between the RB/E2F pathway and p53.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Ginsberg, D (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	doron.ginsberg@weizmann.ac.il		ginsberg, doron/0000-0002-1257-4920				Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Berkovich E, 2001, J BIOL CHEM, V276, P42851, DOI 10.1074/jbc.M103596200; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Brown KD, 1997, P NATL ACAD SCI USA, V94, P1840, DOI 10.1073/pnas.94.5.1840; Byrd PJ, 1996, HUM MOL GENET, V5, P1785, DOI 10.1093/hmg/5.11.1785; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Gottifredi V, 2001, MOL CELL BIOL, V21, P1066, DOI 10.1128/MCB.21.4.1066-1076.2001; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Imai T, 1996, GENOME RES, V6, P439, DOI 10.1101/gr.6.5.439; Imai T, 1997, GENOMICS, V42, P388, DOI 10.1006/geno.1997.4769; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; Lin WC, 2001, GENE DEV, V15, P1833; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Ma TL, 2000, GENE DEV, V14, P2298, DOI 10.1101/gad.829500; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; O'Connor DJ, 2000, ONCOGENE, V19, P2369, DOI 10.1038/sj.onc.1203540; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Polager S, 2002, ONCOGENE, V21, P437, DOI 10.1038/sj.onc.1205102; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Rogoff HA, 2002, MOL CELL BIOL, V22, P5308, DOI 10.1128/MCB.22.15.5308-5318.2002; Russell JL, 2002, MOL CELL BIOL, V22, P1360, DOI 10.1128/MCB.22.5.1360-1368.2002; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Tolbert D, 2002, MOL CELL BIOL, V22, P370, DOI 10.1128/MCB.22.1.370-377.2002; Tsai KY, 2002, CURR BIOL, V12, P159, DOI 10.1016/S0960-9822(01)00659-5; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Wang A, 2000, J BIOL CHEM, V275, P4532, DOI 10.1074/jbc.275.6.4532; Wang Y, 2000, GENE DEV, V14, P927; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; Zhao JY, 2000, GENE DEV, V14, P2283, DOI 10.1101/gad.827700; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	40	97	98	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2003	22	2					161	167		10.1038/sj.onc.1206144	http://dx.doi.org/10.1038/sj.onc.1206144			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527885				2022-12-28	WOS:000180322400001
J	Theis-Febvre, N; Filhol, O; Froment, C; Cazales, M; Cochet, C; Monsarrat, B; Ducommun, B; Baldin, V				Theis-Febvre, N; Filhol, O; Froment, C; Cazales, M; Cochet, C; Monsarrat, B; Ducommun, B; Baldin, V			Protein kinase CK2 regulates CDC25B phosphatase activity	ONCOGENE			English	Article						cell cycle; CDC25B phosphatase; CK2 kinase; phosphorylation	CELL-CYCLE PROGRESSION; BETA-SUBUNIT; SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; MASS-SPECTROMETRY; CASEIN KINASE-2; FISSION YEAST; TYROSINE PHOSPHATASE; CHECKPOINT PATHWAY; G(1)/S TRANSITION	Human dual-specificity phosphatases CDC25 (A, B and C) play an important role in the control of cell cycle progression by activating the cyclin-dependent kinases (CDKs). Regulation of these phosphatases during the cell cycle involves post-translational modifications such as phosphorylation and protein-protein interactions. Given the suspected involvement of the protein kinase CK2 at the G2/M transition, we have investigated its effects on the CDC25B phosphatase. We show that in vitro CK2 phosphorylates CDC25B, but not CDC25C. Mass spectrometry analysis demonstrates that at least two serine residues, Ser-186 and Ser-187, are phosphorylated in vivo. We also report that CDC25B interacts with CK2, and this interaction, mediated by the CK2beta regulatory subunit, involves domains that are located within the first 55 amino acids of CK2beta and between amino acids 122 and 200 on CDC25B. This association was confirmed in vivo, in Sf9 insect cells and in U2OS human cells expressing an HA epitope-tagged CDC25B. Finally, we demonstrate that phosphorylation of CDC25B by protein kinase CK2 increases the catalytic activity of the phosphatase in vitro as well as in vivo. We discuss the possibility that CDC25B phosphorylation by CK2 could play a role in the regulation of the activity of CDC25B as a starter of mitosis.	Univ Toulouse 3, LBCMCP, CNRS, UMR 5088,Inst Explorat Fonct Genomes,IFR 109, F-31062 Toulouse, France; INSERM, EMI 0104, CEA, DBMS, F-38054 Grenoble 9, France; IPBS, UMR 5089, F-31070 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Baldin, V (corresponding author), Univ Toulouse 3, LBCMCP, CNRS, UMR 5088,Inst Explorat Fonct Genomes,IFR 109, 118 Route Narbonne, F-31062 Toulouse, France.		Filhol-Cochet, Odile/I-3962-2016; BALDIN, Véronique/Y-8397-2019; DUCOMMUN, Bernard/B-3208-2008	BALDIN, Véronique/0000-0001-8523-0494; Cochet, Claude/0000-0002-1772-4270; DUCOMMUN, Bernard/0000-0002-7126-8368; Filhol, Odile/0000-0003-1964-7958				ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Baldin V, 1997, J BIOL CHEM, V272, P32731, DOI 10.1074/jbc.272.52.32731; Baldin V, 1997, ONCOGENE, V14, P2485, DOI 10.1038/sj.onc.1201063; Baldin V, 2000, Prog Cell Cycle Res, V4, P49; BALDIN V, 2002, J BIOL CHEM, V9, P9; BIDWAI AP, 1992, J BIOL CHEM, V267, P18790; BIEMANN K, 1990, METHOD ENZYMOL, V193, P886, DOI 10.1016/0076-6879(90)93460-3; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; Bonnet H, 1996, J BIOL CHEM, V271, P24781, DOI 10.1074/jbc.271.40.24781; BOSC DG, 1995, J BIOL CHEM, V270, P25872, DOI 10.1074/jbc.270.43.25872; Cans C, 1999, ANTICANCER RES, V19, P1241; Chantalat L, 1999, EMBO J, V18, P2930, DOI 10.1093/emboj/18.11.2930; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; Davezac N, 2000, PATHOL BIOL, V48, P182; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Escargueil AE, 2000, J BIOL CHEM, V275, P34710, DOI 10.1074/jbc.M005179200; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; FILHOL O, 1991, BIOCHEMISTRY-US, V30, P11133, DOI 10.1021/bi00110a016; FILHOL O, 1992, J BIOL CHEM, V267, P20577; FILHOL O, 1994, BIOCHEM BIOPH RES CO, V198, P660, DOI 10.1006/bbrc.1994.1096; FILHOLCOCHET O, 1994, CELL MOL BIOL RES, V40, P529; Ford HL, 2000, J BIOL CHEM, V275, P22245, DOI 10.1074/jbc.M002446200; Forrest ARR, 1999, BIOCHEM BIOPH RES CO, V260, P510, DOI 10.1006/bbrc.1999.0870; Gabrielli BG, 1996, J CELL SCI, V109, P1081; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; Garner-Hamrick PA, 1998, INT J CANCER, V76, P720, DOI 10.1002/(SICI)1097-0215(19980529)76:5<720::AID-IJC18>3.0.CO;2-7; Gotz C, 2000, BIOCHEM BIOPH RES CO, V268, P882, DOI 10.1006/bbrc.2000.2230; Graves PR, 2001, ONCOGENE, V20, P1839, DOI 10.1038/sj.onc.1204259; HANNA DE, 1995, J BIOL CHEM, V270, P25905, DOI 10.1074/jbc.270.43.25905; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; Lammer C, 1998, J CELL SCI, V111, P2445; Leroy D, 1999, MOL CELL BIOCHEM, V191, P85, DOI 10.1023/A:1006858210835; Li DX, 1997, J BIOL CHEM, V272, P3773, DOI 10.1074/jbc.272.6.3773; Li DX, 1999, J BIOL CHEM, V274, P32988, DOI 10.1074/jbc.274.46.32988; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; LIN WJ, 1991, J BIOL CHEM, V266, P5664; LITCHFIELD DW, 1992, J BIOL CHEM, V267, P13943; Lorenz P, 1999, FEBS LETT, V448, P283, DOI 10.1016/S0014-5793(99)00388-9; Mann M, 2001, ANNU REV BIOCHEM, V70, P437, DOI 10.1146/annurev.biochem.70.1.437; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; McLachlin DT, 2001, CURR OPIN CHEM BIOL, V5, P591, DOI 10.1016/S1367-5931(00)00250-7; Mils V, 2000, ONCOGENE, V19, P1257, DOI 10.1038/sj.onc.1203419; MULNERLORILLON O, 1988, EUR J BIOCHEM, V171, P107, DOI 10.1111/j.1432-1033.1988.tb13765.x; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NAGATA A, 1991, NEW BIOL, V3, P959; Nambirajan S, 2000, J BIOSCIENCE, V25, P33, DOI 10.1007/BF02985179; NASTAINCZYK W, 1995, HYBRIDOMA, V14, P335, DOI 10.1089/hyb.1995.14.335; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; Raman C, 1998, J BIOL CHEM, V273, P19183, DOI 10.1074/jbc.273.30.19183; Rethinaswamy A, 1998, J BIOL CHEM, V273, P5869, DOI 10.1074/jbc.273.10.5869; Reynolds RA, 1999, J MOL BIOL, V293, P559, DOI 10.1006/jmbi.1999.3168; Rice RL, 1997, BIOCHEMISTRY-US, V36, P15965, DOI 10.1021/bi971338h; ROBITZKI A, 1993, J BIOL CHEM, V268, P5694; Romero-Oliva F, 2001, J CELL BIOCHEM, V81, P445, DOI 10.1002/1097-4644(20010601)81:3<445::AID-JCB1058>3.0.CO;2-2; Roshak AK, 2000, CELL SIGNAL, V12, P405, DOI 10.1016/S0898-6568(00)00080-2; RUSSO GL, 1992, J BIOL CHEM, V267, P20317; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SNELL V, 1994, EMBO J, V13, P2066, DOI 10.1002/j.1460-2075.1994.tb06481.x; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; ZANDOMENI R, 1986, J BIOL CHEM, V261, P3414	71	66	69	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 16	2003	22	2					220	232		10.1038/sj.onc.1206107	http://dx.doi.org/10.1038/sj.onc.1206107			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527891				2022-12-28	WOS:000180322400007
J	Zhou, YQ; He, C; Chen, YQ; Wang, D; Wang, MH				Zhou, YQ; He, C; Chen, YQ; Wang, D; Wang, MH			Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential	ONCOGENE			English	Article						receptor tyrosine kinase; splicing variants; colon cancer; oncogenesis	MACROPHAGE-STIMULATING PROTEIN; POINT MUTATIONS; GROWTH-FACTOR; C-MET; GENE; OVEREXPRESSION; IDENTIFICATION; CANCER; ACTIVATION; PRODUCT	The RON receptor tyrosine kinase is a member of the MET proto-oncogene family that has been implicated in regulating motile-invasive phenotypes in certain types of epithelial cancers. The purpose of this study was to determine if RON expression is altered in primary human colorectal adenocarcinomas. Results from immuohistochemical staining showed that RON is highly expressed in the majority of colorectal adenocarcinomas (29/49 cases). Accumulated RON is also constitutively active with autophosphorylation in tyrosine residues. Moreover, three splicing, variants of RON, namely RONDelta165, RONDelta160, and RONDelta155 were detected and cloned from two primary colon cancer samples. These RON variants were generated by deletions in different regions in extracellular domains of the RON beta chain. Functional studies showed that expression of RONDelta160 or RONDelta155 in Martin-Darby canine kidney cells resulted in increased cell dissociation (scatter-like activity). RON variants, RONDelta160 and RONDelta155, also exerted the ability to induce multiple focus formation and sustain anchorage-independent growth of transfected NIH3T3 cells. Moreover, NIH3T3 cells expressing RONDelta160 or RONDelta155 formed tumors in athymic nude mice and colonized in the lungs. These data suggest that RON expression is altered in certain primary colon cancers. Abnormal accumulation of RON variants may play a role in the progression of certain colorectal cancers in vivo.	Univ Colorado, Hlth Sci Ctr, Denver Hlth Med Ctr, Dept Med, Denver, CO 80204 USA; Zhejiang Univ, Sch Med, Div Neurosurg, Affiliated Hosp 1, Hangzhou 310027, Peoples R China; Zhejiang Univ, Sch Med, Dept Surg, Sir Run Run Shaw Hosp, Hangzhou 310027, Peoples R China; Univ Colorado, Sch Med, Dept Med, Denver, CO USA; Univ Colorado, Sch Med, CU Canc Ctr, Denver, CO USA	Denver Health Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Zhejiang University; Zhejiang University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Wang, MH (corresponding author), Univ Colorado, Hlth Sci Ctr, Denver Hlth Med Ctr, Dept Med, 777 Bannock St,Mail 4000, Denver, CO 80204 USA.	ming-hai.wang@uchsc.edu			NATIONAL CANCER INSTITUTE [R01CA091980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043516] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA91980] Funding Source: Medline; NIAID NIH HHS [R01 AI43516] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allred DC, 1998, MODERN PATHOL, V11, P155; Angeloni D, 2000, GENE CHROMOSOME CANC, V29, P147, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1015>3.3.CO;2-E; Birchmeier W, 1997, CIBA F SYMP, V212, P230; Chen YQ, 2000, EXP CELL RES, V261, P229, DOI 10.1006/excr.2000.5012; Collesi C, 1996, MOL CELL BIOL, V16, P5518; Comoglio PM, 1999, EXP CELL RES, V253, P88, DOI 10.1006/excr.1999.4684; Crawford J., 1994, GASTROINTESTINAL TRA; Dorudi Sina, 1993, Current Opinion in Oncology, V5, P130; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; Kinzler KW, 1998, GENETIC BASIS HUMAN, P565; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; Montero-Julian FA, 1998, HYBRIDOMA, V17, P541, DOI 10.1089/hyb.1998.17.541; Okino T, 1999, INT J ONCOL, V15, P709; Peace BE, 2001, ONCOGENE, V20, P6142, DOI 10.1038/sj.onc.1204836; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; Portera CA, 1998, SURG ONCOL, V7, P183, DOI 10.1016/S0960-7404(99)00020-1; RONSIN C, 1993, ONCOGENE, V8, P1195; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; Wang MH, 2000, CARCINOGENESIS, V21, P1507, DOI 10.1093/carcin/21.8.1507; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; WANG MH, 1994, J BIOL CHEM, V269, P3436; Williams TA, 1999, J CELL PHYSIOL, V181, P507, DOI 10.1002/(SICI)1097-4652(199912)181:3<507::AID-JCP15>3.0.CO;2-Q; Xiao ZQ, 2000, BIOCHEM BIOPH RES CO, V267, P669, DOI 10.1006/bbrc.1999.2011; Yokota J, 2000, CARCINOGENESIS, V21, P497, DOI 10.1093/carcin/21.3.497	31	158	177	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2003	22	2					186	197		10.1038/sj.onc.1206075	http://dx.doi.org/10.1038/sj.onc.1206075			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527888				2022-12-28	WOS:000180322400004
J	Salesse, S; Verfaillie, CM				Salesse, S; Verfaillie, CM			BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia	ONCOGENE			English	Review						CML; BCR/ABL; molecular mechanisms; treatments	CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE INHIBITOR; BONE-MARROW-TRANSPLANTATION; FARNESYL-PROTEIN TRANSFERASE; ANTISENSE OLIGODEOXYRIBONUCLEOTIDES SUPPRESS; HEMATOPOIETIC PROGENITOR CELLS; ACUTE LYMPHOBLASTIC-LEUKEMIA; INTEGRIN-MEDIATED ADHESION; CYTOTOXIC T-LYMPHOCYTES; RNA ADENOSINE-DEAMINASE		Univ Minnesota, Ctr Canc, Stell Cell Inst, Minneapolis, MN 55455 USA; Univ Minnesota, Ctr Canc, Dept Med, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Verfaillie, CM (corresponding author), Univ Minnesota, Ctr Canc, Stell Cell Inst, MMC708,420 Delaware St SE, Minneapolis, MN 55455 USA.	verfa001@tc.umn.edu	Verfaillie, Catherine/H-5148-2013	Verfaillie, Catherine/0000-0001-7564-4079				ACKERMAN SK, 1978, AM J MED, V64, P1061, DOI 10.1016/0002-9343(78)90462-X; Adams J, 1999, CANCER RES, V59, P2615; Adams J, 2002, ONCOLOGIST, V7, P9, DOI 10.1634/theoncologist.7-1-9; AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; An WG, 2000, LEUKEMIA, V14, P1276, DOI 10.1038/sj.leu.2401812; ANAFI M, 1993, BLOOD, V82, P3524; ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; Apperley JF, 1998, HEMATOL CELL THER, V40, P229; Barrett AJ, 1998, BONE MARROW TRANSPL, V21, P543, DOI 10.1038/sj.bmt.1701131; BEDI A, 1994, BLOOD, V83, P2038; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; Bhatia R, 1999, EXP HEMATOL, V27, P1384, DOI 10.1016/S0301-472X(99)00084-3; Bhatia R, 1998, BLOOD, V91, P3414, DOI 10.1182/blood.V91.9.3414.3414_3414_3422; Bhatia R, 1998, LEUKEMIA, V12, P1708, DOI 10.1038/sj.leu.2401193; BOCCHIA M, 1995, BLOOD, V85, P2680, DOI 10.1182/blood.V85.10.2680.bloodjournal85102680; BOUTIN JA, 1994, INT J BIOCHEM, V26, P1203, DOI 10.1016/0020-711X(94)90091-4; Buchdunger E, 1996, CANCER RES, V56, P100; Calabretta B, 1997, ANTI-CANCER DRUG DES, V12, P373; CALABRETTA B, 1991, P NATL ACAD SCI USA, V88, P2351, DOI 10.1073/pnas.88.6.2351; Campbell JDM, 2001, TRENDS IMMUNOL, V22, P88, DOI 10.1016/S1471-4906(00)01857-3; CARACCIOLO D, 1990, J CLIN INVEST, V85, P55, DOI 10.1172/JCI114433; Carlo-Stella C, 1999, BLOOD, V93, P3973, DOI 10.1182/blood.V93.11.3973.411k12_3973_3982; CarloStella C, 1996, BLOOD, V88, P3091, DOI 10.1182/blood.V88.8.3091.bloodjournal8883091; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; Choudhury A, 1997, BLOOD, V89, P1133, DOI 10.1182/blood.V89.4.1133; Clark RE, 2000, LEUKEMIA, V14, P347, DOI 10.1038/sj.leu.2401677; Clark RE, 2001, LEUKEMIA LYMPHOMA, V42, P871, DOI 10.3109/10428190109097706; Claxton DF, 2001, CRIT REV IMMUNOL, V21, P147; Cobaleda C, 2000, BLOOD, V95, P731, DOI 10.1182/blood.V95.3.731.003k28_731_737; Cortez D, 1996, ONCOGENE, V13, P2589; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; COTTER TG, 1995, LEUKEMIA LYMPHOMA, V18, P231, DOI 10.3109/10428199509059612; Crooke ST, 1999, BBA-GENE STRUCT EXPR, V1489, P31, DOI 10.1016/S0167-4781(99)00148-7; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Dazzi F, 1999, EXP HEMATOL, V27, P1477, DOI 10.1016/S0301-472X(99)00096-X; de Fabritiis P, 1998, BLOOD, V91, P3156, DOI 10.1182/blood.V91.9.3156; deFabritiis P, 1997, LEUKEMIA, V11, P811, DOI 10.1038/sj.leu.2400664; Deininger MWN, 1997, BLOOD, V90, P3691, DOI 10.1182/blood.V90.9.3691; Deininger MWN, 2000, CANCER RES, V60, P2049; DIAMOND J, 1995, BLOOD, V85, P2171, DOI 10.1182/blood.V85.8.2171.bloodjournal8582171; Dietrich C, 1996, P NATL ACAD SCI USA, V93, P10815, DOI 10.1073/pnas.93.20.10815; Dou QP, 1999, J PHARMACOL EXP THER, V289, P781; Drexler HCA, 1997, P NATL ACAD SCI USA, V94, P855, DOI 10.1073/pnas.94.3.855; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; Emanuel PD, 2000, BLOOD, V95, P639, DOI 10.1182/blood.V95.2.639; End DW, 1999, INVEST NEW DRUG, V17, P241, DOI 10.1023/A:1006380320290; FABER LM, 1995, BLOOD, V86, P2821; FALKENBURG JHF, 1993, J IMMUNOTHER, V14, P305, DOI 10.1097/00002371-199311000-00009; Galderisi U, 1999, J CELL PHYSIOL, V181, P251, DOI 10.1002/(SICI)1097-4652(199911)181:2<251::AID-JCP7>3.0.CO;2-D; GambacortiPasserini C, 1997, BLOOD CELL MOL DIS, V23, P380, DOI 10.1006/bcmd.1997.0155; GarciaHernandez B, 1996, MOL MED, V2, P125, DOI 10.1007/BF03402208; Gewirtz AM, 1998, BLOOD, V92, P712, DOI 10.1182/blood.V92.3.712.415a32_712_736; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; Gibbs JB, 1997, CURR OPIN CHEM BIOL, V1, P197, DOI 10.1016/S1367-5931(97)80010-5; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; Gibson SA, 1997, MOL BIOTECHNOL, V7, P125, DOI 10.1007/BF02761748; GIRALT S, 1995, BLOOD, V86, P4337, DOI 10.1182/blood.V86.11.4337.bloodjournal86114337; GISHIZKY ML, 1995, P NATL ACAD SCI USA, V92, P10889, DOI 10.1073/pnas.92.24.10889; GISHIZKY ML, 1993, P NATL ACAD SCI USA, V90, P3755, DOI 10.1073/pnas.90.8.3755; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; Goodman M, 1998, LEUKEMIA, V12, P1671, DOI 10.1038/sj.leu.2401199; GORDON MY, 1987, NATURE, V328, P342, DOI 10.1038/328342a0; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; Hamada M, 1999, FEBS LETT, V461, P77, DOI 10.1016/S0014-5793(99)01367-8; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; Hideshima T, 2001, CANCER RES, V61, P3071; Hochhaus A, 1996, BLOOD, V88, P2236, DOI 10.1182/blood.V88.6.2236.bloodjournal8862236; Hochhaus A, 2001, SCIENCE, V293, P2163; Holtz MS, 2002, BLOOD, V99, P3792, DOI 10.1182/blood.V99.10.3792; HONMA Y, 1990, JPN J CANCER RES, V81, P1132, DOI 10.1111/j.1349-7006.1990.tb02524.x; HONMA Y, 1989, CANCER RES, V49, P331; ImajohOhmi S, 1995, BIOCHEM BIOPH RES CO, V217, P1070, DOI 10.1006/bbrc.1995.2878; James HA, 1998, BLOOD, V91, P371, DOI 10.1182/blood.V91.2.371.371_371_382; Jiang YH, 2000, P NATL ACAD SCI USA, V97, P10538, DOI 10.1073/pnas.190104497; JIANG YZ, 1995, EXP HEMATOL, V23, P1167; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; Karp JE, 2001, BLOOD, V97, P3361, DOI 10.1182/blood.V97.11.3361; Kasper B, 1999, CANCER CHEMOTH PHARM, V44, P433, DOI 10.1007/s002800051001; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KAWADA M, 1993, DRUG EXP CLIN RES, V19, P235; KIM U, 1994, J BIOL CHEM, V269, P13480; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOLB HJ, 1995, BLOOD, V86, P2041, DOI 10.1182/blood.V86.5.2041.bloodjournal8652041; Kuwabara T, 2001, BIOMACROMOLECULES, V2, P1220, DOI 10.1021/bm010107u; Kuwabara T, 2001, BIOMACROMOLECULES, V2, P788, DOI 10.1021/bm010054g; Kuwabara T, 1998, MOL CELL, V2, P617, DOI 10.1016/S1097-2765(00)80160-4; LANGE W, 1994, FEBS LETT, V338, P175, DOI 10.1016/0014-5793(94)80359-5; LANGE W, 1993, LEUKEMIA, V7, P1786; LANGE W, 1995, KLIN PADIATR, V207, P222, DOI 10.1055/s-2008-1046544; le Coutre P, 2000, BLOOD, V95, P1758, DOI 10.1182/blood.V95.5.1758.005a41_1758_1766; le Coutre P, 1999, J NATL CANCER I, V91, P163, DOI 10.1093/jnci/91.2.163; Lebowitz PF, 1998, ONCOGENE, V17, P1439, DOI 10.1038/sj.onc.1202175; Lebowitz PF, 1997, J BIOL CHEM, V272, P16093, DOI 10.1074/jbc.272.26.16093; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Liu M, 1998, CANCER RES, V58, P4947; Long SB, 2001, P NATL ACAD SCI USA, V98, P12948, DOI 10.1073/pnas.241407898; Luger SM, 2002, BLOOD, V99, P1150, DOI 10.1182/blood.V99.4.1150; Luger SM, 1996, BLOOD, V87, P1326, DOI 10.1182/blood.V87.4.1326.bloodjournal8741326; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Mahon FX, 2000, BLOOD, V96, P1070, DOI 10.1182/blood.V96.3.1070.015k17_1070_1079; Mahon FX, 1995, EXP HEMATOL, V23, P1606; MANDANAS RA, 1993, BLOOD, V82, P1838; Maran A, 1998, BLOOD, V92, P4336, DOI 10.1182/blood.V92.11.4336.423a06_4336_4343; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MELO JV, 1993, BLOOD, V81, P158; Melo JV, 1996, BLOOD, V88, P2375, DOI 10.1182/blood.V88.7.2375.bloodjournal8872375; MELOTTI P, 1994, J EXP MED, V179, P1023, DOI 10.1084/jem.179.3.1023; Mendoza-Maldonado R, 2002, CANCER GENE THER, V9, P71, DOI 10.1038/sj/cgt/7700410; Molldrem JJ, 1997, BLOOD, V90, P2529, DOI 10.1182/blood.V90.7.2529.2529_2529_2534; NAGASU T, 1995, CANCER RES, V55, P5310; NELLEN W, 1993, TRENDS BIOCHEM SCI, V18, P419, DOI 10.1016/0968-0004(93)90137-C; NIMER SD, 1994, TRANSPLANTATION, V57, P82, DOI 10.1097/00007890-199401000-00015; NOWELL PC, 1960, SCIENCE, V132, P1497; OBRIEN SG, 1994, LEUKEMIA, V8, P2156; ODA T, 1995, LEUKEMIA, V9, P295; OKABE M, 1992, BLOOD, V80, P1330; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PAPANDREOU C, 2001, P AN M AM SOC CLIN, V20, pA86; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; Peters DG, 2001, BLOOD, V97, P1404, DOI 10.1182/blood.V97.5.1404; Pinilla-Ibarz J, 2000, BLOOD REV, V14, P111, DOI 10.1054/blre.2000.0127; Pinilla-Ibarz J, 2000, BLOOD, V95, P1781, DOI 10.1182/blood.V95.5.1781.005k46_1781_1787; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; PYLE AM, 1993, SCIENCE, V261, P709, DOI 10.1126/science.7688142; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; RATAJCZAK MZ, 1992, INT J CELL CLONING, V10, P205; Ratajczak MZ, 1998, BLOOD, V91, P1934, DOI 10.1182/blood.V91.6.1934.1934_1934_1946; RATAJCZAK MZ, 1992, P NATL ACAD SCI USA, V89, P11823, DOI 10.1073/pnas.89.24.11823; RATAJCZAK MZ, 1992, BLOOD, V79, P1956; Reichert A, 2001, BLOOD, V97, P1399, DOI 10.1182/blood.V97.5.1399; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; Robinson N, 1996, BLOOD, V87, P1249, DOI 10.1182/blood.V87.4.1249.bloodjournal8741249; Rowinsky EK, 1999, J CLIN ONCOL, V17, P3631, DOI 10.1200/JCO.1999.17.11.3631; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Rowley PT, 1996, LEUKEMIA RES, V20, P473, DOI 10.1016/0145-2126(95)00172-7; Rowley PT, 1999, MOL MED, V5, P693, DOI 10.1007/BF03401988; SAKAI N, 1994, EXP CELL RES, V215, P131, DOI 10.1006/excr.1994.1324; Salgia R, 1997, J CLIN INVEST, V100, P46, DOI 10.1172/JCI119520; SanchezGarcia I, 1997, J MOL BIOL, V267, P225, DOI 10.1006/jmbi.1996.0779; Sattler M, 1998, LEUKEMIA, V12, P637, DOI 10.1038/sj.leu.2401010; Sattler M, 2002, ONCOGENE, V21, P1423, DOI 10.1038/sj.onc.1205202; Sawyers C, 2000, BLOOD, V96, p503A; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SAWYERS CL, 1993, LEUKEMIA LYMPHOMA, V11, P101, DOI 10.3109/10428199309064268; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; Shah SA, 2001, J CELL BIOCHEM, V82, P110, DOI 10.1002/jcb.1150; Shinohara K, 1996, BIOCHEM J, V317, P385, DOI 10.1042/bj3170385; SHORE SK, 1993, ONCOGENE, V8, P3183; SIGURDSSON ST, 1995, TRENDS BIOTECHNOL, V13, P286, DOI 10.1016/S0167-7799(00)88966-0; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; SKORSKI T, 1994, J EXP MED, V179, P1855, DOI 10.1084/jem.179.6.1855; Skorski T, 1997, P NATL ACAD SCI USA, V94, P3966, DOI 10.1073/pnas.94.8.3966; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; SKORSKI T, 1994, P NATL ACAD SCI USA, V91, P4504, DOI 10.1073/pnas.91.10.4504; SKORSKI T, 1993, J CLIN INVEST, V92, P194, DOI 10.1172/JCI116549; Skorski T, 1996, BLOOD, V88, P1005, DOI 10.1182/blood.V88.3.1005.1005; Skorski T, 1997, J NATL CANCER I, V89, P124, DOI 10.1093/jnci/89.2.124; SMETSERS TFCM, 1995, LEUKEMIA, V9, P118; SMETSERS TFCM, 1994, LEUKEMIA, V8, P129; SOIFFER RJ, 1994, BLOOD, V84, P964; Soligo D, 2001, BRIT J HAEMATOL, V113, P126, DOI 10.1046/j.1365-2141.2001.02683.x; SPIERS ASD, 1977, CLIN HAEMATOL, V6, P77; Spiller DG, 1998, ANTISENSE NUCLEIC A, V8, P281, DOI 10.1089/oli.1.1998.8.281; Spiller DG, 1998, BLOOD, V91, P4738, DOI 10.1182/blood.V91.12.4738.412k31_4738_4746; Stinchcombe TE, 2000, BLOOD, V96, p516A; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SZCZYLIK C, 1991, SCIENCE, V253, P562, DOI 10.1126/science.1857987; Talpaz M, 2002, BLOOD, V99, P1928, DOI 10.1182/blood.V99.6.1928; Tanabe T, 2000, BIOMACROMOLECULES, V1, P108, DOI 10.1021/bm990009x; Tari AM, 1997, BIOCHEM BIOPH RES CO, V235, P383, DOI 10.1006/bbrc.1997.6791; ten Bosch GJA, 1999, BLOOD, V94, P1038, DOI 10.1182/blood.V94.3.1038.415k22_1038_1045; tenBosch GJA, 1996, BLOOD, V88, P3522, DOI 10.1182/blood.V88.9.3522.bloodjournal8893522; TIBERGHIEN P, 1994, BLOOD, V84, P1333; VAERMAN JL, 1995, BLOOD, V86, P3891, DOI 10.1182/blood.V86.10.3891.bloodjournal86103891; Vaerman JL, 1997, BLOOD, V90, P331; VANDERPLAS DC, 1991, LEUKEMIA, V5, P457; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; Vey N, 1999, J IMMUNOTHER, V22, P175, DOI 10.1097/00002371-199903000-00009; Warashina M, 1999, CHEM BIOL, V6, P237, DOI 10.1016/S1074-5521(99)80039-8; WARASHINA M, 1997, NUCL AC S SER, V37, P213; Warmuth M, 1999, ANN HEMATOL, V78, P49, DOI 10.1007/s002770050473; Warren EH, 1998, BLOOD, V91, P2197, DOI 10.1182/blood.V91.6.2197; Wu HJ, 1999, J BIOL CHEM, V274, P28270, DOI 10.1074/jbc.274.40.28270; Wu YL, 2000, J CELL BIOCHEM, V76, P596; Wu YP, 1999, HUM GENE THER, V10, P2847, DOI 10.1089/10430349950016573; Zhao RCH, 1997, BLOOD, V90, P4687, DOI 10.1182/blood.V90.12.4687.4687_4687_4698	197	81	85	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2002	21	56					8547	8559		10.1038/sj.onc.1206082	http://dx.doi.org/10.1038/sj.onc.1206082			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZF	12476301	Green Published			2022-12-28	WOS:000179734300004
J	Garner, AP; Weston, CR; Todd, DE; Balmanno, K; Cook, SJ				Garner, AP; Weston, CR; Todd, DE; Balmanno, K; Cook, SJ			Delta MEKK3 : ER* activation induces a p38 alpha/beta 2-dependent cell cycle arrest at the G(2) checkpoint	ONCOGENE			English	Article						MEKK3; p38; G(2); cyclin; CDK; p21(Cip1)	DEPENDENT KINASE INHIBITOR; B1 MESSENGER-RNA; PROTEIN-KINASE; XENOPUS-OOCYTE; DNA-DAMAGE; POSTTRANSCRIPTIONAL REGULATION; SIGNAL-TRANSDUCTION; POTENTIAL MEDIATOR; PHOSPHORYLATION; P38	Whilst many studies have examined the role of the MAP Kinases in regulating the G(1)-->S transition, much less is known about the function of these pathways in regulating other cell cycle transitions. Stimulation of the conditional mutant DeltaMEKK3:ER* in asynchronous hamster (CCl39) and rat (Rat-1) fibroblasts resulted in the strong activation of endogenous JNK and p38 but only a weak activation of ERK. Activation of DeltaMEKK3:ER* inhibited cell proliferation through a combination of an initial G(1) and G(2) cell cycle arrest, followed by a delayed onset of apoptosis. When cells were synchronized in S phase with aphidicolin and then released, activation of DeltaMEKK3:ER* resulted in the up-regulation of p21(CIP1) and a pronounced inhibition of cyclin A/CDK2 and cyclin B1/CDK1 kinase activity. Analysis of mitotic figures indicated that cells failed to enter mitosis, arresting late in G(2). DeltaMEKK3:ER*-mediated CDK inhibition and G(2) arrest did not absolutely require p21(CIP1), since both events were observed in Rat-1 cells in which p21(CIP1) is transcriptionally silenced due to promoter methylation. Rather, CDK inhibition was associated with a down-regulation of cyclin A and 131 expression. Finally, application of the p38 inhibitor SB203580 partially restored cyclin B associated kinase activity and allowed cells to proceed through mitosis into the next G(1) phase, suggesting that activation of the p38alpha/beta2 pathway can promote a G(2) cell cycle arrest.	Babraham Inst, Signalling Programme, Inositide Lab, Cambridge CB2 4AT, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Cook, SJ (corresponding author), Babraham Inst, Signalling Programme, Inositide Lab, Babraham Hall, Cambridge CB2 4AT, England.	simon.cook@bbsrc.ac.uk		Balmanno, Kathryn/0000-0002-6417-3889				Alexander MR, 2001, MOL BIOL CELL, V12, P53, DOI 10.1091/mbc.12.1.53; Allan LA, 2000, MOL CELL BIOL, V20, P1291, DOI 10.1128/MCB.20.4.1291-1298.2000; Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Blasina A, 1997, MOL BIOL CELL, V8, P1013, DOI 10.1091/mbc.8.6.1013; Booher RN, 1997, J BIOL CHEM, V272, P22300, DOI 10.1074/jbc.272.35.22300; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Clarke DJ, 2000, BIOESSAYS, V22, P351, DOI 10.1002/(SICI)1521-1878(200004)22:4<351::AID-BIES5>3.0.CO;2-W; Cook SJ, 2000, BIOCHEM SOC T, V28, P233, DOI 10.1042/bst0280233; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DAWSON IA, 1995, J CELL BIOL, V129, P725, DOI 10.1083/jcb.129.3.725; Deacon K, 1999, J BIOL CHEM, V274, P16604, DOI 10.1074/jbc.274.23.16604; Deacon K, 1997, J BIOL CHEM, V272, P14489, DOI 10.1074/jbc.272.22.14489; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Ellinger-Ziegelbauer H, 1999, MOL CELL BIOL, V19, P3857; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUARDAGNO TM, 1996, CELL, V84, P73; Guo N, 2000, J BIOL CHEM, V275, P1715, DOI 10.1074/jbc.275.3.1715; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; Hagting A, 1999, CURR BIOL, V9, P680, DOI 10.1016/S0960-9822(99)80308-X; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; Kotani S, 1999, J CELL BIOL, V146, P791, DOI 10.1083/jcb.146.4.791; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; LI JK, 1995, MOL BIOL CELL, V6, P1111, DOI 10.1091/mbc.6.9.1111; LI Y, 1994, ONCOGENE, V9, P2261; Liu QH, 2000, GENE DEV, V14, P1448; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Lukas C, 1999, NATURE, V401, P815, DOI 10.1038/44611; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MAITY A, 1995, EMBO J, V14, P603, DOI 10.1002/j.1460-2075.1995.tb07036.x; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; MEIJER L, 1991, EMBO J, V10, P1545, DOI 10.1002/j.1460-2075.1991.tb07674.x; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; MUSCHEL RJ, 1991, CANCER RES, V51, P5113; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PARKER LL, 1995, P NATL ACAD SCI USA, V92, P9638, DOI 10.1073/pnas.92.21.9638; Passalaris TM, 1999, MOL CELL BIOL, V19, P5872, DOI 10.1128/mcb.19.9.5872; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; Petrocelli T, 2000, ONCOGENE, V19, P4480, DOI 10.1038/sj.onc.1203808; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; Piwnica-Worms H, 1999, NATURE, V401, P535, DOI 10.1038/44029; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; Smith JL, 2000, MOL CELL BIOL, V20, P8026, DOI 10.1128/MCB.20.21.8026-8034.2000; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; Spitkovsky D, 1997, CELL GROWTH DIFFER, V8, P699; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang S, 1999, EMBO J, V18, P1559, DOI 10.1093/emboj/18.6.1559; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174; Yang Z, 2001, IEEE T ADV PACKAGING, V24, P309, DOI 10.1109/6040.938298	91	43	47	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2002	21	53					8089	8104		10.1038/sj.onc.1206000	http://dx.doi.org/10.1038/sj.onc.1206000			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615DW	12444545				2022-12-28	WOS:000179231400003
J	Ingram, WJ; Wicking, CA; Grimmond, SM; Forrest, AR; Wainwright, BJ				Ingram, WJ; Wicking, CA; Grimmond, SM; Forrest, AR; Wainwright, BJ			Novel genes regulated by Sonic Hedgehog in pluripotent mesenchymal cells	ONCOGENE			English	Article						Sonic Hedgehog; downstream target genes; C3H/10T1/2; microarray	ANIMAL DEVELOPMENT; CDNA MICROARRAY; CANDIDATE GENE; HUMAN HOMOLOG; GLI PROTEINS; MOUSE EMBRYO; FLOOR PLATE; DROSOPHILA; DIFFERENTIATION; THROMBOMODULIN	Sonic Hedgehog is a secreted morphogen involved in patterning a wide range of structures in the developing embryo. Disruption of the Hedgehog signalling cascade leads to a number of developmental disorders and plays a key role in the formation of a range of human cancers. The identification of genes regulated by Hedgehog is crucial to understanding how disruption of this pathway leads to neoplastic transformation. We have used a Sonic Hedgehog (Shh) responsive mouse cell line, C3H/10T1/2, to provide a model system for hedgehog target gene discovery. Following activation of cell cultures with Shh, RNA was used to interrogate microarrays to investigate downstream transcriptional consequences of hedgehog stimulation. As a result 11 target genes have been identified, seven of which are induced (Thrombomodulin, GILZ, BF-2, Nr4a1, IGF2, PMP22, LASP1) and four of which are repressed (SFRP-1, SFRP-2, Mip1-gamma, Amh) by Shh. These targets have a diverse range of putative functions and include transcriptional regulators and molecules known to be involved in regulating cell growth or apoptosis. The corroboration of genes previously implicated in hedgehog signalling, along with the finding of novel targets, demonstrates both the validity and power of the C3H/10T1/2 system for Shh target gene discovery.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Dept Biochem & Mol Biol, Brisbane, Qld 4072, Australia; Cooperat Res Ctr Discovery Genes Common Human Dis, Richmond, Vic 3121, Australia	University of Queensland; University of Queensland	Wainwright, BJ (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.		Ingram, Wendy J/F-7317-2010; Grimmond, Sean/K-3246-2019; Forrest, Alistair/A-6597-2008; Grimmond, Sean M/J-5304-2016; Wicking, Carol/J-1814-2014	Ingram, Wendy J/0000-0002-7063-1081; Grimmond, Sean/0000-0002-8102-7998; Forrest, Alistair/0000-0003-4543-1675; Grimmond, Sean M/0000-0002-8102-7998; Wicking, Carol/0000-0002-7225-3803; Wainwright, Brandon/0000-0003-0406-2092				Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; Altaba ARI, 1999, DEVELOPMENT, V126, P3205; Barnes EA, 2001, EMBO J, V20, P2214, DOI 10.1093/emboj/20.9.2214; Bieche I, 1996, CANCER RES, V56, P3886; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; Chuang PT, 1999, NATURE, V397, P617, DOI 10.1038/17611; D'Adamio F, 1997, IMMUNITY, V7, P803, DOI 10.1016/S1074-7613(00)80398-2; Dobens LL, 2000, DEVELOPMENT, V127, P745; Dobens LL, 1997, MECH DEVELOP, V65, P197, DOI 10.1016/S0925-4773(97)00080-4; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; Fiorenza MT, 2001, GENE, V278, P125, DOI 10.1016/S0378-1119(01)00715-6; Freedman JE, 2001, CIRC RES, V88, P651, DOI 10.1161/hh0701.089956; Garg V, 2001, DEV BIOL, V235, P62, DOI 10.1006/dbio.2001.0283; Gibson-Brown JJ, 1998, DEVELOPMENT, V125, P2499; Gustafsson MK, 2002, GENE DEV, V16, P114, DOI 10.1101/gad.940702; Hahn H, 2000, J BIOL CHEM, V275, P28341, DOI 10.1074/jbc.C000352200; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Halgren RG, 2001, NUCLEIC ACIDS RES, V29, P582, DOI 10.1093/nar/29.2.582; Hargrave M, 2000, DEV BIOL, V219, P142, DOI 10.1006/dbio.1999.9581; HEALY AM, 1995, P NATL ACAD SCI USA, V92, P850, DOI 10.1073/pnas.92.3.850; Hegde P, 2000, BIOTECHNIQUES, V29, P548, DOI 10.2144/00293bi01; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jetten AM, 2000, PROG NUCLEIC ACID RE, V64, P97, DOI 10.1016/S0079-6603(00)64003-5; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Kato M, 2001, BIOCHEM BIOPH RES CO, V289, P472, DOI 10.1006/bbrc.2001.5976; Kinto N, 1997, FEBS LETT, V404, P319, DOI 10.1016/S0014-5793(97)00014-8; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; Krishnan V, 1997, SCIENCE, V278, P1947, DOI 10.1126/science.278.5345.1947; Lee CS, 2000, DEVELOPMENT, V127, P109; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636; Murone M, 1999, CURR BIOL, V9, P76, DOI 10.1016/S0960-9822(99)80018-9; Nakamura T, 1997, BIOCHEM BIOPH RES CO, V237, P465, DOI 10.1006/bbrc.1997.7156; Pathi S, 2001, MECH DEVELOP, V106, P107, DOI 10.1016/S0925-4773(01)00427-0; Pepinsky RB, 2000, J BIOL CHEM, V275, P10995, DOI 10.1074/jbc.275.15.10995; Pepinsky RB, 1998, J BIOL CHEM, V273, P14037, DOI 10.1074/jbc.273.22.14037; Pola R, 2001, NAT MED, V7, P706, DOI 10.1038/89083; Polakis P, 2000, GENE DEV, V14, P1837; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; Saeki K, 2000, BBA-PROTEIN STRUCT M, V1476, P219, DOI 10.1016/S0167-4838(99)00254-X; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Spinella-Jaegle S, 2001, J CELL SCI, V114, P2085; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; TREISMAN JE, 1995, DEVELOPMENT, V121, P2835; Vasiliauskas D, 1999, MECH DEVELOP, V82, P79, DOI 10.1016/S0925-4773(99)00014-3; Villavicencio EH, 2000, AM J HUM GENET, V67, P1047, DOI 10.1016/S0002-9297(07)62934-6; WeilerGuettler H, 1996, DEVELOPMENT, V122, P2271; Wicking C, 1999, ONCOGENE, V18, P7844, DOI 10.1038/sj.onc.1203282; Wilhelm S, 1998, INT J ONCOL, V13, P645; Williams KP, 1999, J CELL SCI, V112, P4405; Yoon JW, 2002, J BIOL CHEM, V277, P5548, DOI 10.1074/jbc.M105708200	55	104	108	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 21	2002	21	53					8196	8205		10.1038/sj.onc.1205975	http://dx.doi.org/10.1038/sj.onc.1205975			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615DW	12444557				2022-12-28	WOS:000179231400015
J	Song, CH; Satoh, T; Edamatsu, H; Wu, DM; Tadano, M; Gao, XL; Kataoka, T				Song, CH; Satoh, T; Edamatsu, H; Wu, DM; Tadano, M; Gao, XL; Kataoka, T			Differential roles of Ras and Rap1 in growth factor-dependent activation of phospholipase C epsilon	ONCOGENE			English	Article						PLC epsilon; Ras; Rap1	PROTEIN-KINASE-C; GOLGI-COMPLEX; GTPASE; RECEPTOR; IDENTIFICATION; ASSOCIATION; EFFECTOR; ADHESION; PRODUCT; PATHWAY	Phospholipase Cepsilon is a phosphoinositide-specific phospholipase C that selectively associates with Ras and Rap small GTPases as a target. Here we explored the molecular basis of the Rap1- as well as Ras-mediated regulation of phospholipase Cepsilon upon platelet-derived growth factor stimulation by using a receptor mutant deficient in its ability to phosphorylate and activate phospholipase Cgamma. Following platelet-derived growth factor treatment, this receptor induces persistent activation of ectopically expressed PLCepsilon through activation of Ras and Rap1. The rapid and initial phase of the activation is mediated by Ras, whereas Rap1 is responsible for the prolonged activation. We further demonstrate that the CDC25 homology domain, which exhibits guanine nucleotide exchange factor activity toward Rap1, but not Ras, is critical for the prolonged activation of phospholipase Cepsilon. Platelet-derived growth factor prevented the hematopoietic BaF3 cells containing the mutant receptor from undergoing apoptosis, and enabled these cells to proliferate, only when phospholipase Cepsilon was expressed. Therefore, the phospholipase C signal is suggested to be critical for survival and growth of BaF3 cells.	Kobe Univ, Grad Sch Med, Dept Mol & Cellular Biol, Div Mol Biol,Chuo Ku, Kobe, Hyogo 6500017, Japan	Kobe University	Kataoka, T (corresponding author), Kobe Univ, Grad Sch Med, Dept Mol & Cellular Biol, Div Mol Biol,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.		song, chunhua/K-7882-2016; Satoh, Takaya/K-2628-2014; song, chunhua/K-7882-2016	song, chunhua/0000-0001-7563-0339; song, chunhua/0000-0002-4081-2543; Edamatsu, Hironori/0000-0002-1335-4217				Baron CL, 2002, SCIENCE, V295, P325, DOI 10.1126/science.1066759; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; Evellin S, 2002, J BIOL CHEM, V277, P16805, DOI 10.1074/jbc.M112024200; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; Gao XL, 2001, J BIOL CHEM, V276, P42219, DOI 10.1074/jbc.M105760200; Jin TG, 2001, J BIOL CHEM, V276, P30301, DOI 10.1074/jbc.M103530200; JOHNSON DE, 1998, FRONT BIOSCI, V3, P313; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; Kurachi H, 1997, J BIOL CHEM, V272, P28081, DOI 10.1074/jbc.272.44.28081; Lopez I, 2001, J BIOL CHEM, V276, P2758, DOI 10.1074/jbc.M008119200; Matsubara K, 1999, ONCOGENE, V18, P1303, DOI 10.1038/sj.onc.1202425; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Ohba Y, 2000, MOL CELL BIOL, V20, P6074, DOI 10.1128/MCB.20.16.6074-6083.2000; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; Schmidt A, 2001, MOL CELL BIOL, V21, P438, DOI 10.1128/MCB.21.2.438-448.2001; Schmidt M, 2001, NAT CELL BIOL, V3, P1020, DOI 10.1038/ncb1101-1020; Shibatohge M, 1998, J BIOL CHEM, V273, P6218, DOI 10.1074/jbc.273.11.6218; Shima F, 1997, MOL CELL BIOL, V17, P1057, DOI 10.1128/MCB.17.3.1057; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; Wienecke R, 1996, ONCOGENE, V13, P913; Wing MR, 2001, J BIOL CHEM, V276, P48257, DOI 10.1074/jbc.C100574200; York RD, 2000, MOL CELL BIOL, V20, P8069, DOI 10.1128/MCB.20.21.8069-8083.2000; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451	30	76	89	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 21	2002	21	53					8105	8113		10.1038/sj.onc.1206003	http://dx.doi.org/10.1038/sj.onc.1206003			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615DW	12444546				2022-12-28	WOS:000179231400004
J	Hawighorst, T; Oura, H; Streit, M; Janes, L; Nguyen, L; Brown, LF; Oliver, G; Jackson, DG; Detmar, M				Hawighorst, T; Oura, H; Streit, M; Janes, L; Nguyen, L; Brown, LF; Oliver, G; Jackson, DG; Detmar, M			Thrombospondin-1 selectively inhibits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice	ONCOGENE			English	Article						TSP-1; VEGF; Prox1; LYVE-1; chemoprevention	ENDOTHELIAL GROWTH-FACTOR; CARCINOMA CELL-LINE; MULTISTAGE CARCINOGENESIS; SKIN CARCINOGENESIS; VESSEL MATURATION; MOUSE SKIN; CANCER; PROMOTES; PROGRESSION; EXPRESSION	The roles played by the endogenous angiogenesis inhibitor thrombospondin-1 (TSP-1) in the early stages of multi-step carcinogenesis and in the control of hematogenous versus lymphatic metastasis are unknown. To investigate these issues we compared tumor development in normal mice and in transgenic mice with targeted overexpression of TSP-1 in the epidermis following a standard two-step chemical skin carcinogenesis regimen. Overexpression of TSP-1 resulted in delayed and reduced development of premalignant epithelial. hyperplasias, but did not inhibit the malignant conversion to squamous cell carcinomas. TSP-1 overexpression also suppressed tumor angiogenesis and distant organ metastasis, but failed to inhibit tumor-associated lymphangiogenesis or lymphatic tumor spread to regional lymph nodes. Concomitant with these results, we found that the endothelial TSP-1 receptor CD36 was mostly absent from cutaneous lymphatic vessels. Our findings indicate the potential use of TSP-1 for the prevention of premalignant stages of tumorigenesis and are likely to have implications for the further development of anti-angiogenic cancer therapies.	Massachusetts Gen Hosp, Dept Dermatol, CBRC, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; St Jude Childrens Res Hosp, Dept Genet, Memphis, TN 38105 USA; John Radcliffe Hosp, Inst Mol Med, IMCR Human Immunol Unit, Oxford OX3 9DS, England	Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; St Jude Children's Research Hospital; University of Oxford	Detmar, M (corresponding author), Massachusetts Gen Hosp, Dept Dermatol, CBRC, Bldg 149,13st St, Charlestown, MA 02129 USA.	michael.detmar@cbrc2.mgh.harvard.edu		, david/0000-0002-4133-9364	NATIONAL CANCER INSTITUTE [R01CA069184, R01CA086410, R01CA091861] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY012162] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058462] Funding Source: NIH RePORTER; NCI NIH HHS [CA69184, CA86410, CA91861] Funding Source: Medline; NEI NIH HHS [EY12162] Funding Source: Medline; NIGMS NIH HHS [GM58462] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alvarez AA, 2001, GYNECOL ONCOL, V82, P273, DOI 10.1006/gyno.2001.6287; Balmain A, 2000, CARCINOGENESIS, V21, P371, DOI 10.1093/carcin/21.3.371; Banerji S, 1999, J CELL BIOL, V144, P789, DOI 10.1083/jcb.144.4.789; Beasley NJP, 2002, CANCER RES, V62, P1315; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Bleuel K, 1999, P NATL ACAD SCI USA, V96, P2065, DOI 10.1073/pnas.96.5.2065; Bornstein P, 2001, J CLIN INVEST, V107, P929, DOI 10.1172/JCI12749; Brekken RA, 1998, CANCER RES, V58, P1952; CASTLE V, 1991, J CLIN INVEST, V87, P1883, DOI 10.1172/JCI115212; Detmar M, 1998, J INVEST DERMATOL, V111, P1, DOI 10.1046/j.1523-1747.1998.00262.x; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; Eberhard A, 2000, CANCER RES, V60, P1388; Filleur S, 2001, GENE DEV, V15, P1373, DOI 10.1101/gad.193501; Hawighorst T, 2002, AM J PATHOL, V160, P1381, DOI 10.1016/S0002-9440(10)62565-5; Hawighorst T, 2001, EMBO J, V20, P2631, DOI 10.1093/emboj/20.11.2631; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Ito N, 1995, CRIT REV ONCOL HEMAT, V21, P105, DOI 10.1016/1040-8428(94)00169-3; Jackson DG, 2001, TRENDS IMMUNOL, V22, P317, DOI 10.1016/S1471-4906(01)01936-6; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Karpanen T, 2001, CANCER RES, V61, P1786; Kodama J, 2001, CLIN CANCER RES, V7, P2826; Lawler J, 2000, CURR OPIN CELL BIOL, V12, P634, DOI 10.1016/S0955-0674(00)00143-5; LEONE A, 1993, ONCOGENE, V8, P2325; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; Marks F, 2000, EUR J CANCER, V36, P314, DOI 10.1016/S0959-8049(99)00318-4; Oliver G, 2002, GENE DEV, V16, P773, DOI 10.1101/gad.975002; Padera TP, 2002, SCIENCE, V296, P1883, DOI 10.1126/science.1071420; Prevo R, 2001, J BIOL CHEM, V276, P19420, DOI 10.1074/jbc.M011004200; Rodriguez-Manzaneque JC, 2001, P NATL ACAD SCI USA, V98, P12485, DOI 10.1073/pnas.171460498; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Sleeman JP, 2000, RECENT RESULTS CANC, V157, P55; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; Streit M, 2000, EMBO J, V19, P3272, DOI 10.1093/emboj/19.13.3272; Streit M, 1999, AM J PATHOL, V155, P441, DOI 10.1016/S0002-9440(10)65140-1; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; Tuszynski GP, 1996, BIOESSAYS, V18, P71, DOI 10.1002/bies.950180113; VOLPERT OV, 1995, BREAST CANCER RES TR, V36, P119, DOI 10.1007/BF00666034; WEINSTATSASLOW DL, 1994, CANCER RES, V54, P6504; Wigle JT, 1999, CELL, V98, P769, DOI 10.1016/S0092-8674(00)81511-1; Wigle JT, 2002, EMBO J, V21, P1505, DOI 10.1093/emboj/21.7.1505; YUSPA SH, 1994, CANCER RES, V54, P1178; ZABRENETZKY V, 1994, INT J CANCER, V59, P191, DOI 10.1002/ijc.2910590209	42	73	79	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 14	2002	21	52					7945	7956		10.1038/sj.onc.1205956	http://dx.doi.org/10.1038/sj.onc.1205956			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	612VY	12439745				2022-12-28	WOS:000179097200004
J	Wang, QF; Cleaves, R; Kummalue, T; Nerlov, C; Friedman, AD				Wang, QF; Cleaves, R; Kummalue, T; Nerlov, C; Friedman, AD			Cell cycle inhibition mediated by the outer surface of the C/EBP alpha basic region is required but not sufficient for granulopoiesis	ONCOGENE			English	Article						C/EBP alpha; E2F; granulopoiesis; cell cycle; differentiation	ENHANCER-BINDING-PROTEIN; SERUM-ALBUMIN GENE; C-MYB; GRANULOCYTE DIFFERENTIATION; TRANSCRIPTIONAL ACTIVATION; MYELOID-LEUKEMIA; NUCLEAR-PROTEIN; GROWTH ARREST; PROLIFERATION; EXPRESSION	CCAAT/enhancer binding protein alpha (C/EBPalpha) transactivates target genes dependent upon DNA binding via its basic region-leucine zipper domain and slows G1 progression by interaction with E2F, cdk2, or cdk4. E2F interacts with the non-DNA-binding surface of the C/EBPalpha basic region and C/EBPa residues 1-70 are required for repressing E2F targets, while cdk2 and cdk4 bind residues 177-191. C/EBPalpha-ER induces the 32D c13 myeloblast cell line to differentiate to granulocytes. C/EBPalpha-ER variants incapable of binding DNA slowed G1, but did not induce early or late granulopoiesis, indicating that cell cycle inhibition as mediated by C/EBPalpha is not sufficient for differentiation. C/EBPalpha-ER variants lacking residues 1170 or residues 11-70 and 178-200 both slowed the G1 to S transition. C/EBPalpha(GZ)-ER, containing the GCN4 rather than the C/EBPalpha leucine zipper, also slowed G1. In contrast, C/EBPalpha(BRM2)-ER, carrying mutations in the outer surface of the basic region required for interaction with E2F, did not slow G1. C/EBPalpha:(BRM2)-ER induced early markers of granulopoiesis much less efficiently than C/EBPalpha-ER and did not direct terminal maturation. Inhibition of G1 progression using mimosine increased induction of late markers by G-CSF. Thus, both DNA binding and cell cycle arrest, mediated by opposite surfaces of the C/EBPalpha basic region, are required for granulopoiesis.	Johns Hopkins Univ, Div Pediat Oncol, Baltimore, MD 21231 USA; European Mol Biol Lab, I-00016 Monterotondo, Italy	Johns Hopkins University; European Molecular Biology Laboratory (EMBL)	Friedman, AD (corresponding author), Johns Hopkins Univ, Div Pediat Oncol, Canc Res Bldg,Room 253,1650 Orleans St, Baltimore, MD 21231 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062274] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL62274, HL62274] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; ANTONSON P, 1995, BIOCHEM BIOPH RES CO, V215, P105; BIES J, 1995, CELL GROWTH DIFFER, V6, P59; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BritosBray M, 1997, MOL CELL BIOL, V17, P5127, DOI 10.1128/MCB.17.9.5127; Cao WS, 1997, ONCOGENE, V15, P1315, DOI 10.1038/sj.onc.1201305; CHANDRASEKARAN C, 1993, P NATL ACAD SCI USA, V90, P8871, DOI 10.1073/pnas.90.19.8871; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; Friedman AD, 2002, J CELL BIOCHEM, V86, P624, DOI 10.1002/jcb.10271; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; Friedman AD, 2002, ONCOGENE, V21, P3377, DOI 10.1038/sj.onc.1205324; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; Johansen LM, 2001, MOL CELL BIOL, V21, P3789, DOI 10.1128/MCB.21.11.3789-3806.2001; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Lou JR, 2000, ONCOGENE, V19, P2695, DOI 10.1038/sj.onc.1203588; Muller C, 1999, P NATL ACAD SCI USA, V96, P7276, DOI 10.1073/pnas.96.13.7276; NERLOV C, 1994, GENE DEV, V8, P350, DOI 10.1101/gad.8.3.350; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; SCOTT LM, 1992, BLOOD, V80, P1725; Slomiany BA, 2000, MOL CELL BIOL, V20, P5986, DOI 10.1128/MCB.20.16.5986-5997.2000; Strom DK, 1998, CELL GROWTH DIFFER, V9, P59; Timchenko NA, 1999, MOL CELL BIOL, V19, P2936; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; Wang G, 2000, EXP CELL RES, V254, P64, DOI 10.1006/excr.1999.4743; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wang QF, 2002, BLOOD, V99, P2776, DOI 10.1182/blood.V99.8.2776; Wang XP, 1999, BLOOD, V94, P560, DOI 10.1182/blood.V94.2.560.414k41_560_571; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569	43	41	42	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2003	22	17					2548	2557		10.1038/sj.onc.1206360	http://dx.doi.org/10.1038/sj.onc.1206360			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730669				2022-12-28	WOS:000182569000002
J	Perucho, M				Perucho, M			Tumors with microsatellite instability: many mutations, targets and paradoxes	ONCOGENE			English	Editorial Material							SHORT MONONUCLEOTIDE REPEATS; MISMATCH REPAIR; MUTATOR PHENOTYPE; GASTROINTESTINAL CANCER; FRAMESHIFT MUTATIONS; SOMATIC MUTATIONS; COLORECTAL-CANCER; COLON-CANCER; GENE; SEQUENCES		Burnham Inst, La Jolla Canc Res Ctr, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Perucho, M (corresponding author), Burnham Inst, La Jolla Canc Res Ctr, 11099 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Perucho, Manuel/0000-0002-2169-2662				Duval A, 2002, CANCER RES, V62, P1609; Duval A, 2002, ONCOGENE, V21, P8062, DOI 10.1038/sj.onc.1206013; Duval A, 2002, CANCER RES, V62, P2447; Gil J, 1999, CANCER RES, V59, P2034; Ionov Y, 2000, P NATL ACAD SCI USA, V97, P10872, DOI 10.1073/pnas.190210897; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KIM HG, 1994, AM J PATHOL, V145, P148; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Perucho M, 1999, CANCER RES, V59, P249; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Souza RF, 1999, ONCOGENE, V18, P4063, DOI 10.1038/sj.onc.1202768; Suzuki K, 2002, CANCER RES, V62, P1961; WOERNER SM, IN PRESS ONCOGENE; Yamamoto H, 2000, CELL DEATH DIFFER, V7, P238, DOI 10.1038/sj.cdd.4400651; Yamamoto H, 1997, CANCER RES, V57, P4420; Zhang L, 2001, CANCER RES, V61, P3801	18	38	42	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 17	2003	22	15					2223	2225		10.1038/sj.onc.1206580	http://dx.doi.org/10.1038/sj.onc.1206580			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	667KV	12700658	Bronze			2022-12-28	WOS:000182231500001
J	Oster, SK; Mao, DYL; Kennedy, J; Penn, LZ				Oster, SK; Mao, DYL; Kennedy, J; Penn, LZ			Functional analysis of the N-terminal domain of the Myc oncoprotein	ONCOGENE			English	Article						Myc; mutant; oncogene; transcription apoptosis; transformation	CELL-CYCLE PROGRESSION; HUMAN C-MYC; NEOPLASTIC TRANSFORMATION; TRANSCRIPTIONAL REPRESSION; NEGATIVE AUTOREGULATION; MYC/MAX/MAD NETWORK; GENE-EXPRESSION; BETA-RECEPTOR; BOX-II; GROWTH	Myc is a multifunctional nuclear phosphoprotein that can drive cell cycle progression, apoptosis and cellular transformation. Myc orchestrates these activities at the molecular level by functioning as a regulator of gene transcription to activate or repress specific target genes. Previous studies have shown that both the Myc N- terminal domain (NTD) and the C-terminal domain (CTD) are essential for Myc functions. The role of the CTD is relatively well understood as it encodes a basic helix-loop-helix leucine zipper motif important for DNA binding and protein-protein interactions. By contrast, the role of the NTD and the specific domains responsible for different Myc activities are not as well defined. To investigate the regions of the NTD necessary for Myc function and to determine whether these activities are overlapping or independent of one another, we have conducted a detailed structure-function analysis of the Myc NTD. We assessed the ability of a number of deletion and point mutants within the highly conserved regions of the Myc NTD to induce cell cycle progression, apoptosis and transformation as well as repress and activate expression of endogenous target genes. Our analyses highlight the complexity of the Myc NTD and extend previous studies. For example, we show most Myc mutants that were compromised as repressors of gene transcription retained the ability to activate gene transcription, reinforcing the concept that these activities can be uncoupled. Repression of two different target genes could be distinguished by specific mutants, further supporting the notion of at least two different Myc repression mechanisms. Mutants disabled at both inducing and repressing gene transcription could not maximally drive the biological activities of Myc, indicating these functions are tightly linked. Indeed, a close association of Myc repression and apoptosis was also observed.	Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Penn, LZ (corresponding author), Princess Margaret Hosp, Ontario Canc Inst, Div Cellular & Mol Biol, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.			Penn, Linda/0000-0001-8133-5459				AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; BARRETT J, 1992, MOL CELL BIOL, V12, P3130, DOI 10.1128/MCB.12.7.3130; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BIRRER MJ, 1988, MOL CELL BIOL, V8, P2668, DOI 10.1128/MCB.8.6.2668; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; Chang DW, 2000, MOL CELL BIOL, V20, P4309, DOI 10.1128/MCB.20.12.4309-4319.2000; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Conzen SD, 2000, MOL CELL BIOL, V20, P6008, DOI 10.1128/MCB.20.16.6008-6018.2000; Dang CV, 1999, MOL CELL BIOL, V19, P1; DEPINHO RA, 1987, GENE DEV, V1, P1311, DOI 10.1101/gad.1.10.1311; Eberhardy SR, 2001, J BIOL CHEM, V276, P48562, DOI 10.1074/jbc.M109014200; Facchini LM, 1997, MOL CELL BIOL, V17, P100, DOI 10.1128/MCB.17.1.100; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; Flinn EM, 1998, MOL CELL BIOL, V18, P5961, DOI 10.1128/MCB.18.10.5961; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hirst SK, 2000, ONCOGENE, V19, P5189, DOI 10.1038/sj.onc.1203904; Hitoshi Y, 1998, IMMUNITY, V8, P461, DOI 10.1016/S1074-7613(00)80551-8; Izumi H, 2001, J CELL SCI, V114, P1533; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KI KW, 2002, J BIOL CHEM, V13, P13; Kuttler F, 2001, ONCOGENE, V20, P6084, DOI 10.1038/sj.onc.1204827; Landay M, 2000, CELL DEATH DIFFER, V7, P697, DOI 10.1038/sj.cdd.4400701; Lee LA, 1996, J CLIN INVEST, V97, P1687, DOI 10.1172/JCI118595; Lewis BC, 1997, MOL CELL BIOL, V17, P4967, DOI 10.1128/MCB.17.9.4967; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; MAI S, 1995, NUCLEIC ACIDS RES, V23, P1, DOI 10.1093/nar/23.1.1; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; Nesbit CE, 1998, CELL GROWTH DIFFER, V9, P731; Nesbit CE, 2000, ONCOGENE, V19, P3200, DOI 10.1038/sj.onc.1203636; Nolan GP, 1998, CURR OPIN BIOTECH, V9, P447, DOI 10.1016/S0958-1669(98)80027-X; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Oster SK, 2000, MOL CELL BIOL, V20, P6768, DOI 10.1128/MCB.20.18.6768-6778.2000; Park DS, 2001, BIOCHEMISTRY-US, V40, P3354, DOI 10.1021/bi002787b; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; SMALL MB, 1987, MOL CELL BIOL, V7, P1638, DOI 10.1128/MCB.7.5.1638; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Wang XY, 1999, MOL ENDOCRINOL, V13, P254, DOI 10.1210/me.13.2.254; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198; Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245	53	64	66	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 3	2003	22	13					1998	2010		10.1038/sj.onc.1206228	http://dx.doi.org/10.1038/sj.onc.1206228			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	662UR	12673205				2022-12-28	WOS:000181967700010
J	Su, ZZ; Lebedeva, IV; Sarkar, D; Gopalkrishnan, RV; Sauane, M; Sigmon, C; Yacoub, A; Valerie, K; Dent, P; Fisher, PB				Su, ZZ; Lebedeva, IV; Sarkar, D; Gopalkrishnan, RV; Sauane, M; Sigmon, C; Yacoub, A; Valerie, K; Dent, P; Fisher, PB			Melanoma differentiation associated gene-7, mda-7/IL-24, selectively induces growth suppression, apoptosis and radiosensitization in malignant gliomas in a p53-independent manner	ONCOGENE			English	Article						cancer gene therapy; malignant brain tumors; apoptosis; radiosensitization	IMMUNODEFICIENCY-VIRUS TYPE-1; SUBTRACTION HYBRIDIZATION; MITOCHONDRIAL DYSFUNCTION; TRANSGENE EXPRESSION; MDA-7 EXPRESSION; LEUKEMIA-CELLS; CANCER CELLS; THERAPY; DNA; IDENTIFICATION	Malignant gliomas are extremely aggressive cancers currently lacking effective treatment modalities. Gene therapy represents a promising approach for this disease. A requisite component for improving gene-based therapies of brain cancer includes tumor suppressor genes that exhibit cancer constrained inhibitory activity. Subtraction hybridization identified melanoma differentiation associated gene-7 (mda-7) as a gene associated with melanoma cell growth, differentiation and progression. Ectopic expression of mda-7 by means of a replication-incompetent adenovirus (Ad), Ad.mda-7, induces growth suppression and apoptosis selectively in diverse human cancers, without producing any apparent harmful effect in normal cells. We presently demonstrate that Ad.mda-7 induces growth inhibition and apoptosis in malignant human gliomas expressing both mutant and wild-type p53, and these effects correlate with an elevation in expression of members of the growth arrest and DNA damage (GADD) gene family. In contrast, infection with a recombinant Ad expressing wild-type p53, Ad.wtp53, specifically affects mutant p53 expressing gliomas. When tested in early passage normal and immortal human fetal astrocytes, growth inhibition resulting from infection with Ad.mda-7 or Ad.wtp53 is significantly less than in malignant gliomas and no toxicity is evident in these normal cells. Moreover, infection of gliomas with Ad.mda-7 or treatment with purified GST-MDA-7 protein sensitizes both wild-type and mutant p53 expressing tumor cells to the growth inhibitory and antisurvival effects of ionizing radiation, and this response correlates with increased expression of specific members of the GADD gene family. Since heterogeneity in p53 expression is common in evolving gliomas, the present findings suggest that Ad.mda-7 may, in many instances, prove more beneficial for the gene-based therapy of malignant gliomas than administration of wild-type p53.	Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA; Columbia Univ, Coll Phys & Surg, Dept Urol, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Neurosurg, New York, NY 10032 USA	Columbia University; Virginia Commonwealth University; Columbia University; Columbia University	Fisher, PB (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Pathol, BB-1501,630 W 168th St, New York, NY 10032 USA.	pbf1@columbia.edu	Valerie, Kristoffer/AAL-8299-2021; Lebedeva, Irina V/A-3156-2008	Lebedeva, Irina V/0000-0002-1693-9392	NATIONAL CANCER INSTITUTE [R01CA035675, R01CA097318, R01CA088906] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052825] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS031492] Funding Source: NIH RePORTER; NCI NIH HHS [CA35675, CA88906, CA97318] Funding Source: Medline; NIDDK NIH HHS [DK52825] Funding Source: Medline; NINDS NIH HHS [NS31492] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alavi JB, 1998, HEMATOL ONCOL CLIN N, V12, P617, DOI 10.1016/S0889-8588(05)70011-3; Alemany R, 1999, EXP CELL RES, V252, P1, DOI 10.1006/excr.1999.4623; Alexander E, 1998, SEMIN SURG ONCOL, V14, P43; Amundson SA, 1998, ONCOGENE, V17, P2149, DOI 10.1038/sj.onc.1202136; Bencheikh M, 1999, J NEUROVIROL, V5, P115, DOI 10.3109/13550289909021993; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Broaddus WC, 1999, J NEUROSURG, V91, P997, DOI 10.3171/jns.1999.91.6.0997; Canki M, 2001, J VIROL, V75, P7925, DOI 10.1128/JVI.75.17.7925-7933.2001; Carrier F, 1998, BIOCHEM PHARMACOL, V55, P853, DOI 10.1016/S0006-2952(97)00592-3; Carter S, 1998, ONCOGENE, V16, P2787, DOI 10.1038/sj.onc.1201802; Caudell EG, 2002, J IMMUNOL, V168, P6041, DOI 10.4049/jimmunol.168.12.6041; Chadbourne DE, 2001, POPTRONICS, V2, P3; Chaiken IM, 1996, TRENDS BIOTECHNOL, V14, P369, DOI 10.1016/0167-7799(96)10050-0; Cirielli C, 1999, J NEURO-ONCOL, V43, P99, DOI 10.1023/A:1006289505801; Dai Y, 2001, CANCER RES, V61, P5106; Dumoutier L, 2001, J IMMUNOL, V167, P3545, DOI 10.4049/jimmunol.167.7.3545; Ekmekcioglu S, 2001, INT J CANCER, V94, P54, DOI 10.1002/ijc.1437; Ellerhorst JA, 2002, J CLIN ONCOL, V20, P1069, DOI 10.1200/JCO.2002.20.4.1069; FALCKPEDERSEN E, 1994, MOL PHARMACOL, V45, P684; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; Fechner H, 2000, GENE THER, V7, P1954, DOI 10.1038/sj.gt.3301321; Gallagher G, 2000, GENES IMMUN, V1, P442, DOI 10.1038/sj.gene.6363714; Gomez-Navarro J, 1999, EUR J CANCER, V35, P2039, DOI 10.1016/S0959-8049(99)00300-7; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Hidaka C, 1999, J CLIN INVEST, V103, P579, DOI 10.1172/JCI5309; Hollander MC, 1997, J BIOL CHEM, V272, P13731, DOI 10.1074/jbc.272.21.13731; Hong YK, 2000, J KOREAN MED SCI, V15, P315, DOI 10.3346/jkms.2000.15.3.315; Huang EY, 2001, ONCOGENE, V20, P7051, DOI 10.1038/sj.onc.1204897; Jiang HP, 1995, ONCOGENE, V11, P2477; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; Kotenko SV, 2001, J BIOL CHEM, V276, P2725, DOI 10.1074/jbc.M007837200; KOTENKO SV, 2002, CYTOKINE GROWTH F R, V217, P1; Kultz D, 1998, J BIOL CHEM, V273, P13645, DOI 10.1074/jbc.273.22.13645; Kurihara H, 2000, GENE THER, V7, P686, DOI 10.1038/sj.gt.3301129; Kyritsis AP, 1996, MOL CARCINOGEN, V15, P1; LANG FF, 1994, ONCOGENE, V9, P949; Lang FF, 1999, NEUROSURGERY, V45, P1093, DOI 10.1097/00006123-199911000-00016; Lebedeva IV, 2002, ONCOGENE, V21, P708, DOI 10.1038/sj.onc.1205116; LEBEDEVA IV, 2003, IN PRESS SEM CANC BI; Levin VA, 1997, CANC PRINCIPLES PRAC; Li DQ, 1999, CLIN CANCER RES, V5, P4175; Madireddi MT, 2000, ADV EXP MED BIOL, V465, P239; McCormick F, 2001, NAT REV CANCER, V1, P130, DOI 10.1038/35101008; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; Mhashilkar AM, 2001, MOL MED, V7, P271, DOI 10.1007/BF03401847; Oh-Hashi K, 2001, FREE RADICAL BIO MED, V30, P213, DOI 10.1016/S0891-5849(00)00461-5; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Parr MJ, 1997, NAT MED, V3, P1145, DOI 10.1038/nm1097-1145; Pataer A, 2002, CANCER RES, V62, P2239; Pearson AS, 1999, CLIN CANCER RES, V5, P4208; PESTKA S, 2002, ENCY HORMONES; Rosato RR, 2001, INT J ONCOL, V19, P181; Saeki T, 2002, ONCOGENE, V21, P4558, DOI 10.1038/sj.onc.1205553; Saeki T, 2000, GENE THER, V7, P2051, DOI 10.1038/sj.gt.3301330; Sarkar D, 2002, P NATL ACAD SCI USA, V99, P10054, DOI 10.1073/pnas.152327199; Sarkar D, 2002, BIOTECHNIQUES, P30; Sauane M, 2003, CYTOKINE GROWTH F R, V14, P35, DOI 10.1016/S1359-6101(02)00074-6; Shono T, 2002, CANCER RES, V62, P1069; Su ZZ, 1997, P NATL ACAD SCI USA, V94, P9125, DOI 10.1073/pnas.94.17.9125; Su ZZ, 1999, P NATL ACAD SCI USA, V96, P15115, DOI 10.1073/pnas.96.26.15115; Su ZZ, 2001, P NATL ACAD SCI USA, V98, P10332, DOI 10.1073/pnas.171315198; Su ZZ, 2002, ONCOGENE, V21, P3592, DOI 10.1038/sj.onc.1205445; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; VOLKERT FC, 1983, VIROLOGY, V125, P175, DOI 10.1016/0042-6822(83)90072-7; VONDEIMLING A, 1993, BRAIN PATHOL, V3, P19; Vrana JA, 1999, RADIAT RES, V151, P559, DOI 10.2307/3580032; Wang M, 2002, J BIOL CHEM, V277, P7341, DOI 10.1074/jbc.M106043200; WU JK, 1993, AM J HUM GENET, V52, P1273; Xie MH, 2000, J BIOL CHEM, V275, P31335, DOI 10.1074/jbc.M005304200; YOUNG IT, 1977, J HISTOCHEM CYTOCHEM, V25, P935, DOI 10.1177/25.7.894009; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zhang R, 2000, J BIOL CHEM, V275, P24436, DOI 10.1074/jbc.M001958200	76	158	188	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2003	22	8					1164	1180		10.1038/sj.onc.1206062	http://dx.doi.org/10.1038/sj.onc.1206062			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650EK	12606943				2022-12-28	WOS:000181249700005
J	Kim, Y; Park, H; Lim, Y; Han, I; Kwon, HJ; Woods, A; Oh, ES				Kim, Y; Park, H; Lim, Y; Han, I; Kwon, HJ; Woods, A; Oh, ES			Decreased syndecan-2 expression correlates with trichostatin-A induced-morphological changes and reduced tumorigenic activity in colon carcinoma cells	ONCOGENE			English	Article						colon carcinoma; historic deacetylase syndecan-2; tumorigenesis	HISTONE DEACETYLASES; INHIBITION; MODULATION; REVERSION; GROWTH	The inhibition of histone deacetylase activity is known to induce morphological changes of transformed cells. In this study, we investigated the effect of the specific HDAC inhibitor, trichostatin A (TSA), on colon carcinoma cell lines. Treatment of human colorectal carcinoma cells, KM1214 and KM12SM, with TSA induced distinct morphological changes. Both cell lines, which normally piled up in layers without clear boundary, became more flattened, and formed monolayers with evident boundaries between cells, with concomitant increased actin filament organization. Cell-cell interaction was not affected much, based on expression level, membrane localization, and interaction of E-cadherin with P-catenin. In contrast, syndecan-2 expression was dramatically reduced and it was correlated with the morphological changes of colon carcinoma cells. Consistently, downregulation of syndecan-2 expression by antisense cDNA clearly mimicked the morphological changes in KM12SM and reduced anchorage-independent growth of colon cancer cells. All these results indicate that reduced syndecan-2 expression correlates with TSA-induced morphological changes and reduced tumorigenic activity in colon carcinoma cells.	Ewha Womans Univ, Dept Life Sci, Div Mol Life Sci, Seoul 120750, South Korea; Ewha Womans Univ, Ctr Cell Signaling Res, Seoul 120750, South Korea; Natl Caner Canc, Div Radiat & Nucl Med Radiat, Med Branch, Gyeonggi 411764, South Korea; Sejong Univ, Inst Biosci, Dept Biosci & Biotechnol, Seoul 143747, South Korea; Univ Alabama Birmingham, Dept Cell Biol & Cell Adhes, Matrix Res Ctr, Birmingham, AL 35294 USA	Ewha Womans University; Ewha Womans University; National Cancer Center - Korea (NCC); Sejong University; University of Alabama System; University of Alabama Birmingham	Oh, ES (corresponding author), Ewha Womans Univ, Dept Life Sci, Div Mol Life Sci, Seoul 120750, South Korea.	OhES@mm.ewha.ac.kr	권, 호정/AAS-3642-2021					BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; Couchman JR, 1999, J CELL SCI, V112, P3415; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; HOSHIKAWA Y, 1994, EXP CELL RES, V214, P189, DOI 10.1006/excr.1994.1248; Inki P, 1996, ANN MED, V28, P63, DOI 10.3109/07853899608999076; Jayson GC, 1999, INT J CANCER, V82, P298, DOI 10.1002/(SICI)1097-0215(19990719)82:2<298::AID-IJC23>3.3.CO;2-0; Kusano Y, 2000, EXP CELL RES, V256, P434, DOI 10.1006/excr.2000.4802; Kwon HJ, 1998, P NATL ACAD SCI USA, V95, P3356, DOI 10.1073/pnas.95.7.3356; LEPPA S, 1992, P NATL ACAD SCI USA, V89, P932, DOI 10.1073/pnas.89.3.932; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; RACHEL BH, 2000, J CELL BIOL, V148, P779; Rapraeger AC, 2000, J CELL BIOL, V149, P995, DOI 10.1083/jcb.149.5.995; SEALY L, 1978, CELL, V14, P115, DOI 10.1016/0092-8674(78)90306-9; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; SUGITA K, 1992, CANCER RES, V52, P168; Wiksten JP, 2001, INT J CANCER, V95, P1, DOI 10.1002/1097-0215(20010120)95:1<1::AID-IJC1000>3.0.CO;2-5; Woods A, 2000, J BIOL CHEM, V275, P24233, DOI 10.1074/jbc.R000001200; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zimmermann P, 1999, FASEB J, V13, pS91	19	29	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2003	22	6					826	830		10.1038/sj.onc.1206068	http://dx.doi.org/10.1038/sj.onc.1206068			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584561				2022-12-28	WOS:000180864300004
J	Curino, A; Mitola, DJ; Aaronson, H; McMahon, GA; Raja, K; Keegan, AD; Lawrence, DA; Bugge, TH				Curino, A; Mitola, DJ; Aaronson, H; McMahon, GA; Raja, K; Keegan, AD; Lawrence, DA; Bugge, TH			Plasminogen promotes sarcoma growth and suppresses the accumulation of tumor-infiltrating macrophages	ONCOGENE			English	Review						fibrosarcoma; tumor-infiltrating macrophages; plasminogen activator; stroma	RECEPTOR-BOUND UROKINASE; LEWIS LUNG-CARCINOMA; SPONTANEOUS METASTASIS MODEL; SQUAMOUS-CELL CARCINOMA; GENE-INACTIVATED MICE; HUMAN COLON-CANCER; LATENT TGF-BETA; ACTIVATOR INHIBITOR-1; DEFICIENT MICE; BREAST-CANCER	The specific functions of plasminogen, stromal plasminogen activator, stromal plasminogen activator receptor, and stromal plasminogen activator inhibitor in the progression of the murine soft tissue sarcoma, T241 were investigated. Negation of plasminogen to the tumor blunted the orthotopic growth of the sarcoma in syngeneic mice. The reduced tumor growth was associated with a dramatic increase in tumor-infiltrating F4/80-positive macrophages and a diminution of vessel density, but not with obvious differences in fibrin and collagen deposition, or invasiveness of the tumor. Ablation of plasminogen activation by the tumor stroma only modestly impaired the prolonged growth of the sarcoma, suggesting that tumor cell-produced plasminogen activator is sufficient to mediate productive plasminogen activation. Plasminogen facilitated sarcoma progression, angiogenesis, and suppression of macrophage infiltration in the absence of either stromal urokinase plasminogen activator receptor or stromal plasminogen activator inhibitor. These data demonstrate that tumor cell-produced plasminogen activator and host plasminogen cooperate to facilitate soft tissue sarcoma growth and suppress the accumulation of tumor-infiltrating macrophages.	Natl Inst Dent Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; Amer Red Cross, Dept Immunol, Rockville, MD 20855 USA; Amer Red Cross, Dept Vasc Biol, Rockville, MD 20855 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); American Red Cross; American Red Cross	Bugge, TH (corresponding author), Natl Inst Dent Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, 30 Convent Dr, Bethesda, MD 20892 USA.			Lawrence, Daniel/0000-0003-3126-1935	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054710, R01HL055747] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000699] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL55747, P01 HL54710] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEVA DG, 1994, J IMMUNOL, V153, P1674; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; BAKER MS, 1990, CANCER RES, V50, P4676; Beck JM, 1999, INFECT IMMUN, V67, P879, DOI 10.1128/IAI.67.2.879-884.1999; Blasi F, 1999, APMIS, V107, P96, DOI 10.1111/j.1699-0463.1999.tb01531.x; BOER PH, 1990, BIOCHEM GENET, V28, P299, DOI 10.1007/BF02401419; Bugge TH, 1996, P NATL ACAD SCI USA, V93, P5899, DOI 10.1073/pnas.93.12.5899; Bugge TH, 1997, BLOOD, V90, P4522; Bugge TH, 1998, ONCOGENE, V16, P3097, DOI 10.1038/sj.onc.1201869; BUGGE TH, 1995, J BIOL CHEM, V270, P16886, DOI 10.1074/jbc.270.28.16886; BUGGE TH, 1995, GENE DEV, V9, P794, DOI 10.1101/gad.9.7.794; Bugge TH, 1996, CELL, V87, P709, DOI 10.1016/S0092-8674(00)81390-2; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; Chapman HA, 2001, THROMB HAEMOSTASIS, V86, P124; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; CUBELLIS MV, 1989, P NATL ACAD SCI USA, V86, P4828, DOI 10.1073/pnas.86.13.4828; Dano K, 1999, APMIS, V107, P120, DOI 10.1111/j.1699-0463.1999.tb01534.x; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; De Petro G, 1998, CANCER RES, V58, P2234; DECLERCK PJ, 1995, THROMB HAEMOSTASIS, V74, P1305; DECLERCK PJ, 1995, J BIOL CHEM, V270, P8397, DOI 10.1074/jbc.270.15.8397; Devy L, 2002, FASEB J, V16, DOI 10.1096/fj.01-0552com; DiNapoli MR, 1996, J EXP MED, V183, P1323, DOI 10.1084/jem.183.4.1323; Dublin E, 2000, AM J PATHOL, V157, P1219, DOI 10.1016/S0002-9440(10)64637-8; DUFFY MJ, 1990, CANCER RES, V50, P6827; Elgert KD, 1998, J LEUKOCYTE BIOL, V64, P275, DOI 10.1002/jlb.64.3.275; ELLIS V, 1991, J BIOL CHEM, V266, P12752; ELLIS V, 1990, J BIOL CHEM, V265, P9904; ELLIS V, 1991, SEMIN THROMB HEMOST, V17, P194, DOI 10.1055/s-2007-1002609; FOEKENS JA, 1992, CANCER RES, V52, P6101; GANESH S, 1994, LANCET, V344, P401, DOI 10.1016/S0140-6736(94)91427-3; GANESH S, 1994, CANCER RES, V54, P4065; GERAN RI, 1972, CANC CHEMOTHER REP, V3, P1; Goguen JD, 2000, METHODS, V21, P179, DOI 10.1006/meth.2000.0989; GRONDAHLHANSEN J, 1993, CANCER RES, V53, P2513; Gutierrez LS, 2000, CANCER RES, V60, P5839; HALL SW, 1991, J BIOL CHEM, V266, P12329; HEARING VJ, 1988, CANCER RES, V48, P1270; HEISS MM, 1995, NAT MED, V1, P1035, DOI 10.1038/nm1095-1035; HIENERT G, 1988, J UROLOGY, V140, P1466, DOI 10.1016/S0022-5347(17)42074-X; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Hotary KB, 2002, J EXP MED, V195, P295, DOI 10.1084/jem.20010815; Hudson MA, 1997, J NATL CANCER I, V89, P709, DOI 10.1093/jnci/89.10.709; KOBAYASHI H, 1994, THROMB HAEMOSTASIS, V71, P474; KOBAYASHI H, 1994, INT J CANCER, V57, P727, DOI 10.1002/ijc.2910570520; Kono K, 1996, EUR J IMMUNOL, V26, P1308, DOI 10.1002/eji.1830260620; KOOK YH, 1994, EMBO J, V13, P3983, DOI 10.1002/j.1460-2075.1994.tb06714.x; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Lanza F, 1998, BRIT J HAEMATOL, V103, P110; Lee SL, 2000, J BIOL CHEM, V275, P36720, DOI 10.1074/jbc.M007802200; Leek RD, 2000, J PATHOL, V190, P430, DOI 10.1002/(SICI)1096-9896(200003)190:4<430::AID-PATH538>3.0.CO;2-6; Leek RD, 1996, CANCER RES, V56, P4625; Leethanakul C, 2000, ONCOGENE, V19, P3220, DOI 10.1038/sj.onc.1203703; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; List K, 2000, BIOCHEMISTRY-US, V39, P508, DOI 10.1021/bi991701f; Loskutoff DJ, 1999, APMIS, V107, P54, DOI 10.1111/j.1699-0463.1999.tb01526.x; Lund LR, 1999, EMBO J, V18, P4645, DOI 10.1093/emboj/18.17.4645; MANTOVANI A, 1992, IMMUNOL TODAY, V13, P265, DOI 10.1016/0167-5699(92)90008-U; Martin DC, 1999, J CELL BIOL, V146, P881, DOI 10.1083/jcb.146.4.881; May AE, 1998, J EXP MED, V188, P1029, DOI 10.1084/jem.188.6.1029; McMahon GA, 2001, J BIOL CHEM, V276, P33964, DOI 10.1074/jbc.M105980200; Min HY, 1996, CANCER RES, V56, P2428; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; Morita S, 1998, INT J CANCER, V78, P286, DOI 10.1002/(SICI)1097-0215(19981029)78:3<286::AID-IJC4>3.0.CO;2-R; MUELLER BM, 1995, P NATL ACAD SCI USA, V92, P205, DOI 10.1073/pnas.92.1.205; NEKARDA H, 1994, LANCET, V343, P117, DOI 10.1016/S0140-6736(94)90845-1; Nicole O, 2001, NAT MED, V7, P59, DOI 10.1038/83358; Nielsen BS, 1996, LAB INVEST, V74, P168; ODEKON LE, 1994, J CELL PHYSIOL, V158, P398, DOI 10.1002/jcp.1041580303; OHMORI T, 1995, HISTOL HISTOPATHOL, V10, P789; OKA T, 1991, CANCER RES, V51, P3522; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Ossowski L, 2000, CURR OPIN CELL BIOL, V12, P613, DOI 10.1016/S0955-0674(00)00140-X; OSSOWSKI L, 1988, CELL, V52, P321, DOI 10.1016/S0092-8674(88)80025-4; OSSOWSKI L, 1983, CELL, V35, P611, DOI 10.1016/0092-8674(83)90093-4; PEDERSEN H, 1994, CANCER RES, V54, P4671; Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445; Platt N, 1998, TRENDS CELL BIOL, V8, P365, DOI 10.1016/S0962-8924(98)01329-4; PLESNER T, 1994, AM J CLIN PATHOL, V102, P835, DOI 10.1093/ajcp/102.6.835; PLOW EF, 1986, J IMMUNOL, V137, P1910; PLOW EF, 1986, J CELL BIOL, V103, P2411, DOI 10.1083/jcb.103.6.2411; PRENDERGAST GC, 1990, MOL CELL BIOL, V10, P1265, DOI 10.1128/MCB.10.3.1265; PYKE C, 1991, CANCER RES, V51, P4067; PYKE C, 1994, HISTOPATHOLOGY, V24, P131, DOI 10.1111/j.1365-2559.1994.tb01291.x; PYKE C, 1993, CANCER RES, V53, P1911; PYKE C, 1991, AM J PATHOL, V138, P1059; Rabbani SA, 1995, INT J CANCER, V63, P840, DOI 10.1002/ijc.2910630615; Rifkin DB, 1999, APMIS, V107, P80, DOI 10.1111/j.1699-0463.1999.tb01529.x; Rogove AD, 1999, J CELL SCI, V112, P4007; Romisch J, 1999, HAEMOSTASIS, V29, P292; Sabapathy KT, 1997, J CELL BIOL, V137, P953, DOI 10.1083/jcb.137.4.953; SATO Y, 1990, J CELL BIOL, V111, P757, DOI 10.1083/jcb.111.2.757; SAWAYA R, 1988, J NEUROSURG, V68, P73, DOI 10.3171/jns.1988.68.1.0073; Schmidt M, 2000, HEAD NECK-J SCI SPEC, V22, P498, DOI 10.1002/1097-0347(200008)22:5<498::AID-HED9>3.0.CO;2-W; Shapiro RL, 1996, CANCER RES, V56, P3597; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Sier CFM, 1998, CANCER RES, V58, P1843; SIMON DI, 1993, BLOOD, V82, P2414; SKRIVER L, 1984, Journal of Cell Biology, V99, P752; Solberg H, 2001, J HISTOCHEM CYTOCHEM, V49, P237, DOI 10.1177/002215540104900211; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Stefansson S, 2001, J BIOL CHEM, V276, P8135, DOI 10.1074/jbc.M007609200; SUNDERKOTTER C, 1994, J LEUKOCYTE BIOL, V55, P410, DOI 10.1002/jlb.55.3.410; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Taniguchi T, 1998, CANCER RES, V58, P4461; Wahl LM, 1998, J NATL CANCER I, V90, P1583, DOI 10.1093/jnci/90.21.1583; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Whitelock JM, 1996, J BIOL CHEM, V271, P10079, DOI 10.1074/jbc.271.17.10079; YU H, 1990, CANCER RES, V50, P7623	113	22	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 12	2002	21	57					8830	8842		10.1038/sj.onc.1205951	http://dx.doi.org/10.1038/sj.onc.1205951			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483535				2022-12-28	WOS:000179734400016
J	Perry, C; Sklan, EH; Birikh, K; Shapira, M; Trejo, L; Eldor, A; Soreq, H				Perry, C; Sklan, EH; Birikh, K; Shapira, M; Trejo, L; Eldor, A; Soreq, H			Complex regulation of acetylcholinesterase gene expression in human brain tumors	ONCOGENE			English	Article						acetylcholinesterase; human brain tumors; Runx1; AML1	TISSUE-SPECIFIC EXPRESSION; ENDOTHELIAL GROWTH-FACTOR; TRANSCRIPTION FACTOR; NEURONAL DIFFERENTIATION; SPLICE VARIANTS; CELL-GROWTH; BUTYRYLCHOLINESTERASE; PROTEIN; LEUKEMIA; FORMS	To study the regulation of acetylcholinesterase (AChE) gene expression in human brain tumors, 3' splice variants of AChE mRNA and potentially relevant transcription factor mRNAs were labeled in primary astrocytomas and melanomas. AChE-S and AChE-R mRNA, as well as Runx1/AML1 mRNA accumulated in astrocytomas in correlation with tumor aggressiveness, but neither HNF3beta nor c-fos mRNA was observed in melanoma and astrocytomas. immunohistochemistry demonstrated nuclear Runx1/AML1 and cellular AChE-S and AChE-R in melanomas, however, only AChE-S, and not the secreted AChE-R variant, was retained in astrocyte tumor cells. Runx1/AML1 revealed weak linkage with ACHE promoter sequences, yet enhanced ACHE gene expression in co-transfected COS1 cells. The p300 coactivator and the ACHE promoter's distal enhancer facilitated this effect, which was independent of much of the Runx1/AML1 trans-activation domain. Surprisingly, GASP, a fusion product of green fluorescence protein (GFP) and ASP(67), a peptide composed of the 67 C-terminal amino acid residues of AChE-S, localized to COS1 cell nuclei. However, GARP, the corresponding fusion product of GFP with a peptide having the 51 C-terminal residues of AChE-E or GFP alone, remained cytoplasmic. Runx1/AML1 exhibited improved nuclear retention in GASP-expressing COS1 cells, suggesting modulated nuclear localization processes. Together, these findings reveal brain tumor-specific regulation of both expression and cellular retention of variant ACHE gene products.	Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel; Tel Aviv Sourasky Med Ctr, Dept Hematol, IL-64239 Tel Aviv, Israel; Tel Aviv Univ, IL-64239 Tel Aviv, Israel; Tel Aviv Sourasky Med Ctr, Dept Pathol, IL-64239 Tel Aviv, Israel; Tel Aviv Univ, IL-64239 Tel Aviv, Israel; RAS, Shemyakin Ovchinnikov Inst Bioorgan Chem, Moscow 117799, Russia	Hebrew University of Jerusalem; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences	Soreq, H (corresponding author), Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel.	soreq@cc.huji.ac.il	Birikh, Klara/AAO-4069-2021	Birikh, Klara/0000-0001-6124-447X; Soreq, Hermona/0000-0002-0955-526X				ACHESON AL, 1984, J NEUROSCI, V4, P1771; ALOYA RB, 1993, P NATL ACAD SCI USA, V90, P2471; Barbosa M, 2001, SURG NEUROL, V55, P106, DOI 10.1016/S0090-3019(01)00351-2; BEERI R, 1995, CURR BIOL, V5, P1063, DOI 10.1016/S0960-9822(95)00211-9; Ben Aziz-Aloya R, 1998, CELL DEATH DIFFER, V5, P765, DOI 10.1038/sj.cdd.4400415; BERGER R, 1985, CYTOGENET CELL GENET, V40, P490, DOI 10.1159/000132181; Bigbee JW, 1999, ENVIRON HEALTH PERSP, V107, P81, DOI 10.2307/3434475; BROWN LM, 1990, CANCER RES, V50, P6585; Chan RYY, 1999, P NATL ACAD SCI USA, V96, P4627, DOI 10.1073/pnas.96.8.4627; Coleman BA, 1996, J BIOL CHEM, V271, P4410; DAUMASDUPORT C, 1988, CANCER-AM CANCER SOC, V62, P2152, DOI 10.1002/1097-0142(19881115)62:10<2152::AID-CNCR2820621015>3.0.CO;2-T; DUFFY JB, 1991, DEVELOPMENT, V113, P1223; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EHRLICH G, 1992, GENOMICS, V13, P1192, DOI 10.1016/0888-7543(92)90037-S; Etoh T, 2000, GUT, V47, P50, DOI 10.1136/gut.47.1.50; GETMAN DK, 1992, AM J HUM GENET, V51, P170; GETMAN DK, 1995, J BIOL CHEM, V270, P23511, DOI 10.1074/jbc.270.40.23511; Goodman RH, 2000, GENE DEV, V14, P1553; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Grisaru D, 1999, MOL CELL BIOL, V19, P788; Grisaru D, 1999, EUR J BIOCHEM, V264, P672, DOI 10.1046/j.1432-1327.1999.00693.x; Grisaru D, 2001, MOL MED, V7, P93, DOI 10.1007/BF03401943; Haas R, 1996, BIOCHEM J, V314, P817, DOI 10.1042/bj3140817; Karpel R, 1996, J NEUROCHEM, V66, P114; KARPEL R, 1994, EXP CELL RES, V210, P268, DOI 10.1006/excr.1994.1039; Kataoka H, 2000, MECH DEVELOP, V98, P139, DOI 10.1016/S0925-4773(00)00445-7; Kaufer D, 1998, NATURE, V393, P373, DOI 10.1038/30741; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Kitange G, 1999, MODERN PATHOL, V12, P618; Koenigsberger C, 1997, J NEUROCHEM, V69, P1389; LAPIDOTLIFSON Y, 1989, P NATL ACAD SCI USA, V86, P4715, DOI 10.1073/pnas.86.12.4715; LeBeau MM, 1996, BLOOD, V88, P1930; LI Y, 1991, J BIOL CHEM, V266, P23083; Li YK, 2000, J NEUROSCI, V20, P149, DOI 10.1523/JNEUROSCI.20-01-00149.2000; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Meshorer E, 2002, SCIENCE, V295, P508, DOI 10.1126/science.1066752; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Namba K, 2000, ONCOGENE, V19, P106, DOI 10.1038/sj.onc.1203257; Neskovic-Konstantinovic Z, 1999, J EXP CLIN CANC RES, V18, P347; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Perry C, 2002, LEUKEMIA RES, V26, P221, DOI 10.1016/S0145-2126(01)00128-X; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RAZON N, 1984, EXP NEUROL, V84, P681, DOI 10.1016/0014-4886(84)90215-2; Rolhion C, 2001, J NEUROSURG, V94, P97, DOI 10.3171/jns.2001.94.1.0097; SaezValero J, 1996, BBA-MOL BASIS DIS, V1317, P210, DOI 10.1016/S0925-4439(96)00061-0; SaezValero J, 1996, NEUROSCI LETT, V206, P173, DOI 10.1016/S0304-3940(96)12452-6; SEIDMAN S, 1995, MOL CELL BIOL, V15, P2993; Shapira M, 2000, HUM MOL GENET, V9, P1273, DOI 10.1093/hmg/9.9.1273; Shohami E, 2000, J MOL MED-JMM, V78, P228, DOI 10.1007/s001090000104; Silverman E, 1999, J BIOL CHEM, V274, P17987, DOI 10.1074/jbc.274.25.17987; SOREQ H, 1984, EMBO J, V3, P1371, DOI 10.1002/j.1460-2075.1984.tb01979.x; Soreq H, 2001, NAT REV NEUROSCI, V2, P294, DOI 10.1038/35067589; Sternfeld M, 2000, P NATL ACAD SCI USA, V97, P8647, DOI 10.1073/pnas.140004597; Valter MM, 1999, CANCER RES, V59, P5608; VELAN B, 1994, J BIOL CHEM, V269, P22719; Welker P, 2000, BRIT J CANCER, V82, P1453, DOI 10.1054/bjoc.1999.1076; Westendorf JJ, 1999, J CELL BIOCHEM, P51; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Yamada M, 1996, J NEUROSCI RES, V43, P355, DOI 10.1002/(SICI)1097-4547(19960201)43:3<355::AID-JNR10>3.0.CO;2-4; ZAKUT H, 1988, CANCER, V61, P727, DOI 10.1002/1097-0142(19880215)61:4<727::AID-CNCR2820610416>3.0.CO;2-L; Zhang HT, 2000, BRIT J CANCER, V83, P63	61	72	77	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	2002	21	55					8428	8441		10.1038/sj.onc.1205945	http://dx.doi.org/10.1038/sj.onc.1205945			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466963				2022-12-28	WOS:000179480100006
J	Nishimori, H; Sasaki, Y; Yoshida, K; Irifune, H; Zembutsu, H; Tanaka, T; Aoyama, T; Hosaka, T; Kawaguchi, S; Wada, T; Hata, J; Toguchida, J; Nakamura, Y; Tokino, T				Nishimori, H; Sasaki, Y; Yoshida, K; Irifune, H; Zembutsu, H; Tanaka, T; Aoyama, T; Hosaka, T; Kawaguchi, S; Wada, T; Hata, J; Toguchida, J; Nakamura, Y; Tokino, T			The Id2 gene is a novel target of transcriptional activation by EWS-ETS fusion proteins in Ewing family tumors	ONCOGENE			English	Article						ld2; EWS-ETS; Ewing family tumor	DNA-BINDING; CHROMOSOME-TRANSLOCATION; SARCOMA TRANSLOCATION; MOLECULAR ANALYSIS; CDNA MICROARRAY; CELLS; EXPRESSION; CANCER; FUSES; ERG	We report here that the Id2 (inhibitor of DNA binding 2) gene is a novel target of transcriptional activation by EWS-FLI1 and EWS-ERG, two fusion proteins that characterize Ewing family tumors (EFTs). To identify downstream targets of these EWS-ETS fusion proteins, we introduced EWS-ETS fusion constructs into a human fibrosarcoma cell line by retroviral transduction. cDNA microarray analysis revealed that Id2 expression was up-regulated by introducing the EWS-ETS fusion gene but not by the normal full-length ETS gene. An Id2 promoter-luciferase reporter assay showed that transactivation by EWS-ETS involves the minimal Id2 promoter and may function in cooperation with c-Myc within the full-length regulatory region. A chromatin immunoprecipitation assay revealed direct interaction between the Id2 promoter and EWS-FLI1 fusion protein in vivo. Significantly higher expression of Id2 and c-Myc was observed in all of the six EFT cell lines examined compared to six other sarcoma cell lines. Moreover, high levels of Id2 expression were also observed in five of the six primary tumors examined. Id2 is generally thought to affect the balance between cell differentiation and proliferation in development and is highly expressed in several cancer types. Considering these previous studies, our data suggest that the oncogenic effect of EWS-ETS may be mediated in part by up-regulating Id2 expression.	Sapporo Med Univ, Sch Med, Inst Canc Res, Dept Mol Biol,Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Sapporo Med Univ, Sch Med, Dept Orthoped Surg, Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Univ Tokyo, Inst Med Sci, Mol Med Lab, Ctr Human Genome,Minato Ku, Tokyo 1088639, Japan; Kyoto Univ, Inst Frontier Med Sci, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Fac Med, Dept Orthoped Surg, Sakyo Ku, Kyoto 6068507, Japan; Keio Univ, Sch Med, Dept Pathol, Shinjuku Ku, Tokyo 1608582, Japan	Sapporo Medical University; Sapporo Medical University; University of Tokyo; Kyoto University; Kyoto University; Keio University	Tokino, T (corresponding author), Sapporo Med Univ, Sch Med, Inst Canc Res, Dept Mol Biol,Chuo Ku, S-1,W-17, Sapporo, Hokkaido 0608556, Japan.		Tanaka, Toshihiro/J-9310-2014; Sasaki, Yasushi/AAA-3079-2019; Tokino, Takashi/AAI-9887-2021	Tanaka, Toshihiro/0000-0001-6201-9784; Sasaki, Yasushi/0000-0002-3500-8059; 				Arvand A, 1998, ONCOGENE, V17, P2039, DOI 10.1038/sj.onc.1202129; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Dauphinot L, 2001, ONCOGENE, V20, P3258, DOI 10.1038/sj.onc.1204437; de Alava E, 2000, CANCER-AM CANCER SOC, V89, P783, DOI 10.1002/1097-0142(20000815)89:4<783::AID-CNCR10>3.0.CO;2-Q; DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; GIOVANNINI M, 1994, J CLIN INVEST, V94, P489, DOI 10.1172/JCI117360; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Ishida S, 2000, JPN J CANCER RES, V91, P174, DOI 10.1111/j.1349-7006.2000.tb00929.x; JEON IS, 1995, ONCOGENE, V10, P1229; Kaneko Y, 1996, GENE CHROMOSOME CANC, V15, P115, DOI 10.1002/(SICI)1098-2264(199602)15:2<115::AID-GCC6>3.0.CO;2-6; Kihara C, 2001, CANCER RES, V61, P6474; Kleeff J, 1998, CANCER RES, V58, P3769; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lasorella A, 2001, ONCOGENE, V20, P8326, DOI 10.1038/sj.onc.1205093; Lopez-Guerrero JA, 2001, LAB INVEST, V81, P803, DOI 10.1038/labinvest.3780290; MAO XH, 1994, J BIOL CHEM, V269, P18216; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Morimoto I, 2002, GENE CHROMOSOME CANC, V33, P270, DOI 10.1002/gcc.10020; Ono K, 2000, CANCER RES, V60, P5007; OUCHIDA M, 1995, ONCOGENE, V11, P1049; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; Rockman SP, 2001, J BIOL CHEM, V276, P45113, DOI 10.1074/jbc.M107742200; Sasaki Y, 2002, J BIOL CHEM, V277, P719, DOI 10.1074/jbc.M108080200; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Tanaka K, 1997, J CLIN INVEST, V99, P239, DOI 10.1172/JCI119152; Thompson AD, 1996, ONCOGENE, V13, P2649; Urano F, 1998, JPN J CANCER RES, V89, P703, DOI 10.1111/j.1349-7006.1998.tb03274.x; Urano F, 1996, BIOCHEM BIOPH RES CO, V219, P608, DOI 10.1006/bbrc.1996.0281; WEI G, 2000, CANCER, V89, P783; Yokota Y, 2001, ONCOGENE, V20, P8290, DOI 10.1038/sj.onc.1205090; Yokota Y, 1999, NATURE, V397, P702, DOI 10.1038/17812; Zebedee Z, 2001, ONCOGENE, V20, P8317, DOI 10.1038/sj.onc.1205092; Zwerner JP, 2001, ONCOGENE, V20, P626, DOI 10.1038/sj.onc.1204133	38	85	88	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 28	2002	21	54					8302	8309		10.1038/sj.onc.1206025	http://dx.doi.org/10.1038/sj.onc.1206025			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447693				2022-12-28	WOS:000179323900008
J	Pim, D; Thomas, M; Banks, L				Pim, D; Thomas, M; Banks, L			Chimeric HPV E6 proteins allow dissection of the proteolytic pathways regulating different E6 cellular target proteins	ONCOGENE			English	Article						HPV; E6; PDZ; Dlg; MAGI-1	HUMAN-PAPILLOMAVIRUS TYPE-16; LARGE TUMOR-SUPPRESSOR; RECURRENT RESPIRATORY PAPILLOMATOSIS; P53 IN-VITRO; DISCS LARGE; MUTATIONAL ANALYSIS; CERVICAL-CANCER; PDZ DOMAINS; PROGNOSTIC-SIGNIFICANCE; TRANSFORMING FUNCTION	The ability of HPV E6 oneoproteins to induce the degradation of PDZ domain-containing MAGUK proteins correlates with their malignant potential. We previously showed that the HPV-6 E6 protein, when pro-tided with the PDZ-binding domain from HPV-18 E6, acquires the ability to bind the Discs Large (Dlg) turnour suppressor and target it for degradation. Based on this finding we have extended this analysis to E6 proteins from a variety of different papillomavirus types. Cloning a PDZ-binding sequence onto the C-terminus of E6 proteins derived from low-risk mucosal, and low and high-risk cutaneous papillomavirus types, enables them to bind Dlg and a second MAGUK family member, MAGI-1. This renders the mucosally-derived low-risk chimaeric HPV E6 proteins capable of targeting Dlg for degradation, but they are unable to induce significant levels of degradation of MAGI-1. In contrast, none of the E6 proteins derived from cutaneous papillomavirus types induce significant degradation of either MAGI-1 or Dlg when provided with a PDZ-binding domain. These results demonstrate significant differences, both between mucosal and cutaneous HPV E6 proteins and in the pathways required for Dlg and MAGI-1 degradation.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB)	Pim, D (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99,Area Sci Pk, I-34012 Trieste, Italy.	pim@icgeb.org.it						BARNES W, 1988, GYNECOL ONCOL, V29, P267, DOI 10.1016/0090-8258(88)90225-9; Be XB, 2001, BIOCHEMISTRY-US, V40, P1293, DOI 10.1021/bi0019592; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; BURNETT AF, 1992, GYNECOL ONCOL, V47, P343, DOI 10.1016/0090-8258(92)90137-8; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Das K, 2000, J VIROL, V74, P812, DOI 10.1128/JVI.74.2.812-816.2000; Dobrosotskaya I, 1997, J BIOL CHEM, V272, P31589, DOI 10.1074/jbc.272.50.31589; Elbel M, 1997, VIROLOGY, V239, P132, DOI 10.1006/viro.1997.8860; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Gao QS, 2002, CANCER RES, V62, P3315; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Gardiol D, 1998, J GEN VIROL, V79, P1963, DOI 10.1099/0022-1317-79-8-1963; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; Goode S, 1997, GENE DEV, V11, P2532, DOI 10.1101/gad.11.19.2532; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Inoue T, 1998, MOL CARCINOGEN, V21, P215; ISHIWATARI H, 1994, J MED VIROL, V44, P243, DOI 10.1002/jmv.1890440306; Jackson S, 2000, GENE DEV, V14, P3065, DOI 10.1101/gad.182100; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; KURMAN RJ, 1988, AM J OBSTET GYNECOL, V159, P293, DOI 10.1016/S0002-9378(88)80070-X; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; Liu Y, 1999, J VIROL, V73, P7297, DOI 10.1128/JVI.73.9.7297-7307.1999; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; NAKAGAWA S, 1995, VIROLOGY, V212, P535, DOI 10.1006/viro.1995.1511; Petersen BL, 1998, J LARYNGOL OTOL, V112, P1101, DOI 10.1017/S0022215100142586; Pim D, 2000, ONCOGENE, V19, P719, DOI 10.1038/sj.onc.1203374; PIM D, 1994, ONCOGENE, V9, P1869; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Rabah R, 2001, PEDIATR DEVEL PATHOL, V4, P68, DOI 10.1007/s100240010105; Rady PL, 1998, LARYNGOSCOPE, V108, P735, DOI 10.1097/00005537-199805000-00021; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1992, EMBO J, V11, P2425, DOI 10.1002/j.1460-2075.1992.tb05307.x; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Thomas M, 2001, ONCOGENE, V20, P5431, DOI 10.1038/sj.onc.1204719; Thomas M, 2002, ONCOGENE, V21, P5088, DOI 10.1038/sj.onc.1205668; Thomas M, 1999, ONCOGENE, V18, P7690, DOI 10.1038/sj.onc.1202953; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; ZHANG JW, 1995, GYNECOL ONCOL, V57, P170, DOI 10.1006/gyno.1995.1120	46	28	28	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2002	21	53					8140	8148		10.1038/sj.onc.1206026	http://dx.doi.org/10.1038/sj.onc.1206026			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615DW	12444549				2022-12-28	WOS:000179231400007
J	Duval, A; Reperant, M; Hamelin, R				Duval, A; Reperant, M; Hamelin, R			Comparative analysis of mutation frequency of coding and non coding short mononucleotide repeats in mismatch repair deficient colorectal cancers	ONCOGENE			English	Article						short mononucleotide repeats; MSI tumors	REPLICATION ERROR PHENOTYPE; MICROSATELLITE INSTABILITY; FRAMESHIFT MUTATIONS; GENE; COLON; SEQUENCES; RECEPTOR; TUMORS	Coding repeats are usually short mononucleotide tracts (SM7) of 10 or less base pairs in size. A number of such sequences contained in genes suspected to play a role in human carcinogenesis have been found to be mutated in mismatch repair deficient tumors (MSI-H cancers). Because of the high background of instability characterizing these cancers and in the absence of functional criteria, the significance of most frameshift gene alterations is unclear. In the present work, we analysed a series of 22 transcribed but non-coding SMT that are thus unlikely to play a tumorigenic role. Their frequency of size alteration in germline DNA and in DNA from MSI-H and microsatellite stable (MSS) tumors were compared to those previously reported in a series of 25 coding SMT of similar size. Non-coding SMT were either monomorphic or polymorphic in germline DNA whereas coding SMT were all monomorphic. In MSI-H tumors, non-coding SMT showed infrequent alterations (0 - 44%), as opposed to coding SMT which were altered at extremely variable frequencies (0 to 92%). Seven of the 22 non-coding SMT were monomorphic in MSS tumors but presented size alterations in MSI-H tumors with variable frequencies (3-28%). They were thus selected for further comparative statistical analyses for instability in coding SMT in MSI-H colorectal cancers. Only seven out of 25 of the coding SMT showed a significantly higher mutation frequency in these tumors. In the absence of functional criteria, we propose this as a novel and comprehensive approach for distinguishing real target genes amongst the numerous proposed gene mutations. It should allow identification of those that are genuinely selected for during MSI-H tumoral progression from others that play a less important role, if any, in NISI-H carcinogenesis.	CEPH, INSERM, U434, F-75010 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Hamelin, R (corresponding author), CEPH, INSERM, U434, 27 Rue Juliette Dodu, F-75010 Paris, France.							AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Boland CR, 1998, CANCER RES, V58, P5248; Duval A, 1999, CANCER RES, V59, P4213; Duval A, 2002, CANCER RES, V62, P2447; Duval A, 2001, HUM MOL GENET, V10, P513, DOI 10.1093/hmg/10.5.513; Hoang JM, 1997, CANCER RES, V57, P300; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Kim NG, 2001, CANCER RES, V61, P36; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Schwartz S, 1999, CANCER RES, V59, P2995; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; Suzuki K, 2002, CANCER RES, V62, P1961; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Zhang L, 2001, CANCER RES, V61, P3801; Zhou XP, 1998, GENE CHROMOSOME CANC, V21, P101, DOI 10.1002/(SICI)1098-2264(199802)21:2<101::AID-GCC4>3.0.CO;2-4	17	19	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 14	2002	21	52					8062	8066		10.1038/sj.onc.1206013	http://dx.doi.org/10.1038/sj.onc.1206013			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	612VY	12439756				2022-12-28	WOS:000179097200015
J	Kirch, HC; Ruschen, S; Brockmann, D; Esche, H; Horikawa, I; Barrett, JC; Opalka, B; Hengge, UR				Kirch, HC; Ruschen, S; Brockmann, D; Esche, H; Horikawa, I; Barrett, JC; Opalka, B; Hengge, UR			Tumor-specific activation of hTERT-derived promoters by tumor suppressive E1A-mutants involves recruitment of p300/CBP/HAT and suppression of HDAC-1 and defines a combined tumor targeting and suppression system	ONCOGENE			English	Article						E1A; tumor suppressor; hTERT promoter; tumor-specific expression; histone deacetylase	REVERSE-TRANSCRIPTASE GENE; ADENOVIRUS-5 E1A GENE; HISTONE DEACETYLASE; ONCOPROTEIN E1A; MELANOMA-CELLS; C-MYC; TELOMERASE; TRANSFORMATION; PROTEIN; REPRESSION	Adenovirus (Ad) E1A proteins are transcriptional regulators with antioncogenic but also transforming properties. We have previously shown that transformation-defective Ad5 E1A-derivatives are excellent tumor suppressors. For tumor-specific expression of the E1A-derivatives we intend to use tumor specific human telomerase reverse transcriptase (hTER7) core promoters. Here, we show that Spm2 and other E1A proteins with an intact amino terminus activated all hTERT constructs 10-20-fold in malignant tumor cells but not in primary fibroblasts, without affecting the activity of endogenous telomerase. The transcription rate in tumor cells was in the range of transcription from the SV40 promoter, which qualifies an E1A-hTERT system as a putative tumor targeting/expression system. The activation of the hTERT promoter by E1A was enhanced upon deletion of the Wilms' tumor I negative regulatory element and maintained high after deletion of the adjacent c-Myc-responsive E-box, demonstrating an important role of the remaining sequences that contain several Sp1-motifs. E1A-mediated hTERT activation was independent from the presence of the conserved region 3 (CR3) of E1A but dependent on E1A's binding to p300/CBP and recruitment of its histone acetyltransferase activity. Moreover, E1A-Spm2 and histone deacetylase-1 behaved as antagonists with respect to the regulation of transcription from the hTERT promoter. Overall, hTERT promoter/E1A-Spm2 systems may turn out to be excellent tools for transcriptionally targeted anticancer gene therapy.	Univ Essen Gesamthsch, Dept Internal Med Canc Res, D-45147 Essen, Germany; Univ Essen Gesamthsch, Inst Mol Biol Canc Res, D-45147 Essen, Germany; NCI, Canc Res Ctr, Lab Biosyst & Canc Res, NIH, Bethesda, MD 20892 USA; Univ Essen Gesamthsch, Dept Dermatol, D-45147 Essen, Germany	University of Duisburg Essen; University of Duisburg Essen; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Duisburg Essen	Kirch, HC (corresponding author), Univ Essen Gesamthsch, Dept Internal Med Canc Res, Hufelandstr 55, D-45147 Essen, Germany.							Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Cong YS, 2000, J BIOL CHEM, V275, P35665, DOI 10.1074/jbc.C000637200; DENT J, 2002, CANCER RES, V62, P346; Dickopp A, 2000, CANCER GENE THER, V7, P1043, DOI 10.1038/sj.cgt.7700206; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; Fax P, 2000, J BIOL CHEM, V275, P40554, DOI 10.1074/jbc.M004626200; Frisch SM, 2001, ADV CANCER RES, V80, P39, DOI 10.1016/S0065-230X(01)80011-7; FRISCH SM, 1991, P NATL ACAD SCI USA, V88, P9077, DOI 10.1073/pnas.88.20.9077; FRISCH SM, 1995, CANCER RES, V55, P5551; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Gallimore PH, 2001, ONCOGENE, V20, P7824, DOI 10.1038/sj.onc.1204913; Gu J, 2000, CANCER RES, V60, P5359; HALEY KP, 1984, P NATL ACAD SCI-BIOL, V81, P5734, DOI 10.1073/pnas.81.18.5734; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Horikawa I, 1999, CANCER RES, V59, P826; Hou M, 2002, EXP CELL RES, V274, P25, DOI 10.1006/excr.2001.5462; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; Kirch HC, 1999, ONCOGENE, V18, P2728, DOI 10.1038/sj.onc.1202626; Komata T, 2002, ONCOGENE, V21, P656, DOI 10.1038/sj.onc.1205072; Komata T, 2001, CANCER RES, V61, P5796; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Mymryk JS, 1996, ONCOGENE, V13, P1581; Oh S, 1999, J BIOL CHEM, V274, P37473, DOI 10.1074/jbc.274.52.37473; Rumpf H, 1999, VIROLOGY, V257, P45, DOI 10.1006/viro.1999.9651; Schuierer M, 2001, J BIOL CHEM, V276, P27944, DOI 10.1074/jbc.M100070200; Shay JW, 2001, HUM MOL GENET, V10, P677, DOI 10.1093/hmg/10.7.677; Strom AC, 1998, J VIROL, V72, P5978; Sundqvist A, 2001, EXP CELL RES, V268, P284, DOI 10.1006/excr.2001.5280; Takakura M, 1999, CANCER RES, V59, P551; Takakura M, 2001, NUCLEIC ACIDS RES, V29, P3006, DOI 10.1093/nar/29.14.3006; Turner J, 2001, BIOESSAYS, V23, P683, DOI 10.1002/bies.1097; vanGroningen JJM, 1996, BIOCHEM BIOPH RES CO, V225, P808, DOI 10.1006/bbrc.1996.1255; VANMUIJEN GNP, 1991, CLIN EXP METASTAS, V9, P259, DOI 10.1007/BF01753729; White E, 2001, ONCOGENE, V20, P7836, DOI 10.1038/sj.onc.1204861; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Yoshida M, 2001, CANCER CHEMOTH PHARM, V48, pS20, DOI 10.1007/s002800100300; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; Zhang QH, 2000, P NATL ACAD SCI USA, V97, P14323, DOI 10.1073/pnas.011283598	39	18	25	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 14	2002	21	52					7991	8000		10.1038/sj.onc.1205965	http://dx.doi.org/10.1038/sj.onc.1205965			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	612VY	12439749				2022-12-28	WOS:000179097200008
J	He, J; Navarrete, S; Jasinski, M; Vulliamy, T; Dokal, I; Bessler, M; Mason, PK				He, J; Navarrete, S; Jasinski, M; Vulliamy, T; Dokal, I; Bessler, M; Mason, PK			Targeted disruption of Dkc1, the gene mutated in X-linked dyskeratosis congenita, causes embryonic lethality in mice	ONCOGENE			English	Article						dyskerin; dyskeratosis congenita; Dkc1; deficient mice; telomerase	RIBOSOMAL-RNA; IN-VIVO; SHORT TELOMERES; MUTATIONS; INACTIVATION; COMPONENT; CBF5P	Dyskeratosis congenita (DC) is an inherited bone marrow failure syndrome associated with increased cancer susceptibility. The X-linked form is due to mutations in the DKC1 gene encoding dyskerin, a nucleolar protein predicted to be involved in rRNA processing and associated with the telomerase complex. Available evidence suggests the pathology of DC is due to telomerase defects. We have used the inducible Cre/loxP system to produce deletions in the murine Dkc1 gene in early embryogenesis. A large deletion lacking exons 12-15 and a small deletion lacking only the last exon, were produced. We found both deletions showed a parent-of-origin effect with 100% embryonic lethality when the mutation occurred on the maternal Dkc1. Embryonic analysis at day E7.5 and E9.5 showed no male embryos carrying either deletion whereas females with maternally derived deletions died around day E9.5, with degeneration of the extra embryonic tissue, in which the paternal X-chromosome is inactivated. Female mice carrying the deletion in the paternally derived Dkc1 show extreme skewing of X-inactivation with the wild type X-chromosome active in all cells. Since mice with no telomerase are viable in the first generations the lethality we observe is unlikely to be due to the effects of mutated dyskerin on telomerase activity.	Washington Univ, Sch Med, Dept Internal Med, Div Hematol, St Louis, MO 63110 USA; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Hematol, Div Invest Sci, London W12 0NN, England	Washington University (WUSTL); Imperial College London	Bessler, M (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Div Hematol, 660 S euclid Ave,Box 8125, St Louis, MO 63110 USA.			Dokal, Inderjeet/0000-0003-4462-4782	NCI NIH HHS [CA-89091, P30CA91842] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089091, P30CA091842] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTER BP, 1998, HEMATOLOGY INFANCY C, V1, P216; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Cadwell C, 1997, MOL CELL BIOL, V17, P6175, DOI 10.1128/MCB.17.10.6175; Giordano E, 1999, J CELL BIOL, V144, P1123, DOI 10.1083/jcb.144.6.1123; HARPER MI, 1982, J EMBRYOL EXP MORPH, V67, P127; Heiss NS, 1998, NAT GENET, V19, P32, DOI 10.1038/ng0598-32; Hemann MT, 2000, NUCLEIC ACIDS RES, V28, P4474, DOI 10.1093/nar/28.22.4474; Keller P, 1999, P NATL ACAD SCI USA, V96, P7479, DOI 10.1073/pnas.96.13.7479; Knight SW, 1999, BRIT J HAEMATOL, V107, P335, DOI 10.1046/j.1365-2141.1999.01690.x; Knight SW, 1999, AM J HUM GENET, V65, P50, DOI 10.1086/302446; Knight SW, 2001, HUM GENET, V108, P299, DOI 10.1007/s004390100494; Lafontaine DLJ, 1998, GENE DEV, V12, P527, DOI 10.1101/gad.12.4.527; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; Liu Y, 2000, CURR BIOL, V10, P1459, DOI 10.1016/S0960-9822(00)00805-8; Mao XH, 1999, P NATL ACAD SCI USA, V96, P5037, DOI 10.1073/pnas.96.9.5037; Marciniak RA, 2000, TRENDS GENET, V16, P193, DOI 10.1016/S0168-9525(00)01984-3; McDevitt MA, 1997, P NATL ACAD SCI USA, V94, P7976, DOI 10.1073/pnas.94.15.7976; Mitchell JR, 1999, MOL CELL BIOL, V19, P567; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Prescott JC, 1999, CURR OPIN GENET DEV, V9, P368, DOI 10.1016/S0959-437X(99)80055-0; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; Spedaliere CJ, 2000, BIOCHEMISTRY-US, V39, P9459, DOI 10.1021/bi001079n; Vulliamy T, 2001, NATURE, V413, P432, DOI 10.1038/35096585; Vulliamy T, 2002, LANCET, V359, P2168, DOI 10.1016/S0140-6736(02)09087-6; Vulliamy TJ, 1999, BLOOD, V94, P1254, DOI 10.1182/blood.V94.4.1254.416k24_1254_1260; Vulliamy TJ, 2001, BLOOD CELL MOL DIS, V27, P353, DOI 10.1006/bcmd.2001.0389; Zebarjadian Y, 1999, MOL CELL BIOL, V19, P7461	27	71	75	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 31	2002	21	50					7740	7744		10.1038/sj.onc.1205969	http://dx.doi.org/10.1038/sj.onc.1205969			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	606VW	12400016				2022-12-28	WOS:000178756200013
J	Katata, T; Irie, K; Fukuhara, A; Kawakatsu, T; Yamada, A; Shimizu, K; Takai, Y				Katata, T; Irie, K; Fukuhara, A; Kawakatsu, T; Yamada, A; Shimizu, K; Takai, Y			Involvement of nectin in the localization of IQGAP1 at the cell-cell adhesion sites through the actin cytoskeleton in Madin-Darby canine kidney cells	ONCOGENE			English	Article						nectin; IQGAP1; cadherin; adherens junctions; actin	SIMPLEX VIRUS TYPE-1; POLIOVIRUS RECEPTOR GENE; RASGAP-RELATED PROTEIN; ALPHA-CATENIN; CYTOPLASMIC DOMAIN; JUNCTIONAL COMPLEX; EPITHELIAL-CELLS; SMALL GTPASES; MOLECULE UVOMORULIN; ADHERENS JUNCTION	IQGAP1, a putative downstream target of the Rho family small G proteins, Cdc42 and Rac, localizes at adherens junctions (AJs) in epithelial cells. It has been suggested that IQGAP1 localizes at AJs through its binding to beta-catenin, and negatively regulates the E-cadherin-mediated cell-cell adhesion. Nectin is a Ca2+-independent, immunoglobulin-like cell-cell adhesion molecule that localizes at AJs. Nectin is associated with E-cadherin through their respective cytoplasmic tail-binding proteins, afadin and catenins, and involved in the formation of AJs cooperatively with E-cadherin. Here we investigated a role of nectin in the localization of IQGAP1 at AJs. Ca2+ chelation from the medium causes disruption of the E-cadherin-mediated cell-cell adhesion, but not the nectin-based cell-cell adhesion, in Madin-Darby canine kidney (MDCK) cells. IQGAP1 remained at the residual nectin-based cell-cell adhesion sites where the E-cadherin immunofluorescence signal disappeared. Restoration of Ca2+ in the medium causes re-accumulation of E-cadherin to the residual pectin-based cell-cell adhesion sites to reform AJs. Nectin inhibitors inhibit this re-accumulation of E-cadherin to re-form AJs by impairing the pectin-based cell-cell adhesion. The nectin inhibitors also reduced the localization of IQGAP1 at the cell-cell adhesion sites. When MDCK cells were incubated with microbeads coated with the extracellular fragment of nectin that interacts with cellular nectin, IQGAP1 also accumulated at the bead-MDCK cell contact sites. The accumulation of IQGAP1 at the cell-cell adhesion sites was inhibited by actin filament-disrupting agents, latrunculin A and cytochalasin D. These results indicate that nectin is involved in the localization of IQGAP1 at AJs through the actin cytoskeleton.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Fukuhara, Atsunori/A-9601-2018	Fukuhara, Atsunori/0000-0002-6289-3778				AOKI J, 1994, J BIOL CHEM, V269, P8431; Asakura T, 1999, GENES CELLS, V4, P573, DOI 10.1046/j.1365-2443.1999.00283.x; Bashour AM, 1997, J CELL BIOL, V137, P1555, DOI 10.1083/jcb.137.7.1555; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Campadelli-Fiume G, 2000, REV MED VIROL, V10, P305, DOI 10.1002/1099-1654(200009/10)10:5<305::AID-RMV286>3.0.CO;2-T; Cocchi F, 1998, P NATL ACAD SCI USA, V95, P15700, DOI 10.1073/pnas.95.26.15700; Cocchi F, 2000, J VIROL, V74, P3909, DOI 10.1128/JVI.74.8.3909-3917.2000; EBERLE F, 1995, GENE, V159, P267, DOI 10.1016/0378-1119(95)00180-E; Erickson JW, 1997, J BIOL CHEM, V272, P24443, DOI 10.1074/jbc.272.39.24443; Fukata M, 1999, J CELL SCI, V112, P4491; Fukata M, 2001, MOL CELL BIOL, V21, P2165, DOI 10.1128/MCB.21.6.2165-2183.2001; Fukuhara A, 2002, ONCOGENE, V21, P7642, DOI 10.1038/sj.onc.1205875; Fukuhara A, 2002, GENES CELLS, V7, P1059, DOI 10.1046/j.1365-2443.2002.00578.x; GEIGER B, 1991, CELL MOTIL CYTOSKEL, V20, P1, DOI 10.1002/cm.970200102; Geraghty RJ, 1998, SCIENCE, V280, P1618, DOI 10.1126/science.280.5369.1618; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; HONDA T, 2003, IN PRESS GENES CELLS; Ikeda W, 1999, J CELL BIOL, V146, P1117, DOI 10.1083/jcb.146.5.1117; Imamura Y, 1999, J CELL BIOL, V144, P1311, DOI 10.1083/jcb.144.6.1311; KARTENBECK J, 1991, J CELL BIOL, V113, P881, DOI 10.1083/jcb.113.4.881; Kawakatsu T, 2002, J BIOL CHEM, V277, P50749, DOI 10.1074/jbc.M209846200; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li ZG, 1999, J BIOL CHEM, V274, P37885, DOI 10.1074/jbc.274.53.37885; Lopez M, 1998, BLOOD, V92, P4602, DOI 10.1182/blood.V92.12.4602.424k21_4602_4611; Lopez M, 2000, J VIROL, V74, P1267, DOI 10.1128/JVI.74.3.1267-1274.2000; LOPEZ M, 1995, GENE, V155, P261, DOI 10.1016/0378-1119(94)00842-G; Machesky LM, 1998, CURR BIOL, V8, pR202, DOI 10.1016/S0960-9822(98)70125-3; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; McCallum SJ, 1996, J BIOL CHEM, V271, P21732, DOI 10.1074/jbc.271.36.21732; Miyahara M, 2000, J BIOL CHEM, V275, P613, DOI 10.1074/jbc.275.1.613; Mizoguchi A, 2002, J CELL BIOL, V156, P555, DOI 10.1083/jcb.200103113; Momose Y, 2002, BIOCHEM BIOPH RES CO, V293, P45, DOI 10.1016/S0006-291X(02)00183-3; MORRISON ME, 1992, J VIROL, V66, P2807, DOI 10.1128/JVI.66.5.2807-2813.1992; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; Nakagawa M, 2001, J CELL SCI, V114, P1829; Nishioka H, 2000, J COMP NEUROL, V424, P297, DOI 10.1002/1096-9861(20000821)424:2<297::AID-CNE8>3.0.CO;2-J; Ozaki-Kuroda K, 2002, CURR BIOL, V12, P1145, DOI 10.1016/S0960-9822(02)00922-3; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; PRASAD R, 1993, CANCER RES, V53, P5624; Reymond N, 2001, J BIOL CHEM, V276, P43205, DOI 10.1074/jbc.M103810200; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Sakisaka T, 1999, ONCOGENE, V18, P1609, DOI 10.1038/sj.onc.1202451; Sakisaka T, 2001, J VIROL, V75, P4734, DOI 10.1128/JVI.75.10.4734-4743.2001; Satoh-Horikawa K, 2000, J BIOL CHEM, V275, P10291, DOI 10.1074/jbc.275.14.10291; Spear PG, 2000, VIROLOGY, V275, P1, DOI 10.1006/viro.2000.0529; Swart-Mataraza JM, 2002, J BIOL CHEM, V277, P24753, DOI 10.1074/jbc.M111165200; Tachibana K, 2000, J CELL BIOL, V150, P1161, DOI 10.1083/jcb.150.5.1161; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Takai Y, 2003, J CELL SCI, V116, P17, DOI 10.1242/jcs.00167; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Warner MS, 1998, VIROLOGY, V246, P179, DOI 10.1006/viro.1998.9218; Watabe-Uchida M, 1998, J CELL BIOL, V142, P847, DOI 10.1083/jcb.142.3.847; Weiss EE, 1998, J CELL BIOL, V141, P755, DOI 10.1083/jcb.141.3.755; WEISSBACH L, 1994, J BIOL CHEM, V269, P20517; Yagi T, 2000, GENE DEV, V14, P1169; Yokoyama S, 2001, MOL BIOL CELL, V12, P1595, DOI 10.1091/mbc.12.6.1595	64	36	37	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 10	2003	22	14					2097	2109		10.1038/sj.onc.1206255	http://dx.doi.org/10.1038/sj.onc.1206255			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664NJ	12687012				2022-12-28	WOS:000182066900004
J	Dang, TP; Eichenberger, S; Gonzalez, A; Olson, S; Carbone, DP				Dang, TP; Eichenberger, S; Gonzalez, A; Olson, S; Carbone, DP			Constitutive activation of Notch3 inhibits terminal epithelial differentiation in lungs of transgenic mice	ONCOGENE			English	Article						Notch3; differentiation; pneumocytes; transgenics	RESPIRATORY EPITHELIUM; INTRACELLULAR DOMAIN; KAPPA-B; IN-VIVO; EXPRESSION; GENE; MORPHOGENESIS; CELLS; TRANSLOCATION; NEOPLASMS	Notch3 is a transmembrane receptor and a member of the Notch signaling pathway essential for cellular differentiation in a variety of developing tissues in both invertebrates and vertebrates. Emerging data support the role of the Notch signaling pathway in tumorigenesis. We have previously demonstrated the expression of Notch3 in a subset of lung adenocarcinomas. To further elucidate the role of Notch3 in development of lung cancer, we established a transgenic mouse model in which the intracellular domain of Notch3 is expressed using the surfactant protein C promoter/enhancer. Constitutive expression of Notch3 in the peripheral epithelium in the developing lung resulted in altered lung morphology and delayed development, leading to perinatal lethality in these transgenic mice. Cell-specific markers and electron microscopy examination showed that the majority of the epithelial cells are undifferentiated, with some maturation of type 11 pneumocytes. No type I alveolar cells were evident. Metaplasia of undifferentiated cells in the terminal airways was also observed. Although the mice did not live long enough to assess tumor development, these findings demonstrate that ectopic expression of Notch3 in airway epithelium potentially contributes to the multistep evolution of lung cancer through the inhibition of terminal differentiation.	Vanderbilt Univ, Med Ctr, Div Hematol & Med Oncol, Nashville, TN USA; Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Dang, TP (corresponding author), Vanderbilt Ingram Canc Ctr, 642 PRB, Nashville, TN 37232 USA.				NCI NIH HHS [1 P50 CA090949, CA68485] Funding Source: Medline; NIDDK NIH HHS [DK20593] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485, P50CA090949] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020593, P60DK020593] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Apelqvist A, 1999, NATURE, V400, P877, DOI 10.1038/23716; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Beatus P, 1999, DEVELOPMENT, V126, P3925; Beckers J, 1999, MECH DEVELOP, V84, P165, DOI 10.1016/S0925-4773(99)00065-9; Bellavia D, 2000, EMBO J, V19, P3337, DOI 10.1093/emboj/19.13.3337; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Dang TP, 2000, J NATL CANCER I, V92, P1355, DOI 10.1093/jnci/92.16.1355; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Gallahan D, 1997, ONCOGENE, V14, P1883, DOI 10.1038/sj.onc.1201035; GLASSER SW, 1991, AM J PHYSIOL, V261, pL349, DOI 10.1152/ajplung.1991.261.4.L349; Guan E, 1996, J EXP MED, V183, P2025, DOI 10.1084/jem.183.5.2025; Hogan BLM, 1998, CURR OPIN GENET DEV, V8, P481, DOI 10.1016/S0959-437X(98)80121-4; Hogan BLM, 1999, CELL, V96, P225, DOI 10.1016/S0092-8674(00)80562-0; Ito T, 2000, DEVELOPMENT, V127, P3913; Joutel A, 2000, J CLIN INVEST, V105, P597, DOI 10.1172/JCI8047; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; Lardelli M, 1996, MECH DEVELOP, V59, P177, DOI 10.1016/0925-4773(96)00589-8; Linnoila RI, 2000, CANCER RES, V60, P4005; Llimargas M, 1999, DEVELOPMENT, V126, P2355; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Post LC, 2000, MECH DEVELOP, V98, P95, DOI 10.1016/S0925-4773(00)00432-9; Rohn JL, 1996, J VIROL, V70, P8071, DOI 10.1128/JVI.70.11.8071-8080.1996; Shelly LL, 1999, J CELL BIOCHEM, V73, P164, DOI 10.1002/(SICI)1097-4644(19990501)73:2<164::AID-JCB3>3.0.CO;2-0; Taichman DB, 2002, DEV DYNAM, V225, P166, DOI 10.1002/dvdy.10146; TENHAVEOPBROEK AAW, 1991, EXP LUNG RES, V17, P111, DOI 10.3109/01902149109064406; TOURNIERLASSERVE E, 1993, NAT GENET, V3, P256, DOI 10.1038/ng0393-256; Villa N, 2001, MECH DEVELOP, V108, P161, DOI 10.1016/S0925-4773(01)00469-5; Warburton D, 2000, MECH DEVELOP, V92, P55, DOI 10.1016/S0925-4773(99)00325-1; WERT SE, 1993, DEV BIOL, V156, P426, DOI 10.1006/dbio.1993.1090; Zeng X, 2001, DEV DYNAM, V221, P289, DOI 10.1002/dvdy.1140; Zhou L, 1997, DEV DYNAM, V210, P305, DOI 10.1002/(SICI)1097-0177(199711)210:3<305::AID-AJA10>3.0.CO;2-9	31	87	97	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 3	2003	22	13					1988	1997		10.1038/sj.onc.1206230	http://dx.doi.org/10.1038/sj.onc.1206230			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	662UR	12673204				2022-12-28	WOS:000181967700009
J	Wang, Q; Moyret-Lalle, C; Couzon, F; Surbiguet-Clippe, C; Saurin, JC; Lorca, T; Navarro, C; Puisieux, A				Wang, Q; Moyret-Lalle, C; Couzon, F; Surbiguet-Clippe, C; Saurin, JC; Lorca, T; Navarro, C; Puisieux, A			Alterations of anaphase-promoting complex genes in human colon cancer cells	ONCOGENE			English	Article						APC/C; cyclosome; ubiquitination; colon cancer; cyclin B1	APC-DEPENDENT PROTEOLYSIS; HUMAN COLORECTAL CANCERS; B-TYPE CYCLINS; MITOTIC EXIT; OVEREXPRESSION; CHECKPOINT; MUTATIONS; PROTEINS; MITOSIS; KINASE	Ubiquitin-mediated proteolysis of cell cycle regulators is a major element of the cell cycle control. The anaphase-promoting complex (APC/C) is a large multisubunit ubiquitin-protein ligase required for the ubiquitination and degradation of G1 and mitotic checkpoint regulators. APC/C-dependent proteolysis regulates cyclin levels in G1, and triggers the separation of sister chromatids at the metaphase-anaphase transition and the destruction of mitotic cyclins at the end of mitosis. Furthermore, it was recently shown that APC/C regulates the degradation of crucial regulators of signal transduction pathways. We report here gene alterations in several components of this complex in human colon cancer cells, including APC6/CDC16 and APC8/CDC23 which are known to be key function elements. The experimental expression of a truncation mutant of APC8/CDC23 subunit (CDC23DeltaTPR) leads to abnormal levels of APC/C targets such as cyclin B1 and disturbs the cell cycle progression of colon epithelial cells through mitosis. Overall, these data support the hypothesis of a deleterious role of these mutations during colorectal carcinogenesis.	INSERM, Ctr Leon Berard, Ctr Oncol Genet, U453, F-69008 Lyon 08, France; Fac Pharm Lyon, F-69373 Lyon, France; Hop Edouard Herriot, Federat Special Digest, F-69437 Lyon 03, France; CNRS, UPR 1086, Ctr Rech Biochim Macromol, F-34293 Montpellier 5, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Puisieux, A (corresponding author), INSERM, Ctr Leon Berard, Ctr Oncol Genet, U453, 28 Rue Laennec, F-69008 Lyon 08, France.		Moyret-Lalle, Caroline/G-2742-2013	Moyret-Lalle, Caroline/0000-0002-8359-2018; Lorca, Thierry/0000-0003-2007-8924; PUISIEUX, Alain/0000-0002-9938-3798				Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; COMBARET V, 1995, INT J CANCER, V61, P185, DOI 10.1002/ijc.2910610208; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Gieffers C, 2001, MOL CELL, V7, P907, DOI 10.1016/S1097-2765(01)00234-9; Heaney AP, 2000, LANCET, V355, P716, DOI 10.1016/S0140-6736(99)10238-1; Irniger S, 1997, J CELL SCI, V110, P1523; Kawasaki A, 2001, J CELL BIOL, V152, P275, DOI 10.1083/jcb.152.2.275; Noton E, 2000, MOL CELL, V5, P85, DOI 10.1016/S1097-2765(00)80405-0; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Sarafan-Vasseur N, 2002, ONCOGENE, V21, P2051, DOI 10.1038/sj.onc.1205257; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Soria JC, 2000, CANCER RES, V60, P4000; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Wang AJ, 1997, J CANCER RES CLIN, V123, P124, DOI 10.1007/BF01269891; Wang Q, 1999, HUM GENET, V105, P79, DOI 10.1007/s004390051067; Wasch R, 2002, NATURE, V418, P556, DOI 10.1038/nature00856; Yin XY, 2001, CANCER RES, V61, P6487; Zachariae W, 1996, MOL BIOL CELL, V7, P791, DOI 10.1091/mbc.7.5.791; Zhang YK, 2001, MOL CELL BIOL, V21, P5190, DOI 10.1128/MCB.21.15.5190-5199.2001; Zhao ND, 1998, GENOMICS, V53, P184, DOI 10.1006/geno.1998.5473	22	87	93	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 13	2003	22	10					1486	1490		10.1038/sj.onc.1206224	http://dx.doi.org/10.1038/sj.onc.1206224			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652ZZ	12629511	Bronze			2022-12-28	WOS:000181411900005
J	Yamasaki, S; Nishida, K; Yoshida, Y; Itoh, M; Hibi, M; Hirano, T				Yamasaki, S; Nishida, K; Yoshida, Y; Itoh, M; Hibi, M; Hirano, T			Gab1 is required for EGF receptor signaling and the transformation by activated ErbB2	ONCOGENE			English	Article						EGF; Gab1; ERK; transformation; signal transduction	GROWTH-FACTOR RECEPTORS; CELL ANTIGEN RECEPTORS; DOCKING PROTEIN GAB1; TYROSINE KINASE; C-MET; EPITHELIAL MORPHOGENESIS; PLECKSTRIN HOMOLOGY; SEVENLESS PROTEIN; REGULATED KINASE; IN-VIVO	Grb2-associated binder-1 (Gab1) is a pleckstrin homology (PH) domain-containing adapter molecule that is believed to function downstream of receptors for growth factors and cytokines. We previously found that deficiency in the mouse Gab1 gene led to embryonic lethality and defects in ERK activation in response to growth factors and cytokines. Here, we established immortalized Gab1-/- cell lines and analysed roles of Gab1 in growth factor-mediated signaling and oncogenesis. EGF-dependent activation of c-Raf and Mek1/2, which function upstream of ERKs, was perturbed in Gab1-/- cells. EGF-mediated upregulation of GTP-bound form of Ras was also reduced in these cells. EGF-dependent GTP/GDP exchange activity for Ras was suppressed in the Gab1-/- cells and expression of a constitutively active Sos restored ERK activation in these cells, indicating that Gab1 functions upstream of Ras. Furthermore, activated form of ErbB2 (active ErbB2)-mediated transformation, such as colony formation in soft agar and tumor formation in nude mice, was strongly suppressed when the Gab1-/- cells were transfected with active ErbB2, whereas the active Sos efficiently induced transformation of Gab1-/- cells. The data show that Gab1 plays an essential role in EGF-receptor/ErbB-mediated cell proliferation and oncogenesis.	Osaka Univ, Grad Sch Med, Dept Mol Oncol C7, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Frontier Biosci, Lab Dev Immunol, Suita, Osaka 5650871, Japan; RIKEN, RCAI, Lab Cytokine Signaling, Yokohama, Kanagawa, Japan	Osaka University; Osaka University; RIKEN	Hirano, T (corresponding author), Osaka Univ, Grad Sch Med, Dept Mol Oncol C7, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Hibi, Masahiko/I-6215-2014; Hirano, Toshio/C-8194-2009	Hibi, Masahiko/0000-0002-9142-4444; 				AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; Anborgh PH, 1999, MOL CELL BIOL, V19, P4611; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Bausenwein BS, 2000, MECH DEVELOP, V90, P205, DOI 10.1016/S0925-4773(99)00252-X; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; Chen BB, 2000, NAT GENET, V24, P296, DOI 10.1038/73528; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Herbst R, 1999, EMBO J, V18, P6950, DOI 10.1093/emboj/18.24.6950; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; Hibi M, 2000, LEUKEMIA LYMPHOMA, V37, P299, DOI 10.3109/10428190009089430; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Itoh M, 2000, MOL CELL BIOL, V20, P3695, DOI 10.1128/MCB.20.10.3695-3704.2000; Liu Y, 2002, FEBS LETT, V515, P1, DOI 10.1016/S0014-5793(02)02425-0; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; Maroun CR, 2000, MOL CELL BIOL, V20, P8513, DOI 10.1128/MCB.20.22.8513-8525.2000; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Qu CK, 1999, P NATL ACAD SCI USA, V96, P8528, DOI 10.1073/pnas.96.15.8528; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Sachs M, 2000, J CELL BIOL, V150, P1375, DOI 10.1083/jcb.150.6.1375; Sakkab D, 2000, J BIOL CHEM, V275, P10772, DOI 10.1074/jbc.275.15.10772; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Wolf I, 2002, MOL CELL BIOL, V22, P231, DOI 10.1128/MCB.22.1.231-244.2002; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649	37	54	54	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 13	2003	22	10					1546	1556		10.1038/sj.onc.1206284	http://dx.doi.org/10.1038/sj.onc.1206284			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652ZZ	12629518				2022-12-28	WOS:000181411900012
J	Klingelhofer, J; Troyanovsky, RB; Laur, OY; Troyanovsky, S				Klingelhofer, J; Troyanovsky, RB; Laur, OY; Troyanovsky, S			Exchange of catenins in cadherin-catenin complex	ONCOGENE			English	Article						cadherin; catenins; APC; adhesion	APC TUMOR-SUPPRESSOR; BETA-CATENIN; CELL-ADHESION; TYROSINE PHOSPHORYLATION; FUNCTIONAL-ANALYSIS; ALPHA-CATENIN; DROSOPHILA; BINDING; LOCALIZATION; JUNCTIONS	beta-Catenin is an intracellular multifunctional protein. In complex with the transmembrane adhesive receptor E-cadherin, it becomes plasma membrane-associated and mediates intercellular adhesion. A cytosolic pool of beta-catenin interacts with DNA-binding proteins and participates in signal transduction. To reveal the possible cross-talk between these two pools, we studied whether beta-catenin is exchanged between its free and cadherin-bound states. We found that pulse-labeled beta-catenin replaces the beta-catenin bound to the cell surface prebiotinylated E-cadherin immediately after synthesis. Approximately 25% of all pulse-labeled beta-catenin destined for E-cadherin associates with this protein via this mechanism. The rest of the newly synthesized beta-catenin arrives at the plasma membrane in a complex with the E-cadherin precursor. Immediately after arrival, this beta-catenin pool is transferred to the prebiotinylated E-cadherin. beta-Catenin released from E-cadherin may participate in new exchange cycles. This beta-catenin exchange is strongly affected in cells that contain mutations in the tumor suppressor gene APC. This process may contribute significantly to both cell-cell adhesion and beta-catenin-dependent signaling.	Washington Univ, Sch Med, Div Dermatol, St Louis, MO 63110 USA	Washington University (WUSTL)	Troyanovsky, S (corresponding author), Washington Univ, Sch Med, Div Dermatol, Campus Box 8123,660 S Euclid Ave, St Louis, MO 63110 USA.		Klingelhöfer, Jörg/C-1676-2013		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR045254] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR44106-04, AR45254-01] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aono S, 1999, J CELL BIOL, V145, P551, DOI 10.1083/jcb.145.3.551; Balsamo J, 1996, J CELL BIOL, V134, P801, DOI 10.1083/jcb.134.3.801; Bienz M, 1999, CURR OPIN GENET DEV, V9, P595, DOI 10.1016/S0959-437X(99)00016-7; Chitaev NA, 1998, J CELL BIOL, V142, P837, DOI 10.1083/jcb.142.3.837; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; Hamada F, 2002, NAT CELL BIOL, V4, P208, DOI 10.1038/ncb755; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Kaibuchi K, 1999, CURR OPIN CELL BIOL, V11, P591, DOI 10.1016/S0955-0674(99)00014-9; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; Klingelhofer J, 2002, MOL CELL BIOL, V22, P7449, DOI 10.1128/MCB.22.21.7449-7458.2002; KLYMKOWSKY MW, 1995, CELL, V83, P5, DOI 10.1016/0092-8674(95)90226-0; Laur OY, 2002, ARCH BIOCHEM BIOPHYS, V400, P141, DOI 10.1006/abbi.2002.2774; McCartney BM, 2001, NAT CELL BIOL, V3, P933, DOI 10.1038/ncb1001-933; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; Orsulic S, 1999, J CELL SCI, V112, P1237; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; Ozawa M, 1998, J BIOL CHEM, V273, P6166, DOI 10.1074/jbc.273.11.6166; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Piedra J, 2001, J BIOL CHEM, V276, P20436, DOI 10.1074/jbc.M100194200; Provost E, 1999, CURR OPIN CELL BIOL, V11, P567, DOI 10.1016/S0955-0674(99)00015-0; Rosin-Arbesfeld R, 2001, EMBO J, V20, P5929, DOI 10.1093/emboj/20.21.5929; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; Schmelz M, 1998, CELL TISSUE RES, V294, P11, DOI 10.1007/s004410051152; Troyanovsky RB, 1996, J CELL SCI, V109, P3069; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119	27	32	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 27	2003	22	8					1181	1188		10.1038/sj.onc.1206245	http://dx.doi.org/10.1038/sj.onc.1206245			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650EK	12606944				2022-12-28	WOS:000181249700006
J	Li, J; Zhang, ZQ; Dai, ZY; Plass, C; Morrison, C; Wang, Y; Wiest, JS; Anderson, MW; You, M				Li, J; Zhang, ZQ; Dai, ZY; Plass, C; Morrison, C; Wang, Y; Wiest, JS; Anderson, MW; You, M			LOH of chromosome 12p correlates with Kras2 mutation in non-small cell lung cancer	ONCOGENE			English	Article						wild-type Kras2; mutations; lung cancer; loss of heterozygosity; tumor suppressor	ACUTE LYMPHOBLASTIC-LEUKEMIA; RAS ONCOGENE ACTIVATION; SUSCEPTIBILITY LOCUS; CLINICAL-SIGNIFICANCE; FREQUENT DELETION; POINT MUTATION; SHORT ARM; GENE; ADENOCARCINOMA; CARCINOGENESIS	Previous observation has shown that the wild-type Kras2 allele is a suppressor of lung cancer in mice. Here we report that loss of heterozygosity (LOH) of chromosome 12p was detected in similar to50% of human lung adenocarcinomas and large cell carcinomas, and Kras2 mutations were detected at codon 12 in similar to40% of adenocarcinomas and large cell carcinomas. Interestingly, all of the lung adenocarcinomas and large cell carcinomas containing a Kras2 mutation exhibited allelic loss of the wild-type Kras2 allele when a correlation between LOH of the region on chromosome 12p and Kras2 mutation was made. These results from human lung cancer tissues provide a strong evidence in support of our previous observation in mouse models that the wild-type Kras2 is a tumor suppressor of lung cancer.	Ohio State Univ, Ctr Comprehens Canc, Div Human Canc Genet, Columbus, OH 43210 USA; OncoImmune LTD, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Dept Pathol, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Sch Publ Hlth, Columbus, OH 43210 USA; Univ Cincinnati, Dept Environm Hlth, Cincinnati, OH 45267 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; University of Cincinnati	You, M (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Div Human Canc Genet, 420 W 12th Ave, Columbus, OH 43210 USA.	you-l@medctr.osu.edu	Plass, Christoph/H-7192-2014		Intramural NIH HHS [ZIA BC010448-09] Funding Source: Medline; NCI NIH HHS [R01 CA 78797, P30 CA016058, R41 CA 093204, P30 CA 16058, R01 CA 58554, R01 CA058554] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078797, R41CA093204, P30CA016058, R01CA058554] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON MW, 1992, ENVIRON HEALTH PERSP, V98, P13, DOI 10.2307/3431243; Baccichet A, 1997, BRIT J HAEMATOL, V99, P107, DOI 10.1046/j.1365-2141.1997.3663180.x; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Beaupre DM, 1999, J CLIN ONCOL, V17, P1071, DOI 10.1200/JCO.1999.17.3.1071; Beaupre DM, 1999, CANCER RES, V59, P2971; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BOS JL, 1989, CANCER RES, V49, P4682; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; BUCHMANN A, 1991, CANCER RES, V51, P4097; BURMER GC, 1991, ENVIRON HEALTH PERSP, V93, P27, DOI 10.2307/3431164; De Gregorio L, 1998, INT J CANCER, V79, P269, DOI 10.1002/(SICI)1097-0215(19980619)79:3<269::AID-IJC10>3.3.CO;2-J; Dragani TA, 2000, CANCER RES, V60, P5017; GARIBOLDI M, 1993, NAT GENET, V3, P132, DOI 10.1038/ng0293-132; HEGI ME, 1994, CANCER RES, V54, P6257; KIARIS H, 1995, INT J ONCOL, V7, P413; Kibel AS, 1998, CANCER RES, V58, P5652; LI SR, 1994, LUNG CANCER-J IASLC, V11, P19, DOI 10.1016/0169-5002(94)90279-8; Manenti G, 1997, MAMM GENOME, V8, P801, DOI 10.1007/s003359900582; MARIYAMA M, 1989, JPN J CANCER RES, V80, P622, DOI 10.1111/j.1349-7006.1989.tb01687.x; MARSHALL CJ, 1991, TRENDS GENET, V7, P91, DOI 10.1016/0168-9525(91)90063-V; MILLS NE, 1995, CANCER RES, V55, P1444; PERUCHO M, 1981, CELL, V27, P467, DOI 10.1016/0092-8674(81)90388-3; Pinto MM, 1997, ACTA CYTOL, V41, P427, DOI 10.1159/000332535; REYNOLDS SH, 1991, P NATL ACAD SCI USA, V88, P1085, DOI 10.1073/pnas.88.4.1085; RODENHUIS S, 1992, CANCER RES, V52, pS2665; RODENHUIS S, 1988, CANCER RES, V48, P5738; SHIBATA D, 1990, CANCER RES, V50, P1279; SUZUKI Y, 1990, ONCOGENE, V5, P1037; Takeuchi S, 1996, CANCER RES, V56, P738; Takeuchi S, 1996, BLOOD, V87, P3368, DOI 10.1182/blood.V87.8.3368.bloodjournal8783368; Thompson TA, 2002, ONCOGENE, V21, P2797, DOI 10.1038/sj.onc.1205391; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WANG Y, 1993, CANCER RES, V53, P1620; Yanagitani N, 2002, CARCINOGENESIS, V23, P1177, DOI 10.1093/carcin/23.7.1177; YOU M, 1992, P NATL ACAD SCI USA, V89, P5804, DOI 10.1073/pnas.89.13.5804; Zhang ZQ, 2001, NAT GENET, V29, P25, DOI 10.1038/ng721	36	43	45	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2003	22	8					1243	1246		10.1038/sj.onc.1206192	http://dx.doi.org/10.1038/sj.onc.1206192			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650EK	12606951	Green Accepted			2022-12-28	WOS:000181249700013
J	Ochiai, Y; Tamura, Y; Saito, Y; Matsuki, A; Wakabayashi, Y; Aizawa, Y; Niwa, O; Kominami, R				Ochiai, Y; Tamura, Y; Saito, Y; Matsuki, A; Wakabayashi, Y; Aizawa, Y; Niwa, O; Kominami, R			Mapping of genetic modifiers of thymic lymphoma development in p53-knockout mice	ONCOGENE			English	Article						p53 modifier; genetic mapping; thymic lymphoma; skin cancer; consomic mouse	TUMOR-SUPPRESSOR GENE; INTESTINAL NEOPLASIA; P53-DEFICIENT MICE; P53 MUTATIONS; CANCER; TUMORIGENESIS; SUSCEPTIBILITY; RESISTANCE; CANDIDATE; HOMOLOG	The strain dependency of the spectrum and latency of tumors has been reported in p53-deficient (KO) mice, suggesting the presence of modifiers for the outcome of the p53 deficiency. The modifiers provide clues to the oncogenic pathway in cells lacking p53, the most frequently mutated gene in a wide variety of human cancers. To search the modifiers, we induced 160 lymphomas and 69 skin tumors by gamma-irradiation of p53(KO/+) backcross mice between BALB/c and MSM strains and performed genome scan. BALB/c-derived alleles at three loci on chromosome 19, Mp53D1 (modifier of p53-deficiency) at D19Mit5, Mp53D2 at D19Mit90 and Mp53D3 at D19MW23, extended the latency of thymic lymphoma development (P values in Mantel-Cox test were 0.0007, 0.0007 and 0.0003, respectively). Mp53D3 also increased the latency of skin tumors (P value, 0.0008). The linkage of Mp53D2 was confirmed by the experiment using 94 p53-KO mice consomic for chromosome 19, providing a significant linkage. However, the linkage was not confirmed for Mp53D1 or Mp53D3, suggesting epistasis of genes involved in the tumorigenesis.	Niigata Univ, Grad Sch Med & Dent Sci, Dept Gene Regulat, Niigata 9518122, Japan; Niigata Univ, Grad Sch Med & Dent Sci, Dept Cardiovasc & Vital Control, Niigata 9518122, Japan; Kyoto Univ, Ctr Radiat Biol, Sakyo Ku, Kyoto 6068315, Japan	Niigata University; Niigata University; Kyoto University	Kominami, R (corresponding author), Niigata Univ, Grad Sch Med & Dent Sci, Dept Gene Regulat, Asahimachi Doori 1-757, Niigata 9518122, Japan.							Balmain A, 2002, CELL, V108, P145, DOI 10.1016/S0092-8674(02)00622-0; Balmain A, 1998, TRENDS GENET, V14, P139, DOI 10.1016/S0168-9525(98)01422-X; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; Demant P, 1992, Semin Cancer Biol, V3, P159; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, MOL CARCINOGEN, V14, P16, DOI 10.1002/mc.2940140105; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Inoue K, 2001, GENE DEV, V15, P2934, DOI 10.1101/gad.929901; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Manly KF, 2001, MAMM GENOME, V12, P930, DOI 10.1007/s00335-001-1016-3; Markel P, 1997, NAT GENET, V17, P280, DOI 10.1038/ng1197-280; Matsumoto Y, 1998, ONCOGENE, V16, P2747, DOI 10.1038/sj.onc.1201810; Miyazawa T, 2002, JPN J CANCER RES, V93, P994, DOI 10.1111/j.1349-7006.2002.tb02475.x; Mori N, 1999, ONCOGENE, V18, P4282, DOI 10.1038/sj.onc.1202719; Nadeau JH, 2001, NAT REV GENET, V2, P165, DOI 10.1038/35056009; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Ponder BAJ, 2001, NATURE, V411, P336, DOI 10.1038/35077207; Saito Y, 2001, ONCOGENE, V20, P5243, DOI 10.1038/sj.onc.1204675; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0	30	11	11	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 20	2003	22	7					1098	1102		10.1038/sj.onc.1206202	http://dx.doi.org/10.1038/sj.onc.1206202			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	644PB	12592396				2022-12-28	WOS:000180926100015
J	Bougeard, G; Brugieres, L; Chompret, A; Gesta, P; Charbonnier, F; Valent, A; Martin, C; Raux, G; Feunteun, J; Bressac-de Paillerets, B; Frebourg, T				Bougeard, G; Brugieres, L; Chompret, A; Gesta, P; Charbonnier, F; Valent, A; Martin, C; Raux, G; Feunteun, J; Bressac-de Paillerets, B; Frebourg, T			Screening for TP53 rearrangements in families with the Li-Fraumeni syndrome reveals a complete deletion of the TP53 gene	ONCOGENE			English	Article						TP53; Li-Fraumeni syndrome; deletion; PCR	GERMLINE MUTATION; HCHK2 MUTATIONS; P53; PTEN	The absence of detectable germline TP53 mutations in a fraction of families with Li-Fraumeni syndrome (LFS) has suggested the involvement of other genes, but this hypothesis remains controversial. The density of Alu repeats within the TP53 gene led us to search genomic rearrangements of TP53 in families without detectable TP53 mutation. To this aim, we adapted the quantitative multiplex PCR of short fluorescent fragments (QMPSF) method to the analysis of the 11 exons of TP53. We analysed 98 families, either fulfilling (six families) or partially meeting (92 families) the criteria for LFS, and in which classical methods had failed to reveal TP53 alterations. We identified, in a large family fulfilling the criteria for LITS, a complete heterozygous deletion of TP53. Additional QMPSF analyses indicated that this deletion, which partially removed the centromeric FLJ10385 locus, covered approximately 45 kb. This deletion was shown to result from a complex rearrangement involving two distinct Alu-mediated recombinations. We conclude that TP53 germline rearrangements occur as rare events, but must be considered in LFS families without detectable point TP53 mutation.	IFRMP, Fac Med, INSERM, EMI 9906, F-76183 Rouen, France; Inst Gustave Roussy, Dept Pediat, F-94805 Villejuif, France; Ctr Hosp, F-79021 Niort, France; CHU Rouen, Dept Genet, Rouen, France; Inst Gustave Roussy, Dept Cellular Genom Canc, F-94805 Villejuif, France; Inst Gustave Roussy, UMR 8125, F-94805 Villejuif, France; Inst Gustave Roussy, Dept Biol Clin, F-94805 Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; CHU de Rouen; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy	Frebourg, T (corresponding author), IFRMP, Fac Med, INSERM, EMI 9906, F-76183 Rouen, France.		Paillerets, Brigitte Bressac-de/D-8954-2018; Frebourg, Thierry/AAK-8390-2020; BOUGEARD, Gaëlle/ABI-6642-2020; Feunteun, Jean/AAZ-1267-2020	Paillerets, Brigitte Bressac-de/0000-0003-0245-8608; BOUGEARD, Gaëlle/0000-0002-1475-0254; CHARBONNIER, Francoise/0000-0002-4875-2506; Feunteun, Jean/0000-0003-1212-9189				Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; BELL DW, 2000, SCIENCE, V289, P359; BIRCH JM, 1994, BRIT J CANCER, V70, P1176, DOI 10.1038/bjc.1994.468; BIRCH JM, 1994, CANCER RES, V54, P1298; Bougeard G, 2001, J MED GENET, V38, P253, DOI 10.1136/jmg.38.4.253; Brown LTR, 2000, CANCER GENET CYTOGEN, V123, P65, DOI 10.1016/S0165-4608(00)00303-4; Burt EC, 1999, BRIT J CANCER, V80, P9, DOI 10.1038/sj.bjc.6690313; Charbonnier F, 2000, CANCER RES, V60, P2760; Charbonnier F, 2002, CANCER RES, V62, P848; Chompret A, 2002, BIOCHIMIE, V84, P75, DOI 10.1016/S0300-9084(01)01361-X; Chompret A, 2001, J MED GENET, V38, P43, DOI 10.1136/jmg.38.1.43; Eeles RA, 1995, CANCER SURV, V25, P101; LI FP, 1988, CANCER RES, V48, P5358; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Mighell AJ, 1997, FEBS LETT, V417, P1, DOI 10.1016/S0014-5793(97)01259-3; PLUMMER SJ, 1994, ONCOGENE, V9, P3273; Portwine C, 2000, J Med Genet, V37, pE13, DOI 10.1136/jmg.37.8.e13; Slebos RJC, 1998, CANCER RES, V58, P5333; Sodha N, 2000, Science, V289, P359; Stone JG, 1999, CANCER LETT, V147, P181, DOI 10.1016/S0304-3835(99)00291-8; Vahteristo P, 2002, AM J HUM GENET, V71, P432, DOI 10.1086/341943; Vahteristo P, 2001, CANCER RES, V61, P5718; Varley JM, 1997, BRIT J CANCER, V76, P1, DOI 10.1038/bjc.1997.328	23	47	50	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 13	2003	22	6					840	846		10.1038/sj.onc.1206155	http://dx.doi.org/10.1038/sj.onc.1206155			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584563				2022-12-28	WOS:000180864300006
J	Kanai, M; Konda, Y; Nakajaima, T; Izumi, Y; Kanda, N; Nanakin, A; Kubohara, Y; Chiba, T				Kanai, M; Konda, Y; Nakajaima, T; Izumi, Y; Kanda, N; Nanakin, A; Kubohara, Y; Chiba, T			Differentiation-inducing factor-1 (DIF-1) inhibits STAT3 activity involved in gastric cancer cell proliferation via MEK-ERK-dependent pathway	ONCOGENE			English	Article						DIF-1; STAT3; ERK; cell growth; gastric cancer	ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR RECEPTOR; SERINE PHOSPHORYLATION; DICTYOSTELIUM-DISCOIDEUM; CONSTITUTIVE ACTIVATION; PUTATIVE MORPHOGEN; SUPPRESSES GROWTH; LEUKEMIA-CELLS; DNA-BINDING; IN-VITRO	Differentiation-inducing factor-1 (DIF-1) is a chlorinated hexaphenone isolated from Dictyostelium. DIF-1 exhibits antitumor activity in several types of mammalian tumor cells, although the underlying mechanisms remain unknown. On the other hand, recent studies indicate that constitutively activated STAT3 acts as an oncogene and could be a target for antitumor drug. In the present study, we examined the effects of DIF-1 on proliferation of gastric cancer cell lines as well as on its signal transduction pathways, focusing mainly on STAT proteins. DIF-1 inhibited proliferation of gastric cancer cells. Western blot analysis and electrophoretic mobility shift assay showed that DIF-1 inhibited STAT3 activity in an MEK-ERK-dependent manner in gastric cancer cell lines, AGS and MKN28. Moreover, blockade of STAT3 activity by ectopic expression of dominant-negative STAT3 or the Janus kinase inhibitor, tyrphostin AG490, inhibited cell growth of AGS cells. These results suggest that STAT3 activity plays an important role for cell growth in AGS cells, and raises the possibility that inhibition of STAT3 activity is one of the mechanisms responsible for the antitumor effect of DIF-1 in these cells.	Kyoto Univ, Grad Sch Med, Div Gastroenterol & Hepatol, Sakyo Ku, Kyoto 6068507, Japan; Gunma Univ, Inst Mol & Cellular Regulat, Dept Mol Physiol, Maebashi, Gumma 3718512, Japan	Kyoto University; Gunma University	Konda, Y (corresponding author), Kyoto Univ, Grad Sch Med, Div Gastroenterol & Hepatol, Sakyo Ku, 54 Shogoin, Kyoto 6068507, Japan.		Kanai, Motomu/J-6807-2016	Kanai, Motomu/0000-0003-1977-7648				ASAHI KI, 1995, BIOCHEM BIOPH RES CO, V208, P1036, DOI 10.1006/bbrc.1995.1438; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Burke WM, 2001, ONCOGENE, V20, P7925, DOI 10.1038/sj.onc.1204990; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Gollob JA, 1999, J IMMUNOL, V162, P4472; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Ishiyama M, 1997, TALANTA, V44, P1299, DOI 10.1016/S0039-9140(97)00017-9; Jain N, 1998, ONCOGENE, V17, P3157, DOI 10.1038/sj.onc.1202238; Kawata T, 1997, CELL, V89, P909, DOI 10.1016/S0092-8674(00)80276-7; KUBOHARA Y, 1995, FEBS LETT, V359, P119, DOI 10.1016/0014-5793(95)00022-2; Kubohara Y, 1999, BIOCHEM BIOPH RES CO, V263, P790, DOI 10.1006/bbrc.1999.1468; Kubohara Y, 1997, BIOCHEM BIOPH RES CO, V236, P418, DOI 10.1006/bbrc.1997.6964; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; MORRIS HR, 1987, NATURE, V328, P811, DOI 10.1038/328811a0; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Neugut AI, 1996, SEMIN ONCOL, V23, P281; Ni Z, 2000, CANCER RES, V60, P1225; Nielsen M, 1997, P NATL ACAD SCI USA, V94, P6764, DOI 10.1073/pnas.94.13.6764; Niu GL, 2001, CANCER RES, V61, P3276; Sartor CI, 1997, CANCER RES, V57, P978; Sengupta TK, 1998, P NATL ACAD SCI USA, V95, P11107, DOI 10.1073/pnas.95.19.11107; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	31	71	75	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 30	2003	22	4					548	554		10.1038/sj.onc.1206109	http://dx.doi.org/10.1038/sj.onc.1206109			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555068				2022-12-28	WOS:000180538200008
J	Smith-Sorensen, B; Lind, GE; Skotheim, RI; Fossa, SD; Fodstad, O; Stenwig, AE; Jakobsen, KS; Lothe, RA				Smith-Sorensen, B; Lind, GE; Skotheim, RI; Fossa, SD; Fodstad, O; Stenwig, AE; Jakobsen, KS; Lothe, RA			Frequent promoter hypermethylation of the O-6-methylguanine-DNA methyltransferase (MGMT) gene in testicular cancer	ONCOGENE			English	Article						CpG methylation; MGMT; CDKN2A; testicular cancer; germ cell tumour; allelic imbalance	GERM-CELL TUMORS; CPG-ISLAND METHYLATION; DNA-REPAIR GENES; INACTIVATION; EXPRESSION; INHIBITION; NEOPLASIA; PROGNOSIS; AGENTS; REGION	Testicular germ cell tumours are classified into two major histological subgroups, seminomas and nonseminomas. All tumours display several recurrent chromosomal aberrations, but few target genes have been identified. Previous studies have shown that genome-wide hypermethylation of CpG islands is significantly more prevalent in nonseminomas than in seminomas. We have studied two potential target genes in testicular cancer. A series of 70 tumours were analysed for methylation of CpG sites in the O-6-methylguanine-DNA methyltransferase (MGMT) gene promoter, and in exon la of the cyclin-dependent kinase inhibitor 2A gene (CDKN2A). In addition, eight microsatellite markers within and flanking these genes at chromosome arms 10q and 9p, respectively, were analysed for allelic imbalances. Allele alterations were frequently seen at 9p loci (47 out of 70, 67%), but none of the tumours (none out of 55) showed methylation of CDKN2A. On the other hand, a high frequency of MGMT promoter methylation (32 out of 69, 46%) was found, as well as allelic imbalances at 10q markers (50 out of 70, 71%). A significantly higher methylation frequency was found in nonseminomas (24 out of 35, 69%) compared to seminomas (eight out of 33, 24%) (P = 0.0003, Fisher's exact test). Immunohistochemical analysis of the MGMT protein in a subgroup (n = 20) of the testicular tumours supported the hypothesis of gene silencing being the functional consequence of the promoter methylation. In summary, our data suggest that inactivation of MGMT contributes to development of nonseminomatous testicular cancer.	Norwegian Radium Hosp, Inst Canc Res, Dept Genet, N-0310 Oslo, Norway; Univ Oslo, Inst Biol, Div Mol Biol, N-0310 Oslo, Norway; Norwegian Radium Hosp, Dept Pathol, N-0310 Oslo, Norway; Norwegian Radium Hosp, Dept Radiotherapy & Oncol, N-0310 Oslo, Norway	University of Oslo; University of Oslo; University of Oslo; University of Oslo	Lothe, RA (corresponding author), Norwegian Radium Hosp, Inst Canc Res, Dept Genet, N-0310 Oslo, Norway.		Skotheim, Rolf I./H-6192-2017	Skotheim, Rolf I./0000-0002-5609-4048; Lothe, Ragnhild A./0000-0002-1693-1032				ATKIN NB, 1982, LANCET, V2, P1349; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bearzatto A, 2000, CANCER RES, V60, P3262; CASTEDO SMMJ, 1989, CANCER RES, V49, P5696; CASTEDO SMMJ, 1989, CANCER RES, V49, P439; Chaubert P, 1997, AM J PATHOL, V151, P859; COSTELLO JF, 1994, J BIOL CHEM, V269, P17228; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Danam RP, 1999, MOL CARCINOGEN, V24, P85, DOI 10.1002/(SICI)1098-2744(199902)24:2<85::AID-MC2>3.0.CO;2-C; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901; Esteller M, 2000, EUR J CANCER, V36, P2294, DOI 10.1016/S0959-8049(00)00303-8; Faulkner SW, 2000, BRIT J CANCER, V83, P729, DOI 10.1054/bjoc.2000.1334; HARRIS LC, 1994, NUCLEIC ACIDS RES, V22, P4614, DOI 10.1093/nar/22.22.4614; Heidenreich A, 1998, J UROLOGY, V159, P1725, DOI 10.1097/00005392-199805000-00101; Heidenreich A, 2000, EUR UROL, V37, P121, DOI 10.1159/000020128; HERMAN JG, 1995, CANCER RES, V55, P4525; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hui R, 2000, CLIN CANCER RES, V6, P2777; JOSEFSEN D, 1993, BRIT J CANCER, V67, P568, DOI 10.1038/bjc.1993.104; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kraggerud SM, 2002, GENE CHROMOSOME CANC, V34, P168, DOI 10.1002/gcc.10058; Looijenga LHJ, 1999, INT J CANCER, V83, P809, DOI 10.1002/(SICI)1097-0215(19991210)83:6<809::AID-IJC20>3.0.CO;2-0; LOTHE RA, 1993, GENE CHROMOSOME CANC, V7, P96, DOI 10.1002/gcc.2870070206; Matin A, 1999, NAT GENET, V23, P237, DOI 10.1038/13874; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Mertens F, 1997, CANCER RES, V57, P2765; MOSTOFI FK, 1976, WORLD HLTH ORG, V16, P1; MURTY VVVS, 1994, ONCOGENE, V9, P2245; Murty VVVS, 1998, SEMIN ONCOL, V25, P133; Nakamura M, 2001, CARCINOGENESIS, V22, P1715, DOI 10.1093/carcin/22.10.1715; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OOSTERHUIS JW, 1989, LAB INVEST, V60, P14; PEGG AE, 1995, PROG NUCLEIC ACID RE, V51, P167, DOI 10.1016/S0079-6603(08)60879-X; Preuss I, 1996, INT J CANCER, V65, P506, DOI 10.1002/(SICI)1097-0215(19960208)65:4<506::AID-IJC19>3.0.CO;2-7; QIAN XL, 1995, CARCINOGENESIS, V16, P1385, DOI 10.1093/carcin/16.6.1385; Qian XLC, 1997, CANCER RES, V57, P3672; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Shim YH, 2000, LAB INVEST, V80, P689, DOI 10.1038/labinvest.3780072; Skotheim RI, 2001, CANCER GENET CYTOGEN, V127, P64, DOI 10.1016/S0165-4608(00)00433-7; Skotheim RI, 2002, CANCER RES, V62, P2359; Skotheim RI, 2001, NEOPLASIA, V3, P196, DOI 10.1038/sj.neo.7900153; Smiraglia DJ, 2002, ONCOGENE, V21, P3909, DOI 10.1038/sj.onc.1205488; Smiraglia DJ, 1999, GENOMICS, V58, P254, DOI 10.1006/geno.1999.5840	45	62	63	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 12	2002	21	57					8878	8884		10.1038/sj.onc.1205978	http://dx.doi.org/10.1038/sj.onc.1205978			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483540				2022-12-28	WOS:000179734400021
J	Molldrem, JJ; Kant, S; Jiang, WD; Lu, SJ				Molldrem, JJ; Kant, S; Jiang, WD; Lu, SJ			The basis of T-cell-mediated immunity to chronic myelogenous leukemia	ONCOGENE			English	Article						chronic myelogenous leukemia; T-cell; antigen; immunity	GRAFT-VERSUS-LEUKEMIA; MINOR HISTOCOMPATIBILITY ANTIGENS; CHRONIC MYELOID-LEUKEMIA; BONE-MARROW TRANSPLANTS; HUMAN GENE MAGE-3; WEGENERS-GRANULOMATOSIS; HOST-DISEASE; PROTEINASE-3 MYELOBLASTIN; LYMPHOCYTE CLONES; TUMOR-ANTIGENS		Univ Texas, MD Anderson Canc Ctr, Transplantat Immunol Sect, Dept Blood & Marrow Transplantat, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Molldrem, JJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Transplantat Immunol Sect, Dept Blood & Marrow Transplantat, 1515 Holcombe Blvd,Boxc 448, Houston, TX 77030 USA.	jmolldre@notes.mdacc.tmc.edu	Kanodia, Shreya/E-5169-2010		NATIONAL CANCER INSTITUTE [R01CA085843, R01CA081247] Funding Source: NIH RePORTER; NCI NIH HHS [CA81247, CA85843] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alam SM, 1996, NATURE, V381, P616, DOI 10.1038/381616a0; Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Anderton SM, 2002, NAT REV IMMUNOL, V2, P487, DOI 10.1038/nri842; ANTIN JH, 1993, BLOOD, V82, P2273; BALLIEUX BEPB, 1995, CLIN EXP IMMUNOL, V100, P186; Barrett AJ, 2000, BLOOD, V95, P3323; Behre G, 1999, METHODS, V17, P231, DOI 10.1006/meth.1998.0733; BOCCHIA M, 1995, BLOOD, V85, P2680, DOI 10.1182/blood.V85.10.2680.bloodjournal85102680; Bocchia M, 1996, BLOOD, V87, P3587, DOI 10.1182/blood.V87.9.3587.bloodjournal8793587; Boon T, 1997, IMMUNOL TODAY, V18, P267, DOI 10.1016/S0167-5699(97)80020-5; Boon T, 1994, Important Adv Oncol, P53; BORIES D, 1989, CELL, V59, P959, DOI 10.1016/0092-8674(89)90752-6; Borregaard N, 1997, BLOOD, V89, P3503, DOI 10.1182/blood.V89.10.3503.3503_3503_3521; Braunschweig I, 2000, BLOOD, V96, p761A; BROUWER E, 1994, CLIN EXP IMMUNOL, V98, P448; Callan MFC, 1998, J EXP MED, V187, P1395, DOI 10.1084/jem.187.9.1395; CELIS E, 1994, P NATL ACAD SCI USA, V91, P2105, DOI 10.1073/pnas.91.6.2105; CHEN T, 1994, BIOCHEM BIOPH RES CO, V200, P1130, DOI 10.1006/bbrc.1994.1568; Clark RE, 2001, BLOOD, V98, P2887, DOI 10.1182/blood.V98.10.2887; Collins RH, 1997, J CLIN ONCOL, V15, P433, DOI 10.1200/JCO.1997.15.2.433; DENGLER R, 1995, BRIT J HAEMATOL, V89, P250, DOI 10.1111/j.1365-2141.1995.tb03297.x; DENHAAN JMM, 1995, SCIENCE, V268, P1476, DOI 10.1126/science.7539551; Dermime S, 1995, BLOOD, V86, P620; Faber L M, 1996, Biol Blood Marrow Transplant, V2, P31; FABER LM, 1995, J CLIN INVEST, V96, P877, DOI 10.1172/JCI118134; FABER LM, 1995, BLOOD, V86, P2821; Franssen CFM, 1996, LANCET, V347, P116; Franssen CFM, 2000, KIDNEY INT, V57, P2195, DOI 10.1046/j.1523-1755.2000.00080.x; GALE RP, 1994, ANN INTERN MED, V120, P646, DOI 10.7326/0003-4819-120-8-199404150-00004; GAUGLER B, 1994, J EXP MED, V179, P921, DOI 10.1084/jem.179.3.921; Giralt Sergio A., 1996, Current Opinion in Oncology, V8, P96, DOI 10.1097/00001622-199603000-00004; Goulmy E, 1996, NEW ENGL J MED, V334, P281, DOI 10.1056/NEJM199602013340501; Jennette JC, 2001, SEMIN DIAGN PATHOL, V18, P3, DOI 10.1053/sdia.2001.22142; Kochenderfer J N, 2001, Curr Oncol Rep, V3, P193, DOI 10.1007/s11912-001-0050-3; Kolb Hans-Jochem, 1997, Current Opinion in Oncology, V9, P139; KOLB HJ, 1995, BLOOD, V86, P2041, DOI 10.1182/blood.V86.5.2041.bloodjournal8652041; Kolb HJ, 1996, BONE MARROW TRANSPL, V17, P449; Komanduri KV, 2001, VIROLOGY, V279, P459, DOI 10.1006/viro.2000.0697; Komanduri KV, 1998, NAT MED, V4, P953, DOI 10.1038/nm0898-953; Lee PP, 1999, NAT MED, V5, P677, DOI 10.1038/9525; Marchand M, 1995, INT J CANCER, V63, P883, DOI 10.1002/ijc.2910630622; Molldrem J, 1996, BLOOD, V88, P2450, DOI 10.1182/blood.V88.7.2450.bloodjournal8872450; Molldrem JJ, 1999, CANCER RES, V59, P2675; Molldrem JJ, 1997, BLOOD, V90, P2529, DOI 10.1182/blood.V90.7.2529.2529_2529_2534; Molldrem JJ, 2000, NAT MED, V6, P1018, DOI 10.1038/79526; MULLERBERAT N, 1994, CLIN IMMUNOL IMMUNOP, V70, P51, DOI 10.1006/clin.1994.1010; NANDA NK, 1995, CELL, V82, P13, DOI 10.1016/0092-8674(95)90047-0; PARDOLL DM, 1994, NATURE, V369, P357, DOI 10.1038/369357a0; Pardoll DM, 2002, NAT REV IMMUNOL, V2, P227, DOI 10.1038/nri774; Rosenberg SA, 1996, J IMMUNOTHER, V19, P81, DOI 10.1097/00002371-199601000-00009; Savige J, 1999, AM J CLIN PATHOL, V111, P507; STURROCK AB, 1992, J BIOL CHEM, V267, P21193; Tanaka F, 1997, CANCER RES, V57, P4465; VANDERBRUGGEN P, 1994, EUR J IMMUNOL, V24, P3038, DOI 10.1002/eji.1830241218; VANDERHARST D, 1994, BLOOD, V83, P1060; VANRHEE F, 1994, BLOOD, V83, P3377; WILLIAMS RC, 1994, J IMMUNOL, V152, P4722; Zarour H, 1996, J INVEST DERMATOL, V107, P63, DOI 10.1111/1523-1747.ep12298177; Zhang P, 2002, BLOOD, V99, P4406, DOI 10.1182/blood.V99.12.4406	59	8	13	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2002	21	56					8668	8673		10.1038/sj.onc.1206093	http://dx.doi.org/10.1038/sj.onc.1206093			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZF	12476312				2022-12-28	WOS:000179734300015
J	Lang, SE; Hearing, P				Lang, SE; Hearing, P			The adenovirus E1A oncoprotein recruits the cellular TRRAP/GCN5 histone acetyltransferase complex	ONCOGENE			English	Article						E1A; GCN5; TRRAP; HAT	C-MYC; TRANSCRIPTIONAL ACTIVATION; ESSENTIAL COFACTOR; CBP; TRANSFORMATION; P300; PROTEINS; PROMOTER; PCAF; E2F1	The adenovirus E1A oncoprotein stimulates cell growth and inhibits differentiation by deregulating the normal transcription program via interaction with positive and negative cellular effectors. E1A associates with transcriptional regulatory complexes containing p400 and TRRAP involved in chromatin remodeling and decondensation. TRRAP is a component of three distinct human histone acetyltransferase (HAT) complexes: the TIP60 complex and complexes containing GCN5 or PCAF. We demonstrate here that E1A binds a TRRAP complex that contains the GCN5 acetyltransferase during a normal adenovirus infection. E1A binds GCN5 and TRRAP in vivo early after virus infection. E1A is associated with significant HAT activity in vitro that is partly attributable to GCN5. E1A represses c-Myc- and E2F-1-directed transcriptional activation in vivo by sequestering GCN5 and/or TRRAP. Our results demonstrate that E1A distinctly binds TRRAP/GCN5, p300/CBP and PCAF HAT complexes. Through interactions with multiple HAT complexes, E1A may deregulate cellular transcription programs and facilitate infection by recruiting functional HAT coactivators to viral and cellular promoter regions.	SUNY Stony Brook, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Hearing, P (corresponding author), SUNY Stony Brook, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.				NATIONAL CANCER INSTITUTE [T32CA009176, P01CA028146] Funding Source: NIH RePORTER; NCI NIH HHS [CA09176, CA28146] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chan HM, 2001, J CELL SCI, V114, P2363; Deleu L, 2001, ONCOGENE, V20, P8270, DOI 10.1038/sj.onc.1205159; Fax P, 2000, J BIOL CHEM, V275, P40554, DOI 10.1074/jbc.M004626200; Fax P, 2000, J BIOL CHEM, V275, P8911, DOI 10.1074/jbc.275.12.8911; Flinn EM, 2002, J BIOL CHEM, V277, P23399, DOI 10.1074/jbc.M201704200; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; Kulesza CA, 2002, ONCOGENE, V21, P1411, DOI 10.1038/sj.onc.1205201; Lang SE, 2001, J BIOL CHEM, V276, P32627, DOI 10.1074/jbc.M102067200; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5054, DOI 10.1128/MCB.22.14.5054-5063.2002; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Park J, 2001, GENE DEV, V15, P1619, DOI 10.1101/gad.900101; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Reid JL, 1998, EMBO J, V17, P4469, DOI 10.1093/emboj/17.15.4469; Shuen M, 2002, J BIOL CHEM, V277, P30844, DOI 10.1074/jbc.M201877200; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Trouche D, 1996, P NATL ACAD SCI USA, V93, P1439, DOI 10.1073/pnas.93.4.1439; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WONG HK, 1994, J VIROL, V68, P4910, DOI 10.1128/JVI.68.8.4910-4920.1994	29	70	73	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2003	22	18					2836	2841		10.1038/sj.onc.1206376	http://dx.doi.org/10.1038/sj.onc.1206376			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ	12743606				2022-12-28	WOS:000182569300014
J	Post, DE; Van Meir, EG				Post, DE; Van Meir, EG			A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy	ONCOGENE			English	Article						hypoxia; adenovirus; HIF; gene delivery; oncolysis; tumor	REPLICATION-SELECTIVE ADENOVIRUS; GENE-EXPRESSION; CELL; GENERATION; EFFICACY; VECTORS; SYSTEM; MUTANT; GLIOMA	New therapy targeting the hypoxic fraction of tumors needs to be designed as this population of cells is the most resistant to radio- and chemotherapies. Hypoxia-inducible factor (HIF) mediates transcriptional responses to hypoxia by binding to hypoxia-responsive elements (HRE) in target genes. We developed a <(hyp)under bar>oxia/HIF-dependent replicative <(ad)under bar>enovirus (HYPR-Ad) to target hypoxic cells. HYPR-Ad displays hypoxia-dependent E1A expression and conditional cytolysis of hypoxic but not normoxic cells. This work provides proof-of-principle evidence that an attenuated oncolytic adenovirus that selectively lyses cells under hypoxia can be generated. This therapeutic approach can be used to treat all solid tumors that develop hypoxia, regardless of their tissue origin or genetic alterations.	Emory Univ, Winship Canc Ctr, Mol Neurooncol Lab, Dept Neurosurg, Atlanta, GA 30322 USA; Emory Univ, Winship Canc Ctr, Mol Neurooncol Lab, Dept Hematol Oncol, Atlanta, GA 30322 USA	Emory University; Emory University	Van Meir, EG (corresponding author), Emory Univ, Winship Canc Ctr, Mol Neurooncol Lab, Dept Neurosurg, 1365-B Clifton Rd NE,Rm B5103, Atlanta, GA 30322 USA.	evanmei@emory.edu	Core, Vector/CAF-4832-2022	Van Meir, Erwin G./0000-0003-2444-7707	NCI NIH HHS [CA87830] Funding Source: Medline; NINDS NIH HHS [NS41403] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087830] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS041403] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BETT AJ, 1995, VIRUS RES, V39, P75; Boast K, 1999, HUM GENE THER, V10, P2197, DOI 10.1089/10430349950017185; Brown JM, 2000, MOL MED TODAY, V6, P157, DOI 10.1016/S1357-4310(00)01677-4; Dachs GU, 1997, NAT MED, V3, P515, DOI 10.1038/nm0597-515; DERY CV, 1987, ONCOGENE, V2, P15; Fueyo J, 2000, ONCOGENE, V19, P2, DOI 10.1038/sj.onc.1203251; Fulci G, 2003, FRONT BIOSCI-LANDMRK, V8, pE346, DOI 10.2741/976; GLENN GM, 1988, VIRUS RES, V9, P73, DOI 10.1016/0168-1702(88)90051-2; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Griffiths L, 2000, GENE THER, V7, P255, DOI 10.1038/sj.gt.3301058; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x; Kirn D, 2001, GENE THER, V8, P89, DOI 10.1038/sj.gt.3301377; Koshikawa N, 2000, CANCER RES, V60, P2936; Kruyt FAE, 2002, HUM GENE THER, V13, P485, DOI 10.1089/10430340252809784; Markert JM, 2000, GENE THER, V7, P867, DOI 10.1038/sj.gt.3301205; Modlich U, 2000, GENE THER, V7, P896, DOI 10.1038/sj.gt.3301177; PARKS CL, 1988, J VIROL, V62, P54, DOI 10.1128/JVI.62.1.54-67.1988; Post DE, 2001, GENE THER, V8, P1801, DOI 10.1038/sj.gt.3301605; Prentice H, 1997, CARDIOVASC RES, V35, P567, DOI 10.1016/S0008-6363(97)00158-2; Ruan Hangjun, 1999, Neoplasia (New York), V1, P431, DOI 10.1038/sj.neo.7900059; Ruan HJ, 2001, NEOPLASIA, V3, P255, DOI 10.1038/sj.neo.7900157; Semenza GL, 2000, GENE DEV, V14, P1983; Shibata T, 2000, GENE THER, V7, P493, DOI 10.1038/sj.gt.3301124; Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3; TOLLEFSON AE, 1999, METH MOLEC MED, V21, P1; Tsukuda K, 2002, CANCER RES, V62, P3438; Zhong H, 1999, CANCER RES, V59, P5830	28	100	116	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2003	22	14					2065	2072		10.1038/sj.onc.1206464	http://dx.doi.org/10.1038/sj.onc.1206464			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664NJ	12687009				2022-12-28	WOS:000182066900001
J	Baumann, S; Hess, J; Eichhorst, ST; Krueger, A; Angel, P; Krammer, PH; Kirchhoff, S				Baumann, S; Hess, J; Eichhorst, ST; Krueger, A; Angel, P; Krammer, PH; Kirchhoff, S			An unexpected role for FosB in activation-induced cell death of T cells	ONCOGENE			English	Article						activation-induced cell death; CD95 ligand; AP-1; T cells	FAS-LIGAND EXPRESSION; NF-KAPPA-B; INDUCED APOPTOSIS; TRANSCRIPTION FACTORS; GENE-EXPRESSION; CARCINOMA CELLS; CYCLOSPORINE-A; UP-REGULATION; C-FOS; PROMOTER	The CD95 (APO-1/Fas) system plays a major role in induction of apoptosis in lymphoid and nonlymphoid tissues. The CD95 (APO-1/Fas) ligand (CD95L) is induced in response to a variety of signals including TCR/CD3 stimulation or application of chemotherapeutic drugs. Here we report that an AP-1 site located in the 5' untranslated region of the CD95L gene is required for TCR/CD3-mediated induction of the human CD95L promoter. Electrophoretic mobility shift assays using nuclear extracts of Jurkat T cells as well as TCR/CD3-restimulated primary human T cells demonstrated specific binding of AP-1, predominantly composed of c-Jun and FosB, to this sequence. Ectopic expression of transdominant negative Jun mutants strongly reduced CD95L promoter activity and activation-induced cell death (AICD), confirming the functional significance of FosB/c-Jun binding. Thus, our results demonstrate an important novel function for FosB dimerized with c-Jun in TCR/CD3-mediated AICD in human T cells.	German Canc Res Ctr, Div Immunogenet, D-69120 Heidelberg, Germany; Tumor Immunol Program, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Krammer, PH (corresponding author), German Canc Res Ctr, Div Immunogenet, G0300,Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Hess, Jochen/ABE-1144-2021; Krueger, Andreas/B-9427-2009; Krueger, Andreas/M-9769-2019; Piris, Miguel A/AAP-1445-2020	Hess, Jochen/0000-0003-3493-1711; Krueger, Andreas/0000-0001-7873-7334; Krueger, Andreas/0000-0001-7873-7334; Piris, Miguel A/0000-0001-5839-3634				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chow WA, 2000, J IMMUNOL, V164, P3512, DOI 10.4049/jimmunol.164.7.3512; COCKERILL GW, 1995, BLOOD, V86, P2689; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Eichhorst ST, 2000, MOL CELL BIOL, V20, P7826, DOI 10.1128/MCB.20.20.7826-7837.2000; Faris M, 1998, J IMMUNOL, V160, P134; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Hafezi F, 1997, NAT MED, V3, P346, DOI 10.1038/nm0397-346; Harwood FG, 2000, J BIOL CHEM, V275, P10023, DOI 10.1074/jbc.275.14.10023; Holtz-Heppelmann CJ, 1998, J BIOL CHEM, V273, P4416, DOI 10.1074/jbc.273.8.4416; Ivanov VN, 1997, J BIOL CHEM, V272, P8558; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kasibhatla S, 1999, J BIOL CHEM, V274, P987, DOI 10.1074/jbc.274.2.987; Kirchhoff S, 2000, J IMMUNOL, V165, P6293, DOI 10.4049/jimmunol.165.11.6293; Kolbus A, 2000, MOL CELL BIOL, V20, P575, DOI 10.1128/MCB.20.2.575-582.2000; Li-Weber M, 2000, EUR J IMMUNOL, V30, P661, DOI 10.1002/1521-4141(200002)30:2<661::AID-IMMU661>3.3.CO;2-C; Li-Weber M, 1998, EUR J IMMUNOL, V28, P2373, DOI 10.1002/(SICI)1521-4141(199808)28:08<2373::AID-IMMU2373>3.0.CO;2-T; Li-Weber M, 1999, EUR J IMMUNOL, V29, P3017, DOI 10.1002/(SICI)1521-4141(199909)29:09<3017::AID-IMMU3017>3.0.CO;2-R; Lidwell K, 2000, J NEUROSCI RES, V62, P427, DOI 10.1002/1097-4547(20001101)62:3<427::AID-JNR13>3.0.CO;2-O; Macian F, 2000, EMBO J, V19, P4783, DOI 10.1093/emboj/19.17.4783; Matsui K, 2000, J IMMUNOL, V164, P3002, DOI 10.4049/jimmunol.164.6.3002; Mittelstadt PR, 1998, MOL CELL BIOL, V18, P3744, DOI 10.1128/MCB.18.7.3744; Mittelstadt PR, 1999, J BIOL CHEM, V274, P3222, DOI 10.1074/jbc.274.5.3222; Norian LA, 1998, J IMMUNOL, V161, P1078; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rivera I, 1998, J BIOL CHEM, V273, P22382, DOI 10.1074/jbc.273.35.22382; ROONEY JW, 1995, IMMUNITY, V2, P473, DOI 10.1016/1074-7613(95)90028-4; Schmitz I, 2000, INT J BIOCHEM CELL B, V32, P1123, DOI 10.1016/S1357-2725(00)00048-0; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200; Zhang J, 2000, J EXP MED, V191, P1017, DOI 10.1084/jem.191.6.1017	37	32	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2003	22	9					1333	1339		10.1038/sj.onc.1206126	http://dx.doi.org/10.1038/sj.onc.1206126			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618758				2022-12-28	WOS:000181360900007
J	Bigler, D; Gulding, KM; Dann, R; Sheabar, FZ; Conaway, MR; Theodorescu, D				Bigler, D; Gulding, KM; Dann, R; Sheabar, FZ; Conaway, MR; Theodorescu, D			Gene profiling and promoter reporter assays: Novel tools for comparing the biological effects of botanical extracts on human prostate cancer cells and understanding their mechanisms of action	ONCOGENE			English	Article						prostate neoplasms; gene profiling; androgen; estrogen; prostate-specific antigen/PSA; plant extracts	PC-SPES; IN-VITRO; EXPRESSION; ANDROGEN; LNCAP; DIETHYLSTILBESTROL; IDENTIFICATION; THERAPY	The use of botanical mixtures is commonplace in patients with prostate cancer, yet the majority of these products have not been rigorously tested in clinical trials. Here we use PC-SPES, a combination of eight herbs that has been shown to be effective in clinical trials in patients with prostate cancer, as a model system to demonstrate 'proof of principle' as to how gene expression profiling coupled with promoter assays can evaluate the effect of herbal cocktails on human prostate cancer. In addition, we demonstrate how such approaches may be used for standardization of herbal extract activity by comparing the gene profile of PC-SPES with that of PC-CARE, a product with a similar herbal composition. Since prior studies have shown that PC-SPES contains estrogenic organic compounds, and such compounds are known to affect prostate cancer, an important issue is whether these are the primary drivers of the gene profile. Our data suggest that gene expression profiles of LNCaP human prostate cancer cells in response to PC-SPES are different from those found when diethylstilbestrol (DES), a synthetic estrogen, is used, suggesting that the estrogenic moieties within PC-SPES do not drive this expression signature. In contrast, the expression profile of PC-CARE was almost identical to that of DES, highlighting that mixtures containing similar herbal compositions do not necessarily result in similar biological activities. Interestingly, these three agents cause similar in vitro morphological changes and growth effects on LNCaP. To validate the expression profiling data, we evaluated the protein expression and promoter activity of prostate-specific antigen (PSA), a gene induced by PC-SPES but repressed by DES. In order to gain a mechanistic understanding of how PC-SPES and DES affect PSA expression differently, LNCaP cells were transiently transfected with wild-type and mutagenized PSA promoter, ARE concatemers and appropriate controls. We provide evidence that androgen response elements (ARE) II and III within the promoter region are responsible for the suppressive effects of DES and stimulatory effects of PC-SPES. In addition, we show that the effects on PSA transcription are ARE specific in the case of DES while PC-SPES affects this promoter nonspecifically. In conclusion, expression profiting coupled with mechanistic target validation yield valuable clues as to the mode of action of complex botanical mixtures and provides a new way to compare objectively mixtures with similar components either for effect or quality assurance prior to their use in clinical trials.	Univ Virginia, Hlth Sci Ctr, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Ctr Canc, Charlottesville, VA 22908 USA; Kemin Foods, Prot & Bioassays Dev Grp, Des Moines, IA USA; Univ Virginia, Hlth Sci Ctr, Dept Hlth Evaluat Sci Biostat, Charlottesville, VA USA	University of Virginia; University of Virginia; University of Virginia	Theodorescu, D (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Mol Physiol & Biol Phys, Box 422, Charlottesville, VA 22908 USA.	dt9d@virginia.edu						Averboukh L, 1996, PROSTATE, V29, P350; Bonham M, 2002, CANCER RES, V62, P3920; Bubley GJ, 1999, J CLIN ONCOL, V17, P3461, DOI 10.1200/JCO.1999.17.11.3461; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P148, DOI 10.1210/me.11.2.148; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; Darzynkiewicz Z, 2000, INT J ONCOL, V17, P729; De la Taille A, 2000, J UROLOGY, V164, P1229, DOI 10.1097/00005392-200010000-00021; DiPaola RS, 1998, NEW ENGL J MED, V339, P785, DOI 10.1056/NEJM199809173391201; Helps NR, 2000, BIOCHEM J, V349, P509, DOI 10.1042/0264-6021:3490509; Hsieh TC, 1997, BIOCHEM MOL BIOL INT, V42, P535; Kubota T, 2000, PROSTATE, V42, P163; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Malkowicz SB, 2001, UROLOGY, V58, P108, DOI 10.1016/S0090-4295(01)01252-3; MONTGOMERY BT, 1992, PROSTATE, V21, P63, DOI 10.1002/pros.2990210107; Oh MK, 2001, UROLOGY, V57, P122, DOI 10.1016/S0090-4295(00)00986-9; Schadt EE, 2001, J CELL BIOCHEM, V84, P120, DOI 10.1002/jcb.10073; Schadt EE, 2000, J CELL BIOCHEM, V80, P192; Seraj MJ, 2001, CLIN EXP METASTAS, V18, P519, DOI 10.1023/A:1011819621859; Small EJ, 2000, J CLIN ONCOL, V18, P3595, DOI 10.1200/JCO.2000.18.21.3595; SMALL EJ, 2002, J CLIN ONCOL, V21; Sovak M, 2002, J NATL CANCER I, V94, P1275, DOI 10.1093/jnci/94.17.1275; Takezawa Y, 2001, SCAND J UROL NEPHROL, V35, P283; Turner KJ, 2001, MOL CELL ENDOCRINOL, V178, P73, DOI 10.1016/S0303-7207(01)00413-0; White J, 2002, JNCI-J NATL CANCER I, V94, P1261, DOI 10.1093/jnci/94.17.1261; WU HC, 1994, INT J CANCER, V57, P406, DOI 10.1002/ijc.2910570319	25	19	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2003	22	8					1261	1272		10.1038/sj.onc.1206242	http://dx.doi.org/10.1038/sj.onc.1206242			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650EK	12606954				2022-12-28	WOS:000181249700016
J	Logette, E; Wotawa, A; Solier, S; Desoche, L; Solary, E; Corcos, L				Logette, E; Wotawa, A; Solier, S; Desoche, L; Solary, E; Corcos, L			The human caspase-2 gene: alternative promoters, pre-mRNA splicing and AUG usage direct isoform-specific expression	ONCOGENE			English	Article						caspase-2 gene; casp-2S; casp-2L; AUG; mRNA splicing; transcriptional regulation	PROGRAMMED CELL-DEATH; NEDD2 PRECURSOR; GRANZYME-B; BCL-X; APOPTOSIS; PROTEIN; IDENTIFICATION; ACTIVATION; PRODOMAIN; CASCADE	Caspases have been shown to play important roles in apoptotic cell death, cytokine maturation and cell differentiation. However, the transcriptional regulation of the corresponding CASP genes remains poorly known. We describe a 5.1 kb fragment located upstream of the first translated exon in the human CASP-2 gene, which is known to encode caspase-2L, and -2S protein isoforms. Transient transfection experiments, together with transcription start site mapping and transcript analysis, demonstrate that each caspase mRNA is initiated from separate promoter regions, and produced from alternative splicing events in these regions. The CASP-2L promoter is much stronger than the CASP-2S promoter, in good agreement with the respective transcript levels of the two caspases. In addition, several in-frame translational start sites can be identified for each isoform, one of which is common to both, present in the second common exon, and used efficiently. Surprisingly, the short isoform may also be initiated at a downstream AUG codon within the same exon. Thus, promoter strength, alternative transcriptional initiation and 5'-splicing events regulate the expression of the main caspase-2 isoforms that may be translated from alternative translation initiation codons.	INSERM, U517, Fac Med, F-21000 Dijon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne	Corcos, L (corresponding author), INSERM, U517, Fac Med, 7 Bd Jeanne Arc, F-21000 Dijon, France.		Corcos, Laurent/M-8915-2017; SOLIER, STEPHANIE/AAA-6851-2020; Corcos, Laurent/AAJ-2692-2020	Corcos, Laurent/0000-0001-8019-2505; Solary, Eric/0000-0002-8629-1341; SOLIER, Stephanie/0000-0003-3867-4644				Ahmad M, 1997, CANCER RES, V57, P615; Allet B, 1996, J CELL BIOL, V135, P479, DOI 10.1083/jcb.135.2.479; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Asahi M, 1997, J CEREBR BLOOD F MET, V17, P11, DOI 10.1097/00004647-199701000-00003; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bonfoco E, 2001, J BIOL CHEM, V276, P29242, DOI 10.1074/jbc.M100684200; Butt AJ, 1998, J BIOL CHEM, V273, P6763, DOI 10.1074/jbc.273.12.6763; Colussi PA, 1998, J BIOL CHEM, V273, P24535, DOI 10.1074/jbc.273.38.24535; Colussi PA, 1998, J BIOL CHEM, V273, P26566, DOI 10.1074/jbc.273.41.26566; Cote J, 2001, J BIOL CHEM, V276, P8535, DOI 10.1074/jbc.M008924200; Cote J, 2001, P NATL ACAD SCI USA, V98, P938, DOI 10.1073/pnas.031564098; Droin N, 1998, ONCOGENE, V16, P2885, DOI 10.1038/sj.onc.1201821; Droin N, 2001, BLOOD, V97, P1835, DOI 10.1182/blood.V97.6.1835; Droin N, 2001, ONCOGENE, V20, P260, DOI 10.1038/sj.onc.1204066; Droin N, 2000, CANCER RES, V60, P7039; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Harvey NL, 1996, GENES CELLS, V1, P673, DOI 10.1046/j.1365-2443.1996.00255.x; Ito A, 2000, FEBS LETT, V470, P360, DOI 10.1016/S0014-5793(00)01351-X; Jiang ZH, 1999, P SOC EXP BIOL MED, V220, P64, DOI 10.1046/j.1525-1373.1999.d01-11.x; Kojima M, 1998, NEUROSCI RES, V31, P211, DOI 10.1016/S0168-0102(98)00039-X; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; KUMAR S, 1995, FEBS LETT, V368, P69, DOI 10.1016/0014-5793(95)00602-6; Kumar Sharad, 1997, Leukemia (Basingstoke), V11, P385; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; Liu WF, 2002, J BIOL CHEM, V277, P8273, DOI 10.1074/jbc.M110768200; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Mendelsohn AR, 2002, P NATL ACAD SCI USA, V99, P6871, DOI 10.1073/pnas.072290599; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Morita Y, 2001, CELL DEATH DIFFER, V8, P614, DOI 10.1038/sj.cdd.4400845; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Nishiyama J, 2001, BIOCHEM J, V360, P49, DOI 10.1042/0264-6021:3600049; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; Paroni G, 2001, J BIOL CHEM, V276, P21907, DOI 10.1074/jbc.M011565200; Pecci A, 2001, J BIOL CHEM, V276, P21062, DOI 10.1074/jbc.M008665200; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Sato N, 1997, GENE, V202, P127, DOI 10.1016/S0378-1119(97)00463-0; Shikama Y, 2001, EXP CELL RES, V264, P315, DOI 10.1006/excr.2000.5153; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Sordet O, 2002, LEUKEMIA, V16, P1569, DOI 10.1038/sj.leu.2402524; Stefanis L, 1998, J NEUROSCI, V18, P9204; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Swanton E, 1999, ONCOGENE, V18, P1781, DOI 10.1038/sj.onc.1202490; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Troy CM, 2000, J NEUROSCI, V20, P1386; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Willis AE, 1999, INT J BIOCHEM CELL B, V31, P73, DOI 10.1016/S1357-2725(98)00133-2; Wotawa A, 2002, CANCER LETT, V185, P181, DOI 10.1016/S0304-3835(02)00287-2	53	40	44	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 13	2003	22	6					935	946		10.1038/sj.onc.1206172	http://dx.doi.org/10.1038/sj.onc.1206172			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584573				2022-12-28	WOS:000180864300016
J	Mateos, S; Calothy, G; Lamballe, F				Mateos, S; Calothy, G; Lamballe, F			The noncatalytic TrkCNC2 receptor is cleaved by metalloproteases upon neurotrophin-3 stimulation	ONCOGENE			English	Article						neurotrophin; Trk receptor; metalloendoproteases	NERVE GROWTH-FACTOR; TYROSINE PROTEIN-KINASE; EXTRACELLULAR DOMAIN; TRUNCATED RECEPTORS; ERBB-4 RECEPTOR; RAT TRKC; IDENTIFICATION; ENCODES; MEMBER; FAMILY	The trkC locus encodes catalytic and noneatalytic receptors, generated by alternative splicing. These primary high-affinity neurotrophin-3 (NT-3) receptors may act in concert to modulate responsiveness to NT-3. Signal modulation can also be achieved by receptors that are post-translationally processed. We report that the noncatalytic TrkC receptor, TrkCNC2, is cleaved at the membrane-proximal region of its extracellular domain. This generates a soluble ectodomain (gp90(TrkCNC2)) recovered in the cell culture medium and a membrane-bound fragment (p20(TrkCNC2)), which contains the transmembrane and intracellular regions including the juxtamembrane and the NC2-specific cytoplasmic domains. We also show that this processing, which does not occur in the TrkC catalytic counterpart, is upregulated by NT-3 and upon treatment with the tumor promoter 12-O-tetradecanoylphorbol-13-acetate. Moreover, cleavage inhibition after EDTA or 1.10 phenanthroline treatment suggests involvement of a metalloprotease(s). Finally, this post-translational processing was observed not only in TrkCNC2-overexpressing NIH3T3 cells but also in primary cultures of cortical neurons and brain extracts. This study shows that, in addition to alternative splicing, ectodomain shedding represents a novel means of regulating TrkC receptor signaling, and consequently NT-3 biological effects on target cells.	Ctr Univ Orsay, Inst Curie, CNRS UMR 146, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Lamballe, F (corresponding author), IBDM, INSERM, U382, Campus Luminy,Case 907, F-13288 Marseille 09, France.	lamballe@ibdm.univ-mrs.fr	Lamballe, Fabienne/P-4293-2017; Lamballe, Fabienne/GLT-0820-2022	Lamballe, Fabienne/0000-0001-7631-942X				BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; Benn B, 1998, J COMP NEUROL, V401, P47, DOI 10.1002/(SICI)1096-9861(19981109)401:1<47::AID-CNE4>3.0.CO;2-C; BIFFO S, 1995, DEVELOPMENT, V121, P2461; Butowt R, 2001, J NEUROSCI, V21, P8915, DOI 10.1523/JNEUROSCI.21-22-08915.2001; Cabrera N, 1996, J CELL BIOL, V132, P427, DOI 10.1083/jcb.132.3.427; CLARY DO, 1994, P NATL ACAD SCI USA, V91, P11133, DOI 10.1073/pnas.91.23.11133; Diaz-Rodriguez E, 1999, EUR J NEUROSCI, V11, P1421, DOI 10.1046/j.1460-9568.1999.00552.x; DISTEFANO PS, 1988, P NATL ACAD SCI USA, V85, P270, DOI 10.1073/pnas.85.1.270; DISTEFANO PS, 1993, J NEUROSCI, V13, P2405, DOI 10.1523/JNEUROSCI.13-06-02405.1993; Donovan MJ, 1996, NAT GENET, V14, P210, DOI 10.1038/ng1096-210; Eide FF, 1996, J NEUROSCI, V16, P3123; GARNER AS, 1994, NEURON, V13, P457, DOI 10.1016/0896-6273(94)90360-3; GOTZ R, 1994, NATURE, V372, P266, DOI 10.1038/372266a0; Hapner SJ, 1998, DEV BIOL, V201, P90, DOI 10.1006/dbio.1998.8970; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; LAMBALLE F, 1993, EMBO J, V12, P3083, DOI 10.1002/j.1460-2075.1993.tb05977.x; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; Menn B, 2000, EUR J NEUROSCI, V12, P3211, DOI 10.1046/j.1460-9568.2000.00215.x; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; Nilsson AS, 1998, FEBS LETT, V424, P285, DOI 10.1016/S0014-5793(98)00192-6; Ninkina N, 1997, J BIOL CHEM, V272, P13019, DOI 10.1074/jbc.272.20.13019; PANDIELLAALONSO A, 1986, FEBS LETT, V208, P48, DOI 10.1016/0014-5793(86)81529-0; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; SHELTON DL, 1995, J NEUROSCI, V15, P477, DOI 10.1523/jneurosci.15-01-00477.1995; Strohmaier C, 1996, EMBO J, V15, P3332, DOI 10.1002/j.1460-2075.1996.tb00698.x; Tessarollo L, 1997, P NATL ACAD SCI USA, V94, P14776, DOI 10.1073/pnas.94.26.14776; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; VALENZUELA DM, 1993, NEURON, V10, P963, DOI 10.1016/0896-6273(93)90211-9; Vecchi M, 1998, J BIOL CHEM, V273, P20589, DOI 10.1074/jbc.273.32.20589; Vecchi M, 1997, J CELL BIOL, V139, P995, DOI 10.1083/jcb.139.4.995; YEE NS, 1993, J BIOL CHEM, V268, P14189; ZUPAN AA, 1989, J BIOL CHEM, V264, P11714	35	9	10	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2003	22	5					740	745		10.1038/sj.onc.1206213	http://dx.doi.org/10.1038/sj.onc.1206213			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569366				2022-12-28	WOS:000180642100011
J	van Wely, KHM; Molijn, AC; Buijs, A; Meester-Smoor, MA; Aarnoudse, AJ; Hellemons, A; den Besten, P; Grosveld, GC; Zwarthoff, EC				van Wely, KHM; Molijn, AC; Buijs, A; Meester-Smoor, MA; Aarnoudse, AJ; Hellemons, A; den Besten, P; Grosveld, GC; Zwarthoff, EC			The MN1 oncoprotein synergizes with coactivators RAC3 and p300 in RAR-RXR-mediated transcription	ONCOGENE			English	Article						translocation; leukemia; retinoic acid; hormone receptor; coactivator	ACUTE PROMYELOCYTIC LEUKEMIA; FUSION PROTEIN; DNA-BINDING; PROGESTERONE-RECEPTOR; RESPONSE ELEMENTS; MYELOID-LEUKEMIA; CELL-GROWTH; GENE; TEL; DOMAINS	The t(12;22) creates an MN1-TEL fusion gene leading to acute myeloid leukemia. The fusion partner TEL (ETV6) is a member of the ETS family of transcription factors. The nature of the other fusion partner, MAII, has not been investigated in detail until now. We recently described that MN1 activates the transcription activity of the moloney sarcoma virus long terminal repeat, indicating that this protein itself may act as a transcription factor. We show here that MN1 comprises multiple transcription activating domains. A search for a bound DNA sequence revealed that MN1 has affinity for retinoic acid responsive elements. A DR5 retinoic acid responsive element was observed in the LTR. The combination of MN1 and ligand-activated retinoic acid receptor leads to a synergistic induction of expression directed by the LTR. Cotransfection of MN1 with RAC3 or p300, known coactivators of retinoic acid receptors, leads to a further synergistic induction of transcription. In addition, the effect of MN1 can be inhibited by the wild-type adenovirus E1A protein that inhibits p300 function, but not by an E1A mutant lacking the p300-binding site. GAL4-MN1-mediated transcription can be enhanced directly by RAC3 and p300. Taken together, our results indicate that MN1 is a transcription coactivator rather than a sequence-specific transcription factor, and that it may stimulate RAR/RXR-mediated transcription through interaction with p160 and p300.	Erasmus Univ, Dept Pathol, NL-3000 DR Rotterdam, Netherlands; Univ Utrecht Hosp, Dept Hematol, NL-3584 CX Utrecht, Netherlands; St Jude Childrens Res Hosp, Dept Genet, Memphis, TN 38101 USA	Erasmus University Rotterdam; Utrecht University; Utrecht University Medical Center; St Jude Children's Research Hospital	Zwarthoff, EC (corresponding author), Erasmus Univ, Dept Pathol, POB 1738, NL-3000 DR Rotterdam, Netherlands.	zwarthoff@path.fgg.eur.nl		van Wely, Karel Hermanus Martinus/0000-0001-8431-8072	NATIONAL CANCER INSTITUTE [R01CA072996] Funding Source: NIH RePORTER; NCI NIH HHS [CA72996-04] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Beverloo HB, 2001, CANCER RES, V61, P5374; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; Buijs A, 2000, MOL CELL BIOL, V20, P9281, DOI 10.1128/MCB.20.24.9281-9293.2000; Cazzaniga G, 2001, CANCER RES, V61, P4666; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; DENBAKKER MA, 1995, AM J PATHOL, V147, P1339; DEPREZ RHL, 1995, ONCOGENE, V10, P1521; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; DORSMAN JC, 1995, J VIROL, V69, P2962, DOI 10.1128/JVI.69.5.2962-2967.1995; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; Goodman RH, 2000, GENE DEV, V14, P1553; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Li H, 1998, J BIOL CHEM, V273, P5948, DOI 10.1074/jbc.273.10.5948; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; Nakshatri H, 1998, NUCLEIC ACIDS RES, V26, P2491, DOI 10.1093/nar/26.10.2491; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Shao WL, 2000, BLOOD, V96, P2233; SHEMSHEDINI L, 1992, J BIOL CHEM, V267, P1834; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Wang ZG, 1998, SCIENCE, V279, P1547; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; Xu Y, 2000, MOL CELL BIOL, V20, P2138, DOI 10.1128/MCB.20.6.2138-2146.2000; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x	38	65	66	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2003	22	5					699	709		10.1038/sj.onc.1206124	http://dx.doi.org/10.1038/sj.onc.1206124			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569362				2022-12-28	WOS:000180642100007
J	Silva, FPG; Morolli, B; Storlazzi, CT; Anelli, L; Wessels, H; Bezrookove, V; Kluin-Nelemans, HC; Giphart-Gassler, M				Silva, FPG; Morolli, B; Storlazzi, CT; Anelli, L; Wessels, H; Bezrookove, V; Kluin-Nelemans, HC; Giphart-Gassler, M			Identification of RUNX1/AML1 as a classical tumor suppressor gene	ONCOGENE			English	Article						RUNX1; tumor suppressor gene; AML; leukemia	ACUTE MYELOID-LEUKEMIA; PROTEIN-PROTEIN INTERACTIONS; CORE-BINDING FACTOR; RUNT DOMAIN; DNA-BINDING; TRANSCRIPTIONAL REGULATION; AML1/PEBP2-ALPHA-B GENE; POINT MUTATIONS; VIRUS ENHANCERS; C/EBP-ALPHA	Based on our previous results indicating the presence of a tumor suppressor gene (TSG), chromosome 21 was analysed for loss of heterozygosity (LOH) in 18 patients with acute myeloid leukemia (17, AML-M0; one, AML-M1). Allelotyping at polymorphic loci was performed on purified material, allowing unequivocal detection of allelic loss and homozygous deletions. Six AML-M0 patients shared a common region of LOH harboring a single gene: RUNX1 (AML1), the most frequent site of translocations in acute leukemia and a well-known fusion oncogene. Fluorescence in situ hybridization allowed the identification of deletions with breakpoints within RUNX1 in two patients as the cause of LOH. In the four others the LOH pattern and the presence of two karyotypically normal chromosomes 21 were in line with mitotic recombination. Further molecular and cytogenetic analyses showed that this caused homozygosity of primary RUNX1 mutations: two point mutations, a partial deletion and, most significantly, a complete deletion of RUNX1. These findings identify RUNX1 as a classical TSG: both alleles are mutated or absent in cancer cells from four of the 17 AML-M0 patients examined. In contrast to AML-MO, the AML-M1 patient was trisomic for chromosome 21 and has two mutated - and one normal RUNX1 allele, suggesting that the order of mutagenic events leading to leukemia may influence the predominant tumor type.	Leiden Univ, Ctr Med, Dept Radiat Genet & Chem Mutagensis, NL-2600 RA Leiden, Netherlands; Univ Bari, Dept Genet, I-70126 Bari, Italy; Leiden Univ, Ctr Med, Dept Clin Cytogenet, NL-2300 RA Leiden, Netherlands; Leiden Univ, Ctr Med, Dept Mol Cell Biol, NL-2300 RA Leiden, Netherlands; Leiden Univ, Ctr Med, Dept Hematol, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC; Universita degli Studi di Bari Aldo Moro; Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC	Giphart-Gassler, M (corresponding author), Leiden Univ, Ctr Med, Dept Radiat Genet & Chem Mutagensis, POB 9503, NL-2600 RA Leiden, Netherlands.		Kluin-Nelemans, Johanna C/F-8658-2018; Silva, Fernando/N-1847-2014; Anelli, Luisa/K-2661-2016	Kluin-Nelemans, Johanna C/0000-0003-2617-9427; Silva, Fernando/0000-0003-2379-9137; Anelli, Luisa/0000-0002-9185-724X; Storlazzi, Clelia Tiziana/0000-0002-1696-0028				BENNETT JM, 1991, BRIT J HAEMATOL, V78, P325, DOI 10.1111/j.1365-2141.1991.tb04444.x; BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; Buijs A, 2001, BLOOD, V98, P2856, DOI 10.1182/blood.V98.9.2856; Cockerill PN, 1996, CELL GROWTH DIFFER, V7, P917; de Nooij-van Dalen AG, 1998, GENE CHROMOSOME CANC, V21, P30, DOI 10.1002/(SICI)1098-2264(199801)21:1<30::AID-GCC5>3.0.CO;2-9; de Nooij-van Dalen AG, 2001, GENE CHROMOSOME CANC, V30, P323, DOI 10.1002/gcc.1098; Devilee P, 2001, TRENDS GENET, V17, P569, DOI 10.1016/S0168-9525(01)02416-7; Friedman AD, 1996, LEUKEMIA RES, V20, P809, DOI 10.1016/S0145-2126(96)00035-5; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; Giphart-Gassler M, 1998, MUTAT RES-FUND MOL M, V400, P409, DOI 10.1016/S0027-5107(98)00022-0; Hiebert SW, 2001, CURR OPIN HEMATOL, V8, P197, DOI 10.1097/00062752-200107000-00003; Holt D, 1999, AM J HUM GENET, V65, P1423, DOI 10.1086/302614; Kagoshima H, 1996, J BIOL CHEM, V271, P33074, DOI 10.1074/jbc.271.51.33074; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; Krug U, 2002, ONCOGENE, V21, P3475, DOI 10.1038/sj.onc.1205322; Langabeer SE, 2002, GENE CHROMOSOME CANC, V34, P24, DOI 10.1002/gcc.10031; Lenny N, 1997, MOL BIOL REP, V24, P157, DOI 10.1023/A:1006859700409; LICHTER P, 1990, P NATL ACAD SCI USA, V87, P6634, DOI 10.1073/pnas.87.17.6634; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Lund AH, 2002, CANCER CELL, V1, P213, DOI 10.1016/S1535-6108(02)00049-1; Mao SF, 1999, MOL CELL BIOL, V19, P3635; Meyers S, 1995, CRIT REV EUKAR GENE, V5, P365, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.70; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; Michaud J, 2002, BLOOD, V99, P1364, DOI 10.1182/blood.V99.4.1364; Mikhail FM, 2002, LEUKEMIA, V16, P658, DOI 10.1038/sj.leu.2402399; Mitelman F., 1995, ISCN INT SYSTEM HUMA; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; Nagata T, 2001, J MOL BIOL, V308, P191, DOI 10.1006/jmbi.2001.4596; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Preudhomme C, 2000, BLOOD, V96, P2862, DOI 10.1182/blood.V96.8.2862.h8002862_2862_2869; REDONDO JM, 1992, MOL CELL BIOL, V12, P4817, DOI 10.1128/MCB.12.11.4817; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Speck NA, 2002, NAT REV CANCER, V2, P502, DOI 10.1038/nrc840; SUDOL M, 1994, ONCOGENE, V9, P2145; Tahirov TH, 2001, CELL, V104, P755, DOI 10.1016/S0092-8674(01)00271-9; Tanaka Tomoyuki, 1997, Leukemia (Basingstoke), V11, P299; Tanke HJ, 1999, EUR J HUM GENET, V7, P2, DOI 10.1038/sj.ejhg.5200265; Uchida H, 1997, J IMMUNOL, V158, P2251; VANDAM FJ, 1992, MUTAT RES, V271, P231, DOI 10.1016/0165-1161(92)90018-H; Vrieling H, 2001, NAT GENET, V28, P101, DOI 10.1038/88794; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Zhang DE, 1996, MOL CELL BIOL, V16, P1231	48	57	59	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 30	2003	22	4					538	547		10.1038/sj.onc.1206141	http://dx.doi.org/10.1038/sj.onc.1206141			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555067				2022-12-28	WOS:000180538200007
J	Jishage, M; Fujino, T; Yamazaki, Y; Kuroda, H; Nakamura, T				Jishage, M; Fujino, T; Yamazaki, Y; Kuroda, H; Nakamura, T			Identification of target genes for EWS/ATF-1 chimeric transcription factor	ONCOGENE			English	Article						clear cell sarcoma; EWS/ATF-1; transcription factor; target gene; POSH	RNA-POLYMERASE-II; CHROMOSOME-TRANSLOCATION; MALIGNANT-MELANOMA; HOMEOBOX GENES; SOFT PARTS; ATAXIA-TELANGIECTASIA; DNA-BINDING; FUSION; EWS; RECEPTOR	Chromatin immunoprecipitation is a useful technique to detect in vivo direct interaction between any transcription factor and its binding site on genomic DNA. We applied this skill to identify the direct target gene for EWS/ATF-1 by coupling with a GFP reporter assay. This novel approach isolated 62 of cloned DNA fragments responding upon EWS/ATF-1 expression and 16 of 62 clones included putative ATF-1 binding sites. Further analysis revealed that six of the cloned fragments included possible regulatory regions of ATM, GPP34, ARNT2, NKX6.1, NYD-SP28 and POSH. Most of these clones upregulated reporter activity by overexpression of EWS/ATF-1, suggesting that putative ATF-1 binding sites in these clones are functional elements for ATF-1 in vivo. Consistently, endogenous expression of these genes was upregulated by EWS/ATF-1. Interestingly, the clone containing the promoter region of POSH, which is known to be a strong inducer of apoptosis, repressed reporter activity by overexpression of EWS/ATF-1. Correspondingly, EWS/ATF-1 expression decreased endogenous POSH expression, suggesting that six isolated genes may be involved in direct regulation by EWS/ATF-1. Moreover, induction of POSH brought apoptotic cell death to KAS, the clear cell sarcoma (CCS) cell line, suggesting that repressed expression of POSH in CCS may be relevant to the normal signaling pathway in apoptosis.	Japanese Fdn Canc Res, Inst Canc, Dept Carcinogenesis, Toshima Ku, Tokyo 1708455, Japan; Tokyo Med & Dent Univ, Dept Orthoped, Fac Med, Tokyo 1130034, Japan	Japanese Foundation for Cancer Research; Tokyo Medical & Dental University (TMDU)	Nakamura, T (corresponding author), Japanese Fdn Canc Res, Inst Canc, Dept Carcinogenesis, Toshima Ku, 1-37-1 Kami Ikebukuro, Tokyo 1708455, Japan.			Fujino, Takashi/0000-0002-0953-7379				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bell AW, 2001, J BIOL CHEM, V276, P5152, DOI 10.1074/jbc.M006143200; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; BROWN AD, 1995, ONCOGENE, V10, P1749; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; ENZINGER FM, 1995, SOFT TISSUE TUMORS, P889; Fujimura Y, 1996, ONCOGENE, V12, P159; Fujino T, 2001, EXP HEMATOL, V29, P856, DOI 10.1016/S0301-472X(01)00655-5; Gueven N, 2001, J BIOL CHEM, V276, P8884, DOI 10.1074/jbc.M006190200; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Hirose K, 1996, MOL CELL BIOL, V16, P1706; JACOBS Y, 1993, MOL CELL BIOL, V13, P7321, DOI 10.1128/MCB.13.12.7321; Jean D, 2000, ONCOGENE, V19, P2721, DOI 10.1038/sj.onc.1203569; KUO MH, 1996, METHODS, V3, P425; LABELLE Y, 1995, HUM MOL GENET, V4, P2219, DOI 10.1093/hmg/4.12.2219; LADANYI M, 1994, CANCER RES, V54, P2837; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Macaulay VM, 2001, ONCOGENE, V20, P4029, DOI 10.1038/sj.onc.1204565; Maltepe E, 2000, BIOCHEM BIOPH RES CO, V273, P231, DOI 10.1006/bbrc.2000.2928; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; OHNO T, 1994, ONCOGENE, V9, P3087; Orlando V, 2000, TRENDS BIOCHEM SCI, V25, P99, DOI 10.1016/S0968-0004(99)01535-2; Panagopoulos I, 1996, ONCOGENE, V12, P489; Rossow KL, 2001, CANCER RES, V61, P2690; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; RUDNICK A, 1994, P NATL ACAD SCI USA, V91, P12203, DOI 10.1073/pnas.91.25.12203; Sander M, 2000, GENE DEV, V14, P2134, DOI 10.1101/gad.820400; Schaefer KL, 2002, VIRCHOWS ARCH, V440, P476, DOI 10.1007/s00428-001-0558-9; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Tapon N, 1998, EMBO J, V17, P1395, DOI 10.1093/emboj/17.5.1395; Watson D K, 2000, Methods Mol Biol, V130, P1; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Yang L, 2000, J BIOL CHEM, V275, P37612, DOI 10.1074/jbc.M005739200; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341	40	24	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 9	2003	22	1					41	49		10.1038/sj.onc.1206074	http://dx.doi.org/10.1038/sj.onc.1206074			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527906				2022-12-28	WOS:000180166900005
J	Skorski, T				Skorski, T			BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability	ONCOGENE			English	Review						DNA damage; DNA repair; apoptosis; checkpoint	DOUBLE-STRAND BREAKS; CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE INHIBITOR; CHRONIC MYELOGENOUS LEUKEMIA; ABL-MEDIATED RESISTANCE; CELL-CYCLE CHECKPOINTS; HUMAN RAD51 PROTEIN; BONE-MARROW-CELLS; BCR-ABL; HOMOLOGOUS RECOMBINATION	BCR/ABL regulates cell proliferation, apoptosis, differentiation and adhesion. In addition, BCR/ABL can induce resistance to cytostatic drugs and irradiation by modulation of DNA repair mechanisms, cell cycle checkpoints and Bcl-2 protein family members. Upon DNA damage BCR/ABL not only enhances reparation of DNA lesions (e.g. homologous recombination repair), but also prolongs activation of cell cycle checkpoints (e.g. G2/M) providing more time for repair of otherwise lethal lesions. Moreover, by modification of antiapoptotic members of the Bcl-2 family (e.g. upregulation of BCL-x(L) BCR/ABL provides a cytoplasmic 'umbrella' protecting mitochondria from the 'rain' of apoptotic signals coming from the damaged DNA in the nucleus, thus preventing release of cytochrome c and activation of caspases. The unrepaired and/or aberrantly repaired (but not lethal) DNA lesions resulting from spontaneous and/or drug-induced damage can accumulate in BCR/ABL transformed cells leading to genomic instability and malignant progression of the disease. Inhibition of BCR/ABL kinase activity by STI571 (Gleevec, imatinib mesylate) reverses drug resistance and, in combination with standard chemotherapeutics can exert strong antileukemia effect.	Temple Univ, Coll Sci & Technol, Ctr Biotechnol, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Skorski, T (corresponding author), Temple Univ, Coll Sci & Technol, Ctr Biotechnol, Philadelphia, PA 19122 USA.	tskorski@astro.temple.edu						Aitken RJ, 2001, REPRODUCTION, V122, P497, DOI 10.1530/rep.0.1220497; Albala JS, 1997, GENOMICS, V46, P476, DOI 10.1006/geno.1997.5062; Albrecht T, 1996, BRIT J HAEMATOL, V95, P501, DOI 10.1046/j.1365-2141.1996.d01-1934.x; ALIMENA G, 1987, CANCER GENET CYTOGEN, V26, P39, DOI 10.1016/0165-4608(87)90131-2; Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664; AMOS TAS, 1995, BRIT J HAEMATOL, V91, P387, DOI 10.1111/j.1365-2141.1995.tb05308.x; Antonsson B, 2000, EXP CELL RES, V256, P50, DOI 10.1006/excr.2000.4839; Arnaudeau C, 2001, NUCLEIC ACIDS RES, V29, P662, DOI 10.1093/nar/29.3.662; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Beck Z, 2000, LEUKEMIA LYMPHOMA, V38, P587, DOI 10.3109/10428190009059278; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; Benhar M, 2001, MOL CELL BIOL, V21, P6913, DOI 10.1128/MCB.21.20.6913-6926.2001; Bishop AJR, 2001, BBA-REV CANCER, V1471, pM109, DOI 10.1016/S0304-419X(01)00018-X; BLASIAK J, 2002, IN PRESS LEUK RES, V1538; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bracey TS, 1997, CLIN CANCER RES, V3, P1371; Bucka A, 2001, NUCLEIC ACIDS RES, V29, P2464, DOI 10.1093/nar/29.12.2464; Cambier N, 1998, ONCOGENE, V16, P335, DOI 10.1038/sj.onc.1201490; Campbell MJ, 1999, J MOL BIOL, V286, P437, DOI 10.1006/jmbi.1998.2457; Canitrot Y, 1999, ONCOGENE, V18, P2676, DOI 10.1038/sj.onc.1202619; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chan TA, 2000, GENE DEV, V14, P1584; CherbonnelLasserre C, 1996, ONCOGENE, V13, P1489; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; Collis SJ, 2001, NUCLEIC ACIDS RES, V29, P1534, DOI 10.1093/nar/29.7.1534; Coultas L, 2000, APOPTOSIS, V5, P491, DOI 10.1023/A:1009617727938; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; de Groot Rolf P., 2000, Molecular Cell Biology Research Communications, V3, P299, DOI 10.1006/mcbr.2000.0231; de Groot RP, 1999, BLOOD, V94, P1108, DOI 10.1182/blood.V94.3.1108.415k07_1108_1112; Deutsch E, 2001, BLOOD, V97, P2084, DOI 10.1182/blood.V97.7.2084; Dibiase SJ, 2000, CANCER RES, V60, P1245; Donato NJ, 2001, BLOOD, V97, P2846, DOI 10.1182/blood.V97.9.2846; Dosanjh MK, 1998, NUCLEIC ACIDS RES, V26, P1179, DOI 10.1093/nar/26.5.1179; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Dubrez L, 1998, BLOOD, V91, P2415, DOI 10.1182/blood.V91.7.2415.2415_2415_2422; DUBREZ L, 1995, LEUKEMIA, V9, P1013; El-Deiry Wafik S., 1997, Current Opinion in Oncology, V9, P79; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Elliott B, 2001, MOL CELL BIOL, V21, P2671, DOI 10.1128/MCB.21.8.2671-2682.2001; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Falkenburg JHF, 1999, BLOOD, V94, P1201, DOI 10.1182/blood.V94.4.1201.416k08_1201_1208; Fang GF, 2000, BLOOD, V96, P2246, DOI 10.1182/blood.V96.6.2246.h8002246_2246_2253; Fischer T, 1998, BONE MARROW TRANSPL, V21, P1029, DOI 10.1038/sj.bmt.1701229; Fishel R, 1999, NAT MED, V5, P1239, DOI 10.1038/15191; Flores-Rozas H, 2000, TRENDS BIOCHEM SCI, V25, P196, DOI 10.1016/S0968-0004(00)01568-1; FUCHS EJ, 1995, CANCER RES, V55, P463; GAIGER A, 1995, BLOOD, V86, P2371, DOI 10.1182/blood.V86.6.2371.bloodjournal8662371; GALE RP, 1994, ANN INTERN MED, V120, P646, DOI 10.7326/0003-4819-120-8-199404150-00004; Gebow D, 2000, MOL CELL BIOL, V20, P4028, DOI 10.1128/MCB.20.11.4028-4035.2000; Gesbert F, 2000, BLOOD, V96, P2269, DOI 10.1182/blood.V96.6.2269.h8002269_2269_2276; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; Grdina D J, 2000, Drug Metabol Drug Interact, V16, P237; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; GUINN BA, 1995, LEUKEMIA RES, V19, P519, DOI 10.1016/0145-2126(95)00024-I; HARRISON DJ, 1995, J PATHOL, V175, P7, DOI 10.1002/path.1711750103; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Honda H, 2000, BLOOD, V95, P1144, DOI 10.1182/blood.V95.4.1144.004k04_1144_1150; Hoover RR, 2001, ONCOGENE, V20, P5826, DOI 10.1038/sj.onc.1204549; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Ikawa S, 1999, CELL DEATH DIFFER, V6, P1154, DOI 10.1038/sj.cdd.4400631; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Jakupciak JP, 2000, J BIOL CHEM, V275, P40003, DOI 10.1074/jbc.M007153200; Jasin M, 2000, CANCER INVEST, V18, P78, DOI 10.3109/07357900009023065; Jeong SJ, 2001, RADIAT RES, V156, P751, DOI 10.1667/0033-7587(2001)156[0751:PTKIMR]2.0.CO;2; Johnson PA, 1999, CANCER RES, V59, P2696; JONES NJ, 1995, GENOMICS, V26, P619, DOI 10.1016/0888-7543(95)80187-Q; Kano Y, 2001, BLOOD, V97, P1999, DOI 10.1182/blood.V97.7.1999; KELMAN Z, 1989, BLOOD, V74, P2318; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kim C, 2001, GENE, V276, P127, DOI 10.1016/S0378-1119(01)00639-4; Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927_3927_3934; Kohno K, 1997, GENE, V188, P175, DOI 10.1016/S0378-1119(96)00835-9; Kolibaba KS, 1997, BIOCHIM BIOPHYS ACTA, V1333, P217; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; Kolomietz E, 2001, BLOOD, V97, P3581, DOI 10.1182/blood.V97.11.3581; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; LANEUVILLE P, 1992, BLOOD, V80, P1788; Laval J, 1996, PATHOL BIOL, V44, P14; Li GM, 1999, ONCOL RES, V11, P393; Li XR, 1997, MOL CELL BIOL, V17, P2723, DOI 10.1128/MCB.17.5.2723; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Majsterek I, 2002, CELL BIOL INT, V26, P363, DOI 10.1006/cbir.2002.0865; Makin G, 2000, CELL TISSUE RES, V301, P143, DOI 10.1007/s004419900160; Maru Y, 2001, MUTAT RES-FUND MOL M, V483, P83, DOI 10.1016/S0027-5107(01)00229-9; Masson JY, 2001, GENE DEV, V15, P3296, DOI 10.1101/gad.947001; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; Michel B, 2001, P NATL ACAD SCI USA, V98, P8181, DOI 10.1073/pnas.111008798; Modesti M, 2001, CURR BIOL, V11, pR229, DOI 10.1016/S0960-9822(01)00112-9; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; NAKAI H, 1992, CANCER RES, V52, P6588; Namsaraev E, 1997, MOL CELL BIOL, V17, P5359, DOI 10.1128/MCB.17.9.5359; Neshat MS, 2000, MOL CELL BIOL, V20, P1179, DOI 10.1128/MCB.20.4.1179-1186.2000; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; NIEBOROWSKASKORSKA M, 1994, FOLIA HISTOCHEM CYTO, V32, P35; Nishii K, 1996, ONCOGENE, V13, P2225; Norbury CJ, 2001, ANNU REV PHARMACOL, V41, P367, DOI 10.1146/annurev.pharmtox.41.1.367; Papavasiliou FN, 2000, NATURE, V408, P216, DOI 10.1038/35041599; Papazisis KT, 2000, CANCER LETT, V160, P107, DOI 10.1016/S0304-3835(00)00569-3; Pegg AE, 2000, MUTAT RES-REV MUTAT, V462, P83, DOI 10.1016/S1383-5742(00)00017-X; Pegram MD, 1997, ONCOGENE, V15, P537, DOI 10.1038/sj.onc.1201222; Pierce AJ, 2001, GENE DEV, V15, P3237, DOI 10.1101/gad.946401; Pierce AJ, 2001, TRENDS CELL BIOL, V11, pS52, DOI 10.1016/S0962-8924(01)02149-3; Pittman DL, 1998, GENOMICS, V49, P103, DOI 10.1006/geno.1998.5226; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; Quackenbush RC, 2000, BLOOD, V95, P2913, DOI 10.1182/blood.V95.9.2913.009k32_2913_2921; Raderschall E, 2002, CANCER RES, V62, P219; Richardson C, 2000, MOL CELL BIOL, V20, P9068, DOI 10.1128/MCB.20.23.9068-9075.2000; RINEHART FP, 1981, BIOCHEMISTRY-US, V20, P3003, DOI 10.1021/bi00514a003; Riordan FA, 1998, ONCOGENE, V16, P1533, DOI 10.1038/sj.onc.1201680; Roger R, 1996, BLOOD, V87, P1113, DOI 10.1182/blood.V87.3.1113.bloodjournal8731113; Rohlfs EM, 2000, HUM GENET, V107, P385, DOI 10.1007/s004390000372; ROWLEY JD, 1982, ADV CANCER RES, V36, P103, DOI 10.1016/S0065-230X(08)60423-6; Salloukh HF, 2000, ONCOGENE, V19, P4362, DOI 10.1038/sj.onc.1203804; Salloukh HF, 2000, LEUKEMIA, V14, P1401, DOI 10.1038/sj.leu.2401855; Salomoni P, 2000, BLOOD, V96, P676; SANTUCCI MA, 1993, INT J RADIAT ONCOL, V26, P831, DOI 10.1016/0360-3016(93)90498-K; Sattler M, 2000, J BIOL CHEM, V275, P24273, DOI 10.1074/jbc.M002094200; Sawyers CL, 1997, BAILLIERE CLIN HAEM, V10, P223, DOI 10.1016/S0950-3536(97)80004-2; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Shapiro GI, 1999, J CLIN INVEST, V104, P1645, DOI 10.1172/JCI9054; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1995, TRENDS BIOCHEM SCI, V20, P387, DOI 10.1016/S0968-0004(00)89085-4; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; Skorski T, 1996, P NATL ACAD SCI USA, V93, P13137, DOI 10.1073/pnas.93.23.13137; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; SKORSKI T, 1994, J EXP MED, V179, P1855, DOI 10.1084/jem.179.6.1855; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; SKORSKI T, 1993, J CLIN INVEST, V92, P194, DOI 10.1172/JCI116549; Skorski T, 1997, J NATL CANCER I, V89, P124, DOI 10.1093/jnci/89.2.124; Slupianek A, 2001, MOL CELL, V8, P795, DOI 10.1016/S1097-2765(01)00357-4; Slupianek A, 2002, MOL CELL BIOL, V22, P4189, DOI 10.1128/MCB.22.12.4189-4201.2002; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; SONOYAMA J, 2002, J BIOL CHEM, V4, P4; Stuppia L, 1997, CANCER GENET CYTOGEN, V98, P28, DOI 10.1016/S0165-4608(96)00413-X; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Takeda N, 1999, P NATL ACAD SCI USA, V96, P203, DOI 10.1073/pnas.96.1.203; TEBBS RS, 1995, P NATL ACAD SCI USA, V92, P6354, DOI 10.1073/pnas.92.14.6354; THACKER J, 1995, HUM MOL GENET, V4, P113, DOI 10.1093/hmg/4.1.113; Thiesing JT, 2000, BLOOD, V96, P3195, DOI 10.1182/blood.V96.9.3195.h8003195_3195_3199; Topaly J, 2001, LEUKEMIA, V15, P342, DOI 10.1038/sj.leu.2402041; van der Kuip H, 2001, BLOOD, V98, P1532, DOI 10.1182/blood.V98.5.1532; Vispe S, 1998, NUCLEIC ACIDS RES, V26, P2859, DOI 10.1093/nar/26.12.2859; von Willebrand M, 1998, J BIOL CHEM, V273, P3994, DOI 10.1074/jbc.273.7.3994; VONCKEN JW, 1995, BLOOD, V86, P4603, DOI 10.1182/blood.V86.12.4603.bloodjournal86124603; Wang D, 1998, MUTAT RES-FUND MOL M, V400, P99, DOI 10.1016/S0027-5107(98)00066-9; Wang HC, 2001, ONCOGENE, V20, P2212, DOI 10.1038/sj.onc.1204350; Wiese C, 2002, CANCER RES, V62, P1279; Willers H, 2000, ONCOGENE, V19, P632, DOI 10.1038/sj.onc.1203142; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342	159	105	110	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2002	21	56					8591	8604		10.1038/sj.onc.1206087	http://dx.doi.org/10.1038/sj.onc.1206087			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZF	12476306				2022-12-28	WOS:000179734300009
J	Wilson, MB; Schreiner, SJ; Choi, HJ; Kamens, J; Smithgall, TE				Wilson, MB; Schreiner, SJ; Choi, HJ; Kamens, J; Smithgall, TE			Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis	ONCOGENE			English	Article						Bcr-Abl; Src; Hck; Stat5; pyrrolo-pyrimidine inhibitor	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE; CELL-LINE; CYTOGENETIC RESPONSES; HEMATOPOIETIC-CELLS; C-ABL; FIBROBLAST TRANSFORMATION; CLINICAL RESISTANCE; GROWTH-INHIBITION	Chronic myelogenous leukemia (CML) is defined by the presence of the Philadelphia (Ph) chromosome, which results in the expression of the 210 kDa Bcr - Abl tyrosine kinase. Bcr-Abl constitutively activates several signaling proteins important for the proliferation and survival of myeloid progenitors, including the Src family kinases Hck and Lyn, the Stat5 transcription factor and upstream components of the Ras/Erk pathway. Recently, we found that kinase-defective Hck blocks Bcr-Abl-induced transformation of DAGM myeloid leukemia cells to cytokine independence, suggesting that activation of the Src kinase family may be essential to oncogenic signaling by Bcr-Abl. To investigate the contribution of Src kinases to Bcr-Abl signaling in vivo, we used the pyrrolo-pyrimidine Src kinase inhibitors PP2 and A-419259. Treatment of the Ph+ CML cell lines K-562 and Meg-01 with either compound resulted in growth arrest and induction of apoptosis, while the Ph- leukemia cell lines TF-1 and HEL were unaffected over the same concentration ranges. Suppression of Ph+ cell growth by PP2 and A-419259 correlated with a decrease in Src kinase autophosphorylation. Both inhibitors blocked Stat5 and Erk activation, consistent with the suppressive effects of the compounds on survival and proliferation. In contrast, the phosphotyrosine content of Bcr-Abl and its endogenous substrate CrkL was unchanged at inhibitor concentrations that induced apoptosis, blocked oncogenic signaling and inhibited Src kinases. These data implicate the Src kinase family in Stat5 and Erk activation downstream of Bcr-Abl, and identify myeloid-specific Src kinases as potential drug targets in CML.	Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA; Abbott Biores Ctr, Worcester, MA 01605 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Smithgall, TE (corresponding author), Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA.	tsmithga@pitt.edu		Kamens, Joanne/0000-0002-7000-1477	NATIONAL CANCER INSTITUTE [R01CA081398] Funding Source: NIH RePORTER; NCI NIH HHS [CA 81398] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arnold LD, 2000, BIOORG MED CHEM LETT, V10, P2167, DOI 10.1016/S0960-894X(00)00441-8; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Branford S, 2002, BLOOD, V99, P3472, DOI 10.1182/blood.V99.9.3472; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Chin H, 1998, BLOOD, V91, P3734; Cortez D, 1996, ONCOGENE, V13, P2589; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DanhauserRiedl S, 1996, CANCER RES, V56, P3589; de Groot Rolf P., 2000, Molecular Cell Biology Research Communications, V3, P299, DOI 10.1006/mcbr.2000.0231; de Groot RP, 1999, BLOOD, V94, P1108, DOI 10.1182/blood.V94.3.1108.415k07_1108_1112; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; FELLER SM, 1995, ONCOGENE, V10, P1465; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Furstoss O, 2002, EMBO J, V21, P514, DOI 10.1093/emboj/21.4.514; Gambacorti-Passerini C, 2000, JNCI-J NATL CANCER I, V92, P1641, DOI 10.1093/jnci/92.20.1641; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Gesbert F, 2000, BLOOD, V96, P2269, DOI 10.1182/blood.V96.6.2269.h8002269_2269_2276; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hoover RR, 2001, ONCOGENE, V20, P5826, DOI 10.1038/sj.onc.1204549; HUANG M, 2002, IN PRESS ONCOGENE; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KLEIN E, 1976, INT J CANCER, V18, P421, DOI 10.1002/ijc.2910180405; KLEJMAN A, 2002, IN PRESS EMBO J; Li JZ, 1998, J BIOL CHEM, V273, P13828, DOI 10.1074/jbc.273.22.13828; Lionberger JM, 2000, J BIOL CHEM, V275, P18581, DOI 10.1074/jbc.C000126200; LIU JX, 1993, ONCOGENE, V8, P101; Liu Y, 1999, CHEM BIOL, V6, P671, DOI 10.1016/S1074-5521(99)80118-5; LOZZIO BB, 1981, P SOC EXP BIOL MED, V166, P546; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; Morgan MA, 2001, BLOOD, V97, P1823, DOI 10.1182/blood.V97.6.1823; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; Nagar B, 2002, CANCER RES, V62, P4236; Neshat MS, 2000, MOL CELL BIOL, V20, P1179, DOI 10.1128/MCB.20.4.1179-1186.2000; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; NOWELL PC, 1960, SCIENCE, V132, P1497; Oetzel C, 2000, CLIN CANCER RES, V6, P1958; OGURA M, 1985, BLOOD, V66, P1384; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Roumiantsev S, 2002, P NATL ACAD SCI USA, V99, P10700, DOI 10.1073/pnas.162140299; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Sattler M, 1998, LEUKEMIA, V12, P637, DOI 10.1038/sj.leu.2401010; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Sawyers CL, 2002, BLOOD, V99, P3530, DOI 10.1182/blood.V99.10.3530; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; Shuai K, 1996, ONCOGENE, V13, P247; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; Skorski T, 1998, BLOOD, V91, P406, DOI 10.1182/blood.V91.2.406.406_406_418; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Talpaz M, 2002, BLOOD, V99, P1928, DOI 10.1182/blood.V99.6.1928; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Waller CF, 2000, ANTICANCER RES, V20, P809; Warmuth M, 1999, ANN HEMATOL, V78, P49, DOI 10.1007/s002770050473; Warmuth M, 1997, J BIOL CHEM, V272, P33260, DOI 10.1074/jbc.272.52.33260; Weisberg E, 2000, BLOOD, V95, P3498, DOI 10.1182/blood.V95.11.3498.011k27_3498_3505; Woessmann W, 2001, EXP CELL RES, V264, P193, DOI 10.1006/excr.2000.5124	72	110	116	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2002	21	53					8075	8088		10.1038/sj.onc.1206008	http://dx.doi.org/10.1038/sj.onc.1206008			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615DW	12444544				2022-12-28	WOS:000179231400002
J	Maurer, P; T'Sas, F; Coutte, L; Callens, N; Brenner, C; Van Lint, C; de Launoit, Y; Baert, JL				Maurer, P; T'Sas, F; Coutte, L; Callens, N; Brenner, C; Van Lint, C; de Launoit, Y; Baert, JL			FEV acts as a transcriptional repressor through its DNA-binding ETS domain and alanine-rich domain	ONCOGENE			English	Article						Ets; transcription factor; repression	FAMILY MEMBER ERM; SIGNALING CASCADES; GENE-TRANSCRIPTION; FACTOR ER81; PEA3 GROUP; PROTEIN; TEL; CONTAINS; NET; TRANSACTIVATION	Although most Ets transcription factors have been characterized as transcriptional activators, some of them display repressor activity. Here we characterize an Ets-family member, the very specifically expressed human Fifth Ewing Variant (FEV), as a transcriptional repressor. We show that among a broad range of human cell lines, only Dami megakaryocytic cells express FEV. This nuclear protein binds to Ets-binding sites, such as that of the human ICAM-1 promoter. We used this promoter to demonstrate that FEV can repress both basal transcription and, even more strongly, ectopically Ets-activated transcription. We identified two domains responsible for FEV-mediated repression: the ETS domain, responsible for passive repression, and the carboxy-terminal alanine-rich domain, involved in active repression. In the Ets-independent LEXA system also, FEV acts as a transcriptional repressor via its alanine-rich carboxyterminal domain. The mechanism by which FEV actively represses transcription is currently unknown, since FEV-triggered repression is not reversed by the histone deacetylase inhibitor trichostatin A. We also showed that long-term overexpression of FEV proteins containing the alanine-rich domain prevents cell clones from growing, whereas clones expressing a truncated FEV protein lacking this domain develop like control cells. This confirms the importance of this domain in FEV-triggered repression.	Free Univ Brussels, Fac Med, Mol Virol Lab, B-1070 Brussels, Belgium; Univ Lille 1, Inst Pasteur, CNRS, UMR 8117,Inst Biol Lille, F-59021 Lille, France; Free Univ Brussels, Fac Sci, Inst Biol & Med Mol, Dept Mol Biol, B-6041 Gosselies, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille	de Launoit, Y (corresponding author), Free Univ Brussels, Fac Med, Mol Virol Lab, 808 Route Lennik,CP 614, B-1070 Brussels, Belgium.		callens, nathalie/P-2256-2016	callens, nathalie/0000-0002-7508-6596; coutte, laurent/0000-0002-0031-4742				Baert JL, 2002, J BIOL CHEM, V277, P1002, DOI 10.1074/jbc.M107139200; Baert JL, 1997, INT J CANCER, V70, P590, DOI 10.1002/(SICI)1097-0215(19970304)70:5<590::AID-IJC17>3.0.CO;2-H; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Briata P, 1997, FEBS LETT, V402, P131, DOI 10.1016/S0014-5793(96)01512-8; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; Courey AJ, 2001, GENE DEV, V15, P2786; Coutte L, 1999, ONCOGENE, V18, P6278, DOI 10.1038/sj.onc.1203020; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; de Launoit Y, 2000, ADV EXP MED BIOL, V480, P107; de Launoit Y, 1998, ONCOGENE, V16, P2065, DOI 10.1038/sj.onc.1201726; Defossez PA, 1997, NUCLEIC ACIDS RES, V25, P4455, DOI 10.1093/nar/25.22.4455; Ducret C, 2000, ONCOGENE, V19, P5063, DOI 10.1038/sj.onc.1203892; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; Fyodorov D, 1998, J NEUROBIOL, V34, P151, DOI 10.1002/(SICI)1097-4695(19980205)34:2<151::AID-NEU5>3.0.CO;2-1; Goodman FR, 1997, P NATL ACAD SCI USA, V94, P7458, DOI 10.1073/pnas.94.14.7458; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Guidez F, 2000, BLOOD, V96, P2557; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; Hendricks T, 1999, J NEUROSCI, V19, P10348; Janknecht R, 1996, ONCOGENE, V13, P1745; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; Laget MP, 1996, ONCOGENE, V12, P1325; Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; Maira SM, 1996, EMBO J, V15, P5849, DOI 10.1002/j.1460-2075.1996.tb00972.x; Maroulakou IG, 2000, ONCOGENE, V19, P6432, DOI 10.1038/sj.onc.1204039; Mavrothalassitis G, 2000, ONCOGENE, V19, P6524, DOI 10.1038/sj.onc.1204045; MONTE D, 1995, ONCOGENE, V11, P771; MONTE D, 1994, ONCOGENE, V9, P1397; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; Pfaar H, 2002, DEV GENES EVOL, V212, P43, DOI 10.1007/s00427-001-0208-x; RAYGALLET D, 1995, ONCOGENE, V11, P303; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; Xing XM, 2000, NAT MED, V6, P189, DOI 10.1038/72294; YEUNG KC, 1994, GENE DEV, V8, P2097, DOI 10.1101/gad.8.17.2097	40	25	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 22	2003	22	21					3319	3329		10.1038/sj.onc.1206572	http://dx.doi.org/10.1038/sj.onc.1206572			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681MM	12761502				2022-12-28	WOS:000183040000014
J	Unruh, A; Ressel, A; Mohamed, HG; Johnson, RS; Nadrowitz, R; Richter, E; Katschinski, DM; Wenger, RH				Unruh, A; Ressel, A; Mohamed, HG; Johnson, RS; Nadrowitz, R; Richter, E; Katschinski, DM; Wenger, RH			The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy	ONCOGENE			English	Article						chemotherapy resistance; glycolysis; transcriptional gene regulation; tumor irradiation; tumor oxygenation	SOLID TUMORS; GENE-EXPRESSION; FACTOR 1-ALPHA; UP-REGULATION; HIF-ALPHA; FACTOR-I; CELL; GROWTH; HIF-1-ALPHA; P53	Tumor hypoxia negatively regulates cell growth and causes a more malignant phenotype by increasing the expression of genes encoding angiogenic, metabolic and metastatic factors. Of clinical importance, insufficient tumor oxygenation affects the efficiency of chemotherapy and radiotherapy by poorly understood mechanisms. The hypoxia-inducible factor (HIF)-1 is a master transcriptional activator of oxygen-regulated genes and HIF-1 is constitutively upregulated in several tumor types. HIF-1 might thus be implicated in tumor therapy resistance. We found that transformed mouse embryonic fibroblasts deficient for HIF-1alpha are more susceptible to the treatment with carboplatin, etoposide and ionizing radiation than wild-type cells. Increased cell death in HIF-1alpha-deficient cells was because of apoptosis and did not involve p53 induction. Tumor chemotherapy of experimental fibrosarcoma in immunocompromised mice with carboplatin and etoposide confirmed the enhanced susceptibility of HIF1alpha-deficient cells. Agents that did not cause DNA double-strand breaks, such as DNA-synthesis inhibitors or a DNA single-strand break-causing agent equally impaired cell growth, independent of the HIF-1alpha genotype. Functional repair of a fragmented reporter gene was decreased in HIF-la-deficient cells. Thus, hypoxia-independent basal HIF-1alpha expression in tumor cells, as known from untransformed embryonic stem cells, is sufficient to induce target gene expression, probably including DNA double strand break repair enzymes.	Univ Leipzig, Carl Ludwig Inst Physiol, D-04103 Leipzig, Germany; Med Univ Lubeck, Inst Physiol, D-23538 Lubeck, Germany; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Med Univ Lubeck, Clin Radiotherapy & Nucl Med, D-23538 Lubeck, Germany	Leipzig University; University of Lubeck; University of California System; University of California San Diego; University of Lubeck	Wenger, RH (corresponding author), Univ Leipzig, Carl Ludwig Inst Physiol, Liebigstr 27, D-04103 Leipzig, Germany.	wenr@medizin.uni-leipzig.de	Wenger, Roland H./B-7953-2009; Johnson, Randall/AAM-1189-2021	Wenger, Roland H./0000-0001-7592-4839; Johnson, Randall/0000-0002-4084-6639				Aebersold DM, 2001, CANCER RES, V61, P2911; Alarcon R, 1999, CANCER RES, V59, P6046; Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Birner P, 2000, CANCER RES, V60, P4693; Brown JM, 2000, MOL MED TODAY, V6, P157, DOI 10.1016/S1357-4310(00)01677-4; Brown JM, 1998, CANCER RES, V58, P1408; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Comerford KM, 2002, CANCER RES, V62, P3387; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Farinelli SE, 1996, J NEUROSCI, V16, P1150, DOI 10.1523/jneurosci.16-03-01150.1996; Gao J, 2001, BLOOD, V98, P842, DOI 10.1182/blood.V98.3.842; Gassmann M, 1997, KIDNEY INT, V51, P567, DOI 10.1038/ki.1997.81; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Griffiths JR, 2002, CANCER RES, V62, P688; Hammond EM, 2002, MOL CELL BIOL, V22, P1834, DOI 10.1128/MCB.22.6.1834-1843.2002; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hockel M, 1999, CANCER RES, V59, P4525; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; Hopfl G, 2002, CANCER RES, V62, P2962; Isaacs JS, 2002, J BIOL CHEM, V277, P29936, DOI 10.1074/jbc.M204733200; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jewell UR, 2001, FASEB J, V15, P1312, DOI 10.1096/fj.00-0732fje; Jiang BH, 1997, CANCER RES, V57, P5328; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Katschinski DM, 2002, J BIOL CHEM, V277, P9262, DOI 10.1074/jbc.M110377200; Katschinski DM, 1999, CANCER RES, V59, P3404; Koukourakis MI, 2002, INT J RADIAT ONCOL, V53, P1192, DOI 10.1016/S0360-3016(02)02848-1; Krieg M, 2000, ONCOGENE, V19, P5435, DOI 10.1038/sj.onc.1203938; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; LEDERMAN HM, 1984, BLOOD, V64, P748; Mabjeesh NJ, 2002, CANCER RES, V62, P2478; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; Minchenko A, 2002, J BIOL CHEM, V277, P6183, DOI 10.1074/jbc.M110978200; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Rapisarda A, 2002, CANCER RES, V62, P4316; Ravi R, 2000, GENE DEV, V14, P34; Ryan HE, 2000, CANCER RES, V60, P4010; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Seagroves TN, 2001, MOL CELL BIOL, V21, P3436, DOI 10.1128/MCB.21.10.3436-3444.2001; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Semenza GL, 2000, CRIT REV BIOCHEM MOL, V35, P71, DOI 10.1080/10409230091169186; Vaupel P, 2001, MED ONCOL, V18, P243, DOI 10.1385/MO:18:4:243; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wanner RM, 2000, BLOOD, V96, P1558, DOI 10.1182/blood.V96.4.1558.h8001558_1558_1565; Wenger RH, 1998, CANCER RES, V58, P5678; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Williams KJ, 2002, ONCOGENE, V21, P282, DOI 10.1038/sj.onc.1205047; Zhong H, 1999, CANCER RES, V59, P5830; Zundel W, 2000, GENE DEV, V14, P391	54	295	324	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2003	22	21					3213	3220		10.1038/sj.onc.1206385	http://dx.doi.org/10.1038/sj.onc.1206385			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681MM	12761491				2022-12-28	WOS:000183040000003
J	Dekoninck, A; Calomme, C; Nizet, S; de Launoit, Y; Burny, A; Ghysdael, J; Van Lint, C				Dekoninck, A; Calomme, C; Nizet, S; de Launoit, Y; Burny, A; Ghysdael, J; Van Lint, C			Identification and characterization of a PU.1/Spi-B binding site in the bovine leukemia virus long terminal repeat	ONCOGENE			English	Review						BLV; transcription; PU.1; spi-b	TRANSCRIPTION FACTOR PU.1; NF-KAPPA-B; PERIPHERAL-BLOOD LYMPHOCYTES; SPI-B; ETS-DOMAIN; IN-VIVO; REGULATORY ELEMENTS; PUTATIVE ONCOGENE; GENE-EXPRESSION; NUCLEAR-FACTOR	Bovine leukemia virus (BLV) is a B-lymphotropic oncogenic retrovirus whose transcriptional promoter is located in the viral 5' long terminal repeat (LTR). To date, no B-lymphocyte-specific cis-regulatory element has been identified in this region. Since ETS proteins are known to regulate transcription of numerous retroviruses, we searched for the presence in the BLV promoter region of binding sites for PU.1/Spi-1, a B-cell- and macrophage-specific ETS family member. In this report, nucleotide sequence analysis of the viral LTR identified a PUbox located at -95/-84 bp. We demonstrated by gel shift and supershift assays that PU.1 and the related Ets transcription factor Spi-B interacted specifically with this PUbox. A 2-bp mutation (GGAA --> CCAA) within this motif abrogated PU.1/Spi-B binding. This mutation caused a marked decrease in LTR-driven basal gene expression in transient transfection assays of B-lymphoid cell tines, but did not impair the responsiveness of the BLV promoter to the virus-encoded transactivator Tax(BLV). Moreover, ectopically expressed PU.1 and Spi-B proteins transactivated the BLV promoter in a PUbox-dependent manner. Taken together, our results provide the first demonstration of regulation of the BLV promoter by two B-cell-specific Ets transcription factors, PU.1 and Spi-B. The PU.1/Spi-B binding site identified here could play an important role in BLV replication and B-lymphoid tropism.	Free Univ Brussels, IBMM, Serv Chim Biol, Mol Virol Lab, B-6041 Gosselies, Belgium; Free Univ Brussels, Fac Med, Mol Virol Lab, B-1070 Brussels, Belgium; Univ Lille 1, CNRS, UMR 8117, Inst Biol Lille,Inst Pasteur Lille, F-59021 Lille, France; Ctr Univ Orsay, Inst Curie, CNRS, UMR 146, F-91405 Orsay, France	Universite Libre de Bruxelles; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Van Lint, C (corresponding author), Free Univ Brussels, IBMM, Serv Chim Biol, Mol Virol Lab, Rue Profs Jeener & Brachet 12, B-6041 Gosselies, Belgium.	cvlint@ulb.ac.be	GHYSDAEL, Jacques/F-3377-2013					Adam E, 1996, J VIROL, V70, P1990, DOI 10.1128/JVI.70.3.1990-1999.1996; ADAM E, 1994, J VIROL, V68, P5845, DOI 10.1128/JVI.68.9.5845-5853.1994; AIDA Y, 1989, AM J VET RES, V50, P1946; Aurrekoetxea-Hernandez K, 2000, J VIROL, V74, P4988, DOI 10.1128/JVI.74.11.4988-4998.2000; BLOOM JC, 1979, BLOOD, V53, P899; BLOOM JC, 1980, CANCER RES, V40, P2240; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS PA, 1995, J VIROL, V69, P6005, DOI 10.1128/JVI.69.10.6005-6009.1995; Brooks PA, 1998, VIROLOGY, V243, P94, DOI 10.1006/viro.1998.9035; BURNY A, 1987, CANCER SURV, V6, P139; BURNY A, 1994, SYMP SOC GEN MICROBI, V51, P213; BURNY A, 1987, VIRAL ONCOLOGY, P231; Calomme C, 2002, J BIOL CHEM, V277, P8775, DOI 10.1074/jbc.M107441200; Carey JO, 1996, BLOOD, V87, P4316, DOI 10.1182/blood.V87.10.4316.bloodjournal87104316; CARVALHO M, 1993, J VIROL, V67, P6586, DOI 10.1128/JVI.67.11.6586-6595.1993; CARVALHO M, 1993, J VIROL, V67, P3885, DOI 10.1128/JVI.67.7.3885-3890.1993; CHEN HM, 1995, BLOOD, V85, P2918, DOI 10.1182/blood.V85.10.2918.bloodjournal85102918; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CHEN HM, 1995, ONCOGENE, V11, P1549; CLARK NM, 1993, J VIROL, V67, P5522, DOI 10.1128/JVI.67.9.5522-5528.1993; Dahl R, 2002, EMBO J, V21, P2220, DOI 10.1093/emboj/21.9.2220; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DERSE D, 1987, J VIROL, V61, P2462, DOI 10.1128/JVI.61.8.2462-2471.1987; DERSE D, 1986, SCIENCE, V231, P1437, DOI 10.1126/science.3006241; DJILALI S, 1987, LEUKEMIA, V1, P777; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; ERSELIUS JR, 1990, J VIROL, V64, P1657, DOI 10.1128/JVI.64.4.1657-1666.1990; FEINMAN R, 1994, EMBO J, V13, P3852, DOI 10.1002/j.1460-2075.1994.tb06696.x; FERRER JF, 1979, J AM VET MED ASSOC, V175, P1281; Ford AM, 1996, P NATL ACAD SCI USA, V93, P10838, DOI 10.1073/pnas.93.20.10838; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; GITLIN SD, 1993, J VIROL, V67, P7307, DOI 10.1128/JVI.67.12.7307-7316.1993; GITLIN SD, 1991, J VIROL, V65, P5513, DOI 10.1128/JVI.65.10.5513-5523.1991; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; HENKEL G, 1994, P NATL ACAD SCI USA, V91, P7737, DOI 10.1073/pnas.91.16.7737; Heydemann A, 1996, MOL CELL BIOL, V16, P1676; Himmelmann A, 1996, BLOOD, V87, P1036, DOI 10.1182/blood.V87.3.1036.bloodjournal8731036; HOLZMEISTER J, 1993, BIOCHEM BIOPH RES CO, V197, P1229, DOI 10.1006/bbrc.1993.2608; HORVAI A, 1995, P NATL ACAD SCI USA, V92, P5391, DOI 10.1073/pnas.92.12.5391; HROMAS R, 1993, BLOOD, V82, P2998; Hu CJ, 2001, IMMUNITY, V15, P545, DOI 10.1016/S1074-7613(01)00219-9; Jeeninga RE, 2000, J VIROL, V74, P3740, DOI 10.1128/JVI.74.8.3740-3751.2000; JENSEN WA, 1992, J VIROL, V66, P4427, DOI 10.1128/JVI.66.7.4427-4433.1992; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KATOH I, 1989, EMBO J, V8, P497, DOI 10.1002/j.1460-2075.1989.tb03403.x; Kettmann R., 1994, The retroviridae: Volume 3, P39; Kiermer V, 1998, J VIROL, V72, P5526, DOI 10.1128/JVI.72.7.5526-5534.1998; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Kihara-Negishi F, 2001, ONCOGENE, V20, P6039, DOI 10.1038/sj.onc.1204756; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; KOMINATO Y, 1995, MOL CELL BIOL, V15, P58; LAGARIAS DM, 1989, J VIROL, V63, P2099, DOI 10.1128/JVI.63.5.2099-2107.1989; LAUX G, 1994, EMBO J, V13, P5624, DOI 10.1002/j.1460-2075.1994.tb06900.x; LEIDEN JM, 1992, J VIROL, V66, P5890, DOI 10.1128/JVI.66.10.5890-5897.1992; Li SL, 1999, J BIOL CHEM, V274, P32453, DOI 10.1074/jbc.274.45.32453; Lodie TA, 1997, J IMMUNOL, V158, P1848; Lodie TA, 1998, J IMMUNOL, V161, P268; Lopez-Rovira T, 2000, J BIOL CHEM, V275, P28937, DOI 10.1074/jbc.M909923199; Maitra S, 2000, MOL CELL BIOL, V20, P1911, DOI 10.1128/MCB.20.6.1911-1922.2000; Mao C, 1996, ONCOGENE, V12, P863; Marecki S, 2000, CELL BIOCHEM BIOPHYS, V33, P127, DOI 10.1385/CBB:33:2:127; MARKOVITZ DM, 1992, J VIROL, V66, P5479, DOI 10.1128/JVI.66.9.5479-5484.1992; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; Muller S, 1996, ONCOGENE, V13, P1955; Myers GK, 1995, HUMAN RETROVIRUSES A; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; Niermann GL, 1997, VIROLOGY, V239, P249, DOI 10.1006/viro.1997.8868; Nikolajczyk BS, 1999, IMMUNITY, V11, P11, DOI 10.1016/S1074-7613(00)80077-1; Nuchprayoon I, 1997, BLOOD, V89, P4546, DOI 10.1182/blood.V89.12.4546; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PAUL R, 1991, J VIROL, V65, P464, DOI 10.1128/JVI.65.1.464-467.1991; PEREZ C, 1994, MOL CELL BIOL, V14, P5023, DOI 10.1128/MCB.14.8.5023; Pio F, 1996, J BIOL CHEM, V271, P23329, DOI 10.1074/jbc.271.38.23329; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; Posada R, 2000, AIDS RES HUM RETROV, V16, P1981, DOI 10.1089/088922200750054710; QUANG CT, 1995, ONCOGENE, V11, P1229; Rao S, 1999, J BIOL CHEM, V274, P34245, DOI 10.1074/jbc.274.48.34245; Rao S, 1999, J BIOL CHEM, V274, P11115, DOI 10.1074/jbc.274.16.11115; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; RAYGALLET D, 1995, ONCOGENE, V11, P303; ROSEN CA, 1986, J VIROL, V57, P738, DOI 10.1128/JVI.57.3.738-744.1986; ROSEN CA, 1985, SCIENCE, V227, P320, DOI 10.1126/science.2981432; ROSMARIN AG, 1995, P NATL ACAD SCI USA, V92, P801, DOI 10.1073/pnas.92.3.801; ROSMARIN AG, 1995, J BIOL CHEM, V270, P23627, DOI 10.1074/jbc.270.40.23627; SAGATA N, 1985, P NATL ACAD SCI USA, V82, P677, DOI 10.1073/pnas.82.3.677; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SEELER JS, 1993, VIROLOGY, V196, P442, DOI 10.1006/viro.1993.1500; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; Smith LT, 1996, BLOOD, V88, P1234, DOI 10.1182/blood.V88.4.1234.bloodjournal8841234; Smith MF, 1998, J BIOL CHEM, V273, P24272, DOI 10.1074/jbc.273.37.24272; Su GH, 1996, J EXP MED, V184, P203, DOI 10.1084/jem.184.1.203; TANIMURA A, 1993, J VIROL, V67, P5375, DOI 10.1128/JVI.67.9.5375-5382.1993; Tsukada J, 1997, BLOOD, V90, P3142, DOI 10.1182/blood.V90.8.3142; VANLINT C, 1994, J VIROL, V68, P2632, DOI 10.1128/JVI.68.4.2632-2648.1994; Verhoef K, 1999, J VIROL, V73, P1331, DOI 10.1128/JVI.73.2.1331-1340.1999; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WILLEMS L, 1993, J VIROL, V67, P1086, DOI 10.1128/JVI.67.2.1086-1089.1993; Willems L, 2000, AIDS RES HUM RETROV, V16, P1787, DOI 10.1089/08892220050193326; WILLEMS L, 1999, CURRENT TOP VIROL, V1, P139; Xiao JQ, 1998, J VIROL, V72, P5994, DOI 10.1128/JVI.72.7.5994-6003.1998; Yamamoto H, 1999, ONCOGENE, V18, P1495, DOI 10.1038/sj.onc.1202427; Yamamoto H, 2002, CELL GROWTH DIFFER, V13, P69; Yang ZY, 2000, J BIOL CHEM, V275, P21272, DOI 10.1074/jbc.M000145200; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	113	25	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2003	22	19					2882	2896		10.1038/sj.onc.1206392	http://dx.doi.org/10.1038/sj.onc.1206392			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771939				2022-12-28	WOS:000182824800003
J	Zhang, XD; Borrow, JM; Zhang, XY; Nguyen, T; Hersey, P				Zhang, XD; Borrow, JM; Zhang, XY; Nguyen, T; Hersey, P			Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria	ONCOGENE			English	Article						melanoma; TRAIL; Erk1/2; apoptosis; Smac/DIABLO	NF-KAPPA-B; BCL-X-L; ANTITUMOR-ACTIVITY; CYTOCHROME-C; BAX; FAMILY; LIGAND; RECEPTOR; KINASE; MEMBER	We have previously shown that Smac/DIABLO release from mitochondria appears to be the principal pathway by which TRAIL induces apoptosis of human melanoma. We report that TRAIL-induced release of Smac/DIABLO appears to be downregulated by concomitant signaling through the MEK Erk1/2 kinase pathway and that this inhibits TRAIL-induced apoptosis. Inhibition of Erk1/2 signaling by either the MEK inhibitor U0126 or a dominant-negative mutant of MKK1 markedly sensitized melanoma cells to TRAIL-induced apoptosis. The site in the apoptotic pathway acted on by U0126 appeared to be downstream of caspase-8 and Bid but upstream of caspase-3 in that the levels of proteolytic cleavage of caspase-8 and Bid by TRAIL were similar in cells with or without exposure to U0126. Caspase-3 activation and cleavage of its substrates, PARP, ICAD and XIAP, were however increased by cotreatment with U0126. This was associated with a rapid reduction in mitochondrial transmembrane potential (MMP) and increased release of Smac/DIABLO into the cytosol. Exploration of events leading to the changes in MMP revealed an increased translocation of Bax from the cytosol to mitochondria in the presence of U0126. There was also a delayed decrease in the levels of expression of Mcl-1. Bcl-2 and BCI-X-L. Over expression of Bcl-2 blocked TRAIL-induced apoptosis in the presence of U0126. Cytochrome c appeared not to play a major role in sensitization of melanoma to TRAIL in that caspase-9 activation was not detected in most of the cell lines. These results suggest that Erk1/2 signaling may protect melanoma cells against TRAIL-induced apoptosis by inhibiting the relocation of Bax from the cytosol to mitochondria and that this may reduce TRAIL-mediated release of Smac/DIABLO and induction of apoptosis.	Immunol & Oncol Unit, Newcastle, NSW 2300, Australia		Hersey, P (corresponding author), Immunol & Oncol Unit, Room 443,David Maddison Clin Sci Bldg,Cnr King &, Newcastle, NSW 2300, Australia.	Peter.Hersey@newcastle.edu.au	Zhang, xiaoyu/GXA-3206-2022; zhang, xian/GYA-0290-2022; zhang, xu/GRX-9733-2022; zhang, xu/GYE-3558-2022	Zhang, Xu Dong/0000-0001-9457-8003				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Bellosillo B, 2002, BLOOD, V100, P1810, DOI 10.1182/blood-2001-12-0327; Boucher MJ, 2000, J CELL BIOCHEM, V79, P355, DOI 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.0.CO;2-0; Bouillet P, 2002, J CELL SCI, V115, P1567; Burns TF, 2001, J BIOL CHEM, V276, P37879; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Dai Y, 2001, CANCER RES, V61, P5106; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Dhawan P, 2002, J BIOL CHEM, V277, P7920, DOI 10.1074/jbc.M112210200; Franco AV, 2001, J IMMUNOL, V166, P5337, DOI 10.4049/jimmunol.166.9.5337; Ganju N, 2002, BIOCHEM BIOPH RES CO, V291, P1258, DOI 10.1006/bbrc.2002.6584; Gliniak B, 1999, CANCER RES, V59, P6153; Griffith TS, 1998, J IMMUNOL, V161, P2833; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Holmstrom TH, 1999, MOL CELL BIOL, V19, P5991; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Milella M, 2001, J CLIN INVEST, V108, P851, DOI 10.1172/JCI200112807; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Ozoren N, 2000, CANCER RES, V60, P6259; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Sabol SL, 1998, BIOCHEM BIOPH RES CO, V253, P151, DOI 10.1006/bbrc.1998.9770; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Thomas WD, 2000, J IMMUNOL, V165, P5612, DOI 10.4049/jimmunol.165.10.5612; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang XD, 1999, CANCER RES, V59, P2747; Zhang XD, 2001, CANCER RES, V61, P7339	43	121	125	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2003	22	19					2869	2881		10.1038/sj.onc.1206427	http://dx.doi.org/10.1038/sj.onc.1206427			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771938				2022-12-28	WOS:000182824800002
J	Adamson, J; Morgan, EA; Beesley, C; Meil, YQ; Foster, CS; Fujii, H; Rudland, PS; Smith, PH; Ke, YQ				Adamson, J; Morgan, EA; Beesley, C; Meil, YQ; Foster, CS; Fujii, H; Rudland, PS; Smith, PH; Ke, YQ			High-level expression of cutaneous fatty acid-binding protein in prostatic carcinomas and its effect on tumorigenicity	ONCOGENE			English	Article						C-FABP; prostate cancer; antisense transcript; DNA transfection; tumorigenicity	ENDOTHELIAL GROWTH-FACTOR; TRANSITIONAL-CELL CARCINOMAS; DIFFERENTIAL GENE-EXPRESSION; MESSENGER-RNA; TUMOR-CELLS; RECEPTOR; RAT; METASTASIS; DISPLAY; CANCER	The expression of cutaneous fatty acid-binding protein (C-FABP) in prostate tissues was examined by immunohistochemistry. Among the 76 cases, all seven (100%) normal tissues were unstained. Of the 35 benign prostatic hyperplasia (BPH), 25 (71.4%) specimens were unstained and 10 (28.6%) were stained positively. For the 34 prostatic carcinomas, the C-FABP expression was remarkably increased: 25 (73.5%) samples stained positively, and only nine (26.5%) were unstained. Transfection of a vector expressing an antisense C-FABP transcript into the PC-3M prostatic cancer cells yielded two transfectant lines: PC-3M-CFABP-1 and PC-3M-CFABP-3, producing, respectively, a 3.8- and a 6.9-fold reduction in C-FABP levels. Comparing with the control transfectants, the in vitro invasiveness of both PC-3M-CFABP-1 and PC-3M-CFABP-3 was significantly reduced. When tested in nude mouse, the average size of tumours produced by PC-3M-CFABP-1 and by PC-3M-CFABP-3 was reduced by 2.9- and 4.2-fold respectively, in comparison with that of tumours produced by the control transfectants. Analysis showed that the decreased vascular endothelial growth factor (VEGF) and microvessel densities in the tumours were associated with the reduced C-FABP. These data show that C-FABP is increased in prostatic carcinoma cells and suppression of its expression can significantly inhibit the tumorigenicity, probably by reducing the expression of VEGF.	Univ Liverpool, Fac Med, Dept Pathol, Mol Pathol Lab, Liverpool L69 3BX, Merseyside, England; Niigata Univ, Sch Med, Dept Biochem, Niigata 951, Japan; Univ Liverpool, Sch Biol Sci, Liverpool L69 3BX, Merseyside, England	University of Liverpool; Niigata University; University of Liverpool	Ke, YQ (corresponding author), Univ Liverpool, Fac Med, Dept Pathol, Mol Pathol Lab, Liverpool L69 3BX, Merseyside, England.							ALBINI A, 1987, CANCER RES, V47, P3239; BASS NM, 1988, INT REV CYTOL, V111, P143, DOI 10.1016/S0074-7696(08)61733-7; Celis A, 1999, ELECTROPHORESIS, V20, P355, DOI 10.1002/(SICI)1522-2683(19990201)20:2<355::AID-ELPS355>3.0.CO;2-N; Celis JE, 1996, CANCER RES, V56, P4782; Chen HJ, 2000, BRIT J CANCER, V82, P1694; Chen HJ, 1997, ONCOGENE, V14, P1581, DOI 10.1038/sj.onc.1200993; Deshmukh N, 1997, BRIT J UROL, V80, P869, DOI 10.1046/j.1464-410X.1997.00479.x; Foster CS, 1999, BJU INT, V83, P171; Foster CS, 2002, J PATHOL, V197, P551, DOI 10.1002/path.1194; Glatz JFC, 1997, PROSTAG LEUKOTR ESS, V57, P1, DOI 10.1016/S0952-3278(97)90484-1; GLEASON DF, 1974, J UROLOGY, V111, P58, DOI 10.1016/S0022-5347(17)59889-4; Jackson MW, 2002, CANCER RES, V62, P854; JANIK P, 1975, CANCER RES, V35, P3698; Jing C, 2000, CANCER RES, V60, P2390; Jing C, 2002, JNCI-J NATL CANCER I, V94, P482; Jing C, 2001, CANCER RES, V61, P4357; Jing C, 2000, ANAL BIOCHEM, V287, P334, DOI 10.1006/abio.2000.4864; Kaighn M E, 1978, Natl Cancer Inst Monogr, P17; Ke Y, 1998, BRIT J CANCER, V77, P287, DOI 10.1038/bjc.1998.45; KE YQ, 1993, J CELL SCI, V106, P135; Ke YQ, 1997, INT J CANCER, V71, P832, DOI 10.1002/(SICI)1097-0215(19970529)71:5<832::AID-IJC22>3.0.CO;2-8; Ke YQ, 1999, ANAL BIOCHEM, V269, P201, DOI 10.1006/abio.1999.4014; Ke YQ, 1999, NUCLEIC ACIDS RES, V27, P912, DOI 10.1093/nar/27.3.912; KOZLOWSKI JM, 1984, CANCER RES, V44, P3522; Landers J, 1999, COLON LAT AM HIST R, V8, P1; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MADSEN P, 1992, J INVEST DERMATOL, V99, P299, DOI 10.1111/1523-1747.ep12616641; Masood R, 2001, BLOOD, V98, P1904, DOI 10.1182/blood.V98.6.1904; Masouye I, 1997, CIRC RES, V81, P297, DOI 10.1161/01.RES.81.3.297; Ostergaard M, 1997, CANCER RES, V57, P4111; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; Sinha P, 1999, ELECTROPHORESIS, V20, P2952, DOI 10.1002/(SICI)1522-2683(19991001)20:14<2952::AID-ELPS2952>3.0.CO;2-H; Smith P, 1998, FEBS LETT, V423, P19, DOI 10.1016/S0014-5793(98)00050-7; Soker S, 2001, AM J PATHOL, V159, P651, DOI 10.1016/S0002-9440(10)61736-1; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; STORCH J, 1990, J BIOL CHEM, V265, P7827; Veikkola T, 2000, CANCER RES, V60, P203; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; Watanabe R, 1997, J DERMATOL SCI, V16, P17, DOI 10.1016/S0923-1811(97)00615-4; Xu HE, 1999, MOL CELL, V3, P397, DOI 10.1016/S1097-2765(00)80467-0; Yamakawa K, 2000, BIOCHEM BIOPH RES CO, V271, P571, DOI 10.1006/bbrc.2000.2665	42	88	92	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2003	22	18					2739	2749		10.1038/sj.onc.1206341	http://dx.doi.org/10.1038/sj.onc.1206341			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ	12743598				2022-12-28	WOS:000182569300005
J	Kinoshita, I; Leaner, V; Katabami, M; Manzano, RG; Dent, P; Sabichi, A; Birrer, MJ				Kinoshita, I; Leaner, V; Katabami, M; Manzano, RG; Dent, P; Sabichi, A; Birrer, MJ			Identification of cJun-responsive genes in Rat-1a cells using multiple techniques: increased expression of stathmin is necessary for cJun-mediated anchorage-independent growth	ONCOGENE			English	Article						c-jun; transformation; microarray; AP-1	LEUKOCYTE INTEGRIN GENE; V-JUN; C-JUN; TRANSCRIPTION FACTOR; TISSUE INHIBITOR; CANCER-CELLS; PHOSPHOPROTEIN STATHMIN; SIGNAL TRANSDUCTION; GALECTIN-3 GENE; DOWN-REGULATION	cJun is a major component of the transcription factor AP-1 and mediates a diverse set of biologic properties including proliferation, differentiation, and apoptosis. To identify cJun-responsive genes, we inducibly expressed cJun in Rat-1a cells and observed two distinct phenotypes: changes in cellular morphology with adherent growth and anchorage-independent growth. The biologic effects of cJun were entirely reversible demonstrating that they require the continued presence of cJun. To determine the genes, which mediate the biologic effects of cJun, we employed multiple methods including differential gene analysis, suppression subtractive hybridization, and cDNA microarrays. We identified 38 cJun-responsive genes including three uncharacterized genes under adherent and/or nonadherent conditions. Half of the known 36 genes were cytoskeleton- and adhesion-related genes, suggesting a major role of cJun in the regulation of the genes related to cell morphology. As proof of the principle that this approach could identify genes whose upregulation was necessary for nonadherent growth, we investigated one gene, stathmin whose upregulation by cJun was observed only under these conditions. Although overexpression of stathmin did not result in nonadherent growth, inhibition of stathmin protein expression by antisense oligonucleotides in cJun-induced Rat-1a cells prevented nonadherent growth. These results suggest that stathmin plays an essential role in anchorage-independent growth by cJun and may be a potential target for specific inhibitors for AP-1-dependent processes involved in carcinogenesis.	NCI, Cell & Canc Biol Dept, Ctr Canc Res, Rockville, MD 20850 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Virginia Commonwealth University	Birrer, MJ (corresponding author), NCI, Cell & Canc Biol Dept, Ctr Canc Res, Rockville, MD 20850 USA.	birrerm@bprb.nci.nih.gov		Gonzalez Manzano, Ramon/0000-0003-2266-6965				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Arthur JSC, 1998, BBA-PROTEIN STRUCT M, V1388, P247, DOI 10.1016/S0167-4838(98)00166-6; Bader AG, 2001, ONCOGENE, V20, P7524, DOI 10.1038/sj.onc.1204938; Bader AG, 2000, VIROLOGY, V270, P98, DOI 10.1006/viro.2000.0222; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Balogh A, 1996, EXP CELL RES, V224, P8, DOI 10.1006/excr.1996.0106; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; BERGERS G, 1994, EMBO J, V13, P1176, DOI 10.1002/j.1460-2075.1994.tb06367.x; Bieche I, 1998, BRIT J CANCER, V78, P701, DOI 10.1038/bjc.1998.565; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRASELMANN S, 1992, J CELL SCI, P97; BRATTSAND G, 1993, LEUKEMIA, V7, P569; BROWN PH, 1993, ONCOGENE, V8, P877; CERVELLA P, 1993, J BIOL CHEM, V268, P5148; Clark IM, 1997, BIOCHEM J, V324, P611, DOI 10.1042/bj3240611; Clark W, 2000, MOL CELL BIOL, V20, P2529, DOI 10.1128/MCB.20.7.2529-2542.2000; COOPER HL, 1991, J IMMUNOL, V146, P3689; COOPER HL, 1990, J IMMUNOL, V145, P1205; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DiPaolo G, 1996, J CELL BIOL, V133, P1383, DOI 10.1083/jcb.133.6.1383; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; DOYE V, 1992, DIFFERENTIATION, V50, P89, DOI 10.1111/j.1432-0436.1992.tb00489.x; Fey MF, 1996, BBA-GENE STRUCT EXPR, V1306, P160, DOI 10.1016/0167-4781(95)00238-3; Fu SL, 2000, ONCOGENE, V19, P3537, DOI 10.1038/sj.onc.1203691; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Gao MH, 1996, CANCER RES, V56, P4229; Gaudin JC, 1997, GLYCOBIOLOGY, V7, P1089, DOI 10.1093/glycob/7.8.1089; GHOSH PK, 1993, ONCOGENE, V8, P2869; Goller ME, 1998, ONCOGENE, V16, P2945, DOI 10.1038/sj.onc.1201819; GSCHWENDT M, 1989, FEBS LETT, V257, P357, DOI 10.1016/0014-5793(89)81571-6; Hadman M, 1998, ONCOGENE, V16, P655, DOI 10.1038/sj.onc.1201574; HAILAT N, 1990, ONCOGENE, V5, P1615; HARTL M, 1995, P NATL ACAD SCI USA, V92, P11731, DOI 10.1073/pnas.92.25.11731; Hartl M, 2001, P NATL ACAD SCI USA, V98, P13601, DOI 10.1073/pnas.241451198; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; Hosoya H, 1996, CELL STRUCT FUNCT, V21, P237, DOI 10.1247/csf.21.237; Howell B, 1999, J CELL SCI, V112, P3713; Jaworski J, 1999, J BIOL CHEM, V274, P28106, DOI 10.1074/jbc.274.40.28106; Johnston IMP, 2000, ONCOGENE, V19, P5348, DOI 10.1038/sj.onc.1203927; Kadrofske MM, 1998, ARCH BIOCHEM BIOPHYS, V349, P7, DOI 10.1006/abbi.1997.0447; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KATAI H, 1992, MOL CELL BIOCHEM, V118, P119; KOLCH W, 1993, ONCOGENE, V8, P361; KOPPEL J, 1993, FEBS LETT, V331, P65, DOI 10.1016/0014-5793(93)80298-9; Koski C, 1999, J BIOL CHEM, V274, P32619, DOI 10.1074/jbc.274.46.32619; Larsson N, 1999, J CELL BIOL, V146, P1289, DOI 10.1083/jcb.146.6.1289; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; Loo DT, 1998, J BIOL CHEM, V273, P23304, DOI 10.1074/jbc.273.36.23304; LOPEZCABRERA M, 1993, J BIOL CHEM, V268, P1187; LopezRodriguez C, 1996, J IMMUNOL, V156, P3780; Lorenzi MV, 1999, ONCOGENE, V18, P4742, DOI 10.1038/sj.onc.1202851; LUO XN, 1994, J BIOL CHEM, V269, P10312; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; Marklund U, 1996, EMBO J, V15, P5290, DOI 10.1002/j.1460-2075.1996.tb00914.x; MAZZONE A, 1995, HAEMATOLOGICA, V80, P161; MELHEM RF, 1991, BIOCHEM BIOPH RES CO, V179, P1649, DOI 10.1016/0006-291X(91)91764-4; MELHEM RF, 1991, J BIOL CHEM, V266, P17747; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; MISTRY S, 1995, CELL MOL BIOL RES, V41, P103; Mistry SJ, 1999, ANTICANCER RES, V19, P573; Morgan RO, 1995, J MOL EVOL, V41, P979; Noti JD, 1996, MOL IMMUNOL, V33, P115, DOI 10.1016/0161-5890(95)00140-9; NYLANDER K, 1995, HISTOCHEM J, V27, P155; OSEIFRIMPONG J, 1994, MOL CARCINOGEN, V10, P72, DOI 10.1002/mc.2940100204; PHILIPS N, 1995, J BIOL CHEM, V270, P9313, DOI 10.1074/jbc.270.16.9313; PRIETO J, 1994, CELL IMMUNOL, V156, P191, DOI 10.1006/cimm.1994.1164; RAPP UR, 1994, ONCOGENE, V9, P3493; Rodier A, 1999, EXP CELL RES, V249, P337, DOI 10.1006/excr.1999.4486; ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x; Sabichi AL, 1998, J NATL CANCER I, V90, P597, DOI 10.1093/jnci/90.8.597; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SAWADA R, 1993, J BIOL CHEM, V268, P9014; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; SCHUBART UK, 1992, DIFFERENTIATION, V51, P21, DOI 10.1111/j.1432-0436.1992.tb00676.x; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SHARMA CP, 1995, J IMMUNOL, V154, P3461; SIEGFRIED Z, 1990, MOL CELL BIOL, V10, P6073, DOI 10.1128/MCB.10.11.6073; SOBEL A, 1989, J BIOL CHEM, V264, P3765; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; Solito E, 1998, CELL GROWTH DIFFER, V9, P327; Spink BC, 1998, J CELL BIOCHEM, V70, P289, DOI 10.1002/(SICI)1097-4644(19980901)70:3<289::AID-JCB1>3.3.CO;2-H; Szabo E, 1998, CELL GROWTH DIFFER, V9, P475; Tang WM, 1996, J BIOL CHEM, V271, P28324, DOI 10.1074/jbc.271.45.28324; Tiwari B, 1998, DNA CELL BIOL, V17, P957, DOI 10.1089/dna.1998.17.957; Watsuji T, 1997, BIOCHEM BIOPH RES CO, V234, P769, DOI 10.1006/bbrc.1997.6705; Weinstein J, 1998, MOL GENET METAB, V64, P52, DOI 10.1006/mgme.1998.2698; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Xie JP, 1998, GENOMICS, V54, P338, DOI 10.1006/geno.1998.5583; Yet SF, 1998, J BIOL CHEM, V273, P10530, DOI 10.1074/jbc.273.17.10530	94	33	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2003	22	18					2710	2722		10.1038/sj.onc.1206371	http://dx.doi.org/10.1038/sj.onc.1206371			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ	12743595				2022-12-28	WOS:000182569300002
J	Lee, CGL; Ren, JW; Cheong, ISY; Ban, KHK; Ooi, LLPJ; Tan, SY; Kan, A; Nuchprayoon, I; Jin, RX; Lee, KH; Choti, M; Lee, LA				Lee, CGL; Ren, JW; Cheong, ISY; Ban, KHK; Ooi, LLPJ; Tan, SY; Kan, A; Nuchprayoon, I; Jin, RX; Lee, KH; Choti, M; Lee, LA			Expression of the FAT 10 gene is highly upregulated in hepatocellular carcinoma and other gastrointestinal and gynecological cancers	ONCOGENE			English	Article						diubiquitin; FAT10; ubiquitin-like modifier (UBL); hepatocellular carcinoma; gastrointestinal cancers	UBIQUITIN-LIKE PROTEIN; SPINDLE ASSEMBLY CHECKPOINT; MAD2; IDENTIFICATION; CELLS; DEGRADATION; PROTECTION; APOPTOSIS; ANAPHASE; COMPLEX	The ubiquitin-like modifier (UBL) family has recently generated much interest in the scientific community, as it is implicated to play important regulatory roles via novel protein-protein modification. FAT10 (diubiquitin) belongs to this family of proteins, comprising two ubiquitin-like moieties fused in tandem, and has been implicated to be involved in the maintenance of spindle integrity during mitosis. As FAT10 may play a role in the regulation of genomic stability, we examined if there is an association between FAT10 expression and hepatocellular carcinoma (HCC) or other cancers. Northern blot analyses revealed upregulation of FAT10 expression in the tumors of 90% of HCC patients. In situ hybridization as well as immunohistochemistry utilizing anti-FAT10 antibodies localized highest FAT10 expression in the nucleus of HCC hepatocytes rather than the surrounding immune and non-HCC cells. FAT10 expression was also found to be highly upregulated in other cancers of the gastrointestinal tract and female reproductive system. In conclusion, we demonstrated upregulation of FAT10 expression in various gastrointestinal and gynecological cancers. Its overexpression is unrelated to the general increase in protein synthesis or a general immune/inflammatory response to cancer. Rather, FAT10 may modulate tumorigenesis through its reported interaction with the MAD2 spindle-assembly checkpoint protein.	Natl Canc Ctr, Div Med Sci, Lab 5, Singapore 169610, Singapore; Natl Univ Singapore, Dept Biochem, Singapore 117548, Singapore; Johns Hopkins Singapore, Singapore, Singapore; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21218 USA; Natl Canc Ctr, Dept Surg Oncol, Singapore, Singapore; Singapore Gen Hosp, Dept Surg, Singapore 0316, Singapore; Tan Tock Seng Hosp, Dept Pathol & Lab Med, Singapore, Singapore; Chulalongkorn Univ, Fac Med, Dept Pediat, Bangkok 10330, Thailand; Natl Univ Singapore Hosp, Dept Med, Singapore 117548, Singapore; Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21218 USA	National Cancer Centre Singapore (NCCS); National University of Singapore; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; National Cancer Centre Singapore (NCCS); Singapore General Hospital; Tan Tock Seng Hospital; Chulalongkorn University; National University of Singapore; Johns Hopkins University	Lee, CGL (corresponding author), Natl Canc Ctr, Div Med Sci, Lab 5, Level 6,11 Hosp Dr, Singapore 169610, Singapore.	bchleec@nus.edu.sg	Ooi, London Lucien/AGK-1395-2022; Ban, Kenneth/A-1243-2012; Lee, Caroline G/M-8918-2019	Ban, Kenneth/0000-0001-7165-8713; Lee, Caroline G/0000-0002-4323-3635; Tan, Soo-Yong/0000-0002-6348-2823; Cheong, Ian/0000-0002-3062-6878; Nuchprayoon, Issarang/0000-0002-4014-5082				Bates EFM, 1997, EUR J IMMUNOL, V27, P2471, DOI 10.1002/eji.1830271002; Biggins S, 1996, J CELL BIOL, V133, P1331, DOI 10.1083/jcb.133.6.1331; Biggins S, 2001, GENETICS, V159, P453; Boddy MN, 1996, ONCOGENE, V13, P971; Braissant O, 1998, BIOCHEMICA, V1, P10; Fan WF, 1996, IMMUNOGENETICS, V44, P97, DOI 10.1007/s002510050095; Gemma A, 2001, LUNG CANCER-J IASLC, V32, P289, DOI 10.1016/S0169-5002(00)00223-3; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; Hooi SC, 1997, MOL BRAIN RES, V51, P15, DOI 10.1016/S0169-328X(97)00191-5; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Iwanaga Y, 2002, J BIOL CHEM, V277, P31005, DOI 10.1074/jbc.M110666200; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; KOMMINOTH P, 1992, HISTOCHEMISTRY, V98, P217, DOI 10.1007/BF00271035; Lee CGL, 2000, FASEB J, V14, P516, DOI 10.1096/fasebj.14.3.516; Liu YC, 1999, P NATL ACAD SCI USA, V96, P4313, DOI 10.1073/pnas.96.8.4313; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Okura T, 1996, J IMMUNOL, V157, P4277; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; Raasi S, 2001, J BIOL CHEM, V276, P35334, DOI 10.1074/jbc.M105139200; Raasi S, 1999, EUR J IMMUNOL, V29, P4030, DOI 10.1002/(SICI)1521-4141(199912)29:12<4030::AID-IMMU4030>3.0.CO;2-Y; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Tateishi K, 2001, J CELL BIOL, V155, P571, DOI 10.1083/jcb.200104035; Wang XH, 2000, CARCINOGENESIS, V21, P2293, DOI 10.1093/carcin/21.12.2293	29	138	157	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2003	22	17					2592	2603		10.1038/sj.onc.1206337	http://dx.doi.org/10.1038/sj.onc.1206337			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730673				2022-12-28	WOS:000182569000007
J	Comerford, SA; Clouthier, DE; Hinnant, EA; Hammer, RE				Comerford, SA; Clouthier, DE; Hinnant, EA; Hammer, RE			Induction of hepatocyte proliferation and death by modulation of T-Antigen expression	ONCOGENE			English	Article						T-Antigen; apoptosis; Fas; caspase; Akt; hepatocytes	PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; NF-KAPPA-B; ZINC-FINGER PROTEIN; TRANSGENIC MICE; INDUCED APOPTOSIS; CELL-DEATH; CYTOCHROME-C; DIFFERENTIAL REGULATION; DEPENDENT APOPTOSIS; GENE-EXPRESSION	Mice expressing SV40 T-Antigen in liver under control of the phosphoenolpyruvate carboxykinase promoter were generated. By altering the carbohydrate content of the diet, TAg expression, the rate of hepatocyte proliferation and apoptosis, and hence hepatocarcinogenesis, could be regulated. Carbohydrate-mediated suppression of TAg resulted in slow hepatic growth that progressed to focal hepatocellular carcinoma (HCC) after a long latency period. In contrast, induction of TAg by feeding mice a low carbohydrate diet resulted in massive hepatomegaly that progressed rapidly to diffuse multifocal HCC. Hepatic TAg expression could be efficiently repressed by switching mice from the tow to the high-carbohydrate diet, which if instigated prior to the development of HCC, resulted in rapid regression through a p53-independent reduction in hepatocyte proliferation and an increase in hepatocyte apoptosis. Although liver growth was accompanied by compensatory hepatocyte apoptosis, an apoptotic deficit developed following chronic exposure to high levels of TAg. This was associated with Akt phosphorylation and increased expression of the antiapoptotic molecules bfl-1/A1, TIAP, and A20. Mice were resistant to Fas-induced hepatocellular apoptosis due to severely impaired caspase activation and failed activation of the mitochondrial amplification loop. This model will be useful to investigate oncogene-mediated disruption of the cell cycle and apoptosis, and to determine which processes constitute fixed, or reversible aspects of the tumorigenic process.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Cecil H & Ida Green Ctr Reprod Biol Sci, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hammer, RE (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Clouthier, David/A-7062-2009	Hammer, Robert E./0000-0001-5487-7551; Comerford, Sarah Ann/0000-0002-7452-7759	NIDDK NIH HHS [DK 53789] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053789] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abrams JM, 2002, CELL, V110, P403, DOI 10.1016/S0092-8674(02)00904-2; Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Altieri DC, 2001, TRENDS MOL MED, V7, P542, DOI 10.1016/S1471-4914(01)02243-2; Arvelo MB, 2002, HEPATOLOGY, V35, P535, DOI 10.1053/jhep.2002.31309; BEALE EG, 1985, J BIOL CHEM, V260, P748; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bellas RE, 1999, CELL GROWTH DIFFER, V10, P287; Bennoun M, 1998, ONCOGENE, V17, P1253, DOI 10.1038/sj.onc.1202047; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chen ZH, 1999, BIOCHEM BIOPH RES CO, V264, P847, DOI 10.1006/bbrc.1999.1585; Clouthier DE, 1997, J CLIN INVEST, V100, P2697, DOI 10.1172/JCI119815; Cole SL, 2002, J VIROL, V76, P8420, DOI 10.1128/JVI.76.16.8420-8432.2002; Conzen SD, 1997, J VIROL, V71, P4536, DOI 10.1128/JVI.71.6.4536-4543.1997; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deveraux QL, 1999, J CLIN IMMUNOL, V19, P388, DOI 10.1023/A:1020502800208; EISENBERGER CL, 1992, MOL CELL BIOL, V12, P1396, DOI 10.1128/MCB.12.3.1396; Ewald D, 1996, SCIENCE, V273, P1384, DOI 10.1126/science.273.5280.1384; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Gillet R, 2001, BIOCHEM BIOPH RES CO, V284, P369, DOI 10.1006/bbrc.2001.4988; GIRARD J, 1986, BIOL NEONATE, V50, P237, DOI 10.1159/000242605; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Grey ST, 1999, J EXP MED, V190, P1135, DOI 10.1084/jem.190.8.1135; Guo M, 1999, CURR OPIN CELL BIOL, V11, P745, DOI 10.1016/S0955-0674(99)00046-0; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; Hauser HP, 1998, J CELL BIOL, V141, P1415, DOI 10.1083/jcb.141.6.1415; Kanzler S, 2000, SEMIN CANCER BIOL, V10, P173, DOI 10.1006/scbi.2000.0318; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kerouz NJ, 1997, J CLIN INVEST, V100, P3164, DOI 10.1172/JCI119872; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Kobayashi K, 1999, P NATL ACAD SCI USA, V96, P1457, DOI 10.1073/pnas.96.4.1457; Kohlhoff S, 2000, FREE RADICAL BIO MED, V29, P497, DOI 10.1016/S0891-5849(00)00340-3; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Manickan E, 2001, J BIOL CHEM, V276, P13989, DOI 10.1074/jbc.M009770200; MCGRANE MM, 1990, J BIOL CHEM, V265, P22371; MERLINO G, 1994, CANCER INVEST, V12, P203, DOI 10.3109/07357909409024875; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Moens U, 1997, VIRUS GENES, V15, P135, DOI 10.1023/A:1007962908248; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; Park WS, 2002, ONCOGENE, V21, P2919, DOI 10.1038/sj.onc.1205394; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; Rodier F, 2000, ONCOGENE, V19, P6261, DOI 10.1038/sj.onc.1204015; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; ROUQUET N, 1995, ONCOGENE, V11, P1061; Rundell K, 2001, SEMIN CANCER BIOL, V11, P5, DOI 10.1006/scbi.2000.0341; Saenz-Robles MT, 2001, ONCOGENE, V20, P7899, DOI 10.1038/sj.onc.1204936; SARMA V, 1995, J BIOL CHEM, V270, P12343, DOI 10.1074/jbc.270.21.12343; Sartorius U, 2001, CHEMBIOCHEM, V2, P20, DOI 10.1002/1439-7633(20010105)2:1<20::AID-CBIC20>3.3.CO;2-O; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; SHORT MK, 1992, MOL CELL BIOL, V12, P1007, DOI 10.1128/MCB.12.3.1007; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Tsai SC, 2000, J BIOL CHEM, V275, P3239, DOI 10.1074/jbc.275.5.3239; Tzeng YJ, 1998, ONCOGENE, V16, P2103, DOI 10.1038/sj.onc.1201733; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Werner AB, 2002, J BIOL CHEM, V277, P22781, DOI 10.1074/jbc.M201469200; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Yu YJ, 2002, J VIROL, V76, P3731, DOI 10.1128/JVI.76.8.3731-3738.2002; ZIMMER DB, 1990, J HISTOCHEM CYTOCHEM, V38, P171, DOI 10.1177/38.2.1688895; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	74	7	7	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 24	2003	22	16					2515	2530		10.1038/sj.onc.1206259	http://dx.doi.org/10.1038/sj.onc.1206259			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	670AD	12717428				2022-12-28	WOS:000182383500014
J	Shigeno, M; Nako, K; Ichikawa, T; Suzuki, K; Kawakami, A; Abiru, S; Miyazoe, S; Nakagawa, Y; Ishikawa, H; Hamasaki, K; Nakata, K; Ishii, N; Eguchi, K				Shigeno, M; Nako, K; Ichikawa, T; Suzuki, K; Kawakami, A; Abiru, S; Miyazoe, S; Nakagawa, Y; Ishikawa, H; Hamasaki, K; Nakata, K; Ishii, N; Eguchi, K			Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation	ONCOGENE			English	Article						TRAIL; interferon-alpha; hepatoma; DR5 survivin; NF-kappa B	HUMAN HEPATOCELLULAR-CARCINOMA; CYTOTOXIC LIGAND TRAIL; LUNG-CANCER CELLS; IN-VIVO; CHEMOTHERAPEUTIC-AGENTS; TRANSCRIPTION FACTORS; CASPASE-8 ACTIVATION; IONIZING-RADIATION; MEDIATED APOPTOSIS; DEATH RECEPTOR-4	Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), a member of the TNF superfamily, induces apoptosis in a variety of cancer cells with little or no effect on normal cells. Human hepatoma cells, however, are resistant to TRAIL-induced apoptosis. Since interferon-alpha (IFN-alpha) is capable of enhancing TNF-alpha-induced apoptosis in certain cancer cells, we evaluated the effect of IFN-alpha on TRAIL-induced apoptosis of human hepatoma cells. IFN-alpha pretreatment enhanced TRAIL-induced apoptosis of HuH-7 and Hep3B cells, in which IFN-alpha upregulated the expression of DR5, a death receptor of TRAIL, and downregulated the expression of survivin, which has an antiapoptotic function. In contrast, IFN-alpha did not enhance TRAIL-induced apoptosis of HepG2 cells, in which expression of DR5 and survivin was not affected by IFN-alpha. On the other hand, TRAIL activated NF-kappaB composed of RelA-p50 heterodimer, a key transcription factor regulating cell survival, in HuH-7 and HepG2 cells. However, IFN-alpha pretreatment repressed the TRAIL-mediated activation of NF-kappaB and decreased its transcriptional activity in HuH-7 but not in HepG2 cells. Moreover, IFN-alpha pretreatment clearly augmented TRAIL-mediated caspase-8 activation in HuH-7 cells. Our results suggest that IFN-alpha could sensitize certain human hepatoma cells to TRAIL-induced apoptosis by stimulating its death signaling and by repressing the survival function in these cells.	Nagasaki Univ, Sch Med, Dept Internal Med 1, Nagasaki 8528501, Japan; Nagasaki Univ, Hlth Res Ctr, Nagasaki 8528501, Japan; Nagasaki Univ, Dept Clin Pharmacol, Nagasaki 8528501, Japan	Nagasaki University; Nagasaki University; Nagasaki University	Eguchi, K (corresponding author), Nagasaki Univ, Sch Med, Dept Internal Med 1, 1-7-1 Sakamoto, Nagasaki 8528501, Japan.							Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Chawla-Sarkar M, 2001, CLIN CANCER RES, V7, P1821; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chen Q, 2001, BLOOD, V98, P2183, DOI 10.1182/blood.V98.7.2183; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Di Pietro R, 2001, BLOOD, V97, P2596, DOI 10.1182/blood.V97.9.2596; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; Fanger NA, 1999, J EXP MED, V190, P1155, DOI 10.1084/jem.190.8.1155; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Griffith TS, 2002, CANCER RES, V62, P3093; Grossman D, 2001, P NATL ACAD SCI USA, V98, P635, DOI 10.1073/pnas.230450097; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; Ichikawa T, 2001, BIOCHEM BIOPH RES CO, V280, P933, DOI 10.1006/bbrc.2000.4228; Inan MS, 2000, GASTROENTEROLOGY, V118, P724, DOI 10.1016/S0016-5085(00)70142-9; Ito T, 2000, HEPATOLOGY, V31, P1080, DOI 10.1053/he.2000.6496; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Kayagaki N, 1999, J EXP MED, V189, P1451, DOI 10.1084/jem.189.9.1451; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kobayashi K, 1999, P NATL ACAD SCI USA, V96, P1457, DOI 10.1073/pnas.96.4.1457; Lacour S, 2001, CANCER RES, V61, P1645; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Manna SK, 2000, J IMMUNOL, V165, P4927, DOI 10.4049/jimmunol.165.9.4927; Nagane M, 2000, CANCER RES, V60, P847; NAKABAYASHI H, 1984, JPN J CANCER RES, V75, P151; Nakao K, 1999, J BIOL CHEM, V274, P28075, DOI 10.1074/jbc.274.40.28075; Nimmanapalli R, 2001, CANCER RES, V61, P759; Olie RA, 2000, CANCER RES, V60, P2805; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Suk K, 2001, FEBS LETT, V495, P66, DOI 10.1016/S0014-5793(01)02335-3; Sun SY, 2000, CANCER RES, V60, P7149; Tamm I, 1998, CANCER RES, V58, P5315; Toomey NL, 2001, ONCOGENE, V20, P7029, DOI 10.1038/sj.onc.1204895; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wen Y, 2000, CANCER RES, V60, P42; Yamanaka T, 2000, HEPATOLOGY, V32, P482, DOI 10.1053/jhep.2000.16266; Zhou Q, 2000, CANCER RES, V60, P2611	45	103	118	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 20	2003	22	11					1653	1662		10.1038/sj.onc.1206139	http://dx.doi.org/10.1038/sj.onc.1206139			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642868				2022-12-28	WOS:000181580500007
J	Kyng, KJ; May, A; Brosh, RM; Cheng, WH; Chen, C; Becker, KG; Bohr, VA				Kyng, KJ; May, A; Brosh, RM; Cheng, WH; Chen, C; Becker, KG; Bohr, VA			The transcriptional response after oxidative stress is defective in Cockayne syndrome group B cells	ONCOGENE			English	Article						microarray; Cockayne syndrome; transcription; DNA repair; DNA damage; aging	RNA-POLYMERASE-II; ACTIVATED PROTEIN-KINASE; GENE-EXPRESSION PROFILE; BASE EXCISION-REPAIR; HEAT-SHOCK PROTEINS; CALORIC RESTRICTION; HYDROGEN-PEROXIDE; GENOME-WIDE; DNA-REPAIR; SKIN FIBROBLASTS	Cockayne syndrome (CS) is a human hereditary disease belonging to the group of segmental progerias, and the clinical phenotype is characterized by postnatal growth failure, neurological dysfunction, cachetic dwarfism, photosensitivity, sensorineural hearing loss, and retinal degradation. CS-B cells are defective in transcription-coupled DNA repair, base excision repair, transcription, and chromatin structural organization. Using array analysis, we have examined the expression profile in CS complementation group B (CS-B) fibroblasts after exposure to oxidative stress (H2O2) before and after complete complementation with the CSB gene. The following isogenic cell lines were compared: CS-B cells (CS-B null), CS-B cells complemented with wild-type CSB (CS-B wt), and a stably transformed cell fine with a point mutation in the ATPase domain of CSB (CS-B ATPase mutant). In the wt rescued cells, we detected significant induction ( > two-fold) of 112 genes out of the 6912 analysed. The patterns suggested an induction or upregulation of genes involved in several DNA metabolic processes including DNA repair, transcription, and signal transduction. In both CS-B mutant cell lines, we found a general deficiency in transcription after oxidative stress, suggesting that the CSB protein influenced the regulation of transcription of certain genes. Of the 6912 genes, 122 were differentially regulated by more than two-fold. Evidently, the ATPase function of CSB is biologically important as the deficiencies seen in the ATPase mutant cells are very similar to those observed in the CS-B-null cells. Some major defects are in the transcription of genes involved in DNA repair, signal transduction, and ribosomal functions.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; NIA, DNA Array Unit, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Bohr, VA (corresponding author), Aarhus Univ, Danish Ctr Mol Gerontol, Dept Mol & Struct Biol, DK-8000 Aarhus C, Denmark.		Bohr, Vilhelm/AAP-5931-2020; Kyng, Kasper/AAA-5339-2019	Kyng, Kasper/0000-0001-7940-1656; Becker, Kevin/0000-0002-6794-6656	NATIONAL INSTITUTE ON AGING [Z01AG000731] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7; Balajee AS, 1997, P NATL ACAD SCI USA, V94, P4306, DOI 10.1073/pnas.94.9.4306; Balajee AS, 2000, GENE, V250, P15, DOI 10.1016/S0378-1119(00)00172-4; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; Bregman DB, 1996, P NATL ACAD SCI USA, V93, P11586, DOI 10.1073/pnas.93.21.11586; Cao SX, 2001, P NATL ACAD SCI USA, V98, P10630, DOI 10.1073/pnas.191313598; Citterio E, 2000, MOL CELL BIOL, V20, P7643, DOI 10.1128/MCB.20.20.7643-7653.2000; Dalton TD, 1999, ANNU REV PHARMACOL, V39, P67, DOI 10.1146/annurev.pharmtox.39.1.67; De Wit R, 2001, FASEB J, V15, P306; Dhar V, 1996, CELL GROWTH DIFFER, V7, P841; Dianov G, 1999, NUCLEIC ACIDS RES, V27, P1365, DOI 10.1093/nar/27.5.1365; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Feder ME, 1999, ANNU REV PHYSIOL, V61, P243, DOI 10.1146/annurev.physiol.61.1.243; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Friedberg EC, 1996, BIOESSAYS, V18, P731, DOI 10.1002/bies.950180908; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Godon C, 1998, J BIOL CHEM, V273, P22480, DOI 10.1074/jbc.273.35.22480; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HENNING KA, 1995, CELL, V82, P555, DOI 10.1016/0092-8674(95)90028-4; Hollenbach S, 1999, CARCINOGENESIS, V20, P1863, DOI 10.1093/carcin/20.9.1863; Huang CS, 2001, J BIOL CHEM, V276, P40234, DOI 10.1074/jbc.M103684200; Kayo T, 2001, P NATL ACAD SCI USA, V98, P5093, DOI 10.1073/pnas.081061898; KEYSE SM, 1990, MOL CELL BIOL, V10, P4967, DOI 10.1128/MCB.10.9.4967; KEYSE SM, 1987, J BIOL CHEM, V262, P14821; Kim SW, 2001, J BIOL CHEM, V276, P10199, DOI 10.1074/jbc.M010640200; Krokan HE, 1997, BIOCHEM J, V325, P1; Krokan HE, 2001, PROG NUCLEIC ACID RE, V68, P365; KUO ML, 1995, BBA-MOL CELL RES, V1268, P229, DOI 10.1016/0167-4889(95)00076-5; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Lee CK, 2000, NAT GENET, V25, P294, DOI 10.1038/77046; Lee HM, 2002, J NEUROCHEM, V80, P928, DOI 10.1046/j.0022-3042.2002.00774.x; Lee SK, 2001, MOL CELL BIOL, V21, P8651, DOI 10.1128/MCB.21.24.8651-8656.2001; Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486; Mathew A, 1998, MOL CELL BIOL, V18, P5091, DOI 10.1128/MCB.18.9.5091; Miller RA, 2001, J GERONTOL A-BIOL, V56, pB52, DOI 10.1093/gerona/56.2.B52; Morimoto RI, 1998, NAT BIOTECHNOL, V16, P833, DOI 10.1038/nbt0998-833; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; PARSONS R, 1995, CANCER RES, V55, P5548; Selby CP, 1997, P NATL ACAD SCI USA, V94, P11205, DOI 10.1073/pnas.94.21.11205; Selzer RR, 2002, NUCLEIC ACIDS RES, V30, P782, DOI 10.1093/nar/30.3.782; Sitte N, 2000, FASEB J, V14, P2495, DOI 10.1096/fj.00-0209com; Sitte N, 1998, FEBS LETT, V440, P399, DOI 10.1016/S0014-5793(98)01495-1; Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109; Tanaka TS, 2000, P NATL ACAD SCI USA, V97, P9127, DOI 10.1073/pnas.97.16.9127; Tuo J, 2001, J BIOL CHEM, V276, P45772, DOI 10.1074/jbc.M107888200; TYRRELL RM, 1994, METHOD ENZYMOL, V234, P224; Wang YX, 2000, INT J ONCOL, V16, P757; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Weindruch R, 2002, MECH AGEING DEV, V123, P177, DOI 10.1016/S0047-6374(01)00344-X; Wheaton K, 1996, BIOCHEM CELL BIOL, V74, P523, DOI 10.1139/o96-056; Yu AD, 2000, MOL CELL, V5, P801, DOI 10.1016/S1097-2765(00)80320-2; Zhao RB, 2000, GENE DEV, V14, P981; Zou S, 2000, P NATL ACAD SCI USA, V97, P13726, DOI 10.1073/pnas.260496697	55	55	56	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 27	2003	22	8					1135	1149		10.1038/sj.onc.1206187	http://dx.doi.org/10.1038/sj.onc.1206187			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650EK	12606941				2022-12-28	WOS:000181249700003
J	Qiu, CP; Yu, MS; Shan, L; Snyderwine, EG				Qiu, CP; Yu, MS; Shan, L; Snyderwine, EG			Allelic imbalance and altered expression of genes in chromosome 2q11-2q16 from rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine	ONCOGENE			English	Article						heterocyclic amines; allelic imbalance; quantitative real-time polymerase chain reaction; microsatellite instability; loss of heterozygosity; gene expression; rat chromosome 2q	RASGTPASE ACTIVATING PROTEIN; SPRAGUE-DAWLEY RATS; BREAST-CANCER; EPITHELIAL-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; MICROSATELLITE INSTABILITY; PROSTATE-CANCER; ONCOSTATIN-M; DIETARY-FAT; TUMORS	2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), a compound found in cooked meat, is a mammary gland carcinogen in rats. Comparative genomic hybridization of PhIP-induced rat mammary gland carcinomas revealed loss in the centromeric region of 2q, a region known to carry the mammary carcinoma susceptibility 1 (Mcs1) gene and several other genes relevant to carcinogenesis. Allelic imbalance, specifically microsatellite instability and loss of heterozygosity, was examined in mammary gland carcinomas induced by PhIP in Sprague-Dawley (SD) x Wistar Furth F1 hybrid rats. In a polymerase chain reaction (PCR)-based assay with 34 microsatellite markers coinciding to 2q11-2q16, nine markers revealed allelic imbalance. The frequency of imbalance in the tumors varied from 10 to 100% depending on the specific marker. However, none of the markers coinciding with the Mcs1 gene locus showed allelic imbalance, suggesting that alterations at this locus were not associated with PhIP-induced rat mammary gland cancer. The expression of several genes physically mapped to 2q11-2q16 and potentially involved in carcinogenesis including Ccnb (cyclin B1), Ccnh (cyclin H), Rasa (Ras GAP), RasgrJ2, Pi3kr1 (p85alpha), and Il6st (gp130) was also examined by quantitative real-time PCR and immunohistochemistry (IHC) across a large bank of PhIP-induced SD rat mammary gland carcinomas. By quantitative real-time PCR, the mRNA expression of Rasa, Pi3kr1, Ccnh, and 1l6st in carcinomas was, respectively, 22-, 20-, three- and threefold higher in carcinomas than in control mammary gland tissues (P<0.05, Student's t-test). A statistically sixfold lower expression of Rasgrf 2 was detected in carcinomas whereas no significant change in Ccnb1 expression was observed. The findings from quantitative real-time PCR were confirmed by IHC for each gene. In addition, the proliferation index in mammary gland carcinomas as assessed by PCNA was found to correlate with the overexpression of Cyclin H by IHC analysis (P<0.05, Spearman Rank Order Correlation). The findings from the current study implicate molecular alterations in the proximal region of 2q in PhIP-induced rat mammary gland carcinomas.	NCI, Ctr Canc Res,Lab Expt Carcinogenesis, Chem Carcinogenesis Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Snyderwine, EG (corresponding author), NCI, Ctr Canc Res,Lab Expt Carcinogenesis, Chem Carcinogenesis Sect, NIH, Bldg 37,Room 4134,37 Convent Dr MSC 4262, Bethesda, MD 20892 USA.				DIVISION OF BASIC SCIENCES - NCI [Z01BC010037] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barshack I, 1998, MODERN PATHOL, V11, P271; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Christian AT, 2002, MUTAT RES-FUND MOL M, V506, P113, DOI 10.1016/S0027-5107(02)00157-4; Crichton MB, 1996, MOL CELL ENDOCRINOL, V118, P215, DOI 10.1016/0303-7207(96)03761-6; Davidson B, 1998, PATHOL RES PRACT, V194, P399, DOI 10.1016/S0344-0338(98)80030-7; Fernandez-Medarde A, 2002, MOL CELL BIOL, V22, P2498, DOI 10.1128/MCB.22.8.2498-2504.2002; Gershtein ES, 1999, CLIN CHIM ACTA, V287, P59, DOI 10.1016/S0009-8981(99)00118-7; GHOSHAL A, 1994, CARCINOGENESIS, V15, P2429, DOI 10.1093/carcin/15.11.2429; Gire V, 2000, ONCOGENE, V19, P2269, DOI 10.1038/sj.onc.1203544; Grant SL, 2001, GROWTH FACTORS, V19, P153, DOI 10.3109/08977190109001083; Haag JD, 1996, MOL CARCINOGEN, V17, P134, DOI 10.1002/(SICI)1098-2744(199611)17:3<134::AID-MC5>3.3.CO;2-N; Hokaiwado N, 2001, CANCER LETT, V163, P187, DOI 10.1016/S0304-3835(00)00693-5; HSU LC, 1994, CANCER RES, V54, P2765; Karan D, 2002, CARCINOGENESIS, V23, P967, DOI 10.1093/carcin/23.6.967; Kerangueven F, 1997, CANCER RES, V57, P5469; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Laes JF, 2001, MAMM GENOME, V12, P199, DOI 10.1007/s003350010268; LAYTON DW, 1995, CARCINOGENESIS, V16, P39, DOI 10.1093/carcin/16.1.39; Leblanc V, 1999, ONCOGENE, V18, P4884, DOI 10.1038/sj.onc.1202855; Liu JW, 1998, CYTOKINE, V10, P295, DOI 10.1006/cyto.1997.0283; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Mills GB, 2001, SEMIN ONCOL, V28, P125, DOI 10.1053/sonc.2001.28554; Quan X, 2000, CYTOGENET CELL GENET, V88, P119, DOI 10.1159/000015503; Roberts-Thomson SJ, 1997, MOL CARCINOGEN, V20, P348, DOI 10.1002/(SICI)1098-2744(199712)20:4<348::AID-MC4>3.0.CO;2-F; Rodriguez-Viciana P, 2001, METHOD ENZYMOL, V333, P37; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; RUSSO J, 1990, LAB INVEST, V62, P244; Schultz P, 2000, CELL, V102, P599, DOI 10.1016/S0092-8674(00)00082-9; Shan L, 2002, CARCINOGENESIS, V23, P1561, DOI 10.1093/carcin/23.10.1561; Shepel LA, 1998, GENETICS, V149, P289; Sinha R, 2000, J NATL CANCER I, V92, P1352, DOI 10.1093/jnci/92.16.1352; Snyderwine EG, 1998, NUTR CANCER, V31, P160, DOI 10.1080/01635589809514698; SNYDERWINE EG, 2000, FOOD BORNE CARCINOGE, P241; Szpirer C, 1999, MAMM GENOME, V10, P30, DOI 10.1007/s003359900937; Tomlinson IPM, 2002, GENE CHROMOSOME CANC, V34, P349, DOI 10.1002/gcc.10085; Toyota M, 1996, MOL CARCINOGEN, V15, P176, DOI 10.1002/(SICI)1098-2744(199603)15:3<176::AID-MC3>3.0.CO;2-G; Watanabe N, 2001, CANCER RES, V61, P2632; Yang JY, 2002, J BIOL CHEM, V277, P14641, DOI 10.1074/jbc.M111540200; Yu MS, 2002, CARCINOGENESIS, V23, P2123, DOI 10.1093/carcin/23.12.2123; Yu MS, 2000, MOL CARCINOGEN, V27, P76, DOI 10.1002/(SICI)1098-2744(200002)27:2<76::AID-MC3>3.0.CO;2-7	41	15	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 27	2003	22	8					1253	1260		10.1038/sj.onc.1206233	http://dx.doi.org/10.1038/sj.onc.1206233			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650EK	12606953				2022-12-28	WOS:000181249700015
J	Chan, AOO; Kim, SG; Bedeir, A; Issa, JP; Hamilton, SR; Rashid, A				Chan, AOO; Kim, SG; Bedeir, A; Issa, JP; Hamilton, SR; Rashid, A			CpG island methylation in carcinoid and pancreatic endocrine tumors	ONCOGENE			English	Article						methylation; carcinoid tumors; pancreatic; endocrine tumors	ACID RECEPTOR-BETA; DNA METHYLATION; ABERRANT METHYLATION; NEUROENDOCRINE TUMORS; GENE-EXPRESSION; SUPPRESSOR GENE; UP-REGULATION; CYCLOOXYGENASE-2; INACTIVATION; HYPERMETHYLATION	Carcinoid tumors and pancreatic endocrine tumors (PETs) are uncommon neuroendocrine neoplasms and their genetic alterations are not well characterized. CpG island methylation is a mechanism of gene silencing, and concordant methylation of multiple CpG islands as CpG island methylator phenotype (CIMP) has been described in tumors. The aim of this study was to evaluate CIMP in carcinoid tumors and PETs. We studied 16 carcinoid tumors, 11 PETs, and 22 associated normal mucosa or pancreas. Methylation status of the p14, p16, cyclooxygenase 2 (COX2), O-6-methyl-guanine methyltransferase (MGMT), estrogen receptor (ER), thrombospondin 1 (THBS1), retinoic acid receptor beta 2 (RARbeta), T-type calcium channel (CACNA1G), and multiple endocrine neoplasia type-1 (MEN1) genes, and of MINT1, MINT2, MINT25, MINT27 and MINT31 loci was evaluated by methylation-specific-PCR (MSP) or combined bisultite restriction analysis (COBRA). Carcinoid tumors were frequently methylated at RARbeta, MGMT, p16, COX2, p14, THBS1, and ER ranging from 25 to 63% of tumors. Other CpG islands were infrequently methylated or unmethylated. The adjoining normal mucosa was also methylated for ER, COX2, and RARbeta, but methylation at p14, p16, THBS1, and MGMT was tumor-specific. By contrast, PETs and normal pancreas were frequently methylated only at ER. Methylation was more frequent in carcinoid tumors than PETs at MGMT (25 versus 0%, P = 0.03), THBS1 (44 versus 9%, P = 0.04), p14 (44 versus 9%, P = 0.04) and RARP (25 versus 0%, P = 0.03). Loss of p16 protein expression correlated with methylation of p16 gene in carcinoid tumors (P = 0.006). Our study indicates that methylation profile of carcinoid tumors differs from PETs, reflecting different molecular pathogenesis.	Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Rashid, A (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Pathol, 1515 Holcombe Blvd,Box 85, Houston, TX 77030 USA.			Issa, Jean-Pierre/0000-0003-2258-5030				Ahuja N, 1998, CANCER RES, V58, P5489; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Calender A, 1999, RECENT ADV PATHOPHYS, P155; CAPELLA C, 2000, WHO CLASSIFICATION T, P53; Eads CA, 2001, CANCER RES, V61, P3410; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Esteller M, 2000, CANCER RES, V60, P129; Esteller M, 1999, CANCER RES, V59, P793; Fujimori M, 2001, CANCER RES, V61, P6656; GODWIN JD, 1975, CANCER, V36, P560, DOI 10.1002/1097-0142(197508)36:2<560::AID-CNCR2820360235>3.0.CO;2-4; Gortz B, 1999, AM J PATHOL, V154, P429, DOI 10.1016/S0002-9440(10)65289-3; HERMAN JG, 1995, CANCER RES, V55, P4525; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jensen R.T., 1999, RECENT ADV PATHOPHYS, P192; Konishi N, 2002, AM J PATHOL, V160, P1207, DOI 10.1016/S0002-9440(10)62547-3; Li Q, 1999, ONCOGENE, V18, P3284, DOI 10.1038/sj.onc.1202663; Lim HY, 2000, CLIN CANCER RES, V6, P519; Lubomierski N, 2001, CANCER RES, V61, P5905; Marx SJ, 1999, RECENT PROG HORM RES, V54, P397; Mignon M, 2000, DIGESTION, V62, P51, DOI 10.1159/000051856; Muscarella P, 1998, CANCER RES, V58, P237; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Rashid A, 2001, CANCER RES, V61, P3406; Rindi G, 1999, ITAL J GASTROENTEROL, V31, pS135; Rindi G, 1999, RECENT ADV PATHOPHYS, P177; Ristimaki A, 1997, CANCER RES, V57, P1276; Roberts DD, 1996, FASEB J, V10, P1183, DOI 10.1096/fasebj.10.10.8751720; ROMAN SD, 1992, CANCER RES, V52, P2236; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Serrano J, 2000, J CLIN ENDOCR METAB, V85, P4146, DOI 10.1210/jc.85.11.4146; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SOLCIA E, 1997, ATLAS TUMOR PATHOL, P145; SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133; Toyooka S, 2001, MOL CANCER THER, V1, P61; Toyota M, 2001, BLOOD, V97, P2823, DOI 10.1182/blood.V97.9.2823; Toyota M, 2000, CANCER RES, V60, P4044; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Toyota M, 1999, CANCER RES, V59, P5438; Toyota M, 1999, CANCER RES, V59, P4535; Uefuji K, 2000, CLIN CANCER RES, V6, P135; Ueki T, 2000, CANCER RES, V60, P1835; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; WEBER HC, 1996, ADV PANCREATIC DIS M, P55; Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532	47	102	108	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2003	22	6					924	934		10.1038/sj.onc.1206123	http://dx.doi.org/10.1038/sj.onc.1206123			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584572				2022-12-28	WOS:000180864300015
J	Le, XF; Hittelman, WN; Liu, JX; McWatters, A; Li, C; Mills, GB; Bast, RC				Le, XF; Hittelman, WN; Liu, JX; McWatters, A; Li, C; Mills, GB; Bast, RC			Paclitaxel induces inactivation of p70 S6 kinase and phosphorylation of Thr(421) and Ser(424) via multiple signaling pathways in mitosis	ONCOGENE			English	Article						paclitaxel; p70S6K; phosphorylation; activation; mitosis	PROTEIN-KINASE; REGULATORY MECHANISM; GROWTH-REGULATION; MESSENGER-RNA; CELL-CYCLE; IN-VIVO; RAPAMYCIN; P70(S6K); ACTIVATION; INHIBITION	The 70kDa ribosomal S6 kinase (p70S6K) is important for cell growth and survival. Activation of p70S6K requires sequential phosphorylation of multiple serine and threonine sites often triggered by growth factors and hormones. Here, we report that paclitaxel, a microtubule-damaging agent, induces phosphorylation of p70S6K at threonine 421 and serine 424 (T421/S424) in a concentration-and time-dependent manner in multiple breast and ovarian cancer cell lines demonstrated by a T421/S424 phospho-p70S6K antibody. Phosphoamino-acid analysis and Western blot analysis by serine-/threonine-specific antibodies further confirms that both serine and threonine residues are phosphorytated in p70S6K following treatment with paclitaxel. Paclitaxel-induced p70S6K(T421/S424) phosphorylation requires both de novo RNA and protein synthesis via multiple signaling pathways including ERK1/2 MAP kinase, JNK, PKC, Ca++, PI3K, and mammalian target of rapamycin (mTOR). Despite phosphorylation of p70S6K, paclitaxel inactivates this kinase in a concentration- and time-dependent manner as illustrated by in vitro kinase assay. Inhibitors of mTOR, PI3K, and Ca++ impair p70S6K activity, whereas inhibitors of JNK and PKC stimulate p70S6K activity. Inhibition of PKC and JNK prevents paclitaxel-induced p70S6K inactivation. Moreover, the paclitaxel-induced phosphorylation and low activity of p70S6K mainly occurs during mitosis. In summary, paclitaxel is able to induce p70S6K(T421)/(S424) phosphorylation and decrease its activity in mitotic cells via multiple signaling pathways. Our data suggest that paclitaxel-induced p70S6K(T421)/S-424 phosphorylation and kinase inactivation are differentially regulated. Our data also indicate that paclitaxel may exert its antitumor effect, at least in part, via inhibition of p70S6K.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Bast, RC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, 1515 Holcombe Blvd,Box 355, Houston, TX 77030 USA.		Bast, Robert C/E-6585-2011	Bast, Robert C/0000-0003-4621-8462	NATIONAL CANCER INSTITUTE [R01CA039930] Funding Source: NIH RePORTER; NCI NIH HHS [CA-39930] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akimoto K, 1998, BIOCHEM J, V335, P417, DOI 10.1042/bj3350417; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Avruch J, 2001, Prog Mol Subcell Biol, V26, P115; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; Belham C, 2001, CURR BIOL, V11, P1155, DOI 10.1016/S0960-9822(01)00369-4; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BOONSTRA J, 1981, J CELL PHYSIOL, V107, P75, DOI 10.1002/jcp.1041070110; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Conus NM, 1998, J BIOL CHEM, V273, P4776, DOI 10.1074/jbc.273.8.4776; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; Edelmann HML, 1996, J BIOL CHEM, V271, P963, DOI 10.1074/jbc.271.2.963; Grammer TC, 1996, CANCER SURV, V27, P271; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; HORWITZ SB, 1992, TRENDS PHARMACOL SCI, V13, P134; Isotani S, 1999, J BIOL CHEM, V274, P34493, DOI 10.1074/jbc.274.48.34493; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; Le XF, 2001, ONCOGENE, V20, P8258, DOI 10.1038/sj.onc.1205039; Le XF, 1999, J BIOL CHEM, V274, P21651, DOI 10.1074/jbc.274.31.21651; Li C, 1998, CANCER RES, V58, P2404; Luo Y, 1996, MOL CELL BIOL, V16, P6744; Mahalingam M, 1996, MOL CELL BIOL, V16, P405; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; Nakamura M, 2001, CURR BIOL, V11, P1512, DOI 10.1016/S0960-9822(01)00456-0; PANDITA TK, 1994, CYTOGENET CELL GENET, V67, P94, DOI 10.1159/000133807; Papst PJ, 1998, J BIOL CHEM, V273, P15077, DOI 10.1074/jbc.273.24.15077; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Reif K, 1997, J BIOL CHEM, V272, P14426, DOI 10.1074/jbc.272.22.14426; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; SOUZA CPE, 2000, CELL, V102, P293; TEMPLETON DJ, 2001, CURR BIOL, V8, P69; Thomas G, 2000, NAT CELL BIOL, V2, pE71, DOI 10.1038/35010581; Volarevic S, 2001, PROG NUCLEIC ACID RE, V65, P101; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Zhou XZ, 1999, CELL MOL LIFE SCI, V56, P788, DOI 10.1007/s000180050026	48	47	48	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 30	2003	22	4					484	497		10.1038/sj.onc.1206175	http://dx.doi.org/10.1038/sj.onc.1206175			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555062				2022-12-28	WOS:000180538200002
J	Honorio, S; Agathanggelou, A; Wernert, N; Rothe, M; Maher, ER; Latif, F				Honorio, S; Agathanggelou, A; Wernert, N; Rothe, M; Maher, ER; Latif, F			Frequent epigenetic inactivation of the RASSF1A tumour suppressor gene in testicular tumours and distinct methylation profiles of seminoma and nonseminoma testicular germ cell tumours	ONCOGENE			English	Article						methylation; 3p21.3 tumour suppressor gene; testicular tumours	HUMAN-CHROMOSOME 3P21.3; CPG ISLAND; PROMOTER HYPERMETHYLATION; LUNG CARCINOMAS; ABERRANT METHYLATION; HUMAN NEOPLASIA; CANCER; HETEROZYGOSITY; REGION; BREAST	Testicular germ cell tumours (TGCTs) are histologically heterogeneous neoplasms with variable malignant potential. Previously, we demonstrated frequent 3p allele loss in TGCTs, and recently we and others have shown that the 3p21.3 RASSF1A tumour suppressor gene (TSG) is frequently inactivated by promoter hypermethylation in a wide range of cancers including lung, breast, kidney and neuroblastoma. In order to investigate the role of epigenctic events in the pathogenesis of TGCTs, we analysed the promoter methylation status of RASSF1A and nine other genes that may be epigenetically inactivated in cancer (p16(INK4A), APC, MGMT, GSTP1, DAPK, CDH1, CDH13, RARbeta and FHIT) in 24 primary TGCTs (28 histologically distinct components). RASSF1A methylation was detected in four of 10 (40%) seminomas and 15 of 18 (83%) nonseminoma TGCT (NSTGCT) components (P = 0.0346). None of the other nine candidate genes were methylated in seminomas, but MGMT (44%), APC (29%) and FHIT (29%) were frequently methylated in NSTGCTs. Furthermore, in two mixed germ cell tumours, the NSTGCT component for one demonstrated RASSF1A, APC and CDH13 promoter methylation, but the seminoma component was unmethylated for all genes analysed. In the second mixed germ cell tumour, the NSTGCT component was methylated for RASSF1A and MGMT, while the seminoma component was methylated only for RASSF1A. In all, 61% NSTGCT components but no seminoma samples demonstrated promoter methylation at two or more genes (P = 0.0016). These findings are consistent with a multistep model for TGCT pathogenesis in which RASSF1A methylation occurs early in tumorigenesis and additional epigenetic events characterize progression from seminoma to NSTGCTs.	Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England; Univ Bonn, Inst Pathol, D-53011 Bonn, Germany; Univ Birmingham, Sch Med, Canc Res UK Renal Mol Oncol Res Grp, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England	University of Birmingham; University of Bonn; University of Birmingham	Latif, F (corresponding author), Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.		MAHER, EAMONN R/A-9507-2008	MAHER, EAMONN R/0000-0002-6226-6918				Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; ALJEHANI RMA, 1995, GENE CHROMOSOME CANC, V13, P249, DOI 10.1002/gcc.2870130404; Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Byun DS, 2001, CANCER RES, V61, P7034; Chaganti RSK, 2000, CANCER RES, V60, P1475; Chaubert P, 1997, AM J PATHOL, V151, P859; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 1998, CANCER RES, V58, P4515; Esteller M, 2001, CANCER RES, V61, P3225; Faulkner SW, 2000, BRIT J CANCER, V83, P729, DOI 10.1054/bjoc.2000.1334; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Foster K, 1995, EUR J CANCER, V31A, P2392, DOI 10.1016/0959-8049(95)00437-8; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Katzenellenbogen RA, 1999, BLOOD, V93, P4347, DOI 10.1182/blood.V93.12.4347.412k31_4347_4353; Kraggerud SM, 2002, CANCER RES, V62, P512; Lee MG, 2001, CANCER RES, V61, P6688; Lerman MI, 2000, CANCER RES, V60, P6116; Lind Guro Elisabeth, 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P1120; Lo KW, 2001, CANCER RES, V61, P3877; Looijenga LHJ, 1999, REV REPROD, V4, P90, DOI 10.1530/ror.0.0040090; Looijenga LHJ, 1997, AM J PATHOL, V151, P581; LOOIJENGA LHJ, 1994, GENE CHROMOSOME CANC, V9, P153, DOI 10.1002/gcc.2870090302; LOTHE RA, 1995, LAB INVEST, V73, P606; Maruyama R, 2002, CLIN CANCER RES, V8, P514; MATHEW S, 1994, CANCER RES, V54, P6265; Morrissey C, 2001, CANCER RES, V61, P7277; Mostert MC, 1998, ONCOGENE, V16, P2617, DOI 10.1038/sj.onc.1201787; Murty VVVS, 1996, ONCOGENE, V12, P2719; PELTOMAKI P, 1991, BIOCHIM BIOPHYS ACTA, V1096, P187, DOI 10.1016/0925-4439(91)90004-S; Rothe M, 1999, J PATHOL, V188, P389, DOI 10.1002/(SICI)1096-9896(199908)188:4<389::AID-PATH364>3.0.CO;2-K; Smiraglia DJ, 2002, ONCOGENE, V21, P3909, DOI 10.1038/sj.onc.1205488; SUIJKERBUIJK RF, 1994, CANCER GENET CYTOGEN, V78, P145, DOI 10.1016/0165-4608(94)90082-5; Toyooka KO, 2001, CANCER RES, V61, P4556; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Toyota M, 1999, CANCER RES, V59, P5438; Tsuchiya T, 2000, ONCOGENE, V19, P3642, DOI 10.1038/sj.onc.1203704; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; Zochbauer-Muller S, 2001, CANCER RES, V61, P3581	43	93	96	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 23	2003	22	3					461	466		10.1038/sj.onc.1206119	http://dx.doi.org/10.1038/sj.onc.1206119			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545168				2022-12-28	WOS:000180379100016
J	Belka, C; Gruber, C; Jendrossek, V; Wesselborg, S; Budach, W				Belka, C; Gruber, C; Jendrossek, V; Wesselborg, S; Budach, W			The tyrosine kinase Lck is involved in regulation of mitochondrial apoptosis pathways	ONCOGENE			English	Article							RADIATION-INDUCED APOPTOSIS; DRUG-INDUCED APOPTOSIS; IRRADIATION-INDUCED APOPTOSIS; NF-KAPPA-B; LYMPHOMA-CELLS; DIFFERENTIAL REQUIREMENT; CD95-INDUCED APOPTOSIS; IONIZING-RADIATION; CASPASE ACTIVATION; LEUKEMIA-CELLS	The induction of apoptosis requires the activation of a highly coordinated signaling network ultimately leading to the activation of caspases. In previous experiments we and others have shown that the tyrosine kinase Lck is required for adequate apoptosis induction in response to ionizing radiation, ceramide incubation and overexpression of the HIV-TAT protein. However, the position of Lck within given apoptotic signaling cascades remains unclear. We therefore aimed to define the role of Lck during radiation-induced apoptosis. Apoptosis induction in response to ionizing radiation, CD95 or TRAIL receptor stimulation was determined in Jurkat T-cells, the Lck-deficient Jurkat clone JCaM1.6- and Lck-retransfected JCaM1.6/Lck. No apoptosis, release of cytochrome c, breakdown of the mitochondrial potential were detectable during the first 48 h after irradiation of JCaM1.6 cells. In parallel, no activation of caspase-9, -8 and -3 was detectable. Since mitochondrial apoptosis pathways act within a feedback mechanism during death-receptor-mediated apoptosis, the influence of the Lck defect on CD95/Fas/Apo-1-L or TRAIL-induced apoptosis was also tested. Both stimuli induced apoptosis in Lck-deficient cells. However, the kinetics of apoptosis induction determined by caspase-8, -9 and -3 activation as well as DeltaPsi(m) breakdown was slowed. We conclude that the Lck deficiency influences early steps during radiation-induced mitochondrial alterations.	Univ Tubingen, Dept Radiat Oncol, D-72076 Tubingen, Germany; Univ Tubingen, Dept Internal Med 1, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen	Belka, C (corresponding author), Univ Tubingen, Dept Radiat Oncol, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.		Jendrossek, Verena/AAH-4967-2019	Jendrossek, Verena/0000-0003-1058-2107; Wesselborg, Sebastian/0000-0002-5236-942X				Belka C, 2000, ANTICANCER RES, V20, P3243; Belka C, 1998, RADIAT RES, V149, P588, DOI 10.2307/3579905; Belka C, 2002, INT J RADIAT BIOL, V78, P643, DOI 10.1080/09553000210137680; Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Burek C, 2001, ONCOGENE, V20, P6493, DOI 10.1038/sj.onc.1204841; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Couture C, 1996, J BIOL CHEM, V271, P24880, DOI 10.1074/jbc.271.40.24880; Dunkern TR, 2001, ONCOGENE, V20, P6026, DOI 10.1038/sj.onc.1204754; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Farschon DM, 1997, J CELL BIOL, V137, P1117, DOI 10.1083/jcb.137.5.1117; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Gulbins E, 1997, P NATL ACAD SCI USA, V94, P7661, DOI 10.1073/pnas.94.14.7661; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; JIMENEZ B, 1995, ONCOGENE, V10, P811; Kabouridis PS, 1997, EMBO J, V16, P4983, DOI 10.1093/emboj/16.16.4983; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Manna SK, 2000, J BIOL CHEM, V275, P13297, DOI 10.1074/jbc.275.18.13297; Manna SK, 2000, J IMMUNOL, V164, P5156, DOI 10.4049/jimmunol.164.10.5156; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; Ostergaard HL, 1998, J BIOL CHEM, V273, P5692, DOI 10.1074/jbc.273.10.5692; Pena LA, 2000, CANCER RES, V60, P321; Qin SF, 1997, J BIOL CHEM, V272, P17994, DOI 10.1074/jbc.272.29.17994; Rudner J, 2002, APOPTOSIS, V7, P441, DOI 10.1023/A:1020087108926; Rudner J, 2001, J CELL SCI, V114, P4161; Rudner J, 2001, INT J RADIAT BIOL, V77, P1, DOI 10.1080/095530001453069; Samelson LE, 2002, ANNU REV IMMUNOL, V20, P371, DOI 10.1146/annurev.immunol.20.092601.111357; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Schlottmann KE, 1996, J LEUKOCYTE BIOL, V60, P546, DOI 10.1002/jlb.60.4.546; SCHRAVEN B, 1995, FEBS LETT, V368, P491, DOI 10.1016/0014-5793(95)00720-T; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Stepczynska A, 2001, ONCOGENE, V20, P1193, DOI 10.1038/sj.onc.1204221; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Szabo I, 1998, P NATL ACAD SCI USA, V95, P6169, DOI 10.1073/pnas.95.11.6169; Tomicic MT, 2002, ONCOGENE, V21, P2141, DOI 10.1038/sj.onc.1205280; Tuosto L, 2002, J IMMUNOL, V168, P6106, DOI 10.4049/jimmunol.168.12.6106; Uckun FM, 1996, SCIENCE, V273, P1096, DOI 10.1126/science.273.5278.1096; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; von Willebrand M, 1998, J BIOL CHEM, V273, P3994, DOI 10.1074/jbc.273.7.3994; WADDICK KG, 1993, RADIAT RES, V136, P313, DOI 10.2307/3578542; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378	50	30	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 16	2003	22	2					176	185		10.1038/sj.onc.1206103	http://dx.doi.org/10.1038/sj.onc.1206103			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527887				2022-12-28	WOS:000180322400003
J	Bentires-Alj, M; Barbu, V; Fillet, M; Chariot, A; Relic, B; Jacobs, N; Gielen, J; Merville, MP; Bours, V				Bentires-Alj, M; Barbu, V; Fillet, M; Chariot, A; Relic, B; Jacobs, N; Gielen, J; Merville, MP; Bours, V			NF-kappa B transcription factor induces drug resistance through MDR1 expression in cancer cells	ONCOGENE			English	Article						MDR1; apoptosis; cancer; transcription factors; NF-kappa B; chemotherapy	TUMOR-NECROSIS-FACTOR; MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN; CYCLOSPORINE-A; GLUCOCORTICOID RECEPTOR; LIVER DEGENERATION; INDUCED APOPTOSIS; BREAST-CANCER; MICE LACKING; T-CELLS	The ubiquitous NF-kappaB transcription factor has been reported to inhibit apoptosis and to induce drug resistance in cancer cells. Drug resistance is the major reason for cancer therapy failure and neoplastic cells often develop multiple mechanisms of drug resistance during tumor progression. We observed that NF-kappaB or P-glycoprotein inhibition in the HCT15 colon cancer cells led to increased apoptotic cell death in response to daunomycin treatment. Interestingly, NF-kappaB inhibition through transfection of a plasmid coding for a mutated IkappaB-alpha inhibitor increased daunomycin cell uptake. Indeed, the inhibition of NF-kappaB reduced mdr1 mRNA and P-glycoprotein expression in HCT15 cells. We identified a consensus NF-kappaB binding site in the first intron of the human mdr1 gene and demonstrated that NF-kappaB complexes could bind with this intronic site. Moreover, NF-kappaB transactivates an mdr1 promoter luciferase construct. Our data thus demonstrate a role for NF-kappaB in the regulation of the mdr1 gene expression in cancer cells and in drug resistance.	Univ Liege, Ctr Cellular & Mol Therapy, Liege, Belgium; Hop St Antoine, INSERM, Unit 402, Mol Biol Lab, F-75571 Paris, France; Univ Liege, Ctr Res Expt Cancerol, Liege, Belgium	University of Liege; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of Liege	Bours, V (corresponding author), Univ Liege, Dept Genet, CHU B35, B-4000 Liege, Belgium.		Mohamed, Bentires-Alj/F-4484-2015	Mohamed, Bentires-Alj/0000-0001-6344-1127; Fillet, Marianne/0000-0002-1453-6282; Chariot, Alain/0000-0002-1691-4347; Jacobs, Nathalie/0000-0002-9895-8465				Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bentires-Alj M, 1999, CANCER RES, V59, P811; Bezombes C, 1998, FASEB J, V12, P101, DOI 10.1096/fasebj.12.1.101; BIEDLER JL, 1994, CANCER RES, V54, P666; Bonizzi G, 1996, EUR J BIOCHEM, V242, P544, DOI 10.1111/j.1432-1033.1996.0544r.x; BOSCH I, 1996, BIOCHIM BIOPHYS ACTA, V1288, P37; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; Bours V, 2000, BIOCHEM PHARMACOL, V60, P1085, DOI 10.1016/S0006-2952(00)00391-9; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; DEJARDIN E, 1995, ONCOGENE, V11, P1835; GALA JL, 1995, J CLIN PATHOL, V48, P679, DOI 10.1136/jcp.48.7.679; GOLDIE JH, 1992, CHEMOTHERAPY SOURCE, P54; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; Hu Z, 2000, J BIOL CHEM, V275, P2979, DOI 10.1074/jbc.275.4.2979; Johnstone RW, 1999, BLOOD, V93, P1075, DOI 10.1182/blood.V93.3.1075.403k35_1075_1085; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Kolesnick Richard, 1992, Trends in Cell Biology, V2, P232, DOI 10.1016/0962-8924(92)90310-J; Kuo MT, 2002, ONCOGENE, V21, P1945, DOI 10.1038/sj.onc.1205117; Lee JI, 1999, TRANSPLANTATION, V68, P1255, DOI 10.1097/00007890-199911150-00007; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; LING V, 1983, CANCER TREAT REP, V67, P869; MADDEN MJ, 1993, J BIOL CHEM, V268, P8290; Marienfeld R, 1997, EUR J IMMUNOL, V27, P1601, DOI 10.1002/eji.1830270703; Meyer S, 1997, FEBS LETT, V413, P354, DOI 10.1016/S0014-5793(97)00930-7; Ogretmen B, 2000, BIOCHEMISTRY-US, V39, P194, DOI 10.1021/bi991943f; Ogretmen B, 1999, BIOCHEMISTRY-US, V38, P2189, DOI 10.1021/bi982236+; OGURA M, 1992, NUCLEIC ACIDS RES, V20, P5811, DOI 10.1093/nar/20.21.5811; Ohga T, 1998, J BIOL CHEM, V273, P5997, DOI 10.1074/jbc.273.11.5997; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Robinson LJ, 1997, BIOCHEMISTRY-US, V36, P11169, DOI 10.1021/bi9627830; Ros JE, 2001, HEPATOLOGY, V33, P1425, DOI 10.1053/jhep.2001.24667; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Sampath J, 2001, J BIOL CHEM, V276, P39359, DOI 10.1074/jbc.M103429200; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHMIDT A, 1990, J VIROL, V64, P4037, DOI 10.1128/JVI.64.8.4037-4041.1990; Smyth MJ, 1998, P NATL ACAD SCI USA, V95, P7024, DOI 10.1073/pnas.95.12.7024; Sonneveld P, 1997, SEMIN HEMATOL, V34, P34; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Sundseth R, 1997, MOL PHARMACOL, V51, P963, DOI 10.1124/mol.51.6.963; Thevenod F, 2000, J BIOL CHEM, V275, P1887, DOI 10.1074/jbc.275.3.1887; UEDA K, 1987, J BIOL CHEM, V262, P17432; Um JH, 2001, ONCOGENE, V20, P6048, DOI 10.1038/sj.onc.1204732; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Zhou G, 1997, J BIOL CHEM, V272, P15174, DOI 10.1074/jbc.272.24.15174	56	352	394	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 9	2003	22	1					90	97		10.1038/sj.onc.1206056	http://dx.doi.org/10.1038/sj.onc.1206056			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527911	Green Published			2022-12-28	WOS:000180166900010
J	Jaiswal, AS; Marlow, BP; Gupta, N; Narayan, S				Jaiswal, AS; Marlow, BP; Gupta, N; Narayan, S			beta-Catenin-mediated transactivation and cell - cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells	ONCOGENE			English	Article						curcumin; caspase-3; beta-catenin; c-Myc; cell-cell adhesion; G(2)/M arrest; apoptosis	C-MYC; ADENOMATOUS POLYPOSIS; CARCINOMA-CELLS; IN-VITRO; P53-DEPENDENT APOPTOSIS; ADHERENS JUNCTIONS; DIETARY CURCUMIN; CYCLE ARREST; APC PROTEIN; E-CADHERIN	The development of nontoxic natural agents with chemopreventive activity against colon cancer is the focus of investigation in many laboratories. Curcumin (feruylmethane), a natural plant product, possesses such chemopreventive activity, but the mechanisms by which it prevents cancer growth are not well understood. In the present study, we examined the mechanisms by which curcumin treatment affects the growth of colon cancer cells in vitro. Results showed that curcumin treatment causes p53- and p21-independent G(2)/M phase arrest and apoptosis in HCT-116(p53(+/+)), HCT-116(p53(-/-)) and HCT-116(p21(-/-)) cell lines. We further investigated the association of the beta-catenin-mediated c-Myc expression and the cell-cell adhesion pathways in curcumin-induced G(2)/M arrest and apoptosis in HCT-116 cells. Results described a caspase-3-mediated cleavage of beta-catenin, decreased transactivation of beta-catenin/Tcf-Lef, decreased promoter DNA binding activity of the beta-catenin/Tcf-Lef complex, and decreased levels of c-Myc protein. These activities were linked with decreased Cdc2/cyclin B1 kinase activity, a function of the G2/M phase arrest. The decreased transactivation of beta-catenin in curcumin-treated HCT-116 cells was unpreventable by caspase-3 inhibitor Z-DEVD-fmk, even though the curcumin-induced cleavage of beta-catenin was blocked in Z-DEVD-fmk pretreated cells. The curcumin treatment also induced caspase-3-mediated degradation of cell-cell adhesion proteins beta-catenin, E-cadherin and APC, which were linked with apoptosis, and this degradation was prevented with the caspase-3 inhibitor. Our results suggest that curcumin treatment impairs both Wnt signaling and cell-cell adhesion pathways, resulting in G(2)/M phase arrest and apoptosis in HCT-116 cells.	Univ Florida, UF Shands Canc Ctr, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; Univ Florida, Coll Med, UF Shands Canc Ctr, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Narayan, S (corresponding author), Univ Florida, Coll Med, UF Shands Canc Ctr, Acad Res Bldg,Room R4-216,POB 100232, Gainesville, FL 32610 USA.	snarayan@ufscc.ufl.edu			NCI NIH HHS [CA77721] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077721] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad N, 1997, JNCI-J NATL CANCER I, V89, P1881, DOI 10.1093/jnci/89.24.1881; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Bordonaro M, 1999, CELL GROWTH DIFFER, V10, P713; Boxer LM, 2001, ONCOGENE, V20, P5595, DOI 10.1038/sj.onc.1204595; Brancolini C, 1998, CELL DEATH DIFFER, V5, P1042, DOI 10.1038/sj.cdd.4400443; Browne SJ, 1998, CELL DEATH DIFFER, V5, P206, DOI 10.1038/sj.cdd.4400331; BROWNE SJ, 1994, INT J CANCER, V59, P56, DOI 10.1002/ijc.2910590113; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; BUSH JA, 2001, ONCOGENE, V20, P7597; Chan TA, 2000, GENE DEV, V14, P1584; Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87; Citro G, 1998, CANCER RES, V58, P283; Clement MV, 1998, BLOOD, V92, P996; Daniels DL, 2001, TRENDS BIOCHEM SCI, V26, P672, DOI 10.1016/S0968-0004(01)01952-1; Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Goel A, 2001, CANCER LETT, V172, P111, DOI 10.1016/S0304-3835(01)00655-3; Goss KH, 2000, J CLIN ONCOL, V18, P1967, DOI 10.1200/JCO.2000.18.9.1967; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Heatwole V M, 1999, Methods Mol Biol, V115, P141; Huang MT, 1997, J CELL BIOCHEM, P26; Huelsken J, 2001, CURR OPIN GENET DEV, V11, P547, DOI 10.1016/S0959-437X(00)00231-8; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; INOUE M, 1994, BIOCHEM BIOPH RES CO, V204, P898, DOI 10.1006/bbrc.1994.2544; Jaiswal AS, 2001, J BIOL CHEM, V276, P18193, DOI 10.1074/jbc.M101298200; Jee SH, 1998, J INVEST DERMATOL, V111, P656, DOI 10.1046/j.1523-1747.1998.00352.x; Jiang MC, 1996, NUTR CANCER, V26, P111, DOI 10.1080/01635589609514468; Kawamori T, 1999, CANCER RES, V59, P597; KELLOFF GJ, 1994, CANCER RES, V54, pS2015; Kelloff GJ, 1996, J CELL BIOCHEM, P54, DOI 10.1002/jcb.240630705; Kim K, 2000, MOL BIOL CELL, V11, P3509, DOI 10.1091/mbc.11.10.3509; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; KUTTAN R, 1987, TUMORI, V73, P29, DOI 10.1177/030089168707300105; Law BK, 2000, J BIOL CHEM, V275, P38261, DOI 10.1074/jbc.M005545200; Ling YH, 2001, MOL PHARMACOL, V59, P593, DOI 10.1124/mol.59.3.593; Mahmoud NN, 2000, CARCINOGENESIS, V21, P921, DOI 10.1093/carcin/21.5.921; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Manson MM, 2000, TOXICOL LETT, V112, P499, DOI 10.1016/S0378-4274(99)00211-8; McCarty MF, 2001, MED HYPOTHESES, V56, P137, DOI 10.1054/mehy.2000.1126; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Moragoda L, 2001, ANTICANCER RES, V21, P873; Mukhopadhyay A, 2001, ONCOGENE, V20, P7597, DOI 10.1038/sj.onc.1204997; Narayan S, 1997, J BIOL CHEM, V272, P30619, DOI 10.1074/jbc.272.49.30619; Narayan S, 2001, BRIT J CANCER, V85, P898, DOI 10.1054/bjoc.2001.2002; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; Papkoff J, 1997, J BIOL CHEM, V272, P4536; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; Pereira MA, 1999, ADV EXP MED BIOL, V470, P55; Phan TT, 2001, J TRAUMA, V51, P927, DOI 10.1097/00005373-200111000-00017; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; Polakis P, 2000, GENE DEV, V14, P1837; RAO CV, 1995, CANCER RES, V55, P259; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; Schmeiser K, 1999, CELL DEATH DIFFER, V6, P377, DOI 10.1038/sj.cdd.4400504; Schuler M, 2001, BIOCHEM SOC T, V29, P684, DOI 10.1042/0300-5127:0290684; Sharma RA, 2001, CLIN CANCER RES, V7, P1894; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Soldani C, 2002, APOPTOSIS, V7, P321, DOI 10.1023/A:1016119328968; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Steinhusen U, 2000, J BIOL CHEM, V275, P16345, DOI 10.1074/jbc.M001458200; Steinhusen U, 2001, J BIOL CHEM, V276, P4972, DOI 10.1074/jbc.M006102200; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VINDELOV LL, 1990, CYTOMETRY, V11, P753, DOI 10.1002/cyto.990110702; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; Wargovich MJ, 1997, CANCER LETT, V114, P11, DOI 10.1016/S0304-3835(97)04616-8; Williams C, 1999, ANN NY ACAD SCI, V889, P72, DOI 10.1111/j.1749-6632.1999.tb08725.x; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119	70	293	317	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	2002	21	55					8414	8427		10.1038/sj.onc.1205947	http://dx.doi.org/10.1038/sj.onc.1205947			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466962				2022-12-28	WOS:000179480100005
J	Pamment, J; Ramsay, E; Kelleher, M; Dornan, D; Ball, KL				Pamment, J; Ramsay, E; Kelleher, M; Dornan, D; Ball, KL			Regulation of the IRF-1 tumour modifier during the response to genotoxic stress involves an ATM-dependent signalling pathway	ONCOGENE			English	Article						IRF-1; protein turnover; ATM; p53; DNA damage	TRANSCRIPTION FACTOR IRF-1; ATAXIA-TELANGIECTASIA; P53-DEPENDENT TRANSCRIPTION; IONIZING-RADIATION; MESSENGER-RNA; DNA-DAMAGE; LONG ARM; FACTOR-I; C-JUN; P53	The mechanism by which genotoxic stress induces IRF-1 and the signalling components upstream of this anti-oncogenic transcription factor during the response to DNA damage are not known. We demonstrate that IRF-1 and the tumour suppressor protein p53 are coordinately up-regulated during the response to DNA damage in an ATM-dependent manner. Induction of IRF-1 protein by either ionizing radiation (IR) or etoposide occurs through a concerted mechanism involving increased IRF-1 expression/synthesis and an increase in the half-life of the IRF-1 protein. A striking defect in the induction of both IRF-1 mRNA and IRF-1 protein was observed in ATM deficient cells. Although ATM deficient cells failed to increase IRF-1 in response to genotoxic stress, the induction of IRF-1 in response to viral mimetics remained intact. Re-expression of the ATM kinase in AT cells restored the DNA damage inducibility of IRF-1, whilst the PI-3 kinase inhibitor wortmannin inhibited IRF-1 induction by DNA damage in ATM-positive cells. The data highlight a role for the ATM kinase in orchestrating the coordinated induction and transcriptional cooperation of IRF-1 and p53 to regulate p21 expression. Thus, IRF-1 is controlled by two distinct signalling pathways; a JAK/STAT-signalling pathway in viral infected cells and an ATM-signalling pathway in DNA damaged cells.	Univ Dundee, Sch Med, Canc Res UK Labs, Dundee DD1 9SY, Scotland	University of Dundee	Ball, KL (corresponding author), Univ Dundee, Sch Med, Canc Res UK Labs, Dundee DD1 9SY, Scotland.	k.l.ball@dundee.ac.uk		Kelleher, Michael/0000-0002-0005-3079				BAGULEY BC, 1991, ANTI-CANCER DRUG DES, V6, P1; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bar-Shira A, 2002, ONCOGENE, V21, P849, DOI 10.1038/sj.onc.1205127; Beretta L, 1996, ONCOGENE, V12, P1593; Blaydes JP, 2000, ONCOGENE, V19, P3829, DOI 10.1038/sj.onc.1203773; BOULTWOOD J, 1993, BLOOD, V82, P2611; CANMAN CE, 1994, CANCER RES, V54, P5054; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Coccia EM, 1999, ONCOGENE, V18, P2129, DOI 10.1038/sj.onc.1202536; Dornan D, 2001, EMBO REP, V2, P139, DOI 10.1093/embo-reports/kve025; Eason DE, 1999, BBA-GENE STRUCT EXPR, V1446, P140, DOI 10.1016/S0167-4781(99)00078-0; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; FUJITA T, 1989, P NATL ACAD SCI USA, V86, P9936, DOI 10.1073/pnas.86.24.9936; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; Fukao T, 1999, BLOOD, V94, P1998; Gatei M, 2001, ONCOGENE, V20, P289, DOI 10.1038/sj.onc.1204111; Green WB, 1999, LEUKEMIA, V13, P1960, DOI 10.1038/sj.leu.2401596; HARADA H, 1994, ONCOGENE, V9, P3313; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kirchhoff S, 1999, ONCOGENE, V18, P3725, DOI 10.1038/sj.onc.1202704; KIRCHHOFF S, 1995, ONCOGENE, V11, P439; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Lee SA, 1998, J BIOL CHEM, V273, P32889, DOI 10.1074/jbc.273.49.32889; LEE WH, 1991, COLD SH Q B, V56, P211; Li NX, 2001, J BIOL CHEM, V276, P8898, DOI 10.1074/jbc.M009809200; Lin RT, 1999, MOL CELL BIOCHEM, V191, P169, DOI 10.1023/A:1006850009017; Lin WC, 2001, GENE DEV, V15, P1833; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Nakagawa K, 2000, EUR J BIOCHEM, V267, P1680, DOI 10.1046/j.1432-1327.2000.01163.x; Nozawa H, 1999, GENE DEV, V13, P1240, DOI 10.1101/gad.13.10.1240; Ogasawara S, 1996, GASTROENTEROLOGY, V110, P52, DOI 10.1053/gast.1996.v110.pm8536888; PAULES RS, 1995, CANCER RES, V55, P1763; Piret B, 1999, ONCOGENE, V18, P2261, DOI 10.1038/sj.onc.1202541; Prost S, 1998, FASEB J, V12, P181, DOI 10.1096/fasebj.12.2.181; Rizzo V, 1998, J BIOL CHEM, V273, P26323, DOI 10.1074/jbc.273.41.26323; Sarkaria JN, 1998, CANCER RES, V58, P4375; Sharf R, 1997, J BIOL CHEM, V272, P9785; Shiloh Y, 2001, ADV CANCER RES, V83, P209, DOI 10.1016/S0065-230X(01)83007-4; SiddooAtwal C, 1996, CANCER RES, V56, P443; Sikpi MO, 1999, INT J RADIAT BIOL, V75, P893, DOI 10.1080/095530099139953; STEVENS AM, 1994, MOL ENDOCRINOL, V8, P345, DOI 10.1210/me.8.3.345; STEVENS AM, 1992, MOL ENDOCRINOL, V6, P2236, DOI 10.1210/me.6.12.2236; Tamura G, 1996, CANCER RES, V56, P612; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TAMURANISHIMURA M, 1990, FEBS LETT, V261, P343, DOI 10.1016/0014-5793(90)80587-9; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Tang H, 1998, J BIOL CHEM, V273, P29156, DOI 10.1074/jbc.273.44.29156; TANIGUCHI T, 1989, J INTERFERON RES, V9, P633, DOI 10.1089/jir.1989.9.633; Taniguchi T, 1998, EUR CYTOKINE NETW, V9, P43; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; TANIGUCHI T, 1997, BIOCHIM BIOPHYS ACTA, V1333, P9; Wang Q, 1998, GENE, V222, P83, DOI 10.1016/S0378-1119(98)00476-4; WATANABE N, 1991, NUCLEIC ACIDS RES, V19, P4421, DOI 10.1093/nar/19.16.4421; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yang DQ, 2000, NAT CELL BIOL, V2, P893, DOI 10.1038/35046542; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	67	73	78	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2002	21	51					7776	7785		10.1038/sj.onc.1205981	http://dx.doi.org/10.1038/sj.onc.1205981			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	610DT	12420214				2022-12-28	WOS:000178946000002
J	Junqueira, D; Cilenti, L; Musumeci, L; Sedivy, JM; Zervos, AS				Junqueira, D; Cilenti, L; Musumeci, L; Sedivy, JM; Zervos, AS			Random mutagenesis of PDZ(Omi) domain and selection of mutants that specifically bind the Myc proto-oncogene and induce apoptosis	ONCOGENE			English	Article						Omi/HtrA2; PDZ domains; protein-protein interactions; protein design; Myc proto-oncogene; apoptosis; yeast two-hybrid system	TUMOR-SUPPRESSOR PROTEIN; SERINE-PROTEASE; PDZ DOMAINS; C-MYC; CELL-DEATH; MOLECULAR CHARACTERIZATION; TISSUE DISTRIBUTION; SEPTATE JUNCTIONS; CRYSTAL-STRUCTURE; MEMBRANE PROTEIN	Omi is a mammalian serine protease that is localized in the mitochondria and released to the cytoplasm in response to apoptotic stimuli. Omi induces cell death in a caspase-dependent manner by interacting with the X-chromosome linked inhibitor of apoptosis protein, as well as in a caspase-independent way that relies on its proteolytic activity. Omi is synthesized as a precursor polypeptide and is processed to an active serine protease with a unique PDZ domain. PDZ domains recognize the extreme carboxyl terminus of target proteins. Internal peptides that are able to fold into a beta-finger are also reported to bind some PDZ domains. Using a modified yeast two-hybrid system, PDZ(Omi) mutants were isolated by their ability to bind the carboxyl terminus of human Myc oncoprotein in yeast as well as in mammalian cells. One such PDZ(m) domain (PDZ-M1), when transfected into mammalian cells, was able to bind to endogenous Myc protein and induce cell death. PDZ-M1-induced apoptosis was entirely dependent on the presence of Myc protein and was not observed when c-myc null fibroblasts were used. Our studies indicate that the PDZ domain of Omi can provide a prototype that could easily be exploited to target specifically and inactivate oncogenes by binding to their unique carboxyl terminus.	Univ Cent Florida, Biomol Sci Ctr, Orlando, FL 32826 USA; Univ Cent Florida, Dept Mol Biol & Microbiol, Orlando, FL 32826 USA; Brown Univ, Dept Biochem Mol Biol & Cell Biol, Providence, RI 02912 USA	State University System of Florida; University of Central Florida; State University System of Florida; University of Central Florida; Brown University	Zervos, AS (corresponding author), Univ Cent Florida, Biomol Sci Ctr, 12722 Res Pkwy, Orlando, FL 32826 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055734] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK55734-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; Aiyar A, 2000, Methods Mol Biol, V132, P221; Bezprozvanny I, 2001, FEBS LETT, V509, P457, DOI 10.1016/S0014-5793(01)03214-8; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; EVAN G, 1994, PHILOS T R SOC B, V345, P269, DOI 10.1098/rstb.1994.0105; Faccio L, 2000, J BIOL CHEM, V275, P2581, DOI 10.1074/jbc.275.4.2581; Faccio L, 2000, GENOMICS, V68, P343, DOI 10.1006/geno.2000.6263; Faccio L, 2000, AM J PHYSIOL-CELL PH, V278, pC781, DOI 10.1152/ajpcell.2000.278.4.C781; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; Fusco C, 1999, YEAST, V15, P715, DOI 10.1002/(SICI)1097-0061(19990615)15:8<715::AID-YEA406>3.0.CO;2-K; Gee SH, 2000, BIOCHEMISTRY-US, V39, P14638, DOI 10.1021/bi001633t; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Gray CW, 2000, EUR J BIOCHEM, V267, P5699, DOI 10.1046/j.1432-1327.2000.01589.x; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Hoskins R, 1996, DEVELOPMENT, V122, P97; Hu SI, 1998, J BIOL CHEM, V273, P34406, DOI 10.1074/jbc.273.51.34406; HUNG AY, 2001, J BIOL CHEM, V10, P10; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Krojer T, 2002, NATURE, V416, P455, DOI 10.1038/416455a; Levchenko I, 1997, CELL, V91, P939, DOI 10.1016/S0092-8674(00)80485-7; Littlewood T D, 1990, Adv Dent Res, V4, P69; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Pallen MJ, 1997, MOL MICROBIOL, V26, P209, DOI 10.1046/j.1365-2958.1997.5601928.x; Riefler GM, 2001, J BIOL CHEM, V276, P48262, DOI 10.1074/jbc.M106503200; RUFF P, 1991, P NATL ACAD SCI USA, V88, P6595, DOI 10.1073/pnas.88.15.6595; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; Schneider S, 1999, NAT BIOTECHNOL, V17, P170, DOI 10.1038/6172; Schneider S, 1996, BIOTECHNIQUES, V20, P960; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; SOLOMON DLC, 1993, NUCLEIC ACIDS RES, V21, P5372, DOI 10.1093/nar/21.23.5372; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Spiess C, 1999, CELL, V97, P339, DOI 10.1016/S0092-8674(00)80743-6; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; VACCARO P, 2001, J BIOL CHEM, V16, P16; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zumbrunn J, 1996, FEBS LETT, V398, P187, DOI 10.1016/S0014-5793(96)01229-X	50	15	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2003	22	18					2772	2781		10.1038/sj.onc.1206359	http://dx.doi.org/10.1038/sj.onc.1206359			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ	12743600	Green Published			2022-12-28	WOS:000182569300008
J	Hinata, K; Gervin, AM; Zhang, YJ; Khavari, PA				Hinata, K; Gervin, AM; Zhang, YJ; Khavari, PA			Divergent gene regulation and growth effects by NF-kappa B in epithelial and mesenchymal cells of human skin	ONCOGENE			English	Article						NF-kappa B; skin; gene expression profiling; GIF; p21(CIP1)	NECROSIS-FACTOR-ALPHA; IKK-ALPHA; INCONTINENTIA PIGMENTI; TRANSCRIPTION FACTORS; MICE LACKING; CYCLIN D1; EPIDERMIS; DISEASE; PROTEIN; PROLIFERATION	NF-kappaB regulates normal and pathological processes, including neoplasia, in a tissue-context-dependent manner. In skin, NF-kappaB is implicated in epidermal homeostasis as well as in the pathogenesis of squamous cell carcinoma; however, its function in the underlying mesenchymal dermis has been unclear. To gain insight into NF-kappaB roles in these two adjacent cutaneous tissue compartments, NF-kappaB effects on expression of 12 435 genes were determined in epidermal keratinocytes and dermal fibroblasts. Although NF-kappaB induced proinflammatory and antiapoptotic genes in both settings, it exhibited divergent effects on growth regulatory genes. In keratinocytes, but not in fibroblasts, NF-kappaB induced p21(CIP1), which was sufficient to inhibit growth of both cell types. Levels of growth inhibitory factor (GIF), in contrast, were increased by NF-kappaB in both settings but inhibited growth only in keratinocytes. These findings indicate that transcription factors such as NF-kappaB can program tissue-selective effects via both differential target gene induction as well as by inducing common targets that exert differing effects depending on cellular lineage.	Stanford Univ, Sch Med, Program Epithelial Biol, Stanford, CA 94305 USA	Stanford University	Khavari, PA (corresponding author), Stanford Univ, Sch Med, Program Epithelial Biol, 269 Campus Dr,Room 2145, Stanford, CA 94305 USA.		Zhang, Junyi/HDN-7815-2022	Zhang, Jennifer Y./0000-0002-4485-1750				Abeyama K, 2000, J CLIN INVEST, V105, P1751, DOI 10.1172/JCI9745; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; Bash J, 1997, MOL CELL BIOL, V17, P6526, DOI 10.1128/MCB.17.11.6526; Choate KA, 1996, NAT MED, V2, P1263, DOI 10.1038/nm1196-1263; Deng H, 1997, NAT BIOTECHNOL, V15, P1388, DOI 10.1038/nbt1297-1388; ERICKSON JC, 1994, BRAIN RES, V649, P297, DOI 10.1016/0006-8993(94)91076-6; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Govind S, 1999, ONCOGENE, V18, P6875, DOI 10.1038/sj.onc.1203223; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; HARPER JW, 1993, CELL, V75, P805; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kaufman CK, 2000, J CELL BIOL, V149, P999, DOI 10.1083/jcb.149.5.999; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Kouba DJ, 2001, J BIOL CHEM, V276, P6214, DOI 10.1074/jbc.M004511200; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Pasparakis M, 2002, NATURE, V417, P861, DOI 10.1038/nature00820; Pomerantz JL, 2000, NATURE, V406, P26, DOI 10.1038/35017673; Qin JZ, 1999, J BIOL CHEM, V274, P37957, DOI 10.1074/jbc.274.53.37957; SCHAFER BW, 1990, NATURE, V344, P454, DOI 10.1038/344454a0; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; SchmidtUllrich R, 1996, DEVELOPMENT, V122, P2117; Seitz CS, 2000, CANCER RES, V60, P4085; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Seitz CS, 2000, J CLIN INVEST, V105, P253, DOI 10.1172/JCI7630; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; UCHIDA Y, 1991, NEURON, V7, P337, DOI 10.1016/0896-6273(91)90272-2; van Hogerlinden M, 1999, CANCER RES, V59, P3299; Vieira KBL, 1996, CANCER RES, V56, P2452; Zurovec M, 1998, ONCOGENE, V16, P3133, DOI 10.1038/sj.onc.1201860	36	105	111	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 3	2003	22	13					1955	1964		10.1038/sj.onc.1206198	http://dx.doi.org/10.1038/sj.onc.1206198			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	662UR	12673201				2022-12-28	WOS:000181967700006
J	Qiang, YW; Endo, Y; Rubin, JS; Rudikoff, S				Qiang, YW; Endo, Y; Rubin, JS; Rudikoff, S			Wnt signaling in B-cell neoplasia	ONCOGENE			English	Article						Wnt; beta-catenin; myeloma; morphology; Rho	BETA-CATENIN; PROTEIN; RECEPTOR; RHO; PROLIFERATION; INTERLEUKIN-6; WINGLESS; MYELOMA; TRANSDUCTION; ACTIVATION	Wnts comprise a family of secreted proteins that interact with receptors consisting of a Frizzled (Fz) family member alone or complexed with LDL receptor-related proteins (LRP5/6). Wnt signaling plays a crucial role in both development and differentiation, and activation of a 'canonical' Writ pathway resulting in P-catenin stabilization is associated with several types of human cancers. To date, little is known about potential Wnt signaling in mature lymphocytes or lymphoid neoplasia. Herein, we have analysed Wnt signaling in mature B cells (lymphomas) and plasma cells (multiple myeloma). Both Fz and LRP5/6 mRNAs were expressed in myeloma lines, but LRP5/6 were not observed in lymphomas. In myelomas, a canonical Wnt signaling pathway was activated following treatment with Wnt-3a as assessed by accumulation of beta-catenin, but beta-catenin levels actually decreased in lymphoma cells. Wnt-3a treatment further led to striking morphological changes in myeloma cells accompanied by rearrangement of the actin cytoskeleton. Morphological changes were associated with a second Wnt pathway dependent on Rho activation. These results suggest that Writ responsiveness is a stage-specific phenomenon in B-cell development and that the morphological changes associated with Wnt signaling may play a role in the motility and metastatic potential of myeloma cells.	NCI, Cellular & Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rudikoff, S (corresponding author), NCI, Cellular & Mol Biol Lab, NIH, Bldg 37, Bethesda, MD 20892 USA.	Rudikoff@helix.nih.gov	Qiang, Ya-Wei/Q-2206-2019	Qiang, Ya-Wei/0000-0002-2479-1412	DIVISION OF BASIC SCIENCES - NCI [Z01BC005553] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [Z01BC010251, ZIABC010251] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATAILLE R, 1992, HEMATOL ONCOL CLIN N, V6, P285, DOI 10.1016/S0889-8588(18)30345-9; BERGUI L, 1989, J EXP MED, V170, P613, DOI 10.1084/jem.170.2.613; Brandon C, 2000, BLOOD, V96, P4132, DOI 10.1182/blood.V96.13.4132.h8004132_4132_4141; Ferlin M, 2000, BRIT J HAEMATOL, V111, P626, DOI 10.1046/j.1365-2141.2000.02364.x; Ge NL, 2000, BLOOD, V96, P2856; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Habas R, 2001, CELL, V107, P843, DOI 10.1016/S0092-8674(01)00614-6; HILBERT DM, 1995, J EXP MED, V182, P243, DOI 10.1084/jem.182.1.243; Ioannidis V, 2001, NAT IMMUNOL, V2, P691, DOI 10.1038/90623; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lattanzio G, 1997, AM J PATHOL, V151, P689; Lee JS, 1999, J BIOL CHEM, V274, P21464, DOI 10.1074/jbc.274.30.21464; Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450; LU ZY, 1995, BLOOD, V86, P3123; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; McWhirter JR, 1999, P NATL ACAD SCI USA, V96, P11464, DOI 10.1073/pnas.96.20.11464; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Niesvizky R, 1997, CANCER INVEST, V15, P85, DOI 10.3109/07357909709018921; OOSTERWEGEL M, 1993, DEVELOPMENT, V118, P439; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Polakis P, 2000, GENE DEV, V14, P1837; Qiang YW, 2002, BLOOD, V99, P4138, DOI 10.1182/blood.V99.11.4138; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Reya T, 2000, IMMUNITY, V13, P15, DOI 10.1016/S1074-7613(00)00004-2; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; Semenov MV, 1997, GENOMICS, V42, P302, DOI 10.1006/geno.1997.4713; Shibamoto S, 1998, GENES CELLS, V3, P659; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Uren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374; vandeWetering M, 1996, MOL CELL BIOL, V16, P745; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; Winter CG, 2001, CELL, V105, P81, DOI 10.1016/S0092-8674(01)00298-7; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yamane T, 2001, J IMMUNOL, V167, P765, DOI 10.4049/jimmunol.167.2.765; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; ZHANG XG, 1994, BLOOD, V83, P3654; Zhurinsky J, 2000, J CELL SCI, V113, P3127	39	132	138	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2003	22	10					1536	1545		10.1038/sj.onc.1206239	http://dx.doi.org/10.1038/sj.onc.1206239			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652ZZ	12629517				2022-12-28	WOS:000181411900011
J	Gohda, J; Nomura, Y; Suzuki, H; Arai, H; Akiyama, T; Inoue, J				Gohda, J; Nomura, Y; Suzuki, H; Arai, H; Akiyama, T; Inoue, J			Elimination of the vertebrate Escherichia coli Ras-like protein homologue leads to cell cycle arrest at G1 phase and apoptosis	ONCOGENE			English	Article						apoptosis; KH domain; GTP-binding protein; RNA-binding protein	GTP-BINDING PROTEIN; 16S RIBOSOMAL-RNA; FRAGILE-X SYNDROME; STREPTOCOCCUS-PNEUMONIAE; CYTOCHROME-C; ERA GTPASE; KH DOMAIN; GENE; DISRUPTION; FAMILY	Homologues of the Escherichia coli (E. colt) Ras-like protein (ERA), a GTP-binding protein with RNA binding activity, have recently been found in various species, including human, mouse, and Antirrhinum majus. Depletion of prokaryotic ERA blocks cell division without affecting chromosome segregation. However, the physiological function of eukaryotic ERA is largely unknown. We have performed a genetic analysis of chicken ERA (GdERA) in DT40 cells. Depletion of GdERA diminished the growth rate of the cells, accompanied by an accumulation of apoptotic cells. The analysis of cell cycle indicates that the elimination of GdERA caused arrest at G1 phase, but not at M phase, which highlights the distinct role of vertebrate ERA in the cell cycle progression compared to prokaryotic ERA. Furthermore, human ERA (HsERA) rescued the phenotype of GdERA-deficient cells, whereas a mutant of HsERA deprived of RNA-binding activity did not. These data suggest that vertebrate ERA regulates the G1 phase progression via an as yet unknown molecular mechanism, which involves RNA recognition by ERA.	Univ Tokyo, Inst Med Sci, Dept Canc Biol, Div Cellular & Mol Biol,Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Hlth Chem, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo	Inoue, J (corresponding author), Univ Tokyo, Inst Med Sci, Dept Canc Biol, Div Cellular & Mol Biol,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.			Akiyama, Taishin/0000-0002-0341-6154				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; AHNN J, 1986, P NATL ACAD SCI USA, V83, P8849, DOI 10.1073/pnas.83.23.8849; Akiyama T, 2001, GENES CELLS, V6, P987, DOI 10.1046/j.1365-2443.2001.00480.x; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Britton RA, 2000, GENOMICS, V67, P78, DOI 10.1006/geno.2000.6243; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; GOLLOP N, 1991, J BACTERIOL, V173, P2265, DOI 10.1128/JB.173.7.2265-2270.1991; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; Hang JQ, 2001, EUR J BIOCHEM, V268, P5570, DOI 10.1046/j.1432-1033.2001.02493.x; INADA T, 1989, J BACTERIOL, V171, P5017, DOI 10.1128/jb.171.9.5017-5024.1989; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Lahti JM, 1999, METHODS, V17, P305, DOI 10.1006/meth.1999.0744; LERNER CG, 1991, MOL MICROBIOL, V5, P951, DOI 10.1111/j.1365-2958.1991.tb00770.x; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Meier TI, 2000, MICROBIOL-UK, V146, P1071, DOI 10.1099/00221287-146-5-1071; Meier TI, 1999, J BACTERIOL, V181, P5242, DOI 10.1128/JB.181.17.5242-5249.1999; Musco G, 1996, CELL, V85, P237, DOI 10.1016/S0092-8674(00)81100-9; Sayed A, 1999, BIOCHEM BIOPH RES CO, V264, P51, DOI 10.1006/bbrc.1999.1471; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Wang J, 1996, GENE DEV, V10, P2588, DOI 10.1101/gad.10.20.2588; Winding P, 2001, J IMMUNOL METHODS, V249, P1, DOI 10.1016/S0022-1759(00)00333-1	25	13	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2003	22	9					1340	1348		10.1038/sj.onc.1206287	http://dx.doi.org/10.1038/sj.onc.1206287			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618759				2022-12-28	WOS:000181360900008
J	Chen, QH; Lin, J; Jinno, S; Okayama, H				Chen, QH; Lin, J; Jinno, S; Okayama, H			Overexpression of Cdk6-cyclin D3 highly sensitizes cells to physical and chemical transformation	ONCOGENE			English	Article						Cdk6; cyclin D3; BALB/c3T3; C3H10T1/2; 3-methylcholanthrene/ultraviolet-induced transformation	CYCLIN-DEPENDENT KINASE-6; RETINOBLASTOMA PROTEIN; REGULATORY MECHANISMS; CDK INHIBITORS; CANCER; EXPRESSION; D1; PHOSPHORYLATION; COMPLEX; E-CDK2	Virtually all mammalian cells express two seemingly redundant cyclin-D-dependent kinases (Cdk4 and Cdk6) and three partner cyclins (D1, D2 and D3) essential for the G(1)-S transition, with predominant expression of Cdk4 and D1 in mesenchymal cells and Cdk6 and D3 in hematopoietic cells. We recently found two novel functions for Cdk6 executed in fibroblasts although unlike Cdk4 it is dispensable for their proliferation. In the rat fibroblast NRK-49F cells, oncogenic stimulation recruits Cdk6 to participate in a step of the cell cycle start that seems to be critical for anchorage-independent S-phase onset. Among the kinase-D-type cyclin combinations, the Cdk6-cyclin-D3 complex has a unique ability to evade inhibition by cyclin-dependent kinase inhibitors and thereby control the cell's proliferative competence under growth-suppressive conditions. We describe here that 2-5-fold overexpression of both Cdk6 and D3 enhances by 5 x 10(3)-10(6) -fold the susceptibility of the BALB/c3T3 and C3HIOT1/2 mouse fibroblast lines to ultraviolet irradiation- as well as 3-methylcholanthrene-induced transformation. This result suggests that deregulated expression of Cdk6 and cyclinD3 may predispose cells to malignant transformation, supporting the recent finding that cyclin D3 activated by chromosomal rearrangement is the causative gene of non-Hodgkin B lymphoma, in which Cdk6 is the major partner kinase.	Univ Tokyo, Grad Sch Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Okayama, H (corresponding author), Univ Tokyo, Grad Sch Med, Dept Biochem & Mol Biol, Bunkyo Ku, Hongo, Tokyo 1130033, Japan.	okayama@m.u-tokyo.ac.jp						Bartkova J, 1998, ONCOGENE, V17, P1027, DOI 10.1038/sj.onc.1202016; Cenciarelli C, 1999, MOL CELL BIOL, V19, P5203; Chilosi M, 1998, AM J PATHOL, V152, P209; Corcoran MM, 1999, ONCOGENE, V18, P6271, DOI 10.1038/sj.onc.1203033; Costello JF, 1997, CANCER RES, V57, P1250; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Easton J, 1998, CANCER RES, V58, P2624; Ebert MPA, 2001, J CANCER RES CLIN, V127, P449, DOI 10.1007/s004320100235; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Henzinger T, 1998, J BIOL CHEM, V273, P14958, DOI 10.1074/jbc.273.24.14958; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; Jinno S, 1999, ONCOGENE, V18, P565, DOI 10.1038/sj.onc.1202347; Jinno S, 2002, ONCOGENE, V21, P1777, DOI 10.1038/sj.onc.1205249; Jinno S, 1999, P NATL ACAD SCI USA, V96, P13197, DOI 10.1073/pnas.96.23.13197; Kakunaga T, 1985, IARC Sci Publ, V67, P55; KAKUNAGA T, 1980, SCIENCE, V209, P505, DOI 10.1126/science.7394516; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LEBWOHL DE, 1994, ONCOGENE, V9, P1925; Lien HC, 2000, LAB INVEST, V80, P893, DOI 10.1038/labinvest.3780093; Lin J, 2001, ONCOGENE, V20, P2000, DOI 10.1038/sj.onc.1204375; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Okayama H, 1996, ADV CANCER RES, V69, P17, DOI 10.1016/S0065-230X(08)60859-3; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; PINES J, 1995, SEMIN CANCER BIOL, V6, P63, DOI 10.1006/scbi.1995.0009; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; ROBELS AI, 1995, CARCINOGENESIS, V16, P781, DOI 10.1093/carcin/16.4.781; Rogatsky I, 1997, MOL CELL BIOL, V17, P3181, DOI 10.1128/MCB.17.6.3181; SCHAUER IE, 1994, P NATL ACAD SCI USA, V91, P7827, DOI 10.1073/pnas.91.16.7827; Shaughnessy J, 2001, BLOOD, V98, P217, DOI 10.1182/blood.V98.1.217; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sonoki T, 2001, BLOOD, V98, P2837, DOI 10.1182/blood.V98.9.2837; Timmermann S, 1997, CELL GROWTH DIFFER, V8, P361; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Wang J, 1996, CELL GROWTH DIFFER, V7, P1471; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	39	31	33	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2003	22	7					992	1001		10.1038/sj.onc.1206193	http://dx.doi.org/10.1038/sj.onc.1206193			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	644PB	12592386				2022-12-28	WOS:000180926100005
J	Lu, WC; Liu, YN; Kang, BB; Chen, JH				Lu, WC; Liu, YN; Kang, BB; Chen, JH			Trans-activation of heparanase promoter by ETS transcription factors	ONCOGENE			English	Article						ETS; heparanase promoter; tumor metastasis	MAMMALIAN HEPARANASE; PROTEIN; CLONING; CANCER; INVASION	The remodeling of extracellular matrix (ECM) is an important process required for cancer cells to turn into invasive and metastatic cancer cells. To dissolve the protein components of ECM, matrix metalloproteinases are some of the essential enzymes. Another ECM remodeling enzyme is the heparanase (Hpa) that digests the heparin sulfate component of the matrix. In metastatic cancer cells the Hpa gene is upregulated. To investigate the mechanism of why Hpa was upregulated in metastatic cancer cells, the regulatory sequence of heparanase gene was isolated and its function analysed in metastatic breast cancer cells. We found there are four ETS transcription factor binding sites. Two of them flanking the transcription initiation of the Hpa gene are nonfunctional, whereas two others are highly functional and responded to exogenously added ETS transcription factors. Mutation of these two ETS binding sites abolished the transcriptional activation of Hpa promoter by ETS transcription factors. Among four transcription factors tested (ETS1, ETS2, PEA3, and ER81), ETS1 and ETS2 are more potent in transactivating the human Hpa gene. Furthermore, dominant-negative ETS transcription factors failed to transactivate Hpa promoter and could abrogate the function of wild-type transcription factor in transactivation activity of ETS transcription factors on the Hpa promoter. These results suggest that ETS transcription factors play an important role in tumor invasion and metastasis by modulating the remodeling of ECM.	Tzu Chi Univ, Grad Inst Mol & Cell Biol, Hualien, Taiwan; Tzu Chi Univ, Grad Inst Human Genet, Hualien, Taiwan; Tzu Chi Univ, Coll Med, Dept Med Technol, Hualien, Taiwan	Tzu Chi University; Tzu Chi University; Tzu Chi University	Chen, JH (corresponding author), Tzu Chi Univ, Grad Inst Mol & Cell Biol, 701 Chung Yang Rd,Sec 3, Hualien, Taiwan.	jhc@mail.tcu.edu.tw	LU, Wei-Cheng/O-5577-2017					Arias AM, 2001, CELL, V105, P425, DOI 10.1016/S0092-8674(01)00365-8; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chen JH, 1996, ONCOGENE, V13, P1667; Dempsey LA, 2000, TRENDS BIOCHEM SCI, V25, P349, DOI 10.1016/S0968-0004(00)01619-4; Dong J, 2000, GENE, V253, P171, DOI 10.1016/S0378-1119(00)00251-1; Eccles SA, 1999, NAT MED, V5, P735, DOI 10.1038/10455; FOLKMAN J, 1997, CANC MED, P181; Freeman C, 1998, BIOCHEM J, V330, P1341, DOI 10.1042/bj3301341; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HIGASHINO F, 1995, ONCOGENE, V10, P1461; Hiroumi H, 2001, INT J CANCER, V93, P786, DOI 10.1002/ijc.1410; HOOGEWERF AJ, 1995, J BIOL CHEM, V270, P3268, DOI 10.1074/jbc.270.7.3268; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; Jiang P, 2002, J BIOL CHEM, V277, P8989, DOI 10.1074/jbc.M105682200; KOHN EC, 1995, CANCER RES, V55, P1856; NICOLSON GL, 1993, CANCER METAST REV, V12, P325, DOI 10.1007/BF00665961; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8	19	55	57	2	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2003	22	6					919	923		10.1038/sj.onc.1206201	http://dx.doi.org/10.1038/sj.onc.1206201			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584571				2022-12-28	WOS:000180864300014
J	Ngan, ESW; Hashimoto, Y; Ma, ZQ; Tsai, MJ; Tsai, SY				Ngan, ESW; Hashimoto, Y; Ma, ZQ; Tsai, MJ; Tsai, SY			Overexpression of Cdc25B, an androgen receptor coactivator, in prostate cancer	ONCOGENE			English	Article						coactivator; Cdc25B; prostate cancer; androgen receptor	TYROSINE PHOSPHATASES; EXPRESSION; MECHANISM; DOMAIN; ROLES	Cdc25B is a dual-specific phosphatase that mediates cell cycle progression by activating the cyclin-dependent kinases. It has been shown to possess oncogenic potential. To elucidate its potential contribution to human prostate cancer development, the expression profile of Cdc25B protein in human patients was analysed by immunohistocytochemistry. Cdc25B is frequently overexpressed in human prostate cancer tissues (29 of 30; 97%). In addition, the overexpression is more profound in the tumors of high combined Gleason scores and in late stages. Subsequently, we demonstrated that Cdc25B acts as a coactivator for AR in a hormone-dependent manner in the prostate cancer cell line, LNCaP. This coactivator function, surprisingly, is independent of its cell cycle functions. Cdc25B, on the other hand, directly interacts with AR as evidenced in GST-pull down and mammalian two-hybrid assays. In addition, it is also able to enhance AR-mediated transcription in synergy with other coactivators, including CREB-binding protein (CBP) and p300/ CBP associated factor. Therefore, upregulation of Cdc25B in human prostate cancer and its interplay with AR may contribute to prostate cancer development.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	Tsai, SY (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.		Ngan, Elly/N-1543-2019	Ngan, Elly/0000-0002-0022-7999				CATALONA WJ, 1994, NEW ENGL J MED, V331, P996; Eckstein J., 1997, BIOCHIM BIOPHYS ACTA, V1332, P53; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Gasparotto D, 1997, CANCER RES, V57, P2366; Gnanapragasam VJ, 2001, BRIT J CANCER, V85, P1928, DOI 10.1054/bjoc.2001.2179; Gregory CW, 2001, CANCER RES, V61, P4315; Hernandez S, 1998, CANCER RES, V58, P1762; Lombardi DP, 1999, CANCER RES, V59, P5724; Ma ZQ, 1999, ONCOGENE, V18, P4564, DOI 10.1038/sj.onc.1202809; Ma ZQ, 1999, J STEROID BIOCHEM, V69, P155, DOI 10.1016/S0960-0760(98)00154-X; Ma ZQ, 2001, MOL CELL BIOL, V21, P8056, DOI 10.1128/MCB.21.23.8056-8067.2001; McInerney EM, 1996, P NATL ACAD SCI USA, V93, P10069, DOI 10.1073/pnas.93.19.10069; NAGATA A, 1991, NEW BIOL, V3, P959; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Xu X, 1996, J BIOL CHEM, V271, P5118; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624	17	99	104	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 6	2003	22	5					734	739		10.1038/sj.onc.1206121	http://dx.doi.org/10.1038/sj.onc.1206121			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569365				2022-12-28	WOS:000180642100010
J	Maria, DA; Manenti, G; Galbiati, F; Ribeiro, OG; Cabrera, WHK; Barrera, RG; Pettinicchio, A; De Franco, M; Starobinas, N; Siqueira, M; Dragani, TA; Ibanez, OM				Maria, DA; Manenti, G; Galbiati, F; Ribeiro, OG; Cabrera, WHK; Barrera, RG; Pettinicchio, A; De Franco, M; Starobinas, N; Siqueira, M; Dragani, TA; Ibanez, OM			Pulmonary adenoma susceptibility 1 (Pas1) locus affects inflammatory response	ONCOGENE			English	Article						Pas1; cancer modifier loci; linkage disequilibrium; genetic polymorphisms	PREVIOUS LUNG-DISEASE; LINKAGE DISEQUILIBRIUM; RESISTANCE LOCUS; OUTBRED MICE; CANCER; MOUSE; RISK; GENE; RESPONSIVENESS; CHROMOSOME-6	Two outbred mouse lines, phenotypically selected for differential subcutaneous (s.c.) acute inflammatory response (AIR), were analysed for urethane-induced lung inflammatory response and susceptibility to lung tumorigenesis. AIR(min) Mice, which show a low response to s.c. acute inflammation, developed a persistent subacute lung inflammatory response and a 40-fold higher lung tumor multiplicity than did AIR(max) mice, which are selected for high response to s.c. acute inflammation and showed a transient lung inflammatory response. A highly significant linkage disequilibrium pattern was observed in AIR(max) and AIR(min) mice at marker alleles located within a 452-kb pulmonary adenoma susceptibility 1 (Pas1) locus region, thus defining the location of gene candidacy for inflammatory response and for the biological effects of Pas1 in this region. AIRmin and AIRmax mice segregated by descent the Pas1(s) and Pas1(r) alleles, respectively, providing evidence for the involvement of the Pas1 locus in the inflammatory response. The 452-kb region contains Kras2 and four additional genes, including the lymphoid-restricted membrane protein (Lrmp) gene, whose Pro --> Leu nonconservative variation was linked with inflammatory response and Pas1 allelotype. These results provide a model to explore the mechanism underlying inherited predisposition to lung cancer in the context of a link to inflammation.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Inst Butantan, Lab Imunogenet, Sao Paulo, Brazil	Fondazione IRCCS Istituto Nazionale Tumori Milan; Instituto Butantan	Dragani, TA (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via G Venezian 1, I-20133 Milan, Italy.		Starobinas, Nancy/B-9178-2015; Ibañez, Olga CM/B-9627-2015; Dragani, Tommaso A./K-4493-2016; Gianni-Barrera, Roberto/ACU-4280-2022; Manenti, Giacomo/J-3339-2017; DE FRANCO, MARCELO/S-5870-2019; Ribeiro, Orlando Garcia/B-5241-2016; Cabrera, Wafa HK/F-7189-2016	Starobinas, Nancy/0000-0001-5716-3394; Ibañez, Olga CM/0000-0002-2672-4758; Dragani, Tommaso A./0000-0001-5915-4598; Gianni-Barrera, Roberto/0000-0001-6303-4513; Manenti, Giacomo/0000-0002-4887-4482; DE FRANCO, MARCELO/0000-0002-0417-8215; 				Askling J, 1999, AM J RESP CRIT CARE, V160, P1668, DOI 10.1164/ajrccm.160.5.9904045; Bauer AK, 2001, EXP LUNG RES, V27, P197, DOI 10.1080/019021401300053948; Biozzi G, 1998, CARCINOGENESIS, V19, P337, DOI 10.1093/carcin/19.2.337; Brownson RC, 2000, CANCER CAUSE CONTROL, V11, P853, DOI 10.1023/A:1008999202040; De Sanctis GT, 1999, AM J PHYSIOL-LUNG C, V277, pL1118, DOI 10.1152/ajplung.1999.277.6.L1118; DELACHAPELLE A, 1993, J MED GENET, V30, P857, DOI 10.1136/jmg.30.10.857; Eden A, 1999, FEBS LETT, V457, P255, DOI 10.1016/S0014-5793(99)01054-6; GARIBOLDI M, 1993, NAT GENET, V3, P132, DOI 10.1038/ng0293-132; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; JORDE LB, 1995, AM J HUM GENET, V56, P11; Lang SM, 1999, GUT, V44, P822, DOI 10.1136/gut.44.6.822; Malkinson AM, 2002, CARCINOGENESIS, V23, P411, DOI 10.1093/carcin/23.3.411; Manenti G, 1996, NAT GENET, V12, P455, DOI 10.1038/ng0496-455; Manenti G, 1999, GENOME RES, V9, P639; Mayne ST, 1999, AM J EPIDEMIOL, V149, P13; Moody TW, 2001, ANTICANCER RES, V21, P1749; Obata M, 1996, ONCOGENE, V13, P1599; Pataer A, 1997, CANCER RES, V57, P2904; Peissel B, 2000, MAMM GENOME, V11, P979, DOI 10.1007/s003350010184; Prows DR, 1999, AM J PHYSIOL-LUNG C, V277, pL372, DOI 10.1152/ajplung.1999.277.2.L372; Snyder HL, 1997, J EXP MED, V186, P1087, DOI 10.1084/jem.186.7.1087; *STAT SAS I, 1988, SAS US GUID STAT; Talbot CJ, 1999, NAT GENET, V21, P305, DOI 10.1038/6825; Tsunematsu S, 1997, J GASTROEN HEPATOL, V12, P319, DOI 10.1111/j.1440-1746.1997.tb00428.x; YANAGISAWA A, 1993, CANCER RES, V53, P953	25	41	41	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 23	2003	22	3					426	432		10.1038/sj.onc.1206157	http://dx.doi.org/10.1038/sj.onc.1206157			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545163				2022-12-28	WOS:000180379100011
J	Li, WJ; Hu, N; Su, F; Wang, CY; Goldstein, AM; Wang, Y; Emmert-Buck, MR; Roth, MJ; Guo, WJ; Taylor, PR				Li, WJ; Hu, N; Su, F; Wang, CY; Goldstein, AM; Wang, Y; Emmert-Buck, MR; Roth, MJ; Guo, WJ; Taylor, PR			Allelic loss on chromosome 13q14 and mutation in deleted in cancer 1 gene in esophageal squamous cell carcinoma	ONCOGENE			English	Article						DICE1; LOH; SSCP; mutation; polymorphism; esophagus	TUMOR-SUPPRESSOR GENES; SUSCEPTIBILITY GENE; HETEROZYGOSITY; IDENTIFICATION; CHINA; POPULATION; REGIONS	Previous studies have shown frequent allelic loss on chromosome 13 in esophageal squamous cell carcinoma (ESCC). We assessed the frequency of allelic loss on chromosome 13q14 and mutations of deleted in cancer 1 (DICE1) (also found on 13q14) in ESCC patients to determine if this candidate tumor suppressor gene has a role in the development of ESCC, and whether this gene was an inactivation target for allelic loss on chromosome 13q14. Initially, we examined allelic loss at five markers flanking DICE1 in 56 ESCC patients from Shanxi Province, China, and then examined the entire coding sequence of this gene for mutations using polymerase chain reaction-single-strand confirmation polymorphism (PCR-SSCP) analysis and DNA sequencing. Subsequently, we extended our evaluation to an additional 80 ESCC patients and 232 healthy individuals to confirm the germline variant found in the initial 56 ESCC patients. The frequencies of allelic loss were 71, 58, and 75% for D13S325, D13S757, and D13S887, respectively, in the initial 56 ESCC patients studied. Overall, 73% of informative patients had loss of heterozygosity (LOH) for at least one of these three markers. Somatic mutations were identified in three patients (3/56, 5%), and one novel polymorphism was identified in 3% of ESCC patients (4/ 136) and 3% of healthy individuals (6/232). We conclude that DICE1 mutations occur in ESCC but are infrequent. The candidate tumor suppressor gene corresponding to the frequent allelic loss on chromosome 13q14 in ESCC remains unknown.	NCI, Canc Prevent Studies Branch, Ctr Canc Res, Bethesda, MD 20892 USA; Shanxi Canc Hosp & Inst, Taiyuan 030013, Shanxi, Peoples R China; NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Taylor, PR (corresponding author), NCI, Canc Prevent Studies Branch, Ctr Canc Res, 6116 Execut Blvd,Suite 705, Bethesda, MD 20892 USA.							BOYNTON RF, 1991, CANCER RES, V51, P5766; Eiriksdottir G, 1998, EUR J CANCER, V34, P2076, DOI 10.1016/S0959-8049(98)00241-X; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; Hu N, 1999, CLIN CANCER RES, V5, P3476; Hu N, 2002, CLIN CANCER RES, V8, P1121; Hu N, 2001, CLIN CANCER RES, V7, P883; HU N, 1992, INT J EPIDEMIOL, V21, P877, DOI 10.1093/ije/21.5.877; Hu N, 2000, GENE CHROMOSOME CANC, V27, P217, DOI 10.1002/(SICI)1098-2264(200003)27:3<217::AID-GCC1>3.0.CO;2-A; Huang J, 2000, CARCINOGENESIS, V21, P2019, DOI 10.1093/carcin/21.11.2019; HUANG Y, 1992, CANCER RES, V52, P6525; Hyytinen ER, 1999, GENE CHROMOSOME CANC, V25, P108, DOI 10.1002/(SICI)1098-2264(199906)25:2<108::AID-GCC6>3.0.CO;2-Y; KUROKI T, 1995, BRIT J CANCER, V72, P383, DOI 10.1038/bjc.1995.342; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; Li G, 2001, GENE CHROMOSOME CANC, V31, P390, DOI 10.1002/gcc.1158; MACGEE TL, 1989, GENE, V80, P119; MAESAWA C, 1994, INT J CANCER, V57, P21, DOI 10.1002/ijc.2910570105; Montesano R, 1996, INT J CANCER, V69, P225, DOI 10.1002/(SICI)1097-0215(19960621)69:3<225::AID-IJC13>3.0.CO;2-6; Wieland I, 1999, ONCOGENE, V18, P4530, DOI 10.1038/sj.onc.1202806; Wieland I, 2001, ONCOL RES, V12, P491, DOI 10.3727/096504001108747503; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	20	24	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 16	2003	22	2					314	318		10.1038/sj.onc.1206098	http://dx.doi.org/10.1038/sj.onc.1206098			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527901				2022-12-28	WOS:000180322400017
J	Miyamoto, K; Asada, K; Fukutomi, T; Okochi, E; Yagi, Y; Hasegawa, T; Asahara, T; Sugimura, T; Ushijima, T				Miyamoto, K; Asada, K; Fukutomi, T; Okochi, E; Yagi, Y; Hasegawa, T; Asahara, T; Sugimura, T; Ushijima, T			Methylation-associated silencing of heparan sulfate D-glucosaminyl 3-O-sulfotransferase-2 (3-OST-2) in human breast, colon, lung and pancreatic cancers	ONCOGENE			English	Article						DNA methylation; silencing; 3-OST-2; breast cancer	REPRESENTATIONAL DIFFERENCE ANALYSIS; DNA METHYLATION; EXPRESSION; GENE; PLASMA; HYPERMETHYLATION; IDENTIFICATION; PATTERNS; ASSAY	Aberrant CpG methylations play important roles in cancer development and progression. In this study, aberrant methylations in human breast cancer were searched for using methylation-sensitive representational difference analysis (MS-RDA). A CpG island (CGI) in the 5' region of the heparan sulfate D-glucosaminyl 3-O-suffiotransferase-2 (3-OST-2) gene was found to be hypermethylated, while its exon 2 was hypomethylated. In seven breast cancer cell lines, hypermethylation of the 5' region and loss of 3-OST-2 expression were observed. Treatment with a demethylating agent, 5-aza-2'-deoxycyfidine, removed the methylation of the CGI in the 5' region and restored its expression, demonstrating silencing of the 3-OST-2 gene. Methylation-specific PCR (MSP) analysis in 85 primary breast cancers showed that the hypermethylation of the CGI in the 5' region was present in 75 (88%) of them. Quantitative reverse transcriptase-PCR (RTPCR) analysis in 37 primary breast cancers showed that the average expression level was decreased in them. Further, MSP analysis in primary colon, lung and pancreatic cancers showed that hypermethylation of the CGI in the 5' region was present in the colon (8/10, 80%), lung (7/10, 70%) and pancreatic (10/10, 100%) cancers. These results showed that silencing of 3-OST-2 was present in a wide range of human cancers. The 3-OST-2 gene encodes an enzyme involved in the final modification step of heparan sulfate proteoglycans (HSPGs), and its silencing is expected to result in abnormal modification of HSPGs and abnormal signal transduction. From the high incidence, silencing of the 3-OST-2 gene is expected to have high diagnostic, and potentially therapeutic, values.	Natl Canc Ctr, Res Inst, Div Carcinogenesis, Chuo Ku, Tokyo 1040045, Japan; Natl Canc Ctr, Dept Surg, Chuo Ku, Tokyo 1040045, Japan; Natl Canc Ctr, Res Inst, Div Pathol, Chuo Ku, Tokyo 1040045, Japan; Hiroshima Univ, Dept Surg, Grad Sch Biomed Sci, Minami Ku, Hiroshima 7348551, Japan	National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; Hiroshima University	Ushijima, T (corresponding author), Natl Canc Ctr, Res Inst, Div Carcinogenesis, Chuo Ku, 1-1 Tsukiji 5 Chome, Tokyo 1040045, Japan.	tushijim@ncc.go.jp	Asada, Kiyoshi/GPW-7758-2022; Asada, Kiyoshi/AFL-8696-2022; Ushijima, Toshikazu/AAP-5742-2021	Asada, Kiyoshi/0000-0002-4515-6047; Ushijima, Toshikazu/0000-0003-3405-7817				ASADA K, IN PRESS ONCOLOGY; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Clark SJ, 2002, ONCOGENE, V21, P5380, DOI 10.1038/sj.onc.1205598; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Esteller M, 1999, CANCER RES, V59, P67; Esteller M, 2001, CANCER RES, V61, P3225; Feinberg AP, 2001, NAT GENET, V27, P9, DOI 10.1038/83825; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gonzalgo ML, 1998, CANCER RES, V58, P1245; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kaneda A, 2002, INT J CANCER, V100, P57, DOI 10.1002/ijc.10464; KANEDA A, IN PRESS CANC RES; Kawakami K, 2000, J NATL CANCER I, V92, P1805, DOI 10.1093/jnci/92.22.1805; Kelsey G, 1999, GENOMICS, V62, P129, DOI 10.1006/geno.1999.6022; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Matsuda K, 2001, CANCER RES, V61, P5562; Muller K, 2001, J BIOL CHEM, V276, P14271; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Rein T, 1997, MOL CELL BIOL, V17, P416, DOI 10.1128/MCB.17.1.416; SAMBROOK J, 1989, MOL CLONING, V2, P1914; SHAPIRO B, 1983, CANCER, V51, P2116, DOI 10.1002/1097-0142(19830601)51:11<2116::AID-CNCR2820511127>3.0.CO;2-S; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; Silva JM, 1999, BRIT J CANCER, V80, P1262, DOI 10.1038/sj.bjc.6690495; Stanley MJ, 1999, AM J CLIN PATHOL, V112, P377; STROUN M, 1989, ONCOLOGY, V46, P318; Surani MA, 2001, NATURE, V414, P122, DOI 10.1038/35102186; Takai D, 2001, ONCOGENE, V20, P7505, DOI 10.1038/sj.onc.1204940; Ushijima T, 1997, P NATL ACAD SCI USA, V94, P2284, DOI 10.1073/pnas.94.6.2284	35	111	119	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2003	22	2					274	280		10.1038/sj.onc.1206146	http://dx.doi.org/10.1038/sj.onc.1206146			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527896				2022-12-28	WOS:000180322400012
J	Pages, V; Fuchs, RPP				Pages, V; Fuchs, RPP			How DNA lesions are turned into mutations within cells?	ONCOGENE			English	Article						DNA damage tolerance; lesion bypass polymerases; error-prone DNA repair; origin of mutations; mutagens and carcinogens	POLYMERASE-III HOLOENZYME; THYMINE-THYMINE DIMER; ESCHERICHIA-COLI; XERODERMA-PIGMENTOSUM; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; ERROR-PRONE; TRANSLESION SYNTHESIS; GENE ENCODES; Y-FAMILY	Genomes of all living organisms are constantly injured by endogenous and exogenous agents that modify the chemical integrity of DNA and in turn challenge its informational content. Despite the efficient action of numerous repair systems that remove lesions in DNA in an error-free manner, some lesions, that escape these repair mechanisms, are present when DNA is being replicated. Although replicative DNA polymerases are usually unable to copy past such lesions, it was recently discovered that cells are equipped with specialized DNA polymerases that will assist the replicative polymerase during the process of Translesion Synthesis (TLS). These TLS polymerases exhibit relaxed fidelity that allows them to copy past lesions in DNA with an inherent risk of generating mutations at high frequency. We present recent aspects related to the genetics and biochemistry of TLS and highlight some of the remaining hot topics of this field.	Univ Strasbourg 1, UPR 9003 CNRS, ESBS, UPR Conventionnee, F-67400 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Fuchs, RPP (corresponding author), Univ Strasbourg 1, UPR 9003 CNRS, ESBS, UPR Conventionnee, Blvd S Brant, F-67400 Strasbourg, France.		Pagès, Vincent/L-8455-2016	Pagès, Vincent/0000-0002-3059-2903				Baynton K, 1998, MOL CELL BIOL, V18, P960, DOI 10.1128/MCB.18.2.960; Becherel OJ, 2002, DNA REPAIR, V1, P703, DOI 10.1016/S1568-7864(02)00106-4; Becherel OJ, 2001, P NATL ACAD SCI USA, V98, P8566, DOI 10.1073/pnas.141113398; Bresson A, 2002, EMBO J, V21, P3881, DOI 10.1093/emboj/cdf363; Cordonnier AM, 1999, MUTAT RES-DNA REPAIR, V435, P111, DOI 10.1016/S0921-8777(99)00047-6; Cordonnier AM, 1999, MOL CELL BIOL, V19, P2206; Dalrymple BP, 2001, P NATL ACAD SCI USA, V98, P11627, DOI 10.1073/pnas.191384398; de Saro FJL, 2001, P NATL ACAD SCI USA, V98, P8376, DOI 10.1073/pnas.121009498; FUCHS RPP, 1981, NATURE, V294, P657, DOI 10.1038/294657a0; Fuchs RPP, 2001, BIOCHEM SOC T, V29, P191, DOI 10.1042/0300-5127:0290191; Haracska L, 2002, MOL CELL BIOL, V22, P784, DOI 10.1128/MCB.22.3.784-791.2002; Haracska L, 2001, P NATL ACAD SCI USA, V98, P14256, DOI 10.1073/pnas.261560798; Haracska L, 2001, MOL CELL BIOL, V21, P7199, DOI 10.1128/MCB.21.21.7199-7206.2001; Haracska L, 2001, GENE DEV, V15, P945, DOI 10.1101/gad.882301; HUGHES AJ, 1991, J BIOL CHEM, V266, P4568; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; KATO T, 1977, MOL GEN GENET, V156, P121, DOI 10.1007/BF00283484; Kim DR, 1996, J BIOL CHEM, V271, P20699, DOI 10.1074/jbc.271.34.20699; KoffelSchwartz N, 1996, P NATL ACAD SCI USA, V93, P7805, DOI 10.1073/pnas.93.15.7805; LARIMER FW, 1989, J BACTERIOL, V171, P230, DOI 10.1128/jb.171.1.230-237.1989; Lawrence CW, 2002, DNA REPAIR, V1, P425, DOI 10.1016/S1568-7864(02)00038-1; LEMONTT JF, 1971, MUTAT RES, V13, P319, DOI 10.1016/0027-5107(71)90042-X; Lenne-Samuel N, 2000, MOL MICROBIOL, V38, P299, DOI 10.1046/j.1365-2958.2000.02116.x; Lenne-Samuel N, 2002, EMBO REP, V3, P45, DOI 10.1093/embo-reports/kvf007; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; MILLER JH, 1983, ANNU REV GENET, V17, P215, DOI 10.1146/annurev.ge.17.120183.001243; Napolitano R, 2000, EMBO J, V19, P6259, DOI 10.1093/emboj/19.22.6259; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Reuven NB, 1999, J BIOL CHEM, V274, P31763, DOI 10.1074/jbc.274.45.31763; Silvian LF, 2001, NAT STRUCT BIOL, V8, P984, DOI 10.1038/nsb1101-984; STEINBORN G, 1978, MOL GEN GENET, V165, P87, DOI 10.1007/BF00270380; Tang MJ, 2000, NATURE, V404, P1014, DOI 10.1038/35010020; Tang MJ, 1999, P NATL ACAD SCI USA, V96, P8919, DOI 10.1073/pnas.96.16.8919; Trincao J, 2001, MOL CELL, V8, P417, DOI 10.1016/S1097-2765(01)00306-9; Wagner J, 1999, MOL CELL, V4, P281, DOI 10.1016/S1097-2765(00)80376-7; Wagner J, 2002, DNA REPAIR, V1, P159, DOI 10.1016/S1568-7864(01)00012-X; Wagner J, 2000, EMBO REP, V1, P484; Zhou BL, 2001, MOL CELL, V8, P427, DOI 10.1016/S1097-2765(01)00310-0	43	179	181	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 16	2002	21	58					8957	8966		10.1038/sj.onc.1206006	http://dx.doi.org/10.1038/sj.onc.1206006			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	626TP	12483512				2022-12-28	WOS:000179889500007
J	Sedgwick, B; Lindahl, T				Sedgwick, B; Lindahl, T			Recent progress on the Ada response for inducible repair of DNA alkylation damage	ONCOGENE			English	Article						DNA repair; O-6-methylguanine; DNA glycosylases	COLI ALKB MUTANTS; ESCHERICHIA-COLI; ADAPTIVE RESPONSE; EXCISION-REPAIR; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; CONTROLS SENSITIVITY; SPONTANEOUS MUTATION; METHYLATING AGENTS; FUNCTIONAL SWITCH		Canc Res Uk London Res Inst, Clare Hall Labs, S Mimms EN6 3LD, Herts, England	Cancer Research UK	Lindahl, T (corresponding author), Canc Res Uk London Res Inst, Clare Hall Labs, S Mimms EN6 3LD, Herts, England.							AKIMARU H, 1990, J MOL BIOL, V216, P261, DOI 10.1016/S0022-2836(05)80318-3; ARAVIND L, 2001, GENOME BIOL, V2; Berdal KG, 1998, EMBO J, V17, P363, DOI 10.1093/emboj/17.2.363; BHASIN N, 1995, MUTAT RES-DNA REPAIR, V336, P79, DOI 10.1016/0921-8777(94)00044-7; BODELL WJ, 1979, BIOCHEMISTRY-US, V18, P2860, DOI 10.1021/bi00580a029; BOITEUX S, 1982, BIOCHIMIE, V64, P637, DOI 10.1016/S0300-9084(82)80103-X; CALMELS S, 1987, CARCINOGENESIS, V8, P1085, DOI 10.1093/carcin/8.8.1085; CHEN BRJ, 1994, J BACTERIOL, V176, P6255, DOI 10.1128/jb.176.20.6255-6261.1994; Cheng XD, 2001, NUCLEIC ACIDS RES, V29, P3784, DOI 10.1093/nar/29.18.3784; CLARKE ND, 1984, MOL GEN GENET, V197, P368, DOI 10.1007/BF00329931; Colombi D, 1997, J BACTERIOL, V179, P3139, DOI 10.1128/jb.179.10.3139-3145.1997; CRUTZEN PJ, 1990, SCIENCE, V250, P1669, DOI 10.1126/science.250.4988.1669; Daniels DS, 2000, MUTAT RES-DNA REPAIR, V460, P151, DOI 10.1016/S0921-8777(00)00024-0; DEMPLE B, 1985, P NATL ACAD SCI USA, V82, P2688, DOI 10.1073/pnas.82.9.2688; Dinglay S, 2000, GENE DEV, V14, P2097; Falnes PO, 2002, NATURE, V419, P178, DOI 10.1038/nature01048; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Gasparutto D, 2002, DNA REPAIR, V1, P437, DOI 10.1016/S1568-7864(02)00016-2; Harrison KL, 1999, CHEM RES TOXICOL, V12, P106, DOI 10.1021/tx980057n; HIX S, 1995, FREE RADICAL BIO MED, V19, P293, DOI 10.1016/0891-5849(95)00026-T; Hollis T, 2000, MUTAT RES-DNA REPAIR, V460, P201, DOI 10.1016/S0921-8777(00)00027-6; KATAOKA H, 1983, J BACTERIOL, V153, P1301, DOI 10.1128/JB.153.3.1301-1307.1983; KUNISAKI N, 1979, APPL ENVIRON MICROB, V37, P279, DOI 10.1128/AEM.37.2.279-282.1979; Labahn J, 1996, CELL, V86, P321, DOI 10.1016/S0092-8674(00)80103-8; LANDINI P, 1994, J BACTERIOL, V176, P6583, DOI 10.1128/JB.176.21.6583-6589.1994; Landini P, 2000, J BACTERIOL, V182, P6543, DOI 10.1128/JB.182.23.6543-6549.2000; LARSON K, 1985, MUTAT RES, V150, P77, DOI 10.1016/0027-5107(85)90103-4; Lin YX, 2001, BIOCHEMISTRY-US, V40, P4261, DOI 10.1021/bi002109p; LINDAHL T, 1988, ANNU REV BIOCHEM, V57, P133, DOI 10.1146/annurev.bi.57.070188.001025; Lizcano JM, 2000, ANAL BIOCHEM, V286, P75, DOI 10.1006/abio.2000.4782; Marcotte EM, 1999, SCIENCE, V285, P751, DOI 10.1126/science.285.5428.751; Matthews RG, 1997, CURR OPIN CHEM BIOL, V1, P332, DOI 10.1016/S1367-5931(97)80070-1; Monti P, 2002, J BIOL CHEM, V277, P28663, DOI 10.1074/jbc.M203384200; MOORE MH, 1994, EMBO J, V13, P1495, DOI 10.1002/j.1460-2075.1994.tb06410.x; MOROHOSHI F, 1993, J BACTERIOL, V175, P6010, DOI 10.1128/JB.175.18.6010-6017.1993; MOROHOSHI F, 1995, MUTAT RES-DNA REPAIR, V337, P97, DOI 10.1016/0921-8777(95)00013-A; MYERS LC, 1994, CURR OPIN STRUC BIOL, V4, P51, DOI 10.1016/S0959-440X(94)90059-0; O'Rourke EJ, 2000, J BIOL CHEM, V275, P20077, DOI 10.1074/jbc.M001071200; Posnick LM, 1999, J BACTERIOL, V181, P6756, DOI 10.1128/JB.181.21.6756-6762.1999; Posnick LM, 1999, J BACTERIOL, V181, P6763, DOI 10.1128/JB.181.21.6763-6771.1999; POTTER PM, 1989, NUCLEIC ACIDS RES, V17, P8047, DOI 10.1093/nar/17.20.8047; Prescott AG, 2000, NAT PROD REP, V17, P367, DOI 10.1039/a902197c; Privezentzev CV, 2000, BIOCHEMISTRY-US, V39, P14263, DOI 10.1021/bi001337g; REBECK GW, 1989, J BACTERIOL, V171, P4563, DOI 10.1128/jb.171.9.4563-4568.1989; Rebeil R, 2001, P NATL ACAD SCI USA, V98, P9038, DOI 10.1073/pnas.161278998; Ryle MJ, 2002, CURR OPIN CHEM BIOL, V6, P193, DOI 10.1016/S1367-5931(02)00302-2; SAGET BM, 1994, P NATL ACAD SCI USA, V91, P9730, DOI 10.1073/pnas.91.21.9730; SAKASHITA H, 1995, P JPN ACAD B-PHYS, V71, P198, DOI 10.2183/pjab.71.198; SAKUMI K, 1989, J MOL BIOL, V205, P373, DOI 10.1016/0022-2836(89)90348-3; SAMSON L, 1992, MOL MICROBIOL, V6, P825, DOI 10.1111/j.1365-2958.1992.tb01533.x; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; Schofield CJ, 1999, CURR OPIN STRUC BIOL, V9, P722, DOI 10.1016/S0959-440X(99)00036-6; Sedgwick B, 1997, CARCINOGENESIS, V18, P1561, DOI 10.1093/carcin/18.8.1561; SEDGWICK B, 1991, MUTAT RES, V250, P211, DOI 10.1016/0027-5107(91)90178-Q; SEDGWICK B, 1988, J BIOL CHEM, V263, P4430; SEEBERG E, 1999, BASE EXCISION REPAIR, P151; Singer B., 1983, MOL BIOL MUTAGENS CA; TAKAHASHI K, 1987, MUTAT RES, V180, P163, DOI 10.1016/0027-5107(87)90211-9; Taverna P, 1996, J BACTERIOL, V178, P5105, DOI 10.1128/jb.178.17.5105-5111.1996; TEO I, 1986, CELL, V45, P315, DOI 10.1016/0092-8674(86)90396-X; THORNBURG LD, 1993, BIOCHEMISTRY-US, V32, P14023, DOI 10.1021/bi00213a036; Trewick SC, 2002, NATURE, V419, P174, DOI 10.1038/nature00908; VAUGHAN P, 1991, CARCINOGENESIS, V12, P263, DOI 10.1093/carcin/12.2.263; VAUGHAN P, 1993, MUTAT RES, V293, P249, DOI 10.1016/0921-8777(93)90076-S; VOLKERT MR, 1994, J BACTERIOL, V176, P7638, DOI 10.1128/JB.176.24.7638-7645.1994; Vora RA, 1998, PROTEINS, V32, P3; WEI YF, 1995, J BACTERIOL, V177, P5009, DOI 10.1128/jb.177.17.5009-5015.1995; Yamagata Y, 1996, CELL, V86, P311, DOI 10.1016/S0092-8674(00)80102-6; YAMAMOTO Y, 1978, J BACTERIOL, V135, P144, DOI 10.1128/JB.135.1.144-152.1978; YANG CS, 1996, BIOL REACT INTERMED, V5, P385; Zhang ZH, 2000, NAT STRUCT BIOL, V7, P127	71	106	111	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 16	2002	21	58					8886	8894		10.1038/sj.onc.1205998	http://dx.doi.org/10.1038/sj.onc.1205998			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	626TP	12483506				2022-12-28	WOS:000179889500001
J	Zhou, H; Liu, LL; Lee, KY; Qin, XS; Grasso, AW; Kung, HJ; Willis, JE; Kern, J; Wagner, T; Gerson, SL				Zhou, H; Liu, LL; Lee, KY; Qin, XS; Grasso, AW; Kung, HJ; Willis, JE; Kern, J; Wagner, T; Gerson, SL			Lung tumorigenesis associated with erb-B-2 and erb-B-3 overexpression in human erb-B-3 transgenic mice is enhanced by methylnitrosourea	ONCOGENE			English	Article						transgenic mice; erb-B-2; erb-B-3; lung tumor; methylnitrosourea; K-ras	HUMAN MGMT; CELL-LINES; EXPRESSION; GENE; RECEPTOR; HEREGULIN; CANCER; MOUSE; ALKYLTRANSFERASE; EPITHELIUM	Erb-B-3 overexpression is associated with poor prognosis in non-small cell lung cancer and is often overexpressed in breast cancers. MMTVhuman-erb-B-3 transgenic mice were generated to evaluate the impact of erb-B-3 overexpression on lung and mammary gland tumorigenesis. These transgenic mice developed a high incidence of lung adenocarcinomas but not mammary gland tumors. The tumors overexpressed transgenic human [h]-erb-B-3 but also overexpressed endogenous erb-B-2, indicating that the heterodimer of h-erb-B-3-erb-B-2 was required for proliferative signal transduction to the nucleus. Lung tumor latency was shorter and the incidence higher in erb-B-3 transgenic mice treated with the methylating agent, methylnitrosourea [MNU]. In MNU treated mice, K-ras activating point mutations in codon 12, synergized with h-erb-B-3 in lung tumorogenesis. In bitransgenic MMTVrat-erb-B2/MMTV-human-erb-B-3 mice, lung tumor latency was also significantly shortened. Unlike over-expression of rat-erb-B-2, overexpression of h-erb-B-3 did not alter the incidence or latency of mammary tumors. Coupled erb-B-2 and erb-B-3 overexpression as well as K-ras activation induced signaling through mitogen-activated protein kinase (MAPK). This animal model links erb-B-3 with lung cancer, suggests that erbB-2 and erb-B-3 heterodimerization is a necessary intermediate, and documents latency shortening by methylating agent-induced mutation of K-ras. This erb-B-3 mouse lung cancer model will help dissect genetic changes in lung tumorigenesis and may be useful for chemoprevention studies.	Case Western Reserve Univ, Div Hematol Oncol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Comprehens Canc, Cleveland, OH 44106 USA; Greenville Hosp Syst, Oncol Res Inst, Greenville, SC 29605 USA; Univ Calif Davis, Ctr Canc, Sacramento, CA 95819 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Case Western Reserve Univ, Div Pulm Med, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Microbiol & Mol Biol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Greenville Health System; University of California System; University of California Davis; University Hospitals of Cleveland; Case Western Reserve University; University Hospitals of Cleveland; Case Western Reserve University; Case Western Reserve University	Gerson, SL (corresponding author), Case Western Reserve Univ, Div Hematol Oncol, BRB-3W,10900 Euclid Ave, Cleveland, OH 44106 USA.	slg5@po.cwru.edu		Kern, Jeffrey/0000-0001-9709-9622	NATIONAL CANCER INSTITUTE [P30CA043703, R01CA073062, R01CA063193] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006288] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA73062, R01CA63193, P30CA43703] Funding Source: Medline; NIEHS NIH HHS [R01ES06288] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adamson ED, 1997, CURR TOP DEV BIOL, V35, P71, DOI 10.1016/S0070-2153(08)60257-4; Ahrendt SA, 2001, CANCER, V92, P1525, DOI 10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO;2-H; Al Moustafa AE, 1999, ANTICANCER RES, V19, P481; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; Cohen BD, 1998, BIOCHEM SOC SYMP, P199; DEVEREUX TR, 1991, CARCINOGENESIS, V12, P299, DOI 10.1093/carcin/12.2.299; DUMENCO LL, 1993, SCIENCE, V259, P219, DOI 10.1126/science.8421782; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Hung MC, 1999, SEMIN ONCOL, V26, P51; JO SA, 1995, NATURE, V373, P158, DOI 10.1038/373158a0; Kiguchi K, 2000, ONCOGENE, V19, P4243, DOI 10.1038/sj.onc.1203778; Kristiansen G, 2001, EUR J CANCER, V37, P1089, DOI 10.1016/S0959-8049(01)00096-X; Liu LL, 1999, CARCINOGENESIS, V20, P279, DOI 10.1093/carcin/20.2.279; Muller WJ, 1996, MOL CELL BIOL, V16, P5726; Patel NV, 2000, AM J RESP CELL MOL, V22, P432, DOI 10.1165/ajrcmb.22.4.3854; Peterson LA, 2001, CANCER RES, V61, P5757; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; Polosa R, 2000, J ALLERGY CLIN IMMUN, V106, P1124; Qin XS, 1999, ONCOGENE, V18, P4394, DOI 10.1038/sj.onc.1202798; Qin XS, 1999, CARCINOGENESIS, V20, P1667, DOI 10.1093/carcin/20.9.1667; Reese JS, 2001, ONCOGENE, V20, P5258, DOI 10.1038/sj.onc.1204700; Reinmuth N, 2000, EUR RESPIR J, V16, P991, DOI 10.1183/09031936.00.16599100; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; Sundaresan S, 1998, ENDOCRINOLOGY, V139, P4756, DOI 10.1210/en.139.12.4756; Weinstein EJ, 2000, CANCER RES, V60, P3856; Yi ES, 1997, MODERN PATHOL, V10, P142; ZAIDI NH, 1995, CARCINOGENESIS, V16, P451, DOI 10.1093/carcin/16.3.451; Zhou H, 2001, ONCOGENE, V20, P6009, DOI 10.1038/sj.onc.1204830	29	18	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2002	21	57					8732	8740		10.1038/sj.onc.1205984	http://dx.doi.org/10.1038/sj.onc.1205984			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483526				2022-12-28	WOS:000179734400007
J	Wu, X; Lee, H				Wu, X; Lee, H			Human Dbf4/ASK promoter is activated through the Sp1 and MluI cell-cycle box (MCB) transcription elements	ONCOGENE			English	Article						Dbf4; ASK; promoter; Sp1; MluI cell-cycle box (MCB); gene structure; transcription initiation	HUMAN CDC7-RELATED KINASE; DNA-REPLICATION GENES; CDC7 PROTEIN-KINASE; S-PHASE; SACCHAROMYCES-CEREVISIAE; G(1)/S TRANSITION; POLYMERASE-ALPHA; CHECKPOINT; COMPLEX; IDENTIFICATION	Dbf4 is the regulatory subunit of Cdc7 kinase, which is essential for entry into and traversing through S phase. The level of Dbf4, which is critical for the activation of Cdc7, is regulated by transcription and protein degradation. To gain a better understanding as to how the transcription of human Dbf4 (HuDbf4) is regulated, we have cloned and characterized its promoter. We found that HuDbf4 core promoter is localized within -211 to -285 of the translation start-codon. This 75 bp DNA segment contains, among others, a putative Mlu1 Cell-cycle Box (MCB). A point mutation within the NICB dramatically reduced the promoter activity. This is the first example that an MCB element plays an essential role in the activation of a core promoter in mammalian cells. The auxiliary elements required for the full promoter activity are present within 162-bp upstream from the core promoter (i.e., -286/-447). A point mutation within the Sp1 element at -353/-361 resulted in a decrease of promoter activity to the basal level, while the deletion of the putative HES-1 at -326/ - 331 dramatically increased the promoter activity. Taken together, our data suggests that the NICB element is essential for the core promoter activation, while the SpI positive regulator and the HES-1 repressor coordinately determine the efficiency of the HuDbf4 promoter. We have also found: (i) that the major transcription initiations occur at -220, -235 and -245; (ii) that HuDbf4 gene consists of 12 exons, which spread over a 33-kb region.	Northeastern Ontario Reg Canc Ctr, Dept Res, Sudburg, ON P3E 5J1, Canada		Lee, H (corresponding author), Northeastern Ontario Reg Canc Ctr, Dept Res, 41 Ramsey Lake Rd, Sudburg, ON P3E 5J1, Canada.	hlee@neorcc.on.ca						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bousset K, 1998, GENE DEV, V12, P480, DOI 10.1101/gad.12.4.480; Carey M, 2000, TRANSCRIPTIONAL REGU; CHAPMAN JW, 1989, EXP CELL RES, V180, P419, DOI 10.1016/0014-4827(89)90068-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COUDERC JL, 1987, NUCLEIC ACIDS RES, V15, P2549, DOI 10.1093/nar/15.6.2549; Donaldson AD, 1998, GENE DEV, V12, P491, DOI 10.1101/gad.12.4.491; Ferreira MG, 2000, MOL CELL BIOL, V20, P242; GORDON CB, 1991, P NATL ACAD SCI USA, V88, P6058, DOI 10.1073/pnas.88.14.6058; Guo B, 2001, BIOTECHNIQUES, V31, P314, DOI 10.2144/01312st02; Guo BQ, 2001, GENE, V264, P249, DOI 10.1016/S0378-1119(01)00332-8; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; HILLARP A, 1993, J BIOL CHEM, V268, P15017; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JACKSON AL, 1993, MOL CELL BIOL, V13, P2899, DOI 10.1128/MCB.13.5.2899; Jares P, 2000, GENE DEV, V14, P1528; Jiang W, 1999, EMBO J, V18, P5703, DOI 10.1093/emboj/18.20.5703; Kumagai H, 1999, MOL CELL BIOL, V19, P5083; Larner JM, 1999, NUCLEIC ACIDS RES, V27, P803, DOI 10.1093/nar/27.3.803; Lee HY, 1997, P NATL ACAD SCI USA, V94, P526, DOI 10.1073/pnas.94.2.526; Lepke M, 1999, MOL GEN GENET, V262, P220, DOI 10.1007/s004380051078; LEUTWILER LS, 1986, NUCLEIC ACIDS RES, V14, P4051, DOI 10.1093/nar/14.10.4051; Masai H, 2002, J CELL PHYSIOL, V190, P287, DOI 10.1002/jcp.10070; Masai H, 2000, J BIOL CHEM, V275, P29042, DOI 10.1074/jbc.M002713200; Masai H., 1999, FRONT BIOSCI, V4, pD834; Maxam A M, 1980, Methods Enzymol, V65, P499; MCINTOSH EM, 1993, CURR GENET, V24, P185, DOI 10.1007/BF00351790; Mimura S, 1998, EMBO J, V17, P5699, DOI 10.1093/emboj/17.19.5699; Nougarede R, 2000, MOL CELL BIOL, V20, P3795, DOI 10.1128/MCB.20.11.3795-3806.2000; Oshiro G, 1999, MOL CELL BIOL, V19, P4888; Owens JC, 1997, P NATL ACAD SCI USA, V94, P12521, DOI 10.1073/pnas.94.23.12521; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Perier RC, 2000, NUCLEIC ACIDS RES, V28, P302, DOI 10.1093/nar/28.1.302; RAJPUT B, 1994, J BIOL CHEM, V269, P9590; Sambrook J., 2001, MOL CLONING LAB MANU; SANICOLA M, 1990, J MOL BIOL, V212, P259, DOI 10.1016/0022-2836(90)90123-4; SCHAEFER BC, 1995, ANAL BIOCHEM, V227, P255, DOI 10.1006/abio.1995.1279; SIEDE W, 1994, GENETICS, V138, P271; Tercero JA, 2000, EMBO J, V19, P2082, DOI 10.1093/emboj/19.9.2082; Tomic-Canic M, 1996, Methods Mol Biol, V57, P259; Treuner K, 1998, J BIOL CHEM, V273, P31744, DOI 10.1074/jbc.273.48.31744; TREWITT PM, 1988, GENE, V69, P91, DOI 10.1016/0378-1119(88)90381-2; TSUJIMOTO Y, 1979, CELL, V16, P425, DOI 10.1016/0092-8674(79)90018-7; VERMA R, 1991, P NATL ACAD SCI USA, V88, P7155, DOI 10.1073/pnas.88.16.7155; VERMA R, 1992, P NATL ACAD SCI USA, V89, P9479, DOI 10.1073/pnas.89.20.9479; Weinreich M, 1999, EMBO J, V18, P5334, DOI 10.1093/emboj/18.19.5334; Zou L, 2000, MOL CELL BIOL, V20, P3086, DOI 10.1128/MCB.20.9.3086-3096.2000; Zou L, 1998, SCIENCE, V280, P593, DOI 10.1126/science.280.5363.593	48	21	21	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2002	21	51					7786	7796		10.1038/sj.onc.1205914	http://dx.doi.org/10.1038/sj.onc.1205914			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	610DT	12420215				2022-12-28	WOS:000178946000003
J	Ohtsuka, T; Buchsbaum, D; Oliver, P; Makhija, S; Kimberly, R; Zhou, T				Ohtsuka, T; Buchsbaum, D; Oliver, P; Makhija, S; Kimberly, R; Zhou, T			Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway	ONCOGENE			English	Article						apoptosis; TRAIL receptor; chemotherapy; JNK; mitochondria	TRAIL-INDUCED APOPTOSIS; FADD-DEPENDENT APOPTOSIS; CYTOTOXIC LIGAND TRAIL; BLADDER-CANCER CELLS; N-TERMINAL KINASE; MEDIATED APOPTOSIS; DR5-MEDIATED APOPTOSIS; TUMORICIDAL ACTIVITY; ANTITUMOR-ACTIVITY; ANTICANCER AGENTS	Using two agonistic monoclonal antibodies specific for each death receptor of TRAIL, 2E12 (anti-human DR4) and TRA-8 (anti-human DR5), we examined the signal transduction of the death receptors in combination with or without chemotherapy agents such as Adriamycin (doxorubicin hydrochloride) and Cisplatin. Our results demonstrated that chemotherapy agents were able to enhance apoptosis-inducing activity of these antibodies against several different types of tumor cell lines through enhanced caspase activation. The combination of the antibodies and chemotherapy agents led to a synergistical activation of the JNK/p38 MAP kinase, which was mediated by MKK4. The combination also caused an increased release of cytochrome c and Smac/DIABLO from mitochondria in parallel with the profound loss of mitochondrial membrane potential. These results suggest that the enhanced activation of the JNK/p38 kinase and the mitochondrial apoptosis pathways play a crucial role in synergistic induction of the death receptor-mediated apoptosis by chemotherapy agents. Thus, the simultaneous targeting of cell surface death receptors with agonistic antibodies and the intracellular JNK/p38 and the mitochondrial death pathways with chemotherapy agents would enhance the efficacy and selectivity of both agents in cancer therapy.	Sankyo Co Ltd, Biomed Res Labs, Tokyo 1408710, Japan; Univ Alabama, Dept Med Radiobiol, Birmingham, AL 35294 USA; Univ Alabama, Div Gynecol Oncol, Birmingham, AL 35294 USA; Univ Alabama, Dept Math, Birmingham, AL 35294 USA	Daiichi Sankyo Company Limited; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Zhou, T (corresponding author), Univ Alabama, Dept Med, 465 LHRB,701 19th St S, Birmingham, AL 35249 USA.			Kimberly, Robert/0000-0002-5330-3086; Makhija, Sharmila/0000-0002-4078-9822; Buchsbaum, Donald/0000-0003-2797-5847	NCI NIH HHS [CA83591, CA89019] Funding Source: Medline; NIAMS NIH HHS [AR44982] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA083591, P50CA089019] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR044982] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aoki H, 2002, J BIOL CHEM, V277, P10244, DOI 10.1074/jbc.M112355200; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Cuello M, 2001, GYNECOL ONCOL, V81, P380, DOI 10.1006/gyno.2001.6194; Decaudin D, 1997, CANCER RES, V57, P62; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; French LE, 1999, NAT MED, V5, P146, DOI 10.1038/5505; Frese S, 2002, J THORAC CARDIOV SUR, V123, P168, DOI 10.1067/mtc.2002.119694; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Gliniak B, 1999, CANCER RES, V59, P6153; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hernandez A, 2001, J GASTROINTEST SURG, V5, P56, DOI 10.1016/S1091-255X(01)80014-7; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Keane MM, 1999, CANCER RES, V59, P734; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Kidd JF, 2002, J BIOL CHEM, V277, P6504, DOI 10.1074/jbc.M106802200; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; Lacour S, 2001, CANCER RES, V61, P1645; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Matsuzawa A, 2001, J BIOCHEM-TOKYO, V130, P1; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; Mizutani Y, 1999, CLIN CANCER RES, V5, P2605; Mizutani Y, 2001, J UROLOGY, V165, P263, DOI 10.1097/00005392-200101000-00076; Nagane M, 2001, APOPTOSIS, V6, P191, DOI 10.1023/A:1011336726649; Ohtsuka T, 2002, J BIOL CHEM, V277, P29294, DOI 10.1074/jbc.M203342200; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; REERS M, 1991, BIOCHEMISTRY-US, V30, P4480, DOI 10.1021/bi00232a015; Sartorius UA, 2002, INT J CANCER, V97, P584, DOI 10.1002/ijc.10096; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yamanaka T, 2000, HEPATOLOGY, V32, P482, DOI 10.1053/jhep.2000.16266; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhou T, 1999, NAT MED, V5, P42, DOI 10.1038/4723	48	140	165	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 3	2003	22	13					2034	2044		10.1038/sj.onc.1206290	http://dx.doi.org/10.1038/sj.onc.1206290			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	662UR	12673208				2022-12-28	WOS:000181967700013
J	Bebien, M; Salinas, S; Becamel, C; Richard, W; Linares, L; Hipskind, RA				Bebien, M; Salinas, S; Becamel, C; Richard, W; Linares, L; Hipskind, RA			Immediate-early gene induction by the stresses anisomycin and arsenite in human osteosarcoma cells involves MAPK cascade signaling to Elk-1, CREB and SRF	ONCOGENE			English	Article						c-fos; egr-1; mkp-1; ERK; SAPK; p38	ACTIVATED PROTEIN-KINASE; SERUM RESPONSE ELEMENT; TERNARY COMPLEX FACTORS; C-FOS EXPRESSION; HISTONE H3 PHOSPHORYLATION; N-TERMINAL KINASE; TRANSCRIPTIONAL ACTIVATION; TRANSGENIC MICE; TRANSDUCTION PATHWAYS; SODIUM ARSENITE	Cellular stress activates multiple mitogen-activated protein kinase (MAPK) cascades and immediate-early gene (IEG) transcription. To address how these events are linked, we investigated the endogenous signaling/transcription factor network driving IEG activation by arsenite and anisomycin in the human osteosarcoma cell line HOS/TE-85. Induction of IEG transcription by both stresses corresponded temporally with the phosphorylation of the regulatory factors Elk-1 and cAMP response element-binding protein (CREB), along with activation of the extracellular signal-regulated kinase (ERK), stress-activated protein kinase (SAPK) and p38 MAPK cascades. To assess the role of the different cascades, they were selectively inhibited with PD98059, SP600125 and SB203580, respectively. This implicated all three cascades in Elk-1 phosphorylation after arsenite treatment, whereas ERK and SAPK inhibition diminished this, and IEG mRNA levels, downstream of anisomycin. SB blocked phosphorylation of both serum response factor (SRF) and CREB, and strongly reduced IEG activation by both stresses. Combining PD with SB further reduced arsenite induction of IEG transcription. Thus, all three MAPK cascades mediate anisomycin- and arsenite-induced signaling to IEG promoters in HOS cells through the differential targeting of Elk-1, SRF and CREB.	CNRS, Inst Genet Mol Montpellier, UMR 5535, IFR 24, F-34293 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Hipskind, RA (corresponding author), CNRS, Inst Genet Mol Montpellier, UMR 5535, IFR 24, 1919 Route Mende, F-34293 Montpellier, France.	hipskind@soleil.igm.cnrs-mop.fr	Linares, Laetitia LKL/F-9901-2018; Salinas, Sara/O-1150-2019; Salinas, Sara/O-1856-2013	Linares, Laetitia LKL/0000-0003-1661-2119; Salinas, Sara/0000-0003-4492-2093; Salinas, Sara/0000-0003-4492-2093				Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BONNI A, 1995, MOL CELL NEUROSCI, V6, P168, DOI 10.1006/mcne.1995.1015; Buchsbaum RJ, 2002, MOL CELL BIOL, V22, P4073, DOI 10.1128/MCB.22.12.4073-4085.2002; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; CHIOU HY, 1995, CANCER RES, V55, P1296; Chiou HY, 2001, AM J EPIDEMIOL, V153, P411, DOI 10.1093/aje/153.5.411; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Ducret C, 2000, ONCOGENE, V19, P5063, DOI 10.1038/sj.onc.1203892; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; Elbirt KK, 1998, J BIOL CHEM, V273, P8922, DOI 10.1074/jbc.273.15.8922; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; GUBITS RM, 1988, ONCOGENE, V3, P163; Hazzalin CA, 1997, ONCOGENE, V15, P2321, DOI 10.1038/sj.onc.1201403; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; Heidenreich O, 1999, J BIOL CHEM, V274, P14434, DOI 10.1074/jbc.274.20.14434; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Li J, 2001, MOL CELL BIOL, V21, P8213, DOI 10.1128/MCB.21.23.8213-8224.2001; Lim CP, 1998, ONCOGENE, V16, P2915, DOI 10.1038/sj.onc.1201834; LIN XH, 1994, ENVIRON HEALTH PERSP, V102, P289, DOI 10.2307/3431804; Liu YS, 1996, FREE RADICAL BIO MED, V21, P771, DOI 10.1016/0891-5849(96)00176-1; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; MCMAHON SB, 1995, MOL CELL BIOL, V15, P1086; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; MISRA RP, 1994, J BIOL CHEM, V269, P25483; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pierrat B, 1998, J BIOL CHEM, V273, P29661, DOI 10.1074/jbc.273.45.29661; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RANI AS, 1993, CARCINOGENESIS, V14, P947, DOI 10.1093/carcin/14.5.947; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; Rolli M, 1999, J BIOL CHEM, V274, P19559, DOI 10.1074/jbc.274.28.19559; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; RUTHER U, 1989, ONCOGENE, V4, P861; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; Smith AH, 1998, AM J EPIDEMIOL, V147, P660, DOI 10.1093/oxfordjournals.aje.a009507; SNOW ET, 1992, PHARMACOL THERAPEUT, V53, P31, DOI 10.1016/0163-7258(92)90043-Y; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Thomson S, 2001, MOL CELL, V8, P1231, DOI 10.1016/S1097-2765(01)00404-X; TINWELL H, 1991, ENVIRON HEALTH PERSP, V95, P205, DOI 10.2307/3431125; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wiggin GR, 2002, MOL CELL BIOL, V22, P2871, DOI 10.1128/MCB.22.8.2871-2881.2002; Wilhelm D, 1997, MOL CELL BIOL, V17, P4792, DOI 10.1128/MCB.17.8.4792; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	72	50	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2003	22	12					1836	1847		10.1038/sj.onc.1206334	http://dx.doi.org/10.1038/sj.onc.1206334			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660819				2022-12-28	WOS:000181678200010
J	Cruet-Hennequart, S; Maubant, S; Luis, J; Gauduchon, P; Staedel, C; Dedhar, S				Cruet-Hennequart, S; Maubant, S; Luis, J; Gauduchon, P; Staedel, C; Dedhar, S			alpha(v) integrins regulate cell proliferation through integrin-linked kinase (ILK) in ovarian cancer cells	ONCOGENE			English	Article						integrins; ILK; signal transduction; cell cycle; ovarian cancer	FORKHEAD TRANSCRIPTION FACTORS; EXTRACELLULAR-MATRIX; CYCLE PROGRESSION; PROTEIN-KINASE; ALPHA-V-BETA-3 INTEGRINS; GROWTH-FACTOR; BETA-CATENIN; LINE IGROV1; PTEN GENE; ADHESION	Integrins regulate both adhesion and signaling processes involved in proliferation and survival. alpha(v)beta(3) and alpha(v)beta(5) integrins have been shown to mediate cell adhesion and migration. Here we used human ovarian cancer cell lines (IGROV1, SKOV-3) that express alpha(v)beta(3) and alpha(v)beta(5) to study their role in cell proliferation and the signaling pathways involved. We found that alpha(v) integrins regulate cell proliferation through activation of integrin-linked kinase (ILK). An anti-alpha(v)-blocking antibody specifically inhibits the growth of IGROV1 and SKOV-3. The inhibition of cell proliferation involves 043 in IGROV1 cells, and both alpha(v)beta(3) and alpha(v)beta(5) in SKOV-3 cells. The reduced growth rate induced by alpha(v) integrin blockade is linked in both cell lines to G1/S cell cycle arrest. alpha(v) integrin blockade by neutralizing antibody as well as cyclic-RGD peptide caused an inhibition of ILK activity and phosphorylation of PKB/Akt on serine-473 but not on threonine-308, and was accompanied by an increase in p27(Kip1) expression. Overexpression of wild-type ILK rescued the phosphorylation of PKB/Akt on serine-473 in cells treated with anti-alpha(v) antibody. Inhibition of ILK by a pharmacological inhibitor results in inhibition of cell proliferation, PKB/Akt phosphorylation and increase of p27(Kip1). These results demonstrate that alpha(v) integrins regulate ovarian cancer cell proliferation through ILK.	British Columbia Canc Agcy, Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada; Vancouver Hosp & Hlth Sci Ctr, Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V5Z 1M9, Canada; Ctr Francois Baclesse, UPRES EA 1772, Grp Reg Etud Canc, F-14076 Caen 05, France; Fac Pharm Marseille, UMR CNRS 6032, Lab Biochim & Biol Cellulaire, F-13085 Marseille, France; Univ Bordeaux 2, INSERM, U386, F-33076 Bordeaux, France	British Columbia Cancer Agency; University of British Columbia; University of British Columbia; University of British Columbia; UNICANCER; Centre Francois Baclesse; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	Dedhar, S (corresponding author), British Columbia Canc Agcy, Jack Bell Res Ctr, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.		LUIS, José/M-3071-2013; GAUDUCHON, Pascal/K-6492-2015	Staedel, Cathy/0000-0003-0488-0239; Dedhar, Shoukat/0000-0003-4355-1657				Assoian RK, 1997, CURR OPIN CELL BIOL, V9, P93, DOI 10.1016/S0955-0674(97)80157-3; Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; Auersperg N, 1998, SEMIN ONCOL, V25, P281; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CANNISTRA SA, 1995, GYNECOL ONCOL, V58, P216, DOI 10.1006/gyno.1995.1214; CARREIRAS F, 1995, INT J CANCER, V63, P530, DOI 10.1002/ijc.2910630413; Carreiras F, 1999, INT J CANCER, V80, P285; Carreiras F, 1999, GYNECOL ONCOL, V72, P312, DOI 10.1006/gyno.1998.5262; Caruso DA, 2001, CELL DEATH DIFFER, V8, P665, DOI 10.1038/sj.cdd.4400865; Casalini P, 2001, J BIOL CHEM, V276, P12449, DOI 10.1074/jbc.M009732200; Cruet S, 1999, GYNECOL ONCOL, V75, P254, DOI 10.1006/gyno.1999.5572; Dahia PLM, 2000, ENDOCR-RELAT CANCER, V7, P115, DOI 10.1677/erc.0.0070115; Dedhar S, 2000, CURR OPIN CELL BIOL, V12, P250, DOI 10.1016/S0955-0674(99)00083-6; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DESHANE J, 1994, GENE THER, V1, P332; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Eliceiri BP, 2001, CURR OPIN CELL BIOL, V13, P563, DOI 10.1016/S0955-0674(00)00252-0; Friedlander DR, 1996, CANCER RES, V56, P1939; Friedrich EB, 2002, J BIOL CHEM, V277, P16371, DOI 10.1074/jbc.M201240200; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; GARDNER MJ, 1995, CANCER LETT, V91, P229, DOI 10.1016/0304-3835(95)03743-G; Gottschalk AR, 2001, CANCER RES, V61, P2105; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hapke S, 2001, J BIOL CHEM, V276, P26340, DOI 10.1074/jbc.M100181200; Hellstrom I, 2001, CANCER RES, V61, P2420; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Hulleman E, 2001, CELL MOL LIFE SCI, V58, P80, DOI 10.1007/PL00000780; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Kurose K, 2001, AM J PATHOL, V158, P2097, DOI 10.1016/S0002-9440(10)64681-0; LEHMANN M, 1994, CANCER RES, V54, P2102; Leung-Hagesteijn C, 2001, EMBO J, V20, P2160, DOI 10.1093/emboj/20.9.2160; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li FG, 1999, J CELL SCI, V112, P4589; Liu SC, 2000, J CELL SCI, V113, P3563; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Minaguchi T, 1999, CANCER RES, V59, P6063; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Obata K, 1998, CANCER RES, V58, P2095; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Petitclerc E, 1999, CANCER RES, V59, P2724; PFAFF M, 1994, J BIOL CHEM, V269, P20233; Poulain L, 1998, INT J CANCER, V78, P454, DOI 10.1002/(SICI)1097-0215(19981109)78:4<454::AID-IJC11>3.0.CO;2-6; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Saito M, 2000, INT J CANCER, V85, P160, DOI 10.1002/(SICI)1097-0215(20000115)85:2<160::AID-IJC2>3.0.CO;2-5; Seger D, 2001, J BIOL CHEM, V276, P16998, DOI 10.1074/jbc.M003766200; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Tan C, 2002, J BIOL CHEM, V277, P3109, DOI 10.1074/jbc.M108673200; Tan C, 2001, ONCOGENE, V20, P133, DOI 10.1038/sj.onc.1204052; Troussard AA, 2000, ONCOGENE, V19, P5444, DOI 10.1038/sj.onc.1203928; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; van Leeuwen R L, 1996, Exp Dermatol, V5, P308; Wong NC, 1998, CLIN EXP METASTAS, V16, P50; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zheng DQ, 2000, J BIOL CHEM, V275, P24565, DOI 10.1074/jbc.M002646200	57	125	126	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 20	2003	22	11					1688	1702		10.1038/sj.onc.1206347	http://dx.doi.org/10.1038/sj.onc.1206347			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642872				2022-12-28	WOS:000181580500011
J	Haviernik, P; Schmidt, M; Hu, XR; Wolff, L				Haviernik, P; Schmidt, M; Hu, XR; Wolff, L			Consistent inactivation of p19(Arf) but not p15(Ink4b) in murine myeloid cells transformed in vivo by deregulated c-Myc	ONCOGENE			English	Article						INK4; tumor suppressor; p15(Ink4b); p19(Arf); c-myc; myeloid leukemia	ACUTE LYMPHOBLASTIC-LEUKEMIA; KINASE INHIBITOR P15(INK4B); CYCLIN-DEPENDENT KINASES; TUMOR-SUPPRESSOR GENE; RETINOBLASTOMA-PROTEIN; CDK INHIBITORS; GROWTH SUPPRESSION; BREAST-CANCER; INK4 FAMILY; TGF-BETA	Cyclin-dependent kinase inhibitors p16(INK4a) and p-15(INK4b), encoded by the CDKN2A and B loci, play an important role in negative regulation of the cell cycle. Furthermore, p19(ARF) also encoded by the CDKN2A locus, has been shown to regulate positively the p53 pathway leading to growth arrest and apoptosis. All three genes have been inactivated in human tumors. In myeloid cells, p15(INK4b) mRNA is upregulated during cytokine-induced differentiation and/or growth arrest, and hypermethylation of the p15(INK4b) gene promoter region is a common event in acute myeloid leukemia. In the present study, we examined murine monocyte/macrophage tumors with deregulated c-myc for evidence of Ink4 gene inactivation. p15(Ink4b) mRNA and protein were detected in the majority of leukemias, and p16(Ink4a) mRNA and protein were highly expressed in two of them. pRb was in a hypophosphorylated state in most of the neoplasms indicating that the Cdk inhibitors that were expressed in the cells were functional. The observed expression of p15(Ink4b) is inconsistent with their proliferation state, although it might be expected to be expressed owing to the maturity of the cells. These data suggest, therefore, that deregulated c-Myc bypasses the pRb restriction point and cell cycle arrest in these tumors. An examination of p19(Arf) exons revealed deletions of the gene in up to 94% of the tumors. Since this gene shares exon 2 with p16(Ink4),, it is often difficult to determine which gene is the relevant tumor suppressor. However, the loss of only the p19(Arf)-specific exon 1beta was observed in a tumor that had normal p16(Ink4a), protein expression. In addition, the p19(Arf)-specific exon was deleted in another tumor that expressed a functional chimeric protein, p15Ex1-p16Ex2-3; it was demonstrated here that this fusion protein is capable of inducing G1 arrest. These data overall supports the hypothesis that the critical inactivation event in these hematopoietic neoplasms is elimination of p19(Arf), and not Ink4 function.	NCI, Cellular Oncol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wolff, L (corresponding author), NCI, Cellular Oncol Lab, NIH, Bethesda, MD 20892 USA.							Adams PD, 2001, BBA-REV CANCER, V1471, pM123, DOI 10.1016/S0304-419X(01)00019-1; Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Amanullah A, 2000, ONCOGENE, V19, P2967, DOI 10.1038/sj.onc.1203638; Batova A, 1997, CANCER RES, V57, P832; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Cooper CL, 1997, BLOOD, V89, P3155, DOI 10.1182/blood.V89.9.3155; Drexler HG, 1998, LEUKEMIA, V12, P845, DOI 10.1038/sj.leu.2401043; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Esteller M, 2001, CANCER RES, V61, P3225; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; GUTIERREZ MI, 1992, CANCER RES, V52, P1032; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; Herman JG, 1997, CANCER RES, V57, P837; Herzog CR, 1997, MAMM GENOME, V8, P65, DOI 10.1007/s003359900352; Iravani M, 1997, ONCOGENE, V15, P2609, DOI 10.1038/sj.onc.1201428; Ishiguro A, 1996, BLOOD, V87, P5225, DOI 10.1182/blood.V87.12.5225.bloodjournal87125225; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KEYOMARSI K, 1994, CANCER RES, V54, P380; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Kulkarni MS, 2002, LEUKEMIA, V16, P127, DOI 10.1038/sj.leu.2402328; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Malumbres M, 2000, BIOL CHEM, V381, P827, DOI 10.1515/BC.2000.105; Malumbres M, 1999, ONCOGENE, V18, P385, DOI 10.1038/sj.onc.1202299; Malumbres M, 2000, MOL CELL BIOL, V20, P2915, DOI 10.1128/MCB.20.8.2915-2925.2000; Malumbres M, 1997, ONCOGENE, V14, P1361, DOI 10.1038/sj.onc.1200969; MARTIN SL, 1995, GENE, V153, P261, DOI 10.1016/0378-1119(94)00785-Q; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; O'Hagan RC, 2000, GENE DEV, V14, P2185, DOI 10.1101/gad.827200; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; QUELLE DE, 1995, CELL, V83, P993; QUELLE DE, 1995, ONCOGENE, V11, P635; Reinach PS, 2000, CELL PROLIFERAT, V33, P189, DOI 10.1046/j.1365-2184.2000.00162.x; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Schmidt M, 2001, ONCOGENE, V20, P6205, DOI 10.1038/sj.onc.1204821; Schmidt M, 2000, MOL CELL BIOL, V20, P1970, DOI 10.1128/MCB.20.6.1970-1981.2000; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Teofili L, 1998, EXP HEMATOL, V26, P1133; Teofili L, 2000, EXP HEMATOL, V28, P519, DOI 10.1016/S0301-472X(00)00139-9; Uchida T, 1997, BLOOD, V90, P1403, DOI 10.1182/blood.V90.4.1403.1403_1403_1409; Weinberg RA, 1997, CELL, V88, P573, DOI 10.1016/S0092-8674(00)81897-8; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WOLFF L, 1986, CURR TOP MICROBIOL, V132, P33; WOLFF L, 1988, J IMMUNOL, V141, P681; Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245; Zhang SL, 2001, MOL CELL BIOL, V21, P310, DOI 10.1128/MCB.21.1.310-318.2001; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	69	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 20	2003	22	11					1600	1610		10.1038/sj.onc.1206268	http://dx.doi.org/10.1038/sj.onc.1206268			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642863				2022-12-28	WOS:000181580500002
J	Tyagi, A; Agarwal, R; Agarwal, C				Tyagi, A; Agarwal, R; Agarwal, C			Grape seed extract inhibits EGF-induced and constitutively active mitogenic signaling but activates JNK in human prostate carcinoma DU145 cells: possible role in antiproliferation and apoptosis	ONCOGENE			English	Article						prostate cancer; MAPK; AP1; apoptosis; grape seed extract	EPIDERMAL GROWTH-FACTOR; NF-KAPPA-B; PROTEIN-KINASE PATHWAY; CANCER CELLS; C-JUN; MAP KINASES; STRESS; TRANSDUCTION; RECEPTORS; DEATH	A loss of functional androgen receptor and an enhanced expression of growth factor receptors and associated ligands are causal genetic events in prostate cancer (PCA) progression. These genetic alterations lead to an epigenetic mechanism where a feedback autocrine loop between membrane receptor and ligand (e.g. EGFR-TGFalpha) results in a constitutive activation of MAPK-Elk1-AP1-mediated mitogenic signaling in human PCA at an advanced and androgen-independent stage. We rationalized that inhibiting these epigenetic events could be useful in controlling advanced PCA growth. Recently, we found that grape seed extract (GSE), a dietary supplement rich in flavonoid procyanidins, inhibits advanced and androgen-independent human PCA DU145 cell growth in culture and nude mice. Here, we performed detailed mechanistic studies to define the effect of GSE on EGFR-Shc-MAPK-Elk1-AP1-mediated mitogenic signaling in DU145 cells. Pretreatment of serum-starved cells with GSE resulted in 70% to almost complete inhibition of EGF-induced EGFR activation and 50% to complete inhibition of She activation, which corroborated with a comparable decrease in EGF-induced Shc binding to EGFR. Conversely, EGF-induced ERK1/2 phosphorylation was inhibited only by lower doses of GSE; in fact, higher doses showed an increase. Additional studies showed that GSE alone causes a dose- and time-dependent increase in ERK1/2 phosphorylation in starved DU145 cells that is inhibited by an MEK1 inhibitor PD98059. Independent of this increase in ERK1/2 phosphorylation, GSE showed a strong inhibition of ERK1/2 kinase activity to Elk1 in both cellular and cell-free systems. GSE treatment of cells also inhibited both EGF-induced and constitutively active Elk1 phosphorylation and AP1 activation. GSE treatment also showed DNA synthesis inhibition in starved and EGF-stimulated cells as well as loss of cell viability and apoptotic death that was further increased by adding MEK1 inhibitor. Since GSE strongly induced apoptosis independent of its affect on an increase in phospho-ERK1/2, we hypothesized that apoptotic effect of GSE could be by other mechanism(s) including its effect on stress-associated MAPK, the JNK. Indeed, GSE-treated cells showed a strong and sustained increase in phospho-JNK1/JNK2 levels, JNK activity and phospho-cJun levels. An inhibition of GSE-induced JNK activation by a novel JNK inhibitor SP600125 resulted in a significant reversal of GSE-induced apoptotic death suggesting the involvement of JNK activation by GSE in its apoptosis response. Together, these results suggest that anticancer effects of GSE in PCA be mediated via impairment of EGFR-ERK1/2-Elk1-AP1-mediated mitogenic signaling and activation of JNK causing growth inhibition and apoptosis, respectively.	Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Ctr Canc, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Agarwal, C (corresponding author), Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, 4200 E 9th Ave,Box C238, Denver, CO 80262 USA.	Chapia.Agarwal@UCHSC.edu			NATIONAL CANCER INSTITUTE [R01CA083741, R29CA064514, R01CA064514] Funding Source: NIH RePORTER; NCI NIH HHS [CA83741, CA64514] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal C, 2000, MOL CARCINOGEN, V28, P129, DOI 10.1002/1098-2744(200007)28:3&lt;129::AID-MC1&gt;3.0.CO;2-0; Agarwal R, 2000, BIOCHEM PHARMACOL, V60, P1051, DOI 10.1016/S0006-2952(00)00385-3; Bartolome B, 1996, J CHROMATOGR A, V723, P19, DOI 10.1016/0021-9673(95)00839-X; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bhatia N, 2001, PROSTATE, V46, P98; CLARKE PR, 1994, CURR BIOL, V4, P647, DOI 10.1016/S0960-9822(00)00144-5; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; CONNOLLY JM, 1989, PROSTATE, V15, P177, DOI 10.1002/pros.2990150211; DAI TN, 1995, ONCOGENE, V10, P849; Deak JC, 1998, P NATL ACAD SCI USA, V95, P5595, DOI 10.1073/pnas.95.10.5595; Dhanalakshmi S, 2002, ONCOGENE, V21, P1759, DOI 10.1038/sj.onc.1205240; Dragsted L O, 1998, Arch Toxicol Suppl, V20, P209; ESCRIBANOBAILON T, 1992, J AGR FOOD CHEM, V40, P1794, DOI 10.1021/jf00022a013; Gioeli D, 1999, CANCER RES, V59, P279; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; Grasso AW, 1997, ONCOGENE, V15, P2705, DOI 10.1038/sj.onc.1201447; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Harris KA, 2001, DRUGS, V61, P2177, DOI 10.2165/00003495-200161150-00003; Hirota K, 2001, J BIOL CHEM, V276, P25953, DOI 10.1074/jbc.M011021200; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Lin JQ, 1999, CANCER RES, V59, P2891; Liu B, 2001, BRIT J CANCER, V85, P303, DOI 10.1054/bjoc.2001.1910; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Mukhopadhyay A, 2001, ONCOGENE, V20, P7597, DOI 10.1038/sj.onc.1204997; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Palayoor ST, 1999, ONCOGENE, V18, P7389, DOI 10.1038/sj.onc.1203160; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Putz T, 1999, CANCER RES, V59, P227; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sato M, 2001, FREE RADICAL BIO MED, V31, P729, DOI 10.1016/S0891-5849(01)00626-8; Segawa N, 2001, CANCER RES, V61, P6060; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Smith A, 1997, CURR BIOL, V7, P893, DOI 10.1016/S0960-9822(06)00380-0; Sporn MB, 2000, CARCINOGENESIS, V21, P525, DOI 10.1093/carcin/21.3.525; TILLOTSON JK, 1991, CANCER LETT, V60, P109, DOI 10.1016/0304-3835(91)90216-5; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Wattenberg LW, 1997, P SOC EXP BIOL MED, V216, P133; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Yang GY, 1998, CARCINOGENESIS, V19, P611, DOI 10.1093/carcin/19.4.611; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yu R, 2000, CANCER RES, V60, P2384; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zhao J, 1999, CARCINOGENESIS, V20, P1737, DOI 10.1093/carcin/20.9.1737; Zi XL, 2000, CANCER RES, V60, P5617; Zi XL, 1998, CANCER RES, V58, P1920; Zi ZL, 1999, P NATL ACAD SCI USA, V96, P7490, DOI 10.1073/pnas.96.13.7490	58	114	120	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2003	22	9					1302	1316		10.1038/sj.onc.1206265	http://dx.doi.org/10.1038/sj.onc.1206265			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618755				2022-12-28	WOS:000181360900004
J	Zeng, PY; Rane, N; Du, W; Chintapalli, J; Prendergast, GC				Zeng, PY; Rane, N; Du, W; Chintapalli, J; Prendergast, GC			Role for RhoB and PRK in the suppression of epithelial cell transformation by farnesyltransferase inhibitors	ONCOGENE			English	Article						Ras; Rac; Rho; actin	INFLAMMATORY BREAST-CANCER; PROTEIN-KINASE; RAS TRANSFORMATION; SMALL GTPASE; N-RAS; ACTIVATION; MECHANISM; PRENYLATION; APOPTOSIS; REVERSION	Recent genetic investigations have established that RhoB gain-of-function is sufficient to mediate the antitransforming effects of farnesyltransferase inhibitors (FTIs) in H-Ras-transformed fibroblast systems. In this study, we addressed the breadth and mechanism of RhoB action in epithelial cells transformed by oncoproteins which are themselves insensitive to FTI inactivation. Rat intestinal epithelial (RIE) cells transformed by activated K-Ras or Rac1 were highly sensitive to FTI-induced actin reorganization and growth inhibition, despite the inability of FTI to block prenylation of either K-Ras or Rac1. Ectopic expression of the geranylgeranylated RhoB isoform elicited in cells by FTI treatment phenocopied these effects. Analysis of RhoB effector domain mutants pointed to a role for PRK, a Rho effector kinase implicated in the physiological function of RhoB in intracellular receptor trafficking, and these findings were supported further by experiments in a fibroblast system. We propose that FTIs recruit the antioncogenic RhoB protein in the guise of RhoB-GG to interfere with signaling by pro-oncogenic Rho proteins, possibly by sequestering common exchange factors or effectors such as PRK that are important for cell transformation.	Lankenau Inst Med Res, Wynnewood, PA 19096 USA; DuPont Pharmaceut Co, Glenolden Lab, Canc Res Grp, Glenolden, PA USA; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Thomas Jefferson Univ, Jefferson Med Sch, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Lankenau Medical Center; Lankenau Institute for Medical Research; DuPont; The Wistar Institute; Jefferson University	Prendergast, GC (corresponding author), Lankenau Inst Med Res, 100 Lancaster Ave, Wynnewood, PA 19096 USA.	prendergastg@mlhs.org			NATIONAL CANCER INSTITUTE [R01CA082222] Funding Source: NIH RePORTER; NCI NIH HHS [CA82222, R01 CA082222] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Cox AD, 2001, DRUGS, V61, P723, DOI 10.2165/00003495-200161060-00002; Cryns VL, 1997, J BIOL CHEM, V272, P29449, DOI 10.1074/jbc.272.47.29449; Du W, 1999, CANCER RES, V59, P2059; Du W, 1999, MOL CELL BIOL, V19, P1831; Du W, 1999, CANCER RES, V59, P4208; Flynn P, 2000, J BIOL CHEM, V275, P11064, DOI 10.1074/jbc.275.15.11064; Gampel A, 1999, CURR BIOL, V9, P955, DOI 10.1016/S0960-9822(99)80422-9; HAWLEY RG, 1994, GENE THER, V1, P136; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Koh H, 2000, J BIOL CHEM, V275, P34451, DOI 10.1074/jbc.M001753200; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; LEBOWITZ PF, 1995, MOL CELL BIOL, V15, P6613; Lebowitz PF, 1997, CANCER RES, V57, P708; Lebowitz PF, 1997, J BIOL CHEM, V272, P15591, DOI 10.1074/jbc.272.25.15591; Lebowitz PF, 1997, J BIOL CHEM, V272, P16093, DOI 10.1074/jbc.272.26.16093; Lerner EC, 1997, ONCOGENE, V15, P1283, DOI 10.1038/sj.onc.1201296; Liao JF, 1997, J BIOL CHEM, V272, P25951, DOI 10.1074/jbc.272.41.25951; Liu AX, 2001, P NATL ACAD SCI USA, V98, P6192, DOI 10.1073/pnas.111137198; Liu AX, 2001, MOL CELL BIOL, V21, P6906, DOI 10.1128/MCB.21.20.6906-6912.2001; Liu AX, 2000, FEBS LETT, V481, P205, DOI 10.1016/S0014-5793(00)02003-2; Liu AX, 2000, MOL CELL BIOL, V20, P6105, DOI 10.1128/MCB.20.16.6105-6113.2000; Mellor H, 1998, J BIOL CHEM, V273, P4811, DOI 10.1074/jbc.273.9.4811; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Prendergast G C, 2000, Lancet Oncol, V1, P73, DOI 10.1016/S1470-2045(00)00073-5; Prendergast GC, 2001, NAT REV CANCER, V1, P162, DOI 10.1038/35101096; Prendergast GC, 2000, CURR OPIN CELL BIOL, V12, P166, DOI 10.1016/S0955-0674(99)00072-1; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; Prendergast GC, 2001, EXPERT OPIN INV DRUG, V10, P2105, DOI 10.1517/13543784.10.12.2105; Prendergast GC, 2000, SEMIN CANCER BIOL, V10, P443, DOI 10.1006/scbi.2000.0335; Prendergast GC, 1999, CANCER RES, V59, P5924; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; Rowinsky EK, 1999, J CLIN ONCOL, V17, P3631, DOI 10.1200/JCO.1999.17.11.3631; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Sebti SM, 2000, ONCOGENE, V19, P6584, DOI 10.1038/sj.onc.1204146; Suzuki N, 1998, P NATL ACAD SCI USA, V95, P15356, DOI 10.1073/pnas.95.26.15356; Takahashi M, 1998, P NATL ACAD SCI USA, V95, P11566, DOI 10.1073/pnas.95.20.11566; van Golen KL, 1999, CLIN CANCER RES, V5, P2511; van Golen KL, 2000, CANCER RES, V60, P5832; van Golen KL, 2002, MOL CANCER THER, V1, P575; van Golen KL, 2000, NEOPLASIA, V2, P418, DOI 10.1038/sj.neo.7900115; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; Zohar M, 1998, ONCOGENE, V17, P991, DOI 10.1038/sj.onc.1202022	47	36	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2003	22	8					1124	1134		10.1038/sj.onc.1206181	http://dx.doi.org/10.1038/sj.onc.1206181			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650EK	12606940				2022-12-28	WOS:000181249700002
J	Mac Partlin, M; Homer, E; Robinson, H; McCormick, CJ; Crouch, DH; Durant, ST; Matheson, EC; Hall, AG; Gillespie, DAF; Brown, R				Mac Partlin, M; Homer, E; Robinson, H; McCormick, CJ; Crouch, DH; Durant, ST; Matheson, EC; Hall, AG; Gillespie, DAF; Brown, R			Interactions of the DNA mismatch repair proteins MLH1 and MSH2 with c-MYC and MAX	ONCOGENE			English	Article						DNA mismatch repair; MYC; MAX; mutator phenotype; protein interactions	CELL-CYCLE; GENOMIC INSTABILITY; NUCLEAR EXTRACTS; APOPTOSIS; BINDING; DAMAGE; LINES; ALPHA; PCNA; DIFFERENTIATION	MSH2 and MLH1 have a central role in correcting mismatches in DNA occurring during DNA replication and have been implicated in the engagement of apoptosis induced by a number of cytotoxic anticancer agents. The function of MLH1 is not clearly defined, although it is required for mismatch repair (MMR) and engagement of apoptosis after certain types of DNA damage. In order to identify other partners of MLH1 that may be involved in signalling MMR or apoptosis, we used human MLH1 in yeast two-hybrid screens of normal human breast and ovarian cDNA libraries. As well as known partners of MLH1 such as PMS1, MLH3 and MBD4, we identified the carboxy terminus of the human c-MYC protooncogene as an interacting sequence. We demonstrate, both in vitro by yeast two-hybrid and GST-fusion pull-down experiments, as well as in vivo by coimmunoprecipitation from human tumour cell extracts, that MLH1 interacts with the c-MYC protein. We further demonstrate that the heterodimeric partner of c-MYC, MAX, interacts with a different MMR protein, MSH2, both in vitro and in vivo. Using an inducible c-MYC-ER(TM) fusion gene, we show that elevated c-MYC expression leads to an increased HGPRT mutation rate of Rat1 cells and an increase in the number of frameshift mutants at the HGPRT locus. The effect on HGPRT mutation rate is small (2-3-fold), but is consistent with deregulated c-MYC expression partially inhibiting MMR activity.	Univ Glasgow, Dept Med Oncol, Canc Res UK, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Univ Newcastle Upon Tyne, Sch Med, Leukaemia Res Grp, Canc Res Unit, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland	Beatson Institute; Cancer Research UK; University of Glasgow; Newcastle University - UK; University of Dundee	Brown, R (corresponding author), Univ Glasgow, Dept Med Oncol, Canc Res UK, Beatson Labs, Garscube Estate,Swichback Rd, Glasgow G61 1BD, Lanark, Scotland.		Gillespie, David/R-4771-2019; Hall, Andy/AAD-8622-2020; Hall, Andrew G/B-3485-2009	Gillespie, David/0000-0002-6338-0544; Brown, Robert/0000-0001-7960-5755				Adachi S, 2001, MOL CELL BIOL, V21, P4929, DOI 10.1128/MCB.21.15.4929-4937.2001; Bellacosa A, 1999, P NATL ACAD SCI USA, V96, P3969, DOI 10.1073/pnas.96.7.3969; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; Bowers J, 2001, J MOL BIOL, V306, P957, DOI 10.1006/jmbi.2001.4467; Claij N, 2002, ONCOGENE, V21, P2873, DOI 10.1038/sj.onc.1205395; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; Colussi C, 2002, CURR BIOL, V12, P912, DOI 10.1016/S0960-9822(02)00863-1; CROUCH DH, 1993, ONCOGENE, V8, P1849; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; Duckett DR, 1999, P NATL ACAD SCI USA, V96, P12384, DOI 10.1073/pnas.96.22.12384; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Gu LY, 1998, NUCLEIC ACIDS RES, V26, P1173, DOI 10.1093/nar/26.5.1173; Guerrette S, 1999, J BIOL CHEM, V274, P6336, DOI 10.1074/jbc.274.10.6336; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; Hardman RA, 2001, CANCER RES, V61, P1392; HAWN MT, 1995, CANCER RES, V55, P3721; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; Jiricny J, 1998, EMBO J, V17, P6427, DOI 10.1093/emboj/17.22.6427; Karran P, 1996, CANCER SURV, V28, P69; Kondo E, 2001, NUCLEIC ACIDS RES, V29, P1695, DOI 10.1093/nar/29.8.1695; Kuismanen SA, 2000, AM J PATHOL, V156, P1773, DOI 10.1016/S0002-9440(10)65048-1; LAROCCA SA, 1994, ONCOGENE, V9, P3499; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Luria SE, 1943, GENETICS, V28, P491; Mai S, 1996, ONCOGENE, V12, P277; Matton N, 2000, J BIOL CHEM, V275, P17808, DOI 10.1074/jbc.M909794199; Modrich P, 1997, J BIOL CHEM, V272, P24727, DOI 10.1074/jbc.272.40.24727; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Moreland NJ, 1999, CANCER RES, V59, P2102; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; Oliver S, 2000, NATURE, V403, P601, DOI 10.1038/35001165; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Raschle M, 1999, J BIOL CHEM, V274, P32368, DOI 10.1074/jbc.274.45.32368; Rockwood LD, 2002, ONCOGENE, V21, P7235, DOI 10.1038/sj.onc.1205697; Schreiber-Agus N, 1998, BIOESSAYS, V20, P808, DOI 10.1002/(SICI)1521-1878(199810)20:10<808::AID-BIES6>3.0.CO;2-U; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Strathdee G, 2001, ONCOGENE, V20, P1923, DOI 10.1038/sj.onc.1204276; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Yamada M, 1997, NUCLEIC ACIDS RES, V25, P491, DOI 10.1093/nar/25.3.491	45	17	19	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 13	2003	22	6					819	825		10.1038/sj.onc.1206252	http://dx.doi.org/10.1038/sj.onc.1206252			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584560				2022-12-28	WOS:000180864300003
J	Borrmann, L; Seebeck, B; Rogalla, P; Bullerdiek, J				Borrmann, L; Seebeck, B; Rogalla, P; Bullerdiek, J			Human HMGA2 promoter is coregulated by a polymorphic dinucleotide (TC)-repeat	ONCOGENE			English	Article						high-mobility group proteins; HMGA; promoter analysis; cancer; obesity; arteriosclerosis	I-C GENE; TRANSCRIPTION FACTORS; MESENCHYMAL TUMORS; H-DNA; EXPRESSION; ELEMENT; TRIPLEX; REARRANGEMENTS; LIPOMAS; VIVO	HMGA proteins are thought to be causally involved in the progression of different diseases, including benign and malignant tumors, obesity, arteriosclerosis, and restenosis. As HMGA proteins are architectural transcription factors, their binding to DNA leads to changes in DNA-conformation modulating the environment for the assembly and function of transcriptional complexes, thus influencing the expression of a huge variety of genes. Despite the emerging role of HMGA proteins for important diseases, only limited information is available about mechanisms regulating the expression of the HMGA2 gene. In this report, 2240bp of the 5' flanking region of the HMGA2 gene were functionally analyzed by luciferase assay experiments. Besides the identification of novel positive and negative regulatory elements, it was shown that transcription is initiated from two independent promoter regions within cell lines HeLa, MCF7, and L14(TSV40). Furthermore, a functional polymorphic dinucleotide repeat (TCTCT(TC)(n)) 500 bp upstream of the ATG translational start codon was found to regulate strongly the human HMGA2 promoter with an activation pattern that correlates to its TC-repeat length.	Univ Bremen, Ctr Human Genet, D-28359 Bremen, Germany	University of Bremen	Bullerdiek, J (corresponding author), Univ Bremen, Ctr Human Genet, Leobenerstr ZHG, D-28359 Bremen, Germany.							Anand A, 2000, NAT GENET, V24, P377, DOI 10.1038/74207; ASHAR HR, 1995, CELL, V82, P57; Ashar HR, 1996, GENOMICS, V31, P207, DOI 10.1006/geno.1996.0033; Ayoubi TAY, 1999, ONCOGENE, V18, P5076, DOI 10.1038/sj.onc.1202881; Battista S, 1999, CANCER RES, V59, P4793; Borrmann L, 2001, ONCOGENE, V20, P4537, DOI 10.1038/sj.onc.1204577; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; Chau KY, 1999, FEBS LETT, V457, P429, DOI 10.1016/S0014-5793(99)01100-X; CHAU KY, 1995, NUCLEIC ACIDS RES, V23, P4262, DOI 10.1093/nar/23.21.4262; Chiappetta G, 1996, ONCOGENE, V13, P2439; Chin MT, 1999, J MOL CELL CARDIOL, V31, P2199, DOI 10.1006/jmcc.1999.1054; Espinas ML, 1996, J BIOL CHEM, V271, P31807, DOI 10.1074/jbc.271.50.31807; FIRULLI AB, 1994, ARCH BIOCHEM BIOPHYS, V310, P236, DOI 10.1006/abbi.1994.1162; Hirning-Folz U, 1998, GENE CHROMOSOME CANC, V23, P350, DOI 10.1002/(SICI)1098-2264(199812)23:4<350::AID-GCC10>3.0.CO;2-E; HTUN H, 1988, SCIENCE, V241, P1791, DOI 10.1126/science.3175620; HTUN H, 1989, SCIENCE, V243, P1571, DOI 10.1126/science.2648571; Ishwad CS, 1997, HUM GENET, V99, P103; Kazmierczak B, 1996, ONCOGENE, V12, P515; Kim HG, 1998, BIOCHEMISTRY-US, V37, P2299, DOI 10.1021/bi9718191; LU Q, 1993, MOL CELL BIOL, V13, P2802, DOI 10.1128/MCB.13.5.2802; MEILAHN EN, 1989, MATURITAS, V11, P319, DOI 10.1016/0378-5122(89)90028-5; MICHEL D, 1992, NUCLEIC ACIDS RES, V20, P439, DOI 10.1093/nar/20.3.439; PATEL UA, 1994, BIOCHEM BIOPH RES CO, V201, P63, DOI 10.1006/bbrc.1994.1669; Rogalla P, 1996, AM J PATHOL, V149, P775; Rustighi A, 2002, BIOCHEMISTRY-US, V41, P1229, DOI 10.1021/bi011666o; Rustighi A, 1999, BIOCHEM BIOPH RES CO, V265, P439, DOI 10.1006/bbrc.1999.1680; Scala S, 2000, P NATL ACAD SCI USA, V97, P4256, DOI 10.1073/pnas.070029997; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; Tamimi Y, 1996, BRIT J CANCER, V74, P573, DOI 10.1038/bjc.1996.403; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	31	24	26	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 6	2003	22	5					756	760		10.1038/sj.onc.1206073	http://dx.doi.org/10.1038/sj.onc.1206073			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569368				2022-12-28	WOS:000180642100013
J	Baeza, N; Masuoka, J; Kleihues, P; Ohgaki, H				Baeza, N; Masuoka, J; Kleihues, P; Ohgaki, H			AXIN1 mutations but not deletions in cerebellar medulloblastomas	ONCOGENE			English	Article						AXIN1; medulloblastoma; mutation; polymorphism; deletion	PRIMITIVE NEUROECTODERMAL TUMORS; ADENOMATOUS POLYPOSIS-COLI; CENTRAL-NERVOUS-SYSTEM; WNT SIGNALING PATHWAY; COMPARATIVE GENOMIC HYBRIDIZATION; GLYCOGEN-SYNTHASE KINASE-3-BETA; BETA-CATENIN; SPORADIC MEDULLOBLASTOMAS; NEGATIVE REGULATOR; GENE-MUTATIONS	Medulloblastoma is a malignant, invasive embryonal tumour of the cerebellum which manifests preferentially in children. A subset of cases is associated with colon cancer and APC germline mutations (Turcot syndrome), and APC and beta-catenin point mutations occur in up to 10% of sporadic cases, indicating the involvement of the Wnt pathway in the development of medulloblastoma. In 39 sporadic cerebellar medulloblastomas screeened for alterations in the AXIN1 gene, another component of the Wnt pathway, we found missense AXIN1 mutations in two tumours, CCC --> TCC at codon 255 (exon 1, Pro --> Ser) and TCT --> TGT at codon 263 (exon 1, Ser --> Cys). Furthermore, the A allele at the G/A polymorphism at nucleotide 16 in intron 4 was significantly over-represented in medulloblastomas (39 cases; G 0.76 vs-A 0.24) compared to healthy individuals (86 cases; G 0.91 vs A 0.09; P = 0.0027). RT-PCR revealed large deletions in the AXIN1 gene in 5/12 (42%) medulloblastomas, consistent with a previous report. However, we observed such deletions at a similar frequency also in normal brain tissue (6/12, 50%). Since there are multiple complementary, inverted sequences present in the AXIN1 gene, these large deletions may represent RT-PCR errors due to stem-loop secondary structures.										Akiyama T, 2000, CYTOKINE GROWTH F R, V11, P273, DOI 10.1016/S1359-6101(00)00011-3; ALBRECHT S, 1994, NEUROPATH APPL NEURO, V20, P74, DOI 10.1111/j.1365-2990.1994.tb00959.x; Avet-Loiseau H, 1999, BRIT J CANCER, V79, P1843, DOI 10.1038/sj.bjc.6690293; BADIALI M, 1993, DIAGN MOL PATHOL, V2, P23, DOI 10.1097/00019606-199303000-00004; BIGNER SH, 1988, CANCER GENET CYTOGEN, V30, P91, DOI 10.1016/0165-4608(88)90096-9; Brantjes H, 2002, BIOL CHEM, V383, P255, DOI 10.1515/BC.2002.027; CAVENEE WK, 2000, PATHOLOGY GENETICS T, P238; Cogen PH, 1996, J NEURO-ONCOL, V29, P103, DOI 10.1007/BF00165523; Dahmen RP, 2001, CANCER RES, V61, P7039; Eberhart CG, 2000, J NEUROPATH EXP NEUR, V59, P333, DOI 10.1093/jnen/59.4.333; GIANGASPERO F, 2000, PATHOLOGY GENETICS T, P129; GRIFFIN CA, 1988, CANCER RES, V48, P175; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; Hinoi T, 2000, J BIOL CHEM, V275, P34399, DOI 10.1074/jbc.M003997200; Hsu W, 2001, J CELL BIOL, V155, P1055, DOI 10.1083/jcb.200107066; Huang HT, 2000, AM J PATHOL, V156, P433, DOI 10.1016/S0002-9440(10)64747-5; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Itoh K, 1998, CURR BIOL, V8, P591, DOI 10.1016/S0960-9822(98)70229-5; JAMES CD, 1990, GENE CHROMOSOME CANC, V2, P94, DOI 10.1002/gcc.2870020204; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; KUMAR R, 1990, CHILD NERV SYST, V6, P371, DOI 10.1007/BF00302220; Lantos PL, 2002, GREENFIELDS NEUROPAT, P767; Lee YJ, 1999, J BIOL CHEM, V274, P1566, DOI 10.1074/jbc.274.3.1566; Lin YM, 2000, J HUM GENET, V45, P254, DOI 10.1007/s100380070036; Mader RM, 2001, J LAB CLIN MED, V137, P422, DOI 10.1067/mlc.2001.115452; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Neo SY, 2000, BIOCHEM BIOPH RES CO, V272, P144, DOI 10.1006/bbrc.2000.2751; Pietsch T, 1997, CANCER RES, V57, P2085; Raffel C, 1997, CANCER RES, V57, P842; Reardon DA, 1997, CANCER RES, V57, P4042; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Schutz BR, 1996, GENE CHROMOSOME CANC, V16, P196; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; Taniguchi K, 2002, ONCOGENE, V21, P4863, DOI 10.1038/sj.onc.1205591; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; Watanabe K, 1998, ACTA NEUROPATHOL, V95, P559, DOI 10.1007/s004010050840; Wolter M, 1997, CANCER RES, V57, P2581; Wu R, 2001, CANCER RES, V61, P8247; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zurawel RH, 1998, CANCER RES, V58, P896; Zurawel RH, 2000, GENE CHROMOSOME CANC, V27, P44, DOI 10.1002/(SICI)1098-2264(200001)27:1<44::AID-GCC6>3.0.CO;2-V	45	117	122	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 30	2003	22	4					632	636		10.1038/sj.onc.1206156	http://dx.doi.org/10.1038/sj.onc.1206156			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555076				2022-12-28	WOS:000180538200016
J	Rahaman, SO; Harbor, PC; Chernova, O; Barnett, GH; Vogelbaum, MA; Haque, SJ				Rahaman, SO; Harbor, PC; Chernova, O; Barnett, GH; Vogelbaum, MA; Haque, SJ			Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells	ONCOGENE			English	Article						glioblastoma; Jak-Stat signal transduction; apoptosis; IL-6; Stat3	HUMAN-BRAIN; CONFERS RESISTANCE; MALIGNANT GLIOMA; IL-6 FAMILY; JAK-STAT; ACTIVATION; RECEPTOR; GENE; PROTEIN; GROWTH	Glioblastoma multiforme (GBM), the most common and malignant central nervous system tumor in humans, is highly proliferative and resistant to apoptosis. Stat3, a latent transcription factor being activated by aberrant cytokine or growth factor signaling, acts as a suppressor of apoptosis in a number of cancer cells. Here we report that GBM tumors and cell lines contain high levels of constitutively activated Stat3 when compared with normal human astrocytes, white matter, and normal tissue adjacent to tumor. The persistent activation of Stat3 is in part, attributable to an autocrine action of interleukin-6 in the GBM cell tine U251. Janus kinase inhibitor AG490 inhibits Stat3 activation with a concomitant reduction in steady-state levels of Bcl-X-L, Bcl-2 and Mel-1 proteins and induces apoptosis in U251 cells as revealed by Poly (ADP-ribose) polymerase cleavage and Annexin-V staining. Expression of a dominant negative mutant Stat3 protein or treatment with AG490 markedly reduces the proliferation of U251 cells by inhibiting the constitutive activation of Stat3. These results provide evidence that constitutive activation of Stat3 contributes to the pathogenesis of glioblastoma by promoting both proliferation and survival of GBM cells. Therefore, targeting Stat3 signaling may provide a potential therapeutic intervention for GBM.	Cleveland Clin Fdn, Dept Canc Biol, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Neurosurg, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Pulm & Crit Care Med, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Haque, SJ (corresponding author), Cleveland Clin Fdn, Dept Canc Biol, Lerner Res Inst, NB-40,9500 Euclid Ave, Cleveland, OH 44195 USA.	haquej@ccf.org			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060533] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM60533] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Badache A, 2001, CANCER RES, V61, P383; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Goswami S, 1998, J NEUROCHEM, V71, P1837; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Halfter H, 2000, MOL BRAIN RES, V80, P198, DOI 10.1016/S0169-328X(00)00162-5; Haque SJ, 1997, P NATL ACAD SCI USA, V94, P8563, DOI 10.1073/pnas.94.16.8563; Haque SJ, 2000, J BIOL CHEM, V275, P26500, DOI 10.1074/jbc.275.34.26500; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HIRANO T, 1990, IMMUNOL TODAY, V11, P443, DOI 10.1016/0167-5699(90)90173-7; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Holland EC, 2000, P NATL ACAD SCI USA, V97, P6242, DOI 10.1073/pnas.97.12.6242; Ichimura K, 2000, CANCER RES, V60, P417; Ivanchuk SM, 2001, J NEURO-ONCOL, V51, P219, DOI 10.1023/A:1010632309113; Kaptein A, 1996, J BIOL CHEM, V271, P5961, DOI 10.1074/jbc.271.11.5961; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Levin Victor A., 1997, P2022; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; Lilja A, 2001, INT J ONCOL, V19, P495; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Paillaud E, 2002, J NEUROSCI RES, V67, P670, DOI 10.1002/jnr.10110; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; Prados Michael D., 2000, Seminars in Oncology, V27, P1; Rahaman SO, 2002, CANCER RES, V62, P1103; Rasheed B K, 1999, Curr Opin Oncol, V11, P162; REIFENBERGER G, 1993, CANCER RES, V53, P2736; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; Rolhion C, 2001, J NEUROSURG, V94, P97, DOI 10.3171/jns.2001.94.1.0097; Schaefer LK, 2002, ONCOGENE, V21, P2058, DOI 10.1038/sj.onc.1205263; SCHMIDT EE, 1994, CANCER RES, V54, P6321; Schuringa JJ, 2000, BLOOD, V95, P3765, DOI 10.1182/blood.V95.12.3765; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Sun S, 2002, J GEN VIROL, V83, P1651, DOI 10.1099/0022-1317-83-7-1651; Tchirkov A, 2001, BRIT J CANCER, V85, P518, DOI 10.1054/bjoc.2001.1942; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VAN MEIR E, 1990, CANCER RES, V50, P6683; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Wechsler-Reya R, 2001, ANNU REV NEUROSCI, V24, P385, DOI 10.1146/annurev.neuro.24.1.385; WELLER M, 1995, J CLIN INVEST, V95, P2633, DOI 10.1172/JCI117965; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	51	298	324	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	2002	21	55					8404	8413		10.1038/sj.onc.1206047	http://dx.doi.org/10.1038/sj.onc.1206047			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466961				2022-12-28	WOS:000179480100004
J	Cadoret, A; Ovejero, C; Terris, B; Souil, E; Levy, L; Lamers, WH; Kitajewski, J; Kahn, A; Perret, C				Cadoret, A; Ovejero, C; Terris, B; Souil, E; Levy, L; Lamers, WH; Kitajewski, J; Kahn, A; Perret, C			New targets of beta-catenin signaling in the liver are involved in the glutamine metabolism	ONCOGENE			English	Article						beta-catenin; hepatocellular carcinoma; glutamine synthetase; ornithine aminotransferase; glutamate transporter GLT-1	HEPATOCELLULAR CARCINOMAS; TRANSGENIC MICE; T-ANTIGEN; C-MYC; SYNTHETASE; CANCER; CELLS; EXPRESSION; MUTATIONS; GENE	Inappropriate activation of the Wnt/beta-catenin signaling has been implicated in the development of hepatocellular carcinoma (HCC), but exactly how beta-catenin works remains to be elucidated. To identify, in vivo, the target genes of beta-catenin in the liver, we have used the suppression subtractive hybridization technique and transgenic mice expressing an activated beta-catenin in the liver that developed hepatomegaly. We identified three genes involved in glutamine metabolism, encoding glutamine synthetase (GS), ornithine aminotransferase (OAT) and the glutamate transporter GLT-1. By Northern blot and immunohistochemical analysis we demonstrated that these three genes were specifically induced by activation of the beta-catenin pathway in the liver. In different mouse models bearing an activated beta-catenin signaling in the liver known to be associated with hepatocellular proliferation we observed a marked up-regulation of these three genes. The cellular distribution of GS and GLT-1 parallels beta-catenin activity. By contrast no up-regulation of these three genes was observed in the liver in which hepatocyte proliferation was induced by a signal-independent of beta-catenin. In addition, the GS promoter was activated in the liver of GS(+/LacZ) mice by adenovirus vector-mediated beta-catenin overexpression. Strikingly, the overexpression of the GS gene in human HCC samples was strongly correlated with beta-catenin activation. Together, our results indicate that GS is a target of the Wnt/beta-catenin pathway in the liver. Because a linkage of the glutamine pathway to hepatocarcinogenesis has already been demonstrated, we propose that regulation of these three genes of glutamine metabolism by beta-catenin is a contributing factor to liver carcinogenesis.	Univ Paris 05, Dept Genet Dev & Pathol Mol, INSERM U567, CNRS UMR 8104,Inst Cochin, F-75014 Paris, France; Hop Cochin, Serv Anatomopathol, F-75014 Paris, France; Inst Pasteur, INSERM, U163, F-75015 Paris, France; Univ Amsterdam, Acad Med Ctr, AMC Liver Ctr, NL-1105 BK Amsterdam, Netherlands; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Ctr Reprod Sci, New York, NY 10032 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Amsterdam; Academic Medical Center Amsterdam; Columbia University; Columbia University	Perret, C (corresponding author), Univ Paris 05, Dept Genet Dev & Pathol Mol, INSERM U567, CNRS UMR 8104,Inst Cochin, 24 Rue Faubourg St Jacques, F-75014 Paris, France.		Perret-Mayeux, Christine/L-3297-2017; Cadoret, Axelle/L-2529-2017; Terris, Benoit/P-1497-2017; LEVY, Laurence/AAF-5672-2021; Lamers, Wouter H./D-2965-2012	Cadoret, Axelle/0000-0002-4283-6864; perret, christine/0000-0003-4710-7051				Bennoun M, 1998, ONCOGENE, V17, P1253, DOI 10.1038/sj.onc.1202047; Bosch FX, 1999, SEMIN LIVER DIS, V19, P271, DOI 10.1055/s-2007-1007117; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; Cadoret A, 2001, CANCER RES, V61, P3245; CHRISTA L, 1994, GASTROENTEROLOGY, V106, P1312, DOI 10.1016/0016-5085(94)90024-8; de la Coste A, 1999, CANCER RES, V59, P5017; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Ferry N, 1998, HUM GENE THER, V9, P1975, DOI 10.1089/hum.1998.9.14-1975; GEBHARDT R, 1983, EMBO J, V2, P567, DOI 10.1002/j.1460-2075.1983.tb01464.x; GEBHARDT R, 1995, CARCINOGENESIS, V16, P1673; Harada N, 2002, CANCER RES, V62, P1971; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Kallioniemi OP, 2001, HUM MOL GENET, V10, P657, DOI 10.1093/hmg/10.7.657; Koch A, 1999, CANCER RES, V59, P269; KOVACEVIC Z, 1983, PHYSIOL REV, V63, P547, DOI 10.1152/physrev.1983.63.2.547; KUO FC, 1991, MOL CELL BIOL, V11, P6050, DOI 10.1128/MCB.11.12.6050; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Miyasaka Y, 2001, BRIT J CANCER, V85, P228, DOI 10.1054/bjoc.2001.1901; Osada T, 2000, J HEPATOL, V33, P247, DOI 10.1016/S0168-8278(00)80365-7; Palos TP, 1999, J NEUROCHEM, V73, P1012, DOI 10.1046/j.1471-4159.1999.0731012.x; Polakis P, 2000, GENE DEV, V14, P1837; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Umeda T, 2000, INT J ONCOL, V16, P1133; Wei Y, 2000, ONCOGENE, V19, P498, DOI 10.1038/sj.onc.1203356; Young CS, 1998, MOL CELL BIOL, V18, P2474, DOI 10.1128/MCB.18.5.2474	26	315	328	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 28	2002	21	54					8293	8301		10.1038/sj.onc.1206118	http://dx.doi.org/10.1038/sj.onc.1206118			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447692				2022-12-28	WOS:000179323900007
J	Liu, LT; Chang, HC; Chiang, LC; Hung, WC				Liu, LT; Chang, HC; Chiang, LC; Hung, WC			Induction of RECK by nonsteroidal anti-inflammatory drugs in lung cancer cells	ONCOGENE			English	Article						RECK; NSAIDs; lung cancer	MATRIX METALLOPROTEINASES; GENE-EXPRESSION; INHIBITORS; INVASION; ASPIRIN; METASTASIS; TISSUE; COLON	Nonsteroidal anti-inflammatory drugs (NSAIDs) are known to exert anti-angiogenic and anti-metastatic activity both in vitro and in vivo. Block of angiogenesis and metastasis by NSAlDs has been found to be mediated partly via suppression of matrix metalloproteinase (MMP) activity. However, the molecular mechanism of this inhibitory action has not been well defined. Recent works demonstrated that a membrane-anchored MMP inhibitor RECK may potently suppress MMP-2 and -9 activity to inhibit angiogenesis and metastasis in vitro and in vivo. In this study, we test the possibility that NSAlDs may up-regutate RECK to inhibit MMP activity. RT-PCR analyses showed that NS398 and aspirin up-regulated RECK mRNA level in CL-1 human lung cancer cells. Additionally, NSAIDs increased RECK protein level as detected by immuno-blotting. Since RECK is a membrane-anchored glycoprotein, we also performed immunofluorescent staining to assess the expression of RECK on cell surface. Our results showed that fluorescent intensity of RECK was obviously increased after NSAID treatment. Moreover, induction of RECK by NSAlDs was associated with reduction of MMP-2 activity. We also found that NSAID-activated RECK expression might not be mediated via inhibition of cyclo-oxygenases (COXs) because addition of prostaglandin E-2 (PGE(2)) could not counteract the effect of NSAIDs and overexpression of COX-2 could not down-regulate RECK. Taken together, our results suggest that induction of RECK expression may be one of the mechanisms by which NSAlDs suppress MMP activity to block angiogenesis and metastasis.	Kaohsiung Med Univ, Sch Technol Med Sci, Grad Inst Med, Kaohsiung 807, Taiwan; Kaohsiung Med Univ, Dept Physiol, Kaohsiung 807, Taiwan; Kaohsiung Med Univ, Dept Microbiol, Kaohsiung 807, Taiwan; Kaohsiung Med Univ, Sch Technol Med Sci, Kaohsiung 807, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University	Hung, WC (corresponding author), Kaohsiung Med Univ, Sch Technol Med Sci, Grad Inst Med, 100 Shih Chuan 1st Rd, Kaohsiung 807, Taiwan.		Chiang, Lien-Chai/A-1327-2010	Liu, Li-Teh/0000-0002-7993-7263				Akhmedkhanov A, 2002, BRIT J CANCER, V87, P49, DOI 10.1038/sj.bjc.6600370; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Chen JJW, 2001, CANCER RES, V61, P5223; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; Ellerbroek SM, 1999, BIOESSAYS, V21, P940, DOI 10.1002/(SICI)1521-1878(199911)21:11<940::AID-BIES6>3.3.CO;2-A; FRANTZ B, 1995, SCIENCE, V270, P2017, DOI 10.1126/science.270.5244.2017; Furumoto K, 2001, HEPATOLOGY, V33, P189, DOI 10.1053/jhep.2001.21048; FUTAKI N, 1993, J PHARM PHARMACOL, V45, P753, DOI 10.1111/j.2042-7158.1993.tb07103.x; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Masferrer JL, 2000, CANCER RES, V60, P1306; MEREDITH TJ, 1992, THERAPEUTIC APPL NSA, P67; NELSON C, 1995, J NATL CANCER I, V87, P567, DOI 10.1093/jnci/87.8.567; Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9; Pan MR, 2002, J BIOL CHEM, V277, P32775, DOI 10.1074/jbc.M202334200; Pan MR, 2001, FEBS LETT, V508, P365, DOI 10.1016/S0014-5793(01)03118-0; Rozic JG, 2001, INT J CANCER, V93, P497, DOI 10.1002/ijc.1376; Sasahara RM, 1999, BIOCHEM BIOPH RES CO, V264, P668, DOI 10.1006/bbrc.1999.1552; SCHREINEMACHERS DM, 1994, EPIDEMIOLOGY, V5, P138, DOI 10.1097/00001648-199403000-00003; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Takahashi C, 1998, P NATL ACAD SCI USA, V95, P13221, DOI 10.1073/pnas.95.22.13221; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400	23	29	33	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 28	2002	21	54					8347	8350		10.1038/sj.onc.1206017	http://dx.doi.org/10.1038/sj.onc.1206017			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447698				2022-12-28	WOS:000179323900013
J	Yatabe, Y; Osada, H; Tatematsu, Y; Mitsudomi, T; Takahashi, T				Yatabe, Y; Osada, H; Tatematsu, Y; Mitsudomi, T; Takahashi, T			Decreased expression of 14-3-3 sigma in neuroendocrine tumors is independent of origin and malignant potential	ONCOGENE			English	Article						14-3-3 sigma; stratifin; small cell lung cancer; carcinoid; stem cell	CELL LUNG-CANCER; BREAST-CANCER; CARCINOID-TUMORS; P53 MUTATIONS; PROGNOSTIC-SIGNIFICANCE; TRANSGENIC MICE; GENE-MUTATIONS; DNA-DAMAGE; STEM-CELLS; P73 GENE	We recently reported that 14-3-3sigma is frequently inactivated in small cell lung cancer (SCLC) and a part of large cell carcinomas. Subsequent studies revealed that the large cell carcinomas could be morphologically categorized as large cell neuroendocrine carcinomas (LCNEC). The present study therefore examines 14-3-3sigma expression in a spectrum of neuroendocrine lung tumors, which had varied p53 status, proliferative activity and clinical aggressiveness. The expression of 14-3-3sigma was decreased in all four categories of the spectrum, (5 out of 5 typical carcinoids, 2 out of 2 atypical carcinoids, 5 out of 7 LCNECs and 15 out of 18 SCLCs). In sharp contrast, the level of 14-3-3sigma expression in 75 non-small cell lung cancers (NSCLCs) was the same as that in normal lung tissue, with only one exception. The expression status of neuroendocrine tumors and NSCLCs was not affected by p53 status, but dense promoter hypermethylation of the 14-3-3sigma gene was specifically observed in neuroendocrine tumors, suggesting that methylation plays a regulatory role in 14-3-3sigma expression in vivo as well as in vitro. Furthermore, the expression was not only down-regulated in pulmonary neuroendocrine tumors, but also in neuroendocrine tumors arising from various other organs, through examination of 123 non-pulmonary tumors. Since various carcinogenic machineries are involved in the neuroendocrine tumors, a reduced expression of 14-3-3sigma might be required for the development of neuroendocrine tumors. Constitutive 14-3-3sigma expression was distributed exclusively in putative stem cells of the normal lung, namely the basal cells of the bronchus, and type 11 pneumocytes. Notably, 14-3-3sigma expression was up-regulated during the regeneration of type 11 pneumocytes, suggesting that 14-3-3sigma plays a biological role when a regenerative and/or differentiating drive is activated, facilitating exit from stem cells.	Aichi Canc Ctr Hosp, Dept Pathol & Mol Diagnost, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr, Res Inst, Div Mol Oncol, Nagoya, Aichi 464, Japan; Aichi Canc Ctr Hosp, Dept Thorac Surg, Nagoya, Aichi 464, Japan	Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center	Yatabe, Y (corresponding author), Aichi Canc Ctr Hosp, Dept Pathol & Mol Diagnost, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.		Osada, Hiroyuki/AAY-6254-2020; Takahashi, Takashi/I-7262-2014; YATABE, Yasushi/J-6461-2014	Takahashi, Takashi/0000-0003-0615-7001; YATABE, Yasushi/0000-0003-1788-559X; Mitsudomi, Tetsuya/0000-0001-9860-8505				Anbazhagan R, 1999, CANCER RES, V59, P5119; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Boers JE, 1998, AM J RESP CRIT CARE, V157, P2000, DOI 10.1164/ajrccm.157.6.9707011; Brambilla E, 1996, AM J PATHOL, V149, P1941; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; COLBY TV, 1995, TUMORS LOWER RESP TR; Corn PG, 1999, CANCER RES, V59, P3352; Debelenko LV, 2000, GENE CHROMOSOME CANC, V28, P58, DOI 10.1002/(SICI)1098-2264(200005)28:1<58::AID-GCC7>3.0.CO;2-2; Debelenko LV, 1997, GASTROENTEROLOGY, V113, P773, DOI 10.1016/S0016-5085(97)70171-9; Debelenko LV, 1997, HUM MOL GENET, V6, P2285, DOI 10.1093/hmg/6.13.2285; DELLAMBRA E, 1995, J CELL SCI, V108, P3569; Dhar S, 2000, MOL CELL BIOL, V20, P7764, DOI 10.1128/MCB.20.20.7764-7772.2000; Dosaka-Akita H, 2000, CANCER, V88, P550, DOI 10.1002/(SICI)1097-0142(20000201)88:3<550::AID-CNCR9>3.0.CO;2-D; Endl E, 2001, J PATHOL, V195, P457, DOI 10.1002/path.978; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Galanis E, 1997, CANCER-AM CANCER SOC, V79, P1729, DOI 10.1002/(SICI)1097-0142(19970501)79:9<1729::AID-CNCR14>3.0.CO;2-#; GODWIN JD, 1975, CANCER, V36, P560, DOI 10.1002/1097-0142(197508)36:2<560::AID-CNCR2820360235>3.0.CO;2-4; GORDON JI, 1989, J CELL BIOL, V108, P1187, DOI 10.1083/jcb.108.4.1187; Gouyer V, 1998, AM J RESP CELL MOL, V18, P188, DOI 10.1165/ajrcmb.18.2.3008; Gruvberger S, 2001, CANCER RES, V61, P5979; Haruki N, 2000, JPN J CANCER RES, V91, P317, DOI 10.1111/j.1349-7006.2000.tb00947.x; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hida T, 1998, CANCER RES, V58, P3761; Hoos A, 2001, LAB INVEST, V81, P1331, DOI 10.1038/labinvest.3780347; HORIO Y, 1993, CANCER RES, V53, P1; IBRAHIM NBN, 1984, CANCER-AM CANCER SOC, V54, P1645, DOI 10.1002/1097-0142(19841015)54:8<1645::AID-CNCR2820540828>3.0.CO;2-Q; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Konishi H, 2002, CANCER RES, V62, P271; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; LEFFERS H, 1993, J MOL BIOL, V231, P982, DOI 10.1006/jmbi.1993.1346; LOHMANN DR, 1993, CANCER RES, V53, P5797; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; MILLER CW, 1992, CANCER RES, V52, P1695; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MURREN J, 2001, CANC PRINCIPLES PRAC, P1010; Nishio M, 1997, CLIN CANCER RES, V3, P1051; Nomoto S, 1998, CANCER RES, V58, P1380; Onuki N, 1999, CANCER, V85, P600, DOI 10.1002/(SICI)1097-0142(19990201)85:3<600::AID-CNCR10>3.0.CO;2-W; Osada H, 2002, ONCOGENE, V21, P2418, DOI 10.1038/sj.onc.1205303; Ostergaard M, 1997, CANCER RES, V57, P4111; Padberg BC, 1996, AM J SURG PATHOL, V20, P815, DOI 10.1097/00000478-199607000-00004; Pellegrini G, 2001, P NATL ACAD SCI USA, V98, P3156, DOI 10.1073/pnas.061032098; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; PRASAD GL, 1992, CELL GROWTH DIFFER, V3, P507; Przygodzki RM, 1996, AM J PATHOL, V148, P1531; Ramnani DM, 1999, MODERN PATHOL, V12, P443; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; Salgia R, 1998, J CLIN ONCOL, V16, P1207, DOI 10.1200/JCO.1998.16.3.1207; Sampietro G, 2000, APPL IMMUNOHISTO M M, V8, P49, DOI 10.1097/00022744-200003000-00008; Signoretti S, 2000, AM J PATHOL, V157, P1769, DOI 10.1016/S0002-9440(10)64814-6; SIMON TC, 1995, P NATL ACAD SCI USA, V92, P8685, DOI 10.1073/pnas.92.19.8685; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sturm N, 2002, HUM PATHOL, V33, P175, DOI 10.1053/hupa.2002.31299; SUZUKI H, 1992, CANCER RES, V52, P734; TAKAHASHI T, 1991, ONCOGENE, V6, P1775; Testa JR, 1997, CANCER GENET CYTOGEN, V95, P20, DOI 10.1016/S0165-4608(96)00337-8; Travis W, 1999, HISTOLOGICAL TYPING, P7; TRAVIS WD, 1991, AM J SURG PATHOL, V15, P529, DOI 10.1097/00000478-199106000-00003; Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438; Vellucci VF, 1995, GENE, V166, P213, DOI 10.1016/0378-1119(95)00543-9; Vercoutter-Edouart AS, 2001, CANCER RES, V61, P76; VERHAGEN APM, 1992, CANCER RES, V52, P6182; WILLIAMS ED, 1963, LANCET, V1, P238; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang Q, 2001, SCIENCE, V294, P2155, DOI 10.1126/science.1065718; Yatabe Y, 2000, AM J PATHOL, V157, P985, DOI 10.1016/S0002-9440(10)64611-1; Yatabe Y, 2001, P NATL ACAD SCI USA, V98, P10839, DOI 10.1073/pnas.191225998; Yatabe Y, 1998, CANCER RES, V58, P1042; Zhang XH, 2000, MOL BIOL CELL, V11, P2117, DOI 10.1091/mbc.11.6.2117	70	29	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 28	2002	21	54					8310	8319		10.1038/sj.onc.1206014	http://dx.doi.org/10.1038/sj.onc.1206014			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447694				2022-12-28	WOS:000179323900009
